Down	O
-	O
regulation	O
of	O
interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
4	I-Protein
gene	O
expression	O
in	O
leukemic	O
cells	O
due	O
to	O
hypermethylation	O
of	O
CpG	O
motifs	O
in	O
the	O
promoter	O
region	O
<EOS>	B-X
Although	B-X
the	B-X
bcr-abl	B-X
translocation	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
the	B-X
causative	B-X
genetic	B-X
aberration	B-X
in	B-X
chronic	B-X
myeloid	B-X
leukemia	B-X
(	B-X
CML	B-X
)	B-X
,	B-X
there	B-X
is	B-X
mounting	B-X
evidence	B-X
that	B-X
the	B-X
deregulation	B-X
of	B-X
other	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
the	B-X
transcription	B-X
factor	B-X
interferon	B-X
regulatory	B-X
factor	B-X
4	B-X
(	B-X
IRF-4	B-X
)	B-X
,	B-X
is	B-X
also	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
CML	B-X
.	B-X
Promoter	B-X
methylation	B-X
of	B-X
CpG	B-X
target	B-X
sites	B-X
or	B-X
direct	B-X
deletions/insertions	B-X
of	B-X
genes	B-X
are	B-X
mechanisms	B-X
of	B-X
a	B-X
reversible	B-X
or	B-X
permanent	B-X
silencing	B-X
of	B-X
gene	B-X
expression	B-X
,	B-X
respectively	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
IRF-4	B-X
promoter	B-X
methylation	B-X
or	B-X
mutation	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IRF-4	B-X
expression	B-X
in	B-X
leukemia	B-X
cells	B-X
.	B-X
Whereas	B-X
promoter	B-X
mutations	B-X
or	B-X
structural	B-X
rearrangements	B-X
could	B-X
be	B-X
excluded	B-X
as	B-X
a	B-X
cause	B-X
of	B-X
altered	B-X
IRF-4	B-X
expression	B-X
in	B-X
hematopoietic	B-X
cells	B-X
,	B-X
the	B-X
IRF-4	B-X
promoter	B-X
methylation	B-X
status	B-X
was	B-X
found	B-X
to	B-X
significantly	B-X
influence	B-X
IRF-4	B-X
transcription	B-X
.	B-X
First	B-X
,	B-X
treatment	B-X
of	B-X
IRF-4-negative	B-X
lymphoid	B-X
,	B-X
myeloid	B-X
and	B-X
monocytic	B-X
cell	B-X
lines	B-X
with	B-X
the	B-X
methylation-inhibitor	B-X
5-aza-2-deoxycytidine	B-X
resulted	B-X
in	B-X
a	B-X
time-	B-X
and	B-X
concentration-dependent	B-X
increase	B-X
of	B-X
IRF-4	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
.	B-X
Second	B-X
,	B-X
using	B-X
a	B-X
restriction-PCR-assay	B-X
and	B-X
bisulfite-sequencing	B-X
we	B-X
identified	B-X
specifically	B-X
methylated	B-X
CpG	B-X
sites	B-X
in	B-X
IRF-4-negative	B-X
but	B-X
not	B-X
in	B-X
IRF-4-positive	B-X
cells	B-X
.	B-X
Third	B-X
,	B-X
we	B-X
clearly	B-X
determined	B-X
promoter	B-X
methylation	B-X
as	B-X
a	B-X
mechanism	B-X
for	B-X
IRF-4	B-X
down-regulation	B-X
via	B-X
reporter	B-X
gene	B-X
assays	B-X
,	B-X
but	B-X
did	B-X
not	B-X
detect	B-X
an	B-X
association	B-X
of	B-X
methylational	B-X
status	B-X
and	B-X
mRNA	B-X
expression	B-X
of	B-X
DNA	B-X
methyltransferases	B-X
or	B-X
methyl-CpG-binding	B-X
proteins	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
CpG	B-X
site-specific	B-X
IRF-4	B-X
promoter	B-X
methylation	B-X
as	B-X
a	B-X
putative	B-X
mechanism	B-X
of	B-X
down-regulated	B-X
IRF-4	B-X
expression	B-X
in	B-X
leukemia	B-X
.	B-X

Down	O
-	O
regulation	O
of	O
interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
4	I-Protein
gene	O
expression	O
in	O
leukemic	O
cells	O
due	O
to	O
hypermethylation	O
of	O
CpG	O
motifs	O
in	O
the	O
promoter	O
region	O
<EOS>	B-X
Although	B-X
the	B-X
bcr-abl	B-X
translocation	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
the	B-X
causative	B-X
genetic	B-X
aberration	B-X
in	B-X
chronic	B-X
myeloid	B-X
leukemia	B-X
(	B-X
CML	B-X
)	B-X
,	B-X
there	B-X
is	B-X
mounting	B-X
evidence	B-X
that	B-X
the	B-X
deregulation	B-X
of	B-X
other	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
the	B-X
transcription	B-X
factor	B-X
interferon	B-X
regulatory	B-X
factor	B-X
4	B-X
(	B-X
IRF-4	B-X
)	B-X
,	B-X
is	B-X
also	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
CML	B-X
.	B-X
Promoter	B-X
methylation	B-X
of	B-X
CpG	B-X
target	B-X
sites	B-X
or	B-X
direct	B-X
deletions/insertions	B-X
of	B-X
genes	B-X
are	B-X
mechanisms	B-X
of	B-X
a	B-X
reversible	B-X
or	B-X
permanent	B-X
silencing	B-X
of	B-X
gene	B-X
expression	B-X
,	B-X
respectively	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
IRF-4	B-X
promoter	B-X
methylation	B-X
or	B-X
mutation	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IRF-4	B-X
expression	B-X
in	B-X
leukemia	B-X
cells	B-X
.	B-X
Whereas	B-X
promoter	B-X
mutations	B-X
or	B-X
structural	B-X
rearrangements	B-X
could	B-X
be	B-X
excluded	B-X
as	B-X
a	B-X
cause	B-X
of	B-X
altered	B-X
IRF-4	B-X
expression	B-X
in	B-X
hematopoietic	B-X
cells	B-X
,	B-X
the	B-X
IRF-4	B-X
promoter	B-X
methylation	B-X
status	B-X
was	B-X
found	B-X
to	B-X
significantly	B-X
influence	B-X
IRF-4	B-X
transcription	B-X
.	B-X
First	B-X
,	B-X
treatment	B-X
of	B-X
IRF-4-negative	B-X
lymphoid	B-X
,	B-X
myeloid	B-X
and	B-X
monocytic	B-X
cell	B-X
lines	B-X
with	B-X
the	B-X
methylation-inhibitor	B-X
5-aza-2-deoxycytidine	B-X
resulted	B-X
in	B-X
a	B-X
time-	B-X
and	B-X
concentration-dependent	B-X
increase	B-X
of	B-X
IRF-4	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
.	B-X
Second	B-X
,	B-X
using	B-X
a	B-X
restriction-PCR-assay	B-X
and	B-X
bisulfite-sequencing	B-X
we	B-X
identified	B-X
specifically	B-X
methylated	B-X
CpG	B-X
sites	B-X
in	B-X
IRF-4-negative	B-X
but	B-X
not	B-X
in	B-X
IRF-4-positive	B-X
cells	B-X
.	B-X
Third	B-X
,	B-X
we	B-X
clearly	B-X
determined	B-X
promoter	B-X
methylation	B-X
as	B-X
a	B-X
mechanism	B-X
for	B-X
IRF-4	B-X
down-regulation	B-X
via	B-X
reporter	B-X
gene	B-X
assays	B-X
,	B-X
but	B-X
did	B-X
not	B-X
detect	B-X
an	B-X
association	B-X
of	B-X
methylational	B-X
status	B-X
and	B-X
mRNA	B-X
expression	B-X
of	B-X
DNA	B-X
methyltransferases	B-X
or	B-X
methyl-CpG-binding	B-X
proteins	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
CpG	B-X
site-specific	B-X
IRF-4	B-X
promoter	B-X
methylation	B-X
as	B-X
a	B-X
putative	B-X
mechanism	B-X
of	B-X
down-regulated	B-X
IRF-4	B-X
expression	B-X
in	B-X
leukemia	B-X
.	B-X

Although	O
the	O
bcr	B-Protein
-	O
abl	B-Protein
translocation	O
has	O
been	O
shown	O
to	O
be	O
the	O
causative	O
genetic	O
aberration	O
in	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
,	O
there	O
is	O
mounting	O
evidence	O
that	O
the	O
deregulation	O
of	O
other	O
genes	O
,	O
such	O
as	O
the	O
transcription	O
factor	O
interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
4	I-Protein
(	O
IRF	B-Protein
-	I-Protein
4	I-Protein
)	O
,	O
is	O
also	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
CML	O
.	O
<EOS>	B-X
Although	B-X
the	B-X
bcr-abl	B-X
translocation	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
the	B-X
causative	B-X
genetic	B-X
aberration	B-X
in	B-X
chronic	B-X
myeloid	B-X
leukemia	B-X
(	B-X
CML	B-X
)	B-X
,	B-X
there	B-X
is	B-X
mounting	B-X
evidence	B-X
that	B-X
the	B-X
deregulation	B-X
of	B-X
other	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
the	B-X
transcription	B-X
factor	B-X
interferon	B-X
regulatory	B-X
factor	B-X
4	B-X
(	B-X
IRF-4	B-X
)	B-X
,	B-X
is	B-X
also	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
CML	B-X
.	B-X
Promoter	B-X
methylation	B-X
of	B-X
CpG	B-X
target	B-X
sites	B-X
or	B-X
direct	B-X
deletions/insertions	B-X
of	B-X
genes	B-X
are	B-X
mechanisms	B-X
of	B-X
a	B-X
reversible	B-X
or	B-X
permanent	B-X
silencing	B-X
of	B-X
gene	B-X
expression	B-X
,	B-X
respectively	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
IRF-4	B-X
promoter	B-X
methylation	B-X
or	B-X
mutation	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IRF-4	B-X
expression	B-X
in	B-X
leukemia	B-X
cells	B-X
.	B-X
Whereas	B-X
promoter	B-X
mutations	B-X
or	B-X
structural	B-X
rearrangements	B-X
could	B-X
be	B-X
excluded	B-X
as	B-X
a	B-X
cause	B-X
of	B-X
altered	B-X
IRF-4	B-X
expression	B-X
in	B-X
hematopoietic	B-X
cells	B-X
,	B-X
the	B-X
IRF-4	B-X
promoter	B-X
methylation	B-X
status	B-X
was	B-X
found	B-X
to	B-X
significantly	B-X
influence	B-X
IRF-4	B-X
transcription	B-X
.	B-X
First	B-X
,	B-X
treatment	B-X
of	B-X
IRF-4-negative	B-X
lymphoid	B-X
,	B-X
myeloid	B-X
and	B-X
monocytic	B-X
cell	B-X
lines	B-X
with	B-X
the	B-X
methylation-inhibitor	B-X
5-aza-2-deoxycytidine	B-X
resulted	B-X
in	B-X
a	B-X
time-	B-X
and	B-X
concentration-dependent	B-X
increase	B-X
of	B-X
IRF-4	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
.	B-X
Second	B-X
,	B-X
using	B-X
a	B-X
restriction-PCR-assay	B-X
and	B-X
bisulfite-sequencing	B-X
we	B-X
identified	B-X
specifically	B-X
methylated	B-X
CpG	B-X
sites	B-X
in	B-X
IRF-4-negative	B-X
but	B-X
not	B-X
in	B-X
IRF-4-positive	B-X
cells	B-X
.	B-X
Third	B-X
,	B-X
we	B-X
clearly	B-X
determined	B-X
promoter	B-X
methylation	B-X
as	B-X
a	B-X
mechanism	B-X
for	B-X
IRF-4	B-X
down-regulation	B-X
via	B-X
reporter	B-X
gene	B-X
assays	B-X
,	B-X
but	B-X
did	B-X
not	B-X
detect	B-X
an	B-X
association	B-X
of	B-X
methylational	B-X
status	B-X
and	B-X
mRNA	B-X
expression	B-X
of	B-X
DNA	B-X
methyltransferases	B-X
or	B-X
methyl-CpG-binding	B-X
proteins	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
CpG	B-X
site-specific	B-X
IRF-4	B-X
promoter	B-X
methylation	B-X
as	B-X
a	B-X
putative	B-X
mechanism	B-X
of	B-X
down-regulated	B-X
IRF-4	B-X
expression	B-X
in	B-X
leukemia	B-X
.	B-X

Promoter	O
methylation	O
of	O
CpG	O
target	O
sites	O
or	O
direct	O
deletions	O
/	O
insertions	O
of	O
genes	O
are	O
mechanisms	O
of	O
a	O
reversible	O
or	O
permanent	O
silencing	O
of	O
gene	O
expression	O
,	O
respectively	O
.	O
<EOS>	B-X
Identifying	B-X
environmentally	B-X
responsive	B-X
genetic	B-X
loci	B-X
where	B-X
DNA	B-X
methylation	B-X
is	B-X
associated	B-X
with	B-X
coronary	B-X
heart	B-X
disease	B-X
(	B-X
CHD	B-X
)	B-X
may	B-X
reveal	B-X
novel	B-X
pathways	B-X
or	B-X
therapeutic	B-X
targets	B-X
for	B-X
CHD	B-X
.	B-X
We	B-X
conducted	B-X
the	B-X
first	B-X
prospective	B-X
epigenome-wide	B-X
analysis	B-X
of	B-X
DNA	B-X
methylation	B-X
in	B-X
relation	B-X
to	B-X
incident	B-X
CHD	B-X
in	B-X
the	B-X
Asian	B-X
population	B-X
.	B-X
Epigenetic	B-X
studies	B-X
relied	B-X
so	B-X
far	B-X
on	B-X
correlations	B-X
between	B-X
epigenetic	B-X
marks	B-X
and	B-X
gene	B-X
expression	B-X
pattern	B-X
.	B-X
Technologies	B-X
developed	B-X
for	B-X
epigenome	B-X
editing	B-X
now	B-X
enable	B-X
direct	B-X
study	B-X
of	B-X
functional	B-X
relevance	B-X
of	B-X
precise	B-X
epigenetic	B-X
modifications	B-X
and	B-X
gene	B-X
regulation	B-X
.	B-X
The	B-X
reversible	B-X
nature	B-X
of	B-X
epigenetic	B-X
modifications	B-X
,	B-X
including	B-X
DNA	B-X
methylation	B-X
,	B-X
has	B-X
been	B-X
already	B-X
exploited	B-X
in	B-X
cancer	B-X
therapy	B-X
for	B-X
remodeling	B-X
the	B-X
aberrant	B-X
epigenetic	B-X
landscape	B-X
.	B-X
However	B-X
,	B-X
this	B-X
was	B-X
achieved	B-X
non-selectively	B-X
using	B-X
epigenetic	B-X
inhibitors	B-X
.	B-X
Epigenetic	B-X
editing	B-X
at	B-X
specific	B-X
loci	B-X
represents	B-X
a	B-X
novel	B-X
approach	B-X
that	B-X
might	B-X
selectively	B-X
and	B-X
heritably	B-X
alter	B-X
gene	B-X
expression	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
CRISPR-Cas9-based	B-X
tool	B-X
for	B-X
specific	B-X
DNA	B-X
methylation	B-X
consisting	B-X
of	B-X
deactivated	B-X
Cas9	B-X
(	B-X
dCas9	B-X
)	B-X
nuclease	B-X
and	B-X
catalytic	B-X
domain	B-X
of	B-X
the	B-X
DNA	B-X
methyltransferase	B-X
DNMT3A	B-X
targeted	B-X
by	B-X
co-expression	B-X
of	B-X
a	B-X
guide	B-X
RNA	B-X
to	B-X
any	B-X
20	B-X
bp	B-X
DNA	B-X
sequence	B-X
followed	B-X
by	B-X
the	B-X
NGG	B-X
trinucleotide	B-X
.	B-X
We	B-X
demonstrated	B-X
targeted	B-X
CpG	B-X
methylation	B-X
in	B-X
a	B-X
∼35	B-X
bp	B-X
wide	B-X
region	B-X
by	B-X
the	B-X
fusion	B-X
protein	B-X
.	B-X
We	B-X
also	B-X
showed	B-X
that	B-X
multiple	B-X
guide	B-X
RNAs	B-X
could	B-X
target	B-X
the	B-X
dCas9-DNMT3A	B-X
construct	B-X
to	B-X
multiple	B-X
adjacent	B-X
sites	B-X
,	B-X
which	B-X
enabled	B-X
methylation	B-X
of	B-X
a	B-X
larger	B-X
part	B-X
of	B-X
the	B-X
promoter	B-X
.	B-X
DNA	B-X
methylation	B-X
activity	B-X
was	B-X
specific	B-X
for	B-X
the	B-X
targeted	B-X
region	B-X
and	B-X
heritable	B-X
across	B-X
mitotic	B-X
divisions	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
directed	B-X
DNA	B-X
methylation	B-X
of	B-X
a	B-X
wider	B-X
promoter	B-X
region	B-X
of	B-X
the	B-X
target	B-X
loci	B-X
IL6ST	B-X
and	B-X
BACH2	B-X
decreased	B-X
their	B-X
expression	B-X
.	B-X

Therefore	O
,	O
we	O
investigated	O
whether	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
methylation	O
or	O
mutation	O
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
leukemia	O
cells	O
.	O
<EOS>	B-X
As	B-X
mice	B-X
deficient	B-X
in	B-X
regulatory	B-X
T	B-X
cells	B-X
(	B-X
Tregs	B-X
)	B-X
are	B-X
prone	B-X
to	B-X
the	B-X
development	B-X
of	B-X
an	B-X
FT1D-like	B-X
phenotype	B-X
,	B-X
we	B-X
thus	B-X
investigated	B-X
whether	B-X
FT1D	B-X
patients	B-X
manifest	B-X
Treg	B-X
deficiency	B-X
and	B-X
explored	B-X
the	B-X
related	B-X
mechanisms	B-X
.	B-X
We	B-X
first	B-X
noted	B-X
a	B-X
significant	B-X
reduction	B-X
for	B-X
Foxp3	B-X
and	B-X
CTLA4	B-X
expression	B-X
levels	B-X
in	B-X
PBMCs	B-X
of	B-X
FT1D	B-X
patients	B-X
.	B-X
IRF-7	B-X
was	B-X
found	B-X
to	B-X
selectively	B-X
bind	B-X
to	B-X
the	B-X
Foxp3	B-X
promoter	B-X
,	B-X
and	B-X
by	B-X
which	B-X
it	B-X
promotes	B-X
Foxp3	B-X
transcription	B-X
.	B-X
Therefore	B-X
,	B-X
ectopic	B-X
IRF-7	B-X
expression	B-X
significantly	B-X
promoted	B-X
Foxp3	B-X
and	B-X
CTLA4	B-X
expression	B-X
in	B-X
PBMCs	B-X
,	B-X
while	B-X
knockdown	B-X
of	B-X
IRF-7	B-X
manifested	B-X
opposite	B-X
effect	B-X
.	B-X
Importantly	B-X
,	B-X
stimulation	B-X
of	B-X
PBMCs	B-X
with	B-X
CpG	B-X
ODN	B-X
,	B-X
a	B-X
ligand	B-X
for	B-X
TLR9	B-X
,	B-X
significantly	B-X
induced	B-X
Foxp3	B-X
expression	B-X
,	B-X
demonstrating	B-X
that	B-X
TLR9	B-X
signaling	B-X
positively	B-X
regulates	B-X
Treg	B-X
development	B-X
.	B-X
However	B-X
,	B-X
knockdown	B-X
of	B-X
IRF-7	B-X
expression	B-X
almost	B-X
completely	B-X
diminished	B-X
the	B-X
enhancing	B-X
effect	B-X
of	B-X
TLR9	B-X
signaling	B-X
on	B-X
Foxp3	B-X
expression	B-X
,	B-X
suggesting	B-X
that	B-X
IRF-7	B-X
is	B-X
a	B-X
downstream	B-X
molecule	B-X
of	B-X
TLR9	B-X
signaling	B-X
and	B-X
is	B-X
essential	B-X
for	B-X
TLR9	B-X
induced	B-X
Treg	B-X
generation	B-X
.	B-X
Of	B-X
interestingly	B-X
note	B-X
,	B-X
the	B-X
Foxp3	B-X
promoter	B-X
in	B-X
FT1D	B-X
patients	B-X
was	B-X
hypermethylated	B-X
,	B-X
indicating	B-X
that	B-X
DNA	B-X
methylation	B-X
could	B-X
be	B-X
a	B-X
causative	B-X
factor	B-X
responsible	B-X
for	B-X
the	B-X
reduced	B-X
Foxp3	B-X
expression	B-X
in	B-X
FT1D	B-X
patients	B-X
.	B-X
Indeed	B-X
,	B-X
our	B-X
mechanistic	B-X
studies	B-X
revealed	B-X
that	B-X
DNA	B-X
methylation	B-X
blocked	B-X
IRF-7	B-X
binding	B-X
to	B-X
the	B-X
Foxp3	B-X
promoter	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
data	B-X
support	B-X
the	B-X
notion	B-X
that	B-X
environmental	B-X
insults	B-X
in	B-X
genetic	B-X
predisposed	B-X
subjects	B-X
trigger	B-X
Foxp3	B-X
promoter	B-X
hypermethylation	B-X
,	B-X
which	B-X
then	B-X
prevents	B-X
IRF-7	B-X
binding	B-X
to	B-X
the	B-X
Foxp3	B-X
promoter	B-X
and	B-X
impairs	B-X
Treg	B-X
development/functionality	B-X
contributing	B-X
to	B-X
the	B-X
pathogenesis	B-X
of	B-X
FT1D	B-X
.	B-X

Whereas	O
promoter	O
mutations	O
or	O
structural	O
rearrangements	O
could	O
be	O
excluded	O
as	O
a	O
cause	O
of	O
altered	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
hematopoietic	O
cells	O
,	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
methylation	O
status	O
was	O
found	O
to	O
significantly	O
influence	O
IRF	B-Protein
-	I-Protein
4	I-Protein
transcription	O
.	O
<EOS>	B-X
IDH1/2	B-X
mutation	B-X
with	B-X
ATRX	B-X
and	B-X
TP53	B-X
mutations	B-X
defines	B-X
diffuse	B-X
astrocytomas	B-X
,	B-X
whereas	B-X
IDH1/2	B-X
mutations	B-X
with	B-X
1p19q	B-X
loss	B-X
defines	B-X
oligodendroglioma	B-X
.	B-X
Focal	B-X
amplifications	B-X
of	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
genes	B-X
,	B-X
TERT	B-X
promoter	B-X
mutation	B-X
,	B-X
and	B-X
loss	B-X
of	B-X
chromosomes	B-X
10	B-X
and	B-X
13	B-X
with	B-X
trisomy	B-X
of	B-X
chromosome	B-X
7	B-X
are	B-X
characteristic	B-X
features	B-X
of	B-X
glioblastoma	B-X
and	B-X
can	B-X
be	B-X
used	B-X
for	B-X
diagnosis	B-X
.	B-X
BRAF	B-X
gene	B-X
fusions	B-X
and	B-X
mutations	B-X
in	B-X
low-grade	B-X
gliomas	B-X
and	B-X
histone	B-X
H3	B-X
mutations	B-X
in	B-X
high-grade	B-X
gliomas	B-X
also	B-X
can	B-X
be	B-X
used	B-X
for	B-X
diagnostics	B-X
.	B-X
In	B-X
most	B-X
cases	B-X
,	B-X
driver	B-X
mutations	B-X
have	B-X
not	B-X
been	B-X
identified	B-X
,	B-X
although	B-X
there	B-X
are	B-X
reports	B-X
of	B-X
frequent	B-X
chromosome-wide	B-X
copy-number	B-X
alterations	B-X
and	B-X
TP53	B-X
mutations	B-X
,	B-X
especially	B-X
in	B-X
choroid	B-X
plexus	B-X
carcinomas	B-X
(	B-X
CPCs	B-X
)	B-X
.	B-X

First	O
,	O
treatment	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
lymphoid	O
,	O
myeloid	O
and	O
monocytic	O
cell	O
lines	O
with	O
the	O
methylation	O
-	O
inhibitor	O
5	O
-	O
aza	O
-	O
2	O
-	O
deoxycytidine	O
resulted	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
increase	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
mRNA	O
and	O
protein	O
levels	O
.	O

Second	O
,	O
using	O
a	O
restriction	O
-	O
PCR	O
-	O
assay	O
and	O
bisulfite	O
-	O
sequencing	O
we	O
identified	O
specifically	O
methylated	O
CpG	O
sites	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
but	O
not	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
cells	O
.	O

Third	O
,	O
we	O
clearly	O
determined	O
promoter	O
methylation	O
as	O
a	O
mechanism	O
for	O
IRF	B-Protein
-	I-Protein
4	I-Protein
down	O
-	O
regulation	O
via	O
reporter	O
gene	O
assays	O
,	O
but	O
did	O
not	O
detect	O
an	O
association	O
of	O
methylational	O
status	O
and	O
mRNA	O
expression	O
of	O
DNA	O
methyltransferases	O
or	O
methyl	O
-	O
CpG	O
-	O
binding	O
proteins	O
.	O
<EOS>	B-X
DNA	B-X
methylation	B-X
regulates	B-X
many	B-X
cellular	B-X
processes	B-X
,	B-X
including	B-X
embryonic	B-X
development	B-X
,	B-X
transcription	B-X
,	B-X
chromatin	B-X
structure	B-X
,	B-X
X-chromosome	B-X
inactivation	B-X
,	B-X
genomic	B-X
imprinting	B-X
and	B-X
chromosome	B-X
stability	B-X
.	B-X
DNA	B-X
methyltransferases	B-X
establish	B-X
and	B-X
maintain	B-X
the	B-X
presence	B-X
of	B-X
5-methylcytosine	B-X
(	B-X
5mC	B-X
)	B-X
,	B-X
and	B-X
ten-eleven	B-X
translocation	B-X
cytosine	B-X
dioxygenases	B-X
(	B-X
TETs	B-X
)	B-X
oxidise	B-X
5mC	B-X
to	B-X
5-hydroxymethylcytosine	B-X
(	B-X
5hmC	B-X
)	B-X
,	B-X
5-formylcytosine	B-X
(	B-X
5fC	B-X
)	B-X
and	B-X
5-carboxylcytosine	B-X
(	B-X
5caC	B-X
)	B-X
,	B-X
which	B-X
can	B-X
be	B-X
removed	B-X
by	B-X
base	B-X
excision	B-X
repair	B-X
(	B-X
BER	B-X
)	B-X
proteins	B-X
.	B-X
Multiple	B-X
forms	B-X
of	B-X
DNA	B-X
methylation	B-X
are	B-X
recognised	B-X
by	B-X
methyl-CpG	B-X
binding	B-X
proteins	B-X
(	B-X
MeCPs	B-X
)	B-X
,	B-X
which	B-X
play	B-X
vital	B-X
roles	B-X
in	B-X
chromatin-based	B-X
transcriptional	B-X
regulation	B-X
,	B-X
DNA	B-X
repair	B-X
and	B-X
replication	B-X
.	B-X
Accordingly	B-X
,	B-X
defects	B-X
in	B-X
DNA	B-X
methylation	B-X
and	B-X
its	B-X
mediators	B-X
may	B-X
cause	B-X
silencing	B-X
of	B-X
tumour	B-X
suppressor	B-X
genes	B-X
and	B-X
misregulation	B-X
of	B-X
multiple	B-X
cell	B-X
cycles	B-X
,	B-X
DNA	B-X
repair	B-X
and	B-X
chromosome	B-X
stability	B-X
genes	B-X
,	B-X
and	B-X
hence	B-X
contribute	B-X
to	B-X
genome	B-X
instability	B-X
in	B-X
various	B-X
human	B-X
diseases	B-X
,	B-X
including	B-X
cancer	B-X
.	B-X
Thus	B-X
,	B-X
understanding	B-X
functional	B-X
genetic	B-X
mutations	B-X
and	B-X
aberrant	B-X
expression	B-X
of	B-X
these	B-X
DNA	B-X
methylation	B-X
mediators	B-X
is	B-X
critical	B-X
to	B-X
deciphering	B-X
the	B-X
crosstalk	B-X
between	B-X
concurrent	B-X
genetic	B-X
and	B-X
epigenetic	B-X
alterations	B-X
in	B-X
specific	B-X
cancer	B-X
types	B-X
and	B-X
to	B-X
the	B-X
development	B-X
of	B-X
new	B-X
therapeutic	B-X
strategies	B-X
.	B-X

Together	O
,	O
these	O
data	O
suggest	O
CpG	O
site	O
-	O
specific	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
methylation	O
as	O
a	O
putative	O
mechanism	O
of	O
down	O
-	O
regulated	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
leukemia	O
.	O
<EOS>	B-X
Although	B-X
the	B-X
bcr-abl	B-X
translocation	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
the	B-X
causative	B-X
genetic	B-X
aberration	B-X
in	B-X
chronic	B-X
myeloid	B-X
leukemia	B-X
(	B-X
CML	B-X
)	B-X
,	B-X
there	B-X
is	B-X
mounting	B-X
evidence	B-X
that	B-X
the	B-X
deregulation	B-X
of	B-X
other	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
the	B-X
transcription	B-X
factor	B-X
interferon	B-X
regulatory	B-X
factor	B-X
4	B-X
(	B-X
IRF-4	B-X
)	B-X
,	B-X
is	B-X
also	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
CML	B-X
.	B-X
Promoter	B-X
methylation	B-X
of	B-X
CpG	B-X
target	B-X
sites	B-X
or	B-X
direct	B-X
deletions/insertions	B-X
of	B-X
genes	B-X
are	B-X
mechanisms	B-X
of	B-X
a	B-X
reversible	B-X
or	B-X
permanent	B-X
silencing	B-X
of	B-X
gene	B-X
expression	B-X
,	B-X
respectively	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
IRF-4	B-X
promoter	B-X
methylation	B-X
or	B-X
mutation	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IRF-4	B-X
expression	B-X
in	B-X
leukemia	B-X
cells	B-X
.	B-X
Whereas	B-X
promoter	B-X
mutations	B-X
or	B-X
structural	B-X
rearrangements	B-X
could	B-X
be	B-X
excluded	B-X
as	B-X
a	B-X
cause	B-X
of	B-X
altered	B-X
IRF-4	B-X
expression	B-X
in	B-X
hematopoietic	B-X
cells	B-X
,	B-X
the	B-X
IRF-4	B-X
promoter	B-X
methylation	B-X
status	B-X
was	B-X
found	B-X
to	B-X
significantly	B-X
influence	B-X
IRF-4	B-X
transcription	B-X
.	B-X
First	B-X
,	B-X
treatment	B-X
of	B-X
IRF-4-negative	B-X
lymphoid	B-X
,	B-X
myeloid	B-X
and	B-X
monocytic	B-X
cell	B-X
lines	B-X
with	B-X
the	B-X
methylation-inhibitor	B-X
5-aza-2-deoxycytidine	B-X
resulted	B-X
in	B-X
a	B-X
time-	B-X
and	B-X
concentration-dependent	B-X
increase	B-X
of	B-X
IRF-4	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
.	B-X
Second	B-X
,	B-X
using	B-X
a	B-X
restriction-PCR-assay	B-X
and	B-X
bisulfite-sequencing	B-X
we	B-X
identified	B-X
specifically	B-X
methylated	B-X
CpG	B-X
sites	B-X
in	B-X
IRF-4-negative	B-X
but	B-X
not	B-X
in	B-X
IRF-4-positive	B-X
cells	B-X
.	B-X
Third	B-X
,	B-X
we	B-X
clearly	B-X
determined	B-X
promoter	B-X
methylation	B-X
as	B-X
a	B-X
mechanism	B-X
for	B-X
IRF-4	B-X
down-regulation	B-X
via	B-X
reporter	B-X
gene	B-X
assays	B-X
,	B-X
but	B-X
did	B-X
not	B-X
detect	B-X
an	B-X
association	B-X
of	B-X
methylational	B-X
status	B-X
and	B-X
mRNA	B-X
expression	B-X
of	B-X
DNA	B-X
methyltransferases	B-X
or	B-X
methyl-CpG-binding	B-X
proteins	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
CpG	B-X
site-specific	B-X
IRF-4	B-X
promoter	B-X
methylation	B-X
as	B-X
a	B-X
putative	B-X
mechanism	B-X
of	B-X
down-regulated	B-X
IRF-4	B-X
expression	B-X
in	B-X
leukemia	B-X
.	B-X

Chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
is	O
a	O
clonal	O
myeloproliferative	O
disorder	O
with	O
a	O
typical	O
three	O
phased	O
course	O
(	O
chronic	O
,	O
accelerated	O
and	O
blastic	O
phase	O
)	O
reflecting	O
the	O
loss	O
of	O
differentiation	O
and	O
malignant	O
progress	O
which	O
inevitably	O
leads	O
to	O
death	O
after	O
the	O
blastic	O
phase	O
(	O
1	O
,	O
2	O
)	O
.	O

The	O
hallmark	O
genetic	O
aberration	O
of	O
CML	O
is	O
a	O
reciprocal	O
chromosomal	O
translocation	O
t	O
(	O
9	O
;	O
22	O
)	O
leading	O
to	O
expression	O
of	O
a	O
bcr	B-Protein
-	I-Protein
abl	I-Protein
fusion	I-Protein
gene	I-Protein
,	O
an	O
aberrant	O
activated	O
tyrosine	O
kinase	O
(	O
2	O
)	O
.	O
<EOS>	B-X
The	B-X
truncated	B-X
chromosome	B-X
22	B-X
that	B-X
results	B-X
from	B-X
the	B-X
reciprocal	B-X
translocation	B-X
t	B-X
(	B-X
9	B-X
;	B-X
22	B-X
)	B-X
(	B-X
q34	B-X
;	B-X
q11	B-X
)	B-X
is	B-X
known	B-X
as	B-X
the	B-X
Philadelphia	B-X
chromosome	B-X
(	B-X
Ph	B-X
)	B-X
and	B-X
is	B-X
a	B-X
hallmark	B-X
of	B-X
chronic	B-X
myeloid	B-X
leukemia	B-X
(	B-X
CML	B-X
)	B-X
.	B-X
This	B-X
aberrant	B-X
fusion	B-X
gene	B-X
encodes	B-X
the	B-X
breakpoint	B-X
cluster	B-X
region-proto-oncogene	B-X
tyrosine-protein	B-X
kinase	B-X
(	B-X
BCR-ABL1	B-X
)	B-X
oncogenic	B-X
protein	B-X
with	B-X
persistently	B-X
enhanced	B-X
tyrosine	B-X
kinase	B-X
activity	B-X
.	B-X
The	B-X
kinase	B-X
activity	B-X
is	B-X
responsible	B-X
for	B-X
maintaining	B-X
proliferation	B-X
,	B-X
inhibiting	B-X
differentiation	B-X
,	B-X
and	B-X
conferring	B-X
resistance	B-X
to	B-X
cell	B-X
death	B-X
.	B-X
During	B-X
the	B-X
progression	B-X
of	B-X
CML	B-X
from	B-X
the	B-X
chronic	B-X
phase	B-X
to	B-X
the	B-X
accelerated	B-X
phase	B-X
and	B-X
then	B-X
to	B-X
the	B-X
blast	B-X
phase	B-X
,	B-X
the	B-X
expression	B-X
patterns	B-X
of	B-X
different	B-X
BCR-ABL1	B-X
transcripts	B-X
vary	B-X
.	B-X
Besides	B-X
CML	B-X
,	B-X
the	B-X
Ph	B-X
is	B-X
found	B-X
in	B-X
acute	B-X
lymphoblastic	B-X
leukemia	B-X
,	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
,	B-X
and	B-X
mixed-phenotype	B-X
acute	B-X
leukemia	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
clinical	B-X
presentation	B-X
and	B-X
cellular	B-X
biology	B-X
of	B-X
different	B-X
phenotypes	B-X
of	B-X
Ph-positive	B-X
leukemia	B-X
and	B-X
highlight	B-X
key	B-X
findings	B-X
regarding	B-X
leukemogenesis	B-X
.	B-X

Treatment	O
with	O
interferon	B-Protein
alpha	I-Protein
(	O
IFN	B-Protein
-	I-Protein
alpha	I-Protein
)	O
prolongs	O
survival	O
of	O
CML	O
patients	O
and	O
is	O
associated	O
with	O
a	O
complete	O
cytogenetic	O
response	O
in	O
5	O
-	O
33	O
%	O
of	O
CML	O
patients	O
(	O
1	O
,	O
2	O
)	O
.	O

Recently	O
,	O
we	O
described	O
an	O
impaired	O
expression	O
of	O
the	O
interferon	B-Protein
regulatory	I-Protein
factor	I-Protein
4	I-Protein
(	O
IRF	B-Protein
-	I-Protein
4	I-Protein
)	O
in	O
CML	O
,	O
correlating	O
with	O
poor	O
response	O
to	O
IFN	B-Protein
-	I-Protein
alpha	I-Protein
treatment	O
(	O
3	O
)	O
.	O

The	O
cause	O
of	O
the	O
silencing	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
level	O
remained	O
unclear	O
.	O
<EOS>	B-X
The	B-X
interferon	B-X
regulatory	B-X
factor	B-X
(	B-X
IRF	B-X
)	B-X
-5	B-X
located	B-X
downstream	B-X
of	B-X
the	B-X
nutrient	B-X
sensor	B-X
toll-like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
-4	B-X
,	B-X
is	B-X
emerging	B-X
as	B-X
a	B-X
key	B-X
metabolic	B-X
regulator	B-X
.	B-X
It	B-X
remains	B-X
unclear	B-X
how	B-X
glucose	B-X
fluctuations	B-X
may	B-X
alter	B-X
the	B-X
IRF5/TLR4	B-X
expression	B-X
and	B-X
inflammatory	B-X
responses	B-X
in	B-X
monocytes/macrophages	B-X
.	B-X
To	B-X
investigate	B-X
this	B-X
,	B-X
first	B-X
,	B-X
we	B-X
determined	B-X
IRF5	B-X
gene	B-X
expression	B-X
by	B-X
real-time	B-X
qRT-PCR	B-X
in	B-X
the	B-X
white	B-X
adipose	B-X
tissue	B-X
samples	B-X
from	B-X
39	B-X
T2D	B-X
and	B-X
48	B-X
nondiabetic	B-X
individuals	B-X
.	B-X
Next	B-X
,	B-X
we	B-X
cultured	B-X
THP-1	B-X
macrophages	B-X
in	B-X
hypo-	B-X
and	B-X
hyperglycemic	B-X
conditions	B-X
and	B-X
compared	B-X
,	B-X
at	B-X
the	B-X
protein	B-X
and	B-X
transcription	B-X
levels	B-X
,	B-X
the	B-X
expressions	B-X
of	B-X
IRF5	B-X
,	B-X
TLR4	B-X
,	B-X
and	B-X
M1/M2	B-X
polarization	B-X
profile	B-X
and	B-X
inflammatory	B-X
markers	B-X
against	B-X
control	B-X
(	B-X
normoglycemia	B-X
)	B-X
.	B-X
IRF5	B-X
silencing	B-X
was	B-X
achieved	B-X
by	B-X
small	B-X
interfering	B-X
RNA	B-X
(	B-X
siRNA	B-X
)	B-X
transfection	B-X
.	B-X
The	B-X
data	B-X
show	B-X
that	B-X
adipose	B-X
IRF5	B-X
gene	B-X
expression	B-X
was	B-X
higher	B-X
in	B-X
T2D	B-X
than	B-X
nondiabetic	B-X
counterparts	B-X
(	B-X
P	B-X
=	B-X
0.006	B-X
)	B-X
,	B-X
which	B-X
correlated	B-X
with	B-X
glycated	B-X
hemoglobin	B-X
(	B-X
HbA1c	B-X
)	B-X
(	B-X
r	B-X
=	B-X
0.47/P	B-X
<	B-X
0.001	B-X
)	B-X
,	B-X
homeostatic	B-X
model	B-X
assessment	B-X
of	B-X
insulin	B-X
resistance	B-X
(	B-X
HOMA-IR	B-X
)	B-X
(	B-X
r	B-X
=	B-X
0.23/P	B-X
=	B-X
0.03	B-X
)	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-α	B-X
(	B-X
r	B-X
=	B-X
0.56/P	B-X
<	B-X
0.0001	B-X
)	B-X
,	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-1β	B-X
(	B-X
r	B-X
=	B-X
0.40/P	B-X
=	B-X
0.0009	B-X
)	B-X
,	B-X
and	B-X
C-C	B-X
motif	B-X
chemokine	B-X
receptor	B-X
(	B-X
CCR	B-X
)	B-X
-2	B-X
(	B-X
r	B-X
=	B-X
0.49/P	B-X
<	B-X
0.001	B-X
)	B-X
expression	B-X
.	B-X
IRF5	B-X
expression	B-X
in	B-X
macrophages	B-X
was	B-X
induced/upregulated	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
by	B-X
hypoglycemia	B-X
(	B-X
3	B-X
mM/L	B-X
)	B-X
,	B-X
persistent	B-X
hyperglycemia	B-X
(	B-X
15	B-X
mM/L-25	B-X
mM/L	B-X
)	B-X
,	B-X
and	B-X
RIH/glucose	B-X
fluctuations	B-X
(	B-X
3-15	B-X
mM/L	B-X
)	B-X
as	B-X
compared	B-X
to	B-X
normoglycemia	B-X
(	B-X
5	B-X
mM/L	B-X
)	B-X
.	B-X
Notably	B-X
,	B-X
all	B-X
these	B-X
changes	B-X
were	B-X
counteracted	B-X
by	B-X
IRF5	B-X
silencing	B-X
in	B-X
macrophages	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
RIH/glucose	B-X
fluctuations	B-X
promote	B-X
the	B-X
M1	B-X
polarization	B-X
and	B-X
inflammatory	B-X
responses	B-X
in	B-X
macrophages	B-X
via	B-X
the	B-X
mechanism	B-X
involving	B-X
TLR4-IRF5	B-X
pathway	B-X
,	B-X
which	B-X
may	B-X
have	B-X
significance	B-X
for	B-X
metabolic	B-X
inflammation	B-X
.	B-X

Interferon	O
regulatory	O
factors	O
(	O
IRFs	O
)	O
are	O
a	O
family	O
of	O
transcriptional	O
regulators	O
defined	O
by	O
a	O
characteristic	O
homology	O
in	O
their	O
DNA	O
-	O
binding	O
domain	O
.	O

They	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
various	O
genes	O
(	O
such	O
as	O
IFNs	O
,	O
interleukins	O
,	O
MHC	O
class	O
I	O
/	O
II	O
)	O
,	O
apoptosis	O
and	O
differentiation	O
/	O
maturation	O
(	O
4	O
-	O
6	O
)	O
.	O

IRF	B-Protein
-	I-Protein
4	I-Protein
(	O
ICSAT	B-Protein
/	O
Pip	B-Protein
/	O
MUM1	B-Protein
/	O
LSIRF	B-Protein
)	O
is	O
one	O
member	O
with	O
very	O
restricted	O
expression	O
pattern	O
:	O
Predominately	O
B	O
-	O
and	O
activated	O
T	O
-	O
lymphocytes	O
are	O
IRF	B-Protein
-	I-Protein
4	I-Protein
positive	O
(	O
7	O
-	O
11	O
)	O
.	O

In	O
contrast	O
to	O
other	O
IRFs	O
,	O
expression	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
cannot	O
be	O
induced	O
by	O
IFNs	O
,	O
but	O
by	O
antigen	O
stimulation	O
,	O
crosslinking	O
of	O
T	O
-	O
or	O
B	O
-	O
cell	O
receptors	O
or	O
phorbol	O
-	O
myristate	O
-	O
acetate	O
(	O
10	O
,	O
11	O
)	O
.	O
<EOS>	B-X
Nociceptin	B-X
and	B-X
the	B-X
nociceptin	B-X
receptor	B-X
(	B-X
NOP	B-X
)	B-X
have	B-X
been	B-X
described	B-X
as	B-X
targets	B-X
for	B-X
treatment	B-X
of	B-X
pain	B-X
and	B-X
inflammation	B-X
,	B-X
whereas	B-X
toll-like	B-X
receptors	B-X
(	B-X
TLRs	B-X
)	B-X
play	B-X
key	B-X
roles	B-X
in	B-X
inflammation	B-X
and	B-X
impact	B-X
opioid	B-X
receptors	B-X
and	B-X
endogenous	B-X
opioids	B-X
expression	B-X
.	B-X
Human	B-X
THP-1	B-X
cells	B-X
were	B-X
cultured	B-X
with	B-X
or	B-X
without	B-X
phorbol	B-X
myristate	B-X
acetate	B-X
(	B-X
PMA	B-X
5	B-X
ng/mL	B-X
)	B-X
,	B-X
agonists	B-X
specific	B-X
for	B-X
TLR2	B-X
(	B-X
lipoteichoic	B-X
acid	B-X
,	B-X
LTA	B-X
10	B-X
µg/mL	B-X
)	B-X
,	B-X
TLR4	B-X
(	B-X
lipopolysaccharide	B-X
,	B-X
LPS	B-X
100	B-X
ng/mL	B-X
)	B-X
,	B-X
TLR7	B-X
(	B-X
imiquimod	B-X
,	B-X
IMQ	B-X
10	B-X
µg/mL	B-X
)	B-X
,	B-X
TLR9	B-X
(	B-X
oligonucleotide	B-X
(	B-X
ODN	B-X
)	B-X
2216	B-X
1	B-X
µM	B-X
)	B-X
,	B-X
PMA+TLR	B-X
agonists	B-X
,	B-X
or	B-X
nociceptin	B-X
(	B-X
0.01−100	B-X
nM	B-X
)	B-X
.	B-X
PMA	B-X
upregulated	B-X
ppNOC	B-X
mRNA	B-X
,	B-X
intracellular	B-X
nociceptin	B-X
,	B-X
and	B-X
cell	B-X
membrane	B-X
NOP	B-X
proteins	B-X
(	B-X
all	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Nociceptin	B-X
dose-dependently	B-X
suppressed	B-X
TLR2	B-X
,	B-X
TLR4	B-X
,	B-X
TLR7	B-X
,	B-X
and	B-X
TLR9	B-X
proteins	B-X
(	B-X
all	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X

Consistent	O
with	O
the	O
restriction	O
of	O
expression	O
to	O
immunocompetent	O
cells	O
,	O
mice	O
with	O
deletion	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
failed	O
to	O
develop	O
mature	O
and	O
functionally	O
active	O
B	O
-	O
and	O
T	O
-	O
lymphocytes	O
(	O
12	O
)	O
,	O
and	O
the	O
impaired	O
expression	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
in	O
CML	O
was	O
predominately	O
found	O
in	O
T	O
-	O
cells	O
(	O
3	O
)	O
.	O

These	O
data	O
suggest	O
a	O
crucial	O
role	O
for	O
IRF	B-Protein
-	I-Protein
4	I-Protein
in	O
the	O
function	O
of	O
immune	O
cells	O
.	O
<EOS>	B-X
Atherosclerotic	B-X
plaque	B-X
development	B-X
involves	B-X
multiple	B-X
extra-	B-X
and	B-X
intra-cellular	B-X
signals	B-X
engaging	B-X
cells	B-X
from	B-X
the	B-X
immune	B-X
system	B-X
and	B-X
from	B-X
the	B-X
vasculature	B-X
.	B-X
Pro-inflammatory	B-X
pathways	B-X
activated	B-X
by	B-X
interferon	B-X
gamma	B-X
(	B-X
IFNγ	B-X
)	B-X
and	B-X
toll-like	B-X
receptor	B-X
4	B-X
(	B-X
TLR4	B-X
)	B-X
ligands	B-X
are	B-X
profoundly	B-X
involved	B-X
in	B-X
plaque	B-X
formation	B-X
and	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
involve	B-X
cross-talk	B-X
in	B-X
all	B-X
atheroma-interacting	B-X
cell	B-X
types	B-X
leading	B-X
to	B-X
increased	B-X
activation	B-X
of	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription-1	B-X
(	B-X
STAT1	B-X
)	B-X
and	B-X
elevated	B-X
expression	B-X
of	B-X
pro-inflammatory	B-X
mediators	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
in	B-X
Gene	B-X
Expression	B-X
Omnibus	B-X
repository	B-X
(	B-X
GEO	B-X
)	B-X
deposited	B-X
microarray	B-X
datasets	B-X
,	B-X
obtained	B-X
from	B-X
human	B-X
coronary	B-X
and	B-X
carotid	B-X
atherosclerotic	B-X
plaques	B-X
,	B-X
a	B-X
significant	B-X
increase	B-X
in	B-X
expression	B-X
of	B-X
pro-inflammatory	B-X
and	B-X
immunomodulatory	B-X
genes	B-X
can	B-X
be	B-X
detected	B-X
.	B-X
Moreover	B-X
,	B-X
increased	B-X
expression	B-X
of	B-X
multiple	B-X
chemokines	B-X
,	B-X
adhesion	B-X
molecules	B-X
and	B-X
matrix-remodeling	B-X
molecules	B-X
was	B-X
commonly	B-X
detected	B-X
in	B-X
both	B-X
plaque	B-X
types	B-X
and	B-X
correlated	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
putative	B-X
STAT1	B-X
binding	B-X
sites	B-X
in	B-X
their	B-X
promoters	B-X
,	B-X
suggesting	B-X
strong	B-X
involvement	B-X
of	B-X
STAT1	B-X
in	B-X
plaque	B-X
development	B-X
.	B-X
We	B-X
also	B-X
provide	B-X
evidence	B-X
to	B-X
suggest	B-X
that	B-X
STAT1-nuclear	B-X
factor	B-X
kappa-light-chain-enhancer	B-X
of	B-X
activated	B-X
B	B-X
cells	B-X
(	B-X
NFκB	B-X
)	B-X
or	B-X
STAT1-interferon-regulated	B-X
factor	B-X
(	B-X
IRF	B-X
)	B-X
regulatory	B-X
modules	B-X
are	B-X
over-represented	B-X
in	B-X
the	B-X
promoters	B-X
of	B-X
these	B-X
inflammatory	B-X
genes	B-X
,	B-X
which	B-X
points	B-X
to	B-X
a	B-X
possible	B-X
contribution	B-X
of	B-X
IFNγ	B-X
and	B-X
TLR4	B-X
cross-talk	B-X
in	B-X
the	B-X
process	B-X
of	B-X
atherogenesis	B-X
.	B-X
The	B-X
results	B-X
of	B-X
our	B-X
in	B-X
silico	B-X
analysis	B-X
in	B-X
vitro	B-X
provide	B-X
potential	B-X
evidence	B-X
that	B-X
STAT1-dependent	B-X
IFNγ-TLR4	B-X
cross-talk	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
coronary	B-X
and	B-X
carotid	B-X
artery	B-X
plaque	B-X
development	B-X
and	B-X
identifies	B-X
a	B-X
STAT1-dependent	B-X
gene	B-X
signature	B-X
that	B-X
could	B-X
represent	B-X
a	B-X
novel	B-X
diagnostic	B-X
tool	B-X
to	B-X
monitor	B-X
and	B-X
diagnose	B-X
plaque	B-X
progression	B-X
in	B-X
human	B-X
atherosclerosis	B-X
.	B-X

Methylation	O
of	O
dinucleotide	O
cytosine	O
-	O
guanosine	O
motifs	O
(	O
CpG	O
)	O
,	O
especially	O
in	O
CpG	O
islands	O
located	O
in	O
promoter	O
regions	O
,	O
is	O
one	O
of	O
the	O
mechanisms	O
of	O
gene	O
regulation	O
in	O
mammals	O
and	O
a	O
common	O
event	O
of	O
gene	O
silencing	O
in	O
human	O
neoplasias	O
(	O
13	O
,	O
14	O
)	O
.	O

As	O
opposed	O
to	O
normal	O
cells	O
,	O
hypermethylation	O
of	O
CpG	O
islands	O
is	O
a	O
frequently	O
observed	O
phenomenon	O
in	O
every	O
cancer	O
type	O
.	O

De	O
novo	O
DNA	O
methylation	O
of	O
genes	O
such	O
as	O
cell	O
cycle	O
,	O
DNA	O
repair	O
,	O
apoptosis	O
and	O
tumor	O
suppressor	O
genes	O
is	O
therefore	O
thought	O
to	O
be	O
involved	O
in	O
tumorigenesis	O
(	O
15	O
-	O
17	O
)	O
.	O

Examples	O
for	O
such	O
aberrated	O
genes	O
are	O
MGMT	B-Protein
,	O
DAPK	B-Protein
,	O
p14ARF	B-Protein
,	O
p15INK4b	B-Protein
,	O
p16INK4a	B-Protein
,	O
BRCA1	B-Protein
,	O
CDH13	B-Protein
and	O
APAF	B-Protein
-	I-Protein
1	I-Protein
(	O
17	O
-	O
19	O
)	O
.	O

In	O
CML	O
,	O
methylation	O
is	O
known	O
to	O
regulate	O
expression	O
of	O
the	O
c	B-Protein
-	I-Protein
abl	I-Protein
,	O
the	O
bcr	B-Protein
gene	O
and	O
others	O
(	O
20	O
-	O
23	O
)	O
,	O
and	O
the	O
extent	O
of	O
methylation	O
in	O
the	O
c	B-Protein
-	I-Protein
abl	I-Protein
promoter	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
advanced	O
disease	O
(	O
24	O
)	O
.	O

Hypermethylation	O
due	O
to	O
overexpression	O
of	O
DNA	O
methyltransferases	O
(	O
DNMTs	O
)	O
remains	O
one	O
possible	O
explanation	O
for	O
de	O
novo	O
methylation	O
in	O
tumorigenesis	O
.	O

Recently	O
,	O
DNMTs	O
have	O
been	O
shown	O
to	O
be	O
up	O
-	O
regulated	O
in	O
hematopoietic	O
malignancies	O
(	O
25	O
)	O
.	O

Methyl	O
-	O
CpG	O
-	O
binding	O
proteins	O
(	O
MBPs	O
)	O
are	O
thought	O
to	O
inhibit	O
the	O
binding	O
of	O
transcriptional	O
factors	O
to	O
the	O
promoter	O
and	O
are	O
therefore	O
discussed	O
as	O
one	O
mechanism	O
of	O
transcription	O
inhibition	O
by	O
hypermethylation	O
(	O
26	O
)	O
.	O

In	O
this	O
work	O
,	O
we	O
studied	O
mechanisms	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
gene	O
expression	O
silencing	O
in	O
leukemic	O
cells	O
.	O

We	O
analyzed	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
region	O
for	O
genetic	O
aberrations	O
and	O
methylational	O
status	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
and	O
-	O
negative	O
hematopoietic	O
cells	O
.	O

Cell	O
lines	O
<EOS>	B-X
Although	B-X
most	B-X
biotherapeutic	B-X
proteins	B-X
developed	B-X
to	B-X
date	B-X
have	B-X
been	B-X
produced	B-X
using	B-X
the	B-X
mammalian	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
and	B-X
murine	B-X
myeloma	B-X
(	B-X
NS0	B-X
,	B-X
Sp2/0	B-X
)	B-X
cell	B-X
lines	B-X
,	B-X
there	B-X
has	B-X
been	B-X
a	B-X
recent	B-X
shift	B-X
toward	B-X
the	B-X
use	B-X
of	B-X
human	B-X
cell	B-X
lines	B-X
.	B-X
One	B-X
of	B-X
the	B-X
most	B-X
important	B-X
advantages	B-X
of	B-X
using	B-X
human	B-X
cell	B-X
lines	B-X
for	B-X
protein	B-X
production	B-X
is	B-X
the	B-X
greater	B-X
likelihood	B-X
that	B-X
the	B-X
resulting	B-X
recombinant	B-X
protein	B-X
will	B-X
bear	B-X
post-translational	B-X
modifications	B-X
(	B-X
PTMs	B-X
)	B-X
that	B-X
are	B-X
consistent	B-X
with	B-X
those	B-X
seen	B-X
on	B-X
endogenous	B-X
human	B-X
proteins	B-X
.	B-X
Although	B-X
other	B-X
mammalian	B-X
cell	B-X
lines	B-X
can	B-X
produce	B-X
PTMs	B-X
similar	B-X
to	B-X
human	B-X
cells	B-X
,	B-X
they	B-X
also	B-X
produce	B-X
non-human	B-X
PTMs	B-X
,	B-X
such	B-X
as	B-X
galactose-α1,3-galactose	B-X
and	B-X
N-glycolylneuraminic	B-X
acid	B-X
,	B-X
which	B-X
are	B-X
potentially	B-X
immunogenic	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
human	B-X
cell	B-X
lines	B-X
are	B-X
grown	B-X
easily	B-X
in	B-X
a	B-X
serum-free	B-X
suspension	B-X
culture	B-X
,	B-X
reproduce	B-X
rapidly	B-X
and	B-X
have	B-X
efficient	B-X
protein	B-X
production	B-X
.	B-X
A	B-X
possible	B-X
disadvantage	B-X
of	B-X
using	B-X
human	B-X
cell	B-X
lines	B-X
is	B-X
the	B-X
potential	B-X
for	B-X
human-specific	B-X
viral	B-X
contamination	B-X
,	B-X
although	B-X
this	B-X
risk	B-X
can	B-X
be	B-X
mitigated	B-X
with	B-X
multiple	B-X
viral	B-X
inactivation	B-X
or	B-X
clearance	B-X
steps	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
while	B-X
human	B-X
cell	B-X
lines	B-X
are	B-X
currently	B-X
widely	B-X
used	B-X
for	B-X
biopharmaceutical	B-X
research	B-X
,	B-X
vaccine	B-X
production	B-X
and	B-X
production	B-X
of	B-X
some	B-X
licensed	B-X
protein	B-X
therapeutics	B-X
,	B-X
there	B-X
is	B-X
a	B-X
relative	B-X
paucity	B-X
of	B-X
clinical	B-X
experience	B-X
with	B-X
human	B-X
cell	B-X
lines	B-X
because	B-X
they	B-X
have	B-X
only	B-X
recently	B-X
begun	B-X
to	B-X
be	B-X
used	B-X
for	B-X
the	B-X
manufacture	B-X
of	B-X
proteins	B-X
(	B-X
compared	B-X
with	B-X
other	B-X
types	B-X
of	B-X
cell	B-X
lines	B-X
)	B-X
.	B-X
With	B-X
additional	B-X
research	B-X
investment	B-X
,	B-X
human	B-X
cell	B-X
lines	B-X
may	B-X
be	B-X
further	B-X
optimized	B-X
for	B-X
routine	B-X
commercial	B-X
production	B-X
of	B-X
a	B-X
broader	B-X
range	B-X
of	B-X
biotherapeutic	B-X
proteins	B-X
.	B-X

K	O
-	O
562	O
,	O
Jurkat	O
and	O
U	O
-	O
937	O
were	O
obtained	O
from	O
the	O
ATCC	O
(	O
American	O
Type	O
Culture	O
Collection	O
,	O
Rockville	O
,	O
USA	O
)	O
and	O
EM	O
-	O
2	O
,	O
LAMA	O
-	O
84	O
,	O
CML	O
-	O
T1	O
,	O
BV	O
-	O
173	O
,	O
SD	O
-	O
1	O
and	O
RPMI	O
-	O
8226	O
from	O
the	O
DSMZ	O
(	O
Deutsche	O
Sammlung	O
von	O
Mikroorganismen	O
und	O
Zellkulturen	O
GmbH	O
,	O
Braunschweig	O
,	O
Germany	O
)	O
.	O

All	O
cell	O
lines	O
,	O
except	O
BV	O
-	O
173	O
,	O
SD	O
-	O
1	O
and	O
RPMI	O
-	O
8226	O
,	O
were	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
.	O

Cell	O
culture	O
and	O
stimulation	O
<EOS>	B-X
Non-invasive	B-X
direct	B-X
current	B-X
stimulation	B-X
(	B-X
DCS	B-X
)	B-X
of	B-X
the	B-X
human	B-X
brain	B-X
induces	B-X
neuronal	B-X
plasticity	B-X
and	B-X
alters	B-X
plasticity-related	B-X
cognition	B-X
and	B-X
behavior	B-X
.	B-X
Only	B-X
a	B-X
minority	B-X
of	B-X
these	B-X
papers	B-X
used	B-X
cell	B-X
culture	B-X
or	B-X
brain	B-X
slice	B-X
experiments	B-X
with	B-X
DCS	B-X
paradigms	B-X
comparable	B-X
to	B-X
those	B-X
applied	B-X
in	B-X
humans	B-X
.	B-X
Most	B-X
of	B-X
the	B-X
studies	B-X
were	B-X
performed	B-X
in	B-X
brain	B-X
slices	B-X
(	B-X
9	B-X
papers	B-X
)	B-X
,	B-X
whereas	B-X
cell	B-X
culture	B-X
experiments	B-X
(	B-X
2	B-X
papers	B-X
)	B-X
were	B-X
only	B-X
rarely	B-X
conducted	B-X
.	B-X
These	B-X
ex	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
approaches	B-X
underline	B-X
the	B-X
importance	B-X
of	B-X
cell	B-X
and	B-X
electric	B-X
field	B-X
orientation	B-X
,	B-X
cell	B-X
morphology	B-X
,	B-X
cell	B-X
location	B-X
within	B-X
populations	B-X
,	B-X
stimulation	B-X
duration	B-X
(	B-X
acute	B-X
,	B-X
prolonged	B-X
,	B-X
chronic	B-X
)	B-X
,	B-X
and	B-X
molecular	B-X
changes	B-X
,	B-X
such	B-X
as	B-X
Ca2+-dependent	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
,	B-X
for	B-X
the	B-X
effects	B-X
of	B-X
DC	B-X
stimulation	B-X
.	B-X

All	O
cell	O
lines	O
were	O
maintained	O
at	O
5	O
%	O
CO2	O
in	O
RPMI	O
1640	O
medium	O
with	O
1	O
%	O
glutamine	O
(	O
Gibco	O
/	O
BRL	O
Eggenstein	O
,	O
Germany	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
calf	O
serum	O
(	O
Gibco	O
/	O
BRL	O
)	O
,	O
1	O
%	O
penicillin	O
/	O
streptomycin	O
(	O
Biochrom	O
,	O
Berlin	O
,	O
Germany	O
)	O
.	O

When	O
indicated	O
,	O
cells	O
were	O
treated	O
with	O
5	O
-	O
aza	O
-	O
2	O
-	O
deoxycytidine	O
(	O
AzadC	O
)	O
or	O
5	O
-	O
azacytidine	O
(	O
AzaC	O
)	O
(	O
Sigma	O
,	O
Taufkirchen	O
,	O
Germany	O
)	O
for	O
different	O
time	O
periods	O
.	O

Owing	O
to	O
their	O
chemical	O
instability	O
fresh	O
substances	O
were	O
re	O
-	O
added	O
every	O
24	O
h	O
.	O

Sequencing	O
of	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
<EOS>	B-X
The	B-X
interferon	B-X
regulatory	B-X
factor	B-X
3	B-X
(	B-X
IRF-3	B-X
)	B-X
plays	B-X
essential	B-X
roles	B-X
in	B-X
inflammation	B-X
and	B-X
immune	B-X
response	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
cloned	B-X
the	B-X
nucleotide	B-X
sequence	B-X
of	B-X
the	B-X
5'-flanking	B-X
region	B-X
of	B-X
the	B-X
murine	B-X
IRF-3	B-X
gene	B-X
(	B-X
mIRF-3	B-X
)	B-X
and	B-X
characterized	B-X
the	B-X
molecular	B-X
mechanisms	B-X
controlling	B-X
the	B-X
mIRF-3	B-X
transcriptional	B-X
activity	B-X
in	B-X
NIH3T3	B-X
cells	B-X
.	B-X
Analyses	B-X
of	B-X
a	B-X
series	B-X
of	B-X
5	B-X
'	B-X
deletion	B-X
constructs	B-X
demonstrated	B-X
that	B-X
a	B-X
301	B-X
bp	B-X
region	B-X
(	B-X
-255/+46	B-X
)	B-X
of	B-X
the	B-X
mIRF-3	B-X
gene	B-X
is	B-X
sufficient	B-X
for	B-X
full	B-X
promoter	B-X
activity	B-X
.	B-X
Mutation	B-X
of	B-X
Egr2	B-X
or	B-X
YY1	B-X
site	B-X
led	B-X
to	B-X
52-68	B-X
%	B-X
decrease	B-X
of	B-X
the	B-X
mIRF-3	B-X
promoter	B-X
activity	B-X
,	B-X
and	B-X
double	B-X
Egr2	B-X
and	B-X
YY1	B-X
mutation	B-X
reduced	B-X
the	B-X
promoter	B-X
activity	B-X
to	B-X
20	B-X
%	B-X
of	B-X
the	B-X
wild-type	B-X
promoter	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
knockingdown	B-X
of	B-X
endogenous	B-X
Egr2	B-X
or	B-X
YY1	B-X
by	B-X
a	B-X
siRNA	B-X
strategy	B-X
markedly	B-X
inhibited	B-X
the	B-X
mIRF-3	B-X
promoter	B-X
activity	B-X
.	B-X
Chromatin	B-X
immunoprecipitation	B-X
assays	B-X
showed	B-X
that	B-X
Egr2	B-X
and	B-X
YY1	B-X
interact	B-X
with	B-X
the	B-X
mIRF-3	B-X
promoter	B-X
in	B-X
vivo	B-X
.	B-X
These	B-X
results	B-X
suggested	B-X
that	B-X
the	B-X
basal	B-X
promoter	B-X
activity	B-X
of	B-X
the	B-X
mIRF-3	B-X
gene	B-X
is	B-X
regulated	B-X
by	B-X
transcription	B-X
factors	B-X
Egr2	B-X
and	B-X
YY1	B-X
in	B-X
NIH3T3	B-X
cells	B-X
.	B-X

For	O
analysis	O
of	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
region	O
for	O
permanent	O
aberrations	O
such	O
as	O
insertions	O
/	O
deletions	O
or	O
mutation	O
,	O
we	O
PCR	O
-	O
amplified	O
two	O
fragments	O
from	O
genomic	O
DNA	O
,	O
which	O
was	O
extracted	O
from	O
depicted	O
cell	O
lines	O
with	O
a	O
commercial	O
kit	O
(	O
Qiagen	O
,	O
Hilde	O
,	O
Germany	O
)	O
as	O
recommended	O
.	O

The	O
primers	O
were	O
1	O
-	O
forward	O
:	O
5	O
'	O
-	O
TTGAGATGGAGTCTTGCTCTGT	O
-	O
3	O
'	O
,	O
1	O
-	O
reverse	O
:	O
5	O
'	O
-	O
CCAGGACCTCAGGAGGCCAGTCA	O
-	O
3	O
'	O
;	O
2	O
-	O
forward	O
:	O
5	O
'	O
-	O
AGCGGTGAAACTGAGAGTGCGAGGT	O
-	O
3	O
'	O
,	O
2	O
-	O
reverse	O
:	O
5	O
'	O
-	O
GCCACATCGCTGCAGTTTAG	O
-	O
3	O
'	O
.	O
<EOS>	B-X
Newcastle	B-X
disease	B-X
(	B-X
ND	B-X
)	B-X
caused	B-X
by	B-X
avian	B-X
paramyxovirus	B-X
serotype-1	B-X
(	B-X
APMV-1	B-X
)	B-X
is	B-X
long	B-X
known	B-X
as	B-X
an	B-X
acute	B-X
contagious	B-X
and	B-X
infectious	B-X
disease	B-X
of	B-X
various	B-X
bird	B-X
species	B-X
.	B-X
Prior	B-X
studies	B-X
have	B-X
acknowledged	B-X
that	B-X
the	B-X
virus	B-X
could	B-X
cause	B-X
up	B-X
to	B-X
100	B-X
%	B-X
morbidity	B-X
and	B-X
mortality	B-X
as	B-X
well	B-X
as	B-X
reducing	B-X
eggs	B-X
production	B-X
.	B-X
Transcriptomics	B-X
and	B-X
gene	B-X
expression	B-X
analysis	B-X
are	B-X
largely	B-X
dependent	B-X
of	B-X
the	B-X
availability	B-X
of	B-X
efficient	B-X
thermostable	B-X
reverse	B-X
transcriptases	B-X
(	B-X
RTs	B-X
)	B-X
.	B-X
Reported	B-X
error	B-X
rates	B-X
are	B-X
in	B-X
the	B-X
range	B-X
1.2	B-X
×	B-X
10	B-X
(	B-X
-5	B-X
)	B-X
-6.7	B-X
×	B-X
10	B-X
(	B-X
-4	B-X
)	B-X
,	B-X
with	B-X
oncoretroviral	B-X
RTs	B-X
being	B-X
the	B-X
most	B-X
faithful	B-X
enzymes	B-X
.	B-X
Wild-type	B-X
HIV-1	B-X
group	B-X
O	B-X
(	B-X
HIV-1O	B-X
)	B-X
RT	B-X
is	B-X
a	B-X
thermostable	B-X
polymerase	B-X
that	B-X
is	B-X
able	B-X
to	B-X
synthesize	B-X
cDNA	B-X
at	B-X
temperatures	B-X
as	B-X
high	B-X
as	B-X
70	B-X
°C	B-X
.	B-X
At	B-X
37	B-X
°C	B-X
,	B-X
its	B-X
error	B-X
rate	B-X
has	B-X
been	B-X
estimated	B-X
at	B-X
5.8	B-X
×	B-X
10	B-X
(	B-X
-5	B-X
)	B-X
in	B-X
M13mp2	B-X
lacZ-based	B-X
forward	B-X
mutation	B-X
assays	B-X
.	B-X
50	B-X
and	B-X
55	B-X
°C	B-X
)	B-X
,	B-X
the	B-X
accuracy	B-X
of	B-X
HIV-1O	B-X
RT	B-X
is	B-X
increased	B-X
by	B-X
approximately	B-X
two-	B-X
to	B-X
five-fold	B-X
.	B-X
At	B-X
55	B-X
°C	B-X
,	B-X
the	B-X
HIV-1O	B-X
RT	B-X
error	B-X
rate	B-X
(	B-X
1.3	B-X
×	B-X
10	B-X
(	B-X
-5	B-X
)	B-X
)	B-X
was	B-X
similar	B-X
to	B-X
that	B-X
shown	B-X
by	B-X
the	B-X
AffinityScript	B-X
(	B-X
Agilent	B-X
Technologies	B-X
Inc.	B-X
,	B-X
La	B-X
Jolla	B-X
,	B-X
CA	B-X
,	B-X
USA	B-X
)	B-X
RT	B-X
,	B-X
a	B-X
commercially	B-X
available	B-X
thermostable	B-X
murine	B-X
leukaemia	B-X
virus	B-X
RT	B-X
.	B-X
At	B-X
higher	B-X
temperatures	B-X
,	B-X
the	B-X
increased	B-X
accuracy	B-X
of	B-X
the	B-X
HIV-1	B-X
enzyme	B-X
results	B-X
from	B-X
a	B-X
lower	B-X
base	B-X
substitution	B-X
error	B-X
rate	B-X
,	B-X
although	B-X
it	B-X
shows	B-X
a	B-X
higher	B-X
tendency	B-X
to	B-X
introduce	B-X
frameshifts	B-X
.	B-X
Kinetic	B-X
studies	B-X
carried	B-X
out	B-X
with	B-X
model	B-X
template-primers	B-X
suggest	B-X
minor	B-X
differences	B-X
in	B-X
nucleotide	B-X
discrimination	B-X
,	B-X
although	B-X
,	B-X
at	B-X
higher	B-X
temperatures	B-X
,	B-X
HIV-1O	B-X
RT	B-X
showed	B-X
a	B-X
reduced	B-X
ability	B-X
to	B-X
extend	B-X
mispaired	B-X
template-primers	B-X
.	B-X

The	O
products	O
were	O
cloned	O
with	O
the	O
'	O
TOPO	O
TA	O
cloning	O
kit	O
'	O
(	O
Invitrogen	O
,	O
Groningen	O
,	O
The	O
Netherlands	O
)	O
.	O

After	O
bacterial	O
amplification	O
of	O
the	O
cloned	O
PCR	O
fragments	O
by	O
standard	O
procedures	O
,	O
at	O
least	O
three	O
clones	O
from	O
each	O
sample	O
were	O
sequenced	O
with	O
an	O
automated	O
sequencer	O
(	O
ABI	O
Prism	O
377	O
,	O
Applied	O
Bio	O
-	O
systems	O
,	O
Foster	O
City	O
,	O
USA	O
)	O
as	O
recommended	O
by	O
the	O
manufacturer	O
.	O

Expression	O
analysis	O
<EOS>	B-X
The	B-X
reviewed	B-X
methods	B-X
cover	B-X
both	B-X
marginal	B-X
and	B-X
joint	B-X
analysis	B-X
and	B-X
supervised	B-X
and	B-X
unsupervised	B-X
analysis	B-X
.	B-X
Recent	B-X
technical	B-X
advances	B-X
and	B-X
improvements	B-X
are	B-X
accelerating	B-X
the	B-X
analysis	B-X
of	B-X
gene-expression	B-X
profiles	B-X
at	B-X
the	B-X
transcript	B-X
level	B-X
.	B-X
Advances	B-X
have	B-X
been	B-X
made	B-X
in	B-X
approaches	B-X
to	B-X
the	B-X
collection	B-X
of	B-X
cellular	B-X
material	B-X
and	B-X
the	B-X
performance	B-X
of	B-X
single-cell	B-X
gene	B-X
expression	B-X
analysis	B-X
.	B-X
The	B-X
temporal	B-X
and	B-X
quantitative	B-X
analysis	B-X
of	B-X
gene	B-X
expression	B-X
is	B-X
essential	B-X
to	B-X
fully	B-X
exploit	B-X
these	B-X
datasets	B-X
and	B-X
define	B-X
the	B-X
biology	B-X
of	B-X
the	B-X
parasite	B-X
at	B-X
the	B-X
molecular	B-X
level	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
application	B-X
of	B-X
serial	B-X
analysis	B-X
of	B-X
gene	B-X
expression	B-X
(	B-X
SAGE	B-X
)	B-X
for	B-X
this	B-X
purpose	B-X
.	B-X
SAGE	B-X
is	B-X
a	B-X
technique	B-X
that	B-X
allows	B-X
the	B-X
rapid	B-X
,	B-X
quantitative	B-X
analysis	B-X
of	B-X
thousands	B-X
of	B-X
transcripts	B-X
.	B-X
It	B-X
complements	B-X
microarray	B-X
analysis	B-X
with	B-X
the	B-X
advantage	B-X
that	B-X
it	B-X
is	B-X
affordable	B-X
for	B-X
standard	B-X
laboratories	B-X
.	B-X

To	O
analyze	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
transcriptional	O
level	O
,	O
RNA	O
was	O
extracted	O
from	O
cells	O
using	O
the	O
commercial	O
RNAzol	O
-	O
kit	O
(	O
Paesel	O
,	O
Frankfurt	O
,	O
Germany	O
)	O
.	O

An	O
aliquot	O
of	O
1	O
mug	O
total	O
RNA	O
was	O
used	O
for	O
cDNA	O
synthesis	O
as	O
described	O
previously	O
(	O
27	O
)	O
.	O

RNA	O
expression	O
analysis	O
for	O
IRF	B-Protein
-	I-Protein
4	I-Protein
and	O
the	O
reference	O
gene	O
beta	B-Protein
-	I-Protein
actin	I-Protein
was	O
carried	O
out	O
by	O
semi	O
-	O
quantitative	O
PCR	O
as	O
described	O
previously	O
(	O
3	O
,	O
27	O
)	O
.	O

PCR	O
products	O
were	O
verified	O
by	O
automated	O
sequencing	O
.	O
<EOS>	B-X
Automated	B-X
repetitive	B-X
PCR	B-X
(	B-X
rep-PCR	B-X
;	B-X
DiversiLab	B-X
)	B-X
was	B-X
compared	B-X
to	B-X
PCR	B-X
ribotyping	B-X
of	B-X
the	B-X
16S-23S	B-X
RNA	B-X
intergenic	B-X
spacer	B-X
of	B-X
Clostridium	B-X
difficile	B-X
(	B-X
CD	B-X
)	B-X
as	B-X
the	B-X
``	B-X
gold	B-X
standard	B-X
''	B-X
method	B-X
for	B-X
CD	B-X
typing	B-X
.	B-X
PCR	B-X
products	B-X
were	B-X
separated	B-X
on	B-X
DiversiLab	B-X
LabChips	B-X
(	B-X
bioMérieux	B-X
,	B-X
St.	B-X
Laurent	B-X
,	B-X
Quebec	B-X
,	B-X
Canada	B-X
)	B-X
utilizing	B-X
a	B-X
2100	B-X
Bioanalyzer	B-X
(	B-X
Agilent	B-X
Technologies	B-X
,	B-X
Santa	B-X
Clara	B-X
,	B-X
CA	B-X
)	B-X
operating	B-X
the	B-X
DiversiLab	B-X
v1.4	B-X
assay	B-X
.	B-X
Replicability	B-X
of	B-X
each	B-X
method	B-X
was	B-X
verified	B-X
by	B-X
confirming	B-X
that	B-X
the	B-X
5	B-X
CD	B-X
reference	B-X
strains	B-X
(	B-X
RS	B-X
)	B-X
formed	B-X
distinct	B-X
clusters	B-X
(	B-X
CD4	B-X
,	B-X
CD6	B-X
,	B-X
VL0047	B-X
,	B-X
VL0013	B-X
[	B-X
ribotype	B-X
027	B-X
]	B-X
,	B-X
VL0018	B-X
[	B-X
ribotype	B-X
001	B-X
]	B-X
)	B-X
by	B-X
both	B-X
typing	B-X
methods	B-X
.	B-X
A	B-X
similarity	B-X
index	B-X
(	B-X
SI	B-X
)	B-X
of	B-X
≥90	B-X
%	B-X
was	B-X
used	B-X
to	B-X
define	B-X
clusters	B-X
when	B-X
comparing	B-X
the	B-X
known	B-X
RS	B-X
cluster	B-X
to	B-X
the	B-X
PCR	B-X
ribotyping	B-X
and	B-X
rep-PCR	B-X
patterns	B-X
of	B-X
CS	B-X
.	B-X
Fourteen	B-X
different	B-X
PCR-ribotype	B-X
clusters	B-X
were	B-X
identified	B-X
,	B-X
but	B-X
most	B-X
CS	B-X
formed	B-X
4	B-X
major	B-X
clusters	B-X
(	B-X
i.e.	B-X
,	B-X
CD4	B-X
[	B-X
15/90	B-X
;	B-X
17	B-X
%	B-X
]	B-X
,	B-X
CD6	B-X
[	B-X
17	B-X
%	B-X
]	B-X
,	B-X
027	B-X
[	B-X
12	B-X
%	B-X
]	B-X
,	B-X
and	B-X
001	B-X
[	B-X
9	B-X
%	B-X
]	B-X
)	B-X
.	B-X
A	B-X
total	B-X
of	B-X
7	B-X
rep-PCR	B-X
types	B-X
were	B-X
identified	B-X
,	B-X
but	B-X
most	B-X
CS	B-X
formed	B-X
2	B-X
major	B-X
rep-PCR	B-X
clusters	B-X
(	B-X
i.e.	B-X
,	B-X
CD4	B-X
[	B-X
29/90	B-X
;	B-X
32	B-X
%	B-X
]	B-X
and	B-X
CD6	B-X
[	B-X
23	B-X
%	B-X
]	B-X
)	B-X
;	B-X
several	B-X
PCR	B-X
ribotypes	B-X
occurred	B-X
within	B-X
a	B-X
single	B-X
rep-PCR	B-X
cluster	B-X
.	B-X
Rep-PCR	B-X
did	B-X
not	B-X
distinguish	B-X
027	B-X
or	B-X
001	B-X
isolates	B-X
;	B-X
i	B-X
)	B-X
027	B-X
RS	B-X
strain	B-X
did	B-X
not	B-X
cluster	B-X
,	B-X
ii	B-X
)	B-X
eleven	B-X
027	B-X
CS	B-X
strains	B-X
clustered	B-X
as	B-X
CD4	B-X
,	B-X
iii	B-X
)	B-X
no	B-X
027	B-X
CS	B-X
strains	B-X
clustered	B-X
with	B-X
the	B-X
027	B-X
RS	B-X
,	B-X
and	B-X
iv	B-X
)	B-X
only	B-X
2	B-X
001	B-X
CS	B-X
clustered	B-X
with	B-X
the	B-X
RS	B-X
.	B-X
Agreement	B-X
between	B-X
the	B-X
PCR-ribotype	B-X
and	B-X
rep-PCR	B-X
clusters	B-X
only	B-X
occurred	B-X
for	B-X
35/90	B-X
(	B-X
39	B-X
%	B-X
)	B-X
of	B-X
the	B-X
CS	B-X
using	B-X
a	B-X
rep-PCR	B-X
SI	B-X
of	B-X
≥90	B-X
%	B-X
.	B-X
Rep-PCR	B-X
time	B-X
to	B-X
results	B-X
was	B-X
similar	B-X
,	B-X
but	B-X
the	B-X
annual	B-X
costs	B-X
of	B-X
routinely	B-X
using	B-X
this	B-X
method	B-X
are	B-X
32	B-X
%	B-X
higher	B-X
than	B-X
PCR	B-X
ribotyping	B-X
.	B-X
Routine	B-X
use	B-X
of	B-X
rep-PCR	B-X
for	B-X
CD	B-X
typing	B-X
is	B-X
limited	B-X
by	B-X
its	B-X
lack	B-X
of	B-X
definitive	B-X
separation	B-X
of	B-X
the	B-X
hypertoxigenic	B-X
027	B-X
or	B-X
001	B-X
outbreak	B-X
CD	B-X
strains	B-X
.	B-X

PCR	O
primers	O
and	O
conditions	O
for	O
expression	O
analysis	O
of	O
DNMT	O
or	O
MBP	O
(	B-Protein
DNMT1	I-Protein
DNMT3A	B-Protein
,	O
DNMT3B	B-Protein
,	O
MeCP	B-Protein
,	O
MBD1	B-Protein
,	O
MBD2	B-Protein
and	O
MBD4	B-Protein
)	O
were	O
published	O
elsewhere	O
(	O
28	O
)	O
.	O

For	O
analysis	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
protein	O
expression	O
,	O
a	O
standard	O
immunoblotting	O
assay	O
was	O
performed	O
as	O
described	O
previously	O
(	O
29	O
)	O
.	O

Briefly	O
,	O
protein	O
lysates	O
were	O
generated	O
by	O
incubating	O
1	O
x	O
106	O
cells	O
in	O
100	O
microl	O
RIPA	O
buffer	O
(	O
1	O
%	O
NP	O
-	O
40	O
,	O
0	O
.	O
5	O
%	O
sodiumdesoxycholate	O
,	O
0	O
.	O
1	O
%	O
SDS	O
,	O
100	O
microg	O
/	O
ml	O
phenylmethylsulfonyl	O
fluoride	O
,	O
10	O
microl	O
/	O
ml	O
protease	O
-	O
inhibitory	O
-	O
mix	O
,	O
1	O
micromol	O
/	O
ml	O
sodiumorthovanadate	O
in	O
phosphate	O
-	O
buffered	O
saline	O
)	O
for	O
30	O
min	O
on	O
ice	O
.	O

After	O
centrifugation	O
,	O
protein	O
concentration	O
of	O
the	O
supernatant	O
was	O
determined	O
by	O
BCA	O
-	O
method	O
(	O
Pierce	O
,	O
Rockford	O
,	O
IL	O
)	O
as	O
recommended	O
.	O

Protein	O
lysates	O
(	O
70	O
-	O
100	O
microg	O
)	O
were	O
electrophoresed	O
on	O
polyacrylamide	O
gels	O
and	O
transferred	O
to	O
a	O
PVDF	O
-	O
membrane	O
(	O
Immobilon	O
P	O
,	O
0	O
.	O
45	O
microm	O
;	O
Millipore	O
,	O
Eschborn	O
,	O
Germany	O
)	O
.	O

Membranes	O
were	O
blocked	O
with	O
2	O
.	O
5	O
%	O
blocking	O
reagent	O
(	O
Boehringer	O
Mannheim	O
,	O
Germany	O
)	O
in	O
TBST	O
buffer	O
(	O
4	O
.	O
44	O
g	O
/	O
l	O
Tris	O
-	O
HCL	O
,	O
2	O
.	O
65	O
g	O
/	O
l	O
TrisOH	O
,	O
8	O
.	O
07	O
g	O
/	O
l	O
NaCl	O
,	O
0	O
.	O
2	O
g	O
/	O
l	O
KCl	O
and	O
500	O
microl	O
/	O
l	O
Tween	O
-	O
20	O
in	O
H2O	O
)	O
and	O
subsequently	O
incubated	O
with	O
primary	O
antibody	O
as	O
indicated	O
and	O
horseradish	O
peroxidase	O
-	O
conjugated	O
secondary	O
antibody	O
,	O
anti	O
-	O
mouse	O
or	O
anti	O
-	O
goat	O
IgG	O
(	O
DAKO	O
,	O
Hamburg	O
,	O
Germany	O
)	O
,	O
respectively	O
.	O

The	O
membranes	O
were	O
then	O
developed	O
with	O
an	O
ECL	O
detection	O
kit	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
,	O
Freiburg	O
,	O
Germany	O
)	O
.	O

The	O
primary	O
antibodies	O
were	O
goat	O
anti	O
-	O
IRF	B-Protein
-	I-Protein
4	I-Protein
/	O
ICSAT	B-Protein
(	O
M	B-Protein
-	I-Protein
17	I-Protein
)	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
CA	O
)	O
and	O
mouse	O
anti	O
-	O
beta	B-Protein
-	I-Protein
actin	I-Protein
(	O
AC	O
-	O
74	O
)	O
(	O
Sigma	O
)	O
.	O

Methylation	O
-	O
specific	O
restriction	O
-	O
PCR	O
-	O
assay	O
<EOS>	B-X
We	B-X
describe	B-X
a	B-X
new	B-X
method	B-X
,	B-X
MSP	B-X
(	B-X
methylation-specific	B-X
PCR	B-X
)	B-X
,	B-X
which	B-X
can	B-X
rapidly	B-X
assess	B-X
the	B-X
methylation	B-X
status	B-X
of	B-X
virtually	B-X
any	B-X
group	B-X
of	B-X
CpG	B-X
sites	B-X
within	B-X
a	B-X
CpG	B-X
island	B-X
,	B-X
independent	B-X
of	B-X
the	B-X
use	B-X
of	B-X
methylation-sensitive	B-X
restriction	B-X
enzymes	B-X
.	B-X
This	B-X
assay	B-X
entails	B-X
initial	B-X
modification	B-X
of	B-X
DNA	B-X
by	B-X
sodium	B-X
bisulfite	B-X
,	B-X
converting	B-X
all	B-X
unmethylated	B-X
,	B-X
but	B-X
not	B-X
methylated	B-X
,	B-X
cytosines	B-X
to	B-X
uracil	B-X
,	B-X
and	B-X
subsequent	B-X
amplification	B-X
with	B-X
primers	B-X
specific	B-X
for	B-X
methylated	B-X
versus	B-X
unmethylated	B-X
DNA	B-X
.	B-X
MSP	B-X
eliminates	B-X
the	B-X
false	B-X
positive	B-X
results	B-X
inherent	B-X
to	B-X
previous	B-X
PCR-based	B-X
approaches	B-X
which	B-X
relied	B-X
on	B-X
differential	B-X
restriction	B-X
enzyme	B-X
cleavage	B-X
to	B-X
distinguish	B-X
methylated	B-X
from	B-X
unmethylated	B-X
DNA	B-X
.	B-X
Methylation	B-X
of	B-X
5-methylcytosine	B-X
(	B-X
5mC	B-X
)	B-X
is	B-X
widespread	B-X
in	B-X
both	B-X
eukaryotes	B-X
and	B-X
prokaryotes	B-X
,	B-X
and	B-X
it	B-X
is	B-X
a	B-X
very	B-X
important	B-X
epigenetic	B-X
modification	B-X
event	B-X
,	B-X
which	B-X
can	B-X
regulate	B-X
gene	B-X
activity	B-X
and	B-X
influence	B-X
a	B-X
number	B-X
of	B-X
key	B-X
processes	B-X
such	B-X
as	B-X
genomic	B-X
imprinting	B-X
,	B-X
cell	B-X
differentiation	B-X
,	B-X
transcriptional	B-X
regulation	B-X
,	B-X
and	B-X
chromatin	B-X
remodeling	B-X
.	B-X

DNA	O
was	O
extracted	O
with	O
a	O
commercial	O
kit	O
(	O
Qiagen	O
)	O
as	O
recommended	O
.	O
<EOS>	B-X
The	B-X
quantity	B-X
and	B-X
quality	B-X
of	B-X
DNA	B-X
required	B-X
for	B-X
Nanopore	B-X
sequencing	B-X
are	B-X
greater	B-X
than	B-X
for	B-X
Illumina	B-X
,	B-X
and	B-X
the	B-X
DNA	B-X
extraction	B-X
methods	B-X
recommended	B-X
for	B-X
obtaining	B-X
high-molecular-weight	B-X
DNA	B-X
are	B-X
different	B-X
from	B-X
those	B-X
typically	B-X
used	B-X
in	B-X
diagnostic	B-X
laboratories	B-X
.	B-X
However	B-X
,	B-X
latent	B-X
examination	B-X
is	B-X
not	B-X
always	B-X
successful	B-X
and	B-X
trace	B-X
human	B-X
DNA	B-X
can	B-X
not	B-X
always	B-X
be	B-X
obtained	B-X
.	B-X
The	B-X
Zymo	B-X
Research	B-X
ZR	B-X
Bacterial/Fungal	B-X
DNA	B-X
MicroPrep™	B-X
Kit	B-X
,	B-X
Qiagen	B-X
QIAmp	B-X
This	B-X
work	B-X
evaluates	B-X
a	B-X
nondestructive	B-X
method	B-X
for	B-X
sampling	B-X
DNA	B-X
from	B-X
blood	B-X
puncture	B-X
,	B-X
comparing	B-X
the	B-X
performance	B-X
of	B-X
three	B-X
different	B-X
extraction	B-X
protocols	B-X
(	B-X
Qiagen	B-X
Kit	B-X
,	B-X
Salting-out	B-X
and	B-X
Chelex	B-X
)	B-X
.	B-X
We	B-X
collected	B-X
134	B-X
individuals	B-X
of	B-X
Eleutherodactylus	B-X
johnstonei	B-X
,	B-X
extracting	B-X
blood	B-X
via	B-X
puncture	B-X
of	B-X
the	B-X
medial	B-X
vein	B-X
using	B-X
commercial-grade	B-X
glucometer	B-X
lancets	B-X
.	B-X
We	B-X
extracted	B-X
100-1880	B-X
ng	B-X
DNA	B-X
,	B-X
finding	B-X
no	B-X
differences	B-X
between	B-X
the	B-X
extraction	B-X
protocols	B-X
.	B-X
We	B-X
compared	B-X
the	B-X
quality	B-X
of	B-X
the	B-X
resulting	B-X
DNA	B-X
through	B-X
amplification	B-X
and	B-X
sequencing	B-X
of	B-X
the	B-X
16S	B-X
mitochondrial	B-X
gene	B-X
.	B-X
Amplification	B-X
was	B-X
successful	B-X
for	B-X
the	B-X
three	B-X
extraction	B-X
protocols	B-X
,	B-X
although	B-X
Chelex	B-X
showed	B-X
better	B-X
performance	B-X
,	B-X
making	B-X
it	B-X
the	B-X
most	B-X
recommendable	B-X
protocol	B-X
for	B-X
extraction	B-X
of	B-X
DNA	B-X
from	B-X
blood	B-X
.	B-X
Data	B-X
reveal	B-X
that	B-X
blood	B-X
samples	B-X
obtained	B-X
by	B-X
puncture	B-X
are	B-X
a	B-X
convenient	B-X
alternative	B-X
to	B-X
other	B-X
tissues	B-X
(	B-X
phalange	B-X
,	B-X
buccal	B-X
swab	B-X
,	B-X
liver	B-X
)	B-X
that	B-X
have	B-X
traditionally	B-X
been	B-X
used	B-X
as	B-X
DNA	B-X
sources	B-X
for	B-X
anurans	B-X
.	B-X
The	B-X
technique	B-X
is	B-X
applicable	B-X
to	B-X
small	B-X
and	B-X
large	B-X
species	B-X
,	B-X
covering	B-X
most	B-X
anuran	B-X
diversity	B-X
,	B-X
provides	B-X
enough	B-X
DNA	B-X
for	B-X
many	B-X
genetic	B-X
applications	B-X
and	B-X
produces	B-X
no	B-X
noticeable	B-X
effect	B-X
on	B-X
the	B-X
survival	B-X
or	B-X
performance	B-X
,	B-X
given	B-X
that	B-X
it	B-X
does	B-X
not	B-X
affect	B-X
the	B-X
motor	B-X
parts	B-X
or	B-X
the	B-X
dexterity	B-X
of	B-X
the	B-X
animals	B-X
.	B-X

Since	O
the	O
restriction	O
ability	O
of	O
several	O
endonucleases	O
is	O
inhibited	O
by	O
methylation	O
of	O
their	O
target	O
sequence	O
,	O
we	O
used	O
methylation	O
-	O
sensitive	O
enzymes	O
HpaII	O
and	O
HaeII	O
-	O
isochizomer	O
Bsp143II	O
and	O
Bsh1236I	O
(	O
MBI	O
Fermentas	O
,	O
St	O
Leon	O
-	O
Rot	O
,	O
Germany	O
)	O
(	O
20	O
,	O
24	O
)	O
.	O

As	O
control	O
the	O
methylation	O
-	O
resistant	O
enzyme	O
MspI	O
and	O
an	O
enzyme	O
with	O
no	O
recognition	O
site	O
in	O
the	O
target	O
promoter	O
,	O
EcoRI	O
,	O
were	O
used	O
.	O

DNA	O
(	O
0	O
.	O
8	O
microg	O
)	O
was	O
digested	O
by	O
40	O
U	O
the	O
respective	O
enzyme	O
for	O
6	O
h	O
and	O
,	O
to	O
ensure	O
complete	O
cleavage	O
,	O
additional	O
20	O
U	O
for	O
16	O
h	O
.	O

Thereafter	O
100	O
ng	O
of	O
digested	O
DNA	O
was	O
used	O
to	O
a	O
PCR	O
amplification	O
of	O
two	O
fragments	O
(	O
F1	O
and	O
F2	O
)	O
spanning	O
part	O
of	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
(	O
30	O
)	O
(	O
GenBank	O
U52683	O
;	O
see	O
Figure	O
3A	O
)	O
.	O

The	O
sequences	O
of	O
the	O
primers	O
were	O
F1	O
-	O
forward	O
:	O
5	O
'	O
-	O
TTGAGATGGAGTCTTGCTCTGT	O
-	O
3	O
'	O
,	O
F1	O
-	O
reverse	O
:	O
ATCACTTCCAGACTTCAGTTCACCT	O
-	O
3	O
'	O
(	O
341	O
bp	O
)	O
;	O
F2	O
-	O
forward	O
:	O
5	O
'	O
-	O
AAGGTGAACTGAAGTCTGGAAGTGA	O
-	O
3	O
'	O
,	O
F2	O
-	O
reverse	O
:	O
5	O
'	O
-	O
CCAGGACCTCAGGAGGCCAGTCA	O
-	O
3	O
'	O
(	O
474	O
bp	O
)	O
.	O

The	O
PCR	O
conditions	O
were	O
described	O
elsewhere	O
(	O
3	O
)	O
.	O
<EOS>	B-X
WAC13435	B-X
)	B-X
.	B-X
Amplification	B-X
of	B-X
the	B-X
internal	B-X
transcribed	B-X
spacer	B-X
(	B-X
ITS	B-X
)	B-X
1	B-X
and	B-X
ITS2	B-X
regions	B-X
flanking	B-X
the	B-X
5.8S	B-X
rRNA	B-X
gene	B-X
were	B-X
carried	B-X
out	B-X
with	B-X
universal	B-X
primers	B-X
ITS1	B-X
and	B-X
ITS4	B-X
according	B-X
to	B-X
published	B-X
protocol	B-X
(	B-X
3	B-X
)	B-X
.	B-X
The	B-X
DNA	B-X
PCR	B-X
products	B-X
were	B-X
sequenced	B-X
and	B-X
BLAST	B-X
analyses	B-X
was	B-X
used	B-X
to	B-X
compare	B-X
sequences	B-X
with	B-X
those	B-X
in	B-X
GenBank	B-X
.	B-X
Isolates	B-X
also	B-X
showed	B-X
morphological	B-X
(	B-X
e.g.	B-X
,	B-X
1	B-X
)	B-X
and	B-X
molecular	B-X
(	B-X
e.g.	B-X
,	B-X
2	B-X
)	B-X
similarities	B-X
with	B-X
P.	B-X
herbarum	B-X
as	B-X
described	B-X
in	B-X
other	B-X
reports	B-X
.	B-X

PCR	O
was	O
performed	O
with	O
an	O
annealing	O
temperature	O
of	O
62degreesC	O
and	O
35	O
cycles	O
.	O

When	O
DNA	O
was	O
methylated	O
at	O
specific	O
sites	O
,	O
the	O
sensitive	O
enzymes	O
were	O
not	O
able	O
to	O
digest	O
the	O
DNA	O
and	O
amplification	O
took	O
place	O
;	O
in	O
case	O
of	O
no	O
methylation	O
,	O
DNA	O
was	O
digested	O
and	O
no	O
product	O
was	O
generated	O
.	O
<EOS>	B-X
The	B-X
Streptococcus	B-X
pyogenes	B-X
Cas9	B-X
(	B-X
SpCas9	B-X
)	B-X
nuclease	B-X
can	B-X
be	B-X
efficiently	B-X
targeted	B-X
to	B-X
genomic	B-X
loci	B-X
by	B-X
means	B-X
of	B-X
single-guide	B-X
RNAs	B-X
(	B-X
sgRNAs	B-X
)	B-X
to	B-X
enable	B-X
genome	B-X
editing	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
characterize	B-X
SpCas9	B-X
targeting	B-X
specificity	B-X
in	B-X
human	B-X
cells	B-X
to	B-X
inform	B-X
the	B-X
selection	B-X
of	B-X
target	B-X
sites	B-X
and	B-X
avoid	B-X
off-target	B-X
effects	B-X
.	B-X
We	B-X
find	B-X
that	B-X
SpCas9	B-X
tolerates	B-X
mismatches	B-X
between	B-X
guide	B-X
RNA	B-X
and	B-X
target	B-X
DNA	B-X
at	B-X
different	B-X
positions	B-X
in	B-X
a	B-X
sequence-dependent	B-X
manner	B-X
,	B-X
sensitive	B-X
to	B-X
the	B-X
number	B-X
,	B-X
position	B-X
and	B-X
distribution	B-X
of	B-X
mismatches	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
SpCas9-mediated	B-X
cleavage	B-X
is	B-X
unaffected	B-X
by	B-X
DNA	B-X
methylation	B-X
and	B-X
that	B-X
the	B-X
dosage	B-X
of	B-X
SpCas9	B-X
and	B-X
sgRNA	B-X
can	B-X
be	B-X
titrated	B-X
to	B-X
minimize	B-X
off-target	B-X
modification	B-X
.	B-X

The	O
PCR	O
products	O
were	O
electrophoresed	O
on	O
a	O
3	O
%	O
agarose	O
gel	O
,	O
were	O
stained	O
with	O
ethidium	O
bromide	O
and	O
photographed	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
epidemiological	B-X
status	B-X
of	B-X
cutaneous	B-X
leishmaniasis	B-X
outbreak	B-X
,	B-X
isolation	B-X
and	B-X
identification	B-X
of	B-X
the	B-X
agent	B-X
parasite	B-X
,	B-X
Leishmania	B-X
,	B-X
using	B-X
PCR	B-X
method	B-X
in	B-X
Gonbad-e	B-X
Qabus	B-X
County	B-X
,	B-X
north	B-X
Iran	B-X
,	B-X
during	B-X
2006-2007	B-X
.	B-X
A	B-X
reverse	B-X
transcription	B-X
(	B-X
RT	B-X
)	B-X
and	B-X
competitive	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
amplification	B-X
technique	B-X
was	B-X
developed	B-X
to	B-X
quantify	B-X
bovine	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
mRNA	B-X
.	B-X
A	B-X
bovine	B-X
TNF-alpha	B-X
cDNA	B-X
insert	B-X
containing	B-X
plasmid	B-X
was	B-X
used	B-X
to	B-X
produce	B-X
a	B-X
237-bp	B-X
cDNA	B-X
competitive	B-X
template	B-X
which	B-X
,	B-X
when	B-X
PCR-amplified	B-X
with	B-X
primers	B-X
designed	B-X
to	B-X
amplify	B-X
bovine	B-X
TNF-alpha	B-X
cDNA	B-X
,	B-X
resulted	B-X
in	B-X
a	B-X
147-bp	B-X
product	B-X
distinguishable	B-X
by	B-X
agarose	B-X
gel	B-X
electrophoresis	B-X
from	B-X
the	B-X
378-bp	B-X
TNF-alpha	B-X
RT-PCR-amplified	B-X
cDNA	B-X
product	B-X
.	B-X
Products	B-X
were	B-X
separated	B-X
in	B-X
ethidium-bromide-stained	B-X
agarose	B-X
gels	B-X
and	B-X
relative	B-X
amounts	B-X
of	B-X
TNF-alpha	B-X
mRNA	B-X
were	B-X
determined	B-X
by	B-X
densitometric	B-X
scanning	B-X
of	B-X
TNF-alpha	B-X
cDNA	B-X
and	B-X
competitive	B-X
template	B-X
product	B-X
bands	B-X
on	B-X
photographic	B-X
negatives	B-X
.	B-X
Digestions	B-X
with	B-X
Pvu	B-X
II	B-X
and	B-X
Sty	B-X
I	B-X
restriction	B-X
endonucleases	B-X
verified	B-X
that	B-X
RT-PCR-amplified	B-X
TNF-alpha	B-X
cDNA	B-X
products	B-X
were	B-X
authentic	B-X
.	B-X
A	B-X
time	B-X
study	B-X
indicated	B-X
that	B-X
TNF-alpha	B-X
mRNA	B-X
concentrations	B-X
peaked	B-X
3	B-X
h	B-X
after	B-X
endotoxin	B-X
and	B-X
virus	B-X
induction	B-X
of	B-X
BAMs	B-X
.	B-X

PCR	O
products	O
were	O
verified	O
by	O
automated	O
sequencing	O
.	O
<EOS>	B-X
Automated	B-X
repetitive	B-X
PCR	B-X
(	B-X
rep-PCR	B-X
;	B-X
DiversiLab	B-X
)	B-X
was	B-X
compared	B-X
to	B-X
PCR	B-X
ribotyping	B-X
of	B-X
the	B-X
16S-23S	B-X
RNA	B-X
intergenic	B-X
spacer	B-X
of	B-X
Clostridium	B-X
difficile	B-X
(	B-X
CD	B-X
)	B-X
as	B-X
the	B-X
``	B-X
gold	B-X
standard	B-X
''	B-X
method	B-X
for	B-X
CD	B-X
typing	B-X
.	B-X
PCR	B-X
products	B-X
were	B-X
separated	B-X
on	B-X
DiversiLab	B-X
LabChips	B-X
(	B-X
bioMérieux	B-X
,	B-X
St.	B-X
Laurent	B-X
,	B-X
Quebec	B-X
,	B-X
Canada	B-X
)	B-X
utilizing	B-X
a	B-X
2100	B-X
Bioanalyzer	B-X
(	B-X
Agilent	B-X
Technologies	B-X
,	B-X
Santa	B-X
Clara	B-X
,	B-X
CA	B-X
)	B-X
operating	B-X
the	B-X
DiversiLab	B-X
v1.4	B-X
assay	B-X
.	B-X
Replicability	B-X
of	B-X
each	B-X
method	B-X
was	B-X
verified	B-X
by	B-X
confirming	B-X
that	B-X
the	B-X
5	B-X
CD	B-X
reference	B-X
strains	B-X
(	B-X
RS	B-X
)	B-X
formed	B-X
distinct	B-X
clusters	B-X
(	B-X
CD4	B-X
,	B-X
CD6	B-X
,	B-X
VL0047	B-X
,	B-X
VL0013	B-X
[	B-X
ribotype	B-X
027	B-X
]	B-X
,	B-X
VL0018	B-X
[	B-X
ribotype	B-X
001	B-X
]	B-X
)	B-X
by	B-X
both	B-X
typing	B-X
methods	B-X
.	B-X
A	B-X
similarity	B-X
index	B-X
(	B-X
SI	B-X
)	B-X
of	B-X
≥90	B-X
%	B-X
was	B-X
used	B-X
to	B-X
define	B-X
clusters	B-X
when	B-X
comparing	B-X
the	B-X
known	B-X
RS	B-X
cluster	B-X
to	B-X
the	B-X
PCR	B-X
ribotyping	B-X
and	B-X
rep-PCR	B-X
patterns	B-X
of	B-X
CS	B-X
.	B-X
Fourteen	B-X
different	B-X
PCR-ribotype	B-X
clusters	B-X
were	B-X
identified	B-X
,	B-X
but	B-X
most	B-X
CS	B-X
formed	B-X
4	B-X
major	B-X
clusters	B-X
(	B-X
i.e.	B-X
,	B-X
CD4	B-X
[	B-X
15/90	B-X
;	B-X
17	B-X
%	B-X
]	B-X
,	B-X
CD6	B-X
[	B-X
17	B-X
%	B-X
]	B-X
,	B-X
027	B-X
[	B-X
12	B-X
%	B-X
]	B-X
,	B-X
and	B-X
001	B-X
[	B-X
9	B-X
%	B-X
]	B-X
)	B-X
.	B-X
A	B-X
total	B-X
of	B-X
7	B-X
rep-PCR	B-X
types	B-X
were	B-X
identified	B-X
,	B-X
but	B-X
most	B-X
CS	B-X
formed	B-X
2	B-X
major	B-X
rep-PCR	B-X
clusters	B-X
(	B-X
i.e.	B-X
,	B-X
CD4	B-X
[	B-X
29/90	B-X
;	B-X
32	B-X
%	B-X
]	B-X
and	B-X
CD6	B-X
[	B-X
23	B-X
%	B-X
]	B-X
)	B-X
;	B-X
several	B-X
PCR	B-X
ribotypes	B-X
occurred	B-X
within	B-X
a	B-X
single	B-X
rep-PCR	B-X
cluster	B-X
.	B-X
Rep-PCR	B-X
did	B-X
not	B-X
distinguish	B-X
027	B-X
or	B-X
001	B-X
isolates	B-X
;	B-X
i	B-X
)	B-X
027	B-X
RS	B-X
strain	B-X
did	B-X
not	B-X
cluster	B-X
,	B-X
ii	B-X
)	B-X
eleven	B-X
027	B-X
CS	B-X
strains	B-X
clustered	B-X
as	B-X
CD4	B-X
,	B-X
iii	B-X
)	B-X
no	B-X
027	B-X
CS	B-X
strains	B-X
clustered	B-X
with	B-X
the	B-X
027	B-X
RS	B-X
,	B-X
and	B-X
iv	B-X
)	B-X
only	B-X
2	B-X
001	B-X
CS	B-X
clustered	B-X
with	B-X
the	B-X
RS	B-X
.	B-X
Agreement	B-X
between	B-X
the	B-X
PCR-ribotype	B-X
and	B-X
rep-PCR	B-X
clusters	B-X
only	B-X
occurred	B-X
for	B-X
35/90	B-X
(	B-X
39	B-X
%	B-X
)	B-X
of	B-X
the	B-X
CS	B-X
using	B-X
a	B-X
rep-PCR	B-X
SI	B-X
of	B-X
≥90	B-X
%	B-X
.	B-X
Rep-PCR	B-X
time	B-X
to	B-X
results	B-X
was	B-X
similar	B-X
,	B-X
but	B-X
the	B-X
annual	B-X
costs	B-X
of	B-X
routinely	B-X
using	B-X
this	B-X
method	B-X
are	B-X
32	B-X
%	B-X
higher	B-X
than	B-X
PCR	B-X
ribotyping	B-X
.	B-X
Routine	B-X
use	B-X
of	B-X
rep-PCR	B-X
for	B-X
CD	B-X
typing	B-X
is	B-X
limited	B-X
by	B-X
its	B-X
lack	B-X
of	B-X
definitive	B-X
separation	B-X
of	B-X
the	B-X
hypertoxigenic	B-X
027	B-X
or	B-X
001	B-X
outbreak	B-X
CD	B-X
strains	B-X
.	B-X

Bisulfite	O
treatment	O
<EOS>	B-X
Bisulfite	B-X
sequencing	B-X
has	B-X
been	B-X
the	B-X
gold	B-X
standard	B-X
for	B-X
mapping	B-X
DNA	B-X
modifications	B-X
including	B-X
5-methylcytosine	B-X
(	B-X
5mC	B-X
)	B-X
and	B-X
5-hydroxymethylcytosine	B-X
(	B-X
5hmC	B-X
)	B-X
for	B-X
decades	B-X
A	B-X
combination	B-X
of	B-X
bisulfite	B-X
treatment	B-X
of	B-X
DNA	B-X
and	B-X
high-throughput	B-X
sequencing	B-X
(	B-X
BS-Seq	B-X
)	B-X
can	B-X
capture	B-X
a	B-X
snapshot	B-X
of	B-X
a	B-X
cell	B-X
's	B-X
epigenomic	B-X
state	B-X
by	B-X
revealing	B-X
its	B-X
genome-wide	B-X
cytosine	B-X
methylation	B-X
at	B-X
single	B-X
base	B-X
resolution	B-X
.	B-X
Non-denaturing	B-X
bisulfite	B-X
treatment	B-X
modifies	B-X
the	B-X
cytosines	B-X
on	B-X
the	B-X
displaced	B-X
strand	B-X
of	B-X
the	B-X
D-loop	B-X
to	B-X
uracil	B-X
,	B-X
leaving	B-X
a	B-X
permanent	B-X
signature	B-X
for	B-X
the	B-X
displaced	B-X
strand	B-X
.	B-X
The	B-X
assays	B-X
presented	B-X
analyse	B-X
the	B-X
methylation	B-X
status	B-X
of	B-X
single	B-X
loci	B-X
and	B-X
are	B-X
based	B-X
either	B-X
on	B-X
a	B-X
bisulphite-treatment	B-X
or	B-X
on	B-X
methylation-sensitive	B-X
restriction	B-X
of	B-X
the	B-X
DNA	B-X
under	B-X
investigation	B-X
.	B-X

DNA	O
was	O
extracted	O
as	O
described	O
above	O
.	O
<EOS>	B-X
We	B-X
also	B-X
provide	B-X
reliable	B-X
real-time	B-X
PCR	B-X
protocols	B-X
to	B-X
titrate	B-X
lentiviral	B-X
vectors	B-X
based	B-X
on	B-X
proviral	B-X
DNA	B-X
copies	B-X
present	B-X
in	B-X
genomic	B-X
DNA	B-X
extracted	B-X
from	B-X
transduced	B-X
cells	B-X
or	B-X
on	B-X
vector	B-X
RNA	B-X
.	B-X
The	B-X
vector	B-X
production	B-X
and	B-X
titration	B-X
protocol	B-X
described	B-X
here	B-X
can	B-X
be	B-X
completed	B-X
within	B-X
8	B-X
d.	B-X
The	B-X
title	B-X
mol-ecule	B-X
,	B-X
C	B-X
(	B-X
18	B-X
)	B-X
H	B-X
(	B-X
20	B-X
)	B-X
O	B-X
(	B-X
3	B-X
)	B-X
,	B-X
is	B-X
a	B-X
furan-oid	B-X
lignan	B-X
extracted	B-X
from	B-X
the	B-X
leaves	B-X
of	B-X
Larrea	B-X
tridentata	B-X
.	B-X
The	B-X
conformation	B-X
of	B-X
this	B-X
ring	B-X
is	B-X
described	B-X
by	B-X
the	B-X
pseudorotation	B-X
phase	B-X
angle	B-X
P	B-X
=	B-X
171.3°	B-X
and	B-X
the	B-X
maximum	B-X
out-of-plane	B-X
pucker	B-X
ν	B-X
(	B-X
m	B-X
)	B-X
=	B-X
37.7°	B-X
.	B-X
These	B-X
parameters	B-X
indicate	B-X
that	B-X
the	B-X
furan	B-X
ring	B-X
adopts	B-X
the	B-X
same	B-X
conformation	B-X
as	B-X
the	B-X
ribose	B-X
residues	B-X
in	B-X
B-DNA	B-X
.	B-X

Bisulfite	O
treatment	O
of	O
DNA	O
,	O
leading	O
to	O
conversion	O
of	O
unmethylated	O
cytosine	O
to	O
uracil	O
residues	O
and	O
no	O
change	O
of	O
methylated	O
cytosine	O
residues	O
,	O
was	O
performed	O
as	O
described	O
as	O
follows	O
.	O

Briefly	O
,	O
1	O
microg	O
of	O
DNA	O
and	O
2	O
microg	O
of	O
poly	O
(	O
dA	O
-	O
dT	O
)	O
(	O
poly	O
(	O
dA	O
-	O
dT	O
)	O
copolymers	O
(	O
Amersham	O
Pharmacia	O
Biotech	O
)	O
were	O
denaturated	O
for	O
20	O
min	O
at	O
42degreesC	O
in	O
0	O
.	O
3	O
M	O
NaOH	O
in	O
a	O
volume	O
of	O
50	O
microl	O
.	O

Fresh	O
solutions	O
of	O
30	O
microl	O
of	O
10	O
mM	O
hydrochinon	O
(	O
Sigma	O
)	O
and	O
530	O
microl	O
of	O
3	O
M	O
sodium	O
bisulfite	O
(	O
pH	O
5	O
.	O
0	O
;	O
Sigma	O
)	O
were	O
added	O
,	O
the	O
solution	O
was	O
gently	O
mixed	O
,	O
overlayed	O
with	O
mineral	O
oil	O
and	O
incubated	O
in	O
the	O
dark	O
for	O
12	O
-	O
13	O
h	O
at	O
50degreesC	O
.	O

The	O
aqueous	O
phase	O
was	O
recovered	O
using	O
the	O
'	O
Wizard	O
DNA	O
clean	O
-	O
up	O
system	O
'	O
(	O
Promega	O
,	O
Mannheim	O
,	O
Germany	O
)	O
.	O

The	O
purified	O
DNA	O
was	O
subsequently	O
mixed	O
with	O
1	O
M	O
NaOH	O
to	O
a	O
final	O
concentration	O
of	O
0	O
.	O
3	O
M	O
and	O
incubated	O
for	O
20	O
min	O
at	O
37degreesC	O
to	O
ensure	O
complete	O
desulfonisation	O
.	O

DNA	O
was	O
ethanol	O
precipitated	O
in	O
the	O
presence	O
of	O
1	O
/	O
10	O
vol	O
of	O
3	O
M	O
sodium	O
acetate	O
,	O
washed	O
with	O
70	O
%	O
ethanol	O
and	O
resuspended	O
in	O
50	O
microl	O
H2O	O
.	O

Subsequent	O
PCR	O
amplification	O
of	O
4	O
microl	O
bisulfite	O
-	O
treated	O
DNA	O
was	O
used	O
for	O
cloning	O
of	O
two	O
fragments	O
of	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
(	O
BS	O
-	O
I	O
and	O
BS	O
-	O
II	O
)	O
into	O
pCR2	O
.	O
1	O
vector	O
with	O
the	O
'	O
TOPO	O
TA	O
cloning	O
kit	O
'	O
(	O
Invitrogen	O
)	O
(	O
see	O
Figure	O
3A	O
)	O
.	O

The	O
primers	O
used	O
for	O
PCR	O
amplification	O
of	O
the	O
BS	O
-	O
I	O
and	O
BS	O
-	O
II	O
fragments	O
contain	O
the	O
putative	O
altered	O
sequence	O
of	O
the	O
sense	O
strand	O
due	O
to	O
bisulfite	O
treatment	O
(	O
converted	O
cytosine	O
residues	O
are	O
written	O
in	O
bold	O
letters	O
)	O
:	O
BS	O
-	O
I	O
-	O
forward	O
5	O
'	O
-	O
TATTTGGATTTTTAGGGAGTTTTTTTT	O
-	O
3	O
'	O
,	O
BS	O
-	O
I	O
-	O
reverse	O
5	O
'	O
-	O
ACCCAACTCCCTTAAACTATTAAACT	O
-	O
3	O
'	O
(	O
187	O
bp	O
)	O
;	O
BS	O
-	O
II	O
-	O
forward	O
5	O
'	O
-	O
AGTTTAATAGTTTAAGGGAGTTGGGT	O
-	O
3	O
'	O
,	O
BS	O
-	O
II	O
-	O
reverse	O
5	O
'	O
-	O
CTCACCCTAAACTCAAAACTAAAAAC	O
-	O
3	O
'	O
(	O
674	O
bp	O
)	O
.	O

After	O
bacterial	O
amplification	O
of	O
the	O
cloned	O
PCR	O
fragments	O
by	O
standard	O
procedures	O
,	O
eight	O
clones	O
from	O
each	O
sample	O
were	O
sequenced	O
with	O
an	O
automated	O
sequencer	O
(	O
ABI	O
Prism	O
377	O
,	O
Applied	O
Biosystems	O
)	O
.	O

In	O
vitro	O
methylation	O
and	O
reporter	O
gene	O
assays	O
<EOS>	B-X
N6-methyladenosine	B-X
(	B-X
m6A	B-X
)	B-X
methylation	B-X
,	B-X
a	B-X
well-known	B-X
modification	B-X
with	B-X
new	B-X
epigenetic	B-X
functions	B-X
,	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
participate	B-X
in	B-X
the	B-X
tumorigenesis	B-X
of	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
,	B-X
providing	B-X
novel	B-X
insights	B-X
into	B-X
the	B-X
molecular	B-X
pathogenesis	B-X
of	B-X
this	B-X
disease	B-X
.	B-X
However	B-X
,	B-X
as	B-X
the	B-X
key	B-X
component	B-X
of	B-X
m6A	B-X
methylation	B-X
,	B-X
Wilms	B-X
tumor	B-X
1-associated	B-X
protein	B-X
(	B-X
WTAP	B-X
)	B-X
has	B-X
not	B-X
been	B-X
well	B-X
studied	B-X
in	B-X
HCC	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
report	B-X
that	B-X
the	B-X
small	B-X
nucleolar	B-X
RNA	B-X
host	B-X
gene	B-X
1	B-X
(	B-X
SNHG1	B-X
)	B-X
is	B-X
involved	B-X
in	B-X
colorectal	B-X
cancer	B-X
progression	B-X
.	B-X
METTL3	B-X
as	B-X
the	B-X
main	B-X
methyltransferase	B-X
for	B-X
methylation	B-X
process	B-X
has	B-X
been	B-X
found	B-X
to	B-X
be	B-X
upregulated	B-X
in	B-X
many	B-X
cancers	B-X
,	B-X
including	B-X
CRC	B-X
.	B-X

The	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
-	O
reporter	O
gene	O
construct	O
was	O
generously	O
provided	O
by	O
J	O
.	O

Hiscott	O
(	O
31	O
)	O
.	O

Constructs	O
were	O
methylated	O
in	O
vitro	O
with	O
CpG	B-Protein
Methylase	I-Protein
(	O
M	B-Protein
.	I-Protein
Sss	I-Protein
I	I-Protein
)	O
as	O
recommended	O
by	O
the	O
manufacturer	O
(	O
NE	O
Biolabs	O
)	O
and	O
complete	O
methylation	O
was	O
checked	O
via	O
restriction	O
analysis	O
(	O
Figure	O
5A	O
)	O
.	O

Reporter	O
gene	O
assays	O
using	O
the	O
dual	O
luciferase	B-Protein
assay	O
(	O
Promega	O
)	O
were	O
performed	O
similar	O
to	O
previous	O
reports	O
(	O
29	O
)	O
.	O

Briefly	O
,	O
5	O
nM	O
of	O
the	O
reporter	O
construct	O
and	O
the	O
transfection	O
control	O
construct	O
expressing	O
the	O
renilla	O
luciferase	B-Protein
gene	O
were	O
transientlyco	O
-	O
expressed	O
via	O
electroporation	O
.	O

The	O
control	O
construct	O
served	O
as	O
an	O
internal	O
reference	O
for	O
transfection	O
efficiency	O
.	O

Forty	O
-	O
eight	O
hours	O
after	O
transfection	O
,	O
luciferase	B-Protein
activity	O
was	O
measured	O
with	O
a	O
LB	O
96	O
P	O
microlumat	O
(	O
EG	O
&	O
G	O
Berthold	O
,	O
Bad	O
Wildbad	O
,	O
Germany	O
)	O
.	O

IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
activation	O
was	O
quantified	O
as	O
a	O
ratio	O
of	O
measured	O
firefly	O
light	O
units	O
(	O
flu	O
)	O
relative	O
to	O
renilla	O
(	O
rlu	O
)	O
.	O

Each	O
experiment	O
was	O
carried	O
out	O
at	O
least	O
three	O
times	O
.	O
<EOS>	B-X
Evaluation	B-X
of	B-X
spatial	B-X
learning	B-X
and	B-X
memory	B-X
is	B-X
mainly	B-X
carried	B-X
out	B-X
using	B-X
the	B-X
Morris	B-X
water	B-X
maze	B-X
as	B-X
a	B-X
single	B-X
paradigm	B-X
.	B-X
C57BL/6J	B-X
and	B-X
CD1	B-X
male	B-X
mice	B-X
were	B-X
used	B-X
in	B-X
the	B-X
experiments	B-X
.	B-X
Strain-	B-X
and	B-X
task-dependent	B-X
differences	B-X
were	B-X
observed	B-X
using	B-X
the	B-X
three	B-X
mazes	B-X
.	B-X
Therefore	B-X
,	B-X
fair	B-X
evaluation	B-X
of	B-X
spatial	B-X
memory	B-X
demands	B-X
application	B-X
of	B-X
(	B-X
at	B-X
least	B-X
)	B-X
two	B-X
different	B-X
test	B-X
systems	B-X
,	B-X
a	B-X
water-	B-X
and	B-X
a	B-X
land	B-X
maze	B-X
.	B-X
Different	B-X
anxiety-related	B-X
behaviour	B-X
as	B-X
well	B-X
as	B-X
stress-responses	B-X
in	B-X
the	B-X
strains	B-X
used	B-X
may	B-X
help	B-X
to	B-X
interpret	B-X
the	B-X
findings	B-X
reported	B-X
and	B-X
again	B-X
may	B-X
propose	B-X
the	B-X
use	B-X
of	B-X
at	B-X
least	B-X
two	B-X
mouse	B-X
strains	B-X
when	B-X
robust	B-X
evaluation	B-X
of	B-X
spatial	B-X
memory	B-X
is	B-X
considered	B-X
.	B-X

Absence	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
leukemia	O
cells	O
is	O
not	O
due	O
to	O
promoter	O
alterations	O
<EOS>	B-X
Interferon	B-X
regulatory	B-X
factor-1	B-X
(	B-X
IRF-1	B-X
)	B-X
is	B-X
a	B-X
candidate	B-X
transcription	B-X
factor	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
Toll-like	B-X
receptor-4	B-X
(	B-X
TLR-4	B-X
)	B-X
gene	B-X
.	B-X
Using	B-X
a	B-X
small	B-X
interfering	B-X
RNA-based	B-X
(	B-X
siRNA	B-X
)	B-X
process	B-X
to	B-X
silence	B-X
IRF-1	B-X
gene	B-X
expression	B-X
in	B-X
the	B-X
leukemic	B-X
monocytic	B-X
cell	B-X
line	B-X
THP-1	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
such	B-X
a	B-X
modulation	B-X
would	B-X
alter	B-X
TLR-4	B-X
expression	B-X
and	B-X
activation	B-X
status	B-X
in	B-X
these	B-X
cells	B-X
.	B-X
The	B-X
siIRF-1	B-X
cells	B-X
expressed	B-X
elevated	B-X
levels	B-X
of	B-X
TLR-4	B-X
mRNA	B-X
and	B-X
protein	B-X
compared	B-X
to	B-X
controls	B-X
by	B-X
90	B-X
%	B-X
and	B-X
77	B-X
%	B-X
,	B-X
respectively	B-X
.	B-X
ICAM.1	B-X
protein	B-X
expression	B-X
and	B-X
apoptosis	B-X
levels	B-X
were	B-X
increased	B-X
by	B-X
8.35-	B-X
and	B-X
4.25-fold	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
siIRF-1	B-X
cells	B-X
overexpressed	B-X
Bax	B-X
mRNA	B-X
compared	B-X
to	B-X
controls	B-X
.	B-X
Proteomic	B-X
analysis	B-X
revealed	B-X
upmodulation	B-X
of	B-X
the	B-X
Annexin-II	B-X
protein	B-X
in	B-X
siIRF-1	B-X
THP-1	B-X
cells	B-X
.	B-X
Myelodysplastic	B-X
syndrome	B-X
(	B-X
MDS	B-X
)	B-X
patients	B-X
with	B-X
an	B-X
absence	B-X
of	B-X
full-length	B-X
IRF-1	B-X
mRNA	B-X
also	B-X
overexpressed	B-X
Annexin-II	B-X
.	B-X
It	B-X
is	B-X
plausible	B-X
that	B-X
this	B-X
overexpression	B-X
may	B-X
lead	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
TLR-4	B-X
contributing	B-X
to	B-X
the	B-X
increased	B-X
apoptosis	B-X
characterizing	B-X
MDS	B-X
.	B-X

We	O
have	O
previously	O
demonstrated	O
a	O
lack	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
leukemia	O
patients	O
and	O
specifically	O
in	O
CML	O
T	O
-	O
cells	O
(	O
3	O
)	O
.	O

Here	O
,	O
we	O
demonstrate	O
the	O
absence	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
various	O
hematopoietic	O
cell	O
lines	O
,	O
such	O
as	O
Jurkat	O
,	O
a	O
T	O
-	O
cell	O
leukemia	O
,	O
CML	O
-	O
T1	O
,	O
a	O
bcr	B-Protein
-	I-Protein
abl	I-Protein
-	O
positive	O
T	O
-	O
cell	O
line	O
,	O
K	O
-	O
562	O
,	O
a	O
bcr	B-Protein
-	I-Protein
abl	I-Protein
-	O
positve	O
erythroleukemia	O
,	O
U	O
-	O
937	O
,	O
a	O
monocytic	O
leukemia	O
,	O
EM	O
-	O
2	O
and	O
LAMA	O
-	O
84	O
,	O
bcr	B-Protein
-	I-Protein
abl	I-Protein
-	O
positve	O
myeloid	O
leukemia	O
,	O
but	O
not	O
in	O
SD	O
-	O
1	O
,	O
a	O
bcr	B-Protein
-	I-Protein
abl	I-Protein
-	O
positive	O
acute	O
lymphoblastic	O
leukemia	O
(	O
pre	O
B	O
-	O
ALL	O
)	O
,	O
RPMI	O
-	O
8226	O
,	O
a	O
multiple	O
myeloma	O
and	O
BV	O
-	O
173	O
,	O
a	O
bcr	B-Protein
-	I-Protein
abl	I-Protein
-	O
positive	O
B	O
-	O
cell	O
line	O
(	O
Figures	O
1A	O
and	O
5D	O
)	O
.	O

After	O
sequencing	O
of	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
,	O
it	O
could	O
be	O
excluded	O
that	O
absence	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
any	O
of	O
the	O
above	O
cell	O
lines	O
was	O
due	O
to	O
genetic	O
aberrations	O
.	O

However	O
,	O
2	O
bp	O
changes	O
(	O
nucleotide	O
-	O
1081	O
,	O
T	O
to	O
C	O
and	O
-	O
1068	O
,	O
A	O
to	O
C	O
)	O
could	O
be	O
detected	O
in	O
both	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
BV	O
-	O
173	O
and	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
LAMA	O
-	O
84	O
,	O
EM	O
-	O
2	O
and	O
K	O
-	O
562	O
(	O
Figure	O
1B	O
)	O
.	O

At	O
position	O
-	O
116	O
an	O
A	O
to	O
C	O
substitution	O
was	O
found	O
in	O
EM	O
-	O
2	O
,	O
K	O
-	O
562	O
and	O
CML	O
-	O
T1	O
,	O
whereas	O
Jurkat	O
,	O
BV	O
-	O
173	O
and	O
SD	O
-	O
1	O
exhibited	O
a	O
mixed	O
A	O
/	O
C	O
sequence	O
and	O
U	O
-	O
937	O
,	O
LAMA	O
-	O
84	O
and	O
RPMI	O
-	O
8226	O
no	O
substitution	O
at	O
all	O
(	O
Figure	O
1B	O
)	O
.	O

Consequently	O
,	O
these	O
alterations	O
are	O
unlikely	O
to	O
affect	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
.	O

Increase	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
hematopoietic	O
cells	O
after	O
demethylating	O
treatment	O

We	O
next	O
analyzed	O
whether	O
promoter	O
methylation	O
could	O
be	O
responsible	O
for	O
down	O
-	O
regulation	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
.	O

A	O
region	O
including	O
exon1	O
in	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
exhibited	O
a	O
large	O
number	O
of	O
CpG	O
-	O
rich	O
sequences	O
(	O
Figure	O
3A	O
)	O
.	O

Several	O
chemical	O
substances	O
such	O
as	O
5	O
-	O
aza	O
-	O
2	O
-	O
deoxycytidine	O
(	O
AzadC	O
)	O
or	O
5	O
-	O
azacytidine	O
(	O
AzaC	O
)	O
inhibit	O
de	O
novo	O
and	O
maintenance	O
methylation	O
,	O
and	O
thus	O
can	O
be	O
used	O
to	O
discern	O
promoter	O
methylation	O
(	O
32	O
,	O
33	O
)	O
.	O

We	O
used	O
AzadC	O
to	O
generate	O
unmethylated	O
DNA	O
.	O
<EOS>	B-X
DNA	B-X
(	B-X
cytosine-5-carbon	B-X
)	B-X
methylation	B-X
is	B-X
one	B-X
of	B-X
the	B-X
hallmarks	B-X
of	B-X
mammalian	B-X
chromatin	B-X
modifications	B-X
.	B-X
Distinct	B-X
methylation	B-X
pattern	B-X
can	B-X
generate	B-X
synergistic	B-X
or	B-X
antagonistic	B-X
interaction	B-X
affinities	B-X
for	B-X
CpG-islands	B-X
associated	B-X
with	B-X
methylated	B-X
or	B-X
unmethylated	B-X
cytosine	B-X
binding	B-X
proteins	B-X
,	B-X
which	B-X
also	B-X
may	B-X
dictate	B-X
histone	B-X
modifications	B-X
and	B-X
dynamic	B-X
transition	B-X
between	B-X
transcriptionally	B-X
silent	B-X
or	B-X
transcriptionally	B-X
active	B-X
chromatin	B-X
states	B-X
.	B-X
The	B-X
enzymes	B-X
and	B-X
cofactors	B-X
associated	B-X
with	B-X
DNA-methylation	B-X
reactions	B-X
are	B-X
convincing	B-X
in	B-X
terms	B-X
of	B-X
chemistry	B-X
and	B-X
chemical	B-X
thermodynamics	B-X
.	B-X
Use	B-X
of	B-X
azanucleosides	B-X
,	B-X
such	B-X
as	B-X
5-azacytidine	B-X
and	B-X
5-aza-2'-deoxycytidine	B-X
(	B-X
AzadC	B-X
)	B-X
,	B-X
in	B-X
cell	B-X
culture	B-X
produces	B-X
re-expression	B-X
of	B-X
certain	B-X
genes	B-X
,	B-X
which	B-X
otherwise	B-X
were	B-X
repressed	B-X
in	B-X
association	B-X
with	B-X
hypermethylated	B-X
CpG-rich	B-X
promoters	B-X
.	B-X
Hence	B-X
the	B-X
notion	B-X
developed	B-X
that	B-X
AzadC	B-X
is	B-X
a	B-X
demethylating	B-X
agent	B-X
.	B-X
Here	B-X
we	B-X
discuss	B-X
the	B-X
broad	B-X
global	B-X
pictures	B-X
with	B-X
the	B-X
following	B-X
points	B-X
:	B-X
first	B-X
,	B-X
chemical	B-X
definition	B-X
and	B-X
recent	B-X
advances	B-X
regarding	B-X
the	B-X
mechanism	B-X
of	B-X
DNA	B-X
(	B-X
cytosine-5-carbon	B-X
)	B-X
methylation	B-X
(	B-X
(	B-X
Me	B-X
)	B-X
CpG-DNA	B-X
or	B-X
(	B-X
Me	B-X
)	B-X
CpNpG-DNA	B-X
formation	B-X
)	B-X
and	B-X
(	B-X
Me	B-X
)	B-X
CpG/	B-X
(	B-X
Me	B-X
)	B-X
CpNpG-DNA-demethylation	B-X
,	B-X
and	B-X
then	B-X
with	B-X
the	B-X
mechanistic	B-X
basis	B-X
of	B-X
inactivation	B-X
of	B-X
DNA-methyltransferase	B-X
1	B-X
by	B-X
AzadC	B-X
.	B-X
This	B-X
will	B-X
clarify	B-X
that	B-X
:	B-X
(	B-X
i	B-X
)	B-X
AzadC	B-X
has	B-X
nothing	B-X
to	B-X
do	B-X
with	B-X
DNA-demethylation	B-X
;	B-X
(	B-X
ii	B-X
)	B-X
it	B-X
can	B-X
not	B-X
prevent	B-X
even	B-X
de	B-X
novo	B-X
methylation	B-X
in	B-X
non-replicating	B-X
cells	B-X
;	B-X
(	B-X
iii	B-X
)	B-X
it	B-X
can	B-X
only	B-X
prevent	B-X
replication	B-X
coupled	B-X
maintenance	B-X
as	B-X
well	B-X
as	B-X
de	B-X
novo	B-X
methylations	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
would	B-X
like	B-X
to	B-X
suggest	B-X
that	B-X
terming/designating	B-X
AzadC	B-X
as	B-X
DNA-demethylating	B-X
agent	B-X
is	B-X
a	B-X
serious	B-X
misuse	B-X
of	B-X
chemistry	B-X
and	B-X
chemical	B-X
terminology	B-X
.	B-X

A	O
72	O
h	O
AzadC	O
-	O
treatment	O
resulted	O
in	O
a	O
concentration	O
-	O
dependent	O
activation	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
transcription	O
in	O
Jurkat	O
and	O
CML	O
-	O
T1	O
T	O
-	O
cells	O
as	O
well	O
as	O
in	O
U	O
-	O
937	O
,	O
K	O
-	O
562	O
and	O
EM	O
-	O
2	O
cell	O
lines	O
(	O
Figure	O
2A	O
)	O
.	O

IRF	B-Protein
-	I-Protein
4	I-Protein
transcription	O
was	O
induced	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
and	O
was	O
observed	O
as	O
early	O
as	O
24	O
h	O
after	O
treatment	O
with	O
AzadC	O
and	O
increased	O
over	O
time	O
until	O
72	O
h	O
(	O
Figure	O
2B	O
)	O
.	O

Time	O
and	O
strength	O
of	O
the	O
appearance	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
transcripts	O
varied	O
among	O
cell	O
lines	O
,	O
i	O
.	O
e	O
.	O
CML	O
-	O
T1	O
responded	O
strongest	O
to	O
AzadC	O
-	O
treatment	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
line	O
with	O
this	O
,	O
AzadC	O
-	O
treatment	O
of	O
CML	O
-	O
T1	O
and	O
LAMA	O
-	O
84	O
cells	O
also	O
translated	O
in	O
an	O
induction	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
protein	O
expression	O
(	O
Figure	O
2C	O
)	O
.	O

Accordingly	O
,	O
treatment	O
of	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
cell	O
line	O
BV	O
-	O
173	O
,	O
SD	O
-	O
1	O
and	O
RPMI	O
-	O
8226	O
with	O
AzadC	O
had	O
no	O
effect	O
on	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
(	O
Figure	O
2D	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
effects	O
of	O
AzaC	O
versus	O
AzadC	O
,	O
as	O
both	O
increased	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
mRNA	O
level	O
in	O
CML	O
-	O
T1	O
cells	O
as	O
well	O
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
implied	O
that	O
promoter	O
methylation	O
may	O
control	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
,	O
but	O
an	O
alternative	O
explanation	O
may	O
be	O
activation	O
of	O
positive	O
transcriptional	O
regulators	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
by	O
AzadC	O
(	O
or	O
AzaC	O
)	O
.	O

Methylation	O
-	O
sensitive	O
enzymes	O
do	O
not	O
cut	O
specific	O
sites	O
in	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
in	O
hematopoietic	O
cells	O
<EOS>	B-X
We	B-X
identified	B-X
51	B-X
studies	B-X
(	B-X
29	B-X
prospective	B-X
,	B-X
14	B-X
retrospective	B-X
,	B-X
and	B-X
8	B-X
meta-analyses	B-X
)	B-X
.	B-X
Sensitivities	B-X
of	B-X
these	B-X
markers	B-X
for	B-X
detecting	B-X
primary	B-X
colorectal	B-X
carcinoma	B-X
ranged	B-X
from	B-X
70	B-X
to	B-X
98	B-X
%	B-X
and	B-X
specificities	B-X
from	B-X
84	B-X
to	B-X
98.7	B-X
%	B-X
.	B-X
The	B-X
best	B-X
studied	B-X
blood	B-X
marker	B-X
was	B-X
SEPT9	B-X
methylated	B-X
DNA	B-X
,	B-X
which	B-X
showed	B-X
great	B-X
variability	B-X
with	B-X
sensitivities	B-X
ranging	B-X
from	B-X
48.2	B-X
to	B-X
95.6	B-X
%	B-X
and	B-X
specificities	B-X
from	B-X
80	B-X
to	B-X
98.9	B-X
%	B-X
,	B-X
making	B-X
its	B-X
clinical	B-X
applicability	B-X
challenging	B-X
.	B-X
If	B-X
combined	B-X
with	B-X
fecal	B-X
immunochemical	B-X
test	B-X
(	B-X
FIT	B-X
)	B-X
,	B-X
the	B-X
sensitivity	B-X
improved	B-X
from	B-X
78	B-X
to	B-X
94	B-X
%	B-X
in	B-X
detecting	B-X
CRC	B-X
.	B-X
Methylated	B-X
SEPT9	B-X
,	B-X
methylated	B-X
SDC2	B-X
,	B-X
and	B-X
-SIGN/DC-SIGNR	B-X
protein	B-X
had	B-X
better	B-X
sensitivity	B-X
and	B-X
specificity	B-X
than	B-X
CEA	B-X
or	B-X
CA	B-X
19-9	B-X
.	B-X

To	O
further	O
investigate	O
promoter	O
methylation	O
as	O
a	O
regulatory	O
mechanism	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
gene	O
expression	O
,	O
restriction	O
-	O
PCR	O
-	O
assays	O
were	O
performed	O
(	O
20	O
,	O
24	O
)	O
,	O
where	O
only	O
methylated	O
DNA	O
would	O
not	O
be	O
cut	O
enabling	O
subsequent	O
PCR	O
amplification	O
and	O
vice	O
versa	O
.	O

Genomic	O
DNA	O
from	O
leukemic	O
cells	O
Jurkat	O
,	O
CML	O
-	O
T1	O
,	O
U	O
-	O
937	O
,	O
K	O
-	O
562	O
,	O
EM	O
-	O
2	O
and	O
BV	O
-	O
173	O
was	O
digested	O
with	O
the	O
methylation	O
-	O
sensitive	O
enzymes	O
HpaII	O
,	O
Bsh1236I	O
and	O
HaeII	O
-	O
isochizomer	O
Bsp143II	O
.	O

EcoRI	O
,	O
which	O
has	O
no	O
recognition	O
site	O
within	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
,	O
and	O
the	O
methylation	O
-	O
resistant	O
enzyme	O
MspI	O
served	O
as	O
controls	O
.	O

Two	O
separate	O
amplification	O
reactions	O
were	O
performed	O
,	O
generating	O
two	O
fragments	O
,	O
F1	O
and	O
F2	O
(	O
Figure	O
3A	O
)	O
.	O

After	O
digestion	O
with	O
HpaII	O
and	O
Bsp143II	O
a	O
sufficient	O
PCR	O
amplification	O
of	O
F1	O
and	O
F2	O
was	O
detected	O
in	O
DNA	O
from	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
Jurkat	O
,	O
CML	O
-	O
T1	O
,	O
U	O
-	O
937	O
,	O
K	O
-	O
562	O
and	O
EM	O
-	O
2	O
cells	O
,	O
suggesting	O
a	O
promoter	O
methylation	O
(	O
and	O
restriction	O
protection	O
)	O
at	O
the	O
respective	O
recognition	O
sites	O
(	O
Figure	O
3B	O
and	O
C	O
)	O
.	O

Notably	O
,	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
SD	O
-	O
1	O
cells	O
digestion	O
with	O
the	O
methylation	O
-	O
sensitive	O
enzymes	O
completely	O
inhibited	O
amplification	O
of	O
F1	O
and	O
F2	O
.	O

In	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
BV	O
-	O
173	O
cells	O
a	O
HpaII	O
,	O
but	O
not	O
a	O
Bsh1236I	O
digestion	O
,	O
significantly	O
reduced	O
the	O
amplifiable	O
DNA	O
message	O
of	O
F2	O
(	O
Figure	O
3C	O
)	O
,	O
whereas	O
amplification	O
of	O
F1	O
was	O
not	O
affected	O
(	O
Figure	O
3B	O
)	O
.	O

This	O
implied	O
that	O
IRF	B-Protein
-	I-Protein
4	I-Protein
transcription	O
in	O
SD	O
-	O
1	O
and	O
BV	O
-	O
173	O
cells	O
is	O
associated	O
with	O
less	O
promoter	O
methylation	O
(	O
in	O
BV	O
-	O
173	O
especially	O
at	O
HpaII	O
sites	O
)	O
as	O
compared	O
with	O
the	O
tested	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
cells	O
.	O

Specific	O
CpG	O
sites	O
in	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
are	O
methylated	O
in	O
hematopoietic	O
cells	O
<EOS>	B-X
Although	B-X
the	B-X
bcr-abl	B-X
translocation	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
the	B-X
causative	B-X
genetic	B-X
aberration	B-X
in	B-X
chronic	B-X
myeloid	B-X
leukemia	B-X
(	B-X
CML	B-X
)	B-X
,	B-X
there	B-X
is	B-X
mounting	B-X
evidence	B-X
that	B-X
the	B-X
deregulation	B-X
of	B-X
other	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
the	B-X
transcription	B-X
factor	B-X
interferon	B-X
regulatory	B-X
factor	B-X
4	B-X
(	B-X
IRF-4	B-X
)	B-X
,	B-X
is	B-X
also	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
CML	B-X
.	B-X
Promoter	B-X
methylation	B-X
of	B-X
CpG	B-X
target	B-X
sites	B-X
or	B-X
direct	B-X
deletions/insertions	B-X
of	B-X
genes	B-X
are	B-X
mechanisms	B-X
of	B-X
a	B-X
reversible	B-X
or	B-X
permanent	B-X
silencing	B-X
of	B-X
gene	B-X
expression	B-X
,	B-X
respectively	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
IRF-4	B-X
promoter	B-X
methylation	B-X
or	B-X
mutation	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
IRF-4	B-X
expression	B-X
in	B-X
leukemia	B-X
cells	B-X
.	B-X
Whereas	B-X
promoter	B-X
mutations	B-X
or	B-X
structural	B-X
rearrangements	B-X
could	B-X
be	B-X
excluded	B-X
as	B-X
a	B-X
cause	B-X
of	B-X
altered	B-X
IRF-4	B-X
expression	B-X
in	B-X
hematopoietic	B-X
cells	B-X
,	B-X
the	B-X
IRF-4	B-X
promoter	B-X
methylation	B-X
status	B-X
was	B-X
found	B-X
to	B-X
significantly	B-X
influence	B-X
IRF-4	B-X
transcription	B-X
.	B-X
First	B-X
,	B-X
treatment	B-X
of	B-X
IRF-4-negative	B-X
lymphoid	B-X
,	B-X
myeloid	B-X
and	B-X
monocytic	B-X
cell	B-X
lines	B-X
with	B-X
the	B-X
methylation-inhibitor	B-X
5-aza-2-deoxycytidine	B-X
resulted	B-X
in	B-X
a	B-X
time-	B-X
and	B-X
concentration-dependent	B-X
increase	B-X
of	B-X
IRF-4	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
.	B-X
Second	B-X
,	B-X
using	B-X
a	B-X
restriction-PCR-assay	B-X
and	B-X
bisulfite-sequencing	B-X
we	B-X
identified	B-X
specifically	B-X
methylated	B-X
CpG	B-X
sites	B-X
in	B-X
IRF-4-negative	B-X
but	B-X
not	B-X
in	B-X
IRF-4-positive	B-X
cells	B-X
.	B-X
Third	B-X
,	B-X
we	B-X
clearly	B-X
determined	B-X
promoter	B-X
methylation	B-X
as	B-X
a	B-X
mechanism	B-X
for	B-X
IRF-4	B-X
down-regulation	B-X
via	B-X
reporter	B-X
gene	B-X
assays	B-X
,	B-X
but	B-X
did	B-X
not	B-X
detect	B-X
an	B-X
association	B-X
of	B-X
methylational	B-X
status	B-X
and	B-X
mRNA	B-X
expression	B-X
of	B-X
DNA	B-X
methyltransferases	B-X
or	B-X
methyl-CpG-binding	B-X
proteins	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
CpG	B-X
site-specific	B-X
IRF-4	B-X
promoter	B-X
methylation	B-X
as	B-X
a	B-X
putative	B-X
mechanism	B-X
of	B-X
down-regulated	B-X
IRF-4	B-X
expression	B-X
in	B-X
leukemia	B-X
.	B-X

In	O
order	O
to	O
exactly	O
map	O
the	O
methylation	O
sites	O
within	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
,	O
we	O
treated	O
DNA	O
of	O
Jurkat	O
,	O
CML	O
-	O
T1	O
,	O
U	O
-	O
937	O
,	O
K	O
-	O
562	O
and	O
EM	O
-	O
2	O
cells	O
as	O
well	O
as	O
of	O
SD	O
-	O
1	O
,	O
RPMI	O
-	O
8226	O
and	O
BV	O
-	O
173	O
control	O
cells	O
with	O
bisulfite	O
,	O
which	O
chemically	O
converts	O
unmethylated	O
cytosine	O
to	O
uracil	O
,	O
whereas	O
it	O
has	O
no	O
effect	O
on	O
methylated	O
cytosine	O
,	O
i	O
.	O
e	O
.	O
in	O
CpG	O
(	O
34	O
)	O
.	O

This	O
technique	O
is	O
especially	O
useful	O
for	O
detection	O
of	O
unknown	O
methylation	O
patterns	O
.	O
<EOS>	B-X
This	B-X
study	B-X
aims	B-X
to	B-X
identify	B-X
antibodies	B-X
in	B-X
patients	B-X
with	B-X
focal	B-X
epilepsy	B-X
of	B-X
unknown	B-X
etiology	B-X
,	B-X
and	B-X
to	B-X
create	B-X
a	B-X
score	B-X
to	B-X
preselect	B-X
patients	B-X
requiring	B-X
testing	B-X
.	B-X
Evidence	B-X
now	B-X
suggests	B-X
that	B-X
the	B-X
transcriptional	B-X
silencing	B-X
of	B-X
selected	B-X
genes	B-X
by	B-X
DNA	B-X
methylation	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
development	B-X
and	B-X
progression	B-X
of	B-X
human	B-X
gastrointestinal	B-X
malignancies	B-X
.	B-X
To	B-X
date	B-X
,	B-X
genes	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
DNA	B-X
repair	B-X
,	B-X
angiogenesis	B-X
,	B-X
and	B-X
apoptosis	B-X
have	B-X
all	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
inactivated	B-X
by	B-X
the	B-X
hypermethylation	B-X
of	B-X
their	B-X
respective	B-X
5	B-X
'	B-X
CpG	B-X
islands	B-X
.	B-X
The	B-X
specific	B-X
causes	B-X
and	B-X
effects	B-X
of	B-X
the	B-X
changes	B-X
in	B-X
DNA	B-X
methylation	B-X
that	B-X
occur	B-X
in	B-X
cancer	B-X
remain	B-X
unknown	B-X
,	B-X
however	B-X
.	B-X
Nevertheless	B-X
,	B-X
recently	B-X
developed	B-X
techniques	B-X
for	B-X
detecting	B-X
changes	B-X
in	B-X
DNA	B-X
methylation	B-X
have	B-X
dramatically	B-X
increased	B-X
the	B-X
amount	B-X
of	B-X
information	B-X
available	B-X
on	B-X
the	B-X
patterns	B-X
of	B-X
methylation	B-X
that	B-X
occur	B-X
as	B-X
cancers	B-X
progress	B-X
.	B-X
One	B-X
key	B-X
process	B-X
involved	B-X
in	B-X
aberrant	B-X
methylation	B-X
is	B-X
related	B-X
to	B-X
aging	B-X
,	B-X
and	B-X
because	B-X
it	B-X
affects	B-X
a	B-X
large	B-X
number	B-X
of	B-X
CpG	B-X
islands	B-X
,	B-X
age-related	B-X
methylation	B-X
may	B-X
be	B-X
a	B-X
primary	B-X
cause	B-X
of	B-X
the	B-X
increased	B-X
incidence	B-X
of	B-X
cancer	B-X
seen	B-X
among	B-X
older	B-X
individuals	B-X
.	B-X
Other	B-X
patterns	B-X
of	B-X
methylation	B-X
are	B-X
cancer-specific	B-X
and	B-X
are	B-X
detected	B-X
only	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
tumors	B-X
exhibiting	B-X
the	B-X
CpG	B-X
island	B-X
methylator	B-X
phenotype	B-X
(	B-X
CIMP	B-X
)	B-X
.	B-X
In	B-X
this	B-X
regard	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
sporadic	B-X
colorectal	B-X
cancers	B-X
,	B-X
exhibiting	B-X
microsatellite	B-X
instability	B-X
(	B-X
MSI	B-X
)	B-X
appear	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
CIMP	B-X
,	B-X
which	B-X
leads	B-X
to	B-X
aberrant	B-X
methylation	B-X
of	B-X
human	B-X
MutL	B-X
homologue	B-X
(	B-X
hMLH1	B-X
)	B-X
and	B-X
the	B-X
loss	B-X
of	B-X
its	B-X
expression	B-X
.	B-X
We	B-X
anticipate	B-X
that	B-X
as	B-X
the	B-X
various	B-X
components	B-X
of	B-X
the	B-X
molecular	B-X
machinery	B-X
involved	B-X
in	B-X
aberrant	B-X
DNA	B-X
methylation	B-X
become	B-X
better	B-X
understood	B-X
,	B-X
they	B-X
will	B-X
prove	B-X
to	B-X
be	B-X
useful	B-X
targets	B-X
,	B-X
serving	B-X
as	B-X
the	B-X
basis	B-X
for	B-X
the	B-X
development	B-X
of	B-X
new	B-X
methods	B-X
for	B-X
the	B-X
diagnosis	B-X
and	B-X
treatment	B-X
of	B-X
gastrointestinal	B-X
malignancies	B-X
.	B-X

PCR	O
amplification	O
,	O
cloning	O
and	O
sequencing	O
of	O
the	O
bisulfite	O
-	O
treated	O
DNA	O
showed	O
a	O
specific	O
methylation	O
pattern	O
of	O
the	O
analyzed	O
62	O
CpG	O
sites	O
in	O
all	O
cell	O
lines	O
(	O
Figure	O
4	O
and	O
Table	O
1	O
)	O
.	O

In	O
general	O
,	O
the	O
methylational	O
status	O
ranged	O
from	O
one	O
cell	O
line	O
with	O
a	O
nearly	O
non	O
-	O
methylated	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
(	O
SD	O
-	O
1	O
,	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
)	O
to	O
a	O
completely	O
methylated	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
in	O
CML	O
-	O
T1	O
(	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
)	O
.	O

Interestingly	O
,	O
the	O
percentage	O
of	O
CpG	O
methylation	O
in	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
from	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
cells	O
was	O
very	O
low	O
(	O
mean	O
24	O
%	O
)	O
as	O
compared	O
with	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
cells	O
(	O
mean	O
94	O
%	O
)	O
(	O
Figure	O
4A	O
and	O
Table	O
1	O
)	O
.	O

A	O
5	O
'	O
-	O
region	O
(	O
R1	O
)	O
with	O
13	O
hypermethylated	O
CpG	O
sites	O
(	O
mean	O
number	O
of	O
methylated	O
clones	O
5	O
.	O
5	O
of	O
8	O
with	O
77	O
%	O
methylated	O
CpGs	O
)	O
was	O
found	O
in	O
most	O
cells	O
(	O
except	O
SD	O
-	O
1	O
and	O
RPMI	O
-	O
8226	O
)	O
and	O
a	O
3	O
'	O
-	O
region	O
(	O
R3	O
)	O
of	O
6	O
hypomethylated	O
CpG	O
sites	O
(	O
mean	O
number	O
of	O
methylated	O
clones	O
1	O
.	O
7	O
of	O
8	O
with	O
33	O
%	O
methylated	O
CpGs	O
)	O
was	O
found	O
in	O
most	O
cells	O
(	O
except	O
CML	O
-	O
T1	O
and	O
U	O
-	O
937	O
)	O
(	O
Figure	O
4A	O
and	O
Table	O
1	O
)	O
.	O

Intriguingly	O
,	O
a	O
stretch	O
of	O
13	O
CpG	O
sites	O
(	O
#	O
10	O
-	O
22	O
;	O
R2	O
)	O
was	O
detected	O
in	O
between	O
these	O
regions	O
,	O
which	O
were	O
highly	O
methylated	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
(	O
mean	O
number	O
of	O
methylated	O
clones	O
7	O
.	O
1	O
of	O
8	O
with	O
89	O
%	O
methylated	O
CpGs	O
)	O
but	O
totally	O
non	O
-	O
methylated	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
cells	O
(	O
Figure	O
4A	O
and	O
B	O
)	O
.	O

Furthermore	O
,	O
three	O
CpG	O
sites	O
at	O
the	O
5	O
'	O
end	O
(	O
#	O
54	O
,	O
56	O
,	O
58	O
)	O
and	O
two	O
CpG	O
motifs	O
at	O
the	O
3	O
'	O
end	O
(	O
#	O
1	O
,	O
2	O
)	O
showed	O
this	O
direct	O
correlation	O
between	O
high	O
methylation	O
status	O
and	O
absence	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
.	O

In	O
addition	O
,	O
two	O
CpG	O
sites	O
located	O
in	O
a	O
NFkappaB	O
(	O
#	O
48	O
)	O
and	O
a	O
SP1	O
element	O
(	O
#	O
45	O
)	O
are	O
less	O
methylated	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
than	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
cells	O
(	O
mean	O
number	O
of	O
methylated	O
clones	O
:	O
1	O
/	O
8	O
versus	O
8	O
/	O
8	O
)	O
.	O

These	O
results	O
indicate	O
the	O
involvement	O
of	O
CpG	O
methylation	O
in	O
the	O
regulation	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
leukemic	O
cells	O
.	O

In	O
vitro	O
methylation	O
of	O
an	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
-	O
reporter	O
construct	O
decreases	O
its	O
activity	O

To	O
provide	O
evidence	O
for	O
a	O
direct	O
effect	O
of	O
methylational	O
status	O
on	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
activity	O
we	O
performed	O
reporter	O
gene	O
assays	O
with	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
constructs	O
before	O
and	O
after	O
their	O
in	O
vitro	O
methylation	O
.	O

A	O
complete	O
methylation	O
of	O
these	O
constructs	O
was	O
checked	O
via	O
restriction	O
assays	O
with	O
methylation	O
-	O
sensitive	O
endonucleases	O
(	O
Figure	O
5A	O
)	O
.	O

Intriguingly	O
,	O
methylation	O
of	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
significantly	O
decreased	O
promoter	O
activity	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
SD	O
-	O
1	O
cells	O
by	O
85	O
.	O
0	O
%	O
(	O
Figure	O
5B	O
)	O
.	O

The	O
silencing	O
effect	O
of	O
CpG	O
methylation	O
was	O
not	O
restricted	O
to	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
cells	O
,	O
since	O
in	O
vitro	O
methylation	O
led	O
to	O
a	O
92	O
.	O
9	O
%	O
abrogation	O
of	O
promoter	O
activity	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
Jurkat	O
cells	O
(	O
Figure	O
5C	O
)	O
.	O
<EOS>	B-X
DNA	B-X
methylation	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
intensely	B-X
studied	B-X
epigenetic	B-X
modifications	B-X
in	B-X
mammals	B-X
.	B-X
In	B-X
normal	B-X
cells	B-X
,	B-X
it	B-X
assures	B-X
the	B-X
proper	B-X
regulation	B-X
of	B-X
gene	B-X
expression	B-X
and	B-X
stable	B-X
gene	B-X
silencing	B-X
.	B-X
DNA	B-X
methylation	B-X
is	B-X
associated	B-X
with	B-X
histone	B-X
modifications	B-X
and	B-X
the	B-X
interplay	B-X
of	B-X
these	B-X
epigenetic	B-X
modifications	B-X
is	B-X
crucial	B-X
to	B-X
regulate	B-X
the	B-X
functioning	B-X
of	B-X
the	B-X
genome	B-X
by	B-X
changing	B-X
chromatin	B-X
architecture	B-X
.	B-X
The	B-X
covalent	B-X
addition	B-X
of	B-X
a	B-X
methyl	B-X
group	B-X
occurs	B-X
generally	B-X
in	B-X
cytosine	B-X
within	B-X
CpG	B-X
dinucleotides	B-X
which	B-X
are	B-X
concentrated	B-X
in	B-X
large	B-X
clusters	B-X
called	B-X
CpG	B-X
islands	B-X
.	B-X
DNA	B-X
methyltransferases	B-X
are	B-X
responsible	B-X
for	B-X
establishing	B-X
and	B-X
maintenance	B-X
of	B-X
methylation	B-X
pattern	B-X
.	B-X
It	B-X
is	B-X
commonly	B-X
known	B-X
that	B-X
inactivation	B-X
of	B-X
certain	B-X
tumor-suppressor	B-X
genes	B-X
occurs	B-X
as	B-X
a	B-X
consequence	B-X
of	B-X
hypermethylation	B-X
within	B-X
the	B-X
promoter	B-X
regions	B-X
and	B-X
a	B-X
numerous	B-X
studies	B-X
have	B-X
demonstrated	B-X
a	B-X
broad	B-X
range	B-X
of	B-X
genes	B-X
silenced	B-X
by	B-X
DNA	B-X
methylation	B-X
in	B-X
different	B-X
cancer	B-X
types	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
global	B-X
hypomethylation	B-X
,	B-X
inducing	B-X
genomic	B-X
instability	B-X
,	B-X
also	B-X
contributes	B-X
to	B-X
cell	B-X
transformation	B-X
.	B-X
Apart	B-X
from	B-X
DNA	B-X
methylation	B-X
alterations	B-X
in	B-X
promoter	B-X
regions	B-X
and	B-X
repetitive	B-X
DNA	B-X
sequences	B-X
,	B-X
this	B-X
phenomenon	B-X
is	B-X
associated	B-X
also	B-X
with	B-X
regulation	B-X
of	B-X
expression	B-X
of	B-X
noncoding	B-X
RNAs	B-X
such	B-X
as	B-X
microRNAs	B-X
that	B-X
may	B-X
play	B-X
role	B-X
in	B-X
tumor	B-X
suppression	B-X
.	B-X
DNA	B-X
methylation	B-X
seems	B-X
to	B-X
be	B-X
promising	B-X
in	B-X
putative	B-X
translational	B-X
use	B-X
in	B-X
patients	B-X
and	B-X
hypermethylated	B-X
promoters	B-X
may	B-X
serve	B-X
as	B-X
biomarkers	B-X
.	B-X
Moreover	B-X
,	B-X
unlike	B-X
genetic	B-X
alterations	B-X
,	B-X
DNA	B-X
methylation	B-X
is	B-X
reversible	B-X
what	B-X
makes	B-X
it	B-X
extremely	B-X
interesting	B-X
for	B-X
therapy	B-X
approaches	B-X
.	B-X
The	B-X
importance	B-X
of	B-X
DNA	B-X
methylation	B-X
alterations	B-X
in	B-X
tumorigenesis	B-X
encourages	B-X
us	B-X
to	B-X
decode	B-X
the	B-X
human	B-X
epigenome	B-X
.	B-X

In	O
contrast	O
,	O
control	O
methylation	O
of	O
a	O
reporter	O
construct	O
with	O
a	O
different	O
promoter	O
(	O
FasL	B-Protein
)	O
as	O
well	O
as	O
an	O
empty	O
vector	O
had	O
no	O
effect	O
on	O
the	O
reporter	O
activity	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
data	O
proved	O
a	O
direct	O
association	O
between	O
methylation	O
and	O
activity	O
of	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
.	O

mRNA	O
expression	O
of	O
DNA	O
methyltransferases	O
and	O
methyl	O
-	O
CpG	O
-	O
binding	O
proteins	O
may	O
not	O
be	O
associated	O
with	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
methylation	O
<EOS>	B-X
Promoter	B-X
hypermethylation	B-X
is	B-X
an	B-X
important	B-X
means	B-X
for	B-X
the	B-X
transcriptional	B-X
repression	B-X
of	B-X
a	B-X
number	B-X
of	B-X
cancer-associated	B-X
genes	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
examined	B-X
5	B-X
'	B-X
CpG	B-X
island	B-X
methylation	B-X
status	B-X
and	B-X
expression	B-X
of	B-X
the	B-X
p14	B-X
(	B-X
ARF	B-X
)	B-X
,	B-X
p16	B-X
(	B-X
INK4a	B-X
)	B-X
and	B-X
RASSF1A	B-X
tumor	B-X
suppressor	B-X
genes	B-X
,	B-X
and	B-X
investigated	B-X
the	B-X
relationship	B-X
of	B-X
these	B-X
factors	B-X
with	B-X
the	B-X
mRNA	B-X
expression	B-X
of	B-X
DNA	B-X
methyltransferases	B-X
(	B-X
DNMTs	B-X
)	B-X
and/or	B-X
methyl-CpG-binding	B-X
proteins	B-X
(	B-X
MBPs	B-X
)	B-X
in	B-X
30	B-X
lung	B-X
cancer	B-X
cell	B-X
lines	B-X
including	B-X
12	B-X
small	B-X
cell	B-X
lung	B-X
cancers	B-X
(	B-X
SCLCs	B-X
)	B-X
and	B-X
18	B-X
non-small	B-X
cell	B-X
lung	B-X
cancers	B-X
(	B-X
NSCLCs	B-X
)	B-X
.	B-X
When	B-X
beta-actin	B-X
was	B-X
used	B-X
as	B-X
an	B-X
internal	B-X
control	B-X
,	B-X
the	B-X
mRNA	B-X
expression	B-X
of	B-X
three	B-X
DNMTs	B-X
(	B-X
DNMT1	B-X
,	B-X
DNMT3A	B-X
,	B-X
and	B-X
DNMT3B	B-X
)	B-X
and	B-X
five	B-X
MBPs	B-X
(	B-X
MBD1	B-X
,	B-X
MBD2	B-X
,	B-X
MBD3	B-X
,	B-X
MBD4	B-X
,	B-X
and	B-X
MeCP2	B-X
)	B-X
was	B-X
upregulated	B-X
in	B-X
SCLC	B-X
,	B-X
while	B-X
only	B-X
that	B-X
of	B-X
DNMT1	B-X
,	B-X
DNMT3B	B-X
and	B-X
MBD3	B-X
was	B-X
upregulated	B-X
in	B-X
NSCLC	B-X
,	B-X
compared	B-X
with	B-X
normal	B-X
lung	B-X
tissues	B-X
.	B-X
However	B-X
,	B-X
when	B-X
normalized	B-X
using	B-X
proliferating	B-X
cell	B-X
nuclear	B-X
antigen	B-X
(	B-X
PCNA	B-X
)	B-X
as	B-X
an	B-X
internal	B-X
control	B-X
,	B-X
these	B-X
differences	B-X
disappeared	B-X
or	B-X
diminished	B-X
;	B-X
there	B-X
was	B-X
even	B-X
a	B-X
significant	B-X
reduction	B-X
in	B-X
the	B-X
expression	B-X
ratios	B-X
of	B-X
DNMT1	B-X
,	B-X
MBD2	B-X
and	B-X
MeCP2	B-X
in	B-X
SCLC	B-X
and	B-X
DNMT1	B-X
,	B-X
MBD2	B-X
and	B-X
MBD4	B-X
in	B-X
NSCLC	B-X
.	B-X
Furthermore	B-X
,	B-X
although	B-X
significant	B-X
correlations	B-X
between	B-X
PCNA	B-X
expression	B-X
and	B-X
mRNA	B-X
expression	B-X
levels	B-X
of	B-X
the	B-X
three	B-X
DNMTs	B-X
and	B-X
four	B-X
of	B-X
the	B-X
MBPs	B-X
(	B-X
excluding	B-X
MeCP2	B-X
)	B-X
were	B-X
observed	B-X
,	B-X
there	B-X
was	B-X
no	B-X
obvious	B-X
correlation	B-X
between	B-X
promoter	B-X
hypermethylation	B-X
of	B-X
these	B-X
tumor	B-X
suppressor	B-X
genes	B-X
and	B-X
the	B-X
expression	B-X
level	B-X
of	B-X
any	B-X
of	B-X
the	B-X
DNMTs	B-X
or	B-X
MBPs	B-X
.	B-X

Since	O
abundance	O
of	O
DNMT	O
and	O
MBP	O
contribute	O
to	O
promoter	O
regulation	O
via	O
methylation	O
(	O
25	O
,	O
26	O
,	O
28	O
)	O
,	O
we	O
studied	O
their	O
mRNA	O
expression	O
to	O
investigate	O
a	O
possible	O
mechanism	O
for	O
the	O
observed	O
methylation	O
differences	O
in	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
.	O

To	O
this	O
end	O
,	O
we	O
did	O
not	O
detect	O
a	O
significant	O
difference	O
in	O
DNMT	O
(	O
DNMT1	B-Protein
,	O
DNMT3A	B-Protein
and	O
DNMT3B	B-Protein
)	O
or	O
MBP	O
(	O
MBD1	B-Protein
,	O
MBD2	B-Protein
,	O
MBD4	B-Protein
and	O
MeCP	B-Protein
)	O
mRNA	O
expression	O
between	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
and	O
-	O
negative	O
cells	O
(	O
Figure	O
5D	O
)	O
.	O

In	O
fact	O
,	O
all	O
analyzed	O
cells	O
had	O
moderate	O
to	O
high	O
mRNA	O
levels	O
of	O
these	O
tested	O
DNMT	O
/	O
MBPs	O
and	O
differences	O
in	O
expression	O
were	O
not	O
correlated	O
with	O
IRF	B-Protein
-	I-Protein
4	I-Protein
status	O
.	O

These	O
results	O
indicate	O
a	O
distinct	O
cause	O
of	O
the	O
methylation	O
differences	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
and	O
-	O
negative	O
cells	O
rather	O
than	O
changes	O
in	O
the	O
DNMT	O
and	O
MBP	O
mRNA	O
transcription	O
.	O

Many	O
genetic	O
lesions	O
are	O
known	O
to	O
influence	O
gene	O
expression	O
of	O
tumor	O
suppressor	O
genes	O
.	O
<EOS>	B-X
Transgenic	B-X
mice	B-X
expressing	B-X
the	B-X
simian	B-X
virus	B-X
40	B-X
large	B-X
T-antigen	B-X
(	B-X
TAG	B-X
)	B-X
under	B-X
the	B-X
regulatory	B-X
control	B-X
of	B-X
the	B-X
rat	B-X
prostatic	B-X
steroid	B-X
binding	B-X
protein	B-X
C3	B-X
(	B-X
1	B-X
)	B-X
gene	B-X
develop	B-X
mammary	B-X
carcinomas	B-X
(	B-X
in	B-X
females	B-X
)	B-X
and	B-X
prostate	B-X
carcinomas	B-X
(	B-X
in	B-X
males	B-X
)	B-X
.	B-X
The	B-X
development	B-X
of	B-X
carcinomas	B-X
occurs	B-X
several	B-X
months	B-X
after	B-X
the	B-X
appearance	B-X
of	B-X
dysplastic	B-X
lesions	B-X
,	B-X
suggesting	B-X
that	B-X
TAG	B-X
is	B-X
necessary	B-X
but	B-X
insufficient	B-X
for	B-X
tumor	B-X
formation	B-X
and	B-X
that	B-X
other	B-X
genetic	B-X
events	B-X
are	B-X
involved	B-X
in	B-X
this	B-X
process	B-X
.	B-X
TAG	B-X
is	B-X
known	B-X
to	B-X
bind	B-X
to	B-X
p53	B-X
and	B-X
to	B-X
result	B-X
in	B-X
its	B-X
functional	B-X
inactivation	B-X
,	B-X
which	B-X
is	B-X
believed	B-X
to	B-X
be	B-X
a	B-X
critical	B-X
step	B-X
in	B-X
TAG-induced	B-X
transformation	B-X
.	B-X
We	B-X
investigated	B-X
whether	B-X
the	B-X
TAG-p53	B-X
interaction	B-X
is	B-X
rate	B-X
limiting	B-X
in	B-X
the	B-X
development	B-X
of	B-X
phenotypic	B-X
changes	B-X
in	B-X
these	B-X
transgenic	B-X
mice	B-X
by	B-X
crossing	B-X
C3	B-X
(	B-X
1	B-X
)	B-X
/TAG	B-X
transgenics	B-X
with	B-X
mice	B-X
carrying	B-X
null	B-X
mutations	B-X
of	B-X
the	B-X
p53	B-X
gene	B-X
.	B-X
TAG-expressing	B-X
animals	B-X
with	B-X
a	B-X
p53+/-	B-X
genotype	B-X
developed	B-X
much	B-X
more	B-X
aggressive	B-X
mammary	B-X
tumors	B-X
,	B-X
as	B-X
evidenced	B-X
by	B-X
increased	B-X
numbers	B-X
and	B-X
size	B-X
of	B-X
metastases	B-X
,	B-X
than	B-X
did	B-X
TAG-expressing	B-X
animals	B-X
carrying	B-X
two	B-X
wild-type	B-X
p53	B-X
alleles	B-X
.	B-X
While	B-X
p53	B-X
was	B-X
expressed	B-X
in	B-X
primary	B-X
tumors	B-X
,	B-X
p53	B-X
expression	B-X
appeared	B-X
to	B-X
be	B-X
reduced	B-X
or	B-X
lost	B-X
in	B-X
many	B-X
metastases	B-X
in	B-X
mice	B-X
carrying	B-X
either	B-X
the	B-X
p53+/+	B-X
or	B-X
p53+/-	B-X
genotypes	B-X
.	B-X
The	B-X
tumorigenic	B-X
process	B-X
did	B-X
not	B-X
appear	B-X
to	B-X
be	B-X
due	B-X
to	B-X
the	B-X
loss	B-X
of	B-X
the	B-X
second	B-X
wild-type	B-X
p53	B-X
allele	B-X
or	B-X
the	B-X
gain	B-X
of	B-X
dominant	B-X
oncogenic	B-X
mutations	B-X
in	B-X
p53	B-X
,	B-X
as	B-X
no	B-X
mutations	B-X
were	B-X
detected	B-X
in	B-X
either	B-X
primary	B-X
or	B-X
metastatic	B-X
tumors	B-X
by	B-X
polymerase	B-X
chain	B-X
reaction	B-X
--	B-X
single-strand	B-X
conformation	B-X
polymorphism	B-X
analyses	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
despite	B-X
the	B-X
presence	B-X
of	B-X
TAG	B-X
,	B-X
p53	B-X
levels	B-X
influence	B-X
the	B-X
characteristics	B-X
of	B-X
the	B-X
late	B-X
stages	B-X
of	B-X
mammary	B-X
tumor	B-X
growth	B-X
and	B-X
accelerate	B-X
metastases	B-X
.	B-X

Whereas	O
mutations	O
and	O
deletions	O
or	O
insertions	O
have	O
permanent	O
effects	O
,	O
reversible	O
mechanisms	O
are	O
gene	O
methylation	O
,	O
or	O
expression	O
and	O
activation	O
of	O
transcription	O
factors	O
,	O
respectively	O
.	O
<EOS>	B-X
BRCA1	B-X
and	B-X
BRCA2	B-X
screening	B-X
in	B-X
women	B-X
at	B-X
high-risk	B-X
of	B-X
breast	B-X
cancer	B-X
results	B-X
in	B-X
the	B-X
identification	B-X
of	B-X
both	B-X
unambiguously	B-X
defined	B-X
deleterious	B-X
mutations	B-X
and	B-X
sequence	B-X
variants	B-X
of	B-X
unknown	B-X
clinical	B-X
significance	B-X
(	B-X
VUS	B-X
)	B-X
.	B-X
We	B-X
identified	B-X
470	B-X
unique	B-X
sequence	B-X
variants	B-X
,	B-X
of	B-X
which	B-X
113	B-X
were	B-X
deleterious	B-X
mutations	B-X
.	B-X
Deleterious	B-X
mutations	B-X
occurred	B-X
three	B-X
times	B-X
more	B-X
often	B-X
in	B-X
women	B-X
with	B-X
CBC	B-X
(	B-X
15.3	B-X
%	B-X
)	B-X
than	B-X
in	B-X
women	B-X
with	B-X
UBC	B-X
(	B-X
5.2	B-X
%	B-X
)	B-X
,	B-X
whereas	B-X
combined	B-X
,	B-X
VUS	B-X
were	B-X
observed	B-X
in	B-X
similar	B-X
frequencies	B-X
in	B-X
women	B-X
with	B-X
CBC	B-X
and	B-X
UBC	B-X
.	B-X
Despite	B-X
these	B-X
efforts	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
extent	B-X
to	B-X
which	B-X
environmental	B-X
stressors	B-X
accelerate	B-X
mutation	B-X
rates	B-X
and	B-X
influence	B-X
the	B-X
genetic	B-X
load	B-X
of	B-X
populations	B-X
.	B-X
Moreover	B-X
,	B-X
most	B-X
studies	B-X
on	B-X
stressors	B-X
have	B-X
focused	B-X
on	B-X
unicellular	B-X
organisms	B-X
and	B-X
point	B-X
mutations	B-X
rather	B-X
than	B-X
large-scale	B-X
deletions	B-X
and	B-X
duplications	B-X
(	B-X
copy	B-X
number	B-X
variations	B-X
[	B-X
CNVs	B-X
]	B-X
)	B-X
.	B-X

We	O
studied	O
a	O
putative	O
cause	O
for	O
absent	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
leukemia	O
cells	O
and	O
first	O
focused	O
on	O
genetic	O
aberrations	O
of	O
the	O
promoter	O
.	O

We	O
observed	O
no	O
genetic	O
alterations	O
in	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
,	O
which	O
can	O
account	O
for	O
the	O
lack	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
:	O
The	O
detected	O
base	O
pair	O
changes	O
at	O
position	O
-	O
1081	O
(	O
T	O
to	O
C	O
substitution	O
)	O
,	O
at	O
position	O
-	O
1068	O
(	O
A	O
to	O
C	O
substitution	O
)	O
and	O
at	O
position	O
-	O
116	O
(	O
A	O
to	O
C	O
substitution	O
)	O
are	O
unlikely	O
responsible	O
for	O
absent	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
expression	O
since	O
the	O
first	O
two	O
mutations	O
were	O
found	O
both	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
and	O
-	O
negative	O
cells	O
whereas	O
the	O
latter	O
change	O
was	O
not	O
detected	O
consistently	O
in	O
all	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
or	O
-	O
positive	O
cells	O
and	O
may	O
thus	O
be	O
a	O
polymorphism	O
.	O
<EOS>	B-X
CARD9	B-X
is	B-X
a	B-X
cytosolic	B-X
adaptor	B-X
in	B-X
myeloid	B-X
cells	B-X
,	B-X
has	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
inflammatory	B-X
disorders	B-X
,	B-X
and	B-X
provides	B-X
a	B-X
protective	B-X
function	B-X
against	B-X
microbial	B-X
pathogen	B-X
,	B-X
especially	B-X
fungal	B-X
infection	B-X
.	B-X
Recently	B-X
,	B-X
CARD9	B-X
polymorphisms	B-X
are	B-X
of	B-X
interest	B-X
,	B-X
showing	B-X
a	B-X
positive	B-X
correlation	B-X
with	B-X
the	B-X
elevated	B-X
risk	B-X
of	B-X
fungal	B-X
infection	B-X
,	B-X
inflammatory	B-X
bowel	B-X
disease	B-X
,	B-X
and	B-X
other	B-X
autoimmune	B-X
diseases	B-X
.	B-X
Mechanistically	B-X
,	B-X
CARD9	B-X
polymorphisms	B-X
impair	B-X
the	B-X
activation	B-X
of	B-X
RelB	B-X
,	B-X
a	B-X
subunit	B-X
of	B-X
non-canonical	B-X
NF-κB	B-X
,	B-X
which	B-X
lead	B-X
to	B-X
the	B-X
reduced	B-X
cytokine	B-X
and	B-X
chemokine	B-X
production	B-X
by	B-X
innate	B-X
immune	B-X
cells	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
CARD9	B-X
polymorphisms	B-X
show	B-X
a	B-X
defective	B-X
neutrophil	B-X
accumulation	B-X
in	B-X
infectious	B-X
sites	B-X
.	B-X
Furthermore	B-X
,	B-X
CARD9	B-X
polymorphisms	B-X
could	B-X
alter	B-X
the	B-X
composition	B-X
of	B-X
the	B-X
gut	B-X
microbiome	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarize	B-X
the	B-X
latest	B-X
findings	B-X
of	B-X
CARD9	B-X
polymorphisms	B-X
with	B-X
respect	B-X
to	B-X
inflammatory	B-X
diseases	B-X
.	B-X

All	O
three	O
substitutions	O
did	O
not	O
change	O
any	O
known	O
putative	O
transcription	O
factor	O
binding	O
sites	O
(	O
30	O
,	O
31	O
)	O
and	O
also	O
do	O
not	O
affect	O
any	O
restriction	O
sites	O
or	O
primer	O
binding	O
sites	O
of	O
the	O
used	O
assays	O
.	O
<EOS>	B-X
Despite	B-X
the	B-X
publication	B-X
of	B-X
numerous	B-X
guidelines	B-X
,	B-X
the	B-X
actual	B-X
design	B-X
of	B-X
many	B-X
published	B-X
assays	B-X
is	B-X
often	B-X
unsound	B-X
:	B-X
primers	B-X
lack	B-X
the	B-X
claimed	B-X
specificity	B-X
,	B-X
they	B-X
may	B-X
have	B-X
to	B-X
compete	B-X
with	B-X
secondary	B-X
structures	B-X
at	B-X
their	B-X
binding	B-X
sites	B-X
,	B-X
primer	B-X
dimer	B-X
formation	B-X
may	B-X
affect	B-X
the	B-X
assay	B-X
's	B-X
sensitivity	B-X
or	B-X
they	B-X
may	B-X
bind	B-X
only	B-X
within	B-X
a	B-X
narrow	B-X
temperature	B-X
range	B-X
.	B-X
Riboswitches	B-X
are	B-X
intricate	B-X
,	B-X
metabolite-binding	B-X
RNA	B-X
structures	B-X
found	B-X
in	B-X
the	B-X
non-coding	B-X
regions	B-X
of	B-X
mRNA	B-X
.	B-X
Allosteric	B-X
changes	B-X
in	B-X
the	B-X
riboswitch	B-X
that	B-X
are	B-X
induced	B-X
by	B-X
metabolite	B-X
binding	B-X
are	B-X
harnessed	B-X
to	B-X
control	B-X
the	B-X
genes	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
essential	B-X
metabolic	B-X
pathways	B-X
in	B-X
eubacteria	B-X
and	B-X
in	B-X
some	B-X
eukaryotes	B-X
.	B-X
This	B-X
assay	B-X
makes	B-X
use	B-X
of	B-X
the	B-X
natural	B-X
instability	B-X
of	B-X
RNA	B-X
to	B-X
elucidate	B-X
secondary	B-X
structure	B-X
characteristics	B-X
and	B-X
ligand-binding	B-X
capabilities	B-X
of	B-X
riboswitches	B-X
in	B-X
an	B-X
entirely	B-X
protein-free	B-X
manner	B-X
.	B-X
Although	B-X
this	B-X
method	B-X
has	B-X
most	B-X
frequently	B-X
been	B-X
used	B-X
to	B-X
examine	B-X
riboswitches	B-X
,	B-X
the	B-X
structures	B-X
of	B-X
any	B-X
RNAs	B-X
can	B-X
be	B-X
examined	B-X
using	B-X
this	B-X
technique	B-X
.	B-X

However	O
,	O
permanent	O
genetic	O
variations	O
in	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
coding	O
sequence	O
,	O
such	O
as	O
deletions	O
or	O
mutations	O
resulting	O
in	O
stop	O
-	O
codons	O
have	O
not	O
been	O
excluded	O
by	O
sequence	O
analysis	O
.	O
<EOS>	B-X
Dystrophin	B-X
is	B-X
a	B-X
421	B-X
kD	B-X
protein	B-X
which	B-X
links	B-X
F-actin	B-X
to	B-X
the	B-X
extracellular	B-X
matrix	B-X
via	B-X
the	B-X
dystrophin-associated	B-X
protein	B-X
complex	B-X
(	B-X
DAPC	B-X
)	B-X
at	B-X
the	B-X
muscle	B-X
membrane	B-X
.	B-X
However	B-X
,	B-X
there	B-X
are	B-X
several	B-X
promising	B-X
genetic	B-X
therapeutic	B-X
approaches	B-X
at	B-X
the	B-X
preclinical	B-X
stage	B-X
or	B-X
in	B-X
clinical	B-X
trials	B-X
including	B-X
read-through	B-X
of	B-X
stop	B-X
codons	B-X
,	B-X
exon	B-X
skipping	B-X
,	B-X
delivery	B-X
of	B-X
dystrophin	B-X
minigenes	B-X
and	B-X
the	B-X
modulation	B-X
of	B-X
expression	B-X
of	B-X
the	B-X
dystrophin	B-X
related	B-X
protein	B-X
,	B-X
utrophin	B-X
.	B-X
This	B-X
short	B-X
review	B-X
provides	B-X
a	B-X
summary	B-X
of	B-X
the	B-X
current	B-X
status	B-X
of	B-X
DMD	B-X
therapy	B-X
with	B-X
a	B-X
particular	B-X
focus	B-X
on	B-X
those	B-X
genetic	B-X
strategies	B-X
that	B-X
have	B-X
been	B-X
taken	B-X
to	B-X
the	B-X
clinic	B-X
.	B-X
Overall	B-X
,	B-X
we	B-X
present	B-X
a	B-X
compilation	B-X
of	B-X
120	B-X
unique	B-X
variants	B-X
identified	B-X
in	B-X
155	B-X
unrelated	B-X
families	B-X
ranging	B-X
from	B-X
single	B-X
nucleotide	B-X
coding	B-X
variants	B-X
to	B-X
genomic	B-X
rearrangements	B-X
distributed	B-X
throughout	B-X
the	B-X
entire	B-X
coding	B-X
region	B-X
of	B-X
SATB2	B-X
.	B-X
Single	B-X
nucleotide	B-X
variants	B-X
predicted	B-X
to	B-X
result	B-X
in	B-X
the	B-X
occurrence	B-X
of	B-X
a	B-X
premature	B-X
stop	B-X
codon	B-X
were	B-X
the	B-X
most	B-X
commonly	B-X
seen	B-X
(	B-X
51/120	B-X
=	B-X
42.5	B-X
%	B-X
)	B-X
followed	B-X
by	B-X
missense	B-X
variants	B-X
(	B-X
31/120	B-X
=	B-X
25.8	B-X
%	B-X
)	B-X
.	B-X
We	B-X
review	B-X
the	B-X
rather	B-X
limited	B-X
functional	B-X
characterization	B-X
of	B-X
pathogenic	B-X
variants	B-X
and	B-X
discuss	B-X
current	B-X
understanding	B-X
of	B-X
the	B-X
consequences	B-X
of	B-X
the	B-X
different	B-X
molecular	B-X
alterations	B-X
.	B-X

Since	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
cell	O
lines	O
and	O
CML	O
can	O
be	O
induced	O
by	O
demethylation	O
and	O
successful	O
IFN	B-Protein
-	I-Protein
alpha	I-Protein
therapy	O
(	O
3	O
)	O
,	O
respectively	O
,	O
the	O
existence	O
of	O
such	O
genetic	O
aberrations	O
seems	O
unlikely	O
.	O

We	O
then	O
investigated	O
whether	O
the	O
previously	O
described	O
down	O
-	O
regulation	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
human	O
myeloid	O
leukemias	O
was	O
due	O
to	O
a	O
differential	O
hypermethylation	O
of	O
the	O
promoter	O
,	O
since	O
the	O
presented	O
re	O
-	O
expression	O
due	O
to	O
AzadC	O
-	O
treatment	O
might	O
also	O
be	O
a	O
result	O
of	O
activation	O
of	O
positive	O
transcriptional	O
regulators	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
.	O

Methylation	O
of	O
CpG	O
sites	O
is	O
a	O
common	O
mechanism	O
of	O
silencing	O
genes	O
in	O
leukemia	O
and	O
has	O
also	O
been	O
shown	O
for	O
another	O
IRF	O
,	O
IRF	B-Protein
-	I-Protein
7	I-Protein
(	O
35	O
)	O
and	O
for	O
PU	B-Protein
.	I-Protein
1	I-Protein
(	O
36	O
)	O
,	O
an	O
interacting	O
partner	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
.	O

To	O
elucidate	O
the	O
relevance	O
of	O
this	O
mechanism	O
for	O
the	O
regulation	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
,	O
various	O
leukemic	O
cells	O
were	O
treated	O
with	O
demethylating	O
agents	O
and	O
promoters	O
were	O
sequenced	O
after	O
bisulfite	O
treatment	O
.	O

We	O
found	O
that	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
could	O
indeed	O
be	O
connected	O
to	O
the	O
methylation	O
status	O
of	O
distinct	O
CpG	O
motifs	O
in	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
.	O

In	O
Figure	O
4A	O
,	O
those	O
CpG	O
sites	O
are	O
shown	O
(	O
bottom	O
line	O
)	O
,	O
whose	O
hypermethylation	O
may	O
account	O
for	O
the	O
absence	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
the	O
respective	O
cells	O
.	O

One	O
of	O
them	O
(	O
#	O
54	O
)	O
is	O
adjacent	O
to	O
an	O
identified	O
regulatory	O
element	O
(	O
NFkappaB	O
-	O
site	O
)	O
,	O
indicating	O
a	O
possible	O
involvement	O
of	O
this	O
site	O
.	O

At	O
two	O
further	O
CpG	O
sites	O
(	O
#	O
48	O
,	O
45	O
)	O
the	O
methylation	O
status	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
was	O
lower	O
than	O
that	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
negative	O
cells	O
.	O

These	O
CpG	O
sites	O
are	O
located	O
in	O
an	O
NFkappaB	O
and	O
an	O
SP1	O
element	O
(	O
31	O
)	O
and	O
thus	O
may	O
also	O
play	O
a	O
role	O
in	O
regulation	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
.	O

It	O
has	O
been	O
shown	O
that	O
NFkappaB	O
elements	O
play	O
an	O
important	O
role	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
induction	O
as	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
depends	O
on	O
binding	O
of	O
the	O
transactivator	O
c	B-Protein
-	I-Protein
Rel	I-Protein
to	O
these	O
elements	O
in	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
(	O
31	O
,	O
37	O
)	O
.	O

Furthermore	O
,	O
methylation	O
of	O
the	O
central	O
CpG	O
in	O
the	O
NFkappaB	O
element	O
inhibits	O
binding	O
of	O
the	O
NFkappaB	O
protein	O
complexes	O
(	O
38	O
)	O
,	O
promoting	O
the	O
significance	O
of	O
the	O
observed	O
methylation	O
differences	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
positive	O
and	O
-	O
negative	O
cells	O
.	O

Via	O
in	O
vitro	O
methylation	O
and	O
reporter	O
gene	O
assays	O
we	O
could	O
clearly	O
appoint	O
the	O
silencing	O
of	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
to	O
a	O
methylation	O
effect	O
,	O
which	O
may	O
thus	O
be	O
the	O
mechanism	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
deregulation	O
in	O
vivo	O
.	O

One	O
possible	O
cause	O
for	O
the	O
aberrant	O
methylation	O
in	O
tumorigenesis	O
is	O
an	O
increased	O
level	O
of	O
DNMTs	O
during	O
the	O
pathogenetic	O
process	O
.	O

In	O
colon	O
,	O
lung	O
and	O
hematologic	O
malignancies	O
,	O
overexpression	O
of	O
DNMT1	B-Protein
,	O
a	O
maintenance	O
DNMT	O
,	O
has	O
been	O
detected	O
(	O
39	O
-	O
41	O
)	O
.	O

Furthermore	O
,	O
it	O
has	O
been	O
shown	O
that	O
CML	O
cells	O
in	O
the	O
acute	O
phase	O
exhibited	O
elevated	O
levels	O
of	O
the	O
three	O
known	O
DNMTs	O
,	O
while	O
CML	O
cells	O
in	O
chronic	O
phase	O
expressed	O
normal	O
levels	O
of	O
DNMTs	O
if	O
compared	O
with	O
normal	O
bone	O
marrow	O
cells	O
(	O
25	O
)	O
.	O

Interestingly	O
,	O
a	O
positive	O
correlation	O
between	O
DNMT1	B-Protein
expression	O
levels	O
and	O
hypermethylation	O
of	O
p15INK4b	B-Protein
has	O
been	O
detected	O
in	O
AML	O
(	O
25	O
)	O
.	O

In	O
this	O
work	O
,	O
we	O
did	O
not	O
detect	O
significant	O
mRNA	O
expression	O
differences	O
of	O
selected	O
DNMT	O
or	O
MBP	O
,	O
making	O
it	O
an	O
unlikely	O
cause	O
for	O
the	O
observed	O
methylation	O
and	O
thus	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
differences	O
in	O
leukemia	O
cells	O
.	O
<EOS>	B-X
Medication	B-X
administration	B-X
accounts	B-X
for	B-X
40	B-X
%	B-X
of	B-X
the	B-X
nursing	B-X
clinical	B-X
activity	B-X
in	B-X
hospitals	B-X
and	B-X
nurses	B-X
play	B-X
a	B-X
central	B-X
role	B-X
in	B-X
granting	B-X
the	B-X
patient	B-X
safety	B-X
,	B-X
as	B-X
they	B-X
are	B-X
directly	B-X
responsible	B-X
for	B-X
the	B-X
patient	B-X
care	B-X
.	B-X
This	B-X
review	B-X
aims	B-X
at	B-X
analyzing	B-X
the	B-X
correlation	B-X
between	B-X
the	B-X
clinical	B-X
risk	B-X
management	B-X
and	B-X
the	B-X
occurrence	B-X
of	B-X
medication	B-X
errors	B-X
and	B-X
the	B-X
effects	B-X
of	B-X
the	B-X
shift	B-X
work	B-X
(	B-X
such	B-X
as	B-X
excessive	B-X
fatigue	B-X
and	B-X
sleep	B-X
deprivation	B-X
after	B-X
a	B-X
shift	B-X
in	B-X
hospital	B-X
)	B-X
on	B-X
inpatient	B-X
nurses	B-X
.	B-X
Office	B-X
workers	B-X
are	B-X
exposed	B-X
to	B-X
high	B-X
levels	B-X
of	B-X
sedentary	B-X
time	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
cardio-vascular	B-X
and	B-X
metabolic	B-X
health	B-X
risks	B-X
,	B-X
this	B-X
sedentary	B-X
time	B-X
may	B-X
have	B-X
musculoskeletal	B-X
and/or	B-X
cognitive	B-X
impacts	B-X
on	B-X
office	B-X
workers	B-X
.	B-X
Participants	B-X
(	B-X
n	B-X
=	B-X
20	B-X
)	B-X
undertook	B-X
two	B-X
hours	B-X
of	B-X
laboratory-based	B-X
sitting	B-X
computer	B-X
work	B-X
to	B-X
investigate	B-X
changes	B-X
in	B-X
discomfort	B-X
and	B-X
cognitive	B-X
function	B-X
(	B-X
sustained	B-X
attention	B-X
and	B-X
problem	B-X
solving	B-X
)	B-X
,	B-X
along	B-X
with	B-X
muscle	B-X
fatigue	B-X
,	B-X
movement	B-X
and	B-X
mental	B-X
state	B-X
.	B-X
Over	B-X
time	B-X
,	B-X
discomfort	B-X
increased	B-X
in	B-X
all	B-X
body	B-X
areas	B-X
(	B-X
total	B-X
body	B-X
IRR	B-X
[	B-X
95	B-X
%	B-X
confidence	B-X
interval	B-X
]	B-X
:	B-X
1.43	B-X
[	B-X
1.33⁻1.53	B-X
]	B-X
)	B-X
reaching	B-X
clinically	B-X
meaningful	B-X
levels	B-X
in	B-X
the	B-X
low	B-X
back	B-X
and	B-X
hip/thigh/buttock	B-X
areas	B-X
.	B-X
Creative	B-X
problem	B-X
solving	B-X
errors	B-X
increased	B-X
(	B-X
β	B-X
=	B-X
0.25	B-X
[	B-X
0.03⁻1.47	B-X
]	B-X
)	B-X
while	B-X
sustained	B-X
attention	B-X
did	B-X
not	B-X
change	B-X
.	B-X
The	B-X
observed	B-X
changes	B-X
suggest	B-X
prolonged	B-X
sitting	B-X
may	B-X
have	B-X
consequences	B-X
for	B-X
musculoskeletal	B-X
discomfort	B-X
and	B-X
cognitive	B-X
function	B-X
and	B-X
breaks	B-X
to	B-X
interrupt	B-X
prolonged	B-X
sitting	B-X
are	B-X
recommended	B-X
.	B-X

The	O
finding	O
that	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
is	O
silenced	O
by	O
promoter	O
hypermethylation	O
might	O
represent	O
a	O
mechanism	O
that	O
accounts	O
for	O
the	O
previously	O
observed	O
loss	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
in	O
CML	O
.	O

Indeed	O
,	O
several	O
clinical	O
trials	O
with	O
leukemia	O
patients	O
and	O
patients	O
with	O
myelodysplastic	O
syndromes	O
demonstrated	O
the	O
potential	O
clinical	O
benefit	O
of	O
a	O
treatment	O
with	O
demethylating	O
agents	O
(	O
42	O
-	O
45	O
)	O
.	O

The	O
expression	O
of	O
another	O
IRF	O
,	O
IFN	B-Protein
consensus	I-Protein
sequence	I-Protein
binding	I-Protein
protein	I-Protein
(	O
ICSBP	B-Protein
/	O
IRF	B-Protein
-	I-Protein
8	I-Protein
)	O
,	O
is	O
impaired	O
in	O
myeloid	O
leukemias	O
especially	O
CML	O
(	O
27	O
,	O
46	O
,	O
47	O
)	O
.	O

But	O
in	O
contrast	O
to	O
IRF	B-Protein
-	I-Protein
4	I-Protein
,	O
the	O
loss	O
of	O
this	O
IRF	O
could	O
not	O
be	O
reverted	O
in	O
ICSBP	B-Protein
-	O
negative	O
cell	O
lines	O
(	O
EM	O
-	O
2	O
,	O
CML	O
-	O
T1	O
,	O
K	O
-	O
562	O
and	O
LAMA	O
-	O
84	O
)	O
by	O
treatment	O
with	O
AzadC	O
(	O
Figure	O
6	O
)	O
and	O
AzadC	O
has	O
no	O
effect	O
on	O
ICSBP	B-Protein
levels	O
in	O
ICSBP	B-Protein
-	O
positive	O
U	O
-	O
937	O
cells	O
(	O
Figure	O
6	O
)	O
.	O

These	O
data	O
suggest	O
a	O
distinct	O
regulatory	O
mechanism	O
for	O
these	O
two	O
IRFs	O
.	O

IRF	B-Protein
-	I-Protein
4	I-Protein
,	O
similar	O
to	O
many	O
other	O
classical	O
tumor	O
suppressor	O
genes	O
p15INK4b	B-Protein
,	O
p16INK4a	B-Protein
or	O
p53	B-Protein
,	O
may	O
thus	O
be	O
a	O
subject	O
of	O
alterations	O
in	O
the	O
promoter	O
methylation	O
status	O
leading	O
to	O
expression	O
changes	O
,	O
which	O
might	O
contribute	O
to	O
the	O
initiation	O
and	O
/	O
or	O
progression	O
of	O
cancer	O
.	O
<EOS>	B-X
Tumor	B-X
heterogeneity	B-X
represents	B-X
an	B-X
ongoing	B-X
challenge	B-X
in	B-X
the	B-X
field	B-X
of	B-X
cancer	B-X
therapy	B-X
.	B-X
Heterogeneity	B-X
is	B-X
evident	B-X
between	B-X
cancers	B-X
from	B-X
different	B-X
patients	B-X
(	B-X
inter-tumor	B-X
heterogeneity	B-X
)	B-X
and	B-X
within	B-X
a	B-X
single	B-X
tumor	B-X
(	B-X
intra-tumor	B-X
heterogeneity	B-X
)	B-X
.	B-X
The	B-X
latter	B-X
includes	B-X
phenotypic	B-X
diversity	B-X
such	B-X
as	B-X
cell	B-X
surface	B-X
markers	B-X
,	B-X
(	B-X
epi	B-X
)	B-X
genetic	B-X
abnormality	B-X
,	B-X
growth	B-X
rate	B-X
,	B-X
apoptosis	B-X
and	B-X
other	B-X
hallmarks	B-X
of	B-X
cancer	B-X
that	B-X
eventually	B-X
drive	B-X
disease	B-X
progression	B-X
and	B-X
treatment	B-X
failure	B-X
.	B-X
Cancer	B-X
stem	B-X
cells	B-X
(	B-X
CSCs	B-X
)	B-X
have	B-X
been	B-X
put	B-X
forward	B-X
to	B-X
be	B-X
one	B-X
of	B-X
the	B-X
determining	B-X
factors	B-X
that	B-X
contribute	B-X
to	B-X
intra-tumor	B-X
heterogeneity	B-X
.	B-X
However	B-X
,	B-X
recent	B-X
findings	B-X
have	B-X
shown	B-X
that	B-X
the	B-X
stem-like	B-X
state	B-X
in	B-X
a	B-X
given	B-X
tumor	B-X
cell	B-X
is	B-X
a	B-X
plastic	B-X
quality	B-X
.	B-X
A	B-X
corollary	B-X
to	B-X
this	B-X
view	B-X
is	B-X
that	B-X
stemness	B-X
traits	B-X
can	B-X
be	B-X
acquired	B-X
via	B-X
(	B-X
epi	B-X
)	B-X
genetic	B-X
modification	B-X
and/or	B-X
interaction	B-X
with	B-X
the	B-X
tumor	B-X
microenvironment	B-X
(	B-X
TME	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
discuss	B-X
factors	B-X
contributing	B-X
to	B-X
this	B-X
CSC	B-X
heterogeneity	B-X
and	B-X
the	B-X
potential	B-X
implications	B-X
for	B-X
cancer	B-X
therapy	B-X
.	B-X

Still	O
,	O
the	O
obvious	O
functional	O
diversity	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
remains	O
remarkable	O
and	O
cannot	O
be	O
fully	O
explained	O
by	O
the	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
methylation	O
status	O
.	O

For	O
example	O
,	O
IRF	B-Protein
-	I-Protein
4	I-Protein
is	O
primarily	O
known	O
for	O
its	O
oncogenic	O
features	O
.	O

In	O
multiple	O
myeloma	O
(	O
MM	O
)	O
a	O
translocation	O
on	O
chromosome	O
14q	O
was	O
reported	O
to	O
lead	O
to	O
a	O
fusion	O
gene	O
of	O
immunoglobulin	B-Protein
heavy	I-Protein
-	I-Protein
chain	I-Protein
(	O
IgH	B-Protein
)	O
and	O
IRF	B-Protein
-	I-Protein
4	I-Protein
resulting	O
in	O
a	O
subsequent	O
overexpression	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
(	O
48	O
,	O
49	O
)	O
.	O

In	O
addition	O
,	O
abundant	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
was	O
found	O
to	O
be	O
a	O
marker	O
for	O
various	O
subsets	O
of	O
lymphomas	O
,	O
such	O
as	O
diffuse	O
large	O
B	O
-	O
cell	O
lymphomas	O
,	O
primary	O
effusion	O
lymphoma	O
,	O
and	O
marginal	O
zone	O
lymphoma	O
,	O
and	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
11	O
,	O
31	O
,	O
50	O
-	O
52	O
)	O
.	O

This	O
draws	O
a	O
more	O
complex	O
picture	O
of	O
the	O
role	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
.	O

Down	O
-	O
regulation	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
may	O
promote	O
leukemogenesis	O
in	O
myeloid	O
cell	O
context	O
(	O
3	O
)	O
,	O
which	O
was	O
recently	O
confirmed	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
/	O
-	O
ICSBP	B-Protein
-	O
/	O
-	O
double	O
knock	O
-	O
out	O
mice	O
(	O
53	O
)	O
,	O
while	O
IRF	B-Protein
-	I-Protein
4	I-Protein
up	O
-	O
regulation	O
may	O
induce	O
a	O
growth	O
advantage	O
in	O
lymphomas	O
or	O
MM	O
(	O
48	O
)	O
.	O

In	O
multiple	O
myeloma	O
(	O
MM	O
)	O
a	O
translocation	O
on	O
chromosome	O
14q	O
was	O
reported	O
to	O
lead	O
to	O
a	O
fusion	O
gene	O
of	O
immunoglobulin	B-Protein
heavy	I-Protein
-	I-Protein
chain	I-Protein
(	O
IgH	B-Protein
)	O
and	O
IRF	B-Protein
-	I-Protein
4	I-Protein
resulting	O
in	O
a	O
subsequent	O
overexpression	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
(	O
48	O
,	O
49	O
)	O
.	O

In	O
addition	O
,	O
abundant	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
was	O
found	O
to	O
be	O
a	O
marker	O
for	O
various	O
subsets	O
of	O
lymphomas	O
,	O
such	O
as	O
diffuse	O
large	O
B	O
-	O
cell	O
lymphomas	O
,	O
primary	O
effusion	O
lymphoma	O
,	O
and	O
marginal	O
zone	O
lymphoma	O
,	O
and	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
11	O
,	O
31	O
,	O
50	O
-	O
52	O
)	O
.	O

This	O
draws	O
a	O
more	O
complex	O
picture	O
of	O
the	O
role	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
.	O

Down	O
-	O
regulation	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
may	O
promote	O
leukemogenesis	O
in	O
myeloid	O
cell	O
context	O
(	O
3	O
)	O
,	O
which	O
was	O
recently	O
confirmed	O
in	O
IRF	B-Protein
-	I-Protein
4	I-Protein
-	O
/	O
-	O
ICSBP	B-Protein
-	O
/	O
-	O
double	O
knock	O
-	O
out	O
mice	O
(	O
53	O
)	O
,	O
while	O
IRF	B-Protein
-	I-Protein
4	I-Protein
up	O
-	O
regulation	O
may	O
induce	O
a	O
growth	O
advantage	O
in	O
lymphomas	O
or	O
MM	O
(	O
48	O
)	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
methylation	O
regulates	O
IRF	B-Protein
-	I-Protein
4	I-Protein
expression	O
,	O
and	O
that	O
aberrant	O
expression	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
in	O
certain	O
types	O
of	O
leukemia	O
may	O
be	O
a	O
consequence	O
of	O
IRF	B-Protein
-	I-Protein
4	I-Protein
promoter	O
hypermethylation	O
.	O

Foxp3	B-Protein
Represses	O
Retroviral	O
Transcription	O
by	O
Targeting	O
Both	O
NF	O
-	O
kappaB	O
and	O
CREB	O
Pathways	O

Forkhead	O
box	O
(	O
Fox	O
)	O
/	O
winged	O
-	O
helix	O
transcription	O
factors	O
regulate	O
multiple	O
aspects	O
of	O
immune	O
responsiveness	O
and	O
Foxp3	B-Protein
is	O
recognized	O
as	O
an	O
essential	O
functional	O
marker	O
of	O
regulatory	O
T	O
cells	O
.	O
<EOS>	B-X
Forkhead	B-X
box	B-X
(	B-X
Fox	B-X
)	B-X
/winged-helix	B-X
transcription	B-X
factors	B-X
regulate	B-X
multiple	B-X
aspects	B-X
of	B-X
immune	B-X
responsiveness	B-X
and	B-X
Foxp3	B-X
is	B-X
recognized	B-X
as	B-X
an	B-X
essential	B-X
functional	B-X
marker	B-X
of	B-X
regulatory	B-X
T	B-X
cells	B-X
.	B-X
Herein	B-X
we	B-X
describe	B-X
downstream	B-X
signaling	B-X
pathways	B-X
targeted	B-X
by	B-X
Foxp3	B-X
that	B-X
may	B-X
negatively	B-X
impact	B-X
retroviral	B-X
pathogenesis	B-X
.	B-X
Overexpression	B-X
of	B-X
Foxp3	B-X
in	B-X
HEK	B-X
293T	B-X
and	B-X
purified	B-X
CD4+	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
a	B-X
dose-dependent	B-X
and	B-X
time-dependent	B-X
decrease	B-X
in	B-X
basal	B-X
levels	B-X
of	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
activation	B-X
.	B-X
Deletion	B-X
of	B-X
the	B-X
carboxyl-terminal	B-X
forkhead	B-X
(	B-X
FKH	B-X
)	B-X
domain	B-X
,	B-X
critical	B-X
for	B-X
nuclear	B-X
localization	B-X
and	B-X
DNA-binding	B-X
activity	B-X
,	B-X
abrogated	B-X
the	B-X
ability	B-X
of	B-X
Foxp3	B-X
to	B-X
suppress	B-X
NF-kappaB	B-X
activity	B-X
in	B-X
HEK	B-X
293T	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
Jurkat	B-X
or	B-X
primary	B-X
human	B-X
CD4+	B-X
T	B-X
cells	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
Foxp3	B-X
suppressed	B-X
the	B-X
transcription	B-X
of	B-X
two	B-X
human	B-X
retroviral	B-X
promoters	B-X
(	B-X
HIV-1	B-X
and	B-X
human	B-X
T	B-X
cell	B-X
lymphotropic	B-X
virus	B-X
type	B-X
I	B-X
[	B-X
HTLV-I	B-X
]	B-X
)	B-X
utilizing	B-X
NF-kappaB-dependent	B-X
and	B-X
NF-kappaB-independent	B-X
mechanisms	B-X
.	B-X
Examination	B-X
of	B-X
the	B-X
latter	B-X
identified	B-X
the	B-X
cAMP-responsive	B-X
element	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
pathway	B-X
as	B-X
a	B-X
target	B-X
of	B-X
Foxp3	B-X
.	B-X
Finally	B-X
,	B-X
comparison	B-X
of	B-X
the	B-X
percent	B-X
Foxp3+CD4+CD25+	B-X
T	B-X
cells	B-X
to	B-X
the	B-X
HTLV-I	B-X
proviral	B-X
load	B-X
in	B-X
HTLV-I-infected	B-X
asymptomatic	B-X
carriers	B-X
and	B-X
patients	B-X
with	B-X
HTLV-I-associated	B-X
myelopathy/tropical	B-X
spastic	B-X
paraparesis	B-X
suggested	B-X
that	B-X
high	B-X
Foxp3	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
low	B-X
proviral	B-X
load	B-X
and	B-X
absence	B-X
of	B-X
disease	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
an	B-X
expanded	B-X
role	B-X
for	B-X
Foxp3	B-X
in	B-X
regulating	B-X
NF-kappaB-	B-X
and	B-X
CREB-dependent	B-X
cellular	B-X
and	B-X
viral	B-X
gene	B-X
expression	B-X
.	B-X

Herein	O
we	O
describe	O
downstream	O
signaling	O
pathways	O
targeted	O
by	O
Foxp3	B-Protein
that	O
may	O
negatively	O
impact	O
retroviral	O
pathogenesis	O
.	O
<EOS>	B-X
Forkhead	B-X
box	B-X
(	B-X
Fox	B-X
)	B-X
/winged-helix	B-X
transcription	B-X
factors	B-X
regulate	B-X
multiple	B-X
aspects	B-X
of	B-X
immune	B-X
responsiveness	B-X
and	B-X
Foxp3	B-X
is	B-X
recognized	B-X
as	B-X
an	B-X
essential	B-X
functional	B-X
marker	B-X
of	B-X
regulatory	B-X
T	B-X
cells	B-X
.	B-X
Herein	B-X
we	B-X
describe	B-X
downstream	B-X
signaling	B-X
pathways	B-X
targeted	B-X
by	B-X
Foxp3	B-X
that	B-X
may	B-X
negatively	B-X
impact	B-X
retroviral	B-X
pathogenesis	B-X
.	B-X
Overexpression	B-X
of	B-X
Foxp3	B-X
in	B-X
HEK	B-X
293T	B-X
and	B-X
purified	B-X
CD4+	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
a	B-X
dose-dependent	B-X
and	B-X
time-dependent	B-X
decrease	B-X
in	B-X
basal	B-X
levels	B-X
of	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
activation	B-X
.	B-X
Deletion	B-X
of	B-X
the	B-X
carboxyl-terminal	B-X
forkhead	B-X
(	B-X
FKH	B-X
)	B-X
domain	B-X
,	B-X
critical	B-X
for	B-X
nuclear	B-X
localization	B-X
and	B-X
DNA-binding	B-X
activity	B-X
,	B-X
abrogated	B-X
the	B-X
ability	B-X
of	B-X
Foxp3	B-X
to	B-X
suppress	B-X
NF-kappaB	B-X
activity	B-X
in	B-X
HEK	B-X
293T	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
Jurkat	B-X
or	B-X
primary	B-X
human	B-X
CD4+	B-X
T	B-X
cells	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
Foxp3	B-X
suppressed	B-X
the	B-X
transcription	B-X
of	B-X
two	B-X
human	B-X
retroviral	B-X
promoters	B-X
(	B-X
HIV-1	B-X
and	B-X
human	B-X
T	B-X
cell	B-X
lymphotropic	B-X
virus	B-X
type	B-X
I	B-X
[	B-X
HTLV-I	B-X
]	B-X
)	B-X
utilizing	B-X
NF-kappaB-dependent	B-X
and	B-X
NF-kappaB-independent	B-X
mechanisms	B-X
.	B-X
Examination	B-X
of	B-X
the	B-X
latter	B-X
identified	B-X
the	B-X
cAMP-responsive	B-X
element	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
pathway	B-X
as	B-X
a	B-X
target	B-X
of	B-X
Foxp3	B-X
.	B-X
Finally	B-X
,	B-X
comparison	B-X
of	B-X
the	B-X
percent	B-X
Foxp3+CD4+CD25+	B-X
T	B-X
cells	B-X
to	B-X
the	B-X
HTLV-I	B-X
proviral	B-X
load	B-X
in	B-X
HTLV-I-infected	B-X
asymptomatic	B-X
carriers	B-X
and	B-X
patients	B-X
with	B-X
HTLV-I-associated	B-X
myelopathy/tropical	B-X
spastic	B-X
paraparesis	B-X
suggested	B-X
that	B-X
high	B-X
Foxp3	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
low	B-X
proviral	B-X
load	B-X
and	B-X
absence	B-X
of	B-X
disease	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
an	B-X
expanded	B-X
role	B-X
for	B-X
Foxp3	B-X
in	B-X
regulating	B-X
NF-kappaB-	B-X
and	B-X
CREB-dependent	B-X
cellular	B-X
and	B-X
viral	B-X
gene	B-X
expression	B-X
.	B-X

Overexpression	O
of	O
Foxp3	B-Protein
in	O
HEK	O
293T	O
and	O
purified	O
CD4	B-Protein
+	O
T	O
cells	O
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
and	O
time	O
-	O
dependent	O
decrease	O
in	O
basal	O
levels	O
of	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
activation	O
.	O

Deletion	O
of	O
the	O
carboxyl	O
-	O
terminal	O
forkhead	O
(	O
FKH	O
)	O
domain	O
,	O
critical	O
for	O
nuclear	O
localization	O
and	O
DNA	O
-	O
binding	O
activity	O
,	O
abrogated	O
the	O
ability	O
of	O
Foxp3	B-Protein
to	O
suppress	O
NF	O
-	O
kappaB	O
activity	O
in	O
HEK	O
293T	O
cells	O
,	O
but	O
not	O
in	O
Jurkat	O
or	O
primary	O
human	O
CD4	B-Protein
+	O
T	O
cells	O
.	O
<EOS>	B-X
Multiple	B-X
sclerosis	B-X
(	B-X
MS	B-X
)	B-X
has	B-X
long	B-X
been	B-X
considered	B-X
a	B-X
CD4	B-X
T-cell	B-X
disease	B-X
,	B-X
primarily	B-X
because	B-X
of	B-X
the	B-X
findings	B-X
that	B-X
the	B-X
strongest	B-X
genetic	B-X
risk	B-X
for	B-X
MS	B-X
is	B-X
the	B-X
major	B-X
histocompatibility	B-X
complex	B-X
(	B-X
MHC	B-X
)	B-X
class	B-X
II	B-X
locus	B-X
,	B-X
and	B-X
that	B-X
T	B-X
cells	B-X
play	B-X
a	B-X
central	B-X
role	B-X
in	B-X
directing	B-X
the	B-X
immune	B-X
response	B-X
.	B-X
The	B-X
importance	B-X
that	B-X
the	B-X
T	B-X
helper	B-X
(	B-X
Th	B-X
)	B-X
1	B-X
cytokine	B-X
,	B-X
interferon	B-X
γ	B-X
(	B-X
IFN-γ	B-X
)	B-X
,	B-X
and	B-X
the	B-X
Th17	B-X
cytokine	B-X
,	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-17	B-X
,	B-X
play	B-X
in	B-X
MS	B-X
pathogenesis	B-X
is	B-X
indicated	B-X
by	B-X
recent	B-X
clinical	B-X
trial	B-X
data	B-X
by	B-X
the	B-X
enhanced	B-X
presence	B-X
of	B-X
Th1/Th17	B-X
cells	B-X
in	B-X
central	B-X
nervous	B-X
system	B-X
(	B-X
CNS	B-X
)	B-X
tissue	B-X
,	B-X
cerebrospinal	B-X
fluid	B-X
(	B-X
CSF	B-X
)	B-X
,	B-X
and	B-X
blood	B-X
,	B-X
and	B-X
by	B-X
research	B-X
on	B-X
animal	B-X
models	B-X
of	B-X
MS	B-X
,	B-X
such	B-X
as	B-X
experimental	B-X
autoimmune	B-X
encephalomyelitis	B-X
(	B-X
EAE	B-X
)	B-X
.	B-X
Although	B-X
the	B-X
majority	B-X
of	B-X
research	B-X
on	B-X
MS	B-X
pathogenesis	B-X
has	B-X
centered	B-X
on	B-X
the	B-X
role	B-X
of	B-X
effector	B-X
CD4	B-X
T	B-X
cells	B-X
,	B-X
accumulating	B-X
data	B-X
suggests	B-X
that	B-X
CD8	B-X
T	B-X
cells	B-X
may	B-X
play	B-X
a	B-X
significant	B-X
role	B-X
in	B-X
the	B-X
human	B-X
disease	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
most	B-X
animal	B-X
models	B-X
,	B-X
the	B-X
primary	B-X
T	B-X
cell	B-X
found	B-X
in	B-X
the	B-X
CNS	B-X
in	B-X
patients	B-X
with	B-X
MS	B-X
,	B-X
is	B-X
the	B-X
CD8	B-X
T	B-X
cell	B-X
.	B-X
As	B-X
patient-derived	B-X
effector	B-X
T	B-X
cells	B-X
are	B-X
also	B-X
resistant	B-X
to	B-X
mechanisms	B-X
of	B-X
dominant	B-X
tolerance	B-X
such	B-X
as	B-X
that	B-X
induced	B-X
by	B-X
interaction	B-X
with	B-X
regulatory	B-X
T	B-X
cells	B-X
(	B-X
Tregs	B-X
)	B-X
,	B-X
their	B-X
reduced	B-X
response	B-X
to	B-X
regulation	B-X
may	B-X
also	B-X
contribute	B-X
to	B-X
the	B-X
unchecked	B-X
effector	B-X
T-cell	B-X
activity	B-X
in	B-X
patients	B-X
with	B-X
MS	B-X
.	B-X

We	O
further	O
demonstrate	O
that	O
Foxp3	B-Protein
suppressed	O
the	O
transcription	O
of	O
two	O
human	O
retroviral	O
promoters	O
(	O
HIV	O
-	O
1	O
and	O
human	O
T	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
[	O
HTLV	O
-	O
I	O
]	O
)	O
utilizing	O
NF	O
-	O
kappaB	O
-	O
dependent	O
and	O
NF	O
-	O
kappaB	O
-	O
independent	O
mechanisms	O
.	O
<EOS>	B-X
Forkhead	B-X
box	B-X
(	B-X
Fox	B-X
)	B-X
/winged-helix	B-X
transcription	B-X
factors	B-X
regulate	B-X
multiple	B-X
aspects	B-X
of	B-X
immune	B-X
responsiveness	B-X
and	B-X
Foxp3	B-X
is	B-X
recognized	B-X
as	B-X
an	B-X
essential	B-X
functional	B-X
marker	B-X
of	B-X
regulatory	B-X
T	B-X
cells	B-X
.	B-X
Herein	B-X
we	B-X
describe	B-X
downstream	B-X
signaling	B-X
pathways	B-X
targeted	B-X
by	B-X
Foxp3	B-X
that	B-X
may	B-X
negatively	B-X
impact	B-X
retroviral	B-X
pathogenesis	B-X
.	B-X
Overexpression	B-X
of	B-X
Foxp3	B-X
in	B-X
HEK	B-X
293T	B-X
and	B-X
purified	B-X
CD4+	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
a	B-X
dose-dependent	B-X
and	B-X
time-dependent	B-X
decrease	B-X
in	B-X
basal	B-X
levels	B-X
of	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
activation	B-X
.	B-X
Deletion	B-X
of	B-X
the	B-X
carboxyl-terminal	B-X
forkhead	B-X
(	B-X
FKH	B-X
)	B-X
domain	B-X
,	B-X
critical	B-X
for	B-X
nuclear	B-X
localization	B-X
and	B-X
DNA-binding	B-X
activity	B-X
,	B-X
abrogated	B-X
the	B-X
ability	B-X
of	B-X
Foxp3	B-X
to	B-X
suppress	B-X
NF-kappaB	B-X
activity	B-X
in	B-X
HEK	B-X
293T	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
Jurkat	B-X
or	B-X
primary	B-X
human	B-X
CD4+	B-X
T	B-X
cells	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
Foxp3	B-X
suppressed	B-X
the	B-X
transcription	B-X
of	B-X
two	B-X
human	B-X
retroviral	B-X
promoters	B-X
(	B-X
HIV-1	B-X
and	B-X
human	B-X
T	B-X
cell	B-X
lymphotropic	B-X
virus	B-X
type	B-X
I	B-X
[	B-X
HTLV-I	B-X
]	B-X
)	B-X
utilizing	B-X
NF-kappaB-dependent	B-X
and	B-X
NF-kappaB-independent	B-X
mechanisms	B-X
.	B-X
Examination	B-X
of	B-X
the	B-X
latter	B-X
identified	B-X
the	B-X
cAMP-responsive	B-X
element	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
pathway	B-X
as	B-X
a	B-X
target	B-X
of	B-X
Foxp3	B-X
.	B-X
Finally	B-X
,	B-X
comparison	B-X
of	B-X
the	B-X
percent	B-X
Foxp3+CD4+CD25+	B-X
T	B-X
cells	B-X
to	B-X
the	B-X
HTLV-I	B-X
proviral	B-X
load	B-X
in	B-X
HTLV-I-infected	B-X
asymptomatic	B-X
carriers	B-X
and	B-X
patients	B-X
with	B-X
HTLV-I-associated	B-X
myelopathy/tropical	B-X
spastic	B-X
paraparesis	B-X
suggested	B-X
that	B-X
high	B-X
Foxp3	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
low	B-X
proviral	B-X
load	B-X
and	B-X
absence	B-X
of	B-X
disease	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
an	B-X
expanded	B-X
role	B-X
for	B-X
Foxp3	B-X
in	B-X
regulating	B-X
NF-kappaB-	B-X
and	B-X
CREB-dependent	B-X
cellular	B-X
and	B-X
viral	B-X
gene	B-X
expression	B-X
.	B-X

Examination	O
of	O
the	O
latter	O
identified	O
the	O
cAMP	O
-	O
responsive	O
element	O
binding	O
protein	O
(	O
CREB	O
)	O
pathway	O
as	O
a	O
target	O
of	O
Foxp3	B-Protein
.	O
<EOS>	B-X
Forkhead	B-X
box	B-X
(	B-X
Fox	B-X
)	B-X
/winged-helix	B-X
transcription	B-X
factors	B-X
regulate	B-X
multiple	B-X
aspects	B-X
of	B-X
immune	B-X
responsiveness	B-X
and	B-X
Foxp3	B-X
is	B-X
recognized	B-X
as	B-X
an	B-X
essential	B-X
functional	B-X
marker	B-X
of	B-X
regulatory	B-X
T	B-X
cells	B-X
.	B-X
Herein	B-X
we	B-X
describe	B-X
downstream	B-X
signaling	B-X
pathways	B-X
targeted	B-X
by	B-X
Foxp3	B-X
that	B-X
may	B-X
negatively	B-X
impact	B-X
retroviral	B-X
pathogenesis	B-X
.	B-X
Overexpression	B-X
of	B-X
Foxp3	B-X
in	B-X
HEK	B-X
293T	B-X
and	B-X
purified	B-X
CD4+	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
a	B-X
dose-dependent	B-X
and	B-X
time-dependent	B-X
decrease	B-X
in	B-X
basal	B-X
levels	B-X
of	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
activation	B-X
.	B-X
Deletion	B-X
of	B-X
the	B-X
carboxyl-terminal	B-X
forkhead	B-X
(	B-X
FKH	B-X
)	B-X
domain	B-X
,	B-X
critical	B-X
for	B-X
nuclear	B-X
localization	B-X
and	B-X
DNA-binding	B-X
activity	B-X
,	B-X
abrogated	B-X
the	B-X
ability	B-X
of	B-X
Foxp3	B-X
to	B-X
suppress	B-X
NF-kappaB	B-X
activity	B-X
in	B-X
HEK	B-X
293T	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
Jurkat	B-X
or	B-X
primary	B-X
human	B-X
CD4+	B-X
T	B-X
cells	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
Foxp3	B-X
suppressed	B-X
the	B-X
transcription	B-X
of	B-X
two	B-X
human	B-X
retroviral	B-X
promoters	B-X
(	B-X
HIV-1	B-X
and	B-X
human	B-X
T	B-X
cell	B-X
lymphotropic	B-X
virus	B-X
type	B-X
I	B-X
[	B-X
HTLV-I	B-X
]	B-X
)	B-X
utilizing	B-X
NF-kappaB-dependent	B-X
and	B-X
NF-kappaB-independent	B-X
mechanisms	B-X
.	B-X
Examination	B-X
of	B-X
the	B-X
latter	B-X
identified	B-X
the	B-X
cAMP-responsive	B-X
element	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
pathway	B-X
as	B-X
a	B-X
target	B-X
of	B-X
Foxp3	B-X
.	B-X
Finally	B-X
,	B-X
comparison	B-X
of	B-X
the	B-X
percent	B-X
Foxp3+CD4+CD25+	B-X
T	B-X
cells	B-X
to	B-X
the	B-X
HTLV-I	B-X
proviral	B-X
load	B-X
in	B-X
HTLV-I-infected	B-X
asymptomatic	B-X
carriers	B-X
and	B-X
patients	B-X
with	B-X
HTLV-I-associated	B-X
myelopathy/tropical	B-X
spastic	B-X
paraparesis	B-X
suggested	B-X
that	B-X
high	B-X
Foxp3	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
low	B-X
proviral	B-X
load	B-X
and	B-X
absence	B-X
of	B-X
disease	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
an	B-X
expanded	B-X
role	B-X
for	B-X
Foxp3	B-X
in	B-X
regulating	B-X
NF-kappaB-	B-X
and	B-X
CREB-dependent	B-X
cellular	B-X
and	B-X
viral	B-X
gene	B-X
expression	B-X
.	B-X

Finally	O
,	O
comparison	O
of	O
the	O
percent	O
Foxp3	B-Protein
+	O
CD4	B-Protein
+	O
CD25	B-Protein
+	O
T	O
cells	O
to	O
the	O
HTLV	O
-	O
I	O
proviral	O
load	O
in	O
HTLV	O
-	O
I	O
-	O
infected	O
asymptomatic	O
carriers	O
and	O
patients	O
with	O
HTLV	O
-	O
I	O
-	O
associated	O
myelopathy	O
/	O
tropical	O
spastic	O
paraparesis	O
suggested	O
that	O
high	O
Foxp3	B-Protein
expression	O
is	O
associated	O
with	O
low	O
proviral	O
load	O
and	O
absence	O
of	O
disease	O
.	O

These	O
results	O
suggest	O
an	O
expanded	O
role	O
for	O
Foxp3	B-Protein
in	O
regulating	O
NF	O
-	O
kappaB	O
-	O
and	O
CREB	O
-	O
dependent	O
cellular	O
and	O
viral	O
gene	O
expression	O
.	O
<EOS>	B-X
Forkhead	B-X
box	B-X
(	B-X
Fox	B-X
)	B-X
/winged-helix	B-X
transcription	B-X
factors	B-X
regulate	B-X
multiple	B-X
aspects	B-X
of	B-X
immune	B-X
responsiveness	B-X
and	B-X
Foxp3	B-X
is	B-X
recognized	B-X
as	B-X
an	B-X
essential	B-X
functional	B-X
marker	B-X
of	B-X
regulatory	B-X
T	B-X
cells	B-X
.	B-X
Herein	B-X
we	B-X
describe	B-X
downstream	B-X
signaling	B-X
pathways	B-X
targeted	B-X
by	B-X
Foxp3	B-X
that	B-X
may	B-X
negatively	B-X
impact	B-X
retroviral	B-X
pathogenesis	B-X
.	B-X
Overexpression	B-X
of	B-X
Foxp3	B-X
in	B-X
HEK	B-X
293T	B-X
and	B-X
purified	B-X
CD4+	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
a	B-X
dose-dependent	B-X
and	B-X
time-dependent	B-X
decrease	B-X
in	B-X
basal	B-X
levels	B-X
of	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
activation	B-X
.	B-X
Deletion	B-X
of	B-X
the	B-X
carboxyl-terminal	B-X
forkhead	B-X
(	B-X
FKH	B-X
)	B-X
domain	B-X
,	B-X
critical	B-X
for	B-X
nuclear	B-X
localization	B-X
and	B-X
DNA-binding	B-X
activity	B-X
,	B-X
abrogated	B-X
the	B-X
ability	B-X
of	B-X
Foxp3	B-X
to	B-X
suppress	B-X
NF-kappaB	B-X
activity	B-X
in	B-X
HEK	B-X
293T	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
Jurkat	B-X
or	B-X
primary	B-X
human	B-X
CD4+	B-X
T	B-X
cells	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
Foxp3	B-X
suppressed	B-X
the	B-X
transcription	B-X
of	B-X
two	B-X
human	B-X
retroviral	B-X
promoters	B-X
(	B-X
HIV-1	B-X
and	B-X
human	B-X
T	B-X
cell	B-X
lymphotropic	B-X
virus	B-X
type	B-X
I	B-X
[	B-X
HTLV-I	B-X
]	B-X
)	B-X
utilizing	B-X
NF-kappaB-dependent	B-X
and	B-X
NF-kappaB-independent	B-X
mechanisms	B-X
.	B-X
Examination	B-X
of	B-X
the	B-X
latter	B-X
identified	B-X
the	B-X
cAMP-responsive	B-X
element	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
pathway	B-X
as	B-X
a	B-X
target	B-X
of	B-X
Foxp3	B-X
.	B-X
Finally	B-X
,	B-X
comparison	B-X
of	B-X
the	B-X
percent	B-X
Foxp3+CD4+CD25+	B-X
T	B-X
cells	B-X
to	B-X
the	B-X
HTLV-I	B-X
proviral	B-X
load	B-X
in	B-X
HTLV-I-infected	B-X
asymptomatic	B-X
carriers	B-X
and	B-X
patients	B-X
with	B-X
HTLV-I-associated	B-X
myelopathy/tropical	B-X
spastic	B-X
paraparesis	B-X
suggested	B-X
that	B-X
high	B-X
Foxp3	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
low	B-X
proviral	B-X
load	B-X
and	B-X
absence	B-X
of	B-X
disease	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
an	B-X
expanded	B-X
role	B-X
for	B-X
Foxp3	B-X
in	B-X
regulating	B-X
NF-kappaB-	B-X
and	B-X
CREB-dependent	B-X
cellular	B-X
and	B-X
viral	B-X
gene	B-X
expression	B-X
.	B-X

Immunological	O
tolerance	O
to	O
self	O
-	O
antigens	O
is	O
the	O
result	O
of	O
the	O
deletion	O
of	O
self	O
-	O
reactive	O
T	O
lymphocytes	O
in	O
the	O
thymus	O
(	O
central	O
tolerance	O
)	O
and	O
suppression	O
of	O
the	O
activation	O
of	O
potentially	O
self	O
-	O
reactive	O
T	O
lymphocytes	O
in	O
the	O
periphery	O
(	O
peripheral	O
tolerance	O
)	O
[	O
1	O
]	O
.	O

Suppression	O
of	O
pathogenic	O
T	O
cell	O
responses	O
is	O
mediated	O
by	O
naturally	O
arising	O
CD4	B-Protein
+	O
CD25	B-Protein
+	O
T	O
regulatory	O
cells	O
(	O
Tregs	O
)	O
[	O
2	O
,	O
3	O
]	O
.	O

Deficiencies	O
in	O
Treg	O
development	O
and	O
function	O
have	O
been	O
linked	O
to	O
the	O
severe	O
autoimmune	O
disorder	O
known	O
as	O
immune	O
dysregulation	O
,	O
polyendocrinopathy	O
,	O
enteropathy	O
,	O
X	O
-	O
linked	O
syndrome	O
(	O
IPEX	O
)	O
[	O
4	O
]	O
.	O

In	O
addition	O
,	O
recent	O
studies	O
have	O
provided	O
strong	O
evidence	O
that	O
dysregulation	O
of	O
Treg	O
development	O
and	O
/	O
or	O
function	O
may	O
be	O
a	O
significant	O
factor	O
in	O
the	O
pathogenesis	O
of	O
several	O
autoimmune	O
disorders	O
(	O
e	O
.	O
g	O
.	O
,	O
multiple	O
sclerosis	O
[	O
5	O
]	O
,	O
myasthenia	O
gravis	O
[	O
6	O
]	O
,	O
and	O
type	O
1	O
diabetes	O
[	O
7	O
]	O
)	O
and	O
virus	O
-	O
induced	O
immunologic	O
disorders	O
(	O
e	O
.	O
g	O
.	O
,	O
human	O
T	O
lymphotropic	O
virus	O
type	O
I	O
[	O
HTLV	O
-	O
I	O
]	O
-	O
associated	O
myelopathy	O
/	O
tropical	O
spastic	O
paraparesis	O
[	O
HAM	O
/	O
TSP	O
]	O
,	O
and	O
HIV	O
-	O
induced	O
AIDS	O
[	O
8	O
-	O
10	O
]	O
)	O
.	O

The	O
transcription	O
factor	O
Foxp3	B-Protein
is	O
a	O
431	O
-	O
amino	O
acid	O
(	O
48	O
-	O
kDa	O
)	O
protein	O
expressed	O
at	O
very	O
high	O
levels	O
in	O
CD4	B-Protein
+	O
CD25hi	B-Protein
T	O
cells	O
and	O
has	O
previously	O
been	O
shown	O
to	O
be	O
absolutely	O
critical	O
for	O
Treg	O
development	O
and	O
function	O
[	O
11	O
-	O
14	O
]	O
.	O

Foxp3	B-Protein
contains	O
a	O
proline	O
-	O
rich	O
amino	O
-	O
terminal	O
domain	O
reported	O
to	O
function	O
as	O
a	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
and	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
binding	O
domain	O
,	O
a	O
central	O
region	O
containing	O
a	O
zinc	O
finger	O
and	O
leucine	O
zipper	O
potentially	O
important	O
for	O
protein	O
-	O
protein	O
interactions	O
,	O
and	O
a	O
carboxyl	O
-	O
terminal	O
forkhead	O
(	O
FKH	O
)	O
domain	O
required	O
for	O
nuclear	O
localization	O
and	O
DNA	O
-	O
binding	O
activity	O
[	O
14	O
-	O
16	O
]	O
.	O

Functional	O
inactivation	O
of	O
Foxp3	B-Protein
by	O
genetic	O
mutations	O
affecting	O
the	O
Foxp3	B-Protein
coding	O
region	O
,	O
as	O
demonstrated	O
in	O
IPEX	O
,	O
or	O
repression	O
of	O
Foxp3	B-Protein
expression	O
by	O
the	O
HTLV	O
-	O
I	O
-	O
encoded	O
transactivator	O
protein	O
Tax	B-Protein
,	O
as	O
recently	O
reported	O
in	O
patients	O
with	O
HAM	O
/	O
TSP	O
,	O
results	O
in	O
loss	O
of	O
regulatory	O
activity	O
in	O
CD4	B-Protein
+	O
CD25hi	B-Protein
T	O
cells	O
[	O
4	O
,	O
8	O
,	O
17	O
]	O
.	O

Although	O
it	O
is	O
clear	O
that	O
Foxp3	B-Protein
regulates	O
T	O
cell	O
proliferation	O
and	O
cytokine	O
production	O
,	O
very	O
little	O
is	O
known	O
concerning	O
the	O
molecular	O
mechanisms	O
of	O
Foxp3	B-Protein
function	O
.	O

The	O
first	O
evidence	O
to	O
indicate	O
how	O
Foxp3	B-Protein
promotes	O
the	O
development	O
and	O
function	O
of	O
regulatory	O
T	O
cells	O
came	O
from	O
a	O
report	O
by	O
Ziegler	O
and	O
colleagues	O
[	O
16	O
]	O
,	O
which	O
suggested	O
that	O
Foxp3	B-Protein
could	O
inhibit	O
transcriptional	O
activation	O
by	O
physically	O
interacting	O
with	O
forkhead	O
binding	O
sites	O
located	O
immediately	O
adjacent	O
to	O
critical	O
cis	O
-	O
acting	O
NF	O
-	O
AT	O
binding	O
sites	O
found	O
in	O
various	O
cytokine	O
promoters	O
(	O
e	O
.	O
g	O
.	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
)	O
.	O

That	O
study	O
also	O
demonstrated	O
that	O
Foxp3	B-Protein
could	O
repress	O
activation	O
of	O
a	O
synthetic	O
reporter	O
vector	O
containing	O
an	O
SV40	O
promoter	O
and	O
three	O
tandem	O
copies	O
of	O
a	O
forkhead	O
binding	O
site	O
.	O

These	O
results	O
provided	O
additional	O
evidence	O
suggesting	O
that	O
Foxp3	B-Protein
transcriptional	O
repression	O
was	O
mediated	O
by	O
binding	O
in	O
a	O
sequence	O
-	O
specific	O
manner	O
to	O
promoters	O
containing	O
forkhead	O
binding	O
sites	O
.	O

A	O
recent	O
study	O
by	O
Bettelli	O
and	O
colleagues	O
[	O
15	O
]	O
further	O
demonstrated	O
that	O
Foxp3	B-Protein
could	O
inhibit	O
NF	O
-	O
AT	O
as	O
well	O
as	O
NF	O
-	O
kappaB	O
activation	O
,	O
although	O
the	O
mechanism	O
of	O
suppression	O
was	O
shown	O
to	O
involve	O
direct	O
protein	O
-	O
protein	O
interactions	O
between	O
NF	O
-	O
AT	O
or	O
NF	O
-	O
kappaB	O
and	O
Foxp3	B-Protein
rather	O
than	O
binding	O
of	O
Foxp3	B-Protein
to	O
promoter	O
elements	O
adjacent	O
to	O
cis	O
-	O
acting	O
NF	O
-	O
AT	O
or	O
NF	O
-	O
kappaB	O
sites	O
.	O
<EOS>	B-X
It	B-X
is	B-X
characterized	B-X
by	B-X
betaamyloid	B-X
peptide	B-X
fibrils	B-X
which	B-X
are	B-X
extracellular	B-X
deposition	B-X
of	B-X
a	B-X
specific	B-X
protein	B-X
,	B-X
accompanied	B-X
by	B-X
extensive	B-X
neuroinflammation	B-X
.	B-X
NF-κB	B-X
is	B-X
a	B-X
family	B-X
of	B-X
redox	B-X
sensitive	B-X
transcriptional	B-X
factors	B-X
,	B-X
and	B-X
it	B-X
is	B-X
known	B-X
that	B-X
NF-κB	B-X
has	B-X
binding	B-X
sites	B-X
in	B-X
the	B-X
promoter	B-X
region	B-X
of	B-X
the	B-X
genes	B-X
involved	B-X
in	B-X
amyloidogenesis	B-X
and	B-X
inflammation	B-X
.	B-X
Long-term	B-X
use	B-X
of	B-X
non-steroidal	B-X
anti-inflammatory	B-X
drugs	B-X
prevents	B-X
progression	B-X
of	B-X
AD	B-X
and	B-X
delays	B-X
its	B-X
onset	B-X
,	B-X
suggesting	B-X
that	B-X
there	B-X
is	B-X
a	B-X
close	B-X
correlation	B-X
between	B-X
NF-κB	B-X
and	B-X
AD	B-X
pathogenesis	B-X
.	B-X
This	B-X
study	B-X
aims	B-X
to	B-X
(	B-X
1	B-X
)	B-X
assess	B-X
the	B-X
association	B-X
between	B-X
NF-κB	B-X
activity	B-X
and	B-X
AD	B-X
through	B-X
discussion	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
experimental	B-X
and	B-X
clinical	B-X
studies	B-X
on	B-X
AD	B-X
and	B-X
(	B-X
2	B-X
)	B-X
review	B-X
treatment	B-X
strategies	B-X
designed	B-X
to	B-X
treat	B-X
or	B-X
prevent	B-X
AD	B-X
with	B-X
NF-κB	B-X
inhibitors	B-X
.	B-X

Collectively	O
,	O
these	O
data	O
suggested	O
that	O
Foxp3	B-Protein
may	O
function	O
as	O
a	O
transcriptional	O
repressor	O
,	O
potentially	O
through	O
the	O
formation	O
of	O
both	O
DNA	O
-	O
protein	O
and	O
protein	O
-	O
protein	O
interactions	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
expanded	O
upon	O
these	O
observations	O
by	O
defining	O
additional	O
requirements	O
of	O
Foxp3	B-Protein
-	O
mediated	O
repression	O
of	O
NF	O
-	O
kappaB	O
activation	O
,	O
and	O
investigated	O
whether	O
Foxp3	B-Protein
could	O
target	O
additional	O
signaling	O
pathways	O
by	O
examining	O
transcriptional	O
activation	O
of	O
NF	O
-	O
kappaB	O
-	O
dependent	O
and	O
NF	O
-	O
kappaB	O
-	O
independent	O
retroviral	O
pathogens	O
.	O

The	O
characterization	O
of	O
the	O
molecular	O
targets	O
of	O
Foxp3	B-Protein
and	O
the	O
mechanism	O
(	O
s	O
)	O
utilized	O
by	O
Foxp3	B-Protein
to	O
support	O
Treg	O
development	O
and	O
function	O
will	O
aid	O
in	O
our	O
understanding	O
of	O
the	O
role	O
Tregs	O
play	O
in	O
the	O
pathogenesis	O
of	O
human	O
autoimmune	O
disease	O
.	O

Foxp3	B-Protein
Suppresses	O
NF	O
-	O
kappaB	O
Dependent	O
Transcriptional	O
Activation	O

To	O
ascertain	O
the	O
molecular	O
mechanisms	O
by	O
which	O
Foxp3	B-Protein
functions	O
to	O
promote	O
the	O
regulatory	O
function	O
of	O
CD4	B-Protein
+	O
CD25hi	B-Protein
T	O
cells	O
,	O
we	O
first	O
confirmed	O
the	O
function	O
of	O
Foxp3	B-Protein
as	O
a	O
repressor	O
of	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
previously	O
implicated	O
as	O
a	O
target	O
of	O
other	O
forkhead	O
/	O
winged	O
-	O
helix	O
family	O
transcription	O
factors	O
(	O
e	O
.	O
g	O
.	O
,	O
Foxj1	B-Protein
and	O
Foxo3a	B-Protein
)	O
[	O
19	O
,	O
20	O
]	O
.	O

We	O
analyzed	O
the	O
effect	O
of	O
Foxp3	B-Protein
overexpression	O
on	O
NF	O
-	O
kappaB	O
activation	O
in	O
HEK	O
293T	O
cells	O
in	O
dose	O
-	O
response	O
and	O
time	O
course	O
analyses	O
.	O

Transfection	O
of	O
HEK	O
293T	O
cells	O
with	O
an	O
NF	O
-	O
kappaB	O
luciferase	B-Protein
reporter	O
vector	O
in	O
the	O
presence	O
or	O
absence	O
of	O
increasing	O
concentrations	O
of	O
a	O
Foxp3	B-Protein
expression	O
vector	O
or	O
a	O
control	O
vector	O
(	O
enhanced	O
green	B-Protein
fluorescent	I-Protein
protein	I-Protein
[	O
EGFP	O
]	O
)	O
was	O
performed	O
,	O
and	O
cells	O
were	O
harvested	O
after	O
24	O
h	O
to	O
assay	O
for	O
luciferase	B-Protein
activity	O
and	O
Foxp3	B-Protein
mRNA	O
expression	O
.	O

Results	O
indicated	O
that	O
as	O
the	O
concentration	O
of	O
Foxp3	B-Protein
transfected	O
into	O
cells	O
increases	O
(	O
from	O
50	O
to	O
2	O
,	O
400	O
ng	O
)	O
,	O
the	O
level	O
of	O
NF	O
-	O
kappaB	O
activation	O
decreases	O
proportionally	O
(	O
Figure	O
1A	O
)	O
.	O

Foxp3	B-Protein
mRNA	O
was	O
also	O
assayed	O
to	O
monitor	O
activity	O
of	O
the	O
Foxp3	B-Protein
expression	O
vector	O
(	O
Figure	O
1B	O
)	O
.	O

Since	O
NF	O
-	O
kappaB	O
activation	O
was	O
partially	O
affected	O
by	O
transfection	O
of	O
high	O
concentrations	O
of	O
the	O
control	O
vector	O
,	O
we	O
determined	O
the	O
fold	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
by	O
Foxp3	B-Protein
compared	O
to	O
the	O
control	O
vector	O
at	O
each	O
concentration	O
(	O
Figure	O
1A	O
)	O
.	O

Fold	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
was	O
directly	O
proportional	O
to	O
the	O
level	O
of	O
Foxp3	B-Protein
mRNA	O
expression	O
detected	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

To	O
determine	O
the	O
level	O
of	O
Foxp3	B-Protein
-	O
mediated	O
suppression	O
of	O
NF	O
-	O
kappaB	O
activation	O
over	O
time	O
,	O
HEK	O
293T	O
cells	O
were	O
transfected	O
with	O
an	O
NF	O
-	O
kappaB	O
luciferase	B-Protein
reporter	O
vector	O
and	O
an	O
expression	O
vector	O
encoding	O
Foxp3	B-Protein
or	O
EGFP	O
(	O
control	O
vector	O
)	O
and	O
harvested	O
over	O
4	O
d	O
.	O

As	O
shown	O
in	O
Figure	O
1C	O
,	O
NF	O
-	O
kappaB	O
activation	O
was	O
suppressed	O
by	O
overexpression	O
of	O
Foxp3	B-Protein
at	O
all	O
time	O
points	O
.	O

Extending	O
these	O
results	O
from	O
established	O
,	O
in	O
vitro	O
HEK	O
cell	O
lines	O
to	O
primary	O
human	O
lymphocytes	O
,	O
overexpression	O
of	O
Foxp3	B-Protein
in	O
purified	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
three	O
healthy	O
donors	O
also	O
down	O
-	O
regulated	O
the	O
steady	O
-	O
state	O
level	O
of	O
NF	O
-	O
kappaB	O
activation	O
(	O
Figure	O
1D	O
)	O
.	O

These	O
results	O
recapitulate	O
those	O
from	O
Bettelli	O
and	O
colleagues	O
[	O
15	O
]	O
demonstrating	O
that	O
Foxp3	B-Protein
functions	O
,	O
in	O
part	O
,	O
to	O
block	O
NF	O
-	O
kappaB	O
-	O
dependent	O
transcription	O
in	O
human	O
cell	O
lines	O
as	O
well	O
as	O
in	O
primary	O
human	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

The	O
Carboxyl	O
-	O
Terminal	O
FKH	O
Domain	O
Is	O
Not	O
Required	O
for	O
Suppression	O
of	O
NF	O
-	O
kappaB	O
Activation	O
in	O
T	O
Cells	O

To	O
define	O
the	O
requirements	O
of	O
Foxp3	B-Protein
with	O
respect	O
to	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
-	O
dependent	O
transcription	O
,	O
we	O
utilized	O
a	O
mutant	O
of	O
Foxp3	B-Protein
lacking	O
the	O
FKH	O
domain	O
(	O
Figure	O
2A	O
)	O
[	O
16	O
]	O
,	O
similar	O
to	O
the	O
scurfy	O
mutant	O
Foxp3	B-Protein
of	O
mice	O
,	O
and	O
a	O
mutant	O
Foxp3	B-Protein
protein	O
from	O
a	O
patient	O
with	O
IPEX	O
[	O
4	O
,	O
11	O
,	O
14	O
,	O
17	O
]	O
.	O

Unlike	O
full	O
-	O
length	O
Foxp3	B-Protein
,	O
which	O
localizes	O
almost	O
exclusively	O
to	O
the	O
nucleus	O
and	O
can	O
bind	O
in	O
a	O
sequence	O
-	O
specific	O
manner	O
to	O
forkhead	O
binding	O
sites	O
,	O
the	O
deltaFKH	B-Protein
mutant	I-Protein
fails	O
to	O
localize	O
to	O
the	O
nucleus	O
and	O
thus	O
cannot	O
interact	O
with	O
promoter	O
elements	O
or	O
nuclear	O
proteins	O
[	O
16	O
]	O
.	O
<EOS>	B-X
It	B-X
also	B-X
binds	B-X
non-histone	B-X
proteins	B-X
,	B-X
DNA	B-X
and	B-X
RNA	B-X
,	B-X
contributing	B-X
to	B-X
development	B-X
,	B-X
tissue	B-X
growth	B-X
,	B-X
and	B-X
various	B-X
physiological	B-X
processes	B-X
.	B-X
The	B-X
diverse	B-X
roles	B-X
of	B-X
BRD4	B-X
are	B-X
largely	B-X
dependent	B-X
on	B-X
its	B-X
interaction	B-X
partners	B-X
in	B-X
different	B-X
contexts	B-X
.	B-X
In	B-X
this	B-X
review	B-X
we	B-X
discuss	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
BRD4	B-X
with	B-X
its	B-X
interacting	B-X
partners	B-X
in	B-X
physiology	B-X
and	B-X
pathology	B-X
.	B-X
Its	B-X
siblings	B-X
were	B-X
identified	B-X
almost	B-X
20	B-X
years	B-X
later	B-X
and	B-X
interestingly	B-X
enough	B-X
their	B-X
ancestral	B-X
function	B-X
as	B-X
guardians	B-X
of	B-X
the	B-X
germ-line	B-X
was	B-X
one	B-X
of	B-X
the	B-X
last	B-X
to	B-X
be	B-X
identified	B-X
.	B-X

Therefore	O
,	O
we	O
utilized	O
the	O
deltaFKH	B-Protein
mutant	I-Protein
to	O
determine	O
whether	O
nuclear	O
localization	O
(	O
or	O
other	O
function	O
associated	O
with	O
the	O
FKH	O
domain	O
)	O
of	O
Foxp3	B-Protein
was	O
a	O
prerequisite	O
for	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O

Although	O
Foxp3	B-Protein
interaction	O
with	O
NF	O
-	O
kappaB	O
presumably	O
takes	O
place	O
in	O
the	O
nucleus	O
,	O
it	O
may	O
also	O
be	O
possible	O
for	O
a	O
cytoplasmic	O
Foxp3	B-Protein
protein	O
to	O
bind	O
to	O
NF	O
-	O
kappaB	O
in	O
the	O
cytoplasm	O
and	O
prevent	O
localization	O
to	O
the	O
nucleus	O
following	O
an	O
activation	O
stimulus	O
.	O

Overexpression	O
of	O
full	O
-	O
length	O
Foxp3	B-Protein
,	O
but	O
not	O
of	O
deltaFKH	B-Protein
,	O
was	O
able	O
to	O
suppress	O
activation	O
of	O
a	O
cotransfected	O
NF	O
-	O
kappaB	O
reporter	O
vector	O
in	O
HEK	O
293T	O
cells	O
(	O
Figure	O
2B	O
)	O
.	O
<EOS>	B-X
Foxp3	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
development	B-X
and	B-X
function	B-X
of	B-X
regulatory	B-X
T	B-X
cells	B-X
(	B-X
Tregs	B-X
)	B-X
.	B-X
Differences	B-X
in	B-X
translational	B-X
and	B-X
post-translational	B-X
processing	B-X
of	B-X
murine	B-X
and	B-X
human	B-X
Foxp3	B-X
have	B-X
been	B-X
recently	B-X
reported	B-X
.	B-X
Human	B-X
Foxp3	B-X
exists	B-X
as	B-X
four	B-X
isoforms	B-X
generated	B-X
by	B-X
alternative	B-X
splicing	B-X
.	B-X
Mouse	B-X
Foxp3	B-X
only	B-X
exists	B-X
as	B-X
one	B-X
isoform	B-X
,	B-X
but	B-X
can	B-X
be	B-X
proteolytically	B-X
cleaved	B-X
by	B-X
N-terminal	B-X
and/or	B-X
C-terminal	B-X
proprotein	B-X
convertase	B-X
subtilisin/kexins	B-X
(	B-X
PCSKs	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
by	B-X
transcriptome	B-X
analysis	B-X
that	B-X
the	B-X
proprotein	B-X
convertases	B-X
PCSK7	B-X
,	B-X
PCSK5	B-X
and	B-X
Furin	B-X
are	B-X
present	B-X
in	B-X
human	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
with	B-X
different	B-X
expression	B-X
patterns	B-X
.	B-X
Notably	B-X
,	B-X
after	B-X
in	B-X
vitro	B-X
activation	B-X
,	B-X
only	B-X
PCSK7	B-X
and	B-X
Furin	B-X
are	B-X
expressed	B-X
in	B-X
Tregs	B-X
and	B-X
T	B-X
effector	B-X
cells	B-X
(	B-X
Teffs	B-X
)	B-X
,	B-X
with	B-X
overexpression	B-X
of	B-X
PCSK7	B-X
in	B-X
Tregs	B-X
compared	B-X
to	B-X
Teffs	B-X
.	B-X
Human	B-X
Foxp3	B-X
protein	B-X
displays	B-X
specific	B-X
motifs	B-X
that	B-X
can	B-X
be	B-X
potentially	B-X
cleaved	B-X
by	B-X
convertases	B-X
.	B-X
Consequently	B-X
,	B-X
we	B-X
transduced	B-X
human	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
with	B-X
Foxp3-expressing	B-X
lentiviral	B-X
vectors	B-X
and	B-X
assessed	B-X
the	B-X
generation	B-X
of	B-X
proteolytically	B-X
cleaved	B-X
Foxp3	B-X
forms	B-X
by	B-X
Western	B-X
blot	B-X
.	B-X
Three	B-X
different	B-X
Foxp3	B-X
forms	B-X
were	B-X
detected	B-X
,	B-X
indicating	B-X
that	B-X
human	B-X
Foxp3	B-X
can	B-X
also	B-X
be	B-X
subjected	B-X
to	B-X
proteolytic	B-X
cleavage	B-X
at	B-X
the	B-X
N-terminal	B-X
and	B-X
C-terminal	B-X
ends	B-X
.	B-X
These	B-X
results	B-X
prompted	B-X
us	B-X
to	B-X
assess	B-X
the	B-X
suppressive	B-X
activity	B-X
associated	B-X
with	B-X
each	B-X
forms	B-X
.	B-X
We	B-X
observed	B-X
that	B-X
full	B-X
length	B-X
and	B-X
N-cleaved	B-X
Foxp3-transduced	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
similarly	B-X
suppressed	B-X
the	B-X
in	B-X
vitro	B-X
proliferation	B-X
of	B-X
Teffs	B-X
.	B-X
However	B-X
,	B-X
the	B-X
C-cleaved	B-X
or	B-X
N	B-X
&	B-X
C-cleaved	B-X
Foxp3	B-X
forms	B-X
afforded	B-X
almost	B-X
no	B-X
suppressive	B-X
function	B-X
,	B-X
indicating	B-X
a	B-X
crucial	B-X
role	B-X
of	B-X
the	B-X
human	B-X
Foxp3	B-X
C-terminal	B-X
region	B-X
in	B-X
Tregs	B-X
suppressive	B-X
activity	B-X
,	B-X
in	B-X
marked	B-X
contrast	B-X
with	B-X
the	B-X
report	B-X
of	B-X
a	B-X
superior	B-X
suppressive	B-X
activity	B-X
for	B-X
the	B-X
C-cleaved	B-X
murine	B-X
Foxp3	B-X
compared	B-X
to	B-X
the	B-X
full	B-X
length	B-X
.	B-X

Both	O
Foxp3	B-Protein
and	O
deltaFKH	B-Protein
were	O
expressed	O
at	O
very	O
high	O
levels	O
following	O
transfection	O
as	O
detected	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
(	O
unpublished	O
data	O
)	O
.	O

These	O
data	O
appear	O
to	O
suggest	O
that	O
the	O
carboxyl	O
-	O
terminal	O
FKH	O
domain	O
is	O
critically	O
important	O
for	O
Foxp3	B-Protein
to	O
down	O
-	O
regulate	O
NF	O
-	O
kappaB	O
-	O
dependent	O
transcription	O
.	O

However	O
,	O
NF	O
-	O
kappaB	O
activation	O
was	O
blocked	O
to	O
a	O
similar	O
extent	O
by	O
both	O
full	O
-	O
length	O
Foxp3	B-Protein
and	O
deltaFKH	B-Protein
in	O
Jurkat	O
T	O
cells	O
(	O
Figure	O
2C	O
)	O
and	O
primary	O
human	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
Figure	O
2D	O
)	O
.	O

Western	O
blot	O
analysis	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
expression	O
demonstrated	O
that	O
Foxp3	B-Protein
and	O
deltaFKH	B-Protein
does	O
not	O
block	O
NF	O
-	O
kappaB	O
activation	O
at	O
the	O
level	O
of	O
p65	B-Protein
protein	O
expression	O
(	O
Figure	O
2E	O
)	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
lineage-specific	B-X
DNA-binding	B-X
factor	B-X
Foxp3	B-X
controls	B-X
the	B-X
development	B-X
and	B-X
function	B-X
of	B-X
naturally	B-X
occurring	B-X
regulatory	B-X
T	B-X
cells	B-X
.	B-X
Foxp3	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
interact	B-X
with	B-X
a	B-X
multitude	B-X
of	B-X
transcriptional	B-X
regulators	B-X
including	B-X
NFAT	B-X
,	B-X
NF-κB	B-X
(	B-X
p65	B-X
)	B-X
,	B-X
Runx1	B-X
and	B-X
RORγt	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
histone	B-X
modification	B-X
enzymes	B-X
TIP60	B-X
,	B-X
HDAC7	B-X
and	B-X
HDAC9	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
Foxp3	B-X
directly	B-X
or	B-X
as	B-X
part	B-X
of	B-X
a	B-X
multimeric	B-X
complex	B-X
engages	B-X
with	B-X
the	B-X
NF-κB	B-X
component	B-X
c-Rel	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
the	B-X
N-terminal	B-X
region	B-X
of	B-X
Foxp3	B-X
is	B-X
required	B-X
for	B-X
the	B-X
binding	B-X
of	B-X
c-Rel	B-X
,	B-X
but	B-X
not	B-X
NFAT	B-X
.	B-X
Conversely	B-X
,	B-X
deletion	B-X
of	B-X
the	B-X
forkhead	B-X
domain	B-X
causes	B-X
a	B-X
loss	B-X
of	B-X
interaction	B-X
with	B-X
NFAT	B-X
,	B-X
but	B-X
not	B-X
c-Rel	B-X
.	B-X
Our	B-X
findings	B-X
are	B-X
of	B-X
particular	B-X
interest	B-X
,	B-X
as	B-X
c-Rel	B-X
is	B-X
crucial	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
Foxp3	B-X
in	B-X
regulatory	B-X
T	B-X
cells	B-X
during	B-X
thymic	B-X
development	B-X
,	B-X
but	B-X
has	B-X
to	B-X
be	B-X
repressed	B-X
in	B-X
mature	B-X
regulatory	B-X
T	B-X
cells	B-X
to	B-X
maintain	B-X
their	B-X
suppressive	B-X
phenotype	B-X
.	B-X

These	O
results	O
are	O
very	O
interesting	O
with	O
respect	O
to	O
Foxp3	B-Protein
function	O
,	O
because	O
they	O
suggest	O
that	O
the	O
carboxyl	O
-	O
terminal	O
FKH	O
domain	O
,	O
and	O
possibly	O
nuclear	O
localization	O
,	O
are	O
dispensable	O
for	O
Foxp3	B-Protein
function	O
in	O
T	O
cell	O
populations	O
.	O

Alternative	O
interpretations	O
may	O
include	O
the	O
possibility	O
that	O
the	O
localization	O
of	O
deltaFKH	B-Protein
differ	O
between	O
epithelial	O
cells	O
and	O
T	O
cells	O
.	O

In	O
either	O
case	O
,	O
these	O
results	O
suggest	O
a	O
cell	O
type	O
-	O
specific	O
mechanism	O
of	O
action	O
for	O
this	O
Foxp3	B-Protein
mutant	O
.	O
<EOS>	B-X
LT-R192G	B-X
,	B-X
a	B-X
mutant	B-X
of	B-X
the	B-X
thermolabile	B-X
enterotoxin	B-X
of	B-X
E.	B-X
coli	B-X
,	B-X
is	B-X
a	B-X
potent	B-X
adjuvant	B-X
of	B-X
immunization	B-X
.	B-X
To	B-X
investigate	B-X
this	B-X
point	B-X
,	B-X
we	B-X
compared	B-X
B	B-X
and	B-X
T	B-X
cell	B-X
responses	B-X
in	B-X
mice	B-X
after	B-X
one	B-X
and	B-X
two	B-X
intrarectal	B-X
immunizations	B-X
with	B-X
2/6	B-X
rotavirus-like	B-X
particles	B-X
(	B-X
2/6-VLP	B-X
)	B-X
and	B-X
LT-R192G	B-X
.	B-X
After	B-X
a	B-X
boost	B-X
,	B-X
we	B-X
found	B-X
,	B-X
an	B-X
unexpected	B-X
lower	B-X
B	B-X
cell	B-X
expansion	B-X
measured	B-X
by	B-X
flow	B-X
cytometry	B-X
,	B-X
despite	B-X
a	B-X
secondary	B-X
antibody	B-X
response	B-X
.	B-X
We	B-X
then	B-X
analyzed	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
regulatory	B-X
T	B-X
cells	B-X
(	B-X
Tregs	B-X
)	B-X
and	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
Foxp3	B-X
(	B-X
-	B-X
)	B-X
helper	B-X
T	B-X
cells	B-X
after	B-X
in	B-X
vitro	B-X
(	B-X
re	B-X
)	B-X
stimulation	B-X
of	B-X
mesenteric	B-X
lymph	B-X
node	B-X
cells	B-X
with	B-X
the	B-X
antigen	B-X
(	B-X
2/6-VLP	B-X
)	B-X
,	B-X
the	B-X
adjuvant	B-X
(	B-X
LT-R192G	B-X
)	B-X
or	B-X
both	B-X
.	B-X
2/6-VLP	B-X
did	B-X
not	B-X
activate	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
Foxp3	B-X
(	B-X
-	B-X
)	B-X
nor	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
from	B-X
non-immunized	B-X
and	B-X
2/6-VLP	B-X
immunized	B-X
mice	B-X
,	B-X
whereas	B-X
they	B-X
did	B-X
activate	B-X
both	B-X
subsets	B-X
from	B-X
mice	B-X
immunized	B-X
with	B-X
2/6-VLP	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
adjuvant	B-X
.	B-X
LT-R192G	B-X
dramatically	B-X
decreased	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
from	B-X
non-immunized	B-X
and	B-X
2/6-VLP	B-X
immunized	B-X
mice	B-X
but	B-X
not	B-X
from	B-X
mice	B-X
immunized	B-X
with	B-X
2/6-VLP	B-X
and	B-X
adjuvant	B-X
.	B-X
Moreover	B-X
,	B-X
in	B-X
this	B-X
case	B-X
,	B-X
LT-R192G	B-X
increased	B-X
Foxp3	B-X
expression	B-X
on	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
,	B-X
suggesting	B-X
specific	B-X
Treg	B-X
activation	B-X
during	B-X
the	B-X
recall	B-X
.	B-X
Finally	B-X
,	B-X
when	B-X
both	B-X
2/6-VLP	B-X
and	B-X
LT-R192G	B-X
were	B-X
used	B-X
for	B-X
restimulation	B-X
,	B-X
LT-R192G	B-X
clearly	B-X
suppressed	B-X
both	B-X
2/6-VLP-specific	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
Foxp3	B-X
(	B-X
-	B-X
)	B-X
and	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
All	B-X
together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
LT-R192G	B-X
exerts	B-X
different	B-X
effects	B-X
on	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD25	B-X
(	B-X
+	B-X
)	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
,	B-X
depending	B-X
on	B-X
a	B-X
first	B-X
or	B-X
a	B-X
second	B-X
contact	B-X
.	B-X

Foxp3	B-Protein
Suppresses	O
HIV	O
-	O
1	O
Gene	O
Expression	O
in	O
Part	O
through	O
Blocking	O
Activation	O
of	O
NF	O
-	O
kappaB	O

If	O
Foxp3	B-Protein
functions	O
as	O
a	O
repressor	O
of	O
NF	O
-	O
kappaB	O
-	O
dependent	O
gene	O
expression	O
,	O
then	O
we	O
hypothesized	O
that	O
Foxp3	B-Protein
overexpression	O
could	O
selectively	O
down	O
-	O
regulate	O
transcription	O
from	O
promoters	O
previously	O
shown	O
to	O
be	O
responsive	O
to	O
NF	O
-	O
kappaB	O
.	O

To	O
address	O
this	O
question	O
,	O
we	O
examined	O
the	O
transcriptional	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
,	O
which	O
contains	O
two	O
tandem	O
cis	O
-	O
acting	O
NF	O
-	O
kappaB	O
binding	O
sites	O
located	O
between	O
positions	O
-	O
102	O
and	O
-	O
81	O
with	O
respect	O
to	O
the	O
transcription	O
initiation	O
site	O
[	O
21	O
]	O
.	O

NF	O
-	O
kappaB	O
plays	O
a	O
crucial	O
role	O
in	O
regulating	O
gene	O
expression	O
directed	O
from	O
the	O
HIV	O
-	O
1	O
LTR	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
[	O
21	O
]	O
.	O

Overexpression	O
of	O
full	O
-	O
length	O
Foxp3	B-Protein
,	O
but	O
not	O
deltaFKH	B-Protein
,	O
in	O
HEK	O
293T	O
cells	O
was	O
able	O
to	O
inhibit	O
basal	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
(	O
Figure	O
3A	O
)	O
,	O
similar	O
to	O
what	O
was	O
previously	O
demonstrated	O
with	O
the	O
synthetic	O
NF	O
-	O
kappaB	O
reporter	O
vector	O
(	O
Figure	O
2B	O
)	O
.	O

Furthermore	O
,	O
HIV	O
-	O
1	O
LTR	O
activation	O
was	O
suppressed	O
by	O
full	O
-	O
length	O
Foxp3	B-Protein
and	O
deltaFKH	B-Protein
in	O
Jurkat	O
T	O
cells	O
(	O
Figure	O
3B	O
)	O
.	O

To	O
demonstrate	O
that	O
Foxp3	B-Protein
-	O
mediated	O
HIV	O
-	O
1	O
LTR	O
repression	O
was	O
associated	O
with	O
interactions	O
with	O
NF	O
-	O
kappaB	O
bound	O
to	O
the	O
HIV	O
-	O
1	O
LTR	O
,	O
we	O
compared	O
basal	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
or	O
an	O
identical	O
HIV	O
-	O
1	O
LTR	O
lacking	O
the	O
NF	O
-	O
kappaB	O
sites	O
located	O
between	O
-	O
102	O
and	O
-	O
81	O
(	O
HIV	O
-	O
1	O
delta	O
-	O
kappaB	O
LTR	O
)	O
(	O
Figure	O
3C	O
)	O
.	O

This	O
mutant	O
HIV	O
-	O
1	O
LTR	O
construct	O
exhibited	O
reduced	O
levels	O
of	O
transcription	O
compared	O
to	O
the	O
parental	O
HIV	O
-	O
1	O
LTR	O
in	O
purified	O
healthy	O
donor	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
unpublished	O
data	O
)	O
.	O

However	O
,	O
directly	O
comparing	O
the	O
effect	O
of	O
Foxp3	B-Protein
overexpression	O
on	O
the	O
activation	O
of	O
these	O
two	O
viral	O
promoters	O
demonstrated	O
that	O
Foxp3	B-Protein
was	O
more	O
capable	O
of	O
suppressing	O
transcriptional	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
(	O
Figure	O
3D	O
)	O
compared	O
to	O
the	O
mutated	O
HIV	O
-	O
1	O
LTR	O
(	O
Figure	O
3E	O
)	O
.	O

These	O
results	O
suggest	O
that	O
Foxp3	B-Protein
down	O
-	O
regulation	O
of	O
HIV	O
-	O
1	O
LTR	O
activation	O
was	O
mediated	O
at	O
least	O
in	O
part	O
by	O
cis	O
-	O
acting	O
NF	O
-	O
kappaB	O
binding	O
sites	O
.	O

Residual	O
levels	O
of	O
inhibition	O
of	O
the	O
HIV	O
-	O
1	O
delta	O
-	O
kappaB	O
LTR	O
by	O
Foxp3	B-Protein
may	O
be	O
due	O
to	O
NF	O
-	O
AT	O
binding	O
sites	O
located	O
upstream	O
of	O
the	O
NF	O
-	O
kappaB	O
sites	O
within	O
the	O
HIV	O
-	O
1	O
LTR	O
[	O
22	O
,	O
23	O
]	O
.	O

The	O
Transactivation	O
Functions	O
of	O
HTLV	O
-	O
I	O
Tax	B-Protein
Are	O
Suppressed	O
by	O
Foxp3	B-Protein
<EOS>	B-X
Human	B-X
T-lymphotropic	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HTLV-1	B-X
)	B-X
is	B-X
linked	B-X
to	B-X
multiple	B-X
diseases	B-X
,	B-X
including	B-X
the	B-X
neuroinflammatory	B-X
disease	B-X
HTLV-1-associated	B-X
myelopathy/tropical	B-X
spastic	B-X
paraparesis	B-X
(	B-X
HAM/TSP	B-X
)	B-X
and	B-X
adult	B-X
T	B-X
cell	B-X
leukemia/lymphoma	B-X
.	B-X
Evidence	B-X
suggests	B-X
that	B-X
HTLV-1	B-X
,	B-X
via	B-X
the	B-X
viral	B-X
protein	B-X
Tax	B-X
,	B-X
exploits	B-X
CD4+	B-X
T	B-X
cell	B-X
plasticity	B-X
and	B-X
induces	B-X
transcriptional	B-X
changes	B-X
in	B-X
infected	B-X
T	B-X
cells	B-X
that	B-X
cause	B-X
suppressive	B-X
CD4+CD25+CCR4+	B-X
Tregs	B-X
to	B-X
lose	B-X
expression	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
FOXP3	B-X
and	B-X
produce	B-X
IFN-γ	B-X
,	B-X
thus	B-X
promoting	B-X
inflammation	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
transformation	B-X
of	B-X
HTLV-1-infected	B-X
CCR4+	B-X
T	B-X
cells	B-X
into	B-X
Th1-like	B-X
cells	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
HAM/TSP	B-X
.	B-X
Here	B-X
,	B-X
using	B-X
patient	B-X
cells	B-X
and	B-X
cell	B-X
lines	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
Tax	B-X
,	B-X
in	B-X
cooperation	B-X
with	B-X
specificity	B-X
protein	B-X
1	B-X
(	B-X
Sp1	B-X
)	B-X
,	B-X
boosts	B-X
expression	B-X
of	B-X
the	B-X
Th1	B-X
master	B-X
regulator	B-X
T	B-X
box	B-X
transcription	B-X
factor	B-X
(	B-X
T-bet	B-X
)	B-X
and	B-X
consequently	B-X
promotes	B-X
production	B-X
of	B-X
IFN-γ	B-X
.	B-X

Previous	O
studies	O
by	O
Bettelli	O
and	O
colleagues	O
have	O
demonstrated	O
that	O
Foxp3	B-Protein
can	O
repress	O
both	O
the	O
basal	O
levels	O
of	O
NF	O
-	O
kappaB	O
activation	O
as	O
well	O
as	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
-	O
stimulated	O
NF	O
-	O
kappaB	O
activation	O
[	O
15	O
]	O
.	O

Our	O
next	O
step	O
was	O
to	O
determine	O
whether	O
Foxp3	B-Protein
could	O
also	O
suppress	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
caused	O
by	O
a	O
strong	O
viral	O
transactivator	O
protein	O
.	O

HTLV	O
-	O
I	O
encodes	O
a	O
multifunctional	O
transactivator	O
protein	O
,	O
Tax	B-Protein
,	O
capable	O
of	O
activating	O
both	O
the	O
NF	O
-	O
kappaB	O
and	O
CREB	O
pathways	O
[	O
24	O
-	O
29	O
]	O
.	O

Since	O
the	O
HTLV	O
-	O
I	O
Tax	B-Protein
protein	O
can	O
function	O
at	O
multiple	O
levels	O
in	O
both	O
the	O
cytoplasm	O
and	O
the	O
nucleus	O
to	O
stimulate	O
activation	O
of	O
NF	O
-	O
kappaB	O
[	O
28	O
,	O
29	O
]	O
,	O
we	O
hypothesized	O
that	O
overexpression	O
of	O
Foxp3	B-Protein
may	O
interfere	O
with	O
this	O
process	O
.	O

However	O
,	O
since	O
Tax	B-Protein
-	O
dependent	O
HTLV	O
-	O
I	O
gene	O
expression	O
is	O
independent	O
of	O
NF	O
-	O
kappaB	O
[	O
18	O
]	O
,	O
we	O
also	O
hypothesized	O
that	O
Foxp3	B-Protein
would	O
not	O
affect	O
Tax	B-Protein
-	O
dependent	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
.	O

To	O
test	O
these	O
hypotheses	O
,	O
we	O
overexpressed	O
HTLV	O
-	O
I	O
Tax	B-Protein
,	O
full	O
-	O
length	O
Foxp3	B-Protein
,	O
and	O
/	O
or	O
deltaFKH	B-Protein
in	O
HEK	O
293T	O
cells	O
cotransfected	O
with	O
an	O
HTLV	O
-	O
I	O
LTR	O
or	O
NF	O
-	O
kappaB	O
reporter	O
vector	O
.	O
<EOS>	B-X
Studies	B-X
have	B-X
shown	B-X
that	B-X
aerobic	B-X
exercise	B-X
might	B-X
alleviate	B-X
the	B-X
pathological	B-X
development	B-X
of	B-X
VCI	B-X
,	B-X
and	B-X
our	B-X
previous	B-X
study	B-X
observed	B-X
that	B-X
aerobic	B-X
exercise	B-X
could	B-X
alleviate	B-X
VCI	B-X
through	B-X
NF-κB/miR-503/BDNF	B-X
pathway	B-X
.	B-X
In	B-X
tumor	B-X
microenvironment	B-X
,	B-X
STAT3/NF-κB	B-X
pathways	B-X
are	B-X
constitutively	B-X
activated	B-X
in	B-X
stromal	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
in	B-X
cancer	B-X
stem	B-X
cells	B-X
(	B-X
CSCs	B-X
)	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
cloned	B-X
a	B-X
novel	B-X
STAT3/NF-κB-based	B-X
reporter	B-X
system	B-X
to	B-X
drive	B-X
the	B-X
expression	B-X
of	B-X
herpes	B-X
simplex	B-X
virus	B-X
thymidine	B-X
kinase	B-X
(	B-X
HSV-TK	B-X
)	B-X
against	B-X
breast	B-X
cancer	B-X
.	B-X
Lentiviral	B-X
vector	B-X
expressing	B-X
HSV-TK	B-X
under	B-X
the	B-X
regulation	B-X
of	B-X
STAT3/NF-κB	B-X
fused	B-X
response	B-X
element	B-X
was	B-X
developed	B-X
.	B-X
In	B-X
this	B-X
setting	B-X
,	B-X
we	B-X
exploited	B-X
the	B-X
constitutive	B-X
STAT3/NF-κB	B-X
activation	B-X
in	B-X
tumors	B-X
to	B-X
achieve	B-X
higher	B-X
transgene	B-X
expression	B-X
than	B-X
that	B-X
driven	B-X
by	B-X
a	B-X
constitutively	B-X
active	B-X
CMV	B-X
promotor	B-X

As	O
shown	O
in	O
Figure	O
4A	O
,	O
HTLV	O
-	O
I	O
Tax	B-Protein
strongly	O
up	O
-	O
regulated	O
NF	O
-	O
kappaB	O
-	O
dependent	O
transcriptional	O
activation	O
(	O
~	O
60	O
-	O
fold	O
)	O
.	O

Interestingly	O
,	O
overexpression	O
of	O
Foxp3	B-Protein
,	O
but	O
not	O
deltaFKH	B-Protein
,	O
suppressed	O
Tax	B-Protein
-	O
mediated	O
activation	O
of	O
NF	O
-	O
kappaB	O
-	O
dependent	O
transcription	O
.	O
<EOS>	B-X
An	B-X
overexpression	B-X
of	B-X
Th2	B-X
cytokines	B-X
has	B-X
been	B-X
observed	B-X
in	B-X
acute	B-X
and	B-X
subacute	B-X
lesions	B-X
of	B-X
AD	B-X
.	B-X
In	B-X
vitro	B-X
data	B-X
indicate	B-X
,	B-X
however	B-X
,	B-X
that	B-X
the	B-X
T	B-X
cell	B-X
response	B-X
is	B-X
not	B-X
solely	B-X
Th2-polarized	B-X
but	B-X
may	B-X
lead	B-X
to	B-X
heterogeneous	B-X
cytokine	B-X
production	B-X
involving	B-X
IFN-γ	B-X
and	B-X
IL-17	B-X
in	B-X
an	B-X
allergen-dependent	B-X
manner	B-X
.	B-X
Classical	B-X
thymus-derived	B-X
Foxp3	B-X
T	B-X
cells	B-X
have	B-X
interestingly	B-X
been	B-X
detected	B-X
in	B-X
elevated	B-X
numbers	B-X
in	B-X
the	B-X
circulation	B-X
of	B-X
AD	B-X
patients	B-X
.	B-X
Teleost	B-X
Forkhead	B-X
box	B-X
protein	B-X
P3	B-X
(	B-X
Foxp3	B-X
)	B-X
expression	B-X
was	B-X
discovered	B-X
not	B-X
only	B-X
in	B-X
regulatory	B-X
T	B-X
cells	B-X
(	B-X
Tregs	B-X
)	B-X
but	B-X
also	B-X
in	B-X
other	B-X
cells	B-X
.	B-X
Compared	B-X
to	B-X
the	B-X
extensive	B-X
study	B-X
on	B-X
its	B-X
roles	B-X
in	B-X
lymphoid	B-X
cells	B-X
,	B-X
the	B-X
expression	B-X
pattern	B-X
and	B-X
biological	B-X
roles	B-X
of	B-X
Foxp3	B-X
in	B-X
non-lymphoid	B-X
cells	B-X
have	B-X
not	B-X
been	B-X
elucidated	B-X
in	B-X
both	B-X
mammals	B-X
and	B-X
fish	B-X
species	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
grass	B-X
carp	B-X
Foxp3	B-X
(	B-X
gcFoxp3	B-X
)	B-X
mRNA	B-X
expression	B-X
was	B-X
detected	B-X
in	B-X
different	B-X
cell	B-X
types	B-X
,	B-X
showing	B-X
that	B-X
it	B-X
has	B-X
a	B-X
moderate	B-X
expression	B-X
level	B-X
in	B-X
peripheral	B-X
blood	B-X
leukocytes	B-X
(	B-X
PBLs	B-X
)	B-X
,	B-X
head	B-X
kidney	B-X
leukocytes	B-X
(	B-X
HKLs	B-X
)	B-X
and	B-X
grass	B-X
carp	B-X
fibroblast-like	B-X
kidney	B-X
cells	B-X
(	B-X
CIK	B-X
cells	B-X
)	B-X
.	B-X
Interestingly	B-X
,	B-X
gcFoxp3	B-X
mRNA	B-X
and	B-X
protein	B-X
expression	B-X
could	B-X
be	B-X
significantly	B-X
stimulated	B-X
by	B-X
polyinosinic-polycytidylic	B-X
acid	B-X
(	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
)	B-X
in	B-X
CIK	B-X
cells	B-X
,	B-X
indicating	B-X
its	B-X
participation	B-X
in	B-X
poly	B-X
I	B-X
:	B-X
C-induced	B-X
immune	B-X
response	B-X
in	B-X
non-lymphoid	B-X
cells	B-X
.	B-X
To	B-X
further	B-X
investigate	B-X
the	B-X
function	B-X
of	B-X
gcFoxp3	B-X
,	B-X
its	B-X
overexpression	B-X
plasmid	B-X
was	B-X
constructed	B-X
and	B-X
transfected	B-X
into	B-X
CIK	B-X
cells	B-X
.	B-X
After	B-X
24	B-X
h	B-X
of	B-X
transfection	B-X
,	B-X
grass	B-X
carp	B-X
C-X-C	B-X
chemokine	B-X
ligand	B-X
(	B-X
CXCL	B-X
)	B-X
8	B-X
(	B-X
gcCXCL-8	B-X
)	B-X
mRNA	B-X
expression	B-X
was	B-X
elevated	B-X
,	B-X
implying	B-X
the	B-X
modulatory	B-X
role	B-X
of	B-X
gcFoxp3	B-X
in	B-X
gcCXCL-8	B-X
mRNA	B-X
expression	B-X
.	B-X
This	B-X
notion	B-X
was	B-X
further	B-X
supported	B-X
by	B-X
the	B-X
features	B-X
of	B-X
gcCXCL-8	B-X
promoter	B-X
which	B-X
contained	B-X
a	B-X
putative	B-X
Foxp3	B-X
binding	B-X
site	B-X
at	B-X
-2196	B-X
to	B-X
-2190	B-X
region	B-X
.	B-X
Poly	B-X
I	B-X
:	B-X
C	B-X
or	B-X
overexpression	B-X
of	B-X
gcFoxp3	B-X
obviously	B-X
stimulated	B-X
gcCXCL-8	B-X
promoter	B-X
activity	B-X
and	B-X
deletion	B-X
of	B-X
gcFoxp3	B-X
binding	B-X
region	B-X
on	B-X
the	B-X
promoter	B-X
abolished	B-X
this	B-X
stimulation	B-X
,	B-X
revealing	B-X
that	B-X
Foxp3	B-X
is	B-X
pivotal	B-X
for	B-X
transcription	B-X
of	B-X
CXCL-8	B-X
induced	B-X
by	B-X
poly	B-X
I	B-X
:	B-X
C.	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
results	B-X
collectively	B-X
demonstrate	B-X
expression	B-X
pattern	B-X
of	B-X
teleost	B-X
Foxp3	B-X
,	B-X
and	B-X
illuminate	B-X
novel	B-X
immune	B-X
function	B-X
of	B-X
fish	B-X
Foxp3	B-X
in	B-X
regulating	B-X
chemokine	B-X
transcription	B-X
in	B-X
non-lymphoid	B-X
cells	B-X
.	B-X

These	O
observations	O
further	O
suggest	O
that	O
the	O
carboxyl	O
-	O
terminal	O
FKH	O
domain	O
is	O
required	O
for	O
inhibiting	O
activation	O
of	O
NF	O
-	O
kappaB	O
in	O
the	O
presence	O
of	O
Tax	B-Protein
in	O
HEK	O
293T	O
cells	O
,	O
strikingly	O
similar	O
to	O
the	O
requirements	O
of	O
Foxp3	B-Protein
inhibition	O
of	O
basal	O
NF	O
-	O
kappaB	O
activation	O
shown	O
in	O
Figure	O
2B	O
.	O

Transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
was	O
stimulated	O
about	O
55	O
-	O
fold	O
by	O
overexpression	O
of	O
Tax	B-Protein
(	O
Figure	O
4B	O
)	O
,	O
while	O
transfection	O
of	O
Foxp3	B-Protein
suppressed	O
Tax	B-Protein
-	O
dependent	O
HTLV	O
-	O
I	O
LTR	O
activation	O
,	O
although	O
HTLV	O
-	O
I	O
LTR	O
activation	O
in	O
the	O
presence	O
or	O
absence	O
of	O
Tax	B-Protein
is	O
independent	O
of	O
NF	O
-	O
kappaB	O
or	O
NF	O
-	O
AT	O
(	O
another	O
transcriptional	O
activator	O
known	O
to	O
interact	O
with	O
Foxp3	B-Protein
)	O
.	O
<EOS>	B-X
Long	B-X
noncoding	B-X
RNAs	B-X
play	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
T-helper	B-X
cell	B-X
development	B-X
but	B-X
little	B-X
is	B-X
known	B-X
about	B-X
their	B-X
roles	B-X
in	B-X
Treg	B-X
differentiation	B-X
and	B-X
functions	B-X
during	B-X
the	B-X
progression	B-X
of	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
lnc-epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
(	B-X
EGFR	B-X
)	B-X
upregulation	B-X
in	B-X
Tregs	B-X
correlates	B-X
positively	B-X
with	B-X
the	B-X
tumour	B-X
size	B-X
and	B-X
expression	B-X
of	B-X
EGFR/Foxp3	B-X
,	B-X
but	B-X
negatively	B-X
with	B-X
IFN-γ	B-X
expression	B-X
in	B-X
patients	B-X
and	B-X
xenografted	B-X
mouse	B-X
models	B-X
.	B-X
Lnc-EGFR	B-X
stimulates	B-X
Treg	B-X
differentiation	B-X
,	B-X
suppresses	B-X
CTL	B-X
activity	B-X
and	B-X
promotes	B-X
HCC	B-X
growth	B-X
in	B-X
an	B-X
EGFR-dependent	B-X
manner	B-X
.	B-X
Mechanistically	B-X
,	B-X
lnc-EGFR	B-X
specifically	B-X
binds	B-X
to	B-X
EGFR	B-X
and	B-X
blocks	B-X
its	B-X
interaction	B-X
with	B-X
and	B-X
ubiquitination	B-X
by	B-X
c-CBL	B-X
,	B-X
stabilizing	B-X
it	B-X
and	B-X
augmenting	B-X
activation	B-X
of	B-X
itself	B-X
and	B-X
its	B-X
downstream	B-X
AP-1/NF-AT1	B-X
axis	B-X
,	B-X
which	B-X
in	B-X
turn	B-X
elicits	B-X
EGFR	B-X
expression	B-X
.	B-X

Furthermore	O
,	O
overexpression	O
of	O
deltaFKH	B-Protein
also	O
led	O
to	O
suppression	O
of	O
HTLV	O
-	O
I	O
transactivation	O
by	O
Tax	B-Protein
to	O
a	O
similar	O
extent	O
as	O
full	O
-	O
length	O
Foxp3	B-Protein
(	O
Figure	O
4B	O
)	O
.	O

The	O
suppressive	O
effects	O
shown	O
in	O
Figure	O
4A	O
and	O
4B	O
were	O
not	O
the	O
result	O
of	O
Foxp3	B-Protein
down	O
-	O
regulating	O
the	O
expression	O
of	O
the	O
transfected	O
Tax	B-Protein
plasmid	O
as	O
determined	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
(	O
Figure	O
4C	O
)	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
Foxp3	B-Protein
interacts	O
with	O
transcriptional	O
regulators	O
in	O
addition	O
to	O
NF	O
-	O
kappaB	O
and	O
NF	O
-	O
AT	O
,	O
and	O
that	O
the	O
carboxyl	O
-	O
terminal	O
FKH	O
domain	O
,	O
and	O
therefore	O
localization	O
to	O
the	O
nucleus	O
,	O
are	O
not	O
required	O
for	O
inhibition	O
of	O
Tax	B-Protein
-	O
mediated	O
HTLV	O
-	O
I	O
LTR	O
activation	O
(	O
even	O
in	O
HEK	O
293T	O
cells	O
)	O
.	O

To	O
determine	O
whether	O
Foxp3	B-Protein
inhibited	O
the	O
transactivation	O
functions	O
of	O
Tax	B-Protein
by	O
directly	O
associating	O
with	O
this	O
viral	O
protein	O
,	O
we	O
generated	O
an	O
expression	O
vector	O
in	O
which	O
HTLV	O
-	O
I	O
Tax	B-Protein
was	O
fused	O
in	O
-	O
frame	O
to	O
the	O
carboxyl	O
terminus	O
of	O
the	O
Gal4	B-Protein
DNA	O
-	O
binding	O
domain	O
(	O
Gal4	B-Protein
-	O
BD	O
)	O
.	O

This	O
Gal4	B-Protein
-	I-Protein
BD	I-Protein
-	I-Protein
Tax	I-Protein
fusion	O
protein	O
activated	O
transcription	O
of	O
a	O
synthetic	O
promoter	O
containing	O
five	O
Gal4	O
binding	O
sites	O
,	O
while	O
Gal4	B-Protein
-	O
BD	O
was	O
insufficient	O
to	O
stimulate	O
transcription	O
by	O
itself	O
(	O
Figure	O
4D	O
)	O
.	O

Transactivation	O
of	O
the	O
Gal4	O
-	O
resposive	O
promoter	O
by	O
Gal4	B-Protein
-	I-Protein
BD	I-Protein
-	I-Protein
Tax	I-Protein
remained	O
relatively	O
unaffected	O
by	O
overexpression	O
of	O
either	O
EGFP	O
(	O
control	O
)	O
,	O
Foxp3	B-Protein
,	O
or	O
deltaFKH	B-Protein
,	O
suggesting	O
that	O
Foxp3	B-Protein
does	O
not	O
repress	O
Tax	B-Protein
transactivation	O
by	O
directly	O
interfacing	O
with	O
the	O
HTLV	O
-	O
I	O
Tax	B-Protein
protein	O
.	O
<EOS>	B-X
Aggressive	B-X
cancer	B-X
of	B-X
these	B-X
epithelial	B-X
tissues	B-X
often	B-X
correlates	B-X
with	B-X
abnormal	B-X
expression	B-X
of	B-X
FOXP3	B-X
,	B-X
which	B-X
can	B-X
be	B-X
either	B-X
absent	B-X
or	B-X
underexpressed	B-X
at	B-X
transcript	B-X
or	B-X
protein	B-X
levels	B-X
.	B-X
However	B-X
,	B-X
recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
TLOs	B-X
rich	B-X
in	B-X
regulatory	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
are	B-X
present	B-X
in	B-X
long-term	B-X
accepting	B-X
allografts	B-X
.	B-X
Foxp3-lineage	B-X
CD4	B-X
regulatory	B-X
T	B-X
cells	B-X
(	B-X
Tregs	B-X
)	B-X
were	B-X
named	B-X
for	B-X
their	B-X
ability	B-X
to	B-X
maintain	B-X
self	B-X
tolerance	B-X
and	B-X
suppress	B-X
T	B-X
cell	B-X
immunity	B-X
.	B-X
In	B-X
this	B-X
Brief	B-X
Review	B-X
,	B-X
we	B-X
describe	B-X
recent	B-X
progress	B-X
in	B-X
elucidating	B-X
physiologic	B-X
processes	B-X
that	B-X
control	B-X
the	B-X
functional	B-X
status	B-X
of	B-X
Foxp3-lineage	B-X
Tregs	B-X
.	B-X
This	B-X
suggests	B-X
a	B-X
novel	B-X
paradigm	B-X
in	B-X
which	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
Tregs	B-X
intrinsically	B-X
possess	B-X
bifunctional	B-X
potential	B-X
,	B-X
acting	B-X
as	B-X
a	B-X
preformed	B-X
pool	B-X
of	B-X
first-responder	B-X
cells	B-X
at	B-X
sites	B-X
of	B-X
local	B-X
inflammation	B-X
that	B-X
can	B-X
either	B-X
provide	B-X
classical	B-X
regulatory/suppressor	B-X
activity	B-X
,	B-X
or	B-X
rapidly	B-X
reprogram	B-X
to	B-X
supply	B-X
helper/effector	B-X
activity	B-X
,	B-X
contingent	B-X
on	B-X
signals	B-X
that	B-X
manifest	B-X
in	B-X
local	B-X
physiologic	B-X
settings	B-X
.	B-X

To	O
confirm	O
that	O
Foxp3	B-Protein
had	O
a	O
direct	O
effect	O
on	O
HTLV	O
-	O
I	O
replication	O
,	O
we	O
transfected	O
HEK	O
293T	O
cells	O
with	O
a	O
well	O
-	O
characterized	O
HTLV	O
-	O
I	O
infectious	O
molecular	O
clone	O
(	O
termed	O
ACH	O
)	O
[	O
30	O
]	O
in	O
the	O
presence	O
of	O
full	O
-	O
length	O
Foxp3	B-Protein
,	O
deltaFKH	B-Protein
,	O
or	O
control	O
vector	O
.	O
<EOS>	B-X
The	B-X
prospect	B-X
of	B-X
using	B-X
genetic	B-X
methods	B-X
to	B-X
target	B-X
vector	B-X
,	B-X
parasite	B-X
,	B-X
and	B-X
reservoir	B-X
species	B-X
offers	B-X
tremendous	B-X
potential	B-X
benefits	B-X
to	B-X
public	B-X
health	B-X
,	B-X
but	B-X
the	B-X
use	B-X
of	B-X
genome	B-X
editing	B-X
to	B-X
alter	B-X
the	B-X
shared	B-X
environment	B-X
will	B-X
require	B-X
special	B-X
attention	B-X
to	B-X
public	B-X
perception	B-X
and	B-X
community	B-X
governance	B-X
in	B-X
order	B-X
to	B-X
benefit	B-X
the	B-X
world	B-X
.	B-X
Hence	B-X
,	B-X
open	B-X
and	B-X
community-guided	B-X
development	B-X
of	B-X
thoughtfully	B-X
chosen	B-X
applications	B-X
is	B-X
not	B-X
only	B-X
the	B-X
most	B-X
ethical	B-X
approach	B-X
,	B-X
but	B-X
also	B-X
the	B-X
most	B-X
likely	B-X
to	B-X
overcome	B-X
the	B-X
economic	B-X
,	B-X
social	B-X
,	B-X
and	B-X
diplomatic	B-X
barriers	B-X
.	B-X
Some	B-X
microbial	B-X
pesticides	B-X
,	B-X
such	B-X
as	B-X
Bacillus	B-X
thuringiensis	B-X
,	B-X
have	B-X
a	B-X
long	B-X
history	B-X
of	B-X
safe	B-X
and	B-X
effective	B-X
use	B-X
as	B-X
a	B-X
biological	B-X
insecticide	B-X
.	B-X
More	B-X
recent	B-X
developments	B-X
in	B-X
microbial	B-X
pest	B-X
control	B-X
include	B-X
the	B-X
utilisation	B-X
of	B-X
other	B-X
bacterial	B-X
and	B-X
fungal	B-X
species	B-X
that	B-X
may	B-X
competitively	B-X
inhibit	B-X
the	B-X
growth	B-X
of	B-X
pathogenic	B-X
and	B-X
toxigenic	B-X
micro-organisms	B-X
on	B-X
important	B-X
agricultural	B-X
commodities	B-X
.	B-X
The	B-X
use	B-X
of	B-X
microbes	B-X
and	B-X
their	B-X
gene	B-X
products	B-X
introduces	B-X
additional	B-X
considerations	B-X
to	B-X
the	B-X
toxicological	B-X
dose-response	B-X
relationship	B-X
,	B-X
including	B-X
a	B-X
need	B-X
to	B-X
determine	B-X
the	B-X
plausibility	B-X
of	B-X
infectious	B-X
and	B-X
immunological	B-X
effects	B-X
in	B-X
association	B-X
with	B-X
human	B-X
exposure	B-X
to	B-X
these	B-X
biopesticides	B-X
in	B-X
food	B-X
or	B-X
the	B-X
environment	B-X
.	B-X

ACH	O
has	O
been	O
previously	O
shown	O
to	O
direct	O
the	O
expression	O
of	O
viral	O
antigens	O
,	O
produce	O
infectious	O
virus	O
,	O
and	O
transform	O
CD4	B-Protein
+	O
T	O
cells	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
31	O
,	O
32	O
]	O
.	O

After	O
24	O
h	O
,	O
the	O
amount	O
of	O
viral	O
antigen	O
expression	O
,	O
in	O
this	O
case	O
Tax	B-Protein
mRNA	O
,	O
was	O
detected	O
by	O
a	O
sensitive	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assay	O
.	O

As	O
illustrated	O
in	O
Figure	O
5	O
,	O
the	O
level	O
of	O
Tax	B-Protein
mRNA	O
synthesized	O
from	O
ACH	O
was	O
down	O
-	O
regulated	O
in	O
the	O
presence	O
of	O
Foxp3	B-Protein
compared	O
to	O
the	O
level	O
produced	O
in	O
the	O
presence	O
of	O
the	O
control	O
vector	O
.	O

deltaFKH	B-Protein
did	O
not	O
have	O
a	O
discernable	O
affect	O
on	O
Tax	B-Protein
expression	O
.	O

These	O
data	O
indicate	O
that	O
Foxp3	B-Protein
is	O
capable	O
of	O
repressing	O
the	O
expression	O
of	O
Tax	B-Protein
from	O
an	O
infectious	O
HTLV	O
-	O
I	O
molecular	O
clone	O
.	O

Increased	O
Foxp3	B-Protein
Protein	O
Expression	O
Is	O
Associated	O
with	O
Low	O
HTLV	O
-	O
I	O
Proviral	O
Load	O

Since	O
Foxp3	B-Protein
is	O
expressed	O
almost	O
exclusively	O
within	O
CD4	B-Protein
+	O
CD25	B-Protein
+	O
T	O
cells	O
,	O
a	O
major	O
viral	O
reservoir	O
for	O
HTLV	O
-	O
I	O
[	O
33	O
]	O
,	O
it	O
was	O
important	O
to	O
determine	O
whether	O
there	O
was	O
an	O
association	O
between	O
Foxp3	B-Protein
and	O
HTLV	O
-	O
I	O
replication	O
in	O
infected	O
patients	O
.	O

We	O
therefore	O
quantitated	O
the	O
Foxp3	B-Protein
protein	O
expression	O
in	O
CD4	B-Protein
+	O
CD25	B-Protein
+	O
T	O
cells	O
by	O
flow	O
cytometry	O
and	O
the	O
HTLV	O
-	O
I	O
proviral	O
load	O
(	O
a	O
surrogate	O
marker	O
of	O
viral	O
replication	O
)	O
by	O
real	O
-	O
time	O
PCR	O
from	O
eight	O
patients	O
with	O
HAM	O
/	O
TSP	O
and	O
eight	O
asymptomatic	O
carriers	O
(	O
ACs	O
)	O
.	O

The	O
data	O
from	O
this	O
analysis	O
is	O
summarized	O
in	O
Table	O
1	O
.	O
<EOS>	B-X
The	B-X
present	B-X
systematic	B-X
review	B-X
and	B-X
meta-analysis	B-X
summarize	B-X
the	B-X
diagnostic	B-X
information	B-X
provided	B-X
by	B-X
PET/MRI	B-X
in	B-X
patients	B-X
with	B-X
prostate	B-X
cancer	B-X
(	B-X
PCa	B-X
)	B-X
.	B-X
If	B-X
well-executed	B-X
,	B-X
this	B-X
``	B-X
Table	B-X
1	B-X
''	B-X
can	B-X
illuminate	B-X
potential	B-X
threats	B-X
to	B-X
internal	B-X
and	B-X
external	B-X
validity	B-X
.	B-X
However	B-X
,	B-X
little	B-X
guidance	B-X
exists	B-X
on	B-X
best	B-X
practices	B-X
for	B-X
designing	B-X
a	B-X
Table	B-X
1	B-X
,	B-X
especially	B-X
for	B-X
complex	B-X
study	B-X
designs	B-X
and	B-X
analyses	B-X
.	B-X
This	B-X
is	B-X
an	B-X
update	B-X
of	B-X
our	B-X
Cochrane	B-X
review	B-X
published	B-X
first	B-X
in	B-X
2003	B-X
and	B-X
then	B-X
updated	B-X
in	B-X
2008	B-X
and	B-X
now	B-X
in	B-X
2015	B-X
.	B-X

As	O
expected	O
,	O
patients	O
with	O
HAM	O
/	O
TSP	O
exhibited	O
significantly	O
higher	O
proviral	O
loads	O
(	O
indicated	O
as	O
HTLV	O
-	O
I	O
proviral	O
DNA	O
copies	O
/	O
100	O
cells	O
)	O
(	O
34	O
.	O
68	O
+	O
/	O
-	O
23	O
.	O
19	O
)	O
compared	O
to	O
ACs	O
(	O
4	O
.	O
75	O
+	O
/	O
-	O
5	O
.	O
47	O
)	O
(	O
p	O
=	O
0	O
.	O
0008	O
)	O
.	O

The	O
percentage	O
of	O
Foxp3	B-Protein
+	O
cells	O
within	O
the	O
CD4	B-Protein
+	O
CD25	B-Protein
+	O
T	O
cell	O
population	O
was	O
significantly	O
greater	O
in	O
ACs	O
(	O
43	O
.	O
23	O
+	O
/	O
-	O
12	O
.	O
95	O
)	O
than	O
in	O
HAM	O
/	O
TSP	O
patients	O
(	O
18	O
.	O
59	O
+	O
/	O
-	O
5	O
.	O
77	O
)	O
(	O
p	O
=	O
0	O
.	O
0033	O
)	O
.	O

These	O
data	O
suggest	O
that	O
high	O
levels	O
of	O
Foxp3	B-Protein
protein	O
expression	O
are	O
associated	O
with	O
reduced	O
HTLV	O
-	O
I	O
replication	O
in	O
vivo	O
.	O

They	O
also	O
support	O
our	O
recent	O
reports	O
that	O
high	O
proviral	O
loads	O
,	O
which	O
have	O
been	O
shown	O
to	O
correlate	O
with	O
high	O
Tax	B-Protein
mRNA	O
in	O
HTLV	O
-	O
I	O
-	O
infected	O
patients	O
,	O
are	O
associated	O
with	O
reduced	O
Foxp3	B-Protein
expression	O
[	O
8	O
,	O
34	O
]	O
.	O

CREB	O
Is	O
a	O
Target	O
for	O
Transcriptional	O
Repression	O
by	O
Foxp3	B-Protein
<EOS>	B-X
Forkhead	B-X
box	B-X
(	B-X
Fox	B-X
)	B-X
/winged-helix	B-X
transcription	B-X
factors	B-X
regulate	B-X
multiple	B-X
aspects	B-X
of	B-X
immune	B-X
responsiveness	B-X
and	B-X
Foxp3	B-X
is	B-X
recognized	B-X
as	B-X
an	B-X
essential	B-X
functional	B-X
marker	B-X
of	B-X
regulatory	B-X
T	B-X
cells	B-X
.	B-X
Herein	B-X
we	B-X
describe	B-X
downstream	B-X
signaling	B-X
pathways	B-X
targeted	B-X
by	B-X
Foxp3	B-X
that	B-X
may	B-X
negatively	B-X
impact	B-X
retroviral	B-X
pathogenesis	B-X
.	B-X
Overexpression	B-X
of	B-X
Foxp3	B-X
in	B-X
HEK	B-X
293T	B-X
and	B-X
purified	B-X
CD4+	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
a	B-X
dose-dependent	B-X
and	B-X
time-dependent	B-X
decrease	B-X
in	B-X
basal	B-X
levels	B-X
of	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
activation	B-X
.	B-X
Deletion	B-X
of	B-X
the	B-X
carboxyl-terminal	B-X
forkhead	B-X
(	B-X
FKH	B-X
)	B-X
domain	B-X
,	B-X
critical	B-X
for	B-X
nuclear	B-X
localization	B-X
and	B-X
DNA-binding	B-X
activity	B-X
,	B-X
abrogated	B-X
the	B-X
ability	B-X
of	B-X
Foxp3	B-X
to	B-X
suppress	B-X
NF-kappaB	B-X
activity	B-X
in	B-X
HEK	B-X
293T	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
in	B-X
Jurkat	B-X
or	B-X
primary	B-X
human	B-X
CD4+	B-X
T	B-X
cells	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
Foxp3	B-X
suppressed	B-X
the	B-X
transcription	B-X
of	B-X
two	B-X
human	B-X
retroviral	B-X
promoters	B-X
(	B-X
HIV-1	B-X
and	B-X
human	B-X
T	B-X
cell	B-X
lymphotropic	B-X
virus	B-X
type	B-X
I	B-X
[	B-X
HTLV-I	B-X
]	B-X
)	B-X
utilizing	B-X
NF-kappaB-dependent	B-X
and	B-X
NF-kappaB-independent	B-X
mechanisms	B-X
.	B-X
Examination	B-X
of	B-X
the	B-X
latter	B-X
identified	B-X
the	B-X
cAMP-responsive	B-X
element	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
pathway	B-X
as	B-X
a	B-X
target	B-X
of	B-X
Foxp3	B-X
.	B-X
Finally	B-X
,	B-X
comparison	B-X
of	B-X
the	B-X
percent	B-X
Foxp3+CD4+CD25+	B-X
T	B-X
cells	B-X
to	B-X
the	B-X
HTLV-I	B-X
proviral	B-X
load	B-X
in	B-X
HTLV-I-infected	B-X
asymptomatic	B-X
carriers	B-X
and	B-X
patients	B-X
with	B-X
HTLV-I-associated	B-X
myelopathy/tropical	B-X
spastic	B-X
paraparesis	B-X
suggested	B-X
that	B-X
high	B-X
Foxp3	B-X
expression	B-X
is	B-X
associated	B-X
with	B-X
low	B-X
proviral	B-X
load	B-X
and	B-X
absence	B-X
of	B-X
disease	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
an	B-X
expanded	B-X
role	B-X
for	B-X
Foxp3	B-X
in	B-X
regulating	B-X
NF-kappaB-	B-X
and	B-X
CREB-dependent	B-X
cellular	B-X
and	B-X
viral	B-X
gene	B-X
expression	B-X
.	B-X

Although	O
Foxp3	B-Protein
could	O
down	O
-	O
regulate	O
Tax	B-Protein
-	O
dependent	O
transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
(	O
Figure	O
4B	O
)	O
and	O
inhibit	O
Tax	B-Protein
expression	O
from	O
an	O
infectious	O
molecular	O
clone	O
(	O
Figure	O
5	O
)	O
,	O
Foxp3	B-Protein
failed	O
to	O
modulate	O
Tax	B-Protein
function	O
in	O
the	O
absence	O
of	O
the	O
viral	O
promoter	O
(	O
Figure	O
4D	O
)	O
.	O

These	O
results	O
led	O
us	O
to	O
hypothesize	O
that	O
Foxp3	B-Protein
acts	O
on	O
HTLV	O
-	O
I	O
gene	O
expression	O
by	O
interacting	O
with	O
proteins	O
important	O
for	O
driving	O
HTLV	O
-	O
I	O
LTR	O
activity	O
in	O
vivo	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
Tax	O
-	O
responsive	O
elements	O
within	O
the	O
HTLV	O
-	O
I	O
LTR	O
play	O
a	O
crucial	O
role	O
in	O
driving	O
Tax	B-Protein
-	O
mediated	O
transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
[	O
18	O
]	O
.	O

The	O
Tax	O
-	O
responsive	O
elements	O
have	O
been	O
shown	O
to	O
resemble	O
CREB	O
binding	O
sites	O
,	O
bind	O
CREB	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
and	O
facilitate	O
HTLV	O
-	O
I	O
LTR	O
activation	O
both	O
in	O
the	O
presence	O
and	O
in	O
the	O
absence	O
of	O
Tax	B-Protein
[	O
35	O
,	O
36	O
]	O
.	O

Ching	O
and	O
colleagues	O
[	O
18	O
]	O
demonstrated	O
that	O
addition	O
of	O
a	O
dominant	O
-	O
negative	O
CREB	O
expression	O
vector	O
resulted	O
in	O
nearly	O
complete	O
inhibition	O
of	O
Tax	B-Protein
-	O
mediated	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
,	O
while	O
blocking	O
NF	O
-	O
kappaB	O
activation	O
by	O
addition	O
of	O
a	O
dominant	O
-	O
negative	O
IKKbeta	B-Protein
expression	O
vector	O
had	O
no	O
effect	O
on	O
Tax	B-Protein
transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
.	O

Therefore	O
,	O
we	O
hypothesized	O
that	O
Foxp3	B-Protein
may	O
inhibit	O
Tax	B-Protein
transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
via	O
disruption	O
of	O
the	O
CREB	O
signaling	O
pathway	O
.	O

To	O
test	O
this	O
possibility	O
,	O
HEK	O
293T	O
cells	O
were	O
transfected	O
with	O
an	O
HTLV	O
-	O
I	O
LTR	O
or	O
synthetic	O
CREB	O
reporter	O
vector	O
along	O
with	O
a	O
control	O
expression	O
vector	O
(	O
EGFP	O
)	O
or	O
expression	O
vectors	O
encoding	O
Foxp3	B-Protein
or	O
deltaFKH	B-Protein
.	O
<EOS>	B-X
Adoptive	B-X
therapy	B-X
with	B-X
polyclonal	B-X
regulatory	B-X
T	B-X
cells	B-X
(	B-X
Tregs	B-X
)	B-X
has	B-X
shown	B-X
efficacy	B-X
in	B-X
suppressing	B-X
detrimental	B-X
immune	B-X
responses	B-X
in	B-X
experimental	B-X
models	B-X
of	B-X
autoimmunity	B-X
and	B-X
transplantation	B-X
.	B-X
We	B-X
will	B-X
discuss	B-X
that	B-X
vectors	B-X
encoding	B-X
T	B-X
cell	B-X
receptors	B-X
or	B-X
chimeric	B-X
antigen	B-X
receptors	B-X
provide	B-X
an	B-X
efficient	B-X
gene-transfer	B-X
platform	B-X
to	B-X
reliably	B-X
produce	B-X
Tregs	B-X
of	B-X
defined	B-X
antigen	B-X
specificity	B-X
,	B-X
thus	B-X
overcoming	B-X
the	B-X
considerable	B-X
difficulties	B-X
of	B-X
isolating	B-X
low-frequency	B-X
,	B-X
antigen-specific	B-X
cells	B-X
that	B-X
may	B-X
be	B-X
present	B-X
in	B-X
the	B-X
natural	B-X
Treg	B-X
repertoire	B-X
.	B-X
The	B-X
recent	B-X
observations	B-X
that	B-X
Tregs	B-X
can	B-X
polarize	B-X
into	B-X
distinct	B-X
lineages	B-X
similar	B-X
to	B-X
the	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
and	B-X
Th17	B-X
subsets	B-X
described	B-X
for	B-X
conventional	B-X
T	B-X
helper	B-X
cells	B-X
raise	B-X
the	B-X
possibility	B-X
that	B-X
Th1-	B-X
,	B-X
Th2-	B-X
,	B-X
and	B-X
Th17-driven	B-X
pathology	B-X
may	B-X
require	B-X
matching	B-X
Treg	B-X
subsets	B-X
for	B-X
optimal	B-X
therapeutic	B-X
efficacy	B-X
.	B-X
In	B-X
the	B-X
future	B-X
,	B-X
genetic	B-X
engineering	B-X
may	B-X
serve	B-X
not	B-X
only	B-X
to	B-X
enforce	B-X
FoxP3	B-X
expression	B-X
and	B-X
a	B-X
stable	B-X
Treg	B-X
phenotype	B-X
but	B-X
it	B-X
may	B-X
also	B-X
enable	B-X
the	B-X
expression	B-X
of	B-X
particular	B-X
transcription	B-X
factors	B-X
that	B-X
drive	B-X
differentiation	B-X
into	B-X
defined	B-X
Treg	B-X
subsets	B-X
.	B-X

As	O
shown	O
in	O
Figure	O
6A	O
,	O
Foxp3	B-Protein
down	O
-	O
regulated	O
basal	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
and	O
transcription	O
of	O
a	O
synthetic	O
CREB	O
reporter	O
vector	O
,	O
suggesting	O
that	O
Foxp3	B-Protein
down	O
-	O
regulates	O
HTLV	O
-	O
I	O
LTR	O
activation	O
by	O
targeting	O
the	O
CREB	O
pathway	O
.	O

Deletion	O
of	O
the	O
FKH	O
domain	O
of	O
Foxp3	B-Protein
dampened	O
the	O
suppressive	O
effect	O
of	O
Foxp3	B-Protein
,	O
but	O
did	O
not	O
completely	O
abrogate	O
suppression	O
,	O
as	O
is	O
seen	O
with	O
NF	O
-	O
kappaB	O
-	O
responsive	O
promoters	O
in	O
HEK	O
293T	O
cells	O
.	O

Like	O
NF	O
-	O
kappaB	O
activation	O
,	O
CREB	O
transcriptional	O
activation	O
was	O
also	O
suppressed	O
by	O
expression	O
of	O
Foxp3	B-Protein
,	O
and	O
to	O
a	O
similar	O
extent	O
deltaFKH	B-Protein
,	O
in	O
healthy	O
donor	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
Figure	O
6B	O
)	O
.	O

Similarly	O
,	O
Foxp3	B-Protein
and	O
deltaFKH	B-Protein
also	O
repressed	O
basal	O
HTLV	O
-	O
I	O
LTR	O
activation	O
in	O
primary	O
human	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
Figure	O
6C	O
)	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
evidence	O
implicating	O
CREB	O
as	O
a	O
molecular	O
target	O
of	O
Foxp3	B-Protein
.	O

As	O
observed	O
with	O
NF	O
-	O
kappaB	O
activation	O
,	O
deltaFKH	B-Protein
was	O
a	O
more	O
potent	O
inhibitor	O
of	O
CREB	B-Protein
activation	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
than	O
in	O
HEK	O
293T	O
cells	O
,	O
further	O
indicating	O
that	O
a	O
cell	O
type	O
-	O
specific	O
mechanism	O
of	O
action	O
may	O
govern	O
the	O
function	O
of	O
this	O
Foxp3	O
mutant	O
.	O

To	O
determine	O
whether	O
Foxp3	B-Protein
functioned	O
by	O
directly	O
signaling	O
through	O
CREB	O
,	O
we	O
utilized	O
expression	O
vectors	O
encoding	O
CREB	B-Protein
-	I-Protein
1	I-Protein
or	O
c	B-Protein
-	I-Protein
Jun	I-Protein
(	O
a	O
member	O
of	O
the	O
activator	B-Protein
protein	I-Protein
1	I-Protein
family	O
of	O
transcription	O
factors	O
)	O
fused	O
in	O
-	O
frame	O
to	O
the	O
Gal4	B-Protein
-	O
BD	O
(	O
Gal4	B-Protein
-	I-Protein
BD	I-Protein
-	I-Protein
CREB	I-Protein
-	I-Protein
1	I-Protein
and	O
Gal4	B-Protein
-	I-Protein
BD	I-Protein
-	I-Protein
c	I-Protein
-	I-Protein
Jun	I-Protein
)	O
.	O

As	O
shown	O
in	O
Figure	O
6D	O
,	O
activation	O
of	O
a	O
Gal4	B-Protein
-	O
responsive	O
reporter	O
vector	O
by	O
Gal4	B-Protein
-	I-Protein
BD	I-Protein
-	I-Protein
CREB	I-Protein
-	I-Protein
1	I-Protein
was	O
down	O
-	O
regulated	O
by	O
Foxp3	B-Protein
compared	O
to	O
control	O
vector	O
(	O
EGFP	O
)	O
,	O
indicating	O
that	O
Foxp3	B-Protein
functions	O
by	O
directly	O
or	O
indirectly	O
interacting	O
with	O
CREB	B-Protein
-	I-Protein
1	I-Protein
.	O
<EOS>	B-X
Nearly	B-X
70	B-X
%	B-X
of	B-X
damage	B-X
is	B-X
caused	B-X
indirectly	B-X
by	B-X
radiolysis	B-X
of	B-X
intracellular	B-X
water	B-X
leading	B-X
to	B-X
formation	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
and	B-X
free	B-X
radicals	B-X
and	B-X
producing	B-X
a	B-X
state	B-X
of	B-X
oxidative	B-X
stress	B-X
.	B-X
The	B-X
DNA	B-X
DSBs	B-X
repair	B-X
regulated	B-X
by	B-X
MRN	B-X
complex	B-X
,	B-X
immunomodulation	B-X
and	B-X
inflammation	B-X
regulated	B-X
by	B-X
HMGB1	B-X
and	B-X
various	B-X
types	B-X
of	B-X
cytokines	B-X
are	B-X
some	B-X
of	B-X
the	B-X
key	B-X
pathways	B-X
which	B-X
interact	B-X
with	B-X
each	B-X
other	B-X
in	B-X
a	B-X
complex	B-X
manner	B-X
and	B-X
modify	B-X
the	B-X
radiation	B-X
response	B-X
.	B-X
Because	B-X
the	B-X
majority	B-X
of	B-X
radiation	B-X
damage	B-X
is	B-X
via	B-X
oxidative	B-X
stress	B-X
,	B-X
it	B-X
is	B-X
essential	B-X
to	B-X
gain	B-X
in	B-X
depth	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
of	B-X
Nrf2-ARE	B-X
pathway	B-X
and	B-X
understand	B-X
its	B-X
interactions	B-X
with	B-X
MRN	B-X
complex	B-X
,	B-X
HMGB1	B-X
and	B-X
cytokines	B-X
to	B-X
increase	B-X
our	B-X
understanding	B-X
on	B-X
the	B-X
radiation	B-X
responses	B-X
.	B-X
This	B-X
study	B-X
reviews	B-X
the	B-X
Nrf2-ARE	B-X
pathway	B-X
and	B-X
its	B-X
crosstalk	B-X
with	B-X
MRN-complex	B-X
,	B-X
HMGB1	B-X
and	B-X
cytokines	B-X
(	B-X
TNF-a	B-X
,	B-X
IL-6	B-X
,	B-X
IFN-	B-X
?	B-X

However	O
,	O
Foxp3	B-Protein
failed	O
to	O
markedly	O
affect	O
transcriptional	O
activation	O
of	O
Gal4	B-Protein
-	I-Protein
BD	I-Protein
-	I-Protein
c	I-Protein
-	I-Protein
Jun	I-Protein
(	O
c	B-Protein
-	I-Protein
Jun	I-Protein
has	O
also	O
been	O
demonstrated	O
to	O
bind	O
to	O
the	O
HTLV	O
-	O
I	O
LTR	O
)	O
and	O
Gal4	B-Protein
-	I-Protein
BD	I-Protein
-	I-Protein
Tax	I-Protein
(	O
see	O
Figure	O
5	O
)	O
.	O

Importantly	O
,	O
the	O
mechanism	O
of	O
Foxp3	B-Protein
-	O
mediated	O
inhibition	O
of	O
CREB	O
-	O
dependent	O
transcription	O
was	O
not	O
due	O
to	O
a	O
block	O
in	O
CREB	B-Protein
-	I-Protein
1	I-Protein
protein	O
expression	O
,	O
as	O
determined	O
by	O
Western	O
blot	O
analysis	O
(	O
Figure	O
6E	O
)	O
.	O

Although	O
these	O
results	O
demonstrate	O
that	O
Foxp3	B-Protein
functions	O
as	O
a	O
co	O
-	O
repressor	O
of	O
CREB	O
activation	O
(	O
in	O
addition	O
to	O
NF	O
-	O
kappaB	O
and	O
NF	O
-	O
AT	O
)	O
,	O
we	O
were	O
unable	O
to	O
detect	O
a	O
direct	O
physical	O
interaction	O
between	O
CREB	B-Protein
-	I-Protein
1	I-Protein
and	O
Foxp3	B-Protein
by	O
coimmunoprecipitation	O
or	O
mammalian	O
two	O
-	O
hybrid	O
analysis	O
(	O
unpublished	O
data	O
)	O
.	O
<EOS>	B-X
The	B-X
past	B-X
five	B-X
years	B-X
have	B-X
seen	B-X
a	B-X
tremendous	B-X
rise	B-X
in	B-X
porcine	B-X
transcriptomic	B-X
data	B-X
.	B-X
ESTs	B-X
have	B-X
been	B-X
used	B-X
to	B-X
expand	B-X
the	B-X
pig-human	B-X
comparative	B-X
maps	B-X
,	B-X
but	B-X
such	B-X
data	B-X
has	B-X
also	B-X
been	B-X
used	B-X
in	B-X
many	B-X
ways	B-X
to	B-X
understand	B-X
pig	B-X
gene	B-X
expression	B-X
.	B-X
These	B-X
include	B-X
open	B-X
screening	B-X
methods	B-X
such	B-X
as	B-X
suppression	B-X
subtractive	B-X
hybridization	B-X
,	B-X
differential	B-X
display	B-X
,	B-X
serial	B-X
analysis	B-X
of	B-X
gene	B-X
expression	B-X
,	B-X
and	B-X
EST	B-X
sequence	B-X
frequency	B-X
,	B-X
as	B-X
well	B-X
as	B-X
closed	B-X
methods	B-X
that	B-X
measure	B-X
expression	B-X
of	B-X
a	B-X
defined	B-X
set	B-X
of	B-X
sequences	B-X
such	B-X
as	B-X
hybridization	B-X
to	B-X
membrane	B-X
arrays	B-X
and	B-X
microarrays	B-X
.	B-X
The	B-X
use	B-X
of	B-X
microarrays	B-X
to	B-X
begin	B-X
large-scale	B-X
transcriptome	B-X
analysis	B-X
has	B-X
been	B-X
recently	B-X
reported	B-X
,	B-X
using	B-X
either	B-X
specialized	B-X
or	B-X
broad-coverage	B-X
arrays	B-X
.	B-X
This	B-X
review	B-X
covers	B-X
published	B-X
results	B-X
using	B-X
the	B-X
above	B-X
techniques	B-X
in	B-X
the	B-X
pig	B-X
,	B-X
as	B-X
well	B-X
as	B-X
unpublished	B-X
data	B-X
provided	B-X
by	B-X
the	B-X
research	B-X
community	B-X
,	B-X
and	B-X
reports	B-X
on	B-X
unpublished	B-X
Affymetrix	B-X
data	B-X
from	B-X
our	B-X
group	B-X
.	B-X
Published	B-X
and	B-X
unpublished	B-X
bioinformatics	B-X
efforts	B-X
are	B-X
discussed	B-X
,	B-X
including	B-X
recent	B-X
work	B-X
by	B-X
our	B-X
group	B-X
to	B-X
integrate	B-X
two	B-X
broad-coverage	B-X
microarray	B-X
platforms	B-X
.	B-X
We	B-X
conclude	B-X
by	B-X
predicting	B-X
experiments	B-X
that	B-X
will	B-X
become	B-X
possible	B-X
with	B-X
new	B-X
anticipated	B-X
tools	B-X
and	B-X
data	B-X
,	B-X
including	B-X
the	B-X
porcine	B-X
genome	B-X
sequence	B-X
.	B-X
We	B-X
emphasize	B-X
that	B-X
the	B-X
need	B-X
for	B-X
bioinformatics	B-X
infrastructure	B-X
to	B-X
efficiently	B-X
store	B-X
and	B-X
analyze	B-X
the	B-X
expanding	B-X
amounts	B-X
of	B-X
gene	B-X
expression	B-X
data	B-X
is	B-X
critical	B-X
,	B-X
and	B-X
that	B-X
this	B-X
deficit	B-X
has	B-X
emerged	B-X
as	B-X
a	B-X
limiting	B-X
factor	B-X
for	B-X
acceleration	B-X
of	B-X
genomic	B-X
understanding	B-X
in	B-X
the	B-X
pig	B-X
.	B-X

Therefore	O
,	O
our	O
data	O
suggest	O
that	O
Foxp3	B-Protein
may	O
interfere	O
with	O
CREB	O
signaling	O
at	O
an	O
upstream	O
event	O
,	O
such	O
as	O
phosphorylation	O
of	O
CREB	O
or	O
recruitment	O
/	O
function	O
of	O
coactivator	O
proteins	O
CREB	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
(	O
CBP	B-Protein
)	O
/	O
p300	B-Protein
.	O
<EOS>	B-X
BDNF	B-X
signaling	B-X
via	B-X
its	B-X
transmembrane	B-X
receptor	B-X
TrkB	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
neuronal	B-X
survival	B-X
,	B-X
differentiation	B-X
,	B-X
and	B-X
synaptic	B-X
plasticity	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
have	B-X
investigated	B-X
this	B-X
phenomenon	B-X
in	B-X
primary	B-X
cultures	B-X
of	B-X
rat	B-X
cortical	B-X
neurons	B-X
using	B-X
overexpression	B-X
of	B-X
dominant-negative	B-X
forms	B-X
of	B-X
several	B-X
transcription	B-X
factors	B-X
,	B-X
including	B-X
CREB	B-X
,	B-X
ATF2	B-X
,	B-X
C/EBP	B-X
,	B-X
USF	B-X
,	B-X
and	B-X
NFAT	B-X
.	B-X
We	B-X
show	B-X
that	B-X
CREB	B-X
family	B-X
transcription	B-X
factors	B-X
,	B-X
together	B-X
with	B-X
the	B-X
coactivator	B-X
CBP/p300	B-X
,	B-X
but	B-X
not	B-X
the	B-X
CRTC	B-X
family	B-X
,	B-X
are	B-X
the	B-X
main	B-X
regulators	B-X
of	B-X
rat	B-X
The	B-X
transactivation	B-X
domain	B-X
of	B-X
the	B-X
cAMP	B-X
response	B-X
element-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
consists	B-X
of	B-X
two	B-X
major	B-X
domains	B-X
.	B-X
The	B-X
glutamine-rich	B-X
Q2	B-X
domain	B-X
,	B-X
which	B-X
interacts	B-X
with	B-X
the	B-X
general	B-X
transcription	B-X
factor	B-X
TAFII130/135	B-X
,	B-X
is	B-X
sufficient	B-X
for	B-X
the	B-X
recruitment	B-X
of	B-X
a	B-X
functional	B-X
RNA	B-X
polymerase	B-X
II	B-X
complex	B-X
and	B-X
allows	B-X
basal	B-X
transcriptional	B-X
activity	B-X
.	B-X
The	B-X
kinase-inducible	B-X
domain	B-X
,	B-X
however	B-X
,	B-X
mediates	B-X
signal-induced	B-X
activation	B-X
of	B-X
CREB-mediated	B-X
transcription	B-X
.	B-X
It	B-X
is	B-X
generally	B-X
believed	B-X
that	B-X
recruitment	B-X
of	B-X
the	B-X
coactivators	B-X
CREB-binding	B-X
protein	B-X
(	B-X
CBP	B-X
)	B-X
and	B-X
p300	B-X
after	B-X
signal-induced	B-X
phosphorylation	B-X
of	B-X
this	B-X
domain	B-X
at	B-X
serine-133	B-X
strongly	B-X
enhances	B-X
CREB-dependent	B-X
transcription	B-X
.	B-X
Transcriptional	B-X
activity	B-X
of	B-X
CREB	B-X
can	B-X
also	B-X
be	B-X
potentiated	B-X
by	B-X
phosphoserine-133-independent	B-X
mechanisms	B-X
,	B-X
and	B-X
not	B-X
all	B-X
stimuli	B-X
that	B-X
provoke	B-X
phosphorylation	B-X
of	B-X
serine-133	B-X
stimulate	B-X
CREB-dependent	B-X
transcription	B-X
.	B-X
This	B-X
review	B-X
presents	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
diversity	B-X
of	B-X
stimuli	B-X
that	B-X
induce	B-X
CREB	B-X
phosphorylation	B-X
at	B-X
Ser-133	B-X
,	B-X
focuses	B-X
on	B-X
phosphoserine-133-dependent	B-X
and	B-X
-independent	B-X
mechanisms	B-X
that	B-X
affect	B-X
CREB-mediated	B-X
transcription	B-X
,	B-X
and	B-X
discusses	B-X
different	B-X
models	B-X
that	B-X
may	B-X
explain	B-X
the	B-X
discrepancy	B-X
between	B-X
CREB	B-X
Ser-133	B-X
phosphorylation	B-X
and	B-X
activation	B-X
of	B-X
CREB-mediated	B-X
transcription	B-X
.	B-X

Foxp3	B-Protein
Antagonizes	O
CREB	O
Transcriptional	O
Activation	O
by	O
Disrupting	O
Coactivator	O
Recruitment	O

Stimulation	O
of	O
CREB	O
-	O
dependent	O
transcription	O
by	O
reagents	O
that	O
activate	O
adenylate	O
cyclase	O
and	O
increase	O
cAMP	O
levels	O
(	O
e	O
.	O
g	O
.	O
,	O
forskolin	O
)	O
increase	O
the	O
transactivation	O
potential	O
of	O
CREB	O
through	O
phosphorylation	O
of	O
serine	O
133	O
by	O
protein	O
kinase	O
A	O
,	O
which	O
permits	O
binding	O
and	O
recruitment	O
of	O
coactivators	O
CBP	B-Protein
/	O
p300	B-Protein
to	O
the	O
promoter	O
[	O
37	O
,	O
38	O
]	O
.	O

Phosphorylation	O
of	O
serine	O
133	O
does	O
not	O
,	O
however	O
,	O
affect	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
CREB	O
in	O
most	O
cases	O
[	O
39	O
-	O
41	O
]	O
.	O
<EOS>	B-X
This	B-X
study	B-X
tested	B-X
the	B-X
hypothesis	B-X
that	B-X
differences	B-X
in	B-X
brain	B-X
Tau	B-X
amounts	B-X
and	B-X
in	B-X
the	B-X
activity	B-X
of	B-X
mitochondria-adenosine	B-X
triphosphate	B-X
(	B-X
ATP	B-X
)	B-X
-Nuak1-Tau	B-X
cascade	B-X
between	B-X
the	B-X
neonatal	B-X
and	B-X
adult	B-X
mice	B-X
contribute	B-X
to	B-X
the	B-X
age-dependent	B-X
effects	B-X
of	B-X
sevoflurane	B-X
on	B-X
cognitive	B-X
function	B-X
.	B-X
We	B-X
report	B-X
the	B-X
clinical	B-X
phenotypic	B-X
spectrum	B-X
of	B-X
a	B-X
founder	B-X
NPRL3	B-X
pedigree	B-X
(	B-X
c.349delG	B-X
,	B-X
p.Glu117LysFS	B-X
;	B-X
n	B-X
=	B-X
133	B-X
)	B-X
among	B-X
Old	B-X
Order	B-X
Mennonites	B-X
dating	B-X
to	B-X
1727	B-X
.	B-X
The	B-X
mixed	B-X
lineage	B-X
kinase	B-X
domain-like	B-X
protein	B-X
MLKL	B-X
is	B-X
a	B-X
functional	B-X
RIP3	B-X
substrate	B-X
that	B-X
binds	B-X
to	B-X
RIP3	B-X
through	B-X
its	B-X
kinase-like	B-X
domain	B-X
but	B-X
lacks	B-X
kinase	B-X
activity	B-X
of	B-X
its	B-X
own	B-X
.	B-X
O-GlcNAcylation	B-X
is	B-X
a	B-X
dynamic	B-X
form	B-X
of	B-X
protein	B-X
glycosylation	B-X
which	B-X
involves	B-X
the	B-X
addition	B-X
of	B-X
β-d-N-acetylglucosamine	B-X
(	B-X
GlcNAc	B-X
)	B-X
via	B-X
an	B-X
O-linkage	B-X
to	B-X
serine	B-X
or	B-X
threonine	B-X
residues	B-X
of	B-X
nuclear	B-X
,	B-X
cytoplasmic	B-X
,	B-X
mitochondrial	B-X
and	B-X
transmembrane	B-X
proteins	B-X
.	B-X

Addition	O
of	O
forskolin	O
to	O
HEK	O
293T	O
cells	O
stimulated	O
activation	O
of	O
a	O
CREB	O
reporter	O
vector	O
about	O
65	O
fold	O
(	O
Figure	O
7A	O
)	O
.	O

Overexpression	O
of	O
Foxp3	B-Protein
was	O
capable	O
of	O
down	O
-	O
regulating	O
forskolin	O
-	O
induced	O
CREB	O
transcriptional	O
activation	O
.	O

The	O
functional	O
interaction	O
between	O
Foxp3	B-Protein
and	O
CREB	O
did	O
not	O
affect	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
CREB	B-Protein
-	I-Protein
1	I-Protein
,	O
but	O
did	O
show	O
a	O
modest	O
decrease	O
in	O
activating	B-Protein
transcription	I-Protein
factor	I-Protein
2	I-Protein
(	O
ATF	B-Protein
-	I-Protein
2	I-Protein
)	O
DNA	O
-	O
binding	O
activity	O
in	O
the	O
presence	O
of	O
forskolin	O
as	O
determined	O
by	O
transcription	O
factor	O
ELISA	O
(	O
Figure	O
7B	O
)	O
.	O

While	O
Foxp3	B-Protein
has	O
been	O
shown	O
to	O
bind	O
to	O
and	O
repress	O
activation	O
of	O
both	O
NF	O
-	O
kappaB	O
and	O
NF	O
-	O
AT	O
,	O
exactly	O
how	O
Foxp3	B-Protein
functions	O
to	O
bring	O
about	O
this	O
affect	O
has	O
not	O
been	O
elucidated	O
.	O

To	O
determine	O
how	O
Foxp3	B-Protein
blocks	O
CREB	O
-	O
dependent	O
transcription	O
,	O
we	O
examined	O
whether	O
Foxp3	B-Protein
was	O
capable	O
of	O
(	O
1	O
)	O
disrupting	O
the	O
recruitment	O
of	O
coactivator	O
proteins	O
and	O
/	O
or	O
(	O
2	O
)	O
preventing	O
phosphorylation	O
of	O
CREB	O
at	O
serine	O
133	O
(	O
which	O
is	O
a	O
prerequisite	O
for	O
coactivator	O
recruitment	O
)	O
.	O

Since	O
both	O
of	O
these	O
events	O
are	O
required	O
for	O
CREB	O
-	O
dependent	O
gene	O
expression	O
,	O
we	O
hypothesized	O
that	O
Foxp3	B-Protein
may	O
affect	O
CREB	O
activation	O
at	O
both	O
steps	O
.	O

To	O
determine	O
whether	O
Foxp3	B-Protein
can	O
disrupt	O
the	O
function	O
/	O
recruitment	O
of	O
the	O
coactivator	O
protein	O
p300	B-Protein
,	O
we	O
introduced	O
a	O
Gal4	B-Protein
reporter	O
vector	O
and	O
a	O
Gal4	B-Protein
-	I-Protein
BD	I-Protein
-	I-Protein
CREB	I-Protein
-	I-Protein
1	I-Protein
expression	O
vector	O
into	O
HEK	O
293T	O
cells	O
in	O
the	O
absence	O
or	O
presence	O
of	O
Foxp3	B-Protein
,	O
p300	B-Protein
,	O
and	O
/	O
or	O
control	O
expression	O
vectors	O
(	O
Figure	O
7C	O
)	O
.	O
<EOS>	B-X
When	B-X
the	B-X
pictures	B-X
were	B-X
captured	B-X
,	B-X
these	B-X
were	B-X
erroneously	B-X
named	B-X
as	B-X
'control	B-X
1/control	B-X
2	B-X
'	B-X
,	B-X
and	B-X
not	B-X
'normal/vector	B-X
.	B-X
'	B-X
7C	B-X
,	B-X
the	B-X
protein	B-X
expression	B-X
levels	B-X
of	B-X
extracellular-signal-regulated	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
and	B-X
β-actin	B-X
in	B-X
the	B-X
MB231	B-X
cells	B-X
were	B-X
wrongly	B-X
presented	B-X
.	B-X
After	B-X
having	B-X
re-examined	B-X
our	B-X
original	B-X
data	B-X
,	B-X
we	B-X
realize	B-X
that	B-X
the	B-X
Figure	B-X
was	B-X
compiled	B-X
incorrectly	B-X
,	B-X
and	B-X
have	B-X
returned	B-X
to	B-X
our	B-X
source	B-X
data	B-X
.	B-X
[	B-X
the	B-X
original	B-X
article	B-X
was	B-X
published	B-X
in	B-X
the	B-X
Oncology	B-X
Reports	B-X
32	B-X
:	B-X
205-212	B-X
,	B-X
2014	B-X
;	B-X
DOI	B-X
:	B-X
10.3892/or.2014.3201	B-X
]	B-X
.	B-X

As	O
expected	O
,	O
p300	B-Protein
overexpression	O
stimulated	O
transcription	O
of	O
the	O
Gal4	B-Protein
-	I-Protein
BD	I-Protein
-	I-Protein
CREB	I-Protein
-	I-Protein
1	I-Protein
fusion	O
protein	O
.	O

Foxp3	B-Protein
,	O
again	O
,	O
repressed	O
basal	O
levels	O
of	O
Gal4	B-Protein
-	I-Protein
BD	I-Protein
-	I-Protein
CREB	I-Protein
-	I-Protein
1	I-Protein
activation	O
by	O
more	O
than	O
2	O
-	O
fold	O
,	O
while	O
effectively	O
neutralizing	O
Gal4	B-Protein
-	I-Protein
BD	I-Protein
-	I-Protein
CREB	I-Protein
-	I-Protein
1	I-Protein
activation	O
in	O
the	O
presence	O
of	O
p300	B-Protein
.	O

We	O
next	O
analyzed	O
the	O
effect	O
of	O
Foxp3	B-Protein
on	O
phosphorylation	O
of	O
CREB	O
at	O
serine	O
133	O
in	O
forskolin	O
-	O
treated	O
HEK	O
293T	O
cells	O
by	O
Western	O
blot	O
analysis	O
.	O

Overexpression	O
of	O
Foxp3	B-Protein
failed	O
to	O
reduce	O
the	O
detectable	O
levels	O
of	O
CREB	O
phosphorylation	O
using	O
a	O
phosphospecific	O
antibody	O
for	O
CREB	B-Protein
-	I-Protein
1	I-Protein
(	O
unpublished	O
data	O
)	O
.	O

However	O
,	O
when	O
we	O
attempted	O
to	O
determine	O
whether	O
Foxp3	B-Protein
could	O
physically	O
interact	O
with	O
the	O
coactivator	O
protein	O
p300	B-Protein
,	O
we	O
found	O
that	O
p300	B-Protein
immunoprecipitated	O
Foxp3	B-Protein
when	O
both	O
proteins	O
were	O
overexpressed	O
in	O
HEK	O
293T	O
cells	O
(	O
Figure	O
7D	O
)	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
Foxp3	B-Protein
antagonizes	O
CREB	O
-	O
dependent	O
gene	O
expression	O
by	O
directly	O
interacting	O
with	O
coactivator	O
p300	B-Protein
and	O
interfering	O
with	O
its	O
function	O
and	O
/	O
or	O
recruitment	O
to	O
CREB	O
-	O
responsive	O
promoter	O
sequences	O
.	O
<EOS>	B-X
Remarkably	B-X
,	B-X
BDNF	B-X
is	B-X
capable	B-X
of	B-X
modulating	B-X
its	B-X
own	B-X
expression	B-X
levels	B-X
in	B-X
neurons	B-X
,	B-X
forming	B-X
a	B-X
transcriptional	B-X
positive	B-X
feedback	B-X
loop	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
have	B-X
investigated	B-X
this	B-X
phenomenon	B-X
in	B-X
primary	B-X
cultures	B-X
of	B-X
rat	B-X
cortical	B-X
neurons	B-X
using	B-X
overexpression	B-X
of	B-X
dominant-negative	B-X
forms	B-X
of	B-X
several	B-X
transcription	B-X
factors	B-X
,	B-X
including	B-X
CREB	B-X
,	B-X
ATF2	B-X
,	B-X
C/EBP	B-X
,	B-X
USF	B-X
,	B-X
and	B-X
NFAT	B-X
.	B-X
We	B-X
show	B-X
that	B-X
CREB	B-X
family	B-X
transcription	B-X
factors	B-X
,	B-X
together	B-X
with	B-X
the	B-X
coactivator	B-X
CBP/p300	B-X
,	B-X
but	B-X
not	B-X
the	B-X
CRTC	B-X
family	B-X
,	B-X
are	B-X
the	B-X
main	B-X
regulators	B-X
of	B-X
rat	B-X
Japanese	B-X
encephalitis	B-X
virus	B-X
(	B-X
JEV	B-X
)	B-X
NS1	B-X
'	B-X
,	B-X
a	B-X
larger	B-X
NS1-related	B-X
protein	B-X
,	B-X
is	B-X
known	B-X
to	B-X
inhibit	B-X
the	B-X
mitochondrial	B-X
antiviral	B-X
signaling	B-X
(	B-X
MAVS	B-X
)	B-X
-mediated	B-X
IFN-β	B-X
induction	B-X
by	B-X
increasing	B-X
the	B-X
binding	B-X
of	B-X
transcription	B-X
factors	B-X
(	B-X
CREB	B-X
and	B-X
c-Rel	B-X
)	B-X
to	B-X
the	B-X
microRNA	B-X
22	B-X
(	B-X
miRNA-22	B-X
)	B-X
promoter	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
NS1	B-X
'	B-X
induces	B-X
the	B-X
recruitment	B-X
of	B-X
CREB	B-X
and	B-X
c-Rel	B-X
onto	B-X
the	B-X
miRNA-22	B-X
promoter	B-X
is	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
found	B-X
that	B-X
JEV	B-X
NS1	B-X
'	B-X
protein	B-X
interacts	B-X
with	B-X
the	B-X
host	B-X
cyclin-dependent	B-X
kinase	B-X
1	B-X
(	B-X
CDK1	B-X
)	B-X
protein	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
CREB	B-X
phosphorylation	B-X
and	B-X
c-Rel	B-X
activation	B-X
through	B-X
the	B-X
IκBα	B-X
phosphorylation	B-X
were	B-X
observed	B-X
to	B-X
be	B-X
enhanced	B-X
upon	B-X
the	B-X
augmentation	B-X
of	B-X
CDK1	B-X
phosphorylation	B-X
by	B-X
NS1	B-X
'	B-X
.	B-X

In	O
the	O
present	O
study	O
,	O
we	O
show	O
that	O
Foxp3	B-Protein
functions	O
as	O
a	O
potent	O
repressor	O
of	O
NF	O
-	O
kappaB	O
-	O
and	O
CREB	O
-	O
dependent	O
transcriptional	O
activation	O
.	O

Furthermore	O
,	O
the	O
carboxyl	O
-	O
terminal	O
FKH	O
domain	O
appears	O
to	O
be	O
dispensable	O
for	O
mediating	O
these	O
effects	O
,	O
at	O
least	O
in	O
T	O
cell	O
populations	O
.	O

This	O
observation	O
may	O
become	O
important	O
in	O
light	O
of	O
recent	O
reports	O
suggesting	O
that	O
Foxp3	B-Protein
expression	O
in	O
thymic	O
epithelial	O
cells	O
was	O
crucial	O
for	O
directing	O
development	O
of	O
T	O
cells	O
in	O
the	O
thymus	O
[	O
42	O
]	O
.	O

Interestingly	O
,	O
the	O
majority	O
of	O
the	O
genetic	O
mutations	O
associated	O
with	O
IPEX	O
,	O
a	O
severe	O
autoimmune	O
disorder	O
caused	O
by	O
functional	O
inactivation	O
of	O
Foxp3	B-Protein
,	O
map	O
to	O
the	O
carboxyl	O
-	O
terminal	O
FKH	O
domain	O
or	O
the	O
leucine	O
zipper	O
domain	O
in	O
the	O
central	O
region	O
of	O
the	O
protein	O
.	O
<EOS>	B-X
Tick-borne	B-X
encephalitis	B-X
virus	B-X
(	B-X
TBEV	B-X
)	B-X
,	B-X
the	B-X
most	B-X
medically	B-X
relevant	B-X
tick-transmitted	B-X
flavivirus	B-X
in	B-X
Eurasia	B-X
,	B-X
targets	B-X
the	B-X
host	B-X
central	B-X
nervous	B-X
system	B-X
and	B-X
frequently	B-X
causes	B-X
severe	B-X
encephalitis	B-X
.	B-X
Moreover	B-X
,	B-X
SET	B-X
domain-containing	B-X
protein	B-X
8	B-X
(	B-X
SETD8	B-X
)	B-X
,	B-X
ETS-domain	B-X
containing	B-X
protein	B-X
(	B-X
ELK1	B-X
)	B-X
and	B-X
BTB	B-X
and	B-X
CNC	B-X
homology	B-X
1	B-X
(	B-X
bach1	B-X
)	B-X
all	B-X
participate	B-X
in	B-X
endothelial	B-X
injury	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
hypothesize	B-X
that	B-X
the	B-X
SETD8/ELK1/bach1	B-X
functional	B-X
axis	B-X
is	B-X
involved	B-X
in	B-X
mediating	B-X
EndMT	B-X
in	B-X
diabetic	B-X
nephropathy	B-X
.	B-X
As	B-X
a	B-X
Class	B-X
II	B-X
tumor	B-X
suppressor	B-X
,	B-X
ING5	B-X
contains	B-X
nuclear	B-X
localization	B-X
signal	B-X
,	B-X
plant	B-X
homeodomain	B-X
,	B-X
novel	B-X
conserved	B-X
region	B-X
,	B-X
and	B-X
leucine	B-X
zipper-like	B-X
domains	B-X
.	B-X
ING5	B-X
proteins	B-X
form	B-X
homodimer	B-X
into	B-X
a	B-X
coil-coil	B-X
structure	B-X
,	B-X
and	B-X
heterodimers	B-X
with	B-X
ING4	B-X
,	B-X
histone	B-X
H3K4me3	B-X
,	B-X
histone	B-X
acetyltransferase	B-X
(	B-X
HAT	B-X
)	B-X
complex	B-X
,	B-X
Tip60	B-X
,	B-X
Cyclin	B-X
A1/CDK2	B-X
,	B-X
INCA1	B-X
and	B-X
EBNA3C	B-X
for	B-X
the	B-X
transcription	B-X
of	B-X
target	B-X
genes	B-X
.	B-X
The	B-X
acetylated	B-X
proteins	B-X
up-regulated	B-X
by	B-X
ING5	B-X
are	B-X
preferentially	B-X
located	B-X
in	B-X
nucleus	B-X
and	B-X
act	B-X
as	B-X
transcription	B-X
cofactors	B-X
,	B-X
chromatin	B-X
and	B-X
DNA	B-X
binding	B-X
functions	B-X
,	B-X
while	B-X
those	B-X
down-regulated	B-X
by	B-X
ING5	B-X
mostly	B-X
in	B-X
cytoplasm	B-X
and	B-X
contribute	B-X
to	B-X
metabolism	B-X
.	B-X

Only	O
one	O
mutation	O
associated	O
with	O
IPEX	O
to	O
date	O
has	O
been	O
mapped	O
to	O
the	O
amino	O
-	O
terminal	O
proline	O
-	O
rich	O
region	O
[	O
43	O
]	O
.	O

It	O
is	O
possible	O
that	O
the	O
FKH	O
domain	O
has	O
a	O
complex	O
tertiary	O
structure	O
that	O
is	O
particularly	O
sensitive	O
to	O
misfolding	O
caused	O
by	O
genetic	O
mutations	O
and	O
that	O
an	O
intact	O
FKH	O
domain	O
is	O
absolutely	O
critical	O
for	O
promoting	O
Foxp3	B-Protein
function	O
in	O
the	O
nucleus	O
,	O
whereas	O
the	O
structure	O
of	O
the	O
amino	O
-	O
terminal	O
proline	O
-	O
rich	O
region	O
may	O
tolerate	O
certain	O
mutations	O
as	O
long	O
as	O
the	O
NF	O
-	O
kappaB	O
/	O
NF	O
-	O
AT	O
binding	O
motif	O
remains	O
unaltered	O
.	O

This	O
motif	O
may	O
also	O
include	O
the	O
zinc	O
finger	O
domain	O
.	O
<EOS>	B-X
Zinc	B-X
finger	B-X
proteins	B-X
are	B-X
among	B-X
the	B-X
most	B-X
abundant	B-X
proteins	B-X
in	B-X
eukaryotic	B-X
genomes	B-X
.	B-X
Their	B-X
functions	B-X
are	B-X
extraordinarily	B-X
diverse	B-X
and	B-X
include	B-X
DNA	B-X
recognition	B-X
,	B-X
RNA	B-X
packaging	B-X
,	B-X
transcriptional	B-X
activation	B-X
,	B-X
regulation	B-X
of	B-X
apoptosis	B-X
,	B-X
protein	B-X
folding	B-X
and	B-X
assembly	B-X
,	B-X
and	B-X
lipid	B-X
binding	B-X
.	B-X
Zinc	B-X
finger	B-X
structures	B-X
are	B-X
as	B-X
diverse	B-X
as	B-X
their	B-X
functions	B-X
.	B-X
Structures	B-X
have	B-X
recently	B-X
been	B-X
reported	B-X
for	B-X
many	B-X
new	B-X
zinc	B-X
finger	B-X
domains	B-X
with	B-X
novel	B-X
topologies	B-X
,	B-X
providing	B-X
important	B-X
insights	B-X
into	B-X
structure/function	B-X
relationships	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
new	B-X
structural	B-X
studies	B-X
of	B-X
proteins	B-X
containing	B-X
the	B-X
classical	B-X
Cys	B-X
(	B-X
2	B-X
)	B-X
His	B-X
(	B-X
2	B-X
)	B-X
zinc	B-X
finger	B-X
motif	B-X
have	B-X
led	B-X
to	B-X
novel	B-X
insights	B-X
into	B-X
mechanisms	B-X
of	B-X
DNA	B-X
binding	B-X
and	B-X
to	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
their	B-X
broader	B-X
functions	B-X
in	B-X
transcriptional	B-X
regulation	B-X
.	B-X

A	O
logical	O
region	O
that	O
may	O
be	O
targeted	O
by	O
the	O
amino	O
-	O
terminal	O
proline	O
-	O
rich	O
region	O
of	O
Foxp3	B-Protein
is	O
the	O
Rel	O
homology	O
domain	O
found	O
in	O
both	O
NF	O
-	O
kappaB	O
and	O
NF	O
-	O
AT	O
family	O
proteins	O
.	O

A	O
region	O
that	O
may	O
also	O
be	O
important	O
with	O
respect	O
to	O
Foxp3	B-Protein
function	O
is	O
the	O
leucine	O
zipper	O
domain	O
,	O
as	O
demonstrated	O
by	O
the	O
number	O
of	O
mutations	O
associated	O
with	O
IPEX	O
that	O
have	O
been	O
mapped	O
in	O
this	O
region	O
of	O
Foxp3	B-Protein
.	O

The	O
role	O
of	O
this	O
domain	O
in	O
Foxp3	B-Protein
function	O
remains	O
uncharacterized	O
,	O
but	O
may	O
play	O
a	O
role	O
in	O
dimer	O
formation	O
as	O
it	O
does	O
in	O
other	O
Foxp	O
family	O
members	O
[	O
44	O
]	O
.	O

Because	O
the	O
pathogenesis	O
of	O
a	O
number	O
of	O
retroviral	O
-	O
induced	O
immunologic	O
disorders	O
such	O
as	O
HIV	O
-	O
1	O
/	O
AIDS	O
and	O
HTLV	O
-	O
I	O
/	O
HAM	O
/	O
TSP	O
have	O
been	O
associated	O
with	O
dysregulation	O
of	O
Foxp3	B-Protein
expression	O
[	O
8	O
,	O
45	O
]	O
,	O
we	O
also	O
examined	O
the	O
role	O
of	O
Foxp3	B-Protein
in	O
retroviral	O
gene	O
expression	O
.	O

HIV	O
-	O
1	O
LTR	O
activation	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
is	O
critically	O
dependent	O
on	O
two	O
tandem	O
NF	O
-	O
kappaB	O
sites	O
located	O
between	O
nucleotide	O
positions	O
-	O
102	O
and	O
-	O
81	O
within	O
the	O
HIV	O
-	O
1	O
enhancer	O
region	O
,	O
whereas	O
HTLV	O
-	O
I	O
LTR	O
activation	O
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
HTLV	O
-	O
I	O
-	O
encoded	O
transactivator	O
protein	O
Tax	B-Protein
is	O
independent	O
of	O
NF	O
-	O
kappaB	O
[	O
18	O
]	O
.	O
<EOS>	B-X
Biological	B-X
,	B-X
molecular	B-X
,	B-X
and	B-X
epidemiological	B-X
data	B-X
have	B-X
demonstrated	B-X
that	B-X
human	B-X
T	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HTLV-1	B-X
)	B-X
encoded	B-X
Tax	B-X
protein	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
initiation	B-X
of	B-X
T	B-X
cell	B-X
malignancy	B-X
.	B-X
The	B-X
40-kDa	B-X
Tax	B-X
oncoprotein	B-X
serves	B-X
as	B-X
a	B-X
potent	B-X
transcriptional	B-X
activator	B-X
that	B-X
induces	B-X
viral	B-X
gene	B-X
expression	B-X
driven	B-X
by	B-X
the	B-X
HTLV-1	B-X
long	B-X
terminal	B-X
repeats	B-X
and	B-X
also	B-X
stimulates	B-X
multiple	B-X
cellular	B-X
genes	B-X
involved	B-X
in	B-X
T	B-X
cell	B-X
activation	B-X
,	B-X
cell	B-X
cycle	B-X
regulation	B-X
,	B-X
and	B-X
gene	B-X
activation	B-X
.	B-X
Since	B-X
Tax	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
interact	B-X
directly	B-X
and	B-X
indirectly	B-X
with	B-X
the	B-X
NF-kappa	B-X
B/I	B-X
kappa	B-X
B	B-X
regulatory	B-X
proteins	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
significance	B-X
of	B-X
an	B-X
in	B-X
vivo	B-X
association	B-X
between	B-X
Tax	B-X
and	B-X
the	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
inhibitor	B-X
.	B-X
Using	B-X
GST	B-X
affinity	B-X
chromatography	B-X
,	B-X
Tax	B-X
was	B-X
shown	B-X
to	B-X
interact	B-X
with	B-X
the	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
ankyrin	B-X
repeats	B-X
which	B-X
are	B-X
essential	B-X
for	B-X
interaction	B-X
with	B-X
the	B-X
NF-kappa	B-X
B/Rel	B-X
proteins	B-X
.	B-X
In	B-X
vivo	B-X
,	B-X
using	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
mutants	B-X
and	B-X
co-immunoprecipitation	B-X
,	B-X
a	B-X
preferential	B-X
interaction	B-X
between	B-X
HTLV-1	B-X
Tax	B-X
and	B-X
N-terminally	B-X
hypophosphorylated	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
was	B-X
detected	B-X
.	B-X
Tax	B-X
also	B-X
enhanced	B-X
binding	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
to	B-X
the	B-X
proteasome	B-X
subunit	B-X
HsN3	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
Tax-enhanced	B-X
,	B-X
constitutive	B-X
degradation	B-X
of	B-X
wild-type	B-X
and	B-X
mutated	B-X
forms	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
phosphorylation	B-X
and	B-X
ubiquitination	B-X
.	B-X
Binding	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
to	B-X
proteasome	B-X
subunit	B-X
HC9	B-X
was	B-X
also	B-X
observed	B-X
,	B-X
but	B-X
this	B-X
interaction	B-X
occurred	B-X
independently	B-X
of	B-X
Tax	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
a	B-X
role	B-X
for	B-X
Tax	B-X
as	B-X
a	B-X
viral	B-X
chaperone	B-X
resulting	B-X
in	B-X
the	B-X
enhanced	B-X
constitutive	B-X
turnover	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
The	B-X
association	B-X
of	B-X
Tax	B-X
with	B-X
hypophosphorylated	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
may	B-X
prevent	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
from	B-X
binding	B-X
to	B-X
NF-kappa	B-X
B	B-X
and	B-X
also	B-X
target	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
to	B-X
the	B-X
proteasome	B-X
for	B-X
degradation	B-X
via	B-X
a	B-X
phosphorylation-independent	B-X
pathway	B-X
.	B-X

To	O
our	O
knowledge	O
for	O
the	O
first	O
time	O
,	O
Foxp3	B-Protein
was	O
shown	O
to	O
have	O
a	O
direct	O
effect	O
on	O
HIV	O
-	O
1	O
LTR	O
transcription	O
.	O

Deletion	O
of	O
the	O
NF	O
-	O
kappaB	O
sites	O
within	O
the	O
HIV	O
-	O
1	O
enhancer	O
region	O
reduced	O
the	O
responsiveness	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
to	O
Foxp3	B-Protein
-	O
mediated	O
suppression	O
.	O

In	O
addition	O
,	O
the	O
FKH	O
domain	O
of	O
Foxp3	B-Protein
was	O
required	O
for	O
this	O
inhibitory	O
effect	O
in	O
HEK	O
293T	O
cells	O
,	O
but	O
not	O
in	O
Jurkat	O
T	O
cells	O
,	O
similar	O
to	O
Foxp3	B-Protein
-	O
mediated	O
suppression	O
of	O
a	O
synthetic	O
NF	O
-	O
kappaB	O
reporter	O
.	O

The	O
direct	O
effect	O
of	O
Foxp3	B-Protein
down	O
-	O
regulating	O
HIV	O
-	O
1	O
gene	O
expression	O
correlates	O
well	O
with	O
recently	O
reported	O
evidence	O
indicating	O
that	O
higher	O
regulatory	O
activity	O
of	O
CD4	B-Protein
+	O
CD25	B-Protein
+	O
T	O
cells	O
from	O
HIV	O
-	O
1	O
-	O
infected	O
patients	O
was	O
associated	O
with	O
lower	O
HIV	O
-	O
1	O
viral	O
loads	O
in	O
these	O
patients	O
[	O
46	O
]	O
.	O

Foxp3	B-Protein
also	O
affected	O
two	O
well	O
-	O
known	O
functions	O
of	O
HTLV	O
-	O
I	O
Tax	B-Protein
:	O
transactivation	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
and	O
,	O
most	O
surprisingly	O
,	O
transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
.	O

Transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
by	O
Tax	B-Protein
involves	O
the	O
interaction	O
of	O
ATF	O
/	O
CREB	O
factors	O
with	O
Tax	B-Protein
in	O
the	O
nucleus	O
.	O

Binding	O
of	O
Tax	B-Protein
enhances	O
ATF	O
/	O
CREB	O
dimerization	O
and	O
promotes	O
assembly	O
of	O
Tax	B-Protein
-	O
ATF	O
/	O
CREB	O
complexes	O
onto	O
specific	O
sequences	O
in	O
the	O
viral	O
promoter	O
known	O
as	O
Tax	O
-	O
responsive	O
elements	O
.	O

This	O
series	O
of	O
steps	O
allows	O
Tax	B-Protein
to	O
recruit	O
coactivator	O
proteins	O
CBP	B-Protein
/	O
p300	B-Protein
to	O
the	O
viral	O
promoter	O
and	O
facilitate	O
a	O
high	O
level	O
of	O
viral	O
gene	O
expression	O
[	O
24	O
-	O
26	O
]	O
.	O

Transactivation	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
by	O
Tax	B-Protein
was	O
inhibited	O
by	O
overexpression	O
of	O
full	O
-	O
length	O
Foxp3	B-Protein
,	O
but	O
not	O
deltaFKH	B-Protein
,	O
as	O
seen	O
with	O
basal	O
activation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
and	O
a	O
synthetic	O
NF	O
-	O
kappaB	O
reporter	O
in	O
HEK	O
293T	O
cells	O
.	O

However	O
,	O
Tax	B-Protein
-	O
mediated	O
transactivation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
was	O
inhibited	O
by	O
overexpression	O
of	O
both	O
full	O
-	O
length	O
Foxp3	B-Protein
as	O
well	O
as	O
deltaFKH	B-Protein
in	O
both	O
HEK	O
293T	O
cells	O
and	O
CD4	B-Protein
+	O
T	O
cells	O
.	O

We	O
demonstrated	O
that	O
Foxp3	B-Protein
did	O
not	O
directly	O
affect	O
the	O
functioning	O
of	O
Tax	B-Protein
,	O
but	O
rather	O
Foxp3	B-Protein
targeted	O
the	O
transcription	O
factors	O
required	O
for	O
Tax	B-Protein
transactivation	O
(	O
i	O
.	O
e	O
.	O
,	O
NF	O
-	O
kappaB	O
and	O
a	O
then	O
-	O
unknown	O
cellular	O
factor	O
,	O
which	O
we	O
identified	O
in	O
this	O
study	O
as	O
CREB	O
)	O
.	O
<EOS>	B-X
Regulatory	B-X
T	B-X
cells	B-X
(	B-X
Tregs	B-X
)	B-X
prevent	B-X
autoimmunity	B-X
and	B-X
tissue	B-X
damage	B-X
resulting	B-X
from	B-X
excessive	B-X
or	B-X
unnecessary	B-X
immune	B-X
activation	B-X
through	B-X
their	B-X
suppressive	B-X
function	B-X
.	B-X
While	B-X
their	B-X
importance	B-X
for	B-X
proper	B-X
immune	B-X
control	B-X
is	B-X
undeniable	B-X
,	B-X
the	B-X
stability	B-X
of	B-X
the	B-X
Treg	B-X
lineage	B-X
has	B-X
recently	B-X
become	B-X
a	B-X
controversial	B-X
topic	B-X
.	B-X
Many	B-X
reports	B-X
have	B-X
shown	B-X
dramatic	B-X
loss	B-X
of	B-X
the	B-X
signature	B-X
Treg	B-X
transcription	B-X
factor	B-X
Forkhead	B-X
box	B-X
protein	B-X
3	B-X
(	B-X
Foxp3	B-X
)	B-X
and	B-X
Treg	B-X
function	B-X
under	B-X
various	B-X
inflammatory	B-X
conditions	B-X
.	B-X
Other	B-X
recent	B-X
studies	B-X
demonstrate	B-X
that	B-X
most	B-X
Tregs	B-X
are	B-X
extremely	B-X
resilient	B-X
in	B-X
their	B-X
expression	B-X
of	B-X
Foxp3	B-X
and	B-X
the	B-X
retention	B-X
of	B-X
suppressive	B-X
function	B-X
.	B-X
While	B-X
this	B-X
debate	B-X
is	B-X
unlikely	B-X
to	B-X
be	B-X
settled	B-X
in	B-X
the	B-X
immediate	B-X
future	B-X
,	B-X
improved	B-X
understanding	B-X
of	B-X
the	B-X
considerable	B-X
heterogeneity	B-X
within	B-X
the	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
Treg	B-X
population	B-X
and	B-X
how	B-X
Treg	B-X
subsets	B-X
respond	B-X
to	B-X
ranging	B-X
environmental	B-X
cues	B-X
may	B-X
be	B-X
keys	B-X
to	B-X
reconciliation	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
diverse	B-X
mechanisms	B-X
responsible	B-X
for	B-X
the	B-X
observed	B-X
stability	B-X
or	B-X
instability	B-X
of	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
Treg	B-X
identity	B-X
and	B-X
function	B-X
.	B-X
These	B-X
include	B-X
transcriptional	B-X
and	B-X
epigenetic	B-X
programs	B-X
,	B-X
transcript	B-X
targeting	B-X
,	B-X
and	B-X
posttranslational	B-X
modifications	B-X
that	B-X
appear	B-X
responsive	B-X
to	B-X
numerous	B-X
elements	B-X
of	B-X
the	B-X
microenvironment	B-X
.	B-X
These	B-X
mechanisms	B-X
for	B-X
Treg	B-X
functional	B-X
modulation	B-X
add	B-X
to	B-X
the	B-X
discussion	B-X
of	B-X
Treg	B-X
stability	B-X
.	B-X

The	O
negative	O
effect	O
of	O
Foxp3	B-Protein
on	O
HTLV	O
-	O
I	O
gene	O
expression	O
was	O
confirmed	O
utilizing	O
an	O
HTLV	O
-	O
I	O
infectious	O
molecular	O
clone	O
.	O

Importantly	O
,	O
we	O
demonstrated	O
that	O
HTLV	O
-	O
I	O
-	O
infected	O
individuals	O
with	O
the	O
highest	O
levels	O
of	O
Foxp3	B-Protein
protein	O
expression	O
within	O
the	O
CD4	B-Protein
+	O
CD25	B-Protein
+	O
T	O
cells	O
population	O
exhibited	O
lower	O
proviral	O
loads	O
than	O
did	O
individuals	O
with	O
the	O
lowest	O
levels	O
of	O
Foxp3	B-Protein
protein	O
expression	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
HTLV	O
-	O
I	O
proviral	O
load	O
directly	O
correlates	O
with	O
HTLV	O
-	O
I	O
Tax	B-Protein
mRNA	O
load	O
,	O
the	O
frequency	O
of	O
immunopathogenic	O
virus	O
-	O
specific	O
CD8	B-Protein
+	O
T	O
cells	O
,	O
and	O
disease	O
severity	O
in	O
patients	O
with	O
HAM	O
/	O
TSP	O
[	O
47	O
]	O
.	O

These	O
results	O
have	O
important	O
implications	O
on	O
the	O
utility	O
of	O
Foxp3	B-Protein
in	O
controlling	O
viral	O
gene	O
expression	O
and	O
thus	O
pathogenesis	O
of	O
HAM	O
/	O
TSP	O
.	O

Therefore	O
,	O
Foxp3	B-Protein
becomes	O
an	O
attractive	O
target	O
for	O
the	O
development	O
of	O
novel	O
therapeutic	O
applications	O
directed	O
at	O
modulating	O
the	O
expression	O
of	O
this	O
important	O
regulatory	O
protein	O
,	O
especially	O
in	O
light	O
of	O
recent	O
observations	O
that	O
the	O
expression	O
of	O
Foxp3	B-Protein
can	O
also	O
be	O
down	O
-	O
regulated	O
by	O
HTLV	O
-	O
I	O
Tax	B-Protein
[	O
8	O
]	O
.	O

As	O
the	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
depends	O
primarily	O
on	O
ATF	O
/	O
CREB	O
proteins	O
(	O
whether	O
in	O
the	O
presence	O
or	O
the	O
absence	O
of	O
Tax	B-Protein
)	O
,	O
we	O
investigated	O
whether	O
Foxp3	B-Protein
could	O
interact	O
with	O
this	O
additional	O
cellular	O
signaling	O
pathway	O
.	O

While	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
CREB	O
is	O
,	O
in	O
most	O
cases	O
,	O
constitutive	O
,	O
the	O
transactivation	O
potential	O
of	O
CREB	O
is	O
regulated	O
by	O
the	O
phosphorylation	O
of	O
CREB	O
and	O
recruitment	O
of	O
CBP	B-Protein
/	O
p300	B-Protein
[	O
48	O
]	O
.	O

Our	O
data	O
demonstrate	O
that	O
Foxp3	B-Protein
interferes	O
with	O
the	O
latter	O
of	O
these	O
two	O
processes	O
and	O
that	O
the	O
recruitment	O
of	O
the	O
coactivator	O
protein	O
p300	B-Protein
,	O
and	O
resulting	O
transcriptional	O
activation	O
are	O
blocked	O
by	O
Foxp3	B-Protein
.	O

This	O
may	O
be	O
the	O
result	O
of	O
the	O
physical	O
interaction	O
we	O
detected	O
between	O
Foxp3	B-Protein
and	O
p300	B-Protein
.	O

With	O
respect	O
to	O
HTLV	O
-	O
I	O
LTR	O
activity	O
,	O
while	O
full	O
-	O
length	O
Foxp3	B-Protein
inhibited	O
both	O
basal	O
and	O
Tax	B-Protein
-	O
dependent	O
transcription	O
by	O
~	O
50	O
%	O
,	O
deltaFKH	B-Protein
appeared	O
less	O
effective	O
in	O
suppressing	O
basal	O
activation	O
(	O
~	O
25	O
%	O
inhibition	O
)	O
compared	O
to	O
Tax	B-Protein
-	O
dependent	O
activation	O
(	O
~	O
50	O
%	O
inhibition	O
)	O
.	O

The	O
effect	O
of	O
deltaFKH	B-Protein
on	O
basal	O
activation	O
of	O
the	O
HTLV	O
-	O
I	O
LTR	O
in	O
HEK	O
293T	O
cells	O
was	O
very	O
similar	O
to	O
that	O
shown	O
for	O
a	O
synthetic	O
CREB	O
reporter	O
,	O
suggesting	O
that	O
the	O
FKH	O
domain	O
of	O
Foxp3	B-Protein
is	O
important	O
at	O
some	O
level	O
.	O

As	O
observed	O
with	O
NF	O
-	O
kappaB	O
activation	O
,	O
the	O
Foxp3	B-Protein
mutant	O
lacking	O
the	O
FKH	O
domain	O
was	O
a	O
stronger	O
inhibitor	O
of	O
CREB	O
activation	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
than	O
in	O
HEK	O
293T	O
epithelial	O
cells	O
.	O

Therefore	O
,	O
it	O
appears	O
that	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
the	O
FKH	O
domain	O
is	O
dispensable	O
for	O
the	O
proper	O
functioning	O
of	O
Foxp3	B-Protein
with	O
respect	O
to	O
both	O
NF	O
-	O
kappaB	O
and	O
CREB	O
activation	O
.	O

In	O
summary	O
,	O
this	O
is	O
,	O
to	O
our	O
knowledge	O
,	O
the	O
first	O
direct	O
evidence	O
implicating	O
a	O
role	O
for	O
the	O
Treg	O
-	O
specific	O
transcription	O
factor	O
Foxp3	B-Protein
in	O
regulating	O
retroviral	O
gene	O
expression	O
.	O

In	O
addition	O
,	O
we	O
identify	O
the	O
CREB	O
pathway	O
as	O
a	O
molecular	O
target	O
of	O
Foxp3	B-Protein
.	O

Since	O
CREB	O
has	O
been	O
shown	O
to	O
regulate	O
multiple	O
genes	O
involved	O
in	O
transcription	O
(	O
e	O
.	O
g	O
.	O
,	O
JunD	B-Protein
,	O
c	B-Protein
-	I-Protein
Fos	I-Protein
,	O
signal	B-Protein
transducer	I-Protein
of	I-Protein
activated	I-Protein
T	I-Protein
cells	I-Protein
3	I-Protein
[	O
STAT3	B-Protein
]	O
)	O
,	O
cell	O
cycle	O
(	O
e	O
.	O
g	O
.	O
,	O
p15INK4b	B-Protein
,	O
cyclin	B-Protein
A	I-Protein
,	O
cyclin	B-Protein
D1	I-Protein
)	O
,	O
and	O
immune	O
regulation	O
(	O
e	O
.	O
g	O
.	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
T	B-Protein
-	I-Protein
cell	I-Protein
receptor	I-Protein
alpha	I-Protein
)	O
(	O
reviewed	O
in	O
[	O
48	O
]	O
)	O
,	O
the	O
findings	O
presented	O
in	O
this	O
report	O
broaden	O
the	O
potential	O
range	O
of	O
signaling	O
pathways	O
under	O
the	O
control	O
of	O
the	O
regulatory	O
protein	O
Foxp3	B-Protein
.	O

Our	O
evidence	O
stresses	O
the	O
importance	O
of	O
Foxp3	B-Protein
expression	O
and	O
Treg	O
function	O
in	O
the	O
development	O
and	O
maintenance	O
of	O
protective	O
immunity	O
against	O
HIV	O
-	O
1	O
and	O
HTLV	O
-	O
I	O
.	O

Based	O
on	O
recent	O
findings	O
,	O
Foxp3	B-Protein
may	O
limit	O
HIV	O
-	O
1	O
and	O
HTLV	O
-	O
I	O
transcription	O
by	O
interfering	O
with	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
CREB	O
pathways	O
.	O

However	O
,	O
observing	O
that	O
this	O
inhibitory	O
effect	O
is	O
not	O
absolute	O
,	O
a	O
low	O
level	O
of	O
viral	O
gene	O
expression	O
may	O
persist	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
in	O
particular	O
regulatory	O
T	O
cells	O
,	O
which	O
are	O
known	O
reservoirs	O
of	O
HIV	O
-	O
1	O
and	O
HTLV	O
-	O
I	O
)	O
and	O
result	O
in	O
the	O
accumulation	O
of	O
viral	O
proteins	O
that	O
either	O
stimulate	O
NF	O
-	O
kappaB	O
and	O
/	O
or	O
CREB	O
activation	O
or	O
directly	O
inhibit	O
Foxp3	B-Protein
expression	O
or	O
function	O
.	O
<EOS>	B-X
All	B-X
people	B-X
want	B-X
to	B-X
age	B-X
``	B-X
successfully	B-X
,	B-X
''	B-X
maintaining	B-X
functional	B-X
capacity	B-X
and	B-X
quality	B-X
of	B-X
life	B-X
as	B-X
they	B-X
reach	B-X
advanced	B-X
age	B-X
.	B-X
Achieving	B-X
this	B-X
goal	B-X
depends	B-X
on	B-X
preserving	B-X
optimal	B-X
cognitive	B-X
and	B-X
brain	B-X
functioning	B-X
.	B-X
Others	B-X
experience	B-X
declines	B-X
in	B-X
cognitive	B-X
and	B-X
functional	B-X
capacity	B-X
that	B-X
range	B-X
from	B-X
mild	B-X
decrements	B-X
in	B-X
certain	B-X
cognitive	B-X
functions	B-X
over	B-X
time	B-X
to	B-X
severe	B-X
dementia	B-X
among	B-X
those	B-X
with	B-X
neurodegenerative	B-X
diseases	B-X
.	B-X
Even	B-X
among	B-X
relatively	B-X
healthy	B-X
``	B-X
successful	B-X
agers	B-X
,	B-X
''	B-X
certain	B-X
cognitive	B-X
functions	B-X
are	B-X
reduced	B-X
from	B-X
earlier	B-X
levels	B-X
.	B-X
This	B-X
is	B-X
particularly	B-X
true	B-X
for	B-X
cognitive	B-X
functions	B-X
that	B-X
are	B-X
dependent	B-X
on	B-X
cognitive	B-X
processing	B-X
speed	B-X
and	B-X
efficiency	B-X
.	B-X
Working	B-X
memory	B-X
and	B-X
executive	B-X
and	B-X
attentional	B-X
functions	B-X
tend	B-X
to	B-X
be	B-X
most	B-X
vulnerable	B-X
.	B-X
Learning	B-X
and	B-X
memory	B-X
functions	B-X
are	B-X
also	B-X
usually	B-X
reduced	B-X
,	B-X
although	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
neurodegenerative	B-X
disease	B-X
learning	B-X
and	B-X
retrieval	B-X
efficiency	B-X
rather	B-X
than	B-X
memory	B-X
storage	B-X
are	B-X
affected	B-X
.	B-X
Other	B-X
functions	B-X
,	B-X
such	B-X
as	B-X
visual	B-X
perception	B-X
,	B-X
language	B-X
,	B-X
semantics	B-X
,	B-X
and	B-X
knowledge	B-X
,	B-X
are	B-X
often	B-X
well	B-X
preserved	B-X
.	B-X
Structural	B-X
,	B-X
functional	B-X
,	B-X
and	B-X
physiologic/metabolic	B-X
brain	B-X
changes	B-X
correspond	B-X
with	B-X
age-associated	B-X
cognitive	B-X
decline	B-X
.	B-X
Physiologic	B-X
and	B-X
metabolic	B-X
mechanisms	B-X
,	B-X
such	B-X
as	B-X
oxidative	B-X
stress	B-X
and	B-X
neuroinflammation	B-X
,	B-X
may	B-X
contribute	B-X
to	B-X
these	B-X
changes	B-X
,	B-X
along	B-X
with	B-X
the	B-X
contribution	B-X
of	B-X
comorbidities	B-X
that	B-X
secondarily	B-X
affect	B-X
the	B-X
brain	B-X
of	B-X
older	B-X
adults	B-X
.	B-X
Neuropsychologic	B-X
assessment	B-X
provides	B-X
a	B-X
way	B-X
of	B-X
measuring	B-X
the	B-X
cognitive	B-X
and	B-X
functional	B-X
status	B-X
of	B-X
older	B-X
adults	B-X
,	B-X
which	B-X
is	B-X
useful	B-X
for	B-X
monitoring	B-X
changes	B-X
that	B-X
may	B-X
be	B-X
occurring	B-X
.	B-X
Neuroimaging	B-X
is	B-X
also	B-X
useful	B-X
for	B-X
characterizing	B-X
age-associated	B-X
structural	B-X
,	B-X
functional	B-X
,	B-X
physiologic	B-X
,	B-X
and	B-X
metabolic	B-X
brain	B-X
changes	B-X
,	B-X
including	B-X
alterations	B-X
in	B-X
cerebral	B-X
blood	B-X
flow	B-X
and	B-X
metabolite	B-X
concentrations	B-X
.	B-X
Some	B-X
interventions	B-X
that	B-X
may	B-X
enhance	B-X
cognitive	B-X
function	B-X
,	B-X
such	B-X
as	B-X
cognitive	B-X
training	B-X
,	B-X
neuromodulation	B-X
,	B-X
and	B-X
pharmacologic	B-X
approaches	B-X
,	B-X
exist	B-X
or	B-X
are	B-X
being	B-X
developed	B-X
.	B-X
Yet	B-X
,	B-X
preventing	B-X
,	B-X
slowing	B-X
,	B-X
and	B-X
reversing	B-X
the	B-X
adverse	B-X
effects	B-X
of	B-X
cognitive	B-X
aging	B-X
remains	B-X
a	B-X
challenge	B-X
.	B-X

The	O
imbalance	O
of	O
NF	O
-	O
kappaB	O
and	O
CREB	O
activation	O
caused	O
by	O
these	O
viral	O
gene	O
products	O
may	O
be	O
a	O
crucial	O
step	O
in	O
the	O
pathogenesis	O
of	O
virus	O
-	O
induced	O
immunological	O
disorders	O
such	O
as	O
AIDS	O
and	O
HAM	O
/	O
TSP	O
.	O

Future	O
studies	O
will	O
be	O
directed	O
at	O
identifying	O
and	O
characterizing	O
cellular	O
proteins	O
that	O
interact	O
with	O
Foxp3	B-Protein
both	O
in	O
the	O
nucleus	O
and	O
cytoplasm	O
,	O
in	O
order	O
to	O
better	O
address	O
how	O
Foxp3	B-Protein
functions	O
to	O
guide	O
the	O
development	O
and	O
function	O
of	O
regulatory	O
T	O
cells	O
in	O
health	O
and	O
disease	O
.	O

Cell	O
culture	O
.	O
<EOS>	B-X
This	B-X
overview	B-X
describes	B-X
a	B-X
series	B-X
of	B-X
articles	B-X
to	B-X
provide	B-X
an	B-X
unmet	B-X
need	B-X
for	B-X
information	B-X
on	B-X
best	B-X
practices	B-X
in	B-X
animal	B-X
cell	B-X
culture	B-X
.	B-X
The	B-X
target	B-X
audience	B-X
primarily	B-X
consists	B-X
of	B-X
entry-level	B-X
scientists	B-X
with	B-X
minimal	B-X
experience	B-X
in	B-X
cell	B-X
culture	B-X
.	B-X
It	B-X
also	B-X
include	B-X
scientists	B-X
,	B-X
journalists	B-X
,	B-X
and	B-X
educators	B-X
with	B-X
some	B-X
experience	B-X
in	B-X
cell	B-X
culture	B-X
,	B-X
but	B-X
in	B-X
need	B-X
of	B-X
a	B-X
refresher	B-X
in	B-X
best	B-X
practices	B-X
.	B-X
The	B-X
articles	B-X
will	B-X
be	B-X
published	B-X
in	B-X
this	B-X
journal	B-X
over	B-X
a	B-X
six-month	B-X
period	B-X
and	B-X
will	B-X
emphasize	B-X
best	B-X
practices	B-X
in	B-X
:	B-X
(	B-X
1	B-X
)	B-X
media	B-X
selection	B-X
;	B-X
(	B-X
2	B-X
)	B-X
use	B-X
and	B-X
evaluation	B-X
of	B-X
animal	B-X
serum	B-X
as	B-X
a	B-X
component	B-X
of	B-X
cell	B-X
culture	B-X
medium	B-X
;	B-X
(	B-X
3	B-X
)	B-X
receipt	B-X
of	B-X
new	B-X
cells	B-X
into	B-X
the	B-X
laboratory	B-X
;	B-X
(	B-X
4	B-X
)	B-X
naming	B-X
cell	B-X
lines	B-X
;	B-X
(	B-X
5	B-X
)	B-X
authenticating	B-X
cell	B-X
line	B-X
identity	B-X
;	B-X
(	B-X
6	B-X
)	B-X
detecting	B-X
and	B-X
mitigating	B-X
risk	B-X
of	B-X
cell	B-X
culture	B-X
contamination	B-X
;	B-X
(	B-X
7	B-X
)	B-X
cryopreservation	B-X
and	B-X
thawing	B-X
of	B-X
cells	B-X
;	B-X
and	B-X
(	B-X
8	B-X
)	B-X
storing	B-X
and	B-X
shipping	B-X
viable	B-X
cells	B-X
.	B-X

HEK	O
293T	O
cells	O
were	O
cultured	O
in	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
medium	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

Jurkat	O
T	O
cells	O
and	O
primary	O
human	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
cultured	O
in	O
RPMI	O
-	O
1640	O
medium	O
(	O
Invitrogen	O
)	O
.	O

Media	O
were	O
supplemented	O
with	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
100	O
U	O
/	O
ml	O
penicillin	O
,	O
100	O
mug	O
/	O
ml	O
streptomycin	O
(	O
Cambrex	O
,	O
East	O
Rutherford	O
,	O
New	O
Jersey	O
,	O
United	O
States	O
)	O
,	O
and	O
10	O
%	O
fetal	O
bovine	O
serum	O
(	O
Atlanta	O
Biologicals	O
,	O
Norcross	O
,	O
Georgia	O
,	O
United	O
States	O
)	O
.	O

Patients	O
and	O
cell	O
preparation	O
.	O
<EOS>	B-X
Chimeric	B-X
antigen	B-X
receptor	B-X
(	B-X
CAR	B-X
)	B-X
T	B-X
cells	B-X
have	B-X
emerged	B-X
as	B-X
a	B-X
potent	B-X
therapeutic	B-X
approach	B-X
for	B-X
patients	B-X
with	B-X
certain	B-X
haematological	B-X
cancers	B-X
,	B-X
with	B-X
multiple	B-X
CAR	B-X
T	B-X
cell	B-X
products	B-X
currently	B-X
approved	B-X
by	B-X
the	B-X
FDA	B-X
for	B-X
those	B-X
with	B-X
relapsed	B-X
and/or	B-X
refractory	B-X
B	B-X
cell	B-X
malignancies	B-X
.	B-X
However	B-X
,	B-X
in	B-X
order	B-X
to	B-X
derive	B-X
the	B-X
desired	B-X
level	B-X
of	B-X
effectiveness	B-X
,	B-X
patients	B-X
need	B-X
to	B-X
successfully	B-X
receive	B-X
the	B-X
CAR	B-X
T	B-X
cell	B-X
infusion	B-X
in	B-X
a	B-X
timely	B-X
fashion	B-X
.	B-X
This	B-X
process	B-X
entails	B-X
apheresis	B-X
of	B-X
the	B-X
patient	B-X
's	B-X
T	B-X
cells	B-X
,	B-X
followed	B-X
by	B-X
CAR	B-X
T	B-X
cell	B-X
manufacture	B-X
.	B-X
Most	B-X
patients	B-X
will	B-X
also	B-X
receive	B-X
a	B-X
course	B-X
of	B-X
pre-CAR	B-X
T	B-X
cell	B-X
lymphodepletion	B-X
,	B-X
which	B-X
has	B-X
emerged	B-X
as	B-X
an	B-X
important	B-X
factor	B-X
in	B-X
enabling	B-X
durable	B-X
responses	B-X
.	B-X
The	B-X
time	B-X
between	B-X
apheresis	B-X
and	B-X
CAR	B-X
T	B-X
cell	B-X
infusion	B-X
is	B-X
often	B-X
not	B-X
a	B-X
simple	B-X
journey	B-X
,	B-X
with	B-X
each	B-X
milestone	B-X
being	B-X
a	B-X
critical	B-X
step	B-X
that	B-X
can	B-X
have	B-X
important	B-X
downstream	B-X
consequences	B-X
for	B-X
the	B-X
ability	B-X
to	B-X
receive	B-X
the	B-X
infusion	B-X
and	B-X
the	B-X
strength	B-X
of	B-X
clinical	B-X
responses	B-X
.	B-X
In	B-X
this	B-X
Review	B-X
,	B-X
we	B-X
provide	B-X
a	B-X
summary	B-X
of	B-X
the	B-X
many	B-X
considerations	B-X
for	B-X
preparing	B-X
patients	B-X
with	B-X
B	B-X
cell	B-X
non-Hodgkin	B-X
lymphoma	B-X
or	B-X
acute	B-X
lymphoblastic	B-X
leukaemia	B-X
for	B-X
CAR	B-X
T	B-X
cell	B-X
therapy	B-X
,	B-X
and	B-X
outline	B-X
current	B-X
limitations	B-X
and	B-X
areas	B-X
for	B-X
future	B-X
research	B-X
.	B-X

PBMCs	O
were	O
prepared	O
by	O
centrifugation	O
over	O
Ficoll	O
-	O
Hypaque	O
gradients	O
(	O
BioWhittaker	O
,	O
Walkersville	O
,	O
Maryland	O
,	O
United	O
States	O
)	O
from	O
eight	O
HAM	O
/	O
TSP	O
patients	O
and	O
eight	O
ACs	O
,	O
and	O
the	O
cells	O
were	O
viably	O
cryopreserved	O
in	O
liquid	O
nitrogen	O
until	O
tested	O
.	O

HAM	O
/	O
TSP	O
was	O
diagnosed	O
according	O
to	O
WHO	O
guidelines	O
[	O
49	O
]	O
.	O
<EOS>	B-X
Human	B-X
T-lymphotropic	B-X
virus	B-X
type	B-X
1	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
human	B-X
T-lymphotropic	B-X
virus	B-X
type	B-X
1-associated	B-X
myelopathy/tropical	B-X
spastic	B-X
paraparesis	B-X
(	B-X
HAM/TSP	B-X
)	B-X
.	B-X
Regarding	B-X
its	B-X
endemicity	B-X
in	B-X
Iran	B-X
and	B-X
the	B-X
role	B-X
of	B-X
repetitive	B-X
transcranial	B-X
magnetic	B-X
stimulation	B-X
in	B-X
reducing	B-X
spasticity	B-X
,	B-X
we	B-X
decided	B-X
to	B-X
evaluate	B-X
the	B-X
efficacy	B-X
of	B-X
repetitive	B-X
transcranial	B-X
magnetic	B-X
stimulation	B-X
in	B-X
reducing	B-X
spasticity	B-X
(	B-X
as	B-X
primary	B-X
outcome	B-X
)	B-X
and	B-X
pain	B-X
,	B-X
muscle	B-X
power	B-X
,	B-X
and	B-X
quality	B-X
of	B-X
life	B-X
(	B-X
as	B-X
secondary	B-X
outcomes	B-X
)	B-X
in	B-X
patients	B-X
suffering	B-X
from	B-X
HAM/TSP	B-X
.	B-X
After	B-X
the	B-X
first	B-X
description	B-X
of	B-X
TSP/HAM	B-X
in	B-X
1985	B-X
and	B-X
the	B-X
elaboration	B-X
of	B-X
WHO	B-X
's	B-X
diagnostic	B-X
criteria	B-X
in	B-X
1988	B-X
,	B-X
the	B-X
experience	B-X
of	B-X
the	B-X
professionals	B-X
in	B-X
this	B-X
field	B-X
has	B-X
increased	B-X
so	B-X
that	B-X
a	B-X
critical	B-X
reappraisal	B-X
of	B-X
these	B-X
diagnostic	B-X
guidelines	B-X
was	B-X
considered	B-X
timely	B-X
.	B-X
Brazilian	B-X
neurologists	B-X
and	B-X
observers	B-X
from	B-X
other	B-X
countries	B-X
met	B-X
recently	B-X
to	B-X
discuss	B-X
and	B-X
propose	B-X
a	B-X
modified	B-X
model	B-X
for	B-X
diagnosing	B-X
TSP/HAM	B-X
with	B-X
levels	B-X
of	B-X
ascertainment	B-X
as	B-X
definite	B-X
,	B-X
probable	B-X
,	B-X
and	B-X
possible	B-X
,	B-X
according	B-X
to	B-X
myelopathic	B-X
symptoms	B-X
,	B-X
serological	B-X
findings	B-X
,	B-X
and/or	B-X
detection	B-X
of	B-X
HTLV-I	B-X
DNA	B-X
and	B-X
exclusion	B-X
of	B-X
other	B-X
disorders	B-X
.	B-X

HTLV	O
-	O
I	O
seropositivity	O
was	O
determined	O
by	O
ELISA	O
(	O
Abbott	O
Laboratories	O
,	O
Abbott	O
Park	O
,	O
Illinois	O
,	O
United	O
States	O
)	O
,	O
with	O
confirmation	O
by	O
Western	O
blot	O
analysis	O
(	O
Genelabs	O
Technologies	O
,	O
Redwood	O
City	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

Blood	O
samples	O
were	O
obtained	O
after	O
informed	O
consent	O
as	O
part	O
of	O
a	O
clinical	O
protocol	O
reviewed	O
and	O
approved	O
by	O
the	O
NIH	O
institutional	O
review	O
panel	O
.	O

Plasmids	O
.	O
<EOS>	B-X
Plasmids	B-X
mediate	B-X
the	B-X
horizontal	B-X
transmission	B-X
of	B-X
genetic	B-X
information	B-X
between	B-X
bacteria	B-X
,	B-X
facilitating	B-X
their	B-X
adaptation	B-X
to	B-X
multiple	B-X
environmental	B-X
conditions	B-X
.	B-X
Plasmids	B-X
provide	B-X
bacteria	B-X
with	B-X
new	B-X
adaptive	B-X
tools	B-X
,	B-X
but	B-X
they	B-X
also	B-X
entail	B-X
a	B-X
metabolic	B-X
burden	B-X
that	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
selection	B-X
for	B-X
plasmid-encoded	B-X
traits	B-X
,	B-X
reduces	B-X
the	B-X
competitiveness	B-X
of	B-X
the	B-X
plasmid-carrying	B-X
clone	B-X
.	B-X
Plasmids	B-X
are	B-X
important	B-X
vehicles	B-X
for	B-X
rapid	B-X
adaptation	B-X
of	B-X
bacterial	B-X
populations	B-X
to	B-X
changing	B-X
environmental	B-X
conditions	B-X
.	B-X
Plasmids	B-X
provide	B-X
various	B-X
accessory	B-X
traits	B-X
which	B-X
might	B-X
be	B-X
beneficial	B-X
under	B-X
particular	B-X
conditions	B-X
.	B-X

Expression	O
vectors	O
encoding	O
human	O
Foxp3	B-Protein
(	O
pCMV	O
-	O
Foxp3	B-Protein
-	O
IRES	O
-	O
EGFP	O
)	O
and	O
human	O
Foxp3	B-Protein
lacking	O
the	O
forkhead	O
(	O
FKH	O
)	O
domain	O
(	O
pCMV	O
-	O
deltaFKH	O
-	O
IRES	O
-	O
EGFP	O
)	O
were	O
generous	O
gifts	O
from	O
S	O
.	O

Ziegler	O
(	O
Benaroya	O
Research	O
Institute	O
)	O
.	O
<EOS>	B-X
ISPAD	B-X
Clinical	B-X
Practice	B-X
Consensus	B-X
Guidelines	B-X
2022	B-X
:	B-X
Stages	B-X
of	B-X
type	B-X
1	B-X
diabetes	B-X
in	B-X
children	B-X
and	B-X
adolescents	B-X
.	B-X
Editorial	B-X
overview	B-X
:	B-X
Cytokines	B-X
:	B-X
New	B-X
roles	B-X
for	B-X
old	B-X
friends	B-X
!	B-X

pEGFP	O
-	O
C2	O
was	O
provided	O
by	O
I	O
.	O
<EOS>	B-X
To	B-X
construct	B-X
the	B-X
eukaryotic	B-X
expression	B-X
vector	B-X
pEGFP-N1/ACRBP	B-X
and	B-X
stably	B-X
express	B-X
ACRBP	B-X
in	B-X
human	B-X
hepatocarcinoma	B-X
cells	B-X
,	B-X
providing	B-X
functional	B-X
clues	B-X
for	B-X
ACRBP	B-X
.	B-X
The	B-X
cDNA	B-X
sequence	B-X
of	B-X
the	B-X
coding	B-X
region	B-X
of	B-X
FBXO30	B-X
(	B-X
F-box	B-X
only	B-X
protein	B-X
30	B-X
)	B-X
,	B-X
which	B-X
is	B-X
a	B-X
novel	B-X
member	B-X
of	B-X
F-box	B-X
protein	B-X
family	B-X
,	B-X
was	B-X
cloned	B-X
into	B-X
the	B-X
mammalian	B-X
expression	B-X
vector	B-X
pEGFP-C2	B-X
by	B-X
non-directional	B-X
cloning	B-X
method	B-X
and	B-X
introduced	B-X
into	B-X
the	B-X
NIH	B-X
3T3	B-X
cells	B-X
by	B-X
liposome	B-X
transfection	B-X
.	B-X

Lipinski	O
(	O
NIDDK	O
/	O
NIH	O
)	O
.	O
<EOS>	B-X
Guidelines	B-X
for	B-X
the	B-X
use	B-X
and	B-X
interpretation	B-X
of	B-X
assays	B-X
for	B-X
monitoring	B-X
autophagy	B-X
(	B-X
3rd	B-X
edition	B-X
)	B-X
.	B-X
Docking	B-X
studies	B-X
as	B-X
well	B-X
as	B-X
toxicophore	B-X
and	B-X
Lipinski	B-X
analyses	B-X
were	B-X
performed	B-X
.	B-X
The	B-X
currently	B-X
available	B-X
evidence	B-X
suggests	B-X
that	B-X
this	B-X
will	B-X
require	B-X
molecules	B-X
that	B-X
are	B-X
larger	B-X
and	B-X
have	B-X
quite	B-X
different	B-X
chemical	B-X
properties	B-X
than	B-X
typical	B-X
Lipinski-compliant	B-X
molecules	B-X
that	B-X
target	B-X
enzyme	B-X
active	B-X
sites	B-X
.	B-X
SI-2	B-X
meets	B-X
all	B-X
of	B-X
the	B-X
criteria	B-X
of	B-X
Lipinski	B-X
's	B-X
rule	B-X
[	B-X
Lipinski	B-X
et	B-X
al	B-X
.	B-X

pcDNA3	O
was	O
provided	O
by	O
K	O
.	O

T	O
.	O
<EOS>	B-X
RICOCHET-T-T-T-T-T-T	B-X
.	B-X

Jeang	O
(	O
NIAID	O
/	O
NIH	O
)	O
.	O
<EOS>	B-X
RISCy	B-X
business	B-X
:	B-X
MicroRNAs	B-X
,	B-X
pathogenesis	B-X
,	B-X
and	B-X
viruses	B-X
.	B-X
Multifaceted	B-X
activities	B-X
of	B-X
the	B-X
HIV-1	B-X
transactivator	B-X
of	B-X
transcription	B-X
,	B-X
Tat	B-X
.	B-X
Comparison	B-X
of	B-X
regulatory	B-X
features	B-X
among	B-X
primate	B-X
lentiviruses	B-X
.	B-X

pCMV4	O
-	O
Tax	B-Protein
was	O
a	O
generous	O
gift	O
from	O
W	O
.	O

Greene	O
(	O
University	O
of	O
California	O
San	O
Francisco	O
)	O
.	O
<EOS>	B-X
Appropriate	B-X
Use	B-X
Criteria	B-X
for	B-X
Prostate-Specific	B-X
Membrane	B-X
Antigen	B-X
PET	B-X
Imaging	B-X
.	B-X

pGL4	O
-	O
luc2	O
and	O
pGL4	O
-	O
TKhRluc2	O
were	O
purchased	O
from	O
Promega	O
(	O
Madison	O
,	O
Wisconsin	O
,	O
United	O
States	O
)	O
.	O

pUC18	O
was	O
purchased	O
from	O
Stratagene	O
(	O
La	O
Jolla	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

HIV	O
-	O
1	O
wt	O
LTR	O
and	O
HIV	O
-	O
1	O
delta	O
-	O
kappaB	O
LTR	O
luciferase	B-Protein
reporter	O
vectors	O
were	O
constructed	O
by	O
cloning	O
the	O
XhoI	O
/	O
HindIII	O
LTR	O
fragments	O
from	O
pHIV	O
-	O
CAT	B-Protein
and	O
pdelta	O
-	O
kappaB	O
-	O
HIV	O
-	O
CAT	B-Protein
(	O
AIDS	O
Research	O
and	O
Reference	O
Reagent	O
Program	O
,	O
NIAID	O
/	O
NIH	O
)	O
into	O
the	O
multiple	O
cloning	O
site	O
of	O
pGL4	O
-	O
luc2	O
.	O

NF	O
-	O
kappaB	O
,	O
HTLV	O
-	O
I	O
LTR	O
,	O
and	O
CREB	O
luciferase	B-Protein
reporter	O
and	O
pCMV	O
-	O
p300	B-Protein
-	O
HA	O
expression	O
vectors	O
were	O
generously	O
provided	O
by	O
B	O
.	O

Wigdahl	O
(	O
Drexel	O
University	O
College	O
of	O
Medicine	O
)	O
.	O
<EOS>	B-X
This	B-X
study	B-X
examines	B-X
Sanger	B-X
sequencing	B-X
of	B-X
HIV-1	B-X
subtype	B-X
B	B-X
Tat	B-X
from	B-X
2006	B-X
to	B-X
2014	B-X
within	B-X
the	B-X
Drexel	B-X
University	B-X
College	B-X
of	B-X
Medicine	B-X
CNS	B-X
AIDS	B-X
Research	B-X
and	B-X
Eradication	B-X
Study	B-X
(	B-X
CARES	B-X
)	B-X
Cohort	B-X
to	B-X
investigate	B-X
Tat	B-X
length	B-X
in	B-X
patients	B-X
.	B-X

HTLV	O
-	O
I	O
pACH	O
infectious	O
molecular	O
clone	O
has	O
been	O
described	O
previously	O
[	O
30	O
]	O
.	O

pFR	O
-	O
luc	O
,	O
pFA	O
-	O
CMV	O
,	O
pFA2	O
-	O
CREB	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
pFA2	O
-	O
c	B-Protein
-	I-Protein
Jun	I-Protein
were	O
purchased	O
from	O
Stratagene	O
.	O

pFA	O
-	O
Tax	B-Protein
(	O
encoding	O
a	O
fusion	O
protein	O
consisting	O
of	O
the	O
Gal4	B-Protein
DNA	O
-	O
binding	O
domain	O
fused	O
in	O
-	O
frame	O
to	O
HTLV	O
-	O
I	O
Tax	B-Protein
)	O
was	O
constructed	O
by	O
PCR	O
amplification	O
of	O
HTLV	O
-	O
I	O
Tax	B-Protein
using	O
pCMV4	O
-	O
Tax	B-Protein
as	O
a	O
template	O
and	O
BamHI	O
/	O
BglII	O
-	O
tagged	O
primers	O
.	O

The	O
amplified	O
insert	O
was	O
digested	O
and	O
ligated	O
into	O
the	O
BamHI	O
/	O
BglII	O
sites	O
of	O
pFA	O
-	O
CMV	O
.	O

Plasmid	O
contents	O
were	O
confirmed	O
by	O
DNA	O
sequencing	O
.	O
<EOS>	B-X
Although	B-X
most	B-X
rAAV	B-X
DNA	B-X
typically	B-X
remains	B-X
episomal	B-X
,	B-X
some	B-X
rAAV	B-X
DNA	B-X
becomes	B-X
integrated	B-X
into	B-X
genomic	B-X
DNA	B-X
at	B-X
a	B-X
low	B-X
frequency	B-X
,	B-X
and	B-X
rAAV	B-X
insertional	B-X
mutagenesis	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
lead	B-X
to	B-X
tumorigenesis	B-X
in	B-X
neonatal	B-X
mice	B-X
.	B-X
Currently	B-X
,	B-X
the	B-X
risk	B-X
of	B-X
rAAV-mediated	B-X
oncogenesis	B-X
in	B-X
humans	B-X
is	B-X
theoretical	B-X
because	B-X
no	B-X
confirmed	B-X
genotoxic	B-X
events	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
date	B-X
.	B-X
This	B-X
study	B-X
used	B-X
whole	B-X
genome	B-X
sequencing	B-X
(	B-X
WGS	B-X
)	B-X
to	B-X
investigate	B-X
causes	B-X
of	B-X
inconsistent	B-X
PCR	B-X
detection	B-X
of	B-X
stx1	B-X
,	B-X
stx2	B-X
,	B-X
and	B-X
serogroup-specific	B-X
genes	B-X
.	B-X
Eleven	B-X
strains	B-X
were	B-X
confirmed	B-X
by	B-X
WGS	B-X
as	B-X
STEC	B-X
having	B-X
complete	B-X
stxA	B-X
and	B-X
stxB	B-X
subunits	B-X
.	B-X
The	B-X
majority	B-X
of	B-X
STEC	B-X
isolates	B-X
(	B-X
7/11	B-X
)	B-X
did	B-X
not	B-X
have	B-X
identifiable	B-X
bacteriophage	B-X
DNA	B-X
in	B-X
the	B-X
contig	B-X
(	B-X
s	B-X
)	B-X
where	B-X
stx	B-X
was	B-X
located	B-X
,	B-X
likely	B-X
increasing	B-X
the	B-X
stability	B-X
of	B-X
stx	B-X
in	B-X
the	B-X
bacterial	B-X
genome	B-X
and	B-X
its	B-X
detection	B-X
by	B-X
PCR	B-X
.	B-X

Isolation	O
of	O
primary	O
human	O
CD4	B-Protein
+	O
T	O
cells	O
.	O
<EOS>	B-X
CCR5	B-X
is	B-X
the	B-X
major	B-X
coreceptor	B-X
for	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
HIV	B-X
)	B-X
.	B-X
We	B-X
investigated	B-X
whether	B-X
site-specific	B-X
modification	B-X
of	B-X
the	B-X
gene	B-X
(	B-X
``	B-X
gene	B-X
editing	B-X
''	B-X
)	B-X
--	B-X
in	B-X
this	B-X
case	B-X
,	B-X
the	B-X
infusion	B-X
of	B-X
autologous	B-X
CD4	B-X
T	B-X
cells	B-X
in	B-X
which	B-X
the	B-X
CCR5	B-X
gene	B-X
was	B-X
rendered	B-X
permanently	B-X
dysfunctional	B-X
by	B-X
a	B-X
zinc-finger	B-X
nuclease	B-X
(	B-X
ZFN	B-X
)	B-X
--	B-X
is	B-X
safe	B-X
.	B-X
T-regulatory	B-X
(	B-X
Treg	B-X
)	B-X
cells	B-X
suppress	B-X
the	B-X
immune	B-X
response	B-X
to	B-X
maintain	B-X
homeostasis	B-X
.	B-X
There	B-X
are	B-X
2	B-X
main	B-X
subsets	B-X
of	B-X
Treg	B-X
cells	B-X
:	B-X
FOXP3	B-X
(	B-X
forkhead	B-X
box	B-X
protein	B-X
3	B-X
)	B-X
-positive	B-X
Treg	B-X
cells	B-X
,	B-X
which	B-X
do	B-X
not	B-X
produce	B-X
high	B-X
levels	B-X
of	B-X
effector	B-X
cytokines	B-X
,	B-X
and	B-X
type	B-X
1	B-X
Treg	B-X
(	B-X
Tr1	B-X
)	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
FOXP3-negative	B-X
and	B-X
secrete	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
10	B-X
.	B-X
IL10	B-X
is	B-X
an	B-X
anti-inflammatory	B-X
cytokine	B-X
,	B-X
so	B-X
Tr1	B-X
cells	B-X
might	B-X
be	B-X
used	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
inflammatory	B-X
bowel	B-X
diseases	B-X
.	B-X
We	B-X
aimed	B-X
to	B-X
develop	B-X
methods	B-X
to	B-X
isolate	B-X
and	B-X
expand	B-X
human	B-X
Tr1	B-X
cells	B-X
and	B-X
define	B-X
their	B-X
functions	B-X
.	B-X

CD4	B-Protein
+	O
T	O
cells	O
were	O
isolated	O
from	O
cryopreserved	O
healthy	O
donor	O
PBMCs	O
by	O
negative	O
selection	O
with	O
the	O
CD4	B-Protein
+	O
T	O
Cell	O
Isolation	O
Kit	O
II	O
(	O
Miltenyi	O
Biotech	O
,	O
Bergisch	O
Gladbach	O
,	O
Germany	O
)	O
according	O
to	O
manufacturer	O
'	O
s	O
guidelines	O
.	O

Purity	O
of	O
negatively	O
selected	O
CD4	B-Protein
+	O
T	O
cells	O
was	O
consistently	O
higher	O
than	O
96	O
%	O
as	O
determined	O
by	O
flow	O
cytometry	O
.	O

Transient	O
expression	O
and	O
luciferase	B-Protein
assays	O
.	O
<EOS>	B-X
The	B-X
nucleotide	B-X
sequence	B-X
of	B-X
the	B-X
luciferase	B-X
gene	B-X
from	B-X
the	B-X
firefly	B-X
Photinus	B-X
pyralis	B-X
was	B-X
determined	B-X
from	B-X
the	B-X
analysis	B-X
of	B-X
cDNA	B-X
and	B-X
genomic	B-X
clones	B-X
.	B-X
The	B-X
5	B-X
'	B-X
end	B-X
of	B-X
the	B-X
luciferase	B-X
mRNA	B-X
was	B-X
determined	B-X
by	B-X
both	B-X
S1	B-X
nuclease	B-X
analysis	B-X
and	B-X
primer	B-X
extension	B-X
.	B-X
Although	B-X
the	B-X
luciferase	B-X
cDNA	B-X
clone	B-X
lacked	B-X
the	B-X
six	B-X
N-terminal	B-X
codons	B-X
of	B-X
the	B-X
open	B-X
reading	B-X
frame	B-X
,	B-X
we	B-X
were	B-X
able	B-X
to	B-X
reconstruct	B-X
the	B-X
equivalent	B-X
of	B-X
a	B-X
full-length	B-X
cDNA	B-X
using	B-X
the	B-X
genomic	B-X
clone	B-X
as	B-X
a	B-X
source	B-X
of	B-X
the	B-X
missing	B-X
5	B-X
'	B-X
sequence	B-X
.	B-X
The	B-X
full-length	B-X
,	B-X
intronless	B-X
luciferase	B-X
gene	B-X
was	B-X
inserted	B-X
into	B-X
mammalian	B-X
expression	B-X
vectors	B-X
and	B-X
introduced	B-X
into	B-X
monkey	B-X
(	B-X
CV-1	B-X
)	B-X
cells	B-X
in	B-X
which	B-X
enzymatically	B-X
active	B-X
firefly	B-X
luciferase	B-X
was	B-X
transiently	B-X
expressed	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
cell	B-X
lines	B-X
stably	B-X
expressing	B-X
firefly	B-X
luciferase	B-X
were	B-X
isolated	B-X
.	B-X
Deleting	B-X
a	B-X
portion	B-X
of	B-X
the	B-X
5'-untranslated	B-X
region	B-X
of	B-X
the	B-X
luciferase	B-X
gene	B-X
removed	B-X
an	B-X
upstream	B-X
initiation	B-X
(	B-X
AUG	B-X
)	B-X
codon	B-X
and	B-X
resulted	B-X
in	B-X
a	B-X
twofold	B-X
increase	B-X
in	B-X
the	B-X
level	B-X
of	B-X
luciferase	B-X
expression	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
the	B-X
full-length	B-X
luciferase	B-X
gene	B-X
to	B-X
activate	B-X
cryptic	B-X
or	B-X
enhancerless	B-X
promoters	B-X
was	B-X
also	B-X
greatly	B-X
reduced	B-X
or	B-X
eliminated	B-X
by	B-X
this	B-X
5	B-X
'	B-X
deletion	B-X
.	B-X
Assaying	B-X
the	B-X
expression	B-X
of	B-X
luciferase	B-X
provides	B-X
a	B-X
rapid	B-X
and	B-X
inexpensive	B-X
method	B-X
for	B-X
monitoring	B-X
promoter	B-X
activity	B-X
.	B-X
Depending	B-X
on	B-X
the	B-X
instrumentation	B-X
employed	B-X
to	B-X
detect	B-X
luciferase	B-X
activity	B-X
,	B-X
we	B-X
estimate	B-X
this	B-X
assay	B-X
to	B-X
be	B-X
from	B-X
30-	B-X
to	B-X
1,000-fold	B-X
more	B-X
sensitive	B-X
than	B-X
assaying	B-X
chloramphenicol	B-X
acetyltransferase	B-X
expression	B-X
.	B-X

HEK	O
293T	O
cells	O
were	O
plated	O
at	O
a	O
density	O
of	O
5	O
x	O
105	O
cells	O
/	O
well	O
in	O
six	O
-	O
well	O
culture	O
plates	O
(	O
BD	O
Biosciences	O
,	O
San	O
Diego	O
,	O
California	O
,	O
United	O
States	O
)	O
1	O
d	O
prior	O
to	O
transfection	O
with	O
the	O
appropriate	O
plasmid	O
DNA	O
(	O
~	O
2	O
mug	O
total	O
)	O
using	O
FuGene	O
6	O
transfection	O
reagent	O
(	O
Roche	O
,	O
Basel	O
,	O
Switzerland	O
)	O
.	O

Jurkat	O
T	O
cells	O
were	O
plated	O
at	O
1	O
x	O
106	O
cells	O
/	O
well	O
in	O
six	O
-	O
well	O
culture	O
plates	O
the	O
day	O
of	O
transfection	O
with	O
the	O
appropriate	O
plasmid	O
DNA	O
(	O
~	O
2	O
mug	O
total	O
)	O
using	O
FuGene	O
6	O
transfection	O
reagent	O
.	O

Primary	O
human	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
2	O
x	O
106	O
)	O
were	O
nucleofected	O
with	O
the	O
specified	O
plasmid	O
DNA	O
(	O
5	O
mug	O
total	O
)	O
using	O
the	O
Human	O
T	O
Cell	O
Nucleofection	O
Kit	O
(	O
Amaxa	O
,	O
Gaithersburg	O
,	O
Maryland	O
,	O
United	O
States	O
)	O
.	O

Forskolin	O
(	O
10	O
muM	O
;	O
Calbiochem	O
,	O
San	O
Diego	O
,	O
California	O
,	O
United	O
States	O
)	O
was	O
added	O
in	O
some	O
experiments	O
20	O
h	O
posttransfection	O
.	O
<EOS>	B-X
Lipid	B-X
droplets	B-X
(	B-X
LD	B-X
)	B-X
in	B-X
porcine	B-X
oocytes	B-X
form	B-X
a	B-X
dark	B-X
mass	B-X
reaching	B-X
almost	B-X
all	B-X
cytoplasm	B-X
.	B-X
Herein	B-X
we	B-X
investigated	B-X
changes	B-X
in	B-X
fat	B-X
areas	B-X
,	B-X
cytoplasmic	B-X
tone	B-X
and	B-X
LD	B-X
morphology	B-X
during	B-X
in	B-X
vitro	B-X
maturation	B-X
(	B-X
IVM	B-X
)	B-X
of	B-X
porcine	B-X
oocytes	B-X
cultured	B-X
with	B-X
100	B-X
μM	B-X
trans-10	B-X
,	B-X
cis-12	B-X
conjugated	B-X
linoleic	B-X
acid	B-X
(	B-X
t10	B-X
,	B-X
c12	B-X
CLA	B-X
)	B-X
or	B-X
10	B-X
μM	B-X
forskolin	B-X
at	B-X
different	B-X
time	B-X
periods	B-X
.	B-X
Four	B-X
groups	B-X
were	B-X
constituted	B-X
:	B-X
control	B-X
,	B-X
excipient	B-X
,	B-X
t10	B-X
,	B-X
c12	B-X
CLA	B-X
and	B-X
forskolin	B-X
,	B-X
with	B-X
drugs	B-X
being	B-X
supplemented	B-X
during	B-X
44	B-X
to	B-X
48	B-X
h	B-X
and	B-X
the	B-X
initial	B-X
22	B-X
to	B-X
24	B-X
h	B-X
in	B-X
Experiments	B-X
1	B-X
and	B-X
2	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
Experiment	B-X
3	B-X
,	B-X
forskolin	B-X
was	B-X
supplemented	B-X
for	B-X
the	B-X
first	B-X
2	B-X
h.	B-X
Matured	B-X
oocytes	B-X
were	B-X
inseminated	B-X
with	B-X
frozen-thawed	B-X
boar	B-X
semen	B-X
and	B-X
cleavage	B-X
rate	B-X
recorded	B-X
.	B-X
Results	B-X
showed	B-X
that	B-X
forskolin	B-X
supplementation	B-X
during	B-X
44	B-X
to	B-X
48	B-X
h	B-X
or	B-X
22	B-X
to	B-X
24	B-X
h	B-X
inhibits	B-X
oocyte	B-X
maturation	B-X
(	B-X
exp	B-X
.	B-X
Forskolin	B-X
also	B-X
reduced	B-X
oocyte	B-X
and	B-X
fat	B-X
areas	B-X
.	B-X
In	B-X
Experiment	B-X
3	B-X
,	B-X
forskolin	B-X
negative	B-X
effect	B-X
on	B-X
oocyte	B-X
maturation	B-X
and	B-X
cleavage	B-X
disappeared	B-X
,	B-X
although	B-X
minor	B-X
(	B-X
P	B-X
⩽	B-X
0.03	B-X
)	B-X
LD	B-X
and	B-X
oocyte	B-X
fat	B-X
areas	B-X
were	B-X
identified	B-X
at	B-X
22	B-X
to	B-X
24	B-X
h	B-X
of	B-X
IVM	B-X
.	B-X
Oocytes	B-X
supplemented	B-X
with	B-X
t10	B-X
,	B-X
c12	B-X
CLA	B-X
during	B-X
44	B-X
to	B-X
48	B-X
h	B-X
presented	B-X
a	B-X
lighter	B-X
(	B-X
P	B-X
⩽	B-X
0.04	B-X
)	B-X
colour	B-X
tone	B-X
cytoplasm	B-X
than	B-X
those	B-X
of	B-X
control	B-X
and	B-X
forskolin	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
t10	B-X
,	B-X
c12	B-X
CLA	B-X
and	B-X
forskolin	B-X
were	B-X
capable	B-X
of	B-X
modifying	B-X
the	B-X
distribution	B-X
and	B-X
morphology	B-X
of	B-X
cytoplasmic	B-X
LD	B-X
during	B-X
porcine	B-X
oocyte	B-X
maturation	B-X
,	B-X
thus	B-X
reducing	B-X
its	B-X
lipid	B-X
content	B-X
in	B-X
a	B-X
time-dependent	B-X
manner	B-X
.	B-X

Cells	O
were	O
harvested	O
24	O
h	O
posttransfection	O
and	O
luciferase	B-Protein
activity	O
was	O
analyzed	O
using	O
the	O
Dual	O
-	O
luciferase	B-Protein
Reporter	O
Assay	O
System	O
(	O
Promega	O
)	O
and	O
a	O
Monolight	O
2010	O
luminometer	O
(	O
Analytical	O
Luminescence	O
Laboratory	O
,	O
San	O
Diego	O
,	O
California	O
,	O
United	O
States	O
)	O
according	O
to	O
manufacturer	O
'	O
s	O
guidelines	O
.	O

pGL4	O
-	O
TKhRluc2	O
was	O
used	O
as	O
an	O
internal	O
control	O
to	O
normalize	O
for	O
transfection	O
efficiency	O
.	O

Nucleofected	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
also	O
monitored	O
for	O
transfection	O
efficiency	O
and	O
cell	O
viability	O
24	O
h	O
posttransfection	O
as	O
follows	O
.	O

Transfection	O
efficiency	O
was	O
routinely	O
~	O
30	O
%	O
as	O
determined	O
by	O
flow	O
cytometric	O
analysis	O
of	O
EGFP	O
expression	O
.	O

Cell	O
viability	O
,	O
determined	O
by	O
staining	O
with	O
7	O
-	O
amino	O
-	O
actinomycin	O
D	O
(	O
7	O
-	O
AAD	O
;	O
BD	O
Biosciences	O
)	O
,	O
was	O
routinely	O
~	O
70	O
%	O
.	O
<EOS>	B-X
Cell	B-X
death	B-X
and	B-X
its	B-X
recently	B-X
discovered	B-X
regulated	B-X
form	B-X
ferroptosis	B-X
are	B-X
characterized	B-X
by	B-X
distinct	B-X
morphological	B-X
,	B-X
electrophysiological	B-X
,	B-X
and	B-X
pharmacological	B-X
features	B-X
.	B-X
Distinguishing	B-X
cell	B-X
viability	B-X
and	B-X
cell	B-X
death	B-X
is	B-X
essential	B-X
for	B-X
experimental	B-X
and	B-X
clinical	B-X
applications	B-X
and	B-X
a	B-X
key	B-X
component	B-X
in	B-X
flow	B-X
cytometry	B-X
experiments	B-X
.	B-X
Although	B-X
fluorescent	B-X
dyes	B-X
combined	B-X
with	B-X
flow	B-X
cytometry	B-X
have	B-X
been	B-X
used	B-X
to	B-X
confirm	B-X
the	B-X
viability	B-X
of	B-X
sperm	B-X
in	B-X
the	B-X
past	B-X
,	B-X
methods	B-X
to	B-X
detect	B-X
damage	B-X
to	B-X
spermatozoa	B-X
following	B-X
injury	B-X
have	B-X
been	B-X
limited	B-X
to	B-X
use	B-X
of	B-X
dyes	B-X
,	B-X
which	B-X
are	B-X
often	B-X
difficult	B-X
to	B-X
adequately	B-X
compensate	B-X
for	B-X
in	B-X
a	B-X
single	B-X
laser	B-X
system	B-X
.	B-X
Pretest	B-X
factors	B-X
associated	B-X
with	B-X
a	B-X
donor	B-X
's	B-X
medical	B-X
care	B-X
can	B-X
affect	B-X
test	B-X
results	B-X
by	B-X
changing	B-X
the	B-X
number	B-X
,	B-X
viability	B-X
and	B-X
target	B-X
on	B-X
lymphocytes	B-X
(	B-X
such	B-X
as	B-X
rituximab	B-X
on	B-X
CD20	B-X

Both	O
transfection	O
efficiency	O
and	O
cell	O
viability	O
in	O
nucleofected	O
CD4	B-Protein
+	O
T	O
cells	O
was	O
independent	O
of	O
the	O
plasmids	O
used	O
.	O

Foxp3	B-Protein
and	O
HTLV	O
-	O
I	O
Tax	B-Protein
expression	O
analysis	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

Real	O
-	O
time	O
RT	O
-	O
PCR	O
analysis	O
of	O
Foxp3	B-Protein
and	O
HTLV	O
-	O
I	O
Tax	B-Protein
expression	O
was	O
performed	O
as	O
previously	O
described	O
[	O
8	O
,	O
47	O
]	O
.	O

Briefly	O
,	O
total	O
RNA	O
was	O
extracted	O
using	O
the	O
RNeasy	O
Mini	O
Kit	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
California	O
,	O
United	O
States	O
)	O
according	O
to	O
manufacturer	O
'	O
s	O
guidelines	O
,	O
and	O
cDNA	O
was	O
synthesized	O
by	O
reverse	O
transcription	O
using	O
TaqMan	O
Gold	O
RT	O
-	O
PCR	O
Kit	O
using	O
random	O
hexamer	O
primers	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

Foxp3	B-Protein
and	O
HTLV	O
-	O
I	O
Tax	B-Protein
mRNA	O
expression	O
was	O
quantified	O
by	O
real	O
-	O
time	O
PCR	O
using	O
ABI	O
PRISM	O
7700	O
Sequence	O
Detection	O
System	O
(	O
Applied	O
Biosystems	O
)	O
.	O

The	O
normalized	O
values	O
in	O
each	O
sample	O
were	O
calculated	O
as	O
the	O
relative	O
quantity	O
of	O
Foxp3	B-Protein
or	O
HTLV	O
-	O
I	O
Tax	B-Protein
mRNA	O
expression	O
divided	O
by	O
the	O
relative	O
quantity	O
of	O
HPRT	B-Protein
mRNA	O
expression	O
.	O

The	O
values	O
were	O
calculated	O
by	O
the	O
following	O
formula	O
:	O
normalized	O
Foxp3	B-Protein
or	O
HTLV	O
-	O
I	O
Tax	B-Protein
expression	O
=	O
2Ct	O
value	O
of	O
HPRT	B-Protein
-	O
Ct	O
value	O
of	O
Foxp3	B-Protein
or	O
HTLV	O
-	O
I	O
Tax	B-Protein
.	O
<EOS>	B-X
Human	B-X
T	B-X
cell	B-X
leukemia	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HTLV-1	B-X
)	B-X
was	B-X
the	B-X
first	B-X
discovered	B-X
human	B-X
retrovirus	B-X
and	B-X
the	B-X
etiologic	B-X
agent	B-X
of	B-X
adult	B-X
T-cell	B-X
leukemia	B-X
and	B-X
HTLV-1-associated	B-X
myelopathy/tropical	B-X
spastic	B-X
paraparesis	B-X
.	B-X
Shortly	B-X
after	B-X
the	B-X
discovery	B-X
of	B-X
HTLV-1	B-X
,	B-X
human	B-X
T-cell	B-X
leukemia	B-X
virus	B-X
type	B-X
2	B-X
(	B-X
HTLV-2	B-X
)	B-X
was	B-X
isolated	B-X
from	B-X
a	B-X
patient	B-X
with	B-X
hairy	B-X
cell	B-X
leukemia	B-X
.	B-X
Despite	B-X
possession	B-X
of	B-X
similar	B-X
structural	B-X
features	B-X
to	B-X
HTLV-1	B-X
,	B-X
HTLV-2	B-X
has	B-X
not	B-X
been	B-X
definitively	B-X
associated	B-X
with	B-X
lymphoproliferative	B-X
disease	B-X
.	B-X
Since	B-X
their	B-X
discovery	B-X
,	B-X
studies	B-X
have	B-X
been	B-X
performed	B-X
with	B-X
the	B-X
goal	B-X
of	B-X
highlighting	B-X
the	B-X
differences	B-X
between	B-X
HTLV-1	B-X
and	B-X
HTLV-2	B-X
.	B-X
A	B-X
better	B-X
understanding	B-X
of	B-X
these	B-X
differences	B-X
will	B-X
shed	B-X
light	B-X
on	B-X
the	B-X
specific	B-X
pathogenic	B-X
mechanisms	B-X
of	B-X
HTLV-1	B-X
and	B-X
lead	B-X
to	B-X
novel	B-X
therapeutic	B-X
targets	B-X
.	B-X

Real	O
-	O
time	O
PCR	O
.	O
<EOS>	B-X
Quantitative	B-X
real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
is	B-X
a	B-X
technique	B-X
for	B-X
simultaneous	B-X
amplification	B-X
and	B-X
product	B-X
quantification	B-X
of	B-X
a	B-X
target	B-X
DNA	B-X
as	B-X
the	B-X
process	B-X
takes	B-X
place	B-X
in	B-X
real	B-X
time	B-X
in	B-X
a	B-X
``	B-X
closed-tube	B-X
''	B-X
system	B-X
.	B-X
The	B-X
quantification	B-X
process	B-X
employs	B-X
melting	B-X
curve	B-X
analysis	B-X
and/or	B-X
fluorescent	B-X
detection	B-X
systems	B-X
and	B-X
can	B-X
provide	B-X
amplification	B-X
and	B-X
genotyping	B-X
in	B-X
a	B-X
relatively	B-X
short	B-X
time	B-X
.	B-X
In	B-X
this	B-X
regard	B-X
,	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
has	B-X
provided	B-X
the	B-X
necessary	B-X
analytical	B-X
performance	B-X
for	B-X
many	B-X
molecular	B-X
analyses	B-X
.	B-X
PCR-based	B-X
methods	B-X
for	B-X
SNP/mutation	B-X
detection	B-X
are	B-X
broadly	B-X
categorized	B-X
into	B-X
two	B-X
types-	B-X
(	B-X
1	B-X
)	B-X
polymorphic	B-X
or	B-X
mutant	B-X
allele-directed	B-X
specific	B-X
analysis	B-X
using	B-X
primers	B-X
matched	B-X
with	B-X
substituted	B-X
nucleotide	B-X
or	B-X
using	B-X
oligonucleotides	B-X
to	B-X
block	B-X
or	B-X
clamp	B-X
the	B-X
nontargeted	B-X
template	B-X
,	B-X
and	B-X
(	B-X
2	B-X
)	B-X
melting	B-X
curve	B-X
analysis	B-X
,	B-X
which	B-X
is	B-X
combined	B-X
with	B-X
the	B-X
real-time	B-X
PCR	B-X
techniques	B-X
using	B-X
hydrolysis	B-X
probes	B-X
,	B-X
hybridization	B-X
probes	B-X
,	B-X
or	B-X
double-stranded	B-X
DNA-binding	B-X
fluorescent	B-X
dyes	B-X
.	B-X
These	B-X
advances	B-X
include	B-X
DNA/RNA	B-X
preparation	B-X
and	B-X
subsequent	B-X
amplification	B-X
steps	B-X
,	B-X
and	B-X
miniaturization	B-X
of	B-X
PCR	B-X
instruments	B-X
such	B-X
that	B-X
testing	B-X
may	B-X
be	B-X
performed	B-X
with	B-X
relative	B-X
ease	B-X
in	B-X
clinical	B-X
laboratories	B-X
or	B-X
as	B-X
a	B-X
point-of-care	B-X
test	B-X
in	B-X
clinical	B-X
settings	B-X
.	B-X

Real	O
-	O
time	O
PCR	O
analysis	O
of	O
HTLV	O
-	O
I	O
(	O
Tax	B-Protein
)	O
proviral	O
load	O
was	O
performed	O
as	O
previously	O
described	O
[	O
47	O
,	O
50	O
]	O
.	O
<EOS>	B-X
indeterminate	B-X
Western	B-X
blot	B-X
(	B-X
WB	B-X
)	B-X
patterns	B-X
are	B-X
a	B-X
major	B-X
concern	B-X
for	B-X
diagnosis	B-X
of	B-X
human	B-X
T-cell	B-X
lymphotropic	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HTLV-1	B-X
)	B-X
infection	B-X
,	B-X
even	B-X
in	B-X
non-endemic	B-X
areas	B-X
.	B-X

DNA	O
was	O
extracted	O
from	O
1	O
x	O
106	O
cells	O
using	O
Puregene	O
DNA	O
Isolation	O
Kit	O
(	O
Gentra	O
,	O
Minneapolis	O
,	O
Minnesota	O
,	O
United	O
States	O
)	O
,	O
and	O
100	O
ng	O
of	O
the	O
sample	O
DNA	O
solution	O
was	O
analyzed	O
by	O
this	O
system	O
.	O

The	O
HTLV	O
-	O
I	O
proviral	O
DNA	O
load	O
was	O
calculated	O
by	O
the	O
following	O
formula	O
:	O
copy	O
number	O
of	O
HTLV	O
-	O
I	O
(	O
pX	O
)	O
per	O
100	O
cells	O
=	O
(	O
copy	O
number	O
of	O
pX	O
)	O
/	O
(	O
copy	O
number	O
of	O
beta	B-Protein
-	I-Protein
actin	I-Protein
/	O
2	O
)	O
x	O
100	O
.	O

Western	O
blot	O
analysis	O
.	O
<EOS>	B-X
Appropriate	B-X
protein	B-X
extraction	B-X
method	B-X
,	B-X
electrophoresis	B-X
,	B-X
and	B-X
transfer	B-X
of	B-X
proteins	B-X
,	B-X
immunodetection	B-X
of	B-X
blotted	B-X
protein	B-X
by	B-X
antibodies	B-X
,	B-X
and	B-X
the	B-X
ultimate	B-X
step	B-X
of	B-X
imaging	B-X
and	B-X
analyzing	B-X
the	B-X
data	B-X
is	B-X
nothing	B-X
short	B-X
of	B-X
a	B-X
symphony	B-X
.	B-X
Like	B-X
with	B-X
any	B-X
other	B-X
technology	B-X
in	B-X
life-sciences	B-X
research	B-X
,	B-X
Western	B-X
blotting	B-X
can	B-X
produce	B-X
erroneous	B-X
and	B-X
irreproducible	B-X
data	B-X
.	B-X
We	B-X
provide	B-X
a	B-X
systematic	B-X
approach	B-X
to	B-X
generate	B-X
quantitative	B-X
data	B-X
from	B-X
Western	B-X
blot	B-X
experiments	B-X
that	B-X
incorporates	B-X
critical	B-X
validation	B-X
steps	B-X
to	B-X
identify	B-X
and	B-X
minimize	B-X
sources	B-X
of	B-X
error	B-X
and	B-X
variability	B-X
throughout	B-X
the	B-X
Western	B-X
blot	B-X
process	B-X
.	B-X
Electrophoresis	B-X
and	B-X
the	B-X
following	B-X
western	B-X
blot	B-X
analysis	B-X
are	B-X
indispensable	B-X
to	B-X
investigate	B-X
biochemical	B-X
changes	B-X
in	B-X
cells	B-X
and	B-X
tissues	B-X
exposed	B-X
to	B-X
nanoparticles	B-X
or	B-X
nanomaterials	B-X
.	B-X
It	B-X
is	B-X
important	B-X
to	B-X
select	B-X
a	B-X
good	B-X
blocking	B-X
agent	B-X
and	B-X
an	B-X
appropriate	B-X
pair	B-X
of	B-X
primary	B-X
and	B-X
peroxidase-tagged	B-X
secondary	B-X
antibodies	B-X
to	B-X
obtain	B-X
good	B-X
results	B-X
in	B-X
western	B-X
blot	B-X
analysis	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
the	B-X
whole	B-X
process	B-X
of	B-X
western	B-X
blot	B-X
analysis	B-X
,	B-X
from	B-X
sample	B-X
preparation	B-X
to	B-X
quantitative	B-X
measurement	B-X
of	B-X
target	B-X
proteins	B-X
,	B-X
is	B-X
described	B-X
.	B-X

HEK	O
293T	O
cells	O
were	O
plated	O
at	O
a	O
density	O
of	O
5	O
x	O
105	O
cells	O
/	O
well	O
in	O
six	O
-	O
well	O
culture	O
plates	O
(	O
BD	O
Biosciences	O
)	O
1	O
d	O
prior	O
to	O
transfection	O
with	O
the	O
appropriate	O
plasmid	O
DNA	O
(	O
2	O
mug	O
total	O
)	O
using	O
FuGene	O
6	O
transfection	O
reagent	O
(	O
Roche	O
)	O
.	O

Cells	O
were	O
harvested	O
24	O
h	O
posttransfection	O
for	O
whole	O
-	O
cell	O
lysates	O
in	O
RIPA	O
buffer	O
(	O
50	O
mM	O
Tris	O
-	O
HCl	O
[	O
pH	O
7	O
.	O
4	O
]	O
,	O
150	O
mM	O
NaCl	O
,	O
1	O
%	O
Igepal	O
(	O
NP	O
-	O
40	O
)	O
,	O
0	O
.	O
5	O
%	O
sodium	O
deoxycholate	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
mM	O
DTT	O
,	O
1	O
mM	O
PMSF	O
,	O
and	O
1x	O
Complete	O
Mini	O
Protease	O
Inhibitor	O
[	O
Roche	O
]	O
)	O
.	O

Protein	O
concentration	O
was	O
determined	O
by	O
Lowry	O
assay	O
(	O
Bio	O
-	O
Rad	O
,	O
Hercules	O
,	O
California	O
,	O
United	O
States	O
)	O
and	O
colorimetric	O
reactions	O
were	O
read	O
using	O
a	O
VersaMax	O
microplate	O
reader	O
(	O
Molecular	O
Devices	O
,	O
Sunnyvale	O
,	O
California	O
,	O
United	O
States	O
)	O
at	O
an	O
absorbance	O
of	O
750	O
nm	O
.	O

Size	O
fractionation	O
was	O
performed	O
on	O
20	O
mug	O
of	O
protein	O
/	O
sample	O
by	O
SDS	O
-	O
PAGE	O
,	O
and	O
the	O
protein	O
was	O
transferred	O
to	O
nitrocellulose	O
or	O
PVDF	O
membranes	O
and	O
subjected	O
to	O
immunoblotting	O
using	O
the	O
indicated	O
antibodies	O
.	O
<EOS>	B-X
When	B-X
performing	B-X
western	B-X
blots	B-X
for	B-X
protein	B-X
detection	B-X
using	B-X
the	B-X
classical	B-X
Laemmli	B-X
method	B-X
,	B-X
experimenters	B-X
often	B-X
encounter	B-X
difficulties	B-X
with	B-X
the	B-X
detection	B-X
of	B-X
transmembrane	B-X
proteins	B-X
involved	B-X
in	B-X
lipid	B-X
or	B-X
fatty	B-X
acid	B-X
metabolism	B-X
.	B-X
A	B-X
crucial	B-X
phase	B-X
in	B-X
sample	B-X
preparation	B-X
is	B-X
heating	B-X
the	B-X
samples	B-X
to	B-X
100	B-X
°C	B-X
in	B-X
a	B-X
Laemmli	B-X
sample	B-X
buffer	B-X
containing	B-X
SDS	B-X
before	B-X
separation	B-X
by	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
PAGE	B-X
)	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
the	B-X
analysis	B-X
of	B-X
several	B-X
proteins	B-X
was	B-X
performed	B-X
following	B-X
modifications	B-X
of	B-X
the	B-X
heating	B-X
step	B-X
during	B-X
sample	B-X
preparation	B-X
.	B-X
Multiple	B-X
samples	B-X
of	B-X
the	B-X
human	B-X
Jurkat	B-X
cell	B-X
line	B-X
were	B-X
prepared	B-X
using	B-X
commercial	B-X
or	B-X
homemade	B-X
Laemmli	B-X
sample	B-X
buffer	B-X
.	B-X
Samples	B-X
were	B-X
subjected	B-X
to	B-X
incubation	B-X
at	B-X
different	B-X
temperatures	B-X
for	B-X
varying	B-X
periods	B-X
of	B-X
time	B-X
prior	B-X
to	B-X
separation	B-X
by	B-X
SDS-PAGE	B-X
,	B-X
transfer	B-X
onto	B-X
PVDF	B-X
membranes	B-X
and	B-X
detection	B-X
with	B-X
specific	B-X
antibodies	B-X
.	B-X
In	B-X
samples	B-X
incubated	B-X
at	B-X
temperatures	B-X
of	B-X
25	B-X
°C	B-X
,	B-X
40	B-X
°C	B-X
,	B-X
70	B-X
°C	B-X
and	B-X
100	B-X
°C	B-X
,	B-X
detection	B-X
of	B-X
the	B-X
transmembrane	B-X
protein	B-X
elongase	B-X
of	B-X
long	B-X
chain	B-X
fatty	B-X
acids	B-X
5	B-X
(	B-X
ELOVL5	B-X
)	B-X
significantly	B-X
decreased	B-X
with	B-X
temperature	B-X
to	B-X
a	B-X
near	B-X
total	B-X
absence	B-X
of	B-X
signal	B-X
at	B-X
100	B-X
°C	B-X
.	B-X
Heating	B-X
(	B-X
100	B-X
°C	B-X
)	B-X
the	B-X
samples	B-X
even	B-X
for	B-X
1	B-X
min	B-X
resulted	B-X
in	B-X
significant	B-X
loss	B-X
of	B-X
ELOVL5	B-X
band	B-X
intensity	B-X
that	B-X
was	B-X
associated	B-X
with	B-X
the	B-X
appearance	B-X
of	B-X
higher	B-X
molecular	B-X
weight	B-X
immunoreactive	B-X
materials	B-X
.	B-X
Loss	B-X
of	B-X
ELOVL5	B-X
band	B-X
intensity	B-X
was	B-X
also	B-X
observed	B-X
with	B-X
heating	B-X
of	B-X
samples	B-X
at	B-X
100	B-X
°C	B-X
prepared	B-X
from	B-X
HepG2	B-X
,	B-X
HEK293	B-X
,	B-X
MCF-7	B-X
and	B-X
SKRB	B-X
cells	B-X
.	B-X
The	B-X
robust	B-X
induction	B-X
of	B-X
ELOVL5	B-X
in	B-X
stimulated	B-X
primary	B-X
T	B-X
cells	B-X
was	B-X
not	B-X
detected	B-X
when	B-X
sample	B-X
were	B-X
heated	B-X
.	B-X
The	B-X
detection	B-X
of	B-X
fatty	B-X
acid-metabolizing	B-X
enzymes	B-X
stearoyl-CoA	B-X
desaturase-1	B-X
and	B-X
long-chain-fatty-acid-CoA	B-X
ligases	B-X
3	B-X
and	B-X
4	B-X
showed	B-X
bands	B-X
with	B-X
significantly	B-X
less	B-X
intensity	B-X
after	B-X
heating	B-X
at	B-X
100	B-X
°C	B-X
compared	B-X
to	B-X
samples	B-X
prepared	B-X
at	B-X
room	B-X
temperature	B-X
.	B-X
Heating	B-X
samples	B-X
at	B-X
100	B-X
°C	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
detection	B-X
of	B-X
transmembrane	B-X
proteins	B-X
ERBB2	B-X
and	B-X
five-lipoxygenase	B-X
activating	B-X
protein	B-X
,	B-X
or	B-X
the	B-X
soluble	B-X
5-lipoxygenase	B-X
protein	B-X
.	B-X
Overall	B-X
,	B-X
the	B-X
number	B-X
of	B-X
transmembrane	B-X
passes	B-X
of	B-X
a	B-X
protein	B-X
was	B-X
not	B-X
predictive	B-X
of	B-X
loss	B-X
of	B-X
band	B-X
intensity	B-X
after	B-X
heating	B-X
,	B-X
however	B-X
this	B-X
study	B-X
indicates	B-X
that	B-X
sample	B-X
heating	B-X
can	B-X
drastically	B-X
affect	B-X
the	B-X
ability	B-X
to	B-X
detect	B-X
proteins	B-X
following	B-X
separation	B-X
by	B-X
SDS-PAGE	B-X
.	B-X
This	B-X
has	B-X
implications	B-X
for	B-X
any	B-X
detection	B-X
methods	B-X
that	B-X
follow	B-X
SDS-PAGE	B-X
.	B-X

Foxp3	B-Protein
was	O
detected	O
using	O
rabbit	O
anti	O
-	O
human	O
Foxp3	B-Protein
polyclonal	O
antibody	O
(	O
ab4728	O
or	O
ab10563	O
;	O
Abcam	O
,	O
Cambridge	O
,	O
United	O
Kingdom	O
)	O
and	O
anti	O
-	O
rabbit	O
IgG	O
-	O
HRP	O
secondary	O
antibody	O
(	O
Cell	O
Signaling	O
Technology	O
,	O
Beverly	O
,	O
Massachusetts	O
,	O
United	O
States	O
)	O
.	O
<EOS>	B-X
We	B-X
aimed	B-X
to	B-X
evaluate	B-X
the	B-X
involvement	B-X
of	B-X
baseline	B-X
regulatory	B-X
T	B-X
(	B-X
Treg	B-X
)	B-X
cells	B-X
and	B-X
rabbit	B-X
anti-T	B-X
lymphocyte	B-X
globulin	B-X
(	B-X
rATG	B-X
)	B-X
-induced	B-X
Treg	B-X
cells	B-X
in	B-X
GO	B-X
.	B-X

NF	O
-	O
kappaB	O
p65	B-Protein
and	O
CREB	B-Protein
-	I-Protein
1	I-Protein
were	O
detected	O
using	O
rabbit	O
anti	O
-	O
human	O
polyclonal	O
(	O
p65	B-Protein
)	O
or	O
monoclonal	O
antibody	O
(	O
CREB	B-Protein
-	I-Protein
1	I-Protein
;	O
48H2	O
)	O
(	O
Cell	O
Signaling	O
Technology	O
)	O
.	O
<EOS>	B-X
Trastuzumab	B-X
resistance	B-X
followed	B-X
by	B-X
metastasis	B-X
is	B-X
a	B-X
major	B-X
obstacle	B-X
for	B-X
improving	B-X
the	B-X
clinical	B-X
outcome	B-X
of	B-X
patients	B-X
with	B-X
advanced	B-X
human	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
2-positive	B-X
(	B-X
HER-2+	B-X
)	B-X
breast	B-X
cancer	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
the	B-X
transcriptional	B-X
regulators	B-X
activating	B-X
transcription	B-X
factor-1	B-X
(	B-X
ATF-1	B-X
)	B-X
and	B-X
cAMP-responsive	B-X
element	B-X
(	B-X
CRE	B-X
)	B-X
-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
is	B-X
upregulated	B-X
in	B-X
metastatic	B-X
melanoma	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
how	B-X
overexpression	B-X
of	B-X
ATF-1/CREB	B-X
contributes	B-X
to	B-X
the	B-X
acquisition	B-X
of	B-X
the	B-X
metastatic	B-X
phenotype	B-X
is	B-X
unclear	B-X
.	B-X
Monoclonal	B-X
antibodies	B-X
against	B-X
ATF-1	B-X
have	B-X
previously	B-X
been	B-X
used	B-X
to	B-X
inhibit	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
ATF-1	B-X
and	B-X
its	B-X
associated	B-X
proteins	B-X
.	B-X
Here	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
disrupting	B-X
ATF-1	B-X
activity	B-X
was	B-X
investigated	B-X
using	B-X
intracellular	B-X
expression	B-X
of	B-X
an	B-X
inhibitory	B-X
anti-ATF-1	B-X
single	B-X
chain	B-X
antibody	B-X
fragment	B-X
(	B-X
ScFv	B-X
)	B-X
.	B-X
Intracellular	B-X
expression	B-X
of	B-X
ScFv	B-X
anti-ATF-1	B-X
in	B-X
human	B-X
melanoma	B-X
cells	B-X
caused	B-X
significant	B-X
reduction	B-X
in	B-X
CRE-dependent	B-X
promoter	B-X
activation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
expression	B-X
of	B-X
ScFv	B-X
anti-ATF-1	B-X
in	B-X
melanoma	B-X
cells	B-X
suppressed	B-X
their	B-X
tumorigenicity	B-X
and	B-X
metastatic	B-X
potential	B-X
in	B-X
nude	B-X
mice	B-X
.	B-X
Furthermore	B-X
,	B-X
expression	B-X
of	B-X
ScFv	B-X
anti-ATF-1	B-X
rendered	B-X
the	B-X
melanoma	B-X
cells	B-X
susceptible	B-X
to	B-X
thapsigargin-induced	B-X
apoptosis	B-X
in	B-X
vitro	B-X
and	B-X
caused	B-X
massive	B-X
apoptosis	B-X
in	B-X
vivo	B-X
in	B-X
tumors	B-X
transplanted	B-X
subcutaneously	B-X
into	B-X
nude	B-X
mice	B-X
.	B-X
These	B-X
studies	B-X
demonstrate	B-X
the	B-X
potential	B-X
usage	B-X
of	B-X
ScFv	B-X
anti-ATF-1	B-X
as	B-X
an	B-X
inhibitor	B-X
of	B-X
tumor	B-X
growth	B-X
and	B-X
metastasis	B-X
of	B-X
solid	B-X
tumors	B-X
overexpressing	B-X
ATF-1/CREB	B-X
.	B-X

Beta	B-Protein
-	I-Protein
actin	I-Protein
was	O
detected	O
using	O
a	O
mouse	O
monoclonal	O
antibody	O
(	O
AC	O
-	O
15	O
;	O
Sigma	O
,	O
St	O
.	O
Louis	O
,	O
Missouri	O
,	O
United	O
States	O
)	O
.	O

For	O
coimmunoprecipitation	O
analysis	O
,	O
cell	O
lysates	O
were	O
precleared	O
with	O
30	O
mul	O
of	O
protein	O
A	O
/	O
G	O
plus	O
-	O
agarose	O
beads	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
California	O
,	O
United	O
States	O
)	O
and	O
then	O
incubated	O
with	O
mouse	O
monoclonal	O
anti	O
-	O
HA	O
antibody	O
(	O
6E2	O
;	O
1	O
:	O
100	O
;	O
Cell	O
Signaling	O
Technology	O
)	O
and	O
30	O
mul	O
of	O
protein	O
A	O
/	O
G	O
plus	O
-	O
agarose	O
beads	O
overnight	O
.	O

The	O
immunoprecipitates	O
were	O
washed	O
four	O
times	O
with	O
RIPA	O
buffer	O
,	O
resuspended	O
in	O
SDS	O
sample	O
buffer	O
,	O
and	O
heated	O
at	O
95	O
degreesC	O
for	O
5	O
min	O
.	O

Proteins	O
were	O
then	O
treated	O
as	O
described	O
for	O
Western	O
blot	O
analysis	O
.	O
<EOS>	B-X
Western	B-X
blotting	B-X
is	B-X
an	B-X
excellent	B-X
technique	B-X
to	B-X
investigate	B-X
aberrations	B-X
and/or	B-X
therapy-induced	B-X
changes	B-X
in	B-X
signaling	B-X
proteins	B-X
in	B-X
cancer	B-X
.	B-X
Using	B-X
an	B-X
in	B-X
vitro	B-X
system	B-X
,	B-X
we	B-X
prepared	B-X
whole	B-X
cell	B-X
lysates	B-X
from	B-X
HER2-overexpressing	B-X
breast	B-X
cancer	B-X
cell	B-X
lines	B-X
,	B-X
treated	B-X
or	B-X
not	B-X
with	B-X
the	B-X
tyrosine	B-X
kinase	B-X
inhibitor	B-X
,	B-X
lapatinib	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
and	B-X
absence	B-X
of	B-X
IFN-γ	B-X
.	B-X
Herein	B-X
,	B-X
Western	B-X
blot	B-X
analysis	B-X
confirmed	B-X
lapatinib	B-X
dephosphorylated	B-X
HER2	B-X
and	B-X
downstream	B-X
signaling	B-X
proteins	B-X
and	B-X
IFN-γ	B-X
induced	B-X
phosphorylation	B-X
of	B-X
STAT1	B-X
.	B-X
These	B-X
antibodies	B-X
bind	B-X
to	B-X
proteins	B-X
labeled	B-X
with	B-X
IAM	B-X
(	B-X
but	B-X
not	B-X
N-ethylmaleimide	B-X
(	B-X
NEM	B-X
)	B-X
or	B-X
acrylamide	B-X
)	B-X
and	B-X
identify	B-X
multiple	B-X
protein	B-X
bands	B-X
when	B-X
applied	B-X
to	B-X
Western	B-X
blots	B-X
of	B-X
cell	B-X
lysates	B-X
treated	B-X
with	B-X
IAM	B-X
.	B-X

Transcription	O
factor	O
DNA	O
-	O
binding	O
analysis	O
(	O
TF	O
-	O
ELISA	O
)	O
.	O
<EOS>	B-X
DNA-binding	B-X
transcription	B-X
factors	B-X
(	B-X
TFs	B-X
)	B-X
have	B-X
been	B-X
identified	B-X
as	B-X
essential	B-X
factors	B-X
during	B-X
gene	B-X
transcription	B-X
.	B-X
Better	B-X
insight	B-X
into	B-X
the	B-X
TFs	B-X
that	B-X
regulate	B-X
macrophage	B-X
polarization	B-X
could	B-X
provide	B-X
novel	B-X
therapeutic	B-X
targets	B-X
.	B-X
Differential	B-X
gene	B-X
expression	B-X
is	B-X
tightly	B-X
controlled	B-X
by	B-X
transcription	B-X
factors	B-X
(	B-X
TFs	B-X
)	B-X
,	B-X
which	B-X
bind	B-X
close	B-X
to	B-X
target	B-X
genes	B-X
and	B-X
interact	B-X
together	B-X
to	B-X
activate	B-X
and	B-X
coregulate	B-X
transcription	B-X
.	B-X
Bioinformatics	B-X
analysis	B-X
of	B-X
published	B-X
genome-wide	B-X
gene	B-X
expression	B-X
data	B-X
has	B-X
allowed	B-X
the	B-X
development	B-X
of	B-X
comprehensive	B-X
models	B-X
of	B-X
TFs	B-X
likely	B-X
to	B-X
be	B-X
active	B-X
in	B-X
particular	B-X
tissues	B-X
(	B-X
signature	B-X
TFs	B-X
)	B-X
;	B-X
however	B-X
,	B-X
the	B-X
predicted	B-X
activities	B-X
of	B-X
many	B-X
of	B-X
the	B-X
TFs	B-X
have	B-X
not	B-X
been	B-X
experimentally	B-X
confirmed	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
methods	B-X
for	B-X
the	B-X
parallel	B-X
analysis	B-X
of	B-X
the	B-X
activities	B-X
of	B-X
more	B-X
than	B-X
200	B-X
transcription	B-X
factor	B-X
proteins	B-X
,	B-X
using	B-X
an	B-X
advanced	B-X
oligonucleotide	B-X
array-based	B-X
transcription	B-X
factor	B-X
assay	B-X
(	B-X
OATFA	B-X
)	B-X
platform	B-X
,	B-X
to	B-X
assay	B-X
TF	B-X
activities	B-X
in	B-X
mice	B-X
.	B-X
The	B-X
system	B-X
uses	B-X
a	B-X
PCR-based	B-X
system	B-X
to	B-X
translate	B-X
cellular	B-X
levels	B-X
of	B-X
target	B-X
DNA-TF	B-X
complex	B-X
into	B-X
a	B-X
dye-tagged	B-X
DNA	B-X
signal	B-X
,	B-X
which	B-X
is	B-X
read	B-X
by	B-X
the	B-X
developed	B-X
microarray	B-X
.	B-X
The	B-X
PCR	B-X
step	B-X
introduces	B-X
semiquantitative	B-X
amplification	B-X
of	B-X
the	B-X
represented	B-X
TF	B-X
binding	B-X
sequences	B-X
.	B-X
Experimental	B-X
OATFA	B-X
findings	B-X
can	B-X
identify	B-X
many	B-X
TF	B-X
activities	B-X
,	B-X
which	B-X
bioinformatics	B-X
profiling	B-X
does	B-X
not	B-X
predict	B-X
.	B-X
Newly	B-X
identified	B-X
TF	B-X
activities	B-X
can	B-X
be	B-X
confirmed	B-X
by	B-X
antibody-ELISA	B-X
against	B-X
active	B-X
TFs	B-X
.	B-X
The	B-X
PCR-based	B-X
OATFA	B-X
microarray	B-X
analysis	B-X
is	B-X
a	B-X
comprehensive	B-X
method	B-X
that	B-X
can	B-X
be	B-X
used	B-X
to	B-X
reveal	B-X
transcriptional	B-X
systems	B-X
and	B-X
pathways	B-X
which	B-X
may	B-X
function	B-X
in	B-X
different	B-X
mammalian	B-X
tissues	B-X
and	B-X
cells	B-X
.	B-X

CREB	B-Protein
-	I-Protein
1	I-Protein
and	O
ATF	B-Protein
-	I-Protein
2	I-Protein
DNA	O
-	O
binding	O
activity	O
was	O
analyzed	O
with	O
the	O
TransFactor	O
Profiling	O
(	O
Inflammation	O
1	O
)	O
Kit	O
(	O
BD	O
Biosciences	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Nuclear	O
extracts	O
were	O
prepared	O
from	O
HEK	O
293T	O
cells	O
transfected	O
with	O
a	O
control	O
vector	O
(	O
EGFP	O
)	O
or	O
Foxp3	B-Protein
expression	O
vector	O
(	O
1	O
,	O
000	O
ng	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
forskolin	O
(	O
10	O
muM	O
for	O
4	O
h	O
)	O
using	O
the	O
TransFactor	O
Extraction	O
Kit	O
(	O
BD	O
Biosciences	O
)	O
.	O

Protein	O
concentration	O
was	O
determined	O
using	O
a	O
Biophotometer	O
(	O
Eppendorf	O
,	O
Hamburg	O
,	O
Germany	O
)	O
.	O

Nuclear	O
extracts	O
(	O
20	O
mug	O
)	O
were	O
incubated	O
in	O
preblocked	O
wells	O
containing	O
plate	O
-	O
bound	O
double	O
-	O
stranded	O
oligonucleotides	O
corresponding	O
to	O
an	O
ATF	O
/	O
CREB	O
consensus	O
sequence	O
(	O
.	O
.	O
.	O
TGACATCA	O
.	O
.	O
.	O
)	O
.	O

Wells	O
were	O
washed	O
,	O
incubated	O
with	O
the	O
appropriate	O
primary	O
antibody	O
,	O
washed	O
,	O
incubated	O
with	O
secondary	O
antibody	O
(	O
HRP	O
-	O
labeled	O
)	O
,	O
washed	O
again	O
,	O
and	O
finally	O
developed	O
with	O
TMB	O
substrate	O
.	O

Colorimetric	O
reactions	O
were	O
read	O
using	O
a	O
VersaMax	O
microplate	O
reader	O
(	O
Molecular	O
Devices	O
)	O
at	O
an	O
absorbance	O
of	O
655	O
nm	O
.	O

Flow	O
cytometric	O
analysis	O
of	O
Foxp3	B-Protein
protein	O
expression	O
.	O
<EOS>	B-X
IL-21	B-X
Induces	B-X
an	B-X
Imbalance	B-X
of	B-X
Th17/Treg	B-X
Cells	B-X
in	B-X
Moderate-to-Severe	B-X
Plaque	B-X
Psoriasis	B-X
Patients	B-X
.	B-X
CMT167	B-X
subcutaneous	B-X
tumors	B-X
had	B-X
more	B-X
Foxp3	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
monitored	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
in	B-X
bovine	B-X
leukemia	B-X
virus	B-X
(	B-X
BLV	B-X
)	B-X
-infected	B-X
cattle	B-X
.	B-X
By	B-X
flow	B-X
cytometric	B-X
analysis	B-X
,	B-X
the	B-X
proportion	B-X
of	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
from	B-X
persistent	B-X
lymphocytotic	B-X
cattle	B-X
was	B-X
significantly	B-X
increased	B-X
compared	B-X
to	B-X
control	B-X
and	B-X
AL	B-X
cattle	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
proportion	B-X
of	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
correlated	B-X
positively	B-X
with	B-X
the	B-X
increased	B-X
number	B-X
of	B-X
lymphocytes	B-X
,	B-X
virus	B-X
titer	B-X
and	B-X
virus	B-X
load	B-X
,	B-X
whereas	B-X
it	B-X
inversely	B-X
correlated	B-X
with	B-X
IFN-γ	B-X
mRNA	B-X
expression	B-X
,	B-X
suggesting	B-X
that	B-X
Foxp3	B-X
(	B-X
+	B-X
)	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
in	B-X
cattle	B-X
have	B-X
a	B-X
potentially	B-X
immunosuppressive	B-X
function	B-X
.	B-X

Cryopreserved	O
PBMCs	O
from	O
HAM	O
/	O
TSP	O
patients	O
or	O
HTLV	O
-	O
I	O
-	O
infected	O
ACs	O
were	O
thawed	O
and	O
washed	O
with	O
FACS	O
buffer	O
(	O
1x	O
PBS	O
,	O
0	O
.	O
1	O
%	O
NaN3	O
,	O
5	O
%	O
FBS	O
)	O
.	O

Cells	O
(	O
1	O
.	O
5	O
x	O
106	O
)	O
were	O
fixed	O
by	O
sequential	O
formaldehyde	O
/	O
methanol	O
fixation	O
as	O
follows	O
.	O

Cells	O
were	O
carefully	O
resuspended	O
in	O
FACS	O
buffer	O
and	O
fixed	O
with	O
100	O
mul	O
of	O
reagent	O
A	O
(	O
Fix	O
&	O
Perm	O
kit	O
;	O
Caltag	O
Laboratories	O
,	O
Burlingame	O
,	O
California	O
,	O
United	O
States	O
)	O
at	O
room	O
temperature	O
for	O
3	O
min	O
followed	O
by	O
2	O
ml	O
of	O
70	O
%	O
methanol	O
for	O
5	O
min	O
at	O
4	O
degreesC	O
.	O

Cells	O
were	O
washed	O
twice	O
and	O
permeabilized	O
with	O
100	O
mul	O
of	O
reagent	O
B	O
(	O
Fix	O
&	O
Perm	O
kit	O
)	O
and	O
stained	O
for	O
intracellular	O
Foxp3	B-Protein
with	O
mouse	O
anti	O
-	O
human	O
Foxp3	B-Protein
monoclonal	O
antibody	O
(	O
0	O
.	O
5	O
mug	O
of	O
ab22510	O
;	O
Abcam	O
)	O
or	O
the	O
appropriate	O
isotype	O
control	O
for	O
30	O
min	O
.	O

Cells	O
were	O
washed	O
twice	O
and	O
stained	O
with	O
Cy5	O
-	O
conjugated	O
goat	O
anti	O
-	O
mouse	O
immunoglobulin	O
F	O
(	O
ab	O
'	O
)	O
2	O
secondary	O
antibody	O
(	O
Caltag	O
Laboratories	O
)	O
for	O
an	O
additional	O
30	O
min	O
.	O

Cells	O
were	O
washed	O
twice	O
and	O
stained	O
for	O
surface	O
CD4	B-Protein
expression	O
with	O
PE	O
-	O
labeled	O
anti	O
-	O
CD4	B-Protein
(	O
BD	O
)	O
and	O
CD25	B-Protein
expression	O
with	O
FITC	O
-	O
labeled	O
anti	O
-	O
CD25	B-Protein
(	O
BD	O
)	O
.	O

Cells	O
were	O
washed	O
twice	O
and	O
analyzed	O
on	O
a	O
FACSCalibur	O
(	O
BD	O
)	O
.	O

Data	O
analysis	O
was	O
performed	O
using	O
FlowJo	O
(	O
Tree	O
Star	O
,	O
Ashland	O
,	O
Oregon	O
,	O
United	O
States	O
)	O
.	O

Statistical	O
analyses	O
.	O
<EOS>	B-X
Publications	B-X
of	B-X
subgroup	B-X
analyses	B-X
turned	B-X
out	B-X
to	B-X
be	B-X
prevalent	B-X
,	B-X
and	B-X
more	B-X
importantly	B-X
,	B-X
these	B-X
findings	B-X
play	B-X
a	B-X
significant	B-X
role	B-X
in	B-X
strategic	B-X
planning	B-X
and	B-X
decision-making	B-X
processes	B-X
.	B-X
We	B-X
furthermore	B-X
discuss	B-X
the	B-X
concept	B-X
of	B-X
subgroup	B-X
analysis	B-X
;	B-X
the	B-X
motivation	B-X
for	B-X
assessing	B-X
subgroups	B-X
;	B-X
the	B-X
types	B-X
of	B-X
subgroup	B-X
analyses	B-X
and	B-X
the	B-X
paradigm	B-X
of	B-X
hypothesis-generating	B-X
research	B-X
;	B-X
the	B-X
proper	B-X
statistical	B-X
methods	B-X
for	B-X
the	B-X
examination	B-X
of	B-X
subgroup	B-X
effects	B-X
;	B-X
and	B-X
the	B-X
optimal	B-X
approach	B-X
for	B-X
interpretation	B-X
of	B-X
results	B-X
.	B-X
Finally	B-X
,	B-X
this	B-X
review	B-X
establishes	B-X
the	B-X
comprehensive	B-X
users	B-X
'	B-X
guide	B-X
for	B-X
analysing	B-X
and	B-X
reporting	B-X
subgroup	B-X
studies	B-X
on	B-X
a	B-X
point-by-point	B-X
basis	B-X
,	B-X
using	B-X
real-world	B-X
examples	B-X
that	B-X
may	B-X
help	B-X
readers	B-X
to	B-X
gain	B-X
experience	B-X
to	B-X
pursue	B-X
their	B-X
own	B-X
subgroup	B-X
analyses	B-X
or	B-X
interpret	B-X
those	B-X
of	B-X
others	B-X
.	B-X
Over	B-X
the	B-X
past	B-X
decade	B-X
,	B-X
limma	B-X
has	B-X
been	B-X
a	B-X
popular	B-X
choice	B-X
for	B-X
gene	B-X
discovery	B-X
through	B-X
differential	B-X
expression	B-X
analyses	B-X
of	B-X
microarray	B-X
and	B-X
high-throughput	B-X
PCR	B-X
data	B-X
.	B-X
First	B-X
,	B-X
the	B-X
package	B-X
can	B-X
now	B-X
perform	B-X
both	B-X
differential	B-X
expression	B-X
and	B-X
differential	B-X
splicing	B-X
analyses	B-X
of	B-X
RNA	B-X
sequencing	B-X
(	B-X
RNA-seq	B-X
)	B-X
data	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
package	B-X
is	B-X
now	B-X
able	B-X
to	B-X
go	B-X
past	B-X
the	B-X
traditional	B-X
gene-wise	B-X
expression	B-X
analyses	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
ways	B-X
,	B-X
analysing	B-X
expression	B-X
profiles	B-X
in	B-X
terms	B-X
of	B-X
co-regulated	B-X
sets	B-X
of	B-X
genes	B-X
or	B-X
in	B-X
terms	B-X
of	B-X
higher-order	B-X
expression	B-X
signatures	B-X
.	B-X

The	O
Mann	O
-	O
Whitney	O
U	O
test	O
was	O
used	O
to	O
compare	O
the	O
data	O
between	O
patients	O
with	O
HAM	O
/	O
TSP	O
and	O
AC	O
.	O

EBV	O
Latent	B-Protein
Membrane	I-Protein
Protein	I-Protein
1	I-Protein
Activates	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
in	O
B	O
Cell	O
Lymphomas	O

Latent	B-Protein
membrane	I-Protein
protein	I-Protein
1	I-Protein
(	O
LMP1	B-Protein
)	O
is	O
the	O
major	O
oncoprotein	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
.	O
<EOS>	B-X
Nasopharyngeal	B-X
carcinoma	B-X
(	B-X
NPC	B-X
)	B-X
,	B-X
also	B-X
named	B-X
the	B-X
Cantonese	B-X
cancer	B-X
,	B-X
is	B-X
a	B-X
unique	B-X
cancer	B-X
with	B-X
strong	B-X
etiological	B-X
association	B-X
with	B-X
infection	B-X
of	B-X
the	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
.	B-X
With	B-X
particularly	B-X
high	B-X
prevalence	B-X
in	B-X
Southeast	B-X
Asia	B-X
,	B-X
the	B-X
involvement	B-X
of	B-X
EBV	B-X
and	B-X
genetic	B-X
aberrations	B-X
contributive	B-X
to	B-X
NPC	B-X
tumorigenesis	B-X
have	B-X
remained	B-X
unclear	B-X
for	B-X
decades	B-X
.	B-X
Recently	B-X
,	B-X
genomic	B-X
analysis	B-X
of	B-X
NPC	B-X
has	B-X
defined	B-X
it	B-X
as	B-X
a	B-X
genetically	B-X
homogeneous	B-X
cancer	B-X
,	B-X
driven	B-X
largely	B-X
by	B-X
NF-κB	B-X
signaling	B-X
caused	B-X
by	B-X
either	B-X
somatic	B-X
aberrations	B-X
of	B-X
NF-κB	B-X
negative	B-X
regulators	B-X
or	B-X
by	B-X
overexpression	B-X
of	B-X
the	B-X
latent	B-X
membrane	B-X
protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
,	B-X
an	B-X
EBV	B-X
viral	B-X
oncoprotein	B-X
.	B-X
Exome	B-X
and	B-X
RNA	B-X
sequencing	B-X
data	B-X
from	B-X
new	B-X
EBV-positive	B-X
NPC	B-X
models	B-X
also	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
PI3K	B-X
pathway	B-X
aberrations	B-X
in	B-X
NPC	B-X
.	B-X
Our	B-X
next	B-X
decade	B-X
of	B-X
NPC	B-X
research	B-X
should	B-X
focus	B-X
on	B-X
further	B-X
identification	B-X
of	B-X
the	B-X
-omic	B-X
landscapes	B-X
of	B-X
recurrent	B-X
and	B-X
metastatic	B-X
NPC	B-X
,	B-X
development	B-X
of	B-X
gene-based	B-X
precision	B-X
medicines	B-X
,	B-X
as	B-X
well	B-X
as	B-X
large-scale	B-X
drug	B-X
screening	B-X
with	B-X
the	B-X
newly	B-X
developed	B-X
and	B-X
well-characterized	B-X
EBV-positive	B-X
NPC	B-X
models	B-X
.	B-X
Focused	B-X
preclinical	B-X
and	B-X
clinical	B-X
investigations	B-X
on	B-X
these	B-X
major	B-X
directions	B-X
may	B-X
identify	B-X
new	B-X
and	B-X
effective	B-X
targeting	B-X
strategies	B-X
to	B-X
further	B-X
improve	B-X
survival	B-X
of	B-X
NPC	B-X
patients	B-X
.	B-X

In	O
transgenic	O
mice	O
,	O
LMP1	B-Protein
promotes	O
increased	O
lymphoma	O
development	O
by	O
12	O
mo	O
of	O
age	O
.	O
<EOS>	B-X
Latent	B-X
membrane	B-X
protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
is	B-X
the	B-X
major	B-X
oncoprotein	B-X
of	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
.	B-X
In	B-X
transgenic	B-X
mice	B-X
,	B-X
LMP1	B-X
promotes	B-X
increased	B-X
lymphoma	B-X
development	B-X
by	B-X
12	B-X
mo	B-X
of	B-X
age	B-X
.	B-X
This	B-X
study	B-X
reveals	B-X
that	B-X
lymphoma	B-X
develops	B-X
in	B-X
B-1a	B-X
lymphocytes	B-X
,	B-X
a	B-X
population	B-X
that	B-X
is	B-X
associated	B-X
with	B-X
transformation	B-X
in	B-X
older	B-X
mice	B-X
.	B-X
The	B-X
lymphoma	B-X
cells	B-X
have	B-X
deregulated	B-X
cell	B-X
cycle	B-X
markers	B-X
,	B-X
and	B-X
inhibitors	B-X
of	B-X
Akt	B-X
,	B-X
NFkappaB	B-X
,	B-X
and	B-X
Stat3	B-X
block	B-X
the	B-X
enhanced	B-X
viability	B-X
of	B-X
LMP1	B-X
transgenic	B-X
lymphocytes	B-X
and	B-X
lymphoma	B-X
cells	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
same	B-X
targets	B-X
are	B-X
also	B-X
deregulated	B-X
in	B-X
wild-type	B-X
B-1a	B-X
lymphomas	B-X
that	B-X
arise	B-X
spontaneously	B-X
through	B-X
age	B-X
predisposition	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Akt	B-X
,	B-X
NFkappaB	B-X
,	B-X
and	B-X
Stat3	B-X
pathways	B-X
may	B-X
serve	B-X
as	B-X
effective	B-X
targets	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
EBV-associated	B-X
B	B-X
cell	B-X
lymphomas	B-X
.	B-X

This	O
study	O
reveals	O
that	O
lymphoma	O
develops	O
in	O
B	O
-	O
1a	O
lymphocytes	O
,	O
a	O
population	O
that	O
is	O
associated	O
with	O
transformation	O
in	O
older	O
mice	O
.	O

The	O
lymphoma	O
cells	O
have	O
deregulated	O
cell	O
cycle	O
markers	O
,	O
and	O
inhibitors	O
of	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
block	O
the	O
enhanced	O
viability	O
of	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
in	O
vitro	O
.	O
<EOS>	B-X
Latent	B-X
membrane	B-X
protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
is	B-X
the	B-X
major	B-X
oncoprotein	B-X
of	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
.	B-X
In	B-X
transgenic	B-X
mice	B-X
,	B-X
LMP1	B-X
promotes	B-X
increased	B-X
lymphoma	B-X
development	B-X
by	B-X
12	B-X
mo	B-X
of	B-X
age	B-X
.	B-X
This	B-X
study	B-X
reveals	B-X
that	B-X
lymphoma	B-X
develops	B-X
in	B-X
B-1a	B-X
lymphocytes	B-X
,	B-X
a	B-X
population	B-X
that	B-X
is	B-X
associated	B-X
with	B-X
transformation	B-X
in	B-X
older	B-X
mice	B-X
.	B-X
The	B-X
lymphoma	B-X
cells	B-X
have	B-X
deregulated	B-X
cell	B-X
cycle	B-X
markers	B-X
,	B-X
and	B-X
inhibitors	B-X
of	B-X
Akt	B-X
,	B-X
NFkappaB	B-X
,	B-X
and	B-X
Stat3	B-X
block	B-X
the	B-X
enhanced	B-X
viability	B-X
of	B-X
LMP1	B-X
transgenic	B-X
lymphocytes	B-X
and	B-X
lymphoma	B-X
cells	B-X
in	B-X
vitro	B-X
.	B-X
Lymphoma	B-X
cells	B-X
are	B-X
independent	B-X
of	B-X
IL4/Stat6	B-X
signaling	B-X
for	B-X
survival	B-X
and	B-X
proliferation	B-X
,	B-X
but	B-X
have	B-X
constitutively	B-X
activated	B-X
Stat3	B-X
signaling	B-X
.	B-X
These	B-X
same	B-X
targets	B-X
are	B-X
also	B-X
deregulated	B-X
in	B-X
wild-type	B-X
B-1a	B-X
lymphomas	B-X
that	B-X
arise	B-X
spontaneously	B-X
through	B-X
age	B-X
predisposition	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Akt	B-X
,	B-X
NFkappaB	B-X
,	B-X
and	B-X
Stat3	B-X
pathways	B-X
may	B-X
serve	B-X
as	B-X
effective	B-X
targets	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
EBV-associated	B-X
B	B-X
cell	B-X
lymphomas	B-X
.	B-X

Lymphoma	O
cells	O
are	O
independent	O
of	O
IL4	B-Protein
/	O
Stat6	B-Protein
signaling	O
for	O
survival	O
and	O
proliferation	O
,	O
but	O
have	O
constitutively	O
activated	O
Stat3	B-Protein
signaling	O
.	O
<EOS>	B-X
The	B-X
lymphoma	B-X
cells	B-X
have	B-X
deregulated	B-X
cell	B-X
cycle	B-X
markers	B-X
,	B-X
and	B-X
inhibitors	B-X
of	B-X
Akt	B-X
,	B-X
NFkappaB	B-X
,	B-X
and	B-X
Stat3	B-X
block	B-X
the	B-X
enhanced	B-X
viability	B-X
of	B-X
LMP1	B-X
transgenic	B-X
lymphocytes	B-X
and	B-X
lymphoma	B-X
cells	B-X
in	B-X
vitro	B-X
.	B-X
Lymphoma	B-X
cells	B-X
are	B-X
independent	B-X
of	B-X
IL4/Stat6	B-X
signaling	B-X
for	B-X
survival	B-X
and	B-X
proliferation	B-X
,	B-X
but	B-X
have	B-X
constitutively	B-X
activated	B-X
Stat3	B-X
signaling	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Akt	B-X
,	B-X
NFkappaB	B-X
,	B-X
and	B-X
Stat3	B-X
pathways	B-X
may	B-X
serve	B-X
as	B-X
effective	B-X
targets	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
EBV-associated	B-X
B	B-X
cell	B-X
lymphomas	B-X
.	B-X

These	O
same	O
targets	O
are	O
also	O
deregulated	O
in	O
wild	O
-	O
type	O
B	O
-	O
1a	O
lymphomas	O
that	O
arise	O
spontaneously	O
through	O
age	O
predisposition	O
.	O
<EOS>	B-X
Latent	B-X
membrane	B-X
protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
is	B-X
the	B-X
major	B-X
oncoprotein	B-X
of	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
.	B-X
In	B-X
transgenic	B-X
mice	B-X
,	B-X
LMP1	B-X
promotes	B-X
increased	B-X
lymphoma	B-X
development	B-X
by	B-X
12	B-X
mo	B-X
of	B-X
age	B-X
.	B-X
This	B-X
study	B-X
reveals	B-X
that	B-X
lymphoma	B-X
develops	B-X
in	B-X
B-1a	B-X
lymphocytes	B-X
,	B-X
a	B-X
population	B-X
that	B-X
is	B-X
associated	B-X
with	B-X
transformation	B-X
in	B-X
older	B-X
mice	B-X
.	B-X
The	B-X
lymphoma	B-X
cells	B-X
have	B-X
deregulated	B-X
cell	B-X
cycle	B-X
markers	B-X
,	B-X
and	B-X
inhibitors	B-X
of	B-X
Akt	B-X
,	B-X
NFkappaB	B-X
,	B-X
and	B-X
Stat3	B-X
block	B-X
the	B-X
enhanced	B-X
viability	B-X
of	B-X
LMP1	B-X
transgenic	B-X
lymphocytes	B-X
and	B-X
lymphoma	B-X
cells	B-X
in	B-X
vitro	B-X
.	B-X
These	B-X
same	B-X
targets	B-X
are	B-X
also	B-X
deregulated	B-X
in	B-X
wild-type	B-X
B-1a	B-X
lymphomas	B-X
that	B-X
arise	B-X
spontaneously	B-X
through	B-X
age	B-X
predisposition	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Akt	B-X
,	B-X
NFkappaB	B-X
,	B-X
and	B-X
Stat3	B-X
pathways	B-X
may	B-X
serve	B-X
as	B-X
effective	B-X
targets	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
EBV-associated	B-X
B	B-X
cell	B-X
lymphomas	B-X
.	B-X

These	O
results	O
suggest	O
that	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
pathways	O
may	O
serve	O
as	O
effective	O
targets	O
in	O
the	O
treatment	O
of	O
EBV	O
-	O
associated	O
B	O
cell	O
lymphomas	O
.	O
<EOS>	B-X
Latent	B-X
membrane	B-X
protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
is	B-X
the	B-X
major	B-X
oncoprotein	B-X
of	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
.	B-X
This	B-X
study	B-X
reveals	B-X
that	B-X
lymphoma	B-X
develops	B-X
in	B-X
B-1a	B-X
lymphocytes	B-X
,	B-X
a	B-X
population	B-X
that	B-X
is	B-X
associated	B-X
with	B-X
transformation	B-X
in	B-X
older	B-X
mice	B-X
.	B-X
The	B-X
lymphoma	B-X
cells	B-X
have	B-X
deregulated	B-X
cell	B-X
cycle	B-X
markers	B-X
,	B-X
and	B-X
inhibitors	B-X
of	B-X
Akt	B-X
,	B-X
NFkappaB	B-X
,	B-X
and	B-X
Stat3	B-X
block	B-X
the	B-X
enhanced	B-X
viability	B-X
of	B-X
LMP1	B-X
transgenic	B-X
lymphocytes	B-X
and	B-X
lymphoma	B-X
cells	B-X
in	B-X
vitro	B-X
.	B-X
Lymphoma	B-X
cells	B-X
are	B-X
independent	B-X
of	B-X
IL4/Stat6	B-X
signaling	B-X
for	B-X
survival	B-X
and	B-X
proliferation	B-X
,	B-X
but	B-X
have	B-X
constitutively	B-X
activated	B-X
Stat3	B-X
signaling	B-X
.	B-X
These	B-X
same	B-X
targets	B-X
are	B-X
also	B-X
deregulated	B-X
in	B-X
wild-type	B-X
B-1a	B-X
lymphomas	B-X
that	B-X
arise	B-X
spontaneously	B-X
through	B-X
age	B-X
predisposition	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Akt	B-X
,	B-X
NFkappaB	B-X
,	B-X
and	B-X
Stat3	B-X
pathways	B-X
may	B-X
serve	B-X
as	B-X
effective	B-X
targets	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
EBV-associated	B-X
B	B-X
cell	B-X
lymphomas	B-X
.	B-X

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
a	O
ubiquitous	O
gamma	O
-	O
herpesvirus	O
that	O
infects	O
humans	O
predominantly	O
at	O
an	O
early	O
age	O
with	O
greater	O
than	O
90	O
%	O
of	O
the	O
adult	O
population	O
infected	O
with	O
EBV	O
[	O
1	O
]	O
.	O

EBV	O
is	O
linked	O
to	O
the	O
development	O
of	O
both	O
B	O
lymphocyte	O
and	O
epithelial	O
cell	O
malignancies	O
,	O
including	O
Burkitt	O
lymphoma	O
,	O
Hodgkin	O
disease	O
(	O
HD	O
)	O
,	O
and	O
nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
,	O
and	O
cancers	O
linked	O
to	O
immunosuppression	O
,	O
including	O
post	O
-	O
transplant	O
lymphoma	O
and	O
AIDS	O
-	O
associated	O
lymphomas	O
[	O
2	O
,	O
3	O
]	O
.	O

In	O
vitro	O
infection	O
of	O
B	O
lymphocytes	O
with	O
EBV	O
induces	O
permanent	O
growth	O
transformation	O
,	O
and	O
this	O
ability	O
to	O
affect	O
cell	O
growth	O
regulation	O
likely	O
contributes	O
to	O
the	O
development	O
of	O
cancer	O
.	O

Many	O
of	O
the	O
viral	O
proteins	O
expressed	O
in	O
transformed	O
cells	O
,	O
including	O
the	O
EBV	O
nuclear	O
antigens	O
and	O
latent	O
membrane	O
proteins	O
,	O
have	O
profound	O
effects	O
on	O
cell	O
growth	O
regulation	O
and	O
are	O
required	O
for	O
EBV	O
latent	O
infection	O
and	O
B	O
cell	O
transformation	O
[	O
1	O
]	O
.	O

Latent	B-Protein
membrane	I-Protein
protein	I-Protein
1	I-Protein
(	O
LMP1	B-Protein
)	O
is	O
considered	O
the	O
major	O
oncoprotein	O
of	O
EBV	O
,	O
as	O
it	O
transforms	O
rodent	O
fibroblasts	O
to	O
tumorigenicity	O
in	O
nude	O
mice	O
and	O
is	O
expressed	O
in	O
HD	O
,	O
NPC	O
,	O
and	O
immunosuppression	O
-	O
associated	O
tumors	O
[	O
4	O
-	O
8	O
]	O
.	O

In	O
B	O
lymphocytes	O
,	O
LMP1	B-Protein
mimics	O
CD40	B-Protein
signaling	O
,	O
and	O
both	O
LMP1	B-Protein
and	O
CD40	B-Protein
are	O
essential	O
for	O
EBV	O
-	O
mediated	O
B	O
cell	O
transformation	O
[	O
9	O
-	O
11	O
]	O
.	O

While	O
CD40	B-Protein
interacts	O
with	O
CD40	B-Protein
ligand	I-Protein
expressed	O
on	O
activated	O
T	O
cells	O
to	O
induce	O
B	O
cell	O
activation	O
and	O
differentiation	O
,	O
LMP1	B-Protein
acts	O
as	O
a	O
constitutive	O
signal	O
through	O
ligand	O
-	O
independent	O
oligomerization	O
.	O

LMP1	B-Protein
and	O
CD40	B-Protein
interact	O
with	O
the	O
same	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
receptor	O
-	O
associated	O
factors	O
(	O
TRAFs	O
)	O
leading	O
to	O
activation	O
of	O
NFkappaB	O
,	O
c	B-Protein
-	I-Protein
Jun	I-Protein
N	O
terminal	O
kinase	O
(	O
JNK	O
)	O
,	O
and	O
p38	O
MAPK	O
signaling	O
pathways	O
[	O
12	O
-	O
16	O
]	O
.	O

Activation	O
of	O
NFkappaB	O
is	O
required	O
for	O
EBV	O
-	O
induced	O
B	O
cell	O
transformation	O
and	O
its	O
inhibition	O
rapidly	O
results	O
in	O
cell	O
death	O
[	O
17	O
,	O
18	O
]	O
.	O

Recent	O
studies	O
indicate	O
that	O
LMP1	B-Protein
also	O
activates	O
phosphatidylinositol	O
3	O
kinase	O
(	O
PI3K	O
)	O
/	O
Akt	B-Protein
signaling	O
and	O
that	O
this	O
activation	O
is	O
required	O
for	O
LMP1	B-Protein
-	O
mediated	O
transformation	O
of	O
rodent	O
fibroblasts	O
[	O
5	O
,	O
19	O
]	O
.	O

In	O
vitro	O
,	O
primary	O
B	O
cells	O
can	O
be	O
maintained	O
by	O
CD40	B-Protein
ligation	O
in	O
combination	O
with	O
IL4	B-Protein
treatment	O
.	O

In	O
vivo	O
,	O
CD40	B-Protein
signaling	O
is	O
necessary	O
for	O
germinal	O
center	O
(	O
GC	O
)	O
formation	O
such	O
that	O
mice	O
deficient	O
for	O
CD40	B-Protein
or	O
CD40L	B-Protein
are	O
unable	O
to	O
form	O
GCs	O
in	O
response	O
to	O
T	O
cell	O
-	O
dependent	O
antigens	O
[	O
20	O
,	O
21	O
]	O
.	O

Both	O
the	O
membrane	O
proximal	O
and	O
distal	O
cytoplasmic	O
regions	O
of	O
CD40	B-Protein
that	O
bind	O
TRAF6	B-Protein
and	O
TRAFs2	B-Protein
/	O
3	B-Protein
/	O
5	B-Protein
,	O
respectively	O
,	O
are	O
necessary	O
for	O
GC	O
formation	O
,	O
but	O
either	O
region	O
is	O
sufficient	O
to	O
induce	O
extrafollicular	O
B	O
cell	O
differentiation	O
and	O
restore	O
low	O
affinity	O
antibody	O
production	O
[	O
22	O
]	O
.	O

Functionally	O
,	O
LMP1	B-Protein
can	O
rescue	O
CD40	B-Protein
-	O
deficient	O
mice	O
and	O
restore	O
immunoglobulin	O
(	O
Ig	O
)	O
class	O
switching	O
,	O
most	O
likely	O
because	O
LMP1	B-Protein
recruits	O
similar	O
TRAF	O
molecules	O
,	O
TRAFs	B-Protein
1	I-Protein
/	O
2	B-Protein
/	O
3	B-Protein
/	O
5	B-Protein
and	O
TRAF6	B-Protein
,	O
through	O
the	O
C	O
-	O
terminal	O
activation	O
regions	O
1	O
and	O
2	O
domains	O
,	O
respectively	O
.	O

However	O
,	O
LMP1	B-Protein
is	O
unable	O
to	O
restore	O
affinity	O
maturation	O
and	O
GC	O
formation	O
[	O
23	O
]	O
.	O

Several	O
EBV	O
transforming	O
proteins	O
have	O
been	O
studied	O
in	O
transgenic	O
mouse	O
models	O
,	O
however	O
,	O
only	O
LMP1	B-Protein
induces	O
tumor	O
development	O
when	O
expressed	O
under	O
the	O
control	O
of	O
the	O
Ig	O
heavy	O
chain	O
promoter	O
and	O
enhancer	O
[	O
24	O
-	O
26	O
]	O
.	O

The	O
LMP1	B-Protein
transgenic	O
mice	O
(	O
IgLMP1	O
)	O
express	O
LMP1	B-Protein
in	O
B	O
lymphocytes	O
,	O
and	O
in	O
mice	O
older	O
than	O
12	O
mo	O
,	O
lymphoma	O
develops	O
with	O
increased	O
incidence	O
(	O
40	O
%	O
-	O
50	O
%	O
)	O
compared	O
to	O
wild	O
-	O
type	O
control	O
mice	O
(	O
11	O
%	O
)	O
,	O
suggesting	O
that	O
LMP1	B-Protein
contributes	O
to	O
tumor	O
development	O
[	O
26	O
]	O
.	O

The	O
LMP1	B-Protein
lymphomas	O
have	O
rearranged	O
Ig	O
genes	O
and	O
have	O
activated	O
Akt	B-Protein
,	O
JNK	O
,	O
p38	O
,	O
and	O
NFkappaB	O
,	O
with	O
specific	O
activation	O
of	O
the	O
NFkappaB	O
family	O
member	O
cRel	B-Protein
[	O
27	O
]	O
.	O

In	O
this	O
study	O
,	O
the	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
lymphomas	O
were	O
further	O
characterized	O
and	O
their	O
growth	O
properties	O
in	O
vitro	O
were	O
determined	O
.	O

To	O
obtain	O
pure	O
populations	O
of	O
malignant	O
lymphocytes	O
and	O
to	O
enable	O
more	O
detailed	O
biochemical	O
analyses	O
,	O
examples	O
of	O
primary	O
lymphomas	O
were	O
inoculated	O
and	O
passaged	O
in	O
SCID	O
mice	O
.	O

Interestingly	O
,	O
lymphoma	O
development	O
was	O
restricted	O
to	O
B	O
-	O
1a	O
lymphocytes	O
,	O
a	O
self	O
-	O
replenishing	O
population	O
of	O
cells	O
that	O
are	O
prone	O
to	O
malignancy	O
[	O
28	O
,	O
29	O
]	O
.	O

LMP1	B-Protein
transgenic	O
lymphocytes	O
had	O
increased	O
viability	O
in	O
vitro	O
and	O
viability	O
was	O
increased	O
by	O
the	O
addition	O
of	O
IL4	B-Protein
.	O

In	O
contrast	O
,	O
both	O
LMP1	B-Protein
-	O
positive	O
and	O
-	O
negative	O
lymphoma	O
cells	O
were	O
independent	O
of	O
IL4	B-Protein
co	O
-	O
stimulation	O
for	O
survival	O
and	O
proliferation	O
in	O
vitro	O
with	O
a	O
complete	O
absence	O
of	O
activated	O
Stat6	B-Protein
,	O
the	O
IL4	B-Protein
target	O
.	O

The	O
lymphomas	O
were	O
also	O
distinguished	O
by	O
constitutive	O
activation	O
of	O
Stat3	B-Protein
and	O
deregulation	O
of	O
the	O
Rb	B-Protein
cell	O
cycle	O
pathway	O
.	O

Inhibition	O
of	O
the	O
PI3K	O
/	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
signaling	O
pathways	O
blocked	O
the	O
enhanced	O
growth	O
of	O
both	O
LMP1	B-Protein
transgenic	O
and	O
malignant	O
lymphocytes	O
,	O
suggesting	O
that	O
these	O
pathways	O
are	O
required	O
for	O
their	O
growth	O
and	O
survival	O
.	O

These	O
appear	O
to	O
be	O
the	O
same	O
targets	O
that	O
are	O
deregulated	O
in	O
wild	O
-	O
type	O
B	O
-	O
1a	O
lymphomas	O
that	O
arise	O
spontaneously	O
through	O
age	O
predisposition	O
.	O

This	O
study	O
reveals	O
that	O
LMP1	B-Protein
promotes	O
malignancy	O
in	O
cells	O
with	O
the	O
inherent	O
ability	O
to	O
proliferate	O
and	O
that	O
the	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
signaling	O
pathways	O
are	O
required	O
for	O
its	O
growth	O
stimulatory	O
effects	O
.	O

High	O
Levels	O
of	O
LMP1	B-Protein
Expression	O
Correlates	O
with	O
the	O
Development	O
of	O
Lymphoma	O

LMP1	B-Protein
expression	O
in	O
IgLMP1	O
mice	O
was	O
directed	O
to	O
B	O
cells	O
under	O
the	O
control	O
of	O
the	O
Ig	O
heavy	O
chain	O
promoter	O
and	O
enhancer	O
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
in	O
these	O
transgenic	O
mice	O
,	O
LMP1	B-Protein
expression	O
was	O
restricted	O
to	O
B220	O
+	O
B	O
cells	O
with	O
lymphoma	O
detected	O
in	O
greatly	O
enlarged	O
spleens	O
[	O
23	O
,	O
26	O
]	O
.	O

To	O
investigate	O
whether	O
LMP1	B-Protein
expression	O
contributes	O
to	O
lymphoma	O
development	O
,	O
B	O
cells	O
were	O
purified	O
from	O
splenocytes	O
by	O
positive	O
selection	O
using	O
anti	O
-	O
CD19	B-Protein
MACS	O
magnetic	O
beads	O
,	O
and	O
equivalent	O
amounts	O
of	O
B	O
cells	O
were	O
analyzed	O
by	O
immunoblotting	O
.	O

LMP1	B-Protein
was	O
detectable	O
in	O
LMP1	B-Protein
transgenic	O
B	O
cells	O
,	O
but	O
upon	O
development	O
of	O
lymphoma	O
,	O
LMP1	B-Protein
expression	O
was	O
stronger	O
in	O
5	O
/	O
7	O
lymphomas	O
analyzed	O
with	O
concomitant	O
appearance	O
of	O
degradation	O
products	O
(	O
Figure	O
1A	O
)	O
.	O

To	O
determine	O
whether	O
the	O
higher	O
level	O
of	O
LMP1	B-Protein
detected	O
was	O
due	O
to	O
an	O
expansion	O
of	O
malignant	O
lymphocytes	O
,	O
expression	O
of	O
LMP1	B-Protein
in	O
the	O
spleen	O
was	O
further	O
evaluated	O
by	O
immunohistochemical	O
staining	O
.	O

Immunohistochemistry	O
analysis	O
of	O
spleen	O
sections	O
detected	O
LMP1	B-Protein
in	O
the	O
plasma	O
membrane	O
of	O
cells	O
in	O
both	O
the	O
follicular	O
white	O
pulp	O
and	O
circulating	O
lymphocytes	O
in	O
the	O
red	O
pulp	O
(	O
Figure	O
1B	O
)	O
.	O

LMP1	B-Protein
expression	O
was	O
heterogeneous	O
with	O
strong	O
LMP1	B-Protein
staining	O
interspersed	O
amongst	O
a	O
background	O
of	O
cells	O
staining	O
weakly	O
for	O
LMP1	B-Protein
.	O

Upon	O
development	O
to	O
lymphoma	O
,	O
LMP1	B-Protein
expression	O
was	O
more	O
abundantly	O
detected	O
with	O
multiple	O
foci	O
of	O
intense	O
LMP1	B-Protein
staining	O
.	O

This	O
demonstrates	O
that	O
the	O
increased	O
LMP1	B-Protein
detected	O
by	O
immunoblotting	O
upon	O
malignant	O
progression	O
reflects	O
an	O
increase	O
in	O
LMP1	B-Protein
expression	O
and	O
an	O
accumulation	O
of	O
cells	O
expressing	O
high	O
levels	O
of	O
LMP1	B-Protein
.	O

This	O
correlation	O
between	O
high	O
LMP1	B-Protein
expression	O
and	O
the	O
development	O
of	O
lymphoma	O
suggests	O
that	O
progression	O
to	O
lymphoma	O
results	O
from	O
increased	O
levels	O
of	O
LMP1	B-Protein
.	O

LMP1	B-Protein
Promotes	O
B	O
-	O
1a	O
Lymphomas	O
That	O
Can	O
Escape	O
Allelic	O
Exclusion	O

To	O
determine	O
if	O
LMP1	B-Protein
signaling	O
affects	O
B	O
cell	O
differentiation	O
and	O
to	O
immunophenotype	O
the	O
lymphomas	O
that	O
arise	O
from	O
LMP1	B-Protein
expression	O
,	O
surface	O
Ig	O
expression	O
of	O
heavy	O
chains	O
(	O
IgM	O
,	O
IgG	O
,	O
IgD	O
)	O
and	O
light	O
chains	O
(	O
kappa	O
,	O
lambda	O
)	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
.	O

Similar	O
numbers	O
of	O
naive	O
(	O
IgM	O
+	O
IgD	O
+	O
IgG	O
-	O
)	O
splenic	O
B	O
cells	O
with	O
a	O
strong	O
bias	O
towards	O
kappa	O
light	O
chain	O
were	O
detected	O
from	O
wild	O
-	O
type	O
or	O
LMP1	B-Protein
transgenic	O
mice	O
,	O
indicating	O
that	O
LMP1	B-Protein
signaling	O
does	O
not	O
affect	O
B	O
cell	O
maturation	O
(	O
unpublished	O
data	O
)	O
.	O

Flow	O
cytometry	O
analysis	O
of	O
the	O
SCID	O
-	O
passaged	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphomas	O
revealed	O
an	O
IgMhighIgDlow	O
phenotype	O
(	O
Figure	O
2A	O
)	O
,	O
indicative	O
of	O
marginal	O
zone	O
,	O
B	O
-	O
1	O
,	O
or	O
memory	O
B	O
cells	O
.	O
<EOS>	B-X
We	B-X
address	B-X
whether	B-X
T	B-X
cell	B-X
responses	B-X
induced	B-X
by	B-X
different	B-X
vaccine	B-X
platforms	B-X
(	B-X
mRNA-1273	B-X
,	B-X
BNT162b2	B-X
,	B-X
Ad26.COV2.S	B-X
,	B-X
and	B-X
NVX-CoV2373	B-X
)	B-X
cross-recognize	B-X
early	B-X
SARS-CoV-2	B-X
variants	B-X
.	B-X
By	B-X
contrast	B-X
,	B-X
significant	B-X
overall	B-X
decreases	B-X
were	B-X
observed	B-X
for	B-X
memory	B-X
B	B-X
cells	B-X
and	B-X
neutralizing	B-X
antibodies	B-X
.	B-X
Immunological	B-X
memory	B-X
is	B-X
a	B-X
composite	B-X
of	B-X
lasting	B-X
antibody	B-X
titers	B-X
maintained	B-X
by	B-X
plasma	B-X
cells	B-X
in	B-X
conjunction	B-X
with	B-X
memory	B-X
T	B-X
and	B-X
B	B-X
cells	B-X
.	B-X
Memory	B-X
B	B-X
cells	B-X
are	B-X
a	B-X
critical	B-X
reservoir	B-X
for	B-X
plasma	B-X
cell	B-X
generation	B-X
in	B-X
the	B-X
secondary	B-X
response	B-X
.	B-X
Identification	B-X
of	B-X
memory	B-X
B	B-X
cells	B-X
requires	B-X
that	B-X
they	B-X
be	B-X
distinguished	B-X
from	B-X
naïve	B-X
,	B-X
activated	B-X
,	B-X
and	B-X
germinal	B-X
center	B-X
precursors	B-X
and	B-X
from	B-X
plasma	B-X
cells	B-X
.	B-X
Memory	B-X
B	B-X
cells	B-X
are	B-X
heterogeneous	B-X
in	B-X
isotype	B-X
usage	B-X
,	B-X
immunoglobulin	B-X
mutational	B-X
content	B-X
,	B-X
and	B-X
phenotypic	B-X
marker	B-X
expression	B-X
.	B-X
Phenotypic	B-X
subsets	B-X
of	B-X
memory	B-X
B	B-X
cells	B-X
are	B-X
defined	B-X
by	B-X
PD-L2	B-X
,	B-X
CD80	B-X
,	B-X
and	B-X
CD73	B-X
expression	B-X
in	B-X
mice	B-X
,	B-X
by	B-X
CD27	B-X
and	B-X
FCRL4	B-X
expression	B-X
in	B-X
humans	B-X
and	B-X
by	B-X
T-bet	B-X
in	B-X
both	B-X
mice	B-X
and	B-X
humans	B-X
.	B-X
These	B-X
subsets	B-X
display	B-X
marked	B-X
functional	B-X
heterogeneity	B-X
,	B-X
including	B-X
the	B-X
ability	B-X
to	B-X
rapidly	B-X
differentiate	B-X
into	B-X
plasma	B-X
cells	B-X
versus	B-X
seed	B-X
germinal	B-X
centers	B-X
in	B-X
the	B-X
secondary	B-X
response	B-X
.	B-X
Memory	B-X
B	B-X
cells	B-X
are	B-X
located	B-X
in	B-X
the	B-X
spleen	B-X
,	B-X
blood	B-X
,	B-X
other	B-X
lymphoid	B-X
organs	B-X
,	B-X
and	B-X
barrier	B-X
tissues	B-X
,	B-X
and	B-X
recent	B-X
evidence	B-X
indicates	B-X
that	B-X
some	B-X
memory	B-X
B	B-X
cells	B-X
may	B-X
be	B-X
dedicated	B-X
tissue-resident	B-X
populations	B-X
.	B-X
Open	B-X
questions	B-X
about	B-X
memory	B-X
B	B-X
cell	B-X
longevity	B-X
,	B-X
renewal	B-X
and	B-X
progenitor-successor	B-X
relationships	B-X
with	B-X
plasma	B-X
cells	B-X
are	B-X
discussed	B-X
.	B-X

B	O
-	O
1	O
cells	O
are	O
further	O
separated	O
into	O
CD5	B-Protein
+	O
(	O
B	O
-	O
1a	O
)	O
and	O
CD5	B-Protein
-	O
(	O
B	O
-	O
1b	O
)	O
subsets	O
.	O
<EOS>	B-X
In	B-X
this	B-X
paper	B-X
we	B-X
have	B-X
outlined	B-X
the	B-X
evidence	B-X
for	B-X
two	B-X
distinct	B-X
branches	B-X
of	B-X
the	B-X
B-1	B-X
cell	B-X
lineage	B-X
.	B-X
The	B-X
data	B-X
show	B-X
that	B-X
phenotypically	B-X
B-1a	B-X
and	B-X
B-1b	B-X
cells	B-X
are	B-X
essentially	B-X
identical	B-X
,	B-X
distinguished	B-X
only	B-X
by	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
the	B-X
CD5	B-X
antigen	B-X
.	B-X
Both	B-X
produce	B-X
anti-PtC	B-X
antibodies	B-X
,	B-X
a	B-X
specificity	B-X
not	B-X
observed	B-X
in	B-X
conventional	B-X
B	B-X
cells	B-X
.	B-X
Both	B-X
produced	B-X
high	B-X
levels	B-X
of	B-X
IgM	B-X
as	B-X
measured	B-X
in	B-X
adoptive	B-X
transfer	B-X
experiments	B-X
.	B-X
Developmentally	B-X
,	B-X
B-1a	B-X
and	B-X
B-1b	B-X
cells	B-X
are	B-X
indistinguishable	B-X
with	B-X
respect	B-X
to	B-X
generation	B-X
from	B-X
progenitors	B-X
present	B-X
in	B-X
fetal	B-X
liver	B-X
and	B-X
omentum	B-X
,	B-X
feedback	B-X
regulation	B-X
of	B-X
new	B-X
B-1a	B-X
and	B-X
B-1b	B-X
cells	B-X
from	B-X
bone	B-X
marrow	B-X
,	B-X
self-replenishment	B-X
from	B-X
Ig+	B-X
cells	B-X
following	B-X
adoptive	B-X
transfer	B-X
,	B-X
and	B-X
the	B-X
generation	B-X
of	B-X
clonal	B-X
populations	B-X
.	B-X
The	B-X
major	B-X
difference	B-X
in	B-X
the	B-X
two	B-X
populations	B-X
is	B-X
seen	B-X
in	B-X
the	B-X
development	B-X
of	B-X
B-1a	B-X
and	B-X
B-1b	B-X
cells	B-X
from	B-X
B220-	B-X
progenitors	B-X
in	B-X
the	B-X
adult	B-X
bone	B-X
marrow	B-X
.	B-X
Although	B-X
B220-	B-X
B-1a	B-X
progenitors	B-X
are	B-X
rare	B-X
in	B-X
adult	B-X
(	B-X
greater	B-X
than	B-X
6	B-X
weeks	B-X
)	B-X
bone	B-X
marrow	B-X
,	B-X
the	B-X
progenitors	B-X
for	B-X
B-1b	B-X
cells	B-X
persist	B-X
well	B-X
into	B-X
adulthood	B-X
.	B-X
Our	B-X
understanding	B-X
of	B-X
B-1b	B-X
cell	B-X
ontogeny	B-X
is	B-X
at	B-X
a	B-X
stage	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
B-1a	B-X
cells	B-X
five	B-X
years	B-X
ago	B-X
.	B-X
We	B-X
have	B-X
evidence	B-X
from	B-X
transfer	B-X
experiments	B-X
that	B-X
strongly	B-X
suggests	B-X
the	B-X
existence	B-X
of	B-X
two	B-X
distinct	B-X
progenitors	B-X
for	B-X
B-1a	B-X
and	B-X
B-1b	B-X
,	B-X
but	B-X
we	B-X
have	B-X
yet	B-X
to	B-X
physically	B-X
separate	B-X
these	B-X
progenitors	B-X
as	B-X
Solvansen	B-X
et	B-X
al	B-X
.	B-X
have	B-X
done	B-X
for	B-X
B-1	B-X
and	B-X
conventional	B-X
B	B-X
cells	B-X
.	B-X
Furthermore	B-X
we	B-X
must	B-X
determine	B-X
whether	B-X
the	B-X
B-1b	B-X
cells	B-X
that	B-X
develop	B-X
from	B-X
fetal	B-X
liver	B-X
and	B-X
bone	B-X
marrow	B-X
are	B-X
functionally	B-X
and	B-X
developmentally	B-X
equivalent	B-X
to	B-X
those	B-X
that	B-X
develop	B-X
from	B-X
adult	B-X
bone	B-X
marrow	B-X
.	B-X
As	B-X
with	B-X
B-1a	B-X
cells	B-X
,	B-X
the	B-X
role	B-X
of	B-X
B-1b	B-X
cells	B-X
in	B-X
the	B-X
immune	B-X
system	B-X
is	B-X
unclear	B-X
.	B-X
Although	B-X
we	B-X
have	B-X
not	B-X
yet	B-X
discerned	B-X
functional	B-X
differences	B-X
between	B-X
B-1a	B-X
and	B-X
B-1b	B-X
,	B-X
given	B-X
the	B-X
recent	B-X
identification	B-X
of	B-X
CD72	B-X
(	B-X
Lyb-2	B-X
)	B-X
as	B-X
the	B-X
ligand	B-X
for	B-X
CD5	B-X
,	B-X
it	B-X
is	B-X
tempting	B-X
to	B-X
speculate	B-X
that	B-X
B-1a	B-X
cells	B-X
are	B-X
more	B-X
involved	B-X
in	B-X
B-B	B-X
cell	B-X
interactions	B-X
such	B-X
as	B-X
idiotype-anti-idiotype	B-X
regulation	B-X
of	B-X
the	B-X
early	B-X
B-cell	B-X
repertoire	B-X
and	B-X
that	B-X
B-1b	B-X
cells	B-X
are	B-X
more	B-X
involved	B-X
in	B-X
B-T	B-X
cell	B-X
interactions	B-X
.	B-X
Whatever	B-X
their	B-X
function	B-X
,	B-X
it	B-X
is	B-X
clear	B-X
that	B-X
in	B-X
trying	B-X
to	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
the	B-X
B-1	B-X
lineage	B-X
it	B-X
is	B-X
important	B-X
to	B-X
consider	B-X
both	B-X
the	B-X
B-1a	B-X
and	B-X
B-1b	B-X
lineages	B-X
.	B-X

To	O
differentiate	O
between	O
these	O
cell	O
types	O
,	O
lymphoma	O
cells	O
were	O
further	O
analyzed	O
for	O
the	O
B	O
-	O
1a	O
marker	O
CD5	B-Protein
.	O

All	O
(	O
5	O
/	O
5	O
)	O
of	O
the	O
tested	O
LMP1	B-Protein
transgenic	O
lymphomas	O
displayed	O
an	O
IgMhighIgDlowCD5	B-Protein
+	O
phenotype	O
(	O
Figure	O
2A	O
)	O
,	O
an	O
expression	O
pattern	O
that	O
distinguishes	O
B	O
-	O
1a	O
cells	O
.	O

Interestingly	O
,	O
a	O
spontaneous	O
wild	O
-	O
type	O
lymphoma	O
also	O
developed	O
in	O
B	O
-	O
1a	O
cells	O
(	O
Figure	O
2A	O
)	O
.	O

These	O
cells	O
are	O
an	O
interesting	O
population	O
that	O
is	O
self	O
replenishing	O
with	O
an	O
increased	O
likelihood	O
to	O
become	O
malignant	O
in	O
aged	O
mice	O
[	O
30	O
]	O
.	O

Analysis	O
of	O
LMP1	B-Protein
transgenic	O
mice	O
before	O
the	O
development	O
of	O
lymphoma	O
showed	O
similar	O
numbers	O
of	O
splenic	O
B	O
-	O
1a	O
(	O
CD19	B-Protein
+	O
CD5	B-Protein
+	O
)	O
and	O
B	O
-	O
1b	O
or	O
B	O
-	O
2	O
populations	O
(	O
CD19	B-Protein
+	O
CD5	B-Protein
-	O
)	O
,	O
indicating	O
that	O
LMP1	B-Protein
does	O
not	O
affect	O
B	O
cell	O
differentiation	O
(	O
Figure	O
2B	O
)	O
.	O

Due	O
to	O
allelic	O
exclusion	O
,	O
mature	O
B	O
cells	O
that	O
have	O
been	O
exposed	O
to	O
antigen	O
will	O
typically	O
express	O
only	O
one	O
heavy	O
chain	O
isotype	O
(	O
IgG	O
,	O
IgE	O
,	O
or	O
IgA	O
)	O
and	O
either	O
a	O
kappa	O
or	O
lambda	O
light	O
chain	O
.	O
<EOS>	B-X
Laboratory	B-X
methods	B-X
for	B-X
diagnosis	B-X
and	B-X
monitoring	B-X
of	B-X
monoclonal	B-X
gammopathies	B-X
have	B-X
evolved	B-X
to	B-X
include	B-X
serum	B-X
and	B-X
urine	B-X
protein	B-X
electrophoresis	B-X
,	B-X
immunofixation	B-X
electrophoresis	B-X
,	B-X
capillary	B-X
zone	B-X
electrophoresis	B-X
,	B-X
and	B-X
immunosubtraction	B-X
,	B-X
serum-free	B-X
light	B-X
chain	B-X
assay	B-X
,	B-X
mass	B-X
spectrometry	B-X
,	B-X
and	B-X
newly	B-X
described	B-X
QUIET	B-X
.	B-X
It	B-X
is	B-X
associated	B-X
with	B-X
an	B-X
increased	B-X
frequency	B-X
of	B-X
undetectable	B-X
or	B-X
small	B-X
monoclonal	B-X
(	B-X
M	B-X
)	B-X
-protein	B-X
levels	B-X
on	B-X
electrophoresis	B-X
;	B-X
osteolytic	B-X
lesions	B-X
;	B-X
extramedullary	B-X
involvement	B-X
;	B-X
amyloidosis	B-X
;	B-X
a	B-X
lambda	B-X
(	B-X
lambda	B-X
)	B-X
light	B-X
chain	B-X
predilection	B-X
;	B-X
renal	B-X
failure	B-X
;	B-X
hypercalcemia	B-X
;	B-X
and	B-X
,	B-X
often	B-X
,	B-X
advanced	B-X
disease	B-X
at	B-X
diagnosis	B-X
.	B-X
Immunoglobulin	B-X
E	B-X
(	B-X
IgE	B-X
)	B-X
MM	B-X
is	B-X
rare	B-X
,	B-X
with	B-X
fewer	B-X
than	B-X
50	B-X
cases	B-X
reported	B-X
in	B-X
the	B-X
literature	B-X
.	B-X
IgE	B-X
MM	B-X
presents	B-X
with	B-X
features	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
IgD	B-X
MM	B-X
,	B-X
along	B-X
with	B-X
a	B-X
higher	B-X
incidence	B-X
of	B-X
plasma	B-X
cell	B-X
leukemia	B-X
.	B-X
The	B-X
hallmark	B-X
of	B-X
IgE	B-X
MM	B-X
is	B-X
t	B-X
(	B-X
11	B-X
;	B-X
14	B-X
)	B-X
(	B-X
q13	B-X
;	B-X
q32	B-X
)	B-X
.	B-X
IgD	B-X
and	B-X
IgE	B-X
levels	B-X
are	B-X
generally	B-X
very	B-X
low	B-X
and	B-X
hence	B-X
may	B-X
escape	B-X
detection	B-X
;	B-X
thus	B-X
,	B-X
it	B-X
is	B-X
important	B-X
that	B-X
,	B-X
when	B-X
myeloma	B-X
is	B-X
suspected	B-X
,	B-X
patients	B-X
be	B-X
screened	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
IgD	B-X
and	B-X
IgE	B-X
if	B-X
they	B-X
have	B-X
an	B-X
apparently	B-X
free	B-X
monoclonal	B-X
immunoglobulin	B-X
light	B-X
chain	B-X
in	B-X
the	B-X
serum	B-X
.	B-X
Although	B-X
survival	B-X
of	B-X
patients	B-X
with	B-X
IgD	B-X
MM	B-X
or	B-X
IgE	B-X
MM	B-X
is	B-X
shorter	B-X
in	B-X
comparison	B-X
to	B-X
those	B-X
with	B-X
immunoglobulin	B-X
G	B-X
(	B-X
IgG	B-X
)	B-X
MM	B-X
or	B-X
immunoglobulin	B-X
A	B-X
(	B-X
IgA	B-X
)	B-X
MM	B-X
,	B-X
the	B-X
outcome	B-X
for	B-X
patients	B-X
with	B-X
IgD	B-X
and	B-X
IgE	B-X
subtypes	B-X
is	B-X
improving	B-X
with	B-X
the	B-X
use	B-X
of	B-X
novel	B-X
agents	B-X
and	B-X
autologous	B-X
transplantation	B-X
.	B-X

Interestingly	O
,	O
2	O
/	O
5	O
LMP1	B-Protein
transgenic	O
lymphomas	O
analyzed	O
(	O
lymphomas	O
2	O
and	O
4	O
)	O
were	O
doubly	O
positive	O
for	O
low	O
levels	O
of	O
both	O
kappa	O
and	O
lambda	O
light	O
chains	O
(	O
Figure	O
2A	O
)	O
.	O

Previous	O
characterization	O
of	O
the	O
LMP1	B-Protein
lymphomas	O
had	O
revealed	O
that	O
the	O
lymphomas	O
were	O
clonal	O
as	O
determined	O
by	O
Ig	O
heavy	O
chain	O
rearrangement	O
[	O
26	O
]	O
,	O
and	O
analysis	O
of	O
kappa	O
chain	O
rearrangement	O
(	O
Figure	O
S1	O
)	O
of	O
the	O
samples	O
analyzed	O
in	O
this	O
study	O
confirmed	O
clonality	O
.	O

To	O
further	O
assess	O
light	O
chain	O
expression	O
,	O
the	O
passaged	O
samples	O
were	O
tested	O
by	O
immunoblotting	O
for	O
kappa	O
and	O
lambda	O
light	O
chains	O
(	O
Figure	O
2C	O
)	O
.	O

Interestingly	O
,	O
very	O
low	O
levels	O
of	O
expression	O
of	O
both	O
light	O
chains	O
were	O
detected	O
by	O
flow	O
cytometry	O
.	O

The	O
low	O
levels	O
of	O
expression	O
may	O
reflect	O
a	O
limitation	O
of	O
the	O
total	O
number	O
of	O
light	O
chains	O
that	O
can	O
be	O
expressed	O
on	O
the	O
surface	O
of	O
a	O
B	O
cell	O
.	O

In	O
agreement	O
with	O
the	O
flow	O
cytometry	O
analysis	O
,	O
LMP1	B-Protein
transgenic	O
lymphomas	O
2	O
and	O
4	O
were	O
also	O
positive	O
for	O
kappa	O
and	O
lambda	O
light	O
chains	O
by	O
immunoblot	O
analysis	O
(	O
Figure	O
2C	O
)	O
,	O
confirming	O
that	O
these	O
lymphomas	O
express	O
both	O
light	O
chains	O
.	O

A	O
previous	O
study	O
of	O
mice	O
that	O
developed	O
leukemia	O
due	O
to	O
an	O
expansion	O
of	O
self	O
-	O
reactive	O
B	O
-	O
1a	O
cells	O
determined	O
that	O
the	O
B	O
-	O
1a	O
leukemias	O
were	O
also	O
doubly	O
positive	O
for	O
kappa	O
and	O
lambda	O
light	O
chains	O
[	O
31	O
]	O
.	O

These	O
findings	O
indicate	O
that	O
expression	O
of	O
LMP1	B-Protein
in	O
B	O
-	O
1a	O
cells	O
promotes	O
the	O
development	O
of	O
malignancy	O
and	O
can	O
result	O
in	O
the	O
aberrant	O
escape	O
from	O
allelic	O
exclusion	O
.	O

LMP1	B-Protein
Promotes	O
B	O
Cell	O
Survival	O
and	O
Proliferation	O
In	O
Vitro	O
<EOS>	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
,	B-X
an	B-X
oncogenic	B-X
human	B-X
virus	B-X
,	B-X
is	B-X
associated	B-X
with	B-X
several	B-X
lymphoproliferative	B-X
disorders	B-X
,	B-X
including	B-X
Burkitt	B-X
lymphoma	B-X
,	B-X
Hodgkin	B-X
disease	B-X
,	B-X
diffuse	B-X
large	B-X
B-cell	B-X
lymphoma	B-X
(	B-X
DLBCL	B-X
)	B-X
,	B-X
and	B-X
posttransplant	B-X
lymphoproliferative	B-X
disorder	B-X
(	B-X
PTLD	B-X
)	B-X
.	B-X
In	B-X
vitro	B-X
,	B-X
EBV	B-X
transforms	B-X
primary	B-X
B	B-X
cells	B-X
into	B-X
lymphoblastoid	B-X
cell	B-X
lines	B-X
(	B-X
LCLs	B-X
)	B-X
.	B-X
Recently	B-X
,	B-X
several	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
receptor	B-X
tyrosine	B-X
kinases	B-X
(	B-X
RTKs	B-X
)	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
EBV-associated	B-X
neoplasia	B-X
.	B-X
However	B-X
,	B-X
details	B-X
of	B-X
the	B-X
involvement	B-X
of	B-X
RTKs	B-X
in	B-X
EBV-regulated	B-X
B-cell	B-X
neoplasia	B-X
and	B-X
malignancies	B-X
remain	B-X
largely	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
found	B-X
that	B-X
erythropoietin-producing	B-X
hepatocellular	B-X
receptor	B-X
A4	B-X
(	B-X
EphA4	B-X
)	B-X
,	B-X
which	B-X
belongs	B-X
to	B-X
the	B-X
largest	B-X
RTK	B-X
Eph	B-X
family	B-X
,	B-X
was	B-X
downregulated	B-X
in	B-X
primary	B-X
B	B-X
cells	B-X
post-EBV	B-X
infection	B-X
at	B-X
the	B-X
transcriptional	B-X
and	B-X
translational	B-X
levels	B-X
.	B-X
Overexpression	B-X
and	B-X
knockdown	B-X
experiments	B-X
confirmed	B-X
that	B-X
EBV-encoded	B-X
latent	B-X
membrane	B-X
protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
was	B-X
responsible	B-X
for	B-X
this	B-X
EphA4	B-X
suppression	B-X
.	B-X
Mechanistically	B-X
,	B-X
LMP1	B-X
triggered	B-X
the	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
pathway	B-X
and	B-X
promoted	B-X
Sp1	B-X
to	B-X
suppress	B-X
EphA4	B-X
promoter	B-X
activity	B-X
.	B-X
Pathologically	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
EphA4	B-X
was	B-X
detected	B-X
in	B-X
EBV	B-X
(	B-X
-	B-X
)	B-X
tonsils	B-X
but	B-X
not	B-X
in	B-X
EBV	B-X
(	B-X
+	B-X
)	B-X
PTLD	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
an	B-X
inverse	B-X
correlation	B-X
of	B-X
EphA4	B-X
expression	B-X
and	B-X
EBV	B-X
presence	B-X
was	B-X
verified	B-X
by	B-X
immunochemical	B-X
staining	B-X
of	B-X
EBV	B-X
(	B-X
+	B-X
)	B-X
and	B-X
EBV	B-X
(	B-X
-	B-X
)	B-X
DLBCL	B-X
,	B-X
suggesting	B-X
EBV	B-X
infection	B-X
was	B-X
associated	B-X
with	B-X
reduced	B-X
EphA4	B-X
expression	B-X
.	B-X
Analysis	B-X
of	B-X
a	B-X
public	B-X
data	B-X
set	B-X
showed	B-X
that	B-X
lower	B-X
EphA4	B-X
expression	B-X
was	B-X
correlated	B-X
with	B-X
a	B-X
poor	B-X
survival	B-X
rate	B-X
of	B-X
DLBCL	B-X
patients	B-X
.	B-X
Our	B-X
findings	B-X
provide	B-X
a	B-X
novel	B-X
mechanism	B-X
by	B-X
which	B-X
EphA4	B-X
can	B-X
be	B-X
regulated	B-X
by	B-X
an	B-X
oncogenic	B-X
LMP1	B-X
protein	B-X
and	B-X
explore	B-X
its	B-X
possible	B-X
function	B-X
in	B-X
B	B-X
cells	B-X
.	B-X
The	B-X
results	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
role	B-X
of	B-X
EphA4	B-X
in	B-X
EBV	B-X
(	B-X
+	B-X
)	B-X
PTLD	B-X
and	B-X
DLBCL	B-X
.	B-X

Primary	O
B	O
cell	O
cultures	O
can	O
be	O
maintained	O
through	O
CD40	B-Protein
ligation	O
and	O
supplementation	O
with	O
IL4	B-Protein
[	O
32	O
]	O
.	O

To	O
investigate	O
whether	O
LMP1	B-Protein
affects	O
primary	O
B	O
cell	O
survival	O
and	O
proliferation	O
,	O
splenocytes	O
were	O
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
IL4	B-Protein
and	O
analyzed	O
by	O
MTS	O
as	O
a	O
metabolic	O
marker	O
,	O
by	O
ethidium	O
monoazide	O
(	O
EMA	O
)	O
exclusion	O
for	O
viability	O
,	O
and	O
by	O
5	O
-	O
bromo	O
-	O
2	O
'	O
-	O
deoxy	O
-	O
uridine	O
(	O
BrdU	O
)	O
incorporation	O
for	O
proliferation	O
.	O

In	O
the	O
MTS	O
assay	O
,	O
as	O
expected	O
,	O
splenocytes	O
from	O
wild	O
-	O
type	O
mice	O
did	O
not	O
survive	O
even	O
with	O
the	O
addition	O
of	O
IL4	B-Protein
due	O
to	O
a	O
lack	O
of	O
CD40	B-Protein
ligation	O
(	O
Figure	O
3A	O
)	O
.	O

In	O
contrast	O
,	O
LMP1	B-Protein
splenocytes	O
had	O
increased	O
metabolism	O
even	O
in	O
the	O
absence	O
of	O
IL4	B-Protein
,	O
which	O
was	O
further	O
enhanced	O
upon	O
addition	O
of	O
IL4	B-Protein
.	O

Wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
had	O
high	O
levels	O
of	O
MTS	O
activity	O
even	O
in	O
the	O
absence	O
of	O
IL4	B-Protein
(	O
Figure	O
3A	O
)	O
.	O

The	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
had	O
approximately	O
4	O
-	O
fold	O
higher	O
MTS	O
activity	O
than	O
the	O
normal	O
transgenic	O
lymphocytes	O
and	O
were	O
at	O
least	O
2	O
-	O
fold	O
higher	O
than	O
the	O
control	O
lymphoma	O
.	O

As	O
previously	O
published	O
,	O
lymphoma	O
usually	O
develops	O
in	O
mice	O
over	O
12	O
mo	O
of	O
age	O
and	O
all	O
mice	O
are	O
sacrificed	O
by	O
18	O
-	O
20	O
mo	O
.	O

The	O
ages	O
of	O
the	O
transgenic	O
mice	O
with	O
or	O
without	O
lymphoma	O
ranged	O
between	O
6	O
and	O
20	O
mo	O
old	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
describe	B-X
methods	B-X
for	B-X
the	B-X
prospective	B-X
isolation	B-X
and	B-X
purification	B-X
of	B-X
astrocytes	B-X
,	B-X
neurons	B-X
,	B-X
and	B-X
oligodendrocytes	B-X
from	B-X
developing	B-X
and	B-X
mature	B-X
mouse	B-X
forebrain	B-X
.	B-X
We	B-X
used	B-X
FACS	B-X
(	B-X
fluorescent-activated	B-X
cell	B-X
sorting	B-X
)	B-X
to	B-X
isolate	B-X
astrocytes	B-X
from	B-X
transgenic	B-X
mice	B-X
that	B-X
express	B-X
enhanced	B-X
green	B-X
fluorescent	B-X
protein	B-X
(	B-X
EGFP	B-X
)	B-X
under	B-X
the	B-X
control	B-X
of	B-X
an	B-X
S100beta	B-X
promoter	B-X
.	B-X
Using	B-X
Affymetrix	B-X
GeneChip	B-X
Arrays	B-X
,	B-X
we	B-X
then	B-X
created	B-X
a	B-X
transcriptome	B-X
database	B-X
of	B-X
the	B-X
expression	B-X
levels	B-X
of	B-X
>	B-X
20,000	B-X
genes	B-X
by	B-X
gene	B-X
profiling	B-X
these	B-X
three	B-X
main	B-X
CNS	B-X
neural	B-X
cell	B-X
types	B-X
at	B-X
various	B-X
postnatal	B-X
ages	B-X
between	B-X
postnatal	B-X
day	B-X
1	B-X
(	B-X
P1	B-X
)	B-X
and	B-X
P30	B-X
.	B-X
The	B-X
implementation	B-X
of	B-X
this	B-X
technique	B-X
by	B-X
early	B-X
adopters	B-X
has	B-X
facilitated	B-X
detailed	B-X
investigations	B-X
into	B-X
brain	B-X
function	B-X
using	B-X
diverse	B-X
experimental	B-X
applications	B-X
and	B-X
spanning	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
animal	B-X
ages	B-X
,	B-X
brain	B-X
regions	B-X
,	B-X
and	B-X
cell	B-X
types	B-X
.	B-X
Representative	B-X
results	B-X
are	B-X
provided	B-X
from	B-X
multi-neuron	B-X
patch	B-X
clamp	B-X
recording	B-X
experiments	B-X
to	B-X
assay	B-X
synaptic	B-X
connectivity	B-X
in	B-X
neocortical	B-X
brain	B-X
slices	B-X
prepared	B-X
from	B-X
young	B-X
adult	B-X
transgenic	B-X
mice	B-X
and	B-X
mature	B-X
adult	B-X
human	B-X
neurosurgical	B-X
specimens	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
optimized	B-X
NMDG	B-X
protective	B-X
recovery	B-X
method	B-X
of	B-X
brain	B-X
slicing	B-X
is	B-X
compatible	B-X
with	B-X
both	B-X
juvenile	B-X
and	B-X
adult	B-X
animals	B-X
,	B-X
thus	B-X
resolving	B-X
a	B-X
limitation	B-X
of	B-X
the	B-X
original	B-X
methodology	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
a	B-X
single	B-X
media	B-X
formulation	B-X
and	B-X
brain	B-X
slicing	B-X
procedure	B-X
can	B-X
be	B-X
implemented	B-X
across	B-X
various	B-X
species	B-X
and	B-X
ages	B-X
to	B-X
achieve	B-X
excellent	B-X
viability	B-X
and	B-X
tissue	B-X
preservation	B-X
.	B-X

There	O
was	O
no	O
correlation	O
between	O
age	O
and	O
MTS	O
activity	O
.	O
<EOS>	B-X
The	B-X
1102-amino-acid	B-X
activity-dependent	B-X
neuroprotective	B-X
protein	B-X
(	B-X
ADNP	B-X
)	B-X
was	B-X
originally	B-X
discovered	B-X
by	B-X
expression	B-X
cloning	B-X
through	B-X
the	B-X
immunological	B-X
identification	B-X
of	B-X
its	B-X
8-amino-acid	B-X
sequence	B-X
NAPVSIPQ	B-X
(	B-X
NAP	B-X
)	B-X
,	B-X
constituting	B-X
the	B-X
smallest	B-X
active	B-X
neuroprotective	B-X
fragment	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Furthermore	B-X
,	B-X
Adnp	B-X
haploinsufficiency	B-X
in	B-X
mice	B-X
causes	B-X
an	B-X
age-dependent	B-X
reduction	B-X
in	B-X
cognitive	B-X
functions	B-X
coupled	B-X
with	B-X
tauopathy-like	B-X
features	B-X
such	B-X
as	B-X
an	B-X
increased	B-X
formation	B-X
of	B-X
tangle-like	B-X
structures	B-X
,	B-X
defective	B-X
axonal	B-X
transport	B-X
,	B-X
and	B-X
Tau	B-X
hyperphosphorylation	B-X
.	B-X
Here	B-X
we	B-X
review	B-X
the	B-X
molecular	B-X
mechanism	B-X
of	B-X
NAP	B-X
activity	B-X
on	B-X
MTs	B-X
and	B-X
how	B-X
NAP	B-X
modulates	B-X
the	B-X
MT-Tau-EBs	B-X
crosstalk	B-X
.	B-X
Hamstring	B-X
musculotendinous	B-X
stiffness	B-X
(	B-X
MTS	B-X
)	B-X
is	B-X
associated	B-X
with	B-X
lower-extremity	B-X
injury	B-X
risk	B-X
(	B-X
ie	B-X
,	B-X
hamstring	B-X
strain	B-X
,	B-X
anterior	B-X
cruciate	B-X
ligament	B-X
injury	B-X
)	B-X
and	B-X
is	B-X
commonly	B-X
assessed	B-X
using	B-X
the	B-X
damped	B-X
oscillatory	B-X
technique	B-X
.	B-X
However	B-X
,	B-X
despite	B-X
a	B-X
preponderance	B-X
of	B-X
studies	B-X
that	B-X
measure	B-X
MTS	B-X
reliably	B-X
in	B-X
laboratory	B-X
settings	B-X
,	B-X
there	B-X
are	B-X
no	B-X
valid	B-X
clinical	B-X
measurement	B-X
tools	B-X
.	B-X
A	B-X
valid	B-X
clinical	B-X
measurement	B-X
technique	B-X
is	B-X
needed	B-X
to	B-X
assess	B-X
MTS	B-X
and	B-X
permit	B-X
identification	B-X
of	B-X
individuals	B-X
at	B-X
heightened	B-X
risk	B-X
of	B-X
injury	B-X
and	B-X
track	B-X
rehabilitation	B-X
progress	B-X
.	B-X

EMA	O
exclusion	O
of	O
CD19	B-Protein
+	O
gated	O
B	O
cells	O
prepared	O
from	O
two	O
wild	O
-	O
type	O
and	O
two	O
LMP1	B-Protein
transgenic	O
mice	O
indicated	O
a	O
2	O
-	O
fold	O
increase	O
in	O
viability	O
in	O
the	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
compared	O
to	O
wild	O
-	O
type	O
lymphocytes	O
.	O

Two	O
examples	O
of	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
had	O
greatly	O
increased	O
viability	O
that	O
was	O
not	O
increased	O
by	O
IL4	B-Protein
treatment	O
,	O
indicating	O
that	O
the	O
lymphoma	O
cells	O
are	O
independent	O
of	O
IL4	B-Protein
co	O
-	O
stimulation	O
(	O
Figure	O
3B	O
)	O
.	O

Enhancement	O
in	O
MTS	O
activity	O
was	O
observed	O
in	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
by	O
the	O
addition	O
of	O
IL4	B-Protein
;	O
however	O
,	O
EMA	O
exclusion	O
did	O
not	O
reveal	O
a	O
similar	O
increase	O
.	O

This	O
could	O
reflect	O
a	O
difference	O
for	O
IL4	B-Protein
requirement	O
in	O
the	O
metabolic	O
activity	O
versus	O
the	O
viability	O
of	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
.	O

Although	O
expression	O
of	O
LMP1	B-Protein
could	O
enhance	O
survival	O
of	O
non	O
-	O
malignant	O
primary	O
lymphocytes	O
,	O
BrdU	O
incorporation	O
revealed	O
that	O
LMP1	B-Protein
expression	O
alone	O
was	O
not	O
sufficient	O
to	O
induce	O
proliferation	O
in	O
culture	O
(	O
unpublished	O
data	O
)	O
.	O

Only	O
lymphoma	O
cells	O
had	O
detectable	O
levels	O
of	O
BrdU	O
incorporation	O
detected	O
by	O
flow	O
cytometry	O
(	O
Figure	O
3C	O
)	O
.	O

Interestingly	O
,	O
LMP1	B-Protein
lymphoma	O
cells	O
had	O
significantly	O
higher	O
levels	O
of	O
proliferation	O
in	O
comparison	O
to	O
the	O
spontaneous	O
lymphoma	O
that	O
developed	O
in	O
an	O
LMP1	B-Protein
-	O
negative	O
littermate	O
(	O
25	O
%	O
versus	O
4	O
%	O
)	O
.	O

This	O
higher	O
level	O
of	O
proliferation	O
was	O
observed	O
in	O
lymphomas	O
that	O
express	O
both	O
high	O
(	O
Table	O
1	O
,	O
LMP1	B-Protein
-	O
L2	O
and	O
LMP1	B-Protein
-	O
L3	O
)	O
and	O
low	O
(	O
Table	O
1	O
,	O
LMP1	B-Protein
-	O
L5	O
)	O
levels	O
of	O
LMP1	B-Protein
,	O
suggesting	O
that	O
even	O
small	O
amounts	O
of	O
LMP1	B-Protein
is	O
sufficient	O
to	O
induce	O
dramatic	O
effects	O
in	O
proliferation	O
.	O

The	O
level	O
of	O
proliferation	O
was	O
not	O
enhanced	O
upon	O
IL4	B-Protein
addition	O
,	O
confirming	O
the	O
IL4	B-Protein
independence	O
observed	O
in	O
the	O
viability	O
studies	O
(	O
Figure	O
3C	O
;	O
Table1	O
)	O
.	O
<EOS>	B-X
Biochemistry	B-X
textbooks	B-X
and	B-X
cell	B-X
culture	B-X
experiments	B-X
seem	B-X
to	B-X
be	B-X
telling	B-X
us	B-X
two	B-X
different	B-X
things	B-X
about	B-X
the	B-X
significance	B-X
of	B-X
external	B-X
glutamine	B-X
supply	B-X
for	B-X
mammalian	B-X
cell	B-X
growth	B-X
and	B-X
proliferation	B-X
.	B-X
Despite	B-X
the	B-X
fact	B-X
that	B-X
glutamine	B-X
is	B-X
a	B-X
nonessential	B-X
amino	B-X
acid	B-X
that	B-X
can	B-X
be	B-X
synthesized	B-X
by	B-X
cells	B-X
from	B-X
glucose-derived	B-X
carbons	B-X
and	B-X
amino	B-X
acid-derived	B-X
ammonia	B-X
,	B-X
most	B-X
mammalian	B-X
cells	B-X
in	B-X
tissue	B-X
culture	B-X
can	B-X
not	B-X
proliferate	B-X
or	B-X
even	B-X
survive	B-X
in	B-X
an	B-X
environment	B-X
that	B-X
does	B-X
not	B-X
contain	B-X
millimolar	B-X
levels	B-X
of	B-X
glutamine	B-X
.	B-X
Not	B-X
only	B-X
are	B-X
the	B-X
levels	B-X
of	B-X
glutamine	B-X
in	B-X
standard	B-X
tissue	B-X
culture	B-X
media	B-X
at	B-X
least	B-X
ten-fold	B-X
higher	B-X
than	B-X
other	B-X
amino	B-X
acids	B-X
,	B-X
but	B-X
glutamine	B-X
is	B-X
also	B-X
the	B-X
most	B-X
abundant	B-X
amino	B-X
acid	B-X
in	B-X
the	B-X
human	B-X
bloodstream	B-X
,	B-X
where	B-X
it	B-X
is	B-X
assiduously	B-X
maintained	B-X
at	B-X
approximately	B-X
0.5	B-X
mM	B-X
through	B-X
a	B-X
combination	B-X
of	B-X
dietary	B-X
uptake	B-X
,	B-X
Altering	B-X
Ki-67	B-X
expression	B-X
levels	B-X
did	B-X
not	B-X
significantly	B-X
affect	B-X
cell	B-X
proliferation	B-X
in	B-X
vivo	B-X
.	B-X

Wild	O
-	O
Type	O
and	O
LMP1	B-Protein
Transgenic	O
Lymphoma	O
Cells	O
Do	O
Not	O
Require	O
IL4	B-Protein
and	O
Stat6	B-Protein
Signaling	O

To	O
investigate	O
whether	O
IL4	B-Protein
independence	O
was	O
due	O
to	O
endogenous	O
IL4	B-Protein
expression	O
,	O
IL4	B-Protein
transcription	O
was	O
assessed	O
by	O
an	O
Rnase	O
protection	O
assay	O
(	O
RPA	O
)	O
.	O

IL4	B-Protein
transcription	O
was	O
detectable	O
with	O
control	O
RNA	O
and	O
faintly	O
in	O
the	O
mouse	O
lymphoma	O
cell	O
line	O
K46mu	O
(	O
Figure	O
4A	O
)	O
.	O

However	O
,	O
IL4	B-Protein
transcription	O
was	O
not	O
detectable	O
in	O
CD19	B-Protein
+	O
MACS	O
-	O
purified	O
B	O
cells	O
from	O
wild	O
-	O
type	O
lymphocytes	O
(	O
unpublished	O
data	O
)	O
,	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
,	O
or	O
lymphoma	O
cells	O
,	O
although	O
the	O
GAPDH	B-Protein
and	O
L32	B-Protein
controls	O
were	O
effectively	O
protected	O
(	O
Figure	O
4A	O
)	O
.	O

Activated	O
Stat6	B-Protein
(	O
pStat6	B-Protein
)	O
,	O
a	O
target	O
of	O
the	O
IL4	B-Protein
receptor	I-Protein
pathway	O
,	O
was	O
detected	O
in	O
the	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
(	O
Figure	O
4B	O
)	O
.	O

In	O
contrast	O
,	O
pStat6	O
was	O
barely	O
detected	O
in	O
either	O
the	O
wild	O
-	O
type	O
or	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
.	O
<EOS>	B-X
MYC	B-X
translocations	B-X
in	B-X
association	B-X
with	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
infection	B-X
are	B-X
often	B-X
observed	B-X
in	B-X
B-cell	B-X
lymphomas	B-X
.	B-X
A	B-X
subset	B-X
of	B-X
Burkitt	B-X
lymphoma	B-X
(	B-X
BL	B-X
)	B-X
expresses	B-X
EBV	B-X
latent	B-X
membrane	B-X
proteins	B-X
1	B-X
and	B-X
2A	B-X
(	B-X
LMP1	B-X
and	B-X
LMP2A	B-X
)	B-X
in	B-X
addition	B-X
to	B-X
the	B-X
typical	B-X
restricted	B-X
EBV	B-X
latent	B-X
gene	B-X
expression	B-X
.	B-X
EBV-associated	B-X
diffuse	B-X
large	B-X
B-cell	B-X
lymphoma	B-X
(	B-X
DLBCL	B-X
)	B-X
typically	B-X
exhibits	B-X
latency	B-X
type	B-X
II	B-X
or	B-X
III	B-X
and	B-X
expresses	B-X
LMP1	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
LMP1	B-X
in	B-X
MYC-driven	B-X
lymphomagenesis	B-X
in	B-X
our	B-X
murine	B-X
model	B-X
.	B-X
LMP2A/λ-MYC	B-X
double-transgenic	B-X
mice	B-X
develop	B-X
tumors	B-X
significantly	B-X
faster	B-X
than	B-X
mice	B-X
only	B-X
expressing	B-X
MYC	B-X
.	B-X
Similar	B-X
to	B-X
LMP2A/λ-MYC	B-X
mice	B-X
,	B-X
LMP1/λ-MYC	B-X
mice	B-X
also	B-X
have	B-X
accelerated	B-X
MYC-driven	B-X
lymphomagenesis	B-X
.	B-X
As	B-X
observed	B-X
in	B-X
LMP2A/λ-MYC	B-X
mice	B-X
,	B-X
p27kip1	B-X
was	B-X
degraded	B-X
in	B-X
LMP1/λ-MYC	B-X
pretumor	B-X
and	B-X
tumor	B-X
B	B-X
cells	B-X
.	B-X
Coexpression	B-X
of	B-X
LMP1	B-X
and	B-X
LMP2A	B-X
resulted	B-X
in	B-X
the	B-X
enhancement	B-X
of	B-X
B	B-X
cell	B-X
proliferation	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
LMP2A	B-X
,	B-X
the	B-X
inhibition	B-X
of	B-X
Syk	B-X
or	B-X
cyclin-dependant	B-X
kinase	B-X
(	B-X
CDK	B-X
)	B-X
4/6	B-X
activity	B-X
did	B-X
not	B-X
effectively	B-X
inhibit	B-X
LMP1-mediated	B-X
MYC	B-X
lymphomagenesis	B-X
.	B-X
Also	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
LMP2A	B-X
,	B-X
LMP1	B-X
did	B-X
not	B-X
lessen	B-X
abnormal	B-X
p53	B-X
expression	B-X
in	B-X
λ-MYC	B-X
tumors	B-X
.	B-X
To	B-X
investigate	B-X
the	B-X
significance	B-X
of	B-X
LMP1	B-X
expression	B-X
in	B-X
human	B-X
BL	B-X
development	B-X
,	B-X
we	B-X
reanalyzed	B-X
RNA	B-X
sequencing	B-X
(	B-X
RNA-Seq	B-X
)	B-X
data	B-X
of	B-X
primary	B-X
human	B-X
BL	B-X
from	B-X
previous	B-X
studies	B-X
.	B-X
Interestingly	B-X
,	B-X
p53	B-X
mutations	B-X
were	B-X
less	B-X
observed	B-X
in	B-X
LMP1-expressing	B-X
BL	B-X
,	B-X
although	B-X
they	B-X
were	B-X
not	B-X
significantly	B-X
changed	B-X
by	B-X
EBV	B-X
infection	B-X
,	B-X
indicating	B-X
LMP1	B-X
may	B-X
lessen	B-X
p53	B-X
mutations	B-X
in	B-X
human	B-X
primary	B-X
BL	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
LMP1	B-X
effects	B-X
in	B-X
EBV-associated	B-X
human	B-X
BL	B-X
vary	B-X
from	B-X
what	B-X
we	B-X
observe	B-X
in	B-X
our	B-X
murine	B-X
model	B-X
.	B-X
Finally	B-X
,	B-X
our	B-X
studies	B-X
suggest	B-X
a	B-X
novel	B-X
pathogenic	B-X
role	B-X
of	B-X
LMP1	B-X
in	B-X
lymphomagenesis	B-X
.	B-X

However	O
,	O
the	O
pathway	O
was	O
not	O
disabled	O
,	O
as	O
treatment	O
of	O
the	O
lymphoma	O
cells	O
with	O
IL4	B-Protein
induced	O
Stat6	B-Protein
phosphorylation	O
(	O
Figure	O
4C	O
)	O
.	O
<EOS>	B-X
Various	B-X
forms	B-X
of	B-X
cell	B-X
death	B-X
have	B-X
been	B-X
identified	B-X
over	B-X
the	B-X
last	B-X
decades	B-X
with	B-X
each	B-X
relying	B-X
on	B-X
a	B-X
different	B-X
subset	B-X
of	B-X
proteins	B-X
for	B-X
the	B-X
activation	B-X
and	B-X
execution	B-X
of	B-X
their	B-X
respective	B-X
pathway	B-X
(	B-X
s	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
the	B-X
three	B-X
best	B-X
characterized	B-X
pathways-apoptosis	B-X
,	B-X
necroptosis	B-X
,	B-X
and	B-X
pyroptosis-other	B-X
forms	B-X
of	B-X
regulated	B-X
cell	B-X
death	B-X
including	B-X
autophagy-dependent	B-X
cell	B-X
death	B-X
(	B-X
ADCD	B-X
)	B-X
,	B-X
mitochondrial	B-X
permeability	B-X
transition	B-X
pore	B-X
(	B-X
MPTP	B-X
)	B-X
-mediated	B-X
necrosis	B-X
,	B-X
parthanatos	B-X
,	B-X
NETosis	B-X
and	B-X
ferroptosis	B-X
,	B-X
and	B-X
their	B-X
relevance	B-X
for	B-X
organismal	B-X
homeostasis	B-X
are	B-X
becoming	B-X
better	B-X
understood	B-X
.	B-X
Importantly	B-X
,	B-X
it	B-X
is	B-X
increasingly	B-X
clear	B-X
that	B-X
none	B-X
of	B-X
these	B-X
pathways	B-X
operate	B-X
alone	B-X
.	B-X
Instead	B-X
,	B-X
a	B-X
more	B-X
complex	B-X
picture	B-X
is	B-X
emerging	B-X
with	B-X
many	B-X
pathways	B-X
sharing	B-X
components	B-X
and	B-X
signaling	B-X
principles	B-X
.	B-X

Although	O
wild	O
-	O
type	O
lymphocytes	O
cannot	O
be	O
maintained	O
in	O
culture	O
with	O
IL4	B-Protein
supplementation	O
alone	O
(	O
Figure	O
3A	O
)	O
,	O
slight	O
enhancement	O
in	O
MTS	O
activity	O
could	O
be	O
detected	O
if	O
the	O
cells	O
were	O
analyzed	O
at	O
an	O
earlier	O
time	O
point	O
,	O
at	O
1	O
d	O
(	O
Figure	O
4D	O
)	O
versus	O
3	O
d	O
(	O
Figure	O
3A	O
)	O
post	O
-	O
harvest	O
.	O

The	O
enhancement	O
of	O
MTS	O
activity	O
induced	O
by	O
IL4	B-Protein
in	O
wild	O
-	O
type	O
lymphocytes	O
could	O
be	O
neutralized	O
by	O
the	O
addition	O
of	O
IL4	B-Protein
antibody	O
(	O
Figure	O
4D	O
)	O
.	O

However	O
,	O
neutralizing	O
antibodies	O
to	O
IL4	B-Protein
did	O
not	O
affect	O
the	O
MTS	O
activity	O
of	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
(	O
Figure	O
4E	O
)	O
.	O
<EOS>	B-X
The	B-X
cells	B-X
participating	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
atherosclerotic	B-X
plaque	B-X
include	B-X
endothelial	B-X
cells	B-X
,	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
(	B-X
VSMC	B-X
)	B-X
,	B-X
monocytes	B-X
,	B-X
monocytes	B-X
derived	B-X
macrophages	B-X
,	B-X
macrophages	B-X
and	B-X
dendritic	B-X
cells	B-X
and	B-X
regulatory	B-X
T	B-X
cells	B-X
(	B-X
T	B-X
A	B-X
single	B-X
prime	B-X
vaccination	B-X
in	B-X
mice	B-X
led	B-X
to	B-X
robust	B-X
antibody	B-X
responses	B-X
,	B-X
with	B-X
neutralizing	B-X
antibody	B-X
titers	B-X
increasing	B-X
up	B-X
to	B-X
day	B-X
60	B-X
.	B-X
However	B-X
,	B-X
the	B-X
underlying	B-X
mechanism	B-X
of	B-X
M2‑like	B-X
TAMs	B-X
in	B-X
ATC	B-X
remains	B-X
unclear	B-X
.	B-X
Transwell	B-X
and	B-X
sphere	B-X
formation	B-X
assays	B-X
were	B-X
applied	B-X
to	B-X
assess	B-X
the	B-X
invasion	B-X
and	B-X
stemness	B-X
of	B-X
ATC	B-X
cells	B-X
.	B-X
Following	B-X
co‑culture	B-X
with	B-X
M2‑like	B-X
TAMs	B-X
,	B-X
the	B-X
invasive	B-X
ability	B-X
and	B-X
stemness	B-X
of	B-X
ATC	B-X
cells	B-X
were	B-X
significantly	B-X
increased	B-X
.	B-X
Of	B-X
note	B-X
,	B-X
exogenous	B-X
IGF‑1/IGF‑2	B-X
promoted	B-X
the	B-X
invasion	B-X
and	B-X
stemness	B-X
of	B-X
C643	B-X
cells	B-X
,	B-X
whereas	B-X
blocking	B-X
IGF‑1	B-X
and	B-X
IGF‑2	B-X
inhibited	B-X
metastasis	B-X
and	B-X
stemness	B-X
by	B-X
repressing	B-X
IR‑A/IGF‑1R‑mediated	B-X
PI3K/AKT/mTOR	B-X
signalling	B-X
in	B-X
the	B-X
co‑culture	B-X
system	B-X
.	B-X
To	B-X
conclude	B-X
,	B-X
M2‑like	B-X
TAMs	B-X
accelerated	B-X
the	B-X
metastasis	B-X
and	B-X
increased	B-X
the	B-X
stemness	B-X
of	B-X
ATC	B-X
cells	B-X
,	B-X
and	B-X
the	B-X
underlying	B-X
mechanism	B-X
may	B-X
be	B-X
related	B-X
to	B-X
the	B-X
section	B-X
of	B-X
IGF	B-X
by	B-X
M2‑like	B-X
TAMs	B-X
,	B-X
which	B-X
activates	B-X
the	B-X
IR‑A/IGF1R‑mediated	B-X
PI3K/AKT/mTOR	B-X
signalling	B-X
pathway	B-X
.	B-X

In	O
summary	O
,	O
the	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
grew	O
independently	O
of	O
IL4	B-Protein
treatment	O
and	O
did	O
not	O
require	O
Stat6	B-Protein
signaling	O
.	O

LMP1	B-Protein
Upregulates	O
IL10	B-Protein
and	O
Constitutively	O
Activates	O
Stat3	B-Protein

To	O
identify	O
cytokines	O
that	O
may	O
contribute	O
to	O
the	O
increased	O
survival	O
and	O
growth	O
of	O
lymphomas	O
,	O
the	O
expression	O
levels	O
of	O
a	O
panel	O
of	O
cytokines	O
were	O
screened	O
on	O
CD19	B-Protein
+	O
MACS	O
-	O
purified	O
B	O
cells	O
,	O
using	O
an	O
RPA	O
probe	O
set	O
for	O
IL4	B-Protein
,	O
IL5	B-Protein
,	O
IL10	B-Protein
,	O
IL13	B-Protein
,	O
IL15	B-Protein
,	O
IL9	B-Protein
,	O
IL2	B-Protein
,	O
IL6	B-Protein
,	O
and	O
IFNgamma	B-Protein
.	O

Expression	O
levels	O
were	O
quantified	O
with	O
a	O
phosphorimager	O
and	O
normalized	O
to	O
the	O
ribosomal	O
housekeeping	O
gene	O
L32	B-Protein
.	O

None	O
of	O
the	O
tested	O
cytokines	O
were	O
detected	O
in	O
wild	O
-	O
type	O
lymphocytes	O
,	O
therefore	O
cytokine	O
:	O
L32	B-Protein
ratios	O
were	O
set	O
to	O
1	O
in	O
the	O
mouse	O
B	O
cell	O
lymphoma	O
line	O
967	O
.	O

Transcription	O
of	O
IL10	B-Protein
,	O
IL15	B-Protein
,	O
and	O
IFNgamma	B-Protein
were	O
reproducibly	O
detected	O
in	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
and	O
was	O
higher	O
than	O
in	O
the	O
B	O
cell	O
lymphoma	O
cell	O
lines	O
967	O
and	O
K46mu	O
(	O
Figure	O
5A	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
expression	O
of	O
IL15	B-Protein
and	O
IFNgamma	B-Protein
between	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
lymphoma	B-Protein
cells	I-Protein
,	O
suggesting	O
that	O
upregulation	O
of	O
IL15	B-Protein
and	O
IFNgamma	B-Protein
is	O
induced	O
by	O
LMP1	B-Protein
expression	O
in	O
healthy	O
lymphocytes	O
but	O
is	O
not	O
a	O
unique	O
property	O
of	O
malignant	O
lymphocytes	O
.	O

Strikingly	O
,	O
IL10	B-Protein
,	O
a	O
B	O
lymphocyte	O
stimulatory	O
cytokine	O
,	O
was	O
increased	O
1	O
.	O
5	O
-	O
to	O
5	O
-	O
fold	O
in	O
the	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
compared	O
to	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
(	O
Figure	O
5A	O
)	O
.	O

Production	O
of	O
IL15	B-Protein
and	O
IFNgamma	B-Protein
has	O
been	O
associated	O
with	O
induction	O
of	O
cytotoxic	O
effector	O
responses	O
in	O
cells	O
latently	O
infected	O
with	O
EBV	O
[	O
33	O
,	O
34	O
]	O
.	O

However	O
,	O
transformation	O
and	O
growth	O
properties	O
induced	O
by	O
EBV	O
are	O
associated	O
with	O
the	O
upregulation	O
of	O
IL10	B-Protein
[	O
35	O
-	O
38	O
]	O
;	O
hence	O
,	O
the	O
effects	O
of	O
IL10	B-Protein
upregulation	O
on	O
the	O
growth	O
properties	O
of	O
the	O
lymphoma	O
cells	O
were	O
further	O
examined	O
.	O

Immunoblot	O
analysis	O
indicated	O
that	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
had	O
corresponding	O
increased	O
levels	O
of	O
phosphorylated	O
alpha	O
and	O
beta	O
isoforms	O
of	O
activated	O
Stat3	B-Protein
,	O
a	O
target	O
of	O
the	O
IL10	B-Protein
receptor	O
(	O
Figure	O
5B	O
)	O
.	O

However	O
,	O
when	O
comparing	O
the	O
same	O
lymphomas	O
,	O
there	O
was	O
no	O
correlation	O
between	O
the	O
levels	O
of	O
IL10	B-Protein
induction	O
and	O
the	O
levels	O
of	O
Stat3	B-Protein
activation	O
.	O

This	O
suggests	O
that	O
the	O
activation	O
of	O
Stat3	B-Protein
is	O
not	O
solely	O
induced	O
by	O
IL10	B-Protein
or	O
that	O
Stat3	B-Protein
activation	O
may	O
be	O
constitutive	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
potential	B-X
molecular	B-X
mechanisms	B-X
for	B-X
constitutive	B-X
expression	B-X
of	B-X
PD-L1	B-X
by	B-X
inhibiting	B-X
upstream	B-X
STAT1	B-X
and	B-X
STAT3	B-X
signals	B-X
.	B-X
As	B-X
a	B-X
converging	B-X
point	B-X
of	B-X
multiple	B-X
oncogenic	B-X
pathways	B-X
,	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
(	B-X
STAT3	B-X
)	B-X
is	B-X
constitutively	B-X
activated	B-X
both	B-X
in	B-X
tumor	B-X
cells	B-X
and	B-X
tumor-infiltrated	B-X
immune	B-X
cells	B-X
.	B-X
Accumulating	B-X
evidence	B-X
suggests	B-X
that	B-X
targeting	B-X
STAT3	B-X
may	B-X
enhance	B-X
anti-cancer	B-X
immune	B-X
responses	B-X
and	B-X
rescue	B-X
the	B-X
suppressed	B-X
immunologic	B-X
microenvironment	B-X
in	B-X
tumors	B-X
.	B-X
Constitutive	B-X
activation	B-X
of	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
(	B-X
STAT3	B-X
)	B-X
is	B-X
a	B-X
common	B-X
feature	B-X
in	B-X
human	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
.	B-X

Additionally	O
,	O
there	O
was	O
no	O
correlation	O
between	O
the	O
levels	O
of	O
LMP1	B-Protein
expression	O
and	O
the	O
levels	O
of	O
IL10	B-Protein
induction	O
(	O
Figures	O
1A	O
and	O
5A	O
)	O
.	O

This	O
indicates	O
that	O
the	O
induction	O
of	O
IL10	B-Protein
is	O
a	O
general	O
property	O
associated	O
with	O
enhanced	O
survival	O
and	O
may	O
only	O
be	O
indirectly	O
affected	O
by	O
LMP1	B-Protein
.	O

Neutralizing	O
antibodies	O
to	O
IL10	B-Protein
did	O
not	O
affect	O
the	O
survival	O
of	O
lymphoma	O
cells	O
as	O
determined	O
by	O
the	O
MTS	O
assay	O
(	O
unpublished	O
data	O
)	O
,	O
suggesting	O
constitutive	O
activation	O
of	O
Stat3	B-Protein
.	O
<EOS>	B-X
Secondary	B-X
failure	B-X
and	B-X
adverse	B-X
events	B-X
can	B-X
be	B-X
related	B-X
to	B-X
the	B-X
development	B-X
of	B-X
anti-drug	B-X
antibodies	B-X
(	B-X
ADA	B-X
)	B-X
.	B-X
The	B-X
earliest	B-X
studies	B-X
that	B-X
reported	B-X
ADA	B-X
toward	B-X
TNFi	B-X
mainly	B-X
used	B-X
drug-sensitive	B-X
assays	B-X
.	B-X
Drug-tolerant	B-X
ADA	B-X
assays	B-X
also	B-X
detect	B-X
ADA	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
drug	B-X
,	B-X
which	B-X
has	B-X
contributed	B-X
to	B-X
the	B-X
currently	B-X
reported	B-X
higher	B-X
incidence	B-X
of	B-X
ADA	B-X
development	B-X
.	B-X
Comprehension	B-X
and	B-X
awareness	B-X
of	B-X
the	B-X
assay	B-X
format	B-X
used	B-X
for	B-X
ADA	B-X
detection	B-X
is	B-X
thus	B-X
essential	B-X
to	B-X
interpret	B-X
ADA	B-X
measurements	B-X
correctly	B-X
.	B-X
The	B-X
ADA	B-X
response	B-X
generally	B-X
gives	B-X
rise	B-X
to	B-X
high	B-X
affinity	B-X
IgG	B-X
antibodies	B-X
,	B-X
but	B-X
this	B-X
response	B-X
will	B-X
differ	B-X
between	B-X
patients	B-X
.	B-X
It	B-X
will	B-X
highlight	B-X
the	B-X
ADA	B-X
assays	B-X
,	B-X
characteristics	B-X
and	B-X
regulation	B-X
of	B-X
the	B-X
ADA	B-X
response	B-X
,	B-X
impact	B-X
of	B-X
immunogenicity	B-X
on	B-X
the	B-X
pharmacokinetics	B-X
of	B-X
TNFi	B-X
,	B-X
clinical	B-X
implications	B-X
of	B-X
ADA	B-X
formation	B-X
,	B-X
and	B-X
possible	B-X
mitigation	B-X
strategies	B-X
.	B-X

This	O
was	O
confirmed	O
by	O
immunoblot	O
analysis	O
such	O
that	O
in	O
the	O
presence	O
of	O
anti	O
-	O
IL10	B-Protein
neutralizing	O
antibodies	O
,	O
pStat3	B-Protein
levels	O
remained	O
activated	O
in	O
lymphoma	O
cells	O
isolated	O
from	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphomas	O
(	O
Figure	O
5C	O
)	O
.	O

Exogenous	O
addition	O
of	O
IL10	B-Protein
enhanced	O
pStat3	B-Protein
activation	O
above	O
constitutive	O
levels	O
,	O
indicating	O
that	O
lymphoma	O
cells	O
are	O
responsive	O
to	O
IL10	B-Protein
treatment	O
(	O
Figure	O
5C	O
)	O
.	O

This	O
means	O
that	O
although	O
the	O
lymphoma	O
cells	O
have	O
constitutive	O
Stat3	B-Protein
activation	O
,	O
it	O
may	O
be	O
further	O
enhanced	O
by	O
IL10	B-Protein
induction	O
.	O

The	O
neutralizing	O
effect	O
of	O
the	O
anti	O
-	O
IL10	B-Protein
antibody	O
was	O
confirmed	O
by	O
pre	O
-	O
incubation	O
of	O
IL10	B-Protein
with	O
anti	O
-	O
IL10	B-Protein
antibody	O
compared	O
to	O
a	O
rat	O
IgG1	O
isotype	O
control	O
(	O
Figure	O
5C	O
)	O
.	O

Nuclear	O
translocation	O
of	O
pStat3	B-Protein
is	O
a	O
consequence	O
of	O
activation	O
,	O
and	O
nuclear	O
pStat3	B-Protein
was	O
not	O
detected	O
by	O
immunohistochemistry	O
staining	O
of	O
spleen	O
sections	O
from	O
control	O
mice	O
.	O
<EOS>	B-X
Transcription	B-X
factors	B-X
,	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
3	B-X
(	B-X
STAT3	B-X
)	B-X
and	B-X
nuclear	B-X
factor-κB	B-X
(	B-X
NF-κB	B-X
)	B-X
,	B-X
are	B-X
vital	B-X
players	B-X
in	B-X
the	B-X
many	B-X
steps	B-X
of	B-X
carcinogenesis	B-X
.	B-X
B1	B-X
showed	B-X
significant	B-X
dose-response	B-X
inhibitory	B-X
effects	B-X
on	B-X
cytoplasmic	B-X
expression	B-X
and	B-X
nuclear	B-X
translocation	B-X
of	B-X
both	B-X
phosphorylated	B-X
STAT3	B-X
(	B-X
pSTAT3	B-X
)	B-X
and	B-X
NF-κB	B-X
.	B-X

However	O
,	O
nuclear	O
pStat3	B-Protein
was	O
detectable	O
in	O
LMP1	B-Protein
transgenic	O
mice	O
and	O
wild	O
-	O
type	O
lymphomas	O
and	O
was	O
detected	O
more	O
homogeneously	O
in	O
LMP1	B-Protein
transgenic	O
lymphomas	O
(	O
Figure	O
5D	O
)	O
.	O

The	O
constitutive	O
activation	O
of	O
pStat3	B-Protein
and	O
abundant	O
nuclear	O
Stat3	B-Protein
suggests	O
that	O
Stat3	B-Protein
signaling	O
contributes	O
to	O
LMP1	B-Protein
-	O
mediated	O
lymphoma	O
development	O
.	O

LMP1	B-Protein
Activates	O
Akt	B-Protein
Signaling	O
and	O
Deregulates	O
the	O
Rb	B-Protein
Cell	O
Cycle	O
Pathway	O

LMP1	B-Protein
transformation	O
of	O
rodent	O
fibroblasts	O
requires	O
activation	O
of	O
PI3K	O
and	O
Akt	B-Protein
[	O
5	O
]	O
.	O
<EOS>	B-X
The	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
latent	B-X
membrane	B-X
protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
gene	B-X
is	B-X
considered	B-X
the	B-X
EBV	B-X
oncogene	B-X
as	B-X
it	B-X
is	B-X
necessary	B-X
for	B-X
EBV-mediated	B-X
transformation	B-X
of	B-X
B	B-X
lymphocytes	B-X
and	B-X
itself	B-X
transforms	B-X
rodent	B-X
fibroblasts	B-X
.	B-X
LMP1	B-X
activates	B-X
the	B-X
NF-kappaB	B-X
,	B-X
phosphatidylinositol	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
-Akt	B-X
,	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
,	B-X
and	B-X
Jun	B-X
N-terminal	B-X
protein	B-X
kinase	B-X
signaling	B-X
pathways	B-X
through	B-X
its	B-X
two	B-X
signaling	B-X
domains	B-X
,	B-X
carboxyl-terminal	B-X
activating	B-X
regions	B-X
1	B-X
and	B-X
2	B-X
(	B-X
CTAR1	B-X
and	B-X
CTAR2	B-X
)	B-X
.	B-X
CTAR1	B-X
is	B-X
necessary	B-X
for	B-X
LMP1-mediated	B-X
transformation	B-X
as	B-X
well	B-X
as	B-X
activation	B-X
of	B-X
PI3K	B-X
signaling	B-X
and	B-X
induction	B-X
of	B-X
cell	B-X
cycle	B-X
markers	B-X
associated	B-X
with	B-X
G	B-X
(	B-X
1	B-X
)	B-X
/S	B-X
transition	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
activation	B-X
of	B-X
PI3K-Akt	B-X
signaling	B-X
and	B-X
deregulation	B-X
of	B-X
cell	B-X
cycle	B-X
markers	B-X
were	B-X
mapped	B-X
to	B-X
the	B-X
TRAF-binding	B-X
domain	B-X
within	B-X
CTAR1	B-X
and	B-X
to	B-X
the	B-X
residues	B-X
between	B-X
CTAR1	B-X
and	B-X
CTAR2	B-X
.	B-X
LMP1	B-X
CTAR1	B-X
also	B-X
activated	B-X
the	B-X
MEK1/2-extracellular	B-X
signal-regulated	B-X
kinase	B-X
1/2	B-X
signaling	B-X
pathway	B-X
,	B-X
and	B-X
this	B-X
activation	B-X
was	B-X
necessary	B-X
for	B-X
LMP1-induced	B-X
transformation	B-X
of	B-X
Rat-1	B-X
fibroblasts	B-X
.	B-X
Dominant-negative	B-X
forms	B-X
of	B-X
TRAF2	B-X
and	B-X
TRAF3	B-X
inhibited	B-X
but	B-X
did	B-X
not	B-X
fully	B-X
block	B-X
LMP1-mediated	B-X
transformation	B-X
.	B-X
These	B-X
findings	B-X
identify	B-X
a	B-X
new	B-X
signaling	B-X
pathway	B-X
that	B-X
is	B-X
uniquely	B-X
activated	B-X
by	B-X
the	B-X
TRAF-binding	B-X
domain	B-X
of	B-X
LMP1	B-X
and	B-X
is	B-X
required	B-X
for	B-X
transformation	B-X
.	B-X

Additionally	O
,	O
activated	O
pAkt	B-Protein
is	O
frequently	O
detected	O
in	O
NPC	O
and	O
the	O
neoplastic	O
Reed	O
-	O
Sternberg	O
cells	O
of	O
classical	O
HD	O
[	O
39	O
,	O
40	O
]	O
.	O

To	O
determine	O
if	O
Akt	B-Protein
signaling	O
is	O
activated	O
in	O
LMP1	B-Protein
transgenic	O
mice	O
,	O
pAkt	B-Protein
and	O
several	O
of	O
its	O
targets	O
were	O
assessed	O
by	O
immunoblotting	O
of	O
splenic	O
CD19	B-Protein
+	O
MACS	O
-	O
purified	O
B	O
cells	O
.	O

LMP1	B-Protein
transgenic	O
B	O
cells	O
had	O
increased	O
levels	O
of	O
pAkt	B-Protein
compared	O
to	O
wild	O
-	O
type	O
lymphocytes	O
;	O
however	O
,	O
progression	O
to	O
lymphoma	O
in	O
both	O
LMP1	B-Protein
-	O
positive	O
and	O
-	O
negative	O
lymphoma	O
cells	O
did	O
not	O
further	O
increase	O
pAkt	B-Protein
levels	O
.	O

The	O
Akt	B-Protein
target	O
glycogen	B-Protein
synthase	I-Protein
kinase	I-Protein
3	I-Protein
(	O
GSK3	B-Protein
)	O
is	O
inactivated	O
by	O
phosphorylation	O
;	O
however	O
,	O
increased	O
phosphorylated	O
GSK3	B-Protein
was	O
not	O
detected	O
in	O
the	O
transgenic	O
lymphocytes	O
and	O
was	O
almost	O
absent	O
in	O
the	O
lymphoma	O
samples	O
(	O
Figure	O
6A	O
)	O
.	O
<EOS>	B-X
Glycogen	B-X
synthase	B-X
kinase	B-X
3	B-X
(	B-X
GSK-3	B-X
)	B-X
is	B-X
a	B-X
serine/threonine	B-X
(	B-X
S/T	B-X
)	B-X
protein	B-X
kinase	B-X
.	B-X
Although	B-X
GSK-3	B-X
originally	B-X
was	B-X
identified	B-X
to	B-X
have	B-X
functions	B-X
in	B-X
regulation	B-X
of	B-X
glycogen	B-X
synthase	B-X
,	B-X
it	B-X
was	B-X
subsequently	B-X
determined	B-X
to	B-X
have	B-X
roles	B-X
in	B-X
multiple	B-X
normal	B-X
biochemical	B-X
processes	B-X
as	B-X
well	B-X
as	B-X
various	B-X
disease	B-X
conditions	B-X
.	B-X
GSK-3	B-X
is	B-X
sometimes	B-X
referred	B-X
to	B-X
as	B-X
a	B-X
moonlighting	B-X
protein	B-X
due	B-X
to	B-X
the	B-X
multiple	B-X
substrates	B-X
and	B-X
processes	B-X
which	B-X
it	B-X
controls	B-X
.	B-X
Frequently	B-X
,	B-X
when	B-X
GSK-3	B-X
phosphorylates	B-X
proteins	B-X
,	B-X
they	B-X
are	B-X
targeted	B-X
for	B-X
degradation	B-X
.	B-X
GSK-3	B-X
is	B-X
often	B-X
considered	B-X
a	B-X
component	B-X
of	B-X
the	B-X
PI3K/PTEN/AKT/GSK-3/mTORC1	B-X
pathway	B-X
as	B-X
GSK-3	B-X
is	B-X
frequently	B-X
phosphorylated	B-X
by	B-X
AKT	B-X
which	B-X
regulates	B-X
its	B-X
inactivation	B-X
.	B-X
AKT	B-X
is	B-X
often	B-X
active	B-X
in	B-X
human	B-X
cancer	B-X
and	B-X
hence	B-X
,	B-X
GSK-3	B-X
is	B-X
often	B-X
inactivated	B-X
.	B-X
Moreover	B-X
,	B-X
GSK-3	B-X
also	B-X
interacts	B-X
with	B-X
WNT/β-catenin	B-X
signaling	B-X
and	B-X
β-catenin	B-X
and	B-X
other	B-X
proteins	B-X
in	B-X
this	B-X
pathway	B-X
are	B-X
targets	B-X
of	B-X
GSK-3	B-X
.	B-X
GSK-3	B-X
can	B-X
modify	B-X
NF-κB	B-X
activity	B-X
which	B-X
is	B-X
often	B-X
expressed	B-X
at	B-X
high	B-X
levels	B-X
in	B-X
cancer	B-X
cells	B-X
.	B-X
Multiple	B-X
pharmaceutical	B-X
companies	B-X
developed	B-X
small	B-X
molecule	B-X
inhibitors	B-X
to	B-X
suppress	B-X
GSK-3	B-X
activity	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
various	B-X
natural	B-X
products	B-X
will	B-X
modify	B-X
GSK-3	B-X
activity	B-X
.	B-X
This	B-X
review	B-X
will	B-X
focus	B-X
on	B-X
the	B-X
effects	B-X
of	B-X
small	B-X
molecule	B-X
inhibitors	B-X
and	B-X
natural	B-X
products	B-X
on	B-X
GSK-3	B-X
activity	B-X
and	B-X
provide	B-X
examples	B-X
where	B-X
these	B-X
compounds	B-X
were	B-X
effective	B-X
in	B-X
suppressing	B-X
cancer	B-X
growth	B-X
.	B-X

This	O
finding	O
indicates	O
that	O
GSK3	B-Protein
is	O
not	O
a	O
target	O
of	O
activated	O
Akt	B-Protein
in	O
the	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
discovered	B-X
that	B-X
the	B-X
glycogen	B-X
synthase	B-X
kinase	B-X
3	B-X
(	B-X
GSK3	B-X
)	B-X
-like	B-X
kinase	B-X
,	B-X
GmSK2-8	B-X
,	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
inhibiting	B-X
symbiotic	B-X
signaling	B-X
and	B-X
nodule	B-X
formation	B-X
in	B-X
soybean	B-X
(	B-X
Glycine	B-X
max	B-X
)	B-X
under	B-X
salt	B-X
stress	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
findings	B-X
indicate	B-X
that	B-X
GSK3-like	B-X
kinases	B-X
directly	B-X
regulate	B-X
the	B-X
activities	B-X
of	B-X
GmNSP1s	B-X
to	B-X
mediate	B-X
salt-inhibited	B-X
legume-rhizobium	B-X
symbiosis	B-X
,	B-X
providing	B-X
novel	B-X
targets	B-X
for	B-X
improving	B-X
symbiotic	B-X
nitrogen	B-X
fixation	B-X
under	B-X
environmental	B-X
stress	B-X
conditions	B-X
in	B-X
soybean	B-X
and	B-X
possibly	B-X
other	B-X
legumes	B-X
.	B-X
New	B-X
findings	B-X
have	B-X
indicated	B-X
that	B-X
its	B-X
comprehensive	B-X
structure	B-X
may	B-X
contribute	B-X
to	B-X
its	B-X
polypharmacological	B-X
activities	B-X
particularly	B-X
in	B-X
cancer	B-X
and	B-X
neurodegenerative	B-X
disease	B-X
therapy	B-X
,	B-X
as	B-X
both	B-X
of	B-X
these	B-X
diseases	B-X
are	B-X
usually	B-X
accompanied	B-X
by	B-X
a	B-X
common	B-X
molecular	B-X
link	B-X
related	B-X
to	B-X
abnormal	B-X
phosphorylation	B-X
of	B-X
CDKs	B-X
and	B-X
GSK-3	B-X
.	B-X
Recent	B-X
findings	B-X
indicate	B-X
,	B-X
however	B-X
,	B-X
that	B-X
beta-catenin	B-X
also	B-X
plays	B-X
a	B-X
significant	B-X
role	B-X
in	B-X
fibro-proliferative	B-X
diseases	B-X
of	B-X
several	B-X
organ	B-X
systems	B-X
and	B-X
that	B-X
beta-catenin	B-X
regulates	B-X
mitogenic	B-X
responses	B-X
of	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
As	B-X
several	B-X
diseases	B-X
of	B-X
the	B-X
internal	B-X
organs	B-X
are	B-X
characterized	B-X
by	B-X
structural	B-X
and	B-X
phenotypic	B-X
abnormalities	B-X
of	B-X
smooth	B-X
muscle	B-X
,	B-X
including	B-X
increased	B-X
fibro-proliferative	B-X
responses	B-X
,	B-X
these	B-X
findings	B-X
implicate	B-X
that	B-X
beta-catenin	B-X
could	B-X
play	B-X
a	B-X
broad	B-X
pathophysiological	B-X
role	B-X
.	B-X

Similarly	O
,	O
activation	O
of	O
Akt	B-Protein
without	O
phosphorylation	O
of	O
GSK3	B-Protein
has	O
been	O
previously	O
shown	O
in	O
EBV	O
-	O
positive	O
HD	O
[	O
40	O
]	O
.	O

In	O
contrast	O
,	O
the	O
wild	O
-	O
type	O
lymphocytes	O
lacked	O
activated	O
Akt	B-Protein
but	O
did	O
have	O
detectable	O
phosphorylated	O
GSK3	B-Protein
.	O

This	O
further	O
suggests	O
that	O
additional	O
pathways	O
are	O
involved	O
in	O
the	O
regulation	O
of	O
GSK3	B-Protein
.	O
<EOS>	B-X
Given	B-X
the	B-X
inherently	B-X
complex	B-X
nature	B-X
of	B-X
the	B-X
pathophysiology	B-X
of	B-X
bipolar	B-X
disorder	B-X
,	B-X
this	B-X
paper	B-X
aims	B-X
to	B-X
capture	B-X
what	B-X
is	B-X
known	B-X
about	B-X
the	B-X
actions	B-X
of	B-X
lithium	B-X
ranging	B-X
from	B-X
macroscopic	B-X
changes	B-X
in	B-X
mood	B-X
,	B-X
cognition	B-X
and	B-X
brain	B-X
structure	B-X
,	B-X
to	B-X
its	B-X
effects	B-X
at	B-X
the	B-X
microscopic	B-X
level	B-X
on	B-X
neurotransmission	B-X
and	B-X
intracellular	B-X
and	B-X
molecular	B-X
pathways	B-X
.	B-X
Interestingly	B-X
,	B-X
lithium	B-X
appears	B-X
to	B-X
preserve	B-X
or	B-X
increase	B-X
the	B-X
volume	B-X
of	B-X
brain	B-X
structures	B-X
involved	B-X
in	B-X
emotional	B-X
regulation	B-X
such	B-X
as	B-X
the	B-X
prefrontal	B-X
cortex	B-X
,	B-X
hippocampus	B-X
and	B-X
amygdala	B-X
,	B-X
possibly	B-X
reflecting	B-X
its	B-X
neuroprotective	B-X
effects	B-X
.	B-X
For	B-X
instance	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
lithium	B-X
on	B-X
the	B-X
adenyl	B-X
cyclase	B-X
and	B-X
phospho-inositide	B-X
pathways	B-X
,	B-X
as	B-X
well	B-X
as	B-X
protein	B-X
kinase	B-X
C	B-X
,	B-X
may	B-X
serve	B-X
to	B-X
dampen	B-X
excessive	B-X
excitatory	B-X
neurotransmission	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
identify	B-X
novel	B-X
miRNAs	B-X
involved	B-X
in	B-X
GC	B-X
metastasis	B-X
and	B-X
explored	B-X
their	B-X
regulatory	B-X
mechanisms	B-X
and	B-X
therapeutic	B-X
significance	B-X
in	B-X
GC	B-X
.	B-X

To	O
identify	O
other	O
potential	O
Akt	B-Protein
targets	O
,	O
immunoblot	O
analysis	O
for	O
p	B-Protein
-	I-Protein
mTOR	I-Protein
was	O
performed	O
.	O
<EOS>	B-X
Alterations	B-X
of	B-X
the	B-X
Akt/mTOR	B-X
pathway	B-X
have	B-X
been	B-X
observed	B-X
in	B-X
numerous	B-X
types	B-X
of	B-X
cancer	B-X
,	B-X
thus	B-X
this	B-X
pathway	B-X
represents	B-X
an	B-X
exciting	B-X
new	B-X
target	B-X
for	B-X
molecular	B-X
therapeutics	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
expression	B-X
of	B-X
activated	B-X
Akt	B-X
(	B-X
p-Akt	B-X
)	B-X
and	B-X
mTOR	B-X
(	B-X
p-mTOR	B-X
)	B-X
in	B-X
patients	B-X
with	B-X
adenocarcinoma	B-X
of	B-X
the	B-X
cervix	B-X
and	B-X
the	B-X
involvement	B-X
of	B-X
the	B-X
p-Akt/p-mTOR	B-X
pathway	B-X
in	B-X
response	B-X
to	B-X
combination	B-X
of	B-X
inhibitor	B-X
agents	B-X
,	B-X
rapamycin	B-X
and	B-X
LY294002	B-X
,	B-X
with	B-X
conventional	B-X
therapy	B-X
,	B-X
cisplatin	B-X
,	B-X
in	B-X
vitro	B-X
.	B-X
Immunohistochemistry	B-X
analysis	B-X
of	B-X
p-Akt	B-X
and	B-X
p-mTOR	B-X
was	B-X
conducted	B-X
in	B-X
26	B-X
patients	B-X
with	B-X
adenocarcinoma	B-X
of	B-X
the	B-X
cervix	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
was	B-X
performed	B-X
to	B-X
determine	B-X
the	B-X
protein	B-X
expression	B-X
involved	B-X
in	B-X
response	B-X
to	B-X
chemotherapy	B-X
in	B-X
cervical	B-X
cancer	B-X
cell	B-X
lines	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
p-Akt	B-X
and	B-X
p-mTOR	B-X
were	B-X
identified	B-X
in	B-X
50	B-X
%	B-X
and	B-X
53.8	B-X
%	B-X
of	B-X
adenocarcinoma	B-X
of	B-X
the	B-X
cervix	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
p-mTOR	B-X
was	B-X
a	B-X
significant	B-X
independent	B-X
marker	B-X
for	B-X
prognosis	B-X
.	B-X
A	B-X
significant	B-X
correlation	B-X
between	B-X
p-Akt	B-X
and	B-X
p-mTOR	B-X
was	B-X
observed	B-X
.	B-X
There	B-X
was	B-X
no	B-X
correlation	B-X
between	B-X
their	B-X
expressions	B-X
with	B-X
any	B-X
of	B-X
clinicopathological	B-X
factors	B-X
.	B-X
In	B-X
the	B-X
in	B-X
vitro	B-X
study	B-X
,	B-X
cisplatin	B-X
at	B-X
CPI	B-X
(	B-X
50	B-X
)	B-X
targets	B-X
both	B-X
the	B-X
apoptosis	B-X
and	B-X
survival	B-X
pathway	B-X
by	B-X
activating	B-X
the	B-X
caspase-cascade	B-X
;	B-X
inhibiting	B-X
Akt	B-X
,	B-X
mTOR	B-X
,	B-X
p70S6K	B-X
,	B-X
and	B-X
4EBP1	B-X
.	B-X
Combination	B-X
of	B-X
rapamycin	B-X
with	B-X
cisplatin	B-X
induced	B-X
synergistic	B-X
interaction	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
combination	B-X
with	B-X
LY294002	B-X
resulted	B-X
in	B-X
either	B-X
synergistic	B-X
or	B-X
antagonistic	B-X
effect	B-X
depending	B-X
on	B-X
the	B-X
doses	B-X
given	B-X
.	B-X
Rapamycin	B-X
pretreatment	B-X
potentiated	B-X
cisplatin-induced	B-X
apoptosis	B-X
cell	B-X
death	B-X
and	B-X
enhanced	B-X
blocking	B-X
of	B-X
the	B-X
survival	B-X
pathway	B-X
.	B-X
Overall	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
p-mTOR	B-X
is	B-X
a	B-X
significant	B-X
prognostic	B-X
marker	B-X
of	B-X
adenocarcinoma	B-X
of	B-X
the	B-X
cervix	B-X
and	B-X
a	B-X
potential	B-X
molecular	B-X
target	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
cervical	B-X
cancer	B-X
.	B-X
Inhibition	B-X
of	B-X
the	B-X
mTOR	B-X
pathway	B-X
contributes	B-X
to	B-X
cisplatin-induced	B-X
apoptosis	B-X
in	B-X
cervical	B-X
cancer	B-X
cell	B-X
lines	B-X
.	B-X

Activated	O
p	B-Protein
-	I-Protein
mTOR	I-Protein
was	O
not	O
increased	O
in	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
or	O
lymphoma	O
cells	O
,	O
indicating	O
that	O
this	O
pathway	O
is	O
not	O
affected	O
by	O
LMP1	B-Protein
-	O
induced	O
Akt	B-Protein
activation	O
and	O
does	O
not	O
contribute	O
to	O
lymphoma	O
development	O
(	O
Figure	O
6B	O
)	O
.	O
<EOS>	B-X
The	B-X
CD19	B-X
antigen	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
clinical	B-X
oncology	B-X
.	B-X
In	B-X
normal	B-X
cells	B-X
,	B-X
it	B-X
is	B-X
the	B-X
most	B-X
ubiquitously	B-X
expressed	B-X
protein	B-X
in	B-X
the	B-X
B	B-X
lymphocyte	B-X
lineage	B-X
.	B-X
CD19	B-X
expression	B-X
is	B-X
induced	B-X
at	B-X
the	B-X
point	B-X
of	B-X
B	B-X
lineage	B-X
commitment	B-X
during	B-X
the	B-X
differentiation	B-X
of	B-X
the	B-X
hematopoietic	B-X
stem	B-X
cell	B-X
,	B-X
and	B-X
its	B-X
expression	B-X
continues	B-X
through	B-X
preB	B-X
and	B-X
mature	B-X
B	B-X
cell	B-X
differentiation	B-X
until	B-X
it	B-X
is	B-X
finally	B-X
down-regulated	B-X
during	B-X
terminal	B-X
differentiation	B-X
into	B-X
plasma	B-X
cells	B-X
.	B-X
CD19	B-X
expression	B-X
is	B-X
maintained	B-X
in	B-X
B-lineage	B-X
cells	B-X
that	B-X
have	B-X
undergone	B-X
neoplastic	B-X
transformation	B-X
,	B-X
and	B-X
therefore	B-X
CD19	B-X
is	B-X
useful	B-X
in	B-X
diagnosis	B-X
of	B-X
leukemias	B-X
and	B-X
lymphomas	B-X
using	B-X
monoclonal	B-X
antibodies	B-X
(	B-X
mAbs	B-X
)	B-X
and	B-X
flow	B-X
cytometry	B-X
.	B-X
Interestingly	B-X
,	B-X
CD19	B-X
is	B-X
also	B-X
expressed	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
acute	B-X
myelogenous	B-X
leukemias	B-X
(	B-X
AMLs	B-X
)	B-X
indicating	B-X
the	B-X
close	B-X
relationship	B-X
between	B-X
the	B-X
lymphoid	B-X
and	B-X
myeloid	B-X
lineages	B-X
.	B-X
Because	B-X
B	B-X
lineage	B-X
leukemias	B-X
and	B-X
lymphomas	B-X
rarely	B-X
lose	B-X
CD19	B-X
expression	B-X
,	B-X
and	B-X
because	B-X
it	B-X
is	B-X
not	B-X
expressed	B-X
in	B-X
the	B-X
pluripotent	B-X
stem	B-X
cell	B-X
,	B-X
it	B-X
has	B-X
become	B-X
the	B-X
target	B-X
for	B-X
a	B-X
variety	B-X
of	B-X
immunotherapeutic	B-X
agents	B-X
,	B-X
including	B-X
immunotoxins	B-X
.	B-X
Treatment	B-X
of	B-X
non-Hodgkin	B-X
's	B-X
lymphoma	B-X
(	B-X
NHL	B-X
)	B-X
and	B-X
acute	B-X
lymphocytic	B-X
leukemia	B-X
(	B-X
ALL	B-X
)	B-X
with	B-X
anti-CD19	B-X
mAbs	B-X
coupled	B-X
to	B-X
biological	B-X
toxins	B-X
has	B-X
proven	B-X
to	B-X
be	B-X
effective	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
animal	B-X
models	B-X
,	B-X
and	B-X
has	B-X
shown	B-X
some	B-X
promising	B-X
results	B-X
in	B-X
Phase	B-X
I	B-X
clinical	B-X
trials	B-X
.	B-X
Recently	B-X
,	B-X
the	B-X
analysis	B-X
of	B-X
anti-CD19	B-X
effects	B-X
on	B-X
lymphoma	B-X
cell	B-X
growth	B-X
has	B-X
highlighted	B-X
a	B-X
novel	B-X
mechanism	B-X
of	B-X
immunotherapy	B-X
.	B-X
Engagement	B-X
of	B-X
cell	B-X
surface	B-X
receptors	B-X
like	B-X
CD19	B-X
by	B-X
mAbs	B-X
can	B-X
have	B-X
anti-tumor	B-X
effects	B-X
by	B-X
the	B-X
activation	B-X
of	B-X
signal	B-X
transduction	B-X
pathways	B-X
which	B-X
control	B-X
cell	B-X
cycle	B-X
progression	B-X
and	B-X
programmed	B-X
cell	B-X
death	B-X
(	B-X
apoptosis	B-X
)	B-X
.	B-X

Akt	B-Protein
is	O
also	O
known	O
to	O
phosphorylate	O
and	O
induce	O
the	O
degradation	O
of	O
the	O
pro	O
-	O
apoptotic	O
Forkhead	O
family	O
of	O
transcription	O
factors	O
,	O
leading	O
to	O
cell	O
cycle	O
progression	O
and	O
survival	O
in	O
some	O
human	O
tumors	O
[	O
41	O
,	O
42	O
]	O
.	O

Immunoblot	O
analysis	O
of	O
splenic	O
B	O
cells	O
did	O
not	O
consistently	O
detect	O
p	O
-	O
FoxO1	B-Protein
levels	O
,	O
a	O
signal	O
that	O
targets	O
FoxO1	B-Protein
for	O
degradation	O
.	O
<EOS>	B-X
B-1a	B-X
cells	B-X
are	B-X
a	B-X
unique	B-X
subset	B-X
of	B-X
B	B-X
cells	B-X
that	B-X
are	B-X
phenotypically	B-X
and	B-X
functionally	B-X
distinguishable	B-X
from	B-X
conventional	B-X
(	B-X
B-2	B-X
)	B-X
cells	B-X
.	B-X
Here	B-X
we	B-X
detail	B-X
methods	B-X
to	B-X
analyze	B-X
signaling	B-X
events	B-X
in	B-X
B-1a	B-X
cells	B-X
.	B-X
We	B-X
demonstrate	B-X
by	B-X
flow	B-X
cytometry	B-X
and	B-X
Western	B-X
blot	B-X
that	B-X
mouse	B-X
peritoneal	B-X
B-1a	B-X
but	B-X
not	B-X
splenic	B-X
B-2	B-X
cells	B-X
have	B-X
constitutive	B-X
activation	B-X
of	B-X
signal	B-X
transducers	B-X
and	B-X
activators	B-X
of	B-X
transcription-3	B-X
(	B-X
Stat3	B-X
)	B-X
and	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
Erk	B-X
)	B-X
.	B-X
GIMAP	B-X
(	B-X
GTPase	B-X
of	B-X
the	B-X
immunity-associated	B-X
protein	B-X
family	B-X
)	B-X
proteins	B-X
are	B-X
a	B-X
family	B-X
of	B-X
putative	B-X
GTPases	B-X
believed	B-X
to	B-X
be	B-X
regulators	B-X
of	B-X
cell	B-X
death	B-X
in	B-X
lymphomyeloid	B-X
cells	B-X
.	B-X
GIMAP1	B-X
was	B-X
the	B-X
first	B-X
reported	B-X
member	B-X
of	B-X
this	B-X
gene	B-X
family	B-X
,	B-X
identified	B-X
as	B-X
a	B-X
gene	B-X
up-regulated	B-X
at	B-X
the	B-X
RNA	B-X
level	B-X
in	B-X
the	B-X
spleens	B-X
of	B-X
mice	B-X
infected	B-X
with	B-X
the	B-X
malarial	B-X
parasite	B-X
,	B-X
Plasmodium	B-X
chabaudi	B-X
.	B-X

Hence	O
,	O
degradation	O
of	O
FoxO1	B-Protein
was	O
assessed	O
by	O
detection	O
of	O
total	O
FoxO1	B-Protein
levels	O
.	O

Immunoblot	O
analysis	O
indicated	O
that	O
total	O
FoxO1	B-Protein
levels	O
were	O
greatly	O
decreased	O
in	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphomas	O
(	O
Figure	O
6B	O
)	O
,	O
suggesting	O
that	O
inhibition	O
of	O
the	O
Forkhead	O
signaling	O
pathway	O
is	O
an	O
important	O
target	O
of	O
Akt	B-Protein
in	O
lymphoma	O
development	O
.	O

However	O
,	O
considering	O
that	O
Akt	B-Protein
activation	O
did	O
not	O
induce	O
FoxO1	B-Protein
degradation	O
in	O
LMP1	B-Protein
transgenic	O
B	O
cells	O
,	O
Akt	B-Protein
may	O
not	O
be	O
the	O
sole	O
regulator	O
of	O
FoxO1	B-Protein
,	O
and	O
it	O
may	O
be	O
that	O
progression	O
to	O
lymphoma	O
requires	O
modulation	O
of	O
multiple	O
pathways	O
.	O
<EOS>	B-X
Recently	B-X
,	B-X
Nrf2/HO-1	B-X
has	B-X
received	B-X
extensive	B-X
attention	B-X
as	B-X
the	B-X
main	B-X
regulatory	B-X
pathway	B-X
of	B-X
intracellular	B-X
defense	B-X
against	B-X
oxidative	B-X
stress	B-X
and	B-X
is	B-X
considered	B-X
an	B-X
ideal	B-X
target	B-X
for	B-X
alleviating	B-X
endothelial	B-X
cell	B-X
(	B-X
EC	B-X
)	B-X
injury	B-X
.	B-X
Since	B-X
cancer	B-X
stem	B-X
cells	B-X
(	B-X
CSCs	B-X
)	B-X
were	B-X
first	B-X
identified	B-X
in	B-X
leukemia	B-X
in	B-X
1994	B-X
,	B-X
they	B-X
have	B-X
been	B-X
considered	B-X
promising	B-X
therapeutic	B-X
targets	B-X
for	B-X
cancer	B-X
therapy	B-X
.	B-X
These	B-X
cells	B-X
have	B-X
self-renewal	B-X
capacity	B-X
and	B-X
differentiation	B-X
potential	B-X
and	B-X
contribute	B-X
to	B-X
multiple	B-X
tumor	B-X
malignancies	B-X
,	B-X
such	B-X
as	B-X
recurrence	B-X
,	B-X
metastasis	B-X
,	B-X
heterogeneity	B-X
,	B-X
multidrug	B-X
resistance	B-X
,	B-X
and	B-X
radiation	B-X
resistance	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
many	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
,	B-X
such	B-X
as	B-X
Wnt	B-X
,	B-X
NF-κB	B-X
(	B-X
nuclear	B-X
factor-κB	B-X
)	B-X
,	B-X
Notch	B-X
,	B-X
Hedgehog	B-X
,	B-X
JAK-STAT	B-X
(	B-X
Janus	B-X
kinase/signal	B-X
transducers	B-X
and	B-X
activators	B-X
of	B-X
transcription	B-X
)	B-X
,	B-X
PI3K/AKT/mTOR	B-X
(	B-X
phosphoinositide	B-X
3-kinase/AKT/mammalian	B-X
target	B-X
of	B-X
rapamycin	B-X
)	B-X
,	B-X
TGF	B-X
(	B-X
transforming	B-X
growth	B-X
factor	B-X
)	B-X
/SMAD	B-X
,	B-X
and	B-X
PPAR	B-X
(	B-X
peroxisome	B-X
proliferator-activated	B-X
receptor	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
extracellular	B-X
factors	B-X
,	B-X
such	B-X
as	B-X
vascular	B-X
niches	B-X
,	B-X
hypoxia	B-X
,	B-X
tumor-associated	B-X
macrophages	B-X
,	B-X
cancer-associated	B-X
fibroblasts	B-X
,	B-X
cancer-associated	B-X
mesenchymal	B-X
stem	B-X
cells	B-X
,	B-X
extracellular	B-X
matrix	B-X
,	B-X
and	B-X
exosomes	B-X
,	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
very	B-X
important	B-X
regulators	B-X
of	B-X
CSCs	B-X
.	B-X
Molecules	B-X
,	B-X
vaccines	B-X
,	B-X
antibodies	B-X
,	B-X
and	B-X
CAR-T	B-X
(	B-X
chimeric	B-X
antigen	B-X
receptor	B-X
T	B-X
cell	B-X
)	B-X
cells	B-X
have	B-X
been	B-X
developed	B-X
to	B-X
specifically	B-X
target	B-X
CSCs	B-X
,	B-X
and	B-X
some	B-X
of	B-X
these	B-X
factors	B-X
are	B-X
already	B-X
undergoing	B-X
clinical	B-X
trials	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
characterization	B-X
and	B-X
identification	B-X
of	B-X
CSCs	B-X
,	B-X
depicts	B-X
major	B-X
factors	B-X
and	B-X
pathways	B-X
that	B-X
regulate	B-X
CSC	B-X
development	B-X
,	B-X
and	B-X
discusses	B-X
potential	B-X
targeted	B-X
therapy	B-X
for	B-X
CSCs	B-X
.	B-X

The	O
Forkhead	O
family	O
of	O
transcription	O
factors	O
is	O
known	O
to	O
induce	O
the	O
expression	O
of	O
the	O
Cdk	O
inhibitor	O
p27	B-Protein
[	O
43	O
,	O
44	O
]	O
.	O
<EOS>	B-X
The	B-X
PI3K/AKT	B-X
signaling	B-X
pathway	B-X
contributes	B-X
to	B-X
cell	B-X
cycle	B-X
progression	B-X
of	B-X
cytokine-dependent	B-X
hematopoietic	B-X
cells	B-X
under	B-X
normal	B-X
conditions	B-X
,	B-X
and	B-X
it	B-X
is	B-X
absolutely	B-X
required	B-X
to	B-X
override	B-X
DNA	B-X
damage-induced	B-X
cell	B-X
cycle	B-X
arrest	B-X
checkpoints	B-X
in	B-X
these	B-X
cells	B-X
.	B-X
Phosphatidylinositol-3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
/AKT	B-X
activity	B-X
also	B-X
correlates	B-X
with	B-X
Cdk2	B-X
activity	B-X
in	B-X
hematopoietic	B-X
cells	B-X
,	B-X
suggesting	B-X
that	B-X
Cdk2	B-X
activation	B-X
may	B-X
be	B-X
a	B-X
relevant	B-X
end	B-X
point	B-X
for	B-X
this	B-X
signaling	B-X
pathway	B-X
.	B-X
The	B-X
forkhead	B-X
transcription	B-X
factor	B-X
O	B-X
(	B-X
FOXO	B-X
)	B-X
family	B-X
are	B-X
negatively	B-X
regulated	B-X
by	B-X
AKT-dependent	B-X
phosphorylation	B-X
and	B-X
are	B-X
known	B-X
regulators	B-X
of	B-X
genes	B-X
affecting	B-X
cell	B-X
cycle	B-X
progression	B-X
.	B-X
We	B-X
show	B-X
that	B-X
enhanced	B-X
FOXO	B-X
activity	B-X
replicates	B-X
the	B-X
effect	B-X
of	B-X
PI3K	B-X
inhibitors	B-X
in	B-X
enforcing	B-X
G	B-X
(	B-X
1	B-X
)	B-X
and	B-X
G	B-X
(	B-X
2	B-X
)	B-X
phase	B-X
arrest	B-X
after	B-X
DNA	B-X
damage	B-X
.	B-X
Conversely	B-X
,	B-X
knockdown	B-X
of	B-X
endogenous	B-X
FOXO	B-X
proteins	B-X
increased	B-X
Cdk2	B-X
activity	B-X
and	B-X
overrode	B-X
DNA	B-X
damage	B-X
checkpoints	B-X
in	B-X
cells	B-X
lacking	B-X
PI3K	B-X
activity	B-X
.	B-X
Moreover	B-X
,	B-X
loss	B-X
of	B-X
FOXO	B-X
activity	B-X
caused	B-X
an	B-X
increase	B-X
in	B-X
sensitivity	B-X
to	B-X
cisplatin-induced	B-X
cell	B-X
death	B-X
,	B-X
which	B-X
was	B-X
associated	B-X
with	B-X
failure	B-X
to	B-X
arrest	B-X
cell	B-X
cycle	B-X
progression	B-X
in	B-X
the	B-X
face	B-X
of	B-X
DNA	B-X
damage	B-X
caused	B-X
by	B-X
this	B-X
chemotherapeutic	B-X
agent	B-X
.	B-X
These	B-X
cell	B-X
cycle	B-X
arrests	B-X
were	B-X
dependent	B-X
on	B-X
p27	B-X
expression	B-X
when	B-X
mediated	B-X
by	B-X
FOXO3a	B-X
alone	B-X
,	B-X
but	B-X
also	B-X
involve	B-X
p27-independent	B-X
mechanisms	B-X
when	B-X
promoted	B-X
by	B-X
endogenous	B-X
FOXO	B-X
proteins	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
observations	B-X
show	B-X
that	B-X
FOXO	B-X
proteins	B-X
enforce	B-X
DNA	B-X
damage-induced	B-X
cell	B-X
cycle	B-X
arrest	B-X
in	B-X
hematopoietic	B-X
cells	B-X
.	B-X
Inhibition	B-X
of	B-X
FOXO	B-X
activity	B-X
by	B-X
cytokine-induced	B-X
PI3K/AKT	B-X
signaling	B-X
is	B-X
sufficient	B-X
to	B-X
override	B-X
these	B-X
DNA	B-X
damage-induced	B-X
cell	B-X
cycle	B-X
checkpoints	B-X
,	B-X
but	B-X
may	B-X
negatively	B-X
impact	B-X
hematopoietic	B-X
cell	B-X
viability	B-X
.	B-X

LMP1	B-Protein
-	O
transformed	O
rodent	O
fibroblasts	O
have	O
decreased	O
expression	O
of	O
p27	B-Protein
,	O
upregulation	O
of	O
Cdk2	B-Protein
,	O
and	O
subsequent	O
phosphorylation	O
and	O
inactivation	O
of	O
the	O
tumor	O
suppressor	O
gene	O
Rb	B-Protein
[	O
45	O
]	O
.	O

To	O
investigate	O
whether	O
LMP1	B-Protein
affected	O
cell	O
cycle	O
regulation	O
through	O
the	O
Rb	B-Protein
pathway	O
in	O
B	O
cells	O
,	O
immunoblot	O
analyses	O
for	O
pRb	B-Protein
,	O
Cdk2	B-Protein
,	O
and	O
p27	B-Protein
were	O
performed	O
on	O
splenic	O
CD19	B-Protein
+	O
MACS	O
-	O
purified	O
B	O
cells	O
.	O

LMP1	B-Protein
transgenic	O
B	O
cells	O
had	O
enhanced	O
levels	O
of	O
pRb	B-Protein
with	O
concomitant	O
stabilization	O
of	O
total	O
Rb	B-Protein
levels	O
and	O
Cdk2	B-Protein
compared	O
to	O
wild	O
-	O
type	O
B	O
lymphocytes	O
(	O
Figure	O
6C	O
)	O
.	O

Progression	O
to	O
lymphoma	O
in	O
both	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
led	O
to	O
increased	O
levels	O
of	O
Rb	B-Protein
,	O
correspondingly	O
high	O
levels	O
of	O
Cdk2	B-Protein
,	O
and	O
decreased	O
levels	O
of	O
p27	B-Protein
(	O
Figure	O
6C	O
)	O
.	O

These	O
data	O
indicate	O
that	O
the	O
Rb	B-Protein
pathway	O
is	O
deregulated	O
in	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
that	O
lymphoma	O
cells	O
are	O
distinguished	O
by	O
loss	O
of	O
FoxO1	B-Protein
and	O
decreased	O
p27	B-Protein
.	O

LMP1	B-Protein
Promotes	O
Tumor	O
Growth	O
and	O
Survival	O
through	O
Activation	O
of	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
Pathways	O

To	O
explore	O
which	O
pathways	O
were	O
required	O
for	O
the	O
enhanced	O
growth	O
and	O
survival	O
of	O
LMP1	B-Protein
-	O
induced	O
lymphomas	O
,	O
splenocytes	O
from	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
mice	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
inhibitors	O
for	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
Stat3	B-Protein
,	O
mTOR	B-Protein
,	O
or	O
MAPK	O
and	O
assayed	O
for	O
growth	O
and	O
survival	O
by	O
the	O
MTS	O
assay	O
.	O
<EOS>	B-X
It	B-X
was	B-X
found	B-X
that	B-X
hypoxia	B-X
(	B-X
low	B-X
O2	B-X
levels	B-X
)	B-X
is	B-X
a	B-X
common	B-X
character	B-X
in	B-X
many	B-X
types	B-X
of	B-X
solid	B-X
tumors	B-X
.	B-X
As	B-X
an	B-X
adaptive	B-X
response	B-X
to	B-X
hypoxic	B-X
stress	B-X
,	B-X
hypoxic	B-X
tumor	B-X
cells	B-X
activate	B-X
several	B-X
survival	B-X
pathways	B-X
to	B-X
carry	B-X
out	B-X
their	B-X
essential	B-X
biological	B-X
processes	B-X
in	B-X
different	B-X
ways	B-X
compared	B-X
with	B-X
normal	B-X
cells	B-X
.	B-X
Recent	B-X
advances	B-X
in	B-X
cancer	B-X
biology	B-X
at	B-X
the	B-X
cellular	B-X
and	B-X
molecular	B-X
levels	B-X
highlighted	B-X
the	B-X
HIF-1α	B-X
pathway	B-X
as	B-X
a	B-X
crucial	B-X
survival	B-X
pathway	B-X
for	B-X
which	B-X
novel	B-X
strategies	B-X
of	B-X
cancer	B-X
therapy	B-X
could	B-X
be	B-X
developed	B-X
.	B-X
p-Hydroxylcinnamaldehyde	B-X
(	B-X
CMSP	B-X
)	B-X
has	B-X
been	B-X
identified	B-X
as	B-X
an	B-X
inhibitor	B-X
of	B-X
the	B-X
growth	B-X
of	B-X
various	B-X
cancer	B-X
cells	B-X
.	B-X
The	B-X
function	B-X
of	B-X
CMSP	B-X
in	B-X
the	B-X
viability	B-X
,	B-X
colony	B-X
formation	B-X
,	B-X
migration	B-X
and	B-X
invasion	B-X
of	B-X
Kyse30	B-X
and	B-X
TE-13	B-X
cells	B-X
was	B-X
determined	B-X
by	B-X
MTS	B-X
,	B-X
colony-formation	B-X
,	B-X
wound	B-X
healing	B-X
and	B-X
transwell	B-X
assays	B-X
.	B-X
Western	B-X
blotting	B-X
and	B-X
pull-down	B-X
assays	B-X
were	B-X
used	B-X
to	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
CMSP	B-X
on	B-X
the	B-X
expression	B-X
level	B-X
of	B-X
malignant	B-X
markers	B-X
of	B-X
ESCC	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
activity	B-X
of	B-X
MAPKs	B-X
,	B-X
RhoA	B-X
and	B-X
GTP-RhoA	B-X
in	B-X
Kyse30	B-X
and	B-X
TE-13	B-X
cells	B-X
.	B-X
We	B-X
found	B-X
that	B-X
CMSP	B-X
could	B-X
inhibit	B-X
proliferation	B-X
and	B-X
migration	B-X
and	B-X
induce	B-X
Kyse30	B-X
and	B-X
TE-13	B-X
cell	B-X
differentiation	B-X
,	B-X
characterized	B-X
by	B-X
dendrite-like	B-X
outgrowth	B-X
,	B-X
decreased	B-X
expression	B-X
of	B-X
tumour-associated	B-X
antigens	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
decreased	B-X
expression	B-X
of	B-X
malignant	B-X
markers	B-X
.	B-X
These	B-X
results	B-X
indicated	B-X
that	B-X
CMSP	B-X
induced	B-X
the	B-X
differentiation	B-X
of	B-X
Kyse30	B-X
and	B-X
TE-13	B-X
cells	B-X
through	B-X
mediating	B-X
the	B-X
cAMP-RhoA-MAPK	B-X
axis	B-X
,	B-X
which	B-X
might	B-X
provide	B-X
new	B-X
potential	B-X
strategies	B-X
for	B-X
ESCC	B-X
treatment	B-X
.	B-X

As	O
previously	O
shown	O
,	O
wild	O
-	O
type	O
lymphocytes	O
were	O
not	O
viable	O
in	O
culture	O
and	O
could	O
not	O
be	O
tested	O
with	O
the	O
inhibitors	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
GSDME-knockout	B-X
mice	B-X
were	B-X
protected	B-X
from	B-X
radiation-induced	B-X
weight	B-X
loss	B-X
and	B-X
tissue	B-X
damages	B-X
in	B-X
the	B-X
intestine	B-X
,	B-X
stomach	B-X
,	B-X
liver	B-X
and	B-X
pancreas	B-X
compared	B-X
to	B-X
wild-type	B-X
control	B-X
littermates	B-X
.	B-X
Our	B-X
finding	B-X
reveals	B-X
a	B-X
previously	B-X
unrecognized	B-X
link	B-X
between	B-X
radiation	B-X
and	B-X
pyroptosis	B-X
.	B-X
T	B-X
cells	B-X
expressing	B-X
chimeric	B-X
antigen	B-X
receptors	B-X
(	B-X
CAR	B-X
T	B-X
cells	B-X
)	B-X
have	B-X
shown	B-X
impressive	B-X
therapeutic	B-X
efficacy	B-X
against	B-X
leukemias	B-X
and	B-X
lymphomas	B-X
.	B-X
Thus	B-X
,	B-X
testis	B-X
autoantigens	B-X
,	B-X
previously	B-X
considered	B-X
as	B-X
sequestered	B-X
,	B-X
may	B-X
not	B-X
be	B-X
protected	B-X
by	B-X
systemic	B-X
tolerance	B-X
.	B-X
Unlike	B-X
the	B-X
wild-type	B-X
male	B-X
mice	B-X
,	B-X
mice	B-X
deficient	B-X
in	B-X
LDH3	B-X
(	B-X
wild-type	B-X
female	B-X
or	B-X
LDH3	B-X

However	O
,	O
the	O
enhanced	O
viability	O
of	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
was	O
effectively	O
blocked	O
by	O
treatment	O
with	O
triciribine	O
,	O
BAY11	O
-	O
7085	O
,	O
cucurbitacin	O
I	O
,	O
and	O
slightly	O
with	O
SB203580	O
,	O
but	O
not	O
by	O
treatment	O
with	O
rapamycin	O
,	O
U0126	O
,	O
or	O
AG490	O
(	O
Figure	O
7	O
)	O
.	O

Triciribine	O
inhibits	O
the	O
activation	O
of	O
Akt	B-Protein
and	O
at	O
20	O
muM	O
has	O
been	O
shown	O
to	O
induce	O
growth	O
arrest	O
in	O
cancer	O
cells	O
with	O
aberrant	O
Akt	B-Protein
activity	O
[	O
46	O
]	O
.	O

The	O
effects	O
of	O
triciribine	O
on	O
cell	O
growth	O
of	O
the	O
transgenic	O
lymphocytes	O
and	O
lymphomas	O
were	O
apparent	O
as	O
low	O
as	O
1	O
muM	O
,	O
suggesting	O
that	O
activation	O
of	O
Akt	B-Protein
is	O
required	O
for	O
the	O
survival	O
and	O
growth	O
of	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
(	O
Figure	O
7	O
)	O
.	O

The	O
effects	O
of	O
the	O
inhibitors	O
were	O
assessed	O
by	O
identifying	O
phosphorylated	O
Akt	B-Protein
,	O
Stat3	B-Protein
,	O
and	O
total	O
levels	O
of	O
IkappaBalpha	B-Protein
(	O
Figure	O
8	O
)	O
.	O

Treatment	O
with	O
triciribine	O
effectively	O
blocked	O
phosphorylation	O
of	O
Akt	B-Protein
,	O
and	O
phosphorylated	O
Akt	B-Protein
was	O
no	O
longer	O
detected	O
past	O
5	O
muM	O
.	O

Phosphorylated	O
Stat3	B-Protein
and	O
IkappaBalpha	B-Protein
were	O
still	O
present	O
at	O
25	O
muM	O
.	O

These	O
findings	O
suggest	O
that	O
triciribine	O
specifically	O
targets	O
Akt	B-Protein
and	O
that	O
Akt	B-Protein
activation	O
is	O
required	O
for	O
the	O
enhanced	O
viability	O
of	O
the	O
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
.	O

Inhibition	O
of	O
NFkappaB	O
signaling	O
rapidly	O
induces	O
cell	O
death	O
of	O
EBV	O
-	O
transformed	O
lymphocytes	O
[	O
17	O
,	O
18	O
]	O
.	O

BAY11	O
-	O
7085	O
,	O
an	O
inhibitor	O
of	O
NFkappaB	O
signaling	O
,	O
also	O
greatly	O
decreased	O
the	O
viability	O
of	O
the	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
at	O
doses	O
as	O
low	O
as	O
1	O
muM	O
,	O
and	O
at	O
5	O
muM	O
the	O
cells	O
were	O
completely	O
nonviable	O
(	O
Figure	O
7	O
)	O
.	O

This	O
is	O
well	O
within	O
the	O
reported	O
IC50	O
of	O
10	O
muM	O
.	O
<EOS>	B-X
To	B-X
boost	B-X
the	B-X
interest	B-X
on	B-X
this	B-X
intriguing	B-X
target	B-X
,	B-X
the	B-X
present	B-X
review	B-X
updates	B-X
the	B-X
knowledge	B-X
on	B-X
the	B-X
structure-activity	B-X
relationships	B-X
of	B-X
HO-2	B-X
inhibitors	B-X
and	B-X
activators	B-X
,	B-X
as	B-X
well	B-X
as	B-X
their	B-X
potential	B-X
therapeutic	B-X
applications	B-X
.	B-X
To	B-X
the	B-X
best	B-X
of	B-X
our	B-X
knowledge	B-X
,	B-X
among	B-X
HO-2	B-X
inhibitors	B-X
,	B-X
clemizole	B-X
derivatives	B-X
are	B-X
the	B-X
most	B-X
selective	B-X
HO-2	B-X
inhibitors	B-X
reported	B-X
so	B-X
far	B-X
(	B-X
IC	B-X
Solanum	B-X
nudum	B-X
Dunal	B-X
steroids	B-X
have	B-X
been	B-X
reported	B-X
as	B-X
being	B-X
antimalarial	B-X
compounds	B-X
;	B-X
however	B-X
,	B-X
their	B-X
concentration	B-X
in	B-X
plants	B-X
is	B-X
low	B-X
,	B-X
meaning	B-X
that	B-X
the	B-X
species	B-X
could	B-X
be	B-X
threatened	B-X
by	B-X
over-harvesting	B-X
for	B-X
this	B-X
purpose	B-X
.	B-X
Eighteen	B-X
structural	B-X
analogues	B-X
were	B-X
prepared	B-X
;	B-X
three	B-X
of	B-X
them	B-X
were	B-X
found	B-X
to	B-X
be	B-X
more	B-X
active	B-X
than	B-X
diosgenone	B-X
(	B-X
IC50	B-X
27.9	B-X
μM	B-X
vs.	B-X
10.1	B-X
μM	B-X
,	B-X
2.9	B-X
μM	B-X
and	B-X
11.3	B-X
μM	B-X
)	B-X
.	B-X
Quantitative	B-X
correlations	B-X
between	B-X
molecular	B-X
structure	B-X
and	B-X
bioactivity	B-X
were	B-X
thus	B-X
explored	B-X
in	B-X
diosgenone	B-X
and	B-X
several	B-X
derivatives	B-X
using	B-X
well-established	B-X
3D-QSAR	B-X
techniques	B-X
.	B-X

Phosphorylated	O
Akt	B-Protein
,	O
Stat3	B-Protein
,	O
and	O
total	O
IkappaBalpha	B-Protein
were	O
still	O
present	O
up	O
to	O
treatment	O
with	O
15	O
muM	O
and	O
then	O
were	O
no	O
longer	O
detected	O
(	O
Figure	O
8	O
)	O
.	O

This	O
finding	O
suggests	O
that	O
inhibition	O
of	O
NFkappaB	O
can	O
induce	O
cell	O
death	O
in	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
without	O
significant	O
effects	O
on	O
activation	O
of	O
Akt	B-Protein
or	O
Stat3	B-Protein
.	O
<EOS>	B-X
STAT3	B-X
is	B-X
broadly	B-X
hyperactivated	B-X
both	B-X
in	B-X
cancer	B-X
and	B-X
non-cancerous	B-X
cells	B-X
within	B-X
the	B-X
tumor	B-X
ecosystem	B-X
and	B-X
plays	B-X
important	B-X
roles	B-X
in	B-X
inhibiting	B-X
the	B-X
expression	B-X
of	B-X
crucial	B-X
immune	B-X
activation	B-X
regulators	B-X
and	B-X
promoting	B-X
the	B-X
production	B-X
of	B-X
immunosuppressive	B-X
factors	B-X
.	B-X
Autophagy	B-X
is	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
process	B-X
in	B-X
eukaryotes	B-X
that	B-X
eliminates	B-X
harmful	B-X
components	B-X
and	B-X
maintains	B-X
cellular	B-X
homeostasis	B-X
in	B-X
response	B-X
to	B-X
a	B-X
series	B-X
of	B-X
extracellular	B-X
insults	B-X
.	B-X
Recent	B-X
reports	B-X
further	B-X
indicate	B-X
that	B-X
different	B-X
subcellular	B-X
localization	B-X
patterns	B-X
of	B-X
STAT3	B-X
affect	B-X
autophagy	B-X
in	B-X
various	B-X
ways	B-X
.	B-X
Additionally	B-X
,	B-X
the	B-X
mitochondrial	B-X
translocation	B-X
of	B-X
STAT3	B-X
suppresses	B-X
autophagy	B-X
induced	B-X
by	B-X
oxidative	B-X
stress	B-X
and	B-X
may	B-X
effectively	B-X
preserve	B-X
mitochondria	B-X
from	B-X
being	B-X
degraded	B-X
by	B-X
mitophagy	B-X
.	B-X

Cucurbitacin	O
I	O
inhibits	O
activation	O
of	O
Stat3	B-Protein
by	O
suppressing	O
the	O
activation	O
of	O
its	O
kinase	O
JAK2	B-Protein
.	O
<EOS>	B-X
Therefore	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
investigate	B-X
whether	B-X
PBM	B-X
ameliorates	B-X
neuroinflammation	B-X
by	B-X
modulating	B-X
the	B-X
activation	B-X
of	B-X
microglia	B-X
and	B-X
astrocytes	B-X
after	B-X
SCI	B-X
.	B-X
Although	B-X
activation	B-X
of	B-X
Janus	B-X
kinase	B-X
2	B-X
(	B-X
JAK2	B-X
)	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
proliferative	B-X
disorders	B-X
,	B-X
its	B-X
role	B-X
in	B-X
IPF	B-X
is	B-X
unknown	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
analyze	B-X
JAK2	B-X
activation	B-X
in	B-X
IPF	B-X
,	B-X
and	B-X
to	B-X
determine	B-X
whether	B-X
JAK2/STAT3	B-X
inhibition	B-X
is	B-X
a	B-X
potential	B-X
therapeutic	B-X
strategy	B-X
for	B-X
this	B-X
disease	B-X
.	B-X
Cucurbitacin	B-X
I	B-X
(	B-X
CuI	B-X
)	B-X
isolated	B-X
from	B-X
the	B-X
cucurbitacin	B-X
family	B-X
was	B-X
reported	B-X
to	B-X
be	B-X
an	B-X
inhibitor	B-X
of	B-X
STAT3	B-X
signaling	B-X
and	B-X
a	B-X
disruptor	B-X
of	B-X
actin	B-X
cytoskeleton	B-X
.	B-X
We	B-X
further	B-X
demonstrated	B-X
that	B-X
actin	B-X
filaments	B-X
physically	B-X
associated	B-X
with	B-X
JAK2	B-X
and	B-X
STAT3	B-X
in	B-X
A549	B-X
cells	B-X
and	B-X
regulated	B-X
their	B-X
phosphorylation	B-X
through	B-X
two	B-X
signaling	B-X
complexes	B-X
,	B-X
the	B-X
IL-6	B-X
receptor	B-X
complex	B-X
and	B-X
the	B-X
focal	B-X
adhesion	B-X
complex	B-X
.	B-X

It	O
has	O
been	O
shown	O
to	O
selectively	O
inhibit	O
the	O
growth	O
of	O
tumors	O
with	O
constitutively	O
activated	O
Stat3	B-Protein
[	O
47	O
]	O
.	O
<EOS>	B-X
STAT3	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
cancer	B-X
progression	B-X
as	B-X
a	B-X
driver	B-X
oncogene	B-X
and	B-X
acquired	B-X
resistance	B-X
of	B-X
targeted	B-X
therapies	B-X
as	B-X
an	B-X
alternatively	B-X
activated	B-X
pathway	B-X
.	B-X
W2014-S	B-X
with	B-X
pharmacophore	B-X
structure	B-X
of	B-X
imidazopyridine	B-X
,	B-X
which	B-X
was	B-X
firstly	B-X
reported	B-X
to	B-X
be	B-X
utilized	B-X
in	B-X
STAT3	B-X
inhibitor	B-X
discovery	B-X
,	B-X
was	B-X
screened	B-X
out	B-X
as	B-X
a	B-X
potent	B-X
STAT3	B-X
inhibitor	B-X
from	B-X
a	B-X
library	B-X
of	B-X
small	B-X
molecules	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
investigate	B-X
the	B-X
antitumor	B-X
activities	B-X
and	B-X
mechanisms	B-X
of	B-X
W2014-S	B-X
in	B-X
NSCLC	B-X
and	B-X
effect	B-X
on	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor-tyrosine	B-X
kinase	B-X
inhibitors	B-X
(	B-X
EGFR-TKIs	B-X
)	B-X
resistance	B-X
Breast	B-X
cancers	B-X
(	B-X
BrCas	B-X
)	B-X
that	B-X
overexpress	B-X
oncogenic	B-X
tyrosine	B-X
kinase	B-X
receptor	B-X
HER2	B-X
are	B-X
treated	B-X
with	B-X
HER2-targeting	B-X
antibodies	B-X
(	B-X
such	B-X
as	B-X
trastuzumab	B-X
)	B-X
or	B-X
small-molecule	B-X
kinase	B-X
inhibitors	B-X
(	B-X
such	B-X
as	B-X
lapatinib	B-X
)	B-X
.	B-X

Similarly	O
,	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
were	O
susceptible	O
to	O
cucurbitacin	O
I	O
treatment	O
starting	O
at	O
0	O
.	O
1	O
muM	O
,	O
a	O
dose	O
that	O
corresponds	O
closely	O
to	O
the	O
reported	O
IC50	O
of	O
500	O
nM	O
(	O
Figure	O
7	O
)	O
[	O
47	O
]	O
.	O

Phosphorylated	O
Akt	B-Protein
,	O
Stat3	B-Protein
,	O
and	O
total	O
IkappaBalpha	B-Protein
were	O
not	O
detectable	O
past	O
1	O
muM	O
and	O
at	O
higher	O
doses	O
all	O
protein	O
levels	O
were	O
greatly	O
decreased	O
,	O
indicative	O
of	O
the	O
total	O
loss	O
of	O
viability	O
(	O
Figure	O
8	O
)	O
.	O

A	O
second	O
reported	O
inhibitor	O
of	O
Stat3	B-Protein
,	O
AG490	O
,	O
had	O
no	O
effect	O
on	O
growth	O
(	O
Figure	O
7	O
)	O
,	O
but	O
activation	O
of	O
Akt	B-Protein
,	O
Stat3	B-Protein
,	O
or	O
levels	O
of	O
IkappaBalpha	B-Protein
were	O
also	O
not	O
affected	O
(	O
Figure	O
8	O
)	O
.	O
<EOS>	B-X
Uncontrolled	B-X
pulmonary	B-X
arterial	B-X
hypertension	B-X
(	B-X
PAH	B-X
)	B-X
results	B-X
in	B-X
right	B-X
ventricular	B-X
(	B-X
RV	B-X
)	B-X
hypertrophy	B-X
(	B-X
RVH	B-X
)	B-X
,	B-X
progressive	B-X
RV	B-X
failure	B-X
,	B-X
and	B-X
low	B-X
cardiac	B-X
output	B-X
leading	B-X
to	B-X
increased	B-X
morbidity	B-X
and	B-X
mortality	B-X
(	B-X
McLaughlin	B-X
VV	B-X
,	B-X
Archer	B-X
SL	B-X
,	B-X
Badesch	B-X
DB	B-X
,	B-X
Barst	B-X
RJ	B-X
,	B-X
Farber	B-X
HW	B-X
,	B-X
Lindner	B-X
JR	B-X
,	B-X
Mathier	B-X
MA	B-X
,	B-X
McGoon	B-X
MD	B-X
,	B-X
Park	B-X
MH	B-X
,	B-X
Rosenson	B-X
RS	B-X
,	B-X
Rubin	B-X
LJ	B-X
,	B-X
Tapson	B-X
VF	B-X
,	B-X
Varga	B-X
J.	B-X
J	B-X
Am	B-X
Coll	B-X
Cardiol	B-X
53	B-X
:	B-X
1573-1619	B-X
,	B-X
2009	B-X
)	B-X
.	B-X
Although	B-X
the	B-X
exact	B-X
figures	B-X
of	B-X
its	B-X
prevalence	B-X
are	B-X
difficult	B-X
to	B-X
obtain	B-X
because	B-X
of	B-X
the	B-X
diversity	B-X
of	B-X
identifiable	B-X
causes	B-X
,	B-X
it	B-X
is	B-X
estimated	B-X
that	B-X
the	B-X
incidence	B-X
of	B-X
pulmonary	B-X
hypertension	B-X
is	B-X
seven	B-X
to	B-X
nine	B-X
cases	B-X
per	B-X
million	B-X
persons	B-X
in	B-X
the	B-X
general	B-X
population	B-X
and	B-X
is	B-X
most	B-X
prevalent	B-X
in	B-X
the	B-X
age	B-X
group	B-X
of	B-X
20-40	B-X
,	B-X
occurring	B-X
more	B-X
commonly	B-X
in	B-X
women	B-X
than	B-X
in	B-X
men	B-X
(	B-X
ratio	B-X
:	B-X
1.7	B-X
to	B-X
1	B-X
;	B-X
Rubin	B-X
LJ	B-X
.	B-X
N	B-X
Engl	B-X
J	B-X
Med	B-X
336	B-X
:	B-X
111-117	B-X
,	B-X
1997	B-X
)	B-X
.	B-X
Curr	B-X
Opin	B-X
Crit	B-X
Care	B-X
16	B-X
:	B-X
237-243	B-X
,	B-X
2010	B-X
)	B-X
.	B-X
South	B-X
Med	B-X
J	B-X
100	B-X
:	B-X
393-399	B-X
,	B-X
2007	B-X
)	B-X
.	B-X
Validation	B-X
of	B-X
a	B-X
prognostic	B-X
equation	B-X
Circulation	B-X
89	B-X
:	B-X
1733-1744	B-X
,	B-X
1994	B-X
)	B-X
.	B-X
Of	B-X
all	B-X
the	B-X
mechanisms	B-X
involved	B-X
in	B-X
the	B-X
pathogenesis	B-X
,	B-X
inflammation	B-X
and	B-X
oxidative	B-X
stress	B-X
remain	B-X
the	B-X
core	B-X
of	B-X
the	B-X
etiology	B-X
of	B-X
PAH	B-X
that	B-X
leads	B-X
to	B-X
development	B-X
of	B-X
RVH	B-X
(	B-X
Dorfmüller	B-X
P	B-X
,	B-X
Perros	B-X
F	B-X
,	B-X
Balabanian	B-X
K	B-X
,	B-X
Humbert	B-X
M.	B-X
Eur	B-X
Respir	B-X
J	B-X
22	B-X
:	B-X
358-363	B-X
,	B-X
2003	B-X
)	B-X
.	B-X

These	O
findings	O
suggest	O
that	O
inhibition	O
of	O
Stat3	B-Protein
can	O
induce	O
cell	O
death	O
in	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
lymphoma	O
cells	O
,	O
but	O
Stat3	B-Protein
inhibition	O
also	O
has	O
considerable	O
crossover	O
effects	O
on	O
Akt	B-Protein
and	O
NFkappaB	O
signaling	O
.	O

LMP1	B-Protein
has	O
also	O
been	O
shown	O
to	O
activate	O
JNK	O
and	O
p38	O
MAPK	O
pathways	O
[	O
13	O
,	O
48	O
]	O
,	O
and	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
were	O
mildly	O
susceptible	O
to	O
growth	O
inhibition	O
by	O
SB202190	O
,	O
an	O
inhibitor	O
of	O
p38	O
MAPK	O
,	O
but	O
not	O
U0126	O
,	O
an	O
inhibitor	O
of	O
MEK1	B-Protein
/	O
2	B-Protein
activity	O
.	O

However	O
,	O
effects	O
of	O
SB202190	O
were	O
only	O
apparent	O
at	O
high	O
doses	O
(	O
>	O
10	O
muM	O
)	O
,	O
much	O
higher	O
than	O
the	O
reported	O
IC50	O
of	O
0	O
.	O
35	O
muM	O
,	O
suggesting	O
that	O
p38	O
MAPK	O
does	O
not	O
significantly	O
contribute	O
to	O
the	O
enhanced	O
viability	O
in	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
or	O
lymphoma	O
cells	O
(	O
Figure	O
7	O
)	O
.	O
<EOS>	B-X
Elucidating	B-X
the	B-X
signaling	B-X
networks	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
necroptosis	B-X
may	B-X
allow	B-X
this	B-X
form	B-X
of	B-X
regulated	B-X
cell	B-X
death	B-X
to	B-X
be	B-X
exploited	B-X
for	B-X
diagnosis	B-X
and	B-X
treatment	B-X
of	B-X
cancer	B-X
,	B-X
and	B-X
will	B-X
contribute	B-X
to	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
complex	B-X
tumor	B-X
microenvironment	B-X
.	B-X
Pediatric-type	B-X
follicular	B-X
lymphoma	B-X
(	B-X
PTFL	B-X
)	B-X
is	B-X
a	B-X
rare	B-X
and	B-X
recently	B-X
recognized	B-X
subtype	B-X
of	B-X
nodal	B-X
follicular	B-X
B-cell	B-X
lymphoma	B-X
.	B-X
A	B-X
computed	B-X
tomography	B-X
scan	B-X
of	B-X
the	B-X
neck	B-X
performed	B-X
30	B-X
days	B-X
before	B-X
referral	B-X
revealed	B-X
bilateral	B-X
cervical	B-X
and	B-X
supraclavicular	B-X
lymphadenopathy	B-X
(	B-X
6	B-X
×	B-X
5	B-X
cm	B-X
)	B-X
.	B-X
The	B-X
patient	B-X
's	B-X
lactate	B-X
dehydrogenase	B-X
concentration	B-X
was	B-X
327	B-X
U/L	B-X
(	B-X
normal	B-X
range	B-X
,	B-X
118-225	B-X
U/L	B-X
)	B-X
.	B-X
A	B-X
positron	B-X
emission	B-X
tomography	B-X
scan	B-X
revealed	B-X
bilateral	B-X
cervical	B-X
and	B-X
supraclavicular	B-X
lymphadenopathy	B-X
(	B-X
6	B-X
×	B-X
5	B-X
cm	B-X
with	B-X
a	B-X
standardized	B-X
uptake	B-X
value	B-X
[	B-X
SUV	B-X
]	B-X
of	B-X
14	B-X
)	B-X
,	B-X
a	B-X
1.3-cm	B-X
subcutaneous	B-X
nodule	B-X
in	B-X
the	B-X
left	B-X
thigh	B-X
(	B-X
SUV	B-X
16	B-X
)	B-X
,	B-X
and	B-X
two	B-X
2.7-cm	B-X
liver	B-X
lesions	B-X
(	B-X
SUV	B-X
14	B-X
)	B-X
.	B-X
The	B-X
lymph	B-X
node	B-X
revealed	B-X
effacement	B-X
of	B-X
the	B-X
architecture	B-X
by	B-X
an	B-X
interfollicular	B-X
infiltrate	B-X
of	B-X
lymphoid	B-X
cells	B-X
(	B-X
Fig	B-X
1	B-X
)	B-X
.	B-X
Mitotic	B-X
figures	B-X
were	B-X
abundant	B-X
(	B-X
Ki-67	B-X
stain	B-X
80	B-X
%	B-X
to	B-X
90	B-X
%	B-X
positive	B-X
)	B-X
and	B-X
there	B-X
were	B-X
multiple	B-X
foci	B-X
of	B-X
tissue	B-X
necrosis	B-X
.	B-X
A	B-X
subpopulation	B-X
of	B-X
T	B-X
cells	B-X
was	B-X
positive	B-X
for	B-X
both	B-X
CD4	B-X
and	B-X
CD8	B-X
.	B-X
A	B-X
marrow	B-X
aspirate	B-X
and	B-X
biopsy	B-X
revealed	B-X
normal	B-X
trilineage	B-X
hematopoiesis	B-X
with	B-X
no	B-X
evidence	B-X
of	B-X
lymphoma	B-X
and	B-X
a	B-X
normal	B-X
male	B-X
karyotype	B-X
(	B-X
46	B-X
,	B-X
XY	B-X
)	B-X
.	B-X
A	B-X
lumbar	B-X
puncture	B-X
sample	B-X
did	B-X
not	B-X
contain	B-X
lymphoma	B-X
cells	B-X
.	B-X
The	B-X
patient	B-X
's	B-X
diagnosis	B-X
was	B-X
T-lymphoblastic	B-X
lymphoma	B-X
.	B-X

Interestingly	O
,	O
both	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphomas	O
were	O
similarly	O
susceptible	O
to	O
triciribine	O
,	O
BAY11	O
-	O
7085	O
,	O
and	O
cucurbitacin	O
I	O
treatments	O
,	O
but	O
not	O
SB202190	O
,	O
AG490	O
,	O
or	O
U0126	O
treatment	O
,	O
suggesting	O
that	O
activation	O
of	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
but	O
not	O
MAPK	O
pathways	O
are	O
characteristics	O
associated	O
with	O
malignant	O
transformation	O
(	O
Figure	O
7	O
)	O
.	O
rapamycin	O
,	O
an	O
inhibitor	O
of	O
mTOR	B-Protein
,	O
did	O
not	O
affect	O
the	O
viability	O
of	O
the	O
transgenic	O
lymphocytes	O
or	O
lymphoma	O
cells	O
,	O
confirming	O
that	O
mTOR	B-Protein
is	O
not	O
targeted	O
by	O
Akt	B-Protein
activation	O
in	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
or	O
malignant	O
lymphoma	O
cells	O
(	O
Figure	O
7	O
)	O
.	O
<EOS>	B-X
Elucidating	B-X
the	B-X
signaling	B-X
networks	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
necroptosis	B-X
may	B-X
allow	B-X
this	B-X
form	B-X
of	B-X
regulated	B-X
cell	B-X
death	B-X
to	B-X
be	B-X
exploited	B-X
for	B-X
diagnosis	B-X
and	B-X
treatment	B-X
of	B-X
cancer	B-X
,	B-X
and	B-X
will	B-X
contribute	B-X
to	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
complex	B-X
tumor	B-X
microenvironment	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
have	B-X
summarized	B-X
the	B-X
mechanisms	B-X
and	B-X
regulation	B-X
of	B-X
necroptosis	B-X
,	B-X
the	B-X
converging	B-X
and	B-X
diverging	B-X
features	B-X
of	B-X
necroptosis	B-X
in	B-X
tumorigenesis	B-X
,	B-X
activation	B-X
of	B-X
anti-tumor	B-X
immunity	B-X
,	B-X
and	B-X
cancer	B-X
therapy	B-X
,	B-X
as	B-X
well	B-X
as	B-X
attempts	B-X
to	B-X
exploit	B-X
this	B-X
newly	B-X
gained	B-X
knowledge	B-X
to	B-X
provide	B-X
therapeutics	B-X
for	B-X
cancer	B-X
.	B-X
Pediatric-type	B-X
follicular	B-X
lymphoma	B-X
(	B-X
PTFL	B-X
)	B-X
is	B-X
a	B-X
rare	B-X
and	B-X
recently	B-X
recognized	B-X
subtype	B-X
of	B-X
nodal	B-X
follicular	B-X
B-cell	B-X
lymphoma	B-X
.	B-X
Solitary	B-X
fibrous	B-X
tumors	B-X
(	B-X
SFTs	B-X
)	B-X
are	B-X
rare	B-X
tumors	B-X
,	B-X
mostly	B-X
derived	B-X
from	B-X
connective	B-X
tissue	B-X
mesenchymal	B-X
cells	B-X
that	B-X
arise	B-X
from	B-X
the	B-X
pleura	B-X
.	B-X
We	B-X
report	B-X
a	B-X
case	B-X
of	B-X
pancreatic	B-X
SFT	B-X
with	B-X
particularly	B-X
rare	B-X
malignant	B-X
findings	B-X
.	B-X

This	O
study	O
defines	O
the	O
oncogenic	O
properties	O
of	O
LMP1	B-Protein
in	O
promoting	O
B	O
cell	O
lymphomagenesis	O
.	O

LMP1	B-Protein
transgenic	O
mice	O
have	O
a	O
higher	O
incidence	O
of	O
lymphoma	O
[	O
26	O
]	O
and	O
the	O
progression	O
to	O
lymphoma	O
correlates	O
with	O
higher	O
expression	O
levels	O
of	O
LMP1	B-Protein
(	O
Figure	O
1A	O
and	O
1B	O
)	O
,	O
suggesting	O
that	O
LMP1	B-Protein
is	O
directly	O
involved	O
in	O
tumor	O
development	O
.	O

Table	O
1	O
summarizes	O
the	O
biological	O
and	O
molecular	O
properties	O
that	O
were	O
identified	O
in	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphomas	O
.	O

Although	O
many	O
of	O
the	O
molecular	O
properties	O
studied	O
were	O
similar	O
between	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphomas	O
,	O
there	O
were	O
distinguishing	O
biological	O
properties	O
,	O
namely	O
the	O
ability	O
of	O
LMP1	B-Protein
transgenic	O
lymphomas	O
to	O
induce	O
higher	O
levels	O
of	O
survival	O
and	O
proliferation	O
.	O

Interestingly	O
,	O
although	O
LMP1	B-Protein
transgenic	O
mice	O
develop	O
lymphomas	O
in	O
the	O
same	O
B	O
-	O
1a	O
cell	O
type	O
as	O
spontaneous	O
wild	O
-	O
type	O
lymphomas	O
(	O
Figure	O
2	O
)	O
,	O
some	O
signaling	O
effects	O
induced	O
by	O
LMP1	B-Protein
may	O
explain	O
the	O
enhanced	O
promotion	O
to	O
lymphomagenesis	O
.	O

Since	O
CD40	B-Protein
-	O
deficient	O
mice	O
have	O
decreased	O
numbers	O
of	O
IgMhighIgDlow	O
cells	O
,	O
a	O
phenotype	O
associated	O
with	O
B	O
-	O
1	O
,	O
marginal	O
zone	O
,	O
and	O
memory	O
B	O
cells	O
,	O
the	O
mimicry	O
of	O
CD40	B-Protein
signaling	O
by	O
LMP1	B-Protein
could	O
possibly	O
contribute	O
to	O
the	O
expansion	O
of	O
B	O
-	O
1	O
cells	O
[	O
20	O
]	O
.	O

It	O
is	O
noteworthy	O
that	O
expression	O
of	O
LMP1	B-Protein
in	O
transgenic	O
mice	O
has	O
been	O
shown	O
to	O
inhibit	O
the	O
formation	O
of	O
GCs	O
[	O
23	O
,	O
49	O
]	O
,	O
preventing	O
typical	O
B	O
-	O
2	O
cells	O
from	O
antigen	O
-	O
driven	O
selection	O
and	O
expansion	O
.	O

The	O
lack	O
of	O
GC	O
reactions	O
may	O
contribute	O
to	O
the	O
bias	O
of	O
LMP1	B-Protein
transgenic	O
mice	O
towards	O
B	O
-	O
1	O
cell	O
lymphomas	O
.	O

Interestingly	O
,	O
LMP2	B-Protein
signaling	O
also	O
favors	O
development	O
of	O
B	O
-	O
1	O
cells	O
,	O
but	O
this	O
occurs	O
in	O
the	O
absence	O
of	O
transformation	O
.	O

These	O
results	O
suggest	O
that	O
the	O
mimicry	O
of	O
B	O
cell	O
receptor	O
signaling	O
by	O
LMP2	B-Protein
promotes	O
B	O
-	O
1	O
cell	O
differentiation	O
but	O
not	O
transformation	O
[	O
24	O
,	O
50	O
,	O
51	O
]	O
.	O

This	O
promotion	O
of	O
B	O
-	O
1	O
differentiation	O
may	O
account	O
for	O
the	O
ability	O
of	O
LMP2	B-Protein
to	O
exacerbate	O
autoimmunity	O
and	O
bypass	O
anergy	O
induction	O
[	O
52	O
,	O
53	O
]	O
.	O

In	O
contrast	O
,	O
the	O
preponderance	O
of	O
tumors	O
of	O
B	O
-	O
1a	O
origin	O
does	O
not	O
reflect	O
effects	O
of	O
LMP1	B-Protein
signaling	O
on	O
B	O
cell	O
differentiation	O
,	O
as	O
splenic	O
B	O
cells	O
from	O
healthy	O
LMP1	B-Protein
transgenic	O
mice	O
contain	O
similar	O
numbers	O
of	O
B	O
-	O
1	O
and	O
B	O
-	O
2	O
cells	O
as	O
wild	O
-	O
type	O
mice	O
.	O

In	O
support	O
of	O
this	O
lack	O
of	O
effect	O
,	O
the	O
differentiation	O
of	O
B	O
-	O
1	O
versus	O
B	O
-	O
2	O
cells	O
is	O
thought	O
to	O
be	O
independent	O
of	O
CD40	B-Protein
signaling	O
[	O
54	O
]	O
.	O

B	O
-	O
1	O
cells	O
constitute	O
the	O
predominant	O
lymphocyte	O
population	O
in	O
the	O
peritoneal	O
and	O
pleuropericardial	O
cavities	O
,	O
while	O
B	O
-	O
2	O
cells	O
are	O
mainly	O
found	O
in	O
the	O
spleen	O
,	O
lymph	O
node	O
,	O
and	O
peripheral	O
blood	O
.	O

B	O
-	O
1	O
cells	O
produce	O
the	O
main	O
source	O
of	O
IgM	O
and	O
IgA	O
antibodies	O
in	O
serum	O
,	O
which	O
are	O
involved	O
in	O
T	O
cell	O
-	O
independent	O
responses	O
to	O
common	O
microbial	O
antigens	O
.	O

Importantly	O
,	O
B	O
-	O
1	O
cells	O
have	O
the	O
unique	O
capacity	O
to	O
self	O
replenish	O
and	O
are	O
also	O
predisposed	O
to	O
transformation	O
[	O
28	O
,	O
29	O
]	O
.	O

Clonal	O
expansion	O
of	O
B	O
-	O
1	O
cells	O
can	O
be	O
detected	O
in	O
aging	O
mice	O
above	O
18	O
mo	O
of	O
age	O
,	O
and	O
B	O
-	O
1	O
cells	O
are	O
thought	O
to	O
be	O
the	O
murine	O
progenitor	O
of	O
B	O
cell	O
chronic	O
lymphocytic	O
leukemia	O
[	O
30	O
]	O
.	O

The	O
data	O
presented	O
in	O
this	O
study	O
indicate	O
that	O
although	O
LMP1	B-Protein
is	O
expressed	O
in	O
all	O
B	O
lymphocytes	O
in	O
the	O
transgenic	O
mice	O
,	O
malignancy	O
develops	O
in	O
this	O
specific	O
subset	O
of	O
B	O
cells	O
.	O

The	O
elevated	O
expression	O
of	O
LMP1	B-Protein
in	O
B	O
-	O
1a	O
cells	O
and	O
the	O
activation	O
of	O
specific	O
pathways	O
apparently	O
induce	O
malignant	O
growth	O
.	O

These	O
same	O
pathways	O
can	O
also	O
become	O
sporadically	O
activated	O
in	O
aged	O
mice	O
and	O
also	O
result	O
in	O
lymphoma	O
development	O
.	O

This	O
is	O
similar	O
to	O
EBV	O
-	O
associated	O
cancers	O
in	O
vivo	O
,	O
where	O
pathways	O
that	O
are	O
activated	O
by	O
LMP1	B-Protein
are	O
also	O
activated	O
in	O
the	O
less	O
prevalent	O
EBV	O
-	O
negative	O
forms	O
of	O
the	O
cancers	O
[	O
40	O
,	O
55	O
-	O
58	O
]	O
.	O

Thus	O
,	O
the	O
contribution	O
of	O
EBV	O
and	O
LMP1	B-Protein
to	O
tumor	O
development	O
is	O
apparently	O
the	O
continuous	O
activation	O
of	O
pathways	O
that	O
can	O
also	O
be	O
sporadically	O
activated	O
and	O
contribute	O
to	O
tumor	O
development	O
.	O

The	O
lymphomas	O
were	O
marked	O
by	O
the	O
upregulation	O
of	O
IL10	B-Protein
,	O
constitutive	O
activation	O
of	O
Stat3	B-Protein
signaling	O
,	O
and	O
a	O
requirement	O
for	O
activation	O
of	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
pathways	O
(	O
Figures	O
5	O
and	O
7	O
)	O
.	O

Induction	O
of	O
IL10	B-Protein
is	O
associated	O
with	O
the	O
transformation	O
of	O
B	O
-	O
1	O
lymphomas	O
in	O
mice	O
[	O
59	O
,	O
60	O
]	O
and	O
is	O
frequently	O
associated	O
with	O
EBV	O
-	O
positive	O
B	O
cell	O
malignancies	O
acting	O
as	O
a	O
B	O
cell	O
growth	O
factor	O
[	O
35	O
-	O
38	O
]	O
.	O

In	O
addition	O
,	O
LMP1	B-Protein
has	O
been	O
shown	O
to	O
stimulate	O
IL10	B-Protein
expression	O
in	O
Burkitt	O
lymphoma	O
cell	O
lines	O
[	O
61	O
,	O
62	O
]	O
.	O

This	O
suggests	O
that	O
although	O
Stat3	B-Protein
is	O
constitutively	O
activated	O
in	O
the	O
lymphoma	O
cells	O
,	O
the	O
induction	O
of	O
IL10	B-Protein
may	O
further	O
enhance	O
Stat3	B-Protein
activation	O
or	O
may	O
contribute	O
to	O
other	O
IL10	B-Protein
-	O
responsive	O
signaling	O
pathways	O
.	O
<EOS>	B-X
Innate	B-X
and	B-X
adaptive	B-X
immunity	B-X
represent	B-X
a	B-X
harmonic	B-X
counterbalanced	B-X
system	B-X
involved	B-X
in	B-X
the	B-X
induction	B-X
,	B-X
progression	B-X
,	B-X
and	B-X
possibly	B-X
resolution	B-X
of	B-X
the	B-X
inflammatory	B-X
reaction	B-X
that	B-X
characterize	B-X
autoimmune	B-X
rheumatic	B-X
diseases	B-X
(	B-X
ARDs	B-X
)	B-X
,	B-X
including	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
.	B-X
Although	B-X
the	B-X
immunopathophysiological	B-X
mechanisms	B-X
of	B-X
the	B-X
ARDs	B-X
are	B-X
not	B-X
fully	B-X
clarified	B-X
,	B-X
they	B-X
are	B-X
often	B-X
associated	B-X
with	B-X
an	B-X
inappropriate	B-X
macrophage/T-cell	B-X
interaction	B-X
,	B-X
where	B-X
classical	B-X
(	B-X
M1	B-X
)	B-X
or	B-X
alternative	B-X
(	B-X
M2	B-X
)	B-X
macrophage	B-X
activation	B-X
may	B-X
influence	B-X
the	B-X
occurrence	B-X
of	B-X
T-helper	B-X
(	B-X
Th	B-X
)	B-X
1	B-X
or	B-X
Th2	B-X
responses	B-X
.	B-X
In	B-X
RA	B-X
patients	B-X
,	B-X
M1/Th1	B-X
activation	B-X
occurs	B-X
in	B-X
an	B-X
inflammatory	B-X
environment	B-X
dominated	B-X
by	B-X
Toll-like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
and	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
signaling	B-X
,	B-X
and	B-X
it	B-X
promotes	B-X
a	B-X
massive	B-X
production	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
[	B-X
i.e.	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor-α	B-X
(	B-X
TNFα	B-X
)	B-X
,	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-1	B-X
,	B-X
IL-12	B-X
,	B-X
IL-18	B-X
,	B-X
and	B-X
IFNγ	B-X
]	B-X
,	B-X
chemotactic	B-X
factors	B-X
,	B-X
and	B-X
matrix	B-X
metalloproteinases	B-X
resulting	B-X
in	B-X
osteoclastogenesis	B-X
,	B-X
erosion	B-X
,	B-X
and	B-X
progressive	B-X
joint	B-X
destruction	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
the	B-X
activation	B-X
of	B-X
M2/Th2	B-X
response	B-X
determines	B-X
the	B-X
release	B-X
of	B-X
growth	B-X
factors	B-X
and	B-X
cytokines	B-X
[	B-X
i.e.	B-X
,	B-X
IL-4	B-X
,	B-X
IL-10	B-X
,	B-X
IL-13	B-X
,	B-X
and	B-X
transforming	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
-β	B-X
]	B-X
involved	B-X
in	B-X
the	B-X
anti-inflammatory	B-X
process	B-X
leading	B-X
to	B-X
the	B-X
clinical	B-X
remission	B-X
of	B-X
RA	B-X
.	B-X

LMP1	B-Protein
activates	O
both	O
the	O
canonical	O
and	O
non	O
-	O
canonical	O
pathways	O
of	O
NFkappaB	O
signaling	O
[	O
14	O
,	O
63	O
-	O
65	O
]	O
,	O
and	O
inhibition	O
of	O
NFkappaB	O
blocked	O
the	O
survival	O
of	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
and	O
LMP1	B-Protein
-	O
positive	O
and	O
-	O
negative	O
lymphoma	O
cells	O
.	O

NFkappaB	O
and	O
PI3K	O
signaling	O
are	O
crucial	O
for	O
CD40	B-Protein
-	O
induced	O
proliferation	O
,	O
and	O
mice	O
deficient	O
for	O
cRel	B-Protein
or	O
the	O
p85	B-Protein
regulatory	O
subunit	O
of	O
PI3K	O
are	O
unresponsive	O
to	O
mitogenic	O
stimuli	O
,	O
including	O
CD40	B-Protein
ligation	O
[	O
66	O
-	O
68	O
]	O
.	O

We	O
have	O
previously	O
shown	O
that	O
cRel	B-Protein
is	O
specifically	O
activated	O
in	O
both	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphomas	O
,	O
suggesting	O
that	O
activation	O
of	O
cRel	B-Protein
is	O
associated	O
with	O
B	O
cell	O
transformation	O
[	O
27	O
]	O
.	O

Our	O
observations	O
suggest	O
that	O
similar	O
to	O
CD40	B-Protein
-	O
induced	O
proliferation	O
,	O
LMP1	B-Protein
induces	O
proliferation	O
through	O
PI3K	O
-	O
mediated	O
activation	O
of	O
Akt	B-Protein
and	O
activation	O
of	O
NFkappaB	O
components	O
such	O
as	O
cRel	B-Protein
.	O

CD40	B-Protein
also	O
induces	O
downregulation	O
of	O
the	O
cell	O
cycle	O
inhibitor	O
p27	B-Protein
through	O
a	O
PI3K	O
-	O
dependent	O
manner	O
,	O
and	O
the	O
LMP1	B-Protein
lymphoma	O
cells	O
also	O
had	O
decreased	O
levels	O
of	O
p27	B-Protein
with	O
phosphorylation	O
of	O
Rb	B-Protein
and	O
increased	O
Cdk2	B-Protein
(	O
Figure	O
6C	O
)	O
[	O
66	O
]	O
.	O

Although	O
LMP1	B-Protein
has	O
been	O
shown	O
to	O
deregulate	O
the	O
Rb	B-Protein
pathway	O
in	O
epithelial	O
cells	O
[	O
69	O
]	O
,	O
to	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
demonstration	O
of	O
this	O
property	O
in	O
B	O
lymphocytes	O
.	O

The	O
requirement	O
for	O
Akt	B-Protein
activation	O
was	O
confirmed	O
by	O
the	O
striking	O
inhibition	O
of	O
lymphoma	O
viability	O
by	O
triciribine	O
,	O
an	O
Akt	B-Protein
inhibitor	O
.	O

However	O
,	O
the	O
activated	O
pAkt	B-Protein
did	O
not	O
lead	O
to	O
phosphorylation	O
and	O
inactivation	O
of	O
the	O
downstream	O
target	O
GSK3	B-Protein
(	O
Figure	O
6A	O
)	O
.	O
<EOS>	B-X
SIRT1	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
activated	B-X
by	B-X
resveratrol	B-X
treatment	B-X
,	B-X
and	B-X
also	B-X
has	B-X
been	B-X
proved	B-X
to	B-X
prevent	B-X
aging-related	B-X
diseases	B-X
such	B-X
as	B-X
osteoporosis	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
SIRT1	B-X
about	B-X
autophagy	B-X
or	B-X
mitophagy	B-X
of	B-X
osteoblasts	B-X
in	B-X
resveratrol-regulated	B-X
osteoporotic	B-X
rats	B-X
remains	B-X
unclear	B-X
.	B-X
However	B-X
,	B-X
the	B-X
underlying	B-X
mechanisms	B-X
of	B-X
exercise-afforded	B-X
cardioprotection	B-X
are	B-X
still	B-X
unclear	B-X
.	B-X
Loss	B-X
of	B-X
hepatic	B-X
fructose-1	B-X
,	B-X
6-bisphosphate	B-X
aldolase	B-X
B	B-X
(	B-X
Aldob	B-X
)	B-X
leads	B-X
to	B-X
a	B-X
paradoxical	B-X
up-regulation	B-X
of	B-X
glucose	B-X
metabolism	B-X
to	B-X
favor	B-X
hepatocellular	B-X
carcinogenesis	B-X
(	B-X
HCC	B-X
)	B-X
,	B-X
but	B-X
the	B-X
upstream	B-X
signaling	B-X
events	B-X
remain	B-X
poorly	B-X
defined	B-X
.	B-X
Akt	B-X
is	B-X
highly	B-X
activated	B-X
in	B-X
HCC	B-X
,	B-X
and	B-X
targeting	B-X
Akt	B-X
is	B-X
being	B-X
explored	B-X
as	B-X
a	B-X
potential	B-X
therapy	B-X
for	B-X
HCC	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
Aldob	B-X
suppresses	B-X
Akt	B-X
activity	B-X
and	B-X
tumor	B-X
growth	B-X
through	B-X
a	B-X
protein	B-X
complex	B-X
containing	B-X
Aldob	B-X
,	B-X
Akt	B-X
,	B-X
and	B-X
protein	B-X
phosphatase	B-X
2A	B-X
(	B-X
PP2A	B-X
)	B-X
,	B-X
leading	B-X
to	B-X
inhibition	B-X
of	B-X
cell	B-X
viability	B-X
,	B-X
cell	B-X
cycle	B-X
progression	B-X
,	B-X
glucose	B-X
uptake	B-X
,	B-X
and	B-X
metabolism	B-X
.	B-X

This	O
effect	O
has	O
also	O
been	O
described	O
in	O
EBV	O
-	O
positive	O
HD	O
biopsies	O
[	O
40	O
]	O
.	O
<EOS>	B-X
Hodgkin	B-X
's	B-X
disease	B-X
(	B-X
HD	B-X
)	B-X
has	B-X
long	B-X
been	B-X
suspected	B-X
to	B-X
have	B-X
an	B-X
infectious	B-X
precursor	B-X
,	B-X
and	B-X
indirect	B-X
evidence	B-X
has	B-X
implicated	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
,	B-X
a	B-X
ubiquitous	B-X
herpesvirus	B-X
,	B-X
as	B-X
a	B-X
causal	B-X
agent	B-X
.	B-X
Recent	B-X
molecular	B-X
studies	B-X
using	B-X
EBER	B-X
in	B-X
situ	B-X
hybridization	B-X
or	B-X
latency	B-X
membrane	B-X
protein-I	B-X
(	B-X
LMP-I	B-X
)	B-X
immunohistochemistry	B-X
have	B-X
identified	B-X
EBV	B-X
latent	B-X
infection	B-X
in	B-X
up	B-X
to	B-X
50	B-X
%	B-X
of	B-X
HD	B-X
tumors	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
epidemiology	B-X
of	B-X
EBV-positive	B-X
HD	B-X
so	B-X
as	B-X
to	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
EBV	B-X
in	B-X
HD	B-X
etiology	B-X
more	B-X
clearly	B-X
,	B-X
this	B-X
project	B-X
accumulated	B-X
patient	B-X
data	B-X
from	B-X
14	B-X
studies	B-X
that	B-X
had	B-X
applied	B-X
these	B-X
EBV	B-X
assays	B-X
to	B-X
HD	B-X
tumors	B-X
.	B-X
With	B-X
information	B-X
on	B-X
age	B-X
at	B-X
diagnosis	B-X
,	B-X
sex	B-X
,	B-X
ethnicity	B-X
,	B-X
histologic	B-X
subtype	B-X
,	B-X
country	B-X
of	B-X
residence	B-X
,	B-X
clinical	B-X
stage	B-X
and	B-X
EBV	B-X
tumor	B-X
status	B-X
from	B-X
1,546	B-X
HD	B-X
patients	B-X
,	B-X
we	B-X
examined	B-X
risk	B-X
for	B-X
EBV-positive	B-X
disease	B-X
using	B-X
logistic	B-X
regression	B-X
.	B-X
Forty	B-X
percent	B-X
of	B-X
subjects	B-X
had	B-X
EBV-positive	B-X
tumors	B-X
,	B-X
and	B-X
EBV	B-X
prevalence	B-X
varied	B-X
significantly	B-X
across	B-X
groups	B-X
defined	B-X
by	B-X
the	B-X
study	B-X
variables	B-X
.	B-X
Odds	B-X
ratios	B-X
(	B-X
OR	B-X
)	B-X
for	B-X
EBV-associated	B-X
HD	B-X
were	B-X
significantly	B-X
elevated	B-X
for	B-X
Hispanics	B-X
vs.	B-X
whites	B-X
(	B-X
OR	B-X
=	B-X
4.1	B-X
)	B-X
,	B-X
mixed	B-X
cellularity	B-X
vs.	B-X
nodular	B-X
sclerosis	B-X
histologic	B-X
subtypes	B-X
(	B-X
OR	B-X
=	B-X
7.3	B-X
,	B-X
13.4	B-X
,	B-X
4.9	B-X
for	B-X
ages	B-X
0-14	B-X
,	B-X
15-49	B-X
,	B-X
50+	B-X
years	B-X
)	B-X
,	B-X
children	B-X
from	B-X
economically	B-X
less-developed	B-X
vs.	B-X
more-developed	B-X
regions	B-X
and	B-X
young	B-X
adult	B-X
males	B-X
vs.	B-X
females	B-X
(	B-X
OR	B-X
=	B-X
2.5	B-X
)	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
age	B-X
,	B-X
sex	B-X
,	B-X
ethnicity	B-X
and	B-X
the	B-X
physiologic	B-X
effects	B-X
of	B-X
poverty	B-X
may	B-X
represent	B-X
biologic	B-X
modifiers	B-X
of	B-X
the	B-X
EBV	B-X
association	B-X
and	B-X
confirm	B-X
that	B-X
this	B-X
association	B-X
is	B-X
strongly	B-X
but	B-X
variably	B-X
linked	B-X
to	B-X
histologic	B-X
subtype	B-X
.	B-X
The	B-X
data	B-X
augment	B-X
biologic	B-X
evidence	B-X
that	B-X
EBV	B-X
is	B-X
actively	B-X
involved	B-X
in	B-X
HD	B-X
pathogenesis	B-X
in	B-X
some	B-X
cases	B-X
but	B-X
describe	B-X
epidemiologic	B-X
complexity	B-X
in	B-X
this	B-X
process	B-X
.	B-X

In	O
contrast	O
,	O
rapamycin	O
,	O
U0126	O
,	O
and	O
SB202190	O
did	O
not	O
affect	O
the	O
survival	O
of	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
or	O
the	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
(	O
Figure	O
7A	O
,	O
7C	O
,	O
and	O
7E	O
)	O
.	O

This	O
lack	O
of	O
effect	O
by	O
rapamycin	O
confirmed	O
the	O
absence	O
of	O
activated	O
p	B-Protein
-	I-Protein
mTOR	I-Protein
levels	O
(	O
Figure	O
6B	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
other	O
Akt	B-Protein
targets	O
contribute	O
to	O
malignant	O
progression	O
.	O
<EOS>	B-X
Loss	B-X
of	B-X
negative	B-X
control	B-X
of	B-X
Hedgehog	B-X
signaling	B-X
contributes	B-X
to	B-X
tumor	B-X
pathogenesis	B-X
and	B-X
progression	B-X
.	B-X
However	B-X
,	B-X
recent	B-X
evidence	B-X
suggests	B-X
a	B-X
critical	B-X
role	B-X
of	B-X
Smoothened-independent	B-X
regulation	B-X
of	B-X
GLI	B-X
activity	B-X
by	B-X
several	B-X
other	B-X
signaling	B-X
pathways	B-X
including	B-X
the	B-X
PI3K/AKT	B-X
and	B-X
RAS/RAF/MEK/ERK	B-X
axes	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
contribution	B-X
of	B-X
canonical	B-X
Hedgehog	B-X
signaling	B-X
via	B-X
Patched	B-X
and	B-X
Smoothened	B-X
to	B-X
normal	B-X
and	B-X
malignant	B-X
hematopoiesis	B-X
has	B-X
been	B-X
the	B-X
subject	B-X
of	B-X
recent	B-X
controversies	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
current	B-X
understanding	B-X
and	B-X
controversial	B-X
findings	B-X
of	B-X
canonical	B-X
and	B-X
noncanonical	B-X
GLI	B-X
activation	B-X
in	B-X
hematological	B-X
malignancies	B-X
in	B-X
light	B-X
of	B-X
the	B-X
current	B-X
therapeutic	B-X
strategies	B-X
targeting	B-X
the	B-X
Hedgehog	B-X
pathway	B-X
.	B-X

One	O
key	O
target	O
is	O
likely	O
the	O
inhibition	O
of	O
the	O
Fox01	B-Protein
transcription	O
factors	O
.	O

Repression	O
of	O
the	O
pro	O
-	O
apoptotic	O
transcription	O
factor	O
FoxO1	B-Protein
in	O
a	O
PI3K	O
-	O
dependent	O
manner	O
can	O
inhibit	O
expression	O
of	O
bcl6	B-Protein
,	O
a	O
transcription	O
factor	O
necessary	O
for	O
GC	O
formation	O
[	O
49	O
,	O
70	O
]	O
.	O

It	O
has	O
been	O
shown	O
that	O
overstimulation	O
of	O
CD40	B-Protein
signaling	O
with	O
agonistic	O
antibodies	O
inhibits	O
GC	O
formation	O
[	O
71	O
]	O
.	O

Similarly	O
,	O
due	O
to	O
mimicry	O
of	O
CD40	B-Protein
signaling	O
,	O
transgenic	O
LMP1	B-Protein
mice	O
are	O
also	O
defective	O
in	O
GC	O
formation	O
[	O
23	O
,	O
49	O
]	O
.	O

The	O
constitutive	O
signaling	O
by	O
LMP1	B-Protein
likely	O
blocks	O
GC	O
formation	O
through	O
downregulation	O
of	O
bcl6	B-Protein
.	O

Interestingly	O
,	O
clinical	O
studies	O
indicate	O
that	O
expression	O
of	O
LMP1	B-Protein
and	O
bcl6	B-Protein
are	O
mutually	O
exclusive	O
in	O
non	O
-	O
HD	O
and	O
classical	O
HD	O
[	O
72	O
,	O
73	O
]	O
.	O

Thus	O
,	O
the	O
LMP1	B-Protein
transgenic	O
lymphomas	O
mirror	O
aspects	O
of	O
EBV	O
-	O
induced	O
HD	O
.	O

Although	O
the	O
activation	O
of	O
Akt	B-Protein
and	O
the	O
lack	O
of	O
Fox01	B-Protein
in	O
the	O
lymphoma	O
cells	O
suggest	O
that	O
LMP1	B-Protein
affects	O
bcl6	B-Protein
and	O
GC	O
formation	O
through	O
this	O
pathway	O
,	O
regulation	O
of	O
other	O
Forkhead	O
targets	O
involved	O
in	O
cell	O
cycle	O
progression	O
,	O
such	O
as	O
p27	B-Protein
and	O
CyclinD2	B-Protein
,	O
likely	O
contribute	O
to	O
malignant	O
transformation	O
.	O

Indeed	O
,	O
loss	O
of	O
FoxO1	B-Protein
expression	O
in	O
lymphoma	O
cells	O
correlated	O
with	O
a	O
loss	O
of	O
p27	B-Protein
(	O
Figure	O
6B	O
and	O
6C	O
)	O
.	O

CyclinD2	B-Protein
has	O
also	O
been	O
shown	O
to	O
be	O
upregulated	O
by	O
LMP1	B-Protein
through	O
release	O
of	O
FoxO1	B-Protein
-	O
mediated	O
repression	O
[	O
70	O
]	O
.	O

In	O
summary	O
,	O
in	O
this	O
transgenic	O
model	O
of	O
lymphomagenesis	O
,	O
LMP1	B-Protein
promotes	O
malignancy	O
in	O
B	O
-	O
1a	O
cells	O
,	O
a	O
population	O
that	O
is	O
predisposed	O
to	O
clonal	O
expansion	O
with	O
age	O
.	O

The	O
malignant	O
lymphocytes	O
were	O
distinguished	O
by	O
constitutively	O
active	O
Stat3	B-Protein
signaling	O
,	O
decreased	O
p27	B-Protein
,	O
and	O
activated	O
Akt	B-Protein
and	O
NFkappaB	O
pathways	O
,	O
properties	O
that	O
are	O
associated	O
with	O
promoting	O
the	O
growth	O
and	O
survival	O
of	O
B	O
lymphocytes	O
.	O

Importantly	O
,	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
pathways	O
were	O
critically	O
required	O
for	O
the	O
growth	O
and	O
survival	O
of	O
malignant	O
lymphocytes	O
as	O
well	O
as	O
healthy	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
.	O

The	O
growth	O
of	O
EBV	O
-	O
transformed	O
lymphocytes	O
also	O
requires	O
activation	O
of	O
NFkappaB	O
,	O
and	O
these	O
studies	O
provide	O
insight	O
into	O
how	O
LMP1	B-Protein
contributes	O
to	O
EBV	O
-	O
associated	O
transformation	O
.	O

The	O
transgenic	O
lymphomas	O
mirror	O
multiple	O
aspects	O
of	O
EBV	O
-	O
induced	O
tumors	O
and	O
suggest	O
that	O
in	O
vivo	O
these	O
properties	O
of	O
LMP1	B-Protein
are	O
major	O
factors	O
in	O
the	O
development	O
of	O
cancer	O
.	O

Transgenic	O
mice	O
.	O
<EOS>	B-X
For	B-X
the	B-X
past	B-X
20	B-X
years	B-X
researchers	B-X
have	B-X
used	B-X
transgenic	B-X
mice	B-X
to	B-X
help	B-X
understand	B-X
the	B-X
basic	B-X
mechanisms	B-X
associated	B-X
with	B-X
inherited	B-X
human	B-X
and	B-X
animal	B-X
diseases	B-X
.	B-X
Constructing	B-X
different	B-X
lines	B-X
of	B-X
transgenic	B-X
mice	B-X
carrying	B-X
various	B-X
versions	B-X
of	B-X
a	B-X
gene	B-X
,	B-X
therefore	B-X
,	B-X
permits	B-X
cis	B-X
acting	B-X
DNA	B-X
sequences	B-X
involved	B-X
in	B-X
the	B-X
specificity	B-X
of	B-X
expression	B-X
to	B-X
be	B-X
defined	B-X
,	B-X
in	B-X
the	B-X
context	B-X
of	B-X
the	B-X
developing	B-X
animal	B-X
.	B-X
The	B-X
development	B-X
of	B-X
tissue-specific	B-X
inducible	B-X
transgenic	B-X
mice	B-X
has	B-X
provided	B-X
a	B-X
powerful	B-X
tool	B-X
to	B-X
study	B-X
gene	B-X
function	B-X
and	B-X
cell	B-X
biology	B-X
in	B-X
almost	B-X
any	B-X
tissue	B-X
of	B-X
interest	B-X
at	B-X
any	B-X
given	B-X
time	B-X
within	B-X
the	B-X
animal	B-X
's	B-X
life	B-X
.	B-X
Myofiber-	B-X
and	B-X
satellite	B-X
cell-specific	B-X
Cre-loxP	B-X
transgenic	B-X
mice	B-X
are	B-X
described	B-X
as	B-X
is	B-X
how	B-X
these	B-X
mice	B-X
can	B-X
be	B-X
used	B-X
to	B-X
knockout	B-X
a	B-X
gene	B-X
of	B-X
interest	B-X
or	B-X
to	B-X
deplete	B-X
satellite	B-X
cells	B-X
in	B-X
adult	B-X
skeletal	B-X
muscle	B-X
,	B-X
respectively	B-X
.	B-X
A	B-X
myofiber-specific	B-X
Tet-ON	B-X
system	B-X
is	B-X
described	B-X
as	B-X
is	B-X
how	B-X
such	B-X
mice	B-X
can	B-X
be	B-X
used	B-X
to	B-X
overexpress	B-X
a	B-X
gene	B-X
of	B-X
interest	B-X
or	B-X
to	B-X
label	B-X
myonuclei	B-X
.	B-X
How	B-X
to	B-X
effectively	B-X
breed	B-X
and	B-X
genotype	B-X
the	B-X
transgenic	B-X
mice	B-X
are	B-X
also	B-X
described	B-X
in	B-X
detail	B-X
.	B-X
The	B-X
hope	B-X
is	B-X
this	B-X
review	B-X
will	B-X
provide	B-X
the	B-X
basic	B-X
information	B-X
necessary	B-X
to	B-X
facilitate	B-X
the	B-X
incorporation	B-X
of	B-X
tissue-specific	B-X
inducible	B-X
transgenic	B-X
mice	B-X
into	B-X
a	B-X
skeletal	B-X
muscle	B-X
research	B-X
program	B-X
.	B-X

Generation	O
of	O
LMP1	B-Protein
mice	O
under	O
the	O
Ig	O
heavy	O
chain	O
promoter	O
and	O
enhancer	O
have	O
been	O
described	O
previously	O
and	O
were	O
maintained	O
as	O
heterozygotes	O
on	O
a	O
Balbc	O
background	O
[	O
26	O
]	O
.	O

LMP1	B-Protein
mice	O
were	O
genotyped	O
by	O
Southern	O
blot	O
and	O
PCR	O
analysis	O
of	O
tail	O
DNA	O
as	O
described	O
previously	O
[	O
26	O
]	O
.	O

Spleen	O
and	O
liver	O
sections	O
were	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
and	O
embedded	O
in	O
paraffin	O
,	O
and	O
5	O
-	O
mum	O
sections	O
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
for	O
histopathological	O
analysis	O
.	O

Lymphomas	O
were	O
passaged	O
by	O
intraperitoneal	O
injection	O
of	O
1	O
x	O
108	O
splenocytes	O
into	O
SCID	O
mice	O
and	O
sacrificed	O
upon	O
development	O
of	O
an	O
extended	O
abdomen	O
.	O

Animals	O
were	O
housed	O
in	O
the	O
Association	O
for	O
Assessment	O
and	O
Accreditation	O
for	O
Animal	O
Care	O
-	O
approved	O
animal	O
facility	O
at	O
the	O
University	O
of	O
North	O
Carolina	O
at	O
Chapel	O
Hill	O
.	O

All	O
protocols	O
were	O
approved	O
by	O
the	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
.	O
<EOS>	B-X
Tofacitinib	B-X
,	B-X
a	B-X
pan-JAK	B-X
inhibitor	B-X
,	B-X
is	B-X
the	B-X
first	B-X
approved	B-X
JAK	B-X
inhibitor	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
RA	B-X
and	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
effective	B-X
in	B-X
managing	B-X
disease	B-X
.	B-X
The	B-X
Institutional	B-X
Animal	B-X
Care	B-X
and	B-X
Use	B-X
Committee	B-X
(	B-X
IACUC	B-X
)	B-X
of	B-X
Seoul	B-X
National	B-X
University	B-X
(	B-X
SNU	B-X
)	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
monitoring	B-X
and	B-X
managing	B-X
the	B-X
humane	B-X
use	B-X
of	B-X
animals	B-X
in	B-X
scientific	B-X
research	B-X
.	B-X
Here	B-X
,	B-X
as	B-X
one	B-X
of	B-X
the	B-X
pioneers	B-X
of	B-X
the	B-X
IACUC	B-X
in	B-X
Korea	B-X
,	B-X
we	B-X
reported	B-X
SNU-IACUC	B-X
operations	B-X
and	B-X
activities	B-X
including	B-X
committee	B-X
establishment	B-X
and	B-X
legal	B-X
formulation	B-X
,	B-X
protocol	B-X
review	B-X
,	B-X
and	B-X
post-approval	B-X
monitoring	B-X
of	B-X
protocols	B-X
,	B-X
which	B-X
the	B-X
IACUC	B-X
has	B-X
undertaken	B-X
in	B-X
the	B-X
last	B-X
decade	B-X
.	B-X
The	B-X
Institutional	B-X
Animal	B-X
Care	B-X
and	B-X
Use	B-X
Committee	B-X
(	B-X
IACUC	B-X
)	B-X
reviews	B-X
,	B-X
monitors	B-X
,	B-X
and	B-X
approves	B-X
all	B-X
research	B-X
involving	B-X
animal	B-X
subjects	B-X
in	B-X
order	B-X
to	B-X
ensure	B-X
an	B-X
animal	B-X
's	B-X
ethical	B-X
and	B-X
humane	B-X
treatment	B-X
.	B-X
The	B-X
IACUC	B-X
should	B-X
assess	B-X
,	B-X
approve	B-X
,	B-X
and	B-X
monitor	B-X
research	B-X
protocols	B-X
involving	B-X
animals	B-X
prior	B-X
to	B-X
conducting	B-X
every	B-X
study	B-X
to	B-X
safeguard	B-X
AAI	B-X
animal	B-X
welfare	B-X
.	B-X

Isolation	O
and	O
growth	O
of	O
B	O
cells	O
.	O
<EOS>	B-X
In	B-X
this	B-X
platform	B-X
,	B-X
antigen-binding	B-X
splenic	B-X
B	B-X
cells	B-X
from	B-X
immunized	B-X
mice	B-X
are	B-X
isolated	B-X
by	B-X
FACS	B-X
and	B-X
cocultured	B-X
with	B-X
CD40L	B-X
positive	B-X
cells	B-X
to	B-X
induce	B-X
proliferation	B-X
and	B-X
mAb	B-X
production	B-X
.	B-X
Positive-well	B-X
cDNA	B-X
is	B-X
then	B-X
amplified	B-X
by	B-X
PCR	B-X
and	B-X
the	B-X
resulting	B-X
amplicons	B-X
can	B-X
be	B-X
cloned	B-X
into	B-X
ligation-independent	B-X
expression	B-X
vectors	B-X
,	B-X
which	B-X
are	B-X
then	B-X
used	B-X
directly	B-X
to	B-X
transfect	B-X
HEK293	B-X
cells	B-X
for	B-X
recombinant	B-X
antibody	B-X
production	B-X
.	B-X
After	B-X
4days	B-X
of	B-X
growth	B-X
,	B-X
conditioned	B-X
medium	B-X
can	B-X
be	B-X
screened	B-X
using	B-X
biolayer	B-X
interferometry	B-X
for	B-X
antigen	B-X
binding	B-X
and	B-X
affinity	B-X
measurements	B-X
.	B-X
Immunoglobulin	B-X
(	B-X
IG	B-X
)	B-X
gene	B-X
remodeling	B-X
by	B-X
V	B-X
(	B-X
D	B-X
)	B-X
J	B-X
recombination	B-X
plays	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
generation	B-X
of	B-X
normal	B-X
B	B-X
cells	B-X
,	B-X
and	B-X
somatic	B-X
hypermutation	B-X
and	B-X
class	B-X
switching	B-X
of	B-X
IG	B-X
genes	B-X
are	B-X
key	B-X
processes	B-X
during	B-X
antigen-driven	B-X
B	B-X
cell	B-X
differentiation	B-X
.	B-X
However	B-X
,	B-X
errors	B-X
of	B-X
these	B-X
processes	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
development	B-X
of	B-X
B	B-X
cell	B-X
lymphomas	B-X
.	B-X
IG	B-X
locus-associated	B-X
translocations	B-X
of	B-X
proto-oncogenes	B-X
are	B-X
a	B-X
hallmark	B-X
of	B-X
many	B-X
B	B-X
cell	B-X
malignancies	B-X
.	B-X
Additional	B-X
transforming	B-X
events	B-X
include	B-X
inactivating	B-X
mutations	B-X
in	B-X
various	B-X
tumor	B-X
suppressor	B-X
genes	B-X
and	B-X
also	B-X
latent	B-X
infection	B-X
of	B-X
B	B-X
cells	B-X
with	B-X
viruses	B-X
,	B-X
such	B-X
as	B-X
Epstein-Barr	B-X
virus	B-X
.	B-X
Many	B-X
B	B-X
cell	B-X
lymphomas	B-X
require	B-X
B	B-X
cell	B-X
antigen	B-X
receptor	B-X
expression	B-X
,	B-X
and	B-X
in	B-X
several	B-X
instances	B-X
,	B-X
chronic	B-X
antigenic	B-X
stimulation	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
lymphoma	B-X
development	B-X
and/or	B-X
sustaining	B-X
tumor	B-X
growth	B-X
.	B-X
Often	B-X
,	B-X
survival	B-X
and	B-X
proliferation	B-X
signals	B-X
provided	B-X
by	B-X
other	B-X
cells	B-X
in	B-X
the	B-X
microenvironment	B-X
are	B-X
a	B-X
further	B-X
critical	B-X
factor	B-X
in	B-X
lymphoma	B-X
development	B-X
and	B-X
pathophysiology	B-X
.	B-X
Many	B-X
B	B-X
cell	B-X
malignancies	B-X
derive	B-X
from	B-X
germinal	B-X
center	B-X
B	B-X
cells	B-X
,	B-X
most	B-X
likely	B-X
because	B-X
of	B-X
the	B-X
high	B-X
proliferation	B-X
rate	B-X
of	B-X
these	B-X
cells	B-X
and	B-X
the	B-X
high	B-X
activity	B-X
of	B-X
mutagenic	B-X
processes	B-X
.	B-X

Splenocytes	O
were	O
prepared	O
by	O
homogenizing	O
spleen	O
tissue	O
with	O
two	O
frosted	O
slides	O
and	O
debris	O
was	O
filtered	O
through	O
a	O
100	O
-	O
mum	O
cell	O
strainer	O
.	O

Erythrocytes	O
were	O
lysed	O
using	O
0	O
.	O
8	O
%	O
ammonium	O
chloride	O
solution	O
(	O
StemCell	O
Technologies	O
)	O
for	O
10	O
min	O
on	O
ice	O
and	O
washed	O
twice	O
with	O
PBS	O
.	O

B	O
cells	O
were	O
isolated	O
using	O
CD19	B-Protein
-	O
MACS	O
beads	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Miltenyi	O
Biotec	O
)	O
and	O
grown	O
in	O
Iscove	O
'	O
s	O
medium	O
supplemented	O
with	O
heat	O
-	O
inactivated	O
10	O
%	O
fetal	O
bovine	O
serum	O
and	O
antibiotic	O
/	O
antimycotic	O
(	O
GIBCO	O
)	O
.	O

Splenocytes	O
isolated	O
from	O
SCID	O
-	O
passaged	O
lymphomas	O
consisted	O
of	O
80	O
%	O
-	O
90	O
%	O
B	O
cells	O
as	O
determined	O
by	O
flow	O
cytometry	O
,	O
and	O
were	O
hence	O
not	O
further	O
purified	O
with	O
CD19	B-Protein
-	O
MACS	O
beads	O
.	O

Splenocytes	O
were	O
seeded	O
at	O
1	O
.	O
25	O
x	O
106	O
cells	O
/	O
ml	O
and	O
where	O
applicable	O
,	O
recombinant	O
mouse	O
IL4	B-Protein
was	O
added	O
at	O
100	O
ng	O
/	O
ml	O
,	O
recombinant	O
mouse	O
IL10	B-Protein
at	O
10	O
ng	O
/	O
ml	O
,	O
and	O
rat	O
IgG1	O
anti	O
-	O
mouse	O
IL10	B-Protein
and	O
rat	O
IgG1	O
isotype	O
control	O
at	O
10	O
mug	O
/	O
ml	O
(	O
R	O
&	O
D	O
Systems	O
)	O
.	O

For	O
BrdU	O
incorporation	O
assays	O
,	O
splenocytes	O
were	O
pulsed	O
for	O
24	O
h	O
with	O
10	O
muM	O
BrdU	O
1	O
d	O
post	O
-	O
harvest	O
.	O

MTS	O
assay	O
.	O
<EOS>	B-X
The	B-X
MTT/MTS	B-X
in	B-X
vitro	B-X
cell	B-X
proliferation	B-X
assay	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
widely	B-X
used	B-X
assays	B-X
for	B-X
evaluating	B-X
preliminary	B-X
anticancer	B-X
activity	B-X
of	B-X
both	B-X
synthetic	B-X
derivatives	B-X
and	B-X
natural	B-X
products	B-X
and	B-X
natural	B-X
product	B-X
extracts	B-X
.	B-X
The	B-X
highly	B-X
reliable	B-X
,	B-X
colorimetric	B-X
based	B-X
assay	B-X
is	B-X
readily	B-X
performed	B-X
on	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
cell	B-X
lines	B-X
.	B-X
This	B-X
assay	B-X
gives	B-X
an	B-X
indication	B-X
of	B-X
whole	B-X
cell	B-X
cytotoxicity	B-X
;	B-X
however	B-X
,	B-X
to	B-X
determine	B-X
the	B-X
exact	B-X
molecular	B-X
target	B-X
further	B-X
assays	B-X
need	B-X
to	B-X
be	B-X
performed	B-X
.	B-X
Of	B-X
these	B-X
,	B-X
kinase	B-X
inhibition	B-X
assays	B-X
are	B-X
also	B-X
one	B-X
of	B-X
the	B-X
most	B-X
widespread	B-X
enzyme	B-X
inhibition	B-X
screening	B-X
assays	B-X
performed	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
methods	B-X
for	B-X
performing	B-X
both	B-X
in	B-X
vitro	B-X
MTT/MTS	B-X
cytotoxicity	B-X
and	B-X
kinase	B-X
enzyme	B-X
inhibition	B-X
assays	B-X
.	B-X
Both	B-X
assays	B-X
are	B-X
highly	B-X
versatile	B-X
and	B-X
can	B-X
be	B-X
modified	B-X
to	B-X
test	B-X
against	B-X
targeted	B-X
disease	B-X
processes	B-X
by	B-X
using	B-X
specific	B-X
kinase	B-X
enzymes	B-X
or	B-X
cell	B-X
lines	B-X
.	B-X

The	O
3	O
-	O
(	O
4	O
,	O
5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
)	O
-	O
5	O
-	O
(	O
3	O
-	O
carboxymethoxyphenyl	O
)	O
-	O
2	O
-	O
(	O
4	O
-	O
sulfophenyl	O
)	O
-	O
2H	O
-	O
tetrazolium	O
inner	O
salt	O
(	O
MTS	O
)	O
cell	O
cytotoxicity	O
/	O
proliferation	O
assays	O
were	O
performed	O
using	O
the	O
CellTiter	O
96	O
aqueous	O
one	O
-	O
solution	O
cell	O
proliferation	O
assay	O
(	O
Promega	O
)	O
,	O
according	O
to	O
manufacturer	O
'	O
s	O
instructions	O
.	O

For	O
IL4	B-Protein
studies	O
,	O
splenocytes	O
were	O
cultured	O
for	O
3	O
d	O
in	O
the	O
presence	O
or	O
absence	O
of	O
100	O
ng	O
/	O
ml	O
IL4	B-Protein
.	O

Cells	O
were	O
seeded	O
on	O
day	O
3	O
in	O
triplicate	O
in	O
a	O
96	O
-	O
well	O
plate	O
at	O
2	O
.	O
5	O
x	O
106	O
cells	O
/	O
ml	O
at	O
100	O
mul	O
per	O
well	O
.	O

MTS	O
reagent	O
was	O
added	O
for	O
4	O
h	O
and	O
absorbance	O
was	O
read	O
at	O
540	O
nm	O
;	O
values	O
plotted	O
were	O
subtracted	O
from	O
blanks	O
.	O

For	O
neutralization	O
assays	O
,	O
splenocytes	O
were	O
seeded	O
at	O
5	O
x	O
106	O
cells	O
/	O
ml	O
at	O
100	O
mul	O
per	O
well	O
on	O
day	O
of	O
harvest	O
and	O
IL4	B-Protein
,	O
rat	O
IgG1	O
anti	O
-	O
mouse	O
IL4	B-Protein
,	O
or	O
rat	O
IgG1	O
isotype	O
control	O
(	O
R	O
&	O
D	O
Systems	O
)	O
were	O
added	O
at	O
the	O
concentrations	O
indicated	O
in	O
the	O
figures	O
.	O
<EOS>	B-X
The	B-X
unprecedented	B-X
in	B-X
recent	B-X
history	B-X
global	B-X
COVID-19	B-X
pandemic	B-X
urged	B-X
the	B-X
implementation	B-X
of	B-X
all	B-X
existing	B-X
vaccine	B-X
platforms	B-X
to	B-X
ensure	B-X
the	B-X
availability	B-X
of	B-X
the	B-X
vaccines	B-X
against	B-X
COVID-19	B-X
to	B-X
every	B-X
country	B-X
in	B-X
the	B-X
world	B-X
.	B-X
Despite	B-X
the	B-X
multitude	B-X
of	B-X
high-quality	B-X
papers	B-X
describing	B-X
clinical	B-X
trials	B-X
of	B-X
different	B-X
vaccine	B-X
products	B-X
,	B-X
basic	B-X
detailed	B-X
data	B-X
on	B-X
general	B-X
toxicity	B-X
,	B-X
reproductive	B-X
toxicity	B-X
,	B-X
immunogenicity	B-X
,	B-X
protective	B-X
efficacy	B-X
and	B-X
durability	B-X
of	B-X
immune	B-X
response	B-X
in	B-X
animal	B-X
models	B-X
are	B-X
scarce	B-X
.	B-X
The	B-X
vaccine	B-X
showed	B-X
no	B-X
signs	B-X
of	B-X
acute/chronic	B-X
,	B-X
reproductive	B-X
,	B-X
embryo-	B-X
and	B-X
fetotoxicity	B-X
,	B-X
or	B-X
teratogenic	B-X
effects	B-X
,	B-X
as	B-X
well	B-X
as	B-X
no	B-X
allergenic	B-X
properties	B-X
in	B-X
studied	B-X
animal	B-X
species	B-X
.	B-X
The	B-X
vaccine	B-X
induced	B-X
stable	B-X
and	B-X
robust	B-X
humoral	B-X
immune	B-X
response	B-X
both	B-X
in	B-X
form	B-X
of	B-X
specific	B-X
anti-SARS-CoV-2	B-X
IgG	B-X
and	B-X
NAbs	B-X
in	B-X
mice	B-X
,	B-X
Syrian	B-X
hamsters	B-X
,	B-X
and	B-X
common	B-X
marmosets	B-X
.	B-X
Robustness	B-X
of	B-X
the	B-X
vaccine	B-X
manufacturing	B-X
process	B-X
was	B-X
demonstrated	B-X
as	B-X
well	B-X
.	B-X

Cultures	O
were	O
pulsed	O
for	O
4	O
h	O
with	O
MTS	O
reagent	O
1	O
d	O
post	O
-	O
seeding	O
.	O

For	O
inhibitor	O
studies	O
,	O
splenocytes	O
were	O
seeded	O
at	O
1	O
x	O
107	O
cells	O
/	O
ml	O
at	O
100	O
mul	O
per	O
well	O
on	O
day	O
of	O
harvest	O
,	O
and	O
inhibitors	O
were	O
added	O
at	O
the	O
concentrations	O
indicated	O
in	O
the	O
figures	O
.	O

The	O
inhibitors	O
BAY11	O
-	O
7085	O
,	O
rapamycin	O
,	O
triciribine	O
,	O
U0126	O
,	O
SB202190	O
,	O
and	O
cucurbitacin	O
I	O
were	O
purchased	O
from	O
EMD	O
Biosciences	O
.	O

For	O
non	O
-	O
malignant	O
splenocyte	O
cultures	O
,	O
B	O
cell	O
activation	O
was	O
induced	O
with	O
10	O
mug	O
/	O
ml	O
of	O
goat	O
F	O
(	O
ab	O
'	O
)	O
anti	O
-	O
mouse	O
IgM	O
(	O
Jackson	O
ImmunoResearch	O
)	O
.	O

Cultures	O
were	O
pulsed	O
for	O
4	O
h	O
with	O
MTS	O
reagent	O
1	O
d	O
post	O
-	O
seeding	O
.	O

Immunohistochemistry	O
.	O
<EOS>	B-X
Among	B-X
these	B-X
techniques	B-X
,	B-X
multiplex	B-X
Immunohistochemistry/Immunofluorescence	B-X
(	B-X
mIHC/IF	B-X
)	B-X
has	B-X
emerged	B-X
to	B-X
be	B-X
particularly	B-X
promising	B-X
.	B-X
Immunohistochemistry	B-X
is	B-X
an	B-X
integral	B-X
technique	B-X
for	B-X
tissue-based	B-X
diagnostics	B-X
and	B-X
biomarker	B-X
detection	B-X
with	B-X
broad	B-X
worldwide	B-X
adoption	B-X
.	B-X
Immunohistochemistry	B-X
is	B-X
an	B-X
integral	B-X
technique	B-X
in	B-X
many	B-X
veterinary	B-X
laboratories	B-X
for	B-X
diagnostic	B-X
and	B-X
research	B-X
purposes	B-X
.	B-X
Next-Generation	B-X
Pathology	B-X
by	B-X
Multiplexed	B-X
Immunohistochemistry	B-X
.	B-X

Paraffin	O
-	O
embedded	O
spleen	O
sections	O
were	O
deparaffinized	O
in	O
Histoclear	O
(	O
National	O
Diagnostics	O
)	O
and	O
rehydrated	O
in	O
graded	O
ethanol	O
.	O

Sections	O
were	O
antigen	O
retrieved	O
by	O
microwaving	O
in	O
citrate	O
buffer	O
(	O
pH	O
6	O
.	O
0	O
)	O
for	O
15	O
min	O
(	O
LMP1	B-Protein
staining	O
)	O
and	O
10	O
min	O
(	O
pStat3	O
staining	O
)	O
.	O

For	O
LMP1	B-Protein
staining	O
,	O
sections	O
were	O
blocked	O
with	O
1	O
%	O
BSA	O
and	O
0	O
.	O
1	O
%	O
cold	O
fish	O
skin	O
gelatin	O
followed	O
with	O
streptavidin	O
/	O
biotin	O
block	O
(	O
Vector	O
Labs	O
)	O
.	O

Rat	O
IgG	O
anti	O
-	O
LMP1	B-Protein
(	O
clones	O
8G3	O
and	O
1G6	O
,	O
Ascenion	O
)	O
were	O
used	O
at	O
1	O
:	O
10	O
dilution	O
from	O
tissue	O
culture	O
supernatants	O
,	O
followed	O
with	O
8	O
mug	O
/	O
ml	O
biotinylated	O
mouse	O
F	O
(	O
ab	O
'	O
)	O
anti	O
-	O
rat	O
IgG	O
(	O
H	O
+	O
L	O
)	O
pre	O
-	O
adsorbed	O
to	O
mouse	O
serum	O
(	O
Jackson	O
ImmunoResearch	O
)	O
and	O
2	O
mug	O
/	O
ml	O
streptavidin	O
-	O
alkaline	O
phosphatase	O
conjugate	O
(	O
Jackson	O
ImmunoResearch	O
)	O
.	O

Stains	O
were	O
developed	O
with	O
BCIP	O
/	O
NBT	O
and	O
counterstained	O
in	O
Nuclear	O
Fast	O
Red	O
(	O
Dako	O
)	O
.	O

Phospho	O
-	O
Stat3	B-Protein
was	O
detected	O
with	O
4	O
mug	O
/	O
ml	O
of	O
pStat3	O
antibody	O
(	O
Tyr705	O
,	O
Cell	O
Signaling	O
)	O
and	O
detected	O
with	O
anti	O
-	O
rabbit	O
Poly	O
-	O
HRP	O
IHC	O
detection	O
kit	O
(	O
Chemicon	O
)	O
.	O

Flow	O
cytometry	O
.	O
<EOS>	B-X
Flow	B-X
cytometry	B-X
is	B-X
a	B-X
technology	B-X
that	B-X
provides	B-X
rapid	B-X
multi-parametric	B-X
analysis	B-X
of	B-X
single	B-X
cells	B-X
in	B-X
solution	B-X
.	B-X
Flow	B-X
cytometers	B-X
utilize	B-X
lasers	B-X
as	B-X
light	B-X
sources	B-X
to	B-X
produce	B-X
both	B-X
scattered	B-X
and	B-X
fluorescent	B-X
light	B-X
signals	B-X
that	B-X
are	B-X
read	B-X
by	B-X
detectors	B-X
such	B-X
as	B-X
photodiodes	B-X
or	B-X
photomultiplier	B-X
tubes	B-X
.	B-X
A	B-X
variety	B-X
of	B-X
fluorescent	B-X
reagents	B-X
are	B-X
utilized	B-X
in	B-X
flow	B-X
cytometry	B-X
.	B-X
Flow	B-X
cytometry	B-X
is	B-X
a	B-X
powerful	B-X
tool	B-X
that	B-X
has	B-X
applications	B-X
in	B-X
immunology	B-X
,	B-X
molecular	B-X
biology	B-X
,	B-X
bacteriology	B-X
,	B-X
virology	B-X
,	B-X
cancer	B-X
biology	B-X
,	B-X
and	B-X
infectious	B-X
disease	B-X
monitoring	B-X
.	B-X

One	O
million	O
splenocytes	O
were	O
stained	O
with	O
the	O
appropriate	O
primary	O
antibody	O
unconjugated	O
or	O
conjugated	O
to	O
FITC	O
,	O
PE	O
,	O
or	O
APC	O
diluted	O
in	O
stain	O
buffer	O
(	O
PBS	O
with	O
3	O
%	O
FBS	O
)	O
.	O
<EOS>	B-X
Although	B-X
this	B-X
research	B-X
is	B-X
still	B-X
in	B-X
its	B-X
infancy	B-X
,	B-X
further	B-X
developments	B-X
in	B-X
this	B-X
field	B-X
have	B-X
the	B-X
potential	B-X
for	B-X
sustainable	B-X
detection	B-X
of	B-X
SARS-CoV-2	B-X
.	B-X
Mononuclear	B-X
cells	B-X
,	B-X
isolated	B-X
from	B-X
peripheral	B-X
blood	B-X
,	B-X
were	B-X
labelled	B-X
with	B-X
monoclonal	B-X
antibodies	B-X
conjugated	B-X
to	B-X
the	B-X
appropriate	B-X
fluorochromes	B-X
(	B-X
CD15-FITC	B-X
,	B-X
CD14-PE	B-X
,	B-X
CD10-PE-Cy5	B-X
,	B-X
MPO+	B-X
)	B-X
and	B-X
then	B-X
analyzed	B-X
on	B-X
a	B-X
Navios	B-X
Flow	B-X
Cytometer	B-X
(	B-X
Beckman	B-X
Coulter	B-X
)	B-X
.	B-X
Patients	B-X
with	B-X
AIH	B-X
had	B-X
a	B-X
higher	B-X
median	B-X
percentage	B-X
of	B-X
LDG	B-X
(	B-X
1.2	B-X
vs.	B-X
0.1	B-X
;	B-X
p	B-X
=	B-X
0.0001	B-X
)	B-X
and	B-X
LDG	B-X
expressing	B-X
MPO	B-X
(	B-X
0.8	B-X
vs.	B-X
0.3	B-X
;	B-X
p	B-X
=	B-X
0.0017	B-X
)	B-X
when	B-X
compared	B-X
to	B-X
healthy	B-X
volunteers	B-X
.	B-X
The	B-X
goal	B-X
of	B-X
the	B-X
study	B-X
is	B-X
to	B-X
determine	B-X
which	B-X
of	B-X
these	B-X
particles	B-X
is	B-X
primarily	B-X
involved	B-X
in	B-X
releasing	B-X
of	B-X
HCC-specific	B-X
biomarker	B-X
glypican-3	B-X
(	B-X
GPC3	B-X
)	B-X
when	B-X
autophagy	B-X
is	B-X
impaired	B-X
.	B-X

For	O
BrdU	O
detection	O
,	O
the	O
FITC	O
-	O
BrdU	O
flow	O
kit	O
was	O
used	O
as	O
instructed	O
by	O
the	O
manufacturer	O
(	O
BD	O
Bioscience	O
)	O
.	O

Briefly	O
,	O
cells	O
were	O
exposed	O
to	O
EMA	O
(	O
Molecular	O
Probes	O
)	O
for	O
exclusion	O
of	O
dead	O
cells	O
,	O
stained	O
for	O
surface	O
antigens	O
,	O
fixed	O
in	O
paraformaldehyde	O
,	O
and	O
permeabilized	O
with	O
saponin	O
.	O

To	O
expose	O
BrdU	O
epitopes	O
,	O
cells	O
were	O
treated	O
with	O
Dnase	O
and	O
stained	O
with	O
FITC	O
-	O
conjugated	O
anti	O
-	O
BrdU	O
antibody	O
.	O

Flow	O
cytometry	O
was	O
performed	O
on	O
FACScalibur	O
using	O
the	O
CellQuest	O
program	O
(	O
Becton	O
Dickinson	O
)	O
.	O

Further	O
analysis	O
was	O
conducted	O
on	O
the	O
Summit	O
v4	O
.	O
2	O
program	O
(	O
Dako	O
)	O
.	O

Rnase	O
protection	O
assay	O
.	O
<EOS>	B-X
RNase	B-X
A/T1	B-X
protection	B-X
assay	B-X
.	B-X
The	B-X
RNase	B-X
protection	B-X
assay	B-X
(	B-X
RPA	B-X
)	B-X
provides	B-X
a	B-X
sensitive	B-X
alternative	B-X
for	B-X
the	B-X
detection	B-X
and	B-X
quantification	B-X
of	B-X
mRNA	B-X
.	B-X
The	B-X
development	B-X
of	B-X
RNase	B-X
protection	B-X
assays	B-X
,	B-X
structural	B-X
determination	B-X
assays	B-X
,	B-X
and	B-X
the	B-X
production	B-X
of	B-X
small	B-X
interfering	B-X
RNAs	B-X
(	B-X
siRNA	B-X
)	B-X
employed	B-X
in	B-X
RNA	B-X
interference	B-X
(	B-X
RNAi	B-X
)	B-X
experiments	B-X
has	B-X
depended	B-X
on	B-X
the	B-X
unique	B-X
substrate	B-X
specificities	B-X
of	B-X
commercially	B-X
available	B-X
RNases	B-X
,	B-X
including	B-X
RNases	B-X
A	B-X
,	B-X
I	B-X
,	B-X
T1	B-X
,	B-X
V1	B-X
,	B-X
HI	B-X
,	B-X
III	B-X
,	B-X
and	B-X
Dicer	B-X
.	B-X
The	B-X
RNAse	B-X
protection	B-X
assay	B-X
is	B-X
a	B-X
highly	B-X
sensitive	B-X
assay	B-X
which	B-X
is	B-X
commonly	B-X
used	B-X
to	B-X
detect	B-X
specific	B-X
hybridization	B-X
between	B-X
complementary	B-X
RNAs	B-X
and	B-X
to	B-X
determine	B-X
exon	B-X
sizes	B-X
in	B-X
gene	B-X
characterization	B-X
studies	B-X
.	B-X
Unfortunately	B-X
,	B-X
each	B-X
of	B-X
the	B-X
numerous	B-X
steps	B-X
involved	B-X
in	B-X
the	B-X
assay	B-X
could	B-X
give	B-X
artifacts	B-X
depending	B-X
on	B-X
the	B-X
probe	B-X
used	B-X
.	B-X
This	B-X
condition	B-X
was	B-X
further	B-X
analyzed	B-X
for	B-X
its	B-X
specificity	B-X
when	B-X
RNAse	B-X
protection	B-X
assays	B-X
were	B-X
performed	B-X
between	B-X
highly	B-X
homologous	B-X
RNA	B-X
fragments	B-X
from	B-X
two	B-X
different	B-X
species	B-X
.	B-X

Total	O
RNA	O
was	O
isolated	O
from	O
CD19	B-Protein
+	O
MACS	O
-	O
purified	O
B	O
cells	O
using	O
the	O
Rneasy	O
midi	O
purification	O
kit	O
with	O
Dnase	O
treatment	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Qiagen	O
)	O
.	O

The	O
mCK	O
-	O
1	O
probe	O
template	O
set	O
(	O
BD	O
Biosciences	O
)	O
was	O
labeled	O
using	O
the	O
In	O
Vitro	O
Transcription	O
Kit	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
(	O
BD	O
Biosciences	O
)	O
.	O

Briefly	O
,	O
50	O
ng	O
of	O
mCK	O
-	O
1	O
probe	O
set	O
was	O
labeled	O
with	O
[	O
alpha	O
-	O
32P	O
]	O
UTP	O
using	O
T7	O
RNA	O
polymerase	O
and	O
purified	O
using	O
Sephadex	O
G	O
-	O
50	O
columns	O
(	O
NucAway	O
Spin	O
column	O
,	O
Ambion	O
)	O
.	O

The	O
labeled	O
probe	O
was	O
quantitated	O
using	O
a	O
scintillation	O
counter	O
,	O
and	O
6	O
x	O
105	O
cherenkov	O
cpm	O
was	O
used	O
to	O
hybridize	O
to	O
4	O
mug	O
of	O
total	O
RNA	O
using	O
the	O
RPA	O
kit	O
(	O
BD	O
Biosciences	O
)	O
.	O

Samples	O
were	O
denatured	O
at	O
90	O
degreesC	O
and	O
hybridized	O
at	O
56	O
degreesC	O
overnight	O
.	O

Single	O
-	O
stranded	O
RNA	O
was	O
digested	O
with	O
a	O
mixture	O
of	O
Rnase	B-Protein
A	I-Protein
and	O
T1	B-Protein
,	O
and	O
precipitated	O
using	O
isopropanol	O
.	O

Protected	O
probes	O
were	O
resolved	O
on	O
a	O
denaturing	O
4	O
.	O
75	O
%	O
acrylamide	O
gel	O
,	O
dried	O
,	O
and	O
imaged	O
using	O
a	O
phosphorImager	O
(	O
Molecular	O
Dynamics	O
)	O
.	O

Densitometry	O
was	O
performed	O
using	O
the	O
ImageQuant	O
TL	O
v2005	O
software	O
(	O
GE	O
Healthcare	O
)	O
.	O

PCR	O
analysis	O
of	O
kappa	O
chain	O
rearrangement	O
.	O
<EOS>	B-X
In	B-X
a	B-X
European	B-X
BIOMED-2	B-X
collaborative	B-X
study	B-X
,	B-X
multiplex	B-X
PCR	B-X
assays	B-X
have	B-X
successfully	B-X
been	B-X
developed	B-X
and	B-X
standardized	B-X
for	B-X
the	B-X
detection	B-X
of	B-X
clonally	B-X
rearranged	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
and	B-X
T-cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
genes	B-X
and	B-X
the	B-X
chromosome	B-X
aberrations	B-X
t	B-X
(	B-X
11	B-X
;	B-X
14	B-X
)	B-X
and	B-X
t	B-X
(	B-X
14	B-X
;	B-X
18	B-X
)	B-X
.	B-X
This	B-X
has	B-X
resulted	B-X
in	B-X
107	B-X
different	B-X
primers	B-X
in	B-X
only	B-X
18	B-X
multiplex	B-X
PCR	B-X
tubes	B-X
:	B-X
three	B-X
VH-JH	B-X
,	B-X
two	B-X
DH-JH	B-X
,	B-X
two	B-X
Ig	B-X
kappa	B-X
(	B-X
IGK	B-X
)	B-X
,	B-X
one	B-X
Ig	B-X
lambda	B-X
(	B-X
IGL	B-X
)	B-X
,	B-X
three	B-X
TCR	B-X
beta	B-X
(	B-X
TCRB	B-X
)	B-X
,	B-X
two	B-X
TCR	B-X
gamma	B-X
(	B-X
TCRG	B-X
)	B-X
,	B-X
one	B-X
TCR	B-X
delta	B-X
(	B-X
TCRD	B-X
)	B-X
,	B-X
three	B-X
BCL1-Ig	B-X
heavy	B-X
chain	B-X
(	B-X
IGH	B-X
)	B-X
,	B-X
and	B-X
one	B-X
BCL2-IGH	B-X
.	B-X
The	B-X
PCR	B-X
products	B-X
of	B-X
Ig/TCR	B-X
genes	B-X
can	B-X
be	B-X
analyzed	B-X
for	B-X
clonality	B-X
assessment	B-X
by	B-X
heteroduplex	B-X
analysis	B-X
or	B-X
GeneScanning	B-X
.	B-X
The	B-X
detection	B-X
rate	B-X
of	B-X
clonal	B-X
rearrangements	B-X
using	B-X
the	B-X
BIOMED-2	B-X
primer	B-X
sets	B-X
is	B-X
unprecedentedly	B-X
high	B-X
.	B-X
The	B-X
contribution	B-X
of	B-X
IGL	B-X
gene	B-X
rearrangements	B-X
seems	B-X
limited	B-X
.	B-X
The	B-X
BIOMED-2	B-X
multiplex	B-X
tubes	B-X
can	B-X
now	B-X
be	B-X
used	B-X
for	B-X
diagnostic	B-X
clonality	B-X
studies	B-X
as	B-X
well	B-X
as	B-X
for	B-X
the	B-X
identification	B-X
of	B-X
PCR	B-X
targets	B-X
suitable	B-X
for	B-X
the	B-X
detection	B-X
of	B-X
minimal	B-X
residual	B-X
disease	B-X
.	B-X

DNA	O
was	O
isolated	O
from	O
splenocytes	O
using	O
the	O
Dneasy	O
Tissue	O
Kit	O
(	O
Qiagen	O
)	O
,	O
with	O
Rnase	O
treatment	O
.	O

PCR	O
reactions	O
contained	O
100	O
ng	O
of	O
genomic	O
DNA	O
,	O
0	O
.	O
2	O
muM	O
each	O
primer	O
,	O
0	O
.	O
2	O
mM	O
dNTPs	O
,	O
and	O
2	O
.	O
5	O
U	O
Taq	B-Protein
DNA	I-Protein
polymerase	I-Protein
(	O
NEB	O
)	O
performed	O
in	O
1X	O
ThermoPol	O
buffer	O
(	O
NEB	O
)	O
.	O

Primers	O
used	O
were	O
Vkappacon	O
and	O
Jkappa5	O
-	O
1degrees	O
and	O
have	O
been	O
described	O
previously	O
[	O
74	O
]	O
.	O

PCR	O
conditions	O
were	O
94	O
degreesC	O
for	O
2	O
min	O
,	O
40	O
cycles	O
of	O
94	O
degreesC	O
for	O
30	O
s	O
,	O
63	O
degreesC	O
for	O
90	O
s	O
,	O
and	O
72	O
degreesC	O
for	O
1	O
min	O
,	O
followed	O
by	O
1	O
cycle	O
of	O
72	O
degreesC	O
for	O
5	O
min	O
.	O

Immunoblot	O
analysis	O
.	O
<EOS>	B-X
Immunoblotting	B-X
(	B-X
western	B-X
blotting	B-X
)	B-X
is	B-X
a	B-X
rapid	B-X
and	B-X
sensitive	B-X
assay	B-X
for	B-X
the	B-X
detection	B-X
and	B-X
characterization	B-X
of	B-X
proteins	B-X
that	B-X
works	B-X
by	B-X
exploiting	B-X
the	B-X
specificity	B-X
inherent	B-X
in	B-X
antigen-antibody	B-X
recognition	B-X
.	B-X
One	B-X
approach	B-X
is	B-X
to	B-X
detect	B-X
LC3	B-X
conversion	B-X
(	B-X
LC3-I	B-X
to	B-X
LC3-II	B-X
)	B-X
by	B-X
immunoblot	B-X
analysis	B-X
because	B-X
the	B-X
amount	B-X
of	B-X
LC3-II	B-X
is	B-X
clearly	B-X
correlated	B-X
with	B-X
the	B-X
number	B-X
of	B-X
autophagosomes	B-X
.	B-X
Western	B-X
immunoblot	B-X
analysis	B-X
.	B-X
Immunoblotting	B-X
(	B-X
also	B-X
known	B-X
as	B-X
Western	B-X
blotting	B-X
)	B-X
combined	B-X
with	B-X
digital	B-X
image	B-X
analysis	B-X
can	B-X
be	B-X
a	B-X
reliable	B-X
method	B-X
for	B-X
analyzing	B-X
the	B-X
abundance	B-X
of	B-X
proteins	B-X
and	B-X
protein	B-X
modifications	B-X
,	B-X
but	B-X
not	B-X
every	B-X
immunoblot-analysis	B-X
combination	B-X
produces	B-X
an	B-X
accurate	B-X
result	B-X
.	B-X
This	B-X
study	B-X
implemented	B-X
diagnostic	B-X
experiments	B-X
that	B-X
assess	B-X
an	B-X
immunoblot-analysis	B-X
workflow	B-X
for	B-X
accuracy	B-X
and	B-X
precision	B-X
.	B-X

Whole	O
cell	O
lysates	O
were	O
prepared	O
in	O
radioimmunoprecipitation	O
assay	O
(	O
RIPA	O
)	O
buffer	O
(	O
20	O
mM	O
Tris	O
-	O
HCl	O
[	O
pH	O
7	O
.	O
5	O
]	O
,	O
150	O
mM	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
%	O
NP	O
-	O
40	O
,	O
0	O
.	O
1	O
%	O
SDS	O
,	O
0	O
.	O
1	O
%	O
sodium	O
deoxycholate	O
)	O
supplemented	O
with	O
2	O
mM	O
phenylmethylsulfonyl	O
fluoride	O
,	O
1	O
mM	O
Na3VO4	O
,	O
and	O
1	O
:	O
100	O
protease	O
/	O
phosphatase	O
inhibitor	O
cocktails	O
(	O
Sigma	O
)	O
.	O

Crude	O
lysates	O
were	O
centrifuged	O
at	O
13	O
,	O
000	O
rpm	O
for	O
10	O
min	O
at	O
4	O
degreesC	O
and	O
the	O
supernatants	O
were	O
collected	O
for	O
further	O
analysis	O
.	O

Protein	O
concentrations	O
were	O
determined	O
with	O
the	O
Bio	O
-	O
Rad	O
DC	O
protein	O
assay	O
system	O
.	O

Lysates	O
were	O
boiled	O
in	O
the	O
presence	O
of	O
2	O
.	O
5	O
%	O
beta	O
-	O
mecaptoethanol	O
,	O
separated	O
by	O
denaturing	O
SDS	O
-	O
PAGE	O
,	O
and	O
transferred	O
to	O
0	O
.	O
45	O
-	O
mum	O
Optitran	O
membranes	O
(	O
Schleicher	O
&	O
Schuell	O
)	O
in	O
a	O
Bio	O
-	O
Rad	O
transfer	O
unit	O
.	O

Membranes	O
were	O
immunoblotted	O
with	O
the	O
appropriate	O
primary	O
antibody	O
followed	O
by	O
horseradish	O
peroxidase	B-Protein
-	O
tagged	O
secondary	O
antibodies	O
(	O
Amersham	O
Biosciences	O
and	O
Dako	O
)	O
and	O
detected	O
with	O
the	O
SuperSignal	O
West	O
Pico	O
System	O
(	O
Pierce	O
)	O
.	O

Antibodies	O
.	O
<EOS>	B-X
Antibodies	B-X
are	B-X
host	B-X
proteins	B-X
that	B-X
comprise	B-X
one	B-X
of	B-X
the	B-X
principal	B-X
effectors	B-X
of	B-X
the	B-X
adaptive	B-X
immune	B-X
system	B-X
.	B-X
Antibodies	B-X
are	B-X
utilized	B-X
for	B-X
analysis	B-X
,	B-X
purification	B-X
,	B-X
and	B-X
enrichment	B-X
,	B-X
and	B-X
to	B-X
mediate	B-X
or	B-X
modulate	B-X
physiological	B-X
responses	B-X
.	B-X
Structure	B-X
of	B-X
antibodies	B-X
.	B-X
Antibodies	B-X
can	B-X
also	B-X
be	B-X
modified	B-X
to	B-X
deliver	B-X
toxic	B-X
or	B-X
modulatory	B-X
payloads	B-X
(	B-X
small	B-X
molecules	B-X
,	B-X
radionuclides	B-X
and	B-X
enzymes	B-X
)	B-X
and	B-X
engineered	B-X
to	B-X
bind	B-X
multiple	B-X
epitopes	B-X
(	B-X
bispecifics	B-X
)	B-X
or	B-X
even	B-X
to	B-X
have	B-X
novel	B-X
catalytic	B-X
activity	B-X
(	B-X
abzymes	B-X
)	B-X
.	B-X

FITC	O
-	O
conjugated	O
goat	O
anti	O
-	O
mouse	O
IgM	O
,	O
rat	O
IgG2akappa	O
anti	O
-	O
mouse	O
IgD	O
(	O
clone	O
11	O
-	O
26	O
)	O
,	O
rat	O
IgG1kappa	O
anti	O
-	O
mouse	O
kappa	O
(	O
clone	O
187	O
.	O
1	O
)	O
,	O
rat	O
IgG2bkappa	O
anti	O
-	O
mouse	O
lambda	O
(	O
clone	O
JC5	O
-	O
1	O
)	O
;	O
PE	O
-	O
conjugated	O
goat	O
anti	O
-	O
mouse	O
IgG	O
;	O
un	O
-	O
conjugated	O
goat	O
anti	O
-	O
mouse	O
kappa	O
and	O
anti	O
-	O
mouse	O
lambda	O
were	O
purchased	O
from	O
Southern	O
Biotech	O
.	O

APC	O
-	O
conjugated	O
rat	O
IgG2akappa	O
anti	O
-	O
mouse	O
CD19	B-Protein
(	O
clone	O
6D5	O
)	O
,	O
PE	O
-	O
conjugated	O
mouse	O
IgG2akappa	O
anti	O
-	O
LMP1	B-Protein
(	O
clone	O
S12	O
)	O
,	O
un	O
-	O
conjugated	O
mouse	O
IgG2a	O
anti	O
-	O
Rb	B-Protein
(	O
clone	O
2	O
)	O
,	O
and	O
anti	O
-	O
Cdk2	B-Protein
(	O
clone	O
55	O
)	O
were	O
purchased	O
from	O
BD	O
Bioscience	O
.	O

PE	O
-	O
conjugated	O
rat	O
IgG2akappa	O
anti	O
-	O
mouse	O
CD5	B-Protein
(	O
clone	O
53	O
-	O
7	O
.	O
3	O
)	O
was	O
purchased	O
from	O
eBioscience	O
.	O

Rat	O
anti	O
-	O
LMP1	B-Protein
(	O
clones	O
8G3	O
,	O
1G6	O
,	O
7E10	O
,	O
and	O
7G8	O
)	O
was	O
purchased	O
from	O
Ascenion	O
.	O

Rabbit	O
anti	O
-	O
pAkt	B-Protein
(	O
Ser473	O
)	O
,	O
anti	O
-	O
pGSK3alpha	B-Protein
/	O
beta	B-Protein
(	O
Ser21	O
/	O
9	O
)	O
,	O
anti	O
-	O
pStat3	B-Protein
(	O
Tyr705	O
)	O
,	O
anti	O
-	O
pStat6	B-Protein
(	O
Tyr641	O
)	O
,	O
anti	O
-	O
pmTOR	B-Protein
(	O
Ser2448	O
)	O
,	O
anti	O
-	O
Stat6	B-Protein
,	O
anti	O
-	O
Akt	B-Protein
,	O
anti	O
-	O
FoxO1	B-Protein
,	O
and	O
anti	O
-	O
p27	B-Protein
were	O
purchased	O
from	O
Cell	O
Signaling	O
.	O

Rabbit	O
anti	O
-	O
Stat3	B-Protein
(	O
H	O
-	O
190	O
)	O
,	O
anti	O
-	O
IkappaBalpha	B-Protein
(	O
C	O
-	O
21	O
)	O
,	O
and	O
goat	O
anti	O
-	O
beta	B-Protein
actin	I-Protein
(	O
I	O
-	O
19	O
)	O
were	O
purchased	O
from	O
Santa	O
Cruz	O
Biotechnology	O
.	O

Mouse	O
IgG1kappa	O
anti	O
-	O
GSK3	B-Protein
was	O
purchased	O
from	O
Upstate	O
Biotechnology	O
.	O

Rabbit	O
anti	O
-	O
pRb	B-Protein
(	O
Thr373	O
)	O
was	O
purchased	O
from	O
EMD	O
Biosciences	O
.	O

High	O
LMP1	B-Protein
Expression	O
Correlates	O
with	O
the	O
Development	O
of	O
Lymphoma	O
<EOS>	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
EBV	B-X
infection	B-X
,	B-X
BCL-6	B-X
expressing	B-X
AIDS-LCL	B-X
fails	B-X
to	B-X
express	B-X
the	B-X
latent	B-X
membrane	B-X
protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
antigen	B-X
.	B-X
Conversely	B-X
,	B-X
AIDS-IBL	B-X
are	B-X
characterized	B-X
by	B-X
absent	B-X
BCL-6	B-X
expression	B-X
,	B-X
absence	B-X
of	B-X
BCL-6	B-X
rearrangements	B-X
,	B-X
and	B-X
frequent	B-X
expression	B-X
of	B-X
LMP1	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
expression	B-X
of	B-X
LMP1	B-X
and	B-X
LMP2A	B-X
in	B-X
ENKTL	B-X
,	B-X
and	B-X
investigated	B-X
the	B-X
correlations	B-X
between	B-X
LMP1	B-X
and	B-X
LMP2A	B-X
expression	B-X
with	B-X
clinicopathological	B-X
characteristics	B-X
of	B-X
ENKTL	B-X
patients	B-X
.	B-X
To	B-X
study	B-X
the	B-X
EBV	B-X
DNA	B-X
and	B-X
expression	B-X
of	B-X
latent	B-X
membrane	B-X
protein	B-X
I	B-X
(	B-X
LMP1	B-X
)	B-X
in	B-X
patients	B-X
with	B-X
Hodgkin	B-X
's	B-X
disease	B-X
from	B-X
high	B-X
incidence	B-X
area	B-X
of	B-X
nasopharyngeal	B-X
carcinoma	B-X
,	B-X
hot	B-X
starting	B-X
PCR	B-X
and	B-X
microwave	B-X
treatment	B-X
of	B-X
LSAB	B-X
immunohistochemistry	B-X
methods	B-X
were	B-X
used	B-X
to	B-X
detect	B-X
EBV	B-X
DNA	B-X
and	B-X
LMP1	B-X
from	B-X
biopsy	B-X
specimens	B-X
from	B-X
40	B-X
cases	B-X
of	B-X
Hodgkin	B-X
's	B-X
disease	B-X
(	B-X
HD	B-X
)	B-X
and	B-X
20	B-X
cases	B-X
having	B-X
benign	B-X
lymph	B-X
node	B-X
lesions	B-X
,	B-X
randomly	B-X
selected	B-X
from	B-X
a	B-X
high	B-X
incidence	B-X
area	B-X
of	B-X
nasopharyngeal	B-X
carcinoma	B-X
.	B-X
LMP1	B-X
of	B-X
EBV	B-X
was	B-X
detected	B-X
in	B-X
52.5	B-X
%	B-X
of	B-X
HD	B-X
cases	B-X
and	B-X
its	B-X
expression	B-X
was	B-X
restricted	B-X
to	B-X
tumor	B-X
cells	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
detection	B-X
rates	B-X
of	B-X
LMP1	B-X
and	B-X
DNA	B-X
of	B-X
EBV	B-X
in	B-X
patients	B-X
under	B-X
20	B-X
years	B-X
of	B-X
age	B-X
(	B-X
84.6	B-X
%	B-X
and	B-X
76.9	B-X
%	B-X
respectively	B-X
)	B-X
was	B-X
much	B-X
higher	B-X
than	B-X
that	B-X
in	B-X
patients	B-X
over	B-X
20	B-X
years	B-X
of	B-X
age	B-X
(	B-X
56.0	B-X
%	B-X
and	B-X
40.0	B-X
%	B-X
respectively	B-X
)	B-X
P	B-X
<	B-X
0.05	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
there	B-X
was	B-X
latent	B-X
EBV	B-X
infection	B-X
in	B-X
at	B-X
least	B-X
half	B-X
of	B-X
HD	B-X
patients	B-X
,	B-X
which	B-X
may	B-X
have	B-X
a	B-X
role	B-X
in	B-X
the	B-X
genesis	B-X
and	B-X
development	B-X
of	B-X
HD	B-X
,	B-X
and	B-X
HD	B-X
occurring	B-X
in	B-X
youth	B-X
was	B-X
more	B-X
closely	B-X
correlated	B-X
with	B-X
EBV	B-X
latent	B-X
infection	B-X
and	B-X
LMP1	B-X
expression	B-X
.	B-X

LMP1	B-Protein
expression	O
is	O
shown	O
by	O
(	O
A	O
)	O
immunoblotting	O
of	O
purified	O
B	O
cells	O
(	O
CD19	B-Protein
+	O
)	O
and	O
(	O
B	O
)	O
immunohistochemistry	O
staining	O
of	O
spleen	O
tissue	O
from	O
wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
LMP1	B-Protein
transgenic	O
mice	O
.	O

(	O
A	O
)	O
Lymphomas	O
are	O
identified	O
with	O
a	O
number	O
(	O
1	O
-	O
7	O
)	O
.	O

Arrows	O
indicate	O
the	O
LMP1	B-Protein
-	O
specific	O
band	O
and	O
its	O
degradation	O
products	O
as	O
well	O
as	O
a	O
non	O
-	O
specific	O
band	O
.	O

Actin	O
was	O
used	O
as	O
a	O
loading	O
control	O
.	O
<EOS>	B-X
Western	B-X
blotting	B-X
is	B-X
an	B-X
analytical	B-X
method	B-X
widely	B-X
used	B-X
for	B-X
detecting	B-X
and	B-X
(	B-X
semi-	B-X
)	B-X
quantifying	B-X
specific	B-X
proteins	B-X
in	B-X
given	B-X
samples	B-X
.	B-X
This	B-X
review	B-X
article	B-X
focuses	B-X
on	B-X
a	B-X
significant	B-X
,	B-X
but	B-X
not	B-X
yet	B-X
well-established	B-X
,	B-X
improvement	B-X
concerning	B-X
the	B-X
internal	B-X
loading	B-X
control	B-X
as	B-X
a	B-X
prerequisite	B-X
to	B-X
accurately	B-X
quantifying	B-X
Western	B-X
blots	B-X
.	B-X
Currently	B-X
,	B-X
housekeeping	B-X
proteins	B-X
(	B-X
HKPs	B-X
)	B-X
like	B-X
actin	B-X
,	B-X
tubulin	B-X
,	B-X
or	B-X
GAPDH	B-X
are	B-X
often	B-X
used	B-X
to	B-X
check	B-X
for	B-X
equal	B-X
loading	B-X
or	B-X
to	B-X
compensate	B-X
potential	B-X
loading	B-X
differences	B-X
.	B-X
However	B-X
,	B-X
this	B-X
loading	B-X
control	B-X
has	B-X
multiple	B-X
drawbacks	B-X
.	B-X
Staining	B-X
of	B-X
the	B-X
total	B-X
protein	B-X
on	B-X
the	B-X
blotting	B-X
membrane	B-X
has	B-X
emerged	B-X
as	B-X
a	B-X
better	B-X
loading	B-X
control	B-X
.	B-X
Total	B-X
protein	B-X
staining	B-X
(	B-X
TPS	B-X
)	B-X
represents	B-X
the	B-X
actual	B-X
loading	B-X
amount	B-X
more	B-X
accurately	B-X
than	B-X
HKPs	B-X
due	B-X
to	B-X
minor	B-X
technical	B-X
and	B-X
biological	B-X
variation	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
broad	B-X
dynamic	B-X
range	B-X
of	B-X
TPS	B-X
solves	B-X
the	B-X
issue	B-X
of	B-X
HKPs	B-X
that	B-X
commonly	B-X
fail	B-X
to	B-X
show	B-X
loading	B-X
differences	B-X
above	B-X
small	B-X
loading	B-X
amounts	B-X
of	B-X
0.5-10	B-X
μg	B-X
.	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
review	B-X
article	B-X
is	B-X
to	B-X
collect	B-X
and	B-X
compare	B-X
information	B-X
about	B-X
TPS	B-X
options	B-X
and	B-X
to	B-X
invite	B-X
users	B-X
to	B-X
reconsider	B-X
their	B-X
applied	B-X
loading	B-X
control	B-X
.	B-X
I	B-X
conclude	B-X
that	B-X
TPS	B-X
should	B-X
be	B-X
the	B-X
preferred	B-X
loading	B-X
control	B-X
in	B-X
future	B-X
Western	B-X
blot	B-X
approaches	B-X
.	B-X

(	O
B	O
)	O
White	O
and	O
red	O
pulps	O
are	O
shown	O
,	O
but	O
this	O
architecture	O
is	O
lost	O
upon	O
development	O
of	O
lymphoma	O
.	O

Scale	O
bar	O
,	O
20	O
mum	O
.	O
<EOS>	B-X
The	B-X
animals	B-X
were	B-X
distributed	B-X
into	B-X
6	B-X
groups	B-X
:	B-X
D0	B-X
,	B-X
D5	B-X
,	B-X
D20	B-X
and	B-X
C0	B-X
,	B-X
C5	B-X
,	B-X
C20	B-X
,	B-X
for	B-X
diabetic	B-X
(	B-X
D	B-X
)	B-X
and	B-X
control	B-X
animals	B-X
(	B-X
C	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
Twenty-nine	B-X
days	B-X
following	B-X
diabetes	B-X
induction	B-X
,	B-X
PGs	B-X
of	B-X
groups	B-X
D5	B-X
and	B-X
C5	B-X
;	B-X
D20	B-X
and	B-X
C20	B-X
were	B-X
irradiated	B-X
with	B-X
5	B-X
and	B-X
20	B-X
J/cm	B-X
Scale	B-X
bar	B-X
:	B-X
20	B-X
μm	B-X
.	B-X
Disc-shaped	B-X
specimens	B-X
(	B-X
15	B-X
mm	B-X
Ø	B-X
×	B-X
1.2	B-X
mm	B-X
thick	B-X
,	B-X
n	B-X
=	B-X
42	B-X
)	B-X
of	B-X
a	B-X
full-contour	B-X
Y-TZP	B-X
ceramic	B-X
(	B-X
Zirlux	B-X
FC	B-X
,	B-X
Amherst	B-X
)	B-X
were	B-X
manufactured	B-X
according	B-X
to	B-X
ISO:6872-2008	B-X
,	B-X
and	B-X
then	B-X
divided	B-X
into	B-X
:	B-X
Ctrl	B-X
-	B-X
as-sintered	B-X
condition	B-X
;	B-X
Ctrl	B-X
LTD	B-X
-	B-X
as-sintered	B-X
after	B-X
aging	B-X
in	B-X
autoclave	B-X
(	B-X
134°C	B-X
,	B-X
2	B-X
bar	B-X
,	B-X
20	B-X
h	B-X
)	B-X
;	B-X
G	B-X
-	B-X
ground	B-X
with	B-X
coarse	B-X
diamond	B-X
bur	B-X
(	B-X
grit	B-X
size	B-X
181	B-X
μm	B-X
)	B-X
;	B-X
G	B-X
LTD	B-X
-	B-X
ground	B-X
and	B-X
aged	B-X
.	B-X

LMP1	B-Protein
Promotes	O
B	O
-	O
1a	O
Lymphomas	O
That	O
Can	O
Escape	O
Allelic	O
Exclusion	O

(	O
A	O
)	O
Flow	O
cytometry	O
analysis	O
of	O
splenocytes	O
from	O
a	O
WT	O
or	O
LMP1	B-Protein
transgenic	O
lymphoma	O
for	O
the	O
pan	O
-	O
B	O
cell	O
(	O
CD19	B-Protein
)	O
,	O
B	O
-	O
1a	O
cell	O
(	O
CD5	B-Protein
)	O
,	O
and	O
Ig	O
heavy	O
chain	O
(	O
IgM	O
and	O
IgD	O
)	O
and	O
light	O
chain	O
(	O
kappa	O
and	O
lambda	O
)	O
markers	O
.	O

Shown	O
are	O
the	O
results	O
from	O
WT	O
lymphoma	O
1	O
and	O
LMP1	B-Protein
transgenic	O
lymphoma	O
4	O
.	O

This	O
analysis	O
was	O
repeated	O
on	O
four	O
other	O
LMP1	B-Protein
transgenic	O
lymphomas	O
(	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
6	O
)	O
showing	O
a	O
similar	O
B	O
-	O
1a	O
phenotype	O
,	O
of	O
which	O
lymphomas	O
2	O
and	O
4	O
were	O
also	O
doubly	O
positive	O
for	O
kappa	O
and	O
lambda	O
light	O
chains	O
.	O

(	O
B	O
)	O
Flow	O
cytometry	O
analysis	O
of	O
WT	O
or	O
LMP1	B-Protein
transgenic	O
splenocytes	O
for	O
B	O
-	O
1a	O
(	O
CD19	B-Protein
+	O
CD5	B-Protein
+	O
)	O
and	O
B	O
-	O
1b	O
or	O
B2	O
subsets	O
(	O
CD19	B-Protein
+	O
CD5	B-Protein
-	O
)	O
.	O
<EOS>	B-X
The	B-X
pathophysiological	B-X
relevance	B-X
of	B-X
B	B-X
cells	B-X
for	B-X
systemic	B-X
lupus	B-X
erythematosus	B-X
(	B-X
SLE	B-X
)	B-X
,	B-X
particularly	B-X
those	B-X
expressing	B-X
the	B-X
T-cell	B-X
marker	B-X
CD5	B-X
,	B-X
raises	B-X
the	B-X
question	B-X
as	B-X
to	B-X
how	B-X
they	B-X
operate	B-X
upon	B-X
autoimmune	B-X
processes	B-X
.	B-X
Based	B-X
on	B-X
their	B-X
production	B-X
of	B-X
low-affinity	B-X
multispecific	B-X
antibodies	B-X
(	B-X
Abs	B-X
)	B-X
,	B-X
CD5	B-X
(	B-X
+	B-X
)	B-X
B	B-X
lymphocytes	B-X
,	B-X
also	B-X
referred	B-X
to	B-X
as	B-X
B1	B-X
cells	B-X
,	B-X
have	B-X
originally	B-X
been	B-X
endowed	B-X
with	B-X
the	B-X
autoAb	B-X
making	B-X
.	B-X
It	B-X
has	B-X
since	B-X
been	B-X
established	B-X
that	B-X
high-affinity	B-X
Abs	B-X
to	B-X
double-stranded	B-X
DNA	B-X
are	B-X
not	B-X
generated	B-X
by	B-X
these	B-X
cells	B-X
,	B-X
but	B-X
rather	B-X
by	B-X
B2	B-X
cells	B-X
.	B-X
In	B-X
the	B-X
light	B-X
of	B-X
recent	B-X
findings	B-X
,	B-X
CD5	B-X
plays	B-X
a	B-X
paradoxical	B-X
role	B-X
in	B-X
preventing	B-X
autoimmunity	B-X
.	B-X
Hence	B-X
,	B-X
misguided	B-X
signaling	B-X
through	B-X
CD5	B-X
could	B-X
lead	B-X
to	B-X
autoimmunity	B-X
.	B-X
This	B-X
provocative	B-X
view	B-X
differs	B-X
from	B-X
the	B-X
naïve	B-X
interpretation	B-X
that	B-X
the	B-X
increased	B-X
levels	B-X
of	B-X
B1	B-X
cells	B-X
in	B-X
SLE	B-X
represent	B-X
a	B-X
direct	B-X
source	B-X
of	B-X
autoAbs	B-X
responsible	B-X
for	B-X
damaging	B-X
organs	B-X
.	B-X

Percentages	O
of	O
B	O
-	O
1a	O
and	O
B	O
-	O
1b	O
or	O
B2	O
subsets	O
are	O
shown	O
in	O
each	O
quadrant	O
.	O

This	O
analysis	O
was	O
repeated	O
on	O
three	O
other	O
WT	O
and	O
two	O
other	O
LMP1	B-Protein
transgenic	O
mice	O
with	O
similar	O
results	O
.	O

(	O
C	O
)	O
Immunoblot	O
analysis	O
for	O
kappa	O
and	O
lambda	O
light	O
chains	O
of	O
B	O
cells	O
(	O
CD19	B-Protein
+	O
)	O
purified	O
from	O
WT	O
and	O
LMP1	B-Protein
transgenic	O
mice	O
.	O

Actin	O
was	O
used	O
as	O
a	O
loading	O
control	O
.	O
<EOS>	B-X
Western	B-X
blotting	B-X
is	B-X
an	B-X
analytical	B-X
method	B-X
widely	B-X
used	B-X
for	B-X
detecting	B-X
and	B-X
(	B-X
semi-	B-X
)	B-X
quantifying	B-X
specific	B-X
proteins	B-X
in	B-X
given	B-X
samples	B-X
.	B-X
This	B-X
review	B-X
article	B-X
focuses	B-X
on	B-X
a	B-X
significant	B-X
,	B-X
but	B-X
not	B-X
yet	B-X
well-established	B-X
,	B-X
improvement	B-X
concerning	B-X
the	B-X
internal	B-X
loading	B-X
control	B-X
as	B-X
a	B-X
prerequisite	B-X
to	B-X
accurately	B-X
quantifying	B-X
Western	B-X
blots	B-X
.	B-X
Currently	B-X
,	B-X
housekeeping	B-X
proteins	B-X
(	B-X
HKPs	B-X
)	B-X
like	B-X
actin	B-X
,	B-X
tubulin	B-X
,	B-X
or	B-X
GAPDH	B-X
are	B-X
often	B-X
used	B-X
to	B-X
check	B-X
for	B-X
equal	B-X
loading	B-X
or	B-X
to	B-X
compensate	B-X
potential	B-X
loading	B-X
differences	B-X
.	B-X
However	B-X
,	B-X
this	B-X
loading	B-X
control	B-X
has	B-X
multiple	B-X
drawbacks	B-X
.	B-X
Staining	B-X
of	B-X
the	B-X
total	B-X
protein	B-X
on	B-X
the	B-X
blotting	B-X
membrane	B-X
has	B-X
emerged	B-X
as	B-X
a	B-X
better	B-X
loading	B-X
control	B-X
.	B-X
Total	B-X
protein	B-X
staining	B-X
(	B-X
TPS	B-X
)	B-X
represents	B-X
the	B-X
actual	B-X
loading	B-X
amount	B-X
more	B-X
accurately	B-X
than	B-X
HKPs	B-X
due	B-X
to	B-X
minor	B-X
technical	B-X
and	B-X
biological	B-X
variation	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
broad	B-X
dynamic	B-X
range	B-X
of	B-X
TPS	B-X
solves	B-X
the	B-X
issue	B-X
of	B-X
HKPs	B-X
that	B-X
commonly	B-X
fail	B-X
to	B-X
show	B-X
loading	B-X
differences	B-X
above	B-X
small	B-X
loading	B-X
amounts	B-X
of	B-X
0.5-10	B-X
μg	B-X
.	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
review	B-X
article	B-X
is	B-X
to	B-X
collect	B-X
and	B-X
compare	B-X
information	B-X
about	B-X
TPS	B-X
options	B-X
and	B-X
to	B-X
invite	B-X
users	B-X
to	B-X
reconsider	B-X
their	B-X
applied	B-X
loading	B-X
control	B-X
.	B-X
I	B-X
conclude	B-X
that	B-X
TPS	B-X
should	B-X
be	B-X
the	B-X
preferred	B-X
loading	B-X
control	B-X
in	B-X
future	B-X
Western	B-X
blot	B-X
approaches	B-X
.	B-X

LMP1	B-Protein
Promotes	O
B	O
Cell	O
Survival	O
and	O
Proliferation	O
In	O
Vitro	O
<EOS>	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
,	B-X
an	B-X
oncogenic	B-X
human	B-X
virus	B-X
,	B-X
is	B-X
associated	B-X
with	B-X
several	B-X
lymphoproliferative	B-X
disorders	B-X
,	B-X
including	B-X
Burkitt	B-X
lymphoma	B-X
,	B-X
Hodgkin	B-X
disease	B-X
,	B-X
diffuse	B-X
large	B-X
B-cell	B-X
lymphoma	B-X
(	B-X
DLBCL	B-X
)	B-X
,	B-X
and	B-X
posttransplant	B-X
lymphoproliferative	B-X
disorder	B-X
(	B-X
PTLD	B-X
)	B-X
.	B-X
In	B-X
vitro	B-X
,	B-X
EBV	B-X
transforms	B-X
primary	B-X
B	B-X
cells	B-X
into	B-X
lymphoblastoid	B-X
cell	B-X
lines	B-X
(	B-X
LCLs	B-X
)	B-X
.	B-X
Recently	B-X
,	B-X
several	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
receptor	B-X
tyrosine	B-X
kinases	B-X
(	B-X
RTKs	B-X
)	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
EBV-associated	B-X
neoplasia	B-X
.	B-X
However	B-X
,	B-X
details	B-X
of	B-X
the	B-X
involvement	B-X
of	B-X
RTKs	B-X
in	B-X
EBV-regulated	B-X
B-cell	B-X
neoplasia	B-X
and	B-X
malignancies	B-X
remain	B-X
largely	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
found	B-X
that	B-X
erythropoietin-producing	B-X
hepatocellular	B-X
receptor	B-X
A4	B-X
(	B-X
EphA4	B-X
)	B-X
,	B-X
which	B-X
belongs	B-X
to	B-X
the	B-X
largest	B-X
RTK	B-X
Eph	B-X
family	B-X
,	B-X
was	B-X
downregulated	B-X
in	B-X
primary	B-X
B	B-X
cells	B-X
post-EBV	B-X
infection	B-X
at	B-X
the	B-X
transcriptional	B-X
and	B-X
translational	B-X
levels	B-X
.	B-X
Overexpression	B-X
and	B-X
knockdown	B-X
experiments	B-X
confirmed	B-X
that	B-X
EBV-encoded	B-X
latent	B-X
membrane	B-X
protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
was	B-X
responsible	B-X
for	B-X
this	B-X
EphA4	B-X
suppression	B-X
.	B-X
Mechanistically	B-X
,	B-X
LMP1	B-X
triggered	B-X
the	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
ERK	B-X
)	B-X
pathway	B-X
and	B-X
promoted	B-X
Sp1	B-X
to	B-X
suppress	B-X
EphA4	B-X
promoter	B-X
activity	B-X
.	B-X
Pathologically	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
EphA4	B-X
was	B-X
detected	B-X
in	B-X
EBV	B-X
(	B-X
-	B-X
)	B-X
tonsils	B-X
but	B-X
not	B-X
in	B-X
EBV	B-X
(	B-X
+	B-X
)	B-X
PTLD	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
an	B-X
inverse	B-X
correlation	B-X
of	B-X
EphA4	B-X
expression	B-X
and	B-X
EBV	B-X
presence	B-X
was	B-X
verified	B-X
by	B-X
immunochemical	B-X
staining	B-X
of	B-X
EBV	B-X
(	B-X
+	B-X
)	B-X
and	B-X
EBV	B-X
(	B-X
-	B-X
)	B-X
DLBCL	B-X
,	B-X
suggesting	B-X
EBV	B-X
infection	B-X
was	B-X
associated	B-X
with	B-X
reduced	B-X
EphA4	B-X
expression	B-X
.	B-X
Analysis	B-X
of	B-X
a	B-X
public	B-X
data	B-X
set	B-X
showed	B-X
that	B-X
lower	B-X
EphA4	B-X
expression	B-X
was	B-X
correlated	B-X
with	B-X
a	B-X
poor	B-X
survival	B-X
rate	B-X
of	B-X
DLBCL	B-X
patients	B-X
.	B-X
Our	B-X
findings	B-X
provide	B-X
a	B-X
novel	B-X
mechanism	B-X
by	B-X
which	B-X
EphA4	B-X
can	B-X
be	B-X
regulated	B-X
by	B-X
an	B-X
oncogenic	B-X
LMP1	B-X
protein	B-X
and	B-X
explore	B-X
its	B-X
possible	B-X
function	B-X
in	B-X
B	B-X
cells	B-X
.	B-X
The	B-X
results	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
role	B-X
of	B-X
EphA4	B-X
in	B-X
EBV	B-X
(	B-X
+	B-X
)	B-X
PTLD	B-X
and	B-X
DLBCL	B-X
.	B-X

(	O
A	O
)	O
MTS	O
assay	O
of	O
splenocytes	O
from	O
WT	O
and	O
LMP1	B-Protein
transgenic	O
mice	O
.	O

Splenocytes	O
were	O
cultured	O
in	O
the	O
presence	O
(	O
grey	O
bars	O
)	O
or	O
absence	O
(	O
black	O
bars	O
)	O
of	O
IL4	B-Protein
for	O
3	O
d	O
.	O

The	O
results	O
are	O
the	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
triplicate	O
samples	O
averaged	O
from	O
multiple	O
mice	O
where	O
"	O
n	O
"	O
the	O
number	O
of	O
mice	O
analyzed	O
is	O
as	O
follows	O
:	O
n	O
=	O
2	O
for	O
WT	O
lymphocytes	O
and	O
WT	O
lymphomas	O
,	O
n	O
=	O
11	O
for	O
LMP1	B-Protein
transgenic	O
lymphocytes	O
,	O
and	O
n	O
=	O
13	O
for	O
LMP1	B-Protein
transgenic	O
lymphomas	O
.	O

(	O
B	O
)	O
EMA	O
exclusion	O
of	O
CD19	B-Protein
+	O
gated	O
splenocytes	O
from	O
WT	O
and	O
LMP1	B-Protein
transgenic	O
mice	O
showing	O
percentage	O
of	O
viable	O
B	O
cells	O
cultured	O
with	O
(	O
white	O
bars	O
)	O
or	O
without	O
(	O
black	O
bars	O
)	O
IL4	B-Protein
for	O
2	O
d	O
.	O

(	O
C	O
)	O
Flow	O
cytometry	O
analysis	O
for	O
incorporated	O
BrdU	O
in	O
WT	O
and	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
cultured	O
with	O
or	O
without	O
IL4	B-Protein
for	O
2	O
d	O
.	O
<EOS>	B-X
Thus	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
effect	B-X
of	B-X
IL-4	B-X
on	B-X
long-term	B-X
recovery	B-X
and	B-X
microglia/macrophage	B-X
polarization	B-X
in	B-X
2	B-X
well-established	B-X
stroke	B-X
models	B-X
.	B-X
We	B-X
found	B-X
that	B-X
alveolar	B-X
macrophages	B-X
(	B-X
AlvMs	B-X
)	B-X
were	B-X
much	B-X
less	B-X
able	B-X
to	B-X
respond	B-X
to	B-X
the	B-X
canonical	B-X
type	B-X
2	B-X
cytokine	B-X
IL-4	B-X
,	B-X
which	B-X
underpins	B-X
allergic	B-X
disease	B-X
and	B-X
parasitic	B-X
worm	B-X
infections	B-X
,	B-X
than	B-X
macrophages	B-X
from	B-X
lung	B-X
tissue	B-X
or	B-X
the	B-X
peritoneal	B-X
cavity	B-X
.	B-X
Thus	B-X
,	B-X
impaired	B-X
glycolysis	B-X
in	B-X
the	B-X
pulmonary	B-X
niche	B-X
regulates	B-X
AlvM	B-X
responsiveness	B-X
during	B-X
type	B-X
2	B-X
inflammation	B-X
.	B-X
A	B-X
pilot	B-X
study	B-X
was	B-X
conducted	B-X
for	B-X
a	B-X
case	B-X
and	B-X
control	B-X
study	B-X
,	B-X
on	B-X
23	B-X
patients	B-X
at	B-X
risk	B-X
of	B-X
preterm	B-X
delivery	B-X
and	B-X
23	B-X
patients	B-X
without	B-X
risk	B-X
of	B-X
preterm	B-X
delivery	B-X
as	B-X
controls	B-X
.	B-X
All	B-X
patients	B-X
underwent	B-X
periodontal	B-X
assessment	B-X
,	B-X
laboratory	B-X
tests	B-X
(	B-X
complete	B-X
blood	B-X
count	B-X
,	B-X
lipid	B-X
profile	B-X
,	B-X
baseline	B-X
glycemia	B-X
)	B-X
and	B-X
quantification	B-X
of	B-X
cytokines	B-X
(	B-X
IL-2	B-X
,	B-X
IL-4	B-X
,	B-X
IL-6	B-X
,	B-X
IL-10	B-X
,	B-X
TNF-α	B-X
and	B-X
TNF-γ	B-X
)	B-X
.	B-X
Higher	B-X
levels	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
(	B-X
IL-2	B-X
,	B-X
IL-4	B-X
,	B-X
IL-6	B-X
,	B-X
IL-10	B-X
,	B-X
TNF-α	B-X
and	B-X
TNF-γ	B-X
)	B-X
were	B-X
found	B-X
in	B-X
patients	B-X
with	B-X
chronic	B-X
periodontitis	B-X
than	B-X
in	B-X
patients	B-X
with	B-X
gingivitis	B-X
or	B-X
periodontal	B-X
health	B-X
.	B-X
These	B-X
cytokines	B-X
,	B-X
in	B-X
particular	B-X
IL-2	B-X
,	B-X
IL-10	B-X
and	B-X
TNF-α	B-X
,	B-X
were	B-X
higher	B-X
in	B-X
patients	B-X
at	B-X
high	B-X
risk	B-X
of	B-X
preterm	B-X
delivery	B-X
.	B-X
Patients	B-X
with	B-X
high	B-X
risk	B-X
of	B-X
preterm	B-X
delivery	B-X
had	B-X
higher	B-X
severity	B-X
of	B-X
periodontal	B-X
disease	B-X
as	B-X
well	B-X
as	B-X
higher	B-X
levels	B-X
of	B-X
the	B-X
pro-inflammatory	B-X
markers	B-X
IL-2	B-X
,	B-X
IL-4	B-X
,	B-X
IL-6	B-X
,	B-X
IL-10	B-X
,	B-X
TNF-α	B-X
and	B-X
TNF-γ	B-X
.	B-X

Shown	O
are	O
the	O
results	O
from	O
WT	O
lymphoma	O
1	O
and	O
LMP1	B-Protein
transgenic	O
lymphoma	O
2	O
.	O

Percentages	O
of	O
cells	O
in	O
each	O
quadrant	O
are	O
shown	O
.	O
<EOS>	B-X
The	B-X
viability	B-X
of	B-X
neural	B-X
stem	B-X
cells	B-X
directly	B-X
affects	B-X
the	B-X
development	B-X
of	B-X
the	B-X
brain	B-X
.	B-X
However	B-X
,	B-X
it	B-X
is	B-X
unknown	B-X
whether	B-X
the	B-X
use	B-X
of	B-X
sevoflurane	B-X
during	B-X
the	B-X
second	B-X
trimester	B-X
affects	B-X
the	B-X
survival	B-X
of	B-X
fetal	B-X
neural	B-X
stem	B-X
cells	B-X
.	B-X
Therefore	B-X
,	B-X
in	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
exposure	B-X
to	B-X
sevoflurane	B-X
in	B-X
mid-gestation	B-X
induces	B-X
apoptosis	B-X
of	B-X
neural	B-X
stem	B-X
cells	B-X
and	B-X
behavioral	B-X
abnormalities	B-X
.	B-X
Exposure	B-X
to	B-X
high-concentration	B-X
(	B-X
3.5	B-X
%	B-X
)	B-X
sevoflurane	B-X
during	B-X
mid-gestation	B-X
increased	B-X
escape	B-X
latency	B-X
and	B-X
path	B-X
length	B-X
to	B-X
the	B-X
platform	B-X
,	B-X
and	B-X
it	B-X
reduced	B-X
the	B-X
average	B-X
duration	B-X
spent	B-X
in	B-X
the	B-X
target	B-X
quadrant	B-X
and	B-X
platform	B-X
crossing	B-X
times	B-X
.	B-X
At	B-X
6	B-X
,	B-X
24	B-X
and	B-X
48	B-X
hours	B-X
after	B-X
anesthesia	B-X
and	B-X
at	B-X
P0	B-X
,	B-X
P14	B-X
and	B-X
P28	B-X
,	B-X
the	B-X
percentage	B-X
of	B-X
Nestin/terminal	B-X
deoxynucleotidyl	B-X
transferase	B-X
dUTP	B-X
nick	B-X
end	B-X
labeling	B-X
(	B-X
TUNEL	B-X
)	B-X
-positive	B-X
cells	B-X
was	B-X
increased	B-X
,	B-X
but	B-X
Nestin	B-X
and	B-X
SOX-2	B-X
protein	B-X
levels	B-X
were	B-X
decreased	B-X
in	B-X
the	B-X
hippocampus	B-X
of	B-X
the	B-X
offspring	B-X
.	B-X

Wild	O
-	O
Type	O
and	O
LMP1	B-Protein
Transgenic	O
Lymphoma	O
Cells	O
Survive	O
Independently	O
of	O
IL4	B-Protein
/	O
Stat6	B-Protein
Signaling	O
in	O
Culture	O

(	O
A	O
)	O
Rnase	O
protection	O
assay	O
for	O
IL4	B-Protein
mRNA	O
from	O
purified	O
B	O
cells	O
(	O
CD19	B-Protein
+	O
)	O
from	O
WT	O
and	O
LMP1	B-Protein
transgenic	O
splenocytes	O
.	O

The	O
L32	B-Protein
and	O
GAPDH	B-Protein
housekeeping	O
genes	O
were	O
used	O
as	O
a	O
loading	O
control	O
.	O
<EOS>	B-X
This	B-X
multiprobe	B-X
set	B-X
also	B-X
comprises	B-X
probes	B-X
for	B-X
two	B-X
house-keeping	B-X
genes	B-X
,	B-X
L32	B-X
and	B-X
GAPDH	B-X
,	B-X
which	B-X
control	B-X
for	B-X
sample-loading	B-X
errors	B-X
.	B-X

Arrow	O
indicates	O
the	O
position	O
of	O
the	O
protected	O
probe	O
.	O

(	O
B	O
and	O
C	O
)	O
Immunoblot	O
analysis	O
of	O
WT	O
and	O
LMP1	B-Protein
transgenic	O
mice	O
for	O
activated	O
pStat6	B-Protein
in	O
(	O
B	O
)	O
purified	O
B	O
cells	O
(	O
CD19	B-Protein
+	O
)	O
at	O
the	O
time	O
of	O
harvest	O
or	O
in	O
(	O
C	O
)	O
whole	O
splenocytes	O
cultured	O
with	O
or	O
without	O
IL4	B-Protein
.	O
<EOS>	B-X
Interleukin-4	B-X
(	B-X
IL4	B-X
)	B-X
,	B-X
a	B-X
Th2	B-X
cytokine	B-X
,	B-X
and	B-X
the	B-X
IL4/IL4	B-X
receptor	B-X
(	B-X
IL4R	B-X
)	B-X
interaction	B-X
have	B-X
well	B-X
defined	B-X
roles	B-X
in	B-X
the	B-X
immune	B-X
system	B-X
.	B-X
Yet	B-X
,	B-X
IL4	B-X
receptors	B-X
are	B-X
over-expressed	B-X
by	B-X
many	B-X
epithelial	B-X
cancers	B-X
and	B-X
could	B-X
be	B-X
a	B-X
promising	B-X
target	B-X
for	B-X
metastatic	B-X
tumor	B-X
therapy	B-X
.	B-X
The	B-X
IL4/IL4R	B-X
signaling	B-X
axis	B-X
is	B-X
a	B-X
strong	B-X
promoter	B-X
of	B-X
pro-metastatic	B-X
phenotypes	B-X
in	B-X
epithelial	B-X
cancer	B-X
cells	B-X
including	B-X
enhanced	B-X
migration	B-X
,	B-X
invasion	B-X
,	B-X
survival	B-X
,	B-X
and	B-X
proliferation	B-X
.	B-X
The	B-X
promotion	B-X
of	B-X
breast	B-X
cancer	B-X
growth	B-X
specifically	B-X
is	B-X
also	B-X
supported	B-X
in	B-X
part	B-X
by	B-X
IL4-induced	B-X
glutamine	B-X
metabolism	B-X
,	B-X
and	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
IL4	B-X
is	B-X
also	B-X
capable	B-X
of	B-X
inducing	B-X
glucose	B-X
metabolism	B-X
in	B-X
breast	B-X
cancer	B-X
cells	B-X
.	B-X
Importantly	B-X
,	B-X
there	B-X
are	B-X
several	B-X
types	B-X
of	B-X
FDA	B-X
approved	B-X
medications	B-X
for	B-X
use	B-X
in	B-X
asthma	B-X
patients	B-X
that	B-X
inhibit	B-X
the	B-X
IL4/IL4R	B-X
signaling	B-X
axis	B-X
.	B-X
However	B-X
,	B-X
these	B-X
approved	B-X
medications	B-X
inhibit	B-X
both	B-X
the	B-X
type	B-X
I	B-X
IL4	B-X
receptor	B-X
found	B-X
on	B-X
immune	B-X
cells	B-X
,	B-X
and	B-X
the	B-X
type	B-X
II	B-X
IL4	B-X
receptor	B-X
that	B-X
is	B-X
predominantly	B-X
expressed	B-X
by	B-X
some	B-X
non-hematopoietic	B-X
cells	B-X
including	B-X
epithelial	B-X
cancer	B-X
cells	B-X
.	B-X
This	B-X
article	B-X
reviews	B-X
existing	B-X
therapies	B-X
targeting	B-X
IL4	B-X
,	B-X
IL4R	B-X
,	B-X
or	B-X
IL4/IL4R	B-X
signaling	B-X
,	B-X
and	B-X
recent	B-X
findings	B-X
guiding	B-X
the	B-X
creation	B-X
of	B-X
novel	B-X
therapies	B-X
that	B-X
specifically	B-X
inhibit	B-X
the	B-X
type	B-X
II	B-X
IL4R	B-X
,	B-X
while	B-X
taking	B-X
into	B-X
consideration	B-X
effects	B-X
on	B-X
immune	B-X
cells	B-X
within	B-X
the	B-X
tumor	B-X
microenvironment	B-X
.	B-X

(	O
B	O
)	O
Actin	O
was	O
used	O
as	O
a	O
loading	O
control	O
,	O
and	O
the	O
white	O
line	O
indicates	O
that	O
intervening	O
lanes	O
have	O
been	O
spliced	O
out	O
.	O

(	O
D	O
and	O
E	O
)	O
MTS	O
assay	O
of	O
(	O
D	O
)	O
WT	O
lymphocytes	O
and	O
(	O
E	O
)	O
LMP1	B-Protein
transgenic	O
lymphoma	O
cells	O
cultured	O
with	O
IL4	B-Protein
,	O
a	O
neutralizing	O
antibody	O
to	O
IL4	B-Protein
,	O
or	O
a	O
rat	O
IgG	O
isotype	O
control	O
at	O
the	O
indicated	O
concentrations	O
.	O
<EOS>	B-X
Prior	B-X
studies	B-X
describe	B-X
deficiencies	B-X
of	B-X
T-cell-mediated	B-X
immunity	B-X
in	B-X
the	B-X
spontaneously	B-X
hypertensive	B-X
rat	B-X
(	B-X
SHR	B-X
)	B-X
strain	B-X
of	B-X
Okamoto	B-X
and	B-X
Aoki	B-X
.	B-X
This	B-X
report	B-X
describes	B-X
an	B-X
alteration	B-X
of	B-X
humoral	B-X
immunity	B-X
:	B-X
elevation	B-X
of	B-X
the	B-X
plasma	B-X
concentration	B-X
of	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
A	B-X
and	B-X
of	B-X
circulating	B-X
IgA	B-X
autoantibodies	B-X
to	B-X
single-stranded	B-X
DNA	B-X
,	B-X
double-stranded	B-X
DNA	B-X
,	B-X
and	B-X
thyroglobulin	B-X
.	B-X
Plasma	B-X
IgA	B-X
content	B-X
also	B-X
varied	B-X
concordantly	B-X
with	B-X
the	B-X
level	B-X
of	B-X
systolic	B-X
blood	B-X
pressure	B-X
as	B-X
influenced	B-X
by	B-X
age	B-X
(	B-X
older	B-X
>	B-X
younger	B-X
)	B-X
and	B-X
gender	B-X
(	B-X
male	B-X
>	B-X
female	B-X
)	B-X
in	B-X
both	B-X
the	B-X
SHR	B-X
and	B-X
control	B-X
Wistar-Kyoto	B-X
rat	B-X
strains	B-X
.	B-X
Strain	B-X
differences	B-X
in	B-X
plasma	B-X
IgG	B-X
or	B-X
IgM	B-X
were	B-X
not	B-X
observed	B-X
.	B-X
Studies	B-X
of	B-X
peripheral	B-X
blood	B-X
lymphocytes	B-X
indicate	B-X
that	B-X
increased	B-X
production	B-X
of	B-X
IgA	B-X
is	B-X
one	B-X
mechanism	B-X
for	B-X
the	B-X
increment	B-X
in	B-X
plasma	B-X
content	B-X
.	B-X
The	B-X
number	B-X
of	B-X
blood	B-X
lymphocytes	B-X
capable	B-X
of	B-X
producing	B-X
IgA	B-X
in	B-X
vitro	B-X
in	B-X
response	B-X
to	B-X
the	B-X
mitogen	B-X
lipopolysaccharide	B-X
is	B-X
increased	B-X
in	B-X
SHR	B-X
.	B-X
When	B-X
cultured	B-X
in	B-X
the	B-X
absence	B-X
or	B-X
presence	B-X
of	B-X
lipopolysaccharide	B-X
,	B-X
peripheral	B-X
blood	B-X
lymphocytes	B-X
of	B-X
SHR	B-X
secrete	B-X
more	B-X
IgA	B-X
in	B-X
vitro	B-X
than	B-X
do	B-X
cells	B-X
of	B-X
the	B-X
control	B-X
strain	B-X
.	B-X
The	B-X
observed	B-X
alterations	B-X
of	B-X
IgA	B-X
in	B-X
the	B-X
SHR	B-X
either	B-X
are	B-X
causative	B-X
factors	B-X
in	B-X
the	B-X
development	B-X
of	B-X
the	B-X
hypertension	B-X
or	B-X
are	B-X
the	B-X
products	B-X
of	B-X
an	B-X
epiphenomenon	B-X
in	B-X
which	B-X
IgA	B-X
and	B-X
blood	B-X
pressure	B-X
are	B-X
affected	B-X
separately	B-X
,	B-X
but	B-X
in	B-X
parallel	B-X
,	B-X
by	B-X
causative	B-X
factors	B-X
related	B-X
to	B-X
rat	B-X
strain	B-X
,	B-X
age	B-X
,	B-X
and	B-X
gender	B-X
.	B-X

Shown	O
are	O
the	O
results	O
from	O
LMP1	B-Protein
transgenic	O
lymphoma	O
3	O
.	O
<EOS>	B-X
Latent	B-X
membrane	B-X
protein	B-X
1	B-X
(	B-X
LMP1	B-X
)	B-X
is	B-X
the	B-X
major	B-X
oncoprotein	B-X
of	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
.	B-X
In	B-X
transgenic	B-X
mice	B-X
,	B-X
LMP1	B-X
promotes	B-X
increased	B-X
lymphoma	B-X
development	B-X
by	B-X
12	B-X
mo	B-X
of	B-X
age	B-X
.	B-X
This	B-X
study	B-X
reveals	B-X
that	B-X
lymphoma	B-X
develops	B-X
in	B-X
B-1a	B-X
lymphocytes	B-X
,	B-X
a	B-X
population	B-X
that	B-X
is	B-X
associated	B-X
with	B-X
transformation	B-X
in	B-X
older	B-X
mice	B-X
.	B-X
The	B-X
lymphoma	B-X
cells	B-X
have	B-X
deregulated	B-X
cell	B-X
cycle	B-X
markers	B-X
,	B-X
and	B-X
inhibitors	B-X
of	B-X
Akt	B-X
,	B-X
NFkappaB	B-X
,	B-X
and	B-X
Stat3	B-X
block	B-X
the	B-X
enhanced	B-X
viability	B-X
of	B-X
LMP1	B-X
transgenic	B-X
lymphocytes	B-X
and	B-X
lymphoma	B-X
cells	B-X
in	B-X
vitro	B-X
.	B-X
Lymphoma	B-X
cells	B-X
are	B-X
independent	B-X
of	B-X
IL4/Stat6	B-X
signaling	B-X
for	B-X
survival	B-X
and	B-X
proliferation	B-X
,	B-X
but	B-X
have	B-X
constitutively	B-X
activated	B-X
Stat3	B-X
signaling	B-X
.	B-X
These	B-X
same	B-X
targets	B-X
are	B-X
also	B-X
deregulated	B-X
in	B-X
wild-type	B-X
B-1a	B-X
lymphomas	B-X
that	B-X
arise	B-X
spontaneously	B-X
through	B-X
age	B-X
predisposition	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Akt	B-X
,	B-X
NFkappaB	B-X
,	B-X
and	B-X
Stat3	B-X
pathways	B-X
may	B-X
serve	B-X
as	B-X
effective	B-X
targets	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
EBV-associated	B-X
B	B-X
cell	B-X
lymphomas	B-X
.	B-X

The	O
results	O
are	O
the	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
triplicate	O
samples	O
from	O
a	O
single	O
representative	O
experiment	O
that	O
was	O
repeated	O
twice	O
with	O
similar	O
results	O
.	O

LMP1	B-Protein
Upregulates	O
IL10	B-Protein
Expression	O
and	O
Constitutively	O
Activates	O
Stat3	B-Protein

(	O
A	O
)	O
Relative	O
expression	O
of	O
IL10	B-Protein
,	O
IL15	B-Protein
,	O
and	O
IFNgamma	B-Protein
mRNA	O
in	O
WT	O
and	O
LMP1	B-Protein
transgenic	O
B	O
cells	O
(	O
CD19	B-Protein
+	O
)	O
,	O
as	O
detected	O
with	O
an	O
Rnase	O
protection	O
assay	O
.	O

Mouse	O
lymphoma	O
cell	O
lines	O
967	O
and	O
K46mu	O
were	O
used	O
as	O
controls	O
.	O

Expression	O
levels	O
were	O
quantified	O
with	O
a	O
phosphorimager	O
and	O
values	O
were	O
normalized	O
to	O
the	O
ribosomal	O
housekeeping	O
gene	O
L32	B-Protein
.	O

The	O
cytokine	O
:	O
L32	B-Protein
ratio	O
was	O
set	O
to	O
1	O
in	O
the	O
mouse	O
B	O
cell	O
lymphoma	O
line	O
967	O
.	O

(	O
B	O
and	O
C	O
)	O
Immunoblot	O
analysis	O
of	O
activated	O
pStat3	B-Protein
in	O
purified	O
B	O
cells	O
(	O
CD19	B-Protein
+	O
)	O
from	O
WT	O
and	O
LMP1	B-Protein
transgenic	O
mice	O
(	O
B	O
)	O
at	O
the	O
time	O
of	O
harvest	O
,	O
and	O
(	O
C	O
)	O
4	O
h	O
after	O
culture	O
with	O
or	O
without	O
IL10	B-Protein
,	O
a	O
neutralizing	O
antibody	O
to	O
IL10	B-Protein
,	O
or	O
a	O
rat	O
IgG1	O
isotype	O
control	O
.	O
<EOS>	B-X
Tumor	B-X
necrosis	B-X
factor	B-X
inhibitors	B-X
(	B-X
TNFi	B-X
)	B-X
have	B-X
significantly	B-X
improved	B-X
treatment	B-X
outcome	B-X
of	B-X
rheumatic	B-X
diseases	B-X
since	B-X
their	B-X
incorporation	B-X
into	B-X
treatment	B-X
protocols	B-X
two	B-X
decades	B-X
ago	B-X
.	B-X
Nevertheless	B-X
,	B-X
a	B-X
substantial	B-X
fraction	B-X
of	B-X
patients	B-X
experiences	B-X
either	B-X
primary	B-X
or	B-X
secondary	B-X
failure	B-X
to	B-X
TNFi	B-X
due	B-X
to	B-X
ineffectiveness	B-X
of	B-X
the	B-X
drug	B-X
or	B-X
adverse	B-X
reactions	B-X
.	B-X
Secondary	B-X
failure	B-X
and	B-X
adverse	B-X
events	B-X
can	B-X
be	B-X
related	B-X
to	B-X
the	B-X
development	B-X
of	B-X
anti-drug	B-X
antibodies	B-X
(	B-X
ADA	B-X
)	B-X
.	B-X
The	B-X
earliest	B-X
studies	B-X
that	B-X
reported	B-X
ADA	B-X
toward	B-X
TNFi	B-X
mainly	B-X
used	B-X
drug-sensitive	B-X
assays	B-X
.	B-X
Retrospectively	B-X
,	B-X
we	B-X
recognize	B-X
this	B-X
has	B-X
led	B-X
to	B-X
an	B-X
underestimation	B-X
of	B-X
the	B-X
amount	B-X
of	B-X
ADA	B-X
produced	B-X
due	B-X
to	B-X
drug	B-X
interference	B-X
.	B-X
Drug-tolerant	B-X
ADA	B-X
assays	B-X
also	B-X
detect	B-X
ADA	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
drug	B-X
,	B-X
which	B-X
has	B-X
contributed	B-X
to	B-X
the	B-X
currently	B-X
reported	B-X
higher	B-X
incidence	B-X
of	B-X
ADA	B-X
development	B-X
.	B-X
Comprehension	B-X
and	B-X
awareness	B-X
of	B-X
the	B-X
assay	B-X
format	B-X
used	B-X
for	B-X
ADA	B-X
detection	B-X
is	B-X
thus	B-X
essential	B-X
to	B-X
interpret	B-X
ADA	B-X
measurements	B-X
correctly	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
concurrent	B-X
drug	B-X
level	B-X
measurement	B-X
is	B-X
informative	B-X
as	B-X
it	B-X
may	B-X
provide	B-X
insight	B-X
in	B-X
the	B-X
extent	B-X
of	B-X
underestimation	B-X
of	B-X
ADA	B-X
levels	B-X
and	B-X
improves	B-X
understanding	B-X
the	B-X
clinical	B-X
consequences	B-X
of	B-X
ADA	B-X
formation	B-X
.	B-X
The	B-X
clinical	B-X
effects	B-X
are	B-X
dependent	B-X
on	B-X
the	B-X
ratio	B-X
between	B-X
the	B-X
amount	B-X
of	B-X
drug	B-X
that	B-X
is	B-X
neutralized	B-X
by	B-X
ADA	B-X
and	B-X
the	B-X
amount	B-X
of	B-X
unbound	B-X
drug	B-X
.	B-X
Pharmacokinetic	B-X
modeling	B-X
might	B-X
be	B-X
useful	B-X
in	B-X
this	B-X
context	B-X
.	B-X
The	B-X
ADA	B-X
response	B-X
generally	B-X
gives	B-X
rise	B-X
to	B-X
high	B-X
affinity	B-X
IgG	B-X
antibodies	B-X
,	B-X
but	B-X
this	B-X
response	B-X
will	B-X
differ	B-X
between	B-X
patients	B-X
.	B-X
Some	B-X
patients	B-X
will	B-X
not	B-X
reach	B-X
the	B-X
phase	B-X
of	B-X
affinity	B-X
maturation	B-X
while	B-X
others	B-X
generate	B-X
an	B-X
enduring	B-X
high	B-X
titer	B-X
high	B-X
affinity	B-X
IgG	B-X
response	B-X
.	B-X
This	B-X
response	B-X
can	B-X
be	B-X
transient	B-X
in	B-X
some	B-X
patients	B-X
,	B-X
indicating	B-X
a	B-X
mechanism	B-X
of	B-X
tolerance	B-X
induction	B-X
or	B-X
B-cell	B-X
anergy	B-X
.	B-X
In	B-X
this	B-X
review	B-X
several	B-X
different	B-X
aspects	B-X
of	B-X
the	B-X
ADA	B-X
response	B-X
toward	B-X
TNFi	B-X
will	B-X
be	B-X
discussed	B-X
.	B-X
It	B-X
will	B-X
highlight	B-X
the	B-X
ADA	B-X
assays	B-X
,	B-X
characteristics	B-X
and	B-X
regulation	B-X
of	B-X
the	B-X
ADA	B-X
response	B-X
,	B-X
impact	B-X
of	B-X
immunogenicity	B-X
on	B-X
the	B-X
pharmacokinetics	B-X
of	B-X
TNFi	B-X
,	B-X
clinical	B-X
implications	B-X
of	B-X
ADA	B-X
formation	B-X
,	B-X
and	B-X
possible	B-X
mitigation	B-X
strategies	B-X
.	B-X

(	O
C	O
)	O
Shown	O
are	O
the	O
results	O
for	O
WT	O
lymphoma	O
1	O
and	O
LMP1	B-Protein
transgenic	O
lymphoma	O
1	O
.	O

Arrows	O
indicate	O
the	O
positions	O
of	O
the	O
alpha	O
and	O
beta	O
isoforms	O
of	O
Stat3	B-Protein
.	O

Actin	O
was	O
used	O
as	O
a	O
loading	O
control	O
.	O
<EOS>	B-X
Western	B-X
blotting	B-X
is	B-X
an	B-X
analytical	B-X
method	B-X
widely	B-X
used	B-X
for	B-X
detecting	B-X
and	B-X
(	B-X
semi-	B-X
)	B-X
quantifying	B-X
specific	B-X
proteins	B-X
in	B-X
given	B-X
samples	B-X
.	B-X
This	B-X
review	B-X
article	B-X
focuses	B-X
on	B-X
a	B-X
significant	B-X
,	B-X
but	B-X
not	B-X
yet	B-X
well-established	B-X
,	B-X
improvement	B-X
concerning	B-X
the	B-X
internal	B-X
loading	B-X
control	B-X
as	B-X
a	B-X
prerequisite	B-X
to	B-X
accurately	B-X
quantifying	B-X
Western	B-X
blots	B-X
.	B-X
Currently	B-X
,	B-X
housekeeping	B-X
proteins	B-X
(	B-X
HKPs	B-X
)	B-X
like	B-X
actin	B-X
,	B-X
tubulin	B-X
,	B-X
or	B-X
GAPDH	B-X
are	B-X
often	B-X
used	B-X
to	B-X
check	B-X
for	B-X
equal	B-X
loading	B-X
or	B-X
to	B-X
compensate	B-X
potential	B-X
loading	B-X
differences	B-X
.	B-X
However	B-X
,	B-X
this	B-X
loading	B-X
control	B-X
has	B-X
multiple	B-X
drawbacks	B-X
.	B-X
Staining	B-X
of	B-X
the	B-X
total	B-X
protein	B-X
on	B-X
the	B-X
blotting	B-X
membrane	B-X
has	B-X
emerged	B-X
as	B-X
a	B-X
better	B-X
loading	B-X
control	B-X
.	B-X
Total	B-X
protein	B-X
staining	B-X
(	B-X
TPS	B-X
)	B-X
represents	B-X
the	B-X
actual	B-X
loading	B-X
amount	B-X
more	B-X
accurately	B-X
than	B-X
HKPs	B-X
due	B-X
to	B-X
minor	B-X
technical	B-X
and	B-X
biological	B-X
variation	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
broad	B-X
dynamic	B-X
range	B-X
of	B-X
TPS	B-X
solves	B-X
the	B-X
issue	B-X
of	B-X
HKPs	B-X
that	B-X
commonly	B-X
fail	B-X
to	B-X
show	B-X
loading	B-X
differences	B-X
above	B-X
small	B-X
loading	B-X
amounts	B-X
of	B-X
0.5-10	B-X
μg	B-X
.	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
review	B-X
article	B-X
is	B-X
to	B-X
collect	B-X
and	B-X
compare	B-X
information	B-X
about	B-X
TPS	B-X
options	B-X
and	B-X
to	B-X
invite	B-X
users	B-X
to	B-X
reconsider	B-X
their	B-X
applied	B-X
loading	B-X
control	B-X
.	B-X
I	B-X
conclude	B-X
that	B-X
TPS	B-X
should	B-X
be	B-X
the	B-X
preferred	B-X
loading	B-X
control	B-X
in	B-X
future	B-X
Western	B-X
blot	B-X
approaches	B-X
.	B-X

(	O
D	O
)	O
Immunohistochemistry	O
detection	O
of	O
activated	O
nuclear	O
pStat3	B-Protein
in	O
the	O
spleens	O
of	O
WT	O
and	O
LMP1	B-Protein
transgenic	O
mice	O
.	O

Scale	O
bar	O
,	O
20	O
mum	O
.	O
<EOS>	B-X
The	B-X
animals	B-X
were	B-X
distributed	B-X
into	B-X
6	B-X
groups	B-X
:	B-X
D0	B-X
,	B-X
D5	B-X
,	B-X
D20	B-X
and	B-X
C0	B-X
,	B-X
C5	B-X
,	B-X
C20	B-X
,	B-X
for	B-X
diabetic	B-X
(	B-X
D	B-X
)	B-X
and	B-X
control	B-X
animals	B-X
(	B-X
C	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
Twenty-nine	B-X
days	B-X
following	B-X
diabetes	B-X
induction	B-X
,	B-X
PGs	B-X
of	B-X
groups	B-X
D5	B-X
and	B-X
C5	B-X
;	B-X
D20	B-X
and	B-X
C20	B-X
were	B-X
irradiated	B-X
with	B-X
5	B-X
and	B-X
20	B-X
J/cm	B-X
Scale	B-X
bar	B-X
:	B-X
20	B-X
μm	B-X
.	B-X
Disc-shaped	B-X
specimens	B-X
(	B-X
15	B-X
mm	B-X
Ø	B-X
×	B-X
1.2	B-X
mm	B-X
thick	B-X
,	B-X
n	B-X
=	B-X
42	B-X
)	B-X
of	B-X
a	B-X
full-contour	B-X
Y-TZP	B-X
ceramic	B-X
(	B-X
Zirlux	B-X
FC	B-X
,	B-X
Amherst	B-X
)	B-X
were	B-X
manufactured	B-X
according	B-X
to	B-X
ISO:6872-2008	B-X
,	B-X
and	B-X
then	B-X
divided	B-X
into	B-X
:	B-X
Ctrl	B-X
-	B-X
as-sintered	B-X
condition	B-X
;	B-X
Ctrl	B-X
LTD	B-X
-	B-X
as-sintered	B-X
after	B-X
aging	B-X
in	B-X
autoclave	B-X
(	B-X
134°C	B-X
,	B-X
2	B-X
bar	B-X
,	B-X
20	B-X
h	B-X
)	B-X
;	B-X
G	B-X
-	B-X
ground	B-X
with	B-X
coarse	B-X
diamond	B-X
bur	B-X
(	B-X
grit	B-X
size	B-X
181	B-X
μm	B-X
)	B-X
;	B-X
G	B-X
LTD	B-X
-	B-X
ground	B-X
and	B-X
aged	B-X
.	B-X

LMP1	B-Protein
Activates	O
Akt	B-Protein
Signaling	O
and	O
Deregulates	O
the	O
Rb	B-Protein
Cell	O
Cycle	O
Pathway	O

(	O
A	O
and	O
B	O
)	O
Immunoblot	O
analysis	O
of	O
purified	O
B	O
cells	O
(	O
CD19	B-Protein
+	O
)	O
from	O
the	O
spleens	O
of	O
WT	O
and	O
LMP1	B-Protein
transgenic	O
mice	O
for	O
Akt	B-Protein
signaling	O
,	O
probing	O
for	O
(	O
A	O
)	O
activated	O
pAkt	B-Protein
and	O
downstream	O
targets	O
,	O
including	O
inactivated	O
pGSK3alpha	B-Protein
/	O
beta	B-Protein
,	O
and	O
(	O
B	O
)	O
activated	O
p	B-Protein
-	I-Protein
mTOR	I-Protein
,	O
and	O
total	O
levels	O
of	O
FoxO1	B-Protein
.	O

Arrows	O
indicate	O
the	O
positions	O
of	O
alpha	O
and	O
beta	O
isoforms	O
of	O
GSK3	B-Protein
.	O

The	O
white	O
line	O
indicates	O
that	O
intervening	O
lanes	O
have	O
been	O
spliced	O
out	O
.	O

(	O
C	O
)	O
Immunoblot	O
analysis	O
for	O
cell	O
cycle	O
proteins	O
regulating	O
the	O
Rb	B-Protein
pathway	O
,	O
probing	O
for	O
activated	O
pRb	B-Protein
,	O
and	O
total	O
levels	O
of	O
Cdk2	B-Protein
and	O
the	O
Cdk	O
inhibitor	O
p27	B-Protein
.	O

Actin	O
was	O
used	O
as	O
a	O
loading	O
control	O
.	O
<EOS>	B-X
Western	B-X
blotting	B-X
is	B-X
an	B-X
analytical	B-X
method	B-X
widely	B-X
used	B-X
for	B-X
detecting	B-X
and	B-X
(	B-X
semi-	B-X
)	B-X
quantifying	B-X
specific	B-X
proteins	B-X
in	B-X
given	B-X
samples	B-X
.	B-X
This	B-X
review	B-X
article	B-X
focuses	B-X
on	B-X
a	B-X
significant	B-X
,	B-X
but	B-X
not	B-X
yet	B-X
well-established	B-X
,	B-X
improvement	B-X
concerning	B-X
the	B-X
internal	B-X
loading	B-X
control	B-X
as	B-X
a	B-X
prerequisite	B-X
to	B-X
accurately	B-X
quantifying	B-X
Western	B-X
blots	B-X
.	B-X
Currently	B-X
,	B-X
housekeeping	B-X
proteins	B-X
(	B-X
HKPs	B-X
)	B-X
like	B-X
actin	B-X
,	B-X
tubulin	B-X
,	B-X
or	B-X
GAPDH	B-X
are	B-X
often	B-X
used	B-X
to	B-X
check	B-X
for	B-X
equal	B-X
loading	B-X
or	B-X
to	B-X
compensate	B-X
potential	B-X
loading	B-X
differences	B-X
.	B-X
However	B-X
,	B-X
this	B-X
loading	B-X
control	B-X
has	B-X
multiple	B-X
drawbacks	B-X
.	B-X
Staining	B-X
of	B-X
the	B-X
total	B-X
protein	B-X
on	B-X
the	B-X
blotting	B-X
membrane	B-X
has	B-X
emerged	B-X
as	B-X
a	B-X
better	B-X
loading	B-X
control	B-X
.	B-X
Total	B-X
protein	B-X
staining	B-X
(	B-X
TPS	B-X
)	B-X
represents	B-X
the	B-X
actual	B-X
loading	B-X
amount	B-X
more	B-X
accurately	B-X
than	B-X
HKPs	B-X
due	B-X
to	B-X
minor	B-X
technical	B-X
and	B-X
biological	B-X
variation	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
broad	B-X
dynamic	B-X
range	B-X
of	B-X
TPS	B-X
solves	B-X
the	B-X
issue	B-X
of	B-X
HKPs	B-X
that	B-X
commonly	B-X
fail	B-X
to	B-X
show	B-X
loading	B-X
differences	B-X
above	B-X
small	B-X
loading	B-X
amounts	B-X
of	B-X
0.5-10	B-X
μg	B-X
.	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
review	B-X
article	B-X
is	B-X
to	B-X
collect	B-X
and	B-X
compare	B-X
information	B-X
about	B-X
TPS	B-X
options	B-X
and	B-X
to	B-X
invite	B-X
users	B-X
to	B-X
reconsider	B-X
their	B-X
applied	B-X
loading	B-X
control	B-X
.	B-X
I	B-X
conclude	B-X
that	B-X
TPS	B-X
should	B-X
be	B-X
the	B-X
preferred	B-X
loading	B-X
control	B-X
in	B-X
future	B-X
Western	B-X
blot	B-X
approaches	B-X
.	B-X

Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
Signaling	O
Are	O
Required	O
for	O
the	O
Growth	O
and	O
Survival	O
of	O
Lymphoma	O
Cells	O
<EOS>	B-X
Fifth	B-X
,	B-X
curcumin	B-X
suppressed	B-X
the	B-X
Akt	B-X
activation	B-X
pathway	B-X
.	B-X

MTS	O
assay	O
of	O
splenocytes	O
from	O
(	O
A	O
and	O
B	O
)	O
WT	O
or	O
(	O
C	O
and	O
D	O
)	O
LMP1	B-Protein
transgenic	O
lymphomas	O
and	O
(	O
E	O
and	O
F	O
)	O
LMP1	B-Protein
transgenic	O
lymphoctyes	O
.	O

Splenocytes	O
were	O
cultured	O
with	O
or	O
without	O
inhibitors	O
of	O
NFkappaB	O
(	O
BAY11	O
)	O
,	O
mTOR	B-Protein
(	O
rapamycin	O
)	O
,	O
Akt	B-Protein
(	O
triciribine	O
)	O
,	O
MEK1	B-Protein
/	O
2	B-Protein
(	O
U0126	O
)	O
,	O
p38	O
(	O
SB202190	O
)	O
,	O
or	O
Stat3	B-Protein
(	O
cucurbitacin	O
I	O
and	O
AG490	O
)	O
at	O
the	O
indicated	O
concentrations	O
.	O

The	O
results	O
are	O
the	O
mean	O
+	O
/	O
-	O
SEM	O
of	O
triplicate	O
samples	O
.	O
<EOS>	B-X
To	B-X
clarify	B-X
these	B-X
points	B-X
,	B-X
a	B-X
systematic	B-X
study	B-X
with	B-X
organ	B-X
culture	B-X
from	B-X
human	B-X
omental	B-X
adipose	B-X
tissue	B-X
either	B-X
stimulated	B-X
or	B-X
not	B-X
with	B-X
steroid	B-X
hormones	B-X
was	B-X
undertaken	B-X
in	B-X
samples	B-X
obtained	B-X
at	B-X
surgery	B-X
from	B-X
67	B-X
nonobese	B-X
donors	B-X
(	B-X
33	B-X
women	B-X
and	B-X
34	B-X
men	B-X
)	B-X
.	B-X
Each	B-X
adipose	B-X
tissue	B-X
sample	B-X
from	B-X
a	B-X
single	B-X
donor	B-X
was	B-X
incubated	B-X
in	B-X
triplicate	B-X
,	B-X
and	B-X
leptin	B-X
results	B-X
are	B-X
expressed	B-X
as	B-X
the	B-X
mean	B-X
+/-	B-X
SEM	B-X
of	B-X
the	B-X
integrated	B-X
secretion	B-X
to	B-X
the	B-X
medium	B-X
(	B-X
area	B-X
under	B-X
the	B-X
curve	B-X
;	B-X
nanograms	B-X
of	B-X
leptin	B-X
per	B-X
g	B-X
tissue/48	B-X
h	B-X
)	B-X
.	B-X
Control	B-X
nonstimulated	B-X
samples	B-X
showed	B-X
a	B-X
steady	B-X
leptin	B-X
secretion	B-X
along	B-X
the	B-X
96	B-X
h	B-X
studied	B-X
,	B-X
with	B-X
the	B-X
peak	B-X
of	B-X
secretory	B-X
activity	B-X
reached	B-X
at	B-X
48	B-X
h	B-X
;	B-X
afterward	B-X
,	B-X
the	B-X
in	B-X
vitro	B-X
secretion	B-X
reached	B-X
a	B-X
plateau	B-X
state	B-X
.	B-X
Spontaneous	B-X
leptin	B-X
secretion	B-X
in	B-X
samples	B-X
from	B-X
33	B-X
women	B-X
(	B-X
3904	B-X
+/-	B-X
347	B-X
)	B-X
was	B-X
significantly	B-X
higher	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
than	B-X
that	B-X
in	B-X
samples	B-X
from	B-X
34	B-X
men	B-X
(	B-X
2940	B-X
+/-	B-X
323	B-X
)	B-X
.	B-X
Coincubation	B-X
of	B-X
adipose	B-X
tissue	B-X
with	B-X
1	B-X
mumol/L	B-X
dexamethasone	B-X
induced	B-X
a	B-X
clear-cut	B-X
leptin	B-X
increase	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
in	B-X
samples	B-X
from	B-X
women	B-X
(	B-X
5848	B-X
+/-	B-X
624	B-X
;	B-X
n	B-X
=	B-X
12	B-X
)	B-X
,	B-X
but	B-X
did	B-X
not	B-X
change	B-X
the	B-X
spontaneous	B-X
release	B-X
of	B-X
leptin	B-X
in	B-X
samples	B-X
from	B-X
men	B-X
(	B-X
3353	B-X
+/-	B-X
741	B-X
;	B-X
n	B-X
=	B-X
6	B-X
)	B-X
.	B-X
Similarly	B-X
,	B-X
coincubation	B-X
of	B-X
adipose	B-X
tissue	B-X
with	B-X
1	B-X
mumol/L	B-X
estradiol	B-X
induced	B-X
a	B-X
notable	B-X
leptin	B-X
increase	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
in	B-X
samples	B-X
from	B-X
women	B-X
(	B-X
5698	B-X
+/-	B-X
688	B-X
;	B-X
n	B-X
=	B-X
9	B-X
)	B-X
,	B-X
whereas	B-X
it	B-X
did	B-X
not	B-X
alter	B-X
the	B-X
secretion	B-X
in	B-X
the	B-X
male	B-X
samples	B-X
(	B-X
3373	B-X
+/-	B-X
444	B-X
;	B-X
n	B-X
=	B-X
6	B-X
)	B-X
.	B-X
In	B-X
samples	B-X
from	B-X
both	B-X
sexes	B-X
,	B-X
coincubation	B-X
with	B-X
1	B-X
mumol/L	B-X
estrone	B-X
or	B-X
progesterone	B-X
had	B-X
no	B-X
effect	B-X
,	B-X
whereas	B-X
1	B-X
mumol/L	B-X
forskolin	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
reduced	B-X
leptin	B-X
release	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
leptin	B-X
secretion	B-X
from	B-X
omental	B-X
adipose	B-X
tissue	B-X
in	B-X
vitro	B-X
1	B-X
)	B-X
is	B-X
significantly	B-X
higher	B-X
in	B-X
samples	B-X
from	B-X
women	B-X
than	B-X
in	B-X
samples	B-X
from	B-X
men	B-X
,	B-X
2	B-X
)	B-X
is	B-X
stimulated	B-X
by	B-X
dexamethasone	B-X
and	B-X
estradiol	B-X
in	B-X
women	B-X
but	B-X
not	B-X
in	B-X
men	B-X
,	B-X
3	B-X
)	B-X
is	B-X
not	B-X
modified	B-X
by	B-X
progesterone	B-X
or	B-X
estrone	B-X
in	B-X
both	B-X
sexes	B-X
,	B-X
and	B-X
4	B-X
)	B-X
is	B-X
inhibited	B-X
by	B-X
forskolin	B-X
in	B-X
both	B-X
genders	B-X
.	B-X

Shown	O
are	O
the	O
results	O
for	O
(	O
A	O
and	O
B	O
)	O
WT	O
lymphoma	O
1	O
,	O
(	O
C	O
and	O
D	O
)	O
LMP1	B-Protein
transgenic	O
lymphoma	O
2	O
,	O
and	O
(	O
E	O
and	O
F	O
)	O
one	O
out	O
of	O
two	O
LMP1	B-Protein
transgenic	O
mice	O
analyzed	O
.	O

This	O
analysis	O
was	O
repeated	O
with	O
LMP1	B-Protein
transgenic	O
lymphoma	O
4	O
yielding	O
similar	O
results	O
.	O

Analysis	O
of	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
Pathways	O
in	O
Contribution	O
to	O
the	O
Growth	O
and	O
Survival	O
of	O
Lymphoma	O
Cells	O

(	O
A	O
-	O
D	O
)	O
Immunoblot	O
analysis	O
of	O
wild	O
-	O
type	O
and	O
LMP1	B-Protein
transgenic	O
lymphomas	O
for	O
Akt	B-Protein
,	O
NFkappaB	O
,	O
and	O
Stat3	B-Protein
signaling	O
after	O
treatment	O
with	O
(	O
A	O
)	O
an	O
Akt	B-Protein
inhibitor	O
,	O
triciribine	O
,	O
(	O
B	O
)	O
an	O
NFkappaB	O
inhibitor	O
,	O
BAY11	O
-	O
7085	O
,	O
and	O
the	O
Stat3	B-Protein
inhibitors	O
(	O
C	O
)	O
cucurbitacin	O
I	O
and	O
(	O
D	O
)	O
AG490	O
,	O
at	O
the	O
indicated	O
concentrations	O
.	O

Arrows	O
indicate	O
the	O
positions	O
of	O
alpha	O
and	O
beta	O
isoforms	O
of	O
Stat3	B-Protein
.	O

Actin	O
was	O
used	O
as	O
a	O
loading	O
control	O
.	O
<EOS>	B-X
Western	B-X
blotting	B-X
is	B-X
an	B-X
analytical	B-X
method	B-X
widely	B-X
used	B-X
for	B-X
detecting	B-X
and	B-X
(	B-X
semi-	B-X
)	B-X
quantifying	B-X
specific	B-X
proteins	B-X
in	B-X
given	B-X
samples	B-X
.	B-X
This	B-X
review	B-X
article	B-X
focuses	B-X
on	B-X
a	B-X
significant	B-X
,	B-X
but	B-X
not	B-X
yet	B-X
well-established	B-X
,	B-X
improvement	B-X
concerning	B-X
the	B-X
internal	B-X
loading	B-X
control	B-X
as	B-X
a	B-X
prerequisite	B-X
to	B-X
accurately	B-X
quantifying	B-X
Western	B-X
blots	B-X
.	B-X
Currently	B-X
,	B-X
housekeeping	B-X
proteins	B-X
(	B-X
HKPs	B-X
)	B-X
like	B-X
actin	B-X
,	B-X
tubulin	B-X
,	B-X
or	B-X
GAPDH	B-X
are	B-X
often	B-X
used	B-X
to	B-X
check	B-X
for	B-X
equal	B-X
loading	B-X
or	B-X
to	B-X
compensate	B-X
potential	B-X
loading	B-X
differences	B-X
.	B-X
However	B-X
,	B-X
this	B-X
loading	B-X
control	B-X
has	B-X
multiple	B-X
drawbacks	B-X
.	B-X
Staining	B-X
of	B-X
the	B-X
total	B-X
protein	B-X
on	B-X
the	B-X
blotting	B-X
membrane	B-X
has	B-X
emerged	B-X
as	B-X
a	B-X
better	B-X
loading	B-X
control	B-X
.	B-X
Total	B-X
protein	B-X
staining	B-X
(	B-X
TPS	B-X
)	B-X
represents	B-X
the	B-X
actual	B-X
loading	B-X
amount	B-X
more	B-X
accurately	B-X
than	B-X
HKPs	B-X
due	B-X
to	B-X
minor	B-X
technical	B-X
and	B-X
biological	B-X
variation	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
broad	B-X
dynamic	B-X
range	B-X
of	B-X
TPS	B-X
solves	B-X
the	B-X
issue	B-X
of	B-X
HKPs	B-X
that	B-X
commonly	B-X
fail	B-X
to	B-X
show	B-X
loading	B-X
differences	B-X
above	B-X
small	B-X
loading	B-X
amounts	B-X
of	B-X
0.5-10	B-X
μg	B-X
.	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
review	B-X
article	B-X
is	B-X
to	B-X
collect	B-X
and	B-X
compare	B-X
information	B-X
about	B-X
TPS	B-X
options	B-X
and	B-X
to	B-X
invite	B-X
users	B-X
to	B-X
reconsider	B-X
their	B-X
applied	B-X
loading	B-X
control	B-X
.	B-X
I	B-X
conclude	B-X
that	B-X
TPS	B-X
should	B-X
be	B-X
the	B-X
preferred	B-X
loading	B-X
control	B-X
in	B-X
future	B-X
Western	B-X
blot	B-X
approaches	B-X
.	B-X

Summary	O
of	O
Analysis	O
Performed	O
on	O
Wild	O
-	O
Type	O
and	O
LMP1	B-Protein
Transgenic	O
Lymphomas	O

Runx3	B-Protein
and	O
T	O
-	O
box	O
proteins	O
cooperate	O
to	O
establish	O
the	O
transcriptional	O
program	O
of	O
effector	O
CTLs	O

Activation	O
of	O
naive	O
CD8	B-Protein
+	O
T	O
cells	O
with	O
antigen	O
induces	O
their	O
differentiation	O
into	O
effector	O
cytolytic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
.	O
<EOS>	B-X
Naive	B-X
CD8	B-X
Activation	B-X
of	B-X
naive	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
with	B-X
antigen	B-X
induces	B-X
their	B-X
differentiation	B-X
into	B-X
effector	B-X
cytolytic	B-X
T	B-X
lymphocytes	B-X
(	B-X
CTLs	B-X
)	B-X
.	B-X
CTLs	B-X
lyse	B-X
infected	B-X
or	B-X
aberrant	B-X
target	B-X
cells	B-X
by	B-X
exocytosis	B-X
of	B-X
lytic	B-X
granules	B-X
containing	B-X
the	B-X
pore-forming	B-X
protein	B-X
perforin	B-X
and	B-X
a	B-X
family	B-X
of	B-X
proteases	B-X
termed	B-X
granzymes	B-X
.	B-X
We	B-X
show	B-X
that	B-X
effector	B-X
CTL	B-X
differentiation	B-X
occurs	B-X
in	B-X
two	B-X
sequential	B-X
phases	B-X
in	B-X
vitro	B-X
,	B-X
characterized	B-X
by	B-X
early	B-X
induction	B-X
of	B-X
T-bet	B-X
and	B-X
late	B-X
induction	B-X
of	B-X
Eomesodermin	B-X
(	B-X
Eomes	B-X
)	B-X
,	B-X
T-box	B-X
transcription	B-X
factors	B-X
that	B-X
regulate	B-X
the	B-X
early	B-X
and	B-X
late	B-X
phases	B-X
of	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
gamma	B-X
expression	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
demonstrate	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
the	B-X
transcription	B-X
factor	B-X
Runx3	B-X
in	B-X
CTL	B-X
differentiation	B-X
.	B-X
Runx3	B-X
regulates	B-X
Eomes	B-X
expression	B-X
as	B-X
well	B-X
as	B-X
expression	B-X
of	B-X
three	B-X
cardinal	B-X
markers	B-X
of	B-X
the	B-X
effector	B-X
CTL	B-X
program	B-X
:	B-X
IFN-gamma	B-X
,	B-X
perforin	B-X
,	B-X
and	B-X
granzyme	B-X
B	B-X
.	B-X
Our	B-X
data	B-X
point	B-X
to	B-X
the	B-X
existence	B-X
of	B-X
an	B-X
elaborate	B-X
transcriptional	B-X
network	B-X
in	B-X
which	B-X
Runx3	B-X
initially	B-X
induces	B-X
and	B-X
then	B-X
cooperates	B-X
with	B-X
T-box	B-X
transcription	B-X
factors	B-X
to	B-X
regulate	B-X
gene	B-X
transcription	B-X
in	B-X
differentiating	B-X
CTLs	B-X
.	B-X

CTLs	O
lyse	O
infected	O
or	O
aberrant	O
target	O
cells	O
by	O
exocytosis	O
of	O
lytic	O
granules	O
containing	O
the	O
pore	O
-	O
forming	O
protein	O
perforin	B-Protein
and	O
a	O
family	O
of	O
proteases	O
termed	O
granzymes	O
.	O
<EOS>	B-X
Natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
and	B-X
cytotoxic	B-X
T	B-X
lymphocytes	B-X
(	B-X
CTLs	B-X
)	B-X
use	B-X
cytotoxic	B-X
granules	B-X
containing	B-X
perforin	B-X
and	B-X
granzymes	B-X
to	B-X
lyse	B-X
infected	B-X
or	B-X
malignant	B-X
host	B-X
cells	B-X
,	B-X
thereby	B-X
providing	B-X
immunity	B-X
to	B-X
intracellular	B-X
microbes	B-X
and	B-X
tumors	B-X
.	B-X
Perforin	B-X
expression	B-X
is	B-X
regulated	B-X
transcriptionally	B-X
and	B-X
correlates	B-X
tightly	B-X
with	B-X
the	B-X
development	B-X
of	B-X
cells	B-X
that	B-X
can	B-X
exhibit	B-X
cytotoxic	B-X
activity	B-X
.	B-X
Although	B-X
a	B-X
number	B-X
of	B-X
genes	B-X
transcribed	B-X
by	B-X
T	B-X
cells	B-X
and	B-X
NK	B-X
cells	B-X
have	B-X
been	B-X
studied	B-X
,	B-X
the	B-X
cell-specificity	B-X
of	B-X
perforin	B-X
gene	B-X
expression	B-X
makes	B-X
it	B-X
an	B-X
ideal	B-X
model	B-X
system	B-X
in	B-X
which	B-X
to	B-X
clarify	B-X
the	B-X
transcriptional	B-X
mechanisms	B-X
that	B-X
guide	B-X
the	B-X
development	B-X
and	B-X
activation	B-X
of	B-X
cytotoxic	B-X
lymphocytes	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
what	B-X
is	B-X
known	B-X
about	B-X
perforin	B-X
expression	B-X
and	B-X
its	B-X
regulation	B-X
,	B-X
then	B-X
elaborate	B-X
on	B-X
recent	B-X
studies	B-X
that	B-X
utilized	B-X
chromosome	B-X
transfer	B-X
and	B-X
bacterial	B-X
artificial	B-X
chromosome	B-X
transgenics	B-X
to	B-X
define	B-X
a	B-X
comprehensive	B-X
set	B-X
of	B-X
cis-regulatory	B-X
regions	B-X
that	B-X
control	B-X
transcription	B-X
of	B-X
the	B-X
human	B-X
PRF1	B-X
gene	B-X
in	B-X
a	B-X
near-physiologic	B-X
context	B-X
.	B-X

We	O
show	O
that	O
effector	O
CTL	O
differentiation	O
occurs	O
in	O
two	O
sequential	O
phases	O
in	O
vitro	O
,	O
characterized	O
by	O
early	O
induction	O
of	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
late	O
induction	O
of	O
Eomesodermin	B-Protein
(	O
Eomes	B-Protein
)	O
,	O
T	O
-	O
box	O
transcription	O
factors	O
that	O
regulate	O
the	O
early	O
and	O
late	O
phases	O
of	O
interferon	B-Protein
(	I-Protein
IFN	I-Protein
)	I-Protein
gamma	I-Protein
expression	O
,	O
respectively	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
naive	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
with	B-X
antigen	B-X
induces	B-X
their	B-X
differentiation	B-X
into	B-X
effector	B-X
cytolytic	B-X
T	B-X
lymphocytes	B-X
(	B-X
CTLs	B-X
)	B-X
.	B-X
CTLs	B-X
lyse	B-X
infected	B-X
or	B-X
aberrant	B-X
target	B-X
cells	B-X
by	B-X
exocytosis	B-X
of	B-X
lytic	B-X
granules	B-X
containing	B-X
the	B-X
pore-forming	B-X
protein	B-X
perforin	B-X
and	B-X
a	B-X
family	B-X
of	B-X
proteases	B-X
termed	B-X
granzymes	B-X
.	B-X
We	B-X
show	B-X
that	B-X
effector	B-X
CTL	B-X
differentiation	B-X
occurs	B-X
in	B-X
two	B-X
sequential	B-X
phases	B-X
in	B-X
vitro	B-X
,	B-X
characterized	B-X
by	B-X
early	B-X
induction	B-X
of	B-X
T-bet	B-X
and	B-X
late	B-X
induction	B-X
of	B-X
Eomesodermin	B-X
(	B-X
Eomes	B-X
)	B-X
,	B-X
T-box	B-X
transcription	B-X
factors	B-X
that	B-X
regulate	B-X
the	B-X
early	B-X
and	B-X
late	B-X
phases	B-X
of	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
gamma	B-X
expression	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
demonstrate	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
the	B-X
transcription	B-X
factor	B-X
Runx3	B-X
in	B-X
CTL	B-X
differentiation	B-X
.	B-X
Runx3	B-X
regulates	B-X
Eomes	B-X
expression	B-X
as	B-X
well	B-X
as	B-X
expression	B-X
of	B-X
three	B-X
cardinal	B-X
markers	B-X
of	B-X
the	B-X
effector	B-X
CTL	B-X
program	B-X
:	B-X
IFN-gamma	B-X
,	B-X
perforin	B-X
,	B-X
and	B-X
granzyme	B-X
B	B-X
.	B-X
Our	B-X
data	B-X
point	B-X
to	B-X
the	B-X
existence	B-X
of	B-X
an	B-X
elaborate	B-X
transcriptional	B-X
network	B-X
in	B-X
which	B-X
Runx3	B-X
initially	B-X
induces	B-X
and	B-X
then	B-X
cooperates	B-X
with	B-X
T-box	B-X
transcription	B-X
factors	B-X
to	B-X
regulate	B-X
gene	B-X
transcription	B-X
in	B-X
differentiating	B-X
CTLs	B-X
.	B-X

In	O
addition	O
,	O
we	O
demonstrate	O
a	O
critical	O
role	O
for	O
the	O
transcription	O
factor	O
Runx3	B-Protein
in	O
CTL	O
differentiation	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
naive	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
with	B-X
antigen	B-X
induces	B-X
their	B-X
differentiation	B-X
into	B-X
effector	B-X
cytolytic	B-X
T	B-X
lymphocytes	B-X
(	B-X
CTLs	B-X
)	B-X
.	B-X
CTLs	B-X
lyse	B-X
infected	B-X
or	B-X
aberrant	B-X
target	B-X
cells	B-X
by	B-X
exocytosis	B-X
of	B-X
lytic	B-X
granules	B-X
containing	B-X
the	B-X
pore-forming	B-X
protein	B-X
perforin	B-X
and	B-X
a	B-X
family	B-X
of	B-X
proteases	B-X
termed	B-X
granzymes	B-X
.	B-X
We	B-X
show	B-X
that	B-X
effector	B-X
CTL	B-X
differentiation	B-X
occurs	B-X
in	B-X
two	B-X
sequential	B-X
phases	B-X
in	B-X
vitro	B-X
,	B-X
characterized	B-X
by	B-X
early	B-X
induction	B-X
of	B-X
T-bet	B-X
and	B-X
late	B-X
induction	B-X
of	B-X
Eomesodermin	B-X
(	B-X
Eomes	B-X
)	B-X
,	B-X
T-box	B-X
transcription	B-X
factors	B-X
that	B-X
regulate	B-X
the	B-X
early	B-X
and	B-X
late	B-X
phases	B-X
of	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
gamma	B-X
expression	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
demonstrate	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
the	B-X
transcription	B-X
factor	B-X
Runx3	B-X
in	B-X
CTL	B-X
differentiation	B-X
.	B-X
Runx3	B-X
regulates	B-X
Eomes	B-X
expression	B-X
as	B-X
well	B-X
as	B-X
expression	B-X
of	B-X
three	B-X
cardinal	B-X
markers	B-X
of	B-X
the	B-X
effector	B-X
CTL	B-X
program	B-X
:	B-X
IFN-gamma	B-X
,	B-X
perforin	B-X
,	B-X
and	B-X
granzyme	B-X
B	B-X
.	B-X
Our	B-X
data	B-X
point	B-X
to	B-X
the	B-X
existence	B-X
of	B-X
an	B-X
elaborate	B-X
transcriptional	B-X
network	B-X
in	B-X
which	B-X
Runx3	B-X
initially	B-X
induces	B-X
and	B-X
then	B-X
cooperates	B-X
with	B-X
T-box	B-X
transcription	B-X
factors	B-X
to	B-X
regulate	B-X
gene	B-X
transcription	B-X
in	B-X
differentiating	B-X
CTLs	B-X
.	B-X

Runx3	B-Protein
regulates	O
Eomes	B-Protein
expression	O
as	O
well	O
as	O
expression	O
of	O
three	O
cardinal	O
markers	O
of	O
the	O
effector	O
CTL	O
program	O
:	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
perforin	B-Protein
,	O
and	O
granzyme	B-Protein
B	I-Protein
.	O
<EOS>	B-X
Activation	B-X
of	B-X
naive	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
with	B-X
antigen	B-X
induces	B-X
their	B-X
differentiation	B-X
into	B-X
effector	B-X
cytolytic	B-X
T	B-X
lymphocytes	B-X
(	B-X
CTLs	B-X
)	B-X
.	B-X
CTLs	B-X
lyse	B-X
infected	B-X
or	B-X
aberrant	B-X
target	B-X
cells	B-X
by	B-X
exocytosis	B-X
of	B-X
lytic	B-X
granules	B-X
containing	B-X
the	B-X
pore-forming	B-X
protein	B-X
perforin	B-X
and	B-X
a	B-X
family	B-X
of	B-X
proteases	B-X
termed	B-X
granzymes	B-X
.	B-X
We	B-X
show	B-X
that	B-X
effector	B-X
CTL	B-X
differentiation	B-X
occurs	B-X
in	B-X
two	B-X
sequential	B-X
phases	B-X
in	B-X
vitro	B-X
,	B-X
characterized	B-X
by	B-X
early	B-X
induction	B-X
of	B-X
T-bet	B-X
and	B-X
late	B-X
induction	B-X
of	B-X
Eomesodermin	B-X
(	B-X
Eomes	B-X
)	B-X
,	B-X
T-box	B-X
transcription	B-X
factors	B-X
that	B-X
regulate	B-X
the	B-X
early	B-X
and	B-X
late	B-X
phases	B-X
of	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
gamma	B-X
expression	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
demonstrate	B-X
a	B-X
critical	B-X
role	B-X
for	B-X
the	B-X
transcription	B-X
factor	B-X
Runx3	B-X
in	B-X
CTL	B-X
differentiation	B-X
.	B-X
Runx3	B-X
regulates	B-X
Eomes	B-X
expression	B-X
as	B-X
well	B-X
as	B-X
expression	B-X
of	B-X
three	B-X
cardinal	B-X
markers	B-X
of	B-X
the	B-X
effector	B-X
CTL	B-X
program	B-X
:	B-X
IFN-gamma	B-X
,	B-X
perforin	B-X
,	B-X
and	B-X
granzyme	B-X
B	B-X
.	B-X
Our	B-X
data	B-X
point	B-X
to	B-X
the	B-X
existence	B-X
of	B-X
an	B-X
elaborate	B-X
transcriptional	B-X
network	B-X
in	B-X
which	B-X
Runx3	B-X
initially	B-X
induces	B-X
and	B-X
then	B-X
cooperates	B-X
with	B-X
T-box	B-X
transcription	B-X
factors	B-X
to	B-X
regulate	B-X
gene	B-X
transcription	B-X
in	B-X
differentiating	B-X
CTLs	B-X
.	B-X

Our	O
data	O
point	O
to	O
the	O
existence	O
of	O
an	O
elaborate	O
transcriptional	O
network	O
in	O
which	O
Runx3	B-Protein
initially	O
induces	O
and	O
then	O
cooperates	O
with	O
T	O
-	O
box	O
transcription	O
factors	O
to	O
regulate	O
gene	O
transcription	O
in	O
differentiating	O
CTLs	O
.	O

Naive	O
CD8	B-Protein
+	O
T	O
cells	O
differentiate	O
into	O
effector	O
CTLs	O
with	O
the	O
ability	O
to	O
lyse	O
antigen	O
-	O
bearing	O
target	O
cells	O
by	O
exocytosis	O
of	O
lytic	O
granules	O
containing	O
perforin	B-Protein
and	O
granzymes	O
,	O
and	O
to	O
produce	O
inflammatory	O
cytokines	O
such	O
as	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
TNF	B-Protein
upon	O
restimulation	O
through	O
the	O
TCR	O
(	O
1	O
,	O
2	O
)	O
.	O

In	O
vivo	O
experiments	O
have	O
elucidated	O
many	O
critical	O
parameters	O
governing	O
the	O
development	O
and	O
evolution	O
of	O
primary	O
CTL	O
responses	O
(	O
3	O
,	O
4	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
used	O
in	O
vitro	O
systems	O
such	O
as	O
those	O
developed	O
to	O
study	O
CD4	B-Protein
+	O
T	O
cell	O
differentiation	O
to	O
define	O
the	O
molecular	O
basis	O
of	O
effector	O
CTL	O
differentiation	O
(	O
5	O
,	O
6	O
)	O
.	O
The	O
T	O
-	O
box	O
transcription	O
factors	O
Eomesodermin	B-Protein
(	O
Eomes	B-Protein
)	O
and	O
T	B-Protein
-	I-Protein
bet	I-Protein
are	O
needed	O
for	O
important	O
aspects	O
of	O
effector	O
and	O
memory	O
CTL	O
differentiation	O
(	O
7	O
)	O
.	O

In	O
uninfected	O
mice	O
,	O
compound	O
deletion	O
of	O
theTbx21	B-Protein
(	O
encoding	O
T	B-Protein
-	I-Protein
bet	I-Protein
)	O
andeomesodermingenes	B-Protein
is	O
associated	O
with	O
a	O
selective	O
loss	O
of	O
CD8	B-Protein
+	O
T	O
cells	O
with	O
an	O
IL	B-Protein
-	I-Protein
2Rbeta	I-Protein
-	O
high	O
,	O
memory	O
phenotype	O
(	O
8	O
)	O
.	O

Mice	O
deficient	O
for	O
both	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
in	O
T	O
cells	O
have	O
impaired	O
expression	O
of	O
cytolytic	O
mediators	O
,	O
manifest	O
poor	O
cytolytic	O
activity	O
,	O
and	O
fail	O
to	O
control	O
acute	O
lymphocytic	O
choriomeningitis	O
virus	O
infection	O
(	O
9	O
)	O
.	O

Nevertheless	O
,	O
the	O
specific	O
roles	O
of	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
in	O
clonal	O
expansion	O
and	O
CTL	O
differentiation	O
have	O
not	O
yet	O
been	O
resolved	O
:	O
in	O
particular	O
,	O
it	O
is	O
not	O
known	O
whether	O
these	O
transcription	O
factors	O
function	O
redundantly	O
to	O
control	O
effector	O
CD8	B-Protein
+	O
T	O
cell	O
differentiation	O
,	O
and	O
whether	O
they	O
do	O
so	O
directly	O
by	O
targeting	O
specific	O
effector	O
cytokine	O
and	O
cytolytic	O
genes	O
.	O
Runx	O
proteins	O
,	O
a	O
family	O
of	O
three	O
DNA	O
-	O
binding	O
transcription	O
factors	O
,	O
control	O
thymocyte	O
differentiation	O
and	O
the	O
CD4	B-Protein
/	O
CD8	B-Protein
lineage	O
decision	O
(	O
10	O
-	O
13	O
)	O
.	O

Runx3	B-Protein
and	O
perforin	B-Protein
mRNA	O
are	O
expressed	O
by	O
double	O
-	O
positive	O
(	O
DP	O
)	O
thymocytes	O
and	O
CD8	B-Protein
+	O
single	O
-	O
positive	O
(	O
SP	O
)	O
thymocytes	O
but	O
not	O
in	O
CD4	B-Protein
+	O
SP	O
cells	O
(	O
14	O
)	O
.	O

Although	O
Runx3	B-Protein
is	O
not	O
expressed	O
in	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
,	O
its	O
expression	O
is	O
up	O
-	O
regulated	O
during	O
Th1	O
cell	O
differentiation	O
,	O
and	O
Runx3	B-Protein
influences	O
Th1	O
cell	O
differentiation	O
and	O
function	O
through	O
direct	O
regulation	O
of	O
theIl4andIfngcytokine	B-Protein
genes	O
(	O
15	O
,	O
16	O
)	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
function	B-X
of	B-X
circMETTL3/miR-107/PER3	B-X
in	B-X
CRC	B-X
.	B-X
Human	B-X
CRC	B-X
tissues	B-X
from	B-X
diagnosed	B-X
CRC	B-X
patients	B-X
and	B-X
six	B-X
CRC	B-X
cell	B-X
lines	B-X
,	B-X
one	B-X
normal	B-X
human	B-X
colon	B-X
cell	B-X
line	B-X
were	B-X
used	B-X
.	B-X
qRT-PCR	B-X
and	B-X
western	B-X
blotting	B-X
were	B-X
performed	B-X
to	B-X
determine	B-X
expression	B-X
levels	B-X
of	B-X
RUNX3	B-X
,	B-X
circMETTL3	B-X
,	B-X
miR-107	B-X
,	B-X
PER3	B-X
,	B-X
and	B-X
proliferation-	B-X
,	B-X
and	B-X
migration-related	B-X
proteins	B-X
.	B-X
CCK-8	B-X
,	B-X
colony	B-X
formation	B-X
assay	B-X
,	B-X
transwell	B-X
assay	B-X
,	B-X
and	B-X
scratch	B-X
wound	B-X
assay	B-X
were	B-X
utilized	B-X
to	B-X
assess	B-X
CRC	B-X
cell	B-X
proliferation	B-X
and	B-X
invasion	B-X
.	B-X
RUNX3	B-X
,	B-X
circMETTL3	B-X
,	B-X
and	B-X
PER3	B-X
were	B-X
diminished	B-X
while	B-X
miR-107	B-X
was	B-X
elevated	B-X
in	B-X
CRC	B-X
tissues	B-X
and	B-X
cells	B-X
.	B-X
Overexpression	B-X
of	B-X
RUNX3	B-X
,	B-X
circMETTL3	B-X
,	B-X
or	B-X
PER3	B-X
suppressed	B-X
while	B-X
miR-107	B-X
mimics	B-X
promoted	B-X
,	B-X
CRC	B-X
cell	B-X
proliferation	B-X
and	B-X
invasion	B-X
,	B-X
as	B-X
well	B-X
as	B-X
tumor	B-X
growth	B-X
and	B-X
metastasis	B-X
in	B-X
vivo	B-X
.	B-X
circMETTL3	B-X
directly	B-X
bound	B-X
with	B-X
miR-107	B-X
which	B-X
targeted	B-X
PER3	B-X
.	B-X
circMETTL3/miR-107	B-X
regulated	B-X
CRC	B-X
cell	B-X
proliferation	B-X
and	B-X
invasion	B-X
via	B-X
PER3	B-X
.	B-X

In	O
contrast	O
,	O
all	O
three	O
Runx	O
proteins	O
are	O
expressed	O
in	O
mature	O
CD8	B-Protein
+	O
T	O
cells	O
(	O
10	O
,	O
12	O
)	O
,	O
and	O
Runx3	B-Protein
-	O
deficient	O
CD8	B-Protein
+	O
T	O
cells	O
show	O
reduced	O
cytolytic	O
activity	O
(	O
12	O
,	O
13	O
)	O
.	O

We	O
therefore	O
tested	O
whether	O
Runx3	B-Protein
influenced	O
cytolytic	O
T	O
cell	O
differentiation	O
.	O
In	O
this	O
report	O
,	O
we	O
show	O
that	O
Runx3	B-Protein
and	O
T	O
-	O
box	O
factors	O
synergistically	O
regulate	O
CTL	O
differentiation	O
and	O
function	O
.	O

T	B-Protein
-	I-Protein
bet	I-Protein
is	O
induced	O
quickly	O
upon	O
TCR	O
stimulation	O
and	O
is	O
required	O
for	O
early	O
programming	O
of	O
cytokine	O
production	O
(	O
17	O
)	O
,	O
whereas	O
Eomes	B-Protein
is	O
induced	O
later	O
during	O
differentiation	O
and	O
sustains	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
.	O

Runx3	B-Protein
is	O
required	O
for	O
Eomes	B-Protein
and	O
perforin	B-Protein
expression	O
,	O
and	O
both	O
Eomes	B-Protein
and	O
Runx3	B-Protein
bind	O
at	O
thePrf1locus	B-Protein
;	O
in	O
contrast	O
,	O
perforin	B-Protein
expression	O
is	O
unaffected	O
in	O
T	B-Protein
-	I-Protein
bet	I-Protein
-	O
deficient	O
cells	O
.	O

T	O
cells	O
lacking	O
Runx3	B-Protein
show	O
decreased	O
expression	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
granzyme	B-Protein
B	I-Protein
,	O
and	O
Runx3	B-Protein
also	O
binds	O
the	O
promoter	O
regions	O
of	O
theIfngandGzmbgenes	B-Protein
.	O

Collectively	O
,	O
these	O
results	O
provide	O
evidence	O
for	O
a	O
complex	O
transcriptional	O
network	O
in	O
which	O
Runx3	B-Protein
is	O
a	O
primary	O
regulator	O
ofGzmbexpression	B-Protein
but	O
synergizes	O
with	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
,	O
respectively	O
,	O
to	O
promote	O
transcription	O
of	O
theIfngandPrf1genes	B-Protein
.	O

A	O
cell	O
culture	O
system	O
to	O
monitor	O
effector	O
CTL	O
differentiation	O

We	O
used	O
a	O
simple	O
cell	O
culture	O
system	O
to	O
examine	O
the	O
kinetics	O
of	O
effector	O
gene	O
expression	O
during	O
CD8	B-Protein
+	O
T	O
cell	O
differentiation	O
.	O

Naive	O
CD8	B-Protein
+	O
T	O
cells	O
from	O
P14	O
TCR	O
transgenic	O
mice	O
were	O
activated	O
for	O
2	O
d	O
with	O
anti	O
-	O
CD3	B-Protein
and	O
anti	O
-	O
CD28	B-Protein
or	O
with	O
splenic	O
APCs	O
in	O
the	O
presence	O
of	O
Gp33	O
peptide	O
,	O
and	O
were	O
cultured	O
in	O
media	O
containing	O
100	O
U	O
/	O
ml	O
of	O
recombinant	O
human	O
IL	B-Protein
-	I-Protein
2	I-Protein
(	O
rhIL	B-Protein
-	I-Protein
2	I-Protein
)	O
.	O

We	O
used	O
TCR	O
transgenic	O
mice	O
for	O
these	O
experiments	O
because	O
they	O
provide	O
a	O
reliable	O
source	O
of	O
CD8	B-Protein
+	O
T	O
cells	O
that	O
are	O
truly	O
naive	O
;	O
however	O
,	O
we	O
chose	O
not	O
to	O
stimulate	O
cells	O
with	O
antigen	O
in	O
most	O
experiments	O
so	O
as	O
to	O
avoid	O
contamination	O
with	O
proteins	O
and	O
nucleic	O
acids	O
derived	O
from	O
APCs	O
.	O

There	O
were	O
only	O
minor	O
differences	O
in	O
gene	O
expression	O
during	O
differentiation	O
induced	O
by	O
antigen	O
/	O
APC	O
versus	O
anti	O
-	O
CD3	B-Protein
/	O
anti	O
-	O
CD28	B-Protein
,	O
and	O
the	O
major	O
conclusions	O
presented	O
in	O
this	O
report	O
are	O
the	O
same	O
for	O
both	O
activating	O
conditions	O
.	O

Under	O
our	O
culture	O
conditions	O
,	O
activated	O
CD8	B-Protein
+	O
T	O
cells	O
expanded	O
exponentially	O
and	O
accumulated	O
for	O
>	O
8	O
d	O
.	O

We	O
limited	O
our	O
analysis	O
to	O
the	O
first	O
6	O
-	O
8	O
d	O
after	O
activation	O
,	O
a	O
period	O
that	O
coincides	O
with	O
clonal	O
expansion	O
of	O
CD8	B-Protein
+	O
T	O
cells	O
after	O
activation	O
in	O
vivo	O
.	O

Distinct	O
expression	O
kinetics	O
of	O
perforin	B-Protein
and	O
granzyme	B-Protein
B	I-Protein
during	O
CTL	O
development	O
in	O
culture	O

Our	O
experiments	O
revealed	O
clear	O
differences	O
in	O
the	O
kinetics	O
of	O
perforin	B-Protein
,	O
granzyme	B-Protein
B	I-Protein
,	O
and	O
cytokine	O
expression	O
during	O
CD8	B-Protein
+	O
T	O
cell	O
activation	O
(	O
Fig	O
.	O
1	O
)	O
.	O

Naive	O
T	O
cells	O
showed	O
detectable	O
expression	O
of	O
perforin	B-Protein
mRNA	O
as	O
well	O
as	O
perforin	B-Protein
protein	O
(	O
Fig	O
.	O
1	O
,	O
A	O
-	O
D	O
)	O
.	O

Relative	O
to	O
its	O
expression	O
in	O
naive	O
T	O
cells	O
,	O
perforin	B-Protein
(	O
Prf1	B-Protein
)	O
mRNA	O
expression	O
did	O
not	O
increase	O
appreciably	O
at	O
day	O
2	O
but	O
showed	O
a	O
reproducible	O
decrease	O
at	O
day	O
4	O
,	O
followed	O
by	O
robust	O
reexpression	O
between	O
days	O
4	O
and	O
8	O
(	O
Fig	O
.	O
1	O
,	O
A	O
-	O
D	O
)	O
.	O

In	O
contrast	O
,	O
granzyme	B-Protein
B	I-Protein
(	O
Gzmb	B-Protein
)	O
mRNA	O
was	O
low	O
or	O
undetectable	O
in	O
naive	O
T	O
cells	O
but	O
was	O
strongly	O
up	O
-	O
regulated	O
by	O
day	O
2	O
after	O
stimulation	O
and	O
increased	O
progressively	O
until	O
day	O
6	O
(	O
Fig	O
.	O
1	O
,	O
A	O
and	O
B	O
)	O
;	O
similarly	O
,	O
granzyme	B-Protein
B	I-Protein
protein	O
was	O
expressed	O
by	O
day	O
4	O
and	O
remained	O
high	O
until	O
day	O
6	O
(	O
Fig	O
.	O
1	O
E	O
)	O
.	O

As	O
expected	O
,	O
a	O
small	O
fraction	O
of	O
naive	O
T	O
cells	O
expressed	O
the	O
cytokines	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
TNF	B-Protein
in	O
response	O
to	O
stimulation	O
,	O
and	O
this	O
capacity	O
increased	O
significantly	O
in	O
differentiated	O
cells	O
(	O
Fig	O
.	O
1	O
E	O
;	O
see	O
also	O
Fig	O
.	O
2	O
A	O
)	O
.	O

We	O
evaluated	O
antigen	O
-	O
dependent	O
cytolytic	O
function	O
in	O
a	O
short	O
-	O
term	O
assay	O
in	O
which	O
target	O
cell	O
death	O
was	O
measured	O
within	O
2	O
h	O
(	O
Fig	O
.	O
1	O
F	O
)	O
.	O

By	O
limiting	O
the	O
duration	O
of	O
TCR	O
stimulation	O
,	O
this	O
strategy	O
minimizes	O
cytolysis	O
secondary	O
to	O
new	O
gene	O
expression	O
during	O
the	O
period	O
of	O
the	O
assay	O
.	O

Naive	O
T	O
cells	O
did	O
not	O
display	O
significant	O
cytolytic	O
function	O
in	O
this	O
short	O
-	O
term	O
assay	O
(	O
unpublished	O
data	O
)	O
,	O
most	O
likely	O
because	O
they	O
express	O
immature	O
(	O
unprocessed	O
)	O
forms	O
of	O
perforin	B-Protein
and	O
lack	O
the	O
capacity	O
to	O
degranulate	O
(	O
18	O
,	O
19	O
)	O
.	O

Even	O
after	O
activation	O
for	O
2	O
or	O
4	O
d	O
,	O
the	O
cells	O
showed	O
poor	O
cytolytic	O
activity	O
(	O
Fig	O
.	O
1	O
F	O
)	O
,	O
in	O
striking	O
contrast	O
to	O
their	O
capacity	O
for	O
efficient	O
cytokine	O
production	O
(	O
Fig	O
.	O
1	O
E	O
)	O
.	O

Only	O
cells	O
cultured	O
until	O
day	O
6	O
displayed	O
robust	O
cytotoxicity	O
,	O
as	O
judged	O
by	O
their	O
ability	O
to	O
induce	O
apoptosis	O
in	O
a	O
large	O
number	O
of	O
target	O
cells	O
(	O
Fig	O
.	O
1	O
F	O
)	O
.	O

These	O
results	O
show	O
that	O
after	O
a	O
strong	O
priming	O
stimulus	O
through	O
TCRs	O
and	O
co	O
-	O
stimulatory	O
receptors	O
in	O
vitro	O
,	O
granzyme	B-Protein
B	I-Protein
expression	O
and	O
the	O
ability	O
to	O
produce	O
effector	O
cytokines	O
are	O
programmed	O
early	O
,	O
whereas	O
perforin	B-Protein
expression	O
and	O
cytolytic	O
function	O
are	O
induced	O
later	O
,	O
during	O
the	O
phase	O
of	O
clonal	O
expansion	O
in	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

Therefore	O
,	O
the	O
two	O
major	O
effector	O
functions	O
of	O
CTL	O
,	O
cytokine	O
production	O
and	O
cytolytic	O
activity	O
,	O
are	O
not	O
intrinsically	O
coregulated	O
.	O
<EOS>	B-X
The	B-X
autotumor	B-X
(	B-X
AuTu	B-X
)	B-X
-specific	B-X
cytolytic	B-X
T	B-X
lymphocyte	B-X
(	B-X
CTL	B-X
)	B-X
line	B-X
established	B-X
from	B-X
the	B-X
peripheral	B-X
blood	B-X
of	B-X
a	B-X
patient	B-X
with	B-X
oral	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
(	B-X
Cancer	B-X
Res	B-X
.	B-X
This	B-X
CTL	B-X
line	B-X
was	B-X
infected	B-X
with	B-X
Herpesvirus	B-X
saimiri	B-X
to	B-X
increase	B-X
its	B-X
life	B-X
span	B-X
in	B-X
culture	B-X
.	B-X
The	B-X
virus-transformed	B-X
and	B-X
untransformed	B-X
T	B-X
cell	B-X
lines	B-X
were	B-X
compared	B-X
for	B-X
phenotypic	B-X
and	B-X
functional	B-X
characteristics	B-X
,	B-X
including	B-X
the	B-X
ability	B-X
to	B-X
kill	B-X
AuTu	B-X
,	B-X
induce	B-X
expression	B-X
of	B-X
the	B-X
major	B-X
histocompatibility	B-X
complex	B-X
(	B-X
MHC	B-X
)	B-X
antigens	B-X
on	B-X
AuTu	B-X
,	B-X
and	B-X
respond	B-X
to	B-X
AuTu	B-X
by	B-X
cytokine	B-X
production	B-X
and/or	B-X
proliferation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
H.	B-X
saimiri-transformed	B-X
CD8+	B-X
T	B-X
cells	B-X
did	B-X
not	B-X
kill	B-X
AuTu	B-X
or	B-X
release	B-X
cytokines	B-X
in	B-X
response	B-X
to	B-X
AuTu	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
H.	B-X
saimiri-transformed	B-X
tumor-reactive	B-X
T	B-X
cell	B-X
lines	B-X
provide	B-X
a	B-X
useful	B-X
model	B-X
of	B-X
interactions	B-X
between	B-X
immune	B-X
effector	B-X
cells	B-X
and	B-X
AuTu	B-X
,	B-X
and	B-X
that	B-X
CD4+	B-X
T	B-X
cells	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
immune	B-X
responses	B-X
to	B-X
squamous	B-X
cell	B-X
carcinoma	B-X
of	B-X
the	B-X
head	B-X
and	B-X
neck	B-X
.	B-X

Distinct	O
kinetics	O
of	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
expression	O
during	O
CTL	O
differentiation	O

The	O
T	O
-	O
box	O
transcription	O
factors	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
have	O
been	O
linked	O
to	O
the	O
regulation	O
of	O
genes	O
encoding	O
effector	O
cytokines	O
(	O
e	O
.	O
g	O
.	O
,	O
Ifng	B-Protein
)	O
and	O
genes	O
important	O
for	O
cytolytic	O
function	O
(	O
e	O
.	O
g	O
.	O
,	O
Prf1	B-Protein
and	O
GzmB	B-Protein
)	O
(	O
20	O
)	O
.	O

We	O
investigated	O
the	O
kinetics	O
of	O
expression	O
of	O
these	O
transcription	O
factors	O
in	O
our	O
in	O
vitro	O
cultures	O
(	O
Fig	O
.	O
1	O
,	O
A	O
-	O
D	O
)	O
.	O

T	B-Protein
-	I-Protein
bet	I-Protein
mRNA	O
and	O
protein	O
were	O
not	O
detectable	O
in	O
naive	O
CD8	B-Protein
+	O
T	O
cells	O
,	O
but	O
were	O
strongly	O
induced	O
upon	O
TCR	O
priming	O
(	O
day	O
2	O
)	O
and	O
remained	O
expressed	O
through	O
day	O
6	O
of	O
differentiation	O
(	O
Fig	O
.	O
1	O
,	O
A	O
and	O
C	O
;	O
quantified	O
in	O
Fig	O
.	O
1	O
,	O
B	O
and	O
D	O
)	O
.	O
<EOS>	B-X
Breast	B-X
cancer	B-X
is	B-X
a	B-X
prominent	B-X
cause	B-X
of	B-X
death	B-X
among	B-X
women	B-X
worldwide	B-X
.	B-X
Posttranscriptional	B-X
gene	B-X
regulation	B-X
by	B-X
RNA-binding	B-X
proteins	B-X
(	B-X
RBPs	B-X
)	B-X
is	B-X
well-recognized	B-X
,	B-X
and	B-X
the	B-X
biological	B-X
functions	B-X
of	B-X
RBPs	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
many	B-X
diseases	B-X
,	B-X
such	B-X
as	B-X
autoimmune	B-X
diseases	B-X
,	B-X
inflammatory	B-X
diseases	B-X
,	B-X
and	B-X
cancer	B-X
.	B-X
However	B-X
,	B-X
a	B-X
complete	B-X
understanding	B-X
of	B-X
the	B-X
regulation	B-X
mediated	B-X
by	B-X
several	B-X
RBPs	B-X
is	B-X
lacking	B-X
.	B-X
During	B-X
the	B-X
past	B-X
few	B-X
years	B-X
,	B-X
a	B-X
novel	B-X
role	B-X
of	B-X
AT-rich	B-X
interactive	B-X
domain-containing	B-X
protein	B-X
5a	B-X
(	B-X
Arid5a	B-X
)	B-X
as	B-X
an	B-X
RBP	B-X
is	B-X
being	B-X
investigated	B-X
in	B-X
the	B-X
field	B-X
of	B-X
immunology	B-X
owing	B-X
to	B-X
binding	B-X
of	B-X
Arid5a	B-X
protein	B-X
to	B-X
the	B-X
3	B-X
'	B-X
untranslated	B-X
region	B-X
(	B-X
UTR	B-X
)	B-X
of	B-X

In	O
contrast	O
,	O
Eomes	B-Protein
expression	O
was	O
low	O
or	O
undetectable	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
in	O
naive	O
CD8	B-Protein
+	O
T	O
cells	O
,	O
and	O
TCR	O
priming	O
in	O
culture	O
had	O
only	O
a	O
modest	O
effect	O
on	O
its	O
expression	O
at	O
day	O
2	O
(	O
Fig	O
.	O
1	O
,	O
A	O
and	O
C	O
)	O
.	O
<EOS>	B-X
Abundant	B-X
evidence	B-X
shows	B-X
that	B-X
triple-negative	B-X
breast	B-X
cancer	B-X
(	B-X
TNBC	B-X
)	B-X
is	B-X
heterogeneous	B-X
,	B-X
and	B-X
many	B-X
efforts	B-X
have	B-X
been	B-X
devoted	B-X
to	B-X
identifying	B-X
TNBC	B-X
subtypes	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
genomic	B-X
profiling	B-X
.	B-X
However	B-X
,	B-X
few	B-X
studies	B-X
have	B-X
explored	B-X
the	B-X
classification	B-X
of	B-X
TNBC	B-X
specifically	B-X
based	B-X
on	B-X
immune	B-X
signatures	B-X
that	B-X
may	B-X
facilitate	B-X
the	B-X
optimal	B-X
stratification	B-X
of	B-X
TNBC	B-X
patients	B-X
responsive	B-X
to	B-X
immunotherapy	B-X
.	B-X
Human	B-X
skin	B-X
harbors	B-X
two	B-X
major	B-X
T	B-X
cell	B-X
compartments	B-X
of	B-X
equal	B-X
size	B-X
that	B-X
are	B-X
distinguished	B-X
by	B-X
expression	B-X
of	B-X
the	B-X
chemokine	B-X
receptor	B-X
CCR8	B-X
.	B-X
In	B-X
vitro	B-X
studies	B-X
have	B-X
demonstrated	B-X
that	B-X
CCR8	B-X
expression	B-X
is	B-X
regulated	B-X
by	B-X
TCR	B-X
engagement	B-X
and	B-X
the	B-X
skin	B-X
tissue	B-X
microenvironment	B-X
.	B-X
To	B-X
extend	B-X
these	B-X
observations	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
relationship	B-X
between	B-X
CCR8	B-X

Strong	O
induction	O
of	O
Eomes	B-Protein
mRNA	O
and	O
protein	O
was	O
only	O
observed	O
at	O
day	O
4	O
and	O
later	O
(	O
Fig	O
.	O
1	O
,	O
A	O
and	O
C	O
)	O
.	O

T	B-Protein
-	I-Protein
bet	I-Protein
mRNA	O
expression	O
slightly	O
preceded	O
the	O
expression	O
of	O
GzmB	B-Protein
mRNA	O
;	O
similarly	O
,	O
Eomes	B-Protein
mRNA	O
and	O
protein	O
were	O
expressed	O
~	O
1	O
d	O
ahead	O
of	O
the	O
reexpression	O
of	O
perforin	B-Protein
mRNA	O
and	O
protein	O
,	O
respectively	O
(	O
Fig	O
.	O
1	O
,	O
B	O
and	O
D	O
)	O
.	O

This	O
detailed	O
kinetic	O
analysis	O
suggested	O
that	O
,	O
under	O
our	O
culture	O
conditions	O
,	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
contribute	O
to	O
distinct	O
aspects	O
of	O
gene	O
transcription	O
during	O
CTL	O
differentiation	O
.	O

T	B-Protein
-	I-Protein
bet	I-Protein
is	O
required	O
early	O
for	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
,	O
and	O
our	O
data	O
suggested	O
that	O
Eomes	B-Protein
might	O
not	O
function	O
during	O
this	O
early	O
period	O
but	O
rather	O
might	O
contribute	O
later	O
to	O
the	O
control	O
of	O
perforin	B-Protein
expression	O
.	O

Our	O
data	O
seemed	O
most	O
consistent	O
with	O
a	O
model	O
in	O
which	O
TCR	O
signals	O
induce	O
T	B-Protein
-	I-Protein
bet	I-Protein
,	O
which	O
in	O
turn	O
induces	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
(	O
17	O
)	O
and	O
possibly	O
granzyme	B-Protein
B	I-Protein
;	O
subsequently	O
,	O
Eomes	B-Protein
is	O
induced	O
during	O
the	O
period	O
of	O
clonal	O
expansion	O
in	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
activates	O
perforin	B-Protein
expression	O
.	O

Perforin	B-Protein
and	O
granzyme	B-Protein
B	I-Protein
expression	O
are	O
not	O
appreciably	O
regulated	O
by	O
T	B-Protein
-	I-Protein
bet	I-Protein
<EOS>	B-X
A	B-X
defining	B-X
property	B-X
of	B-X
cytotoxic	B-X
lymphocytes	B-X
is	B-X
their	B-X
expression	B-X
and	B-X
regulated	B-X
secretion	B-X
of	B-X
potent	B-X
toxins	B-X
,	B-X
including	B-X
the	B-X
pore-forming	B-X
protein	B-X
perforin	B-X
and	B-X
serine	B-X
protease	B-X
granzymes	B-X
.	B-X
Until	B-X
recently	B-X
,	B-X
mechanisms	B-X
of	B-X
pore	B-X
formation	B-X
and	B-X
granzyme	B-X
transfer	B-X
into	B-X
the	B-X
target	B-X
cell	B-X
were	B-X
poorly	B-X
understood	B-X
,	B-X
but	B-X
advances	B-X
in	B-X
structural	B-X
and	B-X
cellular	B-X
biology	B-X
have	B-X
now	B-X
begun	B-X
to	B-X
unravel	B-X
how	B-X
synergy	B-X
between	B-X
perforin	B-X
and	B-X
granzymes	B-X
brings	B-X
about	B-X
target	B-X
cell	B-X
death	B-X
.	B-X
These	B-X
and	B-X
other	B-X
advances	B-X
are	B-X
demonstrating	B-X
the	B-X
surprisingly	B-X
broad	B-X
pathophysiological	B-X
roles	B-X
of	B-X
the	B-X
perforin–granzyme	B-X
pathway	B-X
,	B-X
and	B-X
this	B-X
has	B-X
important	B-X
implications	B-X
for	B-X
understanding	B-X
immune	B-X
homeostasis	B-X
and	B-X
for	B-X
developing	B-X
immunotherapies	B-X
for	B-X
cancer	B-X
and	B-X
other	B-X
diseases	B-X
.	B-X
In	B-X
this	B-X
Review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
current	B-X
understanding	B-X
of	B-X
the	B-X
structural	B-X
,	B-X
cellular	B-X
and	B-X
clinical	B-X
aspects	B-X
of	B-X
perforin	B-X
and	B-X
granzyme	B-X
biology	B-X
.	B-X

To	O
test	O
the	O
model	O
outlined	O
in	O
the	O
previous	O
paragraph	O
directly	O
,	O
we	O
compared	O
the	O
expression	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
perforin	B-Protein
,	O
and	O
granzyme	B-Protein
B	I-Protein
in	O
CD8	B-Protein
+	O
T	O
cells	O
from	O
WT	O
and	O
Tbx21	B-Protein
(	O
T	B-Protein
-	I-Protein
bet	I-Protein
)	O
-	O
deficient	O
mice	O
.	O

As	O
expected	O
(	O
17	O
,	O
21	O
)	O
,	O
naive	O
Tbx21	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
T	O
cells	O
produced	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
poorly	O
upon	O
activation	O
(	O
Fig	O
.	O
2	O
A	O
)	O
.	O

Notably	O
,	O
this	O
deleterious	O
effect	O
of	O
T	B-Protein
-	I-Protein
bet	I-Protein
deficiency	O
was	O
only	O
observed	O
in	O
differentiating	O
CD8	B-Protein
+	O
T	O
cells	O
until	O
day	O
4	O
of	O
culture	O
but	O
was	O
almost	O
completely	O
mitigated	O
by	O
day	O
6	O
(	O
Fig	O
.	O
2	O
A	O
)	O
.	O

This	O
most	O
likely	O
reflected	O
compensation	O
by	O
Eomes	B-Protein
,	O
which	O
was	O
strongly	O
induced	O
between	O
days	O
4	O
and	O
6	O
(	O
Fig	O
.	O
1	O
)	O
.	O

In	O
contrast	O
,	O
T	B-Protein
-	I-Protein
bet	I-Protein
-	O
deficient	O
T	O
cells	O
cultured	O
for	O
6	O
d	O
showed	O
no	O
defect	O
in	O
perforin	B-Protein
mRNA	O
expression	O
(	O
Fig	O
.	O
2	O
B	O
,	O
compare	O
lanes	O
1	O
and	O
4	O
)	O
.	O

We	O
consistently	O
observed	O
a	O
modest	O
reduction	O
in	O
GzmB	B-Protein
mRNA	O
in	O
T	B-Protein
-	I-Protein
bet	I-Protein
-	O
deficient	O
T	O
cells	O
(	O
Fig	O
.	O
2	O
B	O
,	O
compare	O
lanes	O
1	O
and	O
4	O
)	O
,	O
which	O
did	O
not	O
translate	O
into	O
a	O
decrease	O
in	O
expression	O
of	O
granzyme	B-Protein
B	I-Protein
protein	O
(	O
Fig	O
.	O
2	O
C	O
)	O
.	O

To	O
examine	O
the	O
role	O
of	O
Eomes	B-Protein
,	O
we	O
transduced	O
naive	O
CD8	B-Protein
+	O
T	O
cells	O
from	O
WT	O
and	O
Tbx21	B-Protein
-	O
/	O
-	O
mice	O
with	O
retroviruses	O
containing	O
internal	O
ribosome	O
entry	O
site	O
(	O
IRES	O
)	O
-	O
GFP	B-Protein
that	O
were	O
either	O
empty	O
or	O
encoded	O
a	O
strongly	O
transactivating	O
version	O
of	O
Eomes	B-Protein
(	O
Eo	B-Protein
-	I-Protein
VP16	I-Protein
)	O
(	O
8	O
)	O
,	O
and	O
expanded	O
them	O
for	O
6	O
d	O
under	O
our	O
culture	O
conditions	O
.	O

Eo	B-Protein
-	I-Protein
VP16	I-Protein
,	O
but	O
not	O
the	O
empty	O
GFP	B-Protein
retrovirus	O
,	O
increased	O
perforin	B-Protein
expression	O
in	O
both	O
WT	O
and	O
T	B-Protein
-	I-Protein
bet	I-Protein
-	O
deficient	O
CD8	B-Protein
+	O
T	O
cells	O
(	O
Fig	O
.	O
2	O
B	O
,	O
lanes	O
2	O
,	O
3	O
,	O
5	O
,	O
and	O
6	O
)	O
.	O

As	O
expected	O
,	O
Eo	B-Protein
-	I-Protein
VP16	I-Protein
also	O
rescued	O
the	O
early	O
defect	O
in	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
observed	O
in	O
T	B-Protein
-	I-Protein
bet	I-Protein
-	O
deficient	O
CD8	B-Protein
+	O
T	O
cells	O
(	O
Fig	O
.	O
2	O
D	O
)	O
.	O

However	O
,	O
Eo	B-Protein
-	I-Protein
VP16	I-Protein
did	O
not	O
induce	O
GzmB	B-Protein
mRNA	O
expression	O
in	O
either	O
WT	O
or	O
T	B-Protein
-	I-Protein
bet	I-Protein
-	O
deficient	O
cells	O
;	O
thus	O
,	O
the	O
partial	O
T	B-Protein
-	I-Protein
bet	I-Protein
dependence	O
of	O
GzmB	B-Protein
mRNA	O
expression	O
cannot	O
be	O
compensated	O
for	O
by	O
Eo	B-Protein
-	I-Protein
VP16	I-Protein
.	O
<EOS>	B-X
Generalized	B-X
decidualization	B-X
also	B-X
includes	B-X
massive	B-X
infiltration	B-X
and	B-X
enrichment	B-X
of	B-X
NK	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
underlying	B-X
mechanism	B-X
of	B-X
decidual	B-X
NK	B-X
(	B-X
dNK	B-X
)	B-X
cell	B-X
residence	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
observe	B-X
that	B-X
the	B-X
increased	B-X
macroautophagy/autophagy	B-X
of	B-X
decidual	B-X
stromal	B-X
cells	B-X
(	B-X
DSCs	B-X
)	B-X
during	B-X
decidualization	B-X
,	B-X
facilitates	B-X
the	B-X
adhesion	B-X
and	B-X
retention	B-X
of	B-X
dNK	B-X
cells	B-X
during	B-X
normal	B-X
pregnancy	B-X
.	B-X
In	B-X
therapeutic	B-X
studies	B-X
,	B-X
low	B-X
doses	B-X
of	B-X
rapamycin	B-X
,	B-X
a	B-X
known	B-X
autophagy	B-X
inducer	B-X
that	B-X
significantly	B-X
promotes	B-X
endometrium	B-X
autophagy	B-X
and	B-X
NK	B-X
cell	B-X
residence	B-X
,	B-X
and	B-X
improves	B-X
embryo	B-X
absorption	B-X
in	B-X
spontaneous	B-X
abortion	B-X
mice	B-X
models	B-X
,	B-X
which	B-X
should	B-X
be	B-X
dependent	B-X
on	B-X
the	B-X
activation	B-X
of	B-X
MITF-TNFRSF14/HVEM-MMP9-adhension	B-X
molecules	B-X
axis	B-X
.	B-X

Runx3	B-Protein
controls	O
multiple	O
aspects	O
of	O
the	O
CTL	O
differentiation	O
program	O
,	O
in	O
part	O
through	O
induction	O
of	O
Eomes	B-Protein

Because	O
Runx3	B-Protein
is	O
highly	O
expressed	O
in	O
peripheral	O
CD8	B-Protein
+	O
T	O
cells	O
,	O
and	O
because	O
of	O
the	O
T	B-Protein
-	I-Protein
bet	I-Protein
-	O
Runx3	B-Protein
cooperation	O
we	O
observed	O
earlier	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
15	O
)	O
,	O
we	O
examined	O
the	O
role	O
of	O
Runx3	B-Protein
in	O
effector	O
CTL	O
differentiation	O
.	O

We	O
isolated	O
CD8	B-Protein
+	O
T	O
cells	O
from	O
Runx3	B-Protein
-	O
/	O
-	O
(	O
KO	O
)	O
mice	O
of	O
the	O
outbred	O
ICR	O
background	O
and	O
their	O
WT	O
Runx3	B-Protein
+	O
/	O
+	O
littermates	O
by	O
positive	O
selection	O
with	O
anti	O
-	O
CD8	B-Protein
magnetic	O
beads	O
(	O
Figs	O
.	O
S1	O
and	O
S2	O
,	O
available	O
at	O
http	O
:	O
/	O
/	O
www	O
.	O
jem	O
.	O
org	O
/	O
cgi	O
/	O
content	O
/	O
full	O
/	O
jem	O
.	O
20081242	O
/	O
DC1	O
)	O
.	O

Strikingly	O
,	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
T	O
cells	O
were	O
strongly	O
impaired	O
in	O
their	O
ability	O
to	O
differentiate	O
into	O
effector	O
CTLs	O
,	O
as	O
judged	O
by	O
expression	O
of	O
perforin	B-Protein
,	O
granzyme	B-Protein
B	I-Protein
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
(	O
Fig	O
.	O
3	O
)	O
.	O

Compared	O
with	O
WT	O
T	O
cells	O
,	O
perforin	B-Protein
mRNA	O
and	O
protein	O
expression	O
were	O
essentially	O
undetectable	O
in	O
Runx3	B-Protein
-	O
/	O
-	O
T	O
cells	O
at	O
day	O
6	O
of	O
culture	O
(	O
Fig	O
.	O
3	O
,	O
A	O
and	O
B	O
)	O
.	O

Runx3	B-Protein
-	O
/	O
-	O
T	O
cells	O
also	O
had	O
no	O
detectable	O
Eomes	B-Protein
expression	O
;	O
in	O
contrast	O
,	O
T	B-Protein
-	I-Protein
bet	I-Protein
expression	O
was	O
unimpaired	O
(	O
Fig	O
.	O
3	O
A	O
)	O
.	O
<EOS>	B-X
Eomesodermin	B-X
(	B-X
Eomes	B-X
)	B-X
,	B-X
a	B-X
T-box	B-X
transcription	B-X
factor	B-X
,	B-X
is	B-X
a	B-X
key	B-X
molecule	B-X
associated	B-X
with	B-X
function	B-X
and	B-X
differentiation	B-X
of	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
and	B-X
NK	B-X
cells	B-X
.	B-X
Previously	B-X
,	B-X
two	B-X
teleost	B-X
Eomes	B-X
genes	B-X
(	B-X
Eomes-a	B-X
and	B-X
-b	B-X
)	B-X
,	B-X
which	B-X
are	B-X
located	B-X
on	B-X
different	B-X
chromosomes	B-X
,	B-X
were	B-X
identified	B-X
and	B-X
shown	B-X
to	B-X
be	B-X
expressed	B-X
in	B-X
zebrafish	B-X
lymphocytes	B-X
.	B-X
Deduced	B-X
Eomes-a	B-X
and	B-X
-b	B-X
amino	B-X
acid	B-X
sequences	B-X
in	B-X
both	B-X
fish	B-X
species	B-X
contain	B-X
a	B-X
highly	B-X
conserved	B-X
T-box	B-X
DNA	B-X
binding	B-X
domain	B-X
.	B-X
In	B-X
RT-PCR	B-X
,	B-X
both	B-X
Eomes	B-X
transcripts	B-X
were	B-X
readily	B-X
detectable	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
tissues	B-X
in	B-X
rainbow	B-X
trout	B-X
and	B-X
ginbuna	B-X
.	B-X
The	B-X
high	B-X
expression	B-X
of	B-X
Eomes-a	B-X
and	B-X
-b	B-X
in	B-X
brain	B-X
and	B-X
ovary	B-X
suggests	B-X
involvement	B-X
in	B-X
neurogenesis	B-X
and	B-X
oogenesis	B-X
,	B-X
respectively	B-X
,	B-X
while	B-X
their	B-X
expression	B-X
in	B-X
lymphoid	B-X
tissues	B-X
presumably	B-X
is	B-X
associated	B-X
with	B-X
immune	B-X
functions	B-X
.	B-X
Investigation	B-X
of	B-X
separated	B-X
lymphocyte	B-X
populations	B-X
from	B-X
pronephros	B-X
indicated	B-X
that	B-X
both	B-X
Eomes-a	B-X
and	B-X
-b	B-X
transcripts	B-X
were	B-X
few	B-X
or	B-X
absent	B-X
in	B-X
IgM	B-X
(	B-X
+	B-X
)	B-X
lymphocytes	B-X
,	B-X
while	B-X
relatively	B-X
abundant	B-X
in	B-X
IgM	B-X
(	B-X
-	B-X
)	B-X
/CD8α	B-X
(	B-X
+	B-X
)	B-X
and	B-X
IgM	B-X
(	B-X
-	B-X
)	B-X
/CD8α	B-X
(	B-X
-	B-X
)	B-X
populations	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
sorted	B-X
trout	B-X
CD8α	B-X
(	B-X
+	B-X
)	B-X
lymphocytes	B-X
from	B-X
mucosal	B-X
and	B-X
non-mucosal	B-X
lymphoid	B-X
tissues	B-X
and	B-X
compared	B-X
the	B-X
expression	B-X
profiles	B-X
of	B-X
Eomes-a	B-X
and	B-X
-b	B-X
with	B-X
those	B-X
of	B-X
other	B-X
T	B-X
cell-related	B-X
transcription	B-X
factor	B-X
genes	B-X
(	B-X
GATA-3	B-X
,	B-X
T-bet	B-X
and	B-X
Runx3	B-X
)	B-X
,	B-X
a	B-X
Th1	B-X
cytokine	B-X
gene	B-X
(	B-X
IFN-γ	B-X
)	B-X
and	B-X
a	B-X
Th2	B-X
cytokine	B-X
gene	B-X
(	B-X
IL-4/13A	B-X
)	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
tissue	B-X
distribution	B-X
of	B-X
Eomes-a/b	B-X
,	B-X
T-bet	B-X
,	B-X
and	B-X
Runx3	B-X
versus	B-X
IFN-γ	B-X
transcripts	B-X
did	B-X
not	B-X
reveal	B-X
simple	B-X
correlations	B-X
,	B-X
suggesting	B-X
tissue-specific	B-X
properties	B-X
of	B-X
CD8α	B-X
(	B-X
+	B-X
)	B-X
lymphocytes	B-X
and/or	B-X
multiple	B-X
modes	B-X
that	B-X
drive	B-X
IFN-γ	B-X
expressions	B-X
.	B-X

Furthermore	O
,	O
Runx3	B-Protein
was	O
required	O
for	O
maximal	O
production	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
but	O
not	O
TNF	B-Protein
or	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
by	O
CD8	B-Protein
+	O
T	O
cells	O
restimulated	O
at	O
day	O
6	O
(	O
Fig	O
.	O
3	O
C	O
)	O
.	O

We	O
previously	O
reported	O
that	O
Th1	O
cell	O
differentiation	O
was	O
regulated	O
through	O
a	O
feed	O
-	O
forward	O
loop	O
in	O
which	O
T	B-Protein
-	I-Protein
bet	I-Protein
is	O
up	O
-	O
regulated	O
early	O
and	O
induces	O
Runx3	B-Protein
,	O
after	O
which	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Runx3	B-Protein
cooperate	O
to	O
induce	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
silence	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
thus	O
promoting	O
stable	O
differentiation	O
toward	O
the	O
Th1	O
lineage	O
(	O
15	O
,	O
22	O
)	O
.	O

Because	O
(	O
a	O
)	O
Runx3	B-Protein
appeared	O
necessary	O
for	O
Eomes	B-Protein
induction	O
(	O
Fig	O
.	O
3	O
A	O
)	O
,	O
(	O
b	O
)	O
the	O
kinetics	O
of	O
Eomes	B-Protein
expression	O
paralleled	O
those	O
of	O
perforin	B-Protein
expression	O
(	O
Fig	O
.	O
2	O
)	O
,	O
and	O
(	O
c	O
)	O
overexpression	O
of	O
Eo	B-Protein
-	I-Protein
VP16	I-Protein
in	O
either	O
WT	O
or	O
T	B-Protein
-	I-Protein
bet	I-Protein
-	O
deficient	O
T	O
cells	O
led	O
to	O
an	O
increase	O
in	O
both	O
perforin	B-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
(	O
Fig	O
.	O
2	O
,	O
B	O
and	O
D	O
)	O
,	O
we	O
asked	O
whether	O
CTL	O
differentiation	O
was	O
also	O
potentially	O
regulated	O
by	O
a	O
feed	O
-	O
forward	O
loop	O
involving	O
these	O
same	O
two	O
classes	O
of	O
Runx	O
and	O
T	O
-	O
box	O
transcription	O
factors	O
.	O

Specifically	O
,	O
we	O
asked	O
whether	O
Runx3	B-Protein
,	O
which	O
was	O
necessary	O
for	O
Eomes	B-Protein
induction	O
,	O
then	O
cooperated	O
with	O
Eomes	B-Protein
to	O
regulate	O
transcription	O
of	O
the	O
effector	O
CTL	O
markers	O
perforin	B-Protein
,	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
and	O
granzyme	B-Protein
B	I-Protein
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
used	O
chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assays	O
to	O
ask	O
whether	O
Eomes	B-Protein
and	O
Runx3	B-Protein
bound	O
regulatory	O
regions	O
of	O
the	O
Prf1	B-Protein
,	O
Ifng	B-Protein
,	O
and	O
Gzmb	B-Protein
genes	O
(	O
Fig	O
.	O
3	O
D	O
)	O
.	O

Both	O
proteins	O
associated	O
with	O
gene	O
regulatory	O
regions	O
in	O
differentiated	O
CTLs	O
.	O
<EOS>	B-X
Tax	B-X
,	B-X
which	B-X
is	B-X
the	B-X
most	B-X
important	B-X
regulatory	B-X
protein	B-X
of	B-X
HTLV-1	B-X
,	B-X
is	B-X
associated	B-X
with	B-X
aggressive	B-X
proliferation	B-X
of	B-X
host	B-X
cells	B-X
and	B-X
is	B-X
also	B-X
a	B-X
major	B-X
target	B-X
antigen	B-X
for	B-X
CD8⁺	B-X
cytotoxic	B-X
T-cells	B-X
(	B-X
CTLs	B-X
)	B-X
.	B-X
Recently	B-X
,	B-X
allogeneic	B-X
hematopoietic	B-X
stem	B-X
cell	B-X
transplantation	B-X
(	B-X
allo-HSCT	B-X
)	B-X
has	B-X
proven	B-X
effective	B-X
for	B-X
ATL	B-X
,	B-X
and	B-X
donor-derived	B-X
Tax-specific	B-X
CTL	B-X
might	B-X
contribute	B-X
to	B-X
graft-versus-ATL	B-X
effects	B-X
in	B-X
some	B-X
recipients	B-X
who	B-X
maintained	B-X
complete	B-X
remission	B-X
after	B-X
allo-HSCT	B-X
.	B-X
We	B-X
,	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
analyzed	B-X
the	B-X
Tax-specific	B-X
T-cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
repertoire	B-X
,	B-X
phenotypes	B-X
and	B-X
functions	B-X
of	B-X
Tax-specific	B-X
CTLs	B-X
at	B-X
single-cell	B-X
levels	B-X
in	B-X
HLA-A24⁺	B-X
ATL	B-X
patients	B-X
who	B-X
underwent	B-X
allo-HSCT	B-X
.	B-X
We	B-X
found	B-X
that	B-X
1	B-X
)	B-X
a	B-X
particular	B-X
amino	B-X
acid	B-X
sequence	B-X
motif	B-X
(	B-X
PDR	B-X
)	B-X
in	B-X
the	B-X
CDR3	B-X
region	B-X
of	B-X
TCR-β	B-X
was	B-X
conserved	B-X
in	B-X
different	B-X
patients	B-X
and	B-X
also	B-X
within	B-X
the	B-X
same	B-X
patient	B-X
before	B-X
and	B-X
after	B-X
allo-HSCT	B-X
,	B-X
and	B-X
2	B-X
)	B-X
the	B-X
PDR⁺	B-X
Tax-specific	B-X
CTL	B-X
clone	B-X
selectively	B-X
expanded	B-X
in	B-X
ATL	B-X
long-term	B-X
survivors	B-X
as	B-X
less-differentiated	B-X
effector	B-X
memory	B-X
CTLs	B-X
.	B-X

Runx3	B-Protein
bound	O
to	O
the	O
Prf1	B-Protein
and	O
Gzmb	B-Protein
transcription	O
start	O
sites	O
(	O
TSS	O
)	O
;	O
to	O
a	O
known	O
IL	O
-	O
2	O
responsive	O
enhancer	O
located	O
near	O
-	O
1	O
kb	O
of	O
the	O
Prf1	B-Protein
gene	O
(	O
23	O
)	O
;	O
to	O
the	O
distal	O
CTL	O
-	O
specific	O
DNase	O
I	O
hypersensitive	O
site	O
9	O
in	O
the	O
Prf1	B-Protein
locus	O
(	O
24	O
)	O
;	O
to	O
the	O
Ifng	B-Protein
promoter	O
near	O
the	O
TSS	O
,	O
as	O
previously	O
reported	O
for	O
Th1	O
cells	O
(	O
10	O
)	O
;	O
and	O
to	O
several	O
DNase	O
I	O
hypersensitive	O
sites	O
in	O
the	O
Ifng	B-Protein
locus	O
(	O
Fig	O
.	O
3	O
D	O
and	O
not	O
depicted	O
)	O
(	O
25	O
)	O
.	O

Eomes	B-Protein
bound	O
primarily	O
to	O
the	O
Prf1	B-Protein
TSS	O
and	O
the	O
-	O
1	O
kb	O
enhancer	O
;	O
this	O
binding	O
was	O
substantially	O
greater	O
than	O
that	O
observed	O
at	O
the	O
promoter	O
of	O
the	O
Il2rb	B-Protein
gene	O
,	O
a	O
known	O
direct	O
target	O
of	O
Eomes	B-Protein
(	O
8	O
)	O
,	O
and	O
comparable	O
to	O
that	O
observed	O
at	O
the	O
Ifng	B-Protein
TSS	O
,	O
a	O
known	O
target	O
of	O
T	O
-	O
box	O
proteins	O
in	O
both	O
Th1	O
and	O
CD8	B-Protein
+	O
T	O
cells	O
(	O
Fig	O
.	O
3	O
D	O
)	O
(	O
17	O
)	O
.	O

To	O
determine	O
whether	O
Runx3	B-Protein
controlled	O
the	O
expression	O
of	O
CTL	O
effector	O
genes	O
through	O
its	O
induction	O
of	O
Eomes	B-Protein
,	O
we	O
retrovirally	O
expressed	O
Runx3	B-Protein
and	O
Eo	B-Protein
-	I-Protein
VP16	I-Protein
in	O
CD8	B-Protein
+	O
T	O
cells	O
from	O
Runx3	B-Protein
-	O
/	O
-	O
mice	O
.	O

Because	O
of	O
the	O
limited	O
number	O
of	O
CD8	B-Protein
+	O
T	O
cells	O
in	O
these	O
mice	O
,	O
and	O
because	O
we	O
saw	O
no	O
difference	O
between	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
CD4	B-Protein
-	O
SP	O
and	O
CD8	B-Protein
+	O
CD4	B-Protein
+	O
DP	O
cells	O
in	O
our	O
previous	O
experiments	O
,	O
we	O
used	O
total	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
T	O
cells	O
without	O
further	O
fractionation	O
as	O
recipients	O
for	O
retroviral	O
transduction	O
.	O

Reconstitution	O
of	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
T	O
cells	O
with	O
Runx3	B-Protein
restored	O
expression	O
of	O
Eomes	B-Protein
as	O
well	O
as	O
perforin	B-Protein
,	O
granzyme	B-Protein
B	I-Protein
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
(	O
Fig	O
.	O
4	O
,	O
A	O
and	O
B	O
)	O
.	O

In	O
addition	O
,	O
Runx3	B-Protein
-	O
/	O
-	O
T	O
cells	O
showed	O
a	O
compensatory	O
up	O
-	O
regulation	O
of	O
Runx1	B-Protein
,	O
which	O
was	O
suppressed	O
upon	O
reconstitution	O
with	O
Runx3	B-Protein
,	O
indicating	O
that	O
Runx1	B-Protein
is	O
a	O
target	O
of	O
repression	O
by	O
Runx3	B-Protein
.	O

Notably	O
,	O
Eo	B-Protein
-	I-Protein
VP16	I-Protein
did	O
not	O
up	O
-	O
regulate	O
perforin	B-Protein
expression	O
when	O
expressed	O
in	O
Runx3	B-Protein
-	O
/	O
-	O
cells	O
,	O
even	O
though	O
it	O
restored	O
the	O
capacity	O
to	O
induce	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
upon	O
TCR	O
restimulation	O
(	O
Fig	O
.	O
4	O
,	O
A	O
and	O
B	O
)	O
.	O

This	O
result	O
suggests	O
strongly	O
that	O
perforin	B-Protein
expression	O
requires	O
Runx3	B-Protein
and	O
Eomes	B-Protein
.	O

As	O
expected	O
from	O
their	O
defect	O
in	O
perforin	B-Protein
and	O
granzyme	B-Protein
B	I-Protein
expression	O
,	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
T	O
cells	O
showed	O
defective	O
cytolytic	O
activity	O
in	O
a	O
mixed	O
lymphocyte	O
reaction	O
(	O
12	O
)	O
.	O

However	O
,	O
TCR	O
-	O
stimulated	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
cells	O
were	O
as	O
effective	O
as	O
WT	O
cells	O
in	O
killing	O
tumor	O
cells	O
in	O
a	O
redirected	O
CTL	O
assay	O
(	O
12	O
)	O
.	O

Furthermore	O
,	O
CD8	B-Protein
+	O
cells	O
from	O
the	O
peritoneal	O
cavity	O
of	O
Runx3	B-Protein
-	O
/	O
-	O
mice	O
immunized	O
with	O
certain	O
tumor	O
cells	O
effectively	O
killed	O
these	O
targets	O
(	O
13	O
)	O
.	O

Therefore	O
,	O
although	O
activation	O
of	O
the	O
perforin	B-Protein
/	O
granzyme	B-Protein
B	I-Protein
machinery	O
is	O
defective	O
in	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
cells	O
,	O
these	O
cells	O
are	O
not	O
entirely	O
devoid	O
of	O
cytolytic	O
activity	O
and	O
could	O
still	O
effectively	O
kill	O
targets	O
,	O
possibly	O
by	O
alternative	O
mechanisms	O
such	O
as	O
the	O
Fas	B-Protein
-	O
Fas	B-Protein
ligand	I-Protein
pathway	O
.	O

Runx3	B-Protein
and	O
T	O
-	O
box	O
factors	O
control	O
a	O
complex	O
program	O
of	O
transcriptional	O
regulation	O
during	O
CTL	O
differentiation	O

Collectively	O
,	O
these	O
data	O
provide	O
evidence	O
that	O
Runx3	B-Protein
,	O
together	O
with	O
T	O
-	O
box	O
factors	O
,	O
orchestrates	O
a	O
complex	O
program	O
of	O
transcriptional	O
regulation	O
in	O
differentiating	O
CTL	O
(	O
Fig	O
.	O
4	O
C	O
)	O
.	O

Runx3	B-Protein
is	O
present	O
in	O
naive	O
CD8	B-Protein
+	O
T	O
cells	O
before	O
activation	O
(	O
12	O
)	O
.	O

It	O
represses	O
Runx1	B-Protein
and	O
has	O
a	O
positive	O
role	O
in	O
the	O
induction	O
of	O
Eomes	B-Protein
,	O
granzyme	B-Protein
B	I-Protein
,	O
perforin	B-Protein
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
.	O

Runx3	B-Protein
binds	O
to	O
promoters	O
and	O
putative	O
regulatory	O
regions	O
of	O
the	O
latter	O
three	O
genes	O
,	O
suggesting	O
a	O
direct	O
effect	O
on	O
gene	O
expression	O
.	O

Additional	O
experiments	O
are	O
needed	O
to	O
determine	O
whether	O
Eomes	B-Protein
and	O
Runx1	B-Protein
are	O
also	O
direct	O
target	O
genes	O
of	O
Runx3	B-Protein
.	O

Surprisingly	O
,	O
Runx3	B-Protein
contributed	O
to	O
the	O
optimal	O
expression	O
of	O
TNF	B-Protein
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
at	O
day	O
4	O
(	O
Fig	O
.	O
S2	O
)	O
.	O

For	O
TNF	B-Protein
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
the	O
requirement	O
for	O
Runx3	B-Protein
subsides	O
by	O
day	O
6	O
(	O
Fig	O
.	O
3	O
C	O
)	O
,	O
possibly	O
because	O
of	O
compensation	O
by	O
Runx1	B-Protein
,	O
which	O
is	O
derepressed	O
in	O
Runx3	B-Protein
-	O
/	O
-	O
cells	O
(	O
Fig	O
.	O
4	O
A	O
)	O
.	O

Runx3	B-Protein
continues	O
to	O
be	O
required	O
for	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
even	O
at	O
day	O
6	O
,	O
perhaps	O
because	O
of	O
its	O
role	O
in	O
the	O
induction	O
of	O
Eomes	B-Protein
expression	O
(	O
Fig	O
.	O
4	O
A	O
)	O
.	O

An	O
unexpected	O
finding	O
was	O
that	O
the	O
two	O
T	O
-	O
box	O
transcription	O
factors	O
,	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
,	O
are	O
up	O
-	O
regulated	O
with	O
very	O
different	O
kinetics	O
in	O
CD8	B-Protein
+	O
T	O
cells	O
under	O
our	O
culture	O
conditions	O
and	O
have	O
nonredundant	O
roles	O
in	O
the	O
subsequent	O
expression	O
of	O
key	O
effector	O
proteins	O
(	O
Fig	O
.	O
4	O
C	O
)	O
.	O

T	B-Protein
-	I-Protein
bet	I-Protein
is	O
needed	O
early	O
to	O
confer	O
on	O
activated	O
CD8	B-Protein
+	O
T	O
cells	O
the	O
competence	O
to	O
produce	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
upon	O
restimulation	O
,	O
but	O
its	O
function	O
is	O
less	O
important	O
at	O
later	O
times	O
.	O

Eomes	B-Protein
,	O
which	O
is	O
induced	O
late	O
and	O
functions	O
downstream	O
of	O
Runx3	B-Protein
,	O
may	O
substitute	O
for	O
T	B-Protein
-	I-Protein
bet	I-Protein
in	O
promoting	O
the	O
acute	O
expression	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
in	O
restimulated	O
CTLs	O
(	O
8	O
)	O
.	O

Indeed	O
,	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
both	O
contribute	O
to	O
perforin	B-Protein
expression	O
in	O
NK	O
cells	O
(	O
8	O
,	O
26	O
)	O
,	O
and	O
Eomes	B-Protein
induces	O
granzyme	B-Protein
B	I-Protein
as	O
effectively	O
as	O
T	B-Protein
-	I-Protein
bet	I-Protein
in	O
developing	O
Th2	O
cells	O
(	O
7	O
)	O
;	O
thus	O
,	O
the	O
relative	O
roles	O
of	O
these	O
T	O
-	O
box	O
transcription	O
factors	O
vary	O
depending	O
on	O
cell	O
type	O
.	O

Surprisingly	O
,	O
however	O
,	O
Eomes	B-Protein
and	O
T	B-Protein
-	I-Protein
bet	I-Protein
appeared	O
nonredundant	O
in	O
their	O
ability	O
to	O
induce	O
two	O
other	O
markers	O
of	O
CTL	O
function	O
,	O
Prf1	B-Protein
and	O
Gzmb	B-Protein
(	O
Fig	O
.	O
4	O
C	O
)	O
.	O

Rather	O
,	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
were	O
involved	O
in	O
regulating	O
granzyme	B-Protein
B	I-Protein
and	O
perforin	B-Protein
expression	O
,	O
respectively	O
:	O
up	O
-	O
regulation	O
of	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
mRNA	O
and	O
protein	O
closely	O
preceded	O
up	O
-	O
regulation	O
of	O
Gzmb	B-Protein
and	O
Prf1	B-Protein
mRNA	O
and	O
protein	O
,	O
respectively	O
.	O

T	B-Protein
-	I-Protein
bet	I-Protein
had	O
no	O
role	O
in	O
perforin	B-Protein
expression	O
under	O
our	O
culture	O
conditions	O
,	O
and	O
Eo	B-Protein
-	I-Protein
VP16	I-Protein
did	O
not	O
affect	O
granzyme	B-Protein
B	I-Protein
expression	O
when	O
expressed	O
in	O
T	B-Protein
-	I-Protein
bet	I-Protein
-	O
/	O
-	O
or	O
Runx3	B-Protein
-	O
/	O
-	O
cells	O
.	O
<EOS>	B-X
T	B-X
cells	B-X
are	B-X
key	B-X
elements	B-X
of	B-X
cancer	B-X
immunotherapy	B-X
Ihh	B-X
,	B-X
expressed	B-X
in	B-X
prehypertrophic	B-X
and	B-X
hypertrophic	B-X
chondrocytes	B-X
,	B-X
is	B-X
required	B-X
for	B-X
the	B-X
specification	B-X
of	B-X
Runx2	B-X
Nevertheless	B-X
,	B-X
mature	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
/CD8	B-X
(	B-X
+	B-X
)	B-X
DP	B-X
T	B-X
cells	B-X
have	B-X
been	B-X
described	B-X
in	B-X
the	B-X
blood	B-X
and	B-X
peripheral	B-X
lymphoid	B-X
tissues	B-X
of	B-X
numerous	B-X
species	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
numerous	B-X
disease	B-X
settings	B-X
,	B-X
including	B-X
cancer	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
CD4	B-X
and	B-X
CD8	B-X
is	B-X
regulated	B-X
by	B-X
a	B-X
very	B-X
strict	B-X
transcriptional	B-X
program	B-X
involving	B-X
the	B-X
transcription	B-X
factors	B-X
Runx3	B-X
and	B-X
ThPOK	B-X
.	B-X
Initially	B-X
thought	B-X
to	B-X
be	B-X
mutually	B-X
exclusive	B-X
within	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
and	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
,	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
/CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cell	B-X
populations	B-X
,	B-X
outside	B-X
of	B-X
the	B-X
thymus	B-X
,	B-X
have	B-X
recently	B-X
been	B-X
described	B-X
to	B-X
express	B-X
concurrently	B-X
ThPOK	B-X
and	B-X
Runx3	B-X
.	B-X
Considerable	B-X
heterogeneity	B-X
exists	B-X
within	B-X
the	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
/CD8	B-X
(	B-X
+	B-X
)	B-X
DP	B-X
T	B-X
cell	B-X
pool	B-X
,	B-X
and	B-X
the	B-X
function	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
/CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cell	B-X
populations	B-X
remains	B-X
controversial	B-X
,	B-X
with	B-X
conflicting	B-X
reports	B-X
describing	B-X
cytotoxic	B-X
or	B-X
suppressive	B-X
roles	B-X
for	B-X
these	B-X
cells	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
describe	B-X
how	B-X
transcriptional	B-X
regulation	B-X
,	B-X
lineage	B-X
of	B-X
origin	B-X
,	B-X
heterogeneity	B-X
of	B-X
CD4	B-X
and	B-X
CD8	B-X
expression	B-X
,	B-X
age	B-X
,	B-X
species	B-X
,	B-X
and	B-X
specific	B-X
disease	B-X
settings	B-X
influence	B-X
the	B-X
functionality	B-X
of	B-X
this	B-X
rarely	B-X
studied	B-X
T	B-X
cell	B-X
population	B-X
.	B-X

Because	O
conventional	O
Eomes	B-Protein
-	O
deficient	O
mice	O
die	O
before	O
precursor	O
cells	O
can	O
be	O
isolated	O
for	O
bone	O
marrow	O
transfers	O
(	O
27	O
)	O
and	O
because	O
T	O
cells	O
conditionally	O
deficient	O
in	O
Eomes	B-Protein
have	O
only	O
recently	O
been	O
described	O
(	O
9	O
)	O
,	O
we	O
were	O
unable	O
to	O
introduce	O
Runx3	B-Protein
into	O
Eomes	B-Protein
-	O
deficient	O
CD8	B-Protein
+	O
T	O
cells	O
to	O
test	O
formally	O
whether	O
Eomes	B-Protein
cooperated	O
with	O
Runx3	B-Protein
to	O
induce	O
perforin	B-Protein
expression	O
.	O

Collectively	O
,	O
our	O
data	O
are	O
consistent	O
with	O
a	O
transcriptional	O
network	O
in	O
which	O
preexisting	O
Runx3	B-Protein
cooperates	O
with	O
the	O
induced	O
T	O
-	O
box	O
factors	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
and	O
IL	B-Protein
-	I-Protein
2Rbeta	I-Protein
signals	O
(	O
unpublished	O
data	O
)	O
to	O
orchestrate	O
CTL	O
differentiation	O
(	O
Fig	O
.	O
4	O
C	O
)	O
.	O

Our	O
data	O
recall	O
the	O
"	O
feed	O
-	O
forward	O
"	O
interaction	O
between	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Runx3	B-Protein
that	O
we	O
previously	O
described	O
in	O
CD4	B-Protein
+	O
(	O
Th1	O
)	O
T	O
cells	O
(	O
15	O
)	O
but	O
are	O
distinct	O
in	O
two	O
respects	O
:	O
in	O
differentiating	O
Th1	O
cells	O
,	O
T	B-Protein
-	I-Protein
bet	I-Protein
is	O
induced	O
by	O
TCR	O
signals	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
and	O
in	O
turn	O
induces	O
Runx3	B-Protein
(	O
15	O
)	O
,	O
whereas	O
in	O
differentiating	O
CD8	B-Protein
+	O
T	O
cells	O
,	O
preexisting	O
Runx3	B-Protein
is	O
required	O
to	O
induce	O
the	O
T	O
-	O
box	O
transcription	O
factor	O
Eomes	B-Protein
.	O

Whole	O
-	O
genome	O
experiments	O
in	O
these	O
and	O
other	O
systems	O
will	O
be	O
required	O
to	O
establish	O
whether	O
cooperation	O
between	O
T	O
-	O
box	O
and	O
Runx	O
family	O
transcription	O
factors	O
is	O
a	O
general	O
feature	O
of	O
cellular	O
differentiation	O
programs	O
.	O

Antibodies	O
and	O
reagents	O
.	O
<EOS>	B-X
Antibodies	B-X
are	B-X
host	B-X
proteins	B-X
that	B-X
comprise	B-X
one	B-X
of	B-X
the	B-X
principal	B-X
effectors	B-X
of	B-X
the	B-X
adaptive	B-X
immune	B-X
system	B-X
.	B-X
Antibodies	B-X
are	B-X
utilized	B-X
for	B-X
analysis	B-X
,	B-X
purification	B-X
,	B-X
and	B-X
enrichment	B-X
,	B-X
and	B-X
to	B-X
mediate	B-X
or	B-X
modulate	B-X
physiological	B-X
responses	B-X
.	B-X
A	B-X
limited	B-X
review	B-X
of	B-X
their	B-X
use	B-X
as	B-X
specific	B-X
research	B-X
,	B-X
diagnostic	B-X
,	B-X
and	B-X
therapeutic	B-X
reagents	B-X
and	B-X
a	B-X
list	B-X
of	B-X
printed	B-X
and	B-X
electronic	B-X
resources	B-X
that	B-X
can	B-X
be	B-X
utilized	B-X
to	B-X
garner	B-X
additional	B-X
information	B-X
on	B-X
these	B-X
topics	B-X
are	B-X
also	B-X
included	B-X
.	B-X
Antibody	B-X
reagents	B-X
that	B-X
are	B-X
used	B-X
for	B-X
flow	B-X
cytometry	B-X
immunophenotyping	B-X
have	B-X
traditionally	B-X
been	B-X
prepared	B-X
by	B-X
combining	B-X
individual	B-X
liquid	B-X
antibody	B-X
conjugates	B-X
into	B-X
mixtures	B-X
.	B-X
Manufacturers	B-X
of	B-X
these	B-X
reagents	B-X
,	B-X
in	B-X
collaboration	B-X
with	B-X
several	B-X
clinical	B-X
and	B-X
research	B-X
centers	B-X
,	B-X
have	B-X
made	B-X
advances	B-X
in	B-X
constructing	B-X
dried	B-X
antibody	B-X
cocktails	B-X
which	B-X
have	B-X
addressed	B-X
many	B-X
of	B-X
the	B-X
problems	B-X
inherent	B-X
in	B-X
preparing	B-X
the	B-X
liquid	B-X
cocktails	B-X
on	B-X
the	B-X
lab	B-X
bench	B-X
.	B-X
This	B-X
chapter	B-X
discusses	B-X
methods	B-X
for	B-X
the	B-X
use	B-X
of	B-X
dried	B-X
reagents	B-X
.	B-X

The	O
following	O
antibodies	O
used	O
for	O
intracellular	O
or	O
surface	O
stains	O
were	O
obtained	O
from	O
eBioscience	O
:	O
anti	O
-	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
anti	O
-	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
anti	O
-	O
TNF	B-Protein
,	O
anti	O
-	O
granzyme	B-Protein
B	I-Protein
,	O
anti	O
-	O
CD8	B-Protein
,	O
anti	O
-	O
CD25	B-Protein
,	O
and	O
anti	O
-	O
CD44	B-Protein
.	O
<EOS>	B-X
Antineutrophil	B-X
cytoplasm	B-X
antibody	B-X
(	B-X
ANCA	B-X
)	B-X
-associated	B-X
vasculitis	B-X
(	B-X
AAV	B-X
)	B-X
is	B-X
a	B-X
rare	B-X
systemic	B-X
autoimmune	B-X
disease	B-X
that	B-X
is	B-X
characterized	B-X
by	B-X
necrotizing	B-X
inflammation	B-X
of	B-X
predominantly	B-X
the	B-X
small	B-X
blood	B-X
vessels	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
circulating	B-X
ANCAs	B-X
directed	B-X
against	B-X
myeloperoxidase	B-X
or	B-X
proteinase	B-X
3	B-X
.	B-X
Recent	B-X
advances	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
pathogenesis	B-X
of	B-X
AAV	B-X
have	B-X
led	B-X
to	B-X
the	B-X
identification	B-X
of	B-X
novel	B-X
therapeutic	B-X
targets	B-X
that	B-X
may	B-X
address	B-X
these	B-X
problems	B-X
,	B-X
including	B-X
strategies	B-X
directed	B-X
at	B-X
the	B-X
aberrant	B-X
adaptive	B-X
autoimmune	B-X
response	B-X
(	B-X
B	B-X
and	B-X
T	B-X
cell-directed	B-X
treatments	B-X
)	B-X
and	B-X
those	B-X
targeting	B-X
innate	B-X
immune	B-X
elements	B-X
(	B-X
complement	B-X
,	B-X
monocytes	B-X
,	B-X
and	B-X
neutrophils	B-X
)	B-X
.	B-X
It	B-X
is	B-X
anticipated	B-X
that	B-X
these	B-X
novel	B-X
treatments	B-X
,	B-X
used	B-X
alone	B-X
or	B-X
in	B-X
combination	B-X
,	B-X
will	B-X
lead	B-X
to	B-X
more	B-X
effective	B-X
and	B-X
less	B-X
toxic	B-X
treatment	B-X
regimens	B-X
for	B-X
patients	B-X
with	B-X
AAV	B-X
.	B-X
However	B-X
,	B-X
the	B-X
robustness	B-X
and	B-X
functionality	B-X
of	B-X
the	B-X
humoral	B-X
and	B-X
T-cell	B-X
response	B-X
to	B-X
SARS-CoV-2	B-X
remains	B-X
unknown	B-X
12	B-X
months	B-X
after	B-X
initial	B-X
infection	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
investigate	B-X
the	B-X
durability	B-X
and	B-X
functionality	B-X
of	B-X
the	B-X
humoral	B-X
and	B-X
T-cell	B-X
response	B-X
to	B-X
the	B-X
original	B-X
SARS-CoV-2	B-X
strain	B-X
and	B-X
variants	B-X
in	B-X
recovered	B-X
patients	B-X
12	B-X
months	B-X
after	B-X
infection	B-X
.	B-X

Anti	O
-	O
CD69	B-Protein
was	O
purchased	O
from	O
BD	O
.	O

For	O
ChIP	O
experiments	O
,	O
the	O
anti	O
-	O
Eomes	B-Protein
antibody	O
was	O
obtained	O
from	O
Abcam	O
and	O
the	O
anti	O
-	O
Runx3	B-Protein
antibody	O
was	O
produced	O
by	O
the	O
Groner	O
laboratory	O
.	O

The	O
following	O
antibodies	O
were	O
used	O
for	O
immunoblotting	O
:	O
antiperforin	B-Protein
(	O
Abcam	O
)	O
,	O
anti	O
-	O
Eomes	B-Protein
(	O
Abcam	O
)	O
,	O
and	O
anti	O
-	O
Pol	O
-	O
II	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
)	O
.	O

The	O
T	B-Protein
-	I-Protein
bet	I-Protein
antibody	O
was	O
provided	O
by	O
L	O
.	O

Glimcher	O
(	O
Harvard	O
School	O
of	O
Public	O
Health	O
,	O
Boston	O
,	O
MA	O
)	O
.	O

The	O
following	O
reagents	O
were	O
used	O
for	O
the	O
experiments	O
presented	O
in	O
this	O
report	O
:	O
Annexin	B-Protein
V	I-Protein
-	O
FITC	O
Apoptosis	O
Detection	O
Kit	O
(	O
BD	O
)	O
,	O
CD8	B-Protein
Negative	O
Isolation	O
Kit	O
(	O
Invitrogen	O
)	O
,	O
CD8	B-Protein
MicroBeads	O
(	O
Miltenyi	O
Biotec	O
)	O
,	O
and	O
SYBR	O
Green	O
PCR	O
Core	O
Reagents	O
(	O
Applied	O
Biosystems	O
)	O
.	O

The	O
Gp33	O
peptide	O
(	O
KAVYNFATC	O
)	O
was	O
synthesized	O
by	O
the	O
Tufts	O
University	O
Core	O
Facility	O
,	O
and	O
10	O
mM	O
of	O
stock	O
solutions	O
was	O
prepared	O
in	O
DMSO	O
.	O

Isolation	O
and	O
culture	O
of	O
primary	O
CD8	O
+	O
T	O
cells	O
.	O
<EOS>	B-X
Tumor	B-X
cells	B-X
can	B-X
be	B-X
recognized	B-X
and	B-X
killed	B-X
by	B-X
cytotoxic	B-X
lymphocytes-	B-X
such	B-X
as	B-X
CD8+	B-X
T	B-X
lymphocytes	B-X
and	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells-mainly	B-X
through	B-X
the	B-X
immune	B-X
secretion	B-X
of	B-X
lytic	B-X
granules	B-X
that	B-X
kill	B-X
target	B-X
cells	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
,	B-X
we	B-X
detail	B-X
the	B-X
steps	B-X
required	B-X
to	B-X
isolate	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
,	B-X
coculture	B-X
them	B-X
with	B-X
target	B-X
tumor	B-X
cell	B-X
lines	B-X
,	B-X
and	B-X
evaluate	B-X
the	B-X
cytotoxic	B-X
immune	B-X
function	B-X
by	B-X
means	B-X
of	B-X
flow	B-X
cytometry	B-X
evaluation	B-X
of	B-X
CD107a	B-X
expression	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
NK	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
interactions	B-X
between	B-X
CAFs	B-X
and	B-X
tumor	B-X
cells	B-X
and	B-X
immune	B-X
cells	B-X
in	B-X
triple-negative	B-X
breast	B-X
cancer	B-X
(	B-X
TNBC	B-X
)	B-X
are	B-X
still	B-X
poorly	B-X
explored	B-X
.	B-X
The	B-X
RNA	B-X
and	B-X
culture	B-X
medium	B-X
of	B-X
fibroblasts	B-X
were	B-X
subjected	B-X
to	B-X
RNA	B-X
sequencing	B-X
and	B-X
mass	B-X
spectrometry	B-X
to	B-X
explore	B-X
the	B-X
upregulated	B-X
signatures	B-X
in	B-X
CAFs	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
biglycan	B-X
was	B-X
negatively	B-X
correlated	B-X
with	B-X
CD8	B-X
+	B-X
T	B-X
cells	B-X
.	B-X

CD8	B-Protein
+	O
T	O
cells	O
from	O
4	O
-	O
8	O
-	O
wk	O
-	O
old	O
Tcra	B-Protein
-	O
/	O
-	O
x	O
P14	O
TCR	O
transgenic	O
(	O
Taconic	O
)	O
,	O
C57BL	O
/	O
6J	O
WT	O
,	O
or	O
Tbx21	B-Protein
-	O
/	O
-	O
(	O
The	O
Jackson	O
Laboratory	O
)	O
mice	O
were	O
purified	O
(	O
>	O
95	O
%	O
purity	O
)	O
by	O
negative	O
selection	O
(	O
Invitrogen	O
)	O
from	O
pooled	O
spleen	O
and	O
lymph	O
node	O
cells	O
.	O

CD8	B-Protein
+	O
T	O
cells	O
from	O
Runx3	B-Protein
-	O
/	O
-	O
mice	O
on	O
the	O
ICR	O
background	O
were	O
purified	O
by	O
positive	O
selection	O
(	O
Miltenyi	O
Biotec	O
)	O
.	O

All	O
mice	O
were	O
maintained	O
in	O
specific	O
pathogen	O
-	O
free	O
barrier	O
facilities	O
and	O
used	O
according	O
to	O
protocols	O
approved	O
by	O
the	O
Immune	O
Disease	O
Institute	O
and	O
the	O
Harvard	O
Medical	O
School	O
Animal	O
Care	O
and	O
Use	O
Committees	O
.	O

For	O
stimulation	O
,	O
purified	O
CD8	B-Protein
+	O
T	O
cells	O
were	O
cultured	O
at	O
106	O
cells	O
/	O
ml	O
(	O
10	O
ml	O
)	O
in	O
T25	O
flasks	O
coated	O
with	O
1	O
mug	O
/	O
ml	O
each	O
of	O
anti	O
-	O
CD3	B-Protein
(	O
clone	O
2C11	O
)	O
and	O
anti	O
-	O
CD28	B-Protein
(	O
clone	O
37	O
.	O
51	O
)	O
by	O
pretreatment	O
with	O
300	O
mug	O
/	O
ml	O
goat	O
anti	O
-	O
hamster	O
IgG	O
.	O

After	O
48	O
h	O
,	O
cells	O
were	O
removed	O
from	O
the	O
TCR	O
stimulation	O
and	O
recultured	O
at	O
a	O
concentration	O
of	O
5	O
x	O
105	O
cells	O
/	O
ml	O
in	O
media	O
supplemented	O
with	O
100	O
U	O
/	O
ml	O
rhIL	O
-	O
2	O
.	O

Every	O
24	O
h	O
,	O
viable	O
cells	O
were	O
counted	O
and	O
readjusted	O
to	O
5	O
x	O
105	O
cells	O
/	O
ml	O
with	O
fresh	O
media	O
containing	O
the	O
corresponding	O
amount	O
of	O
rhIL	B-Protein
-	I-Protein
2	I-Protein
.	O

Isolation	O
of	O
CD8	O
+	O
T	O
cells	O
from	O
Runx3	B-Protein
-	O
/	O
-	O
mice	O
.	O
<EOS>	B-X
Runx	B-X
proteins	B-X
are	B-X
essential	B-X
for	B-X
hematopoiesis	B-X
and	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
T	B-X
cell	B-X
development	B-X
by	B-X
regulating	B-X
key	B-X
target	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
CD4	B-X
and	B-X
CD8	B-X
as	B-X
well	B-X
as	B-X
lymphokine	B-X
genes	B-X
,	B-X
during	B-X
the	B-X
specialization	B-X
of	B-X
naive	B-X
CD4	B-X
T	B-X
cells	B-X
into	B-X
distinct	B-X
T	B-X
helper	B-X
subsets	B-X
.	B-X
In	B-X
regulatory	B-X
T	B-X
(	B-X
T	B-X
reg	B-X
)	B-X
cells	B-X
,	B-X
the	B-X
signature	B-X
transcription	B-X
factor	B-X
Foxp3	B-X
interacts	B-X
with	B-X
and	B-X
modulates	B-X
the	B-X
function	B-X
of	B-X
several	B-X
other	B-X
DNA	B-X
binding	B-X
proteins	B-X
,	B-X
including	B-X
Runx	B-X
family	B-X
members	B-X
,	B-X
at	B-X
the	B-X
protein	B-X
level	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Runx	B-X
proteins	B-X
also	B-X
regulate	B-X
the	B-X
initiation	B-X
and	B-X
the	B-X
maintenance	B-X
of	B-X
Foxp3	B-X
gene	B-X
expression	B-X
in	B-X
CD4	B-X
T	B-X
cells	B-X
.	B-X
Foxp3	B-X
expression	B-X
in	B-X
natural	B-X
T	B-X
reg	B-X
cells	B-X
remained	B-X
dependent	B-X
on	B-X
Runx	B-X
proteins	B-X
and	B-X
correlated	B-X
with	B-X
the	B-X
binding	B-X
of	B-X
Runx/core-binding	B-X
factor	B-X
beta	B-X
to	B-X
regulatory	B-X
elements	B-X
within	B-X
the	B-X
Foxp3	B-X
locus	B-X
.	B-X

Runx3	B-Protein
-	O
deficient	O
T	O
cells	O
fail	O
to	O
silence	O
CD4	B-Protein
expression	O
normally	O
(	O
Fig	O
.	O
S1	O
)	O
(	O
12	O
,	O
13	O
)	O
.	O

We	O
therefore	O
further	O
fractionated	O
the	O
positively	O
selected	O
CD8	B-Protein
+	O
T	O
cells	O
from	O
Runx3	B-Protein
KO	O
mice	O
into	O
CD8	B-Protein
+	O
CD4	B-Protein
-	O
SP	O
or	O
CD8	B-Protein
+	O
CD4	B-Protein
+	O
DP	O
cells	O
by	O
separation	O
using	O
anti	O
-	O
CD4	B-Protein
magnetic	O
beads	O
.	O

This	O
yielded	O
a	O
Runx3	B-Protein
KO	O
SP	O
"	O
enriched	O
"	O
population	O
that	O
contained	O
75	O
%	O
CD8	B-Protein
+	O
CD4	B-Protein
-	O
cells	O
and	O
a	O
KO	O
DP	O
enriched	O
population	O
that	O
contained	O
85	O
%	O
CD8	B-Protein
+	O
CD4	B-Protein
+	O
cells	O
(	O
Fig	O
.	O
S1	O
)	O
.	O

The	O
cells	O
were	O
stimulated	O
with	O
anti	O
-	O
CD3	B-Protein
+	O
anti	O
-	O
CD28	B-Protein
for	O
2	O
d	O
before	O
removing	O
them	O
from	O
the	O
TCR	O
stimulus	O
and	O
culturing	O
them	O
in	O
media	O
containing	O
100	O
U	O
/	O
ml	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

As	O
previously	O
reported	O
,	O
TCR	O
-	O
induced	O
proliferation	O
of	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
T	O
cells	O
was	O
severely	O
impaired	O
,	O
irrespective	O
of	O
CD4	B-Protein
expression	O
(	O
Fig	O
.	O
S1	O
)	O
(	O
12	O
,	O
13	O
)	O
.	O

However	O
,	O
the	O
Runx3	B-Protein
-	O
/	O
-	O
cells	O
showed	O
cell	O
-	O
surface	O
expression	O
patterns	O
indicative	O
of	O
activated	O
cells	O
,	O
including	O
up	O
-	O
regulation	O
of	O
CD25	B-Protein
and	O
CD69	B-Protein
(	O
Fig	O
.	O
S1	O
)	O
.	O

As	O
expected	O
from	O
their	O
ability	O
to	O
up	O
-	O
regulate	O
CD25	B-Protein
,	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
T	O
cells	O
responded	O
to	O
IL	B-Protein
-	I-Protein
2	I-Protein
supplementation	O
after	O
day	O
2	O
and	O
efficiently	O
expanded	O
until	O
day	O
6	O
of	O
the	O
culture	O
period	O
,	O
albeit	O
at	O
slower	O
rates	O
compared	O
with	O
WT	O
cells	O
(	O
Fig	O
.	O
S1	O
)	O
.	O

Although	O
a	O
fraction	O
of	O
the	O
KO	O
DP	O
cells	O
silenced	O
CD4	B-Protein
expression	O
after	O
activation	O
,	O
the	O
ratio	O
of	O
SP	O
/	O
DP	O
cells	O
in	O
each	O
enriched	O
population	O
remained	O
constant	O
thereafter	O
,	O
and	O
we	O
did	O
not	O
observe	O
any	O
major	O
differences	O
between	O
these	O
two	O
populations	O
throughout	O
the	O
culture	O
period	O
,	O
indicating	O
that	O
in	O
terms	O
of	O
effector	O
CTL	O
differentiation	O
and	O
under	O
our	O
culture	O
conditions	O
,	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
T	O
cells	O
that	O
also	O
coexpress	O
CD4	B-Protein
are	O
indistinguishable	O
from	O
those	O
that	O
do	O
not	O
.	O

The	O
data	O
presented	O
in	O
Fig	O
.	O
<EOS>	B-X
Development	B-X
of	B-X
more	B-X
severe	B-X
outcomes	B-X
likely	B-X
depends	B-X
on	B-X
three	B-X
factors	B-X
:	B-X
epidemiological	B-X
conditions	B-X
,	B-X
host	B-X
susceptibility	B-X
,	B-X
and	B-X
pathogen	B-X
virulence	B-X
(	B-X
Fig	B-X
.	B-X
They	B-X
arise	B-X
from	B-X
the	B-X
ampullary	B-X
complex	B-X
,	B-X
distal	B-X
to	B-X
the	B-X
confluence	B-X
of	B-X
the	B-X
common	B-X
bile	B-X
and	B-X
pancreatic	B-X
duct	B-X
(	B-X
Fig	B-X
.	B-X
In	B-X
patients	B-X
with	B-X
true	B-X
ampullary	B-X
cancer	B-X
,	B-X
there	B-X
is	B-X
very	B-X
limited	B-X
data	B-X
to	B-X
guide	B-X
physicians	B-X
on	B-X
the	B-X
choice	B-X
of	B-X
therapy	B-X
,	B-X
largely	B-X
because	B-X
of	B-X
the	B-X
rarity	B-X
of	B-X
the	B-X
disease	B-X
and	B-X
the	B-X
paucity	B-X
of	B-X
related	B-X
research	B-X
.	B-X
Following	B-X
the	B-X
publication	B-X
of	B-X
this	B-X
paper	B-X
,	B-X
it	B-X
was	B-X
drawn	B-X
to	B-X
the	B-X
Editors	B-X
'	B-X
attention	B-X
by	B-X
a	B-X
concerned	B-X
reader	B-X
that	B-X
several	B-X
of	B-X
the	B-X
data	B-X
panels	B-X
shown	B-X
in	B-X
Fig	B-X
.	B-X
Given	B-X
the	B-X
number	B-X
of	B-X
overlaps	B-X
of	B-X
data	B-X
that	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
the	B-X
Editor	B-X
of	B-X

S2	O
are	O
from	O
Runx3	B-Protein
KO	O
SP	O
cells	O
,	O
whereas	O
those	O
shown	O
in	O
Figs	O
.	O

3	O
and	O
4	O
are	O
from	O
total	O
Runx3	B-Protein
KO	O
CD8	B-Protein
cells	O
.	O

FACS	O
-	O
based	O
cytotoxicity	O
assay	O
.	O
<EOS>	B-X
A	B-X
limited	B-X
number	B-X
of	B-X
assays	B-X
allow	B-X
for	B-X
direct	B-X
monitoring	B-X
and	B-X
mechanistic	B-X
insights	B-X
into	B-X
the	B-X
interactions	B-X
between	B-X
tumor	B-X
and	B-X
immune	B-X
cells	B-X
,	B-X
amongst	B-X
which	B-X
,	B-X
T-cells	B-X
play	B-X
a	B-X
significant	B-X
role	B-X
in	B-X
executing	B-X
the	B-X
cytotoxic	B-X
response	B-X
of	B-X
the	B-X
adaptive	B-X
immune	B-X
system	B-X
to	B-X
cancer	B-X
cells	B-X
.	B-X
Most	B-X
assays	B-X
are	B-X
based	B-X
on	B-X
two-dimensional	B-X
(	B-X
2D	B-X
)	B-X
co-culture	B-X
of	B-X
cells	B-X
due	B-X
to	B-X
the	B-X
relative	B-X
ease	B-X
of	B-X
use	B-X
but	B-X
with	B-X
limited	B-X
representation	B-X
of	B-X
the	B-X
invasive	B-X
growth	B-X
phenotype	B-X
,	B-X
one	B-X
of	B-X
the	B-X
hallmarks	B-X
of	B-X
cancer	B-X
cells	B-X
.	B-X
Here	B-X
we	B-X
describe	B-X
an	B-X
approach	B-X
to	B-X
simultaneously	B-X
monitor	B-X
the	B-X
invasive	B-X
behavior	B-X
in	B-X
3D	B-X
of	B-X
cancer	B-X
cell	B-X
spheroids	B-X
and	B-X
T-cell	B-X
cytotoxicity	B-X
in	B-X
co-culture	B-X
.	B-X
Both	B-X
T-cell	B-X
co-culture	B-X
and	B-X
cancer	B-X
cell	B-X
invasion	B-X
into	B-X
type	B-X
I	B-X
collagen	B-X
matrix	B-X
are	B-X
performed	B-X
within	B-X
the	B-X
microwells	B-X
of	B-X
the	B-X
agarose	B-X
casts	B-X
without	B-X
the	B-X
need	B-X
to	B-X
transfer	B-X
the	B-X
cells	B-X
,	B-X
thus	B-X
maintaining	B-X
an	B-X
intact	B-X
3D	B-X
co-culture	B-X
system	B-X
throughout	B-X
the	B-X
assay	B-X
.	B-X
Also	B-X
,	B-X
cells	B-X
can	B-X
be	B-X
isolated	B-X
for	B-X
further	B-X
growth	B-X
or	B-X
subjected	B-X
to	B-X
analyses	B-X
such	B-X
as	B-X
for	B-X
gene	B-X
expression	B-X
or	B-X
fluorescence	B-X
activated	B-X
cell	B-X
sorting	B-X
(	B-X
FACS	B-X
)	B-X
.	B-X
Possible	B-X
modifications	B-X
of	B-X
the	B-X
assay	B-X
include	B-X
altered	B-X
compositions	B-X
of	B-X
the	B-X
extracellular	B-X
matrix	B-X
(	B-X
ECM	B-X
)	B-X
as	B-X
well	B-X
as	B-X
the	B-X
inclusion	B-X
of	B-X
different	B-X
stromal	B-X
or	B-X
immune	B-X
cells	B-X
with	B-X
the	B-X
cancer	B-X
cells	B-X
.	B-X

To	O
measure	O
cytotoxicity	O
,	O
EL4	O
thymoma	O
target	O
cells	O
were	O
loaded	O
with	O
0	O
or	O
1	O
muM	O
Gp33	O
peptide	O
for	O
2	O
h	O
before	O
a	O
2	O
-	O
h	O
coincubation	O
with	O
P14	O
CD8	B-Protein
+	O
T	O
cells	O
at	O
the	O
effector	O
-	O
to	O
-	O
target	O
ratios	O
indicated	O
in	O
the	O
figures	O
in	O
96	O
-	O
well	O
round	O
-	O
bottom	O
plates	O
.	O

After	O
the	O
coincubation	O
period	O
,	O
cells	O
were	O
stained	O
with	O
Annexin	B-Protein
V	I-Protein
-	O
FITC	O
and	O
anti	O
-	O
CD8	B-Protein
-	O
allophycocyanin	O
.	O

Data	O
analysis	O
was	O
performed	O
with	O
FlowJo	O
software	O
(	O
Tree	O
Star	O
,	O
Inc	O
.	O
)	O
;	O
EL4	O
target	O
cells	O
(	O
CD8	B-Protein
-	O
negative	O
events	O
)	O
were	O
gated	O
,	O
and	O
the	O
percentage	O
of	O
Annexin	B-Protein
V	I-Protein
+	O
target	O
cells	O
was	O
determined	O
.	O
<EOS>	B-X
Effective	B-X
quality	B-X
assessment	B-X
is	B-X
an	B-X
important	B-X
part	B-X
of	B-X
any	B-X
high-throughput	B-X
flow	B-X
cytometry	B-X
data	B-X
analysis	B-X
pipeline	B-X
,	B-X
especially	B-X
when	B-X
considering	B-X
the	B-X
complex	B-X
designs	B-X
of	B-X
the	B-X
typical	B-X
flow	B-X
experiments	B-X
applied	B-X
in	B-X
clinical	B-X
trials	B-X
.	B-X

Cytokine	O
and	O
surface	O
marker	O
staining	O
.	O
<EOS>	B-X
It	B-X
is	B-X
commonly	B-X
used	B-X
to	B-X
determine	B-X
the	B-X
expression	B-X
of	B-X
cell	B-X
surface	B-X
markers	B-X
and	B-X
intracellular	B-X
molecules	B-X
to	B-X
define	B-X
cells	B-X
into	B-X
different	B-X
populations	B-X
using	B-X
cell	B-X
size	B-X
,	B-X
granularity	B-X
,	B-X
and	B-X
fluorescently	B-X
labeled	B-X
antibodies	B-X
.	B-X
Thus	B-X
,	B-X
flow	B-X
cytometry	B-X
enables	B-X
simultaneous	B-X
and	B-X
mutliparameter	B-X
analysis	B-X
of	B-X
single	B-X
cells.During	B-X
the	B-X
staining	B-X
procedure	B-X
,	B-X
a	B-X
single	B-X
cell	B-X
suspension	B-X
is	B-X
created	B-X
for	B-X
staining	B-X
with	B-X
flow	B-X
cytometry	B-X
antibodies	B-X
for	B-X
analysis	B-X
on	B-X
the	B-X
flow	B-X
cytometer	B-X
.	B-X
The	B-X
staining	B-X
methods	B-X
from	B-X
this	B-X
technique	B-X
can	B-X
be	B-X
used	B-X
for	B-X
different	B-X
cell	B-X
types	B-X
by	B-X
changing	B-X
the	B-X
surface	B-X
marker	B-X
targeted	B-X
by	B-X
the	B-X
flow	B-X
antibody	B-X
,	B-X
provided	B-X
all	B-X
antibodies	B-X
are	B-X
titrated	B-X
prior	B-X
to	B-X
use	B-X
,	B-X
and	B-X
are	B-X
chosen	B-X
with	B-X
knowledge	B-X
of	B-X
the	B-X
density	B-X
of	B-X
surface	B-X
molecule	B-X
for	B-X
detection	B-X
and	B-X
brightness	B-X
of	B-X
fluorochrome	B-X
to	B-X
guide	B-X
antibody	B-X
selection.This	B-X
chapter	B-X
's	B-X
protocol	B-X
has	B-X
been	B-X
designed	B-X
specifically	B-X
for	B-X
detection	B-X
of	B-X
human	B-X
CD4	B-X
Flow	B-X
cytometry	B-X
is	B-X
a	B-X
powerful	B-X
technique	B-X
allowing	B-X
multiparameter	B-X
detection	B-X
and	B-X
quantification	B-X
of	B-X
single	B-X
cells	B-X
or	B-X
particles	B-X
including	B-X
cell	B-X
size	B-X
,	B-X
granularity	B-X
,	B-X
cell	B-X
components	B-X
(	B-X
DNA	B-X
,	B-X
mRNA	B-X
)	B-X
,	B-X
surface	B-X
receptors	B-X
,	B-X
intracellular	B-X
proteins	B-X
,	B-X
and	B-X
signaling	B-X
events	B-X
.	B-X
Flow	B-X
cytometry	B-X
is	B-X
thus	B-X
a	B-X
powerful	B-X
technique	B-X
,	B-X
which	B-X
is	B-X
commonly	B-X
used	B-X
to	B-X
determine	B-X
the	B-X
expression	B-X
of	B-X
cell	B-X
surface	B-X
markers	B-X
and	B-X
intracellular	B-X
molecules	B-X
to	B-X
define	B-X
cells	B-X
into	B-X
different	B-X
populations	B-X
by	B-X
fluorescently	B-X
labeled	B-X
antibodies.The	B-X
staining	B-X
procedure	B-X
outlined	B-X
below	B-X
creates	B-X
a	B-X
single-cell	B-X
suspension	B-X
for	B-X
staining	B-X
with	B-X
a	B-X
panel	B-X
of	B-X
flow	B-X
cytometry	B-X
antibodies	B-X
,	B-X
which	B-X
target	B-X
different	B-X
surface	B-X
markers	B-X
,	B-X
to	B-X
identify	B-X
an	B-X
array	B-X
of	B-X
cell	B-X
types	B-X
.	B-X
After	B-X
staining	B-X
the	B-X
sample	B-X
is	B-X
loaded	B-X
into	B-X
the	B-X
flow	B-X
cytometer	B-X
,	B-X
where	B-X
the	B-X
fluorescently	B-X
labeled	B-X
cells	B-X
are	B-X
excited	B-X
as	B-X
they	B-X
pass	B-X
by	B-X
the	B-X
laser	B-X
emitting	B-X
light	B-X
at	B-X
various	B-X
wavelengths	B-X
which	B-X
are	B-X
detected	B-X
by	B-X
the	B-X
flow	B-X
cytometer	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
important	B-X
to	B-X
have	B-X
good	B-X
compensation	B-X
controls	B-X
to	B-X
eliminate	B-X
any	B-X
antibody	B-X
spillover.The	B-X
staining	B-X
methods	B-X
from	B-X
this	B-X
technique	B-X
can	B-X
be	B-X
used	B-X
for	B-X
different	B-X
cell	B-X
types	B-X
by	B-X
changing	B-X
the	B-X
surface	B-X
marker	B-X
targeted	B-X
by	B-X
the	B-X
flow	B-X
antibody	B-X
.	B-X
It	B-X
is	B-X
also	B-X
important	B-X
to	B-X
use	B-X
knowledge	B-X
of	B-X
the	B-X
density	B-X
of	B-X
surface	B-X
molecule	B-X
for	B-X
detection	B-X
and	B-X
brightness	B-X
of	B-X
fluorochrome	B-X
to	B-X
guide	B-X
antibody	B-X
selection	B-X
and	B-X
also	B-X
to	B-X
titrate	B-X
all	B-X
antibodies	B-X
prior	B-X
to	B-X
use.This	B-X
chapter	B-X
's	B-X
protocol	B-X
has	B-X
been	B-X
designed	B-X
specifically	B-X
for	B-X
detection	B-X
of	B-X
human	B-X
CD8	B-X

To	O
assess	O
cytokine	O
production	O
,	O
cells	O
were	O
restimulated	O
with	O
10	O
nM	O
PMA	O
+	O
1	O
muM	O
ionomycin	O
for	O
6	O
h	O
(	O
unless	O
indicated	O
otherwise	O
in	O
the	O
figures	O
)	O
,	O
and	O
intracellular	O
cytokine	O
stains	O
were	O
performed	O
as	O
previously	O
described	O
(	O
28	O
)	O
.	O

To	O
detect	O
expression	O
of	O
surface	O
molecules	O
,	O
cells	O
were	O
washed	O
in	O
PBS	O
,	O
resuspended	O
in	O
FACS	O
wash	O
buffer	O
(	O
3	O
%	O
FBS	O
,	O
0	O
.	O
1	O
%	O
sodium	O
azide	O
,	O
30	O
mM	O
Hepes	O
,	O
1x	O
PBS	O
)	O
containing	O
the	O
antibodies	O
indicated	O
in	O
the	O
figures	O
at	O
previously	O
optimized	O
concentrations	O
,	O
incubated	O
for	O
15	O
min	O
at	O
room	O
temperature	O
(	O
RT	O
)	O
,	O
washed	O
,	O
and	O
resuspended	O
in	O
2	O
%	O
formaldehyde	O
fixative	O
solution	O
before	O
acquisition	O
on	O
a	O
FACSCalibur	O
(	O
BD	O
)	O
.	O

Retroviral	O
transduction	O
of	O
primary	O
CD8	O
+	O
T	O
cells	O
.	O
<EOS>	B-X
As	B-X
genome	B-X
engineering	B-X
advances	B-X
cell-based	B-X
therapies	B-X
,	B-X
a	B-X
versatile	B-X
approach	B-X
to	B-X
introducing	B-X
both	B-X
CRISPR-Cas9	B-X
ribonucleoproteins	B-X
(	B-X
RNPs	B-X
)	B-X
and	B-X
therapeutic	B-X
transgenes	B-X
into	B-X
specific	B-X
cells	B-X
would	B-X
be	B-X
transformative	B-X
.	B-X
Autologous	B-X
T	B-X
cells	B-X
expressing	B-X
a	B-X
chimeric	B-X
antigen	B-X
receptor	B-X
(	B-X
CAR	B-X
)	B-X
manufactured	B-X
by	B-X
viral	B-X
transduction	B-X
are	B-X
approved	B-X
to	B-X
treat	B-X
multiple	B-X
blood	B-X
cancers	B-X
,	B-X
but	B-X
additional	B-X
genetic	B-X
modifications	B-X
to	B-X
alter	B-X
cell	B-X
programs	B-X
will	B-X
likely	B-X
be	B-X
required	B-X
to	B-X
treat	B-X
solid	B-X
tumors	B-X
and	B-X
for	B-X
allogeneic	B-X
cellular	B-X
therapies	B-X
.	B-X
We	B-X
have	B-X
developed	B-X
a	B-X
one-step	B-X
strategy	B-X
using	B-X
engineered	B-X
lentiviral	B-X
particles	B-X
to	B-X
introduce	B-X
Cas9	B-X
RNPs	B-X
and	B-X
a	B-X
CAR	B-X
transgene	B-X
into	B-X
primary	B-X
human	B-X
T	B-X
cells	B-X
without	B-X
electroporation	B-X
.	B-X
T	B-X
cells	B-X
can	B-X
be	B-X
engineered	B-X
to	B-X
express	B-X
the	B-X
genes	B-X
of	B-X
chimeric	B-X
antigen	B-X
receptors	B-X
(	B-X
CARs	B-X
)	B-X
that	B-X
recognize	B-X
tumor-associated	B-X
antigens	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
gammaretroviruses	B-X
encoding	B-X
this	B-X
receptor	B-X
could	B-X
transduce	B-X
human	B-X
T	B-X
cells	B-X
.	B-X
Anti-CD19-CAR-transduced	B-X
CD8+	B-X
and	B-X
CD4+	B-X
T	B-X
cells	B-X
produced	B-X
interferon-gamma	B-X
and	B-X
interleukin-2	B-X
specifically	B-X
in	B-X
response	B-X
to	B-X
CD19+	B-X
target	B-X
cells	B-X
.	B-X
The	B-X
transduced	B-X
T	B-X
cells	B-X
specifically	B-X
killed	B-X
primary	B-X
chronic	B-X
lymphocytic	B-X
leukemia	B-X
(	B-X
CLL	B-X
)	B-X
cells	B-X
.	B-X
We	B-X
transduced	B-X
T	B-X
cells	B-X
from	B-X
CLL	B-X
patients	B-X
that	B-X
had	B-X
been	B-X
previously	B-X
treated	B-X
with	B-X
chemotherapy	B-X
.	B-X
We	B-X
induced	B-X
these	B-X
T	B-X
cells	B-X
to	B-X
proliferate	B-X
sufficiently	B-X
to	B-X
provide	B-X
enough	B-X
cells	B-X
for	B-X
clinical	B-X
adoptive	B-X
T	B-X
cell	B-X
transfer	B-X
with	B-X
a	B-X
protocol	B-X
consisting	B-X
of	B-X
an	B-X
initial	B-X
stimulation	B-X
with	B-X
an	B-X
anti-CD3	B-X
monoclonal	B-X
antibody	B-X
(	B-X
OKT3	B-X
)	B-X
before	B-X
transduction	B-X
followed	B-X
by	B-X
a	B-X
second	B-X
OKT3	B-X
stimulation	B-X
7	B-X
days	B-X
after	B-X
transduction	B-X
.	B-X
This	B-X
protocol	B-X
was	B-X
successfully	B-X
adapted	B-X
for	B-X
use	B-X
in	B-X
CLL	B-X
patients	B-X
with	B-X
high	B-X
peripheral	B-X
blood	B-X
leukemia	B-X
cell	B-X
counts	B-X
by	B-X
depleting	B-X
CD19+	B-X
cells	B-X
before	B-X
the	B-X
initial	B-X
OKT3	B-X
stimulation	B-X
.	B-X

For	O
transduction	O
experiments	O
,	O
viral	O
supernatants	O
were	O
generated	O
by	O
calcium	O
phosphate	O
transfection	O
of	O
Phoenix	O
cells	O
and	O
concentration	O
by	O
overnight	O
centrifugation	O
at	O
6	O
,	O
000	O
g	O
.	O

At	O
~	O
42	O
h	O
after	O
the	O
initial	O
TCR	O
activation	O
of	O
106	O
CD8	B-Protein
+	O
T	O
cells	O
per	O
well	O
in	O
12	O
-	O
well	O
plates	O
,	O
the	O
culture	O
media	O
was	O
removed	O
and	O
replaced	O
with	O
complete	O
media	O
supplemented	O
with	O
8	O
mug	O
/	O
ml	O
polybrene	O
containing	O
fresh	O
plus	O
concentrated	O
virus	O
.	O

The	O
plates	O
were	O
centrifuged	O
at	O
700	O
g	O
for	O
1	O
h	O
at	O
RT	O
before	O
returning	O
to	O
37degreesC	O
for	O
an	O
additional	O
5	O
h	O
.	O

Retroviral	O
constructs	O
for	O
Eomes	B-Protein
-	I-Protein
VP16	I-Protein
and	O
the	O
MIG	O
control	O
empty	O
vector	O
were	O
a	O
gift	O
from	O
S	O
.	O
L	O
.	O

Reiner	O
(	O
University	O
of	O
Pennsylvania	O
,	O
Philadelphia	O
,	O
PA	O
)	O
(	O
8	O
)	O
.	O

ChIP	O
and	O
real	O
-	O
time	O
PCR	O
analysis	O
.	O
<EOS>	B-X
Chromatin	B-X
immunoprecipitation	B-X
(	B-X
ChIP	B-X
)	B-X
coupled	B-X
with	B-X
quantitative	B-X
PCR	B-X
(	B-X
qPCR	B-X
)	B-X
has	B-X
in	B-X
the	B-X
last	B-X
15	B-X
years	B-X
become	B-X
a	B-X
basic	B-X
mainstream	B-X
tool	B-X
in	B-X
genomic	B-X
research	B-X
.	B-X
Numerous	B-X
commercially	B-X
available	B-X
ChIP	B-X
kits	B-X
,	B-X
qPCR	B-X
kits	B-X
,	B-X
and	B-X
real-time	B-X
PCR	B-X
systems	B-X
allow	B-X
for	B-X
quick	B-X
and	B-X
easy	B-X
analysis	B-X
of	B-X
virtually	B-X
anything	B-X
chromatin-related	B-X
as	B-X
long	B-X
as	B-X
there	B-X
is	B-X
an	B-X
available	B-X
antibody	B-X
.	B-X
However	B-X
,	B-X
the	B-X
highly	B-X
accurate	B-X
quantitative	B-X
dimension	B-X
added	B-X
by	B-X
using	B-X
qPCR	B-X
to	B-X
analyze	B-X
ChIP	B-X
samples	B-X
significantly	B-X
raises	B-X
the	B-X
bar	B-X
in	B-X
terms	B-X
of	B-X
experimental	B-X
accuracy	B-X
,	B-X
appropriate	B-X
controls	B-X
,	B-X
data	B-X
analysis	B-X
,	B-X
and	B-X
data	B-X
presentation	B-X
.	B-X
This	B-X
chapter	B-X
will	B-X
address	B-X
these	B-X
potential	B-X
pitfalls	B-X
by	B-X
providing	B-X
protocols	B-X
and	B-X
procedures	B-X
that	B-X
address	B-X
the	B-X
difficulties	B-X
inherent	B-X
in	B-X
ChIP-qPCR	B-X
assays	B-X
.	B-X

20	O
x	O
106	O
CD8	B-Protein
+	O
T	O
cells	O
per	O
immunoprecipitation	O
were	O
fixed	O
by	O
adding	O
a	O
1	O
/	O
10th	O
volume	O
of	O
fixation	O
solution	O
(	O
11	O
.	O
1	O
%	O
formaldehyde	O
,	O
100	O
mM	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
,	O
0	O
.	O
5	O
mM	O
EGTA	O
,	O
50	O
mM	O
Hepes	O
)	O
to	O
1	O
volume	O
of	O
culture	O
media	O
and	O
were	O
incubated	O
for	O
10	O
or	O
30	O
min	O
at	O
RT	O
.	O

Fixation	O
was	O
stopped	O
with	O
120	O
mM	O
glycine	O
on	O
ice	O
for	O
5	O
min	O
.	O

Fixed	O
cells	O
were	O
washed	O
2x	O
with	O
cold	O
PBS	O
,	O
1x	O
with	O
cold	O
solution	O
I	O
(	O
10	O
mM	O
Tris	O
[	O
pH	O
7	O
.	O
5	O
]	O
,	O
10	O
mM	O
EDTA	O
,	O
0	O
.	O
5	O
mM	O
EGTA	O
,	O
1	O
%	O
Triton	O
X	O
-	O
100	O
)	O
,	O
and	O
1x	O
with	O
cold	O
solution	O
II	O
(	O
10	O
mM	O
Tris	O
[	O
pH	O
7	O
.	O
5	O
]	O
,	O
1	O
mM	O
EDTA	O
,	O
0	O
.	O
5	O
mM	O
EGTA	O
,	O
200	O
mM	O
NaCl	O
)	O
.	O

After	O
washes	O
,	O
cell	O
pellets	O
were	O
resuspended	O
at	O
40	O
x	O
106	O
cells	O
/	O
ml	O
in	O
ChIP	O
lysis	O
buffer	O
(	O
150	O
mM	O
NaCl	O
,	O
25	O
mM	O
Tris	O
[	O
pH	O
7	O
.	O
5	O
]	O
,	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
0	O
.	O
1	O
%	O
SDS	O
,	O
0	O
.	O
5	O
%	O
deoxycholate	O
plus	O
protease	O
and	O
phosphatase	O
inhibitors	O
)	O
,	O
and	O
chromatin	O
was	O
sheared	O
with	O
a	O
sonicator	O
to	O
yield	O
0	O
.	O
5	O
-	O
1	O
-	O
kb	O
DNA	O
fragments	O
.	O

After	O
preclearing	O
the	O
sheared	O
chromatin	O
with	O
protein	O
A	O
-	O
sepharose	O
beads	O
and	O
removing	O
5	O
%	O
as	O
input	O
chromatin	O
,	O
immunoprecipitation	O
was	O
performed	O
by	O
adding	O
optimized	O
antibody	O
amounts	O
(	O
per	O
20	O
x	O
106	O
cell	O
equivalents	O
:	O
2	O
.	O
5	O
mug	O
anti	O
-	O
Eomes	B-Protein
,	O
1	O
:	O
100	O
dilution	O
anti	O
-	O
Runx3	B-Protein
)	O
,	O
followed	O
by	O
overnight	O
incubation	O
at	O
4degreesC	O
;	O
protein	O
A	O
-	O
sepharose	O
beads	O
were	O
added	O
for	O
the	O
last	O
3	O
h	O
of	O
the	O
incubation	O
period	O
.	O

Beads	O
were	O
washed	O
2x	O
with	O
RIPA	O
buffer	O
(	O
50	O
mM	O
Tris	O
[	O
pH	O
8	O
]	O
,	O
150	O
mM	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
%	O
NP	O
-	O
40	O
,	O
0	O
.	O
1	O
%	O
SDS	O
,	O
0	O
.	O
5	O
%	O
deoxycholate	O
)	O
,	O
1x	O
with	O
high	O
salt	O
buffer	O
(	O
50	O
mM	O
Tris	O
[	O
pH	O
8	O
]	O
,	O
500	O
mM	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
%	O
NP	O
-	O
40	O
,	O
0	O
.	O
1	O
%	O
SDS	O
)	O
,	O
and	O
1x	O
with	O
TE	O
buffer	O
.	O

After	O
the	O
last	O
wash	O
,	O
DNA	O
was	O
eluted	O
by	O
resuspending	O
the	O
beads	O
in	O
elution	O
buffer	O
(	O
1	O
%	O
SDS	O
,	O
100	O
mM	O
NaHCO3	O
)	O
.	O

Both	O
input	O
and	O
ChIP	O
chromatin	O
were	O
then	O
treated	O
with	O
RNase	O
A	O
(	O
5	O
mug	O
total	O
)	O
for	O
1	O
h	O
at	O
37degreesC	O
,	O
followed	O
by	O
the	O
addition	O
of	O
proteinase	O
K	O
(	O
100	O
mug	O
total	O
)	O
and	O
overnight	O
incubation	O
at	O
65degreesC	O
to	O
reverse	O
cross	O
-	O
linking	O
.	O

DNA	O
was	O
then	O
purified	O
with	O
QIAquick	O
columns	O
(	O
Gel	O
Extraction	O
Kit	O
;	O
QIAGEN	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
and	O
resuspended	O
in	O
a	O
50	O
-	O
mul	O
volume	O
.	O
<EOS>	B-X
Microbial	B-X
profiling	B-X
using	B-X
the	B-X
chaperonin60	B-X
(	B-X
cpn60	B-X
)	B-X
universal	B-X
target	B-X
(	B-X
UT	B-X
)	B-X
improves	B-X
resolution	B-X
of	B-X
vaginal	B-X
species	B-X
associated	B-X
with	B-X
negative	B-X
health	B-X
outcomes	B-X
compared	B-X
to	B-X
the	B-X
more	B-X
commonly	B-X
used	B-X
16S	B-X
ribosomal	B-X
DNA	B-X
target	B-X
.	B-X
However	B-X
,	B-X
the	B-X
choice	B-X
of	B-X
DNA	B-X
extraction	B-X
and	B-X
PCR	B-X
product	B-X
purification	B-X
methods	B-X
may	B-X
bias	B-X
sequencing-based	B-X
microbial	B-X
studies	B-X
and	B-X
should	B-X
be	B-X
optimized	B-X
for	B-X
the	B-X
sample	B-X
type	B-X
and	B-X
molecular	B-X
target	B-X
used	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
compared	B-X
two	B-X
commercial	B-X
DNA	B-X
extraction	B-X
kits	B-X
and	B-X
two	B-X
commercial	B-X
PCR	B-X
product	B-X
purification	B-X
kits	B-X
for	B-X
the	B-X
microbial	B-X
profiling	B-X
of	B-X
cervicovaginal	B-X
samples	B-X
using	B-X
the	B-X
cpn60	B-X
UT	B-X
.	B-X

For	O
real	O
-	O
time	O
PCR	O
detection	O
of	O
immunoprecipitated	O
targets	O
using	O
the	O
SYBR	O
Green	O
PCR	O
Kit	O
,	O
a	O
standard	O
curve	O
was	O
obtained	O
with	O
serial	O
dilutions	O
of	O
input	O
DNA	O
for	O
each	O
sample	O
,	O
and	O
1	O
mul	O
ChIP	O
DNA	O
was	O
used	O
per	O
PCR	O
reaction	O
(	O
performed	O
in	O
duplicates	O
)	O
.	O

Melt	O
curves	O
and	O
agarose	O
gels	O
were	O
analyzed	O
to	O
ensure	O
amplification	O
of	O
specific	O
target	O
sequences	O
.	O

Refer	O
to	O
Table	O
S1	O
(	O
available	O
at	O
http	O
:	O
/	O
/	O
www	O
.	O
jem	O
.	O
org	O
/	O
cgi	O
/	O
content	O
/	O
full	O
/	O
jem	O
.	O
20081242	O
/	O
DC1	O
)	O
for	O
a	O
list	O
of	O
primer	O
sets	O
.	O

The	O
data	O
are	O
presented	O
as	O
the	O
number	O
of	O
immunoprecipitated	O
target	O
sequences	O
relative	O
to	O
input	O
chromatin	O
,	O
assuming	O
two	O
copies	O
of	O
target	O
sequence	O
per	O
cell	O
equivalent	O
used	O
for	O
the	O
ChIP	O
.	O

Northern	O
and	O
Western	O
blot	O
analyses	O
.	O
<EOS>	B-X
Northern	B-X
blots	B-X
on	B-X
Drosophila	B-X
heads	B-X
showed	B-X
that	B-X
mRNA	B-X
of	B-X
Rh1	B-X
(	B-X
the	B-X
predominant	B-X
rhodopsin	B-X
)	B-X
was	B-X
high	B-X
in	B-X
vitamin	B-X
A	B-X
replete	B-X
controls	B-X
,	B-X
very	B-X
low	B-X
in	B-X
deprived	B-X
flies	B-X
,	B-X
and	B-X
increased	B-X
upon	B-X
feeding	B-X
carrot	B-X
juice	B-X
to	B-X
deprived	B-X
flies	B-X
as	B-X
early	B-X
as	B-X
1	B-X
hr	B-X
.	B-X
Recovery	B-X
of	B-X
Rh1	B-X
protein	B-X
upon	B-X
such	B-X
carotenoid	B-X
replacement	B-X
followed	B-X
,	B-X
barely	B-X
detectable	B-X
on	B-X
Western	B-X
blots	B-X
at	B-X
4	B-X
hr	B-X
but	B-X
conspicuous	B-X
by	B-X
8	B-X
hr	B-X
.	B-X
Alternative	B-X
chromophore	B-X
deprivation	B-X
with	B-X
yeast-glucose	B-X
food	B-X
yielded	B-X
flies	B-X
with	B-X
opsin	B-X
mRNA	B-X
on	B-X
Northerns	B-X
but	B-X
not	B-X
rhodopsin	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
Western	B-X
blots	B-X
,	B-X
spectrophotometry	B-X
and	B-X
the	B-X
electroretinogram	B-X
(	B-X
ERG	B-X
)	B-X
.	B-X
Individually	B-X
wrapped	B-X
,	B-X
sterile	B-X
disposable	B-X
transfer	B-X
pipets	B-X
can	B-X
be	B-X
used	B-X
in	B-X
the	B-X
isolation	B-X
of	B-X
ds-DNA	B-X
and	B-X
ds-RNA	B-X
fragments	B-X
from	B-X
gels	B-X
as	B-X
well	B-X
as	B-X
in	B-X
the	B-X
screening	B-X
of	B-X
multiple	B-X
samples	B-X
in	B-X
Southern	B-X
,	B-X
Northern	B-X
,	B-X
and	B-X
Western	B-X
blots	B-X
without	B-X
potential	B-X
contamination	B-X
by	B-X
exogenous	B-X
nucleases	B-X
and	B-X
proteases	B-X
.	B-X
Strip	B-X
blots	B-X
are	B-X
stable	B-X
in	B-X
appropriate	B-X
buffers	B-X
within	B-X
the	B-X
liquepipets	B-X
which	B-X
can	B-X
be	B-X
shipped	B-X
easily	B-X
worldwide	B-X
for	B-X
comparative	B-X
analyses	B-X
by	B-X
collaborative	B-X
investigators	B-X
.	B-X

RNA	O
isolation	O
and	O
Northern	O
blot	O
analysis	O
was	O
performed	O
as	O
previously	O
described	O
(	O
29	O
)	O
.	O
<EOS>	B-X
Poly	B-X
(	B-X
A	B-X
)	B-X
-rich	B-X
RNA	B-X
was	B-X
purified	B-X
from	B-X
a	B-X
pool	B-X
of	B-X
five	B-X
human	B-X
tracheobronchial	B-X
mucosa	B-X
.	B-X
After	B-X
hybridization	B-X
with	B-X
mucin	B-X
cDNA	B-X
probe	B-X
TH	B-X
29	B-X
described	B-X
by	B-X
Crepin	B-X
et	B-X
al	B-X
.	B-X
[	B-X
Crepin	B-X
,	B-X
M.	B-X
,	B-X
Porchet	B-X
,	B-X
N.	B-X
,	B-X
Aubert	B-X
,	B-X
J.	B-X
P.	B-X
&	B-X
Degand	B-X
,	B-X
P.	B-X
(	B-X
1990	B-X
)	B-X
Biorheology	B-X
27	B-X
,	B-X
471-484	B-X
]	B-X
respiratory	B-X
mucin	B-X
mRNAs	B-X
also	B-X
appeared	B-X
polydisperse	B-X
.	B-X
Although	B-X
degradation	B-X
or	B-X
incomplete	B-X
translation	B-X
of	B-X
high-molecular-mass	B-X
mRNA	B-X
can	B-X
not	B-X
be	B-X
entirely	B-X
ruled	B-X
out	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
human	B-X
respiratory	B-X
apomucins	B-X
consist	B-X
of	B-X
a	B-X
family	B-X
of	B-X
peptides	B-X
which	B-X
share	B-X
some	B-X
common	B-X
epitopes	B-X
.	B-X
This	B-X
possibility	B-X
is	B-X
in	B-X
agreement	B-X
with	B-X
(	B-X
a	B-X
)	B-X
the	B-X
diversity	B-X
of	B-X
mucin	B-X
precursors	B-X
observed	B-X
previously	B-X
with	B-X
pulse/chase	B-X
experiments	B-X
performed	B-X
with	B-X
explants	B-X
of	B-X
human	B-X
respiratory	B-X
mucosa	B-X
and	B-X
(	B-X
b	B-X
)	B-X
the	B-X
polydispersity	B-X
of	B-X
secreted	B-X
respiratory	B-X
mucins	B-X
observed	B-X
by	B-X
electron	B-X
microscopy	B-X
.	B-X

In	O
brief	O
,	O
10	O
mug	O
of	O
total	O
RNA	O
was	O
loaded	O
per	O
lane	O
and	O
transferred	O
to	O
positively	O
charged	O
nylon	O
membranes	O
(	O
Hybond	O
-	O
N	O
+	O
;	O
GE	O
Healthcare	O
)	O
,	O
which	O
was	O
confirmed	O
by	O
ethidium	O
bromide	O
staining	O
of	O
ribosomal	O
RNA	O
species	O
on	O
the	O
membrane	O
.	O

Membranes	O
were	O
hybridized	O
with	O
1	O
ng	O
/	O
ml	O
alpha	O
-	O
[	O
32P	O
]	O
dCTP	O
-	O
labeled	O
trichloroacetic	O
acid	O
precipitable	O
probe	O
in	O
ExpressHyb	O
hybridization	O
buffer	O
(	O
Clontech	O
Laboratories	O
,	O
Inc	O
.	O
)	O
.	O

All	O
cDNA	O
probes	O
were	O
confirmed	O
to	O
have	O
the	O
appropriate	O
single	O
-	O
copy	O
specificity	O
under	O
these	O
conditions	O
using	O
genomic	O
Southern	O
blot	O
analysis	O
.	O

Band	O
intensities	O
were	O
acquired	O
by	O
phosphorimaging	O
analysis	O
.	O

For	O
Western	O
analysis	O
,	O
whole	O
-	O
cell	O
protein	O
lysates	O
were	O
obtained	O
from	O
CD8	B-Protein
+	O
T	O
cells	O
at	O
the	O
time	O
points	O
indicated	O
in	O
the	O
figures	O
during	O
clonal	O
expansion	O
in	O
100	O
U	O
/	O
ml	O
IL	B-Protein
-	I-Protein
2	I-Protein
with	O
lysis	O
buffer	O
(	O
50	O
mM	O
Tris	O
[	O
pH	O
7	O
.	O
5	O
]	O
,	O
150	O
mM	O
NaCl	O
,	O
10	O
%	O
glycerol	O
,	O
5	O
mM	O
EDTA	O
,	O
1	O
%	O
NP	O
-	O
40	O
)	O
by	O
resuspending	O
samples	O
in	O
10	O
mul	O
per	O
106	O
cells	O
and	O
incubating	O
on	O
ice	O
for	O
30	O
min	O
in	O
the	O
presence	O
of	O
protease	O
inhibitors	O
.	O

Immunoblot	O
analysis	O
was	O
performed	O
with	O
the	O
antibodies	O
indicated	O
in	O
the	O
figures	O
after	O
SDS	O
-	O
PAGE	O
(	O
10	O
-	O
30	O
mug	O
of	O
total	O
protein	O
was	O
loaded	O
per	O
well	O
)	O
.	O

Quantification	O
of	O
detected	O
protein	O
was	O
performed	O
with	O
an	O
Intelligent	O
Dark	O
Box	O
unit	O
(	O
LAS	O
-	O
3000	O
;	O
Fujifilm	O
)	O
and	O
normalized	O
for	O
loading	O
with	O
the	O
amount	O
of	O
RNA	O
Pol	O
-	O
II	O
detected	O
in	O
each	O
lane	O
.	O

Online	O
supplemental	O
material	O
.	O
<EOS>	B-X
Novel	B-X
techniques	B-X
in	B-X
the	B-X
field	B-X
of	B-X
breast	B-X
imaging	B-X
may	B-X
soon	B-X
play	B-X
a	B-X
role	B-X
in	B-X
breast	B-X
cancer	B-X
screening	B-X
:	B-X
digital	B-X
breast	B-X
tomosynthesis	B-X
,	B-X
contrast	B-X
material-enhanced	B-X
spectral	B-X
mammography	B-X
,	B-X
US	B-X
(	B-X
automated	B-X
three-dimensional	B-X
breast	B-X
US	B-X
,	B-X
transmission	B-X
tomography	B-X
,	B-X
elastography	B-X
,	B-X
optoacoustic	B-X
imaging	B-X
)	B-X
,	B-X
MRI	B-X
(	B-X
abbreviated	B-X
and	B-X
ultrafast	B-X
,	B-X
diffusion-weighted	B-X
imaging	B-X
)	B-X
,	B-X
and	B-X
molecular	B-X
breast	B-X
imaging	B-X
.	B-X
To	B-X
view	B-X
the	B-X
original	B-X
version	B-X
of	B-X
this	B-X
poem	B-X
,	B-X
see	B-X
the	B-X
supplemental	B-X
material	B-X
section	B-X
of	B-X
this	B-X
article	B-X
online	B-X
.	B-X
To	B-X
view	B-X
the	B-X
original	B-X
version	B-X
of	B-X
this	B-X
poem	B-X
,	B-X
see	B-X
the	B-X
supplemental	B-X
material	B-X
section	B-X
of	B-X
this	B-X
article	B-X
online	B-X
.	B-X
Without	B-X
utilizing	B-X
radiation	B-X
,	B-X
iodinated	B-X
contrast	B-X
material	B-X
,	B-X
or	B-X
sedation	B-X
and/or	B-X
anesthesia	B-X
,	B-X
US	B-X
provides	B-X
a	B-X
means	B-X
for	B-X
quick	B-X
and	B-X
cost-effective	B-X
acquisition	B-X
of	B-X
information	B-X
,	B-X
including	B-X
the	B-X
location	B-X
,	B-X
size	B-X
,	B-X
shape	B-X
,	B-X
internal	B-X
content	B-X
,	B-X
and	B-X
vascularity	B-X
of	B-X
the	B-X
mass	B-X
.	B-X
Online	B-X
supplemental	B-X
material	B-X
is	B-X
available	B-X
for	B-X
this	B-X
article	B-X
.	B-X

Fig	O
.	O
<EOS>	B-X
Fig	B-X
mosaic	B-X
disease	B-X
(	B-X
FMD	B-X
)	B-X
is	B-X
a	B-X
complex	B-X
viral	B-X
disease	B-X
with	B-X
which	B-X
12	B-X
viruses	B-X
,	B-X
including	B-X
a	B-X
confirmed	B-X
causal	B-X
agent	B-X
,	B-X
fig	B-X
mosaic	B-X
emaravirus	B-X
(	B-X
FMV	B-X
)	B-X
,	B-X
and	B-X
three	B-X
viroids	B-X
are	B-X
associated	B-X
worldwide	B-X
.	B-X
Fig	B-X
pollination	B-X
is	B-X
now	B-X
widely	B-X
regarded	B-X
as	B-X
a	B-X
model	B-X
system	B-X
for	B-X
the	B-X
study	B-X
of	B-X
coevolved	B-X
mutualism	B-X
,	B-X
and	B-X
earlier	B-X
reviews	B-X
have	B-X
focused	B-X
on	B-X
the	B-X
evolution	B-X
of	B-X
resource	B-X
conflicts	B-X
between	B-X
pollinating	B-X
fig	B-X
wasps	B-X
,	B-X
their	B-X
hosts	B-X
,	B-X
and	B-X
their	B-X
parasites	B-X
.	B-X
Fig	B-X
wasps	B-X
have	B-X
also	B-X
been	B-X
a	B-X
focus	B-X
of	B-X
research	B-X
on	B-X
sex	B-X
ratio	B-X
evolution	B-X
,	B-X
the	B-X
evolution	B-X
of	B-X
virulence	B-X
,	B-X
coevolution	B-X
,	B-X
population	B-X
genetics	B-X
,	B-X
host-parasitoid	B-X
interactions	B-X
,	B-X
community	B-X
ecology	B-X
,	B-X
historical	B-X
biogeography	B-X
,	B-X
and	B-X
conservation	B-X
biology	B-X
.	B-X
Fig	B-X
plants	B-X
appear	B-X
to	B-X
have	B-X
discriminatively	B-X
enforced	B-X
fig	B-X
wasps	B-X
to	B-X
evolve	B-X
``	B-X
adaptation	B-X
characteristics	B-X
''	B-X
that	B-X
provide	B-X
greater	B-X
benefit	B-X
to	B-X
the	B-X
fig	B-X
,	B-X
and	B-X
fig	B-X
wasps	B-X
appear	B-X
to	B-X
have	B-X
diversified	B-X
their	B-X
evolutionary	B-X
strategies	B-X
in	B-X
response	B-X
to	B-X
discriminative	B-X
enforcement	B-X
by	B-X
figs	B-X
and	B-X
competition	B-X
among	B-X
different	B-X
fig	B-X
wasp	B-X
species	B-X
.	B-X

S1	O
shows	O
the	O
characterization	O
of	O
peripheral	O
CD8	B-Protein
+	O
T	O
cells	O
from	O
Runx3	B-Protein
-	O
/	O
-	O
mice	O
.	O

Fig	O
.	O
<EOS>	B-X
Fig	B-X
mosaic	B-X
disease	B-X
(	B-X
FMD	B-X
)	B-X
is	B-X
a	B-X
complex	B-X
viral	B-X
disease	B-X
with	B-X
which	B-X
12	B-X
viruses	B-X
,	B-X
including	B-X
a	B-X
confirmed	B-X
causal	B-X
agent	B-X
,	B-X
fig	B-X
mosaic	B-X
emaravirus	B-X
(	B-X
FMV	B-X
)	B-X
,	B-X
and	B-X
three	B-X
viroids	B-X
are	B-X
associated	B-X
worldwide	B-X
.	B-X
Fig	B-X
pollination	B-X
is	B-X
now	B-X
widely	B-X
regarded	B-X
as	B-X
a	B-X
model	B-X
system	B-X
for	B-X
the	B-X
study	B-X
of	B-X
coevolved	B-X
mutualism	B-X
,	B-X
and	B-X
earlier	B-X
reviews	B-X
have	B-X
focused	B-X
on	B-X
the	B-X
evolution	B-X
of	B-X
resource	B-X
conflicts	B-X
between	B-X
pollinating	B-X
fig	B-X
wasps	B-X
,	B-X
their	B-X
hosts	B-X
,	B-X
and	B-X
their	B-X
parasites	B-X
.	B-X
Fig	B-X
wasps	B-X
have	B-X
also	B-X
been	B-X
a	B-X
focus	B-X
of	B-X
research	B-X
on	B-X
sex	B-X
ratio	B-X
evolution	B-X
,	B-X
the	B-X
evolution	B-X
of	B-X
virulence	B-X
,	B-X
coevolution	B-X
,	B-X
population	B-X
genetics	B-X
,	B-X
host-parasitoid	B-X
interactions	B-X
,	B-X
community	B-X
ecology	B-X
,	B-X
historical	B-X
biogeography	B-X
,	B-X
and	B-X
conservation	B-X
biology	B-X
.	B-X
Fig	B-X
plants	B-X
appear	B-X
to	B-X
have	B-X
discriminatively	B-X
enforced	B-X
fig	B-X
wasps	B-X
to	B-X
evolve	B-X
``	B-X
adaptation	B-X
characteristics	B-X
''	B-X
that	B-X
provide	B-X
greater	B-X
benefit	B-X
to	B-X
the	B-X
fig	B-X
,	B-X
and	B-X
fig	B-X
wasps	B-X
appear	B-X
to	B-X
have	B-X
diversified	B-X
their	B-X
evolutionary	B-X
strategies	B-X
in	B-X
response	B-X
to	B-X
discriminative	B-X
enforcement	B-X
by	B-X
figs	B-X
and	B-X
competition	B-X
among	B-X
different	B-X
fig	B-X
wasp	B-X
species	B-X
.	B-X

S2	O
shows	O
effector	O
protein	O
expression	O
by	O
Runx3	B-Protein
WT	O
and	O
KO	O
cells	O
at	O
day	O
4	O
of	O
in	O
vitro	O
culture	O
.	O

Primer	O
sequences	O
used	O
for	O
ChIP	O
experiments	O
are	O
shown	O
in	O
Table	O
S1	O
.	O

Online	O
supplemental	O
material	O
is	O
available	O
at	O
http	O
:	O
/	O
/	O
www	O
.	O
jem	O
.	O
org	O
/	O
cgi	O
/	O
content	O
/	O
full	O
/	O
jem	O
.	O
20081242	O
/	O
DC1	O
.	O

Kinetics	O
of	O
gene	O
expression	O
during	O
CD8	B-Protein
+	O
T	O
cell	O
differentiation	O
.	O
<EOS>	B-X
The	B-X
differentiation	B-X
of	B-X
human	B-X
memory	B-X
CD8	B-X
T	B-X
cells	B-X
is	B-X
not	B-X
well	B-X
understood	B-X
.	B-X
We	B-X
used	B-X
in	B-X
vivo	B-X
deuterium	B-X
labelling	B-X
to	B-X
mark	B-X
CD8	B-X
T	B-X
cells	B-X
that	B-X
proliferated	B-X
in	B-X
response	B-X
to	B-X
the	B-X
virus	B-X
and	B-X
then	B-X
assessed	B-X
cellular	B-X
turnover	B-X
and	B-X
longevity	B-X
by	B-X
quantifying	B-X
deuterium	B-X
dilution	B-X
kinetics	B-X
in	B-X
YFV-specific	B-X
CD8	B-X
T	B-X
cells	B-X
using	B-X
mass	B-X
spectrometry	B-X
.	B-X
This	B-X
longitudinal	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
memory	B-X
pool	B-X
originates	B-X
from	B-X
CD8	B-X
T	B-X
cells	B-X
that	B-X
divided	B-X
extensively	B-X
during	B-X
the	B-X
first	B-X
two	B-X
weeks	B-X
after	B-X
infection	B-X
and	B-X
is	B-X
maintained	B-X
by	B-X
quiescent	B-X
cells	B-X
that	B-X
divide	B-X
less	B-X
than	B-X
once	B-X
every	B-X
year	B-X
(	B-X
doubling	B-X
time	B-X
of	B-X
over	B-X
450	B-X
days	B-X
)	B-X
.	B-X
Although	B-X
these	B-X
long-lived	B-X
YFV-specific	B-X
memory	B-X
CD8	B-X
T	B-X
cells	B-X
did	B-X
not	B-X
express	B-X
effector	B-X
molecules	B-X
,	B-X
their	B-X
epigenetic	B-X
landscape	B-X
resembled	B-X
that	B-X
of	B-X
effector	B-X
CD8	B-X
T	B-X
cells	B-X
.	B-X
This	B-X
open	B-X
chromatin	B-X
profile	B-X
at	B-X
effector	B-X
genes	B-X
was	B-X
maintained	B-X
in	B-X
memory	B-X
CD8	B-X
T	B-X
cells	B-X
isolated	B-X
even	B-X
a	B-X
decade	B-X
after	B-X
vaccination	B-X
,	B-X
indicating	B-X
that	B-X
these	B-X
cells	B-X
retain	B-X
an	B-X
epigenetic	B-X
fingerprint	B-X
of	B-X
their	B-X
effector	B-X
history	B-X
and	B-X
remain	B-X
poised	B-X
to	B-X
respond	B-X
rapidly	B-X
upon	B-X
re-exposure	B-X
to	B-X
the	B-X
pathogen	B-X
.	B-X

(	O
A	O
)	O
Kinetics	O
of	O
Prf1	B-Protein
,	O
Gzmb	B-Protein
,	O
Tbx21	B-Protein
(	O
T	B-Protein
-	I-Protein
bet	I-Protein
)	O
,	O
and	O
Eomes	B-Protein
mRNA	O
expression	O
in	O
differentiating	O
P14	O
CD8	B-Protein
+	O
T	O
cells	O
analyzed	O
by	O
Northern	O
blotting	O
.	O

RNA	O
from	O
day	O
7	O
Th1	O
cells	O
was	O
used	O
as	O
a	O
control	O
.	O
<EOS>	B-X
MicroRNAs	B-X
(	B-X
miRNAs	B-X
)	B-X
are	B-X
short	B-X
,	B-X
non-coding	B-X
RNA	B-X
which	B-X
regulate	B-X
gene	B-X
expression	B-X
of	B-X
target	B-X
mRNAs	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
profile	B-X
miRNA	B-X
and	B-X
mRNA	B-X
in	B-X
IIM	B-X
and	B-X
identify	B-X
miRNA-mRNA	B-X
relationships	B-X
which	B-X
may	B-X
be	B-X
relevant	B-X
to	B-X
disease	B-X
.	B-X
To	B-X
provide	B-X
rapid	B-X
immunosuppression	B-X
without	B-X
side	B-X
effects	B-X
,	B-X
we	B-X
analyzed	B-X
whether	B-X
rapamycin	B-X
alone	B-X
,	B-X
and	B-X
regulatory	B-X
T	B-X
cells	B-X
(	B-X
Tregs	B-X
)	B-X
expanded	B-X
ex	B-X
vivo	B-X
by	B-X
rapamycin	B-X
,	B-X
suppressed	B-X
colitis	B-X
in	B-X
a	B-X
mouse	B-X
model	B-X
.	B-X
In	B-X
this	B-X
study	B-X
we	B-X
investigated	B-X
the	B-X
immmunomodulatory	B-X
effects	B-X
of	B-X
adenovirus-mediated	B-X
gene	B-X
transfer	B-X
of	B-X
a	B-X
Th1	B-X
antagonist	B-X
,	B-X
interleukin-12p40	B-X
(	B-X
IL-12p40	B-X
)	B-X
,	B-X
in	B-X
vitro	B-X
and	B-X
on	B-X
allogeneic	B-X
graft	B-X
survival	B-X
in	B-X
a	B-X
rat	B-X
experimental	B-X
keratoplasty	B-X
model	B-X
.	B-X

Sizes	O
of	O
mRNA	O
transcripts	O
are	O
indicated	O
.	O
<EOS>	B-X
The	B-X
complex	B-X
life	B-X
of	B-X
pre-mRNA	B-X
from	B-X
transcription	B-X
to	B-X
the	B-X
production	B-X
of	B-X
mRNA	B-X
that	B-X
can	B-X
be	B-X
exported	B-X
from	B-X
the	B-X
nucleus	B-X
to	B-X
the	B-X
cytoplasm	B-X
to	B-X
encode	B-X
for	B-X
proteins	B-X
entails	B-X
intricate	B-X
coordination	B-X
and	B-X
regulation	B-X
of	B-X
a	B-X
network	B-X
of	B-X
processing	B-X
events	B-X
.	B-X
Because	B-X
most	B-X
pre-mRNAs	B-X
are	B-X
multiintronic	B-X
that	B-X
undergo	B-X
alternative	B-X
splicing	B-X
,	B-X
the	B-X
in	B-X
vivo	B-X
splicing	B-X
machine	B-X
requires	B-X
additional	B-X
elements	B-X
to	B-X
those	B-X
of	B-X
the	B-X
in	B-X
vitro	B-X
machine	B-X
,	B-X
to	B-X
account	B-X
for	B-X
all	B-X
these	B-X
diverse	B-X
functions	B-X
.	B-X
Another	B-X
source	B-X
comes	B-X
from	B-X
studies	B-X
of	B-X
the	B-X
in	B-X
vivo	B-X
assembled	B-X
spliceosome	B-X
,	B-X
isolated	B-X
from	B-X
cell	B-X
nuclei	B-X
under	B-X
native	B-X
conditions-the	B-X
supraspliceosome-that	B-X
individually	B-X
package	B-X
pre-mRNA	B-X
transcripts	B-X
of	B-X
different	B-X
sizes	B-X
and	B-X
number	B-X
of	B-X
introns	B-X
into	B-X
complexes	B-X
of	B-X
a	B-X
unique	B-X
structure	B-X
,	B-X
indicating	B-X
their	B-X
universal	B-X
nature	B-X
.	B-X
Over	B-X
the	B-X
past	B-X
decade	B-X
,	B-X
various	B-X
studies	B-X
have	B-X
indicated	B-X
that	B-X
most	B-X
of	B-X
the	B-X
eukaryotic	B-X
genome	B-X
is	B-X
transcribed	B-X
at	B-X
some	B-X
level	B-X
.	B-X
As	B-X
a	B-X
result	B-X
,	B-X
the	B-X
eukaryotic	B-X
gene	B-X
expression	B-X
machinery	B-X
must	B-X
effectively	B-X
evaluate	B-X
whether	B-X
or	B-X
not	B-X
a	B-X
transcript	B-X
has	B-X
all	B-X
the	B-X
hallmarks	B-X
of	B-X
a	B-X
protein-coding	B-X
mRNA	B-X
.	B-X
However	B-X
if	B-X
a	B-X
transcript	B-X
lacks	B-X
features	B-X
associated	B-X
with	B-X
``	B-X
mRNA	B-X
identity	B-X
''	B-X
,	B-X
then	B-X
the	B-X
RNA	B-X
is	B-X
degraded	B-X
and/or	B-X
used	B-X
to	B-X
inhibit	B-X
further	B-X
transcription	B-X
and	B-X
translation	B-X
of	B-X
the	B-X
gene	B-X
.	B-X
Here	B-X
we	B-X
discuss	B-X
how	B-X
mRNA	B-X
identity	B-X
is	B-X
assessed	B-X
by	B-X
the	B-X
nuclear	B-X
export	B-X
machinery	B-X
in	B-X
order	B-X
to	B-X
extract	B-X
meaningful	B-X
information	B-X
from	B-X
the	B-X
eukaryotic	B-X
genome	B-X
.	B-X
In	B-X
the	B-X
process	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
explanation	B-X
of	B-X
why	B-X
certain	B-X
sequences	B-X
that	B-X
are	B-X
enriched	B-X
in	B-X
protein-coding	B-X
genes	B-X
,	B-X
such	B-X
as	B-X
the	B-X
signal	B-X
sequence	B-X
coding	B-X
region	B-X
,	B-X
promote	B-X
mRNA	B-X
nuclear	B-X
export	B-X
in	B-X
vertebrates	B-X
.	B-X

(	O
B	O
)	O
Quantification	O
of	O
relative	O
mRNA	O
amounts	O
by	O
phosphorimager	O
analysis	O
.	O

(	O
C	O
)	O
Kinetics	O
of	O
protein	O
expression	O
in	O
differentiating	O
P14	O
CD8	B-Protein
+	O
T	O
cells	O
analyzed	O
by	O
immunoblotting	O
.	O

Sizes	O
of	O
protein	O
bands	O
are	O
indicated	O
.	O
<EOS>	B-X
We	B-X
discuss	B-X
here	B-X
a	B-X
method	B-X
for	B-X
producing	B-X
pure	B-X
populations	B-X
of	B-X
amyloid	B-X
β-protein	B-X
(	B-X
Aβ	B-X
)	B-X
of	B-X
specific	B-X
sizes	B-X
using	B-X
the	B-X
most	B-X
pathologic	B-X
form	B-X
of	B-X
the	B-X
peptide	B-X
,	B-X
Aβ42	B-X
.	B-X
In	B-X
studies	B-X
of	B-X
Aβ40	B-X
,	B-X
we	B-X
have	B-X
used	B-X
the	B-X
method	B-X
of	B-X
photo-induced	B-X
cross-linking	B-X
of	B-X
unmodified	B-X
proteins	B-X
(	B-X
PICUP	B-X
)	B-X
to	B-X
produce	B-X
zero-length	B-X
carbon-carbon	B-X
bonds	B-X
among	B-X
the	B-X
monomers	B-X
comprising	B-X
each	B-X
oligomer	B-X
,	B-X
thus	B-X
stabilizing	B-X
the	B-X
oligomers	B-X
.	B-X
We	B-X
then	B-X
isolated	B-X
pure	B-X
populations	B-X
of	B-X
oligomers	B-X
by	B-X
fractionating	B-X
the	B-X
oligomers	B-X
by	B-X
size	B-X
using	B-X
SDS-PAGE	B-X
and	B-X
then	B-X
extracting	B-X
each	B-X
population	B-X
from	B-X
the	B-X
stained	B-X
gel	B-X
bands	B-X
.	B-X
Titin	B-X
,	B-X
a	B-X
giant	B-X
sarcomeric	B-X
protein	B-X
,	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
generation	B-X
of	B-X
passive	B-X
tension	B-X
during	B-X
muscle	B-X
contraction	B-X
,	B-X
assembly	B-X
and	B-X
stability	B-X
of	B-X
the	B-X
sarcomere	B-X
in	B-X
striated	B-X
muscles	B-X
.	B-X
Titin	B-X
gene	B-X
produces	B-X
numerous	B-X
titin	B-X
protein	B-X
isoforms	B-X
with	B-X
different	B-X
sizes	B-X
(	B-X
∼3-4	B-X
MDa	B-X
)	B-X
resulting	B-X
from	B-X
alternative	B-X
splicing	B-X
.	B-X
To	B-X
study	B-X
titin	B-X
and	B-X
titin	B-X
isoform	B-X
changes	B-X
under	B-X
disease	B-X
conditions	B-X
,	B-X
the	B-X
method	B-X
to	B-X
detect	B-X
and	B-X
quantify	B-X
titin	B-X
protein	B-X
isoforms	B-X
is	B-X
needed	B-X
.	B-X
Sodium	B-X
dodecyl	B-X
sulfate	B-X
(	B-X
SDS	B-X
)	B-X
-agarose	B-X
gel	B-X
electrophoresis	B-X
is	B-X
an	B-X
important	B-X
tool	B-X
in	B-X
revealing	B-X
the	B-X
size	B-X
and	B-X
quantity	B-X
of	B-X
giant	B-X
proteins	B-X
in	B-X
the	B-X
sarcomere	B-X
.	B-X
Muscle	B-X
proteins	B-X
were	B-X
resolved	B-X
on	B-X
1	B-X
%	B-X
SDS-agarose	B-X
gels	B-X
that	B-X
were	B-X
silver-stained	B-X
subsequently	B-X
.	B-X
Titin	B-X
isoform	B-X
bands	B-X
with	B-X
different	B-X
sizes	B-X
were	B-X
separated	B-X
on	B-X
the	B-X
gel	B-X
.	B-X
At	B-X
the	B-X
end	B-X
,	B-X
we	B-X
also	B-X
validated	B-X
the	B-X
method	B-X
for	B-X
large	B-X
protein	B-X
detection	B-X
.	B-X
Our	B-X
results	B-X
indicated	B-X
that	B-X
this	B-X
electrophoresis	B-X
method	B-X
is	B-X
efficient	B-X
to	B-X
study	B-X
the	B-X
transitions	B-X
in	B-X
titin	B-X
isoforms	B-X
.	B-X
•This	B-X
method	B-X
provides	B-X
efficient	B-X
protein	B-X
extraction	B-X
with	B-X
urea-thiourea-glycerol	B-X
buffer	B-X
from	B-X
hard	B-X
tissues	B-X
such	B-X
as	B-X
striated	B-X
muscles•This	B-X
method	B-X
provides	B-X
an	B-X
efficient	B-X
way	B-X
to	B-X
separate	B-X
large	B-X
proteins	B-X
over	B-X
500	B-X
kDa•Combining	B-X
with	B-X
silver	B-X
staining	B-X
,	B-X
our	B-X
method	B-X
can	B-X
detect	B-X
large	B-X
protein	B-X
isoforms	B-X
and	B-X
quantify	B-X
the	B-X
separated	B-X
protein	B-X
bands	B-X
.	B-X

(	O
D	O
)	O
Relative	O
protein	O
amounts	O
quantified	O
from	O
the	O
Western	O
blots	O
.	O
<EOS>	B-X
Scavenger	B-X
receptor	B-X
class	B-X
B	B-X
type	B-X
I	B-X
(	B-X
SR-BI	B-X
)	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
high	B-X
density	B-X
lipoproteins	B-X
(	B-X
HDL	B-X
)	B-X
metabolism	B-X
.	B-X
This	B-X
study	B-X
was	B-X
to	B-X
characterize	B-X
the	B-X
protein	B-X
markers	B-X
of	B-X
dysfunctional	B-X
HDL	B-X
in	B-X
SR-BI	B-X
deficient	B-X
(	B-X
SR-BI	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
protocol	B-X
that	B-X
allows	B-X
measuring	B-X
SIAH-mediated	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
its	B-X
client	B-X
proteins	B-X
as	B-X
exemplified	B-X
by	B-X
acetyl	B-X
transferases	B-X
using	B-X
simple	B-X
overexpression	B-X
experiments	B-X
.	B-X
The	B-X
impact	B-X
of	B-X
SIAH	B-X
expression	B-X
on	B-X
the	B-X
relative	B-X
amounts	B-X
of	B-X
target	B-X
proteins	B-X
and	B-X
their	B-X
mRNAs	B-X
can	B-X
be	B-X
quantified	B-X
by	B-X
Western	B-X
blotting	B-X
and	B-X
quantitative	B-X
PCR	B-X
(	B-X
qPCR	B-X
)	B-X
as	B-X
described	B-X
here	B-X
.	B-X

(	O
E	O
)	O
Intracellular	O
staining	O
for	O
granzyme	B-Protein
B	I-Protein
,	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
and	O
TNF	B-Protein
.	O
<EOS>	B-X
Enzyme-linked	B-X
immune	B-X
absorbent	B-X
spot	B-X
(	B-X
Elispot	B-X
)	B-X
is	B-X
a	B-X
quantitative	B-X
method	B-X
for	B-X
measuring	B-X
relevant	B-X
parameters	B-X
of	B-X
T	B-X
cell	B-X
activation	B-X
.	B-X
The	B-X
sensitivity	B-X
of	B-X
Elispot	B-X
allows	B-X
the	B-X
detection	B-X
of	B-X
low-frequency	B-X
antigen-specific	B-X
T	B-X
cells	B-X
that	B-X
secrete	B-X
cytokines	B-X
and	B-X
effector	B-X
molecules	B-X
,	B-X
such	B-X
as	B-X
granzyme	B-X
B	B-X
and	B-X
perforin	B-X
.	B-X
Accuracy	B-X
,	B-X
sensitivity	B-X
,	B-X
reproducibility	B-X
,	B-X
and	B-X
robustness	B-X
of	B-X
Elispot	B-X
resulted	B-X
in	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
applications	B-X
in	B-X
research	B-X
as	B-X
well	B-X
as	B-X
in	B-X
diagnostic	B-X
field	B-X
.	B-X
Actually	B-X
,	B-X
CTL	B-X
monitoring	B-X
by	B-X
Elispot	B-X
is	B-X
a	B-X
gold	B-X
standard	B-X
for	B-X
the	B-X
evaluation	B-X
of	B-X
antigen-specific	B-X
T	B-X
cell	B-X
immunity	B-X
in	B-X
clinical	B-X
trials	B-X
and	B-X
vaccine	B-X
candidates	B-X
where	B-X
the	B-X
ability	B-X
to	B-X
detect	B-X
rare	B-X
antigen-specific	B-X
T	B-X
cells	B-X
is	B-X
of	B-X
relevance	B-X
for	B-X
immune	B-X
diagnostic	B-X
.	B-X
The	B-X
most	B-X
utilized	B-X
Elispot	B-X
assay	B-X
is	B-X
the	B-X
interferon-gamma	B-X
(	B-X
IFN-γ	B-X
)	B-X
test	B-X
,	B-X
a	B-X
marker	B-X
for	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
CTL	B-X
activation	B-X
,	B-X
but	B-X
Elispot	B-X
can	B-X
also	B-X
be	B-X
used	B-X
to	B-X
distinguish	B-X
different	B-X
subsets	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
by	B-X
using	B-X
other	B-X
cytokines	B-X
such	B-X
as	B-X
T-helper	B-X
(	B-X
Th	B-X
)	B-X
1-type	B-X
cells	B-X
(	B-X
characterized	B-X
by	B-X
the	B-X
production	B-X
of	B-X
IFN-γ	B-X
,	B-X
IL-2	B-X
,	B-X
IL-6	B-X
,	B-X
IL-12	B-X
,	B-X
IL-21	B-X
,	B-X
and	B-X
TNF-α	B-X
)	B-X
,	B-X
Th2	B-X
(	B-X
producing	B-X
cytokines	B-X
like	B-X
IL-4	B-X
,	B-X
IL-5	B-X
,	B-X
IL-10	B-X
,	B-X
and	B-X
IL-13	B-X
)	B-X
,	B-X
and	B-X
Th17	B-X
(	B-X
IL-17	B-X
)	B-X
cells	B-X
.	B-X
The	B-X
reliability	B-X
of	B-X
Elispot-generated	B-X
data	B-X
,	B-X
by	B-X
the	B-X
evaluation	B-X
of	B-X
T	B-X
cell	B-X
frequency	B-X
recognizing	B-X
individual	B-X
antigen/peptide	B-X
,	B-X
is	B-X
the	B-X
core	B-X
of	B-X
this	B-X
method	B-X
currently	B-X
applied	B-X
widely	B-X
to	B-X
investigate	B-X
specific	B-X
immune	B-X
responses	B-X
in	B-X
cancer	B-X
,	B-X
infections	B-X
,	B-X
allergies	B-X
,	B-X
and	B-X
autoimmune	B-X
diseases	B-X
.	B-X
The	B-X
Elispot	B-X
assay	B-X
is	B-X
competing	B-X
with	B-X
other	B-X
methods	B-X
measuring	B-X
single-cell	B-X
cytokine	B-X
production	B-X
,	B-X
e.g.	B-X
,	B-X
intracellular	B-X
cytokine	B-X
by	B-X
FACS	B-X
or	B-X
Miltenyi	B-X
cytokine	B-X
secretion	B-X
assay	B-X
.	B-X
Other	B-X
types	B-X
of	B-X
lymphocyte	B-X
frequency	B-X
and	B-X
function	B-X
assays	B-X
include	B-X
limiting	B-X
dilution	B-X
assay	B-X
(	B-X
LDA	B-X
)	B-X
,	B-X
cytotoxic	B-X
T	B-X
cell	B-X
assay	B-X
(	B-X
CTL	B-X
)	B-X
,	B-X
and	B-X
tetramer	B-X
staining	B-X
.	B-X
Compared	B-X
with	B-X
respect	B-X
to	B-X
sensitivity	B-X
the	B-X
Elispot	B-X
assay	B-X
is	B-X
outranking	B-X
other	B-X
methods	B-X
to	B-X
define	B-X
frequency	B-X
of	B-X
antigen-specific	B-X
lymphocytes	B-X
.	B-X
The	B-X
method	B-X
described	B-X
herein	B-X
would	B-X
like	B-X
to	B-X
offer	B-X
helpful	B-X
and	B-X
clear	B-X
protocols	B-X
for	B-X
researchers	B-X
that	B-X
apply	B-X
Elispot	B-X
.	B-X
IFN-γ	B-X
and	B-X
perforin	B-X
Elispot	B-X
assays	B-X
are	B-X
described	B-X
.	B-X

Granzyme	B-Protein
B	I-Protein
staining	O
was	O
specific	O
relative	O
to	O
an	O
isotype	O
control	O
(	O
not	O
depicted	O
)	O
.	O

Cells	O
were	O
restimulated	O
with	O
PMA	O
and	O
ionomycin	O
for	O
4	O
h	O
.	O
<EOS>	B-X
Despite	B-X
the	B-X
availability	B-X
of	B-X
an	B-X
effective	B-X
vaccine	B-X
and	B-X
antiviral	B-X
treatments	B-X
,	B-X
hepatitis	B-X
B	B-X
is	B-X
still	B-X
a	B-X
global	B-X
public	B-X
health	B-X
problem	B-X
.	B-X
Hepatitis	B-X
B	B-X
vaccination	B-X
can	B-X
prevent	B-X
the	B-X
disease	B-X
.	B-X
Vaccination	B-X
induces	B-X
long-lasting	B-X
protective	B-X
immune	B-X
memory	B-X
,	B-X
and	B-X
the	B-X
identification	B-X
of	B-X
memory	B-X
cell	B-X
subsets	B-X
can	B-X
indicate	B-X
the	B-X
effectiveness	B-X
of	B-X
vaccines	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
frequency	B-X
of	B-X
CD4	B-X

(	O
F	O
)	O
FACS	O
-	O
based	O
assay	O
to	O
measure	O
cytolytic	O
activity	O
of	O
P14	O
CD8	B-Protein
+	O
T	O
cells	O
against	O
EL4	O
targets	O
loaded	O
with	O
0	O
(	O
-	O
)	O
or	O
1	O
(	O
+	O
)	O
muM	O
Gp33	O
peptide	O
(	O
effector	O
-	O
to	O
-	O
target	O
ratio	O
=	O
5	O
:	O
1	O
)	O
.	O

Percentage	O
of	O
Annexin	B-Protein
V	I-Protein
+	O
(	O
apoptotic	O
)	O
target	O
cells	O
in	O
the	O
CD8	B-Protein
-	O
negative	O
EL4	O
target	O
population	O
(	O
dot	O
plots	O
)	O
was	O
determined	O
(	O
histograms	O
)	O
.	O

Cytolytic	O
activity	O
was	O
blocked	O
by	O
incubation	O
with	O
2	O
mM	O
EGTA	O
(	O
not	O
depicted	O
)	O
,	O
confirming	O
involvement	O
of	O
the	O
granule	O
exocytosis	O
(	O
perforin	B-Protein
-	O
granzyme	B-Protein
B	I-Protein
)	O
pathway	O
.	O

Data	O
are	O
representative	O
of	O
at	O
least	O
five	O
(	O
A	O
-	O
E	O
)	O
or	O
three	O
(	O
F	O
)	O
independent	O
experiments	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
introduce	B-X
``	B-X
sci-Plex	B-X
,	B-X
''	B-X
which	B-X
uses	B-X
``	B-X
nuclear	B-X
hashing	B-X
''	B-X
to	B-X
quantify	B-X
global	B-X
transcriptional	B-X
responses	B-X
to	B-X
thousands	B-X
of	B-X
independent	B-X
perturbations	B-X
at	B-X
single-cell	B-X
resolution	B-X
.	B-X
As	B-X
a	B-X
proof	B-X
of	B-X
concept	B-X
,	B-X
we	B-X
applied	B-X
sci-Plex	B-X
to	B-X
screen	B-X
three	B-X
cancer	B-X
cell	B-X
lines	B-X
exposed	B-X
to	B-X
188	B-X
compounds	B-X
.	B-X
In	B-X
total	B-X
,	B-X
we	B-X
profiled	B-X
~650,000	B-X
single-cell	B-X
transcriptomes	B-X
across	B-X
~5000	B-X
independent	B-X
samples	B-X
in	B-X
one	B-X
experiment	B-X
.	B-X
MRTF-A	B-X
(	B-X
myocardin-related	B-X
transcription	B-X
factor	B-X
A	B-X
)	B-X
is	B-X
a	B-X
coactivator	B-X
for	B-X
SRF-mediated	B-X
gene	B-X
expression	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
MRTF-A	B-X
is	B-X
critically	B-X
dependent	B-X
on	B-X
the	B-X
dissociation	B-X
of	B-X
G-actin	B-X
from	B-X
N-terminal	B-X
RPEL	B-X
motifs	B-X
.	B-X
MRTF-SRF	B-X
induction	B-X
often	B-X
correlates	B-X
with	B-X
enhanced	B-X
polymerization	B-X
of	B-X
F-actin	B-X
.	B-X
Here	B-X
we	B-X
investigate	B-X
MRTF	B-X
regulation	B-X
by	B-X
the	B-X
multifunctional	B-X
JMY	B-X
protein	B-X
,	B-X
which	B-X
contains	B-X
three	B-X
WASP/verprolin	B-X
homology	B-X
2	B-X
(	B-X
WH2/V	B-X
)	B-X
domains	B-X
and	B-X
facilitates	B-X
Arp2/3-dependent	B-X
and	B-X
-independent	B-X
actin	B-X
nucleation	B-X
.	B-X

Regulation	O
of	O
perforin	B-Protein
,	O
granzyme	B-Protein
B	I-Protein
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
by	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
Eomes	B-Protein
in	O
differentiating	O
CTLs	O
.	O

(	O
A	O
)	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
by	O
WT	O
(	O
Tbx21	B-Protein
+	O
/	O
+	O
)	O
and	O
T	B-Protein
-	I-Protein
bet	I-Protein
-	O
deficient	O
(	O
Tbx21	B-Protein
-	O
/	O
-	O
)	O
T	O
cells	O
.	O

Naive	O
CD8	B-Protein
+	O
T	O
cells	O
,	O
or	O
cells	O
activated	O
and	O
cultured	O
for	O
4	O
or	O
6	O
d	O
,	O
were	O
restimulated	O
with	O
PMA	O
and	O
ionomycin	O
for	O
6	O
h	O
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
was	O
assessed	O
by	O
intracellular	O
staining	O
.	O
<EOS>	B-X
The	B-X
T	B-X
cell	B-X
compartment	B-X
can	B-X
form	B-X
a	B-X
powerful	B-X
defense	B-X
against	B-X
extrinsic	B-X
(	B-X
e.g.	B-X
,	B-X
pathogens	B-X
)	B-X
and	B-X
intrinsic	B-X
danger	B-X
(	B-X
e.g.	B-X
,	B-X
malignant	B-X
cells	B-X
)	B-X
.	B-X
At	B-X
the	B-X
same	B-X
time	B-X
,	B-X
specific	B-X
subsets	B-X
of	B-X
T	B-X
cells	B-X
control	B-X
this	B-X
process	B-X
to	B-X
keep	B-X
the	B-X
immune	B-X
system	B-X
in	B-X
check	B-X
and	B-X
prevent	B-X
autoimmunity	B-X
.	B-X
A	B-X
wide	B-X
variety	B-X
in	B-X
T	B-X
cell	B-X
functionalities	B-X
exists	B-X
,	B-X
which	B-X
is	B-X
dependent	B-X
on	B-X
the	B-X
differentiation	B-X
and	B-X
maturation	B-X
state	B-X
of	B-X
the	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
report	B-X
an	B-X
overview	B-X
for	B-X
the	B-X
identification	B-X
of	B-X
CD4	B-X

Numbers	O
show	O
the	O
percentage	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
+	O
cells	O
.	O
<EOS>	B-X
Compelling	B-X
evidence	B-X
suggests	B-X
that	B-X
targeting	B-X
cancer	B-X
stem	B-X
cells	B-X
(	B-X
CSCs	B-X
)	B-X
have	B-X
a	B-X
crucial	B-X
impact	B-X
on	B-X
overcoming	B-X
the	B-X
current	B-X
shortcomings	B-X
of	B-X
chemotherapy	B-X
and	B-X
radiotherapy	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
study	B-X
the	B-X
effects	B-X
of	B-X
T	B-X
cells	B-X
and	B-X
a	B-X
critical	B-X
anti-tumor	B-X
cytokine	B-X
,	B-X
interferon-gamma	B-X
(	B-X
IFN-γ	B-X
)	B-X
,	B-X
on	B-X
breast	B-X
cancer	B-X
stem	B-X
cells	B-X
.	B-X
There	B-X
are	B-X
limited	B-X
clinical	B-X
investigations	B-X
identifying	B-X
the	B-X
percentage	B-X
of	B-X
T	B-X
helper	B-X
1	B-X
(	B-X
Th1	B-X
)	B-X
and	B-X
T	B-X
regulatory	B-X
(	B-X
Treg	B-X
)	B-X
cells	B-X
in	B-X
stable	B-X
as	B-X
well	B-X
as	B-X
rejected	B-X
kidney	B-X
allografts	B-X
,	B-X
a	B-X
concept	B-X
which	B-X
needs	B-X
to	B-X
be	B-X
more	B-X
studied	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
our	B-X
study	B-X
was	B-X
to	B-X
compare	B-X
the	B-X
percentage	B-X
of	B-X
CD4+	B-X
IFN-γ+	B-X
cells	B-X
,	B-X
the	B-X
number	B-X
of	B-X
IFN-γ	B-X
secreting	B-X
cells	B-X
and	B-X
the	B-X
amount	B-X
of	B-X
FoxP3	B-X
expression	B-X
in	B-X
patients	B-X
with	B-X
or	B-X
without	B-X
stable	B-X
graft	B-X
function	B-X
,	B-X
to	B-X
determine	B-X
the	B-X
roles	B-X
of	B-X
these	B-X
immunological	B-X
factors	B-X
in	B-X
stable	B-X
and	B-X
rejected	B-X
renal	B-X
allografts	B-X
.	B-X
The	B-X
percentage	B-X
of	B-X
Th1	B-X
CD4+	B-X
IFN-γ+	B-X
cells	B-X
was	B-X
determined	B-X
on	B-X
PBMC	B-X
by	B-X
flow	B-X
cytometry	B-X
and	B-X
the	B-X
number	B-X
of	B-X
IFN-γ	B-X
secreting	B-X
cells	B-X
by	B-X
ELISPOT	B-X
method	B-X
.	B-X
Our	B-X
results	B-X
showed	B-X
that	B-X
the	B-X
percentage	B-X
of	B-X
Th1	B-X
CD4+	B-X
IFN-γ+	B-X
cells	B-X
and	B-X
the	B-X
number	B-X
of	B-X
IFN-γ	B-X
secreting	B-X
cells	B-X
were	B-X
significantly	B-X
higher	B-X
in	B-X
the	B-X
patients	B-X
with	B-X
acute	B-X
rejection	B-X
in	B-X
comparison	B-X
to	B-X
the	B-X
stable	B-X
graft	B-X
function	B-X
group	B-X
(	B-X
p	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
The	B-X
higher	B-X
percentage	B-X
of	B-X
CD4+	B-X
IFN-γ+Th1	B-X
subset	B-X
and	B-X
number	B-X
of	B-X
IFN-γ	B-X
secreting	B-X
cells	B-X
and	B-X
also	B-X
the	B-X
lower	B-X
expression	B-X
of	B-X
Foxp3	B-X
could	B-X
prone	B-X
the	B-X
patients	B-X
to	B-X
acute	B-X
rejection	B-X
episode	B-X
post	B-X
transplantation	B-X
.	B-X
By	B-X
these	B-X
preliminary	B-X
data	B-X
,	B-X
it	B-X
is	B-X
suggested	B-X
that	B-X
monitoring	B-X
of	B-X
Th1	B-X
cells	B-X
post	B-X
transplantation	B-X
,	B-X
as	B-X
an	B-X
immunologic	B-X
marker	B-X
could	B-X
predict	B-X
the	B-X
possibility	B-X
of	B-X
rejection	B-X
episodes	B-X
.	B-X

(	O
B	O
)	O
Northern	O
blot	O
analysis	O
of	O
Prf1	B-Protein
and	O
GzmB	B-Protein
mRNA	O
expression	O
in	O
WT	O
or	O
T	B-Protein
-	I-Protein
bet	I-Protein
-	O
deficient	O
CD8	B-Protein
+	O
T	O
cells	O
activated	O
and	O
either	O
left	O
uninfected	O
(	O
uninf	O
)	O
or	O
transduced	O
with	O
retroviruses	O
expressing	O
Eomes	B-Protein
-	I-Protein
VP16	I-Protein
(	O
Eo	B-Protein
-	I-Protein
VP16	I-Protein
)	O
or	O
an	O
empty	O
IRES	O
-	O
GFP	B-Protein
cassette	O
(	O
GFP	O
)	O
.	O
<EOS>	B-X
We	B-X
tested	B-X
the	B-X
effect	B-X
of	B-X
these	B-X
MDR1	B-X
variants	B-X
on	B-X
Human	B-X
Ether-Related	B-X
A	B-X
Go-Go	B-X
(	B-X
HERG	B-X
)	B-X
block	B-X
by	B-X
ibutilide	B-X
in	B-X
CHO	B-X
cells	B-X
48	B-X
h	B-X
following	B-X
transient	B-X
transfection	B-X
with	B-X
an	B-X
IRES-dsRed	B-X
vector	B-X
containing	B-X
MDR1	B-X
,	B-X
G2677T	B-X
MDR1	B-X
,	B-X
G2677T/C3435T	B-X
MDR1	B-X
or	B-X
an	B-X
empty	B-X
bicistronic	B-X
site	B-X
and	B-X
an	B-X
IRES-GFP	B-X
vector	B-X
containing	B-X
HERG	B-X
(	B-X
KCNH2	B-X
)	B-X
.	B-X
However	B-X
,	B-X
G2677T/C3435T	B-X
cells	B-X
showed	B-X
ibutilide	B-X
sensitivity	B-X
similar	B-X
to	B-X
cells	B-X
expressing	B-X
HERG	B-X
alone	B-X
(	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
:	B-X
22.2+/-0.9	B-X
nM	B-X
)	B-X
.	B-X
Coculture	B-X
with	B-X
fexofenadine	B-X
(	B-X
1	B-X
microM	B-X
)	B-X
,	B-X
an	B-X
MDR1	B-X
substrate	B-X
known	B-X
to	B-X
rescue	B-X
misfolding	B-X
in	B-X
other	B-X
membrane	B-X
proteins	B-X
,	B-X
restored	B-X
cell	B-X
surface	B-X
expression	B-X
of	B-X
MDR1	B-X
G2677T/C3435T	B-X
and	B-X
restored	B-X
resistance	B-X
to	B-X
block	B-X
HERG	B-X
by	B-X
ibutilide	B-X
200	B-X
nM	B-X
(	B-X
98.5+/-0.98	B-X
%	B-X
vs	B-X
42.3+/-2.2	B-X
%	B-X
,	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
.	B-X
The	B-X
non-synonymous	B-X
MDR1	B-X
variant	B-X
G2677	B-X
T	B-X
(	B-X
A893S	B-X
)	B-X
confers	B-X
resistance	B-X
to	B-X
ibutilide	B-X
block	B-X
of	B-X
I	B-X
(	B-X
Kr	B-X
)	B-X
,	B-X
which	B-X
is	B-X
mitigated	B-X
by	B-X
the	B-X
C3435T	B-X
polymorphism	B-X
through	B-X
reduced	B-X
protein	B-X
expression	B-X
,	B-X
an	B-X
effect	B-X
that	B-X
can	B-X
be	B-X
restored	B-X
by	B-X
coculture	B-X
with	B-X
fexofenadine	B-X
.	B-X

Total	O
cellular	O
RNA	O
was	O
analyzed	O
on	O
day	O
6	O
of	O
culture	O
.	O
<EOS>	B-X
Co-culture	B-X
experiments	B-X
were	B-X
performed	B-X
with	B-X
endometrial	B-X
epithelial	B-X
cells	B-X
(	B-X
EEC	B-X
)	B-X
and	B-X
cryopreserved	B-X
day	B-X
5	B-X
blastocysts	B-X
(	B-X
Suppression	B-X
of	B-X
Aurora	B-X
kinase	B-X
A	B-X
(	B-X
Aurora-A	B-X
,	B-X
AURKA	B-X
)	B-X
by	B-X
siRNA	B-X
of	B-X
Aurora-A	B-X
(	B-X
siAurora-A	B-X
,	B-X
siA	B-X
)	B-X
has	B-X
been	B-X
used	B-X
in	B-X
lung	B-X
tumor	B-X
treatment	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
morphology	B-X
,	B-X
cellular	B-X
viability	B-X
and	B-X
stem	B-X
cell	B-X
marker	B-X
expression	B-X
of	B-X
three-dimensional	B-X
cultures	B-X
of	B-X
bone	B-X
marrow	B-X
and	B-X
gingiva-derived	B-X
stem	B-X
cells	B-X
in	B-X
different	B-X
ratios	B-X
.	B-X
Stem	B-X
cell	B-X
spheroids	B-X
were	B-X
made	B-X
with	B-X
bone	B-X
marrow	B-X
and	B-X
gingiva-derived	B-X
stem	B-X
cells	B-X
using	B-X
ratios	B-X
of	B-X
6:0	B-X
(	B-X
Group	B-X
1	B-X
)	B-X
,	B-X
4:2	B-X
(	B-X
Group	B-X
2	B-X
)	B-X
,	B-X
3:3	B-X
(	B-X
Group	B-X
3	B-X
)	B-X
,	B-X
2:4	B-X
(	B-X
Group	B-X
4	B-X
)	B-X
and	B-X
0:6	B-X
(	B-X
Group	B-X
5	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
viability	B-X
of	B-X
cell	B-X
spheroids	B-X
was	B-X
analyzed	B-X
using	B-X
a	B-X
Live/Dead	B-X
kit	B-X
assay	B-X
and	B-X
a	B-X
Cell	B-X
Counting	B-X
Kit-8	B-X
assay	B-X
.	B-X
Total	B-X
RNA	B-X
extraction	B-X
and	B-X
reverse	B-X
transcription-quantitative	B-X
PCR	B-X
were	B-X
performed	B-X
to	B-X
detect	B-X
the	B-X
mRNA	B-X
expression	B-X
levels	B-X
of	B-X

The	O
frequency	O
of	O
transduced	O
cells	O
in	O
the	O
cultures	O
was	O
equivalent	O
for	O
both	O
constructs	O
(	O
~	O
65	O
-	O
70	O
%	O
GFP	O
+	O
cells	O
;	O
not	O
depicted	O
)	O
.	O

(	O
C	O
)	O
Granzyme	B-Protein
B	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
by	O
Tbx21	B-Protein
+	O
/	O
+	O
and	O
Tbx21	B-Protein
-	O
/	O
-	O
T	O
cells	O
analyzed	O
in	O
restimulated	O
cells	O
that	O
had	O
been	O
cultured	O
for	O
5	O
d	O
.	O

(	O
D	O
)	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
by	O
cells	O
transduced	O
with	O
Eo	B-Protein
-	I-Protein
VP16	I-Protein
or	O
control	O
(	O
GFP	B-Protein
)	O
retroviruses	O
(	O
RV	O
)	O
measured	O
on	O
day	O
4	O
after	O
6	O
h	O
of	O
restimulation	O
with	O
PMA	O
and	O
ionomycin	O
.	O

Numbers	O
show	O
the	O
percentage	O
of	O
GFP	B-Protein
+	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
+	O
cells	O
.	O
<EOS>	B-X
The	B-X
main	B-X
pathogenesis	B-X
of	B-X
saphenous	B-X
vein	B-X
graft	B-X
neointimal	B-X
hyperplasia	B-X
after	B-X
coronary	B-X
artery	B-X
bypass	B-X
grafting	B-X
(	B-X
CABG	B-X
)	B-X
is	B-X
inflammation-caused	B-X
migration	B-X
and	B-X
proliferation	B-X
of	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
(	B-X
VSMCs	B-X
)	B-X
.	B-X
Growing	B-X
studies	B-X
show	B-X
that	B-X
SOCS3	B-X
plays	B-X
an	B-X
important	B-X
anti-inflammatory	B-X
role	B-X
in	B-X
numerous	B-X
autoimmune	B-X
diseases	B-X
,	B-X
inflammatory	B-X
diseases	B-X
and	B-X
inflammation-related	B-X
tumors	B-X
.	B-X
The	B-X
small	B-X
interference	B-X
RNA	B-X
plasmid	B-X
targeting	B-X
rat	B-X
SOCS3	B-X
(	B-X
SiRNA-rSOCS3	B-X
)	B-X
and	B-X
the	B-X
recombinant	B-X
adenovirus	B-X
vector	B-X
carrying	B-X
rat	B-X
SOCS3	B-X
gene	B-X
(	B-X
pYrAd-rSOCS3	B-X
)	B-X
were	B-X
constructed	B-X
,	B-X
and	B-X
the	B-X
empty	B-X
plamid	B-X
(	B-X
SiRNA-control	B-X
)	B-X
and	B-X
vector	B-X
(	B-X
pYrAd-GFP	B-X
)	B-X
only	B-X
carrying	B-X
GFP	B-X
reported	B-X
gene	B-X
were	B-X
constructed	B-X
as	B-X
control	B-X
.	B-X
There	B-X
were	B-X
two	B-X
large	B-X
groups	B-X
of	B-X
A	B-X
(	B-X
SOCS3	B-X
up-regulated	B-X
)	B-X
:	B-X
control	B-X
group	B-X
,	B-X
IL-6/IFN-γ	B-X
group	B-X
,	B-X
IL-6/IFN-γ+pYrAd-rSOCS3	B-X
group	B-X
,	B-X
IL-6/IFN-γ	B-X
(	B-X
+	B-X
)	B-X
pYrAd-GFP	B-X
group	B-X
;	B-X
and	B-X
B	B-X
(	B-X
SOCS3	B-X
down-regulated	B-X
)	B-X
:	B-X
control	B-X
group	B-X
,	B-X
IL-6/IFN-γ	B-X
group	B-X
,	B-X
IL-6/IFN-γ+SiRNA-rSOCS3	B-X
group	B-X
and	B-X
IL-6/	B-X
IFN	B-X
-γ+SiRNA-control	B-X
group	B-X
.	B-X
The	B-X
pYrAd-rSOCS3	B-X
and	B-X
SiRNA-rSOCS3	B-X
were	B-X
transfected	B-X
into	B-X
VSMCs	B-X
induced	B-X
by	B-X
IL-6/IFN-γ	B-X
.	B-X
As	B-X
compared	B-X
with	B-X
control	B-X
group	B-X
,	B-X
the	B-X
mRNA	B-X
and	B-X
protein	B-X
expression	B-X
of	B-X
SOCS3	B-X
,	B-X
STAT3	B-X
,	B-X
P-STAT3	B-X
,	B-X
IL-1β	B-X
,	B-X
IL-6	B-X
,	B-X
TNF-α	B-X
,	B-X
MCP-1	B-X
and	B-X
ICAM-1	B-X
was	B-X
significantly	B-X
up-regulated	B-X
in	B-X
VSMCs	B-X
stimulated	B-X
by	B-X
IL-6/IFN-γ	B-X
.	B-X
However	B-X
,	B-X
in	B-X
VSMCs	B-X
transfected	B-X
with	B-X
pYrAd-rSOCS3	B-X
before	B-X
stimulation	B-X
with	B-X
IL-6/IFN-γ	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
SOCS3	B-X
mRNA	B-X
and	B-X
protein	B-X
was	B-X
further	B-X
up-regulated	B-X
,	B-X
and	B-X
that	B-X
of	B-X
STAT3	B-X
,	B-X
P-STAT3	B-X
,	B-X
IL-1β	B-X
,	B-X
IL-6	B-X
,	B-X
TNF-α	B-X
,	B-X
MCP-1	B-X
and	B-X
ICAM-1	B-X
was	B-X
significantly	B-X
down-regulated	B-X
as	B-X
compared	B-X
with	B-X
IL-6/IFN-γ	B-X
group	B-X
and	B-X
IL-6/IFN-γ+pYrAd-GFP	B-X
group	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
those	B-X
related-cytokines	B-X
in	B-X
IL-6/IFN-γ+SiRNA-rSOCS3	B-X
group	B-X
was	B-X
markedly	B-X
increased	B-X
as	B-X
compared	B-X
with	B-X
IL-6/IFN-γ	B-X
group	B-X
and	B-X
IL-6/IFN-γ+SiRNA-control	B-X
group	B-X
.	B-X
The	B-X
absorbance	B-X
(	B-X
A	B-X
)	B-X
values	B-X
,	B-X
the	B-X
number	B-X
of	B-X
cells	B-X
migrating	B-X
to	B-X
the	B-X
lower	B-X
chamber	B-X
,	B-X
and	B-X
percentage	B-X
of	B-X
cells	B-X
in	B-X
the	B-X
G2/M+S	B-X
phase	B-X
were	B-X
increased	B-X
in	B-X
VSMCs	B-X
stimulated	B-X
by	B-X
IL-6/IFN-γ	B-X
.	B-X
In	B-X
VSMCs	B-X
incubated	B-X
with	B-X
pYrAd-rSOCS3	B-X
or	B-X
SiRNA-rSOCS3	B-X
before	B-X
IL-6/IFN-γ	B-X
stimulation	B-X
,	B-X
the	B-X
A	B-X
values	B-X
,	B-X
the	B-X
number	B-X
of	B-X
cells	B-X
migrating	B-X
to	B-X
the	B-X
lower	B-X
chamber	B-X
,	B-X
and	B-X
the	B-X
percentage	B-X
of	B-X
cells	B-X
in	B-X
the	B-X
G2/M+S	B-X
phase	B-X
were	B-X
significantly	B-X
decreased	B-X
,	B-X
and	B-X
increased	B-X
respectively	B-X
.	B-X
These	B-X
results	B-X
imply	B-X
that	B-X
IL-6/IFN-γ	B-X
,	B-X
strong	B-X
inflammatory	B-X
stimulators	B-X
,	B-X
can	B-X
promote	B-X
transformation	B-X
of	B-X
VSMCs	B-X
phenotype	B-X
form	B-X
a	B-X
quiescent	B-X
contractile	B-X
state	B-X
to	B-X
a	B-X
synthetic	B-X
state	B-X
by	B-X
activating	B-X
JAK2/STAT3	B-X
pathway	B-X
.	B-X

Results	O
are	O
representative	O
of	O
three	O
(	O
A	O
and	O
C	O
)	O
or	O
two	O
(	O
B	O
and	O
D	O
)	O
independent	O
experiments	O
.	O

Key	O
role	O
for	O
Runx3	B-Protein
in	O
effector	O
CTL	O
differentiation	O
.	O

(	O
A	O
)	O
Western	O
analysis	O
of	O
Runx3	B-Protein
,	O
Eomes	B-Protein
,	O
T	B-Protein
-	I-Protein
bet	I-Protein
,	O
and	O
perforin	B-Protein
expression	O
in	O
Runx3	B-Protein
+	O
/	O
+	O
versus	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
SP	O
T	O
cells	O
differentiated	O
for	O
6	O
d	O
.	O

beta	B-Protein
-	I-Protein
Actin	I-Protein
was	O
used	O
as	O
a	O
loading	O
control	O
.	O
<EOS>	B-X
Western	B-X
blotting	B-X
is	B-X
an	B-X
analytical	B-X
method	B-X
widely	B-X
used	B-X
for	B-X
detecting	B-X
and	B-X
(	B-X
semi-	B-X
)	B-X
quantifying	B-X
specific	B-X
proteins	B-X
in	B-X
given	B-X
samples	B-X
.	B-X
This	B-X
review	B-X
article	B-X
focuses	B-X
on	B-X
a	B-X
significant	B-X
,	B-X
but	B-X
not	B-X
yet	B-X
well-established	B-X
,	B-X
improvement	B-X
concerning	B-X
the	B-X
internal	B-X
loading	B-X
control	B-X
as	B-X
a	B-X
prerequisite	B-X
to	B-X
accurately	B-X
quantifying	B-X
Western	B-X
blots	B-X
.	B-X
Currently	B-X
,	B-X
housekeeping	B-X
proteins	B-X
(	B-X
HKPs	B-X
)	B-X
like	B-X
actin	B-X
,	B-X
tubulin	B-X
,	B-X
or	B-X
GAPDH	B-X
are	B-X
often	B-X
used	B-X
to	B-X
check	B-X
for	B-X
equal	B-X
loading	B-X
or	B-X
to	B-X
compensate	B-X
potential	B-X
loading	B-X
differences	B-X
.	B-X
However	B-X
,	B-X
this	B-X
loading	B-X
control	B-X
has	B-X
multiple	B-X
drawbacks	B-X
.	B-X
Staining	B-X
of	B-X
the	B-X
total	B-X
protein	B-X
on	B-X
the	B-X
blotting	B-X
membrane	B-X
has	B-X
emerged	B-X
as	B-X
a	B-X
better	B-X
loading	B-X
control	B-X
.	B-X
Total	B-X
protein	B-X
staining	B-X
(	B-X
TPS	B-X
)	B-X
represents	B-X
the	B-X
actual	B-X
loading	B-X
amount	B-X
more	B-X
accurately	B-X
than	B-X
HKPs	B-X
due	B-X
to	B-X
minor	B-X
technical	B-X
and	B-X
biological	B-X
variation	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
broad	B-X
dynamic	B-X
range	B-X
of	B-X
TPS	B-X
solves	B-X
the	B-X
issue	B-X
of	B-X
HKPs	B-X
that	B-X
commonly	B-X
fail	B-X
to	B-X
show	B-X
loading	B-X
differences	B-X
above	B-X
small	B-X
loading	B-X
amounts	B-X
of	B-X
0.5-10	B-X
μg	B-X
.	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
review	B-X
article	B-X
is	B-X
to	B-X
collect	B-X
and	B-X
compare	B-X
information	B-X
about	B-X
TPS	B-X
options	B-X
and	B-X
to	B-X
invite	B-X
users	B-X
to	B-X
reconsider	B-X
their	B-X
applied	B-X
loading	B-X
control	B-X
.	B-X
I	B-X
conclude	B-X
that	B-X
TPS	B-X
should	B-X
be	B-X
the	B-X
preferred	B-X
loading	B-X
control	B-X
in	B-X
future	B-X
Western	B-X
blot	B-X
approaches	B-X
.	B-X

(	O
B	O
)	O
Northern	O
blot	O
analysis	O
of	O
Prf1	B-Protein
mRNA	O
expression	O
in	O
Runx3	B-Protein
+	O
/	O
+	O
versus	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
T	O
cells	O
differentiated	O
for	O
6	O
d	O
.	O

beta	B-Protein
-	I-Protein
Actin	I-Protein
was	O
used	O
as	O
a	O
loading	O
control	O
.	O
<EOS>	B-X
Western	B-X
blotting	B-X
is	B-X
an	B-X
analytical	B-X
method	B-X
widely	B-X
used	B-X
for	B-X
detecting	B-X
and	B-X
(	B-X
semi-	B-X
)	B-X
quantifying	B-X
specific	B-X
proteins	B-X
in	B-X
given	B-X
samples	B-X
.	B-X
This	B-X
review	B-X
article	B-X
focuses	B-X
on	B-X
a	B-X
significant	B-X
,	B-X
but	B-X
not	B-X
yet	B-X
well-established	B-X
,	B-X
improvement	B-X
concerning	B-X
the	B-X
internal	B-X
loading	B-X
control	B-X
as	B-X
a	B-X
prerequisite	B-X
to	B-X
accurately	B-X
quantifying	B-X
Western	B-X
blots	B-X
.	B-X
Currently	B-X
,	B-X
housekeeping	B-X
proteins	B-X
(	B-X
HKPs	B-X
)	B-X
like	B-X
actin	B-X
,	B-X
tubulin	B-X
,	B-X
or	B-X
GAPDH	B-X
are	B-X
often	B-X
used	B-X
to	B-X
check	B-X
for	B-X
equal	B-X
loading	B-X
or	B-X
to	B-X
compensate	B-X
potential	B-X
loading	B-X
differences	B-X
.	B-X
However	B-X
,	B-X
this	B-X
loading	B-X
control	B-X
has	B-X
multiple	B-X
drawbacks	B-X
.	B-X
Staining	B-X
of	B-X
the	B-X
total	B-X
protein	B-X
on	B-X
the	B-X
blotting	B-X
membrane	B-X
has	B-X
emerged	B-X
as	B-X
a	B-X
better	B-X
loading	B-X
control	B-X
.	B-X
Total	B-X
protein	B-X
staining	B-X
(	B-X
TPS	B-X
)	B-X
represents	B-X
the	B-X
actual	B-X
loading	B-X
amount	B-X
more	B-X
accurately	B-X
than	B-X
HKPs	B-X
due	B-X
to	B-X
minor	B-X
technical	B-X
and	B-X
biological	B-X
variation	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
broad	B-X
dynamic	B-X
range	B-X
of	B-X
TPS	B-X
solves	B-X
the	B-X
issue	B-X
of	B-X
HKPs	B-X
that	B-X
commonly	B-X
fail	B-X
to	B-X
show	B-X
loading	B-X
differences	B-X
above	B-X
small	B-X
loading	B-X
amounts	B-X
of	B-X
0.5-10	B-X
μg	B-X
.	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
review	B-X
article	B-X
is	B-X
to	B-X
collect	B-X
and	B-X
compare	B-X
information	B-X
about	B-X
TPS	B-X
options	B-X
and	B-X
to	B-X
invite	B-X
users	B-X
to	B-X
reconsider	B-X
their	B-X
applied	B-X
loading	B-X
control	B-X
.	B-X
I	B-X
conclude	B-X
that	B-X
TPS	B-X
should	B-X
be	B-X
the	B-X
preferred	B-X
loading	B-X
control	B-X
in	B-X
future	B-X
Western	B-X
blot	B-X
approaches	B-X
.	B-X

(	O
C	O
)	O
Expression	O
of	O
granzyme	B-Protein
B	I-Protein
,	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
TNF	B-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
2	I-Protein
by	O
resting	O
or	O
restimulated	O
(	O
6	O
h	O
)	O
Runx3	B-Protein
+	O
/	O
+	O
versus	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
SP	O
T	O
cells	O
differentiated	O
for	O
6	O
d	O
.	O

The	O
vertical	O
gray	O
line	O
indicates	O
the	O
granzyme	B-Protein
B	I-Protein
MFI	O
for	O
WT	O
GFP	B-Protein
+	O
cells	O
.	O

Results	O
in	O
A	O
-	O
C	O
are	O
representative	O
of	O
two	O
independent	O
experiments	O
.	O

(	O
D	O
)	O
ChIP	O
analysis	O
of	O
binding	O
of	O
endogenous	O
Runx3	B-Protein
and	O
Eomes	B-Protein
to	O
the	O
Prf1	B-Protein
locus	O
.	O

Enrichment	O
of	O
the	O
indicated	O
genomic	O
regions	O
was	O
evaluated	O
by	O
real	O
-	O
time	O
PCR	O
of	O
DNA	O
from	O
immunoprecipitated	O
and	O
input	O
chromatin	O
.	O

The	O
data	O
are	O
the	O
means	O
of	O
duplicate	O
measurements	O
from	O
two	O
chromatin	O
preparations	O
from	O
two	O
independent	O
CD8	B-Protein
+	O
T	O
cell	O
differentiations	O
.	O

The	O
efficiency	O
of	O
recovery	O
of	O
input	O
for	O
the	O
-	O
1	O
-	O
kb	O
region	O
of	O
Prf1	B-Protein
was	O
0	O
.	O
97	O
%	O
for	O
the	O
Runx3	B-Protein
ChIP	O
and	O
0	O
.	O
5	O
%	O
for	O
the	O
Eomes	B-Protein
ChIP	O
.	O

Runx3	B-Protein
controls	O
Eomes	B-Protein
,	O
perforin	B-Protein
,	O
granzyme	B-Protein
B	I-Protein
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
in	O
effector	O
CTLs	O
.	O

Runx3	B-Protein
+	O
/	O
+	O
or	O
Runx3	B-Protein
-	O
/	O
-	O
CD8	B-Protein
+	O
T	O
cells	O
were	O
activated	O
and	O
transduced	O
with	O
retroviruses	O
bearing	O
an	O
empty	O
IRES	O
-	O
GFP	B-Protein
cassette	O
(	O
GFP	O
)	O
or	O
also	O
encoding	O
Eomes	B-Protein
-	I-Protein
VP16	I-Protein
(	O
Eo	B-Protein
-	I-Protein
VP16	I-Protein
)	O
or	O
Myc	B-Protein
-	O
Runx3	B-Protein
(	O
Runx3	B-Protein
)	O
.	O
<EOS>	B-X
Although	B-X
RUNX3	B-X
is	B-X
expressed	B-X
in	B-X
normal	B-X
hematopoietic	B-X
stem	B-X
and	B-X
progenitor	B-X
cells	B-X
,	B-X
its	B-X
expression	B-X
decreases	B-X
with	B-X
aging	B-X
in	B-X
humans	B-X
.	B-X
The	B-X
loss	B-X
of	B-X
Runx3	B-X
did	B-X
not	B-X
result	B-X
in	B-X
the	B-X
development	B-X
of	B-X
lethal	B-X
hematological	B-X
diseases	B-X
in	B-X
mice	B-X
despite	B-X
the	B-X
expansion	B-X
of	B-X
myeloid	B-X
cells	B-X
.	B-X
Therefore	B-X
,	B-X
RUNX3	B-X
does	B-X
not	B-X
appear	B-X
to	B-X
initiate	B-X
the	B-X
transformation	B-X
of	B-X
normal	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
overexpression	B-X
of	B-X
RUNX3	B-X
inhibits	B-X
the	B-X
expression	B-X
and	B-X
transcriptional	B-X
function	B-X
of	B-X
the	B-X
RUNX1	B-X
gene	B-X
,	B-X
but	B-X
activates	B-X
the	B-X
expression	B-X
of	B-X
key	B-X
oncogenic	B-X
pathways	B-X
,	B-X
such	B-X
as	B-X
MYC	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
transformation	B-X
of	B-X
premalignant	B-X
stem	B-X
cells	B-X
harboring	B-X
a	B-X
driver	B-X
genetic	B-X
mutation	B-X
.	B-X
We	B-X
herein	B-X
discuss	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
RUNX3	B-X
is	B-X
activated	B-X
and	B-X
how	B-X
RUNX3	B-X
exerts	B-X
oncogenic	B-X
effects	B-X
on	B-X
the	B-X
cellular	B-X
function	B-X
of	B-X
and	B-X
transcriptional	B-X
program	B-X
in	B-X
premalignant	B-X
stem	B-X
cells	B-X
to	B-X
drive	B-X
myeloid	B-X
transformation	B-X
.	B-X

The	O
frequency	O
of	O
transduced	O
cells	O
in	O
the	O
cultures	O
was	O
equivalent	O
for	O
all	O
constructs	O
(	O
~	O
75	O
-	O
90	O
%	O
GFP	O
+	O
cells	O
;	O
not	O
depicted	O
)	O
.	O

(	O
A	O
)	O
Protein	O
expression	O
in	O
whole	O
-	O
cell	O
extracts	O
(	O
day	O
6	O
)	O
was	O
analyzed	O
by	O
immunoblotting	O
.	O

Overexpression	O
of	O
Eomes	B-Protein
-	I-Protein
VP16	I-Protein
cannot	O
be	O
detected	O
with	O
the	O
Eomes	B-Protein
antibody	O
,	O
as	O
the	O
C	O
-	O
terminal	O
epitope	O
is	O
within	O
the	O
region	O
that	O
has	O
been	O
replaced	O
with	O
the	O
VP16	B-Protein
transactivation	O
domain	O
.	O

(	O
B	O
)	O
Expression	O
of	O
granzyme	B-Protein
B	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
after	O
culture	O
for	O
6	O
d	O
and	O
restimulation	O
for	O
4	O
h	O
with	O
PMA	O
and	O
ionomycin	O
was	O
determined	O
by	O
intracellular	O
staining	O
.	O

The	O
percentage	O
of	O
positively	O
stained	O
cells	O
is	O
shown	O
above	O
the	O
gate	O
;	O
the	O
mean	O
fluorescence	O
intensity	O
(	O
MFI	O
)	O
of	O
granzyme	B-Protein
B	I-Protein
staining	O
for	O
the	O
total	O
population	O
is	O
shown	O
below	O
the	O
gate	O
.	O
<EOS>	B-X
[	B-X
Effects	B-X
of	B-X
allogeneic	B-X
bone	B-X
marrow	B-X
mesenchymal	B-X
stem	B-X
cells	B-X
on	B-X
polarization	B-X
of	B-X
peritoneal	B-X
macrophages	B-X
in	B-X
rats	B-X
with	B-X
sepsis	B-X
]	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
in	B-X
vivo	B-X
corticosteroids	B-X
on	B-X
lymphocyte	B-X
subpopulations	B-X
,	B-X
their	B-X
surface	B-X
molecules	B-X
and	B-X
externalization	B-X
of	B-X
phosphatidylserine	B-X
(	B-X
apoptosis	B-X
)	B-X
is	B-X
examined	B-X
.	B-X
Blood	B-X
samples	B-X
were	B-X
withdrawn	B-X
before	B-X
and	B-X
30	B-X
min	B-X
,	B-X
2	B-X
,	B-X
5	B-X
,	B-X
23	B-X
and	B-X
29	B-X
h	B-X
thereafter	B-X
.	B-X
Externalization	B-X
of	B-X
phosphatidylserine	B-X
was	B-X
measured	B-X
by	B-X
Annexin-V	B-X
;	B-X
cell	B-X
fragments	B-X
were	B-X
excluded	B-X
by	B-X
propidium	B-X
iodide	B-X
staining	B-X
.	B-X
Lymphocyte	B-X
number	B-X
decreased	B-X
from	B-X
2,007	B-X
+/-	B-X
473	B-X
to	B-X
634	B-X
+/-	B-X
119	B-X
microl	B-X
after	B-X
5	B-X
h	B-X
and	B-X
rose	B-X
to	B-X
3,112	B-X
+/-	B-X
436	B-X
microl	B-X
after	B-X
23	B-X
h.	B-X
CD4	B-X
,	B-X
CD8	B-X
and	B-X
B	B-X
cell	B-X
counts	B-X
declined	B-X
significantly	B-X
after	B-X
5	B-X
h	B-X
(	B-X
P	B-X
<	B-X
or	B-X
=	B-X
0.01	B-X
)	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
CD28	B-X
or	B-X
CD95	B-X
on	B-X
T	B-X
cells	B-X
and	B-X
the	B-X
natural	B-X
killer	B-X
cells	B-X
were	B-X
unaffected	B-X
.	B-X
At	B-X
baseline	B-X
9.9	B-X
+/-	B-X
3.8	B-X
%	B-X
of	B-X
cells	B-X
in	B-X
the	B-X
lymphocyte	B-X
gate	B-X
did	B-X
not	B-X
stain	B-X
for	B-X
CD3	B-X
,	B-X
CD20	B-X
or	B-X
CD56	B-X
(	B-X
referred	B-X
to	B-X
as	B-X
``	B-X
null	B-X
cells	B-X
''	B-X
)	B-X
.	B-X
5	B-X
h	B-X
after	B-X
application	B-X
of	B-X
prednisolone	B-X
,	B-X
there	B-X
was	B-X
a	B-X
significant	B-X
increase	B-X
of	B-X
``	B-X
null	B-X
cells	B-X
''	B-X
(	B-X
28	B-X
+/-	B-X
12	B-X
%	B-X
,	B-X
P	B-X
=	B-X
0.018	B-X
)	B-X
.	B-X
The	B-X
percentage	B-X
of	B-X
phosphatidylserine	B-X
positive	B-X
CD4	B-X
cells	B-X
rose	B-X
from	B-X
8.1	B-X
+/-	B-X
3.3	B-X
to	B-X
19.8	B-X
+/-	B-X
8	B-X
%	B-X
after	B-X
intravenous	B-X
prednisolone	B-X
,	B-X
while	B-X
the	B-X
percentage	B-X
of	B-X
phosphatidylserine	B-X
positive	B-X
CD8	B-X
,	B-X
B	B-X
and	B-X
NK	B-X
cells	B-X
remained	B-X
largely	B-X
unchanged	B-X
.	B-X
Prednisolone	B-X
induces	B-X
a	B-X
most	B-X
significant	B-X
depletion	B-X
of	B-X
CD4	B-X
cells	B-X
,	B-X
which	B-X
to	B-X
some	B-X
degree	B-X
is	B-X
associated	B-X
with	B-X
apoptosis	B-X
.	B-X

The	O
vertical	O
gray	O
lines	O
indicate	O
the	O
MFI	O
for	O
WT	O
GFP	B-Protein
+	O
cells	O
.	O

Results	O
are	O
representative	O
of	O
at	O
least	O
two	O
independent	O
experiments	O
.	O
<EOS>	B-X
Across	B-X
two	B-X
studies	B-X
(	B-X
The	B-X
presence	B-X
of	B-X
hybrid	B-X
genotypes	B-X
has	B-X
been	B-X
widely	B-X
reported	B-X
in	B-X
surveys	B-X
of	B-X
natural	B-X
populations	B-X
,	B-X
genetic	B-X
variation	B-X
reported	B-X
in	B-X
a	B-X
number	B-X
of	B-X
Leishmania	B-X
species	B-X
,	B-X
and	B-X
the	B-X
extant	B-X
capacity	B-X
for	B-X
genetic	B-X
exchange	B-X
demonstrated	B-X
in	B-X
laboratory	B-X
experiments	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
these	B-X
hybrids	B-X
originate	B-X
from	B-X
recombination	B-X
between	B-X
two	B-X
different	B-X
lineages	B-X
of	B-X
Ethiopian	B-X
L.	B-X
donovani	B-X
occurring	B-X
in	B-X
the	B-X
same	B-X
region	B-X
.	B-X
Patterns	B-X
of	B-X
inheritance	B-X
are	B-X
more	B-X
complex	B-X
than	B-X
previously	B-X
reported	B-X
with	B-X
multiple	B-X
,	B-X
apparently	B-X
independent	B-X
,	B-X
origins	B-X
from	B-X
similar	B-X
parents	B-X
that	B-X
include	B-X
backcrossing	B-X
with	B-X
parental	B-X
types	B-X
.	B-X
Analysis	B-X
indicates	B-X
that	B-X
hybrids	B-X
are	B-X
representative	B-X
of	B-X
at	B-X
least	B-X
three	B-X
different	B-X
histories	B-X
.	B-X

(	O
C	O
)	O
Schematic	O
diagram	O
of	O
the	O
transcriptional	O
network	O
involving	O
Runx3	B-Protein
and	O
T	O
-	O
box	O
factors	O
.	O

T	B-Protein
-	I-Protein
bet	I-Protein
is	O
induced	O
by	O
TCR	O
signals	O
and	O
is	O
essential	O
for	O
early	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
.	O
<EOS>	B-X
T-bet	B-X
is	B-X
a	B-X
Th1-specific	B-X
transcription	B-X
factor	B-X
that	B-X
is	B-X
directly	B-X
involved	B-X
in	B-X
three	B-X
important	B-X
pathways	B-X
for	B-X
Th1	B-X
cell	B-X
differentiation	B-X
,	B-X
namely	B-X
TCR	B-X
signaling	B-X
,	B-X
and	B-X
the	B-X
IFN-gamma-STAT1	B-X
and	B-X
IL-12-STAT4	B-X
pathways	B-X
.	B-X
A	B-X
recent	B-X
study	B-X
also	B-X
showed	B-X
that	B-X
T-bet	B-X
plays	B-X
a	B-X
vital	B-X
role	B-X
in	B-X
innate	B-X
immunity	B-X
.	B-X
However	B-X
,	B-X
the	B-X
molecular	B-X
mechanism	B-X
responsible	B-X
for	B-X
transcriptional	B-X
activation	B-X
of	B-X
T-bet	B-X
during	B-X
T	B-X
cell	B-X
development	B-X
is	B-X
not	B-X
yet	B-X
known	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
characterize	B-X
the	B-X
essential	B-X
human	B-X
T-bet	B-X
promoter	B-X
elements	B-X
and	B-X
show	B-X
that	B-X
binding	B-X
of	B-X
EGR1	B-X
to	B-X
this	B-X
promoter	B-X
induces	B-X
T-bet	B-X
transcription	B-X
.	B-X
Notably	B-X
,	B-X
overexpression	B-X
of	B-X
EGR1	B-X
transactivates	B-X
and	B-X
,	B-X
synergistically	B-X
in	B-X
concert	B-X
with	B-X
TCR	B-X
signaling	B-X
,	B-X
induces	B-X
T-bet	B-X
expression	B-X
in	B-X
activated	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
depletion	B-X
of	B-X
EGR1	B-X
significantly	B-X
decreases	B-X
T-bet	B-X
induction	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
report	B-X
a	B-X
positive	B-X
correlation	B-X
between	B-X
EGR1	B-X
and	B-X
T-bet	B-X
expression	B-X
during	B-X
T	B-X
helper	B-X
cell	B-X
differentiation	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
findings	B-X
provide	B-X
molecular	B-X
insight	B-X
into	B-X
T-bet	B-X
transcription	B-X
and	B-X
suggest	B-X
that	B-X
EGR1	B-X
is	B-X
an	B-X
upstream	B-X
regulator	B-X
of	B-X
T-bet	B-X
induction	B-X
.	B-X

Runx3	B-Protein
is	O
present	O
in	O
naive	O
CD8	B-Protein
+	O
T	O
cells	O
and	O
represses	O
Runx1	B-Protein
and	O
induces	O
Eomes	B-Protein
,	O
perforin	B-Protein
,	O
granzyme	B-Protein
B	I-Protein
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
.	O

Eomes	B-Protein
may	O
participate	O
in	O
sustaining	O
late	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
,	O
whereas	O
Runx3	B-Protein
and	O
Eomes	B-Protein
(	O
but	O
not	O
T	B-Protein
-	I-Protein
bet	I-Protein
)	O
may	O
cooperate	O
to	O
activate	O
perforin	B-Protein
expression	O
.	O

The	O
dotted	O
line	O
indicates	O
the	O
partial	O
effect	O
of	O
T	B-Protein
-	I-Protein
bet	I-Protein
deficiency	O
on	O
Gzmb	B-Protein
mRNA	O
but	O
not	O
granzyme	B-Protein
B	I-Protein
protein	O
expression	O
.	O

Insights	O
into	O
the	O
Regulation	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
Production	O
in	O
Human	O
Mononuclear	O
Cells	O
:	O
The	O
Effects	O
of	O
Non	O
-	O
Specific	O
Phosphodiesterase	O
Inhibition	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
effect	B-X
of	B-X
nonspecific	B-X
phosphodiesterase	B-X
inhibition	B-X
on	B-X
transcription	B-X
factor	B-X
activation	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
production	B-X
in	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
-stimulated	B-X
human	B-X
mononuclear	B-X
cells	B-X
.	B-X

OBJECTIVE	O
<EOS>	B-X
Objective	B-X
Metabolomics	B-X
Research	B-X
.	B-X
Goal-setting	B-X
in	B-X
physiotherapy	B-X
:	B-X
exploring	B-X
a	B-X
person-centered	B-X
perspective	B-X
.	B-X
Stress	B-X
in	B-X
Simulation-Based	B-X
Resuscitation	B-X
Education-Seeking	B-X
Objective	B-X
Measures	B-X
to	B-X
Spit	B-X
and	B-X
Swallow	B-X
?	B-X
Specifically	B-X
objective	B-X
.	B-X

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
nonspecific	O
phosphodiesterase	O
inhibition	O
on	O
transcription	O
factor	O
activation	O
and	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
production	O
in	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
stimulated	O
human	O
mononuclear	O
cells	O
.	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
effect	B-X
of	B-X
nonspecific	B-X
phosphodiesterase	B-X
inhibition	B-X
on	B-X
transcription	B-X
factor	B-X
activation	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
production	B-X
in	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
-stimulated	B-X
human	B-X
mononuclear	B-X
cells	B-X
.	B-X

INTRODUCTION	O

The	O
production	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
following	O
LPS	O
stimulation	O
is	O
one	O
of	O
the	O
key	O
steps	O
in	O
bacterial	O
sepsis	O
and	O
inflammation	O
.	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
effect	B-X
of	B-X
nonspecific	B-X
phosphodiesterase	B-X
inhibition	B-X
on	B-X
transcription	B-X
factor	B-X
activation	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
production	B-X
in	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
-stimulated	B-X
human	B-X
mononuclear	B-X
cells	B-X
.	B-X

The	O
mechanism	O
by	O
which	O
phosphodiesterase	O
inhibition	O
alters	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
in	O
the	O
presence	O
of	O
LPS	O
remains	O
unclear	O
.	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
effect	B-X
of	B-X
nonspecific	B-X
phosphodiesterase	B-X
inhibition	B-X
on	B-X
transcription	B-X
factor	B-X
activation	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
production	B-X
in	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
-stimulated	B-X
human	B-X
mononuclear	B-X
cells	B-X
.	B-X

METHODS	O

Human	O
mononuclear	O
cells	O
were	O
stimulated	O
with	O
LPS	O
(	O
1	O
mug	O
/	O
mL	O
)	O
,	O
in	O
the	O
presence	O
and	O
absence	O
of	O
Pentoxifylline	O
(	O
PTX	O
;	O
20	O
mM	O
)	O
,	O
a	O
nonspecific	O
phosphodiesterase	O
inhibitor	O
.	O

Western	O
blotting	O
of	O
phosphorylated	O
cytoplasmic	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
,	O
nuclear	O
factor	O
-	O
kappaB	O
p65	B-Protein
(	O
NF	O
-	O
kappaB	O
)	O
,	O
and	O
nuclear	O
cAMP	O
-	O
response	O
element	O
binding	O
protein	O
(	O
CREB	O
)	O
was	O
performed	O
.	O

DNA	O
binding	O
of	O
NF	O
-	O
kappaB	O
and	O
CREB	O
was	O
verified	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O
<EOS>	B-X
Next	B-X
,	B-X
the	B-X
binding	B-X
of	B-X
activating	B-X
protein	B-X
1	B-X
(	B-X
AP-1	B-X
)	B-X
,	B-X
CCAAT	B-X
enhancer-binding	B-X
protein	B-X
(	B-X
C/EBP	B-X
)	B-X
,	B-X
CRE-binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
,	B-X
and	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
was	B-X
measured	B-X
by	B-X
electrophoretic	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
using	B-X
four	B-X
different	B-X
consensus	B-X
transcriptional	B-X
control	B-X
motifs	B-X
at	B-X
0	B-X
,	B-X
0.5	B-X
,	B-X
1.5	B-X
,	B-X
4	B-X
,	B-X
and	B-X
8	B-X
h	B-X
after	B-X
oral	B-X
exposure	B-X
to	B-X
25	B-X
mg/kg	B-X
of	B-X
VT.	B-X
AP-1	B-X
binding	B-X
activity	B-X
was	B-X
differentially	B-X
elevated	B-X
from	B-X
0.5	B-X
h	B-X
to	B-X
8	B-X
h	B-X
,	B-X
whereas	B-X
C/EBP	B-X
binding	B-X
was	B-X
elevated	B-X
only	B-X
at	B-X
0.5	B-X
h.	B-X
CREB	B-X
binding	B-X
decreased	B-X
slightly	B-X
at	B-X
0.5	B-X
h	B-X
but	B-X
gradually	B-X
increased	B-X
,	B-X
reaching	B-X
a	B-X
maximum	B-X
at	B-X
4	B-X
h.	B-X
NF-kappaB	B-X
binding	B-X
was	B-X
increased	B-X
only	B-X
slightly	B-X
at	B-X
4	B-X
and	B-X
8	B-X
h.	B-X
The	B-X
specificities	B-X
of	B-X
AP-1	B-X
,	B-X
C/EBP	B-X
,	B-X
CREB	B-X
,	B-X
and	B-X
NF-kappaB	B-X
for	B-X
relevant	B-X
DNA	B-X
motifs	B-X
were	B-X
verified	B-X
by	B-X
competition	B-X
assays	B-X
,	B-X
using	B-X
an	B-X
excess	B-X
of	B-X
unlabeled	B-X
consensus	B-X
and	B-X
mutant	B-X
oligonucleotides	B-X
.	B-X
Supershift	B-X
EMSAs	B-X
and	B-X
Western	B-X
blot	B-X
analysis	B-X
identified	B-X
specific	B-X
VT-inducible	B-X
DNA	B-X
binding	B-X
proteins	B-X
for	B-X
AP-1	B-X
(	B-X
cJun	B-X
,	B-X
phospho	B-X
c-jun	B-X
,	B-X
JunB	B-X
,	B-X
and	B-X
JunD	B-X
)	B-X
,	B-X
C/EBP	B-X
(	B-X
C/EBPbeta	B-X
)	B-X
,	B-X
CREB	B-X
(	B-X
CREB-1	B-X
and	B-X
ATF-2	B-X
)	B-X
,	B-X
and	B-X
NF-kappaB	B-X
(	B-X
p50	B-X
and	B-X
cRel	B-X
)	B-X
.	B-X
Finally	B-X
,	B-X
when	B-X
the	B-X
effects	B-X
of	B-X
oral	B-X
VT	B-X
exposure	B-X
on	B-X
proinflammatory	B-X
gene	B-X
expression	B-X
were	B-X
assessed	B-X
at	B-X
3	B-X
,	B-X
6	B-X
,	B-X
and	B-X
9	B-X
h	B-X
,	B-X
splenic	B-X
TNF-alpha	B-X
,	B-X
IL-1beta	B-X
,	B-X
and	B-X
IL-6	B-X
mRNA	B-X
were	B-X
found	B-X
to	B-X
peak	B-X
at	B-X
3	B-X
h	B-X
and	B-X
were	B-X
still	B-X
significantly	B-X
elevated	B-X
at	B-X
6	B-X
h	B-X
but	B-X
not	B-X
at	B-X
9	B-X
h.	B-X
Taken	B-X
together	B-X
,	B-X
VT	B-X
first	B-X
activated	B-X
MAPKs	B-X
in	B-X
vivo	B-X
and	B-X
either	B-X
concurrently	B-X
(	B-X
AP-1	B-X
,	B-X
C/EBP	B-X
)	B-X
or	B-X
subsequently	B-X
(	B-X
AP-1	B-X
,	B-X
CREB	B-X
,	B-X
NF-kappaB	B-X
)	B-X
modulated	B-X
binding	B-X
activities	B-X
of	B-X
transcription	B-X
factors	B-X
specific	B-X
for	B-X
potential	B-X
regulatory	B-X
motifs	B-X
in	B-X
cytokine	B-X
promoters	B-X
.	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
effect	B-X
of	B-X
nonspecific	B-X
phosphodiesterase	B-X
inhibition	B-X
on	B-X
transcription	B-X
factor	B-X
activation	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
production	B-X
in	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
-stimulated	B-X
human	B-X
mononuclear	B-X
cells	B-X
.	B-X

TNF	B-Protein
-	I-Protein
alpha	I-Protein
levels	O
were	O
determined	O
in	O
the	O
supernatant	O
of	O
stimulated	O
cells	O
in	O
the	O
presence	O
and	O
absence	O
Protein	O
kinase	O
A	O
inhibition	O
by	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
effect	B-X
of	B-X
nonspecific	B-X
phosphodiesterase	B-X
inhibition	B-X
on	B-X
transcription	B-X
factor	B-X
activation	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
production	B-X
in	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
-stimulated	B-X
human	B-X
mononuclear	B-X
cells	B-X
.	B-X

RESULTS	O

PTX	O
was	O
demonstrated	O
to	O
significantly	O
reduce	O
cytoplasmic	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
phosphorylation	O
,	O
nuclear	O
p65	B-Protein
phosphorylation	O
,	O
and	O
the	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
.	O

In	O
contrast	O
,	O
PTX	O
markedly	O
enhanced	O
the	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
of	O
CREB	O
.	O

Cells	O
concomitantly	O
treated	O
with	O
PTX	O
and	O
LPS	O
secreted	O
similar	O
levels	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
in	O
the	O
presence	O
and	O
absence	O
Protein	O
kinase	O
A	O
inhibition	O
.	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
effect	B-X
of	B-X
nonspecific	B-X
phosphodiesterase	B-X
inhibition	B-X
on	B-X
transcription	B-X
factor	B-X
activation	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
production	B-X
in	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
-stimulated	B-X
human	B-X
mononuclear	B-X
cells	B-X
.	B-X

DISCUSSION	O

The	O
increased	O
level	O
of	O
cAMP	O
that	O
results	O
from	O
phosphodiesterase	O
inhibition	O
affects	O
cytoplasmic	O
and	O
nuclear	O
events	O
,	O
resulting	O
in	O
the	O
attenuation	O
of	O
NF	O
-	O
kappaB	O
and	O
the	O
activation	O
of	O
CREB	O
transcriptional	O
DNA	O
binding	O
through	O
pathways	O
that	O
are	O
partially	O
Protein	O
kinase	O
A	O
-	O
independent	O
.	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
effect	B-X
of	B-X
nonspecific	B-X
phosphodiesterase	B-X
inhibition	B-X
on	B-X
transcription	B-X
factor	B-X
activation	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
production	B-X
in	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
-stimulated	B-X
human	B-X
mononuclear	B-X
cells	B-X
.	B-X

CONCLUSION	O
<EOS>	B-X
Conclusion	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X

PTX	O
-	O
mediated	O
phosphodiesterase	O
inhibition	O
occurs	O
partially	O
through	O
a	O
Protein	O
kinase	O
A	O
-	O
independent	O
pathway	O
and	O
may	O
serve	O
as	O
a	O
useful	O
tool	O
in	O
the	O
attenuation	O
of	O
LPS	O
-	O
induced	O
inflammation	O
.	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
effect	B-X
of	B-X
nonspecific	B-X
phosphodiesterase	B-X
inhibition	B-X
on	B-X
transcription	B-X
factor	B-X
activation	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
production	B-X
in	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
-stimulated	B-X
human	B-X
mononuclear	B-X
cells	B-X
.	B-X

The	O
bacterial	O
membrane	O
component	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
capable	O
of	O
initiating	O
phosphorylation	O
and	O
activation	O
of	O
multiple	O
host	O
intracellular	O
protein	O
kinases	O
and	O
transcription	O
factors	O
.	O

Transcription	O
factor	O
activation	O
,	O
which	O
results	O
in	O
the	O
modulation	O
of	O
gene	O
transcription	O
and	O
protein	O
synthesis	O
,	O
is	O
a	O
critical	O
element	O
in	O
the	O
defense	O
mechanism	O
of	O
the	O
host	O
immune	O
system	O
.	O
1	O
,	O
2	O

LPS	O
-	O
induced	O
transcription	O
factor	O
activation	O
has	O
been	O
shown	O
to	O
be	O
a	O
key	O
regulator	O
of	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
(	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
production	O
.	O
3	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
is	O
a	O
potent	O
pro	O
-	O
inflammatory	O
cytokine	O
involved	O
in	O
a	O
wide	O
spectrum	O
of	O
cellular	O
responses	O
.	O

Furthermore	O
,	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
synthesis	O
can	O
be	O
attenuated	O
in	O
immune	O
cells	O
exposed	O
to	O
phosphodiesterase	O
(	O
PDE	O
)	O
inhibition	O
after	O
challenge	O
by	O
a	O
variety	O
of	O
pro	O
-	O
inflammatory	O
stimulants	O
.	O
4	O
The	O
signaling	O
mechanisms	O
affected	O
by	O
PDE	O
inhibition	O
,	O
which	O
ultimately	O
lead	O
to	O
the	O
downregulation	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
,	O
have	O
not	O
been	O
well	O
characterized	O
in	O
inflammatory	O
cells	O
.	O

Classically	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
PDE	O
inhibition	O
results	O
in	O
the	O
intracellular	O
accumulation	O
of	O
the	O
second	O
messenger	O
cyclic	O
adenosine	O
-	O
3	O
,	O
5	O
-	O
monophosphate	O
(	O
cAMP	O
)	O
and	O
subsequent	O
activation	O
of	O
Protein	O
kinase	O
A	O
(	O
PKA	O
)	O
.	O
5	O
PKA	O
activation	O
then	O
leads	O
to	O
the	O
phosphorylation	O
of	O
the	O
transcription	O
factor	O
cAMP	O
-	O
response	O
element	O
binding	O
protein	O
(	O
CREB	O
)	O
,	O
transmission	O
of	O
signals	O
into	O
the	O
nucleus	O
,	O
and	O
the	O
subsequent	O
modulation	O
of	O
gene	O
transcription	O
.	O
6	O
This	O
apparently	O
simple	O
linear	O
cascade	O
does	O
not	O
fully	O
explain	O
the	O
mechanism	O
by	O
which	O
an	O
elevation	O
in	O
the	O
intracellular	O
cAMP	O
level	O
exerts	O
wide	O
-	O
ranging	O
effects	O
on	O
multiple	O
cellular	O
functions	O
.	O

There	O
is	O
a	O
growing	O
body	O
of	O
evidence	O
suggesting	O
that	O
cAMP	O
may	O
function	O
through	O
both	O
PKA	O
-	O
dependent	O
and	O
-	O
independent	O
mechanisms	O
.	O
6	O
-	O
8	O

LPS	O
-	O
induced	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
has	O
also	O
been	O
the	O
focus	O
of	O
a	O
great	O
deal	O
of	O
research	O
.	O

It	O
has	O
been	O
clearly	O
demonstrated	O
that	O
agents	O
that	O
increase	O
intracellular	O
cAMP	O
also	O
inhibit	O
NF	O
-	O
kappaB	O
-	O
dependent	O
pro	O
-	O
inflammatory	O
gene	O
transcription	O
,	O
particularly	O
of	O
the	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
gene	O
.	O
9	O

Controversy	O
exists	O
regarding	O
the	O
exact	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
PDE	O
inhibition	O
down	O
-	O
regulates	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
.	O

Possibilities	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
,	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
,	O
downregulation	O
of	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
,	O
increased	O
CREB	O
activation	O
,	O
and	O
competition	O
between	O
NF	O
-	O
kappaB	O
and	O
CREB	O
for	O
common	O
co	O
-	O
activators	O
such	O
as	O
CREB	O
binding	O
protein	O
(	O
CBP	O
)	O
.	O
<EOS>	B-X
Neuroretinitis	B-X
is	B-X
an	B-X
inflammatory	B-X
disorder	B-X
of	B-X
the	B-X
eye	B-X
presenting	B-X
with	B-X
optic	B-X
disc	B-X
edema	B-X
and	B-X
the	B-X
delayed	B-X
development	B-X
of	B-X
a	B-X
macular	B-X
star	B-X
secondary	B-X
to	B-X
optic	B-X
nerve	B-X
swelling	B-X
toward	B-X
the	B-X
macular	B-X
structures	B-X
.	B-X
Use	B-X
of	B-X
high-resolution	B-X
micro-computed	B-X
tomography	B-X
(	B-X
microCT	B-X
)	B-X
imaging	B-X
to	B-X
assess	B-X
trabecular	B-X
and	B-X
cortical	B-X
bone	B-X
morphology	B-X
has	B-X
grown	B-X
immensely	B-X
.	B-X
There	B-X
are	B-X
several	B-X
commercially	B-X
available	B-X
microCT	B-X
systems	B-X
,	B-X
each	B-X
with	B-X
different	B-X
approaches	B-X
to	B-X
image	B-X
acquisition	B-X
,	B-X
evaluation	B-X
,	B-X
and	B-X
reporting	B-X
of	B-X
outcomes	B-X
.	B-X
This	B-X
lack	B-X
of	B-X
consistency	B-X
makes	B-X
it	B-X
difficult	B-X
to	B-X
interpret	B-X
reported	B-X
results	B-X
and	B-X
to	B-X
compare	B-X
findings	B-X
across	B-X
different	B-X
studies	B-X
.	B-X
This	B-X
article	B-X
addresses	B-X
this	B-X
critical	B-X
need	B-X
for	B-X
standardized	B-X
terminology	B-X
and	B-X
consistent	B-X
reporting	B-X
of	B-X
parameters	B-X
related	B-X
to	B-X
image	B-X
acquisition	B-X
and	B-X
analysis	B-X
,	B-X
and	B-X
key	B-X
outcome	B-X
assessments	B-X
,	B-X
particularly	B-X
with	B-X
respect	B-X
to	B-X
ex	B-X
vivo	B-X
analysis	B-X
of	B-X
rodent	B-X
specimens	B-X
.	B-X
Thus	B-X
the	B-X
guidelines	B-X
herein	B-X
provide	B-X
recommendations	B-X
regarding	B-X
(	B-X
1	B-X
)	B-X
standardized	B-X
terminology	B-X
and	B-X
units	B-X
,	B-X
(	B-X
2	B-X
)	B-X
information	B-X
to	B-X
be	B-X
included	B-X
in	B-X
describing	B-X
the	B-X
methods	B-X
for	B-X
a	B-X
given	B-X
experiment	B-X
,	B-X
and	B-X
(	B-X
3	B-X
)	B-X
a	B-X
minimal	B-X
set	B-X
of	B-X
outcome	B-X
variables	B-X
that	B-X
should	B-X
be	B-X
reported	B-X
.	B-X
Whereas	B-X
the	B-X
specific	B-X
research	B-X
objective	B-X
will	B-X
determine	B-X
the	B-X
experimental	B-X
design	B-X
,	B-X
these	B-X
guidelines	B-X
are	B-X
intended	B-X
to	B-X
ensure	B-X
accurate	B-X
and	B-X
consistent	B-X
reporting	B-X
of	B-X
microCT-derived	B-X
bone	B-X
morphometry	B-X
and	B-X
density	B-X
measurements	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
the	B-X
methods	B-X
section	B-X
for	B-X
papers	B-X
that	B-X
present	B-X
microCT-based	B-X
outcomes	B-X
must	B-X
include	B-X
details	B-X
of	B-X
the	B-X
following	B-X
scan	B-X
aspects	B-X
:	B-X
(	B-X
1	B-X
)	B-X
image	B-X
acquisition	B-X
,	B-X
including	B-X
the	B-X
scanning	B-X
medium	B-X
,	B-X
X-ray	B-X
tube	B-X
potential	B-X
,	B-X
and	B-X
voxel	B-X
size	B-X
,	B-X
as	B-X
well	B-X
as	B-X
clear	B-X
descriptions	B-X
of	B-X
the	B-X
size	B-X
and	B-X
location	B-X
of	B-X
the	B-X
volume	B-X
of	B-X
interest	B-X
and	B-X
the	B-X
method	B-X
used	B-X
to	B-X
delineate	B-X
trabecular	B-X
and	B-X
cortical	B-X
bone	B-X
regions	B-X
,	B-X
and	B-X
(	B-X
2	B-X
)	B-X
image	B-X
processing	B-X
,	B-X
including	B-X
the	B-X
algorithms	B-X
used	B-X
for	B-X
image	B-X
filtration	B-X
and	B-X
the	B-X
approach	B-X
used	B-X
for	B-X
image	B-X
segmentation	B-X
.	B-X
When	B-X
reporting	B-X
microCT	B-X
results	B-X
,	B-X
the	B-X
minimal	B-X
set	B-X
of	B-X
variables	B-X
that	B-X
should	B-X
be	B-X
used	B-X
to	B-X
describe	B-X
trabecular	B-X
bone	B-X
morphometry	B-X
includes	B-X
bone	B-X
volume	B-X
fraction	B-X
and	B-X
trabecular	B-X
number	B-X
,	B-X
thickness	B-X
,	B-X
and	B-X
separation	B-X
.	B-X
The	B-X
minimal	B-X
set	B-X
of	B-X
variables	B-X
that	B-X
should	B-X
be	B-X
used	B-X
to	B-X
describe	B-X
cortical	B-X
bone	B-X
morphometry	B-X
includes	B-X
total	B-X
cross-sectional	B-X
area	B-X
,	B-X
cortical	B-X
bone	B-X
area	B-X
,	B-X
cortical	B-X
bone	B-X
area	B-X
fraction	B-X
,	B-X
and	B-X
cortical	B-X
thickness	B-X
.	B-X

It	O
is	O
also	O
not	O
known	O
whether	O
these	O
processes	O
rely	O
solely	O
upon	O
the	O
activation	O
of	O
PKA	O
.	O

Therefore	O
,	O
the	O
objective	O
of	O
the	O
present	O
study	O
is	O
to	O
determine	O
the	O
effects	O
of	O
nonspecific	O
PDE	O
inhibition	O
with	O
1	O
-	O
[	O
5	O
-	O
oxohexyl	O
]	O
-	O
3	O
,	O
7	O
-	O
dimethylxanthine	O
(	O
Pentoxifylline	O
;	O
PTX	O
)	O
on	O
NF	O
-	O
kappaB	O
and	O
CREB	O
activation	O
in	O
vitro	O
in	O
human	O
mononuclear	O
cells	O
.	O

With	O
the	O
use	O
of	O
specific	O
inhibitors	O
,	O
we	O
also	O
investigated	O
the	O
role	O
of	O
PKA	O
in	O
LPS	O
-	O
induced	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
.	O
<EOS>	B-X
Neuroinflammation	B-X
and	B-X
oxidative	B-X
stress	B-X
play	B-X
key	B-X
roles	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
neurodegenerative	B-X
diseases	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
use	B-X
of	B-X
potent	B-X
anti-inflammatory/antioxidant	B-X
agents	B-X
has	B-X
been	B-X
suggested	B-X
as	B-X
a	B-X
promising	B-X
therapeutic	B-X
strategy	B-X
for	B-X
neurodegenerative	B-X
diseases	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
anti-inflammatory	B-X
and	B-X
antioxidant	B-X
effects	B-X
of	B-X
nootkatone	B-X
(	B-X
NKT	B-X
)	B-X
,	B-X
a	B-X
sesquiterpenoid	B-X
compound	B-X
isolated	B-X
from	B-X
grapefruit	B-X
,	B-X
in	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
models	B-X
of	B-X
neuroinflammation	B-X
.	B-X
In	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
-stimulated	B-X
BV2	B-X
microglial	B-X
cells	B-X
,	B-X
NKT	B-X
inhibited	B-X
the	B-X
expression	B-X
of	B-X
iNOS	B-X
,	B-X
COX-2	B-X
,	B-X
and	B-X
pro-inflammatory	B-X
cytokines	B-X
,	B-X
and	B-X
increased	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
anti-inflammatory	B-X
cytokine	B-X
,	B-X
IL-10	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
NKT	B-X
inhibited	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
production	B-X
and	B-X
upregulated	B-X
the	B-X
expression	B-X
of	B-X
antioxidant	B-X
enzymes	B-X
,	B-X
such	B-X
as	B-X
NQO1	B-X
and	B-X
HO-1	B-X
.	B-X
Molecular	B-X
mechanistic	B-X
studies	B-X
showed	B-X
that	B-X
NKT	B-X
inhibited	B-X
Akt	B-X
,	B-X
p38	B-X
MAPK	B-X
,	B-X
and	B-X
NF-κB	B-X
activities	B-X
,	B-X
while	B-X
increasing	B-X
AMPK	B-X
,	B-X
PKA/CREB	B-X
,	B-X
and	B-X
Nrf2/ARE	B-X
signaling	B-X
in	B-X
LPS-stimulated	B-X
BV2	B-X
cells	B-X
.	B-X
Since	B-X
NKT	B-X
dramatically	B-X
increased	B-X
NQO1	B-X
expression	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
this	B-X
enzyme	B-X
using	B-X
pharmacological	B-X
inhibition	B-X
or	B-X
knockdown	B-X
experiments	B-X
.	B-X
Treatment	B-X
of	B-X
BV2	B-X
cells	B-X
with	B-X
the	B-X
NQO1-specific	B-X
inhibitor	B-X
,	B-X
dicoumarol	B-X
,	B-X
or	B-X
with	B-X
NQO1	B-X
siRNA	B-X
significantly	B-X
blocked	B-X
NKT-mediated	B-X
inhibition	B-X
of	B-X
NO	B-X
,	B-X
ROS	B-X
,	B-X
TNF-α	B-X
,	B-X
IL-1β	B-X
,	B-X
and	B-X
upregulation	B-X
of	B-X
IL-10	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
NKT	B-X
inhibited	B-X
microglial	B-X
activation	B-X
,	B-X
lipid	B-X
peroxidation	B-X
,	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
pro-inflammatory	B-X
markers	B-X
in	B-X
the	B-X
brains	B-X
of	B-X
LPS-injected	B-X
mice	B-X
,	B-X
which	B-X
was	B-X
also	B-X
reversed	B-X
by	B-X
dicoumarol	B-X
.	B-X
These	B-X
data	B-X
collectively	B-X
suggest	B-X
that	B-X
NQO1	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
mediating	B-X
the	B-X
anti-inflammatory	B-X
and	B-X
antioxidant	B-X
effects	B-X
of	B-X
NKT	B-X
in	B-X
LPS-induced	B-X
neuroinflammation	B-X
by	B-X
modulating	B-X
AMPK	B-X
and	B-X
its	B-X
downstream	B-X
signaling	B-X
pathways	B-X
.	B-X

This	O
study	O
was	O
approved	O
by	O
the	O
Human	O
Research	O
Protections	O
Program	O
and	O
the	O
Institutional	O
Review	O
Board	O
.	O
<EOS>	B-X
In	B-X
our	B-X
study	B-X
protocol	B-X
,	B-X
we	B-X
complement	B-X
prior	B-X
experiences	B-X
in	B-X
DV	B-X
prevention	B-X
by	B-X
promoting	B-X
protective	B-X
factors	B-X
(	B-X
or	B-X
assets	B-X
)	B-X
against	B-X
gender	B-X
violence	B-X
such	B-X
as	B-X
communication	B-X
skills	B-X
,	B-X
empathy	B-X
and	B-X
problem-solving	B-X
capability	B-X
through	B-X
``	B-X
Cinema	B-X
Voice	B-X
''	B-X
,	B-X
a	B-X
participatory	B-X
educational	B-X
intervention	B-X
based	B-X
on	B-X
adolescents	B-X
'	B-X
strengths	B-X
to	B-X
tackle	B-X
DV	B-X
.	B-X
The	B-X
study	B-X
aimed	B-X
to	B-X
determine	B-X
the	B-X
efficacy	B-X
of	B-X
melatonin	B-X
supplementation	B-X
for	B-X
sleep	B-X
disturbances	B-X
in	B-X
patients	B-X
with	B-X
traumatic	B-X
brain	B-X
injury	B-X
(	B-X
TBI	B-X
)	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
pilot	B-X
study	B-X
is	B-X
to	B-X
investigate	B-X
the	B-X
effectiveness	B-X
of	B-X
T	B-X
&	B-X
CM	B-X
interventions	B-X
on	B-X
smoking	B-X
cessation	B-X
.	B-X
We	B-X
report	B-X
final	B-X
results	B-X
from	B-X
the	B-X
largest	B-X
prospective	B-X
,	B-X
observational	B-X
,	B-X
multicenter	B-X
study	B-X
of	B-X
patients	B-X
with	B-X
aHUS	B-X
treated	B-X
with	B-X
eculizumab	B-X
.	B-X

Written	O
consent	O
to	O
participate	O
in	O
the	O
study	O
was	O
obtained	O
from	O
all	O
volunteers	O
prior	O
to	O
blood	O
donation	O
.	O
Heparinized	O
Vacutainers	O
were	O
purchased	O
from	O
Becton	O
Dickinson	O
(	O
San	O
Jose	O
,	O
CA	O
)	O
.	O

1	O
.	O
5	O
-	O
mL	O
Eppendorf	O
centrifuge	O
tubes	O
were	O
purchased	O
from	O
Fisher	O
Scientific	O
(	O
Pittsburg	O
,	O
PA	O
)	O
.	O

Hank	O
'	O
s	O
balanced	O
salt	O
solution	O
(	O
HBSS	O
)	O
and	O
RPMI	O
1640	O
were	O
obtained	O
from	O
Irvine	O
Scientific	O
(	O
Santa	O
Ana	O
,	O
CA	O
)	O
.	O

LPS	O
fromEscherichia	O
coliserotype	O
0111	O
:	O
B4	O
and	O
PTX	O
were	O
purchased	O
from	O
Sigma	O
(	O
St	O
.	O
Louis	O
,	O
MO	O
)	O
.	O

The	O
PKA	O
inhibitor	O
,	O
N	O
-	O
[	O
2	O
-	O
(	O
(	O
p	O
-	O
bromocinnamyl	O
)	O
amino	O
)	O
ethyl	O
]	O
-	O
5	O
-	O
isoguinolinesulfonamide	O
-	O
2HCl	O
]	O
(	O
H89	O
)	O
,	O
was	O
purchased	O
from	O
Calbiochem	O
(	O
La	O
Jolla	O
,	O
CA	O
)	O
.	O

Antibodies	O
for	O
phosphorylated	O
CREB	B-Protein
(	O
serine	O
133	O
)	O
,	O
phosphorylated	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
(	O
serines	O
32	O
and	O
36	O
)	O
,	O
phosphorylated	O
NF	O
-	O
kappaB	O
p65	B-Protein
subunit	O
(	O
serine	O
276	O
)	O
,	O
and	O
secondary	O
antibodies	O
were	O
purchased	O
from	O
Cell	O
Signaling	O
(	O
Beverly	O
,	O
MA	O
)	O
.	O
Dextran	O
T500	O
and	O
Percoll	O
were	O
received	O
from	O
GE	O
Healthcare	O
/	O
Amersham	O
Biosciences	O
(	O
Piscataway	O
,	O
NJ	O
)	O
.	O

The	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
was	O
obtained	O
from	O
Quantikine	O
R	O
&	O
D	O
Systems	O
(	O
Minneapolis	O
,	O
MN	O
)	O
.	O
Tris	O
-	O
glycine	O
and	O
DNA	O
retardation	O
gels	O
,	O
nitrocellulose	O
membranes	O
,	O
and	O
western	O
blot	O
running	O
buffers	O
were	O
obtained	O
from	O
Invitrogen	O
(	O
Carlsbad	O
,	O
CA	O
)	O
.	O
<EOS>	B-X
In	B-X
order	B-X
to	B-X
study	B-X
the	B-X
relation	B-X
to	B-X
the	B-X
metastatic	B-X
profile	B-X
and	B-X
survival	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
association	B-X
between	B-X
pretreatment	B-X
serum	B-X
levels	B-X
of	B-X
IL-6	B-X
,	B-X
TNF-alpha	B-X
,	B-X
and	B-X
erythropoietin	B-X
(	B-X
EPO	B-X
)	B-X
and	B-X
metastatic	B-X
distribution	B-X
and	B-X
survival	B-X
in	B-X
16	B-X
patients	B-X
with	B-X
metastatic	B-X
malignant	B-X
melanoma	B-X
.	B-X
IL-6	B-X
and	B-X
TNF-alpha	B-X
immunoassay	B-X
(	B-X
R	B-X
&	B-X
D	B-X
Systems	B-X
,	B-X
Inc.	B-X
Minneapolis	B-X
,	B-X
USA	B-X
)	B-X
employs	B-X
the	B-X
quantitative	B-X
sandwich	B-X
enzyme	B-X
immunoassay	B-X
technique	B-X
.	B-X
The	B-X
Quantikine	B-X
IVD	B-X
EPO	B-X
ELISA	B-X
(	B-X
R	B-X
&	B-X
D	B-X
Systems	B-X
,	B-X
Inc.	B-X
)	B-X
is	B-X
based	B-X
on	B-X
the	B-X
double-antibody	B-X
sandwich	B-X
method	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
both	B-X
serum	B-X
TNF-alpha	B-X
and	B-X
EPO	B-X
levels	B-X
were	B-X
of	B-X
no	B-X
prognostic	B-X
value	B-X
.	B-X

NE	O
-	O
PER	O
(	O
R	O
)	O
nuclear	O
and	O
cytoplasmic	O
extraction	O
reagents	O
,	O
the	O
BCA	O
protein	O
reagent	O
kit	O
,	O
the	O
Supersignal	O
West	O
Pico	O
Chemiluminescent	O
Kit	O
,	O
and	O
the	O
LightShift	O
Chemiluminescent	O
EMSA	O
Kit	O
were	O
purchased	O
from	O
Pierce	O
(	O
Rockland	O
,	O
IL	O
)	O
.	O

CREB	O
and	O
NF	O
-	O
kappaB	O
DNA	O
oligonucleotide	O
probes	O
were	O
synthesized	O
by	O
IDT	O
(	O
Coralville	O
,	O
IA	O
)	O
.	O

Nylon	O
membranes	O
were	O
purchased	O
from	O
Roche	O
Applied	O
Sciences	O
(	O
Indianapolis	O
,	O
IN	O
)	O
.	O

Western	O
blot	O
band	O
quantification	O
was	O
performed	O
with	O
the	O
UN	O
-	O
SCAN	O
-	O
IT	O
Gel	O
Digitizing	O
software	O
(	O
Silk	O
Scientific	O
,	O
Orem	O
,	O
UT	O
)	O
.	O

Human	O
Peripheral	O
Blood	O
Mononuclear	O
Cell	O
Isolation	O
and	O
Stimulation	O
<EOS>	B-X
Cell	B-X
recovery	B-X
and	B-X
viability	B-X
were	B-X
assessed	B-X
using	B-X
a	B-X
hemacytometer	B-X
and	B-X
trypan	B-X
blue	B-X
.	B-X
Cell	B-X
functionality	B-X
was	B-X
assessed	B-X
in	B-X
stimulated	B-X
(	B-X
100	B-X
ng/mL	B-X
staphylococcal	B-X
enterotoxin	B-X
B	B-X
[	B-X
SEB	B-X
]	B-X
)	B-X
and	B-X
unstimulated	B-X
24	B-X
hours	B-X
PBMC	B-X
cultures	B-X
,	B-X
with	B-X
cytokine	B-X
production	B-X
and	B-X
lactate	B-X
dehydrogenase	B-X
(	B-X
LDH	B-X
)	B-X
release	B-X
as	B-X
readout	B-X
measures	B-X
.	B-X
Cell	B-X
viability	B-X
,	B-X
assessed	B-X
by	B-X
trypan	B-X
blue	B-X
exclusion	B-X
,	B-X
was	B-X
100	B-X
%	B-X
for	B-X
all	B-X
three	B-X
isolation	B-X
techniques	B-X
.	B-X
Stimulation	B-X
of	B-X
BPMC	B-X
by	B-X
LPS	B-X
seems	B-X
to	B-X
activate	B-X
the	B-X
initial	B-X
steps	B-X
of	B-X
the	B-X
immune	B-X
response	B-X
(	B-X
macrophages	B-X
and	B-X
granulocytes	B-X
)	B-X
only	B-X
,	B-X
while	B-X
infection	B-X
with	B-X
live	B-X
Borrelia	B-X
also	B-X
stimulates	B-X
the	B-X
later	B-X
phase	B-X
of	B-X
the	B-X
immune	B-X
response	B-X
,	B-X
probably	B-X
due	B-X
to	B-X
effect	B-X
of	B-X
initially	B-X
produced	B-X
cytokines	B-X
.	B-X

Human	O
mononuclear	O
cells	O
were	O
isolated	O
from	O
the	O
peripheral	O
blood	O
of	O
four	O
healthy	O
human	O
volunteers	O
.	O
<EOS>	B-X
CircRNAs	B-X
remain	B-X
unexplored	B-X
in	B-X
specific	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
during	B-X
sepsis	B-X
.	B-X
We	B-X
here	B-X
sought	B-X
to	B-X
identify	B-X
and	B-X
characterize	B-X
circRNA	B-X
expression	B-X
in	B-X
specific	B-X
PBMCs	B-X
of	B-X
patients	B-X
with	B-X
sepsis	B-X
due	B-X
to	B-X
community-acquired	B-X
pneumonia	B-X
(	B-X
CAP	B-X
)	B-X
relative	B-X
to	B-X
healthy	B-X
subjects	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
evaluate	B-X
immunomodulatory	B-X
effect	B-X
of	B-X
four	B-X
different	B-X
AgNPs	B-X
on	B-X
human	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
hPBMCs	B-X
)	B-X
.	B-X
Fresh	B-X
hPBMCs	B-X
were	B-X
exposed	B-X
to	B-X
the	B-X
small	B-X
sized	B-X
(	B-X
~	B-X
10	B-X
nm	B-X
)	B-X
AgNPs	B-X
immediately	B-X
after	B-X
isolation	B-X
from	B-X
the	B-X
whole	B-X
blood	B-X
of	B-X
healthy	B-X
volunteers	B-X
.	B-X
The	B-X
AgNPs	B-X
differed	B-X
in	B-X
surface	B-X
charge	B-X
and	B-X
were	B-X
stabilised	B-X
with	B-X
polyvinyl	B-X
pyrrolidone	B-X
(	B-X
PVP	B-X
)	B-X
,	B-X
poly-L-lysine	B-X
(	B-X
PLL	B-X
)	B-X
,	B-X
bis	B-X
(	B-X
2-ethylhexyl	B-X
)	B-X
sulfosuccinate	B-X
sodium	B-X
(	B-X
AOT	B-X
)	B-X
or	B-X
blood	B-X
serum	B-X
albumin	B-X
(	B-X
BSA	B-X
)	B-X
.	B-X
The	B-X
T-cells	B-X
and	B-X
monocytes	B-X
were	B-X
not	B-X
activated	B-X
after	B-X
treatment	B-X
with	B-X
AgNPs	B-X
,	B-X
but	B-X
the	B-X
highest	B-X
concentration	B-X
of	B-X
PLL-	B-X
and	B-X
BSA-AgNPs	B-X
decreased	B-X
density	B-X
of	B-X
CD4	B-X
and	B-X
CD8	B-X
markers	B-X
on	B-X
T-helper	B-X
and	B-X
T-cytotoxic	B-X
cells	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
same	B-X
AgNPs	B-X
activated	B-X
B-	B-X
and	B-X
NK-cells	B-X
.	B-X
Ionic	B-X
Ag	B-X
activated	B-X
T-	B-X
,	B-X
B-	B-X
and	B-X
NK-cells	B-X
,	B-X
but	B-X
at	B-X
very	B-X
higher	B-X
concentration	B-X
,	B-X
whereas	B-X
only	B-X
PLL	B-X
exhibited	B-X
immunomodulatory	B-X
activity	B-X
.	B-X

The	O
sample	O
size	O
was	O
chosen	O
from	O
our	O
previously	O
published	O
work	O
,	O
which	O
demonstrated	O
reliable	O
results	O
.	O
10	O
Cell	O
isolation	O
and	O
all	O
subsequent	O
experiments	O
were	O
conducted	O
under	O
sterile	O
and	O
pyrogen	O
-	O
free	O
conditions	O
.	O

Blood	O
collected	O
in	O
heparin	O
tubes	O
was	O
incubated	O
with	O
Dextran	O
T500	O
and	O
the	O
red	O
cells	O
were	O
sedimented	O
for	O
40	O
minutes	O
at	O
room	O
temperature	O
.	O

The	O
resultant	O
serum	O
was	O
then	O
washed	O
with	O
HBSS	O
and	O
separated	O
by	O
Percoll	O
gradient	O
centrifugation	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Cell	O
viability	O
was	O
assessed	O
by	O
trypan	O
blue	O
dye	O
exclusion	O
,	O
with	O
purity	O
of	O
greater	O
than	O
95	O
%	O
.	O

Isolated	O
cells	O
were	O
resuspended	O
in	O
RPMI	O
1640	O
supplemented	O
with	O
10	O
%	O
FBS	O
and	O
5	O
mM	O
HEPES	O
at	O
a	O
concentration	O
of	O
1	O
x	O
107cells	O
/	O
mL	O
.	O

Each	O
subsequent	O
experiment	O
listed	O
below	O
was	O
conducted	O
on	O
samples	O
of	O
5	O
x	O
106	O
cells	O
per	O
treatment	O
group	O
.	O

Isolated	O
cells	O
were	O
stimulated	O
with	O
either	O
HBSS	O
as	O
a	O
negative	O
control	O
,	O
LPS	O
(	O
1	O
mug	O
/	O
mL	O
)	O
,	O
PTX	O
(	O
20	O
mM	O
)	O
,	O
or	O
concomitant	O
LPS	O
/	O
PTX	O
,	O
at	O
the	O
above	O
-	O
mentioned	O
concentrations	O
,	O
for	O
30	O
minutes	O
at	O
37degreesC	O
.	O

Cells	O
were	O
placed	O
on	O
ice	O
for	O
10	O
minutes	O
to	O
stop	O
the	O
reaction	O
and	O
the	O
samples	O
were	O
then	O
stored	O
at	O
-	O
70degreesC	O
for	O
further	O
analysis	O
.	O

The	O
stimulation	O
times	O
and	O
concentrations	O
of	O
LPS	O
and	O
PTX	O
utilized	O
in	O
this	O
study	O
were	O
determined	O
in	O
previous	O
pilot	O
studies	O
done	O
in	O
our	O
laboratory	O
,	O
which	O
examined	O
the	O
effects	O
of	O
increasing	O
concentrations	O
of	O
PTX	O
on	O
LPS	O
-	O
induced	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
.	O

LPS	O
at	O
a	O
concentration	O
of	O
1	O
mug	O
/	O
mL	O
and	O
PTX	O
at	O
a	O
concentration	O
of	O
20	O
mM	O
were	O
the	O
minimum	O
concentrations	O
necessary	O
to	O
produce	O
a	O
reproducible	O
and	O
reliable	O
up	O
-	O
regulation	O
and	O
down	O
-	O
regulation	O
in	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
,	O
respectively	O
,	O
in	O
quantitative	O
assays	O
(	O
data	O
not	O
shown	O
)	O
.	O

Effect	O
of	O
PTX	O
on	O
LPS	O
-	O
induced	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
by	O
mononuclear	O
cells	O
<EOS>	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
effect	B-X
of	B-X
nonspecific	B-X
phosphodiesterase	B-X
inhibition	B-X
on	B-X
transcription	B-X
factor	B-X
activation	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
production	B-X
in	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
-stimulated	B-X
human	B-X
mononuclear	B-X
cells	B-X
.	B-X
Pentoxifylline	B-X
(	B-X
PTX	B-X
)	B-X
is	B-X
a	B-X
methylxanthine	B-X
compound	B-X
known	B-X
to	B-X
inhibit	B-X
the	B-X
production	B-X
of	B-X
tumour	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
by	B-X
monocytic	B-X
cells	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
found	B-X
that	B-X
PTX	B-X
differentially	B-X
regulates	B-X
the	B-X
production	B-X
of	B-X
TNF-alpha	B-X
and	B-X
interleukin-6	B-X
(	B-X
IL-6	B-X
)	B-X
.	B-X
Indeed	B-X
,	B-X
PTX	B-X
at	B-X
high	B-X
concentrations	B-X
triggers	B-X
the	B-X
production	B-X
of	B-X
IL-6	B-X
but	B-X
not	B-X
of	B-X
TNF-alpha	B-X
by	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMC	B-X
)	B-X
.	B-X
Further	B-X
experiments	B-X
indicated	B-X
that	B-X
monocytes	B-X
are	B-X
responsible	B-X
for	B-X
this	B-X
PTX-induced	B-X
IL-6	B-X
production	B-X
.	B-X
When	B-X
PBMC	B-X
were	B-X
stimulated	B-X
with	B-X
LPS	B-X
,	B-X
PTX	B-X
was	B-X
found	B-X
to	B-X
inhibit	B-X
the	B-X
secretion	B-X
of	B-X
TNF-alpha	B-X
as	B-X
well	B-X
as	B-X
the	B-X
accumulation	B-X
of	B-X
TNF-alpha	B-X
messenger	B-X
RNA	B-X
(	B-X
mRNA	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
in	B-X
vivo	B-X
administration	B-X
of	B-X
PTX	B-X
in	B-X
transplant	B-X
patients	B-X
receiving	B-X
the	B-X
first	B-X
dose	B-X
of	B-X
OKT3	B-X
allowed	B-X
to	B-X
decrease	B-X
the	B-X
systemic	B-X
release	B-X
of	B-X
TNF-alpha	B-X
but	B-X
not	B-X
of	B-X
IL-6	B-X
.	B-X
Since	B-X
monocytes	B-X
represent	B-X
a	B-X
major	B-X
source	B-X
of	B-X
TNF-alpha	B-X
and	B-X
IL-6	B-X
in	B-X
these	B-X
settings	B-X
,	B-X
additional	B-X
experiments	B-X
were	B-X
performed	B-X
in	B-X
vitro	B-X
on	B-X
purified	B-X
T	B-X
cells	B-X
stimulated	B-X
with	B-X
the	B-X
CLB-T3/3	B-X
,	B-X
an	B-X
anti-CD3	B-X
mAb	B-X
which	B-X
does	B-X
not	B-X
require	B-X
the	B-X
presence	B-X
of	B-X
accessory	B-X
cells	B-X
to	B-X
activate	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
this	B-X
system	B-X
,	B-X
PTX	B-X
was	B-X
found	B-X
to	B-X
inhibit	B-X
the	B-X
secretion	B-X
of	B-X
both	B-X
TNF-alpha	B-X
and	B-X
IL-6	B-X
by	B-X
T	B-X
cells	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
cAMP	B-X
could	B-X
be	B-X
involved	B-X
in	B-X
these	B-X
differential	B-X
effects	B-X
of	B-X
PTX	B-X
on	B-X
production	B-X
of	B-X
TNF-alpha	B-X
and	B-X
of	B-X
IL-6	B-X
.	B-X

The	O
concentration	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
was	O
quantitatively	O
determined	O
by	O
ELISA	O
in	O
the	O
media	O
of	O
cells	O
exposed	O
to	O
the	O
treatments	O
described	O
above	O
after	O
stimulation	O
for	O
up	O
to	O
a	O
maximum	O
of	O
18	O
hours	O
,	O
at	O
3	O
-	O
hour	O
intervals	O
.	O

The	O
results	O
are	O
expressed	O
in	O
pg	O
/	O
mL	O
.	O
<EOS>	B-X
Using	B-X
GTEx	B-X
and	B-X
TCGA	B-X
data	B-X
,	B-X
we	B-X
compared	B-X
genes	B-X
differentially	B-X
expressed	B-X
with	B-X
age	B-X
and	B-X
genes	B-X
differentially	B-X
expressed	B-X
in	B-X
cancer	B-X
among	B-X
nine	B-X
human	B-X
tissues	B-X
.	B-X
The	B-X
overlapping	B-X
sets	B-X
between	B-X
genes	B-X
differentially	B-X
expressed	B-X
with	B-X
age	B-X
and	B-X
genes	B-X
differentially	B-X
expressed	B-X
in	B-X
cancer	B-X
across	B-X
tissues	B-X
were	B-X
enriched	B-X
for	B-X
several	B-X
processes	B-X
,	B-X
mainly	B-X
cell	B-X
cycle	B-X
and	B-X
the	B-X
immune	B-X
system	B-X
.	B-X
Our	B-X
results	B-X
highlight	B-X
the	B-X
complex	B-X
relationship	B-X
between	B-X
aging	B-X
and	B-X
cancer	B-X
and	B-X
suggest	B-X
that	B-X
,	B-X
while	B-X
in	B-X
general	B-X
aging	B-X
processes	B-X
might	B-X
be	B-X
opposite	B-X
to	B-X
cancer	B-X
,	B-X
the	B-X
transcriptomic	B-X
links	B-X
between	B-X
human	B-X
aging	B-X
and	B-X
cancer	B-X
are	B-X
tissue-specific	B-X
.	B-X
We	B-X
have	B-X
characterized	B-X
the	B-X
expression	B-X
of	B-X
15	B-X
genes	B-X
from	B-X
all	B-X
stages	B-X
of	B-X
the	B-X
PG	B-X
pathway	B-X
in	B-X
human	B-X
pregnant	B-X
and	B-X
non-pregnant	B-X
(	B-X
NP	B-X
)	B-X
myometrium	B-X
and	B-X
in	B-X
other	B-X
uterine	B-X
tissues	B-X
at	B-X
delivery	B-X
,	B-X
and	B-X
the	B-X
results	B-X
show	B-X
patterns	B-X
indicative	B-X
of	B-X
different	B-X
capacities	B-X
for	B-X
PG	B-X
synthesis	B-X
and	B-X
catabolism	B-X
in	B-X
each	B-X
tissue	B-X
.	B-X
In	B-X
umbilical	B-X
cord	B-X
,	B-X
PGI₂	B-X
synthase	B-X
is	B-X
highly	B-X
expressed	B-X
.	B-X
In	B-X
pregnant	B-X
myometrium	B-X
,	B-X
PGI₂	B-X
,	B-X
PGD₂	B-X
and	B-X
PGF₂	B-X
synthases	B-X
are	B-X
highly	B-X
expressed	B-X
,	B-X
whereas	B-X
PG	B-X
dehydrogenase	B-X
is	B-X
underexpressed	B-X
.	B-X

SDS	O
-	O
PAGE	O
and	O
Immunoblotting	O
(	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
,	O
NF	O
-	O
kappaB	O
p65	B-Protein
,	O
and	O
CREB	B-Protein
)	O

Following	O
stimulation	O
,	O
PBMCs	O
were	O
washed	O
with	O
ice	O
-	O
cold	O
PBS	O
and	O
centrifuged	O
to	O
collect	O
a	O
cell	O
pellet	O
.	O

The	O
pellet	O
was	O
resuspended	O
in	O
ice	O
-	O
cold	O
SDS	O
sample	O
buffer	O
supplemented	O
with	O
100	O
mM	O
dithiothreitol	O
.	O

Cytoplasmic	O
and	O
nuclear	O
extracts	O
were	O
isolated	O
with	O
NE	O
-	O
PER	O
nuclear	O
and	O
cytoplasmic	O
extraction	O
reagents	O
with	O
1x	O
Halt	O
Protease	O
Inhibitor	O
Cocktail	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Protein	O
concentrations	O
were	O
determined	O
with	O
the	O
BCA	O
protein	O
reagent	O
kit	O
for	O
each	O
sample	O
according	O
to	O
a	O
standardized	O
curve	O
for	O
albumin	O
.	O

Cell	O
lysates	O
were	O
collected	O
by	O
boiling	O
the	O
samples	O
in	O
a	O
100degreesC	O
water	O
bath	O
for	O
5	O
minutes	O
.	O

Ten	O
mug	O
of	O
protein	O
per	O
sample	O
was	O
separated	O
by	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
through	O
8	O
-	O
16	O
%	O
tris	O
-	O
glycine	O
polyacrylamide	O
gradient	O
gels	O
and	O
transferred	O
to	O
nitrocellulose	O
membranes	O
.	O

The	O
membranes	O
were	O
blocked	O
with	O
5	O
%	O
milk	O
in	O
Tris	O
-	O
buffered	O
saline	O
/	O
Tween	O
20	O
(	O
Fischer	O
Scientific	O
,	O
Pittsburgh	O
,	O
PA	O
)	O
for	O
1	O
hour	O
.	O

Cytoplasmic	O
extracts	O
were	O
incubated	O
with	O
phosphorylated	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
antibody	O
(	O
1	O
:	O
200	O
)	O
,	O
while	O
nuclear	O
extracts	O
were	O
incubated	O
with	O
either	O
phosphorylated	O
NF	O
-	O
kappaB	O
p65	B-Protein
antibody	O
(	O
1	O
:	O
500	O
)	O
or	O
phosphorylated	O
CREB	O
antibody	O
(	O
1	O
:	O
500	O
)	O
overnight	O
at	O
4degreesC	O
in	O
separate	O
experiments	O
.	O

The	O
membranes	O
were	O
washed	O
with	O
Tris	O
-	O
buffered	O
saline	O
/	O
Tween	O
20	O
and	O
incubated	O
for	O
1	O
hour	O
at	O
room	O
temperature	O
with	O
the	O
secondary	O
antibody	O
,	O
horseradish	O
peroxidase	O
-	O
linked	O
anti	O
-	O
rabbit	O
IgG	O
diluted	O
1	O
:	O
2000	O
in	O
blocking	O
solution	O
.	O

After	O
repeated	O
washing	O
of	O
the	O
membrane	O
,	O
the	O
Supersignal	O
West	O
Pico	O
Chemiluminescent	O
Kit	O
was	O
applied	O
for	O
antibody	O
detection	O
per	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Western	O
blot	O
data	O
is	O
presented	O
as	O
a	O
percentage	O
of	O
LPS	O
stimulation	O
.	O
<EOS>	B-X
Herein	B-X
,	B-X
we	B-X
report	B-X
that	B-X
CTN	B-X
significantly	B-X
suppressed	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
/interferon	B-X
(	B-X
IFN	B-X
)	B-X
-γ-induced	B-X
NO	B-X
production	B-X
in	B-X
MES-13	B-X
cells	B-X
,	B-X
a	B-X
glomerular	B-X
mesangial	B-X
cell	B-X
line	B-X
.	B-X
The	B-X
percentage	B-X
of	B-X
NO	B-X
reduction	B-X
caused	B-X
by	B-X
CTN	B-X
was	B-X
far	B-X
greater	B-X
than	B-X
that	B-X
of	B-X
the	B-X
decline	B-X
in	B-X
cell	B-X
viability	B-X
.	B-X
CTN	B-X
caused	B-X
declines	B-X
in	B-X
LPS/IFN-γ-induced	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription-1α	B-X
(	B-X
STAT-1α	B-X
)	B-X
phosphorylation	B-X
.	B-X
Furthermore	B-X
,	B-X
LPS/IFN-γ	B-X
's	B-X
induction	B-X
of	B-X
interferon	B-X
response	B-X
factor-1	B-X
(	B-X
IRF-1	B-X
)	B-X
mRNA	B-X
expression	B-X
was	B-X
inhibited	B-X
by	B-X
CTN	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
data	B-X
indicated	B-X
that	B-X
CTN	B-X
significantly	B-X
suppressed	B-X
NO	B-X
and	B-X
iNOS	B-X
expressions	B-X
in	B-X
MES-13	B-X
cells	B-X
via	B-X
inhibition	B-X
of	B-X
the	B-X
JAK/STAT-1α	B-X
and	B-X
NF-κB	B-X
signaling	B-X
pathways	B-X
.	B-X

The	O
percentage	O
of	O
LPS	O
stimulation	O
was	O
calculated	O
by	O
dividing	O
the	O
mean	O
band	O
pixel	O
total	O
for	O
each	O
treatment	O
arm	O
divided	O
by	O
the	O
mean	O
pixel	O
total	O
of	O
samples	O
stimulated	O
with	O
LPS	O
and	O
multiplying	O
by	O
100	O
.	O

Thus	O
,	O
LPS	O
stimulation	O
is	O
reported	O
as	O
100	O
%	O
and	O
each	O
of	O
the	O
treatment	O
arms	O
is	O
reported	O
as	O
a	O
percent	O
of	O
LPS	O
stimulation	O
.	O

NF	O
-	O
kappaB	O
and	O
CREB	O
Electrophoretic	O
Mobility	O
Shift	O
Assay	O
(	O
EMSA	O
)	O
<EOS>	B-X
In	B-X
a	B-X
forebrain	B-X
neuronal	B-X
conditional	B-X
NF-kappaB-deficient	B-X
mouse	B-X
model	B-X
,	B-X
we	B-X
demonstrate	B-X
here	B-X
that	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
regulates	B-X
spatial	B-X
memory	B-X
formation	B-X
,	B-X
synaptic	B-X
transmission	B-X
,	B-X
and	B-X
plasticity	B-X
.	B-X
Gene	B-X
profiling	B-X
experiments	B-X
and	B-X
analysis	B-X
of	B-X
regulatory	B-X
regions	B-X
identified	B-X
the	B-X
alpha	B-X
catalytic	B-X
subunit	B-X
of	B-X
protein	B-X
kinase	B-X
A	B-X
(	B-X
PKA	B-X
)	B-X
,	B-X
an	B-X
essential	B-X
memory	B-X
regulator	B-X
,	B-X
as	B-X
a	B-X
new	B-X
NF-kappaB	B-X
target	B-X
gene	B-X
.	B-X
Consequently	B-X
,	B-X
NF-kappaB	B-X
inhibition	B-X
led	B-X
to	B-X
a	B-X
decrease	B-X
in	B-X
forskolin-induced	B-X
CREB	B-X
phosphorylation	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
results	B-X
disclose	B-X
a	B-X
novel	B-X
hierarchical	B-X
transcriptional	B-X
network	B-X
involving	B-X
NF-kappaB	B-X
,	B-X
PKA	B-X
,	B-X
and	B-X
CREB	B-X
that	B-X
leads	B-X
to	B-X
concerted	B-X
nuclear	B-X
transduction	B-X
of	B-X
synaptic	B-X
signals	B-X
in	B-X
neurons	B-X
,	B-X
accounting	B-X
for	B-X
the	B-X
critical	B-X
function	B-X
of	B-X
NF-kappaB	B-X
in	B-X
learning	B-X
and	B-X
memory	B-X
.	B-X

The	O
non	O
-	O
radioactive	O
LightShift	O
Chemiluminescent	O
EMSA	O
Kit	O
was	O
used	O
to	O
detect	O
DNA	O
-	O
protein	O
interactions	O
.	O

The	O
NF	O
-	O
kappaB	O
3	O
'	O
biotin	O
end	O
-	O
labeled	O
DNA	O
oligonucleotide	O
used	O
as	O
a	O
probe	O
for	O
the	O
EMSA	O
was	O
a	O
42	O
-	O
bp	O
double	O
stranded	O
construct	O
(	O
5	O
'	O
-	O
TTGTTACAA	O
-	O
GGGGACTTTCCGCTGGGGACTTTCCAGGGAGGC	O
-	O
3	O
'	O
)	O
containing	O
two	O
tandemly	O
repeated	O
NF	O
-	O
kappaB	O
binding	O
sites	O
(	O
underlined	O
)	O
.	O

Specificity	O
was	O
determined	O
by	O
a	O
competition	O
assay	O
with	O
the	O
addition	O
of	O
200	O
molar	O
excess	O
of	O
unlabeled	O
double	O
stranded	O
NF	O
-	O
kappaB	O
oligonucleotide	O
.	O

The	O
CREB	O
3	O
'	O
biotin	O
end	O
-	O
labeled	O
DNA	O
oligonucleotide	O
used	O
as	O
a	O
probe	O
for	O
the	O
EMSA	O
was	O
a	O
23	O
-	O
bp	O
double	O
stranded	O
construct	O
(	O
5	O
'	O
-	O
TTT	O
TCG	O
AGC	O
TCTGACGTCAGA	O
-	O
GC	O
-	O
3	O
'	O
)	O
containing	O
the	O
CRE	O
consensus	O
sequence	O
(	O
underlined	O
)	O
.	O

Specificity	O
was	O
determined	O
by	O
a	O
competition	O
assay	O
with	O
the	O
addition	O
of	O
200	O
molar	O
excess	O
of	O
unlabeled	O
double	O
stranded	O
CREB	O
oligonucleotide	O
.	O

Nuclear	O
extracts	O
(	O
10	O
mug	O
)	O
were	O
incubated	O
with	O
5	O
nM	O
NF	O
-	O
kappaB	O
or	O
CREB	O
probe	O
(	O
NF	O
-	O
kB	O
:	O
1x	O
binding	O
buffer	O
,	O
50	O
mM	O
KCl	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
mM	O
DTT	O
,	O
0	O
.	O
1	O
%	O
NP40	O
,	O
10	O
%	O
glycerol	O
,	O
and	O
50	O
ng	O
/	O
mul	O
poly	O
dI	O
-	O
dC	O
,	O
CREB	O
:	O
1x	O
binding	O
buffer	O
,	O
20	O
mM	O
Tris	O
,	O
pH	O
7	O
.	O
5	O
,	O
50	O
mM	O
KCl	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
mM	O
DTT	O
,	O
0	O
.	O
10	O
%	O
NP40	O
,	O
6	O
%	O
glycerol	O
,	O
0	O
.	O
1	O
mg	O
/	O
mL	O
BSA	O
and	O
50	O
ng	O
/	O
mul	O
poly	O
dI	O
-	O
dC	O
)	O
and	O
were	O
then	O
electrophoresed	O
through	O
a	O
6	O
%	O
DNA	O
retardation	O
gel	O
at	O
100V	O
for	O
90	O
minutes	O
.	O

The	O
gels	O
were	O
electrophoretically	O
transferred	O
at	O
380mA	O
for	O
1	O
hour	O
on	O
ice	O
to	O
a	O
positively	O
charged	O
nylon	O
membrane	O
and	O
immediately	O
cross	O
-	O
linked	O
for	O
15	O
minutes	O
with	O
a	O
UV	O
transilluminator	O
equipped	O
with	O
a	O
312	O
nm	O
bulb	O
.	O

Streptavidin	O
-	O
horseradish	O
peroxidase	O
conjugate	O
and	O
the	O
LightShift	O
Chemiluminescent	O
Substrate	O
were	O
used	O
to	O
detect	O
the	O
biotin	O
end	O
-	O
labeled	O
DNA	O
.	O

The	O
nylon	O
membranes	O
were	O
exposed	O
to	O
x	O
-	O
ray	O
film	O
for	O
1	O
-	O
3	O
minutes	O
for	O
detection	O
.	O

Role	O
of	O
PKA	O
on	O
LPS	O
-	O
induced	O
mononuclear	O
cell	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O

To	O
evaluate	O
the	O
role	O
of	O
PKA	O
on	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
in	O
mononuclear	O
cells	O
and	O
its	O
involvement	O
in	O
the	O
attenuation	O
of	O
LPS	O
-	O
induced	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
observed	O
following	O
PTX	O
treatment	O
,	O
H89	O
,	O
a	O
specific	O
PKA	O
inhibitor	O
,	O
was	O
utilized	O
.	O

Isolated	O
mononuclear	O
cells	O
were	O
incubated	O
according	O
to	O
the	O
treatment	O
groups	O
described	O
above	O
in	O
the	O
presence	O
and	O
absence	O
of	O
pretreatment	O
with	O
H89	O
(	O
10	O
muM	O
)	O
for	O
1	O
hour	O
at	O
37degreesC	O
.	O

The	O
dose	O
of	O
H89	O
was	O
chosen	O
based	O
on	O
previous	O
work	O
which	O
demonstrated	O
specific	O
and	O
complete	O
inhibition	O
of	O
PKA	O
at	O
this	O
concentration	O
.	O
10	O
Since	O
the	O
activity	O
of	O
this	O
inhibitor	O
is	O
both	O
specific	O
and	O
consistent	O
at	O
this	O
specified	O
dose	O
,	O
we	O
did	O
not	O
include	O
experiments	O
with	O
additional	O
PKA	O
inhibitors	O
with	O
this	O
set	O
of	O
experiments	O
.	O

The	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
concentration	O
in	O
the	O
supernatant	O
was	O
measured	O
quantitatively	O
by	O
ELISA	O
.	O
<EOS>	B-X
TNF-α	B-X
is	B-X
abundant	B-X
in	B-X
fibroblast-like	B-X
synoviocytes	B-X
of	B-X
RA	B-X
(	B-X
RA-FLSs	B-X
)	B-X
and	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
pyroptosis	B-X
by	B-X
inducing	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-κB	B-X
activation	B-X
.	B-X
Therefore	B-X
,	B-X
this	B-X
study	B-X
investigated	B-X
the	B-X
effects	B-X
and	B-X
mechanism	B-X
of	B-X
IL-37	B-X
on	B-X
RA-FLS	B-X
pyroptosis	B-X
induced	B-X
by	B-X
TNF-α	B-X
.	B-X
Expression	B-X
levels	B-X
of	B-X
hypoxia-inducible	B-X
factor	B-X
(	B-X
HIF	B-X
)	B-X
-1α	B-X
and	B-X
AKT1	B-X
mRNA	B-X
in	B-X
all	B-X
groups	B-X
were	B-X
determined	B-X
by	B-X
reverse	B-X
transcriptase-quantitative	B-X
polymerase	B-X
chain	B-X
reaction	B-X
and	B-X
concentrations	B-X
of	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
(	B-X
VEGF	B-X
)	B-X
,	B-X
angiotensin	B-X
II	B-X
(	B-X
ANG-II	B-X
)	B-X
,	B-X
transforming	B-X
growth	B-X
factor	B-X
(	B-X
TGF	B-X
)	B-X
-α/β1	B-X
,	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-α	B-X
in	B-X
the	B-X
culture	B-X
supernatant	B-X
were	B-X
measured	B-X
by	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
.	B-X
Compared	B-X
to	B-X
the	B-X
normoxic	B-X
control	B-X
and	B-X
normoxic	B-X
suppression	B-X
groups	B-X
,	B-X
the	B-X
concentrations	B-X
of	B-X
VEGF	B-X
and	B-X
TNF-α	B-X
in	B-X
supernatant	B-X
were	B-X
higher	B-X
in	B-X
the	B-X
hypoxic	B-X
control	B-X
and	B-X
hypoxic	B-X
suppression	B-X
groups	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
concentration	B-X
of	B-X
ANG-II	B-X
in	B-X
the	B-X
hypoxic	B-X
suppression	B-X
group	B-X
was	B-X
higher	B-X
than	B-X
that	B-X
in	B-X
the	B-X
normoxic	B-X
suppression	B-X
group	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
compared	B-X
to	B-X
the	B-X
normoxic	B-X
control	B-X
group	B-X
and	B-X
hypoxic	B-X
control	B-X
group	B-X
,	B-X
the	B-X
concentrations	B-X
of	B-X
VEGF	B-X
and	B-X
TGF-β1	B-X
in	B-X
supernatant	B-X
were	B-X
lower	B-X
in	B-X
the	B-X
normoxic	B-X
suppression	B-X
group	B-X
and	B-X
in	B-X
the	B-X
hypoxic	B-X
suppression	B-X
group	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
the	B-X
results	B-X
of	B-X
the	B-X
present	B-X
study	B-X
suggest	B-X
that	B-X
hypoxia	B-X
can	B-X
stimulate	B-X
A549	B-X
lung	B-X
cancer	B-X
cells	B-X
to	B-X
secrete	B-X
VEGF	B-X
and	B-X
TNF-α	B-X
and	B-X
inhibit	B-X
TGF-α	B-X
and	B-X
TGF-β1	B-X
.	B-X

The	O
results	O
are	O
expressed	O
in	O
pg	O
/	O
mL	O
.	O
<EOS>	B-X
Using	B-X
GTEx	B-X
and	B-X
TCGA	B-X
data	B-X
,	B-X
we	B-X
compared	B-X
genes	B-X
differentially	B-X
expressed	B-X
with	B-X
age	B-X
and	B-X
genes	B-X
differentially	B-X
expressed	B-X
in	B-X
cancer	B-X
among	B-X
nine	B-X
human	B-X
tissues	B-X
.	B-X
The	B-X
overlapping	B-X
sets	B-X
between	B-X
genes	B-X
differentially	B-X
expressed	B-X
with	B-X
age	B-X
and	B-X
genes	B-X
differentially	B-X
expressed	B-X
in	B-X
cancer	B-X
across	B-X
tissues	B-X
were	B-X
enriched	B-X
for	B-X
several	B-X
processes	B-X
,	B-X
mainly	B-X
cell	B-X
cycle	B-X
and	B-X
the	B-X
immune	B-X
system	B-X
.	B-X
Our	B-X
results	B-X
highlight	B-X
the	B-X
complex	B-X
relationship	B-X
between	B-X
aging	B-X
and	B-X
cancer	B-X
and	B-X
suggest	B-X
that	B-X
,	B-X
while	B-X
in	B-X
general	B-X
aging	B-X
processes	B-X
might	B-X
be	B-X
opposite	B-X
to	B-X
cancer	B-X
,	B-X
the	B-X
transcriptomic	B-X
links	B-X
between	B-X
human	B-X
aging	B-X
and	B-X
cancer	B-X
are	B-X
tissue-specific	B-X
.	B-X
We	B-X
have	B-X
characterized	B-X
the	B-X
expression	B-X
of	B-X
15	B-X
genes	B-X
from	B-X
all	B-X
stages	B-X
of	B-X
the	B-X
PG	B-X
pathway	B-X
in	B-X
human	B-X
pregnant	B-X
and	B-X
non-pregnant	B-X
(	B-X
NP	B-X
)	B-X
myometrium	B-X
and	B-X
in	B-X
other	B-X
uterine	B-X
tissues	B-X
at	B-X
delivery	B-X
,	B-X
and	B-X
the	B-X
results	B-X
show	B-X
patterns	B-X
indicative	B-X
of	B-X
different	B-X
capacities	B-X
for	B-X
PG	B-X
synthesis	B-X
and	B-X
catabolism	B-X
in	B-X
each	B-X
tissue	B-X
.	B-X
In	B-X
umbilical	B-X
cord	B-X
,	B-X
PGI₂	B-X
synthase	B-X
is	B-X
highly	B-X
expressed	B-X
.	B-X
In	B-X
pregnant	B-X
myometrium	B-X
,	B-X
PGI₂	B-X
,	B-X
PGD₂	B-X
and	B-X
PGF₂	B-X
synthases	B-X
are	B-X
highly	B-X
expressed	B-X
,	B-X
whereas	B-X
PG	B-X
dehydrogenase	B-X
is	B-X
underexpressed	B-X
.	B-X

Statistical	O
Analysis	O

The	O
experimental	O
results	O
obtained	O
in	O
this	O
study	O
were	O
derived	O
from	O
four	O
separate	O
experiments	O
with	O
healthy	O
volunteer	O
donors	O
.	O

Each	O
assay	O
was	O
performed	O
in	O
duplicate	O
or	O
triplicate	O
where	O
appropriate	O
.	O
<EOS>	B-X
We	B-X
performed	B-X
a	B-X
metaepidemiologic	B-X
study	B-X
to	B-X
evaluate	B-X
the	B-X
extent	B-X
of	B-X
potential	B-X
redundancy	B-X
in	B-X
published	B-X
meta-analyses	B-X
in	B-X
genetic	B-X
epidemiology	B-X
.	B-X
With	B-X
the	B-X
increasing	B-X
use	B-X
of	B-X
meta-analysis	B-X
,	B-X
duplicate	B-X
publication	B-X
of	B-X
original	B-X
research	B-X
is	B-X
particularly	B-X
problematic	B-X
.	B-X
Duplicate	B-X
publication	B-X
can	B-X
result	B-X
in	B-X
an	B-X
inappropriate	B-X
weighting	B-X
of	B-X
the	B-X
study	B-X
results	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
our	B-X
study	B-X
was	B-X
to	B-X
assess	B-X
the	B-X
incidence	B-X
and	B-X
characteristics	B-X
of	B-X
duplicate	B-X
publications	B-X
in	B-X
Korea	B-X
,	B-X
and	B-X
to	B-X
estimate	B-X
the	B-X
impact	B-X
of	B-X
duplicate	B-X
publication	B-X
on	B-X
meta-analyses	B-X
.	B-X
To	B-X
estimate	B-X
the	B-X
multiple	B-X
publication	B-X
bias	B-X
,	B-X
we	B-X
performed	B-X
a	B-X
meta-analysis	B-X
with	B-X
and	B-X
without	B-X
duplicated	B-X
data	B-X
.	B-X
We	B-X
estimated	B-X
that	B-X
6	B-X
(	B-X
6.9	B-X
%	B-X
)	B-X
of	B-X
the	B-X
86	B-X
analyzed	B-X
meta-analyses	B-X
included	B-X
duplicate	B-X
publications	B-X
,	B-X
and	B-X
6	B-X
of	B-X
the	B-X
1,194	B-X
articles	B-X
(	B-X
0.5	B-X
%	B-X
)	B-X
used	B-X
in	B-X
the	B-X
meta-analyses	B-X
were	B-X
duplicate	B-X
publications	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
duplicate	B-X
publications	B-X
were	B-X
usually	B-X
due	B-X
to	B-X
disaggregation	B-X
and	B-X
overlapping	B-X
(	B-X
imalas	B-X
)	B-X
publications	B-X
.	B-X
Of	B-X
6	B-X
duplicated	B-X
articles	B-X
,	B-X
1	B-X
was	B-X
considered	B-X
a	B-X
copy	B-X
(	B-X
16.6	B-X
%	B-X
)	B-X
;	B-X
1	B-X
,	B-X
a	B-X
fragmentation	B-X
(	B-X
16.6	B-X
%	B-X
)	B-X
;	B-X
2	B-X
,	B-X
imalas	B-X
(	B-X
33.3	B-X
%	B-X
)	B-X
;	B-X
and	B-X
2	B-X
,	B-X
disaggregations	B-X
(	B-X
33.3	B-X
%	B-X
)	B-X
.	B-X
There	B-X
was	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
mean	B-X
effect	B-X
size	B-X
and	B-X
fail-safe	B-X
number	B-X
with	B-X
duplicated	B-X
data	B-X
.	B-X
Our	B-X
study	B-X
found	B-X
only	B-X
6	B-X
instances	B-X
of	B-X
duplicate	B-X
publication	B-X
after	B-X
analyzing	B-X
1,194	B-X
articles	B-X
used	B-X
in	B-X
meta-analyses	B-X
written	B-X
by	B-X
Korean	B-X
authors	B-X
.	B-X
However	B-X
,	B-X
6.9	B-X
%	B-X
of	B-X
the	B-X
meta-analyses	B-X
included	B-X
duplicate	B-X
publications	B-X
.	B-X
Our	B-X
findings	B-X
suggest	B-X
that	B-X
meta-analyses	B-X
should	B-X
be	B-X
interpreted	B-X
cautiously	B-X
,	B-X
taking	B-X
into	B-X
account	B-X
the	B-X
possibility	B-X
of	B-X
duplicated	B-X
studies	B-X
.	B-X

Data	O
is	O
presented	O
as	O
the	O
mean	O
+	O
/	O
-	O
SEM	O
.	O
<EOS>	B-X
Absolute	B-X
reliability	B-X
was	B-X
determined	B-X
by	B-X
test-retest	B-X
studies	B-X
presenting	B-X
standard	B-X
error	B-X
of	B-X
measurement	B-X
(	B-X
SEM	B-X
%	B-X
)	B-X
and/or	B-X
minimal	B-X
detectable	B-X
change	B-X
(	B-X
MDC	B-X
%	B-X
)	B-X
expressed	B-X
as	B-X
percentage	B-X
of	B-X
the	B-X
mean	B-X
.	B-X
In	B-X
most	B-X
clinical	B-X
and	B-X
experimental	B-X
studies	B-X
,	B-X
the	B-X
standard	B-X
deviation	B-X
(	B-X
SD	B-X
)	B-X
and	B-X
the	B-X
estimated	B-X
standard	B-X
error	B-X
of	B-X
the	B-X
mean	B-X
(	B-X
SEM	B-X
)	B-X
are	B-X
used	B-X
to	B-X
present	B-X
the	B-X
characteristics	B-X
of	B-X
sample	B-X
data	B-X
and	B-X
to	B-X
explain	B-X
statistical	B-X
analysis	B-X
results	B-X
.	B-X
However	B-X
,	B-X
some	B-X
authors	B-X
occasionally	B-X
muddle	B-X
the	B-X
distinctive	B-X
usage	B-X
between	B-X
the	B-X
SD	B-X
and	B-X
SEM	B-X
in	B-X
medical	B-X
literature	B-X
.	B-X
Because	B-X
the	B-X
process	B-X
of	B-X
calculating	B-X
the	B-X
SD	B-X
and	B-X
SEM	B-X
includes	B-X
different	B-X
statistical	B-X
inferences	B-X
,	B-X
each	B-X
of	B-X
them	B-X
has	B-X
its	B-X
own	B-X
meaning	B-X
.	B-X
In	B-X
other	B-X
words	B-X
,	B-X
SD	B-X
indicates	B-X
how	B-X
accurately	B-X
the	B-X
mean	B-X
represents	B-X
sample	B-X
data	B-X
.	B-X
However	B-X
the	B-X
meaning	B-X
of	B-X
SEM	B-X
includes	B-X
statistical	B-X
inference	B-X
based	B-X
on	B-X
the	B-X
sampling	B-X
distribution	B-X
.	B-X
SEM	B-X
is	B-X
the	B-X
SD	B-X
of	B-X
the	B-X
theoretical	B-X
distribution	B-X
of	B-X
the	B-X
sample	B-X
means	B-X
(	B-X
the	B-X
sampling	B-X
distribution	B-X
)	B-X
.	B-X
While	B-X
either	B-X
SD	B-X
or	B-X
SEM	B-X
can	B-X
be	B-X
applied	B-X
to	B-X
describe	B-X
data	B-X
and	B-X
statistical	B-X
results	B-X
,	B-X
one	B-X
should	B-X
be	B-X
aware	B-X
of	B-X
reasonable	B-X
methods	B-X
with	B-X
which	B-X
to	B-X
use	B-X
SD	B-X
and	B-X
SEM	B-X
.	B-X
We	B-X
aim	B-X
to	B-X
elucidate	B-X
the	B-X
distinctions	B-X
between	B-X
SD	B-X
and	B-X
SEM	B-X
and	B-X
to	B-X
provide	B-X
proper	B-X
usage	B-X
guidelines	B-X
for	B-X
both	B-X
,	B-X
which	B-X
summarize	B-X
data	B-X
and	B-X
describe	B-X
statistical	B-X
results	B-X
.	B-X

Statistical	O
differences	O
between	O
groups	O
were	O
determined	O
by	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
with	O
a	O
Bonferroni	O
correction	O
.	O
<EOS>	B-X
Methods	B-X
A	B-X
retrospective	B-X
analysis	B-X
of	B-X
a	B-X
single-center	B-X
,	B-X
prospectively	B-X
collected	B-X
database	B-X
was	B-X
performed	B-X
on	B-X
77	B-X
patients	B-X
to	B-X
compare	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
number	B-X
of	B-X
decompression	B-X
levels	B-X
in	B-X
patients	B-X
that	B-X
received	B-X
single-level	B-X
fusion	B-X
surgery	B-X
.	B-X
Group	B-X
one	B-X
had	B-X
one	B-X
level	B-X
decompressed	B-X
,	B-X
group	B-X
two	B-X
had	B-X
two	B-X
levels	B-X
decompressed	B-X
,	B-X
and	B-X
group	B-X
three	B-X
had	B-X
three	B-X
or	B-X
four	B-X
levels	B-X
decompressed	B-X
.	B-X
Student	B-X
's	B-X
t-tests	B-X
,	B-X
one-way	B-X
analysis	B-X
of	B-X
variance	B-X
(	B-X
ANOVA	B-X
)	B-X
,	B-X
and	B-X
post	B-X
hoc	B-X
comparison	B-X
using	B-X
unpaired	B-X
two-tailed	B-X
student	B-X
's	B-X
t-test	B-X
with	B-X
Holm-Bonferroni	B-X
correction	B-X
were	B-X
performed	B-X
.	B-X
We	B-X
developed	B-X
a	B-X
new	B-X
method	B-X
of	B-X
3D-SSP	B-X
analysis	B-X
for	B-X
amyloid	B-X
PET	B-X
imaging	B-X
,	B-X
and	B-X
used	B-X
it	B-X
to	B-X
analyze	B-X
(	B-X
11	B-X
)	B-X
C-labeled	B-X
2-	B-X
(	B-X
2-	B-X
[	B-X
2-dimethylaminothiazol-5-yl	B-X
]	B-X
ethenyl	B-X
)	B-X
-6-	B-X
(	B-X
2-	B-X
[	B-X
fluoro	B-X
]	B-X
ethoxy	B-X
)	B-X
benzoxazole	B-X
(	B-X
BF-227	B-X
)	B-X
PET	B-X
images	B-X
of	B-X
subjects	B-X
with	B-X
mild	B-X
cognitive	B-X
impairment	B-X
(	B-X
MCI	B-X
)	B-X
and	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
.	B-X

Statistical	O
significance	O
was	O
defined	O
as	O
P	O
<	O
0	O
.	O
05	O
.	O

The	O
effects	O
of	O
PTX	O
on	O
LPS	O
-	O
induced	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
<EOS>	B-X
Cytokines	B-X
such	B-X
as	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
and	B-X
interleukin-1beta	B-X
(	B-X
IL-1beta	B-X
)	B-X
are	B-X
assumed	B-X
to	B-X
mediate	B-X
anorexia	B-X
during	B-X
bacterial	B-X
infections	B-X
.	B-X
To	B-X
improve	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
role	B-X
that	B-X
these	B-X
two	B-X
cytokines	B-X
serve	B-X
in	B-X
mediating	B-X
infection	B-X
during	B-X
anorexia	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
ability	B-X
of	B-X
pentoxifylline	B-X
(	B-X
PTX	B-X
)	B-X
,	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
TNF-alpha	B-X
production	B-X
,	B-X
to	B-X
block	B-X
the	B-X
anorectic	B-X
effects	B-X
of	B-X
the	B-X
bacterial	B-X
products	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
and	B-X
muramyl	B-X
dipeptide	B-X
(	B-X
MDP	B-X
)	B-X
in	B-X
rats	B-X
.	B-X
Intraperitoneally	B-X
injected	B-X
PTX	B-X
(	B-X
100	B-X
mg/kg	B-X
body	B-X
wt	B-X
)	B-X
completely	B-X
eliminated	B-X
the	B-X
anorectic	B-X
effect	B-X
of	B-X
intraperitoneally	B-X
injected	B-X
LPS	B-X
(	B-X
100	B-X
microg/kg	B-X
body	B-X
wt	B-X
)	B-X
and	B-X
attenuated	B-X
the	B-X
anorectic	B-X
effect	B-X
of	B-X
a	B-X
higher	B-X
dose	B-X
of	B-X
intraperitoneally	B-X
injected	B-X
LPS	B-X
(	B-X
250	B-X
microg/kg	B-X
body	B-X
wt	B-X
)	B-X
.	B-X
Concurrently	B-X
,	B-X
PTX	B-X
pretreatment	B-X
suppressed	B-X
low-dose	B-X
LPS-induced	B-X
TNF-alpha	B-X
production	B-X
by	B-X
more	B-X
than	B-X
95	B-X
%	B-X
and	B-X
IL-1beta	B-X
production	B-X
39	B-X
%	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
ELISA	B-X
.	B-X
Similarly	B-X
,	B-X
high-dose	B-X
LPS-induced	B-X
TNF-alpha	B-X
production	B-X
was	B-X
reduced	B-X
by	B-X
approximately	B-X
90	B-X
%	B-X
.	B-X
PTX	B-X
administration	B-X
also	B-X
attenuated	B-X
the	B-X
tolerance	B-X
that	B-X
is	B-X
normally	B-X
observed	B-X
with	B-X
a	B-X
second	B-X
injection	B-X
of	B-X
LPS	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
PTX	B-X
pretreatment	B-X
attenuated	B-X
the	B-X
hypophagic	B-X
effect	B-X
of	B-X
intraperitoneally	B-X
injected	B-X
MDP	B-X
(	B-X
2	B-X
mg/kg	B-X
body	B-X
wt	B-X
)	B-X
but	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
the	B-X
anorectic	B-X
response	B-X
to	B-X
intraperitoneally	B-X
injected	B-X
recombinant	B-X
human	B-X
TNF-alpha	B-X
(	B-X
150	B-X
ug/kg	B-X
body	B-X
wt	B-X
)	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
suppression	B-X
of	B-X
TNF-alpha	B-X
production	B-X
is	B-X
sufficient	B-X
to	B-X
attenuate	B-X
LPS-	B-X
and	B-X
MDP-induced	B-X
anorexia	B-X
.	B-X
This	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
hypothesis	B-X
that	B-X
TNF-alpha	B-X
plays	B-X
a	B-X
major	B-X
role	B-X
in	B-X
the	B-X
anorexia	B-X
associated	B-X
with	B-X
bacterial	B-X
infection	B-X
.	B-X

To	O
determine	O
the	O
duration	O
of	O
PDE	O
inhibition	O
on	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
after	O
LPS	O
stimulation	O
,	O
time	O
course	O
studies	O
were	O
conducted	O
.	O

In	O
accordance	O
with	O
prior	O
work	O
,	O
PTX	O
had	O
a	O
rapid	O
and	O
sustained	O
effect	O
on	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
in	O
vitro	O
(	O
Figure	O
1	O
)	O
.	O

PTX	O
decreases	O
LPS	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
<EOS>	B-X
Pentoxifylline	B-X
(	B-X
PTX	B-X
)	B-X
,	B-X
a	B-X
phosphodiesterase	B-X
inhibitor	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
decrease	B-X
TNF-alpha	B-X
levels	B-X
and	B-X
to	B-X
down-regulate	B-X
neutrophil	B-X
activation	B-X
,	B-X
likely	B-X
because	B-X
of	B-X
increases	B-X
in	B-X
intracellular	B-X
cyclic	B-X
AMP	B-X
.	B-X
Its	B-X
effects	B-X
on	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
induced	B-X
lung	B-X
injury	B-X
,	B-X
more	B-X
specifically	B-X
on	B-X
tissue	B-X
neutrophil	B-X
infiltration	B-X
and	B-X
degranulation	B-X
,	B-X
adhesion	B-X
molecule	B-X
expression	B-X
,	B-X
and	B-X
transcriptional	B-X
factor	B-X
activation	B-X
,	B-X
have	B-X
not	B-X
been	B-X
fully	B-X
investigated	B-X
.	B-X
We	B-X
postulated	B-X
that	B-X
PTX	B-X
treatment	B-X
in	B-X
acute	B-X
endotoxemia	B-X
downregulates	B-X
the	B-X
inflammatory	B-X
response	B-X
and	B-X
may	B-X
decrease	B-X
lung	B-X
injury	B-X
.	B-X
The	B-X
increased	B-X
levels	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
seen	B-X
in	B-X
patients	B-X
with	B-X
acquired	B-X
immune	B-X
deficiency	B-X
syndrome	B-X
(	B-X
AIDS	B-X
)	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
AIDS-related	B-X
wasting	B-X
syndrome	B-X
.	B-X
TNF	B-X
also	B-X
induces	B-X
expression	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
HIV	B-X
)	B-X
through	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappa	B-X
B	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
the	B-X
viral	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
.	B-X
Because	B-X
TNF	B-X
can	B-X
decrease	B-X
the	B-X
antiretroviral	B-X
activity	B-X
of	B-X
zidovudine	B-X
(	B-X
AZT	B-X
)	B-X
in	B-X
vitro	B-X
,	B-X
pentoxifylline	B-X
(	B-X
PTX	B-X
)	B-X
may	B-X
increase	B-X
the	B-X
efficacy	B-X
of	B-X
AZT	B-X
.	B-X
PTX	B-X
decreases	B-X
HIV	B-X
replication	B-X
in	B-X
acutely	B-X
infected	B-X
cells	B-X
and	B-X
inhibits	B-X
gene	B-X
expression	B-X
controlled	B-X
by	B-X
the	B-X
HIV-1	B-X
LTR	B-X
.	B-X
The	B-X
antiretroviral	B-X
activity	B-X
of	B-X
PTX	B-X
is	B-X
associated	B-X
with	B-X
decreased	B-X
binding	B-X
of	B-X
NF-kappa	B-X
B	B-X
to	B-X
its	B-X
recognition	B-X
sequences	B-X
.	B-X
Therefore	B-X
,	B-X
PTX	B-X
may	B-X
inhibit	B-X
HIV	B-X
expression	B-X
indirectly	B-X
by	B-X
diminishing	B-X
TNF	B-X
production	B-X
and	B-X
directly	B-X
,	B-X
by	B-X
decreasing	B-X
activity	B-X
of	B-X
NF-kappa	B-X
B.	B-X
PTX	B-X
,	B-X
and	B-X
an	B-X
inhibitor	B-X
of	B-X
the	B-X
viral	B-X
transactivator	B-X
TAT	B-X
,	B-X
Ro24-7429	B-X
,	B-X
may	B-X
inhibit	B-X
HIV	B-X
gene	B-X
expression	B-X
in	B-X
a	B-X
cooperative	B-X
fashion	B-X
.	B-X
The	B-X
first	B-X
clinical	B-X
study	B-X
of	B-X
PTX	B-X
in	B-X
AIDS	B-X
patients	B-X
was	B-X
conducted	B-X
by	B-X
us	B-X
through	B-X
the	B-X
AIDS	B-X
Clinical	B-X
Trial	B-X
Group	B-X
of	B-X
the	B-X
National	B-X
Institutes	B-X
of	B-X
Health	B-X
.	B-X
AIDS	B-X
patients	B-X
on	B-X
antiretroviral	B-X
therapy	B-X
received	B-X
PTX	B-X
400	B-X
or	B-X
800	B-X
mg	B-X
three	B-X
times	B-X
daily	B-X
for	B-X
8	B-X
weeks	B-X
.	B-X
TNF	B-X
assays	B-X
included	B-X
TNF	B-X
mRNA	B-X
levels	B-X
in	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
and	B-X
inducible	B-X
TNF	B-X
protein	B-X
levels	B-X
in	B-X
the	B-X
supernatant	B-X
of	B-X
PBMCs	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
0.1	B-X
microgram/ml	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
.	B-X
The	B-X
median	B-X
change	B-X
in	B-X
TNF	B-X
mRNA	B-X
was	B-X
a	B-X
30	B-X
%	B-X
decrease	B-X
.	B-X
There	B-X
was	B-X
a	B-X
median	B-X
and	B-X
significant	B-X
40	B-X
%	B-X
decrease	B-X
in	B-X
the	B-X
production	B-X
of	B-X
inducible	B-X
TNF	B-X
protein	B-X
.	B-X
In	B-X
a	B-X
placebo-controlled	B-X
trial	B-X
,	B-X
TNF	B-X
production	B-X
by	B-X
unstimulated	B-X
PBMCs	B-X
decreased	B-X
by	B-X
52	B-X
%	B-X
in	B-X
the	B-X
PTX	B-X
arm	B-X
and	B-X
increased	B-X
by	B-X
7.2	B-X
%	B-X
in	B-X
the	B-X
placebo	B-X
arm	B-X
.	B-X
In	B-X
a	B-X
study	B-X
comparing	B-X
AZT	B-X
,	B-X
PTX	B-X
,	B-X
or	B-X
a	B-X
combination	B-X
of	B-X
the	B-X
two	B-X
,	B-X
viral	B-X
load	B-X
after	B-X
treatment	B-X
was	B-X
ninefold	B-X
above	B-X
baseline	B-X
in	B-X
the	B-X
AZT	B-X
or	B-X
PTX	B-X
alone	B-X
arm	B-X
,	B-X
compared	B-X
to	B-X
only	B-X
twofold	B-X
in	B-X
the	B-X
combination	B-X
arm	B-X
.	B-X
In	B-X
a	B-X
quality	B-X
of	B-X
life	B-X
trial	B-X
,	B-X
PTX	B-X
was	B-X
associated	B-X
with	B-X
improvement	B-X
in	B-X
depression	B-X
,	B-X
anger	B-X
,	B-X
and	B-X
social	B-X
and	B-X
cognitive	B-X
function	B-X
:	B-X
a	B-X
placebo	B-X
effect	B-X
,	B-X
however	B-X
,	B-X
was	B-X
not	B-X
ruled	B-X
out	B-X
.	B-X
PTX	B-X
400	B-X
mg	B-X
three	B-X
times	B-X
daily	B-X
is	B-X
safe	B-X
and	B-X
well	B-X
tolerated	B-X
.	B-X
PTX	B-X
decreases	B-X
PBMC	B-X
TNF	B-X
expression	B-X
in	B-X
HIV-infected	B-X
patients	B-X
,	B-X
measured	B-X
as	B-X
protein	B-X
in	B-X
culture	B-X
supernatant	B-X
or	B-X
as	B-X
mRNA	B-X
,	B-X
and	B-X
may	B-X
decrease	B-X
viral	B-X
replication	B-X
.	B-X
Further	B-X

Since	O
phosphorylation	O
leads	O
to	O
ubiquitination	O
and	O
degradation	O
of	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
and	O
subsequent	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
,	O
we	O
first	O
examined	O
the	O
effects	O
of	O
PTX	O
on	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
.	O

Cytoplasmic	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
phosphorylation	O
was	O
markedly	O
increased	O
following	O
LPS	O
stimulation	O
when	O
compared	O
to	O
control	O
(	O
100	O
+	O
/	O
-	O
0	O
vs	O
.	O
20	O
+	O
/	O
-	O
18	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
addition	O
of	O
PTX	O
significantly	O
downregulated	O
LPS	O
-	O
induced	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
phosphorylation	O
(	O
P	O
=	O
0	O
.	O
02	O
;	O
Figure	O
2	O
)	O

In	O
a	O
similar	O
fashion	O
,	O
nuclear	O
NF	O
-	O
kappaB	O
p65	B-Protein
phosphorylation	O
was	O
increased	O
following	O
LPS	O
stimulation	O
(	O
100	O
+	O
/	O
-	O
0	O
vs	O
.	O
38	O
+	O
/	O
-	O
20	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

PTX	O
similarly	O
decreased	O
LPS	O
-	O
induced	O
NF	O
-	O
kappaB	O
p65	B-Protein
nuclear	O
phosphorylation	O
,	O
a	O
marker	O
of	O
NF	O
-	O
kappaB	O
activation	O
and	O
nuclear	O
translocation	O
(	O
100	O
+	O
/	O
-	O
0	O
vs	O
.	O
40	O
+	O
/	O
-	O
6	O
;	O
P	O
=	O
0	O
.	O
03	O
;	O
Figure	O
3A	O
)	O
.	O

EMSAs	O
were	O
then	O
performed	O
to	O
verify	O
the	O
PTX	O
-	O
induced	O
alterations	O
in	O
nuclear	O
phosphorylation	O
resulted	O
in	O
similar	O
effects	O
on	O
the	O
DNA	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
.	O

The	O
addition	O
of	O
PTX	O
to	O
LPS	O
-	O
stimulated	O
mononuclear	O
cells	O
resulted	O
in	O
comparable	O
downregulation	O
of	O
DNA	O
binding	O
activity	O
,	O
similar	O
to	O
the	O
observed	O
downregulation	O
of	O
NF	O
-	O
kappaB	O
phosphorylation	O
(	O
Figure	O
3B	O
)	O
.	O

PTX	O
upregulates	O
CREB	O
phosphorylation	O
and	O
activation	O
after	O
LPS	O
stimulation	O

Phosphorylation	O
of	O
nuclear	O
CREB	O
was	O
used	O
as	O
a	O
marker	O
for	O
CREB	O
activation	O
.	O
<EOS>	B-X
Excessive	B-X
activation	B-X
of	B-X
the	B-X
mTOR/S6K1	B-X
signaling	B-X
pathway	B-X
promotes	B-X
abnormal	B-X
cell	B-X
growth	B-X
and	B-X
survival	B-X
,	B-X
thereby	B-X
resulting	B-X
in	B-X
tumorigenesis	B-X
.	B-X
S6K1	B-X
nuclear	B-X
localization	B-X
was	B-X
serum	B-X
dependent	B-X
and	B-X
serum	B-X
deprivation	B-X
or	B-X
rapamycin	B-X
treatment	B-X
inhibited	B-X
S6K1	B-X
Thr389	B-X
phosphorylation	B-X
and	B-X
,	B-X
thereby	B-X
,	B-X
S6K1	B-X
was	B-X
retained	B-X
in	B-X
the	B-X
cytoplasm	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
found	B-X
that	B-X
endogenous	B-X
S6K1	B-X
interacted	B-X
with	B-X
CREB	B-X
in	B-X
the	B-X
cervical	B-X
cancer	B-X
cells	B-X
.	B-X
The	B-X
binding	B-X
of	B-X
CREB/S6K1	B-X
to	B-X
the	B-X
c-JUN	B-X
promoter	B-X
,	B-X
altered	B-X
by	B-X
serum	B-X
restimulation	B-X
,	B-X
was	B-X
associated	B-X
with	B-X
active	B-X
epigenetic	B-X
markers	B-X
.	B-X

LPS	O
stimulation	O
caused	O
a	O
negligible	O
increase	O
in	O
CREB	O
phosphorylation	O
when	O
compared	O
to	O
control	O
(	O
Figure	O
4A	O
)	O
.	O

PTX	O
alone	O
caused	O
a	O
marked	O
increase	O
in	O
CREB	O
phosphorylation	O
(	O
P	O
<	O
0	O
.	O
01	O
vs	O
.	O
HBSS	O
)	O
.	O

When	O
LPS	O
and	O
PTX	O
exposure	O
occurred	O
simultaneously	O
,	O
CREB	O
phosphorylation	O
was	O
significantly	O
higher	O
than	O
with	O
LPS	O
stimulation	O
alone	O
(	O
543	O
+	O
/	O
-	O
92	O
vs	O
.	O
100	O
+	O
/	O
-	O
0	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

In	O
addition	O
,	O
the	O
amount	O
of	O
CREB	O
phosphorylation	O
seen	O
with	O
concomitant	O
LPS	O
and	O
PTX	O
treatment	O
was	O
less	O
than	O
that	O
seen	O
with	O
PTX	O
alone	O
,	O
although	O
this	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
P	O
=	O
0	O
.	O
08	O
)	O
.	O

To	O
determine	O
if	O
CREB	O
-	O
DNA	O
binding	O
was	O
affected	O
by	O
PTX	O
in	O
a	O
manner	O
similar	O
to	O
CREB	O
phosphorylation	O
,	O
an	O
EMSA	O
was	O
performed	O
.	O

Exposure	O
of	O
LPS	O
-	O
stimulated	O
cells	O
to	O
PTX	O
similarly	O
increased	O
CREB	B-Protein
DNA	O
-	O
binding	O
compared	O
to	O
LPS	O
alone	O
(	O
Figure	O
4B	O
)	O
.	O

Effect	O
of	O
PTX	O
on	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
in	O
the	O
presence	O
of	O
PKA	O
inhibition	O

The	O
role	O
of	O
PKA	O
in	O
PTX	O
-	O
induced	O
downregulation	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
in	O
LPS	O
-	O
stimulated	O
mononuclear	O
cells	O
was	O
assessed	O
by	O
treating	O
mononuclear	O
cells	O
with	O
H89	O
,	O
a	O
PKA	O
inhibitor	O
,	O
prior	O
to	O
LPS	O
and	O
PTX	O
exposure	O
.	O

The	O
addition	O
PTX	O
to	O
LPS	O
-	O
stimulated	O
cells	O
resulted	O
in	O
a	O
reduction	O
in	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
,	O
similar	O
to	O
that	O
observed	O
in	O
our	O
previous	O
experiments	O
(	O
529	O
pg	O
/	O
mL	O
+	O
/	O
-	O
112	O
vs	O
.	O
37	O
pg	O
/	O
mL	O
+	O
/	O
-	O
10	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Pre	O
-	O
incubation	O
of	O
cells	O
with	O
H89	O
prior	O
to	O
LPS	O
and	O
PTX	O
exposure	O
did	O
not	O
result	O
in	O
any	O
significant	O
modulation	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
when	O
compared	O
to	O
that	O
demonstrated	O
with	O
PTX	O
alone	O
(	O
P	O
=	O
0	O
.	O
2	O
;	O
Figure	O
5	O
)	O
.	O

These	O
results	O
suggest	O
that	O
downregulation	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
by	O
PTX	O
in	O
LPS	O
-	O
stimulated	O
mononuclear	O
cells	O
is	O
,	O
at	O
least	O
in	O
part	O
,	O
PKA	O
-	O
independent	O
.	O

The	O
exposure	O
of	O
inflammatory	O
cells	O
to	O
a	O
variety	O
of	O
extracellular	O
stimuli	O
results	O
in	O
the	O
initiation	O
of	O
transcriptional	O
and	O
posttranscriptional	O
events	O
,	O
which	O
culminate	O
in	O
the	O
production	O
of	O
pro	O
-	O
inflammatory	O
mediators	O
.	O
11	O
-	O
14	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
is	O
released	O
very	O
early	O
following	O
shock	O
and	O
is	O
considered	O
an	O
important	O
mediator	O
of	O
the	O
inflammatory	O
cascade	O
,	O
since	O
it	O
regulates	O
the	O
synthesis	O
of	O
several	O
other	O
critical	O
cytokines	O
and	O
chemokines	O
.	O
15	O
A	O
clear	O
relationship	O
between	O
increased	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
synthesis	O
and	O
the	O
development	O
of	O
shock	O
and	O
multiple	O
organ	O
dysfunction	O
has	O
been	O
observed	O
in	O
animal	O
models	O
of	O
sepsis	O
.	O
15	O
-	O
17	O

Because	O
of	O
its	O
importance	O
in	O
orchestrating	O
multiple	O
steps	O
of	O
the	O
inflammatory	O
response	O
,	O
strategies	O
aimed	O
at	O
decreasing	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
levels	O
or	O
attenuating	O
its	O
production	O
seem	O
attractive	O
.	O
<EOS>	B-X
We	B-X
consider	B-X
the	B-X
complex	B-X
backdrop	B-X
of	B-X
VZV	B-X
virology	B-X
,	B-X
pathogenesis	B-X
and	B-X
immune	B-X
responses	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
suitable	B-X
animal	B-X
models	B-X
and	B-X
examine	B-X
the	B-X
changing	B-X
epidemiology	B-X
of	B-X
VZV	B-X
disease	B-X
.	B-X
As	B-X
these	B-X
live	B-X
vaccines	B-X
have	B-X
the	B-X
potential	B-X
to	B-X
reactivate	B-X
and	B-X
cause	B-X
clinical	B-X
disease	B-X
,	B-X
developing	B-X
alternatives	B-X
that	B-X
do	B-X
not	B-X
establish	B-X
latency	B-X
is	B-X
an	B-X
attractive	B-X
prospect	B-X
but	B-X
will	B-X
require	B-X
better	B-X
understanding	B-X
of	B-X
latency	B-X
mechanisms	B-X
.	B-X
Metabolic	B-X
endotoxemia	B-X
is	B-X
a	B-X
condition	B-X
in	B-X
which	B-X
blood	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
levels	B-X
are	B-X
elevated	B-X
,	B-X
regardless	B-X
of	B-X
the	B-X
presence	B-X
of	B-X
obvious	B-X
infection	B-X
.	B-X
PDC	B-X
drives	B-X
mitochondrial	B-X
conversion	B-X
of	B-X
pyruvate	B-X
to	B-X
acetyl-coenzyme	B-X
A	B-X
(	B-X
acetyl-CoA	B-X
)	B-X
,	B-X
thereby	B-X
increasing	B-X
the	B-X
tricarboxylic	B-X
acid	B-X
cycle	B-X
,	B-X
oxidative	B-X
phosphorylation	B-X
,	B-X
and	B-X
ATP	B-X
production	B-X
.	B-X
Virus-	B-X
and	B-X
cytokine-storm-driven	B-X
control	B-X
of	B-X
the	B-X
pineal	B-X
and	B-X
mitochondrial	B-X
melatonergic	B-X
pathway	B-X
therefore	B-X
regulates	B-X
immune	B-X
responses	B-X
.	B-X
Virus-and	B-X
cytokine	B-X
storm-driven	B-X
changes	B-X
also	B-X
increase	B-X
gut	B-X
permeability	B-X
and	B-X
dysbiosis	B-X
,	B-X
thereby	B-X
suppressing	B-X
levels	B-X
of	B-X
the	B-X
short-chain	B-X
fatty	B-X
acid	B-X
,	B-X
butyrate	B-X
,	B-X
and	B-X
increasing	B-X
circulating	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
.	B-X

PDE	O
inhibitors	O
have	O
been	O
shown	O
to	O
downregulate	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
in	O
distinct	O
human	O
cell	O
populations	O
.	O

We	O
have	O
previously	O
shown	O
that	O
,	O
in	O
general	O
,	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
levels	O
continue	O
to	O
increase	O
after	O
LPS	O
exposure	O
and	O
that	O
concomitant	O
infusion	O
of	O
phosphodiesterase	O
inhibitors	O
can	O
markedly	O
decrease	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
levels	O
.	O
18	O
-	O
19	O
In	O
this	O
in	O
vitro	O
study	O
,	O
we	O
verified	O
the	O
sustained	O
attenuation	O
of	O
LPS	O
-	O
induced	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
expression	O
over	O
time	O
in	O
an	O
isolated	O
human	O
mononuclear	O
cell	O
population	O
.	O

The	O
mechanisms	O
by	O
which	O
PTX	O
,	O
a	O
non	O
-	O
specific	O
phosphodiesterase	O
inhibitor	O
,	O
significantly	O
and	O
consistently	O
decreases	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
have	O
not	O
been	O
completely	O
elucidated	O
.	O

It	O
has	O
been	O
postulated	O
that	O
drugs	O
that	O
increase	O
intracellular	O
cAMP	O
exert	O
their	O
anti	O
-	O
inflammatory	O
effects	O
through	O
the	O
activation	O
of	O
PKA	O
.	O

This	O
classic	O
pathway	O
has	O
been	O
challenged	O
as	O
the	O
sole	O
mechanism	O
involved	O
in	O
the	O
modulation	O
of	O
inflammation	O
by	O
cAMP	O
-	O
enhancing	O
drugs	O
,	O
and	O
alternative	O
mechanisms	O
involving	O
PKA	O
-	O
independent	O
pathways	O
have	O
been	O
proposed	O
.	O
6	O
-	O
8	O
In	O
this	O
series	O
of	O
experiments	O
,	O
we	O
observed	O
a	O
significant	O
attenuation	O
of	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
in	O
LPS	O
-	O
stimulated	O
human	O
mononuclear	O
cells	O
following	O
PTX	O
administration	O
,	O
independent	O
of	O
PKA	O
activation	O
.	O

We	O
used	O
a	O
nonspecific	O
phosphodiesterase	O
inhibitor	O
,	O
PTX	O
,	O
in	O
the	O
present	O
study	O
because	O
it	O
has	O
been	O
used	O
clinically	O
in	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
conditions	O
in	O
which	O
inflammation	O
is	O
an	O
important	O
component	O
of	O
the	O
pathophysiology	O
of	O
the	O
disease	O
process	O
.	O
19	O
Additionally	O
,	O
the	O
use	O
of	O
PTX	O
in	O
sepsis	O
as	O
an	O
adjunct	O
to	O
other	O
treatments	O
to	O
maintain	O
adequate	O
organ	O
function	O
has	O
been	O
explored	O
based	O
upon	O
its	O
effects	O
on	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
synthesis	O
.	O

However	O
,	O
the	O
reported	O
beneficial	O
effects	O
of	O
PTX	O
are	O
not	O
only	O
related	O
to	O
the	O
downregulation	O
of	O
TNF	B-Protein
-	I-Protein
alphabut	I-Protein
also	O
to	O
PTX	O
'	O
s	O
hemorrheologic	O
properties	O
,	O
its	O
ability	O
to	O
reduce	O
neutrophil	O
activation	O
,	O
and	O
its	O
beneficial	O
effects	O
on	O
microcirculation	O
,	O
cardiac	O
performance	O
,	O
and	O
organ	O
injury	O
.	O
20	O
-	O
25	O
Herein	O
,	O
we	O
demonstrated	O
that	O
the	O
downregulatory	O
effects	O
of	O
PTX	O
in	O
human	O
mononuclear	O
cells	O
involves	O
modulation	O
of	O
pathways	O
that	O
involve	O
NF	O
-	O
kappaB	O
and	O
CREB	O
,	O
two	O
major	O
transcription	O
factors	O
involved	O
in	O
the	O
inflammatory	O
cascade	O
.	O
<EOS>	B-X
Parathyroidectomy	B-X
(	B-X
PTX	B-X
)	B-X
is	B-X
often	B-X
used	B-X
to	B-X
treat	B-X
severe	B-X
secondary	B-X
hyperparathyroidism	B-X
(	B-X
SHPT	B-X
)	B-X
in	B-X
patients	B-X
receiving	B-X
maintenance	B-X
dialysis	B-X
.	B-X
However	B-X
,	B-X
most	B-X
evidence	B-X
for	B-X
the	B-X
proposed	B-X
benefits	B-X
of	B-X
PTX	B-X
originates	B-X
from	B-X
observational	B-X
studies	B-X
,	B-X
which	B-X
can	B-X
not	B-X
demonstrate	B-X
causality	B-X
.	B-X
A	B-X
reconsideration	B-X
of	B-X
the	B-X
potential	B-X
role	B-X
of	B-X
PTX	B-X
might	B-X
help	B-X
guide	B-X
its	B-X
appropriate	B-X
use	B-X
.	B-X
Application	B-X
of	B-X
nonspecific	B-X
phosphodiesterases	B-X
inhibitors	B-X
,	B-X
such	B-X
as	B-X
pentoxifylline	B-X
(	B-X
PTX	B-X
)	B-X
,	B-X
is	B-X
a	B-X
strategy	B-X
utilised	B-X
to	B-X
aid	B-X
sperm	B-X
selection	B-X
from	B-X
immotile	B-X
sperm	B-X
samples	B-X
prior	B-X
to	B-X
ICSI	B-X
.	B-X
No	B-X
extensive	B-X
studies	B-X
have	B-X
yet	B-X
been	B-X
performed	B-X
to	B-X
verify	B-X
the	B-X
safety	B-X
of	B-X
the	B-X
clinical	B-X
outcomes	B-X
of	B-X
ICSI	B-X
after	B-X
PTX	B-X
administration	B-X
.	B-X
In	B-X
this	B-X
article	B-X
,	B-X
we	B-X
summarise	B-X
the	B-X
data	B-X
reported	B-X
in	B-X
the	B-X
literature	B-X
that	B-X
assess	B-X
the	B-X
implication	B-X
of	B-X
in	B-X
vitro	B-X
usage	B-X
of	B-X
PTX	B-X
on	B-X
sperm	B-X
parameters	B-X
,	B-X
as	B-X
well	B-X
as	B-X
clinical	B-X
outcomes	B-X
during	B-X
assisted	B-X
male	B-X
reproduction	B-X
programme	B-X
.	B-X

NF	O
-	O
kappaB	O
/	O
Rel	O
constitutes	O
a	O
family	O
of	O
transcriptional	O
factors	O
involved	O
in	O
the	O
regulation	O
of	O
numerous	O
cytokine	O
genes	O
and	O
immune	O
responses	O
in	O
different	O
cell	O
populations	O
.	O

The	O
most	O
abundant	O
form	O
of	O
NF	O
-	O
kappaB	O
is	O
the	O
p50	B-Protein
-	O
p65	B-Protein
heterodimer	O
.	O
26	O
The	O
inactive	O
form	O
of	O
NF	O
-	O
kappaB	O
exists	O
in	O
the	O
cytoplasm	O
bound	O
to	O
an	O
inhibitory	O
complex	O
containing	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
.	O

Following	O
cellular	O
stimulation	O
with	O
LPS	O
and	O
chemotactic	O
factors	O
,	O
NF	O
-	O
kappaB	O
inducible	O
kinase	O
phosphorylates	O
and	O
activates	O
the	O
I	O
-	O
kappaB	O
kinase	O
(	O
IKK	O
)	O
complex	O
consisting	O
of	O
IKK	B-Protein
-	I-Protein
1	I-Protein
and	O
IKK	B-Protein
-	I-Protein
2	I-Protein
,	O
which	O
in	O
turn	O
phosphorylates	O
the	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
subunit	O
.	O

Phosphorylation	O
,	O
ubiquitination	O
,	O
and	O
subsequent	O
degradation	O
of	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
results	O
in	O
NF	O
-	O
kappaB	O
nuclear	O
translocation	O
.	O

This	O
allows	O
the	O
transcription	O
factor	O
to	O
bind	O
to	O
promoter	O
regions	O
of	O
specific	O
pro	O
-	O
inflammatory	O
genes	O
and	O
influence	O
transcription	O
.	O
27	O
,	O
28	O
Because	O
a	O
number	O
of	O
potential	O
kappaB	O
sites	O
are	O
present	O
in	O
the	O
nucleotide	O
sequences	O
of	O
the	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
gene	O
,	O
NF	O
-	O
kappaB	O
is	O
considered	O
to	O
be	O
a	O
critical	O
transcriptional	O
factor	O
involved	O
in	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
gene	O
expression	O
and	O
protein	O
synthesis	O
.	O
29	O
,	O
30	O

In	O
this	O
set	O
of	O
experiments	O
,	O
we	O
demonstrated	O
that	O
PTX	O
downregulates	O
cytoplasmic	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
phosphorylation	O
,	O
nuclear	O
NF	O
-	O
kappaB	O
p65	B-Protein
phosphorylation	O
/	O
translocation	O
,	O
as	O
well	O
as	O
NF	O
-	O
kappaB	O
DNA	O
-	O
binding	O
after	O
LPS	O
stimulation	O
,	O
suggesting	O
that	O
PTX	O
exerts	O
its	O
function	O
proximal	O
to	O
or	O
at	O
the	O
level	O
of	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
phosphorylation	O
.	O
<EOS>	B-X
Phenotypic	B-X
switch	B-X
of	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
(	B-X
VSMCs	B-X
)	B-X
is	B-X
characterized	B-X
by	B-X
increased	B-X
expressions	B-X
of	B-X
VSMC	B-X
synthetic	B-X
markers	B-X
and	B-X
decreased	B-X
levels	B-X
of	B-X
VSMC	B-X
contractile	B-X
markers	B-X
,	B-X
which	B-X
is	B-X
an	B-X
important	B-X
step	B-X
for	B-X
VSMC	B-X
proliferation	B-X
and	B-X
migration	B-X
during	B-X
the	B-X
development	B-X
and	B-X
progression	B-X
of	B-X
cardiovascular	B-X
diseases	B-X
including	B-X
atherosclerosis	B-X
.	B-X
Mechanistically	B-X
,	B-X
PDGF-BB-treated	B-X
VSMCs	B-X
exhibited	B-X
higher	B-X
mammalian	B-X
target	B-X
of	B-X
rapamycin	B-X
(	B-X
mTOR	B-X
)	B-X
and	B-X
P70S6K	B-X
phosphorylation	B-X
,	B-X
which	B-X
was	B-X
attenuated	B-X
by	B-X
CA	B-X
pretreatment	B-X
,	B-X
diphenyleneiodonium	B-X
chloride	B-X
(	B-X
DPI	B-X
)	B-X
,	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
scavenger	B-X
N-acetyl-l-cysteine	B-X
(	B-X
NAC	B-X
)	B-X
and	B-X
nuclear	B-X
factor-κB	B-X
(	B-X
NFκB	B-X
)	B-X
inhibitor	B-X
Bay117082	B-X
.	B-X
PDGF-BB-triggered	B-X
ROS	B-X
production	B-X
and	B-X
p65-NFκB	B-X
activation	B-X
were	B-X
inhibited	B-X
by	B-X
CA	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
both	B-X
NAC	B-X
and	B-X
DPI	B-X
abolished	B-X
PDGF-BB-evoked	B-X
p65-NFκB	B-X
nuclear	B-X
translocation	B-X
,	B-X
phosphorylation	B-X
and	B-X
degradation	B-X
of	B-X
Inhibitor	B-X
κBα	B-X
(	B-X
IκBα	B-X
)	B-X
.	B-X
Of	B-X
note	B-X
,	B-X
blockade	B-X
of	B-X
ROS/NFκB/mTOR/P70S6K	B-X
signaling	B-X
cascade	B-X
prevented	B-X
PDGF-BB-evoked	B-X
VSMC	B-X
phenotypic	B-X
transformation	B-X
,	B-X
proliferation	B-X
and	B-X
migration	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
CA	B-X
impedes	B-X
PDGF-BB-induced	B-X
VSMC	B-X
phenotypic	B-X
switching	B-X
,	B-X
proliferation	B-X
,	B-X
migration	B-X
and	B-X
neointima	B-X
formation	B-X
via	B-X
inhibition	B-X
of	B-X
ROS/NFκB/mTOR/P70S6K	B-X
signaling	B-X
cascade	B-X
.	B-X

Previous	O
studies	O
that	O
have	O
evaluated	O
the	O
effects	O
of	O
cAMP	O
-	O
elevating	O
drugs	O
on	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
and	O
NF	O
-	O
kappaB	O
have	O
reported	O
conflicting	O
results	O
.	O

Haddad	O
et	O
al	O
.	O
reported	O
results	O
similar	O
to	O
ours	O
with	O
respect	O
to	O
the	O
effects	O
of	O
PTX	O
on	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
and	O
NF	O
-	O
kappaB	O
in	O
pulmonary	O
epithelial	O
cells	O
.	O
31	O
Conversely	O
,	O
Neumann	O
et	O
al	O
.	O
proposed	O
that	O
increased	O
intracellular	O
cAMP	O
stabilizes	O
the	O
interaction	O
between	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
and	O
NF	O
-	O
kappaB	O
,	O
therefore	O
reducing	O
NF	O
-	O
kappaB	O
activation	O
.	O
32	O
In	O
contrast	O
,	O
Takahashi	O
et	O
al	O
.	O
showed	O
no	O
difference	O
in	O
I	B-Protein
-	I-Protein
kappaBalpha	I-Protein
degradation	O
in	O
Jurkat	O
T	O
-	O
lymphocytes	O
in	O
the	O
presence	O
and	O
absence	O
of	O
forskolin	O
,	O
an	O
alternative	O
cAMP	O
inducing	O
compound	O
.	O

This	O
group	O
also	O
demonstrated	O
that	O
forskolin	O
did	O
not	O
inhibit	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
NF	O
-	O
kappaB	O
and	O
that	O
CREB	O
was	O
not	O
involved	O
in	O
forskolin	O
-	O
induced	O
decrease	O
in	O
p65	B-Protein
transcriptional	O
activity	O
.	O
33	O
Similar	O
results	O
were	O
reported	O
by	O
Ollivier	O
et	O
al	O
.	O
using	O
THP	O
-	O
1	O
cells	O
and	O
endothelial	O
cells	O
treated	O
with	O
forskolin	O
or	O
dibutyryl	O
cAMP	O
,	O
two	O
agents	O
known	O
to	O
function	O
through	O
cAMP	O
elevation	O
and	O
subsequent	O
PKA	O
activation	O
.	O
9	O
The	O
differences	O
between	O
our	O
results	O
and	O
those	O
mentioned	O
above	O
may	O
be	O
explained	O
by	O
the	O
use	O
of	O
different	O
cell	O
types	O
and	O
exogenous	O
stimulants	O
.	O
<EOS>	B-X
Nicotinamide	B-X
mononucleotide	B-X
(	B-X
NMN	B-X
)	B-X
is	B-X
a	B-X
representative	B-X
anti-aging	B-X
drug	B-X
that	B-X
,	B-X
after	B-X
long-term	B-X
administration	B-X
in	B-X
mice	B-X
,	B-X
causes	B-X
an	B-X
increase	B-X
in	B-X
energy	B-X
and	B-X
lipid	B-X
metabolism	B-X
,	B-X
improves	B-X
eye	B-X
function	B-X
,	B-X
immune	B-X
response	B-X
,	B-X
and	B-X
increases	B-X
insulin	B-X
sensitivity	B-X
.	B-X
However	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
NMN	B-X
on	B-X
skin	B-X
pigmentation	B-X
are	B-X
still	B-X
unknown	B-X
.	B-X
Rat	B-X
pancreatic	B-X
acinar	B-X
cells	B-X
possess	B-X
only	B-X
the	B-X
p21-activated	B-X
kinase	B-X
(	B-X
PAKs	B-X
)	B-X
,	B-X
PAK4	B-X
of	B-X
the	B-X
group	B-X
II	B-X
PAK	B-X
,	B-X
and	B-X
it	B-X
is	B-X
activated	B-X
by	B-X
gastrointestinal	B-X
hormones/neurotransmitters	B-X
stimulating	B-X
PLC	B-X
and	B-X
by	B-X
a	B-X
number	B-X
of	B-X
growth	B-X
factors	B-X
.	B-X
However	B-X
,	B-X
little	B-X
is	B-X
known	B-X
generally	B-X
of	B-X
cAMP	B-X
agents	B-X
causing	B-X
PAK4	B-X
activation	B-X
,	B-X
and	B-X
there	B-X
are	B-X
no	B-X
studies	B-X
with	B-X
gastrointestinal	B-X
hormones/neurotransmitters	B-X
activating	B-X
cAMP	B-X
cascades	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
VIP	B-X
and	B-X
secretin	B-X
,	B-X
which	B-X
stimulate	B-X
cAMP	B-X
generation	B-X
in	B-X
pancreatic	B-X
acini	B-X
,	B-X
to	B-X
stimulate	B-X
PAK4	B-X
activation	B-X
,	B-X
the	B-X
signaling	B-X
cascades	B-X
involved	B-X
,	B-X
and	B-X
their	B-X
possible	B-X
role	B-X
in	B-X
activating	B-X
sodium-potassium	B-X
adenosine	B-X
triphosphatase	B-X
(	B-X
Na	B-X

It	O
is	O
also	O
possible	O
that	O
PTX	O
exerts	O
its	O
anti	O
-	O
inflammatory	O
effects	O
on	O
the	O
NF	O
-	O
kappaB	O
pathway	O
independent	O
of	O
PKA	O
,	O
as	O
suggested	O
by	O
the	O
continued	O
attenuation	O
of	O
LPS	O
-	O
induced	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
by	O
PTX	O
in	O
the	O
presence	O
or	O
absence	O
of	O
PKA	O
inhibition	O
observed	O
in	O
this	O
study	O
.	O
<EOS>	B-X
Liquiritin	B-X
Attenuates	B-X
Pathological	B-X
Cardiac	B-X
Hypertrophy	B-X
by	B-X
Activating	B-X
the	B-X
PKA/LKB1/AMPK	B-X
Pathway	B-X
.	B-X
Sepsis	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
common	B-X
comorbidities	B-X
observed	B-X
in	B-X
diabetic	B-X
patients	B-X
,	B-X
associated	B-X
with	B-X
a	B-X
deficient	B-X
innate	B-X
immune	B-X
response	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
glucagon	B-X
possesses	B-X
anti-inflammatory	B-X
properties	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
if	B-X
hyperglucagonemia	B-X
triggered	B-X
by	B-X
diabetes	B-X
might	B-X
reduce	B-X
the	B-X
migration	B-X
of	B-X
neutrophils	B-X
,	B-X
increasing	B-X
sepsis	B-X
susceptibility	B-X
.	B-X
21	B-X
days	B-X
after	B-X
diabetes	B-X
induction	B-X
by	B-X
intravenous	B-X
injection	B-X
of	B-X
alloxan	B-X
,	B-X
we	B-X
induced	B-X
moderate	B-X
sepsis	B-X
in	B-X
Swiss-Webster	B-X
mice	B-X
through	B-X
cecum	B-X
ligation	B-X
and	B-X
puncture	B-X
(	B-X
CLP	B-X
)	B-X
.	B-X
We	B-X
also	B-X
tested	B-X
the	B-X
effect	B-X
of	B-X
glucagon	B-X
on	B-X
CXCL1/KC-induced	B-X
neutrophil	B-X
migration	B-X
to	B-X
the	B-X
peritoneal	B-X
cavity	B-X
in	B-X
mice	B-X
.	B-X

This	O
hypothesis	O
is	O
currently	O
under	O
investigation	O
in	O
our	O
laboratory	O
.	O
<EOS>	B-X
Their	B-X
role	B-X
in	B-X
aggravating	B-X
seborrheic	B-X
dermatitis	B-X
,	B-X
dandruff	B-X
,	B-X
folliculitis	B-X
,	B-X
and	B-X
onychomycosis	B-X
,	B-X
though	B-X
often	B-X
supported	B-X
by	B-X
histopathological	B-X
evidence	B-X
and	B-X
favorable	B-X
antifungal	B-X
therapeutic	B-X
outcomes	B-X
,	B-X
remains	B-X
under	B-X
investigation	B-X
.	B-X
A	B-X
close	B-X
association	B-X
between	B-X
skin	B-X
and	B-X
Malassezia	B-X
IgE	B-X
binding	B-X
allergens	B-X
in	B-X
atopic	B-X
eczema	B-X
has	B-X
been	B-X
shown	B-X
,	B-X
while	B-X
laboratory	B-X
data	B-X
support	B-X
a	B-X
role	B-X
in	B-X
psoriasis	B-X
exacerbations	B-X
.	B-X
Finally	B-X
,	B-X
metabolomic	B-X
research	B-X
resulted	B-X
in	B-X
the	B-X
proposal	B-X
of	B-X
a	B-X
hypothesis	B-X
on	B-X
the	B-X
contribution	B-X
of	B-X
Malassezia-synthesized	B-X
aryl	B-X
hydrocarbon	B-X
receptor	B-X
(	B-X
AhR	B-X
)	B-X
ligands	B-X
to	B-X
basal	B-X
cell	B-X
carcinoma	B-X
through	B-X
UV	B-X
radiation-induced	B-X
carcinogenesis	B-X
.	B-X
The	B-X
design	B-X
of	B-X
the	B-X
energy	B-X
metabolism	B-X
system	B-X
in	B-X
striated	B-X
muscle	B-X
remains	B-X
a	B-X
major	B-X
area	B-X
of	B-X
investigation	B-X
.	B-X
Recent	B-X
structural	B-X
and	B-X
functional	B-X
studies	B-X
have	B-X
supported	B-X
the	B-X
hypothesis	B-X
that	B-X
the	B-X
mitochondrial	B-X
reticulum	B-X
provides	B-X
a	B-X
rapid	B-X
energy	B-X
distribution	B-X
system	B-X
via	B-X
the	B-X
conduction	B-X
of	B-X
the	B-X
mitochondrial	B-X
membrane	B-X
potential	B-X
to	B-X
maintain	B-X
metabolic	B-X
homeostasis	B-X
during	B-X
contractile	B-X
activity	B-X
.	B-X

Furthermore	O
,	O
we	O
utilized	O
a	O
broad	O
PKA	O
inhibitor	O
in	O
this	O
study	O
in	O
addition	O
to	O
H89	O
,	O
but	O
did	O
not	O
examine	O
the	O
effect	O
of	O
specific	O
inhibition	O
of	O
various	O
PKA	O
isoforms	O
.	O

This	O
information	O
may	O
yield	O
more	O
insight	O
into	O
the	O
mechanism	O
by	O
which	O
PTX	O
exerts	O
its	O
down	O
-	O
regulatory	O
effects	O
.	O

PDE	O
inhibitors	O
may	O
also	O
downregulate	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
by	O
altering	O
the	O
competitive	O
binding	O
of	O
CREB	O
and	O
NF	O
-	O
kappaB	O
to	O
the	O
promoter	O
regions	O
of	O
pro	O
-	O
inflammatory	O
genes	O
.	O

Herein	O
,	O
we	O
showed	O
that	O
the	O
activation	O
and	O
DNA	O
binding	O
activity	O
of	O
CREB	O
is	O
upregulated	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
by	O
PTX	O
.	O

Of	O
note	O
,	O
the	O
increase	O
in	O
CREB	O
activity	O
was	O
slightly	O
alleviated	O
by	O
the	O
addition	O
of	O
LPS	O
,	O
suggesting	O
competition	O
between	O
PTX	O
-	O
induced	O
CREB	O
-	O
associated	O
gene	O
transcription	O
and	O
those	O
factors	O
,	O
such	O
as	O
NF	O
-	O
kappaB	O
,	O
which	O
may	O
be	O
upregulated	O
by	O
LPS	O
exposure	O
.	O

This	O
competition	O
has	O
been	O
postulated	O
to	O
involve	O
the	O
recruitment	O
of	O
the	O
co	O
-	O
activator	O
CBP	B-Protein
and	O
its	O
homologue	O
p30034	B-Protein
,	O
suggesting	O
an	O
alternative	O
mechanism	O
that	O
may	O
be	O
involved	O
in	O
the	O
anti	O
-	O
inflammatory	O
actions	O
of	O
PTX	O
.	O

Future	O
studies	O
are	O
planned	O
to	O
delineate	O
the	O
validity	O
of	O
this	O
potential	O
mechanism	O
.	O
<EOS>	B-X
Whilst	B-X
these	B-X
two	B-X
types	B-X
of	B-X
breathing	B-X
abnormalities	B-X
might	B-X
be	B-X
related	B-X
,	B-X
studies	B-X
tend	B-X
to	B-X
focus	B-X
on	B-X
only	B-X
one	B-X
of	B-X
them	B-X
and	B-X
do	B-X
not	B-X
consider	B-X
their	B-X
relationship	B-X
.	B-X
These	B-X
observations	B-X
tantalizingly	B-X
parallel	B-X
epidemiological	B-X
studies	B-X
characterizing	B-X
the	B-X
increasing	B-X
prevalence	B-X
and	B-X
severity	B-X
of	B-X
asthma	B-X
that	B-X
also	B-X
occurs	B-X
amongst	B-X
females	B-X
after	B-X
puberty	B-X
.	B-X
It	B-X
should	B-X
be	B-X
properly	B-X
delineated	B-X
as	B-X
it	B-X
might	B-X
be	B-X
causally	B-X
related	B-X
to	B-X
specific	B-X
treatable	B-X
factors	B-X
.	B-X
Dysfunctional	B-X
breathing	B-X
is	B-X
associated	B-X
with	B-X
asthma	B-X
morbidity	B-X
through	B-X
a	B-X
number	B-X
of	B-X
potential	B-X
mechanisms	B-X
.	B-X
Future	B-X
challenges	B-X
include	B-X
the	B-X
need	B-X
for	B-X
studies	B-X
characterizing	B-X
all	B-X
types	B-X
of	B-X
dysfunctional	B-X
breathing	B-X
in	B-X
pediatric	B-X
and	B-X
adult	B-X
patient	B-X
cohorts	B-X
and	B-X
clearly	B-X
defined	B-X
,	B-X
age	B-X
appropriate	B-X
,	B-X
interventional	B-X
studies	B-X
.	B-X

The	O
effects	O
of	O
PTX	O
on	O
other	O
transcription	O
factors	O
,	O
such	O
as	O
AP	O
-	O
1	O
,	O
c	B-Protein
-	I-Protein
fos	I-Protein
,	O
and	O
c	B-Protein
-	I-Protein
jun	I-Protein
,	O
cannot	O
be	O
ruled	O
out	O
by	O
our	O
experiments	O
.	O

Activation	O
of	O
AP	O
-	O
1	O
and	O
its	O
components	O
(	O
c	B-Protein
-	I-Protein
fos	I-Protein
and	O
c	B-Protein
-	I-Protein
jun	I-Protein
)	O
by	O
agents	O
that	O
enhance	O
mononuclear	O
cell	O
activity	O
has	O
been	O
implicated	O
in	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
expression	O
.	O

Moreover	O
,	O
AP	O
-	O
1	O
and	O
CREB	O
recognize	O
a	O
similar	O
DNA	O
binding	O
sequence	O
in	O
the	O
promoter	O
region	O
of	O
the	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
gene35	O
.	O

Given	O
these	O
relationships	O
,	O
it	O
is	O
conceivable	O
that	O
PTX	O
may	O
exert	O
some	O
of	O
its	O
anti	O
-	O
inflammatory	O
actions	O
by	O
affecting	O
AP	O
-	O
1	O
activation	O
and	O
favoring	O
CREB	O
binding	O
,	O
thus	O
inhibiting	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
gene	O
transcription	O
.	O

Additional	O
studies	O
are	O
necessary	O
to	O
elucidate	O
the	O
complex	O
interactions	O
between	O
CREB	O
,	O
NF	O
-	O
kappaB	O
,	O
and	O
AP	O
-	O
1	O
following	O
LPS	O
exposure	O
and	O
PDE	O
inhibition	O
.	O

Furthermore	O
,	O
the	O
effect	O
of	O
PTX	O
on	O
the	O
cGMP	O
pathway	O
after	O
LPS	O
stimulation	O
has	O
not	O
been	O
explored	O
,	O
although	O
we	O
plan	O
to	O
do	O
so	O
in	O
the	O
future	O
.	O

In	O
summary	O
,	O
we	O
have	O
demonstrated	O
that	O
PDE	O
inhibition	O
of	O
human	O
mononuclear	O
cells	O
downregulates	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
a	O
PKA	O
-	O
independent	O
mechanism	O
.	O

In	O
addition	O
,	O
PTX	O
attenuates	O
the	O
activity	O
of	O
NF	O
-	O
B	O
while	O
upregulating	O
CREB	O
activation	O
after	O
LPS	O
stimulation	O
,	O
which	O
may	O
result	O
in	O
modulation	O
of	O
pro	O
-	O
inflammatory	O
mediator	O
synthesis	O
.	O

Therefore	O
,	O
PTX	O
may	O
serve	O
as	O
a	O
potential	O
adjunct	O
therapeutic	O
for	O
the	O
treatment	O
of	O
conditions	O
in	O
which	O
TNF	B-Protein
-	I-Protein
alpha	I-Protein
production	O
plays	O
a	O
significant	O
role	O
.	O

Interleukin	B-Protein
-	I-Protein
10	I-Protein
Production	O
by	O
Th1	O
Cells	O
Requires	O
Interleukin	B-Protein
-	I-Protein
12	I-Protein
-	O
Induced	O
STAT4	B-Protein
Transcription	O
Factor	O
and	O
ERK	B-Protein
MAP	O
Kinase	O
Activation	O
by	O
High	O
Antigen	O
Dose	O
<EOS>	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
producing	B-X
interleukin-10	B-X
(	B-X
IL-10	B-X
)	B-X
and	B-X
interferon-gamma	B-X
(	B-X
IFN-gamma	B-X
)	B-X
are	B-X
reported	B-X
in	B-X
chronic	B-X
infections	B-X
.	B-X
However	B-X
,	B-X
the	B-X
signals	B-X
that	B-X
direct	B-X
the	B-X
development	B-X
of	B-X
IL-10-producing	B-X
T	B-X
helper	B-X
1	B-X
(	B-X
Th1	B-X
)	B-X
cells	B-X
are	B-X
undefined	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
development	B-X
of	B-X
IL-10-producing	B-X
Th1	B-X
cells	B-X
required	B-X
high	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
ligation	B-X
,	B-X
sustained	B-X
ERK1	B-X
and	B-X
ERK2	B-X
MAP	B-X
kinases	B-X
phosphorylation	B-X
,	B-X
and	B-X
IL-12-induced	B-X
STAT4	B-X
transcription	B-X
factor	B-X
activation	B-X
.	B-X
Repeated	B-X
TCR	B-X
triggering	B-X
led	B-X
to	B-X
enhanced	B-X
IL-10	B-X
production	B-X
by	B-X
Th1	B-X
cells	B-X
,	B-X
and	B-X
continued	B-X
IL-12	B-X
action	B-X
and	B-X
high-dose	B-X
TCR	B-X
signaling	B-X
were	B-X
required	B-X
for	B-X
the	B-X
development	B-X
and	B-X
maintenance	B-X
of	B-X
IL-10-producing	B-X
Th1	B-X
cells	B-X
.	B-X
Although	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
and	B-X
Th17	B-X
cells	B-X
require	B-X
the	B-X
activation	B-X
of	B-X
distinct	B-X
STATs	B-X
for	B-X
their	B-X
differentiation	B-X
,	B-X
activation	B-X
of	B-X
ERK1	B-X
and	B-X
ERK2	B-X
was	B-X
a	B-X
common	B-X
requirement	B-X
for	B-X
production	B-X
of	B-X
IL-10	B-X
by	B-X
all	B-X
Th	B-X
cell	B-X
subsets	B-X
.	B-X
IL-10	B-X
expression	B-X
also	B-X
correlated	B-X
with	B-X
c-maf	B-X
expression	B-X
.	B-X
Despite	B-X
having	B-X
distinct	B-X
functions	B-X
in	B-X
protection	B-X
against	B-X
pathogens	B-X
,	B-X
all	B-X
Th	B-X
cells	B-X
share	B-X
the	B-X
important	B-X
task	B-X
of	B-X
controlling	B-X
overexuberant	B-X
immune	B-X
responses	B-X
by	B-X
means	B-X
of	B-X
IL-10	B-X
production	B-X
.	B-X

Summary	O
<EOS>	B-X
Improving	B-X
Patient	B-X
Discharge	B-X
Summary	B-X
Communication	B-X
.	B-X
The	B-X
International	B-X
Patient	B-X
Summary	B-X
(	B-X
IPS	B-X
)	B-X
standard	B-X
is	B-X
a	B-X
step	B-X
towards	B-X
communicating	B-X
safe	B-X
,	B-X
relevant	B-X
patient	B-X
summaries	B-X
for	B-X
use	B-X
throughout	B-X
the	B-X
world	B-X
.	B-X
This	B-X
Is	B-X
the	B-X
Story	B-X
of	B-X
a	B-X
Discharge	B-X
Summary	B-X
.	B-X
The	B-X
discharge	B-X
summary	B-X
as	B-X
a	B-X
medium	B-X
for	B-X
teaching	B-X
and	B-X
learning	B-X
.	B-X

CD4	B-Protein
+	O
T	O
cells	O
producing	O
interleukin	B-Protein
-	I-Protein
10	I-Protein
(	O
IL	B-Protein
-	I-Protein
10	I-Protein
)	O
and	O
interferon	B-Protein
-	I-Protein
gamma	I-Protein
(	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
)	O
are	O
reported	O
in	O
chronic	O
infections	O
.	O
<EOS>	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
producing	B-X
interleukin-10	B-X
(	B-X
IL-10	B-X
)	B-X
and	B-X
interferon-gamma	B-X
(	B-X
IFN-gamma	B-X
)	B-X
are	B-X
reported	B-X
in	B-X
chronic	B-X
infections	B-X
.	B-X
However	B-X
,	B-X
the	B-X
signals	B-X
that	B-X
direct	B-X
the	B-X
development	B-X
of	B-X
IL-10-producing	B-X
T	B-X
helper	B-X
1	B-X
(	B-X
Th1	B-X
)	B-X
cells	B-X
are	B-X
undefined	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
development	B-X
of	B-X
IL-10-producing	B-X
Th1	B-X
cells	B-X
required	B-X
high	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
ligation	B-X
,	B-X
sustained	B-X
ERK1	B-X
and	B-X
ERK2	B-X
MAP	B-X
kinases	B-X
phosphorylation	B-X
,	B-X
and	B-X
IL-12-induced	B-X
STAT4	B-X
transcription	B-X
factor	B-X
activation	B-X
.	B-X
Repeated	B-X
TCR	B-X
triggering	B-X
led	B-X
to	B-X
enhanced	B-X
IL-10	B-X
production	B-X
by	B-X
Th1	B-X
cells	B-X
,	B-X
and	B-X
continued	B-X
IL-12	B-X
action	B-X
and	B-X
high-dose	B-X
TCR	B-X
signaling	B-X
were	B-X
required	B-X
for	B-X
the	B-X
development	B-X
and	B-X
maintenance	B-X
of	B-X
IL-10-producing	B-X
Th1	B-X
cells	B-X
.	B-X
Although	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
and	B-X
Th17	B-X
cells	B-X
require	B-X
the	B-X
activation	B-X
of	B-X
distinct	B-X
STATs	B-X
for	B-X
their	B-X
differentiation	B-X
,	B-X
activation	B-X
of	B-X
ERK1	B-X
and	B-X
ERK2	B-X
was	B-X
a	B-X
common	B-X
requirement	B-X
for	B-X
production	B-X
of	B-X
IL-10	B-X
by	B-X
all	B-X
Th	B-X
cell	B-X
subsets	B-X
.	B-X
IL-10	B-X
expression	B-X
also	B-X
correlated	B-X
with	B-X
c-maf	B-X
expression	B-X
.	B-X
Despite	B-X
having	B-X
distinct	B-X
functions	B-X
in	B-X
protection	B-X
against	B-X
pathogens	B-X
,	B-X
all	B-X
Th	B-X
cells	B-X
share	B-X
the	B-X
important	B-X
task	B-X
of	B-X
controlling	B-X
overexuberant	B-X
immune	B-X
responses	B-X
by	B-X
means	B-X
of	B-X
IL-10	B-X
production	B-X
.	B-X

However	O
,	O
the	O
signals	O
that	O
direct	O
the	O
development	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
T	O
helper	O
1	O
(	O
Th1	O
)	O
cells	O
are	O
undefined	O
.	O
<EOS>	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
producing	B-X
interleukin-10	B-X
(	B-X
IL-10	B-X
)	B-X
and	B-X
interferon-gamma	B-X
(	B-X
IFN-gamma	B-X
)	B-X
are	B-X
reported	B-X
in	B-X
chronic	B-X
infections	B-X
.	B-X
However	B-X
,	B-X
the	B-X
signals	B-X
that	B-X
direct	B-X
the	B-X
development	B-X
of	B-X
IL-10-producing	B-X
T	B-X
helper	B-X
1	B-X
(	B-X
Th1	B-X
)	B-X
cells	B-X
are	B-X
undefined	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
development	B-X
of	B-X
IL-10-producing	B-X
Th1	B-X
cells	B-X
required	B-X
high	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
ligation	B-X
,	B-X
sustained	B-X
ERK1	B-X
and	B-X
ERK2	B-X
MAP	B-X
kinases	B-X
phosphorylation	B-X
,	B-X
and	B-X
IL-12-induced	B-X
STAT4	B-X
transcription	B-X
factor	B-X
activation	B-X
.	B-X
Repeated	B-X
TCR	B-X
triggering	B-X
led	B-X
to	B-X
enhanced	B-X
IL-10	B-X
production	B-X
by	B-X
Th1	B-X
cells	B-X
,	B-X
and	B-X
continued	B-X
IL-12	B-X
action	B-X
and	B-X
high-dose	B-X
TCR	B-X
signaling	B-X
were	B-X
required	B-X
for	B-X
the	B-X
development	B-X
and	B-X
maintenance	B-X
of	B-X
IL-10-producing	B-X
Th1	B-X
cells	B-X
.	B-X
Although	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
and	B-X
Th17	B-X
cells	B-X
require	B-X
the	B-X
activation	B-X
of	B-X
distinct	B-X
STATs	B-X
for	B-X
their	B-X
differentiation	B-X
,	B-X
activation	B-X
of	B-X
ERK1	B-X
and	B-X
ERK2	B-X
was	B-X
a	B-X
common	B-X
requirement	B-X
for	B-X
production	B-X
of	B-X
IL-10	B-X
by	B-X
all	B-X
Th	B-X
cell	B-X
subsets	B-X
.	B-X
IL-10	B-X
expression	B-X
also	B-X
correlated	B-X
with	B-X
c-maf	B-X
expression	B-X
.	B-X
Despite	B-X
having	B-X
distinct	B-X
functions	B-X
in	B-X
protection	B-X
against	B-X
pathogens	B-X
,	B-X
all	B-X
Th	B-X
cells	B-X
share	B-X
the	B-X
important	B-X
task	B-X
of	B-X
controlling	B-X
overexuberant	B-X
immune	B-X
responses	B-X
by	B-X
means	B-X
of	B-X
IL-10	B-X
production	B-X
.	B-X

We	O
showed	O
that	O
development	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
required	O
high	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
ligation	O
,	O
sustained	O
ERK1	B-Protein
and	O
ERK2	B-Protein
MAP	O
kinases	O
phosphorylation	O
,	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
-	O
induced	O
STAT4	B-Protein
transcription	O
factor	O
activation	O
.	O

Repeated	O
TCR	O
triggering	O
led	O
to	O
enhanced	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
cells	O
,	O
and	O
continued	O
IL	B-Protein
-	I-Protein
12	I-Protein
action	O
and	O
high	O
-	O
dose	O
TCR	O
signaling	O
were	O
required	O
for	O
the	O
development	O
and	O
maintenance	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
.	O
<EOS>	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
producing	B-X
interleukin-10	B-X
(	B-X
IL-10	B-X
)	B-X
and	B-X
interferon-gamma	B-X
(	B-X
IFN-gamma	B-X
)	B-X
are	B-X
reported	B-X
in	B-X
chronic	B-X
infections	B-X
.	B-X
However	B-X
,	B-X
the	B-X
signals	B-X
that	B-X
direct	B-X
the	B-X
development	B-X
of	B-X
IL-10-producing	B-X
T	B-X
helper	B-X
1	B-X
(	B-X
Th1	B-X
)	B-X
cells	B-X
are	B-X
undefined	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
development	B-X
of	B-X
IL-10-producing	B-X
Th1	B-X
cells	B-X
required	B-X
high	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
ligation	B-X
,	B-X
sustained	B-X
ERK1	B-X
and	B-X
ERK2	B-X
MAP	B-X
kinases	B-X
phosphorylation	B-X
,	B-X
and	B-X
IL-12-induced	B-X
STAT4	B-X
transcription	B-X
factor	B-X
activation	B-X
.	B-X
Repeated	B-X
TCR	B-X
triggering	B-X
led	B-X
to	B-X
enhanced	B-X
IL-10	B-X
production	B-X
by	B-X
Th1	B-X
cells	B-X
,	B-X
and	B-X
continued	B-X
IL-12	B-X
action	B-X
and	B-X
high-dose	B-X
TCR	B-X
signaling	B-X
were	B-X
required	B-X
for	B-X
the	B-X
development	B-X
and	B-X
maintenance	B-X
of	B-X
IL-10-producing	B-X
Th1	B-X
cells	B-X
.	B-X
Although	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
and	B-X
Th17	B-X
cells	B-X
require	B-X
the	B-X
activation	B-X
of	B-X
distinct	B-X
STATs	B-X
for	B-X
their	B-X
differentiation	B-X
,	B-X
activation	B-X
of	B-X
ERK1	B-X
and	B-X
ERK2	B-X
was	B-X
a	B-X
common	B-X
requirement	B-X
for	B-X
production	B-X
of	B-X
IL-10	B-X
by	B-X
all	B-X
Th	B-X
cell	B-X
subsets	B-X
.	B-X
IL-10	B-X
expression	B-X
also	B-X
correlated	B-X
with	B-X
c-maf	B-X
expression	B-X
.	B-X
Despite	B-X
having	B-X
distinct	B-X
functions	B-X
in	B-X
protection	B-X
against	B-X
pathogens	B-X
,	B-X
all	B-X
Th	B-X
cells	B-X
share	B-X
the	B-X
important	B-X
task	B-X
of	B-X
controlling	B-X
overexuberant	B-X
immune	B-X
responses	B-X
by	B-X
means	B-X
of	B-X
IL-10	B-X
production	B-X
.	B-X

Although	O
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
cells	O
require	O
the	O
activation	O
of	O
distinct	O
STATs	O
for	O
their	O
differentiation	O
,	O
activation	O
of	O
ERK1	B-Protein
and	O
ERK2	B-Protein
was	O
a	O
common	O
requirement	O
for	O
production	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
by	O
all	O
Th	O
cell	O
subsets	O
.	O
<EOS>	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
producing	B-X
interleukin-10	B-X
(	B-X
IL-10	B-X
)	B-X
and	B-X
interferon-gamma	B-X
(	B-X
IFN-gamma	B-X
)	B-X
are	B-X
reported	B-X
in	B-X
chronic	B-X
infections	B-X
.	B-X
However	B-X
,	B-X
the	B-X
signals	B-X
that	B-X
direct	B-X
the	B-X
development	B-X
of	B-X
IL-10-producing	B-X
T	B-X
helper	B-X
1	B-X
(	B-X
Th1	B-X
)	B-X
cells	B-X
are	B-X
undefined	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
development	B-X
of	B-X
IL-10-producing	B-X
Th1	B-X
cells	B-X
required	B-X
high	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
ligation	B-X
,	B-X
sustained	B-X
ERK1	B-X
and	B-X
ERK2	B-X
MAP	B-X
kinases	B-X
phosphorylation	B-X
,	B-X
and	B-X
IL-12-induced	B-X
STAT4	B-X
transcription	B-X
factor	B-X
activation	B-X
.	B-X
Repeated	B-X
TCR	B-X
triggering	B-X
led	B-X
to	B-X
enhanced	B-X
IL-10	B-X
production	B-X
by	B-X
Th1	B-X
cells	B-X
,	B-X
and	B-X
continued	B-X
IL-12	B-X
action	B-X
and	B-X
high-dose	B-X
TCR	B-X
signaling	B-X
were	B-X
required	B-X
for	B-X
the	B-X
development	B-X
and	B-X
maintenance	B-X
of	B-X
IL-10-producing	B-X
Th1	B-X
cells	B-X
.	B-X
Although	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
and	B-X
Th17	B-X
cells	B-X
require	B-X
the	B-X
activation	B-X
of	B-X
distinct	B-X
STATs	B-X
for	B-X
their	B-X
differentiation	B-X
,	B-X
activation	B-X
of	B-X
ERK1	B-X
and	B-X
ERK2	B-X
was	B-X
a	B-X
common	B-X
requirement	B-X
for	B-X
production	B-X
of	B-X
IL-10	B-X
by	B-X
all	B-X
Th	B-X
cell	B-X
subsets	B-X
.	B-X
IL-10	B-X
expression	B-X
also	B-X
correlated	B-X
with	B-X
c-maf	B-X
expression	B-X
.	B-X
Despite	B-X
having	B-X
distinct	B-X
functions	B-X
in	B-X
protection	B-X
against	B-X
pathogens	B-X
,	B-X
all	B-X
Th	B-X
cells	B-X
share	B-X
the	B-X
important	B-X
task	B-X
of	B-X
controlling	B-X
overexuberant	B-X
immune	B-X
responses	B-X
by	B-X
means	B-X
of	B-X
IL-10	B-X
production	B-X
.	B-X

IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
also	O
correlated	O
with	O
c	B-Protein
-	I-Protein
maf	I-Protein
expression	O
.	O

Despite	O
having	O
distinct	O
functions	O
in	O
protection	O
against	O
pathogens	O
,	O
all	O
Th	O
cells	O
share	O
the	O
important	O
task	O
of	O
controlling	O
overexuberant	O
immune	O
responses	O
by	O
means	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
.	O
<EOS>	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
producing	B-X
interleukin-10	B-X
(	B-X
IL-10	B-X
)	B-X
and	B-X
interferon-gamma	B-X
(	B-X
IFN-gamma	B-X
)	B-X
are	B-X
reported	B-X
in	B-X
chronic	B-X
infections	B-X
.	B-X
However	B-X
,	B-X
the	B-X
signals	B-X
that	B-X
direct	B-X
the	B-X
development	B-X
of	B-X
IL-10-producing	B-X
T	B-X
helper	B-X
1	B-X
(	B-X
Th1	B-X
)	B-X
cells	B-X
are	B-X
undefined	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
development	B-X
of	B-X
IL-10-producing	B-X
Th1	B-X
cells	B-X
required	B-X
high	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
ligation	B-X
,	B-X
sustained	B-X
ERK1	B-X
and	B-X
ERK2	B-X
MAP	B-X
kinases	B-X
phosphorylation	B-X
,	B-X
and	B-X
IL-12-induced	B-X
STAT4	B-X
transcription	B-X
factor	B-X
activation	B-X
.	B-X
Repeated	B-X
TCR	B-X
triggering	B-X
led	B-X
to	B-X
enhanced	B-X
IL-10	B-X
production	B-X
by	B-X
Th1	B-X
cells	B-X
,	B-X
and	B-X
continued	B-X
IL-12	B-X
action	B-X
and	B-X
high-dose	B-X
TCR	B-X
signaling	B-X
were	B-X
required	B-X
for	B-X
the	B-X
development	B-X
and	B-X
maintenance	B-X
of	B-X
IL-10-producing	B-X
Th1	B-X
cells	B-X
.	B-X
Although	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
and	B-X
Th17	B-X
cells	B-X
require	B-X
the	B-X
activation	B-X
of	B-X
distinct	B-X
STATs	B-X
for	B-X
their	B-X
differentiation	B-X
,	B-X
activation	B-X
of	B-X
ERK1	B-X
and	B-X
ERK2	B-X
was	B-X
a	B-X
common	B-X
requirement	B-X
for	B-X
production	B-X
of	B-X
IL-10	B-X
by	B-X
all	B-X
Th	B-X
cell	B-X
subsets	B-X
.	B-X
IL-10	B-X
expression	B-X
also	B-X
correlated	B-X
with	B-X
c-maf	B-X
expression	B-X
.	B-X
Despite	B-X
having	B-X
distinct	B-X
functions	B-X
in	B-X
protection	B-X
against	B-X
pathogens	B-X
,	B-X
all	B-X
Th	B-X
cells	B-X
share	B-X
the	B-X
important	B-X
task	B-X
of	B-X
controlling	B-X
overexuberant	B-X
immune	B-X
responses	B-X
by	B-X
means	B-X
of	B-X
IL-10	B-X
production	B-X
.	B-X

Interleukin	B-Protein
-	I-Protein
10	I-Protein
(	O
IL	B-Protein
-	I-Protein
10	I-Protein
)	O
is	O
a	O
cytokine	O
with	O
broad	O
anti	O
-	O
inflammatory	O
properties	O
that	O
inhibits	O
macrophage	O
and	O
dendritic	O
cell	O
(	O
DC	O
)	O
function	O
(	O
Moore	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
limits	O
the	O
immune	O
and	O
inflammatory	O
responses	O
to	O
pathogens	O
and	O
gut	O
flora	O
and	O
prevents	O
damage	O
to	O
the	O
host	O
(	O
Moore	O
et	O
al	O
.	O
,	O
2001	O
;	O
O	O
'	O
Garra	O
and	O
Vieira	O
,	O
2004	O
)	O
,	O
but	O
when	O
dysregulated	O
may	O
result	O
in	O
chronic	O
infection	O
(	O
Brooks	O
et	O
al	O
.	O
,	O
2006	O
;	O
Ejrnaes	O
et	O
al	O
.	O
,	O
2006	O
;	O
Moore	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
is	O
expressed	O
by	O
T	O
helper	O
2	O
(	O
Th2	O
)	O
cells	O
,	O
B	O
cells	O
,	O
DCs	O
,	O
and	O
macrophages	O
(	O
Moore	O
et	O
al	O
.	O
,	O
2001	O
)	O
,	O
and	O
also	O
by	O
Th1	O
cells	O
(	O
Anderson	O
et	O
al	O
.	O
,	O
2007	O
;	O
Assenmacher	O
et	O
al	O
.	O
,	O
1994	O
;	O
Del	O
Prete	O
et	O
al	O
.	O
,	O
1993	O
;	O
Gerosa	O
et	O
al	O
.	O
,	O
1996	O
;	O
Jankovic	O
et	O
al	O
.	O
,	O
2007	O
;	O
Pohl	O
-	O
Koppe	O
et	O
al	O
.	O
,	O
1998	O
)	O
and	O
(	O
reviewed	O
in	O
O	O
'	O
Garra	O
and	O
Vieira	O
,	O
2007	O
;	O
Trinchieri	O
,	O
2007	O
)	O
,	O
certain	O
regulatory	O
(	O
Treg	O
)	O
T	O
cells	O
(	O
Moore	O
et	O
al	O
.	O
,	O
2001	O
;	O
O	O
'	O
Garra	O
and	O
Vieira	O
,	O
2004	O
;	O
Roncarolo	O
et	O
al	O
.	O
,	O
2006	O
)	O
,	O
and	O
Th17	O
cells	O
(	O
Awasthi	O
et	O
al	O
.	O
,	O
2007	O
;	O
Fitzgerald	O
et	O
al	O
.	O
,	O
2007	O
;	O
McGeachy	O
et	O
al	O
.	O
,	O
2007	O
;	O
Stumhofer	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

In	O
vitro	O
human	O
CD4	B-Protein
+	O
and	O
CD8	B-Protein
+	O
T	O
cell	O
clones	O
,	O
or	O
mouse	O
CD4	B-Protein
+	O
T	O
cells	O
that	O
produce	O
both	O
interferon	B-Protein
-	I-Protein
gamma	I-Protein
(	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
)	O
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
can	O
be	O
differentiated	O
by	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
-	O
stimulation	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
(	O
Chang	O
et	O
al	O
.	O
,	O
2007	O
;	O
Gerosa	O
et	O
al	O
.	O
,	O
1996	O
;	O
Jeannin	O
et	O
al	O
.	O
,	O
1996	O
;	O
Meyaard	O
et	O
al	O
.	O
,	O
1996	O
;	O
Windhagen	O
et	O
al	O
.	O
,	O
1996	O
)	O
.	O

Furthermore	O
,	O
Th1	O
cell	O
clones	O
coproducing	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
have	O
been	O
isolated	O
from	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
of	O
active	O
pulmonary	O
tuberculosis	O
(	O
TB	O
)	O
patients	O
(	O
Gerosa	O
et	O
al	O
.	O
,	O
1999	O
)	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
cells	O
was	O
also	O
reported	O
in	O
animals	O
infected	O
with	O
Toxoplasma	O
gondii	O
(	O
Jankovic	O
et	O
al	O
.	O
,	O
2002	O
;	O
Shaw	O
et	O
al	O
.	O
,	O
2006	O
)	O
or	O
with	O
Leishmania	O
major	O
(	O
Anderson	O
et	O
al	O
.	O
,	O
2007	O
)	O
and	O
shown	O
to	O
be	O
required	O
for	O
regulation	O
of	O
the	O
immune	O
response	O
in	O
these	O
infections	O
(	O
Anderson	O
et	O
al	O
.	O
,	O
2007	O
;	O
Jankovic	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

The	O
relative	O
amounts	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
produced	O
by	O
Th1	O
cells	O
may	O
influence	O
the	O
balance	O
between	O
clearance	O
and	O
persistent	O
infection	O
with	O
certain	O
pathogens	O
(	O
Moore	O
et	O
al	O
.	O
,	O
2001	O
;	O
Trinchieri	O
,	O
2007	O
)	O
,	O
thus	O
determining	O
whether	O
chronic	O
infection	O
or	O
immunopathology	O
ensues	O
.	O

Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
cell	O
responses	O
differentiate	O
along	O
distinct	O
signaling	O
pathways	O
(	O
Glimcher	O
and	O
Murphy	O
,	O
2000	O
;	O
Ivanov	O
et	O
al	O
.	O
,	O
2007	O
;	O
Stockinger	O
and	O
Veldhoen	O
,	O
2007	O
)	O
.	O

Th1	O
cell	O
development	O
requires	O
signal	B-Protein
transducer	I-Protein
and	I-Protein
activator	I-Protein
of	I-Protein
transcription	I-Protein
(	I-Protein
STAT	I-Protein
)	I-Protein
1	I-Protein
activation	O
,	O
induced	O
by	O
type	B-Protein
I	I-Protein
IFN	I-Protein
or	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
the	O
transcription	O
factor	O
T	B-Protein
-	I-Protein
box	I-Protein
21	I-Protein
(	O
T	B-Protein
-	I-Protein
bet	I-Protein
)	O
,	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
-	O
induced	O
STAT4	B-Protein
signaling	O
,	O
which	O
can	O
couple	O
with	O
IL	B-Protein
-	I-Protein
18	I-Protein
-	O
induced	O
IRAK	B-Protein
and	O
NF	O
-	O
kappaB	O
transcription	O
factors	O
to	O
drive	O
the	O
high	O
amounts	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
required	O
to	O
eradicate	O
intracellular	O
pathogens	O
(	O
Glimcher	O
and	O
Murphy	O
,	O
2000	O
)	O
.	O

Th2	O
cell	O
development	O
,	O
with	O
expression	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
IL	B-Protein
-	I-Protein
5	I-Protein
,	O
and	O
IL	B-Protein
-	I-Protein
13	I-Protein
,	O
requires	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
STAT6	B-Protein
,	O
and	O
the	O
transcription	O
factor	O
GATA	B-Protein
binding	I-Protein
protein	I-Protein
(	I-Protein
GATA	I-Protein
)	I-Protein
-	I-Protein
3	I-Protein
(	O
Glimcher	O
and	O
Murphy	O
,	O
2000	O
)	O
.	O

The	O
development	O
of	O
Th17	O
cells	O
requires	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
,	O
and	O
the	O
STAT3	B-Protein
-	O
dependent	O
expression	O
of	O
the	O
transcription	O
factor	O
RORgammat	B-Protein
(	O
Ivanov	O
et	O
al	O
.	O
,	O
2007	O
;	O
Stockinger	O
and	O
Veldhoen	O
,	O
2007	O
)	O
.	O

Th1	O
and	O
Th2	O
cell	O
responses	O
can	O
also	O
be	O
induced	O
by	O
varying	O
the	O
dose	O
of	O
antigen	O
presented	O
to	O
the	O
naive	O
T	O
cell	O
by	O
the	O
antigen	O
-	O
presenting	O
cell	O
(	O
APC	O
)	O
.	O

Whereas	O
high	O
doses	O
of	O
antigen	O
,	O
with	O
sustained	O
TCR	O
signaling	O
and	O
extracellular	O
-	O
signal	O
regulated	O
(	O
ERK	O
)	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
phosphorylation	O
,	O
result	O
in	O
Th1	O
cells	O
producing	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
via	O
an	O
IL	B-Protein
-	I-Protein
12	I-Protein
-	O
independent	O
mechanism	O
,	O
low	O
doses	O
of	O
antigen	O
,	O
with	O
transient	O
ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
,	O
favor	O
Th2	O
responses	O
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
secretion	O
(	O
Constant	O
et	O
al	O
.	O
,	O
1995	O
;	O
Hosken	O
et	O
al	O
.	O
,	O
1995	O
;	O
Jorritsma	O
et	O
al	O
.	O
,	O
2003	O
;	O
Yamane	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O

Because	O
Th1	O
and	O
Th2	O
cells	O
cross	O
regulate	O
each	O
other	O
'	O
s	O
development	O
and	O
function	O
and	O
can	O
suppress	O
Th17	O
cell	O
responses	O
,	O
and	O
all	O
differentiate	O
along	O
distinct	O
signaling	O
pathways	O
(	O
Glimcher	O
and	O
Murphy	O
,	O
2000	O
;	O
Stockinger	O
and	O
Veldhoen	O
,	O
2007	O
)	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
produced	O
by	O
all	O
these	O
Th	O
cells	O
may	O
thus	O
act	O
as	O
a	O
feedback	O
regulator	O
to	O
control	O
the	O
pathology	O
associated	O
with	O
an	O
overexuberant	O
,	O
albeit	O
efficacious	O
,	O
inflammatory	O
response	O
.	O

Whether	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
these	O
different	O
Th	O
cell	O
subsets	O
is	O
induced	O
by	O
independent	O
and	O
/	O
or	O
common	O
mechanisms	O
is	O
unknown	O
.	O
<EOS>	B-X
Interstitial	B-X
lung	B-X
diseases	B-X
(	B-X
ILDs	B-X
)	B-X
,	B-X
which	B-X
can	B-X
arise	B-X
from	B-X
a	B-X
broad	B-X
spectrum	B-X
of	B-X
distinct	B-X
aetiologies	B-X
,	B-X
can	B-X
manifest	B-X
as	B-X
a	B-X
pulmonary	B-X
complication	B-X
of	B-X
an	B-X
underlying	B-X
autoimmune	B-X
and	B-X
connective	B-X
tissue	B-X
disease	B-X
(	B-X
CTD-ILD	B-X
)	B-X
,	B-X
such	B-X
as	B-X
rheumatoid	B-X
arthritis-ILD	B-X
and	B-X
systemic	B-X
sclerosis	B-X
(	B-X
SSc-ILD	B-X
)	B-X
.	B-X
Patients	B-X
with	B-X
clinically	B-X
distinct	B-X
ILDs	B-X
,	B-X
whether	B-X
CTD-related	B-X
or	B-X
not	B-X
,	B-X
can	B-X
exhibit	B-X
a	B-X
pattern	B-X
of	B-X
common	B-X
clinical	B-X
disease	B-X
behaviour	B-X
(	B-X
declining	B-X
lung	B-X
function	B-X
,	B-X
worsening	B-X
respiratory	B-X
symptoms	B-X
and	B-X
higher	B-X
mortality	B-X
)	B-X
,	B-X
attributable	B-X
to	B-X
progressive	B-X
fibrosis	B-X
in	B-X
the	B-X
lungs	B-X
.	B-X
In	B-X
recent	B-X
years	B-X
,	B-X
the	B-X
tyrosine	B-X
kinase	B-X
inhibitor	B-X
nintedanib	B-X
has	B-X
demonstrated	B-X
efficacy	B-X
and	B-X
safety	B-X
in	B-X
idiopathic	B-X
pulmonary	B-X
fibrosis	B-X
(	B-X
IPF	B-X
)	B-X
,	B-X
SSc-ILD	B-X
and	B-X
a	B-X
broad	B-X
range	B-X
of	B-X
other	B-X
fibrosing	B-X
ILDs	B-X
with	B-X
a	B-X
progressive	B-X
phenotype	B-X
,	B-X
including	B-X
those	B-X
associated	B-X
with	B-X
CTDs	B-X
.	B-X
Data	B-X
from	B-X
phase	B-X
II	B-X
studies	B-X
also	B-X
suggest	B-X
that	B-X
pirfenidone	B-X
,	B-X
which	B-X
has	B-X
a	B-X
different-yet	B-X
largely	B-X
unknown-mechanism	B-X
of	B-X
action	B-X
,	B-X
may	B-X
also	B-X
have	B-X
activity	B-X
in	B-X
other	B-X
fibrosing	B-X
ILDs	B-X
with	B-X
a	B-X
progressive	B-X
phenotype	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
its	B-X
known	B-X
efficacy	B-X
in	B-X
IPF	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
studies	B-X
add	B-X
weight	B-X
to	B-X
the	B-X
hypothesis	B-X
that	B-X
,	B-X
irrespective	B-X
of	B-X
the	B-X
original	B-X
clinical	B-X
diagnosis	B-X
of	B-X
ILD	B-X
,	B-X
a	B-X
progressive	B-X
fibrosing	B-X
phenotype	B-X
may	B-X
arise	B-X
from	B-X
common	B-X
,	B-X
underlying	B-X
pathophysiological	B-X
mechanisms	B-X
of	B-X
fibrosis	B-X
involving	B-X
pathways	B-X
associated	B-X
with	B-X
the	B-X
targets	B-X
of	B-X
nintedanib	B-X
and	B-X
,	B-X
potentially	B-X
,	B-X
pirfenidone	B-X
.	B-X
However	B-X
,	B-X
despite	B-X
the	B-X
early	B-X
proof	B-X
of	B-X
concept	B-X
provided	B-X
by	B-X
these	B-X
clinical	B-X
studies	B-X
,	B-X
very	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
mechanistic	B-X
commonalities	B-X
and	B-X
differences	B-X
between	B-X
ILDs	B-X
with	B-X
a	B-X
progressive	B-X
phenotype	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
explore	B-X
the	B-X
biological	B-X
and	B-X
genetic	B-X
mechanisms	B-X
that	B-X
drive	B-X
fibrosis	B-X
,	B-X
and	B-X
identify	B-X
the	B-X
missing	B-X
evidence	B-X
needed	B-X
to	B-X
provide	B-X
the	B-X
rationale	B-X
for	B-X
further	B-X
studies	B-X
that	B-X
use	B-X
the	B-X
progressive	B-X
phenotype	B-X
as	B-X
a	B-X
target	B-X
population	B-X
.	B-X

Here	O
,	O
we	O
showed	O
that	O
in	O
vitro	O
differentiation	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
from	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
required	O
IL	B-Protein
-	I-Protein
12	I-Protein
-	O
induced	O
STAT4	B-Protein
signaling	O
,	O
strong	O
TCR	O
activation	O
(	O
high	O
antigen	O
dose	O
)	O
,	O
and	O
sustained	O
ERK1	B-Protein
and	O
ERK2	B-Protein
phosphorylation	O
.	O

Furthermore	O
,	O
we	O
showed	O
that	O
activation	O
of	O
ERK1	B-Protein
and	O
ERK2	B-Protein
is	O
a	O
requirement	O
for	O
production	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
by	O
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
cell	O
subsets	O
.	O

This	O
common	O
but	O
highly	O
regulated	O
pathway	O
for	O
IL	B-Protein
-	I-Protein
10	I-Protein
induction	O
and	O
maintenance	O
ensures	O
its	O
function	O
as	O
a	O
feedback	O
loop	O
to	O
control	O
damage	O
to	O
the	O
host	O
and	O
also	O
allows	O
a	O
protective	O
response	O
to	O
ensue	O
as	O
opposed	O
to	O
chronic	O
infection	O
.	O

IL	B-Protein
-	I-Protein
12	I-Protein
and	O
High	O
Doses	O
of	O
Antigen	O
Induce	O
the	O
Development	O
of	O
Th1	O
Cells	O
Producing	O
IL	B-Protein
-	I-Protein
10	I-Protein
<EOS>	B-X
Dendritic	B-X
cells	B-X
initiate	B-X
adaptive	B-X
immune	B-X
responses	B-X
,	B-X
leading	B-X
either	B-X
to	B-X
control	B-X
cancer	B-X
by	B-X
effector	B-X
T	B-X
cells	B-X
or	B-X
to	B-X
exacerbate	B-X
cancer	B-X
by	B-X
regulatory	B-X
T	B-X
cells	B-X
that	B-X
inhibit	B-X
IFN-γ-mediated	B-X
Th1-type	B-X
response	B-X
.	B-X
Dendritic	B-X
cells	B-X
can	B-X
also	B-X
induce	B-X
Th17-type	B-X
immunity	B-X
,	B-X
mediated	B-X
by	B-X
IL-17A	B-X
.	B-X
We	B-X
generated	B-X
dendritic	B-X
cells	B-X
from	B-X
peripheral	B-X
blood	B-X
monocytes	B-X
to	B-X
investigate	B-X
lifespan	B-X
,	B-X
phenotype	B-X
and	B-X
chemoresistance	B-X
of	B-X
dendritic	B-X
cells	B-X
,	B-X
treated	B-X
with	B-X
IL-17A	B-X
with	B-X
or	B-X
without	B-X
IFN-γ	B-X
.	B-X
IL-17A-treated	B-X
DC	B-X
exhibited	B-X
a	B-X
semi-mature	B-X
(	B-X
CD40	B-X
(	B-X
high	B-X
)	B-X
HLADR	B-X
(	B-X
low	B-X
)	B-X
)	B-X
pre-M2	B-X
(	B-X
CCL22	B-X
(	B-X
+	B-X
)	B-X
CD206	B-X
(	B-X
+	B-X
)	B-X
CD163	B-X
(	B-X
+	B-X
)	B-X
IL1RN	B-X
(	B-X
+	B-X
)	B-X
IL-10	B-X
(	B-X
-	B-X
)	B-X
CXCL10	B-X
(	B-X
-	B-X
)	B-X
IL-12	B-X
(	B-X
-	B-X
)	B-X
)	B-X
mixed	B-X
(	B-X
CD1a	B-X
(	B-X
+	B-X
)	B-X
CD14+	B-X
CD68	B-X
(	B-X
+	B-X
)	B-X
)	B-X
macrophage-dendritic	B-X
cell	B-X
phenotype	B-X
.	B-X
Interestingly	B-X
,	B-X
IL-17A	B-X
promoted	B-X
a	B-X
long-term	B-X
survival	B-X
of	B-X
dendritic	B-X
cells	B-X
,	B-X
beyond	B-X
12	B-X
days	B-X
,	B-X
that	B-X
correlated	B-X
to	B-X
BCL2A1	B-X
induction	B-X
,	B-X
a	B-X
pro-survival	B-X
Bcl-2	B-X
family	B-X
member	B-X
.	B-X
BCL2A1	B-X
transcription	B-X
was	B-X
activated	B-X
by	B-X
NF-κB	B-X
,	B-X
downstream	B-X
of	B-X
IL-17A	B-X
transduction	B-X
.	B-X
Thus	B-X
,	B-X
immature	B-X
dendritic	B-X
cells	B-X
only	B-X
express	B-X
MCL1	B-X
,	B-X
whereas	B-X
IL-17A-treated	B-X
dendritic	B-X
cells	B-X
concomitantly	B-X
expressed	B-X
two	B-X
pro-survival	B-X
Bcl-2	B-X
family	B-X
members	B-X
:	B-X
MCL1	B-X
and	B-X
BCL2A1	B-X
.	B-X
When	B-X
IL-17A	B-X
is	B-X
produced	B-X
in	B-X
vivo	B-X
,	B-X
administration	B-X
of	B-X
anti-IL-17A	B-X
biotherapy	B-X
may	B-X
impair	B-X
dendritic	B-X
cell	B-X
survival	B-X
by	B-X
targeting	B-X
BCL2A1	B-X
expression	B-X
.	B-X
Consequently	B-X
,	B-X
depending	B-X
on	B-X
the	B-X
effector	B-X
or	B-X
regulatory	B-X
role	B-X
of	B-X
dendritic	B-X
cells	B-X
,	B-X
blocking	B-X
IL-17A	B-X
,	B-X
may	B-X
be	B-X
either	B-X
dangerous	B-X
or	B-X
beneficial	B-X
for	B-X
cancer	B-X
outcomes	B-X
,	B-X
thus	B-X
contributing	B-X
to	B-X
the	B-X
apparent	B-X
controversy	B-X
around	B-X
the	B-X
role	B-X
of	B-X
IL-17A	B-X
in	B-X
cancer	B-X
.	B-X

To	O
study	O
the	O
differentiation	O
of	O
Th1	O
cells	O
coproducing	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
we	O
cultured	O
purified	O
TCR	O
-	O
transgenic	O
DO11	O
.	O
10	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
with	O
purified	O
DCs	O
as	O
APCs	O
and	O
increasing	O
doses	O
of	O
ovalbumin	B-Protein
peptide	O
323	O
-	O
339	O
(	O
OVA	B-Protein
)	O
.	O

Culture	O
with	O
high	O
doses	O
of	O
antigen	O
for	O
7	O
days	O
gave	O
rise	O
to	O
Th1	O
cells	O
expressing	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
upon	O
restimulation	O
(	O
Constant	O
et	O
al	O
.	O
,	O
1995	O
;	O
Hosken	O
et	O
al	O
.	O
,	O
1995	O
)	O
,	O
but	O
not	O
IL	B-Protein
-	I-Protein
10	I-Protein
(	O
Figure	O
S1A	O
available	O
online	O
)	O
.	O

Culture	O
with	O
low	O
antigen	O
doses	O
under	O
the	O
same	O
conditions	O
led	O
to	O
the	O
differentiation	O
of	O
Th2	O
cells	O
,	O
which	O
expressed	O
both	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
upon	O
restimulation	O
(	O
Figure	O
S1A	O
)	O
.	O

Culture	O
of	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
in	O
an	O
APC	O
-	O
free	O
system	O
by	O
stimulation	O
with	O
anti	O
-	O
CD3	B-Protein
and	O
anti	O
-	O
CD28	B-Protein
antibodies	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
resulted	O
in	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
producing	O
Th1	O
cells	O
,	O
a	O
proportion	O
of	O
which	O
coproduced	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
as	O
did	O
Th2	O
cells	O
resulting	O
from	O
culture	O
in	O
IL	B-Protein
-	I-Protein
4	I-Protein
(	O
Figure	O
S1B	O
)	O
.	O

To	O
investigate	O
whether	O
the	O
lack	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
produced	O
by	O
Th1	O
cells	O
resulted	O
from	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
DCs	O
and	O
high	O
antigen	O
dose	O
or	O
alternatively	O
required	O
IL	B-Protein
-	I-Protein
12	I-Protein
,	O
we	O
cultured	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
with	O
increasing	O
doses	O
of	O
antigen	O
presented	O
by	O
DC	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
.	O

At	O
low	O
doses	O
of	O
antigen	O
,	O
IL	B-Protein
-	I-Protein
12	I-Protein
abrogated	O
the	O
development	O
of	O
Th2	O
cells	O
and	O
induced	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
but	O
only	O
low	O
levels	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
,	O
suggesting	O
that	O
IL	B-Protein
-	I-Protein
12	I-Protein
per	O
se	O
was	O
not	O
sufficient	O
to	O
induce	O
significant	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
in	O
Th1	O
cells	O
(	O
Figure	O
1A	O
)	O
.	O

Strikingly	O
,	O
as	O
the	O
antigen	O
dose	O
was	O
increased	O
,	O
Th1	O
populations	O
driven	O
with	O
IL	B-Protein
-	I-Protein
12	I-Protein
now	O
contained	O
higher	O
numbers	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
cells	O
(	O
Figure	O
1A	O
)	O
and	O
produced	O
more	O
IL	B-Protein
-	I-Protein
10	I-Protein
protein	O
upon	O
restimulation	O
(	O
Figures	O
1A	O
and	O
1B	O
)	O
.	O

Thus	O
,	O
the	O
development	O
of	O
Th1	O
cells	O
producing	O
IL	B-Protein
-	I-Protein
10	I-Protein
required	O
both	O
IL	B-Protein
-	I-Protein
12	I-Protein
and	O
high	O
doses	O
of	O
antigen	O
.	O
<EOS>	B-X
Dendritic	B-X
cells	B-X
initiate	B-X
adaptive	B-X
immune	B-X
responses	B-X
,	B-X
leading	B-X
either	B-X
to	B-X
control	B-X
cancer	B-X
by	B-X
effector	B-X
T	B-X
cells	B-X
or	B-X
to	B-X
exacerbate	B-X
cancer	B-X
by	B-X
regulatory	B-X
T	B-X
cells	B-X
that	B-X
inhibit	B-X
IFN-γ-mediated	B-X
Th1-type	B-X
response	B-X
.	B-X
Dendritic	B-X
cells	B-X
can	B-X
also	B-X
induce	B-X
Th17-type	B-X
immunity	B-X
,	B-X
mediated	B-X
by	B-X
IL-17A	B-X
.	B-X
We	B-X
generated	B-X
dendritic	B-X
cells	B-X
from	B-X
peripheral	B-X
blood	B-X
monocytes	B-X
to	B-X
investigate	B-X
lifespan	B-X
,	B-X
phenotype	B-X
and	B-X
chemoresistance	B-X
of	B-X
dendritic	B-X
cells	B-X
,	B-X
treated	B-X
with	B-X
IL-17A	B-X
with	B-X
or	B-X
without	B-X
IFN-γ	B-X
.	B-X
Studying	B-X
the	B-X
expression	B-X
of	B-X
Bcl-2	B-X
family	B-X
members	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
dendritic	B-X
cells	B-X
constitutively	B-X
express	B-X
one	B-X
pro-survival	B-X
Bcl-2	B-X
member	B-X
:	B-X
MCL1	B-X
.	B-X
Immature	B-X
dendritic	B-X
cells	B-X
were	B-X
CD40	B-X
(	B-X
low	B-X
)	B-X
HLADR	B-X
(	B-X
low	B-X
)	B-X
CD1a	B-X
(	B-X
+	B-X
)	B-X
MCL1	B-X
(	B-X
+	B-X
)	B-X
,	B-X
did	B-X
not	B-X
express	B-X
CD14	B-X
,	B-X
CD68	B-X
or	B-X
BCL2A1	B-X
,	B-X
and	B-X
displayed	B-X
a	B-X
short	B-X
2-day	B-X
lifespan	B-X
.	B-X
IL-17A-treated	B-X
DC	B-X
exhibited	B-X
a	B-X
semi-mature	B-X
(	B-X
CD40	B-X
(	B-X
high	B-X
)	B-X
HLADR	B-X
(	B-X
low	B-X
)	B-X
)	B-X
pre-M2	B-X
(	B-X
CCL22	B-X
(	B-X
+	B-X
)	B-X
CD206	B-X
(	B-X
+	B-X
)	B-X
CD163	B-X
(	B-X
+	B-X
)	B-X
IL1RN	B-X
(	B-X
+	B-X
)	B-X
IL-10	B-X
(	B-X
-	B-X
)	B-X
CXCL10	B-X
(	B-X
-	B-X
)	B-X
IL-12	B-X
(	B-X
-	B-X
)	B-X
)	B-X
mixed	B-X
(	B-X
CD1a	B-X
(	B-X
+	B-X
)	B-X
CD14+	B-X
CD68	B-X
(	B-X
+	B-X
)	B-X
)	B-X
macrophage-dendritic	B-X
cell	B-X
phenotype	B-X
.	B-X
Interestingly	B-X
,	B-X
IL-17A	B-X
promoted	B-X
a	B-X
long-term	B-X
survival	B-X
of	B-X
dendritic	B-X
cells	B-X
,	B-X
beyond	B-X
12	B-X
days	B-X
,	B-X
that	B-X
correlated	B-X
to	B-X
BCL2A1	B-X
induction	B-X
,	B-X
a	B-X
pro-survival	B-X
Bcl-2	B-X
family	B-X
member	B-X
.	B-X
BCL2A1	B-X
transcription	B-X
was	B-X
activated	B-X
by	B-X
NF-κB	B-X
,	B-X
downstream	B-X
of	B-X
IL-17A	B-X
transduction	B-X
.	B-X
Thus	B-X
,	B-X
immature	B-X
dendritic	B-X
cells	B-X
only	B-X
express	B-X
MCL1	B-X
,	B-X
whereas	B-X
IL-17A-treated	B-X
dendritic	B-X
cells	B-X
concomitantly	B-X
expressed	B-X
two	B-X
pro-survival	B-X
Bcl-2	B-X
family	B-X
members	B-X
:	B-X
MCL1	B-X
and	B-X
BCL2A1	B-X
.	B-X
However	B-X
,	B-X
high	B-X
doses	B-X
of	B-X
either	B-X
vinblastine	B-X
or	B-X
cytarabine	B-X
decreased	B-X
MCL1	B-X
expression	B-X
and	B-X
induced	B-X
dendritic	B-X
cell	B-X
death	B-X
.	B-X
When	B-X
IL-17A	B-X
is	B-X
produced	B-X
in	B-X
vivo	B-X
,	B-X
administration	B-X
of	B-X
anti-IL-17A	B-X
biotherapy	B-X
may	B-X
impair	B-X
dendritic	B-X
cell	B-X
survival	B-X
by	B-X
targeting	B-X
BCL2A1	B-X
expression	B-X
.	B-X
Consequently	B-X
,	B-X
depending	B-X
on	B-X
the	B-X
effector	B-X
or	B-X
regulatory	B-X
role	B-X
of	B-X
dendritic	B-X
cells	B-X
,	B-X
blocking	B-X
IL-17A	B-X
,	B-X
may	B-X
be	B-X
either	B-X
dangerous	B-X
or	B-X
beneficial	B-X
for	B-X
cancer	B-X
outcomes	B-X
,	B-X
thus	B-X
contributing	B-X
to	B-X
the	B-X
apparent	B-X
controversy	B-X
around	B-X
the	B-X
role	B-X
of	B-X
IL-17A	B-X
in	B-X
cancer	B-X
.	B-X

Th1	O
cells	O
differentiated	O
to	O
produce	O
large	O
amounts	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
lost	O
their	O
capacity	O
to	O
produce	O
IL	B-Protein
-	I-Protein
2	I-Protein
(	O
Figure	O
1B	O
)	O
.	O

Because	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
reduced	O
the	O
proliferation	O
of	O
CD4	B-Protein
+	O
T	O
cells	O
at	O
both	O
high	O
and	O
low	O
antigen	O
doses	O
(	O
Table	O
S1	O
)	O
,	O
and	O
only	O
the	O
former	O
showed	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
,	O
the	O
development	O
of	O
high	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
cells	O
is	O
most	O
likely	O
not	O
related	O
to	O
limited	O
IL	B-Protein
-	I-Protein
2	I-Protein
.	O

Naive	O
CD4	B-Protein
+	O
T	O
cells	O
from	O
DO11	O
.	O
10	O
/	O
recombination	B-Protein
-	I-Protein
activating	I-Protein
gene	I-Protein
1	I-Protein
(	O
Rag1	B-Protein
)	O
-	O
deficient	O
animals	O
,	O
cultured	O
with	O
high	O
doses	O
of	O
antigen	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
,	O
also	O
resulted	O
in	O
IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
by	O
Th1	O
cells	O
,	O
showing	O
that	O
this	O
expression	O
was	O
not	O
dependent	O
on	O
the	O
presence	O
of	O
effector	O
or	O
memory	O
T	O
cells	O
or	O
Treg	O
cells	O
(	O
Figure	O
S2	O
)	O
.	O

Although	O
it	O
has	O
been	O
suggested	O
that	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
can	O
induce	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
Kitani	O
et	O
al	O
.	O
,	O
2003	O
;	O
Schiott	O
et	O
al	O
.	O
,	O
2000	O
)	O
,	O
we	O
found	O
that	O
in	O
developing	O
Th1	O
and	O
Th2	O
cells	O
this	O
was	O
not	O
the	O
case	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
fact	O
,	O
neutralization	O
of	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
led	O
to	O
increased	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
both	O
T	O
cell	O
subsets	O
(	O
Figure	O
S3	O
)	O
.	O

Thus	O
,	O
the	O
development	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
only	O
depended	O
on	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
together	O
with	O
high	O
antigen	O
dose	O
and	O
not	O
on	O
other	O
soluble	O
factors	O
such	O
as	O
IL	B-Protein
-	I-Protein
2	I-Protein
or	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
or	O
on	O
the	O
presence	O
of	O
other	O
T	O
cell	O
types	O
.	O
<EOS>	B-X
The	B-X
transforming	B-X
growth	B-X
factor-β	B-X
(	B-X
TGF-β	B-X
)	B-X
is	B-X
the	B-X
prototype	B-X
of	B-X
the	B-X
TGF-β	B-X
family	B-X
of	B-X
growth	B-X
and	B-X
differentiation	B-X
factors	B-X
,	B-X
which	B-X
is	B-X
encoded	B-X
by	B-X
33	B-X
genes	B-X
in	B-X
mammals	B-X
and	B-X
comprises	B-X
homo-	B-X
and	B-X
heterodimers	B-X
.	B-X
This	B-X
review	B-X
introduces	B-X
the	B-X
reader	B-X
to	B-X
the	B-X
TGF-β	B-X
family	B-X
with	B-X
its	B-X
complexity	B-X
of	B-X
names	B-X
and	B-X
biological	B-X
activities	B-X
.	B-X
It	B-X
also	B-X
introduces	B-X
TGF-β	B-X
as	B-X
the	B-X
best-studied	B-X
factor	B-X
among	B-X
the	B-X
TGF-β	B-X
family	B-X
proteins	B-X
,	B-X
with	B-X
its	B-X
diversity	B-X
of	B-X
roles	B-X
in	B-X
the	B-X
control	B-X
of	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
,	B-X
wound	B-X
healing	B-X
and	B-X
immune	B-X
system	B-X
,	B-X
and	B-X
its	B-X
key	B-X
roles	B-X
in	B-X
pathology	B-X
,	B-X
for	B-X
example	B-X
,	B-X
skeletal	B-X
diseases	B-X
,	B-X
fibrosis	B-X
,	B-X
and	B-X
cancer	B-X
.	B-X
Transforming	B-X
growth	B-X
factor	B-X
β	B-X
(	B-X
TGF-β	B-X
)	B-X
has	B-X
long	B-X
been	B-X
identified	B-X
with	B-X
its	B-X
intensive	B-X
involvement	B-X
in	B-X
early	B-X
embryonic	B-X
development	B-X
and	B-X
organogenesis	B-X
,	B-X
immune	B-X
supervision	B-X
,	B-X
tissue	B-X
repair	B-X
,	B-X
and	B-X
adult	B-X
homeostasis	B-X
.	B-X
The	B-X
role	B-X
of	B-X
TGF-β	B-X
in	B-X
fibrosis	B-X
and	B-X
cancer	B-X
is	B-X
complex	B-X
and	B-X
sometimes	B-X
even	B-X
contradictory	B-X
,	B-X
exhibiting	B-X
either	B-X
inhibitory	B-X
or	B-X
promoting	B-X
effects	B-X
depending	B-X
on	B-X
the	B-X
stage	B-X
of	B-X
the	B-X
disease	B-X
.	B-X
Under	B-X
pathological	B-X
conditions	B-X
,	B-X
overexpressed	B-X
TGF-β	B-X
causes	B-X
epithelial-mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
,	B-X
extracellular	B-X
matrix	B-X
(	B-X
ECM	B-X
)	B-X
deposition	B-X
,	B-X
cancer-associated	B-X
fibroblast	B-X
(	B-X
CAF	B-X
)	B-X
formation	B-X
,	B-X
which	B-X
leads	B-X
to	B-X
fibrotic	B-X
disease	B-X
,	B-X
and	B-X
cancer	B-X
.	B-X
Given	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
TGF-β	B-X
and	B-X
its	B-X
downstream	B-X
molecules	B-X
in	B-X
the	B-X
progression	B-X
of	B-X
fibrosis	B-X
and	B-X
cancers	B-X
,	B-X
therapeutics	B-X
targeting	B-X
TGF-β	B-X
signaling	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
promising	B-X
strategy	B-X
.	B-X
However	B-X
,	B-X
due	B-X
to	B-X
potential	B-X
systemic	B-X
cytotoxicity	B-X
,	B-X
the	B-X
development	B-X
of	B-X
TGF-β	B-X
therapeutics	B-X
has	B-X
lagged	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarized	B-X
the	B-X
biological	B-X
process	B-X
of	B-X
TGF-β	B-X
,	B-X
with	B-X
its	B-X
dual	B-X
role	B-X
in	B-X
fibrosis	B-X
and	B-X
tumorigenesis	B-X
,	B-X
and	B-X
the	B-X
clinical	B-X
application	B-X
of	B-X
TGF-β-targeting	B-X
therapies	B-X
.	B-X

IL	B-Protein
-	I-Protein
10	I-Protein
Production	O
by	O
Th1	O
Cells	O
Is	O
Dependent	O
on	O
STAT4	B-Protein
but	O
Not	O
on	O
STAT6	B-Protein
,	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
or	O
IL	B-Protein
-	I-Protein
4	I-Protein
Signaling	O
<EOS>	B-X
Interleukin	B-X
(	B-X
IL	B-X
)	B-X
-4	B-X
and	B-X
IL-13	B-X
are	B-X
related	B-X
cytokines	B-X
that	B-X
regulate	B-X
many	B-X
aspects	B-X
of	B-X
allergic	B-X
inflammation	B-X
.	B-X
In	B-X
T-cells	B-X
,	B-X
IL-4	B-X
induces	B-X
the	B-X
differentiation	B-X
of	B-X
naïve	B-X
CD4	B-X
T	B-X
cells	B-X
into	B-X
Th2	B-X
cells	B-X
,	B-X
in	B-X
B	B-X
cells	B-X
,	B-X
IL-4	B-X
drives	B-X
the	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
class	B-X
switch	B-X
to	B-X
IgG1	B-X
and	B-X
IgE	B-X
,	B-X
and	B-X
in	B-X
macrophages	B-X
,	B-X
IL-4	B-X
and	B-X
IL-13	B-X
induce	B-X
alternative	B-X
macrophage	B-X
activation	B-X
.	B-X
Work	B-X
initiated	B-X
in	B-X
part	B-X
by	B-X
William	B-X
(	B-X
Bill	B-X
)	B-X
E.	B-X
Paul	B-X
on	B-X
IL-4	B-X
some	B-X
30	B-X
years	B-X
ago	B-X
has	B-X
now	B-X
grown	B-X
into	B-X
a	B-X
major	B-X
building	B-X
block	B-X
of	B-X
our	B-X
current	B-X
understanding	B-X
of	B-X
basic	B-X
immunology	B-X
and	B-X
the	B-X
immune	B-X
response	B-X
.	B-X
This	B-X
knowledge	B-X
on	B-X
IL-4	B-X
has	B-X
growing	B-X
clinical	B-X
importance	B-X
,	B-X
as	B-X
therapeutic	B-X
approaches	B-X
targeting	B-X
the	B-X
cytokine	B-X
and	B-X
its	B-X
signal	B-X
transduction	B-X
are	B-X
becoming	B-X
a	B-X
part	B-X
of	B-X
the	B-X
clinical	B-X
practice	B-X
in	B-X
treating	B-X
allergic	B-X
diseases	B-X
.	B-X
Just	B-X
by	B-X
reading	B-X
the	B-X
reference	B-X
list	B-X
of	B-X
this	B-X
short	B-X
review	B-X
,	B-X
one	B-X
can	B-X
appreciate	B-X
the	B-X
enormous	B-X
input	B-X
Bill	B-X
has	B-X
had	B-X
on	B-X
shaping	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
pathophysiology	B-X
of	B-X
allergic	B-X
inflammation	B-X
and	B-X
in	B-X
particular	B-X
the	B-X
role	B-X
of	B-X
IL-4	B-X
in	B-X
this	B-X
process	B-X
.	B-X

To	O
further	O
elucidate	O
the	O
mechanisms	O
required	O
for	O
the	O
development	O
of	O
Th1	O
cells	O
producing	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
we	O
investigated	O
the	O
role	O
of	O
STAT4	B-Protein
,	O
one	O
of	O
the	O
signaling	O
pathways	O
activated	O
by	O
IL	B-Protein
-	I-Protein
12	I-Protein
(	O
Murphy	O
et	O
al	O
.	O
,	O
2000	O
)	O
.	O

Naive	O
CD4	B-Protein
+	O
D011	O
.	O
10	O
T	O
cells	O
deficient	O
in	O
STAT4	B-Protein
(	O
Ouyang	O
et	O
al	O
.	O
,	O
1998	O
)	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
and	O
OVA	B-Protein
.	O

Again	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
were	O
differentiated	O
at	O
the	O
high	O
antigen	O
dose	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
in	O
DO11	O
.	O
10	O
T	O
cells	O
(	O
Figure	O
2A	O
)	O
.	O

In	O
contrast	O
,	O
in	O
the	O
absence	O
of	O
STAT4	B-Protein
,	O
the	O
percentage	O
of	O
cells	O
expressing	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
was	O
dramatically	O
diminished	O
as	O
expected	O
and	O
resulted	O
in	O
an	O
increase	O
in	O
the	O
percentage	O
of	O
cells	O
expressing	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
but	O
not	O
IL	B-Protein
-	I-Protein
10	I-Protein
(	O
Figure	O
2A	O
)	O
,	O
suggesting	O
that	O
STAT4	B-Protein
contributes	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
by	O
Th1	O
cells	O
.	O

Because	O
IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
is	O
associated	O
with	O
an	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
induced	O
Th2	O
cell	O
phenotype	O
,	O
we	O
investigated	O
whether	O
the	O
differentiation	O
of	O
the	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
depended	O
on	O
signaling	O
through	O
the	O
IL	B-Protein
-	I-Protein
4	I-Protein
receptor	O
via	O
STAT6	B-Protein
activation	O
(	O
Glimcher	O
and	O
Murphy	O
,	O
2000	O
;	O
Murphy	O
et	O
al	O
.	O
,	O
2000	O
)	O
.	O

The	O
absence	O
of	O
STAT6	B-Protein
did	O
not	O
impair	O
the	O
differentiation	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
and	O
OVA	B-Protein
(	O
Figure	O
2A	O
)	O
.	O
<EOS>	B-X
The	B-X
signals	B-X
driving	B-X
the	B-X
adaptation	B-X
of	B-X
type	B-X
2	B-X
dendritic	B-X
cells	B-X
(	B-X
DC2s	B-X
)	B-X
to	B-X
diverse	B-X
peripheral	B-X
environments	B-X
remain	B-X
mostly	B-X
undefined	B-X
.	B-X
We	B-X
show	B-X
that	B-X
differentiation	B-X
of	B-X
CD11b	B-X
Electroacupuncture	B-X
Improves	B-X
M2	B-X
Microglia	B-X
Polarization	B-X
and	B-X
Glia	B-X
Anti-inflammation	B-X
of	B-X
Hippocampus	B-X
in	B-X
Alzheimer	B-X
's	B-X
Disease	B-X
.	B-X
Macrophages	B-X
,	B-X
a	B-X
major	B-X
subset	B-X
of	B-X
innate	B-X
immune	B-X
cells	B-X
,	B-X
are	B-X
main	B-X
infiltrating	B-X
cells	B-X
in	B-X
the	B-X
kidney	B-X
in	B-X
lupus	B-X
nephritis	B-X
.	B-X

In	O
fact	O
,	O
a	O
higher	O
percentage	O
of	O
STAT6	B-Protein
-	O
deficient	O
cells	O
compared	O
with	O
WT	O
cells	O
produced	O
both	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
(	O
Figure	O
2A	O
)	O
,	O
which	O
may	O
be	O
the	O
result	O
of	O
the	O
loss	O
of	O
Th2	O
cell	O
control	O
over	O
a	O
Th1	O
cell	O
response	O
.	O

As	O
expected	O
,	O
lack	O
of	O
STAT6	B-Protein
abrogated	O
both	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
T	O
cells	O
developed	O
with	O
IL	B-Protein
-	I-Protein
4	I-Protein
or	O
with	O
low	O
antigen	O
dose	O
(	O
Figures	O
2B	O
and	O
2C	O
)	O
.	O

However	O
,	O
in	O
the	O
absence	O
of	O
STAT4	B-Protein
signaling	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
production	O
by	O
Th2	O
cells	O
was	O
if	O
anything	O
increased	O
(	O
Figures	O
2B	O
and	O
2C	O
)	O
.	O

Thus	O
,	O
in	O
contrast	O
to	O
what	O
was	O
observed	O
under	O
Th1	O
conditions	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
by	O
Th2	O
cells	O
depended	O
on	O
STAT6	B-Protein
,	O
but	O
not	O
on	O
STAT4	B-Protein
,	O
signaling	O
(	O
Figures	O
2B	O
and	O
2C	O
)	O
.	O

To	O
investigate	O
whether	O
the	O
inability	O
of	O
STAT4	B-Protein
-	O
deficient	O
T	O
cells	O
to	O
produce	O
IL	B-Protein
-	I-Protein
10	I-Protein
might	O
be	O
due	O
to	O
the	O
absence	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
as	O
suggested	O
before	O
(	O
Shaw	O
et	O
al	O
.	O
,	O
2006	O
)	O
,	O
we	O
differentiated	O
DO11	O
.	O
10	O
or	O
DO11	O
.	O
10	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
deficient	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
and	O
increasing	O
doses	O
of	O
OVA	B-Protein
.	O

The	O
secretion	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
as	O
induced	O
by	O
high	O
antigen	O
dose	O
,	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
was	O
not	O
affected	O
by	O
an	O
absence	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
(	O
Figure	O
2D	O
)	O
,	O
showing	O
that	O
the	O
expression	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
by	O
Th1	O
cells	O
is	O
independent	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
.	O
<EOS>	B-X
The	B-X
present	B-X
short	B-X
review	B-X
focuses	B-X
on	B-X
the	B-X
regulation	B-X
of	B-X
prostanoid	B-X
synthesis	B-X
in	B-X
microglial	B-X
cultures	B-X
and	B-X
on	B-X
the	B-X
possible	B-X
role	B-X
of	B-X
PGE2	B-X
in	B-X
the	B-X
down-regulation	B-X
of	B-X
microglial	B-X
activation	B-X
induced	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
.	B-X
LPS	B-X
induced	B-X
a	B-X
dose-dependent	B-X
expression	B-X
of	B-X
the	B-X
inducible	B-X
isoform	B-X
of	B-X
cyclooxygenase	B-X
(	B-X
COX-2	B-X
)	B-X
,	B-X
both	B-X
in	B-X
neonatal	B-X
and	B-X
adult	B-X
microglial	B-X
cultures	B-X
.	B-X
The	B-X
LPS-induced	B-X
COX-2	B-X
expression	B-X
and	B-X
prostanoid	B-X
production	B-X
were	B-X
down-regulated	B-X
by	B-X
potentially	B-X
neurotoxic	B-X
agents	B-X
,	B-X
such	B-X
as	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
,	B-X
the	B-X
proinflammatory	B-X
cytokine	B-X
IFN-gamma	B-X
(	B-X
which	B-X
acted	B-X
both	B-X
directly	B-X
and	B-X
indirectly	B-X
,	B-X
through	B-X
its	B-X
NO-inducing	B-X
activity	B-X
)	B-X
and	B-X
the	B-X
HIV	B-X
regulatory	B-X
protein	B-X
tat	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
COX-2	B-X
expression	B-X
was	B-X
up-regulated	B-X
by	B-X
the	B-X
macrophage-deactivating	B-X
cytokine	B-X
TGF-beta	B-X
1	B-X
,	B-X
by	B-X
exogenous	B-X
PGE2	B-X
itself	B-X
,	B-X
which	B-X
acted	B-X
through	B-X
EP2	B-X
receptors	B-X
linked	B-X
to	B-X
cyclic	B-X
AMP	B-X
generation	B-X
,	B-X
and	B-X
by	B-X
non	B-X
steroidal	B-X
anti-inflammatory	B-X
drugs	B-X
.	B-X
Interestingly	B-X
,	B-X
PGE2	B-X
utilized	B-X
the	B-X
same	B-X
EP2	B-X
receptor-mediated	B-X
signal	B-X
transduction	B-X
mechanism	B-X
to	B-X
down-regulate	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
inducible	B-X
NO	B-X
synthase	B-X
and	B-X
the	B-X
production	B-X
of	B-X
NO	B-X
.	B-X
Largely	B-X
,	B-X
but	B-X
not	B-X
exclusively	B-X
,	B-X
through	B-X
its	B-X
effect	B-X
on	B-X
cyclic	B-X
AMP	B-X
,	B-X
PGE2	B-X
can	B-X
also	B-X
:	B-X
i	B-X
)	B-X
depress	B-X
the	B-X
expression	B-X
of	B-X
major	B-X
histocompatibility	B-X
complex	B-X
class	B-X
II	B-X
antigens	B-X
and	B-X
of	B-X
the	B-X
costimulatory	B-X
molecule	B-X
B7-2	B-X
;	B-X
ii	B-X
)	B-X
down-regulate	B-X
TNF	B-X
and	B-X
up-regulate	B-X
IL-10	B-X
microglial	B-X
production	B-X
;	B-X
iii	B-X
)	B-X
inhibit	B-X
microglial	B-X
IL-12	B-X
secretion	B-X
.	B-X

In	O
the	O
absence	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
we	O
observed	O
an	O
increase	O
in	O
the	O
secreted	O
IL	B-Protein
-	I-Protein
4	I-Protein
as	O
expected	O
(	O
data	O
not	O
shown	O
)	O
.	O
<EOS>	B-X
IL-4Ralpha-dependent	B-X
responses	B-X
are	B-X
essential	B-X
for	B-X
granuloma	B-X
formation	B-X
and	B-X
host	B-X
survival	B-X
during	B-X
acute	B-X
schistosomiasis	B-X
.	B-X
Previously	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
mice	B-X
deficient	B-X
for	B-X
macrophage-specific	B-X
IL-4Ralpha	B-X
(	B-X
LysM	B-X
(	B-X
cre	B-X
)	B-X
Il4ra	B-X
(	B-X
-/lox	B-X
)	B-X
)	B-X
developed	B-X
increased	B-X
hepatotoxicity	B-X
and	B-X
gut	B-X
inflammation	B-X
;	B-X
whereas	B-X
inflammation	B-X
was	B-X
restricted	B-X
to	B-X
the	B-X
liver	B-X
of	B-X
mice	B-X
lacking	B-X
T	B-X
cell-specific	B-X
IL-4Ralpha	B-X
expression	B-X
(	B-X
iLck	B-X
(	B-X
cre	B-X
)	B-X
Il4ra	B-X
(	B-X
-/lox	B-X
)	B-X
)	B-X
.	B-X
Frequencies	B-X
and	B-X
numbers	B-X
of	B-X
macrophage	B-X
,	B-X
lymphocyte	B-X
or	B-X
granulocyte	B-X
populations	B-X
,	B-X
as	B-X
well	B-X
as	B-X
Th1/Th2	B-X
cytokine	B-X
responses	B-X
were	B-X
similar	B-X
in	B-X
Schistosoma	B-X
mansoni-infected	B-X
LysM	B-X
(	B-X
cre	B-X
)	B-X
Il4ra	B-X
(	B-X
-/lox	B-X
)	B-X
liver	B-X
granulomas	B-X
,	B-X
when	B-X
compared	B-X
to	B-X
Il4ra	B-X
(	B-X
-/lox	B-X
)	B-X
control	B-X
mice	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
a	B-X
shift	B-X
to	B-X
Th1	B-X
responses	B-X
with	B-X
high	B-X
IFN-gamma	B-X
and	B-X
low	B-X
IL-4	B-X
,	B-X
IL-10	B-X
and	B-X
IL-13	B-X
was	B-X
observed	B-X
in	B-X
the	B-X
severely	B-X
disrupted	B-X
granulomas	B-X
of	B-X
iLck	B-X
(	B-X
cre	B-X
)	B-X
Il4ra	B-X
(	B-X
-/lox	B-X
)	B-X
and	B-X
Il4ra	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X
As	B-X
expected	B-X
,	B-X
alternative	B-X
macrophage	B-X
activation	B-X
was	B-X
reduced	B-X
in	B-X
both	B-X
LysM	B-X
(	B-X
cre	B-X
)	B-X
Il4ra	B-X
(	B-X
-/lox	B-X
)	B-X
and	B-X
iLck	B-X
(	B-X
cre	B-X
)	B-X
Il4ra	B-X
(	B-X
-/lox	B-X
)	B-X
granulomas	B-X
with	B-X
low	B-X
arginase	B-X
1	B-X
and	B-X
heightened	B-X
nitric	B-X
oxide	B-X
synthase	B-X
RNA	B-X
expression	B-X
in	B-X
granuloma	B-X
macrophages	B-X
of	B-X
both	B-X
mouse	B-X
strains	B-X
.	B-X
Interestingly	B-X
,	B-X
a	B-X
discrete	B-X
subpopulation	B-X
of	B-X
SSC	B-X
(	B-X
high	B-X
)	B-X
CD11b+I-A/I-E	B-X
(	B-X
high	B-X
)	B-X
CD204+	B-X
macrophages	B-X
retained	B-X
expression	B-X
of	B-X
mannose	B-X
receptor	B-X
(	B-X
MMR	B-X
)	B-X
and	B-X
Ym1	B-X
in	B-X
LysM	B-X
(	B-X
cre	B-X
)	B-X
Il4ra	B-X
(	B-X
-/lox	B-X
)	B-X
but	B-X
not	B-X
in	B-X
iLck	B-X
(	B-X
cre	B-X
)	B-X
Il4ra	B-X
(	B-X
-/lox	B-X
)	B-X
granulomas	B-X
.	B-X
While	B-X
aaMphi	B-X
were	B-X
in	B-X
close	B-X
proximity	B-X
to	B-X
the	B-X
parasite	B-X
eggs	B-X
in	B-X
Il4ra	B-X
(	B-X
-/lox	B-X
)	B-X
control	B-X
mice	B-X
,	B-X
MMR+Ym1+	B-X
macrophages	B-X
in	B-X
LysM	B-X
(	B-X
cre	B-X
)	B-X
Il4ra	B-X
(	B-X
-/lox	B-X
)	B-X
mice	B-X
were	B-X
restricted	B-X
to	B-X
the	B-X
periphery	B-X
of	B-X
the	B-X
granuloma	B-X
,	B-X
indicating	B-X
that	B-X
they	B-X
might	B-X
have	B-X
different	B-X
functions	B-X
.	B-X
In	B-X
vivo	B-X
IL-10	B-X
neutralisation	B-X
resulted	B-X
in	B-X
the	B-X
disappearance	B-X
of	B-X
MMR+Ym1+	B-X
macrophages	B-X
in	B-X
LysM	B-X
(	B-X
cre	B-X
)	B-X
Il4ra	B-X
(	B-X
-/lox	B-X
)	B-X
mice	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
show	B-X
that	B-X
IL-4Ralpha-responsive	B-X
T	B-X
cells	B-X
are	B-X
essential	B-X
to	B-X
drive	B-X
alternative	B-X
macrophage	B-X
activation	B-X
and	B-X
to	B-X
control	B-X
granulomatous	B-X
inflammation	B-X
in	B-X
the	B-X
liver	B-X
.	B-X
The	B-X
data	B-X
further	B-X
suggest	B-X
that	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
macrophage-specific	B-X
IL-4Ralpha	B-X
signalling	B-X
,	B-X
IL-10	B-X
is	B-X
able	B-X
to	B-X
drive	B-X
mannose	B-X
receptor-	B-X
and	B-X
Ym1-positive	B-X
macrophages	B-X
,	B-X
associated	B-X
with	B-X
control	B-X
of	B-X
hepatic	B-X
granulomatous	B-X
inflammation	B-X
.	B-X

We	O
also	O
tested	O
for	O
any	O
potential	O
role	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
in	O
the	O
development	O
of	O
Th1	O
cells	O
producing	O
IL	B-Protein
-	I-Protein
10	I-Protein
by	O
culturing	O
DO11	O
.	O
10	O
or	O
DO11	O
.	O
10	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
deficient	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
with	O
IL	B-Protein
-	I-Protein
12	I-Protein
and	O
increasing	O
doses	O
of	O
antigen	O
.	O

As	O
observed	O
in	O
the	O
absence	O
of	O
STAT6	B-Protein
(	O
Figure	O
2A	O
)	O
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
deficiency	O
had	O
no	O
effect	O
on	O
the	O
development	O
of	O
Th1	O
cells	O
producing	O
IL	B-Protein
-	I-Protein
10	I-Protein
(	O
Figure	O
2E	O
)	O
,	O
but	O
compromised	O
the	O
development	O
of	O
Th2	O
cells	O
producing	O
IL	B-Protein
-	I-Protein
10	I-Protein
(	O
Figure	O
2F	O
)	O
.	O

Thus	O
,	O
our	O
data	O
suggested	O
that	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
or	O
Th2	O
cells	O
was	O
dependent	O
on	O
the	O
specific	O
signaling	O
pathways	O
required	O
for	O
their	O
differentiation	O
,	O
given	O
that	O
STAT4	B-Protein
is	O
required	O
for	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
cells	O
and	O
STAT6	B-Protein
for	O
Th2	O
cells	O
.	O
<EOS>	B-X
Although	B-X
the	B-X
reason	B-X
for	B-X
this	B-X
development	B-X
is	B-X
unknown	B-X
,	B-X
epidemiological	B-X
studies	B-X
and	B-X
experimental	B-X
data	B-X
have	B-X
lead	B-X
to	B-X
the	B-X
suggestion	B-X
that	B-X
this	B-X
phenomenon	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
decline	B-X
of	B-X
infectious	B-X
diseases	B-X
,	B-X
which	B-X
induce	B-X
T	B-X
helper	B-X
1	B-X
and/or	B-X
T	B-X
regulatory	B-X
responses	B-X
.	B-X
One	B-X
approach	B-X
is	B-X
based	B-X
on	B-X
vaccinations	B-X
using	B-X
live	B-X
or	B-X
killed	B-X
bacteria	B-X
or	B-X
their	B-X
components	B-X
,	B-X
CpG-ODNs	B-X
or	B-X
DNA	B-X
vaccination	B-X
,	B-X
which	B-X
all	B-X
induce	B-X
allergen-specific	B-X
or	B-X
unspecific	B-X
Th1	B-X
responses	B-X
.	B-X
Th1	B-X
responses	B-X
lead	B-X
to	B-X
the	B-X
production	B-X
of	B-X
IFN-gamma	B-X
,	B-X
IL-12	B-X
,	B-X
IL-18	B-X
and	B-X
IL-23	B-X
,	B-X
thereby	B-X
inhibiting	B-X
Th2	B-X
responses	B-X
and	B-X
thus	B-X
the	B-X
development	B-X
of	B-X
asthma	B-X
.	B-X
A	B-X
further	B-X
strategy	B-X
both	B-X
for	B-X
the	B-X
prevention	B-X
and	B-X
therapy	B-X
of	B-X
asthma	B-X
is	B-X
the	B-X
induction	B-X
of	B-X
Tr	B-X
cells	B-X
.	B-X
Tr	B-X
cells	B-X
have	B-X
also	B-X
been	B-X
shown	B-X
to	B-X
suppress	B-X
allergic	B-X
Th2	B-X
responses	B-X
,	B-X
however	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
Th1	B-X
cells	B-X
through	B-X
a	B-X
cell/cell	B-X
contact	B-X
mediated	B-X
mechanism	B-X
or	B-X
by	B-X
the	B-X
secretion	B-X
of	B-X
the	B-X
anti-inflammatory	B-X
cytokines	B-X
IL-10	B-X
and/or	B-X
TGF-beta	B-X
.	B-X
Furthermore	B-X
,	B-X
there	B-X
is	B-X
growing	B-X
information	B-X
on	B-X
how	B-X
to	B-X
induce	B-X
Tr	B-X
cells	B-X
both	B-X
in	B-X
animals	B-X
and	B-X
humans	B-X
.	B-X
Here	B-X
we	B-X
review	B-X
the	B-X
data	B-X
showing	B-X
that	B-X
animals	B-X
can	B-X
be	B-X
protected	B-X
from	B-X
developing	B-X
asthma	B-X
by	B-X
immune	B-X
stimulation	B-X
leading	B-X
to	B-X
Th1	B-X
or	B-X
Tr	B-X
responses	B-X
.	B-X

High	O
Antigen	O
Doses	O
and	O
STAT4	B-Protein
Are	O
Required	O
for	O
the	O
In	O
Vivo	O
Generation	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
Producing	O
Th1	O
Cells	O

To	O
address	O
the	O
mechanisms	O
regulating	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
cells	O
in	O
vivo	O
,	O
we	O
transferred	O
DO11	O
.	O
10	O
cells	O
into	O
BALB	O
/	O
c	O
recipient	O
mice	O
and	O
immunized	O
the	O
recipients	O
with	O
very	O
high	O
doses	O
of	O
OVA	B-Protein
-	O
protein	O
with	O
or	O
without	O
added	O
lipopolysacharide	O
(	O
LPS	O
)	O
.	O
<EOS>	B-X
Lipopolysacharide	B-X
(	B-X
LPS	B-X
)	B-X
causes	B-X
gastrointestinal	B-X
ileus	B-X
and	B-X
gastric	B-X
luminal	B-X
fluid	B-X
accumulation	B-X
.	B-X
Ketamine	B-X
,	B-X
an	B-X
anti-inflammatory	B-X
anesthetic	B-X
agent	B-X
attenuates	B-X
accumulation	B-X
of	B-X
luminal	B-X
fluid	B-X
.	B-X
However	B-X
,	B-X
its	B-X
effects	B-X
on	B-X
gastrointestinal	B-X
transit	B-X
induced	B-X
by	B-X
endotoxemia	B-X
are	B-X
unknown	B-X
.	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
if	B-X
the	B-X
anti-inflammatory	B-X
properties	B-X
of	B-X
ketamine	B-X
improve	B-X
impaired	B-X
gastric	B-X
emptying	B-X
and	B-X
gastrointestinal	B-X
transit	B-X
because	B-X
of	B-X
LPS	B-X
.	B-X

T	O
cells	O
were	O
recovered	O
from	O
the	O
inguinal	O
lymph	O
nodes	O
3	O
days	O
after	O
priming	O
and	O
restimulated	O
in	O
vitro	O
with	O
OVA	B-Protein
peptide	O
for	O
48	O
hr	O
.	O

This	O
in	O
vivo	O
immunization	O
induced	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
,	O
and	O
the	O
amount	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
was	O
enhanced	O
by	O
addition	O
of	O
LPS	O
in	O
the	O
immunization	O
(	O
Figure	O
3A	O
)	O
and	O
with	O
higher	O
doses	O
of	O
OVA	B-Protein
(	O
3	O
muM	O
versus	O
1	O
muM	O
,	O
data	O
not	O
shown	O
)	O
.	O

To	O
test	O
the	O
role	O
of	O
STAT4	B-Protein
and	O
STAT6	B-Protein
signaling	O
in	O
the	O
in	O
vivo	O
development	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
,	O
we	O
transferred	O
STAT4	B-Protein
-	O
or	O
STAT6	B-Protein
-	O
deficient	O
or	O
WT	O
DO11	O
.	O
10	O
cells	O
into	O
recipient	O
BALB	O
/	O
c	O
mice	O
and	O
immunized	O
with	O
OVA	B-Protein
-	O
protein	O
plus	O
LPS	O
as	O
before	O
.	O
<EOS>	B-X
Efferocytosis	B-X
,	B-X
or	B-X
phagocytic	B-X
clearance	B-X
of	B-X
dead/dying	B-X
cells	B-X
by	B-X
brain-resident	B-X
microglia	B-X
and/or	B-X
infiltrating	B-X
macrophages	B-X
,	B-X
is	B-X
instrumental	B-X
for	B-X
inflammation	B-X
resolution	B-X
and	B-X
restoration	B-X
of	B-X
brain	B-X
homeostasis	B-X
after	B-X
stroke	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identify	B-X
the	B-X
signal	B-X
transducer	B-X
and	B-X
activator	B-X
of	B-X
transcription	B-X
6/arginase1	B-X
(	B-X
STAT6/Arg1	B-X
)	B-X
signaling	B-X
axis	B-X
as	B-X
a	B-X
potentially	B-X
novel	B-X
mechanism	B-X
that	B-X
orchestrates	B-X
microglia/macrophage	B-X
responses	B-X
in	B-X
the	B-X
ischemic	B-X
brain	B-X
.	B-X
Activation	B-X
of	B-X
STAT6	B-X
was	B-X
observed	B-X
in	B-X
microglia/macrophages	B-X
in	B-X
the	B-X
ischemic	B-X
territory	B-X
in	B-X
a	B-X
mouse	B-X
model	B-X
of	B-X
stroke	B-X
and	B-X
in	B-X
stroke	B-X
patients	B-X
.	B-X
STAT6	B-X
deficiency	B-X
resulted	B-X
in	B-X
reduced	B-X
clearance	B-X
of	B-X
dead/dying	B-X
neurons	B-X
,	B-X
increased	B-X
inflammatory	B-X
gene	B-X
signature	B-X
in	B-X
microglia/macrophages	B-X
,	B-X
and	B-X
enlarged	B-X
infarct	B-X
volume	B-X
early	B-X
after	B-X
experimental	B-X
stroke	B-X
.	B-X
All	B-X
of	B-X
these	B-X
pathological	B-X
changes	B-X
culminated	B-X
in	B-X
an	B-X
increased	B-X
brain	B-X
tissue	B-X
loss	B-X
and	B-X
exacerbated	B-X
long-term	B-X
functional	B-X
deficits	B-X
.	B-X
Combined	B-X
in	B-X
vivo	B-X
analyses	B-X
using	B-X
BM	B-X
chimeras	B-X
and	B-X
in	B-X
vitro	B-X
experiments	B-X
using	B-X
microglia/macrophage-neuron	B-X
cocultures	B-X
confirmed	B-X
that	B-X
STAT6	B-X
activation	B-X
in	B-X
both	B-X
microglia	B-X
and	B-X
macrophages	B-X
was	B-X
essential	B-X
for	B-X
neuroprotection	B-X
.	B-X
Adoptive	B-X
transfer	B-X
of	B-X
WT	B-X
macrophages	B-X
into	B-X
STAT6-KO	B-X
mice	B-X
reduced	B-X
accumulation	B-X
of	B-X
dead	B-X
neurons	B-X
in	B-X
the	B-X
ischemic	B-X
territory	B-X
and	B-X
ameliorated	B-X
brain	B-X
infarction	B-X
.	B-X
Furthermore	B-X
,	B-X
decreased	B-X
expression	B-X
of	B-X
Arg1	B-X
in	B-X
STAT6-/-	B-X
microglia/macrophages	B-X
was	B-X
responsible	B-X
for	B-X
impairments	B-X
in	B-X
efferocytosis	B-X
and	B-X
loss	B-X
of	B-X
antiinflammatory	B-X
modality	B-X
.	B-X
Our	B-X
study	B-X
suggests	B-X
that	B-X
efferocytosis	B-X
via	B-X
STAT6/Arg1	B-X
modulates	B-X
microglia/macrophage	B-X
phenotype	B-X
,	B-X
accelerates	B-X
inflammation	B-X
resolution	B-X
,	B-X
and	B-X
improves	B-X
stroke	B-X
outcomes	B-X
.	B-X

In	O
vivo	O
expression	O
of	O
both	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
was	O
markedly	O
reduced	O
but	O
not	O
completely	O
abrogated	O
in	O
the	O
absence	O
of	O
STAT4	B-Protein
signaling	O
(	O
Figures	O
3B	O
and	O
3C	O
)	O
,	O
suggesting	O
the	O
existence	O
of	O
compensatory	O
mechanisms	O
that	O
were	O
absent	O
in	O
the	O
in	O
vitro	O
system	O
.	O
<EOS>	B-X
Evaluate	B-X
the	B-X
effect	B-X
of	B-X
the	B-X
miRNA-106a/20b	B-X
on	B-X
the	B-X
efficacy	B-X
of	B-X
DCs	B-X
pulsed	B-X
with	B-X
GSCs	B-X
in	B-X
activating	B-X
GSC-specific	B-X
T	B-X
cell	B-X
responses	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
is	B-X
to	B-X
investigate	B-X
the	B-X
anti-arthritic	B-X
potential	B-X
and	B-X
clarify	B-X
the	B-X
bone	B-X
protective	B-X
actions	B-X
of	B-X
RvD1	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
However	B-X
,	B-X
its	B-X
immunomodulatory	B-X
effects	B-X
in	B-X
the	B-X
context	B-X
of	B-X
LPS	B-X
challenge	B-X
are	B-X
incompletely	B-X
defined	B-X
.	B-X
To	B-X
define	B-X
this	B-X
protection	B-X
further	B-X
,	B-X
we	B-X
measured	B-X
effects	B-X
of	B-X
CDDO-Me	B-X
pretreatment	B-X
on	B-X
splenocyte	B-X
populations	B-X
and	B-X
cytokine	B-X
production	B-X
following	B-X
LPS	B-X
challenge	B-X
,	B-X
using	B-X
low-level	B-X
LPS	B-X
pretreatment	B-X
as	B-X
an	B-X
in	B-X
vivo	B-X
control	B-X
for	B-X
reducing	B-X
cytokine	B-X
production	B-X
.	B-X
Despite	B-X
similar	B-X
decreases	B-X
in	B-X
levels	B-X
of	B-X
LPS-inducible	B-X
,	B-X
circulating	B-X
proinflammatory	B-X
cytokines	B-X
(	B-X
IL-12p70	B-X
,	B-X
IFN-gamma	B-X
,	B-X
IL-6	B-X
,	B-X
IL-17	B-X
,	B-X
and	B-X
IL-23	B-X
)	B-X
and	B-X
increases	B-X
in	B-X
heme	B-X
oxygenase	B-X
1	B-X
(	B-X
HO-1	B-X
)	B-X
protein	B-X
expression	B-X
,	B-X
low-dose	B-X
LPS	B-X
and	B-X
CDDO-Me	B-X
pretreatments	B-X
markedly	B-X
differed	B-X
in	B-X
their	B-X
overall	B-X
response	B-X
profiles	B-X
.	B-X
Splenocytes	B-X
from	B-X
LPS-pretreated	B-X
mice	B-X
contained	B-X
reduced	B-X
numbers	B-X
of	B-X
dendritic	B-X
cells	B-X
,	B-X
increased	B-X
percentages	B-X
of	B-X
Th17	B-X
and	B-X
T-regulatory	B-X
cells	B-X
,	B-X
lower	B-X
levels	B-X
of	B-X
TLR-inducible	B-X
IL-6	B-X
,	B-X
and	B-X
higher	B-X
levels	B-X
of	B-X
TLR-inducible	B-X
IL-10	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
CDDO-Me	B-X
protection	B-X
against	B-X
LPS	B-X
challenge	B-X
had	B-X
no	B-X
impact	B-X
on	B-X
absolute	B-X
numbers	B-X
or	B-X
distribution	B-X
of	B-X
splenocyte	B-X
subsets	B-X
,	B-X
despite	B-X
attenuating	B-X
in	B-X
vivo	B-X
induction	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
in	B-X
an	B-X
IL-10-independent	B-X
manner	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
CDDO-Me	B-X
pretreatment	B-X
uniquely	B-X
confers	B-X
protection	B-X
against	B-X
LPS	B-X
challenge	B-X
by	B-X
modulating	B-X
the	B-X
in	B-X
vivo	B-X
immune	B-X
response	B-X
to	B-X
LPS	B-X
.	B-X

Signaling	O
through	O
STAT6	B-Protein
had	O
no	O
effect	O
on	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
cells	O
as	O
shown	O
by	O
intracellular	O
cytokine	O
staining	O
(	O
ICS	O
)	O
and	O
by	O
immunoassay	O
in	O
STAT6	B-Protein
-	O
deficient	O
T	O
cells	O
(	O
Figures	O
3B	O
and	O
3C	O
)	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
Production	O
Is	O
Maintained	O
by	O
High	O
TCR	O
Signal	O
Strength	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein

We	O
next	O
investigated	O
whether	O
repeated	O
strong	O
TCR	O
activation	O
is	O
a	O
compensatory	O
signal	O
for	O
IL	B-Protein
-	I-Protein
12	I-Protein
-	O
induced	O
STAT4	B-Protein
signaling	O
in	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
Th1	O
cells	O
.	O

For	O
this	O
,	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
differentiated	O
for	O
2	O
consecutive	O
weeks	O
with	O
high	O
antigen	O
doses	O
in	O
the	O
presence	O
or	O
absence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
throughout	O
(	O
Figures	O
4A	O
-	O
4D	O
)	O
.	O

High	O
antigen	O
dose	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
cooperated	O
to	O
induce	O
maximal	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
(	O
Figures	O
4A	O
and	O
4B	O
)	O
,	O
given	O
that	O
this	O
combination	O
resulted	O
in	O
the	O
highest	O
numbers	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
.	O

Repeated	O
high	O
antigen	O
dose	O
stimulation	O
in	O
the	O
absence	O
of	O
exogenously	O
added	O
IL	B-Protein
-	I-Protein
12	I-Protein
resulted	O
in	O
the	O
production	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
by	O
Th1	O
cells	O
,	O
suggesting	O
that	O
repeated	O
strong	O
TCR	O
triggering	O
may	O
overcome	O
the	O
need	O
for	O
IL	B-Protein
-	I-Protein
12	I-Protein
for	O
IL	B-Protein
-	I-Protein
10	I-Protein
induction	O
(	O
Figures	O
4C	O
and	O
4D	O
)	O
.	O

However	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
induction	O
under	O
these	O
conditions	O
was	O
abrogated	O
when	O
IL	B-Protein
-	I-Protein
12p40	I-Protein
-	O
deficient	O
DCs	O
were	O
used	O
as	O
APCs	O
(	O
Figure	O
4E	O
)	O
.	O

Thus	O
,	O
IL	B-Protein
-	I-Protein
12	I-Protein
is	O
essential	O
during	O
both	O
primary	O
and	O
secondary	O
antigenic	O
stimulation	O
for	O
production	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
by	O
Th1	O
cells	O
.	O
<EOS>	B-X
During	B-X
an	B-X
immune	B-X
response	B-X
the	B-X
brain	B-X
and	B-X
the	B-X
immune	B-X
system	B-X
``	B-X
talk	B-X
to	B-X
each	B-X
other	B-X
''	B-X
and	B-X
this	B-X
process	B-X
is	B-X
essential	B-X
for	B-X
maintaining	B-X
homeostasis	B-X
.	B-X
Thus	B-X
,	B-X
primary	B-X
and	B-X
secondary	B-X
lymphoid	B-X
organs	B-X
receive	B-X
extensive	B-X
sympathetic/noradrenergic	B-X
innervation	B-X
.	B-X
Under	B-X
stimulation	B-X
,	B-X
NE	B-X
is	B-X
released	B-X
from	B-X
the	B-X
sympathetic	B-X
nerve	B-X
terminals	B-X
in	B-X
these	B-X
organs	B-X
,	B-X
and	B-X
the	B-X
target	B-X
immune	B-X
cells	B-X
express	B-X
adrenoreceptors	B-X
.	B-X
Through	B-X
stimulation	B-X
of	B-X
these	B-X
receptors	B-X
,	B-X
locally	B-X
released	B-X
NE	B-X
,	B-X
or	B-X
circulating	B-X
catecholamines	B-X
such	B-X
as	B-X
epinephrine	B-X
,	B-X
affect	B-X
lymphocyte	B-X
traffic	B-X
,	B-X
circulation	B-X
,	B-X
and	B-X
proliferation	B-X
,	B-X
and	B-X
modulate	B-X
cytokine	B-X
production	B-X
and	B-X
the	B-X
functional	B-X
activity	B-X
of	B-X
different	B-X
lymphoid	B-X
cells	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
recent	B-X
evidence	B-X
is	B-X
discussed	B-X
that	B-X
NE	B-X
and	B-X
epinephrine	B-X
,	B-X
through	B-X
stimulation	B-X
of	B-X
the	B-X
beta	B-X
(	B-X
2	B-X
)	B-X
-adrenoreceptor-cAMP-protein	B-X
kinase	B-X
A	B-X
pathway	B-X
,	B-X
inhibit	B-X
the	B-X
production	B-X
of	B-X
type	B-X
1/proinflammatory	B-X
cytokines	B-X
,	B-X
such	B-X
as	B-X
interleukin	B-X
(	B-X
IL-12	B-X
)	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
and	B-X
interferon-gamma	B-X
by	B-X
antigen-presenting	B-X
cells	B-X
and	B-X
T	B-X
helper	B-X
(	B-X
Th	B-X
)	B-X
1	B-X
cells	B-X
,	B-X
whereas	B-X
they	B-X
stimulate	B-X
the	B-X
production	B-X
of	B-X
type	B-X
2/anti-inflammatory	B-X
cytokines	B-X
such	B-X
as	B-X
IL-10	B-X
and	B-X
transforming	B-X
growth	B-X
factor-beta	B-X
.	B-X
Through	B-X
this	B-X
mechanism	B-X
,	B-X
systemically	B-X
,	B-X
endogenous	B-X
catecholamines	B-X
may	B-X
cause	B-X
a	B-X
selective	B-X
suppression	B-X
of	B-X
Th1	B-X
responses	B-X
and	B-X
cellular	B-X
immunity	B-X
,	B-X
and	B-X
a	B-X
Th2	B-X
shift	B-X
toward	B-X
dominance	B-X
of	B-X
humoral	B-X
immunity	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
in	B-X
certain	B-X
local	B-X
responses	B-X
,	B-X
and	B-X
under	B-X
certain	B-X
conditions	B-X
,	B-X
catecholamines	B-X
may	B-X
actually	B-X
boost	B-X
regional	B-X
immune	B-X
responses	B-X
,	B-X
through	B-X
induction	B-X
of	B-X
IL-1	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
and	B-X
primarily	B-X
IL-8	B-X
production	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
activation	B-X
of	B-X
SNS	B-X
during	B-X
an	B-X
immune	B-X
response	B-X
might	B-X
be	B-X
aimed	B-X
to	B-X
localize	B-X
the	B-X
inflammatory	B-X
response	B-X
,	B-X
through	B-X
induction	B-X
of	B-X
neutrophil	B-X
accumulation	B-X
and	B-X
stimulation	B-X
of	B-X
more	B-X
specific	B-X
humoral	B-X
immune	B-X
responses	B-X
,	B-X
although	B-X
systemically	B-X
it	B-X
may	B-X
suppress	B-X
Th1	B-X
responses	B-X
,	B-X
and	B-X
,	B-X
thus	B-X
protect	B-X
the	B-X
organism	B-X
from	B-X
the	B-X
detrimental	B-X
effects	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
and	B-X
other	B-X
products	B-X
of	B-X
activated	B-X
macrophages	B-X
.	B-X

To	O
determine	O
the	O
requirements	O
for	O
stability	O
of	O
the	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
,	O
we	O
differentiated	O
CD4	B-Protein
+	O
T	O
cells	O
for	O
1	O
week	O
with	O
high	O
antigen	O
doses	O
with	O
or	O
without	O
IL	B-Protein
-	I-Protein
12	I-Protein
(	O
Figures	O
4A	O
and	O
4C	O
)	O
,	O
washed	O
them	O
,	O
and	O
then	O
restimulated	O
them	O
for	O
an	O
additional	O
week	O
with	O
a	O
low	O
antigen	O
dose	O
,	O
in	O
the	O
absence	O
or	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
(	O
Figure	O
4F	O
)	O
.	O

Th1	O
cells	O
induced	O
in	O
the	O
first	O
week	O
to	O
produce	O
IL	B-Protein
-	I-Protein
10	I-Protein
by	O
culture	O
with	O
high	O
antigen	O
doses	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
lost	O
their	O
ability	O
to	O
express	O
IL	B-Protein
-	I-Protein
10	I-Protein
when	O
recultured	O
with	O
low	O
doses	O
of	O
OVA	B-Protein
,	O
which	O
could	O
be	O
compensated	O
for	O
,	O
to	O
some	O
extent	O
,	O
by	O
addition	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
to	O
the	O
secondary	O
cultures	O
(	O
Figure	O
4F	O
)	O
,	O
again	O
suggesting	O
that	O
antigen	O
dose	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
signals	O
cooperate	O
for	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
.	O

Finally	O
,	O
DO11	O
.	O
10	O
CD4	B-Protein
+	O
cells	O
that	O
were	O
exposed	O
to	O
low	O
doses	O
of	O
antigen	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
during	O
the	O
primary	O
differentiation	O
phase	O
produced	O
high	O
amounts	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
but	O
little	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
but	O
they	O
could	O
be	O
induced	O
to	O
produce	O
IL	B-Protein
-	I-Protein
10	I-Protein
when	O
both	O
high	O
antigen	O
dose	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
were	O
present	O
during	O
the	O
recall	O
phase	O
(	O
Figure	O
S4	O
)	O
.	O

Thus	O
,	O
high	O
antigen	O
dose	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
are	O
required	O
for	O
sustaining	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
cells	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
Production	O
by	O
Th1	O
Cells	O
Requires	O
ERK1	B-Protein
and	O
ERK2	B-Protein
Activation	O
<EOS>	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
producing	B-X
interleukin-10	B-X
(	B-X
IL-10	B-X
)	B-X
and	B-X
interferon-gamma	B-X
(	B-X
IFN-gamma	B-X
)	B-X
are	B-X
reported	B-X
in	B-X
chronic	B-X
infections	B-X
.	B-X
However	B-X
,	B-X
the	B-X
signals	B-X
that	B-X
direct	B-X
the	B-X
development	B-X
of	B-X
IL-10-producing	B-X
T	B-X
helper	B-X
1	B-X
(	B-X
Th1	B-X
)	B-X
cells	B-X
are	B-X
undefined	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
development	B-X
of	B-X
IL-10-producing	B-X
Th1	B-X
cells	B-X
required	B-X
high	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
ligation	B-X
,	B-X
sustained	B-X
ERK1	B-X
and	B-X
ERK2	B-X
MAP	B-X
kinases	B-X
phosphorylation	B-X
,	B-X
and	B-X
IL-12-induced	B-X
STAT4	B-X
transcription	B-X
factor	B-X
activation	B-X
.	B-X
Repeated	B-X
TCR	B-X
triggering	B-X
led	B-X
to	B-X
enhanced	B-X
IL-10	B-X
production	B-X
by	B-X
Th1	B-X
cells	B-X
,	B-X
and	B-X
continued	B-X
IL-12	B-X
action	B-X
and	B-X
high-dose	B-X
TCR	B-X
signaling	B-X
were	B-X
required	B-X
for	B-X
the	B-X
development	B-X
and	B-X
maintenance	B-X
of	B-X
IL-10-producing	B-X
Th1	B-X
cells	B-X
.	B-X
Although	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
and	B-X
Th17	B-X
cells	B-X
require	B-X
the	B-X
activation	B-X
of	B-X
distinct	B-X
STATs	B-X
for	B-X
their	B-X
differentiation	B-X
,	B-X
activation	B-X
of	B-X
ERK1	B-X
and	B-X
ERK2	B-X
was	B-X
a	B-X
common	B-X
requirement	B-X
for	B-X
production	B-X
of	B-X
IL-10	B-X
by	B-X
all	B-X
Th	B-X
cell	B-X
subsets	B-X
.	B-X
IL-10	B-X
expression	B-X
also	B-X
correlated	B-X
with	B-X
c-maf	B-X
expression	B-X
.	B-X
Despite	B-X
having	B-X
distinct	B-X
functions	B-X
in	B-X
protection	B-X
against	B-X
pathogens	B-X
,	B-X
all	B-X
Th	B-X
cells	B-X
share	B-X
the	B-X
important	B-X
task	B-X
of	B-X
controlling	B-X
overexuberant	B-X
immune	B-X
responses	B-X
by	B-X
means	B-X
of	B-X
IL-10	B-X
production	B-X
.	B-X

Our	O
data	O
showed	O
that	O
the	O
maintenance	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
induction	O
in	O
Th1	O
cells	O
required	O
stimulation	O
with	O
high	O
antigen	O
dose	O
,	O
which	O
to	O
some	O
extent	O
could	O
be	O
compensated	O
for	O
by	O
the	O
addition	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
.	O

Signaling	O
through	O
the	O
TCR	O
with	O
high	O
doses	O
of	O
antigen	O
induced	O
stronger	O
ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
than	O
that	O
induced	O
by	O
low	O
antigen	O
dose	O
,	O
not	O
only	O
in	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
data	O
not	O
shown	O
)	O
as	O
previously	O
demonstrated	O
(	O
Jorritsma	O
et	O
al	O
.	O
,	O
2003	O
)	O
but	O
also	O
in	O
CD4	B-Protein
+	O
T	O
cells	O
restimulated	O
with	O
the	O
same	O
high	O
and	O
low	O
antigen	O
doses	O
(	O
Figure	O
5A	O
)	O
.	O

Although	O
the	O
apparent	O
peak	O
and	O
amount	O
of	O
ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
varied	O
slightly	O
between	O
experiments	O
,	O
a	O
consistent	O
finding	O
was	O
that	O
high	O
antigen	O
dose	O
differentiated	O
Th1	O
cells	O
always	O
showed	O
enhanced	O
and	O
prolonged	O
ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
,	O
regardless	O
of	O
whether	O
they	O
were	O
restimulated	O
with	O
high	O
or	O
low	O
antigen	O
dose	O
(	O
Figure	O
5B	O
)	O
.	O

We	O
then	O
investigated	O
whether	O
ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
was	O
required	O
for	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
Th1	O
cells	O
by	O
using	O
U0126	O
(	O
Figure	O
5C	O
)	O
,	O
a	O
compound	O
that	O
blocks	O
downstream	O
ERK	O
activation	O
.	O

To	O
ensure	O
that	O
only	O
T	O
cell	O
signaling	O
was	O
being	O
affected	O
by	O
U0126	O
,	O
we	O
used	O
an	O
APC	O
-	O
free	O
system	O
in	O
which	O
the	O
T	O
cells	O
were	O
differentiated	O
in	O
the	O
presence	O
of	O
increasing	O
doses	O
of	O
anti	O
-	O
CD3	B-Protein
and	O
a	O
constant	O
amount	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
.	O

As	O
in	O
the	O
APC	O
-	O
driven	O
cultures	O
,	O
stronger	O
TCR	O
stimulation	O
together	O
with	O
IL	B-Protein
-	I-Protein
12	I-Protein
led	O
to	O
higher	O
percentages	O
of	O
cells	O
producing	O
both	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
after	O
1	O
week	O
of	O
culture	O
(	O
Figure	O
5C	O
)	O
.	O

Addition	O
of	O
U0126	O
to	O
the	O
cultures	O
abrogated	O
the	O
production	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
at	O
all	O
doses	O
of	O
anti	O
-	O
CD3	B-Protein
(	O
Figure	O
5C	O
)	O
.	O

Because	O
U0126	O
inhibits	O
the	O
MEK5	B-Protein
-	O
catalyzed	O
activation	O
of	O
ERK5	B-Protein
,	O
as	O
well	O
as	O
the	O
MEK1	B-Protein
-	O
and	O
MEK2	B-Protein
-	O
catalyzed	O
activation	O
of	O
ERK1	B-Protein
and	O
ERK2	B-Protein
(	O
Bain	O
et	O
al	O
.	O
,	O
2007	O
;	O
Mody	O
et	O
al	O
.	O
,	O
2001	O
)	O
,	O
we	O
also	O
used	O
the	O
more	O
specific	O
,	O
structurally	O
unrelated	O
MEK1	B-Protein
and	O
MEK2	B-Protein
inhibitor	O
PD184352	O
at	O
concentrations	O
in	O
which	O
it	O
inhibits	O
MEK1	B-Protein
and	O
MEK2	B-Protein
but	O
not	O
MEK5	B-Protein
(	O
Bain	O
et	O
al	O
.	O
,	O
2007	O
;	O
Mody	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O

PD184352	O
caused	O
a	O
similar	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
(	O
Figure	O
5D	O
and	O
Figure	O
S5A	O
)	O
.	O

Upon	O
addition	O
of	O
inhibitors	O
to	O
other	O
signaling	O
pathways	O
,	O
including	O
a	O
p38	B-Protein
MAPK	I-Protein
inhibitor	O
,	O
SB203580	O
,	O
or	O
the	O
GSK3beta	B-Protein
inhibitor	O
,	O
CT99021	O
(	O
Bain	O
et	O
al	O
.	O
,	O
2007	O
)	O
,	O
no	O
effect	O
on	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
was	O
observed	O
(	O
Figure	O
S5B	O
)	O
.	O

Our	O
data	O
thus	O
suggested	O
that	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
cells	O
in	O
response	O
to	O
high	O
antigen	O
dose	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
requires	O
ERK1	B-Protein
and	O
ERK2	B-Protein
signaling	O
,	O
but	O
not	O
the	O
activation	O
of	O
the	O
p38	B-Protein
or	O
the	O
GSK3beta	B-Protein
pathways	O
.	O
<EOS>	B-X
Signal	B-X
transduction	B-X
proteins	B-X
including	B-X
those	B-X
in	B-X
the	B-X
Wnt	B-X
,	B-X
GSK-3β	B-X
,	B-X
PI3K-AKT	B-X
,	B-X
and	B-X
AMPK	B-X
pathways	B-X
are	B-X
involved	B-X
in	B-X
regulating	B-X
these	B-X
networks	B-X
.	B-X
Additionally	B-X
,	B-X
glycolytic	B-X
enzymes	B-X
and	B-X
metabolites	B-X
,	B-X
such	B-X
as	B-X
hexokinase	B-X
2	B-X
,	B-X
acetyl-CoA	B-X
,	B-X
and	B-X
enolase	B-X
2	B-X
,	B-X
are	B-X
implicated	B-X
in	B-X
the	B-X
modulation	B-X
of	B-X
cellular	B-X
function	B-X
,	B-X
microglial	B-X
activation	B-X
,	B-X
glycation	B-X
,	B-X
and	B-X
acetylation	B-X
of	B-X
biomolecules	B-X
.	B-X
This	B-X
review	B-X
characterizes	B-X
the	B-X
glucose	B-X
metabolism	B-X
networks	B-X
of	B-X
the	B-X
brain	B-X
based	B-X
on	B-X
molecular	B-X
signaling	B-X
and	B-X
cellular	B-X
and	B-X
regional	B-X
interactions	B-X
,	B-X
and	B-X
elucidates	B-X
glucose	B-X
metabolism-based	B-X
mechanisms	B-X
of	B-X
neurological	B-X
diseases	B-X
and	B-X
therapeutic	B-X
approaches	B-X
that	B-X
may	B-X
ameliorate	B-X
metabolic	B-X
abnormalities	B-X
in	B-X
those	B-X
diseases	B-X
.	B-X
In	B-X
recent	B-X
years	B-X
,	B-X
many	B-X
signaling	B-X
pathways	B-X
associated	B-X
with	B-X
AD	B-X
neuropathology	B-X
have	B-X
been	B-X
explored	B-X
as	B-X
possible	B-X
candidate	B-X
targets	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
this	B-X
condition	B-X
including	B-X
glycogen	B-X
synthase	B-X
kinase-3β	B-X
(	B-X
GSK3-β	B-X
)	B-X
.	B-X
GSK3-β	B-X
is	B-X
considered	B-X
a	B-X
key	B-X
player	B-X
in	B-X
AD	B-X
pathophysiology	B-X
since	B-X
dysregulation	B-X
of	B-X
this	B-X
kinase	B-X
influences	B-X
all	B-X
the	B-X
major	B-X
hallmarks	B-X
of	B-X
the	B-X
disease	B-X
including	B-X
:	B-X
tau	B-X
phosphorylation	B-X
,	B-X
amyloid-β	B-X
production	B-X
,	B-X
memory	B-X
,	B-X
neurogenesis	B-X
and	B-X
synaptic	B-X
function	B-X
.	B-X
The	B-X
present	B-X
review	B-X
summarizes	B-X
the	B-X
current	B-X
understanding	B-X
of	B-X
the	B-X
GSK3-β	B-X
neurobiology	B-X
with	B-X
particular	B-X
emphasis	B-X
on	B-X
its	B-X
effects	B-X
on	B-X
specific	B-X
signaling	B-X
pathways	B-X
associated	B-X
with	B-X
AD	B-X
pathophysiology	B-X
.	B-X

IL	B-Protein
-	I-Protein
10	I-Protein
Production	O
by	O
Th2	O
and	O
Th17	O
Cells	O
Also	O
Requires	O
ERK1	B-Protein
and	O
ERK2	B-Protein
Activation	O
<EOS>	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
producing	B-X
interleukin-10	B-X
(	B-X
IL-10	B-X
)	B-X
and	B-X
interferon-gamma	B-X
(	B-X
IFN-gamma	B-X
)	B-X
are	B-X
reported	B-X
in	B-X
chronic	B-X
infections	B-X
.	B-X
However	B-X
,	B-X
the	B-X
signals	B-X
that	B-X
direct	B-X
the	B-X
development	B-X
of	B-X
IL-10-producing	B-X
T	B-X
helper	B-X
1	B-X
(	B-X
Th1	B-X
)	B-X
cells	B-X
are	B-X
undefined	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
development	B-X
of	B-X
IL-10-producing	B-X
Th1	B-X
cells	B-X
required	B-X
high	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
ligation	B-X
,	B-X
sustained	B-X
ERK1	B-X
and	B-X
ERK2	B-X
MAP	B-X
kinases	B-X
phosphorylation	B-X
,	B-X
and	B-X
IL-12-induced	B-X
STAT4	B-X
transcription	B-X
factor	B-X
activation	B-X
.	B-X
Repeated	B-X
TCR	B-X
triggering	B-X
led	B-X
to	B-X
enhanced	B-X
IL-10	B-X
production	B-X
by	B-X
Th1	B-X
cells	B-X
,	B-X
and	B-X
continued	B-X
IL-12	B-X
action	B-X
and	B-X
high-dose	B-X
TCR	B-X
signaling	B-X
were	B-X
required	B-X
for	B-X
the	B-X
development	B-X
and	B-X
maintenance	B-X
of	B-X
IL-10-producing	B-X
Th1	B-X
cells	B-X
.	B-X
Although	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
and	B-X
Th17	B-X
cells	B-X
require	B-X
the	B-X
activation	B-X
of	B-X
distinct	B-X
STATs	B-X
for	B-X
their	B-X
differentiation	B-X
,	B-X
activation	B-X
of	B-X
ERK1	B-X
and	B-X
ERK2	B-X
was	B-X
a	B-X
common	B-X
requirement	B-X
for	B-X
production	B-X
of	B-X
IL-10	B-X
by	B-X
all	B-X
Th	B-X
cell	B-X
subsets	B-X
.	B-X
IL-10	B-X
expression	B-X
also	B-X
correlated	B-X
with	B-X
c-maf	B-X
expression	B-X
.	B-X
Despite	B-X
having	B-X
distinct	B-X
functions	B-X
in	B-X
protection	B-X
against	B-X
pathogens	B-X
,	B-X
all	B-X
Th	B-X
cells	B-X
share	B-X
the	B-X
important	B-X
task	B-X
of	B-X
controlling	B-X
overexuberant	B-X
immune	B-X
responses	B-X
by	B-X
means	B-X
of	B-X
IL-10	B-X
production	B-X
.	B-X

To	O
address	O
whether	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th2	O
and	O
Th17	O
cells	O
was	O
also	O
dependent	O
on	O
ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
,	O
we	O
differentiated	O
these	O
cells	O
with	O
anti	O
-	O
CD3	B-Protein
and	O
anti	O
-	O
CD28	B-Protein
in	O
the	O
absence	O
of	O
APCs	O
(	O
Shoemaker	O
et	O
al	O
.	O
,	O
2006	O
;	O
Veldhoen	O
et	O
al	O
.	O
,	O
2009	O
;	O
Veldhoen	O
et	O
al	O
.	O
,	O
2006	O
)	O
,	O
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
MEK	B-Protein
inhibitor	O
(	O
PD184352	O
)	O
.	O

We	O
showed	O
that	O
ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
is	O
a	O
common	O
pathway	O
required	O
for	O
induction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
different	O
Th	O
cell	O
subsets	O
because	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
both	O
Th2	O
and	O
Th17	O
cells	O
was	O
markedly	O
inhibited	O
in	O
the	O
presence	O
of	O
the	O
MEK	B-Protein
inhibitor	O
(	O
PD184352	O
)	O
(	O
Figure	O
5D	O
and	O
Figure	O
S5B	O
)	O
.	O

In	O
contrast	O
,	O
inhibitors	O
of	O
p38	B-Protein
MAPK	I-Protein
or	O
of	O
GSK	B-Protein
-	I-Protein
3beta	I-Protein
activation	O
did	O
not	O
affect	O
the	O
expression	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
by	O
these	O
subsets	O
(	O
Figure	O
S5B	O
)	O
.	O
<EOS>	B-X
Orally	B-X
available	B-X
small	B-X
molecule	B-X
compounds	B-X
have	B-X
recently	B-X
been	B-X
developed	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
RA	B-X
,	B-X
and	B-X
inhibitors	B-X
of	B-X
signalling	B-X
cascades	B-X
,	B-X
specifically	B-X
inhibitors	B-X
of	B-X
kinases	B-X
,	B-X
have	B-X
reached	B-X
advanced	B-X
stages	B-X
of	B-X
clinical	B-X
development	B-X
.	B-X
The	B-X
p38	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
blockers	B-X
have	B-X
shown	B-X
poor	B-X
clinical	B-X
response	B-X
despite	B-X
encouraging	B-X
preclinical	B-X
data	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
inhibitors	B-X
of	B-X
the	B-X
non-receptor	B-X
tyrosine	B-X
kinases	B-X
,	B-X
spleen	B-X
tyrosine	B-X
kinase	B-X
and	B-X
janus	B-X
kinase	B-X
3	B-X
,	B-X
have	B-X
demonstrated	B-X
a	B-X
significant	B-X
clinical	B-X
efficacy	B-X
together	B-X
with	B-X
an	B-X
acceptable	B-X
safety	B-X
profile	B-X
.	B-X
C16	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
manganese-induced	B-X
activation	B-X
of	B-X
the	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
/p38	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
pathway	B-X
,	B-X
indicating	B-X
that	B-X
PKR	B-X
functions	B-X
downstream	B-X
of	B-X
JNK	B-X
and	B-X
p38	B-X
MAPK	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
C16	B-X
triggered	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
p44/42	B-X
MAPK	B-X
(	B-X
ERK1/2	B-X
)	B-X
pathway	B-X
and	B-X
induced	B-X
hemoxygenase-1	B-X
,	B-X
both	B-X
in	B-X
the	B-X
absence	B-X
and	B-X
presence	B-X
of	B-X
manganese	B-X
.	B-X
Moreover	B-X
,	B-X
C16	B-X
did	B-X
not	B-X
affect	B-X
manganese-induced	B-X
ER	B-X
stress	B-X
at	B-X
concentrations	B-X
that	B-X
almost	B-X
prevented	B-X
caspase-3	B-X
activation	B-X
and	B-X
DNA	B-X
fragmentation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
PKR	B-X
is	B-X
involved	B-X
in	B-X
manganese-induced	B-X
apoptotic	B-X
cell	B-X
death	B-X
and	B-X
stress	B-X
response	B-X
,	B-X
such	B-X
as	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
p44/42	B-X
MAPK	B-X
pathway	B-X
and	B-X
the	B-X
induction	B-X
of	B-X
hemoxygenase-1	B-X
.	B-X

Activation	O
of	O
the	O
ERK1	B-Protein
and	O
ERK2	B-Protein
signaling	O
pathway	O
is	O
therefore	O
a	O
common	O
requirement	O
for	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
cells	O
.	O

c	B-Protein
-	I-Protein
maf	I-Protein
Expression	O
Correlates	O
with	O
IL	B-Protein
-	I-Protein
10	I-Protein
Production	O
in	O
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
Cells	O
<EOS>	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
producing	B-X
interleukin-10	B-X
(	B-X
IL-10	B-X
)	B-X
and	B-X
interferon-gamma	B-X
(	B-X
IFN-gamma	B-X
)	B-X
are	B-X
reported	B-X
in	B-X
chronic	B-X
infections	B-X
.	B-X
However	B-X
,	B-X
the	B-X
signals	B-X
that	B-X
direct	B-X
the	B-X
development	B-X
of	B-X
IL-10-producing	B-X
T	B-X
helper	B-X
1	B-X
(	B-X
Th1	B-X
)	B-X
cells	B-X
are	B-X
undefined	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
development	B-X
of	B-X
IL-10-producing	B-X
Th1	B-X
cells	B-X
required	B-X
high	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
ligation	B-X
,	B-X
sustained	B-X
ERK1	B-X
and	B-X
ERK2	B-X
MAP	B-X
kinases	B-X
phosphorylation	B-X
,	B-X
and	B-X
IL-12-induced	B-X
STAT4	B-X
transcription	B-X
factor	B-X
activation	B-X
.	B-X
Repeated	B-X
TCR	B-X
triggering	B-X
led	B-X
to	B-X
enhanced	B-X
IL-10	B-X
production	B-X
by	B-X
Th1	B-X
cells	B-X
,	B-X
and	B-X
continued	B-X
IL-12	B-X
action	B-X
and	B-X
high-dose	B-X
TCR	B-X
signaling	B-X
were	B-X
required	B-X
for	B-X
the	B-X
development	B-X
and	B-X
maintenance	B-X
of	B-X
IL-10-producing	B-X
Th1	B-X
cells	B-X
.	B-X
Although	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
and	B-X
Th17	B-X
cells	B-X
require	B-X
the	B-X
activation	B-X
of	B-X
distinct	B-X
STATs	B-X
for	B-X
their	B-X
differentiation	B-X
,	B-X
activation	B-X
of	B-X
ERK1	B-X
and	B-X
ERK2	B-X
was	B-X
a	B-X
common	B-X
requirement	B-X
for	B-X
production	B-X
of	B-X
IL-10	B-X
by	B-X
all	B-X
Th	B-X
cell	B-X
subsets	B-X
.	B-X
IL-10	B-X
expression	B-X
also	B-X
correlated	B-X
with	B-X
c-maf	B-X
expression	B-X
.	B-X
Despite	B-X
having	B-X
distinct	B-X
functions	B-X
in	B-X
protection	B-X
against	B-X
pathogens	B-X
,	B-X
all	B-X
Th	B-X
cells	B-X
share	B-X
the	B-X
important	B-X
task	B-X
of	B-X
controlling	B-X
overexuberant	B-X
immune	B-X
responses	B-X
by	B-X
means	B-X
of	B-X
IL-10	B-X
production	B-X
.	B-X

To	O
investigate	O
further	O
the	O
downstream	O
factors	O
involved	O
in	O
regulating	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
,	O
we	O
differentiated	O
DO11	O
.	O
10	O
CD4	B-Protein
+	O
T	O
cells	O
with	O
increasing	O
doses	O
of	O
OVA	B-Protein
,	O
in	O
the	O
presence	O
or	O
absence	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
,	O
and	O
quantified	O
the	O
expression	O
of	O
cytokines	O
and	O
transcription	O
factors	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O
<EOS>	B-X
We	B-X
previously	B-X
demonstrated	B-X
that	B-X
the	B-X
novel	B-X
guggulsterone	B-X
derivative	B-X
guggulsterone-52	B-X
(	B-X
GG-52	B-X
)	B-X
inhibited	B-X
the	B-X
activation	B-X
of	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-κB	B-X
signaling	B-X
in	B-X
intestinal	B-X
epithelial	B-X
cells	B-X
and	B-X
had	B-X
preventive	B-X
and	B-X
therapeutic	B-X
effects	B-X
on	B-X
dextran	B-X
sulfate	B-X
sodium-induced	B-X
acute	B-X
colitis	B-X
.	B-X
This	B-X
study	B-X
investigates	B-X
the	B-X
anti-inflammatory	B-X
effects	B-X
of	B-X
GG-52	B-X
on	B-X
bone	B-X
marrow-derived	B-X
dendritic	B-X
cells	B-X
(	B-X
BMDCs	B-X
)	B-X
and	B-X
chronic	B-X
colitis	B-X
in	B-X
IL-10	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
.	B-X

Low	O
-	O
dose	O
antigen	O
resulted	O
in	O
transcription	O
of	O
Il4	B-Protein
and	O
this	O
was	O
abrogated	O
by	O
both	O
high	O
antigen	O
doses	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
(	O
Figure	O
6A	O
)	O
.	O

A	O
low	O
amount	O
of	O
transcription	O
of	O
Ifngamma	B-Protein
was	O
induced	O
by	O
IL	B-Protein
-	I-Protein
12	I-Protein
when	O
cells	O
were	O
differentiated	O
with	O
low	O
antigen	O
dose	O
,	O
but	O
this	O
effect	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
was	O
markedly	O
upregulated	O
with	O
increasing	O
doses	O
of	O
antigen	O
(	O
Figure	O
6A	O
)	O
.	O

A	O
low	O
amount	O
of	O
Il10	B-Protein
transcription	O
was	O
observed	O
at	O
low	O
doses	O
of	O
antigen	O
accompanying	O
Il4	B-Protein
expression	O
(	O
Th2	O
cell	O
response	O
)	O
,	O
and	O
this	O
was	O
abrogated	O
by	O
increased	O
doses	O
of	O
antigen	O
as	O
was	O
Il4	B-Protein
expression	O
(	O
Figure	O
6A	O
)	O
.	O

At	O
low	O
doses	O
of	O
antigen	O
,	O
IL	B-Protein
-	I-Protein
12	I-Protein
had	O
little	O
effect	O
to	O
increase	O
IL	B-Protein
-	I-Protein
10	I-Protein
mRNA	O
expression	O
(	O
Figure	O
6A	O
)	O
in	O
keeping	O
with	O
the	O
protein	O
data	O
(	O
Figure	O
1A	O
)	O
.	O

However	O
,	O
IL	B-Protein
-	I-Protein
12	I-Protein
induced	O
a	O
high	O
amount	O
of	O
Il10	B-Protein
transcription	O
as	O
well	O
as	O
Ifngamma	B-Protein
expression	O
with	O
increased	O
antigen	O
doses	O
(	O
Figure	O
6A	O
)	O
,	O
again	O
in	O
keeping	O
with	O
the	O
protein	O
data	O
(	O
Figure	O
1A	O
)	O
.	O

CD4	B-Protein
+	O
T	O
cells	O
differentiated	O
with	O
increasing	O
doses	O
of	O
antigen	O
did	O
not	O
express	O
high	O
amounts	O
of	O
Tbx	B-Protein
-	I-Protein
21	I-Protein
(	O
T	B-Protein
-	I-Protein
bet	I-Protein
)	O
mRNA	O
,	O
unless	O
they	O
were	O
cocultured	O
with	O
IL	B-Protein
-	I-Protein
12	I-Protein
(	O
Figure	O
6B	O
)	O
.	O

In	O
contrast	O
,	O
high	O
amounts	O
of	O
GATA	B-Protein
-	I-Protein
3	I-Protein
mRNA	O
expression	O
were	O
only	O
observed	O
under	O
Th2	O
cell	O
differentiation	O
conditions	O
(	O
low	O
-	O
dose	O
antigen	O
)	O
(	O
Figure	O
6B	O
)	O
,	O
and	O
this	O
expression	O
was	O
markedly	O
downregulated	O
by	O
both	O
increasing	O
antigen	O
dose	O
and	O
coculture	O
in	O
IL	B-Protein
-	I-Protein
12	I-Protein
(	O
Figure	O
6B	O
)	O
.	O

Differentiation	O
of	O
T	O
cells	O
under	O
low	O
antigen	O
dose	O
led	O
to	O
expression	O
of	O
c	B-Protein
-	I-Protein
maf	I-Protein
,	O
in	O
keeping	O
with	O
the	O
Th2	O
cell	O
profile	O
(	O
Ho	O
et	O
al	O
.	O
,	O
1996	O
)	O
,	O
which	O
was	O
almost	O
completely	O
abrogated	O
by	O
increasing	O
doses	O
of	O
antigen	O
(	O
Figure	O
6B	O
)	O
.	O

Interestingly	O
,	O
IL	B-Protein
-	I-Protein
12	I-Protein
sustained	O
the	O
high	O
expression	O
of	O
c	B-Protein
-	I-Protein
Maf	I-Protein
mRNA	O
even	O
at	O
the	O
highest	O
antigen	O
dose	O
(	O
Figure	O
6B	O
)	O
.	O

Moreover	O
,	O
IL	B-Protein
-	I-Protein
12	I-Protein
maintenance	O
of	O
c	B-Protein
-	I-Protein
maf	I-Protein
expression	O
required	O
STAT4	B-Protein
activation	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
Th17	O
cells	O
that	O
expressed	O
IL	B-Protein
-	I-Protein
17a	I-Protein
as	O
well	O
as	O
IL	B-Protein
-	I-Protein
10	I-Protein
mRNA	O
(	O
Figure	O
6C	O
)	O
,	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
GATA	B-Protein
-	I-Protein
3	I-Protein
mRNA	O
were	O
undetectable	O
(	O
data	O
not	O
shown	O
)	O
,	O
whereas	O
that	O
of	O
ROR	B-Protein
-	I-Protein
gammat	I-Protein
was	O
high	O
(	O
Figure	O
6C	O
)	O
(	O
Ivanov	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

Th17	O
cells	O
also	O
expressed	O
high	O
amounts	O
of	O
c	B-Protein
-	I-Protein
maf	I-Protein
(	O
Figure	O
6C	O
)	O
,	O
confirming	O
a	O
recent	O
report	O
(	O
Bauquet	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

c	B-Protein
-	I-Protein
Maf	I-Protein
is	O
therefore	O
expressed	O
in	O
all	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
expressing	O
T	O
cell	O
populations	O
tested	O
(	O
Figures	O
6B	O
and	O
6C	O
)	O
and	O
may	O
not	O
be	O
just	O
a	O
Th2	O
cell	O
-	O
specific	O
transcription	O
factor	O
as	O
originally	O
thought	O
(	O
Ho	O
et	O
al	O
.	O
,	O
1996	O
)	O
.	O

We	O
showed	O
also	O
that	O
like	O
Il10	B-Protein
expression	O
,	O
c	B-Protein
-	I-Protein
maf	I-Protein
expression	O
was	O
inhibited	O
in	O
Th1	O
and	O
Th17	O
cells	O
in	O
the	O
presence	O
of	O
the	O
MEK1	B-Protein
and	O
MEK2	B-Protein
inhibitor	O
(	O
PD184352	O
)	O
,	O
whereas	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
RORgammat	B-Protein
expression	O
was	O
hardly	O
affected	O
(	O
Figure	O
6D	O
)	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
by	O
cells	O
of	O
the	O
innate	O
and	O
adaptive	O
immune	O
systems	O
reflects	O
the	O
importance	O
of	O
this	O
cytokine	O
in	O
the	O
tight	O
regulation	O
of	O
the	O
immune	O
response	O
,	O
to	O
minimize	O
pathology	O
during	O
infection	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
by	O
Th1	O
cells	O
has	O
been	O
reported	O
to	O
regulate	O
the	O
immune	O
response	O
in	O
leishmaniasis	O
and	O
toxoplasmosis	O
.	O

However	O
,	O
in	O
many	O
situations	O
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
is	O
not	O
produced	O
by	O
Th1	O
cells	O
in	O
response	O
to	O
antigenic	O
stimulation	O
.	O
<EOS>	B-X
This	B-X
review	B-X
focuses	B-X
on	B-X
CD9	B-X
expression	B-X
by	B-X
hematopoietic	B-X
cells	B-X
and	B-X
its	B-X
role	B-X
in	B-X
modulating	B-X
cellular	B-X
processes	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
inflammation	B-X
.	B-X
CD9	B-X
is	B-X
functionally	B-X
very	B-X
important	B-X
in	B-X
many	B-X
diseases	B-X
and	B-X
is	B-X
involved	B-X
either	B-X
in	B-X
the	B-X
regulation	B-X
or	B-X
in	B-X
the	B-X
mediation	B-X
of	B-X
the	B-X
disease	B-X
.	B-X
It	B-X
was	B-X
also	B-X
described	B-X
as	B-X
a	B-X
marker	B-X
of	B-X
murine	B-X
IL-10-competent	B-X
Breg	B-X
cells	B-X
and	B-X
IL-10-secreting	B-X
CD9	B-X
Critically	B-X
ill	B-X
COVID-19	B-X
patients	B-X
have	B-X
higher	B-X
pro-inflammatory	B-X
(	B-X
IL-1	B-X
,	B-X
IL-2	B-X
,	B-X
IL-6	B-X
,	B-X
tumor	B-X
necrosis	B-X
alpha	B-X
)	B-X
and	B-X
anti-inflammatory	B-X
(	B-X
IL-4	B-X
,	B-X
IL-10	B-X
)	B-X
cytokine	B-X
levels	B-X
,	B-X
less	B-X
CD	B-X

Our	O
goal	O
was	O
to	O
address	O
the	O
molecular	O
signals	O
that	O
determine	O
whether	O
Th1	O
cells	O
develop	O
to	O
produce	O
IL	B-Protein
-	I-Protein
10	I-Protein
(	O
Trinchieri	O
,	O
2007	O
)	O
.	O

Here	O
,	O
we	O
showed	O
that	O
Th1	O
cells	O
required	O
high	O
-	O
antigen	O
-	O
dose	O
-	O
induced	O
ERK1	B-Protein
and	O
ERK2	B-Protein
phosphorylation	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
-	O
induced	O
STAT	B-Protein
-	I-Protein
4	I-Protein
activation	O
to	O
produce	O
IL	B-Protein
-	I-Protein
10	I-Protein
.	O

Our	O
findings	O
that	O
ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
was	O
a	O
common	O
pathway	O
required	O
for	O
the	O
production	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
by	O
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
cell	O
subsets	O
,	O
which	O
differentiate	O
along	O
distinct	O
pathways	O
,	O
such	O
that	O
IL	B-Protein
-	I-Protein
10	I-Protein
provides	O
a	O
highly	O
regulated	O
feedback	O
loop	O
to	O
avoid	O
the	O
extremes	O
of	O
excessive	O
inflammation	O
or	O
chronic	O
infections	O
and	O
also	O
allow	O
a	O
protective	O
response	O
to	O
diverse	O
pathogens	O
.	O

In	O
certain	O
viral	O
or	O
parasitic	O
infections	O
(	O
Anderson	O
et	O
al	O
.	O
,	O
2007	O
;	O
Brooks	O
et	O
al	O
.	O
,	O
2006	O
;	O
Ejrnaes	O
et	O
al	O
.	O
,	O
2006	O
)	O
,	O
high	O
amounts	O
of	O
stimulation	O
may	O
lead	O
to	O
the	O
chronic	O
nonhealing	O
infection	O
shown	O
to	O
be	O
regulated	O
by	O
IL	B-Protein
-	I-Protein
10	I-Protein
.	O
<EOS>	B-X
Clinical	B-X
and	B-X
experimental	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
the	B-X
coronavirus	B-X
family	B-X
has	B-X
a	B-X
certain	B-X
tropism	B-X
for	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
.	B-X
Malignancies	B-X
were	B-X
one	B-X
of	B-X
the	B-X
earliest	B-X
recognized	B-X
manifestations	B-X
that	B-X
led	B-X
to	B-X
the	B-X
description	B-X
of	B-X
the	B-X
acquired	B-X
immune	B-X
deficiency	B-X
syndrome	B-X
(	B-X
AIDS	B-X
)	B-X
.	B-X
The	B-X
majority	B-X
of	B-X
cancers	B-X
in	B-X
AIDS	B-X
patients	B-X
are	B-X
associated	B-X
with	B-X
coinfection	B-X
with	B-X
oncogenic	B-X
viruses	B-X
,	B-X
such	B-X
as	B-X
Epstein-Barr	B-X
virus	B-X
,	B-X
human	B-X
herpesvirus	B-X
8	B-X
,	B-X
and	B-X
human	B-X
papillomavirus	B-X
,	B-X
with	B-X
resulting	B-X
malignancies	B-X
occurring	B-X
secondary	B-X
to	B-X
diminished	B-X
immune	B-X
surveillance	B-X
against	B-X
viruses	B-X
and	B-X
virus-infected	B-X
tumor	B-X
cells	B-X
.	B-X
Over	B-X
50	B-X
%	B-X
of	B-X
AIDS	B-X
lymphomas	B-X
are	B-X
associated	B-X
with	B-X
Epstein-Barr	B-X
virus	B-X
(	B-X
EBV	B-X
)	B-X
and/or	B-X
HHV8	B-X
infection	B-X
.	B-X
EBV	B-X
is	B-X
associated	B-X
with	B-X
several	B-X
malignancies	B-X
,	B-X
including	B-X
Hodgkin	B-X
lymphoma	B-X
(	B-X
HL	B-X
)	B-X
and	B-X
non-Hodgkin	B-X
lymphoma	B-X
(	B-X
NHL	B-X
)	B-X
.	B-X
Coinfection	B-X
with	B-X
HIV	B-X
and	B-X
HPV	B-X
is	B-X
associated	B-X
with	B-X
an	B-X
increased	B-X
risk	B-X
of	B-X
various	B-X
squamous	B-X
cell	B-X
carcinomas	B-X
of	B-X
epithelial	B-X
tissues	B-X
.	B-X
HAART	B-X
has	B-X
significantly	B-X
impacted	B-X
the	B-X
incidence	B-X
,	B-X
management	B-X
,	B-X
and	B-X
prognosis	B-X
of	B-X
AIDS-related	B-X
malignancies	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
changing	B-X
the	B-X
natural	B-X
history	B-X
of	B-X
HIV	B-X
infection	B-X
in	B-X
regard	B-X
to	B-X
incidence	B-X
and	B-X
survival	B-X
,	B-X
HAART	B-X
has	B-X
dramatically	B-X
decreased	B-X
the	B-X
incidence	B-X
of	B-X
certain	B-X
virally	B-X
mediated	B-X
HIV-associated	B-X
malignancies	B-X
such	B-X
as	B-X
KS	B-X
and	B-X
primary	B-X
CNS	B-X
lymphoma	B-X
.	B-X
The	B-X
beneficial	B-X
effects	B-X
of	B-X
HAART	B-X
on	B-X
these	B-X
tumors	B-X
are	B-X
attributed	B-X
to	B-X
drug-mediated	B-X
HIV	B-X
suppression	B-X
and	B-X
immune	B-X
reconstitution	B-X
.	B-X
However	B-X
,	B-X
HAART	B-X
has	B-X
had	B-X
a	B-X
less	B-X
favorable	B-X
impact	B-X
on	B-X
EBV-	B-X
and	B-X
HPV-related	B-X
malignancies	B-X
.	B-X
This	B-X
chapter	B-X
presents	B-X
an	B-X
overview	B-X
of	B-X
HIV-associated	B-X
malignancies	B-X
mediated	B-X
by	B-X
HHV-8	B-X
,	B-X
EBV	B-X
,	B-X
and	B-X
HPV	B-X
,	B-X
and	B-X
reviews	B-X
the	B-X
effect	B-X
of	B-X
HAART	B-X
on	B-X
the	B-X
epidemiology	B-X
,	B-X
presentation	B-X
,	B-X
treatment	B-X
,	B-X
and	B-X
outcomes	B-X
of	B-X
these	B-X
cancers	B-X
.	B-X

During	O
the	O
course	O
of	O
infection	O
,	O
after	O
initial	O
triggering	O
with	O
antigen	O
,	O
T	O
cells	O
migrate	O
to	O
the	O
tissue	O
encountering	O
high	O
doses	O
of	O
antigen	O
and	O
factors	O
produced	O
by	O
the	O
innate	O
immune	O
response	O
.	O

Under	O
these	O
conditions	O
,	O
we	O
speculate	O
that	O
Th1	O
cells	O
will	O
be	O
induced	O
to	O
express	O
high	O
amounts	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
in	O
keeping	O
with	O
reports	O
that	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
were	O
found	O
in	O
CD4	B-Protein
+	O
clones	O
isolated	O
from	O
BAL	O
but	O
not	O
blood	O
of	O
TB	O
patients	O
(	O
Gerosa	O
et	O
al	O
.	O
,	O
1999	O
)	O
.	O

Similarly	O
,	O
the	O
immune	O
response	O
to	O
a	O
clinical	O
isolate	O
of	O
L	O
.	O
major	O
,	O
which	O
produces	O
heavily	O
infected	O
nonhealing	O
lesions	O
,	O
was	O
found	O
to	O
be	O
regulated	O
by	O
IL	B-Protein
-	I-Protein
10	I-Protein
derived	O
from	O
Foxp3	B-Protein
-	O
Th1	O
cells	O
that	O
coproduce	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
(	O
Anderson	O
et	O
al	O
.	O
,	O
2007	O
)	O
,	O
and	O
the	O
immune	O
response	O
during	O
T	O
.	O
gondii	O
infection	O
was	O
found	O
also	O
to	O
be	O
regulated	O
by	O
Foxp3	B-Protein
-	O
Th1	O
cells	O
(	O
Jankovic	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

It	O
is	O
likely	O
that	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
cells	O
is	O
evoked	O
under	O
conditions	O
of	O
high	O
inflammation	O
and	O
antigenic	O
stimulation	O
,	O
whereas	O
regulatory	O
CD4	B-Protein
+	O
T	O
cells	O
producing	O
IL	B-Protein
-	I-Protein
10	I-Protein
may	O
operate	O
to	O
regulate	O
the	O
immune	O
response	O
under	O
conditions	O
in	O
which	O
the	O
pathogen	O
is	O
clinically	O
controlled	O
,	O
such	O
as	O
in	O
infection	O
with	O
L	O
.	O
major	O
(	O
Friedlin	O
strain	O
)	O
(	O
Belkaid	O
et	O
al	O
.	O
,	O
2002	O
;	O
Suffia	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

We	O
now	O
also	O
reported	O
that	O
CD4	B-Protein
+	O
T	O
cells	O
cultured	O
with	O
high	O
antigen	O
dose	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
differentiate	O
into	O
canonical	O
Th1	O
effector	O
cells	O
,	O
which	O
,	O
in	O
addition	O
to	O
expressing	O
large	O
amounts	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
lose	O
their	O
IL	B-Protein
-	I-Protein
2	I-Protein
expression	O
as	O
described	O
before	O
in	O
certain	O
chronic	O
infection	O
models	O
(	O
Sallusto	O
et	O
al	O
.	O
,	O
2004	O
)	O
.	O

Our	O
demonstration	O
that	O
loss	O
of	O
IL	B-Protein
-	I-Protein
2	I-Protein
is	O
accompanied	O
by	O
production	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
offers	O
potential	O
additional	O
mechanisms	O
whereby	O
effector	O
T	O
cell	O
responses	O
may	O
be	O
dampened	O
during	O
chronic	O
disease	O
.	O

Using	O
an	O
in	O
vivo	O
transfer	O
model	O
of	O
DO11	O
.	O
10	O
TCR	O
transgenic	O
cells	O
(	O
Castro	O
et	O
al	O
.	O
,	O
2000	O
)	O
,	O
we	O
showed	O
that	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
cells	O
were	O
differentiated	O
in	O
the	O
presence	O
of	O
high	O
doses	O
of	O
OVA	B-Protein
protein	O
and	O
LPS	O
.	O

We	O
showed	O
here	O
that	O
this	O
induction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
Th1	O
cells	O
in	O
vivo	O
was	O
markedly	O
,	O
but	O
not	O
totally	O
,	O
reduced	O
in	O
STAT4	B-Protein
-	O
deficient	O
T	O
cells	O
as	O
observed	O
during	O
T	O
.	O
gondii	O
infection	O
(	O
Jankovic	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
have	B-X
determined	B-X
that	B-X
the	B-X
absence	B-X
of	B-X
MyD88	B-X
enhances	B-X
the	B-X
tolerogenicity	B-X
of	B-X
dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
,	B-X
suggesting	B-X
that	B-X
inhibiting	B-X
innate	B-X
immunity	B-X
may	B-X
be	B-X
a	B-X
potential	B-X
strategy	B-X
to	B-X
facilitate	B-X
the	B-X
induction	B-X
of	B-X
transplant	B-X
tolerance	B-X
by	B-X
DCs	B-X
.	B-X
Studies	B-X
have	B-X
indicated	B-X
that	B-X
there	B-X
is	B-X
a	B-X
development	B-X
of	B-X
generalized	B-X
immune	B-X
dysfunction	B-X
after	B-X
septic	B-X
insult	B-X
.	B-X
Recently	B-X
,	B-X
accumulating	B-X
evidence	B-X
shows	B-X
that	B-X
several	B-X
lymphocyte	B-X
subpopulations	B-X
such	B-X
as	B-X
NKT-	B-X
,	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
-Th2-T-	B-X
,	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
-T-	B-X
,	B-X
gammadelta-T-	B-X
,	B-X
and	B-X
CD4+	B-X
CD25+	B-X
T	B-X
regulatory	B-X
cells	B-X
are	B-X
capable	B-X
of	B-X
actively	B-X
contributing	B-X
to	B-X
the	B-X
induction	B-X
of	B-X
septic	B-X
immune	B-X
suppression	B-X
.	B-X
Thus	B-X
,	B-X
our	B-X
aim	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
contribution	B-X
of	B-X
CD4+	B-X
CD25+	B-X
cells	B-X
to	B-X
the	B-X
immune	B-X
dysfunction	B-X
seen	B-X
in	B-X
sepsis	B-X
.	B-X
To	B-X
study	B-X
this	B-X
,	B-X
C57BL/6J	B-X
,	B-X
C57BL/6-Il6	B-X
(	B-X
tm1Kopf	B-X
)	B-X
(	B-X
interleukin	B-X
[	B-X
IL	B-X
]	B-X
6	B-X
-/-	B-X
)	B-X
,	B-X
and	B-X
C57BL/6-Il10	B-X
(	B-X
tm1Cgn	B-X
)	B-X
(	B-X
IL-10	B-X
-/-	B-X
)	B-X
mice	B-X
were	B-X
subjected	B-X
to	B-X
cecal	B-X
ligation	B-X
and	B-X
puncture	B-X
(	B-X
CLP	B-X
)	B-X
or	B-X
sham	B-X
operations	B-X
.	B-X
CD4+	B-X
CD25-	B-X
cells	B-X
from	B-X
sham	B-X
and	B-X
CLP	B-X
mice	B-X
proliferated	B-X
equally	B-X
.	B-X
However	B-X
,	B-X
coculture	B-X
of	B-X
CD4+	B-X
CD25-	B-X
with	B-X
CD4+	B-X
CD25+	B-X
cells	B-X
suppressed	B-X
their	B-X
proliferation	B-X
in	B-X
both	B-X
sham	B-X
and	B-X
CLP	B-X
mice	B-X
.	B-X
Depletion	B-X
of	B-X
CD25+	B-X
cells	B-X
in	B-X
vivo	B-X
before	B-X
CLP	B-X
markedly	B-X
restored	B-X
CD4+	B-X
CD25-	B-X
proliferative	B-X
capacity	B-X
and	B-X
Th1	B-X
cytokine	B-X
release	B-X
while	B-X
not	B-X
altering	B-X
plasma	B-X
proinflammatory	B-X
cytokine	B-X
levels	B-X
.	B-X
Subsequently	B-X
,	B-X
IL-6	B-X
-/-	B-X
and	B-X
IL-10	B-X
-/-	B-X
mice	B-X
were	B-X
used	B-X
to	B-X
elucidate	B-X
the	B-X
possible	B-X
mediator	B-X
(	B-X
s	B-X
)	B-X
regulating	B-X
the	B-X
changes	B-X
seen	B-X
after	B-X
sepsis	B-X
.	B-X
Although	B-X
CD4+	B-X
CD25+	B-X
cells	B-X
increased	B-X
after	B-X
septic	B-X
insult	B-X
in	B-X
both	B-X
C57BL/6J	B-X
and	B-X
IL-6	B-X
-/-	B-X
mice	B-X
,	B-X
this	B-X
was	B-X
not	B-X
observed	B-X
in	B-X
IL-10	B-X
-/-	B-X
mice	B-X
.	B-X
Similarly	B-X
,	B-X
in	B-X
vitro	B-X
proliferation	B-X
studies	B-X
showed	B-X
that	B-X
proliferation	B-X
index	B-X
increased	B-X
in	B-X
CD4+	B-X
CD25+	B-X
cells	B-X
from	B-X
septic	B-X
C57BL/6J	B-X
and	B-X
IL6	B-X
-/-	B-X
mice	B-X
,	B-X
but	B-X
it	B-X
remained	B-X
the	B-X
same	B-X
in	B-X
IL-10	B-X
-/-	B-X
mice	B-X
.	B-X
Surprisingly	B-X
,	B-X
depletion	B-X
of	B-X
CD25+	B-X
cells	B-X
before	B-X
inducing	B-X
sepsis	B-X
did	B-X
not	B-X
alter	B-X
septic	B-X
mortality	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
suggest	B-X
that	B-X
although	B-X
CD4+	B-X
CD25+	B-X
T	B-X
regulatory	B-X
cells	B-X
induced	B-X
by	B-X
IL-10	B-X
seem	B-X
to	B-X
contribute	B-X
to	B-X
aspects	B-X
of	B-X
sepsis-induced	B-X
lymphoid	B-X
immune	B-X
suppression	B-X
,	B-X
the	B-X
oblation	B-X
of	B-X
CD25+	B-X
cells	B-X
does	B-X
not	B-X
provide	B-X
a	B-X
survival	B-X
advantage	B-X
or	B-X
disadvantage	B-X
.	B-X

A	O
high	O
antigenic	O
activation	O
during	O
T	O
.	O
gondii	O
infection	O
or	O
high	O
antigen	O
doses	O
delivered	O
in	O
the	O
presence	O
of	O
LPS	O
,	O
as	O
seen	O
in	O
our	O
system	O
,	O
may	O
compensate	O
for	O
an	O
absolute	O
requirement	O
for	O
IL	B-Protein
-	I-Protein
12	I-Protein
in	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
by	O
Th1	O
cells	O
.	O

In	O
our	O
in	O
vitro	O
system	O
,	O
repeated	O
stimulation	O
of	O
Th1	O
cells	O
with	O
high	O
antigen	O
doses	O
allowed	O
the	O
development	O
of	O
Th1	O
cells	O
producing	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
an	O
IL	B-Protein
-	I-Protein
12	I-Protein
-	O
dependent	O
manner	O
.	O

IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
Th1	O
cells	O
induced	O
by	O
high	O
antigen	O
dose	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
was	O
independent	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
,	O
in	O
keeping	O
with	O
previous	O
findings	O
(	O
Jankovic	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O

However	O
,	O
a	O
role	O
for	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
in	O
mediating	O
IL	B-Protein
-	I-Protein
10	I-Protein
reactivation	O
by	O
Th1	O
cells	O
during	O
secondary	O
infection	O
with	O
T	O
.	O
gondii	O
has	O
been	O
suggested	O
(	O
Shaw	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

We	O
have	O
found	O
that	O
CD4	B-Protein
+	O
T	O
cells	O
exposed	O
to	O
a	O
high	O
dose	O
of	O
antigen	O
do	O
not	O
express	O
IL	B-Protein
-	I-Protein
10	I-Protein
upon	O
restimulation	O
,	O
but	O
can	O
be	O
induced	O
to	O
produce	O
IL	B-Protein
-	I-Protein
10	I-Protein
upon	O
re	O
-	O
exposure	O
to	O
a	O
high	O
dose	O
of	O
antigen	O
in	O
the	O
recall	O
phase	O
in	O
the	O
absence	O
of	O
added	O
IL	B-Protein
-	I-Protein
12	I-Protein
.	O
<EOS>	B-X
We	B-X
find	B-X
that	B-X
bendiocarb	B-X
is	B-X
present	B-X
at	B-X
high	B-X
levels	B-X
in	B-X
maternal	B-X
,	B-X
umbilical	B-X
cord	B-X
,	B-X
and	B-X
infant	B-X
plasma	B-X
of	B-X
individuals	B-X
exposed	B-X
during	B-X
pregnancy	B-X
,	B-X
indicating	B-X
that	B-X
it	B-X
is	B-X
systemically	B-X
absorbed	B-X
and	B-X
trans-placentally	B-X
transferred	B-X
to	B-X
the	B-X
fetus	B-X
.	B-X
Moreover	B-X
,	B-X
bendiocarb	B-X
exposure	B-X
is	B-X
associated	B-X
with	B-X
numerous	B-X
changes	B-X
in	B-X
fetal	B-X
immune	B-X
cell	B-X
homeostasis	B-X
and	B-X
function	B-X
,	B-X
including	B-X
a	B-X
dose-dependent	B-X
decrease	B-X
in	B-X
regulatory	B-X
CD4	B-X
T	B-X
cells	B-X
,	B-X
increased	B-X
cytokine	B-X
production	B-X
,	B-X
and	B-X
inhibition	B-X
of	B-X
antigen-driven	B-X
proliferation	B-X
.	B-X
Additionally	B-X
,	B-X
prenatal	B-X
bendiocarb	B-X
exposure	B-X
is	B-X
associated	B-X
with	B-X
higher	B-X
post-vaccination	B-X
measles	B-X
titers	B-X
at	B-X
one	B-X
year	B-X
of	B-X
age	B-X
,	B-X
suggesting	B-X
that	B-X
its	B-X
impact	B-X
on	B-X
functional	B-X
immunity	B-X
may	B-X
persist	B-X
for	B-X
many	B-X
months	B-X
after	B-X
birth	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
in	B-X
utero	B-X
bendiocarb	B-X
exposure	B-X
has	B-X
multiple	B-X
previously	B-X
unrecognized	B-X
biological	B-X
effects	B-X
on	B-X
the	B-X
fetal	B-X
immune	B-X
system	B-X
.	B-X

However	O
,	O
this	O
is	O
dependent	O
on	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
by	O
antigen	O
-	O
presenting	O
DCs	O
.	O
<EOS>	B-X
Dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
are	B-X
the	B-X
dominant	B-X
class	B-X
of	B-X
antigen-presenting	B-X
cells	B-X
in	B-X
humans	B-X
and	B-X
are	B-X
largely	B-X
responsible	B-X
for	B-X
the	B-X
initiation	B-X
and	B-X
guidance	B-X
of	B-X
innate	B-X
and	B-X
adaptive	B-X
immune	B-X
responses	B-X
involved	B-X
in	B-X
maintenance	B-X
of	B-X
immunological	B-X
homeostasis	B-X
.	B-X
Immature	B-X
dendritic	B-X
cells	B-X
(	B-X
iDCs	B-X
)	B-X
phagocytize	B-X
pathogens	B-X
and	B-X
toxic	B-X
proteins	B-X
and	B-X
in	B-X
endosomal	B-X
vesicles	B-X
degrade	B-X
them	B-X
into	B-X
small	B-X
fragments	B-X
for	B-X
presentation	B-X
on	B-X
major	B-X
histocompatibility	B-X
complex	B-X
(	B-X
MHC	B-X
)	B-X
II	B-X
receptor	B-X
molecules	B-X
to	B-X
naïve	B-X
cognate	B-X
T	B-X
cells	B-X
(	B-X
Th0	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
their	B-X
role	B-X
in	B-X
stimulation	B-X
of	B-X
immunity	B-X
,	B-X
DCs	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
induction	B-X
and	B-X
maintenance	B-X
of	B-X
immune	B-X
tolerance	B-X
toward	B-X
self-antigens	B-X
.	B-X
During	B-X
activation	B-X
,	B-X
the	B-X
iDCs	B-X
become	B-X
mature	B-X
.	B-X
Maturation	B-X
begins	B-X
when	B-X
the	B-X
DCs	B-X
cease	B-X
taking	B-X
up	B-X
antigens	B-X
and	B-X
begin	B-X
to	B-X
migrate	B-X
from	B-X
their	B-X
location	B-X
in	B-X
peripheral	B-X
tissues	B-X
to	B-X
adjacent	B-X
lymph	B-X
nodes	B-X
or	B-X
the	B-X
spleen	B-X
where	B-X
during	B-X
their	B-X
continued	B-X
maturation	B-X
the	B-X
DCs	B-X
present	B-X
stored	B-X
antigens	B-X
on	B-X
surface	B-X
MHCII	B-X
receptor	B-X
molecules	B-X
to	B-X
naive	B-X
Th0	B-X
cells	B-X
.	B-X
During	B-X
antigen	B-X
presentation	B-X
,	B-X
the	B-X
DCs	B-X
upregulate	B-X
the	B-X
biosynthesis	B-X
of	B-X
costimulatory	B-X
receptor	B-X
molecules	B-X
CD86	B-X
,	B-X
CD80	B-X
,	B-X
CD83	B-X
,	B-X
and	B-X
CD40	B-X
on	B-X
their	B-X
plasma	B-X
membrane	B-X
.	B-X
These	B-X
activated	B-X
DC	B-X
receptor	B-X
molecules	B-X
bind	B-X
cognate	B-X
CD28	B-X
receptors	B-X
presented	B-X
on	B-X
the	B-X
Th0	B-X
cell	B-X
membrane	B-X
,	B-X
which	B-X
triggers	B-X
DC	B-X
secretion	B-X
of	B-X
IL-12	B-X
or	B-X
IL-10	B-X
cytokines	B-X
resulting	B-X
in	B-X
T	B-X
cell	B-X
differentiation	B-X
into	B-X
pro-	B-X
or	B-X
anti-inflammatory	B-X
T	B-X
cell	B-X
subsets	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
detail	B-X
what	B-X
is	B-X
known	B-X
about	B-X
the	B-X
process	B-X
of	B-X
DC	B-X
maturation	B-X
and	B-X
its	B-X
role	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
insulin-dependent	B-X
diabetes	B-X
mellitus	B-X
autoimmunity	B-X
.	B-X

The	O
combination	O
of	O
both	O
high	O
antigen	O
dose	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
resulted	O
in	O
the	O
highest	O
levels	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
and	O
correlated	O
with	O
the	O
high	O
levels	O
of	O
ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
.	O

The	O
increased	O
expression	O
of	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
observed	O
during	O
the	O
secondary	O
phase	O
will	O
induce	O
increased	O
IL	B-Protein
-	I-Protein
12	I-Protein
production	O
by	O
DCs	O
and	O
suggests	O
that	O
repeated	O
high	O
-	O
level	O
TCR	O
activation	O
feeds	O
back	O
to	O
upregulate	O
IL	B-Protein
-	I-Protein
12	I-Protein
production	O
by	O
DC	O
.	O

It	O
is	O
thus	O
likely	O
that	O
in	O
T	O
.	O
gondii	O
infection	O
in	O
vivo	O
(	O
Shaw	O
et	O
al	O
.	O
,	O
2006	O
)	O
,	O
the	O
requirement	O
for	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
to	O
induce	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
was	O
for	O
feedback	O
upregulation	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
by	O
DCs	O
,	O
which	O
in	O
turn	O
induced	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
the	O
Th1	O
cells	O
.	O

Although	O
IL	B-Protein
-	I-Protein
10	I-Protein
may	O
be	O
differentially	O
regulated	O
in	O
Th1	O
and	O
Th2	O
cells	O
as	O
has	O
been	O
reported	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2007	O
;	O
Wang	O
et	O
al	O
.	O
,	O
2005	O
)	O
,	O
some	O
studies	O
suggest	O
the	O
existence	O
of	O
common	O
pathways	O
,	O
but	O
the	O
molecular	O
basis	O
for	O
these	O
is	O
as	O
yet	O
unclear	O
.	O

Costimulatory	O
OX	B-Protein
-	I-Protein
40	I-Protein
signals	O
have	O
been	O
shown	O
to	O
negatively	O
regulate	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
(	O
Ito	O
et	O
al	O
.	O
,	O
2005	O
)	O
both	O
in	O
Th1	O
and	O
Th2	O
cells	O
,	O
whereas	O
ICOS	B-Protein
signaling	O
has	O
been	O
suggested	O
to	O
induce	O
IL	B-Protein
-	I-Protein
10	I-Protein
(	O
Ito	O
et	O
al	O
.	O
,	O
2007	O
;	O
Witsch	O
et	O
al	O
.	O
,	O
2002	O
)	O
in	O
both	O
Th1	O
and	O
Th2	O
cells	O
.	O

However	O
,	O
in	O
some	O
cases	O
,	O
ICOS	B-Protein
signaling	O
also	O
regulates	O
IL	B-Protein
-	I-Protein
4	I-Protein
production	O
and	O
Th2	O
responses	O
(	O
Greenwald	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O

We	O
now	O
provide	O
a	O
common	O
mechanism	O
of	O
ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
for	O
the	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
in	O
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
cells	O
,	O
although	O
each	O
subset	O
differentiates	O
along	O
a	O
distinct	O
and	O
subset	O
-	O
specific	O
transcriptional	O
pathway	O
.	O

This	O
reinforces	O
the	O
fact	O
that	O
IL	B-Protein
-	I-Protein
10	I-Protein
is	O
not	O
a	O
Th	O
cell	O
-	O
subset	O
-	O
specific	O
cytokine	O
,	O
but	O
instead	O
is	O
produced	O
in	O
a	O
tightly	O
regulated	O
fashion	O
during	O
each	O
differentiation	O
pathway	O
.	O
<EOS>	B-X
We	B-X
have	B-X
read	B-X
with	B-X
great	B-X
interest	B-X
the	B-X
article	B-X
entitled	B-X
``	B-X
Identification	B-X
of	B-X
an	B-X
immune-related	B-X
signature	B-X
indicating	B-X
the	B-X
dedifferentiation	B-X
of	B-X
thyroid	B-X
cells	B-X
''	B-X
by	B-X
Wang	B-X
et	B-X
al	B-X
.	B-X
Their	B-X
data	B-X
reinforce	B-X
our	B-X
own	B-X
previous	B-X
results	B-X
,	B-X
here	B-X
compiled	B-X
.	B-X
Anaplastic	B-X
thyroid	B-X
carcinoma	B-X
had	B-X
higher	B-X
stromal	B-X
scores	B-X
,	B-X
immune	B-X
scores	B-X
and	B-X
enrichment	B-X
of	B-X
most	B-X
immune	B-X
cells	B-X
than	B-X
the	B-X
control	B-X
groups	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
immune	B-X
microenvironment	B-X
may	B-X
correlate	B-X
with	B-X
differentiation	B-X
status	B-X
in	B-X
thyroid	B-X
cancer	B-X
.	B-X
We	B-X
previously	B-X
demonstrated	B-X
that	B-X
the	B-X
differentiation	B-X
status	B-X
expressed	B-X
by	B-X
the	B-X
pattern	B-X
of	B-X
protein	B-X
expression	B-X
may	B-X
be	B-X
related	B-X
to	B-X
the	B-X
profile	B-X
of	B-X
immune	B-X
cell	B-X
infiltration	B-X
of	B-X
differentiated	B-X
thyroid	B-X
carcinoma	B-X
.	B-X
Among	B-X
the	B-X
distinct	B-X
signaling	B-X
pathways	B-X
enriched	B-X
in	B-X
the	B-X
high-risk	B-X
score	B-X
group	B-X
,	B-X
the	B-X
epithelial	B-X
to	B-X
mesenchymal	B-X
transition	B-X
,	B-X
TNFα	B-X
signaling	B-X
,	B-X
and	B-X
some	B-X
common	B-X
immune-related	B-X
signaling	B-X
pathways	B-X
,	B-X
including	B-X
the	B-X
IL-6/JAK/STAT3	B-X
pathway	B-X
,	B-X
interferon	B-X
alpha	B-X
response	B-X
,	B-X
interferon	B-X
gamma	B-X
response	B-X
and	B-X
inflammatory	B-X
response	B-X
were	B-X
observed	B-X
with	B-X
high	B-X
normalized	B-X
enrichment	B-X
score	B-X
.	B-X
We	B-X
also	B-X
investigated	B-X
the	B-X
IL-6	B-X
protein	B-X
immune-histochemical	B-X
expression	B-X
in	B-X
a	B-X
retrospective	B-X
study	B-X
of	B-X
114	B-X
patients	B-X
with	B-X
papillary	B-X
thyroid	B-X
carcinoma	B-X
and	B-X
39	B-X
patients	B-X
with	B-X
follicular	B-X
thyroid	B-X
carcinoma	B-X
.	B-X
We	B-X
found	B-X
IL-6	B-X
more	B-X
frequently	B-X
positive	B-X
among	B-X
malignant	B-X
tumors	B-X
than	B-X
non-malignant	B-X
samples	B-X
.	B-X
We	B-X
demonstrated	B-X
that	B-X
IL-6	B-X
positivity	B-X
was	B-X
associated	B-X
with	B-X
infiltration	B-X
of	B-X
CD3	B-X
+	B-X
cells	B-X
,	B-X
CD16	B-X
+	B-X
cells	B-X
and	B-X
CD68	B-X
+	B-X
macrophages	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
IL-6	B-X
expression	B-X
was	B-X
associated	B-X
with	B-X
infiltration	B-X
of	B-X
activated	B-X
lymphocytes	B-X
such	B-X
as	B-X
Granzyme	B-X
B	B-X
+	B-X
cells	B-X
and	B-X
CD69	B-X
+	B-X
cells	B-X
.	B-X
IL-6	B-X
positivity	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
infiltration	B-X
of	B-X
CD4+	B-X
,	B-X
CD8+	B-X
,	B-X
CD20+	B-X
,	B-X
FOXP3+	B-X
,	B-X
CD25	B-X
+	B-X
cells	B-X
but	B-X
IL-6	B-X
was	B-X
associated	B-X
with	B-X
tumor	B-X
expression	B-X
of	B-X
PD-L1	B-X
,	B-X
FOXP3	B-X
,	B-X
IL-17	B-X
,	B-X
COX2	B-X
,	B-X
IL-1β	B-X
,	B-X
IL-10	B-X
,	B-X
CD134	B-X
,	B-X
IL-23	B-X
.	B-X
beautiful	B-X
data	B-X
reinforce	B-X
the	B-X
seminal	B-X
idea	B-X
that	B-X
the	B-X
immune	B-X
landscape	B-X
is	B-X
closely	B-X
related	B-X
to	B-X
the	B-X
differentiation	B-X
status	B-X
of	B-X
the	B-X
tumor	B-X
.	B-X
This	B-X
concept	B-X
may	B-X
help	B-X
select	B-X
individuals	B-X
who	B-X
deserve	B-X
more	B-X
careful	B-X
attention	B-X
,	B-X
an	B-X
essential	B-X
point	B-X
in	B-X
the	B-X
management	B-X
of	B-X
patients	B-X
with	B-X
mostly	B-X
indolent	B-X
tumors	B-X
such	B-X
as	B-X
those	B-X
of	B-X
the	B-X
thyroid	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
our	B-X
results	B-X
,	B-X
here	B-X
compiled	B-X
,	B-X
were	B-X
obtained	B-X
with	B-X
immune-histochemistry	B-X
,	B-X
a	B-X
routine	B-X
laboratory	B-X
technique	B-X
that	B-X
offers	B-X
the	B-X
possibility	B-X
of	B-X
simpler	B-X
and	B-X
practical	B-X
execution	B-X
.	B-X

Of	O
note	O
,	O
a	O
role	O
for	O
ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
in	O
the	O
induction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
has	O
already	O
been	O
described	O
for	O
macrophages	O
and	O
DC	O
(	O
Agrawal	O
et	O
al	O
.	O
,	O
2006	O
;	O
Hacker	O
et	O
al	O
.	O
,	O
1999	O
)	O
.	O

Differential	O
transcriptional	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
in	O
Th1	O
and	O
Th2	O
cells	O
has	O
been	O
suggested	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2007	O
;	O
Wang	O
et	O
al	O
.	O
,	O
2005	O
)	O
,	O
and	O
extensive	O
histone	B-Protein
acetylation	O
of	O
the	O
IL	B-Protein
-	I-Protein
10	I-Protein
gene	O
is	O
detectable	O
in	O
fully	O
polarized	O
Th2	O
cells	O
,	O
but	O
not	O
Th1	O
cells	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

We	O
provide	O
evidence	O
that	O
IL	B-Protein
-	I-Protein
10	I-Protein
is	O
produced	O
in	O
canonical	O
Th1	O
cells	O
and	O
that	O
its	O
expression	O
correlates	O
with	O
the	O
expression	O
of	O
T	B-Protein
-	I-Protein
bet	I-Protein
and	O
the	O
highest	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
production	O
,	O
in	O
keeping	O
with	O
our	O
observations	O
that	O
high	O
-	O
dose	O
antigen	O
stimulation	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
signaling	O
are	O
required	O
for	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
expression	O
.	O

It	O
has	O
also	O
been	O
shown	O
that	O
maintenance	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
is	O
conditional	O
on	O
IL	B-Protein
-	I-Protein
12	I-Protein
or	O
IL	B-Protein
-	I-Protein
4	I-Protein
unless	O
the	O
IL	B-Protein
-	I-Protein
10	I-Protein
gene	O
is	O
imprinted	O
by	O
GATA	B-Protein
-	I-Protein
3	I-Protein
(	O
Chang	O
et	O
al	O
.	O
,	O
2007	O
)	O
,	O
which	O
can	O
remodel	O
the	O
IL	B-Protein
-	I-Protein
10	I-Protein
locus	O
,	O
thus	O
explaining	O
the	O
highest	O
amounts	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
produced	O
by	O
Th2	O
cells	O
(	O
Chang	O
et	O
al	O
.	O
,	O
2007	O
;	O
Shoemaker	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

We	O
show	O
here	O
that	O
high	O
antigen	O
dose	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
drastically	O
downregulate	O
Gata	B-Protein
-	I-Protein
3	I-Protein
expression	O
,	O
suggesting	O
that	O
additional	O
factors	O
are	O
in	O
place	O
to	O
induce	O
IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
in	O
Th1	O
cells	O
,	O
albeit	O
transiently	O
.	O

Expression	O
of	O
c	B-Protein
-	I-Protein
maf	I-Protein
was	O
greatly	O
diminished	O
by	O
high	O
antigen	O
doses	O
in	O
T	O
cells	O
and	O
yet	O
was	O
unexpectedly	O
maintained	O
by	O
IL	B-Protein
-	I-Protein
12	I-Protein
and	O
present	O
in	O
Th17	O
cells	O
.	O

That	O
c	B-Protein
-	I-Protein
maf	I-Protein
expression	O
is	O
common	O
to	O
IL	B-Protein
-	I-Protein
10	I-Protein
-	O
producing	O
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
cells	O
and	O
,	O
like	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
is	O
dependent	O
on	O
ERK	B-Protein
activation	O
in	O
Th1	O
and	O
Th17	O
cells	O
for	O
its	O
expression	O
is	O
of	O
interest	O
because	O
c	B-Protein
-	I-Protein
Maf	I-Protein
has	O
been	O
shown	O
to	O
be	O
an	O
essential	O
transcription	O
factor	O
for	O
IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
in	O
macrophages	O
(	O
Cao	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O

In	O
summary	O
,	O
we	O
show	O
that	O
although	O
Th1	O
,	O
Th2	O
,	O
and	O
Th17	O
CD4	B-Protein
+	O
T	O
cell	O
subsets	O
differentiate	O
along	O
distinct	O
signaling	O
and	O
transcriptional	O
pathways	O
,	O
they	O
can	O
all	O
be	O
induced	O
to	O
make	O
IL	B-Protein
-	I-Protein
10	I-Protein
.	O

ERK1	B-Protein
and	O
ERK2	B-Protein
activation	O
is	O
required	O
for	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
by	O
all	O
these	O
Th	O
cell	O
subsets	O
.	O
<EOS>	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
producing	B-X
interleukin-10	B-X
(	B-X
IL-10	B-X
)	B-X
and	B-X
interferon-gamma	B-X
(	B-X
IFN-gamma	B-X
)	B-X
are	B-X
reported	B-X
in	B-X
chronic	B-X
infections	B-X
.	B-X
However	B-X
,	B-X
the	B-X
signals	B-X
that	B-X
direct	B-X
the	B-X
development	B-X
of	B-X
IL-10-producing	B-X
T	B-X
helper	B-X
1	B-X
(	B-X
Th1	B-X
)	B-X
cells	B-X
are	B-X
undefined	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
development	B-X
of	B-X
IL-10-producing	B-X
Th1	B-X
cells	B-X
required	B-X
high	B-X
T	B-X
cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
ligation	B-X
,	B-X
sustained	B-X
ERK1	B-X
and	B-X
ERK2	B-X
MAP	B-X
kinases	B-X
phosphorylation	B-X
,	B-X
and	B-X
IL-12-induced	B-X
STAT4	B-X
transcription	B-X
factor	B-X
activation	B-X
.	B-X
Repeated	B-X
TCR	B-X
triggering	B-X
led	B-X
to	B-X
enhanced	B-X
IL-10	B-X
production	B-X
by	B-X
Th1	B-X
cells	B-X
,	B-X
and	B-X
continued	B-X
IL-12	B-X
action	B-X
and	B-X
high-dose	B-X
TCR	B-X
signaling	B-X
were	B-X
required	B-X
for	B-X
the	B-X
development	B-X
and	B-X
maintenance	B-X
of	B-X
IL-10-producing	B-X
Th1	B-X
cells	B-X
.	B-X
Although	B-X
Th1	B-X
,	B-X
Th2	B-X
,	B-X
and	B-X
Th17	B-X
cells	B-X
require	B-X
the	B-X
activation	B-X
of	B-X
distinct	B-X
STATs	B-X
for	B-X
their	B-X
differentiation	B-X
,	B-X
activation	B-X
of	B-X
ERK1	B-X
and	B-X
ERK2	B-X
was	B-X
a	B-X
common	B-X
requirement	B-X
for	B-X
production	B-X
of	B-X
IL-10	B-X
by	B-X
all	B-X
Th	B-X
cell	B-X
subsets	B-X
.	B-X
IL-10	B-X
expression	B-X
also	B-X
correlated	B-X
with	B-X
c-maf	B-X
expression	B-X
.	B-X
Despite	B-X
having	B-X
distinct	B-X
functions	B-X
in	B-X
protection	B-X
against	B-X
pathogens	B-X
,	B-X
all	B-X
Th	B-X
cells	B-X
share	B-X
the	B-X
important	B-X
task	B-X
of	B-X
controlling	B-X
overexuberant	B-X
immune	B-X
responses	B-X
by	B-X
means	B-X
of	B-X
IL-10	B-X
production	B-X
.	B-X

With	O
regard	O
to	O
the	O
expression	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
by	O
Th1	O
cells	O
,	O
our	O
data	O
provide	O
a	O
mechanism	O
for	O
how	O
IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
is	O
induced	O
and	O
then	O
amplified	O
and	O
regulated	O
by	O
the	O
levels	O
of	O
antigen	O
and	O
IL	B-Protein
-	I-Protein
12	I-Protein
encountered	O
in	O
the	O
environment	O
.	O

This	O
provides	O
a	O
mechanism	O
whereby	O
a	O
Th1	O
cell	O
responds	O
to	O
extrinsic	O
signals	O
,	O
reflecting	O
increased	O
inflammation	O
in	O
the	O
tissue	O
,	O
to	O
tightly	O
regulate	O
the	O
production	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
so	O
as	O
to	O
allow	O
a	O
protective	O
response	O
to	O
eradicate	O
a	O
pathogen	O
with	O
minimal	O
damage	O
to	O
the	O
host	O
and	O
also	O
prevent	O
chronic	O
infection	O
.	O

Moreover	O
,	O
our	O
findings	O
have	O
important	O
implications	O
for	O
the	O
regulation	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
production	O
during	O
an	O
inflammatory	O
Th1	O
response	O
in	O
infection	O
and	O
may	O
be	O
of	O
relevance	O
for	O
the	O
design	O
of	O
vaccines	O
and	O
for	O
strategies	O
in	O
immunotherapy	O
in	O
infectious	O
diseases	O
.	O

Mice	O
,	O
Cytokines	O
,	O
Antibodies	O
,	O
and	O
Other	O
Reagents	O
<EOS>	B-X
Antibodies	B-X
to	B-X
these	B-X
targets	B-X
,	B-X
including	B-X
CD56/neural	B-X
cell	B-X
adhesion	B-X
molecule	B-X
(	B-X
NCAM	B-X
)	B-X
,	B-X
promoted	B-X
phagocytosis	B-X
in	B-X
human	B-X
SCLC	B-X
cell	B-X
lines	B-X
that	B-X
was	B-X
enhanced	B-X
when	B-X
combined	B-X
with	B-X
CD47-blocking	B-X
therapies	B-X
.	B-X
Cytokines	B-X
and	B-X
other	B-X
immunologically	B-X
active	B-X
molecules	B-X
are	B-X
being	B-X
predominantly	B-X
detected	B-X
by	B-X
enzyme-linked	B-X
immunosorbent	B-X
assays	B-X
(	B-X
ELISA	B-X
)	B-X
and	B-X
newly	B-X
also	B-X
by	B-X
immuno-polymerase	B-X
chain	B-X
reactions	B-X
(	B-X
iPCR	B-X
)	B-X
.	B-X
Mice	B-X
with	B-X
a	B-X
conditional	B-X
deletion	B-X
of	B-X
the	B-X
LIGHT	B-X
receptor	B-X
HVEM	B-X
(	B-X
herpesvirus	B-X
entry	B-X
mediator	B-X
)	B-X
in	B-X
keratinocytes	B-X
phenocopied	B-X
LIGHT-deficient	B-X
mice	B-X
in	B-X
exhibiting	B-X
reduced	B-X
epidermal	B-X
thickening	B-X
and	B-X
dermal	B-X
collagen	B-X
deposition	B-X
in	B-X
a	B-X
model	B-X
of	B-X
atopic	B-X
dermatitis	B-X
driven	B-X
by	B-X
house	B-X
dust	B-X
mite	B-X
allergen	B-X
.	B-X

BALB	O
/	O
c	O
DO11	O
.	O
10	O
mice	O
transgenic	O
for	O
OVA	B-Protein
-	O
specific	O
TCR	O
WT	O
or	O
crossed	O
back	O
with	O
Rag1	B-Protein
-	O
,	O
IL	B-Protein
-	I-Protein
4	I-Protein
-	O
,	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
,	O
STAT4	B-Protein
-	O
,	O
and	O
STAT6	B-Protein
-	O
deficient	O
mice	O
were	O
used	O
as	O
a	O
source	O
of	O
antigen	O
-	O
specific	O
T	O
cells	O
(	O
Murphy	O
et	O
al	O
.	O
,	O
1990	O
;	O
Ouyang	O
et	O
al	O
.	O
,	O
1998	O
;	O
Shoemaker	O
et	O
al	O
.	O
,	O
2006	O
)	O
and	O
were	O
bred	O
and	O
maintained	O
under	O
SPF	O
conditions	O
at	O
the	O
NIMR	O
,	O
London	O
,	O
Home	O
Office	O
,	O
UK	O
,	O
Animals	O
(	O
Scientific	O
Procedures	O
)	O
Act	O
1986	O
or	O
at	O
the	O
Washington	O
University	O
School	O
of	O
Medicine	O
.	O
<EOS>	B-X
Regulatory	B-X
T	B-X
cells	B-X
(	B-X
Treg	B-X
)	B-X
are	B-X
important	B-X
for	B-X
maintaining	B-X
immune	B-X
homeostasis	B-X
.	B-X
Adoptive	B-X
transfer	B-X
of	B-X
Tregs	B-X
is	B-X
protective	B-X
in	B-X
renal	B-X
disease	B-X
models	B-X
in	B-X
both	B-X
immunocompetent	B-X
and	B-X
immunodeficient	B-X
mice	B-X
.	B-X
However	B-X
the	B-X
involvement	B-X
of	B-X
TCR	B-X
recognition	B-X
of	B-X
renal	B-X
antigens	B-X
remains	B-X
to	B-X
be	B-X
clarified	B-X
.	B-X
To	B-X
address	B-X
this	B-X
question	B-X
,	B-X
we	B-X
made	B-X
use	B-X
of	B-X
Tregs	B-X
from	B-X
the	B-X
DO11.10	B-X
mouse	B-X
(	B-X
a	B-X
TCR	B-X
transgenic	B-X
(	B-X
Tg	B-X
)	B-X
mouse	B-X
)	B-X
,	B-X
that	B-X
recognise	B-X
the	B-X
non-murine	B-X
antigen	B-X
Ovalbumin	B-X
(	B-X
OVA	B-X
)	B-X
and	B-X
therefore	B-X
are	B-X
not	B-X
activated	B-X
by	B-X
renal	B-X
antigens	B-X
.	B-X
DO11.10	B-X
Tregs	B-X
were	B-X
assessed	B-X
functionally	B-X
in	B-X
vitro	B-X
and	B-X
demonstrated	B-X
equivalent	B-X
suppression	B-X
to	B-X
WT	B-X
BALB/c	B-X
Tregs	B-X
.	B-X
Adriamycin	B-X
Nephropathy	B-X
(	B-X
AN	B-X
)	B-X
was	B-X
induced	B-X
in	B-X
mice	B-X
which	B-X
had	B-X
been	B-X
transfused	B-X
with	B-X
CD4+CD25+Tregs	B-X
isolated	B-X
from	B-X
DO11.10	B-X
or	B-X
BALB/c	B-X
mice	B-X
.	B-X
To	B-X
eliminate	B-X
the	B-X
memory/activation	B-X
state	B-X
as	B-X
a	B-X
cause	B-X
of	B-X
differences	B-X
in	B-X
activity	B-X
,	B-X
the	B-X
protective	B-X
capacity	B-X
of	B-X
DO11.10	B-X
Tregs	B-X
pre-activated	B-X
with	B-X
OVA	B-X
in	B-X
vivo	B-X
was	B-X
assessed	B-X
.	B-X
Transfer	B-X
of	B-X
WT	B-X
BALB/c	B-X
Tregs	B-X
significantly	B-X
attenuated	B-X
the	B-X
development	B-X
of	B-X
AN	B-X
with	B-X
less	B-X
glomerulosclerosis	B-X
,	B-X
tubular	B-X
atrophy	B-X
and	B-X
macrophage	B-X
infiltration	B-X
as	B-X
compared	B-X
to	B-X
AN	B-X
mice	B-X
without	B-X
Treg	B-X
transfer	B-X
.	B-X
However	B-X
,	B-X
mice	B-X
receiving	B-X
either	B-X
naïve	B-X
or	B-X
pre-activated	B-X
DO11.10	B-X
Tregs	B-X
were	B-X
not	B-X
protected	B-X
from	B-X
AN	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
protection	B-X
by	B-X
DO11.10	B-X
Tregs	B-X
was	B-X
not	B-X
due	B-X
to	B-X
failure	B-X
to	B-X
traffic	B-X
to	B-X
the	B-X
affected	B-X
kidney	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
antigen	B-X
recognition	B-X
in	B-X
the	B-X
kidney	B-X
is	B-X
important	B-X
for	B-X
Treg	B-X
protection	B-X
against	B-X
injury	B-X
.	B-X

Female	O
mice	O
were	O
used	O
at	O
8	O
-	O
12	O
weeks	O
old	O
,	O
and	O
animal	O
protocols	O
were	O
approved	O
according	O
to	O
the	O
Animals	O
(	O
Scientific	O
Procedures	O
)	O
Act	O
1986	O
,	O
Home	O
Office	O
,	O
UK	O
.	O

Reagents	O
,	O
including	O
antibodies	O
for	O
T	O
cell	O
and	O
DC	O
preparation	O
,	O
purification	O
and	O
culture	O
,	O
media	O
,	O
cytokines	O
,	O
and	O
cytokine	O
mAbs	O
have	O
been	O
described	O
(	O
Hosken	O
et	O
al	O
.	O
,	O
1995	O
;	O
Shoemaker	O
et	O
al	O
.	O
,	O
2006	O
;	O
Veldhoen	O
et	O
al	O
.	O
,	O
2009	O
;	O
Veldhoen	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

LPS	O
(	O
S	O
.	O
minnesota	O
)	O
was	O
from	O
Alexis	O
,	O
chicken	O
ovalbumin	B-Protein
protein	O
(	O
OVA	B-Protein
protein	O
)	O
was	O
from	O
from	O
Sigma	O
-	O
Aldrich	O
,	O
and	O
ovalbumin	B-Protein
peptide323	O
-	O
339	O
(	O
OVA	O
)	O
(	O
endotoxin	O
-	O
free	O
)	O
was	O
from	O
Biosynthesis	O
.	O

U0126	O
was	O
from	O
BioMol	O
International	O
.	O

PD184352	O
(	O
MEK	B-Protein
inhibitors	O
)	O
,	O
SB203580	O
(	O
p38	B-Protein
inhibitor	O
)	O
,	O
and	O
CT99021	O
(	O
GSK3beta	B-Protein
inhibitor	O
)	O
were	O
kind	O
gifts	O
from	O
P	O
.	O

Cohen	O
and	O
N	O
.	O

Shpiro	O
,	O
University	O
of	O
Dundee	O
,	O
UK	O
.	O
<EOS>	B-X
Myeloid	B-X
cell	B-X
deficiency	B-X
of	B-X
p38γ/p38δ	B-X
protects	B-X
against	B-X
candidiasis	B-X
and	B-X
regulates	B-X
antifungal	B-X
immunity	B-X
.	B-X

Isolation	O
of	O
CD4	B-Protein
+	O
T	O
Cells	O
and	O
of	O
Splenic	O
DC	O
and	O
Cell	O
Culture	O
for	O
T	O
Cell	O
Phenotype	O
Differentiation	O

T	O
cells	O
were	O
sorted	O
for	O
CD4	B-Protein
+	O
CD62Lhi	B-Protein
,	O
CD4	B-Protein
+	O
CD62LhiCD25	B-Protein
-	O
,	O
or	O
CD4	B-Protein
+	O
CD44loCD25	B-Protein
-	O
to	O
>	O
98	O
%	O
on	O
a	O
Moflo	O
cytometer	O
(	O
Cytomation	O
)	O
as	O
before	O
(	O
Shoemaker	O
et	O
al	O
.	O
,	O
2006	O
;	O
Veldhoen	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O
<EOS>	B-X
Bovine	B-X
tuberculosis	B-X
(	B-X
bTB	B-X
)	B-X
remains	B-X
a	B-X
globally	B-X
significant	B-X
veterinary	B-X
health	B-X
problem	B-X
.	B-X
As	B-X
the	B-X
cultured	B-X
IFNγ	B-X
ELISPOT	B-X
(	B-X
cELISPOT	B-X
)	B-X
assay	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
predict	B-X
protection	B-X
and	B-X
duration	B-X
of	B-X
immunity	B-X
in	B-X
vaccinated	B-X
cattle	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
characterize	B-X
the	B-X
phenotype	B-X
of	B-X
the	B-X
responding	B-X
T-cells	B-X
.	B-X
Using	B-X
expression	B-X
of	B-X
CD45RO	B-X
and	B-X
CD62L	B-X
we	B-X
purified	B-X
by	B-X
cytometric	B-X
cell	B-X
sorting	B-X
four	B-X
distinct	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
populations	B-X
:	B-X
CD45RO	B-X
(	B-X
+	B-X
)	B-X
CD62L	B-X
(	B-X
hi	B-X
)	B-X
,	B-X
CD45RO	B-X
(	B-X
+	B-X
)	B-X
CD62L	B-X
(	B-X
lo	B-X
)	B-X
,	B-X
CD45RO	B-X
(	B-X
-	B-X
)	B-X
CD62L	B-X
(	B-X
hi	B-X
)	B-X
and	B-X
CD45RO	B-X
(	B-X
-	B-X
)	B-X
CD62L	B-X
(	B-X
lo	B-X
)	B-X
(	B-X
although	B-X
due	B-X
to	B-X
low	B-X
and	B-X
inconsistent	B-X
cell	B-X
recovery	B-X
,	B-X
this	B-X
population	B-X
was	B-X
not	B-X
considered	B-X
further	B-X
in	B-X
this	B-X
study	B-X
)	B-X
,	B-X
in	B-X
BCG	B-X
vaccinated	B-X
and	B-X
Mycobacterium	B-X
bovis	B-X
infected	B-X
cattle	B-X
.	B-X
The	B-X
main	B-X
populations	B-X
contributing	B-X
to	B-X
production	B-X
of	B-X
IFNγ	B-X
in	B-X
the	B-X
cELISPOT	B-X
were	B-X
of	B-X
the	B-X
CD45RO	B-X
(	B-X
+	B-X
)	B-X
CD62L	B-X
(	B-X
hi	B-X
)	B-X
and	B-X
CD45RO	B-X
(	B-X
+	B-X
)	B-X
CD62L	B-X
(	B-X
lo	B-X
)	B-X
phenotypes	B-X
.	B-X
These	B-X
cell	B-X
populations	B-X
have	B-X
been	B-X
described	B-X
in	B-X
other	B-X
species	B-X
as	B-X
central	B-X
and	B-X
effector	B-X
memory	B-X
cells	B-X
,	B-X
respectively	B-X
.	B-X
Following	B-X
in	B-X
vitro	B-X
culture	B-X
and	B-X
flow	B-X
cytometry	B-X
we	B-X
observed	B-X
plasticity	B-X
within	B-X
the	B-X
bovine	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T-cell	B-X
phenotype	B-X
.	B-X
Populations	B-X
switched	B-X
phenotype	B-X
,	B-X
increasing	B-X
or	B-X
decreasing	B-X
expression	B-X
of	B-X
CD45RO	B-X
and	B-X
CD62L	B-X
within	B-X
24h	B-X
of	B-X
in	B-X
vitro	B-X
stimulation	B-X
.	B-X
After	B-X
14	B-X
days	B-X
all	B-X
IFNγ	B-X
producing	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
expressed	B-X
CD45RO	B-X
regardless	B-X
of	B-X
the	B-X
original	B-X
phenotype	B-X
of	B-X
the	B-X
sorted	B-X
population	B-X
.	B-X
No	B-X
differences	B-X
were	B-X
detected	B-X
in	B-X
behavior	B-X
of	B-X
cells	B-X
derived	B-X
from	B-X
BCG-vaccinated	B-X
animals	B-X
compared	B-X
to	B-X
cells	B-X
derived	B-X
from	B-X
naturally	B-X
infected	B-X
animals	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
although	B-X
multiple	B-X
populations	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
memory	B-X
cells	B-X
from	B-X
both	B-X
BCG	B-X
vaccinated	B-X
and	B-X
M.	B-X
bovis	B-X
infected	B-X
animals	B-X
contributed	B-X
to	B-X
cELISPOT	B-X
responses	B-X
,	B-X
the	B-X
dominant	B-X
contributing	B-X
population	B-X
consists	B-X
of	B-X
central-memory-like	B-X
T	B-X
cells	B-X
(	B-X
CD45RO	B-X
(	B-X
+	B-X
)	B-X
CD62L	B-X
(	B-X
hi	B-X
)	B-X
)	B-X
.	B-X

In	O
most	O
cases	O
,	O
experiments	O
were	O
reproduced	O
with	O
each	O
type	O
of	O
purified	O
CD4	B-Protein
+	O
T	O
cell	O
population	O
with	O
similar	O
results	O
obtained	O
.	O

Splenic	O
DCs	O
were	O
prepared	O
as	O
described	O
(	O
Hosken	O
et	O
al	O
.	O
,	O
1995	O
)	O
,	O
and	O
sort	O
purified	O
CD11c	B-Protein
+	O
cells	O
were	O
added	O
to	O
the	O
T	O
cell	O
culture	O
.	O

Purified	O
DO11	O
.	O
10	O
CD4	B-Protein
+	O
T	O
cells	O
(	O
1	O
x	O
105	O
cells	O
/	O
ml	O
)	O
were	O
cultured	O
as	O
before	O
(	O
Hosken	O
et	O
al	O
.	O
,	O
1995	O
)	O
,	O
in	O
a	O
total	O
volume	O
of	O
1	O
ml	O
cRPMI	O
medium	O
in	O
a	O
48	O
-	O
well	O
plate	O
,	O
with	O
splenic	O
DCs	O
(	O
2	O
x	O
104	O
cells	O
/	O
ml	O
)	O
,	O
and	O
varying	O
amounts	O
of	O
OVA	B-Protein
and	O
of	O
IL	B-Protein
-	I-Protein
12	I-Protein
.	O

APC	O
-	O
independent	O
differentiation	O
of	O
naive	O
CD4	B-Protein
+	O
T	O
cells	O
into	O
Th1	O
and	O
Th2	O
cells	O
used	O
stimulation	O
with	O
anti	O
-	O
CD3	B-Protein
and	O
anti	O
-	O
CD28	B-Protein
and	O
appropriate	O
cytokine	O
conditions	O
,	O
and	O
control	O
Th1	O
and	O
Th2	O
cells	O
were	O
cultured	O
as	O
described	O
before	O
(	O
Hosken	O
et	O
al	O
.	O
,	O
1995	O
;	O
Shoemaker	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Culture	O
conditions	O
for	O
Th17	O
cells	O
were	O
as	O
described	O
before	O
(	O
Veldhoen	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Importantly	O
,	O
Th1	O
and	O
Th2	O
cells	O
could	O
be	O
differentiated	O
in	O
cRPMI	O
or	O
IMDM	O
(	O
Hosken	O
et	O
al	O
.	O
,	O
1995	O
;	O
Shoemaker	O
et	O
al	O
.	O
,	O
2006	O
;	O
Veldhoen	O
et	O
al	O
.	O
,	O
2006	O
)	O
,	O
but	O
Th17	O
cells	O
were	O
only	O
differentiated	O
optimally	O
in	O
IMDM	O
(	O
Veldhoen	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

When	O
indicated	O
,	O
U0126	O
or	O
PD184352	O
(	O
MEK	B-Protein
inhibitors	O
)	O
,	O
SB203580	O
(	O
p38	B-Protein
inhibitor	O
)	O
,	O
CT99021	O
(	O
GSK3beta	B-Protein
inhibitor	O
)	O
,	O
or	O
a	O
similar	O
amount	O
of	O
DMSO	O
were	O
present	O
in	O
the	O
culture	O
.	O
<EOS>	B-X
Murine	B-X
erythroleukemia	B-X
(	B-X
MEL	B-X
or	B-X
Friend	B-X
)	B-X
cells	B-X
grown	B-X
in	B-X
culture	B-X
and	B-X
induced	B-X
to	B-X
differentiate	B-X
into	B-X
cells	B-X
resembling	B-X
orthochromatic	B-X
normoblasts	B-X
provide	B-X
a	B-X
suitable	B-X
system	B-X
for	B-X
uncovering	B-X
molecular	B-X
and	B-X
cellular	B-X
mechanisms	B-X
of	B-X
hemopoiesis	B-X
and	B-X
for	B-X
understanding	B-X
globin	B-X
gene	B-X
regulation	B-X
.	B-X
Inducer-treated	B-X
cells	B-X
undergo	B-X
an	B-X
irreversible	B-X
commitment	B-X
to	B-X
maturation	B-X
and	B-X
accumulate	B-X
large	B-X
amounts	B-X
of	B-X
hemoglobin	B-X
.	B-X
Inducer-treated	B-X
cells	B-X
express	B-X
an	B-X
ability	B-X
to	B-X
remember	B-X
(	B-X
``	B-X
memory	B-X
response	B-X
''	B-X
)	B-X
previous	B-X
exposure	B-X
to	B-X
inducer	B-X
and	B-X
to	B-X
continue	B-X
their	B-X
differentiation	B-X
after	B-X
discontinuous	B-X
exposure	B-X
to	B-X
inducer	B-X
;	B-X
expression	B-X
of	B-X
``	B-X
memory	B-X
response	B-X
''	B-X
occurs	B-X
early	B-X
in	B-X
differentiation	B-X
and	B-X
affects	B-X
both	B-X
the	B-X
initiation	B-X
of	B-X
commitment	B-X
and	B-X
accumulation	B-X
of	B-X
globin	B-X
mRNA	B-X
in	B-X
a	B-X
similar	B-X
manner	B-X
in	B-X
inducer-treated	B-X
cells	B-X
.	B-X
The	B-X
role	B-X
of	B-X
the	B-X
MEL	B-X
system	B-X
as	B-X
a	B-X
model	B-X
for	B-X
studying	B-X
mouse	B-X
and	B-X
human	B-X
globin	B-X
gene	B-X
regulation	B-X
is	B-X
presented	B-X
.	B-X

More	O
details	O
of	O
specific	O
culture	O
conditions	O
are	O
provided	O
in	O
Figures	O
S6	O
and	O
S7	O
.	O

Cytokine	O
Detection	O
by	O
ICS	O
and	O
ELISA	O
<EOS>	B-X
Basic	B-X
Protocol	B-X
1	B-X
:	B-X
LCMV	B-X
infection	B-X
routes	B-X
in	B-X
mice	B-X
Support	B-X
Protocol	B-X
1	B-X
:	B-X
Preparation	B-X
of	B-X
LCMV	B-X
stocks	B-X
ASSAYS	B-X
TO	B-X
MEASURE	B-X
LCMV	B-X
TITERS	B-X
Support	B-X
Protocol	B-X
2	B-X
:	B-X
Plaque	B-X
assay	B-X
Support	B-X
Protocol	B-X
3	B-X
:	B-X
Immunofluorescence	B-X
focus	B-X
assay	B-X
(	B-X
IFA	B-X
)	B-X
to	B-X
measure	B-X
LCMV	B-X
titer	B-X
MEASUREMENT	B-X
OF	B-X
T	B-X
CELL	B-X
AND	B-X
B	B-X
CELL	B-X
RESPONSES	B-X
TO	B-X
LCMV	B-X
INFECTION	B-X
Basic	B-X
Protocol	B-X
2	B-X
:	B-X
Triple	B-X
tetramer	B-X
staining	B-X
for	B-X
detection	B-X
of	B-X
LCMV-specific	B-X
CD8	B-X
T	B-X
cells	B-X
Basic	B-X
Protocol	B-X
3	B-X
:	B-X
Intracellular	B-X
cytokine	B-X
staining	B-X
(	B-X
ICS	B-X
)	B-X
for	B-X
detection	B-X
of	B-X
LCMV-specific	B-X
T	B-X
cells	B-X
Basic	B-X
Protocol	B-X
4	B-X
:	B-X
Enumeration	B-X
of	B-X
direct	B-X
ex	B-X
vivo	B-X
LCMV-specific	B-X
antibody-secreting	B-X
cells	B-X
(	B-X
ASC	B-X
)	B-X
Basic	B-X
Protocol	B-X
5	B-X
:	B-X
Limiting	B-X
dilution	B-X
assay	B-X
(	B-X
LDA	B-X
)	B-X
for	B-X
detection	B-X
of	B-X
LCMV-specific	B-X
memory	B-X
B	B-X
cells	B-X
Basic	B-X
Protocol	B-X
6	B-X
:	B-X
ELISA	B-X
for	B-X
quantification	B-X
of	B-X
LCMV-specific	B-X
IgG	B-X
antibody	B-X
Support	B-X
Protocol	B-X
4	B-X
:	B-X
Preparation	B-X
of	B-X
splenic	B-X
lymphocytes	B-X
Support	B-X
Protocol	B-X
5	B-X
:	B-X
Making	B-X
BHK21-LCMV	B-X
lysate	B-X
Basic	B-X
Protocol	B-X
7	B-X
:	B-X
Challenge	B-X
models	B-X
TRANSGENIC	B-X
MODELS	B-X
Basic	B-X
Protocol	B-X
8	B-X
:	B-X
Transfer	B-X
of	B-X
P14	B-X
cells	B-X
to	B-X
interrogate	B-X
the	B-X
role	B-X
of	B-X
IFN-I	B-X
on	B-X
CD8	B-X
T	B-X
cell	B-X
responses	B-X
Basic	B-X
Protocol	B-X
9	B-X
:	B-X
Comparing	B-X
the	B-X
expansion	B-X
of	B-X
naïve	B-X
versus	B-X
memory	B-X
CD4	B-X
T	B-X
cells	B-X
following	B-X
chronic	B-X
viral	B-X
challenge	B-X
.	B-X
We	B-X
included	B-X
31	B-X
LT	B-X
recipients	B-X
in	B-X
whom	B-X
SARS-CoV-2-CMI	B-X
was	B-X
assessed	B-X
by	B-X
intracellular	B-X
cytokine	B-X
staining	B-X
(	B-X
ICS	B-X
)	B-X
and	B-X
interferon	B-X
(	B-X
IFN	B-X
)	B-X
-γ	B-X
FluoroSpot	B-X
assay	B-X
after	B-X
a	B-X
median	B-X
of	B-X
103	B-X
days	B-X
from	B-X
COVID-19	B-X
diagnosis	B-X
.	B-X
Serum	B-X
SARS-CoV-2	B-X
IgG	B-X
antibodies	B-X
were	B-X
measured	B-X
by	B-X
ELISA	B-X
.	B-X
Post-transplant	B-X
SARS-CoV-2-CMI	B-X
was	B-X
detected	B-X
by	B-X
ICS	B-X
in	B-X
90.3	B-X
%	B-X
(	B-X
28/31	B-X
)	B-X
of	B-X
recipients	B-X
,	B-X
with	B-X
higher	B-X
proportions	B-X
for	B-X
IFN-γ-producing	B-X
CD4	B-X

At	O
day	O
5	O
or	O
7	O
,	O
cells	O
were	O
restimulated	O
with	O
immobilized	O
anti	O
-	O
CD3	B-Protein
(	O
2	O
mug	O
/	O
ml	O
)	O
and	O
anti	O
-	O
CD28	B-Protein
(	O
2	O
mug	O
/	O
ml	O
)	O
(	O
4	O
hr	O
with	O
BrefeldinA	O
[	O
10	O
mug	O
/	O
ml	O
]	O
in	O
the	O
last	O
2	O
hr	O
)	O
or	O
with	O
PdBU	O
and	O
Ionomycin	O
(	O
5	O
hr	O
with	O
BrefeldinA	O
[	O
1	O
mug	O
/	O
ml	O
]	O
)	O
.	O

After	O
ICS	O
FACS	O
,	O
data	O
were	O
collected	O
on	O
a	O
FACSCalibur	O
(	O
Becton	O
Dickinson	O
)	O
and	O
analyzed	O
with	O
FlowJo	O
(	O
Tree	O
Star	O
)	O
.	O

For	O
ELISA	O
,	O
cells	O
were	O
similarly	O
restimulated	O
for	O
48	O
hr	O
and	O
supernatant	O
was	O
collected	O
and	O
analyzed	O
for	O
IL	B-Protein
-	I-Protein
4	I-Protein
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
as	O
described	O
before	O
(	O
Shoemaker	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

In	O
Vivo	O
Studies	O

BALB	O
/	O
c	O
mice	O
were	O
injected	O
intravenously	O
(	O
i	O
.	O
v	O
.	O
)	O
with	O
a	O
red	O
blood	O
cell	O
-	O
depleted	O
single	O
-	O
cell	O
spleen	O
suspension	O
(	O
2	O
.	O
5	O
x	O
107	O
cells	O
)	O
(	O
Castro	O
et	O
al	O
.	O
,	O
2000	O
)	O
from	O
DO11	O
.	O
10	O
WT	O
or	O
STAT	B-Protein
-	O
deficient	O
mice	O
.	O
<EOS>	B-X
Obesity	B-X
is	B-X
a	B-X
major	B-X
driver	B-X
of	B-X
cancer	B-X
,	B-X
especially	B-X
hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
.	B-X
The	B-X
prevailing	B-X
view	B-X
is	B-X
that	B-X
non-alcoholic	B-X
steatohepatitis	B-X
(	B-X
NASH	B-X
)	B-X
and	B-X
fibrosis	B-X
or	B-X
cirrhosis	B-X
are	B-X
required	B-X
for	B-X
HCC	B-X
in	B-X
obesity	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
NASH	B-X
and	B-X
fibrosis	B-X
and	B-X
HCC	B-X
in	B-X
obesity	B-X
can	B-X
be	B-X
dissociated	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
oxidative	B-X
hepatic	B-X
environment	B-X
in	B-X
obesity	B-X
inactivates	B-X
the	B-X
STAT-1	B-X
and	B-X
STAT-3	B-X
phosphatase	B-X
T	B-X
cell	B-X
protein	B-X
tyrosine	B-X
phosphatase	B-X
(	B-X
TCPTP	B-X
)	B-X
and	B-X
increases	B-X
STAT-1	B-X
and	B-X
STAT-3	B-X
signaling	B-X
.	B-X
TCPTP	B-X
deletion	B-X
in	B-X
hepatocytes	B-X
promoted	B-X
T	B-X
cell	B-X
recruitment	B-X
and	B-X
ensuing	B-X
NASH	B-X
and	B-X
fibrosis	B-X
as	B-X
well	B-X
as	B-X
HCC	B-X
in	B-X
obese	B-X
C57BL/6	B-X
mice	B-X
that	B-X
normally	B-X
do	B-X
not	B-X
develop	B-X
NASH	B-X
and	B-X
fibrosis	B-X
or	B-X
HCC	B-X
.	B-X
Attenuating	B-X
the	B-X
enhanced	B-X
STAT-1	B-X
signaling	B-X
prevented	B-X
T	B-X
cell	B-X
recruitment	B-X
and	B-X
NASH	B-X
and	B-X
fibrosis	B-X
but	B-X
did	B-X
not	B-X
prevent	B-X
HCC	B-X
.	B-X
By	B-X
contrast	B-X
,	B-X
correcting	B-X
STAT-3	B-X
signaling	B-X
prevented	B-X
HCC	B-X
without	B-X
affecting	B-X
NASH	B-X
and	B-X
fibrosis	B-X
.	B-X
TCPTP-deletion	B-X
in	B-X
hepatocytes	B-X
also	B-X
markedly	B-X
accelerated	B-X
HCC	B-X
in	B-X
mice	B-X
treated	B-X
with	B-X
a	B-X
chemical	B-X
carcinogen	B-X
that	B-X
promotes	B-X
HCC	B-X
without	B-X
NASH	B-X
and	B-X
fibrosis	B-X
.	B-X
Our	B-X
studies	B-X
reveal	B-X
how	B-X
obesity-associated	B-X
hepatic	B-X
oxidative	B-X
stress	B-X
can	B-X
independently	B-X
contribute	B-X
to	B-X
the	B-X
pathogenesis	B-X
of	B-X
NASH	B-X
,	B-X
fibrosis	B-X
,	B-X
and	B-X
HCC	B-X
.	B-X

After	O
48	O
hr	O
,	O
they	O
were	O
injected	O
subcutaneously	O
with	O
PBS	O
or	O
with	O
OVA	B-Protein
protein	O
(	O
5	O
mg	O
)	O
plus	O
LPS	O
(	O
5	O
mug	O
)	O
.	O

The	O
inguinal	O
lymph	O
nodes	O
were	O
removed	O
48	O
hr	O
later	O
.	O

A	O
single	O
-	O
cell	O
suspension	O
(	O
1	O
x	O
106	O
cells	O
)	O
was	O
restimulated	O
for	O
24	O
or	O
48	O
hr	O
with	O
1	O
muM	O
or	O
3	O
muM	O
of	O
OVA	B-Protein
and	O
with	O
BrefeldinA	O
for	O
the	O
last	O
6	O
hr	O
.	O
<EOS>	B-X
We	B-X
assessed	B-X
the	B-X
joint	B-X
association	B-X
of	B-X
various	B-X
air	B-X
pollutants	B-X
with	B-X
the	B-X
risk	B-X
of	B-X
T2D	B-X
and	B-X
examined	B-X
potential	B-X
modification	B-X
by	B-X
obesity	B-X
status	B-X
and	B-X
genetic	B-X
susceptibility	B-X
on	B-X
the	B-X
relationship	B-X
.	B-X
Four	B-X
new	B-X
19-nor-clerodane	B-X
diterpenoids	B-X
(	B-X
1-4	B-X
)	B-X
,	B-X
one	B-X
new	B-X
15,16-dinor-ent-pimarane	B-X
diterpenoid	B-X
(	B-X
5	B-X
)	B-X
together	B-X
with	B-X
four	B-X
known	B-X
diterpenoids	B-X
(	B-X
6-9	B-X
)	B-X
were	B-X
isolated	B-X
from	B-X
whole	B-X
plants	B-X
of	B-X
Croton	B-X
yunnanensis	B-X
.	B-X
The	B-X
structures	B-X
of	B-X
these	B-X
compounds	B-X
were	B-X
determined	B-X
by	B-X
extensive	B-X
spectroscopic	B-X
methods	B-X
including	B-X
1D	B-X
,	B-X
2D	B-X
NMR	B-X
,	B-X
HR-ESI-MS	B-X
,	B-X
and	B-X
by	B-X
comparing	B-X
their	B-X
NMR	B-X
data	B-X
with	B-X
those	B-X
of	B-X
previously	B-X
reported	B-X
compounds	B-X
.	B-X
The	B-X
experimental	B-X
and	B-X
calculated	B-X
electronic	B-X
circular	B-X
dichroism	B-X
data	B-X
were	B-X
used	B-X
to	B-X
define	B-X
their	B-X
absolute	B-X
configurations	B-X
.	B-X

Half	O
of	O
the	O
supernatant	O
was	O
removed	O
before	O
the	O
addition	O
of	O
BrefeldinA	O
for	O
use	O
in	O
an	O
ELISA	O
assay	O
.	O

The	O
cells	O
were	O
fixed	O
and	O
stained	O
as	O
before	O
.	O
<EOS>	B-X
A	B-X
number	B-X
of	B-X
fluorescent	B-X
stains	B-X
are	B-X
available	B-X
that	B-X
label	B-X
DNA	B-X
and	B-X
allow	B-X
easy	B-X
visualization	B-X
of	B-X
the	B-X
nucleus	B-X
in	B-X
interphase	B-X
cells	B-X
and	B-X
chromosomes	B-X
in	B-X
mitotic	B-X
cells	B-X
,	B-X
including	B-X
Hoechst	B-X
,	B-X
4',6-diamidino-2-phenylindole	B-X
(	B-X
DAPI	B-X
)	B-X
,	B-X
ethidium	B-X
bromide	B-X
,	B-X
propidium	B-X
iodide	B-X
,	B-X
and	B-X
acridine	B-X
orange	B-X
.	B-X
Cells	B-X
must	B-X
be	B-X
permeabilized	B-X
and/or	B-X
fixed	B-X
for	B-X
DAPI	B-X
to	B-X
enter	B-X
the	B-X
cell	B-X
and	B-X
to	B-X
bind	B-X
DNA	B-X
.	B-X
This	B-X
protocol	B-X
describes	B-X
the	B-X
use	B-X
of	B-X
DAPI	B-X
to	B-X
label	B-X
nuclear	B-X
DNA	B-X
of	B-X
cells	B-X
grown	B-X
in	B-X
culture	B-X
.	B-X
Propidium	B-X
iodide	B-X
(	B-X
PI	B-X
)	B-X
is	B-X
widely	B-X
used	B-X
in	B-X
conjunction	B-X
with	B-X
Annexin	B-X
V	B-X
to	B-X
determine	B-X
if	B-X
cells	B-X
are	B-X
viable	B-X
,	B-X
apoptotic	B-X
,	B-X
or	B-X
necrotic	B-X
through	B-X
differences	B-X
in	B-X
plasma	B-X
membrane	B-X
integrity	B-X
and	B-X
permeability	B-X
.	B-X
The	B-X
Annexin	B-X
V/PI	B-X
protocol	B-X
is	B-X
a	B-X
commonly	B-X
used	B-X
approach	B-X
for	B-X
studying	B-X
apoptotic	B-X
cells	B-X
.	B-X
PI	B-X
is	B-X
used	B-X
more	B-X
often	B-X
than	B-X
other	B-X
nuclear	B-X
stains	B-X
because	B-X
it	B-X
is	B-X
economical	B-X
,	B-X
stable	B-X
and	B-X
a	B-X
good	B-X
indicator	B-X
of	B-X
cell	B-X
viability	B-X
,	B-X
based	B-X
on	B-X
its	B-X
capacity	B-X
to	B-X
exclude	B-X
dye	B-X
in	B-X
living	B-X
cells	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
PI	B-X
to	B-X
enter	B-X
a	B-X
cell	B-X
is	B-X
dependent	B-X
upon	B-X
the	B-X
permeability	B-X
of	B-X
the	B-X
membrane	B-X
;	B-X
PI	B-X
does	B-X
not	B-X
stain	B-X
live	B-X
or	B-X
early	B-X
apoptotic	B-X
cells	B-X
due	B-X
to	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
intact	B-X
plasma	B-X
membrane	B-X
.	B-X
In	B-X
late	B-X
apoptotic	B-X
and	B-X
necrotic	B-X
cells	B-X
,	B-X
the	B-X
integrity	B-X
of	B-X
the	B-X
plasma	B-X
and	B-X
nuclear	B-X
membranes	B-X
decreases	B-X
,	B-X
allowing	B-X
PI	B-X
to	B-X
pass	B-X
through	B-X
the	B-X
membranes	B-X
,	B-X
intercalate	B-X
into	B-X
nucleic	B-X
acids	B-X
,	B-X
and	B-X
display	B-X
red	B-X
fluorescence	B-X
.	B-X
Primary	B-X
cells	B-X
and	B-X
cell	B-X
lines	B-X
in	B-X
a	B-X
broad	B-X
range	B-X
of	B-X
animal	B-X
models	B-X
are	B-X
affected	B-X
,	B-X
with	B-X
large	B-X
cells	B-X
(	B-X
nuclear	B-X
:	B-X
cytoplasmic	B-X
ratios	B-X
<	B-X
0.5	B-X
)	B-X
showing	B-X
the	B-X
highest	B-X
occurrence	B-X
.	B-X
This	B-X
protocol	B-X
takes	B-X
advantage	B-X
of	B-X
changes	B-X
in	B-X
cellular	B-X
permeability	B-X
during	B-X
cell	B-X
fixing	B-X
to	B-X
promote	B-X
entry	B-X
of	B-X
RNase	B-X
A	B-X
into	B-X
cells	B-X
following	B-X
staining	B-X
.	B-X

Those	O
positive	O
for	O
KJ1	B-Protein
-	I-Protein
26	I-Protein
-	O
Bio	O
and	O
for	O
CD4	B-Protein
-	O
PerCP	O
were	O
gated	O
,	O
and	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
staining	O
was	O
examined	O
for	O
this	O
population	O
and	O
analyzed	O
as	O
before	O
.	O

Real	O
-	O
Time	O
Quantitative	O
RT	O
-	O
PCR	O
<EOS>	B-X
The	B-X
real-time	B-X
reverse	B-X
transcription	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-PCR	B-X
)	B-X
uses	B-X
fluorescent	B-X
reporter	B-X
molecules	B-X
to	B-X
monitor	B-X
the	B-X
production	B-X
of	B-X
amplification	B-X
products	B-X
during	B-X
each	B-X
cycle	B-X
of	B-X
the	B-X
PCR	B-X
reaction	B-X
.	B-X
Its	B-X
simplicity	B-X
,	B-X
specificity	B-X
and	B-X
sensitivity	B-X
,	B-X
together	B-X
with	B-X
its	B-X
potential	B-X
for	B-X
high	B-X
throughput	B-X
and	B-X
the	B-X
ongoing	B-X
introduction	B-X
of	B-X
new	B-X
chemistries	B-X
,	B-X
more	B-X
reliable	B-X
instrumentation	B-X
and	B-X
improved	B-X
protocols	B-X
,	B-X
has	B-X
made	B-X
real-time	B-X
RT-PCR	B-X
the	B-X
benchmark	B-X
technology	B-X
for	B-X
the	B-X
detection	B-X
and/or	B-X
comparison	B-X
of	B-X
RNA	B-X
levels	B-X
.	B-X
Two-step	B-X
quantitative	B-X
real-time	B-X
RT-PCR	B-X
(	B-X
RT-qPCR	B-X
)	B-X
,	B-X
also	B-X
known	B-X
as	B-X
real-time	B-X
RT-PCR	B-X
,	B-X
kinetic	B-X
RT-PCR	B-X
,	B-X
or	B-X
quantitative	B-X
fluorescent	B-X
RT-PCR	B-X
,	B-X
has	B-X
become	B-X
the	B-X
method	B-X
of	B-X
choice	B-X
for	B-X
gene	B-X
expression	B-X
analysis	B-X
during	B-X
the	B-X
last	B-X
few	B-X
years	B-X
.	B-X
It	B-X
is	B-X
a	B-X
fast	B-X
and	B-X
convenient	B-X
PCR	B-X
method	B-X
that	B-X
combines	B-X
traditional	B-X
RT-PCR	B-X
with	B-X
the	B-X
phenomenon	B-X
of	B-X
fluorescence	B-X
resonance	B-X
energy	B-X
transfer	B-X
(	B-X
FRET	B-X
)	B-X
using	B-X
fluorogenic	B-X
primers	B-X
.	B-X
The	B-X
detection	B-X
of	B-X
changes	B-X
in	B-X
fluorescence	B-X
intensity	B-X
during	B-X
the	B-X
reaction	B-X
enables	B-X
the	B-X
user	B-X
to	B-X
follow	B-X
the	B-X
PCR	B-X
reaction	B-X
in	B-X
real	B-X
time.RT-qPCR	B-X
comprises	B-X
several	B-X
steps	B-X
:	B-X
(	B-X
1	B-X
)	B-X
RNA	B-X
is	B-X
isolated	B-X
from	B-X
target	B-X
tissue/cells	B-X
;	B-X
(	B-X
2	B-X
)	B-X
mRNA	B-X
is	B-X
reverse-transcribed	B-X
to	B-X
cDNA	B-X
;	B-X
(	B-X
3	B-X
)	B-X
modified	B-X
gene-specific	B-X
PCR	B-X
primers	B-X
are	B-X
used	B-X
to	B-X
amplify	B-X
a	B-X
segment	B-X
of	B-X
the	B-X
cDNA	B-X
of	B-X
interest	B-X
,	B-X
following	B-X
the	B-X
reaction	B-X
in	B-X
real	B-X
time	B-X
;	B-X
and	B-X
(	B-X
4	B-X
)	B-X
the	B-X
initial	B-X
concentration	B-X
of	B-X
the	B-X
selected	B-X
transcript	B-X
in	B-X
a	B-X
specific	B-X
tissue	B-X
or	B-X
cell	B-X
type	B-X
is	B-X
calculated	B-X
from	B-X
the	B-X
exponential	B-X
phase	B-X
of	B-X
the	B-X
reaction	B-X
.	B-X
Relative	B-X
quantification	B-X
or	B-X
absolute	B-X
quantification	B-X
compared	B-X
to	B-X
standards	B-X
that	B-X
are	B-X
run	B-X
in	B-X
parallel	B-X
can	B-X
be	B-X
performed.This	B-X
chapter	B-X
describes	B-X
the	B-X
entire	B-X
procedure	B-X
from	B-X
isolation	B-X
of	B-X
total	B-X
RNA	B-X
from	B-X
liver	B-X
and	B-X
fatty	B-X
tissues/cells	B-X
to	B-X
the	B-X
use	B-X
of	B-X
RT-qPCR	B-X
to	B-X
study	B-X
gene	B-X
expression	B-X
in	B-X
these	B-X
tissues	B-X
.	B-X

Cells	O
were	O
harvested	O
and	O
restimulated	O
in	O
the	O
presence	O
of	O
immobilized	O
anti	O
-	O
CD3	B-Protein
(	O
2	O
mug	O
/	O
ml	O
)	O
plus	O
anti	O
-	O
CD28	B-Protein
(	O
2	O
mug	O
/	O
ml	O
)	O
for	O
3	O
hr	O
or	O
immediately	O
lysed	O
.	O
<EOS>	B-X
In	B-X
this	B-X
procedure	B-X
,	B-X
yeast	B-X
cells	B-X
are	B-X
incubated	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
translational	B-X
inhibitor	B-X
cycloheximide	B-X
.	B-X
Aliquots	B-X
of	B-X
cells	B-X
are	B-X
collected	B-X
immediately	B-X
after	B-X
and	B-X
at	B-X
specific	B-X
time	B-X
points	B-X
following	B-X
addition	B-X
of	B-X
cycloheximide	B-X
.	B-X
Cells	B-X
are	B-X
lysed	B-X
,	B-X
and	B-X
the	B-X
lysates	B-X
are	B-X
separated	B-X
by	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
for	B-X
western	B-X
blot	B-X
analysis	B-X
of	B-X
protein	B-X
abundance	B-X
at	B-X
each	B-X
time	B-X
point	B-X
.	B-X
The	B-X
rationale	B-X
for	B-X
thrombolysis	B-X
,	B-X
the	B-X
most	B-X
promising	B-X
pharmacological	B-X
approach	B-X
in	B-X
acute	B-X
ischaemic	B-X
stroke	B-X
,	B-X
is	B-X
centred	B-X
on	B-X
the	B-X
principal	B-X
cause	B-X
of	B-X
most	B-X
ischaemic	B-X
strokes	B-X
:	B-X
the	B-X
thrombus	B-X
that	B-X
occludes	B-X
the	B-X
cerebral	B-X
artery	B-X
,	B-X
and	B-X
renders	B-X
part	B-X
of	B-X
the	B-X
brain	B-X
ischaemic	B-X
.	B-X
The	B-X
occluding	B-X
thrombus	B-X
is	B-X
bound	B-X
together	B-X
within	B-X
fibrin	B-X
.	B-X
Thrombolytic	B-X
agents	B-X
include	B-X
streptokinase	B-X
(	B-X
SK	B-X
)	B-X
and	B-X
recombinant	B-X
tissue-type	B-X
plasminogen	B-X
activator	B-X
(	B-X
rt-PA	B-X
)	B-X
amongst	B-X
others	B-X
under	B-X
test	B-X
or	B-X
development	B-X
.	B-X
For	B-X
clinical	B-X
application	B-X
,	B-X
some	B-X
outcome	B-X
data	B-X
from	B-X
the	B-X
Cochrane	B-X
Database	B-X
of	B-X
Systematic	B-X
Reviews	B-X
which	B-X
includes	B-X
all	B-X
randomized	B-X
evidence	B-X
available	B-X
on	B-X
thrombolysis	B-X
in	B-X
man	B-X
were	B-X
used	B-X
.	B-X
The	B-X
chief	B-X
immediate	B-X
hazard	B-X
of	B-X
thrombolytic	B-X
therapy	B-X
is	B-X
fatal	B-X
intracranial	B-X
bleeding	B-X
.	B-X
However	B-X
,	B-X
despite	B-X
the	B-X
risk	B-X
,	B-X
the	B-X
human	B-X
trial	B-X
data	B-X
suggest	B-X
the	B-X
immediate	B-X
hazards	B-X
and	B-X
the	B-X
apparent	B-X
substantial	B-X
scope	B-X
for	B-X
net	B-X
benefit	B-X
of	B-X
thrombolytic	B-X
therapy	B-X
given	B-X
up	B-X
to	B-X
6	B-X
h	B-X
of	B-X
acute	B-X
ischaemic	B-X
stroke	B-X
.	B-X
The	B-X
molecular	B-X
mechanisms	B-X
with	B-X
regards	B-X
to	B-X
fibrin-specificity	B-X
in	B-X
thrombolytic	B-X
agents	B-X
should	B-X
,	B-X
if	B-X
further	B-X
studied	B-X
,	B-X
be	B-X
addressed	B-X
in	B-X
within-trial	B-X
comparisons	B-X
.	B-X
rt-PA	B-X
has	B-X
antigenic	B-X
properties	B-X
and	B-X
although	B-X
their	B-X
long-term	B-X
clinical	B-X
relevance	B-X
is	B-X
unclear	B-X
there	B-X
should	B-X
be	B-X
surveillance	B-X
for	B-X
allergic	B-X
reactions	B-X
in	B-X
relation	B-X
to	B-X
treatment	B-X
.	B-X

RNA	O
was	O
extracted	O
and	O
reverse	O
-	O
transcribed	O
and	O
cDNA	O
was	O
analyzed	O
for	O
the	O
expression	O
of	O
cytokines	O
and	O
transcription	O
factors	O
by	O
real	O
-	O
time	O
PCR	O
assay	O
as	O
before	O
(	O
Shoemaker	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Target	O
gene	O
mRNA	O
expression	O
was	O
quantified	O
either	O
with	O
SYBR	O
Green	O
(	O
Applied	O
Biosystems	O
)	O
or	O
with	O
Master	O
Mix	O
(	O
Applied	O
Biosystems	O
)	O
and	O
normalized	O
to	O
ubiquitin	B-Protein
or	O
HPRT	B-Protein
mRNA	O
levels	O
,	O
respectively	O
.	O
<EOS>	B-X
The	B-X
genes	B-X
encoding	B-X
β-actin	B-X
(	B-X
ACTB	B-X
in	B-X
human	B-X
or	B-X
Actb	B-X
in	B-X
mouse	B-X
)	B-X
and	B-X
glyceraldehyde-3-phosphate	B-X
dehydrogenase	B-X
(	B-X
GAPDH	B-X
in	B-X
human	B-X
or	B-X
Gapdh	B-X
in	B-X
mouse	B-X
)	B-X
are	B-X
the	B-X
two	B-X
most	B-X
commonly	B-X
used	B-X
references	B-X
for	B-X
sample	B-X
normalization	B-X
in	B-X
determination	B-X
of	B-X
the	B-X
mRNA	B-X
level	B-X
of	B-X
interested	B-X
genes	B-X
by	B-X
reverse	B-X
transcription	B-X
(	B-X
RT	B-X
)	B-X
and	B-X
ensuing	B-X
polymerase	B-X
chain	B-X
reactions	B-X
(	B-X
PCR	B-X
)	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
bioinformatic	B-X
analyses	B-X
revealed	B-X
that	B-X
the	B-X
ACTB	B-X
,	B-X
Actb	B-X
,	B-X
GAPDH	B-X
and	B-X
Gapdh	B-X
had	B-X
64	B-X
,	B-X
69	B-X
,	B-X
67	B-X
and	B-X
197	B-X
pseudogenes	B-X
(	B-X
PGs	B-X
)	B-X
,	B-X
respectively	B-X
,	B-X
in	B-X
the	B-X
corresponding	B-X
genome	B-X
.	B-X
Most	B-X
of	B-X
these	B-X
PGs	B-X
are	B-X
intronless	B-X
and	B-X
similar	B-X
in	B-X
size	B-X
to	B-X
the	B-X
authentic	B-X
mRNA	B-X
.	B-X
Alignment	B-X
of	B-X
several	B-X
PGs	B-X
of	B-X
these	B-X
genes	B-X
with	B-X
the	B-X
corresponding	B-X
mRNA	B-X
reveals	B-X
that	B-X
they	B-X
are	B-X
highly	B-X
homologous	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
hypoxanthine	B-X
phosphoribosyltransferase-1	B-X
gene	B-X
(	B-X
HPRT1	B-X
in	B-X
human	B-X
or	B-X
Hprt	B-X
in	B-X
mouse	B-X
)	B-X
only	B-X
had	B-X
3	B-X
or	B-X
1	B-X
PG	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
the	B-X
mRNA	B-X
has	B-X
unique	B-X
regions	B-X
for	B-X
primer	B-X
design	B-X
.	B-X
PCR	B-X
with	B-X
cDNA	B-X
or	B-X
genomic	B-X
DNA	B-X
(	B-X
gDNA	B-X
)	B-X
as	B-X
templates	B-X
revealed	B-X
that	B-X
our	B-X
HPRT1	B-X
,	B-X
Hprt	B-X
and	B-X
GAPDH	B-X
primers	B-X
were	B-X
specific	B-X
,	B-X
whereas	B-X
our	B-X
ACTB	B-X
and	B-X
Actb	B-X
primers	B-X
were	B-X
not	B-X
specific	B-X
enough	B-X
both	B-X
vertically	B-X
(	B-X
within	B-X
the	B-X
cDNA	B-X
)	B-X
and	B-X
horizontally	B-X
(	B-X
compared	B-X
cDNA	B-X
with	B-X
gDNA	B-X
)	B-X
.	B-X

Immunoblotting	O
<EOS>	B-X
Immunoblotting	B-X
(	B-X
also	B-X
known	B-X
as	B-X
Western	B-X
blotting	B-X
)	B-X
combined	B-X
with	B-X
digital	B-X
image	B-X
analysis	B-X
can	B-X
be	B-X
a	B-X
reliable	B-X
method	B-X
for	B-X
analyzing	B-X
the	B-X
abundance	B-X
of	B-X
proteins	B-X
and	B-X
protein	B-X
modifications	B-X
,	B-X
but	B-X
not	B-X
every	B-X
immunoblot-analysis	B-X
combination	B-X
produces	B-X
an	B-X
accurate	B-X
result	B-X
.	B-X
Grid-Immunoblotting	B-X
is	B-X
a	B-X
fast	B-X
,	B-X
simple	B-X
,	B-X
and	B-X
efficient	B-X
method	B-X
for	B-X
simultaneously	B-X
testing	B-X
multiple	B-X
allergens	B-X
utilizing	B-X
small	B-X
amount	B-X
of	B-X
antibody	B-X
.	B-X
Immunoblotting	B-X
(	B-X
western	B-X
blotting	B-X
)	B-X
is	B-X
used	B-X
to	B-X
identify	B-X
specific	B-X
antigens	B-X
recognized	B-X
by	B-X
polyclonal	B-X
or	B-X
monoclonal	B-X
antibodies	B-X
.	B-X
Immunoblotting	B-X
(	B-X
western	B-X
blotting	B-X
)	B-X
is	B-X
used	B-X
to	B-X
identify	B-X
specific	B-X
antigens	B-X
recognized	B-X
by	B-X
polyclonal	B-X
or	B-X
monoclonal	B-X
antibodies	B-X
.	B-X

Differentiated	O
CD4	B-Protein
+	O
T	O
cells	O
were	O
rested	O
for	O
5	O
hr	O
in	O
1	O
%	O
FCS	O
-	O
containing	O
medium	O
and	O
restimulated	O
as	O
described	O
for	O
specific	O
experiments	O
.	O

Cell	O
lysates	O
were	O
prepared	O
,	O
equal	O
amounts	O
of	O
protein	O
were	O
separated	O
by	O
SDS	O
-	O
PAGE	O
,	O
and	O
phosphorylated	O
or	O
total	O
ERK	B-Protein
and	O
actin	B-Protein
were	O
detected	O
as	O
described	O
before	O
(	O
Beinke	O
et	O
al	O
.	O
,	O
2004	O
)	O
.	O

Differential	O
cytokine	O
regulation	O
by	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
in	O
Jurkat	O
T	O
-	O
cells	O

Background	O
<EOS>	B-X
Background	B-X
matching	B-X
is	B-X
the	B-X
most	B-X
familiar	B-X
and	B-X
widespread	B-X
camouflage	B-X
strategy	B-X
:	B-X
avoiding	B-X
detection	B-X
by	B-X
having	B-X
a	B-X
similar	B-X
colour	B-X
and	B-X
pattern	B-X
to	B-X
the	B-X
background	B-X
.	B-X
Background	B-X
is	B-X
thus	B-X
a	B-X
relatively	B-X
modest	B-X
correction	B-X
for	B-X
all	B-X
Z	B-X
opacity	B-X
data	B-X
published	B-X
to	B-X
date	B-X
.	B-X
Background	B-X
estimation	B-X
and	B-X
foreground	B-X
segmentation	B-X
are	B-X
important	B-X
steps	B-X
in	B-X
many	B-X
high-level	B-X
vision	B-X
tasks	B-X
.	B-X
Patient	B-X
Preference	B-X
for	B-X
Telehealth	B-X
Background	B-X
Shapes	B-X
Impressions	B-X
of	B-X
Physicians	B-X
and	B-X
Information	B-X
Recall	B-X
:	B-X
A	B-X
Randomized	B-X
Experiment	B-X
.	B-X

Activator	O
protein	O
(	O
AP	O
)	O
-	O
1	O
and	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
largely	O
control	O
T	O
-	O
cell	O
activation	O
,	O
following	O
binding	O
of	O
foreign	O
antigens	O
to	O
the	O
T	O
-	O
cell	O
receptor	O
leading	O
to	O
cytokine	O
secretion	O
.	O

Elevated	O
levels	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
and	O
chemokines	O
such	O
as	O
TNF	O
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
CXCL8	B-Protein
are	O
associated	O
with	O
several	O
human	O
diseases	O
including	O
cystic	O
fibrosis	O
,	O
pulmonary	O
fibrosis	O
and	O
AIDS	O
.	O
<EOS>	B-X
Activator	B-X
protein	B-X
(	B-X
AP	B-X
)	B-X
-1	B-X
and	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
largely	B-X
control	B-X
T-cell	B-X
activation	B-X
,	B-X
following	B-X
binding	B-X
of	B-X
foreign	B-X
antigens	B-X
to	B-X
the	B-X
T-cell	B-X
receptor	B-X
leading	B-X
to	B-X
cytokine	B-X
secretion	B-X
.	B-X
Elevated	B-X
levels	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
such	B-X
as	B-X
TNF	B-X
,	B-X
IL-6	B-X
and	B-X
CXCL8	B-X
are	B-X
associated	B-X
with	B-X
several	B-X
human	B-X
diseases	B-X
including	B-X
cystic	B-X
fibrosis	B-X
,	B-X
pulmonary	B-X
fibrosis	B-X
and	B-X
AIDS	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
the	B-X
transcription	B-X
factors	B-X
,	B-X
AP-1	B-X
and	B-X
NF-kappaB	B-X
,	B-X
in	B-X
IL-6	B-X
and	B-X
CXCL8	B-X
regulation	B-X
in	B-X
Jurkat	B-X
T-cells	B-X
.	B-X

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
the	O
transcription	O
factors	O
,	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
,	O
in	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
CXCL8	B-Protein
regulation	O
in	O
Jurkat	O
T	O
-	O
cells	O
.	O

Results	O

Phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
exposure	O
resulted	O
in	O
an	O
up	O
-	O
regulation	O
of	O
AP	O
-	O
1	O
and	O
down	O
-	O
regulation	O
of	O
NF	O
-	O
kappaB	O
activity	O
,	O
however	O
,	O
exposure	O
to	O
heat	O
killed	O
(	O
HK	O
)	O
Escherichia	O
.	O
coli	O
MG1655	O
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
NF	O
-	O
kappaB	O
activity	O
without	O
affecting	O
AP	O
-	O
1	O
.	O

The	O
cytokine	O
profile	O
revealed	O
an	O
up	O
-	O
regulation	O
of	O
the	O
chemokine	O
CXCL8	B-Protein
and	O
the	O
pro	O
-	O
inflammatory	O
cytokines	O
TNF	O
,	O
IL	B-Protein
-	I-Protein
2	I-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
following	O
treatment	O
with	O
both	O
PMA	O
and	O
HK	O
E	O
.	O
coli	O
,	O
while	O
the	O
levels	O
of	O
the	O
anti	O
-	O
inflammatory	O
cytokine	O
IL	B-Protein
-	I-Protein
10	I-Protein
were	O
not	O
affected	O
by	O
PMA	O
but	O
were	O
significantly	O
down	O
-	O
regulated	O
by	O
HK	O
E	O
.	O
coli	O
.	O

AP	O
-	O
1	O
activation	O
was	O
significantly	O
increased	O
2	O
h	O
after	O
PMA	O
exposure	O
and	O
continued	O
to	O
increase	O
thereafter	O
.	O
<EOS>	B-X
Activator	B-X
protein	B-X
(	B-X
AP	B-X
)	B-X
-1	B-X
and	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
largely	B-X
control	B-X
T-cell	B-X
activation	B-X
,	B-X
following	B-X
binding	B-X
of	B-X
foreign	B-X
antigens	B-X
to	B-X
the	B-X
T-cell	B-X
receptor	B-X
leading	B-X
to	B-X
cytokine	B-X
secretion	B-X
.	B-X
Elevated	B-X
levels	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
such	B-X
as	B-X
TNF	B-X
,	B-X
IL-6	B-X
and	B-X
CXCL8	B-X
are	B-X
associated	B-X
with	B-X
several	B-X
human	B-X
diseases	B-X
including	B-X
cystic	B-X
fibrosis	B-X
,	B-X
pulmonary	B-X
fibrosis	B-X
and	B-X
AIDS	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
the	B-X
transcription	B-X
factors	B-X
,	B-X
AP-1	B-X
and	B-X
NF-kappaB	B-X
,	B-X
in	B-X
IL-6	B-X
and	B-X
CXCL8	B-X
regulation	B-X
in	B-X
Jurkat	B-X
T-cells	B-X
.	B-X

In	O
contrast	O
,	O
NF	O
-	O
kappaB	O
responded	O
to	O
PMA	O
exposure	O
by	O
a	O
rapid	O
up	O
-	O
regulation	O
followed	O
by	O
a	O
subsequent	O
down	O
-	O
regulation	O
.	O
<EOS>	B-X
Activator	B-X
protein	B-X
(	B-X
AP	B-X
)	B-X
-1	B-X
and	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
largely	B-X
control	B-X
T-cell	B-X
activation	B-X
,	B-X
following	B-X
binding	B-X
of	B-X
foreign	B-X
antigens	B-X
to	B-X
the	B-X
T-cell	B-X
receptor	B-X
leading	B-X
to	B-X
cytokine	B-X
secretion	B-X
.	B-X
Elevated	B-X
levels	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
such	B-X
as	B-X
TNF	B-X
,	B-X
IL-6	B-X
and	B-X
CXCL8	B-X
are	B-X
associated	B-X
with	B-X
several	B-X
human	B-X
diseases	B-X
including	B-X
cystic	B-X
fibrosis	B-X
,	B-X
pulmonary	B-X
fibrosis	B-X
and	B-X
AIDS	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
the	B-X
transcription	B-X
factors	B-X
,	B-X
AP-1	B-X
and	B-X
NF-kappaB	B-X
,	B-X
in	B-X
IL-6	B-X
and	B-X
CXCL8	B-X
regulation	B-X
in	B-X
Jurkat	B-X
T-cells	B-X
.	B-X

Increased	O
intracellular	O
Ca2	O
+	O
concentrations	O
countered	O
the	O
down	O
-	O
regulation	O
of	O
NF	O
-	O
kappaB	O
by	O
PMA	O
,	O
while	O
similar	O
treatment	O
with	O
calcium	O
ionophore	O
resulted	O
in	O
a	O
reduced	O
NF	O
-	O
kappaB	O
activity	O
following	O
induction	O
with	O
HK	O
E	O
.	O
coli	O
.	O

In	O
order	O
to	O
further	O
study	O
NF	O
-	O
kappaB	O
activation	O
,	O
we	O
considered	O
two	O
up	O
-	O
stream	O
signalling	O
proteins	O
,	O
PKC	O
and	O
Bcl10	B-Protein
.	O
<EOS>	B-X
Activator	B-X
protein	B-X
(	B-X
AP	B-X
)	B-X
-1	B-X
and	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
largely	B-X
control	B-X
T-cell	B-X
activation	B-X
,	B-X
following	B-X
binding	B-X
of	B-X
foreign	B-X
antigens	B-X
to	B-X
the	B-X
T-cell	B-X
receptor	B-X
leading	B-X
to	B-X
cytokine	B-X
secretion	B-X
.	B-X
Elevated	B-X
levels	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
such	B-X
as	B-X
TNF	B-X
,	B-X
IL-6	B-X
and	B-X
CXCL8	B-X
are	B-X
associated	B-X
with	B-X
several	B-X
human	B-X
diseases	B-X
including	B-X
cystic	B-X
fibrosis	B-X
,	B-X
pulmonary	B-X
fibrosis	B-X
and	B-X
AIDS	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
the	B-X
transcription	B-X
factors	B-X
,	B-X
AP-1	B-X
and	B-X
NF-kappaB	B-X
,	B-X
in	B-X
IL-6	B-X
and	B-X
CXCL8	B-X
regulation	B-X
in	B-X
Jurkat	B-X
T-cells	B-X
.	B-X

Phosphorylated	O
-	O
PKC	O
levels	O
increased	O
in	O
response	O
to	O
PMA	O
and	O
HK	O
E	O
.	O
coli	O
,	O
while	O
Bcl10	B-Protein
levels	O
significantly	O
decreased	O
following	O
PMA	O
treatment	O
.	O
<EOS>	B-X
Activator	B-X
protein	B-X
(	B-X
AP	B-X
)	B-X
-1	B-X
and	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
largely	B-X
control	B-X
T-cell	B-X
activation	B-X
,	B-X
following	B-X
binding	B-X
of	B-X
foreign	B-X
antigens	B-X
to	B-X
the	B-X
T-cell	B-X
receptor	B-X
leading	B-X
to	B-X
cytokine	B-X
secretion	B-X
.	B-X
Elevated	B-X
levels	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
such	B-X
as	B-X
TNF	B-X
,	B-X
IL-6	B-X
and	B-X
CXCL8	B-X
are	B-X
associated	B-X
with	B-X
several	B-X
human	B-X
diseases	B-X
including	B-X
cystic	B-X
fibrosis	B-X
,	B-X
pulmonary	B-X
fibrosis	B-X
and	B-X
AIDS	B-X
.	B-X

Using	O
an	O
NF	O
-	O
kappaB	O
activation	O
inhibitor	O
,	O
we	O
observed	O
complete	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
expression	O
while	O
CXCL8	B-Protein
levels	O
only	O
decreased	O
by	O
40	O
%	O
at	O
the	O
highest	O
concentration	O
.	O
<EOS>	B-X
Activator	B-X
protein	B-X
(	B-X
AP	B-X
)	B-X
-1	B-X
and	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
largely	B-X
control	B-X
T-cell	B-X
activation	B-X
,	B-X
following	B-X
binding	B-X
of	B-X
foreign	B-X
antigens	B-X
to	B-X
the	B-X
T-cell	B-X
receptor	B-X
leading	B-X
to	B-X
cytokine	B-X
secretion	B-X
.	B-X
Elevated	B-X
levels	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
such	B-X
as	B-X
TNF	B-X
,	B-X
IL-6	B-X
and	B-X
CXCL8	B-X
are	B-X
associated	B-X
with	B-X
several	B-X
human	B-X
diseases	B-X
including	B-X
cystic	B-X
fibrosis	B-X
,	B-X
pulmonary	B-X
fibrosis	B-X
and	B-X
AIDS	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
the	B-X
transcription	B-X
factors	B-X
,	B-X
AP-1	B-X
and	B-X
NF-kappaB	B-X
,	B-X
in	B-X
IL-6	B-X
and	B-X
CXCL8	B-X
regulation	B-X
in	B-X
Jurkat	B-X
T-cells	B-X
.	B-X

Treatment	O
of	O
Jurkat	O
T	O
-	O
cells	O
with	O
PMA	O
in	O
the	O
presence	O
of	O
JNK	O
-	O
inhibitor	O
suppressed	O
both	O
CXCL8	B-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
while	O
PKC	O
-	O
inhibitor	O
primarily	O
decreased	O
CXCL8	B-Protein
expression	O
.	O

Conclusion	O
<EOS>	B-X
Conclusion	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X
[	B-X
Conclusion	B-X
]	B-X
.	B-X

The	O
present	O
study	O
shows	O
that	O
NF	O
-	O
kappaB	O
regulated	O
IL	B-Protein
-	I-Protein
6	I-Protein
but	O
not	O
CXCL8	B-Protein
.	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
roles	B-X
of	B-X
miRNAs	B-X
in	B-X
OA	B-X
inflammation	B-X
and	B-X
the	B-X
underlying	B-X
molecular	B-X
mechanism	B-X
.	B-X
Using	B-X
this	B-X
LPS‑induced	B-X
chondrocyte	B-X
injury	B-X
model	B-X
,	B-X
the	B-X
overexpression	B-X
of	B-X
miR‑93	B-X
enhanced	B-X
cell	B-X
viability	B-X
,	B-X
improved	B-X
cell	B-X
apoptosis	B-X
and	B-X
attenuated	B-X
the	B-X
inflammatory	B-X
response	B-X
,	B-X
as	B-X
reflected	B-X
by	B-X
reductions	B-X
in	B-X
pro‑inflammatory	B-X
cytokines	B-X
,	B-X
including	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
‑α	B-X
,	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
‑1β	B-X
and	B-X
IL‑6	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
Toll‑like	B-X
receptor	B-X
4	B-X
(	B-X
TLR4	B-X
)	B-X
,	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
the	B-X
nuclear	B-X
factor‑κB	B-X
(	B-X
NF‑κB	B-X
)	B-X
signaling	B-X
pathway	B-X
,	B-X
was	B-X
identified	B-X
as	B-X
a	B-X
direct	B-X
target	B-X
of	B-X
miR‑93	B-X
in	B-X
chondrocytes	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
the	B-X
results	B-X
of	B-X
the	B-X
study	B-X
suggested	B-X
that	B-X
miR‑93	B-X
may	B-X
be	B-X
a	B-X
promising	B-X
therapeutic	B-X
target	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
human	B-X
OA	B-X
.	B-X

This	O
complex	O
regulation	O
of	O
CXCL8	B-Protein
suggests	O
that	O
there	O
is	O
a	O
need	O
to	O
further	O
evaluate	O
the	O
signalling	O
pathways	O
in	O
order	O
to	O
develop	O
new	O
treatment	O
for	O
diseases	O
with	O
elevated	O
CXCL8	B-Protein
levels	O
,	O
such	O
as	O
AIDS	O
and	O
autoimmune	O
diseases	O
.	O
<EOS>	B-X
Elevated	B-X
levels	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
such	B-X
as	B-X
TNF	B-X
,	B-X
IL-6	B-X
and	B-X
CXCL8	B-X
are	B-X
associated	B-X
with	B-X
several	B-X
human	B-X
diseases	B-X
including	B-X
cystic	B-X
fibrosis	B-X
,	B-X
pulmonary	B-X
fibrosis	B-X
and	B-X
AIDS	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
the	B-X
transcription	B-X
factors	B-X
,	B-X
AP-1	B-X
and	B-X
NF-kappaB	B-X
,	B-X
in	B-X
IL-6	B-X
and	B-X
CXCL8	B-X
regulation	B-X
in	B-X
Jurkat	B-X
T-cells	B-X
.	B-X

Cytokines	O
and	O
chemokines	O
are	O
important	O
in	O
immune	O
cell	O
recruitment	O
and	O
in	O
regulation	O
of	O
inflammatory	O
responses	O
[	O
1	O
]	O
.	O
<EOS>	B-X
Transforming	B-X
growth	B-X
factor	B-X
beta	B-X
(	B-X
TGF-beta	B-X
)	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
tumor	B-X
initiation	B-X
and	B-X
progression	B-X
,	B-X
functioning	B-X
as	B-X
both	B-X
a	B-X
suppressor	B-X
and	B-X
a	B-X
promoter	B-X
.	B-X
TGF-beta	B-X
exerts	B-X
systemic	B-X
immune	B-X
suppression	B-X
and	B-X
inhibits	B-X
host	B-X
immunosurveillance	B-X
.	B-X
Neutralizing	B-X
TGF-beta	B-X
enhances	B-X
CD8+	B-X
T-cell-	B-X
and	B-X
NK-cell-mediated	B-X
anti-tumor	B-X
immune	B-X
responses	B-X
.	B-X
It	B-X
also	B-X
increases	B-X
neutrophil-attracting	B-X
chemokines	B-X
resulting	B-X
in	B-X
recruitment	B-X
and	B-X
activation	B-X
of	B-X
neutrophils	B-X
with	B-X
an	B-X
antitumor	B-X
phenotype	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
its	B-X
systemic	B-X
effects	B-X
,	B-X
TGF-beta	B-X
regulates	B-X
infiltration	B-X
of	B-X
inflammatory/immune	B-X
cells	B-X
and	B-X
cancer-associated	B-X
fibroblasts	B-X
in	B-X
the	B-X
tumor	B-X
microenvironment	B-X
causing	B-X
direct	B-X
changes	B-X
in	B-X
tumor	B-X
cells	B-X
.	B-X
Understanding	B-X
TGF-beta	B-X
regulation	B-X
at	B-X
the	B-X
interface	B-X
of	B-X
tumor	B-X
and	B-X
host	B-X
immunity	B-X
should	B-X
provide	B-X
insights	B-X
into	B-X
developing	B-X
effective	B-X
TGF-beta	B-X
antagonists	B-X
and	B-X
biomarkers	B-X
for	B-X
patient	B-X
selection	B-X
and	B-X
efficacy	B-X
of	B-X
TGF-beta	B-X
antagonist	B-X
treatment	B-X
.	B-X

T	O
-	O
cells	O
produce	O
a	O
broad	O
range	O
of	O
inflammatory	O
mediators	O
,	O
including	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
TNF	O
and	O
CXCL8	B-Protein
,	O
all	O
of	O
which	O
are	O
important	O
in	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
communication	O
and	O
initiation	O
of	O
inflammatory	O
responses	O
[	O
2	O
]	O
.	O

Elevated	O
levels	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
and	O
chemokines	O
,	O
such	O
as	O
TNF	O
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
CXCL8	B-Protein
,	O
are	O
associated	O
with	O
several	O
human	O
diseases	O
including	O
cystic	O
fibrosis	O
[	O
3	O
-	O
5	O
]	O
,	O
pulmonary	O
fibrosis	O
[	O
6	O
,	O
7	O
]	O
and	O
AIDS	O
[	O
8	O
,	O
9	O
]	O
.	O
<EOS>	B-X
Activator	B-X
protein	B-X
(	B-X
AP	B-X
)	B-X
-1	B-X
and	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
largely	B-X
control	B-X
T-cell	B-X
activation	B-X
,	B-X
following	B-X
binding	B-X
of	B-X
foreign	B-X
antigens	B-X
to	B-X
the	B-X
T-cell	B-X
receptor	B-X
leading	B-X
to	B-X
cytokine	B-X
secretion	B-X
.	B-X
Elevated	B-X
levels	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
such	B-X
as	B-X
TNF	B-X
,	B-X
IL-6	B-X
and	B-X
CXCL8	B-X
are	B-X
associated	B-X
with	B-X
several	B-X
human	B-X
diseases	B-X
including	B-X
cystic	B-X
fibrosis	B-X
,	B-X
pulmonary	B-X
fibrosis	B-X
and	B-X
AIDS	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
the	B-X
transcription	B-X
factors	B-X
,	B-X
AP-1	B-X
and	B-X
NF-kappaB	B-X
,	B-X
in	B-X
IL-6	B-X
and	B-X
CXCL8	B-X
regulation	B-X
in	B-X
Jurkat	B-X
T-cells	B-X
.	B-X

Induction	O
of	O
CXCL8	B-Protein
has	O
been	O
suggested	O
to	O
be	O
mediated	O
through	O
NF	O
-	O
kappaB	O
in	O
cooperation	O
with	O
AP	O
-	O
1	O
[	O
10	O
,	O
11	O
]	O
,	O
however	O
the	O
precise	O
mechanism	O
is	O
not	O
fully	O
elucidated	O
,	O
and	O
treatment	O
strategies	O
aimed	O
at	O
inhibiting	O
CXCL8	B-Protein
have	O
failed	O
[	O
12	O
]	O
.	O

Persistent	O
production	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
CXCL8	B-Protein
leads	O
to	O
chronic	O
inflammation	O
and	O
enhanced	O
survival	O
of	O
lymphocytes	O
increasing	O
serum	O
cytokine	O
/	O
chemokine	O
levels	O
.	O

This	O
forms	O
the	O
basis	O
of	O
several	O
autoimmune	O
disorders	O
including	O
plasmacytosis	O
and	O
hyperplasia	O
[	O
13	O
]	O
.	O

To	O
develop	O
viable	O
CXCL8	B-Protein
based	O
treatment	O
strategies	O
,	O
it	O
is	O
necessary	O
to	O
identify	O
the	O
signalling	O
pathways	O
regulating	O
CXCL8	B-Protein
and	O
determine	O
how	O
this	O
is	O
coupled	O
to	O
NF	O
-	O
kappaB	O
,	O
AP	O
-	O
1	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
.	O

The	O
signalling	O
pathways	O
leading	O
to	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
activation	O
are	O
overlapping	O
,	O
where	O
both	O
are	O
involved	O
in	O
the	O
induction	O
and	O
regulation	O
of	O
cytokines	O
/	O
chemokines	O
.	O

NF	O
-	O
kappaB	O
is	O
activated	O
in	O
response	O
to	O
stress	O
,	O
such	O
as	O
oxidative	O
stress	O
,	O
bacterial	O
toxins	O
,	O
viruses	O
and	O
UV	O
light	O
[	O
14	O
]	O
,	O
and	O
is	O
essential	O
for	O
differentiation	O
,	O
proliferation	O
and	O
survival	O
of	O
many	O
cell	O
types	O
including	O
T	O
-	O
lymphocytes	O
[	O
15	O
]	O
.	O

AP	O
-	O
1	O
activation	O
requires	O
Fos	O
(	O
c	B-Protein
-	I-Protein
Fos	I-Protein
,	O
FosB	B-Protein
,	O
Fra	B-Protein
-	I-Protein
1	I-Protein
,	O
Fra	B-Protein
-	I-Protein
2	I-Protein
)	O
and	O
Jun	O
(	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
v	B-Protein
-	I-Protein
Jun	I-Protein
,	O
JunB	B-Protein
,	O
JunD	B-Protein
)	O
through	O
the	O
formation	O
of	O
homo	O
-	O
and	O
hetero	O
-	O
dimers	O
[	O
16	O
,	O
17	O
]	O
,	O
and	O
regulates	O
transcription	O
of	O
a	O
broad	O
range	O
of	O
genes	O
involved	O
in	O
immune	O
responses	O
[	O
18	O
-	O
21	O
]	O
.	O

Both	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
binding	O
sites	O
have	O
been	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
CXCL8	B-Protein
[	O
12	O
,	O
22	O
]	O
,	O
however	O
,	O
the	O
mechanism	O
by	O
which	O
these	O
interleukins	O
are	O
regulated	O
in	O
T	O
-	O
cells	O
is	O
still	O
not	O
clear	O
.	O

CXCL8	B-Protein
is	O
a	O
C	O
-	O
X	O
-	O
C	O
chemokine	O
with	O
properties	O
enabling	O
it	O
to	O
recruit	O
T	O
-	O
cells	O
and	O
basophils	O
and	O
to	O
activate	O
neutrophils	O
and	O
monocytes	O
[	O
23	O
]	O
.	O

IL	B-Protein
-	I-Protein
6	I-Protein
is	O
a	O
cytokine	O
that	O
possesses	O
both	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
characteristics	O
and	O
that	O
plays	O
a	O
key	O
role	O
in	O
haematopoiesis	O
and	O
acute	O
-	O
phase	O
responses	O
[	O
24	O
,	O
25	O
]	O
.	O

The	O
present	O
study	O
suggests	O
that	O
the	O
regulation	O
of	O
CXCL8	B-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
is	O
uncoupled	O
.	O

Using	O
Jurkat	O
T	O
-	O
cells	O
exposed	O
to	O
PMA	O
and	O
heat	O
killed	O
(	O
HK	O
)	O
Escherichia	O
coli	O
MG1655	O
in	O
combination	O
with	O
inhibitors	O
of	O
NF	O
-	O
kappaB	O
,	O
JNK	O
and	O
PKC	O
,	O
we	O
demonstrated	O
that	O
NF	O
-	O
kappaB	O
regulates	O
IL	B-Protein
-	I-Protein
6	I-Protein
expression	O
while	O
the	O
regulation	O
of	O
CXCL8	B-Protein
more	O
closely	O
correlated	O
to	O
AP	B-Protein
-	I-Protein
1	I-Protein
activity	O
.	O

These	O
results	O
indicate	O
that	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
is	O
not	O
an	O
effective	O
strategy	O
in	O
countering	O
the	O
high	O
CXCL8	B-Protein
activities	O
in	O
diseases	O
such	O
as	O
cystic	O
fibrosis	O
,	O
AIDS	O
and	O
pulmonary	O
fibrosis	O
.	O
<EOS>	B-X
Through	B-X
multi-omics	B-X
joint	B-X
analysis	B-X
,	B-X
it	B-X
was	B-X
found	B-X
that	B-X
ASFV	B-X
infection	B-X
regulates	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
host	B-X
NF-B	B-X
signal	B-X
pathway	B-X
and	B-X
related	B-X
cytokines	B-X
.	B-X
Additionally	B-X
,	B-X
changes	B-X
in	B-X
the	B-X
NF-κB	B-X
signaling	B-X
pathway	B-X
and	B-X
IL-1β	B-X
and	B-X
IL-8	B-X
expression	B-X
in	B-X
porcine	B-X
alveolar	B-X
macrophages	B-X
(	B-X
PAMs	B-X
)	B-X
infected	B-X
with	B-X
ASFV	B-X
were	B-X
examined	B-X
.	B-X
Results	B-X
show	B-X
that	B-X
ASFV	B-X
infection	B-X
activates	B-X
the	B-X
NF-κB	B-X
signaling	B-X
pathway	B-X
and	B-X
up-regulates	B-X
the	B-X
expression	B-X
of	B-X
IL-1β	B-X
and	B-X
IL-8	B-X
.	B-X
The	B-X
NF-κB	B-X
inhibitor	B-X
BAY11-7082	B-X
inhibited	B-X
the	B-X
expression	B-X
profiles	B-X
of	B-X
phospho-NF-κB	B-X
p65	B-X
,	B-X
p-IκB	B-X
,	B-X
and	B-X
MyD88	B-X
proteins	B-X
,	B-X
and	B-X
inhibited	B-X
ASFV-induced	B-X
NF-κB	B-X
signaling	B-X
pathway	B-X
activation	B-X
.	B-X
Additionally	B-X
,	B-X
the	B-X
results	B-X
show	B-X
that	B-X
the	B-X
NF-κB	B-X
inhibitor	B-X
BAY11-7082	B-X
can	B-X
inhibit	B-X
the	B-X
replication	B-X
of	B-X
ASFV	B-X
and	B-X
can	B-X
inhibit	B-X
IL-1β	B-X
and	B-X
,	B-X
IL-8	B-X
expression	B-X
.	B-X
Overall	B-X
,	B-X
the	B-X
findings	B-X
of	B-X
this	B-X
study	B-X
indicate	B-X
that	B-X
ASFV	B-X
infection	B-X
activates	B-X
the	B-X
NF-κB	B-X
signaling	B-X
pathway	B-X
and	B-X
up-regulates	B-X
the	B-X
expression	B-X
of	B-X
IL-1β	B-X
and	B-X
IL-8	B-X
,	B-X
and	B-X
inhibits	B-X
the	B-X
replication	B-X
of	B-X
ASFV	B-X
by	B-X
inhibiting	B-X
the	B-X
NF-κB	B-X
signaling	B-X
pathway	B-X
and	B-X
interleukin-1	B-X
beta	B-X
and	B-X
interleukin-8	B-X
production	B-X
.	B-X
These	B-X
findings	B-X
not	B-X
only	B-X
provide	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
molecular	B-X
mechanism	B-X
of	B-X
the	B-X
association	B-X
between	B-X
the	B-X
NF-κB	B-X
signaling	B-X
pathway	B-X
and	B-X
ASFV	B-X
infection	B-X
,	B-X
but	B-X
also	B-X
indicate	B-X
that	B-X
the	B-X
NF-κB	B-X
signaling	B-X
pathway	B-X
is	B-X
a	B-X
potential	B-X
immunomodulatory	B-X
pathway	B-X
that	B-X
controls	B-X
ASF	B-X
.	B-X

Regulation	O
of	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
activation	O
<EOS>	B-X
Recent	B-X
studies	B-X
have	B-X
indicated	B-X
that	B-X
the	B-X
regulation	B-X
of	B-X
innate	B-X
immunity	B-X
and	B-X
energy	B-X
metabolism	B-X
are	B-X
connected	B-X
together	B-X
through	B-X
an	B-X
antagonistic	B-X
crosstalk	B-X
between	B-X
NF-κB	B-X
and	B-X
SIRT1	B-X
signaling	B-X
pathways	B-X
.	B-X
NF-κB	B-X
signaling	B-X
has	B-X
a	B-X
major	B-X
role	B-X
in	B-X
innate	B-X
immunity	B-X
defense	B-X
while	B-X
SIRT1	B-X
regulates	B-X
the	B-X
oxidative	B-X
respiration	B-X
and	B-X
cellular	B-X
survival	B-X
.	B-X
However	B-X
,	B-X
NF-κB	B-X
signaling	B-X
can	B-X
stimulate	B-X
glycolytic	B-X
energy	B-X
flux	B-X
during	B-X
acute	B-X
inflammation	B-X
,	B-X
whereas	B-X
SIRT1	B-X
activation	B-X
inhibits	B-X
NF-κB	B-X
signaling	B-X
and	B-X
enhances	B-X
oxidative	B-X
metabolism	B-X
and	B-X
the	B-X
resolution	B-X
of	B-X
inflammation	B-X
.	B-X
SIRT1	B-X
inhibits	B-X
NF-κB	B-X
signaling	B-X
directly	B-X
by	B-X
deacetylating	B-X
the	B-X
p65	B-X
subunit	B-X
of	B-X
NF-κB	B-X
complex	B-X
.	B-X
SIRT1	B-X
stimulates	B-X
oxidative	B-X
energy	B-X
production	B-X
via	B-X
the	B-X
activation	B-X
of	B-X
AMPK	B-X
,	B-X
PPARα	B-X
and	B-X
PGC-1α	B-X
and	B-X
simultaneously	B-X
,	B-X
these	B-X
factors	B-X
inhibit	B-X
NF-κB	B-X
signaling	B-X
and	B-X
suppress	B-X
inflammation	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
NF-κB	B-X
signaling	B-X
down-regulates	B-X
SIRT1	B-X
activity	B-X
through	B-X
the	B-X
expression	B-X
of	B-X
miR-34a	B-X
,	B-X
IFNγ	B-X
,	B-X
and	B-X
reactive	B-X
oxygen	B-X
species	B-X
.	B-X
The	B-X
inhibition	B-X
of	B-X
SIRT1	B-X
disrupts	B-X
oxidative	B-X
energy	B-X
metabolism	B-X
and	B-X
stimulates	B-X
the	B-X
NF-κB-induced	B-X
inflammatory	B-X
responses	B-X
present	B-X
in	B-X
many	B-X
chronic	B-X
metabolic	B-X
and	B-X
age-related	B-X
diseases	B-X
.	B-X
We	B-X
will	B-X
examine	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
the	B-X
antagonistic	B-X
signaling	B-X
between	B-X
NF-κB	B-X
and	B-X
SIRT1	B-X
and	B-X
describe	B-X
how	B-X
this	B-X
crosstalk	B-X
controls	B-X
inflammatory	B-X
process	B-X
and	B-X
energy	B-X
metabolism	B-X
.	B-X

The	O
transcription	O
factors	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
play	O
key	O
roles	O
in	O
the	O
initiation	O
of	O
an	O
inflammatory	O
response	O
by	O
inducing	O
the	O
expression	O
and	O
secretion	O
of	O
chemokines	O
and	O
cytokines	O
that	O
attract	O
and	O
activate	O
immune	O
cells	O
.	O

However	O
,	O
the	O
signal	O
transduction	O
pathways	O
and	O
subsequent	O
inflammatory	O
cytokine	O
induction	O
by	O
these	O
transcription	O
factors	O
is	O
not	O
fully	O
elucidated	O
.	O
<EOS>	B-X
SPTBN1	B-X
inhibits	B-X
inflammatory	B-X
responses	B-X
and	B-X
hepatocarcinogenesis	B-X
via	B-X
the	B-X
stabilization	B-X
of	B-X
SOCS1	B-X
and	B-X
downregulation	B-X
of	B-X
p65	B-X
in	B-X
hepatocellular	B-X
carcinoma	B-X
.	B-X
Advanced	B-X
oxidation	B-X
protein	B-X
products	B-X
(	B-X
AOPPs	B-X
)	B-X
are	B-X
novel	B-X
markers	B-X
of	B-X
oxidative	B-X
stress	B-X
and	B-X
their	B-X
role	B-X
in	B-X
inflammatory	B-X
response	B-X
after	B-X
SCI	B-X
remained	B-X
unclear	B-X
.	B-X
We	B-X
observe	B-X
a	B-X
strong	B-X
correlation	B-X
between	B-X
inflammatory	B-X
responses	B-X
and	B-X
disease	B-X
progression	B-X
and	B-X
fatal	B-X
outcome	B-X
.	B-X
Quantitative	B-X
proteomic	B-X
analysis	B-X
of	B-X
SFTSV	B-X
infection	B-X
confirms	B-X
the	B-X
induction	B-X
of	B-X
inflammation	B-X
and	B-X
further	B-X
reveals	B-X
virus-induced	B-X
mitochondrial	B-X
dysfunction	B-X
.	B-X
Mechanistically	B-X
,	B-X
SFTSV	B-X
infection	B-X
triggers	B-X
BCL2	B-X
antagonist/killer	B-X
1	B-X
(	B-X
BAK	B-X
)	B-X
upregulation	B-X
and	B-X
BAK/BCL2-associated	B-X
X	B-X
(	B-X
BAX	B-X
)	B-X
activation	B-X
,	B-X
leading	B-X
to	B-X
mitochondrial	B-X
DNA	B-X
(	B-X
mtDNA	B-X
)	B-X
oxidization	B-X
and	B-X
subsequent	B-X
cytosolic	B-X
release	B-X
.	B-X

The	O
present	O
study	O
is	O
aimed	O
at	O
determining	O
the	O
involvement	O
of	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
in	O
cytokine	O
induction	O
and	O
regulation	O
.	O

PMA	O
treatment	O
resulted	O
in	O
an	O
up	O
-	O
regulation	O
of	O
AP	O
-	O
1	O
after	O
2	O
h	O
exposure	O
and	O
continued	O
to	O
increase	O
throughout	O
the	O
analysis	O
period	O
(	O
figure	O
1a	O
)	O
.	O

HK	O
E	O
.	O
coli	O
treatment	O
did	O
not	O
affect	O
AP	O
-	O
1	O
activation	O
in	O
Jurkat	O
T	O
-	O
cells	O
(	O
figure	O
1b	O
)	O
.	O
<EOS>	B-X
Colorectal	B-X
cancer	B-X
(	B-X
CRC	B-X
)	B-X
accounts	B-X
for	B-X
about	B-X
10	B-X
%	B-X
of	B-X
all	B-X
new	B-X
cancer	B-X
cases	B-X
globally	B-X
.	B-X
Located	B-X
at	B-X
close	B-X
proximity	B-X
to	B-X
the	B-X
colorectal	B-X
epithelium	B-X
,	B-X
the	B-X
gut	B-X
microbiota	B-X
comprises	B-X
a	B-X
large	B-X
population	B-X
of	B-X
microorganisms	B-X
that	B-X
interact	B-X
with	B-X
host	B-X
cells	B-X
to	B-X
regulate	B-X
many	B-X
physiological	B-X
processes	B-X
,	B-X
such	B-X
as	B-X
energy	B-X
harvest	B-X
,	B-X
metabolism	B-X
and	B-X
immune	B-X
response	B-X
.	B-X
Sequencing	B-X
studies	B-X
have	B-X
revealed	B-X
microbial	B-X
compositional	B-X
and	B-X
ecological	B-X
changes	B-X
in	B-X
patients	B-X
with	B-X
CRC	B-X
,	B-X
whereas	B-X
functional	B-X
studies	B-X
in	B-X
animal	B-X
models	B-X
have	B-X
pinpointed	B-X
the	B-X
roles	B-X
of	B-X
several	B-X
bacteria	B-X
in	B-X
colorectal	B-X
carcinogenesis	B-X
,	B-X
including	B-X
Fusobacterium	B-X
nucleatum	B-X
and	B-X
certain	B-X
strains	B-X
of	B-X
Escherichia	B-X
coli	B-X
and	B-X
Bacteroides	B-X
fragilis	B-X
.	B-X
These	B-X
findings	B-X
give	B-X
new	B-X
opportunities	B-X
to	B-X
take	B-X
advantage	B-X
of	B-X
our	B-X
knowledge	B-X
on	B-X
the	B-X
gut	B-X
microbiota	B-X
for	B-X
clinical	B-X
applications	B-X
,	B-X
such	B-X
as	B-X
gut	B-X
microbiota	B-X
analysis	B-X
as	B-X
screening	B-X
,	B-X
prognostic	B-X
or	B-X
predictive	B-X
biomarkers	B-X
,	B-X
or	B-X
modulating	B-X
microorganisms	B-X
to	B-X
prevent	B-X
cancer	B-X
,	B-X
augment	B-X
therapies	B-X
and	B-X
reduce	B-X
adverse	B-X
effects	B-X
of	B-X
treatment	B-X
.	B-X
This	B-X
Review	B-X
aims	B-X
to	B-X
provide	B-X
an	B-X
overview	B-X
and	B-X
discussion	B-X
of	B-X
the	B-X
gut	B-X
microbiota	B-X
in	B-X
colorectal	B-X
neoplasia	B-X
,	B-X
including	B-X
relevant	B-X
mechanisms	B-X
in	B-X
microbiota-related	B-X
carcinogenesis	B-X
,	B-X
the	B-X
potential	B-X
of	B-X
utilizing	B-X
the	B-X
microbiota	B-X
as	B-X
CRC	B-X
biomarkers	B-X
,	B-X
and	B-X
the	B-X
prospect	B-X
for	B-X
modulating	B-X
the	B-X
microbiota	B-X
for	B-X
CRC	B-X
prevention	B-X
or	B-X
treatment	B-X
.	B-X

To	O
determine	O
the	O
involvement	O
of	O
associated	O
pathways	O
,	O
we	O
exposed	O
cells	O
to	O
Ca2	O
+	O
ionophore	O
with	O
or	O
without	O
PMA	O
and	O
observed	O
a	O
modest	O
involvement	O
of	O
Ca2	O
+	O
in	O
PMA	O
-	O
dependent	O
AP	O
-	O
1	O
activation	O
(	O
figure	O
1c	O
)	O
while	O
Ca2	O
+	O
alone	O
did	O
not	O
alter	O
AP	O
-	O
1	O
activity	O
(	O
data	O
not	O
shown	O
)	O
.	O

Furthermore	O
,	O
AP	O
-	O
1	O
activity	O
decreased	O
in	O
a	O
TCR	O
-	O
deficient	O
Jurkat	O
cell	O
line	O
when	O
exposed	O
to	O
PMA	O
compared	O
to	O
the	O
parent	O
cell	O
line	O
indicating	O
that	O
regulation	O
of	O
AP	O
-	O
1	O
was	O
only	O
partially	O
T	O
-	O
cell	O
receptor	O
dependent	O
(	O
figure	O
1d	O
)	O
.	O

NF	O
-	O
kappaB	O
levels	O
showed	O
a	O
transient	O
increase	O
at	O
1	O
min	O
after	O
exposure	O
to	O
PMA	O
(	O
figure	O
2a	O
)	O
.	O

However	O
,	O
1	O
h	O
after	O
exposure	O
the	O
NF	O
-	O
kappaB	O
levels	O
began	O
to	O
drop	O
reaching	O
the	O
lowest	O
levels	O
by	O
6	O
h	O
,	O
after	O
which	O
they	O
increased	O
again	O
by	O
24	O
h	O
.	O

Exposure	O
of	O
Jurkat	O
T	O
-	O
cells	O
to	O
HK	O
E	O
.	O
coli	O
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
NF	O
-	O
kappaB	O
activation	O
,	O
with	O
the	O
highest	O
activity	O
observed	O
at	O
a	O
relative	O
concentration	O
of	O
5	O
x	O
107	O
CFU	O
/	O
ml	O
(	O
figure	O
2b	O
)	O
.	O

The	O
time	O
-	O
dependent	O
activation	O
of	O
NF	O
-	O
kappaB	O
by	O
HK	O
E	O
.	O
coli	O
was	O
assessed	O
further	O
using	O
the	O
optimal	O
concentration	O
obtained	O
from	O
figure	O
2b	O
and	O
showed	O
that	O
the	O
NF	O
-	O
kappaB	O
activity	O
increased	O
after	O
3	O
h	O
of	O
exposure	O
(	O
figure	O
2c	O
)	O
.	O

Furthermore	O
,	O
increased	O
intracellular	O
Ca2	O
+	O
reversed	O
the	O
PMA	O
dependent	O
NF	O
-	O
kappaB	O
inhibition	O
(	O
figure	O
2d	O
)	O
and	O
reduced	O
the	O
HK	O
E	O
.	O
coli	O
-	O
dependent	O
NF	O
-	O
kappaB	O
activation	O
(	O
figure	O
2e	O
)	O
.	O

Induction	O
of	O
inflammatory	O
responses	O
<EOS>	B-X
To	B-X
analyze	B-X
the	B-X
influence	B-X
of	B-X
anesthetic	B-X
induction	B-X
of	B-X
propofol	B-X
combined	B-X
with	B-X
esketamine	B-X
on	B-X
perioperative	B-X
stress	B-X
and	B-X
inflammatory	B-X
responses	B-X
and	B-X
postoperative	B-X
cognition	B-X
in	B-X
elderly	B-X
surgical	B-X
patients	B-X
.	B-X
During	B-X
microbial	B-X
infection	B-X
,	B-X
macrophages	B-X
link	B-X
recognition	B-X
of	B-X
microbial	B-X
stimuli	B-X
to	B-X
the	B-X
induction	B-X
of	B-X
Type	B-X
I	B-X
inflammatory	B-X
responses	B-X
.	B-X
Such	B-X
inflammatory	B-X
responses	B-X
coordinate	B-X
host	B-X
defense	B-X
and	B-X
pathogen	B-X
elimination	B-X
but	B-X
induce	B-X
significant	B-X
tissue	B-X
damage	B-X
if	B-X
sustained	B-X
,	B-X
so	B-X
macrophages	B-X
are	B-X
initially	B-X
activated	B-X
to	B-X
induce	B-X
inflammatory	B-X
responses	B-X
but	B-X
then	B-X
shift	B-X
to	B-X
a	B-X
tolerant	B-X
state	B-X
to	B-X
suppress	B-X
inflammatory	B-X
responses	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
recent	B-X
studies	B-X
that	B-X
indicate	B-X
that	B-X
macrophage	B-X
metabolism	B-X
changes	B-X
dynamically	B-X
over	B-X
the	B-X
course	B-X
of	B-X
microbial	B-X
exposure	B-X
to	B-X
influence	B-X
a	B-X
shift	B-X
in	B-X
the	B-X
inflammatory	B-X
response	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
an	B-X
initial	B-X
increase	B-X
in	B-X
oxidative	B-X
metabolism	B-X
boosts	B-X
the	B-X
induction	B-X
of	B-X
inflammatory	B-X
responses	B-X
,	B-X
but	B-X
is	B-X
followed	B-X
by	B-X
a	B-X
shutdown	B-X
of	B-X
oxidative	B-X
metabolism	B-X
that	B-X
contributes	B-X
to	B-X
suppression	B-X
of	B-X
inflammatory	B-X
responses	B-X
.	B-X
We	B-X
propose	B-X
a	B-X
unifying	B-X
model	B-X
for	B-X
how	B-X
dynamic	B-X
changes	B-X
to	B-X
oxidative	B-X
metabolism	B-X
influences	B-X
regulation	B-X
of	B-X
macrophage	B-X
inflammatory	B-X
responses	B-X
during	B-X
microbial	B-X
exposure	B-X
.	B-X

The	O
ability	O
of	O
PMA	O
and	O
HK	O
E	O
.	O
coli	O
to	O
induce	O
an	O
inflammatory	O
response	O
in	O
Jurkat	O
T	O
-	O
cells	O
was	O
evaluated	O
using	O
a	O
multiplex	O
cytokine	O
assay	O
following	O
24	O
h	O
stimulation	O
.	O

The	O
cytokine	O
profile	O
revealed	O
an	O
enhanced	O
induction	O
of	O
the	O
pro	O
-	O
inflammatory	O
cytokines	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
TNF	O
and	O
the	O
chemokine	O
CXCL8	B-Protein
.	O

The	O
levels	O
of	O
the	O
anti	O
-	O
inflammatory	O
cytokine	O
IL	B-Protein
-	I-Protein
10	I-Protein
were	O
unaffected	O
by	O
PMA	O
but	O
were	O
significantly	O
decreased	O
by	O
HK	O
E	O
.	O
coli	O
(	O
Table	O
1	O
)	O
.	O

These	O
results	O
confirmed	O
that	O
PMA	O
and	O
HK	O
E	O
.	O
coli	O
induced	O
an	O
inflammatory	O
response	O
in	O
the	O
Jurkat	O
T	O
-	O
cells	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
PMA	O
was	O
120	O
-	O
fold	O
more	O
effective	O
at	O
inducing	O
CXCL8	B-Protein
than	O
HK	O
E	O
.	O
coli	O
.	O

PMA	O
-	O
dependent	O
induction	O
of	O
AP	O
-	O
1	O
and	O
down	O
-	O
regulation	O
of	O
NF	O
-	O
kappaB	O
suggests	O
an	O
involvement	O
of	O
AP	O
-	O
1	O
in	O
CXCL8	B-Protein
regulation	O
.	O

Determination	O
of	O
the	O
time	O
course	O
of	O
cytokine	O
induction	O
in	O
response	O
to	O
PMA	O
showed	O
that	O
CXCL8	B-Protein
was	O
already	O
released	O
between	O
2	O
-	O
6	O
h	O
,	O
while	O
TNF	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
were	O
released	O
between	O
6	O
-	O
24	O
h	O
(	O
figure	O
3	O
)	O
.	O

These	O
results	O
indicated	O
that	O
the	O
cytokines	O
were	O
differentially	O
regulated	O
and	O
that	O
the	O
release	O
was	O
not	O
associated	O
with	O
the	O
early	O
transient	O
induction	O
of	O
NF	O
-	O
kappaB	O
.	O
<EOS>	B-X
Increased	B-X
uterine	B-X
contractility	B-X
at	B-X
term	B-X
and	B-X
preterm	B-X
results	B-X
from	B-X
activation	B-X
and	B-X
then	B-X
stimulation	B-X
of	B-X
the	B-X
myometrium	B-X
.	B-X
Thus	B-X
,	B-X
regulation	B-X
of	B-X
PGHS2	B-X
at	B-X
term	B-X
is	B-X
differentially	B-X
controlled	B-X
in	B-X
fetal	B-X
(	B-X
trophoblast	B-X
)	B-X
and	B-X
maternal	B-X
(	B-X
uterine	B-X
epithelium	B-X
)	B-X
tissue	B-X
.	B-X
Other	B-X
agents	B-X
,	B-X
such	B-X
as	B-X
proinflammatory	B-X
cytokines	B-X
,	B-X
similarly	B-X
upregulate	B-X
PGHS2	B-X
and	B-X
decrease	B-X
expression	B-X
of	B-X
PGDH	B-X
,	B-X
indicating	B-X
the	B-X
presence	B-X
of	B-X
several	B-X
mechanisms	B-X
by	B-X
which	B-X
labor	B-X
at	B-X
term	B-X
or	B-X
preterm	B-X
may	B-X
be	B-X
initiated	B-X
.	B-X
Hepatic	B-X
steatosis	B-X
in	B-X
particular	B-X
,	B-X
as	B-X
well	B-X
as	B-X
visceral	B-X
and	B-X
ectopic	B-X
fat	B-X
accumulation	B-X
within	B-X
tissues	B-X
,	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
development	B-X
of	B-X
the	B-X
disease	B-X
.	B-X
The	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
function	B-X
of	B-X
adipocytes	B-X
depends	B-X
on	B-X
the	B-X
overall	B-X
metabolic	B-X
status	B-X
in	B-X
humans	B-X
which	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
differentially	B-X
affects	B-X
islet	B-X
hormone	B-X
release	B-X
.	B-X

The	O
temporal	O
induction	O
of	O
AP	O
-	O
1	O
correlated	O
to	O
the	O
CXCL8	B-Protein
levels	O
and	O
preceded	O
the	O
TNF	O
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
release	O
.	O

This	O
suggests	O
an	O
association	O
between	O
CXCL8	B-Protein
release	O
and	O
AP	O
-	O
1	O
signalling	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
a	B-X
functionally	B-X
uncharacterized	B-X
H.	B-X
pylori	B-X
secreted	B-X
protein	B-X
HP1173	B-X
on	B-X
macrophage	B-X
responses	B-X
.	B-X
In	B-X
a	B-X
screen	B-X
of	B-X
eight	B-X
H.	B-X
pylori	B-X
strains	B-X
,	B-X
similar	B-X
expression	B-X
levels	B-X
of	B-X
the	B-X
HP1173	B-X
protein	B-X
were	B-X
observed	B-X
in	B-X
the	B-X
whole-cell	B-X
extracts	B-X
,	B-X
however	B-X
;	B-X
the	B-X
amount	B-X
of	B-X
protein	B-X
released	B-X
into	B-X
the	B-X
culture	B-X
medium	B-X
varied	B-X
significantly	B-X
among	B-X
strains	B-X
.	B-X
Recombinant	B-X
purified	B-X
HP1173	B-X
(	B-X
rHP1173	B-X
)	B-X
was	B-X
found	B-X
to	B-X
bind	B-X
to	B-X
THP-1	B-X
cells	B-X
that	B-X
were	B-X
differentiated	B-X
into	B-X
macrophages	B-X
via	B-X
phorbol-12-myristate-13-acetate	B-X
(	B-X
PMA	B-X
)	B-X
treatment	B-X
.	B-X
The	B-X
exposure	B-X
of	B-X
macrophages	B-X
to	B-X
rHP1173	B-X
led	B-X
to	B-X
the	B-X
production	B-X
of	B-X
the	B-X
proinflammatory	B-X
cytokines	B-X
TNF	B-X
and	B-X
IL-1β	B-X
and	B-X
the	B-X
chemokine	B-X
CXCL8	B-X
in	B-X
a	B-X
dose-	B-X
and	B-X
time-dependent	B-X
manner	B-X
.	B-X
Under	B-X
similar	B-X
conditions	B-X
,	B-X
rHP1173	B-X
failed	B-X
to	B-X
induce	B-X
apoptosis	B-X
in	B-X
macrophages	B-X
.	B-X
Furthermore	B-X
,	B-X
rHP1173-induced	B-X
expression	B-X
of	B-X
TNF	B-X
,	B-X
IL-1β	B-X
and	B-X
CXCL8	B-X
was	B-X
observed	B-X
at	B-X
the	B-X
level	B-X
of	B-X
gene	B-X
transcription	B-X
.	B-X
Incubation	B-X
of	B-X
macrophages	B-X
in	B-X
the	B-X
conditioned	B-X
medium	B-X
from	B-X
a	B-X
mutant	B-X
H.	B-X
pylori	B-X
strain	B-X
26695	B-X
lacking	B-X
HP1173	B-X
protein	B-X
expression	B-X
resulted	B-X
in	B-X
the	B-X
reduced	B-X
induction	B-X
of	B-X
TNF	B-X
,	B-X
CXCL8	B-X
and	B-X
IL-1β	B-X
,	B-X
confirming	B-X
the	B-X
role	B-X
of	B-X
the	B-X
endogenous	B-X
protein	B-X
.	B-X
Intracellular	B-X
signaling	B-X
involving	B-X
MAPKs	B-X
,	B-X
NF-κB	B-X
and	B-X
the	B-X
AP-1	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
was	B-X
required	B-X
for	B-X
rHP1173-induced	B-X
TNF	B-X
,	B-X
CXCL8	B-X
and	B-X
IL-1β	B-X
release	B-X
from	B-X
macrophages	B-X
.	B-X
The	B-X
blocking	B-X
of	B-X
MyD88	B-X
,	B-X
which	B-X
is	B-X
an	B-X
adaptor	B-X
for	B-X
multiple	B-X
toll-like	B-X
receptors	B-X
(	B-X
TLRs	B-X
)	B-X
,	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
rHP1173-induced	B-X
TNF	B-X
,	B-X
CXCL8	B-X
and	B-X
IL-1β	B-X
release	B-X
from	B-X
macrophages	B-X
,	B-X
suggesting	B-X
that	B-X
Myd88-dependent	B-X
TLR	B-X
signaling	B-X
was	B-X
not	B-X
involved	B-X
in	B-X
the	B-X
recognition	B-X
of	B-X
and	B-X
responses	B-X
to	B-X
rHP1173	B-X
.	B-X
These	B-X
findings	B-X
provide	B-X
novel	B-X
insights	B-X
into	B-X
the	B-X
potential	B-X
role	B-X
of	B-X
HP1173	B-X
in	B-X
H.	B-X
pylori	B-X
infection-associated	B-X
disease	B-X
development	B-X
.	B-X

Cooperative	O
induction	O
of	O
cytokines	O
by	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
<EOS>	B-X
The	B-X
differentiation	B-X
of	B-X
osteoclasts	B-X
is	B-X
dependent	B-X
on	B-X
a	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
family	B-X
cytokine	B-X
,	B-X
receptor	B-X
activator	B-X
of	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
ligand	B-X
(	B-X
RANKL	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
)	B-X
.	B-X
Congenital	B-X
lack	B-X
of	B-X
osteoclasts	B-X
causes	B-X
osteopetrosis	B-X
,	B-X
investigation	B-X
of	B-X
which	B-X
has	B-X
provided	B-X
insights	B-X
into	B-X
the	B-X
essential	B-X
molecules	B-X
for	B-X
osteoclastogenesis	B-X
,	B-X
including	B-X
TNF	B-X
receptor-associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
6	B-X
,	B-X
NF-kappaB	B-X
and	B-X
c-Fos	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
genome-wide	B-X
screening	B-X
techniques	B-X
have	B-X
shed	B-X
light	B-X
on	B-X
an	B-X
additional	B-X
set	B-X
of	B-X
gene	B-X
products	B-X
such	B-X
as	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
(	B-X
NFAT	B-X
)	B-X
c1	B-X
.	B-X
TRAF6	B-X
activates	B-X
NF-kappaB	B-X
,	B-X
which	B-X
is	B-X
important	B-X
for	B-X
the	B-X
initial	B-X
induction	B-X
of	B-X
NFATc1	B-X
.	B-X
NFATc1	B-X
is	B-X
activated	B-X
by	B-X
calcium	B-X
signaling	B-X
and	B-X
binds	B-X
to	B-X
its	B-X
own	B-X
promoter	B-X
,	B-X
thus	B-X
switching	B-X
on	B-X
an	B-X
autoregulatory	B-X
loop	B-X
.	B-X
An	B-X
activator	B-X
protein	B-X
(	B-X
AP	B-X
)	B-X
-1	B-X
complex	B-X
containing	B-X
c-Fos	B-X
is	B-X
required	B-X
for	B-X
the	B-X
autoamplification	B-X
of	B-X
NFATc1	B-X
,	B-X
enabling	B-X
the	B-X
robust	B-X
induction	B-X
of	B-X
NFATc1	B-X
.	B-X
Finally	B-X
,	B-X
NFATc1	B-X
cooperates	B-X
with	B-X
other	B-X
transcriptional	B-X
partners	B-X
to	B-X
activate	B-X
osteoclast-specific	B-X
genes	B-X
.	B-X
NFATc1	B-X
autoregulation	B-X
is	B-X
controlled	B-X
by	B-X
an	B-X
epigenetic	B-X
mechanism	B-X
,	B-X
which	B-X
has	B-X
profound	B-X
implications	B-X
for	B-X
an	B-X
understanding	B-X
of	B-X
the	B-X
general	B-X
mechanism	B-X
of	B-X
irreversible	B-X
cell	B-X
fate	B-X
determination	B-X
.	B-X

To	O
further	O
characterize	O
the	O
involvement	O
of	O
NF	O
-	O
kappaB	O
in	O
cytokine	O
regulation	O
,	O
we	O
treated	O
cells	O
with	O
an	O
NF	O
-	O
kappaB	O
activation	O
inhibitor	O
(	O
NAI	O
)	O
.	O

The	O
results	O
showed	O
that	O
NAI	O
selectively	O
down	O
-	O
regulated	O
NF	O
-	O
kappaB	O
activation	O
(	O
figures	O
4a	O
and	O
4b	O
)	O
and	O
did	O
not	O
alter	O
AP	O
-	O
1	O
activity	O
(	O
figures	O
4c	O
and	O
4d	O
)	O
.	O

Exposure	O
of	O
Jurkat	O
T	O
-	O
cells	O
to	O
NAI	O
resulted	O
in	O
a	O
modest	O
reduction	O
of	O
CXCL8	B-Protein
following	O
PMA	O
exposure	O
,	O
while	O
it	O
did	O
not	O
alter	O
the	O
CXCL8	B-Protein
release	O
following	O
HK	O
E	O
.	O
coli	O
exposure	O
(	O
figure	O
5a	O
)	O
.	O

NAI	O
did	O
not	O
affect	O
TNF	O
expression	O
(	O
figure	O
5b	O
)	O
indicating	O
that	O
NF	O
-	O
kappaB	O
is	O
not	O
the	O
main	O
regulator	O
of	O
CXCL8	B-Protein
or	O
TNF	O
following	O
either	O
PMA	O
or	O
HK	O
E	O
.	O
coli	O
exposure	O
in	O
Jurkat	O
T	O
-	O
cells	O
.	O
<EOS>	B-X
This	B-X
is	B-X
because	B-X
,	B-X
following	B-X
differentiation	B-X
using	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
PMA	B-X
)	B-X
,	B-X
THP-1	B-X
cells	B-X
acquire	B-X
a	B-X
macrophage-like	B-X
phenotype	B-X
,	B-X
which	B-X
mimics	B-X
,	B-X
in	B-X
many	B-X
respects	B-X
,	B-X
primary	B-X
human	B-X
macrophages	B-X
.	B-X
Despite	B-X
the	B-X
widespread	B-X
use	B-X
of	B-X
THP-1	B-X
cells	B-X
in	B-X
studies	B-X
elucidating	B-X
macrophage	B-X
responses	B-X
to	B-X
inflammatory	B-X
stimuli	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
development	B-X
and	B-X
screening	B-X
of	B-X
potential	B-X
therapeutics	B-X
,	B-X
there	B-X
is	B-X
currently	B-X
no	B-X
standardised	B-X
protocol	B-X
for	B-X
the	B-X
reliable	B-X
differentiation	B-X
of	B-X
THP-1	B-X
monocytes	B-X
to	B-X
a	B-X
macrophage	B-X
phenotype	B-X
using	B-X
PMA	B-X
.	B-X
Consequently	B-X
,	B-X
reports	B-X
using	B-X
THP-1	B-X
cells	B-X
have	B-X
demonstrated	B-X
significant	B-X
phenotypic	B-X
and	B-X
functional	B-X
differences	B-X
between	B-X
resultant	B-X
THP-1	B-X
macrophage	B-X
populations	B-X
,	B-X
which	B-X
are	B-X
largely	B-X
attributable	B-X
to	B-X
the	B-X
varying	B-X
PMA	B-X
differentiation	B-X
methods	B-X
used	B-X
.	B-X
Thus	B-X
,	B-X
to	B-X
guarantee	B-X
consistency	B-X
and	B-X
reproducibility	B-X
between	B-X
studies	B-X
,	B-X
and	B-X
to	B-X
ensure	B-X
the	B-X
relevance	B-X
of	B-X
THP-1	B-X
cells	B-X
as	B-X
an	B-X
appropriate	B-X
model	B-X
for	B-X
primary	B-X
human	B-X
macrophages	B-X
,	B-X
it	B-X
is	B-X
crucial	B-X
to	B-X
develop	B-X
a	B-X
standardised	B-X
protocol	B-X
for	B-X
the	B-X
differentiation	B-X
of	B-X
THP-1	B-X
macrophages	B-X
.	B-X
Accordingly	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
function	B-X
and	B-X
phenotype	B-X
of	B-X
THP-1	B-X
macrophages	B-X
generated	B-X
using	B-X
the	B-X
range	B-X
of	B-X
published	B-X
PMA	B-X
differentiation	B-X
protocols	B-X
,	B-X
specifically	B-X
in	B-X
response	B-X
to	B-X
the	B-X
pro-inflammatory	B-X
stimulus	B-X
,	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
.	B-X
Our	B-X
results	B-X
demonstrated	B-X
that	B-X
the	B-X
function	B-X
of	B-X
the	B-X
resultant	B-X
THP-1	B-X
macrophage	B-X
populations	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
tumour	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
secretion	B-X
in	B-X
response	B-X
to	B-X
LPS	B-X
stimulation	B-X
,	B-X
varied	B-X
significantly	B-X
,	B-X
and	B-X
was	B-X
dependent	B-X
upon	B-X
the	B-X
concentration	B-X
of	B-X
PMA	B-X
used	B-X
to	B-X
stimulate	B-X
the	B-X
differentiation	B-X
of	B-X
monocytes	B-X
,	B-X
and	B-X
the	B-X
period	B-X
of	B-X
rest	B-X
following	B-X
PMA	B-X
exposure	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
exposure	B-X
of	B-X
monocytic	B-X
THP-1	B-X
cells	B-X
to	B-X
25	B-X
nM	B-X
PMA	B-X
over	B-X
48	B-X
h	B-X
,	B-X
followed	B-X
by	B-X
a	B-X
recovery	B-X
period	B-X
of	B-X
24h	B-X
in	B-X
culture	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
PMA	B-X
,	B-X
was	B-X
the	B-X
optimal	B-X
protocol	B-X
for	B-X
the	B-X
differentiation	B-X
of	B-X
THP-1	B-X
cells	B-X
.	B-X

In	O
contrast	O
,	O
NAI	O
resulted	O
in	O
a	O
complete	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
following	O
PMA	O
exposure	O
and	O
a	O
45	O
%	O
inhibition	O
following	O
HK	O
E	O
.	O
coli	O
exposure	O
(	O
figure	O
5c	O
)	O
,	O
suggesting	O
an	O
involvement	O
of	O
NF	O
-	O
kappaB	O
in	O
IL	B-Protein
-	I-Protein
6	I-Protein
regulation	O
.	O

Ca2	O
+	O
was	O
observed	O
to	O
increase	O
AP	O
-	O
1	O
activity	O
(	O
figure	O
1c	O
)	O
and	O
reduce	O
NF	O
-	O
kappaB	O
activity	O
(	O
figure	O
2e	O
)	O
;	O
therefore	O
,	O
we	O
exposed	O
T	O
-	O
cells	O
to	O
a	O
PKC	O
inhibitor	O
together	O
with	O
PMA	O
to	O
determine	O
its	O
effect	O
on	O
cytokine	O
expression	O
.	O

Inhibition	O
of	O
PKC	O
reduced	O
CXCL8	B-Protein
release	O
from	O
7	O
ng	O
/	O
ml	O
to	O
3	O
ng	O
/	O
ml	O
while	O
it	O
had	O
a	O
modest	O
effect	O
on	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
TNF	O
(	O
figure	O
6a	O
-	O
c	O
)	O
.	O

This	O
prompted	O
us	O
to	O
test	O
the	O
effect	O
of	O
JNK	O
inhibition	O
on	O
PMA	O
-	O
induced	O
cytokine	O
expression	O
.	O

JNK	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
a	O
multitude	O
of	O
different	O
transcription	O
factors	O
,	O
including	O
the	O
phosphorylation	O
and	O
activation	O
of	O
c	B-Protein
-	I-Protein
Jun	I-Protein
,	O
c	B-Protein
-	I-Protein
Fos	I-Protein
and	O
p53	B-Protein
,	O
leading	O
to	O
cellular	O
apoptosis	O
[	O
26	O
]	O
.	O

Inhibition	O
of	O
the	O
JNK	O
pathways	O
resulted	O
in	O
a	O
down	O
-	O
regulation	O
of	O
both	O
CXCL8	B-Protein
and	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
while	O
no	O
clear	O
effect	O
was	O
observed	O
on	O
TNF	O
expression	O
(	O
figure	O
6a	O
-	O
c	O
)	O
.	O

Analysis	O
of	O
mRNA	O
levels	O
using	O
RT	O
-	O
qPCR	O
(	O
table	O
2	O
)	O
showed	O
that	O
PMA	O
induced	O
both	O
il	B-Protein
-	I-Protein
6	I-Protein
and	O
cxcl8	B-Protein
mRNA	O
(	O
5	O
.	O
1	O
-	O
fold	O
and	O
111	O
.	O
8	O
fold	O
respectively	O
)	O
.	O

Addition	O
of	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
NAI	O
and	O
the	O
JNK	O
inhibitor	O
reduced	O
the	O
il	B-Protein
-	I-Protein
6	I-Protein
expression	O
below	O
basal	O
levels	O
.	O

In	O
contrast	O
,	O
while	O
the	O
cxcl8	B-Protein
levels	O
were	O
suppressed	O
by	O
the	O
same	O
treatments	O
the	O
levels	O
remained	O
elevated	O
above	O
basal	O
level	O
.	O

NF	O
-	O
kappaB	O
inhibition	O
due	O
to	O
PKC	O
-	O
dependent	O
Bcl10	B-Protein
degradation	O
<EOS>	B-X
In	B-X
T	B-X
lymphocytes	B-X
,	B-X
the	B-X
``	B-X
novel	B-X
''	B-X
protein	B-X
kinase	B-X
C	B-X
theta	B-X
(	B-X
PKC	B-X
theta	B-X
)	B-X
isoform	B-X
and	B-X
the	B-X
transcription	B-X
factor	B-X
nuclear	B-X
factor-kappaB	B-X
(	B-X
NF-kappaB	B-X
)	B-X
are	B-X
required	B-X
for	B-X
cell	B-X
proliferation	B-X
and	B-X
the	B-X
production	B-X
of	B-X
cytokines	B-X
in	B-X
response	B-X
to	B-X
T	B-X
cell	B-X
activation	B-X
;	B-X
however	B-X
,	B-X
the	B-X
molecular	B-X
interactions	B-X
that	B-X
link	B-X
PKCtheta	B-X
and	B-X
NF-kappaB	B-X
have	B-X
remained	B-X
unknown	B-X
.	B-X
Two	B-X
recent	B-X
reports	B-X
demonstrate	B-X
that	B-X
CARMA1	B-X
(	B-X
caspase	B-X
recruitment	B-X
domain-containing	B-X
membrane-associated	B-X
guanylate	B-X
kinase	B-X
protein-1	B-X
)	B-X
bridges	B-X
the	B-X
gap	B-X
between	B-X
PKCtheta	B-X
and	B-X
the	B-X
IkappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
-dependent	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
in	B-X
T	B-X
cells	B-X
.	B-X
Given	B-X
that	B-X
CARMA1	B-X
is	B-X
specifically	B-X
expressed	B-X
in	B-X
lymphoid	B-X
tissues	B-X
,	B-X
could	B-X
pharmacological	B-X
inhibitors	B-X
be	B-X
designed	B-X
to	B-X
inhibit	B-X
CARMA1	B-X
's	B-X
(	B-X
or	B-X
PKCtheta	B-X
's	B-X
)	B-X
ability	B-X
to	B-X
promote	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
?	B-X
Activator	B-X
protein	B-X
(	B-X
AP	B-X
)	B-X
-1	B-X
and	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
largely	B-X
control	B-X
T-cell	B-X
activation	B-X
,	B-X
following	B-X
binding	B-X
of	B-X
foreign	B-X
antigens	B-X
to	B-X
the	B-X
T-cell	B-X
receptor	B-X
leading	B-X
to	B-X
cytokine	B-X
secretion	B-X
.	B-X
Elevated	B-X
levels	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
such	B-X
as	B-X
TNF	B-X
,	B-X
IL-6	B-X
and	B-X
CXCL8	B-X
are	B-X
associated	B-X
with	B-X
several	B-X
human	B-X
diseases	B-X
including	B-X
cystic	B-X
fibrosis	B-X
,	B-X
pulmonary	B-X
fibrosis	B-X
and	B-X
AIDS	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
the	B-X
transcription	B-X
factors	B-X
,	B-X
AP-1	B-X
and	B-X
NF-kappaB	B-X
,	B-X
in	B-X
IL-6	B-X
and	B-X
CXCL8	B-X
regulation	B-X
in	B-X
Jurkat	B-X
T-cells	B-X
.	B-X

Western	O
blot	O
analysis	O
revealed	O
an	O
up	O
-	O
regulation	O
of	O
phosphorylated	O
-	O
PKC	O
after	O
24	O
h	O
treatment	O
of	O
Jurkat	O
T	O
-	O
cells	O
with	O
PMA	O
or	O
HK	O
E	O
.	O
coli	O
(	O
figure	O
7a	O
)	O
,	O
while	O
IkappaBbeta	B-Protein
levels	O
remained	O
unaffected	O
(	O
figure	O
7b	O
)	O
.	O

Bcl10	B-Protein
is	O
a	O
signalling	O
protein	O
that	O
acts	O
upstream	O
of	O
NF	O
-	O
kappaB	O
in	O
concert	O
with	O
CARMA1	B-Protein
and	O
MALT1	B-Protein
and	O
has	O
been	O
suggested	O
to	O
directly	O
regulate	O
NF	O
-	O
kappaB	O
activity	O
in	O
T	O
-	O
cells	O
[	O
27	O
]	O
.	O

Therefore	O
,	O
Bcl10	B-Protein
activation	O
was	O
evaluated	O
in	O
both	O
control	O
and	O
PMA	O
stimulated	O
cells	O
after	O
10	O
min	O
,	O
1	O
h	O
,	O
6	O
h	O
,	O
and	O
24	O
h	O
using	O
western	O
blot	O
analysis	O
.	O

The	O
Bcl10	B-Protein
levels	O
decreased	O
following	O
treatment	O
with	O
PMA	O
,	O
while	O
in	O
control	O
cells	O
,	O
Bcl10	B-Protein
returned	O
to	O
higher	O
levels	O
by	O
24	O
h	O
(	O
figure	O
7c	O
)	O
.	O

This	O
suggests	O
that	O
Bcl10	B-Protein
is	O
involved	O
in	O
the	O
PMA	O
dependent	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O
<EOS>	B-X
Although	B-X
the	B-X
caspase	B-X
recruitment	B-X
domain	B-X
(	B-X
CARD	B-X
)	B-X
9-Bcl10	B-X
complex	B-X
is	B-X
essential	B-X
for	B-X
FcRgamma/DAP12-mediated	B-X
NF-kappaB	B-X
activation	B-X
in	B-X
myeloid	B-X
cells	B-X
,	B-X
its	B-X
involvement	B-X
in	B-X
NK	B-X
cell	B-X
receptor	B-X
signaling	B-X
is	B-X
unknown	B-X
.	B-X
Herein	B-X
we	B-X
show	B-X
that	B-X
the	B-X
deficiency	B-X
of	B-X
CARMA1	B-X
or	B-X
Bcl10	B-X
,	B-X
but	B-X
not	B-X
CARD9	B-X
,	B-X
resulted	B-X
in	B-X
severe	B-X
impairment	B-X
of	B-X
cytokine/chemokine	B-X
production	B-X
mediated	B-X
by	B-X
activating	B-X
NK	B-X
cell	B-X
receptors	B-X
due	B-X
to	B-X
a	B-X
selective	B-X
defect	B-X
in	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
whereas	B-X
cytotoxicity	B-X
mediated	B-X
by	B-X
the	B-X
same	B-X
receptors	B-X
did	B-X
not	B-X
require	B-X
CARMA1-Bcl10-mediated	B-X
signaling	B-X
.	B-X
IkappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
activation	B-X
by	B-X
direct	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
stimulation	B-X
with	B-X
PMA	B-X
plus	B-X
ionomycin	B-X
(	B-X
P/I	B-X
)	B-X
was	B-X
abrogated	B-X
in	B-X
CARMA1-deficient	B-X
NK	B-X
cells	B-X
,	B-X
similar	B-X
to	B-X
T	B-X
and	B-X
B	B-X
lymphocytes	B-X
,	B-X
whereas	B-X
CARD9-deficient	B-X
dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
exhibited	B-X
normal	B-X
P/I-induced	B-X
IKK	B-X
activation	B-X
.	B-X
Surprisingly	B-X
,	B-X
CARMA1	B-X
deficiency	B-X
also	B-X
abrogated	B-X
P/I-induced	B-X
IKK	B-X
activation	B-X
in	B-X
DCs	B-X
,	B-X
indicating	B-X
that	B-X
CARMA1	B-X
is	B-X
essential	B-X
for	B-X
PKC-mediated	B-X
NF-kappaB	B-X
activation	B-X
in	B-X
all	B-X
cell	B-X
types	B-X
,	B-X
although	B-X
the	B-X
PKC-CARMA1	B-X
axis	B-X
is	B-X
not	B-X
used	B-X
downstream	B-X
of	B-X
myeloid	B-X
ITAM	B-X
receptors	B-X
.	B-X
Consistently	B-X
,	B-X
PKC	B-X
inhibition	B-X
abrogated	B-X
ITAM	B-X
receptor-mediated	B-X
activation	B-X
only	B-X
in	B-X
NK	B-X
cells	B-X
but	B-X
not	B-X
in	B-X
DCs	B-X
,	B-X
suggesting	B-X
PKC-CARMA1-independent	B-X
,	B-X
CARD9-dependent	B-X
ITAM	B-X
receptor	B-X
signaling	B-X
in	B-X
myeloid	B-X
cells	B-X
.	B-X
Conversely	B-X
,	B-X
the	B-X
overexpression	B-X
of	B-X
CARD9	B-X
in	B-X
CARMA1-deficient	B-X
cells	B-X
failed	B-X
to	B-X
restore	B-X
the	B-X
PKC-mediated	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
Thus	B-X
,	B-X
NF-kappaB	B-X
activation	B-X
signaling	B-X
through	B-X
ITAM	B-X
receptors	B-X
is	B-X
regulated	B-X
by	B-X
a	B-X
cell	B-X
type-specific	B-X
mechanism	B-X
depending	B-X
on	B-X
the	B-X
usage	B-X
of	B-X
adaptors	B-X
CARMA1	B-X
and	B-X
CARD9	B-X
,	B-X
which	B-X
determines	B-X
the	B-X
PKC	B-X
dependence	B-X
of	B-X
the	B-X
signaling	B-X
.	B-X

NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
are	O
critical	O
regulators	O
of	O
inflammatory	O
responses	O
,	O
proliferation	O
and	O
differentiation	O
of	O
T	O
-	O
cells	O
[	O
28	O
-	O
30	O
]	O
,	O
however	O
,	O
the	O
signal	O
transduction	O
and	O
subsequent	O
cytokine	O
/	O
chemokine	O
expression	O
is	O
not	O
fully	O
understood	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
CXCL8	B-Protein
regulation	O
by	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
in	O
Jurkat	O
T	O
-	O
cells	O
.	O

Our	O
results	O
demonstrated	O
that	O
PMA	O
induced	O
AP	O
-	O
1	O
activation	O
,	O
indicating	O
a	O
specific	O
activation	O
of	O
the	O
MAPK	O
pathway	O
.	O
<EOS>	B-X
Our	B-X
previous	B-X
study	B-X
has	B-X
demonstrated	B-X
that	B-X
the	B-X
methanol	B-X
extract	B-X
of	B-X
Hyul-Tong-Ryung	B-X
(	B-X
HM	B-X
)	B-X
specifically	B-X
suppresses	B-X
the	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
PMA	B-X
)	B-X
-induced	B-X
matrix	B-X
metalloproteinase-9	B-X
(	B-X
MMP-9	B-X
)	B-X
production	B-X
through	B-X
the	B-X
inhibition	B-X
of	B-X
MMP-9	B-X
mRNA	B-X
expression	B-X
in	B-X
MCF-7	B-X
human	B-X
breast	B-X
carcinoma	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
the	B-X
molecular	B-X
mechanisms	B-X
involved	B-X
in	B-X
transcriptional	B-X
suppression	B-X
of	B-X
MMP-9	B-X
by	B-X
HM	B-X
in	B-X
PMA-induced	B-X
MCF-7	B-X
cells	B-X
are	B-X
not	B-X
known	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
elucidate	B-X
the	B-X
molecular	B-X
mechanisms	B-X
involved	B-X
in	B-X
the	B-X
inhibition	B-X
of	B-X
MMP-9	B-X
expression	B-X
by	B-X
HM	B-X
in	B-X
PMA-induced	B-X
MCF-7	B-X
cells	B-X
.	B-X
The	B-X
results	B-X
of	B-X
promoter	B-X
assay	B-X
and	B-X
EMSA	B-X
showed	B-X
that	B-X
HM	B-X
specifically	B-X
inhibits	B-X
MMP-9	B-X
gene	B-X
expression	B-X
by	B-X
blocking	B-X
PMA-stimulated	B-X
activation	B-X
of	B-X
activator	B-X
protein-1	B-X
(	B-X
AP-1	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
PMA-stimulated	B-X
phosphorylation	B-X
of	B-X
extracellular	B-X
signal	B-X
regulated	B-X
kinase	B-X
1/2	B-X
(	B-X
ERK	B-X
1/2	B-X
)	B-X
was	B-X
suppressed	B-X
by	B-X
HM	B-X
treatment	B-X
,	B-X
whereas	B-X
the	B-X
phosphorylation	B-X
of	B-X
either	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
or	B-X
p38	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
was	B-X
not	B-X
affected	B-X
.	B-X
HM	B-X
could	B-X
inhibit	B-X
the	B-X
PMA-induced	B-X
MMP-9	B-X
expression	B-X
through	B-X
suppression	B-X
of	B-X
the	B-X
transcriptional	B-X
activity	B-X
of	B-X
MMP-9	B-X
gene	B-X
in	B-X
MCF-7	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
HM	B-X
inhibits	B-X
PMA-induced	B-X
MMP-9	B-X
expression	B-X
by	B-X
blocking	B-X
the	B-X
activation	B-X
of	B-X
activator	B-X
protein-1	B-X
(	B-X
AP-1	B-X
)	B-X
via	B-X
extracellular	B-X
signal	B-X
regulated	B-X
kinase	B-X
1/2	B-X
(	B-X
ERK	B-X
1/2	B-X
)	B-X
signaling	B-X
pathway	B-X
.	B-X

Furthermore	O
,	O
we	O
demonstrated	O
that	O
PMA	O
dependent	O
AP	O
-	O
1	O
activation	O
in	O
T	O
-	O
cells	O
was	O
delayed	O
(	O
>	O
2	O
h	O
)	O
and	O
increased	O
following	O
long	O
-	O
term	O
treatment	O
.	O

MAPK	O
is	O
one	O
of	O
the	O
main	O
signalling	O
pathways	O
in	O
T	O
-	O
cells	O
that	O
regulate	O
cell	O
-	O
and	O
transcriptional	O
activation	O
[	O
31	O
,	O
32	O
]	O
.	O

Several	O
studies	O
[	O
20	O
,	O
33	O
,	O
34	O
]	O
have	O
indicated	O
the	O
importance	O
of	O
AP	O
-	O
1	O
in	O
T	O
-	O
cell	O
activation	O
and	O
the	O
induction	O
of	O
inflammatory	O
responses	O
[	O
35	O
]	O
,	O
including	O
pro	O
-	O
inflammatory	O
cytokine	O
release	O
.	O

In	O
contrast	O
to	O
AP	O
-	O
1	O
,	O
NF	O
-	O
kappaB	O
activity	O
rapidly	O
increased	O
(	O
1	O
min	O
)	O
during	O
PMA	O
exposure	O
followed	O
by	O
a	O
down	O
-	O
regulation	O
to	O
the	O
lowest	O
levels	O
at	O
6	O
h	O
.	O

This	O
is	O
in	O
line	O
with	O
Park	O
and	O
colleagues	O
[	O
36	O
]	O
who	O
demonstrated	O
a	O
rapid	O
increase	O
in	O
NF	O
-	O
kappaB	O
activity	O
following	O
short	O
-	O
term	O
stimulation	O
with	O
PMA	O
,	O
but	O
prolonged	O
challenge	O
resulted	O
in	O
a	O
persistent	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
.	O

They	O
showed	O
that	O
the	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
was	O
due	O
to	O
PKC	O
-	O
dependent	O
degradation	O
of	O
IkappaB	B-Protein
kinase	I-Protein
beta	I-Protein
and	O
gamma	B-Protein
in	O
response	O
to	O
PMA	O
.	O

Interestingly	O
,	O
the	O
HK	O
E	O
.	O
coli	O
exposure	O
induced	O
NF	O
-	O
kappaB	O
activation	O
without	O
affecting	O
AP	O
-	O
1	O
activity	O
.	O

Wang	O
and	O
colleagues	O
[	O
37	O
]	O
reported	O
an	O
elevated	O
inflammatory	O
response	O
by	O
obtaining	O
expression	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
following	O
the	O
exposure	O
of	O
T	O
-	O
cells	O
to	O
peptidoglycan	O
.	O

Reduction	O
in	O
NF	O
-	O
kappaB	O
by	O
calcium	O
ionophore	O
following	O
HK	O
E	O
.	O
coli	O
stimulation	O
may	O
be	O
due	O
to	O
the	O
Ca2	O
+	O
binding	O
protein	O
calmodulin	O
(	O
CaM	O
)	O
,	O
which	O
has	O
been	O
shown	O
to	O
negatively	O
regulate	O
c	B-Protein
-	I-Protein
Rel	I-Protein
when	O
activated	O
[	O
38	O
]	O
.	O

The	O
regulation	O
of	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
observed	O
in	O
the	O
present	O
study	O
was	O
in	O
agreement	O
with	O
earlier	O
studies	O
.	O

T	O
-	O
cells	O
produce	O
a	O
broad	O
range	O
of	O
pro	O
-	O
and	O
anti	O
-	O
inflammatory	O
cytokines	O
,	O
including	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
CXCL8	B-Protein
,	O
TNF	O
and	O
IL	B-Protein
-	I-Protein
10	I-Protein
,	O
in	O
response	O
to	O
infections	O
or	O
other	O
stress	O
factors	O
[	O
39	O
]	O
.	O
<EOS>	B-X
It	B-X
is	B-X
notjust	B-X
the	B-X
dramatic	B-X
stressful	B-X
events	B-X
that	B-X
exact	B-X
their	B-X
toll	B-X
,	B-X
but	B-X
rather	B-X
the	B-X
many	B-X
events	B-X
of	B-X
daily	B-X
life	B-X
that	B-X
elevate	B-X
and	B-X
sustain	B-X
activities	B-X
of	B-X
physiological	B-X
systems	B-X
and	B-X
cause	B-X
sleep	B-X
deprivation	B-X
,	B-X
overeating	B-X
,	B-X
and	B-X
other	B-X
health-damaging	B-X
behaviors	B-X
,	B-X
producing	B-X
the	B-X
feeling	B-X
of	B-X
being	B-X
``	B-X
stressed	B-X
out	B-X
.	B-X
''	B-X
Hormones	B-X
associated	B-X
with	B-X
stress	B-X
and	B-X
allostatic	B-X
load	B-X
protect	B-X
the	B-X
body	B-X
in	B-X
the	B-X
short	B-X
run	B-X
and	B-X
promote	B-X
adaptation	B-X
by	B-X
the	B-X
process	B-X
known	B-X
as	B-X
allostasis	B-X
,	B-X
but	B-X
in	B-X
the	B-X
long	B-X
run	B-X
allostatic	B-X
load	B-X
causes	B-X
changes	B-X
in	B-X
the	B-X
body	B-X
that	B-X
can	B-X
lead	B-X
to	B-X
disease	B-X
.	B-X
The	B-X
brain	B-X
is	B-X
the	B-X
key	B-X
organ	B-X
of	B-X
stress	B-X
,	B-X
allostasis	B-X
,	B-X
and	B-X
allostatic	B-X
load	B-X
,	B-X
because	B-X
it	B-X
determines	B-X
what	B-X
is	B-X
threatening	B-X
and	B-X
therefore	B-X
stressful	B-X
,	B-X
and	B-X
also	B-X
determines	B-X
the	B-X
physiological	B-X
and	B-X
behavioral	B-X
responses	B-X
.	B-X
Brain	B-X
regions	B-X
such	B-X
as	B-X
the	B-X
hippocampus	B-X
,	B-X
amygdala	B-X
,	B-X
and	B-X
prefrontal	B-X
cortex	B-X
respond	B-X
to	B-X
acute	B-X
and	B-X
chronic	B-X
stress	B-X
by	B-X
undergoing	B-X
structural	B-X
remodeling	B-X
,	B-X
which	B-X
alters	B-X
behavioral	B-X
and	B-X
physiological	B-X
responses	B-X
.	B-X
Translational	B-X
studies	B-X
in	B-X
humans	B-X
with	B-X
structural	B-X
and	B-X
functional	B-X
imaging	B-X
reveal	B-X
smaller	B-X
hippocampal	B-X
volume	B-X
in	B-X
stress-related	B-X
conditions	B-X
,	B-X
such	B-X
as	B-X
mild	B-X
cognitive	B-X
impairment	B-X
in	B-X
aging	B-X
and	B-X
prolonged	B-X
major	B-X
depressive	B-X
illness	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
individuals	B-X
with	B-X
low	B-X
self-esteem	B-X
.	B-X
Besides	B-X
pharmaceuticals	B-X
,	B-X
approaches	B-X
to	B-X
alleviate	B-X
chronic	B-X
stress	B-X
and	B-X
reduce	B-X
allostatic	B-X
load	B-X
and	B-X
the	B-X
incidence	B-X
of	B-X
diseases	B-X
of	B-X
modern	B-X
life	B-X
include	B-X
lifestyle	B-X
change	B-X
,	B-X
and	B-X
policies	B-X
of	B-X
government	B-X
and	B-X
business	B-X
that	B-X
would	B-X
improve	B-X
the	B-X
ability	B-X
of	B-X
individuals	B-X
to	B-X
reduce	B-X
their	B-X
own	B-X
chronic	B-X
stress	B-X
burden	B-X
.	B-X

The	O
assessment	O
of	O
Jurkat	O
T	O
-	O
cell	O
inflammatory	O
responses	O
(	O
Table	O
1	O
)	O
revealed	O
an	O
enhanced	O
IL	B-Protein
-	I-Protein
2	I-Protein
expression	O
upon	O
exposure	O
to	O
PMA	O
or	O
HK	O
E	O
.	O
coli	O
due	O
to	O
PKC	O
activation	O
[	O
40	O
]	O
.	O
<EOS>	B-X
Activator	B-X
protein	B-X
(	B-X
AP	B-X
)	B-X
-1	B-X
and	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
largely	B-X
control	B-X
T-cell	B-X
activation	B-X
,	B-X
following	B-X
binding	B-X
of	B-X
foreign	B-X
antigens	B-X
to	B-X
the	B-X
T-cell	B-X
receptor	B-X
leading	B-X
to	B-X
cytokine	B-X
secretion	B-X
.	B-X
Elevated	B-X
levels	B-X
of	B-X
pro-inflammatory	B-X
cytokines	B-X
and	B-X
chemokines	B-X
such	B-X
as	B-X
TNF	B-X
,	B-X
IL-6	B-X
and	B-X
CXCL8	B-X
are	B-X
associated	B-X
with	B-X
several	B-X
human	B-X
diseases	B-X
including	B-X
cystic	B-X
fibrosis	B-X
,	B-X
pulmonary	B-X
fibrosis	B-X
and	B-X
AIDS	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
the	B-X
transcription	B-X
factors	B-X
,	B-X
AP-1	B-X
and	B-X
NF-kappaB	B-X
,	B-X
in	B-X
IL-6	B-X
and	B-X
CXCL8	B-X
regulation	B-X
in	B-X
Jurkat	B-X
T-cells	B-X
.	B-X

In	O
addition	O
to	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
AP	O
-	O
1	O
binding	O
sites	O
have	O
been	O
identified	O
in	O
the	O
IL	B-Protein
-	I-Protein
6	I-Protein
promoter	O
region	O
,	O
indicating	O
multiple	O
regulation	O
[	O
22	O
]	O
.	O

AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
have	O
also	O
been	O
demonstrated	O
to	O
regulate	O
CXCL8	B-Protein
expression	O
during	O
induction	O
of	O
inflammatory	O
responses	O
in	O
T	O
-	O
cells	O
[	O
12	O
]	O
.	O

Furthermore	O
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
CXCL8	B-Protein
gene	O
-	O
expression	O
is	O
associated	O
with	O
an	O
early	O
immune	O
response	O
in	O
Jurkat	O
T	O
-	O
cells	O
[	O
41	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
both	O
PMA	O
and	O
HK	O
E	O
.	O
coli	O
resulted	O
in	O
comparable	O
increases	O
in	O
IL	B-Protein
-	I-Protein
6	I-Protein
while	O
PMA	O
was	O
more	O
potent	O
at	O
activating	O
CXCL8	B-Protein
release	O
.	O

PMA	O
and	O
HK	O
E	O
.	O
coli	O
treatment	O
also	O
induced	O
TNF	O
expression	O
.	O

TNF	O
is	O
one	O
of	O
the	O
first	O
cytokines	O
induced	O
by	O
T	O
-	O
cells	O
[	O
42	O
]	O
and	O
its	O
expression	O
is	O
regulated	O
by	O
calcineurin	O
,	O
NFAT	O
and	O
ATF	B-Protein
-	I-Protein
2	I-Protein
/	O
Jun	O
[	O
20	O
]	O
.	O

However	O
,	O
PMA	O
-	O
stimulated	O
Jurkat	O
T	O
-	O
cells	O
showed	O
no	O
difference	O
in	O
IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
indicating	O
an	O
induced	O
inflammatory	O
response	O
.	O

HK	O
E	O
.	O
coli	O
treatment	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
IL	B-Protein
-	I-Protein
10	I-Protein
expression	O
.	O

The	O
anti	O
-	O
inflammatory	O
cytokine	O
IL	B-Protein
-	I-Protein
10	I-Protein
is	O
known	O
to	O
inhibit	O
T	O
-	O
cell	O
activation	O
,	O
proliferation	O
and	O
the	O
expression	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
such	O
as	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
5	I-Protein
and	O
INF	B-Protein
-	I-Protein
gamma	I-Protein
[	O
39	O
,	O
43	O
]	O
and	O
regulate	O
inflammatory	O
responses	O
by	O
inducing	O
T	O
-	O
cell	O
anergy	O
[	O
44	O
]	O
.	O

The	O
time	O
course	O
analysis	O
of	O
cytokine	O
expression	O
showed	O
a	O
correlation	O
between	O
AP	O
-	O
1	O
and	O
the	O
chemokine	O
CXCL8	B-Protein
where	O
CXCL8	O
expression	O
was	O
significantly	O
elevated	O
already	O
at	O
2	O
-	O
6	O
h	O
after	O
PMA	O
exposure	O
.	O

The	O
CXCL8	O
expression	O
did	O
not	O
correlate	O
with	O
the	O
early	O
NF	O
-	O
kappaB	O
activation	O
(	O
1	O
min	O
)	O
or	O
with	O
the	O
down	O
-	O
regulation	O
of	O
NF	O
-	O
kappaB	O
at	O
2	O
h	O
post	O
exposure	O
.	O
<EOS>	B-X
Our	B-X
understanding	B-X
of	B-X
the	B-X
regulatory	B-X
processes	B-X
of	B-X
reepithelialization	B-X
during	B-X
wound	B-X
healing	B-X
is	B-X
incomplete	B-X
.	B-X
In	B-X
an	B-X
attempt	B-X
to	B-X
map	B-X
the	B-X
genes	B-X
involved	B-X
in	B-X
epidermal	B-X
regeneration	B-X
and	B-X
differentiation	B-X
,	B-X
we	B-X
measured	B-X
gene	B-X
expression	B-X
in	B-X
formalin-fixed	B-X
,	B-X
paraffin-embedded	B-X
standardized	B-X
epidermal	B-X
wounds	B-X
induced	B-X
by	B-X
the	B-X
suction-blister	B-X
technique	B-X
with	B-X
associated	B-X
nonwounded	B-X
skin	B-X
using	B-X
NanoString	B-X
technology	B-X
.	B-X
The	B-X
transcripts	B-X
of	B-X
139	B-X
selected	B-X
genes	B-X
involved	B-X
in	B-X
clotting	B-X
,	B-X
immune	B-X
response	B-X
to	B-X
tissue	B-X
injury	B-X
,	B-X
signaling	B-X
pathways	B-X
,	B-X
cell	B-X
adhesion	B-X
and	B-X
proliferation	B-X
,	B-X
extracellular	B-X
matrix	B-X
remodeling	B-X
,	B-X
zinc	B-X
transport	B-X
and	B-X
keratinocyte	B-X
differentiation	B-X
were	B-X
evaluated	B-X
.	B-X
We	B-X
identified	B-X
22	B-X
upregulated	B-X
differentially	B-X
expressed	B-X
genes	B-X
(	B-X
DEGs	B-X
)	B-X
in	B-X
descending	B-X
order	B-X
of	B-X
fold	B-X
change	B-X
(	B-X

Both	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
TNF	O
expression	O
were	O
up	O
regulated	O
between	O
6	O
-	O
24	O
h	O
.	O
<EOS>	B-X
The	B-X
present	B-X
study	B-X
aimed	B-X
to	B-X
evaluate	B-X
the	B-X
anti-colitis	B-X
effect	B-X
and	B-X
underlying	B-X
mechanisms	B-X
of	B-X
cardamonin	B-X
,	B-X
a	B-X
natural	B-X
flavone	B-X
isolated	B-X
from	B-X
Alpinia	B-X
katsumadai	B-X
Hayata	B-X
.	B-X
The	B-X
results	B-X
showed	B-X
that	B-X
oral	B-X
cardamonin	B-X
significantly	B-X
inhibited	B-X
dextran	B-X
sulfate	B-X
sodium	B-X
(	B-X
DSS	B-X
)	B-X
-	B-X
and	B-X
2,4,6-trinitrobenzene	B-X
sulfonic	B-X
acid	B-X
(	B-X
TNBS	B-X
)	B-X
-induced	B-X
colitis	B-X
in	B-X
mice	B-X
,	B-X
evidenced	B-X
by	B-X
improvement	B-X
of	B-X
disease	B-X
activity	B-X
index	B-X
scores	B-X
,	B-X
myeloperoxidase	B-X
activity	B-X
,	B-X
length	B-X
shortening	B-X
and	B-X
histopathological	B-X
changes	B-X
of	B-X
colons	B-X
.	B-X
A	B-X
rectal	B-X
administration	B-X
of	B-X
cardamonin	B-X
also	B-X
exhibited	B-X
marked	B-X
anti-colitis	B-X
effect	B-X
,	B-X
suggesting	B-X
that	B-X
oral	B-X
cardamonin	B-X
might	B-X
function	B-X
in	B-X
a	B-X
prototype	B-X
form	B-X
.	B-X
Cardamonin	B-X
down-regulated	B-X
levels	B-X
of	B-X
IL-1β	B-X
,	B-X
TNF-α	B-X
,	B-X
IL-6	B-X
,	B-X
NLRP3	B-X
,	B-X
cleaved	B-X
caspase-1	B-X
,	B-X
ASC	B-X
,	B-X
cleaved	B-X
IL-1β	B-X
in	B-X
colons	B-X
of	B-X
colitis	B-X
mice	B-X
.	B-X
In	B-X
vitro	B-X
,	B-X
cardamonin	B-X
inhibited	B-X
NLRP3	B-X
inflammasome	B-X
activation	B-X
in	B-X
THP-1	B-X
and	B-X
bone	B-X
marrow-derived	B-X
macrophages	B-X
.	B-X
It	B-X
acted	B-X
as	B-X
an	B-X
AhR	B-X
activator	B-X
,	B-X
enhanced	B-X
dissociation	B-X
of	B-X
AhR/HSP90	B-X
complexes	B-X
,	B-X
association	B-X
of	B-X
AhR/ARNT	B-X
complexes	B-X
,	B-X
AhR	B-X
nuclear	B-X
translocation	B-X
,	B-X
XRE	B-X
reporter	B-X
gene	B-X
activity	B-X
,	B-X
and	B-X
AhR/ARNT/XRE	B-X
DNA	B-X
binding	B-X
activity	B-X
in	B-X
THP-1	B-X
cells	B-X
.	B-X
The	B-X
AhR	B-X
antagonist	B-X
CH223191	B-X
obviously	B-X
abolished	B-X
NLRP3	B-X
inflammasome	B-X
activation	B-X
inhibited	B-X
by	B-X
cardamonin	B-X
.	B-X
Furthermore	B-X
,	B-X
cardamonin	B-X
elevated	B-X
levels	B-X
of	B-X
Nrf2	B-X
and	B-X
its	B-X
target	B-X
genes	B-X
NQO1	B-X
,	B-X
Trx1	B-X
,	B-X
SOD2	B-X
,	B-X
HO-1	B-X
,	B-X
and	B-X
the	B-X
effect	B-X
on	B-X
NQO1	B-X
was	B-X
the	B-X
most	B-X
obvious	B-X
.	B-X
The	B-X
relationship	B-X
of	B-X
cardamonin-adjusted	B-X
AhR	B-X
activation	B-X
,	B-X
expressions	B-X
of	B-X
Nrf2	B-X
and	B-X
NQO1	B-X
,	B-X
and	B-X
NLRP3	B-X
inflammasome	B-X
activation	B-X
was	B-X
confirmed	B-X
by	B-X
using	B-X
CH223191	B-X
,	B-X
siAhR	B-X
,	B-X
ML385	B-X
and	B-X
siNQO1	B-X
,	B-X
respectively	B-X
.	B-X
Finally	B-X
,	B-X
CH223191	B-X
was	B-X
shown	B-X
to	B-X
abolish	B-X
amelioration	B-X
of	B-X
cardamonin	B-X
on	B-X
DSS-	B-X
and	B-X
TNBS-induced	B-X
colitis	B-X
,	B-X
inhibition	B-X
of	B-X
NLRP3	B-X
inflammasome	B-X
activation	B-X
and	B-X
up-regulation	B-X
of	B-X
Nrf2	B-X
and	B-X
NQO1	B-X
levels	B-X
in	B-X
colons	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
cardamonin	B-X
ameliorated	B-X
colitis	B-X
in	B-X
mice	B-X
through	B-X
the	B-X
activation	B-X
of	B-X
AhR/Nrf2/NQO1	B-X
pathway	B-X
and	B-X
consequent	B-X
inhibition	B-X
of	B-X
NLRP3	B-X
inflammasome	B-X
activation	B-X
.	B-X

During	O
this	O
period	O
,	O
NF	O
-	O
kappaB	O
increased	O
from	O
its	O
minimum	O
level	O
at	O
6	O
h	O
.	O

PKC	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
the	O
activation	O
of	O
AP	O
-	O
1	O
,	O
but	O
not	O
with	O
NF	O
-	O
kappaB	O
activation	O
of	O
the	O
IL	B-Protein
-	I-Protein
2	I-Protein
promoter	O
[	O
45	O
]	O
.	O
<EOS>	B-X
miR-155-5p	B-X
and	B-X
miR-155-3p	B-X
are	B-X
processed	B-X
from	B-X
the	B-X
B-cell	B-X
Integration	B-X
Cluster	B-X
(	B-X
BIC	B-X
)	B-X
gene	B-X
(	B-X
now	B-X
designated	B-X
,	B-X
MIR155	B-X
host	B-X
gene	B-X
or	B-X
MIR155HG	B-X
)	B-X
.	B-X
MiR-155-5p	B-X
is	B-X
highly	B-X
expressed	B-X
in	B-X
both	B-X
activated	B-X
B-	B-X
and	B-X
T-cells	B-X
and	B-X
in	B-X
monocytes/macrophages	B-X
.	B-X
MiR-155-5p	B-X
is	B-X
one	B-X
of	B-X
the	B-X
best	B-X
characterized	B-X
miRNAs	B-X
and	B-X
recent	B-X
data	B-X
indicate	B-X
that	B-X
miR-155-5p	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
various	B-X
physiological	B-X
and	B-X
pathological	B-X
processes	B-X
such	B-X
as	B-X
hematopoietic	B-X
lineage	B-X
differentiation	B-X
,	B-X
immunity	B-X
,	B-X
inflammation	B-X
,	B-X
viral	B-X
infections	B-X
,	B-X
cancer	B-X
,	B-X
cardiovascular	B-X
disease	B-X
,	B-X
and	B-X
Down	B-X
syndrome	B-X
.	B-X
In	B-X
this	B-X
review	B-X
we	B-X
summarize	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
MIR155HG	B-X
expression	B-X
can	B-X
be	B-X
regulated	B-X
.	B-X
Given	B-X
that	B-X
the	B-X
pathologies	B-X
mediated	B-X
by	B-X
miR-155-5p	B-X
result	B-X
from	B-X
the	B-X
over-expression	B-X
of	B-X
this	B-X
miRNA	B-X
it	B-X
may	B-X
be	B-X
possible	B-X
to	B-X
therapeutically	B-X
attenuate	B-X
miR-155-5p	B-X
levels	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
several	B-X
pathological	B-X
processes	B-X
.	B-X

Mutation	O
of	O
the	O
NF	O
-	O
kappaB	O
site	O
did	O
not	O
affect	O
IL	B-Protein
-	I-Protein
2	I-Protein
expression	O
,	O
whereas	O
mutation	O
of	O
the	O
AP	O
-	O
1	O
site	O
or	O
PKC	O
depletion	O
almost	O
revoked	O
IL	B-Protein
-	I-Protein
2	I-Protein
release	O
.	O
<EOS>	B-X
Nuclear	B-X
factor	B-X
κB	B-X
(	B-X
NF-κB	B-X
)	B-X
is	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
inflammation	B-X
and	B-X
cell	B-X
death	B-X
.	B-X
Whereas	B-X
most	B-X
of	B-X
the	B-X
activity	B-X
of	B-X
NF-κB	B-X
is	B-X
regulated	B-X
through	B-X
the	B-X
inhibitor	B-X
of	B-X
κB	B-X
(	B-X
IκB	B-X
)	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
-dependent	B-X
degradation	B-X
of	B-X
IκB	B-X
,	B-X
IKK	B-X
also	B-X
phosphorylates	B-X
subunits	B-X
of	B-X
NF-κB	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
contribution	B-X
of	B-X
the	B-X
phosphorylation	B-X
of	B-X
the	B-X
NF-κB	B-X
subunit	B-X
p65	B-X
at	B-X
the	B-X
IKK	B-X
phosphorylation	B-X
site	B-X
serine	B-X
536	B-X
(	B-X
Ser	B-X
(	B-X
536	B-X
)	B-X
)	B-X
in	B-X
humans	B-X
,	B-X
which	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
required	B-X
for	B-X
the	B-X
activation	B-X
and	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF-κB	B-X
.	B-X
Through	B-X
experiments	B-X
with	B-X
knock-in	B-X
mice	B-X
(	B-X
S534A	B-X
mice	B-X
)	B-X
expressing	B-X
a	B-X
mutant	B-X
p65	B-X
with	B-X
an	B-X
alanine-to-serine	B-X
substitution	B-X
at	B-X
position	B-X
534	B-X
(	B-X
the	B-X
murine	B-X
homolog	B-X
of	B-X
human	B-X
Ser	B-X
(	B-X
536	B-X
)	B-X
)	B-X
,	B-X
we	B-X
observed	B-X
increased	B-X
expression	B-X
of	B-X
NF-κB-dependent	B-X
genes	B-X
after	B-X
injection	B-X
of	B-X
mice	B-X
with	B-X
the	B-X
inflammatory	B-X
stimulus	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
or	B-X
exposure	B-X
to	B-X
gamma	B-X
irradiation	B-X
,	B-X
and	B-X
the	B-X
enhanced	B-X
gene	B-X
expression	B-X
was	B-X
most	B-X
pronounced	B-X
at	B-X
late	B-X
time	B-X
points	B-X
.	B-X
Increased	B-X
NF-κB	B-X
signaling	B-X
in	B-X
the	B-X
S534A	B-X
mice	B-X
was	B-X
at	B-X
least	B-X
in	B-X
part	B-X
explained	B-X
by	B-X
the	B-X
increased	B-X
stability	B-X
of	B-X
the	B-X
S534A	B-X
p65	B-X
protein	B-X
compared	B-X
to	B-X
that	B-X
of	B-X
the	B-X
Ser	B-X
(	B-X
534	B-X
)	B-X
-phosphorylated	B-X
wild-type	B-X
protein	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
Ser	B-X
(	B-X
534	B-X
)	B-X
phosphorylation	B-X
of	B-X
p65	B-X
in	B-X
mice	B-X
(	B-X
and	B-X
,	B-X
by	B-X
extension	B-X
,	B-X
Ser	B-X
(	B-X
536	B-X
)	B-X
phosphorylation	B-X
of	B-X
human	B-X
p65	B-X
)	B-X
is	B-X
not	B-X
required	B-X
for	B-X
its	B-X
nuclear	B-X
translocation	B-X
,	B-X
but	B-X
instead	B-X
inhibits	B-X
NF-κB	B-X
signaling	B-X
to	B-X
prevent	B-X
deleterious	B-X
inflammation	B-X
.	B-X

These	O
observations	O
indicate	O
that	O
the	O
MAPK	O
pathway	O
and	O
the	O
transcription	O
factor	O
AP	O
-	O
1	O
play	O
an	O
important	O
role	O
in	O
the	O
induction	O
of	O
inflammatory	O
responses	O
in	O
Jurkat	O
T	O
-	O
cells	O
[	O
12	O
,	O
20	O
,	O
22	O
]	O
.	O

The	O
obtained	O
results	O
signify	O
that	O
CXCL8	O
was	O
primarily	O
regulated	O
through	O
the	O
MAPK	O
pathway	O
.	O

The	O
NF	O
-	O
kappaB	O
activation	O
inhibitor	O
(	O
NAI	O
)	O
showed	O
specificity	O
against	O
NF	O
-	O
kappaB	O
and	O
resulted	O
in	O
a	O
complete	O
IL	B-Protein
-	I-Protein
6	I-Protein
inhibition	O
following	O
induction	O
with	O
PMA	O
and	O
significant	O
IL	B-Protein
-	I-Protein
6	I-Protein
reduction	O
after	O
HK	O
E	O
.	O
coli	O
treatment	O
.	O

CXCL8	O
was	O
highly	O
up	O
regulated	O
by	O
PMA	O
and	O
the	O
addition	O
of	O
NAI	O
resulted	O
in	O
a	O
minor	O
reduction	O
in	O
CXCL8	B-Protein
expression	O
.	O

Furthermore	O
,	O
CXCL8	B-Protein
expression	O
was	O
not	O
affected	O
by	O
NAI	O
following	O
HK	O
E	O
.	O
coli	O
treatment	O
,	O
indicating	O
a	O
lack	O
of	O
correlation	O
between	O
CXCL8	B-Protein
and	O
NF	O
-	O
kappaB	O
.	O
<EOS>	B-X
Detailed	B-X
deciphering	B-X
gene	B-X
expression	B-X
perturbations	B-X
and	B-X
cell-cell	B-X
interactions	B-X
of	B-X
leukocytes	B-X
and	B-X
non-myocytes	B-X
is	B-X
required	B-X
to	B-X
understand	B-X
cell-type-specific	B-X
pathology	B-X
in	B-X
the	B-X
failing	B-X
human	B-X
myocardium	B-X
.	B-X
A	B-X
novel	B-X
transcription	B-X
factor	B-X
AEBP1	B-X
was	B-X
identified	B-X
as	B-X
a	B-X
crucial	B-X
cardiac	B-X
fibrosis	B-X
regulator	B-X
in	B-X
ACTA2	B-X
IL-17A	B-X
and	B-X
IL-22	B-X
induce	B-X
not	B-X
only	B-X
keratinocyte	B-X
proliferation	B-X
,	B-X
but	B-X
also	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-α	B-X
,	B-X
chemokine	B-X
(	B-X
C-X-C	B-X
motif	B-X
)	B-X
ligand	B-X
(	B-X
CXCL	B-X
)	B-X
1	B-X
and	B-X
CXCL8	B-X
production	B-X
.	B-X
TNF-α	B-X
accelerates	B-X
the	B-X
infiltration	B-X
of	B-X
inflammatory	B-X
cells	B-X
,	B-X
including	B-X
lymphocytes	B-X
,	B-X
monocytes	B-X
and	B-X
neutrophils	B-X
,	B-X
from	B-X
the	B-X
peripheral	B-X
blood	B-X
into	B-X
skin	B-X
with	B-X
dendritic	B-X
cell	B-X
activation	B-X
.	B-X
Furthermore	B-X
,	B-X
activation	B-X
of	B-X
nuclear	B-X
factor-κB	B-X
signal	B-X
induces	B-X
the	B-X
expression	B-X
of	B-X
keratins	B-X
6	B-X
and	B-X
16	B-X
in	B-X
keratinocytes	B-X
,	B-X
which	B-X
are	B-X
associated	B-X
with	B-X
acanthosis	B-X
and	B-X
reduced	B-X
turnover	B-X
time	B-X
in	B-X
the	B-X
epidermis	B-X
.	B-X

Further	O
analysis	O
of	O
CXCL8	B-Protein
expression	O
revealed	O
a	O
down	O
-	O
regulation	O
by	O
PKC	O
-	O
and	O
JNK	O
-	O
inhibitors	O
,	O
suggesting	O
an	O
involvement	O
of	O
AP	O
-	O
1	O
via	O
PKC	O
and	O
JNK	O
,	O
respectively	O
.	O

Analysis	O
of	O
gene	O
expression	O
further	O
confirmed	O
that	O
il	B-Protein
-	I-Protein
6	I-Protein
and	O
cxcl8	B-Protein
were	O
upregulated	O
by	O
PMA	O
.	O

Expression	O
of	O
il	B-Protein
-	I-Protein
6	I-Protein
dropped	O
below	O
basal	O
levels	O
following	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
and	O
JNK	O
whereas	O
cxcl8	B-Protein
remained	O
elevated	O
above	O
basal	O
levels	O
(	O
16	O
.	O
5	O
-	O
fold	O
and	O
7	O
.	O
1	O
-	O
fold	O
respectively	O
)	O
following	O
the	O
same	O
treatment	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
PKC	O
did	O
not	O
result	O
in	O
a	O
significant	O
decrease	O
of	O
il	B-Protein
-	I-Protein
6	I-Protein
or	O
cxcl8	B-Protein
,	O
which	O
is	O
in	O
accordance	O
with	O
protein	O
data	O
(	O
figure	O
6	O
)	O
.	O
<EOS>	B-X
The	B-X
neuropeptide	B-X
calcitonin	B-X
gene-related	B-X
peptide	B-X
(	B-X
CGRP	B-X
)	B-X
and	B-X
CGRP1	B-X
receptor	B-X
play	B-X
important	B-X
pathological	B-X
roles	B-X
in	B-X
facilitating	B-X
central	B-X
sensitization	B-X
in	B-X
CM	B-X
.	B-X
Protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
is	B-X
a	B-X
family	B-X
of	B-X
protein	B-X
kinase	B-X
enzymes	B-X
that	B-X
can	B-X
phosphorylate	B-X
other	B-X
proteins	B-X
and	B-X
influence	B-X
their	B-X
functions	B-X
,	B-X
such	B-X
as	B-X
signal	B-X
transduction	B-X
,	B-X
cell	B-X
survival	B-X
,	B-X
and	B-X
death	B-X
.	B-X
Increased	B-X
diacylglycerol	B-X
(	B-X
DAG	B-X
)	B-X
concentrations	B-X
,	B-X
which	B-X
are	B-X
typically	B-X
observed	B-X
raised	B-X
in	B-X
hyperglycemic	B-X
situations	B-X
such	B-X
as	B-X
diabetes	B-X
mellitus	B-X
,	B-X
can	B-X
also	B-X
activate	B-X
PKC	B-X
enzymes	B-X
(	B-X
DM	B-X
)	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
PKC	B-X
isomers	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
diabetes	B-X
and	B-X
many	B-X
hyperglycemic	B-X
complications	B-X
,	B-X
most	B-X
importantly	B-X
atherosclerosis	B-X
and	B-X
diabetic	B-X
cardiomyopathy	B-X
(	B-X
DCM	B-X
)	B-X
.	B-X
As	B-X
a	B-X
result	B-X
,	B-X
blocking	B-X
PKC	B-X
activation	B-X
via	B-X
DAG	B-X
can	B-X
prevent	B-X
hyperglycemia	B-X
and	B-X
related	B-X
consequences	B-X
,	B-X
such	B-X
as	B-X
DCM	B-X
.	B-X
Furthermore	B-X
,	B-X
several	B-X
investigations	B-X
show	B-X
that	B-X
wogonin	B-X
also	B-X
attenuates	B-X
diacylglycerol	B-X
DAG	B-X
levels	B-X
in	B-X
diabetic	B-X
mice	B-X
.	B-X
Since	B-X
the	B-X
DAG-PKC	B-X
pathway	B-X
is	B-X
linked	B-X
with	B-X
hyperglycemia	B-X
and	B-X
its	B-X
complications	B-X
,	B-X
Wogonin-mediated	B-X
DAG-PKC	B-X
attenuation	B-X
can	B-X
help	B-X
treat	B-X
hyperglycemia	B-X
and	B-X
its	B-X
complications	B-X
.	B-X

These	O
results	O
suggest	O
that	O
NF	O
-	O
kappaB	O
is	O
involved	O
in	O
IL	B-Protein
-	I-Protein
6	I-Protein
regulation	O
and	O
release	O
while	O
it	O
is	O
not	O
required	O
for	O
the	O
expression	O
of	O
CXCL8	B-Protein
in	O
Jurkat	O
T	O
cells	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
anti-inflammatory	B-X
potential	B-X
of	B-X
punicalagin	B-X
in	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
induced	B-X
RAW264.7	B-X
macrophages	B-X
and	B-X
uncovered	B-X
the	B-X
underlying	B-X
mechanisms	B-X
.	B-X
Punicalagin	B-X
significantly	B-X
attenuated	B-X
,	B-X
in	B-X
a	B-X
concentration-dependent	B-X
manner	B-X
,	B-X
LPS-induced	B-X
release	B-X
of	B-X
NO	B-X
and	B-X
decreased	B-X
pro-inflammatory	B-X
cytokines	B-X
TNF-α	B-X
and	B-X
IL-6	B-X
release	B-X
at	B-X
the	B-X
highest	B-X
concentration	B-X
.	B-X
We	B-X
found	B-X
that	B-X
punicalagin	B-X
inhibited	B-X
NF-κB	B-X
and	B-X
MAPK	B-X
activation	B-X
in	B-X
LPS-induced	B-X
RAW264.7	B-X
macrophages	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
revealed	B-X
that	B-X
punicalagin	B-X
pre-treatment	B-X
enhanced	B-X
LC3II	B-X
,	B-X
p62	B-X
expression	B-X
,	B-X
and	B-X
decreased	B-X
Beclin1	B-X
expression	B-X
in	B-X
LPS-induced	B-X
macrophages	B-X
.	B-X
MDC	B-X
assays	B-X
were	B-X
used	B-X
to	B-X
determine	B-X
the	B-X
autophagic	B-X
process	B-X
and	B-X
the	B-X
results	B-X
worked	B-X
in	B-X
concert	B-X
with	B-X
Western	B-X
blot	B-X
analysis	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
our	B-X
observations	B-X
indicated	B-X
that	B-X
LPS-induced	B-X
releases	B-X
of	B-X
NO	B-X
,	B-X
TNF-α	B-X
,	B-X
and	B-X
IL-6	B-X
were	B-X
attenuated	B-X
by	B-X
treatment	B-X
with	B-X
autophagy	B-X
inhibitor	B-X
chloroquine	B-X
,	B-X
suggesting	B-X
that	B-X
autophagy	B-X
inhibition	B-X
participated	B-X
in	B-X
anti-inflammatory	B-X
effect	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
punicalagin	B-X
downregulated	B-X
FoxO3a	B-X
expression	B-X
,	B-X
resulting	B-X
in	B-X
autophagy	B-X
inhibition	B-X
.	B-X
Overall	B-X
these	B-X
results	B-X
suggested	B-X
that	B-X
punicalagin	B-X
played	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
attenuation	B-X
of	B-X
LPS-induced	B-X
inflammatory	B-X
responses	B-X
in	B-X
RAW264.7	B-X
macrophages	B-X
and	B-X
that	B-X
the	B-X
mechanisms	B-X
involved	B-X
downregulation	B-X
of	B-X
the	B-X
FoxO3a/autophagy	B-X
signaling	B-X
pathway	B-X
.	B-X

The	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
is	O
responsible	O
for	O
a	O
rapid	O
immune	O
response	O
which	O
is	O
followed	O
by	O
an	O
increase	O
in	O
transcription	O
of	O
IkappaB	O
thus	O
inhibiting	O
NF	O
-	O
kappaB	O
[	O
46	O
]	O
.	O

Activation	O
of	O
NF	O
-	O
kappaB	O
in	O
Jurkat	O
T	O
-	O
cells	O
is	O
dependent	O
on	O
Bcl10	B-Protein
activation	O
,	O
which	O
in	O
turn	O
is	O
regulated	O
by	O
PKC	O
.	O

Recent	O
studies	O
have	O
established	O
the	O
importance	O
of	O
a	O
protein	O
complex	O
consisting	O
of	O
CARMA1	B-Protein
,	O
Bcl10	B-Protein
and	O
MALT1	B-Protein
(	O
CBM	O
)	O
,	O
in	O
the	O
induction	O
of	O
NF	O
-	O
kappaB	O
.	O

Investigating	O
Bcl10	B-Protein
,	O
Scharschmidt	O
and	O
colleagues	O
[	O
47	O
]	O
demonstrated	O
that	O
it	O
is	O
a	O
critical	O
regulator	O
of	O
NF	O
-	O
kappaB	O
activity	O
.	O

Down	O
-	O
regulation	O
of	O
Bcl10	B-Protein
from	O
signals	O
transduced	O
via	O
the	O
TCR	O
/	O
CD28	B-Protein
and	O
PKC	O
resulted	O
in	O
a	O
concomitant	O
down	O
-	O
regulation	O
of	O
NF	O
-	O
kappaB	O
.	O

They	O
suggested	O
that	O
Bcl10	B-Protein
is	O
initially	O
activated	O
by	O
TCR	O
/	O
PKC	O
but	O
that	O
continued	O
activation	O
(	O
>	O
1	O
h	O
)	O
promotes	O
its	O
degradation	O
.	O

Narayan	O
and	O
colleagues	O
[	O
27	O
]	O
suggested	O
that	O
deletion	O
in	O
any	O
of	O
the	O
three	O
CBM	O
complex	O
proteins	O
impairs	O
antigen	O
-	O
receptor	O
dependent	O
activation	O
of	O
NF	O
-	O
kappaB	O
.	O

They	O
showed	O
that	O
NF	O
-	O
kappaB	O
activation	O
via	O
Akt	O
requires	O
CARMA1	B-Protein
and	O
acts	O
in	O
cooperation	O
with	O
PKC	O
following	O
short	O
-	O
term	O
exposure	O
(	O
30	O
min	O
)	O
of	O
Jurkat	O
T	O
-	O
cells	O
with	O
PMA	O
.	O

Akt	O
phosphorylates	O
and	O
thus	O
activates	O
Bcl10	B-Protein
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
from	B-X
our	B-X
group	B-X
and	B-X
others	B-X
have	B-X
shown	B-X
that	B-X
the	B-X
Akt	B-X
kinase	B-X
can	B-X
contribute	B-X
to	B-X
induction	B-X
of	B-X
NF-κB	B-X
by	B-X
antigen	B-X
receptor	B-X
signaling	B-X
.	B-X
However	B-X
,	B-X
the	B-X
direct	B-X
targets	B-X
of	B-X
Akt	B-X
in	B-X
this	B-X
pathway	B-X
are	B-X
not	B-X
known	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
Akt-mediated	B-X
NF-κB	B-X
activation	B-X
is	B-X
mediated	B-X
at	B-X
least	B-X
in	B-X
part	B-X
through	B-X
direct	B-X
phosphorylation	B-X
of	B-X
the	B-X
adaptor	B-X
protein	B-X
Carma1	B-X
,	B-X
which	B-X
we	B-X
previously	B-X
demonstrated	B-X
could	B-X
interact	B-X
with	B-X
Akt	B-X
in	B-X
a	B-X
TCR	B-X
ligation-dependent	B-X
manner	B-X
.	B-X
The	B-X
putative	B-X
Akt	B-X
phosphorylation	B-X
sites	B-X
in	B-X
Carma1	B-X
are	B-X
distinct	B-X
from	B-X
known	B-X
PKC	B-X
consensus	B-X
sites	B-X
.	B-X
Mutation	B-X
of	B-X
S551	B-X
,	B-X
S637	B-X
and	B-X
S645	B-X
in	B-X
Carma1	B-X
to	B-X
non-phosphorylatable	B-X
residues	B-X
decreased	B-X
phosphorylation	B-X
of	B-X
GST-Carma1-linker	B-X
construct	B-X
by	B-X
Akt	B-X
in	B-X
vitro	B-X
.	B-X
Thus	B-X
,	B-X
our	B-X
data	B-X
reveal	B-X
Carma1	B-X
as	B-X
a	B-X
novel	B-X
target	B-X
for	B-X
Akt	B-X
phosphorylation	B-X
and	B-X
suggest	B-X
that	B-X
Akt-mediated	B-X
phosphorylation	B-X
of	B-X
Carma1	B-X
is	B-X
an	B-X
additional	B-X
regulatory	B-X
mechanism	B-X
tuning	B-X
the	B-X
NF-κB	B-X
response	B-X
downstream	B-X
of	B-X
antigen	B-X
receptor	B-X
and	B-X
co-stimulatory	B-X
signaling	B-X
.	B-X

These	O
studies	O
indicate	O
that	O
PKC	O
is	O
crucial	O
for	O
NF	O
-	O
kappaB	O
activation	O
following	O
short	O
-	O
term	O
treatment	O
through	O
signals	O
via	O
membrane	O
bound	O
receptors	O
such	O
as	O
the	O
TCR	O
and	O
the	O
co	O
-	O
stimulatory	O
receptor	O
CD28	B-Protein
.	O

Thus	O
,	O
the	O
CBM	O
complex	O
proteins	O
play	O
a	O
key	O
role	O
in	O
this	O
signalling	O
process	O
.	O
<EOS>	B-X
Antigen	B-X
receptor-induced	B-X
signaling	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
inflammation	B-X
and	B-X
immunity	B-X
.	B-X
Formation	B-X
of	B-X
a	B-X
CARD11-BCL10-MALT1	B-X
(	B-X
CBM	B-X
)	B-X
signaling	B-X
complex	B-X
is	B-X
a	B-X
key	B-X
event	B-X
in	B-X
T-	B-X
and	B-X
B	B-X
cell	B-X
receptor-induced	B-X
gene	B-X
expression	B-X
by	B-X
regulating	B-X
NF-κB	B-X
activation	B-X
and	B-X
mRNA	B-X
stability	B-X
.	B-X
Deregulated	B-X
CARD11	B-X
,	B-X
BCL10	B-X
or	B-X
MALT1	B-X
expression	B-X
or	B-X
CBM	B-X
signaling	B-X
have	B-X
been	B-X
associated	B-X
with	B-X
immunodeficiency	B-X
,	B-X
autoimmunity	B-X
and	B-X
cancer	B-X
,	B-X
indicating	B-X
that	B-X
CBM	B-X
formation	B-X
and	B-X
function	B-X
have	B-X
to	B-X
be	B-X
tightly	B-X
regulated	B-X
.	B-X
Over	B-X
the	B-X
past	B-X
years	B-X
great	B-X
progress	B-X
has	B-X
been	B-X
made	B-X
in	B-X
deciphering	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
assembly	B-X
and	B-X
disassembly	B-X
of	B-X
the	B-X
CBM	B-X
complex	B-X
.	B-X
In	B-X
this	B-X
context	B-X
,	B-X
several	B-X
posttranslational	B-X
modifications	B-X
play	B-X
an	B-X
indispensable	B-X
role	B-X
in	B-X
regulating	B-X
CBM	B-X
function	B-X
and	B-X
downstream	B-X
signal	B-X
transduction	B-X
.	B-X
In	B-X
this	B-X
review	B-X
we	B-X
summarize	B-X
how	B-X
the	B-X
different	B-X
CBM	B-X
components	B-X
as	B-X
well	B-X
as	B-X
their	B-X
interplay	B-X
are	B-X
regulated	B-X
by	B-X
protein	B-X
ubiquitination	B-X
and	B-X
phosphorylation	B-X
in	B-X
the	B-X
context	B-X
of	B-X
T	B-X
cell	B-X
receptor	B-X
signaling	B-X
.	B-X

PMA	O
diffuses	O
into	O
the	O
cytosol	O
and	O
directly	O
activates	O
PKC	O
since	O
it	O
is	O
an	O
analogue	O
to	O
diacylglycerol	O
[	O
48	O
]	O
.	O

Several	O
studies	O
have	O
demonstrated	O
that	O
inhibition	O
of	O
PKC	O
blocks	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
activity	O
,	O
suggesting	O
a	O
direct	O
regulation	O
of	O
these	O
transcription	O
factors	O
by	O
PKC	O
[	O
49	O
,	O
50	O
]	O
.	O

PKC	O
is	O
activated	O
at	O
an	O
early	O
stage	O
following	O
T	O
-	O
cell	O
stimulation	O
and	O
is	O
therefore	O
an	O
important	O
regulator	O
of	O
downstream	O
inflammatory	O
signalling	O
pathways	O
leading	O
to	O
cytokine	O
expression	O
[	O
50	O
]	O
.	O

We	O
have	O
shown	O
that	O
phosphorylated	O
-	O
PKC	O
is	O
up	O
regulated	O
in	O
response	O
to	O
PMA	O
and	O
HK	O
E	O
.	O
coli	O
,	O
indicating	O
an	O
association	O
between	O
PKC	O
and	O
the	O
transcription	O
factors	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappaB	O
.	O

Bcl10	B-Protein
levels	O
were	O
down	O
-	O
regulated	O
following	O
extended	O
treatment	O
of	O
Jurkat	O
T	O
-	O
cells	O
with	O
PMA	O
.	O

In	O
the	O
control	O
groups	O
,	O
a	O
loss	O
of	O
Bcl10	B-Protein
occurred	O
after	O
6	O
h	O
,	O
followed	O
by	O
an	O
increase	O
after	O
24	O
h	O
,	O
which	O
is	O
in	O
accordance	O
with	O
the	O
observed	O
NF	O
-	O
kappaB	O
activity	O
(	O
figure	O
7	O
)	O
.	O

These	O
results	O
are	O
supported	O
by	O
an	O
earlier	O
study	O
[	O
47	O
]	O
,	O
demonstrating	O
that	O
prolonged	O
PKC	O
activation	O
by	O
PMA	O
leads	O
to	O
an	O
inhibition	O
of	O
Bcl10	B-Protein
and	O
NF	O
-	O
kappaB	O
.	O

It	O
has	O
been	O
shown	O
that	O
NF	O
-	O
kappaB	O
is	O
an	O
important	O
transcription	O
factor	O
complex	O
involved	O
in	O
almost	O
every	O
aspect	O
of	O
cell	O
regulation	O
including	O
apoptosis	O
,	O
differentiation	O
,	O
proliferation	O
and	O
initiation	O
of	O
immune	O
responses	O
[	O
51	O
-	O
53	O
]	O
.	O

NF	O
-	O
kappaB	O
is	O
constitutively	O
active	O
in	O
many	O
human	O
malignancies	O
,	O
which	O
makes	O
it	O
an	O
attractive	O
therapeutic	O
target	O
[	O
54	O
]	O
.	O

Elevated	O
CXCL8	B-Protein
levels	O
during	O
chronic	O
inflammation	O
result	O
in	O
an	O
enhanced	O
recruitment	O
of	O
immune	O
cells	O
to	O
the	O
site	O
of	O
infection	O
,	O
which	O
may	O
lead	O
to	O
the	O
development	O
of	O
autoimmune	O
diseases	O
following	O
secretion	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
.	O

In	O
HIV	O
infected	O
persons	O
,	O
serum	O
CXCL8	B-Protein
levels	O
are	O
elevated	O
and	O
this	O
could	O
recruit	O
more	O
T	O
-	O
cells	O
potentially	O
leading	O
to	O
a	O
more	O
rapid	O
progression	O
of	O
the	O
disease	O
since	O
there	O
will	O
be	O
more	O
T	O
-	O
cells	O
available	O
to	O
infect	O
.	O

In	O
the	O
present	O
study	O
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
release	O
was	O
found	O
to	O
be	O
associated	O
with	O
NF	O
-	O
kappaB	O
activity	O
while	O
CXCL8	B-Protein
release	O
more	O
closely	O
correlated	O
with	O
AP	O
-	O
1	O
activity	O
.	O

Treatment	O
of	O
Jurkat	O
T	O
-	O
cells	O
with	O
PMA	O
was	O
more	O
potent	O
than	O
HK	O
E	O
.	O
coli	O
at	O
elevating	O
the	O
CXCL8	B-Protein
levels	O
.	O

PMA	O
induced	O
AP	O
-	O
1	O
activation	O
and	O
down	O
-	O
regulated	O
NF	O
-	O
kappaB	O
while	O
HK	O
E	O
.	O
coli	O
up	O
-	O
regulated	O
NF	O
-	O
kappaB	O
without	O
affecting	O
AP	O
-	O
1	O
activity	O
.	O

In	O
addition	O
,	O
the	O
temporal	O
induction	O
pattern	O
of	O
AP	O
-	O
1	O
correlated	O
to	O
the	O
release	O
of	O
CXCL8	B-Protein
while	O
IL	B-Protein
-	I-Protein
6	I-Protein
followed	O
the	O
NF	O
-	O
kappaB	O
activity	O
.	O

Likewise	O
,	O
blocking	O
NF	O
-	O
kappaB	O
activation	O
resulted	O
in	O
a	O
complete	O
inhibition	O
of	O
IL	B-Protein
-	I-Protein
6	I-Protein
while	O
the	O
CXCL8	B-Protein
levels	O
remained	O
elevated	O
as	O
shown	O
both	O
at	O
the	O
protein	O
and	O
mRNA	O
level	O
.	O

Furthermore	O
,	O
the	O
CXCL8	B-Protein
release	O
was	O
down	O
-	O
regulated	O
by	O
inhibition	O
of	O
JNK	O
activity	O
.	O

The	O
present	O
study	O
indicates	O
that	O
in	O
Jurkat	O
T	O
-	O
cells	O
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
is	O
regulated	O
through	O
NF	O
-	O
kappaB	O
while	O
CXCL8	B-Protein
regulation	O
is	O
independent	O
of	O
NF	O
-	O
kappaB	O
and	O
closely	O
associated	O
with	O
AP	O
-	O
1	O
activation	O
.	O

Chemicals	O
<EOS>	B-X
Chemicals	B-X
that	B-X
were	B-X
bioassayed	B-X
by	B-X
the	B-X
National	B-X
Toxicology	B-X
Program	B-X
(	B-X
NTP	B-X
)	B-X
and	B-X
that	B-X
also	B-X
produce	B-X
allergic	B-X
dermatitis	B-X
(	B-X
ACD	B-X
)	B-X
in	B-X
humans	B-X
were	B-X
evaluated	B-X
for	B-X
their	B-X
tumorigenic	B-X
characteristics	B-X
.	B-X
``	B-X
A	B-X
Silent	B-X
Pandemic	B-X
:	B-X
Industrial	B-X
Chemicals	B-X
Are	B-X
Impairing	B-X
the	B-X
Brain	B-X
Development	B-X
of	B-X
Children	B-X
Worldwide	B-X
''	B-X
Fetal	B-X
and	B-X
early	B-X
childhood	B-X
exposures	B-X
to	B-X
industrial	B-X
chemicals	B-X
in	B-X
the	B-X
environment	B-X
can	B-X
damage	B-X
the	B-X
developing	B-X
brain	B-X
and	B-X
can	B-X
lead	B-X
to	B-X
neurodevelopmental	B-X
disorders	B-X
(	B-X
NDDs	B-X
)	B-X
--	B-X
autism	B-X
,	B-X
attention	B-X
deficit	B-X
disorder	B-X
(	B-X
ADHD	B-X
)	B-X
,	B-X
and	B-X
mental	B-X
retardation	B-X
.	B-X

The	O
following	O
chemicals	O
were	O
used	O
in	O
the	O
present	O
study	O
:	O
PMA	O
(	O
Phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
,	O
(	O
Sigma	O
#	O
P1585	O
,	O
USA	O
)	O
)	O
;	O
NF	O
-	O
kappaB	O
activation	O
inhibitor	O
(	O
NAI	O
)	O
,	O
(	O
InSolution	O
(	O
TM	O
)	O
NF	O
-	O
kappaB	O
Activation	O
Inhibitor	O
,	O
Calbiochem	O
#	O
481407	O
,	O
USA	O
)	O
;	O
JNK	O
inhibitor	O
,	O
(	O
InSolution	O
(	O
TM	O
)	O
JNK	O
Inhibitor	O
II	O
,	O
Calbiochem	O
#	O
420128	O
,	O
USA	O
)	O
;	O
PKC	O
Inhibitor	O
,	O
(	O
InSolution	O
(	O
TM	O
)	O
Bisindolylmaleimide	O
I	O
,	O
Calbiochem	O
#	O
203293	O
,	O
USA	O
)	O
;	O
Calcium	O
Ionophore	O
,	O
(	O
Calcium	O
Ionophore	O
A23187	O
mixed	O
calcium	O
magnesium	O
salt	O
,	O
Sigma	O
#	O
C5149	O
,	O
USA	O
)	O
.	O

Heat	O
killed	O
(	O
HK	O
)	O
Escherichia	O
coli	O
<EOS>	B-X
This	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
investigate	B-X
how	B-X
live	B-X
Escherichia	B-X
coli	B-X
influence	B-X
the	B-X
fate	B-X
of	B-X
polymorphonuclear	B-X
neutrophils	B-X
(	B-X
PMNs	B-X
)	B-X
in	B-X
vitro	B-X
.	B-X
PMNs	B-X
from	B-X
10	B-X
healthy	B-X
volunteers	B-X
were	B-X
cocultured	B-X
with	B-X
or	B-X
without	B-X
live	B-X
E.	B-X
coli	B-X
at	B-X
different	B-X
ratios	B-X
.	B-X
Heat-killed	B-X
E.	B-X
coli	B-X
(	B-X
Hk	B-X
)	B-X
were	B-X
also	B-X
added	B-X
to	B-X
PMNs	B-X
at	B-X
a	B-X
ratio	B-X
of	B-X
1:10	B-X
.	B-X
Low	B-X
doses	B-X
of	B-X
E.	B-X
coli	B-X
(	B-X
PMN	B-X
:	B-X
E.	B-X
coli	B-X
ratios	B-X
of	B-X
1:0.01	B-X
and	B-X
1:0.1	B-X
)	B-X
inhibited	B-X
PMN	B-X
apoptosis	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
a	B-X
high	B-X
dose	B-X
of	B-X
E.	B-X
coli	B-X
(	B-X
PMN	B-X
:	B-X
E.	B-X
coli	B-X
ratio	B-X
of	B-X
1:10	B-X
)	B-X
increased	B-X
PMN	B-X
necrosis	B-X
.	B-X
ROI	B-X
production	B-X
was	B-X
significantly	B-X
greater	B-X
at	B-X
PMN	B-X
:	B-X
E.	B-X
coli	B-X
ratios	B-X
of	B-X
1:10	B-X
and	B-X
1:10	B-X
(	B-X
Hk	B-X
)	B-X
than	B-X
at	B-X
ratios	B-X
of	B-X
1:0.01	B-X
and	B-X
1:0.1	B-X
,	B-X
or	B-X
in	B-X
PMNs	B-X
cultured	B-X
alone	B-X
after	B-X
a	B-X
15	B-X
or	B-X
30	B-X
minute	B-X
coculture	B-X
.	B-X
CD16	B-X
expressions	B-X
were	B-X
significantly	B-X
lower	B-X
in	B-X
PMNs	B-X
cocultured	B-X
with	B-X
E.	B-X
coli	B-X
than	B-X
in	B-X
those	B-X
cultured	B-X
alone	B-X
after	B-X
a	B-X
4	B-X
or	B-X
12-h	B-X
coculture	B-X
.	B-X
The	B-X
mean	B-X
percentages	B-X
of	B-X
apoptosis	B-X
at	B-X
PMN	B-X
:	B-X
E.	B-X
coli	B-X
ratios	B-X
of	B-X
1:0.01	B-X
and	B-X
1:10	B-X
(	B-X
Hk	B-X
)	B-X
,	B-X
and	B-X
in	B-X
PMNs	B-X
cultured	B-X
alone	B-X
after	B-X
a	B-X
12-h	B-X
coculture	B-X
showed	B-X
significant	B-X
inverse	B-X
correlations	B-X
with	B-X
these	B-X
cytokine	B-X
levels	B-X
in	B-X
cell-free	B-X
supernatants	B-X
at	B-X
12	B-X
h.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
low	B-X
doses	B-X
of	B-X
live	B-X
E.	B-X
coli	B-X
inhibits	B-X
predominantly	B-X
PMN	B-X
apoptosis	B-X
,	B-X
whereas	B-X
a	B-X
high	B-X
dose	B-X
of	B-X
E.	B-X
coli	B-X
increases	B-X
necrosis	B-X
.	B-X

E	O
.	O
coli	O
MG1655	O
were	O
grown	O
on	O
Luria	O
-	O
Bertani	O
(	O
LB	O
)	O
agar	O
and	O
incubated	O
at	O
37degreesC	O
overnight	O
.	O

One	O
colony	O
was	O
inoculated	O
into	O
10	O
ml	O
LB	O
broth	O
and	O
incubated	O
on	O
a	O
shaker	O
(	O
200	O
rpm	O
)	O
at	O
37degreesC	O
overnight	O
.	O

The	O
bacteria	O
were	O
centrifuged	O
for	O
10	O
min	O
at	O
3000	O
x	O
g	O
,	O
washed	O
with	O
3	O
ml	O
phosphate	O
buffered	O
saline	O
(	O
PBS	O
;	O
8	O
g	O
NaCl	O
,	O
1	O
.	O
16	O
g	O
Na2HPO4	O
,	O
0	O
.	O
2	O
g	O
KH2PO4	O
,	O
0	O
.	O
2	O
g	O
KCl	O
,	O
pH7	O
)	O
and	O
resuspended	O
in	O
50	O
mul	O
PBS	O
.	O

The	O
bacteria	O
were	O
killed	O
by	O
heating	O
to	O
70degreesC	O
for	O
1	O
h	O
.	O

To	O
ensure	O
that	O
the	O
bacteria	O
were	O
killed	O
;	O
10	O
mul	O
of	O
the	O
heat	O
-	O
killed	O
suspension	O
was	O
spread	O
on	O
a	O
LB	O
plate	O
and	O
incubated	O
overnight	O
at	O
37degreesC	O
.	O
<EOS>	B-X
To	B-X
facilitate	B-X
host	B-X
homeostasis	B-X
,	B-X
the	B-X
immune	B-X
system	B-X
ensures	B-X
that	B-X
the	B-X
microbial	B-X
load	B-X
is	B-X
tolerated	B-X
,	B-X
but	B-X
anatomically	B-X
contained	B-X
,	B-X
while	B-X
remaining	B-X
reactive	B-X
to	B-X
microbial	B-X
invasion	B-X
.	B-X
Although	B-X
the	B-X
microbiota	B-X
is	B-X
required	B-X
for	B-X
intestinal	B-X
immune	B-X
development	B-X
,	B-X
immune	B-X
responses	B-X
regulate	B-X
the	B-X
structure	B-X
and	B-X
composition	B-X
of	B-X
the	B-X
intestinal	B-X
microbiota	B-X
by	B-X
evolving	B-X
unique	B-X
immune	B-X
adaptations	B-X
that	B-X
manage	B-X
this	B-X
high-bacterial	B-X
load	B-X
.	B-X
The	B-X
immune	B-X
mechanisms	B-X
work	B-X
together	B-X
to	B-X
ensure	B-X
that	B-X
commensal	B-X
bacteria	B-X
rarely	B-X
breach	B-X
the	B-X
intestinal	B-X
barrier	B-X
and	B-X
that	B-X
any	B-X
that	B-X
do	B-X
invade	B-X
should	B-X
be	B-X
killed	B-X
rapidly	B-X
to	B-X
prevent	B-X
penetration	B-X
to	B-X
systemic	B-X
sites	B-X
.	B-X
The	B-X
communication	B-X
between	B-X
microbiota	B-X
and	B-X
the	B-X
immune	B-X
system	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
interaction	B-X
of	B-X
bacterial	B-X
components	B-X
with	B-X
pattern	B-X
recognition	B-X
receptors	B-X
expressed	B-X
by	B-X
intestinal	B-X
epithelium	B-X
and	B-X
various	B-X
antigen-presenting	B-X
cells	B-X
resulting	B-X
in	B-X
activation	B-X
of	B-X
both	B-X
innate	B-X
and	B-X
adaptive	B-X
immune	B-X
responses	B-X
.	B-X
The	B-X
accumulation	B-X
and	B-X
function	B-X
of	B-X
these	B-X
mucosal	B-X
leukocytes	B-X
are	B-X
regulated	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
intestinal	B-X
microbiota	B-X
,	B-X
which	B-X
regulate	B-X
these	B-X
immune	B-X
cells	B-X
and	B-X
enhance	B-X
the	B-X
mucosal	B-X
barrier	B-X
function	B-X
allowing	B-X
the	B-X
host	B-X
to	B-X
mount	B-X
robust	B-X
immune	B-X
responses	B-X
against	B-X
invading	B-X
pathogens	B-X
,	B-X
and	B-X
simultaneously	B-X
maintains	B-X
immune	B-X
homeostasis	B-X
.	B-X

Cell	O
culturing	O
,	O
transfection	O
and	O
stimulation	O
<EOS>	B-X
Plasmid	B-X
DNA	B-X
transfection	B-X
of	B-X
mammalian	B-X
cells	B-X
is	B-X
widely	B-X
used	B-X
in	B-X
biomedical	B-X
research	B-X
and	B-X
genetic	B-X
drug	B-X
delivery	B-X
,	B-X
but	B-X
low	B-X
transfection	B-X
efficiency	B-X
,	B-X
especially	B-X
in	B-X
the	B-X
context	B-X
of	B-X
the	B-X
primary	B-X
cells	B-X
,	B-X
limits	B-X
its	B-X
application	B-X
.	B-X
To	B-X
improve	B-X
the	B-X
efficiency	B-X
of	B-X
plasmid	B-X
transfection	B-X
,	B-X
a	B-X
fully	B-X
integrated	B-X
self-powered	B-X
electrical	B-X
stimulation	B-X
cell	B-X
culture	B-X
dish	B-X
(	B-X
SESD	B-X
)	B-X
has	B-X
been	B-X
developed	B-X
to	B-X
provide	B-X
self-powered	B-X
electrical	B-X
stimulation	B-X
(	B-X
ES	B-X
)	B-X
of	B-X
adherent	B-X
cells	B-X
,	B-X
significantly	B-X
improving	B-X
the	B-X
efficiency	B-X
of	B-X
plasmid	B-X
transfection	B-X
into	B-X
mammalian	B-X
cells	B-X
and	B-X
cell	B-X
survival	B-X
by	B-X
the	B-X
standard	B-X
lipofectamine	B-X
transfection	B-X
method	B-X
.	B-X
Mechanistically	B-X
,	B-X
ES	B-X
can	B-X
safely	B-X
increase	B-X
the	B-X
intracellular	B-X
calcium	B-X
concentration	B-X
by	B-X
opening	B-X
calcium-ion	B-X
channels	B-X
,	B-X
leading	B-X
to	B-X
a	B-X
higher	B-X
efficiency	B-X
of	B-X
plasmid	B-X
transfection	B-X
.	B-X
Therefore	B-X
,	B-X
SESD	B-X
has	B-X
the	B-X
potential	B-X
to	B-X
become	B-X
an	B-X
effective	B-X
platform	B-X
for	B-X
high-efficiency	B-X
plasmid	B-X
DNA	B-X
transfection	B-X
in	B-X
biomedical	B-X
research	B-X
and	B-X
drug	B-X
delivery	B-X
.	B-X

Jurkat	O
T	O
-	O
cells	O
(	O
wild	O
type	O
and	O
TCR	O
deficient	O
-	O
TCR	O
-	O
/	O
-	O
)	O
were	O
maintained	O
in	O
90	O
%	O
RPMI	O
1640	O
medium	O
(	O
PAA	O
laboratories	O
,	O
Austria	O
)	O
with	O
1	O
.	O
5	O
mM	O
L	O
-	O
glutamine	O
(	O
Invitrogen	O
,	O
USA	O
)	O
,	O
10	O
%	O
foetal	O
bovine	O
serum	O
(	O
Invitrogen	O
,	O
USA	O
)	O
and	O
1	O
%	O
antibiotic	O
-	O
antimycotic	O
(	O
Invitrogen	O
,	O
USA	O
)	O
and	O
incubated	O
in	O
a	O
stable	O
environment	O
of	O
5	O
%	O
CO2	O
at	O
37degreesC	O
.	O

The	O
cells	O
were	O
centrifuged	O
at	O
1000	O
x	O
g	O
for	O
8	O
min	O
and	O
resuspended	O
in	O
fresh	O
media	O
to	O
a	O
final	O
cell	O
density	O
of	O
1	O
.	O
6	O
x	O
107	O
cells	O
/	O
ml	O
in	O
a	O
24	O
-	O
well	O
plate	O
.	O

Reporter	O
plasmid	O
(	O
pNFkappaB	O
-	O
Luc	O
,	O
pAP1	O
(	O
PMA	O
)	O
-	O
TA	O
-	O
Luc	O
,	O
pNFkappaB	O
-	O
SEAP	O
)	O
,	O
internal	O
control	O
plasmid	O
(	O
pRL	O
)	O
(	O
Promega	O
,	O
USA	O
)	O
and	O
lipofectamine	O
2000	O
(	O
Invitrogen	O
,	O
USA	O
)	O
were	O
added	O
to	O
each	O
well	O
at	O
0	O
.	O
54	O
mug	O
/	O
well	O
,	O
0	O
.	O
06	O
mug	O
/	O
well	O
and	O
1	O
.	O
5	O
mul	O
/	O
well	O
,	O
respectively	O
.	O

Initially	O
,	O
the	O
reporter	O
plasmid	O
and	O
pRL	O
were	O
mixed	O
separately	O
with	O
OptiMEM	O
(	O
Gibco	O
,	O
USA	O
)	O
.	O

After	O
5	O
min	O
of	O
incubation	O
at	O
room	O
temperature	O
,	O
lipofectamine	O
2000	O
was	O
added	O
and	O
the	O
mixture	O
was	O
incubated	O
further	O
for	O
20	O
min	O
at	O
room	O
temperature	O
.	O

The	O
transfection	O
was	O
allowed	O
to	O
proceed	O
overnight	O
at	O
37degreesC	O
,	O
after	O
which	O
,	O
the	O
cells	O
were	O
centrifuged	O
,	O
the	O
media	O
removed	O
and	O
fresh	O
pre	O
-	O
warmed	O
media	O
added	O
.	O

The	O
cells	O
were	O
pre	O
-	O
incubated	O
with	O
NF	O
-	O
kappaB	O
,	O
JNK	O
and	O
PKC	O
inhibitors	O
and	O
stimulated	O
in	O
24	O
-	O
well	O
plates	O
with	O
different	O
concentrations	O
of	O
PMA	O
,	O
HK	O
E	O
.	O
coli	O
MG1655	O
and	O
Calcium	O
Ionophore	O
A23187	O
.	O

The	O
cells	O
were	O
lysed	O
and	O
luciferase	B-Protein
activity	O
(	O
NF	O
-	O
kappaB	O
and	O
AP	O
-	O
1	O
)	O
was	O
measured	O
using	O
the	O
Dual	O
-	O
Luciferase	O
(	O
R	O
)	O
reporter	O
assay	O
system	O
(	O
Promega	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
on	O
a	O
TD	O
20	O
/	O
20	O
luminometer	O
(	O
Turner	O
Designs	O
,	O
Sunnyvale	O
,	O
CA	O
)	O
.	O

Secreted	O
alkaline	O
phosphatase	O
(	O
NFkappaB	O
-	O
SEAP	O
,	O
figure	O
4a	O
,	O
b	O
)	O
levels	O
were	O
measured	O
using	O
Great	O
EscAPe	O
(	O
TM	O
)	O
SEAP	O
Detection	O
Kit	O
(	O
Clontech	O
,	O
USA	O
)	O
.	O

Multiplex	O
cytokine	O
assay	O
<EOS>	B-X
Quantification	B-X
of	B-X
cytokines	B-X
has	B-X
significant	B-X
value	B-X
in	B-X
both	B-X
clinical	B-X
medicine	B-X
and	B-X
biology	B-X
as	B-X
the	B-X
levels	B-X
provide	B-X
insights	B-X
into	B-X
physiological	B-X
and	B-X
pathological	B-X
processes	B-X
and	B-X
can	B-X
be	B-X
used	B-X
to	B-X
aid	B-X
diagnosis	B-X
and	B-X
treatment	B-X
.	B-X
Factors	B-X
affecting	B-X
cytokines	B-X
quantification	B-X
in	B-X
biological	B-X
fluids	B-X
,	B-X
native	B-X
levels	B-X
in	B-X
different	B-X
body	B-X
fluids	B-X
,	B-X
sample	B-X
processing	B-X
and	B-X
storage	B-X
conditions	B-X
,	B-X
sensitivity	B-X
to	B-X
freeze-thaw	B-X
,	B-X
and	B-X
soluble	B-X
cytokine	B-X
receptors	B-X
are	B-X
discussed	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
recent	B-X
advances	B-X
in	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
assays	B-X
,	B-X
biosensors	B-X
based	B-X
on	B-X
different	B-X
signal	B-X
outputs	B-X
and	B-X
intracellular	B-X
to	B-X
extracellular	B-X
protein	B-X
expression	B-X
are	B-X
summarized	B-X
.	B-X
Various	B-X
quantification	B-X
platforms	B-X
for	B-X
high-sensitivity	B-X
and	B-X
reliable	B-X
measurement	B-X
of	B-X
cytokines	B-X
in	B-X
different	B-X
scenarios	B-X
are	B-X
discussed	B-X
,	B-X
and	B-X
commercially	B-X
available	B-X
cytokine	B-X
assays	B-X
are	B-X
compared	B-X
.	B-X
A	B-X
discussion	B-X
of	B-X
challenges	B-X
in	B-X
the	B-X
development	B-X
and	B-X
advancement	B-X
of	B-X
technologies	B-X
for	B-X
cytokine	B-X
quantification	B-X
that	B-X
aim	B-X
to	B-X
achieve	B-X
real-time	B-X
multiplex	B-X
cytokine	B-X
analysis	B-X
for	B-X
point-of-care	B-X
situations	B-X
applicable	B-X
for	B-X
both	B-X
biomedical	B-X
research	B-X
and	B-X
clinical	B-X
practice	B-X
are	B-X
discussed	B-X
.	B-X

Quantification	O
of	O
the	O
levels	O
of	O
cytokines	O
IL	B-Protein
-	I-Protein
2	I-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
IL	B-Protein
-	I-Protein
10	I-Protein
and	O
TNF	O
and	O
the	O
chemokine	O
CXCL8	B-Protein
was	O
performed	O
on	O
culture	O
supernatants	O
using	O
multiplexed	O
biomarker	O
immunoassay	O
kits	O
according	O
to	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
,	O
Hercules	O
,	O
CA	O
)	O
.	O

A	O
Bio	O
-	O
Plex	O
(	O
TM	O
)	O
200	O
readout	O
System	O
was	O
used	O
(	O
Bio	O
-	O
Rad	O
)	O
,	O
which	O
utilizes	O
Luminex	O
(	O
R	O
)	O
xMAP	O
(	O
TM	O
)	O
fluorescent	O
bead	O
-	O
based	O
technology	O
(	O
Luminex	O
Corp	O
.	O
,	O
Austin	O
)	O
.	O

Levels	O
were	O
automatically	O
calculated	O
from	O
standard	O
curves	O
using	O
Bio	O
-	O
Plex	O
Manager	O
software	O
(	O
v	O
.	O
4	O
.	O
1	O
.	O
1	O
,	O
Bio	O
-	O
Rad	O
)	O
.	O

Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
<EOS>	B-X
Enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
(	B-X
ELISA	B-X
)	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
specific	B-X
and	B-X
straightforward	B-X
assays	B-X
for	B-X
detecting	B-X
biomolecules	B-X
in	B-X
research	B-X
and	B-X
clinics	B-X
.	B-X
With	B-X
advances	B-X
in	B-X
analytical	B-X
methods	B-X
,	B-X
ELISA	B-X
assay	B-X
has	B-X
been	B-X
constantly	B-X
optimized	B-X
to	B-X
improve	B-X
its	B-X
sensitivity	B-X
,	B-X
and	B-X
different	B-X
types	B-X
of	B-X
ELISA	B-X
are	B-X
now	B-X
available	B-X
to	B-X
detect	B-X
various	B-X
biomarkers	B-X
.	B-X
This	B-X
chapter	B-X
provides	B-X
an	B-X
overall	B-X
summary	B-X
of	B-X
the	B-X
basic	B-X
principle	B-X
of	B-X
ELISA	B-X
,	B-X
discusses	B-X
different	B-X
components	B-X
of	B-X
ELISA	B-X
assay	B-X
,	B-X
and	B-X
clearly	B-X
outline	B-X
protocols	B-X
for	B-X
different	B-X
types	B-X
of	B-X
ELISA	B-X
assays	B-X
,	B-X
including	B-X
direct	B-X
,	B-X
indirect	B-X
,	B-X
sandwich	B-X
,	B-X
competitive	B-X
,	B-X
and	B-X
nanoparticle-based	B-X
ELISA	B-X
.	B-X
This	B-X
brief	B-X
note	B-X
addresses	B-X
the	B-X
historical	B-X
background	B-X
of	B-X
the	B-X
invention	B-X
of	B-X
the	B-X
enzyme	B-X
immunoassay	B-X
(	B-X
EIA	B-X
)	B-X
and	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
(	B-X
ELISA	B-X
)	B-X
.	B-X
These	B-X
assays	B-X
were	B-X
developed	B-X
independently	B-X
and	B-X
simultaneously	B-X
by	B-X
the	B-X
research	B-X
group	B-X
of	B-X
Peter	B-X
Perlmann	B-X
and	B-X
Eva	B-X
Engvall	B-X
at	B-X
Stockholm	B-X
University	B-X
in	B-X
Sweden	B-X
and	B-X
by	B-X
the	B-X
research	B-X
group	B-X
of	B-X
Anton	B-X
Schuurs	B-X
and	B-X
Bauke	B-X
van	B-X
Weemen	B-X
in	B-X
The	B-X
Netherlands	B-X
.	B-X
Today	B-X
,	B-X
fully	B-X
automated	B-X
instruments	B-X
in	B-X
medical	B-X
laboratories	B-X
around	B-X
the	B-X
world	B-X
use	B-X
the	B-X
immunoassay	B-X
principle	B-X
with	B-X
an	B-X
enzyme	B-X
as	B-X
the	B-X
reporter	B-X
label	B-X
for	B-X
routine	B-X
measurements	B-X
of	B-X
innumerable	B-X
analytes	B-X
in	B-X
patient	B-X
samples	B-X
.	B-X
The	B-X
impact	B-X
of	B-X
EIA/ELISA	B-X
is	B-X
reflected	B-X
in	B-X
the	B-X
overwhelmingly	B-X
large	B-X
number	B-X
of	B-X
times	B-X
it	B-X
has	B-X
appeared	B-X
as	B-X
a	B-X
keyword	B-X
in	B-X
the	B-X
literature	B-X
since	B-X
the	B-X
1970s	B-X
.	B-X

ELISA	O
was	O
performed	O
on	O
supernatants	O
from	O
challenged	O
Jurkat	O
T	O
-	O
cells	O
to	O
quantify	O
IL	B-Protein
-	I-Protein
6	I-Protein
,	O
CXCL8	B-Protein
and	O
TNF	O
(	O
BD	O
OptEIA	O
Human	O
IL	B-Protein
-	I-Protein
6	I-Protein
Elisa	O
Set	O
,	O
BD	O
OptEIA	O
Human	O
CXCL8	B-Protein
Elisa	O
Set	O
and	O
BD	O
OptEIA	O
Human	O
TNF	B-Protein
Elisa	O
Set	O
,	O
Biosciences	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Briefly	O
,	O
Jurkat	O
T	O
-	O
cells	O
were	O
stimulated	O
with	O
PMA	O
(	O
162	O
nM	O
)	O
for	O
1	O
h	O
,	O
centrifuged	O
(	O
1000	O
x	O
g	O
,	O
8	O
min	O
)	O
and	O
the	O
supernatants	O
were	O
collected	O
and	O
stored	O
at	O
-	O
80degreesC	O
until	O
use	O
.	O

Following	O
centrifugation	O
,	O
the	O
cells	O
were	O
resuspended	O
in	O
1	O
h	O
aged	O
media	O
,	O
where	O
cells	O
have	O
been	O
grown	O
in	O
,	O
containing	O
PMA	O
.	O

The	O
same	O
procedure	O
was	O
performed	O
to	O
collect	O
media	O
after	O
2	O
h	O
and	O
6	O
h	O
.	O
<EOS>	B-X
To	B-X
determine	B-X
the	B-X
imaging	B-X
and	B-X
clinical-pathologic	B-X
factors	B-X
associated	B-X
with	B-X
recurrence	B-X
in	B-X
patients	B-X
with	B-X
early	B-X
stage	B-X
triple-negative	B-X
breast	B-X
cancer	B-X
.	B-X
Acute	B-X
otitis	B-X
media	B-X
(	B-X
AOM	B-X
)	B-X
is	B-X
a	B-X
common	B-X
childhood	B-X
infectious	B-X
disease	B-X
.	B-X
The	B-X
efficacy	B-X
of	B-X
antibiotic	B-X
dosing	B-X
regimens	B-X
is	B-X
usually	B-X
assessed	B-X
by	B-X
antibiotic	B-X
plasma	B-X
pharmacokinetics	B-X
or	B-X
middle	B-X
ear	B-X
fluid	B-X
(	B-X
MEF	B-X
)	B-X
concentration	B-X
at	B-X
one	B-X
or	B-X
two	B-X
time	B-X
points	B-X
.	B-X
It	B-X
is	B-X
currently	B-X
thought	B-X
that	B-X
most-but	B-X
not	B-X
all-individuals	B-X
infected	B-X
with	B-X
SARS-CoV-2	B-X
develop	B-X
symptoms	B-X
,	B-X
but	B-X
the	B-X
infectious	B-X
period	B-X
starts	B-X
on	B-X
average	B-X
2	B-X
days	B-X
before	B-X
the	B-X
first	B-X
overt	B-X
symptoms	B-X
appear	B-X
.	B-X
It	B-X
is	B-X
estimated	B-X
that	B-X
pre-	B-X
and	B-X
asymptomatic	B-X
individuals	B-X
are	B-X
responsible	B-X
for	B-X
more	B-X
than	B-X
half	B-X
of	B-X
all	B-X
transmissions	B-X
.	B-X
By	B-X
detecting	B-X
infected	B-X
individuals	B-X
before	B-X
they	B-X
have	B-X
overt	B-X
symptoms	B-X
,	B-X
wearable	B-X
devices	B-X
could	B-X
potentially	B-X
and	B-X
significantly	B-X
reduce	B-X
the	B-X
proportion	B-X
of	B-X
transmissions	B-X
by	B-X
pre-symptomatic	B-X
individuals	B-X
.	B-X
Using	B-X
laboratory-confirmed	B-X
SARS-CoV-2	B-X
infections	B-X
(	B-X
detected	B-X
via	B-X
serology	B-X
tests	B-X
[	B-X
to	B-X
determine	B-X
if	B-X
there	B-X
are	B-X
antibodies	B-X
against	B-X
the	B-X
SARS-CoV-2	B-X
in	B-X
the	B-X
blood	B-X
]	B-X
or	B-X
SARS-CoV-2	B-X
infection	B-X
tests	B-X
such	B-X
as	B-X
polymerase	B-X
chain	B-X
reaction	B-X
[	B-X
PCR	B-X
]	B-X
or	B-X
antigen	B-X
tests	B-X
)	B-X
as	B-X
the	B-X
gold	B-X
standard	B-X
,	B-X
we	B-X
will	B-X
determine	B-X
the	B-X
sensitivity	B-X
,	B-X
specificity	B-X
,	B-X
positive	B-X
predictive	B-X
value	B-X
(	B-X
PPV	B-X
)	B-X
and	B-X
negative	B-X
predictive	B-X
value	B-X
(	B-X
NPV	B-X
)	B-X
for	B-X
the	B-X
following	B-X
two	B-X
algorithms	B-X
to	B-X
detect	B-X
first	B-X
time	B-X
SARS-CoV-2	B-X
infection	B-X
including	B-X
early	B-X
or	B-X
asymptomatic	B-X
infection	B-X
:	B-X
•	B-X
The	B-X
algorithm	B-X
using	B-X
Ava	B-X
bracelet	B-X
data	B-X
when	B-X
coupled	B-X
with	B-X
self-reported	B-X
Daily	B-X
Symptom	B-X
Diary	B-X
data	B-X
(	B-X
Wearable	B-X
+	B-X
Symptom	B-X
Data	B-X
Algo	B-X
;	B-X
experimental	B-X
condition	B-X
)	B-X
•	B-X
The	B-X
algorithm	B-X
using	B-X
self-reported	B-X
Daily	B-X
Symptom	B-X
Diary	B-X
data	B-X
alone	B-X
(	B-X
Symptom	B-X
Only	B-X
Algo	B-X
;	B-X
control	B-X
condition	B-X
)	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
will	B-X
determine	B-X
which	B-X
of	B-X
the	B-X
two	B-X
algorithms	B-X
has	B-X
superior	B-X
performance	B-X
characteristics	B-X
for	B-X
detecting	B-X
SARS-CoV-2	B-X
infection	B-X
including	B-X
early	B-X
or	B-X
asymptomatic	B-X
infection	B-X
as	B-X
confirmed	B-X
by	B-X
SARS-CoV-2	B-X
virus	B-X
testing	B-X
.	B-X

The	O
final	O
collection	O
of	O
media	O
was	O
performed	O
after	O
24	O
h	O
.	O
<EOS>	B-X
Gadolinium-DTPA	B-X
(	B-X
Gd-DTPA	B-X
)	B-X
is	B-X
routinely	B-X
used	B-X
as	B-X
a	B-X
marker	B-X
for	B-X
inflammation	B-X
in	B-X
MRI	B-X
to	B-X
visualize	B-X
breakdown	B-X
of	B-X
the	B-X
blood-brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
in	B-X
multiple	B-X
sclerosis	B-X
.	B-X
Recent	B-X
data	B-X
suggest	B-X
that	B-X
ultra-small	B-X
superparamagnetic	B-X
particles	B-X
of	B-X
iron	B-X
oxide	B-X
(	B-X
USPIO	B-X
)	B-X
can	B-X
be	B-X
used	B-X
to	B-X
visualize	B-X
cellular	B-X
infiltration	B-X
,	B-X
another	B-X
aspect	B-X
of	B-X
inflammation	B-X
.	B-X
This	B-X
project	B-X
aimed	B-X
to	B-X
compare	B-X
the	B-X
novel	B-X
USPIO	B-X
particle	B-X
SHU555C	B-X
to	B-X
the	B-X
longitudinal	B-X
pattern	B-X
of	B-X
Gd-DTPA	B-X
enhancement	B-X
in	B-X
multiple	B-X
sclerosis	B-X
.	B-X
Nineteen	B-X
relapsing-remitting	B-X
patients	B-X
were	B-X
screened	B-X
monthly	B-X
using	B-X
Gd-enhanced	B-X
MRI	B-X
.	B-X
In	B-X
case	B-X
of	B-X
new	B-X
enhancing	B-X
lesions	B-X
,	B-X
USPIO	B-X
were	B-X
injected	B-X
and	B-X
24	B-X
h	B-X
later	B-X
,	B-X
MRI	B-X
was	B-X
performed	B-X
and	B-X
blood	B-X
was	B-X
collected	B-X
to	B-X
confirm	B-X
USPIO	B-X
loading	B-X
of	B-X
circulating	B-X
monocytes	B-X
.	B-X
Lesion	B-X
development	B-X
was	B-X
monitored	B-X
by	B-X
3	B-X
monthly	B-X
Gd-DTPA-enhanced	B-X
scans	B-X
and	B-X
a	B-X
final	B-X
scan	B-X
7-11	B-X
months	B-X
after	B-X
injection	B-X
.	B-X
USPIO-enhancement	B-X
was	B-X
observed	B-X
as	B-X
hyperintensity	B-X
on	B-X
T1-weighted	B-X
images	B-X
,	B-X
whereas	B-X
no	B-X
signal	B-X
changes	B-X
were	B-X
observed	B-X
on	B-X
T2-weighted-gradient-echo	B-X
images	B-X
.	B-X
In	B-X
14	B-X
patients	B-X
with	B-X
disease	B-X
activity	B-X
,	B-X
188	B-X
USPIO-positive	B-X
lesions	B-X
were	B-X
seen	B-X
,	B-X
144	B-X
of	B-X
which	B-X
were	B-X
Gd-negative	B-X
.	B-X
By	B-X
contrast	B-X
,	B-X
there	B-X
were	B-X
a	B-X
total	B-X
of	B-X
59	B-X
Gd-positive	B-X
lesions	B-X
,	B-X
15	B-X
of	B-X
which	B-X
were	B-X
USPIO	B-X
negative	B-X
.	B-X
Three	B-X
patterns	B-X
of	B-X
USPIO-enhancement	B-X
were	B-X
seen	B-X
:	B-X
(	B-X
i	B-X
)	B-X
focal	B-X
enhancement	B-X
;	B-X
(	B-X
ii	B-X
)	B-X
ring-like	B-X
enhancement	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
return	B-X
to	B-X
isointensity	B-X
of	B-X
a	B-X
previously	B-X
hypointense	B-X
lesion	B-X
.	B-X
The	B-X
latter	B-X
pattern	B-X
was	B-X
most	B-X
frequently	B-X
observed	B-X
for	B-X
lesions	B-X
that	B-X
turned	B-X
out	B-X
to	B-X
be	B-X
transiently	B-X
hypointense	B-X
on	B-X
follow-up	B-X
scans	B-X
,	B-X
and	B-X
ring-enhancing	B-X
lesions	B-X
were	B-X
less	B-X
likely	B-X
to	B-X
evolve	B-X
into	B-X
black	B-X
holes	B-X
at	B-X
follow-up	B-X
than	B-X
lesions	B-X
without	B-X
ring-like	B-X
USPIO-enhancement	B-X
;	B-X
we	B-X
speculate	B-X
this	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
repair	B-X
.	B-X
In	B-X
4	B-X
%	B-X
of	B-X
the	B-X
USPIO-positive/Gd	B-X
negative	B-X
lesions	B-X
,	B-X
USPIO-enhancement	B-X
preceded	B-X
Gd-enhancement	B-X
by	B-X
1	B-X
month	B-X
.	B-X
USPIO-enhancement	B-X
remained	B-X
visible	B-X
for	B-X
up	B-X
to	B-X
3	B-X
months	B-X
in	B-X
1.5	B-X
%	B-X
of	B-X
all	B-X
USPIO-positive	B-X
lesions	B-X
.	B-X
In	B-X
29	B-X
%	B-X
of	B-X
the	B-X
lesions	B-X
enhancing	B-X
with	B-X
both	B-X
contrast	B-X
agents	B-X
,	B-X
USPIO-enhancement	B-X
persisted	B-X
whereas	B-X
Gd-enhancement	B-X
had	B-X
already	B-X
resolved	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
the	B-X
new	B-X
nano-particle	B-X
SHU555C	B-X
provides	B-X
complementary	B-X
information	B-X
to	B-X
Gd-enhanced	B-X
MRI	B-X
,	B-X
probably	B-X
related	B-X
to	B-X
monocyte	B-X
infiltration	B-X
.	B-X
The	B-X
use	B-X
of	B-X
USPIO-enhanced	B-X
MRI	B-X
is	B-X
likely	B-X
to	B-X
lead	B-X
to	B-X
more	B-X
insight	B-X
in	B-X
the	B-X
pluriformity	B-X
of	B-X
inflammation	B-X
in	B-X
multiple	B-X
sclerosis	B-X
.	B-X

Western	O
blot	O
analysis	O
<EOS>	B-X
Appropriate	B-X
protein	B-X
extraction	B-X
method	B-X
,	B-X
electrophoresis	B-X
,	B-X
and	B-X
transfer	B-X
of	B-X
proteins	B-X
,	B-X
immunodetection	B-X
of	B-X
blotted	B-X
protein	B-X
by	B-X
antibodies	B-X
,	B-X
and	B-X
the	B-X
ultimate	B-X
step	B-X
of	B-X
imaging	B-X
and	B-X
analyzing	B-X
the	B-X
data	B-X
is	B-X
nothing	B-X
short	B-X
of	B-X
a	B-X
symphony	B-X
.	B-X
Like	B-X
with	B-X
any	B-X
other	B-X
technology	B-X
in	B-X
life-sciences	B-X
research	B-X
,	B-X
Western	B-X
blotting	B-X
can	B-X
produce	B-X
erroneous	B-X
and	B-X
irreproducible	B-X
data	B-X
.	B-X
We	B-X
provide	B-X
a	B-X
systematic	B-X
approach	B-X
to	B-X
generate	B-X
quantitative	B-X
data	B-X
from	B-X
Western	B-X
blot	B-X
experiments	B-X
that	B-X
incorporates	B-X
critical	B-X
validation	B-X
steps	B-X
to	B-X
identify	B-X
and	B-X
minimize	B-X
sources	B-X
of	B-X
error	B-X
and	B-X
variability	B-X
throughout	B-X
the	B-X
Western	B-X
blot	B-X
process	B-X
.	B-X
Electrophoresis	B-X
and	B-X
the	B-X
following	B-X
western	B-X
blot	B-X
analysis	B-X
are	B-X
indispensable	B-X
to	B-X
investigate	B-X
biochemical	B-X
changes	B-X
in	B-X
cells	B-X
and	B-X
tissues	B-X
exposed	B-X
to	B-X
nanoparticles	B-X
or	B-X
nanomaterials	B-X
.	B-X
It	B-X
is	B-X
important	B-X
to	B-X
select	B-X
a	B-X
good	B-X
blocking	B-X
agent	B-X
and	B-X
an	B-X
appropriate	B-X
pair	B-X
of	B-X
primary	B-X
and	B-X
peroxidase-tagged	B-X
secondary	B-X
antibodies	B-X
to	B-X
obtain	B-X
good	B-X
results	B-X
in	B-X
western	B-X
blot	B-X
analysis	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
the	B-X
whole	B-X
process	B-X
of	B-X
western	B-X
blot	B-X
analysis	B-X
,	B-X
from	B-X
sample	B-X
preparation	B-X
to	B-X
quantitative	B-X
measurement	B-X
of	B-X
target	B-X
proteins	B-X
,	B-X
is	B-X
described	B-X
.	B-X

Following	O
stimulation	O
,	O
Jurkat	O
T	O
-	O
cells	O
were	O
centrifuged	O
at	O
1000	O
x	O
g	O
for	O
8	O
min	O
and	O
lysed	O
on	O
ice	O
for	O
2	O
h	O
using	O
sodium	O
hydroxide	O
with	O
the	O
addition	O
of	O
a	O
protease	O
inhibitor	O
cocktail	O
(	O
Roche	O
,	O
Mannheim	O
)	O
.	O

The	O
cells	O
were	O
further	O
centrifuged	O
at	O
8000	O
x	O
g	O
,	O
4degreesC	O
for	O
10	O
min	O
and	O
the	O
supernatants	O
were	O
transferred	O
to	O
new	O
tubes	O
.	O

Cytoplasmic	O
proteins	O
(	O
~	O
8	O
mug	O
)	O
were	O
separated	O
by	O
SDS	O
-	O
PAGE	O
(	O
10	O
%	O
)	O
followed	O
by	O
western	O
blotting	O
using	O
anti	O
-	O
IkappaBbeta	O
,	O
phospho	O
-	O
PKC	O
(	O
pan	O
)	O
(	O
zeta	O
Thr410	O
)	O
(	O
190D10	O
)	O
,	O
anti	O
-	O
Bcl10	O
(	O
Cell	O
Signalling	O
Technology	O
,	O
Boston	O
)	O
and	O
beta	B-Protein
-	I-Protein
actin	I-Protein
(	O
Abcam	O
,	O
Cambridge	O
)	O
.	O

Detection	O
was	O
performed	O
following	O
incubation	O
with	O
ECL	O
(	O
TM	O
)	O
Anti	O
-	O
rabbit	O
IgG	O
,	O
horseradish	O
peroxidase	O
linked	O
whole	O
antibodies	O
(	O
Amersham	O
Biosciences	O
,	O
Buckinghamshire	O
)	O
and	O
developed	O
using	O
ECL	O
(	O
TM	O
)	O
Western	O
Blotting	O
Detection	O
Reagents	O
(	O
GE	O
Healthcare	O
,	O
UK	O
)	O
.	O

RNA	O
extraction	O
<EOS>	B-X
Extraction	B-X
of	B-X
DNA	B-X
,	B-X
RNA	B-X
,	B-X
and	B-X
protein	B-X
is	B-X
the	B-X
basic	B-X
method	B-X
used	B-X
in	B-X
molecular	B-X
biology	B-X
.	B-X
In	B-X
the	B-X
past	B-X
,	B-X
the	B-X
process	B-X
of	B-X
extraction	B-X
and	B-X
purification	B-X
of	B-X
nucleic	B-X
acids	B-X
used	B-X
to	B-X
be	B-X
complicated	B-X
,	B-X
time-consuming	B-X
,	B-X
labor-intensive	B-X
,	B-X
and	B-X
limited	B-X
in	B-X
terms	B-X
of	B-X
overall	B-X
throughput	B-X
.	B-X
Current	B-X
extraction	B-X
methods	B-X
often	B-X
extract	B-X
DNA	B-X
and	B-X
RNA	B-X
separately	B-X
,	B-X
and	B-X
few	B-X
methods	B-X
are	B-X
capable	B-X
of	B-X
co-extracting	B-X
DNA	B-X
and	B-X
RNA	B-X
from	B-X
sputum	B-X
.	B-X
We	B-X
established	B-X
a	B-X
nucleic	B-X
acid	B-X
co-extraction	B-X
method	B-X
from	B-X
sputum	B-X
based	B-X
on	B-X
magnetic	B-X
beads	B-X
and	B-X
optimized	B-X
the	B-X
method	B-X
by	B-X
evaluating	B-X
influencing	B-X
factors	B-X
,	B-X
such	B-X
as	B-X
the	B-X
guanidinium	B-X
thiocyanate	B-X
(	B-X
GTC	B-X
)	B-X
and	B-X
dithiothreitol	B-X
(	B-X
DTT	B-X
)	B-X
concentrations	B-X
,	B-X
magnetic	B-X
bead	B-X
amount	B-X
,	B-X
incubation	B-X
temperature	B-X
,	B-X
lysis	B-X
buffer	B-X
pH	B-X
and	B-X
RNA	B-X
carrier	B-X
type	B-X
.	B-X
The	B-X
feasibility	B-X
of	B-X
the	B-X
simultaneous	B-X
nucleic	B-X
acid	B-X
co-extraction	B-X
method	B-X
was	B-X
evaluated	B-X
by	B-X
amplifying	B-X
DNA	B-X
and	B-X
RNA	B-X
viruses	B-X
from	B-X
a	B-X
single	B-X
clinical	B-X
specimen	B-X
with	B-X
a	B-X
multiplex	B-X
RT-qPCR	B-X
method	B-X
.	B-X
Both	B-X
DNA	B-X
and	B-X
RNA	B-X
were	B-X
most	B-X
efficiently	B-X
extracted	B-X
when	B-X
the	B-X
GTC	B-X
and	B-X
DTT	B-X
concentrations	B-X
were	B-X
2.0	B-X
M	B-X
and	B-X
80	B-X
mM	B-X
,	B-X
respectively	B-X
,	B-X
20	B-X
μl	B-X
magnetic	B-X
beads	B-X
were	B-X
added	B-X
,	B-X
the	B-X
incubation	B-X
temperature	B-X
was	B-X
80	B-X
°C	B-X
,	B-X
the	B-X
pH	B-X
was	B-X
8	B-X
or	B-X
9	B-X
,	B-X
and	B-X
RNA	B-X
carrier	B-X
A	B-X
was	B-X
used	B-X
.	B-X
This	B-X
magnetic	B-X
beads-based	B-X
co-extraction	B-X
method	B-X
for	B-X
sputum	B-X
followed	B-X
by	B-X
a	B-X
multiplex	B-X
RT-qPCR	B-X
can	B-X
rapidly	B-X
and	B-X
precisely	B-X
detect	B-X
DNA	B-X
and	B-X
RNA	B-X
viruses	B-X
from	B-X
a	B-X
single	B-X
clinical	B-X
specimen	B-X
and	B-X
has	B-X
many	B-X
advantages	B-X
,	B-X
such	B-X
as	B-X
decreased	B-X
time	B-X
,	B-X
low	B-X
cost	B-X
,	B-X
and	B-X
a	B-X
lack	B-X
of	B-X
harmful	B-X
chemicals	B-X
.	B-X

Jurkat	O
T	O
-	O
cells	O
were	O
treated	O
with	O
NF	O
-	O
kappaB	O
,	O
JNK	O
and	O
PKC	O
inhibitors	O
for	O
2	O
h	O
in	O
6	O
-	O
well	O
plates	O
followed	O
by	O
stimulation	O
with	O
162	O
nM	O
PMA	O
for	O
24	O
h	O
.	O

At	O
sampling	O
the	O
cells	O
were	O
pelleted	O
followed	O
by	O
RNA	O
extraction	O
using	O
100	O
mul	O
TRI	O
-	O
reagent	O
(	O
Sigma	O
,	O
USA	O
)	O
.	O

This	O
was	O
followed	O
by	O
addition	O
of	O
100	O
mul	O
chloroform	O
/	O
isoamylalcohol	O
(	O
24	O
/	O
1	O
)	O
.	O

The	O
solutions	O
were	O
mixed	O
by	O
vortexing	O
followed	O
by	O
centrifugation	O
at	O
12	O
,	O
000	O
rpm	O
for	O
15	O
min	O
at	O
4degreesC	O
.	O

The	O
upper	O
phase	O
was	O
transferred	O
to	O
a	O
new	O
tube	O
followed	O
by	O
addition	O
of	O
100	O
mul	O
iso	O
-	O
propanol	O
and	O
incubated	O
at	O
room	O
temperature	O
for	O
10	O
min	O
.	O

RNA	O
was	O
then	O
pelleted	O
by	O
centrifugation	O
at	O
12	O
,	O
000	O
rpm	O
for	O
15	O
min	O
at	O
4degreesC	O
and	O
washed	O
with	O
70	O
%	O
ethanol	O
.	O

The	O
RNA	O
pellet	O
was	O
dissolved	O
in	O
25	O
mul	O
RNase	O
free	O
water	O
and	O
the	O
yield	O
and	O
ratio	O
(	O
A260	O
/	O
A280	O
)	O
was	O
determined	O
using	O
NanoVue	O
(	O
GE	O
Healthcare	O
,	O
UK	O
)	O
.	O

The	O
samples	O
were	O
stored	O
at	O
-	O
80degreesC	O
until	O
further	O
use	O
.	O
<EOS>	B-X
Blood	B-X
samples	B-X
were	B-X
taken	B-X
immediately	B-X
before	B-X
the	B-X
start	B-X
of	B-X
MLT	B-X
administration	B-X
and	B-X
30	B-X
days	B-X
after	B-X
therapy	B-X
.	B-X
Plasma	B-X
was	B-X
collected	B-X
in	B-X
EDTA	B-X
tubes	B-X
on	B-X
ice	B-X
,	B-X
centrifuged	B-X
immediately	B-X
at	B-X
4-degrees-C	B-X
and	B-X
stored	B-X
frozen	B-X
at	B-X
-80-degrees-C	B-X
until	B-X
assayed	B-X
.	B-X

Reverse	O
transcription	O
quantitative	O
PCR	O
(	O
RT	O
-	O
qPCR	O
)	O
<EOS>	B-X
SARS-CoV-2	B-X
RNA	B-X
in	B-X
saliva	B-X
was	B-X
detected	B-X
using	B-X
a	B-X
quantitative	B-X
reverse	B-X
transcription-PCR	B-X
(	B-X
RT-qPCR	B-X
)	B-X
laboratory-developed	B-X
test	B-X
(	B-X
LDT	B-X
)	B-X
,	B-X
a	B-X
cobas	B-X
SARS-CoV-2	B-X
high-throughput	B-X
system	B-X
,	B-X
three	B-X
direct	B-X
RT-qPCR	B-X
kits	B-X
,	B-X
and	B-X
reverse	B-X
transcription-loop-mediated	B-X
isothermal	B-X
amplification	B-X
(	B-X
RT-LAMP	B-X
)	B-X
.	B-X
The	B-X
RT-qPCR	B-X
LDT	B-X
,	B-X
a	B-X
cobas	B-X
SARS-CoV-2	B-X
high-throughput	B-X
system	B-X
,	B-X
direct	B-X
RT-qPCR	B-X
kits	B-X
(	B-X
except	B-X
for	B-X
one	B-X
commercial	B-X
kit	B-X
)	B-X
,	B-X
and	B-X
RT-LAMP	B-X
showed	B-X
sufficient	B-X
sensitivities	B-X
in	B-X
clinical	B-X
use	B-X
to	B-X
be	B-X
selectively	B-X
used	B-X
in	B-X
clinical	B-X
settings	B-X
and	B-X
facilities	B-X
.	B-X
The	B-X
real-time	B-X
reverse	B-X
transcription	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-qPCR	B-X
)	B-X
addresses	B-X
the	B-X
evident	B-X
requirement	B-X
for	B-X
quantitative	B-X
data	B-X
analysis	B-X
in	B-X
molecular	B-X
medicine	B-X
,	B-X
biotechnology	B-X
,	B-X
microbiology	B-X
and	B-X
diagnostics	B-X
and	B-X
has	B-X
become	B-X
the	B-X
method	B-X
of	B-X
choice	B-X
for	B-X
the	B-X
quantification	B-X
of	B-X
mRNA	B-X
.	B-X
As	B-X
a	B-X
first	B-X
step	B-X
towards	B-X
standardization	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
series	B-X
of	B-X
RT-qPCR	B-X
protocols	B-X
that	B-X
illustrate	B-X
the	B-X
essential	B-X
technical	B-X
steps	B-X
required	B-X
to	B-X
generate	B-X
quantitative	B-X
data	B-X
that	B-X
are	B-X
reliable	B-X
and	B-X
reproducible	B-X
.	B-X
We	B-X
would	B-X
like	B-X
to	B-X
emphasize	B-X
,	B-X
however	B-X
,	B-X
that	B-X
RT-qPCR	B-X
data	B-X
constitute	B-X
only	B-X
a	B-X
snapshot	B-X
of	B-X
information	B-X
regarding	B-X
the	B-X
quantity	B-X
of	B-X
a	B-X
given	B-X
transcript	B-X
in	B-X
a	B-X
cell	B-X
or	B-X
tissue	B-X
.	B-X
The	B-X
entire	B-X
protocol	B-X
described	B-X
here	B-X
,	B-X
encompassing	B-X
all	B-X
stages	B-X
from	B-X
initial	B-X
assay	B-X
design	B-X
to	B-X
reliable	B-X
qPCR	B-X
data	B-X
analysis	B-X
,	B-X
requires	B-X
approximately	B-X
15	B-X
h	B-X
.	B-X

RT	O
-	O
qPCR	O
was	O
used	O
to	O
determine	O
gene	O
expression	O
levels	O
of	O
il	B-Protein
-	I-Protein
6	I-Protein
and	O
cxcl8	B-Protein
in	O
response	O
to	O
PMA	O
following	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
,	O
JNK	O
and	O
PKC	O
.	O

The	O
following	O
primer	O
sequences	O
were	O
used	O
,	O
il	B-Protein
-	I-Protein
6	I-Protein
:	O
forward	O
-	O
TGTGAAAGCAGCAAAGAGGCACTG	O
,	O
reverse	O
-	O
ACAGCTCTGGCTTGTTCCTCACTA	O
;	O
cxcl8	B-Protein
:	O
forward	O
-	O
ACCACACTGCGCCAACACAGAAAT	O
,	O
reverse	O
-	O
AAACTTCTCCACAACCCTCTGCAC	O
.	O

Thermocycling	O
conditions	O
for	O
CYBR	O
Green	O
(	O
Quanta	O
,	O
USA	O
)	O
consisted	O
of	O
a	O
denaturation	O
step	O
for	O
10	O
min	O
at	O
95	O
degreesC	O
followed	O
by	O
60	O
cycles	O
of	O
95degreesC	O
for	O
1s	O
and	O
60degreesC	O
for	O
30s	O
.	O

Gene	O
expression	O
was	O
analysed	O
using	O
Stratagene	O
(	O
Mx3000p	O
(	O
TM	O
)	O
)	O
(	O
AH	O
diagnostics	O
)	O
.	O

The	O
obtained	O
Ct	O
values	O
were	O
normalized	O
against	O
18S	O
.	O
<EOS>	B-X
Commonly	B-X
used	B-X
reference	B-X
genes	B-X
including	B-X
18S	B-X
rRNA	B-X
(	B-X
18S	B-X
)	B-X
,	B-X
H2A	B-X
histone	B-X
family	B-X
,	B-X
member	B-X
Z	B-X
(	B-X
H2A	B-X
)	B-X
,	B-X
hypoxanthine	B-X
phosphoribosyltransferase1	B-X
(	B-X
HPRT1	B-X
)	B-X
,	B-X
glyceraldehyde-3-phosphate	B-X
dehydrogenase	B-X
(	B-X
GAPDH	B-X
)	B-X
,	B-X
ribosomal	B-X
protein	B-X
4	B-X
(	B-X
RPL4	B-X
)	B-X
,	B-X
peptidylprolyl	B-X
isomerase	B-X
A	B-X
(	B-X
PPIA	B-X
)	B-X
,	B-X
beta	B-X
actin	B-X
(	B-X
ACTB	B-X
)	B-X
,	B-X
succinate	B-X
dehydrogenase	B-X
complex	B-X
,	B-X
subunit	B-X
A	B-X
(	B-X
SDHA	B-X
)	B-X
and	B-X
hydroxymethylbilane	B-X
synthase	B-X
(	B-X
HMBS2	B-X
)	B-X
were	B-X
analysed	B-X
;	B-X
most	B-X
of	B-X
them	B-X
resulted	B-X
in	B-X
significantly	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
different	B-X
cycle	B-X
threshold	B-X
(	B-X
CT	B-X
)	B-X
values	B-X
in	B-X
porcine	B-X
embryos	B-X
except	B-X
for	B-X
SDHA	B-X
and	B-X
H2A	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
SDHA	B-X
and	B-X
H2A	B-X
were	B-X
determined	B-X
as	B-X
the	B-X
most	B-X
appropriate	B-X
reference	B-X
genes	B-X
for	B-X
reliable	B-X
normalisation	B-X
in	B-X
order	B-X
to	B-X
find	B-X
the	B-X
comparative	B-X
gene	B-X
expression	B-X
in	B-X
porcine	B-X
blastocysts	B-X
produced	B-X
by	B-X
different	B-X
methods	B-X
,	B-X
whereas	B-X
18S	B-X
was	B-X
regarded	B-X
as	B-X
a	B-X
less-stable	B-X
reference	B-X
gene	B-X
.	B-X
The	B-X
qRT-PCR	B-X
assay	B-X
detects	B-X
18S	B-X
rRNA	B-X
transcripts	B-X
from	B-X
both	B-X
parasites	B-X
,	B-X
that	B-X
is	B-X
,	B-X
the	B-X
cycle	B-X
threshold	B-X
for	B-X
18S	B-X
rRNA	B-X
from	B-X
parasites	B-X
(	B-X
C	B-X
(	B-X
T	B-X
)	B-X
(	B-X
[	B-X
P18S	B-X
]	B-X
)	B-X
)	B-X
and	B-X
host	B-X
cells	B-X
(	B-X
C	B-X
(	B-X
T	B-X
)	B-X
(	B-X
[	B-X
H18S	B-X
]	B-X
)	B-X
)	B-X
,	B-X
and	B-X
evaluates	B-X
the	B-X
relative	B-X
expression	B-X
between	B-X
parasite	B-X
and	B-X
host	B-X
rRNA	B-X
levels	B-X
(	B-X
i.e.	B-X
,	B-X
deltaC	B-X
(	B-X
T	B-X
)	B-X
=	B-X
C	B-X
(	B-X
T	B-X
)	B-X
(	B-X
[	B-X
P18S	B-X
]	B-X
)	B-X
-	B-X
C	B-X
(	B-X
T	B-X
)	B-X
(	B-X
[	B-X
H18S	B-X
]	B-X
)	B-X
)	B-X
to	B-X
minimize	B-X
experimental	B-X
and	B-X
operational	B-X
errors	B-X
.	B-X
The	B-X
choice	B-X
of	B-X
qRT-PCR	B-X
over	B-X
quantitative	B-X
PCR	B-X
(	B-X
qPCR	B-X
)	B-X
in	B-X
this	B-X
study	B-X
is	B-X
based	B-X
on	B-X
the	B-X
observations	B-X
that	B-X
(	B-X
i	B-X
)	B-X
the	B-X
relationship	B-X
between	B-X
the	B-X
logarithm	B-X
of	B-X
infected	B-X
parasites	B-X
(	B-X
log	B-X
[	B-X
P	B-X
]	B-X
)	B-X
and	B-X
the	B-X
normalized	B-X
relative	B-X
level	B-X
of	B-X
rRNA	B-X
(	B-X
deltadeltaC	B-X
(	B-X
T	B-X
)	B-X
)	B-X
is	B-X
linear	B-X
,	B-X
with	B-X
a	B-X
fourfold	B-X
dynamic	B-X
range	B-X
,	B-X
by	B-X
qRT-PCR	B-X
but	B-X
sigmoidal	B-X
(	B-X
nonlinear	B-X
)	B-X
by	B-X
qPCR	B-X
;	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
the	B-X
level	B-X
of	B-X
RNA	B-X
represents	B-X
that	B-X
of	B-X
live	B-X
parasites	B-X
better	B-X
than	B-X
that	B-X
of	B-X
DNA	B-X
,	B-X
because	B-X
the	B-X
decay	B-X
of	B-X
RNA	B-X
(	B-X
99	B-X
%	B-X
in	B-X
approximately	B-X
3	B-X
h	B-X
)	B-X
in	B-X
dead	B-X
parasites	B-X
is	B-X
faster	B-X
than	B-X
that	B-X
of	B-X
DNA	B-X
(	B-X
99	B-X
%	B-X
in	B-X
approximately	B-X
24	B-X
to	B-X
48	B-X
h	B-X
)	B-X
under	B-X
in	B-X
vitro	B-X
conditions	B-X
.	B-X
The	B-X
observed	B-X
MIC50	B-X
values	B-X
for	B-X
nitazoxanide	B-X
and	B-X
paromomycin	B-X
were	B-X
0.30	B-X
to	B-X
0.45	B-X
micro/ml	B-X
and	B-X
89.7	B-X
to	B-X
119.0	B-X
microg/ml	B-X
,	B-X
respectively	B-X
,	B-X
comparable	B-X
to	B-X
the	B-X
values	B-X
reported	B-X
previously	B-X
.	B-X

Initially	O
,	O
all	O
measured	O
18S	O
Ct	O
values	O
were	O
used	O
to	O
calculate	O
a	O
mean	O
Ct	O
value	O
that	O
was	O
used	O
to	O
determine	O
the	O
deltaCt	O
values	O
for	O
each	O
sample	O
.	O

Gene	O
expression	O
patterns	O
for	O
il	B-Protein
-	I-Protein
6	I-Protein
and	O
cxcl8	B-Protein
were	O
then	O
normalized	O
with	O
regard	O
to	O
the	O
samples	O
18S	O
deltaCt	O
.	O

Statistical	O
analysis	O

Statistical	O
significant	O
differences	O
were	O
determined	O
using	O
two	O
-	O
tailed	O
Student	O
'	O
s	O
t	O
-	O
test	O
(	O
*	O
p	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
p	O
<	O
0	O
.	O
01	O
;	O
*	O
*	O
*	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

AP	O
-	O
1	O
activation	O
following	O
long	O
-	O
term	O
exposure	O
of	O
Jurkat	O
T	O
-	O
cells	O
to	O
PMA	O
.	O

Jurkat	O
T	O
-	O
cells	O
were	O
transfected	O
with	O
luciferase	B-Protein
reporter	O
plasmids	O
containing	O
the	O
AP	O
-	O
1	O
cis	O
-	O
elements	O
.	O

(	O
A	O
)	O
Time	O
-	O
dependent	O
AP	O
-	O
1	O
activation	O
in	O
response	O
to	O
PMA	O
.	O
<EOS>	B-X
The	B-X
central	B-X
role	B-X
of	B-X
cytokines	B-X
in	B-X
regulating	B-X
the	B-X
immune	B-X
response	B-X
suggests	B-X
a	B-X
possible	B-X
mechanism	B-X
by	B-X
which	B-X
DCPA	B-X
inhibits	B-X
the	B-X
immune	B-X
system	B-X
.	B-X
Using	B-X
the	B-X
human	B-X
T	B-X
lymphoma	B-X
line	B-X
,	B-X
Jurkat	B-X
,	B-X
stimulated	B-X
with	B-X
phorbol-12-myristate	B-X
acetate	B-X
(	B-X
PMA	B-X
)	B-X
and	B-X
the	B-X
calcium	B-X
ionophore	B-X
A23187	B-X
(	B-X
Io	B-X
)	B-X
,	B-X
we	B-X
determined	B-X
that	B-X
DCPA	B-X
exposure	B-X
decreased	B-X
IL-2	B-X
secretion	B-X
and	B-X
mRNA	B-X
levels	B-X
in	B-X
a	B-X
dose	B-X
dependent	B-X
manner	B-X
.	B-X
Activating	B-X
protein	B-X
1	B-X
(	B-X
AP-1	B-X
)	B-X
is	B-X
a	B-X
transcription	B-X
factor	B-X
that	B-X
has	B-X
been	B-X
demonstrated	B-X
to	B-X
be	B-X
required	B-X
for	B-X
optimal	B-X
IL-2	B-X
gene	B-X
transcription	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
(	B-X
EMSAs	B-X
)	B-X
demonstrated	B-X
a	B-X
decreased	B-X
level	B-X
of	B-X
AP-1	B-X
DNA	B-X
binding	B-X
activity	B-X
in	B-X
DCPA-exposed	B-X
Jurkat	B-X
cells	B-X
compared	B-X
to	B-X
control	B-X
cells	B-X
from	B-X
30	B-X
min	B-X
to	B-X
2	B-X
h	B-X
after	B-X
stimulation	B-X
.	B-X
The	B-X
altered	B-X
AP-1	B-X
DNA	B-X
binding	B-X
kinetics	B-X
was	B-X
associated	B-X
with	B-X
a	B-X
decrease	B-X
in	B-X
c-jun	B-X
protein	B-X
in	B-X
these	B-X
cells	B-X
at	B-X
1	B-X
and	B-X
2	B-X
h	B-X
after	B-X
exposure	B-X
and	B-X
a	B-X
decreased	B-X
level	B-X
of	B-X
phosphorylated	B-X
c-jun	B-X
at	B-X
1-4	B-X
h	B-X
after	B-X
exposure	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
a	B-X
possible	B-X
mechanism	B-X
for	B-X
DCPA-induced	B-X
IL-2	B-X
inhibition	B-X
;	B-X
alteration	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
c-jun	B-X
component	B-X
of	B-X
AP-1	B-X
.	B-X

(	O
B	O
)	O
HK	O
E	O
.	O
coli	O
does	O
not	O
activate	O
AP	O
-	O
1	O
.	O

(	O
C	O
)	O
Dose	O
-	O
dependent	O
activation	O
of	O
AP	O
-	O
1	O
were	O
performed	O
using	O
PMA	O
alone	O
(	O
grey	O
bars	O
)	O
and	O
in	O
combination	O
with	O
calcium	O
ionophore	O
(	O
CaI	O
955	O
muM	O
,	O
black	O
bars	O
)	O
.	O

(	O
D	O
)	O
TCR	O
-	O
/	O
-	O
deficient	O
cells	O
responded	O
to	O
PMA	O
(	O
162	O
nM	O
)	O
by	O
up	O
-	O
regulating	O
AP	O
-	O
1	O
activity	O
.	O

Statistical	O
significance	O
from	O
the	O
control	O
was	O
determined	O
using	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

(	O
n	O
=	O
4	O
)	O
.	O
<EOS>	B-X
T-cell	B-X
immunoglobulin	B-X
domain	B-X
and	B-X
mucin	B-X
domain	B-X
4	B-X
(	B-X
TIM-4	B-X
)	B-X
is	B-X
a	B-X
transmembrane	B-X
protein	B-X
that	B-X
promotes	B-X
epithelial-mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
,	B-X
migration	B-X
and	B-X
invasion	B-X
of	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
cells	B-X
.	B-X
Most	B-X
transmembrane	B-X
proteins	B-X
are	B-X
modified	B-X
by	B-X
N-glycosylation	B-X
and	B-X
the	B-X
importance	B-X
of	B-X
protein	B-X
N-glycosylation	B-X
in	B-X
cancer	B-X
cell	B-X
metastasis	B-X
has	B-X
been	B-X
well	B-X
appreciated	B-X
.	B-X
However	B-X
,	B-X
whether	B-X
TIM-4	B-X
is	B-X
modified	B-X
by	B-X
N-glycosylation	B-X
and	B-X
the	B-X
role	B-X
of	B-X
TIM-4	B-X
N-glycosylation	B-X
in	B-X
NSCLC	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
reported	B-X
that	B-X
TIM-4	B-X
was	B-X
extensively	B-X
N-glycosylated	B-X
at	B-X
Asn291	B-X
.	B-X
After	B-X
the	B-X
removal	B-X
of	B-X
N-glycosylation	B-X
,	B-X
the	B-X
stability	B-X
of	B-X
TIM-4	B-X
protein	B-X
was	B-X
decreased	B-X
and	B-X
TIM-4	B-X
was	B-X
more	B-X
susceptible	B-X
to	B-X
degradation	B-X
by	B-X
ER-localized	B-X
ubiquitin	B-X
ligase-mediated	B-X
ERAD	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
TIM-4	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
was	B-X
decreased	B-X
,	B-X
which	B-X
suppressed	B-X
TIM-4-mediated	B-X
metastasis	B-X
in	B-X
NSCLC	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
the	B-X
present	B-X
study	B-X
identifies	B-X
TIM-4	B-X
N-glycosylation	B-X
and	B-X
its	B-X
role	B-X
in	B-X
NSCLS	B-X
migration	B-X
,	B-X
which	B-X
would	B-X
provide	B-X
a	B-X
valuable	B-X
biomarker	B-X
for	B-X
developing	B-X
drugs	B-X
targeting	B-X
N-glycosylation	B-X
at	B-X
Asn291	B-X
on	B-X
TIM-4	B-X
.	B-X

Controls	O
were	O
arbitrarily	O
set	O
to	O
1	O
.	O
<EOS>	B-X
Other	B-X
investigators	B-X
set	B-X
the	B-X
cutoff	B-X
arbitrarily	B-X
at	B-X
a	B-X
certain	B-X
absorbance	B-X
value	B-X
.	B-X
The	B-X
mathematical	B-X
formula	B-X
which	B-X
defines	B-X
the	B-X
upper	B-X
prediction	B-X
limit	B-X
is	B-X
expressed	B-X
as	B-X
the	B-X
standard	B-X
deviation	B-X
multiplied	B-X
by	B-X
a	B-X
factor	B-X
which	B-X
is	B-X
based	B-X
on	B-X
the	B-X
number	B-X
of	B-X
negative	B-X
controls	B-X
and	B-X
the	B-X
confidence	B-X
level	B-X
(	B-X
1	B-X
-	B-X
alpha	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
we	B-X
can	B-X
arbitrarily	B-X
set	B-X
the	B-X
remanent	B-X
ferroelectric	B-X
polarization	B-X
at	B-X
nanometric	B-X
dimensions	B-X
.	B-X
A	B-X
new	B-X
objective	B-X
methodology	B-X
is	B-X
proposed	B-X
to	B-X
select	B-X
the	B-X
parsimonious	B-X
set	B-X
of	B-X
important	B-X
covariates	B-X
that	B-X
are	B-X
associated	B-X
with	B-X
a	B-X
censored	B-X
outcome	B-X
variable	B-X
Y	B-X
;	B-X
the	B-X
method	B-X
simplifies	B-X
to	B-X
accommodate	B-X
uncensored	B-X
outcomes	B-X
.	B-X
A	B-X
sequence	B-X
of	B-X
working	B-X
regression	B-X
models	B-X
for	B-X
the	B-X
event	B-X
(	B-X
Y≤y	B-X
)	B-X
given	B-X
a	B-X
covariate	B-X
set	B-X
is	B-X
fit	B-X
among	B-X
subjects	B-X
not	B-X
censored	B-X
before	B-X
y	B-X
and	B-X
the	B-X
corresponding	B-X
process	B-X
(	B-X
through	B-X
y	B-X
)	B-X
of	B-X
conditional	B-X
prediction	B-X
error	B-X
estimated	B-X
;	B-X
the	B-X
direction	B-X
and	B-X
magnitude	B-X
of	B-X
covariate	B-X
effects	B-X
can	B-X
arbitrarily	B-X
change	B-X
with	B-X
y	B-X
.	B-X
The	B-X
newly	B-X
proposed	B-X
adequacy	B-X
measure	B-X
for	B-X
the	B-X
covariate	B-X
set	B-X
is	B-X
the	B-X
slope	B-X
coefficient	B-X
resulting	B-X
from	B-X
a	B-X
regression	B-X
(	B-X
with	B-X
no	B-X
intercept	B-X
)	B-X
between	B-X
the	B-X
baseline	B-X
prediction	B-X
error	B-X
process	B-X
for	B-X
the	B-X
intercept-only	B-X
model	B-X
and	B-X
that	B-X
process	B-X
corresponding	B-X
to	B-X
the	B-X
covariate	B-X
set	B-X
.	B-X
Under	B-X
quite	B-X
general	B-X
conditions	B-X
on	B-X
the	B-X
censoring	B-X
variable	B-X
,	B-X
the	B-X
methods	B-X
are	B-X
shown	B-X
to	B-X
asymptotically	B-X
control	B-X
the	B-X
false	B-X
selection	B-X
rate	B-X
at	B-X
the	B-X
nominal	B-X
level	B-X
while	B-X
consistently	B-X
ranking	B-X
covariate	B-X
sets	B-X
which	B-X
permits	B-X
recruitment	B-X
of	B-X
all	B-X
important	B-X
covariates	B-X
from	B-X
those	B-X
available	B-X
with	B-X
probability	B-X
tending	B-X
to	B-X
1	B-X
.	B-X

NF	O
-	O
kappaB	O
down	O
-	O
regulation	O
by	O
PMA	O
and	O
up	O
-	O
regulation	O
by	O
heat	O
killed	O
E	O
.	O
coli	O
MG1655	O
following	O
long	O
-	O
term	O
stimulation	O
.	O

Transfection	O
of	O
Jurkat	O
T	O
-	O
cells	O
was	O
performed	O
using	O
luciferase	B-Protein
reporter	O
plasmids	O
containing	O
NF	O
-	O
kappaB	O
cis	O
-	O
elements	O
.	O

(	O
A	O
)	O
Time	O
-	O
dependent	O
stimulation	O
of	O
Jurkat	O
T	O
-	O
cells	O
using	O
PMA	O
.	O

NF	O
-	O
kappaB	O
activation	O
was	O
evaluated	O
using	O
HK	O
E	O
.	O
coli	O
in	O
a	O
(	O
B	O
)	O
dose	O
-	O
and	O
(	O
C	O
)	O
time	O
-	O
dependant	O
manner	O
.	O

Calcium	O
ionophore	O
increased	O
NF	O
-	O
kappaB	O
activity	O
following	O
PMA	O
exposure	O
(	O
E	O
)	O
and	O
resulted	O
in	O
a	O
negative	O
regulation	O
in	O
response	O
to	O
HK	O
E	O
.	O
coli	O
stimulation	O
(	O
D	O
)	O
.	O

Statistical	O
significance	O
from	O
the	O
control	O
was	O
determined	O
using	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

(	O
n	O
=	O
4	O
)	O
.	O
<EOS>	B-X
T-cell	B-X
immunoglobulin	B-X
domain	B-X
and	B-X
mucin	B-X
domain	B-X
4	B-X
(	B-X
TIM-4	B-X
)	B-X
is	B-X
a	B-X
transmembrane	B-X
protein	B-X
that	B-X
promotes	B-X
epithelial-mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
,	B-X
migration	B-X
and	B-X
invasion	B-X
of	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
cells	B-X
.	B-X
Most	B-X
transmembrane	B-X
proteins	B-X
are	B-X
modified	B-X
by	B-X
N-glycosylation	B-X
and	B-X
the	B-X
importance	B-X
of	B-X
protein	B-X
N-glycosylation	B-X
in	B-X
cancer	B-X
cell	B-X
metastasis	B-X
has	B-X
been	B-X
well	B-X
appreciated	B-X
.	B-X
However	B-X
,	B-X
whether	B-X
TIM-4	B-X
is	B-X
modified	B-X
by	B-X
N-glycosylation	B-X
and	B-X
the	B-X
role	B-X
of	B-X
TIM-4	B-X
N-glycosylation	B-X
in	B-X
NSCLC	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
reported	B-X
that	B-X
TIM-4	B-X
was	B-X
extensively	B-X
N-glycosylated	B-X
at	B-X
Asn291	B-X
.	B-X
After	B-X
the	B-X
removal	B-X
of	B-X
N-glycosylation	B-X
,	B-X
the	B-X
stability	B-X
of	B-X
TIM-4	B-X
protein	B-X
was	B-X
decreased	B-X
and	B-X
TIM-4	B-X
was	B-X
more	B-X
susceptible	B-X
to	B-X
degradation	B-X
by	B-X
ER-localized	B-X
ubiquitin	B-X
ligase-mediated	B-X
ERAD	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
TIM-4	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
was	B-X
decreased	B-X
,	B-X
which	B-X
suppressed	B-X
TIM-4-mediated	B-X
metastasis	B-X
in	B-X
NSCLC	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
the	B-X
present	B-X
study	B-X
identifies	B-X
TIM-4	B-X
N-glycosylation	B-X
and	B-X
its	B-X
role	B-X
in	B-X
NSCLS	B-X
migration	B-X
,	B-X
which	B-X
would	B-X
provide	B-X
a	B-X
valuable	B-X
biomarker	B-X
for	B-X
developing	B-X
drugs	B-X
targeting	B-X
N-glycosylation	B-X
at	B-X
Asn291	B-X
on	B-X
TIM-4	B-X
.	B-X

Controls	O
were	O
arbitrarily	O
set	O
to	O
1	O
.	O
<EOS>	B-X
Other	B-X
investigators	B-X
set	B-X
the	B-X
cutoff	B-X
arbitrarily	B-X
at	B-X
a	B-X
certain	B-X
absorbance	B-X
value	B-X
.	B-X
The	B-X
mathematical	B-X
formula	B-X
which	B-X
defines	B-X
the	B-X
upper	B-X
prediction	B-X
limit	B-X
is	B-X
expressed	B-X
as	B-X
the	B-X
standard	B-X
deviation	B-X
multiplied	B-X
by	B-X
a	B-X
factor	B-X
which	B-X
is	B-X
based	B-X
on	B-X
the	B-X
number	B-X
of	B-X
negative	B-X
controls	B-X
and	B-X
the	B-X
confidence	B-X
level	B-X
(	B-X
1	B-X
-	B-X
alpha	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
we	B-X
can	B-X
arbitrarily	B-X
set	B-X
the	B-X
remanent	B-X
ferroelectric	B-X
polarization	B-X
at	B-X
nanometric	B-X
dimensions	B-X
.	B-X
A	B-X
new	B-X
objective	B-X
methodology	B-X
is	B-X
proposed	B-X
to	B-X
select	B-X
the	B-X
parsimonious	B-X
set	B-X
of	B-X
important	B-X
covariates	B-X
that	B-X
are	B-X
associated	B-X
with	B-X
a	B-X
censored	B-X
outcome	B-X
variable	B-X
Y	B-X
;	B-X
the	B-X
method	B-X
simplifies	B-X
to	B-X
accommodate	B-X
uncensored	B-X
outcomes	B-X
.	B-X
A	B-X
sequence	B-X
of	B-X
working	B-X
regression	B-X
models	B-X
for	B-X
the	B-X
event	B-X
(	B-X
Y≤y	B-X
)	B-X
given	B-X
a	B-X
covariate	B-X
set	B-X
is	B-X
fit	B-X
among	B-X
subjects	B-X
not	B-X
censored	B-X
before	B-X
y	B-X
and	B-X
the	B-X
corresponding	B-X
process	B-X
(	B-X
through	B-X
y	B-X
)	B-X
of	B-X
conditional	B-X
prediction	B-X
error	B-X
estimated	B-X
;	B-X
the	B-X
direction	B-X
and	B-X
magnitude	B-X
of	B-X
covariate	B-X
effects	B-X
can	B-X
arbitrarily	B-X
change	B-X
with	B-X
y	B-X
.	B-X
The	B-X
newly	B-X
proposed	B-X
adequacy	B-X
measure	B-X
for	B-X
the	B-X
covariate	B-X
set	B-X
is	B-X
the	B-X
slope	B-X
coefficient	B-X
resulting	B-X
from	B-X
a	B-X
regression	B-X
(	B-X
with	B-X
no	B-X
intercept	B-X
)	B-X
between	B-X
the	B-X
baseline	B-X
prediction	B-X
error	B-X
process	B-X
for	B-X
the	B-X
intercept-only	B-X
model	B-X
and	B-X
that	B-X
process	B-X
corresponding	B-X
to	B-X
the	B-X
covariate	B-X
set	B-X
.	B-X
Under	B-X
quite	B-X
general	B-X
conditions	B-X
on	B-X
the	B-X
censoring	B-X
variable	B-X
,	B-X
the	B-X
methods	B-X
are	B-X
shown	B-X
to	B-X
asymptotically	B-X
control	B-X
the	B-X
false	B-X
selection	B-X
rate	B-X
at	B-X
the	B-X
nominal	B-X
level	B-X
while	B-X
consistently	B-X
ranking	B-X
covariate	B-X
sets	B-X
which	B-X
permits	B-X
recruitment	B-X
of	B-X
all	B-X
important	B-X
covariates	B-X
from	B-X
those	B-X
available	B-X
with	B-X
probability	B-X
tending	B-X
to	B-X
1	B-X
.	B-X

CXCL8	B-Protein
,	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
TNF	O
expression	O
following	O
long	O
-	O
term	O
stimulation	O
with	O
PMA	O
.	O

Jurkat	O
T	O
-	O
cells	O
were	O
either	O
treated	O
with	O
media	O
(	O
white	O
bars	O
)	O
or	O
stimulated	O
with	O
PMA	O
(	O
black	O
bars	O
)	O
and	O
incubated	O
for	O
1	O
h	O
,	O
2	O
h	O
,	O
6	O
h	O
and	O
24	O
h	O
.	O

Aged	O
media	O
was	O
added	O
following	O
each	O
centrifugation	O
step	O
representative	O
to	O
the	O
stimulation	O
time	O
(	O
see	O
Materials	O
and	O
methods	O
)	O
.	O

Cytokine	O
levels	O
(	O
A	O
)	O
CXCL8	B-Protein
,	O
(	O
B	O
)	O
IL	B-Protein
-	I-Protein
6	I-Protein
and	O
(	O
C	O
)	O
TNF	O
were	O
detected	O
by	O
ELISA	O
.	O

Statistical	O
significance	O
from	O
the	O
control	O
was	O
determined	O
using	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

(	O
n	O
=	O
3	O
)	O
.	O
<EOS>	B-X
The	B-X
title	B-X
compound	B-X
,	B-X
{	B-X
[	B-X
NiCl	B-X
(	B-X
2	B-X
)	B-X
(	B-X
C	B-X
(	B-X
5	B-X
)	B-X
H	B-X
(	B-X
6	B-X
)	B-X
N	B-X
(	B-X
2	B-X
)	B-X
)	B-X
(	B-X
C	B-X
(	B-X
3	B-X
)	B-X
H	B-X
(	B-X
7	B-X
)	B-X
NO	B-X
)	B-X
]	B-X
·C	B-X
(	B-X
3	B-X
)	B-X
H	B-X
(	B-X
7	B-X
)	B-X
NO	B-X
}	B-X
(	B-X
n	B-X
)	B-X
,	B-X
is	B-X
a	B-X
two-dimensional	B-X
polymer	B-X
in	B-X
which	B-X
the	B-X
Ni	B-X
(	B-X
II	B-X
)	B-X
atom	B-X
is	B-X
coordinated	B-X
by	B-X
two	B-X
N	B-X
atoms	B-X
from	B-X
two	B-X
3-amino-pyridine	B-X
ligands	B-X
,	B-X
one	B-X
O	B-X
atom	B-X
from	B-X
a	B-X
dimethyl-formamide	B-X
(	B-X
DMF	B-X
)	B-X
group	B-X
,	B-X
one	B-X
terminal	B-X
Cl	B-X
and	B-X
two	B-X
bridging	B-X
Cl	B-X
atoms	B-X
in	B-X
a	B-X
distorted	B-X
octa-hedral	B-X
geometry	B-X
.	B-X
The	B-X
Ni	B-X
(	B-X
II	B-X
)	B-X
atoms	B-X
are	B-X
bridged	B-X
by	B-X
the	B-X
3-amino-pyridine	B-X
ligands	B-X
[	B-X
Ni⋯N	B-X
=	B-X
6.7048	B-X
(	B-X
3	B-X
)	B-X
Å	B-X
]	B-X
and	B-X
Cl	B-X
(	B-X
-	B-X
)	B-X
atoms	B-X
[	B-X
Ni⋯N	B-X
=	B-X
3.5698	B-X
(	B-X
3	B-X
)	B-X
Å	B-X
]	B-X
,	B-X
forming	B-X
(	B-X
4,4	B-X
)	B-X
two-dimensional	B-X
nets	B-X
.	B-X
The	B-X
DMF	B-X
solvent	B-X
mol-ecule	B-X
and	B-X
the	B-X
non-bridged	B-X
Cl	B-X
(	B-X
-	B-X
)	B-X
ions	B-X
participate	B-X
in	B-X
N-H⋯O	B-X
and	B-X
N-H⋯Cl	B-X
hydrogen	B-X
bonds	B-X
with	B-X
the	B-X
amino	B-X
groups	B-X
.	B-X
Electrides	B-X
,	B-X
a	B-X
unique	B-X
type	B-X
of	B-X
compound	B-X
where	B-X
electrons	B-X
act	B-X
as	B-X
anions	B-X
,	B-X
have	B-X
a	B-X
high	B-X
electron	B-X
mobility	B-X
and	B-X
a	B-X
low	B-X
work	B-X
function	B-X
,	B-X
which	B-X
makes	B-X
them	B-X
promising	B-X
for	B-X
applications	B-X
in	B-X
electronic	B-X
devices	B-X
and	B-X
high-performance	B-X
catalysts	B-X
.	B-X
The	B-X
discovery	B-X
of	B-X
novel	B-X
electrides	B-X
and	B-X
the	B-X
expansion	B-X
of	B-X
the	B-X
electride	B-X
family	B-X
have	B-X
great	B-X
significance	B-X
for	B-X
their	B-X
promising	B-X
applications	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
reported	B-X
four	B-X
three-dimensional	B-X
(	B-X
3D	B-X
)	B-X
electrides	B-X
by	B-X
coupling	B-X
crystal	B-X
structure	B-X
database	B-X
searches	B-X
and	B-X
first-principles	B-X
electronic	B-X
structure	B-X
analysis	B-X
.	B-X
Subnitrides	B-X
(	B-X
Ba	B-X

Inhibition	O
of	O
NF	O
-	O
kappaB	O
activity	O
by	O
NAI	O
.	O
<EOS>	B-X
EGCG-pretreated	B-X
DC	B-X
inhibited	B-X
LPS-induced	B-X
MAPKs	B-X
,	B-X
such	B-X
as	B-X
ERK1/2	B-X
,	B-X
p38	B-X
,	B-X
JNK	B-X
,	B-X
and	B-X
NF-kappaB	B-X
p65	B-X
translocation	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
molecular	B-X
mechanisms	B-X
by	B-X
which	B-X
EGCG	B-X
antagonized	B-X
LPS-induced	B-X
DC	B-X
maturation	B-X
appeared	B-X
to	B-X
involve	B-X
the	B-X
inhibition	B-X
of	B-X
MAPK	B-X
and	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
NF-κB	B-X
is	B-X
activated	B-X
at	B-X
an	B-X
early	B-X
stage	B-X
of	B-X
development	B-X
and	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
interact	B-X
with	B-X
steroidogenic	B-X
factor-1	B-X
in	B-X
mammals	B-X
,	B-X
leading	B-X
to	B-X
the	B-X
suppression	B-X
of	B-X
anti-Müllerian	B-X
hormone	B-X
(	B-X
Amh	B-X
)	B-X
gene	B-X
expression	B-X
.	B-X
Because	B-X
steroidogenic	B-X
factor-1	B-X
and	B-X
Amh	B-X
are	B-X
important	B-X
for	B-X
proper	B-X
testis	B-X
development	B-X
,	B-X
NF-κB-mediated	B-X
induction	B-X
of	B-X
anti-apoptotic	B-X
genes	B-X
could	B-X
,	B-X
therefore	B-X
,	B-X
also	B-X
play	B-X
a	B-X
role	B-X
in	B-X
zebrafish	B-X
gonad	B-X
differentiation	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
the	B-X
potential	B-X
role	B-X
of	B-X
NF-κB	B-X
in	B-X
zebrafish	B-X
gonad	B-X
differentiation	B-X
.	B-X
Exposure	B-X
of	B-X
juvenile	B-X
zebrafish	B-X
to	B-X
heat-killed	B-X
Escherichia	B-X
coli	B-X
activated	B-X
the	B-X
NF-κB	B-X
pathways	B-X
and	B-X
resulted	B-X
in	B-X
an	B-X
increased	B-X
ratio	B-X
of	B-X
females	B-X
from	B-X
30	B-X
to	B-X
85	B-X
%	B-X
.	B-X
Microarray	B-X
and	B-X
quantitative	B-X
real-time-PCR	B-X
analysis	B-X
of	B-X
gonads	B-X
showed	B-X
elevated	B-X
expression	B-X
of	B-X
NF-κB-regulated	B-X
genes	B-X
.	B-X
To	B-X
confirm	B-X
the	B-X
involvement	B-X
of	B-X
NF-κB-induced	B-X
anti-apoptotic	B-X
effects	B-X
,	B-X
zebrafish	B-X
were	B-X
treated	B-X
with	B-X
sodium	B-X
deoxycholate	B-X
,	B-X
a	B-X
known	B-X
inducer	B-X
of	B-X
NF-κB	B-X
or	B-X
NF-κB	B-X
activation	B-X
inhibitor	B-X
(	B-X
NAI	B-X
)	B-X
.	B-X
Sodium	B-X
deoxycholate	B-X
treatment	B-X
mimicked	B-X
the	B-X
effect	B-X
of	B-X
heat-killed	B-X
bacteria	B-X
and	B-X
resulted	B-X
in	B-X
an	B-X
increased	B-X
proportion	B-X
of	B-X
females	B-X
from	B-X
25	B-X
to	B-X
45	B-X
%	B-X
,	B-X
whereas	B-X
the	B-X
inhibition	B-X
of	B-X
NF-κB	B-X
using	B-X
NAI	B-X
resulted	B-X
in	B-X
a	B-X
decrease	B-X
in	B-X
females	B-X
from	B-X
45	B-X
to	B-X
20	B-X
%	B-X
.	B-X
This	B-X
study	B-X
provides	B-X
proof	B-X
for	B-X
an	B-X
essential	B-X
role	B-X
of	B-X
NF-κB	B-X
in	B-X
gonadal	B-X
differentiation	B-X
of	B-X
zebrafish	B-X
and	B-X
represents	B-X
an	B-X
important	B-X
step	B-X
toward	B-X
the	B-X
complete	B-X
understanding	B-X
of	B-X
the	B-X
complicated	B-X
process	B-X
of	B-X
sex	B-X
differentiation	B-X
in	B-X
this	B-X
species	B-X
and	B-X
possibly	B-X
other	B-X
cyprinid	B-X
teleosts	B-X
as	B-X
well	B-X
.	B-X

Jurkat	O
T	O
-	O
cells	O
were	O
transfected	O
with	O
luciferase	B-Protein
reporter	O
plasmids	O
containing	O
either	O
NF	O
-	O
kappaB	O
or	O
AP	O
-	O
1	O
cis	O
-	O
acting	O
elements	O
.	O
<EOS>	B-X
DRE/CRT	B-X
is	B-X
a	B-X
cis-acting	B-X
element	B-X
that	B-X
is	B-X
involved	B-X
in	B-X
gene	B-X
expression	B-X
responsive	B-X
to	B-X
drought	B-X
and	B-X
low-temperature	B-X
stress	B-X
in	B-X
higher	B-X
plants	B-X
.	B-X
DREB1A/CBF3	B-X
and	B-X
DREB2A	B-X
are	B-X
transcription	B-X
factors	B-X
that	B-X
specifically	B-X
bind	B-X
to	B-X
DRE/CRT	B-X
in	B-X
Arabidopsis	B-X
.	B-X
We	B-X
precisely	B-X
analyzed	B-X
the	B-X
DNA-binding	B-X
specificity	B-X
of	B-X
DREBs	B-X
.	B-X
Gel	B-X
mobility	B-X
shift	B-X
assay	B-X
using	B-X
mutant	B-X
DREB	B-X
proteins	B-X
showed	B-X
that	B-X
the	B-X
two	B-X
amino	B-X
acids	B-X
,	B-X
valine	B-X
and	B-X
glutamic	B-X
acid	B-X
conserved	B-X
in	B-X
the	B-X
ERF/AP2	B-X
domains	B-X
,	B-X
especially	B-X
valine	B-X
,	B-X
have	B-X
important	B-X
roles	B-X
in	B-X
DNA-binding	B-X
specificity	B-X
.	B-X
In	B-X
the	B-X
Arabidopsis	B-X
genome	B-X
,	B-X
145	B-X
DREB/ERF-related	B-X
proteins	B-X
are	B-X
encoded	B-X
.	B-X
These	B-X
proteins	B-X
were	B-X
classified	B-X
into	B-X
five	B-X
groups-AP-2	B-X
subfamily	B-X
,	B-X
RAV	B-X
subfamily	B-X
,	B-X
DREB	B-X
subfamily	B-X
,	B-X
ERF	B-X
subfamily	B-X
,	B-X
and	B-X
others	B-X
.	B-X
The	B-X
DREB	B-X
subfamily	B-X
included	B-X
three	B-X
novel	B-X
DREB1A-	B-X
and	B-X
six	B-X
DREB2A-related	B-X
proteins	B-X
.	B-X

The	O
cells	O
were	O
incubated	O
with	O
NF	O
-	O
kappaB	O
activation	O
inhibitor	O
(	O
NAI	O
)	O
for	O
1	O
h	O
followed	O
by	O
stimulation	O
with	O
PMA	O
(	O
162	O
nM	O
,	O
A	O
and	O
C	O
)	O
or	O
HK	O
E	O
.	O
coli	O
(	O
5	O
x	O
107	O
CFU	O
/	O
ml	O
,	O
B	O
and	O
D	O
)	O
for	O
24	O
h	O
.	O

(	O
A	O
,	O
B	O
)	O
NF	O
-	O
kappaB	O
,	O
but	O
not	O
(	O
C	O
,	O
D	O
)	O
AP	O
-	O
1	O
was	O
inhibited	O
.	O

Statistical	O
significance	O
from	O
the	O
positive	O
control	O
(	O
PMA	O
/	O
HK	O
E	O
.	O
coli	O
)	O
was	O
determined	O
using	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

(	O
n	O
=	O
4	O
)	O
.	O
<EOS>	B-X
T-cell	B-X
immunoglobulin	B-X
domain	B-X
and	B-X
mucin	B-X
domain	B-X
4	B-X
(	B-X
TIM-4	B-X
)	B-X
is	B-X
a	B-X
transmembrane	B-X
protein	B-X
that	B-X
promotes	B-X
epithelial-mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
,	B-X
migration	B-X
and	B-X
invasion	B-X
of	B-X
non-small	B-X
cell	B-X
lung	B-X
cancer	B-X
(	B-X
NSCLC	B-X
)	B-X
cells	B-X
.	B-X
Most	B-X
transmembrane	B-X
proteins	B-X
are	B-X
modified	B-X
by	B-X
N-glycosylation	B-X
and	B-X
the	B-X
importance	B-X
of	B-X
protein	B-X
N-glycosylation	B-X
in	B-X
cancer	B-X
cell	B-X
metastasis	B-X
has	B-X
been	B-X
well	B-X
appreciated	B-X
.	B-X
However	B-X
,	B-X
whether	B-X
TIM-4	B-X
is	B-X
modified	B-X
by	B-X
N-glycosylation	B-X
and	B-X
the	B-X
role	B-X
of	B-X
TIM-4	B-X
N-glycosylation	B-X
in	B-X
NSCLC	B-X
remains	B-X
largely	B-X
unknown	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
reported	B-X
that	B-X
TIM-4	B-X
was	B-X
extensively	B-X
N-glycosylated	B-X
at	B-X
Asn291	B-X
.	B-X
After	B-X
the	B-X
removal	B-X
of	B-X
N-glycosylation	B-X
,	B-X
the	B-X
stability	B-X
of	B-X
TIM-4	B-X
protein	B-X
was	B-X
decreased	B-X
and	B-X
TIM-4	B-X
was	B-X
more	B-X
susceptible	B-X
to	B-X
degradation	B-X
by	B-X
ER-localized	B-X
ubiquitin	B-X
ligase-mediated	B-X
ERAD	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
TIM-4	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
was	B-X
decreased	B-X
,	B-X
which	B-X
suppressed	B-X
TIM-4-mediated	B-X
metastasis	B-X
in	B-X
NSCLC	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
the	B-X
present	B-X
study	B-X
identifies	B-X
TIM-4	B-X
N-glycosylation	B-X
and	B-X
its	B-X
role	B-X
in	B-X
NSCLS	B-X
migration	B-X
,	B-X
which	B-X
would	B-X
provide	B-X
a	B-X
valuable	B-X
biomarker	B-X
for	B-X
developing	B-X
drugs	B-X
targeting	B-X
N-glycosylation	B-X
at	B-X
Asn291	B-X
on	B-X
TIM-4	B-X
.	B-X

Controls	O
were	O
set	O
to	O
1	O
.	O
<EOS>	B-X
Computer	B-X
vision	B-X
syndrome	B-X
is	B-X
a	B-X
term	B-X
for	B-X
a	B-X
set	B-X
of	B-X
symptoms	B-X
that	B-X
often	B-X
manifest	B-X
themselves	B-X
during	B-X
a	B-X
long-term	B-X
work	B-X
on	B-X
a	B-X
digital	B-X
device	B-X
.	B-X
Then	B-X
we	B-X
created	B-X
a	B-X
research	B-X
and	B-X
a	B-X
control	B-X
group	B-X
and	B-X
finally	B-X
we	B-X
set	B-X
a	B-X
questionnaire	B-X
evaluating	B-X
computer	B-X
vision	B-X
syndrome	B-X
.	B-X
The	B-X
research	B-X
included	B-X
56	B-X
participants	B-X
,	B-X
wherein	B-X
30	B-X
%	B-X
(	B-X
17	B-X
)	B-X
were	B-X
men	B-X
and	B-X
70	B-X
%	B-X
(	B-X
39	B-X
)	B-X
were	B-X
women	B-X
.	B-X
Participants	B-X
who	B-X
were	B-X
heterophoric	B-X
had	B-X
a	B-X
better	B-X
average	B-X
score	B-X
of	B-X
the	B-X
questionnaire	B-X
,	B-X
7.1	B-X
±	B-X
5.5	B-X
points	B-X
.	B-X

Involvement	O
of	O
NF	O
-	O
kappaB	O
in	O
cytokine	O
regulation	O
.	O
<EOS>	B-X
The	B-X
nuclear	B-X
factor-κB	B-X
(	B-X
NF-κB	B-X
)	B-X
is	B-X
a	B-X
transcription	B-X
factor	B-X
that	B-X
regulates	B-X
the	B-X
expression	B-X
of	B-X
genes	B-X
that	B-X
control	B-X
cell	B-X
proliferation	B-X
and	B-X
apoptosis	B-X
,	B-X
as	B-X
well	B-X
as	B-X
genes	B-X
that	B-X
respond	B-X
to	B-X
inflammation	B-X
and	B-X
immune	B-X
responses	B-X
.	B-X
There	B-X
are	B-X
two	B-X
means	B-X
of	B-X
NF-κB	B-X
activation	B-X
:	B-X
the	B-X
classical	B-X
pathway	B-X
,	B-X
which	B-X
involves	B-X
the	B-X
degradation	B-X
of	B-X
the	B-X
inhibitor	B-X
of	B-X
κBα	B-X
(	B-X
IκBα	B-X
)	B-X
,	B-X
and	B-X
the	B-X
alternative	B-X
pathway	B-X
,	B-X
which	B-X
involves	B-X
the	B-X
NF-κB-inducing	B-X
kinase	B-X
(	B-X
NIK	B-X
,	B-X
also	B-X
known	B-X
as	B-X
MAP3K14	B-X
)	B-X
.	B-X
Inhibiting	B-X
the	B-X
classical	B-X
NF-κB	B-X
signaling	B-X
pathway	B-X
blocks	B-X
growth	B-X
hormone	B-X
(	B-X
GH	B-X
)	B-X
or	B-X
insulin-like	B-X
growth	B-X
factor	B-X
(	B-X
IGF-1	B-X
)	B-X
signaling	B-X
,	B-X
suppresses	B-X
cell	B-X
proliferation	B-X
,	B-X
and	B-X
suppresses	B-X
bone	B-X
morphogenetic	B-X
protein	B-X
2	B-X
(	B-X
BMP2	B-X
)	B-X
expression	B-X
,	B-X
thereby	B-X
promoting	B-X
apoptosis	B-X
.	B-X
Since	B-X
the	B-X
production	B-X
of	B-X
autoantibodies	B-X
and	B-X
inflammatory	B-X
cytokines	B-X
,	B-X
such	B-X
as	B-X
tumor	B-X
necrosis	B-X
factor-α	B-X
(	B-X
TNFα	B-X
)	B-X
,	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-1β	B-X
,	B-X
IL-6	B-X
,	B-X
and	B-X
IL-17	B-X
,	B-X
are	B-X
regulated	B-X
by	B-X
the	B-X
classical	B-X
pathways	B-X
and	B-X
are	B-X
increased	B-X
in	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
,	B-X
NF-κB	B-X
inhibitors	B-X
are	B-X
used	B-X
to	B-X
suppress	B-X
inflammation	B-X
and	B-X
joint	B-X
destruction	B-X
in	B-X
RA	B-X
models	B-X
.	B-X
In	B-X
osteoarthritis	B-X
(	B-X
OA	B-X
)	B-X
models	B-X
,	B-X
the	B-X
strength	B-X
of	B-X
NF-κB-activation	B-X
is	B-X
found	B-X
to	B-X
regulate	B-X
the	B-X
facilitation	B-X
or	B-X
suppression	B-X
of	B-X
OA	B-X
.	B-X
Thus	B-X
,	B-X
NF-κB	B-X
is	B-X
an	B-X
important	B-X
molecule	B-X
that	B-X
controls	B-X
normal	B-X
development	B-X
and	B-X
the	B-X
pathological	B-X
destruction	B-X
of	B-X
cartilage	B-X
.	B-X

Cytokine	O
/	O
chemokine	O
levels	O
were	O
determined	O
using	O
ELISA	O
following	O
incubation	O
of	O
Jurkat	O
T	O
-	O
cells	O
with	O
NAI	O
(	O
1	O
h	O
)	O
and	O
stimulation	O
(	O
24	O
h	O
)	O
.	O

(	O
A	O
)	O
CXCL8	B-Protein
expression	O
was	O
partially	O
inhibited	O
following	O
PMA	O
stimulation	O
(	O
grey	O
bars	O
)	O
,	O
whereas	O
the	O
levels	O
were	O
not	O
altered	O
following	O
stimulation	O
with	O
HK	O
E	O
.	O
coli	O
(	O
black	O
bars	O
)	O
,	O
this	O
indicates	O
an	O
induction	O
mainly	O
regulated	O
by	O
AP	O
-	O
1	O
.	O

(	O
B	O
)	O
TNF	O
expression	O
was	O
not	O
affected	O
by	O
NAI	O
.	O
<EOS>	B-X
This	B-X
study	B-X
examines	B-X
CXCL13	B-X
production	B-X
by	B-X
lung	B-X
tissue	B-X
macrophages	B-X
from	B-X
patients	B-X
with	B-X
IPF	B-X
and	B-X
the	B-X
signaling	B-X
pathways	B-X
controlling	B-X
CXCL13	B-X
gene	B-X
expression	B-X
in	B-X
human	B-X
alveolar	B-X
macrophages	B-X
(	B-X
AM	B-X
)	B-X
and	B-X
monocyte-derived	B-X
macrophages	B-X
(	B-X
MoDM	B-X
)	B-X
.	B-X
We	B-X
found	B-X
that	B-X
TNF-α	B-X
and	B-X
IL-10	B-X
control	B-X
optimal	B-X
CXCL13	B-X
gene	B-X
expression	B-X
in	B-X
MoDM	B-X
and	B-X
possibly	B-X
in	B-X
AM	B-X
by	B-X
activating	B-X
the	B-X
NF-κB	B-X
and	B-X
JAK/STAT	B-X
pathways	B-X
,	B-X
respectively	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
blood	B-X
TNF-α	B-X
and	B-X
CXCL13	B-X
concentrations	B-X
are	B-X
significantly	B-X
correlated	B-X
in	B-X
patients	B-X
with	B-X
IPF	B-X
,	B-X
suggesting	B-X
that	B-X
TNF-α	B-X
contributes	B-X
to	B-X
CXCL13	B-X
production	B-X
in	B-X
humans	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
the	B-X
results	B-X
of	B-X
this	B-X
study	B-X
demonstrate	B-X
that	B-X
AM	B-X
from	B-X
patients	B-X
with	B-X
IPF	B-X
produces	B-X
CXCL13	B-X
and	B-X
that	B-X
the	B-X
NF-κB	B-X
and	B-X
JAK/STAT	B-X
pathways	B-X
are	B-X
required	B-X
to	B-X
induce	B-X
the	B-X
expression	B-X
of	B-X
this	B-X
major	B-X
chemokine	B-X
.	B-X

(	O
C	O
)	O
IL	B-Protein
-	I-Protein
6	I-Protein
release	O
was	O
completely	O
inhibited	O
by	O
NAI	O
following	O
PMA	O
exposure	O
,	O
indicating	O
regulation	O
through	O
NF	O
-	O
kappaB	O
since	O
IL	B-Protein
-	I-Protein
6	I-Protein
expression	O
was	O
significantly	O
increased	O
in	O
response	O
to	O
HK	O
E	O
.	O
coli	O
than	O
PMA	O
.	O

Statistical	O
significance	O
from	O
the	O
positive	O
control	O
(	O
PMA	O
/	O
HK	O
E	O
.	O
coli	O
)	O
was	O
determined	O
using	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

(	O
n	O
=	O
3	O
)	O
.	O
<EOS>	B-X
The	B-X
title	B-X
compound	B-X
,	B-X
{	B-X
[	B-X
NiCl	B-X
(	B-X
2	B-X
)	B-X
(	B-X
C	B-X
(	B-X
5	B-X
)	B-X
H	B-X
(	B-X
6	B-X
)	B-X
N	B-X
(	B-X
2	B-X
)	B-X
)	B-X
(	B-X
C	B-X
(	B-X
3	B-X
)	B-X
H	B-X
(	B-X
7	B-X
)	B-X
NO	B-X
)	B-X
]	B-X
·C	B-X
(	B-X
3	B-X
)	B-X
H	B-X
(	B-X
7	B-X
)	B-X
NO	B-X
}	B-X
(	B-X
n	B-X
)	B-X
,	B-X
is	B-X
a	B-X
two-dimensional	B-X
polymer	B-X
in	B-X
which	B-X
the	B-X
Ni	B-X
(	B-X
II	B-X
)	B-X
atom	B-X
is	B-X
coordinated	B-X
by	B-X
two	B-X
N	B-X
atoms	B-X
from	B-X
two	B-X
3-amino-pyridine	B-X
ligands	B-X
,	B-X
one	B-X
O	B-X
atom	B-X
from	B-X
a	B-X
dimethyl-formamide	B-X
(	B-X
DMF	B-X
)	B-X
group	B-X
,	B-X
one	B-X
terminal	B-X
Cl	B-X
and	B-X
two	B-X
bridging	B-X
Cl	B-X
atoms	B-X
in	B-X
a	B-X
distorted	B-X
octa-hedral	B-X
geometry	B-X
.	B-X
The	B-X
Ni	B-X
(	B-X
II	B-X
)	B-X
atoms	B-X
are	B-X
bridged	B-X
by	B-X
the	B-X
3-amino-pyridine	B-X
ligands	B-X
[	B-X
Ni⋯N	B-X
=	B-X
6.7048	B-X
(	B-X
3	B-X
)	B-X
Å	B-X
]	B-X
and	B-X
Cl	B-X
(	B-X
-	B-X
)	B-X
atoms	B-X
[	B-X
Ni⋯N	B-X
=	B-X
3.5698	B-X
(	B-X
3	B-X
)	B-X
Å	B-X
]	B-X
,	B-X
forming	B-X
(	B-X
4,4	B-X
)	B-X
two-dimensional	B-X
nets	B-X
.	B-X
The	B-X
DMF	B-X
solvent	B-X
mol-ecule	B-X
and	B-X
the	B-X
non-bridged	B-X
Cl	B-X
(	B-X
-	B-X
)	B-X
ions	B-X
participate	B-X
in	B-X
N-H⋯O	B-X
and	B-X
N-H⋯Cl	B-X
hydrogen	B-X
bonds	B-X
with	B-X
the	B-X
amino	B-X
groups	B-X
.	B-X
Electrides	B-X
,	B-X
a	B-X
unique	B-X
type	B-X
of	B-X
compound	B-X
where	B-X
electrons	B-X
act	B-X
as	B-X
anions	B-X
,	B-X
have	B-X
a	B-X
high	B-X
electron	B-X
mobility	B-X
and	B-X
a	B-X
low	B-X
work	B-X
function	B-X
,	B-X
which	B-X
makes	B-X
them	B-X
promising	B-X
for	B-X
applications	B-X
in	B-X
electronic	B-X
devices	B-X
and	B-X
high-performance	B-X
catalysts	B-X
.	B-X
The	B-X
discovery	B-X
of	B-X
novel	B-X
electrides	B-X
and	B-X
the	B-X
expansion	B-X
of	B-X
the	B-X
electride	B-X
family	B-X
have	B-X
great	B-X
significance	B-X
for	B-X
their	B-X
promising	B-X
applications	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
reported	B-X
four	B-X
three-dimensional	B-X
(	B-X
3D	B-X
)	B-X
electrides	B-X
by	B-X
coupling	B-X
crystal	B-X
structure	B-X
database	B-X
searches	B-X
and	B-X
first-principles	B-X
electronic	B-X
structure	B-X
analysis	B-X
.	B-X
Subnitrides	B-X
(	B-X
Ba	B-X

Involvement	O
of	O
PKC	O
and	O
JNK	O
in	O
cytokine	O
expression	O
.	O
<EOS>	B-X
Those	B-X
include	B-X
G-protein-coupled	B-X
chemokine	B-X
and	B-X
chemoattractant	B-X
receptors	B-X
,	B-X
Fc-receptors	B-X
,	B-X
adhesion	B-X
receptors	B-X
such	B-X
as	B-X
selectins/selectin	B-X
ligands	B-X
and	B-X
integrins	B-X
,	B-X
various	B-X
cytokine	B-X
receptors	B-X
,	B-X
as	B-X
well	B-X
as	B-X
innate	B-X
immune	B-X
receptors	B-X
such	B-X
as	B-X
Toll-like	B-X
receptors	B-X
and	B-X
C-type	B-X
lectins	B-X
.	B-X
Those	B-X
include	B-X
G-protein-coupled	B-X
chemokine	B-X
and	B-X
chemoattractant	B-X
receptors	B-X
,	B-X
Fc-receptors	B-X
,	B-X
adhesion	B-X
receptors	B-X
such	B-X
as	B-X
selectins/selectin	B-X
ligands	B-X
and	B-X
integrins	B-X
,	B-X
various	B-X
cytokine	B-X
receptors	B-X
,	B-X
as	B-X
well	B-X
as	B-X
innate	B-X
immune	B-X
receptors	B-X
such	B-X
as	B-X
Toll-like	B-X
receptors	B-X
and	B-X
C-type	B-X
lectins	B-X
.	B-X
We	B-X
investigated	B-X
a	B-X
role	B-X
of	B-X
the	B-X
TP	B-X
receptor	B-X
in	B-X
the	B-X
endothelial	B-X
expression	B-X
of	B-X
tissue	B-X
factor	B-X
(	B-X
TF	B-X
)	B-X
,	B-X
a	B-X
key	B-X
trigger	B-X
to	B-X
thrombosis	B-X
.	B-X
Treatment	B-X
of	B-X
HeLa	B-X
cells	B-X
with	B-X
apicidin	B-X
leads	B-X
to	B-X
an	B-X
increase	B-X
in	B-X
transcriptional	B-X
activity	B-X
of	B-X
NF-kappaB	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
its	B-X
target	B-X
genes	B-X
,	B-X
IL-8	B-X
and	B-X
TNF-alpha	B-X
.	B-X
TNF-alpha	B-X
expression	B-X
by	B-X
apicidin	B-X
is	B-X
induced	B-X
at	B-X
earlier	B-X
time	B-X
points	B-X
than	B-X
NF-kappaB	B-X
activation	B-X
or	B-X
IL-8	B-X
expression	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
our	B-X
data	B-X
show	B-X
that	B-X
the	B-X
early	B-X
expression	B-X
of	B-X
TNF-alpha	B-X
does	B-X
not	B-X
lead	B-X
to	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
,	B-X
because	B-X
disruption	B-X
of	B-X
TNF-alpha	B-X
activity	B-X
by	B-X
a	B-X
neutralizing	B-X
antibody	B-X
does	B-X
not	B-X
affect	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF-kappaB	B-X
,	B-X
IkappaBalpha	B-X
degradation	B-X
or	B-X
reporter	B-X
gene	B-X
activation	B-X
by	B-X
apicidin	B-X
.	B-X
However	B-X
,	B-X
this	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
requires	B-X
the	B-X
PI3K	B-X
and	B-X
PKC	B-X
signaling	B-X
pathways	B-X
,	B-X
but	B-X
not	B-X
ERK	B-X
or	B-X
JNK	B-X
.	B-X
Furthermore	B-X
,	B-X
apicidin	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
seems	B-X
to	B-X
result	B-X
from	B-X
HDAC1	B-X
inhibition	B-X
,	B-X
as	B-X
evidenced	B-X
by	B-X
the	B-X
observation	B-X
that	B-X
overexpression	B-X
of	B-X
HDAC1	B-X
,	B-X
but	B-X
not	B-X
HDAC2	B-X
,	B-X
3	B-X
or	B-X
4	B-X
,	B-X
dramatically	B-X
inhibits	B-X
NF-kappaB	B-X
reporter	B-X
gene	B-X
activity	B-X
.	B-X
Collectively	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
signaling	B-X
by	B-X
apicidin	B-X
requires	B-X
both	B-X
the	B-X
PI3K/PKC	B-X
signaling	B-X
pathways	B-X
and	B-X
HDAC1	B-X
,	B-X
and	B-X
functions	B-X
as	B-X
a	B-X
critical	B-X
modulator	B-X
in	B-X
determining	B-X
the	B-X
cellular	B-X
effect	B-X
of	B-X
apicidin	B-X
.	B-X

Jurkat	O
T	O
-	O
cells	O
were	O
incubated	O
with	O
PKC	O
-	O
and	O
JNK	O
inhibitors	O
for	O
1	O
h	O
followed	O
by	O
stimulation	O
with	O
PMA	O
(	O
162	O
nM	O
)	O
for	O
24	O
h	O
.	O

(	O
A	O
)	O
CXCL8	B-Protein
expression	O
was	O
inhibited	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
by	O
both	O
inhibitors	O
.	O

(	O
B	O
)	O
JNK	O
-	O
I	O
revealed	O
a	O
stronger	O
inhibitory	O
effect	O
on	O
IL	B-Protein
-	I-Protein
6	I-Protein
expression	O
than	O
the	O
PKC	O
-	O
I	O
.	O

(	O
C	O
)	O
TNF	O
expression	O
was	O
not	O
affected	O
by	O
either	O
inhibitor	O
.	O
<EOS>	B-X
Cellular-FLICE	B-X
inhibitory	B-X
protein	B-X
(	B-X
c-FLIP	B-X
)	B-X
is	B-X
a	B-X
key	B-X
anti-apoptotic	B-X
regulator	B-X
that	B-X
inhibits	B-X
cell	B-X
death	B-X
mediated	B-X
by	B-X
the	B-X
death	B-X
receptors	B-X
Fas	B-X
,	B-X
DR4	B-X
,	B-X
DR5	B-X
,	B-X
and	B-X
TNF-R1	B-X
.	B-X
Three	B-X
splice	B-X
variants	B-X
of	B-X
c-FLIP	B-X
function	B-X
at	B-X
the	B-X
DISC	B-X
level	B-X
by	B-X
blocking	B-X
the	B-X
processing	B-X
and	B-X
activation	B-X
of	B-X
procaspase-8	B-X
and	B-X
-10	B-X
.	B-X
Overexpression	B-X
of	B-X
c-FLIP	B-X
has	B-X
been	B-X
identified	B-X
in	B-X
many	B-X
different	B-X
tumour	B-X
types	B-X
,	B-X
and	B-X
its	B-X
downregulation	B-X
in	B-X
vitro	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
restore	B-X
apoptosis	B-X
mediated	B-X
by	B-X
CD95L	B-X
and	B-X
TRAIL	B-X
.	B-X
This	B-X
review	B-X
focuses	B-X
on	B-X
the	B-X
molecular	B-X
mechanisms	B-X
that	B-X
control	B-X
c-FLIP	B-X
expression	B-X
and	B-X
current	B-X
research	B-X
into	B-X
inhibitors	B-X
of	B-X
the	B-X
protein	B-X
.	B-X

Statistical	O
significance	O
from	O
the	O
positive	O
control	O
(	O
PMA	O
)	O
was	O
determined	O
using	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

(	O
n	O
=	O
3	O
)	O
.	O
<EOS>	B-X
The	B-X
title	B-X
compound	B-X
,	B-X
{	B-X
[	B-X
NiCl	B-X
(	B-X
2	B-X
)	B-X
(	B-X
C	B-X
(	B-X
5	B-X
)	B-X
H	B-X
(	B-X
6	B-X
)	B-X
N	B-X
(	B-X
2	B-X
)	B-X
)	B-X
(	B-X
C	B-X
(	B-X
3	B-X
)	B-X
H	B-X
(	B-X
7	B-X
)	B-X
NO	B-X
)	B-X
]	B-X
·C	B-X
(	B-X
3	B-X
)	B-X
H	B-X
(	B-X
7	B-X
)	B-X
NO	B-X
}	B-X
(	B-X
n	B-X
)	B-X
,	B-X
is	B-X
a	B-X
two-dimensional	B-X
polymer	B-X
in	B-X
which	B-X
the	B-X
Ni	B-X
(	B-X
II	B-X
)	B-X
atom	B-X
is	B-X
coordinated	B-X
by	B-X
two	B-X
N	B-X
atoms	B-X
from	B-X
two	B-X
3-amino-pyridine	B-X
ligands	B-X
,	B-X
one	B-X
O	B-X
atom	B-X
from	B-X
a	B-X
dimethyl-formamide	B-X
(	B-X
DMF	B-X
)	B-X
group	B-X
,	B-X
one	B-X
terminal	B-X
Cl	B-X
and	B-X
two	B-X
bridging	B-X
Cl	B-X
atoms	B-X
in	B-X
a	B-X
distorted	B-X
octa-hedral	B-X
geometry	B-X
.	B-X
The	B-X
Ni	B-X
(	B-X
II	B-X
)	B-X
atoms	B-X
are	B-X
bridged	B-X
by	B-X
the	B-X
3-amino-pyridine	B-X
ligands	B-X
[	B-X
Ni⋯N	B-X
=	B-X
6.7048	B-X
(	B-X
3	B-X
)	B-X
Å	B-X
]	B-X
and	B-X
Cl	B-X
(	B-X
-	B-X
)	B-X
atoms	B-X
[	B-X
Ni⋯N	B-X
=	B-X
3.5698	B-X
(	B-X
3	B-X
)	B-X
Å	B-X
]	B-X
,	B-X
forming	B-X
(	B-X
4,4	B-X
)	B-X
two-dimensional	B-X
nets	B-X
.	B-X
The	B-X
DMF	B-X
solvent	B-X
mol-ecule	B-X
and	B-X
the	B-X
non-bridged	B-X
Cl	B-X
(	B-X
-	B-X
)	B-X
ions	B-X
participate	B-X
in	B-X
N-H⋯O	B-X
and	B-X
N-H⋯Cl	B-X
hydrogen	B-X
bonds	B-X
with	B-X
the	B-X
amino	B-X
groups	B-X
.	B-X
Electrides	B-X
,	B-X
a	B-X
unique	B-X
type	B-X
of	B-X
compound	B-X
where	B-X
electrons	B-X
act	B-X
as	B-X
anions	B-X
,	B-X
have	B-X
a	B-X
high	B-X
electron	B-X
mobility	B-X
and	B-X
a	B-X
low	B-X
work	B-X
function	B-X
,	B-X
which	B-X
makes	B-X
them	B-X
promising	B-X
for	B-X
applications	B-X
in	B-X
electronic	B-X
devices	B-X
and	B-X
high-performance	B-X
catalysts	B-X
.	B-X
The	B-X
discovery	B-X
of	B-X
novel	B-X
electrides	B-X
and	B-X
the	B-X
expansion	B-X
of	B-X
the	B-X
electride	B-X
family	B-X
have	B-X
great	B-X
significance	B-X
for	B-X
their	B-X
promising	B-X
applications	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
reported	B-X
four	B-X
three-dimensional	B-X
(	B-X
3D	B-X
)	B-X
electrides	B-X
by	B-X
coupling	B-X
crystal	B-X
structure	B-X
database	B-X
searches	B-X
and	B-X
first-principles	B-X
electronic	B-X
structure	B-X
analysis	B-X
.	B-X
Subnitrides	B-X
(	B-X
Ba	B-X

NF	O
-	O
kappaB	O
inhibition	O
by	O
PMA	O
correlated	O
to	O
PKC	O
-	O
dependent	O
Bcl10	B-Protein
degradation	O
.	O

Levels	O
of	O
intracellular	O
protein	O
were	O
assessed	O
following	O
24	O
h	O
stimulation	O
with	O
PMA	O
(	O
162	O
nM	O
)	O
or	O
HK	O
E	O
.	O
coli	O
(	O
5	O
x	O
107	O
CFU	O
/	O
ml	O
)	O
.	O
<EOS>	B-X
By	B-X
coupling	B-X
graphene	B-X
sheet	B-X
and	B-X
plasmonic	B-X
photocatalysis	B-X
technologies	B-X
,	B-X
a	B-X
series	B-X
of	B-X
AgAgX/RGOs	B-X
(	B-X
X	B-X
=	B-X
Cl	B-X
,	B-X
Br	B-X
,	B-X
I	B-X
;	B-X
RGO	B-X
=	B-X
reduced	B-X
graphene	B-X
oxide	B-X
)	B-X
composites	B-X
were	B-X
prepared	B-X
and	B-X
found	B-X
to	B-X
be	B-X
efficient	B-X
antimicrobial	B-X
agents	B-X
for	B-X
water	B-X
disinfection	B-X
upon	B-X
visible	B-X
light	B-X
.	B-X
Attributed	B-X
to	B-X
the	B-X
efficient	B-X
charge	B-X
transfer	B-X
by	B-X
RGO	B-X
sheets	B-X
,	B-X
the	B-X
optimum	B-X
AgAgBr/0.5	B-X
%	B-X
RGO	B-X
could	B-X
completely	B-X
inactivate	B-X
2	B-X
×	B-X
10	B-X
(	B-X
7	B-X
)	B-X
cfu	B-X
mL	B-X
(	B-X
-1	B-X
)	B-X
of	B-X
Escherichia	B-X
coli	B-X
within	B-X
8	B-X
min	B-X
,	B-X
much	B-X
faster	B-X
than	B-X
bare	B-X
AgAgBr	B-X
within	B-X
35	B-X
min	B-X
.	B-X
The	B-X
synergistic	B-X
antimicrobial	B-X
mechanism	B-X
of	B-X
AgAgBr/0.5	B-X
%	B-X
RGO	B-X
was	B-X
studied	B-X
by	B-X
Ag	B-X
(	B-X
+	B-X
)	B-X
ions	B-X
release	B-X
evaluation	B-X
,	B-X
radical	B-X
scavengers	B-X
study	B-X
,	B-X
and	B-X
radical	B-X
determination	B-X
.	B-X
The	B-X
enhanced	B-X
photocatalytic	B-X
activity	B-X
of	B-X
irradiated	B-X
AgAgBr/0.5	B-X
%	B-X
RGO	B-X
originated	B-X
from	B-X
the	B-X
synergistic	B-X
activities	B-X
of	B-X
its	B-X
three	B-X
components	B-X
including	B-X
Ag	B-X
,	B-X
AgBr	B-X
and	B-X
RGO	B-X
,	B-X
and	B-X
the	B-X
proposed	B-X
mechanisms	B-X
contained	B-X
enhanced	B-X
attraction	B-X
by	B-X
RGO	B-X
followed	B-X
by	B-X
two	B-X
pathways	B-X
:	B-X
primary	B-X
oxidative	B-X
stress	B-X
caused	B-X
by	B-X
plasma	B-X
induced	B-X
reactive	B-X
species	B-X
like	B-X
H2O2	B-X
and	B-X
bactericidal	B-X
effect	B-X
of	B-X
released	B-X
Ag	B-X
(	B-X
+	B-X
)	B-X
ions	B-X
.	B-X
Furthermore	B-X
,	B-X
characterization	B-X
of	B-X
E.	B-X
coli	B-X
cells	B-X
using	B-X
SEM	B-X
,	B-X
fluorescent	B-X
microscopy	B-X
,	B-X
and	B-X
cytoplasmic	B-X
substance	B-X
leakage	B-X
illustrated	B-X
that	B-X
VL	B-X
irradiated	B-X
AgAgBr/0.5	B-X
%	B-X
RGO	B-X
could	B-X
not	B-X
only	B-X
cause	B-X
metabolic	B-X
dysfunction	B-X
but	B-X
also	B-X
destroy	B-X
the	B-X
cell	B-X
envelope	B-X
and	B-X
biomolecular	B-X
,	B-X
while	B-X
irradiated	B-X
Ag	B-X
(	B-X
+	B-X
)	B-X
ions	B-X
play	B-X
a	B-X
differential	B-X
bactericidal	B-X
action	B-X
with	B-X
a	B-X
limited	B-X
metabolic	B-X
injury	B-X
and	B-X
no	B-X
cell-membrane	B-X
damage	B-X
.	B-X
The	B-X
present	B-X
work	B-X
provides	B-X
an	B-X
efficient	B-X
water	B-X
disinfection	B-X
technology	B-X
and	B-X
also	B-X
opens	B-X
a	B-X
new	B-X
idea	B-X
in	B-X
studying	B-X
the	B-X
antimicrobial	B-X
mechanism	B-X
of	B-X
plasmonic	B-X
photocatalyst	B-X
.	B-X

(	O
A	O
)	O
Phospho	O
-	O
PKC	O
increased	O
in	O
response	O
to	O
PMA	O
and	O
HK	O
E	O
.	O
coli	O
stimulation	O
.	O

(	O
B	O
)	O
IkappaB	O
decreased	O
following	O
stimulation	O
with	O
HK	O
E	O
.	O
coli	O
indicating	O
NF	O
-	O
kappaB	O
activation	O
.	O

(	O
C	O
)	O
Bcl10	B-Protein
activation	O
was	O
inhibited	O
following	O
long	O
-	O
term	O
stimulation	O
with	O
PMA	O
,	O
which	O
explains	O
the	O
inhibitory	O
effect	O
of	O
PMA	O
on	O
NF	O
-	O
kappaB	O
activation	O
.	O
beta	B-Protein
-	I-Protein
actin	I-Protein
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

(	O
n	O
=	O
3	O
)	O
.	O
<EOS>	B-X
The	B-X
title	B-X
compound	B-X
,	B-X
{	B-X
[	B-X
NiCl	B-X
(	B-X
2	B-X
)	B-X
(	B-X
C	B-X
(	B-X
5	B-X
)	B-X
H	B-X
(	B-X
6	B-X
)	B-X
N	B-X
(	B-X
2	B-X
)	B-X
)	B-X
(	B-X
C	B-X
(	B-X
3	B-X
)	B-X
H	B-X
(	B-X
7	B-X
)	B-X
NO	B-X
)	B-X
]	B-X
·C	B-X
(	B-X
3	B-X
)	B-X
H	B-X
(	B-X
7	B-X
)	B-X
NO	B-X
}	B-X
(	B-X
n	B-X
)	B-X
,	B-X
is	B-X
a	B-X
two-dimensional	B-X
polymer	B-X
in	B-X
which	B-X
the	B-X
Ni	B-X
(	B-X
II	B-X
)	B-X
atom	B-X
is	B-X
coordinated	B-X
by	B-X
two	B-X
N	B-X
atoms	B-X
from	B-X
two	B-X
3-amino-pyridine	B-X
ligands	B-X
,	B-X
one	B-X
O	B-X
atom	B-X
from	B-X
a	B-X
dimethyl-formamide	B-X
(	B-X
DMF	B-X
)	B-X
group	B-X
,	B-X
one	B-X
terminal	B-X
Cl	B-X
and	B-X
two	B-X
bridging	B-X
Cl	B-X
atoms	B-X
in	B-X
a	B-X
distorted	B-X
octa-hedral	B-X
geometry	B-X
.	B-X
The	B-X
Ni	B-X
(	B-X
II	B-X
)	B-X
atoms	B-X
are	B-X
bridged	B-X
by	B-X
the	B-X
3-amino-pyridine	B-X
ligands	B-X
[	B-X
Ni⋯N	B-X
=	B-X
6.7048	B-X
(	B-X
3	B-X
)	B-X
Å	B-X
]	B-X
and	B-X
Cl	B-X
(	B-X
-	B-X
)	B-X
atoms	B-X
[	B-X
Ni⋯N	B-X
=	B-X
3.5698	B-X
(	B-X
3	B-X
)	B-X
Å	B-X
]	B-X
,	B-X
forming	B-X
(	B-X
4,4	B-X
)	B-X
two-dimensional	B-X
nets	B-X
.	B-X
The	B-X
DMF	B-X
solvent	B-X
mol-ecule	B-X
and	B-X
the	B-X
non-bridged	B-X
Cl	B-X
(	B-X
-	B-X
)	B-X
ions	B-X
participate	B-X
in	B-X
N-H⋯O	B-X
and	B-X
N-H⋯Cl	B-X
hydrogen	B-X
bonds	B-X
with	B-X
the	B-X
amino	B-X
groups	B-X
.	B-X
Electrides	B-X
,	B-X
a	B-X
unique	B-X
type	B-X
of	B-X
compound	B-X
where	B-X
electrons	B-X
act	B-X
as	B-X
anions	B-X
,	B-X
have	B-X
a	B-X
high	B-X
electron	B-X
mobility	B-X
and	B-X
a	B-X
low	B-X
work	B-X
function	B-X
,	B-X
which	B-X
makes	B-X
them	B-X
promising	B-X
for	B-X
applications	B-X
in	B-X
electronic	B-X
devices	B-X
and	B-X
high-performance	B-X
catalysts	B-X
.	B-X
The	B-X
discovery	B-X
of	B-X
novel	B-X
electrides	B-X
and	B-X
the	B-X
expansion	B-X
of	B-X
the	B-X
electride	B-X
family	B-X
have	B-X
great	B-X
significance	B-X
for	B-X
their	B-X
promising	B-X
applications	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
reported	B-X
four	B-X
three-dimensional	B-X
(	B-X
3D	B-X
)	B-X
electrides	B-X
by	B-X
coupling	B-X
crystal	B-X
structure	B-X
database	B-X
searches	B-X
and	B-X
first-principles	B-X
electronic	B-X
structure	B-X
analysis	B-X
.	B-X
Subnitrides	B-X
(	B-X
Ba	B-X

Jurkat	O
T	O
-	O
cells	O
were	O
stimulated	O
with	O
162	O
nM	O
PMA	O
and	O
5	O
x	O
107	O
CFU	O
/	O
ml	O
HK	O
E	O
.	O
coli	O
for	O
24	O
h	O
.	O

Jurkat	O
T	O
-	O
cells	O
were	O
treated	O
with	O
10	O
nM	O
NAI	O
,	O
10	O
muM	O
JNK	O
-	O
I	O
or10	O
nM	O
PKC	O
-	O
I	O
for	O
2	O
h	O
followed	O
by	O
induction	O
with	O
162	O
nM	O
PMA	O
for	O
24	O
h	O
.	O

HOIL	B-Protein
-	I-Protein
1L	I-Protein
Interacting	I-Protein
Protein	I-Protein
(	O
HOIP	B-Protein
)	O
Is	O
Essential	O
for	O
CD40	B-Protein
Signaling	O
<EOS>	B-X
CD40	B-X
is	B-X
a	B-X
cell	B-X
surface	B-X
receptor	B-X
important	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
antigen-presenting	B-X
cells	B-X
during	B-X
immune	B-X
responses	B-X
.	B-X
In	B-X
macrophages	B-X
and	B-X
dendritic	B-X
cells	B-X
,	B-X
engagement	B-X
of	B-X
CD40	B-X
by	B-X
its	B-X
ligand	B-X
CD154	B-X
provides	B-X
signals	B-X
critical	B-X
for	B-X
anti-microbial	B-X
and	B-X
T	B-X
cell-mediated	B-X
immune	B-X
responses	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
B	B-X
cells	B-X
,	B-X
CD40	B-X
signaling	B-X
has	B-X
a	B-X
major	B-X
role	B-X
in	B-X
regulating	B-X
cell	B-X
proliferation	B-X
,	B-X
antibody	B-X
production	B-X
,	B-X
and	B-X
memory	B-X
B	B-X
cell	B-X
development	B-X
.	B-X
CD40	B-X
engagement	B-X
results	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
a	B-X
receptor-associated	B-X
complex	B-X
that	B-X
mediates	B-X
activation	B-X
of	B-X
NF-κB	B-X
,	B-X
stress-activated	B-X
protein	B-X
kinases	B-X
,	B-X
and	B-X
other	B-X
signaling	B-X
molecules	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanisms	B-X
that	B-X
link	B-X
CD40	B-X
to	B-X
these	B-X
signaling	B-X
events	B-X
have	B-X
been	B-X
only	B-X
partially	B-X
characterized	B-X
.	B-X
Known	B-X
components	B-X
of	B-X
the	B-X
CD40	B-X
signaling	B-X
complex	B-X
include	B-X
members	B-X
of	B-X
the	B-X
TNF	B-X
receptor-associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
family	B-X
of	B-X
proteins	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
the	B-X
TRAF	B-X
family	B-X
member	B-X
TRAF2	B-X
mediates	B-X
recruitment	B-X
of	B-X
HOIL-1L-interacting	B-X
protein	B-X
(	B-X
HOIP	B-X
)	B-X
to	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
CD40	B-X
,	B-X
suggesting	B-X
that	B-X
HOIP	B-X
has	B-X
a	B-X
role	B-X
in	B-X
the	B-X
CD40	B-X
signaling	B-X
pathway	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
role	B-X
of	B-X
HOIP	B-X
in	B-X
CD40	B-X
signaling	B-X
,	B-X
we	B-X
used	B-X
somatic	B-X
cell	B-X
gene	B-X
targeting	B-X
to	B-X
generate	B-X
mouse	B-X
B	B-X
cell	B-X
lines	B-X
deficient	B-X
in	B-X
HOIP	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
CD40-induced	B-X
upregulation	B-X
of	B-X
CD80	B-X
and	B-X
activation	B-X
of	B-X
germline	B-X
immunoglobulin	B-X
epsilon	B-X
transcription	B-X
were	B-X
defective	B-X
in	B-X
HOIP-deficient	B-X
cells	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
the	B-X
CD40-mediated	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
c-Jun	B-X
kinase	B-X
was	B-X
impaired	B-X
.	B-X
Recruitment	B-X
of	B-X
IκB	B-X
kinase	B-X
proteins	B-X
to	B-X
the	B-X
CD40	B-X
signaling	B-X
complex	B-X
was	B-X
undetectable	B-X
in	B-X
HOIP-deficient	B-X
cells	B-X
,	B-X
potentially	B-X
explaining	B-X
the	B-X
defect	B-X
in	B-X
NF-κB	B-X
activation	B-X
.	B-X
Restoration	B-X
of	B-X
HOIP	B-X
expression	B-X
reversed	B-X
the	B-X
defects	B-X
in	B-X
cellular	B-X
activation	B-X
and	B-X
signaling	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
HOIP	B-X
as	B-X
a	B-X
key	B-X
component	B-X
of	B-X
the	B-X
CD40	B-X
signaling	B-X
pathway	B-X
.	B-X

CD40	B-Protein
is	O
a	O
cell	O
surface	O
receptor	O
important	O
in	O
the	O
activation	O
of	O
antigen	O
-	O
presenting	O
cells	O
during	O
immune	O
responses	O
.	O
<EOS>	B-X
It	B-X
is	B-X
known	B-X
that	B-X
colony-stimulating	B-X
factor	B-X
1	B-X
(	B-X
CSF1	B-X
)	B-X
/CSF1	B-X
receptor	B-X
(	B-X
CSF1R	B-X
)	B-X
and	B-X
CSF2/CSF2R	B-X
signaling	B-X
play	B-X
important	B-X
roles	B-X
in	B-X
macrophage	B-X
polarization	B-X
.	B-X
Other	B-X
targets	B-X
for	B-X
M2	B-X
macrophage	B-X
reprogramming	B-X
include	B-X
Toll-like	B-X
receptor	B-X
7	B-X
(	B-X
TLR7	B-X
)	B-X
,	B-X
TLR8	B-X
,	B-X
TLR9	B-X
,	B-X
CD40	B-X
,	B-X
histone	B-X
deacetylase	B-X
(	B-X
HDAC	B-X
)	B-X
,	B-X
and	B-X
PI3Kγ	B-X
.	B-X
Although	B-X
macrophages	B-X
are	B-X
involved	B-X
in	B-X
innate	B-X
and	B-X
adaptive	B-X
immune	B-X
responses	B-X
,	B-X
M1	B-X
macrophages	B-X
are	B-X
less	B-X
effective	B-X
at	B-X
phagocytosis	B-X
and	B-X
antigen	B-X
presenting	B-X
,	B-X
which	B-X
are	B-X
required	B-X
properties	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
and	B-X
eradication	B-X
of	B-X
cancer	B-X
cells	B-X
.	B-X
Similar	B-X
to	B-X
T	B-X
and	B-X
dendritic	B-X
cells	B-X
,	B-X
the	B-X
``	B-X
functionally	B-X
exhausted	B-X
''	B-X
status	B-X
might	B-X
be	B-X
attributed	B-X
to	B-X
the	B-X
high	B-X
expression	B-X
of	B-X
programmed	B-X
death-ligand	B-X
1	B-X
(	B-X
PD-L1	B-X
)	B-X
or	B-X
programmed	B-X
cell	B-X
death	B-X
protein	B-X
1	B-X
(	B-X
PD-1	B-X
)	B-X
.	B-X

In	O
macrophages	O
and	O
dendritic	O
cells	O
,	O
engagement	O
of	O
CD40	B-Protein
by	O
its	O
ligand	B-Protein
CD154	B-Protein
provides	O
signals	O
critical	O
for	O
anti	O
-	O
microbial	O
and	O
T	O
cell	O
-	O
mediated	O
immune	O
responses	O
,	O
respectively	O
.	O

In	O
B	O
cells	O
,	O
CD40	B-Protein
signaling	O
has	O
a	O
major	O
role	O
in	O
regulating	O
cell	O
proliferation	O
,	O
antibody	O
production	O
,	O
and	O
memory	O
B	O
cell	O
development	O
.	O

CD40	B-Protein
engagement	O
results	O
in	O
the	O
formation	O
of	O
a	O
receptor	O
-	O
associated	O
complex	O
that	O
mediates	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
stress	O
-	O
activated	O
protein	O
kinases	O
,	O
and	O
other	O
signaling	O
molecules	O
.	O
<EOS>	B-X
CD40	B-X
is	B-X
a	B-X
cell	B-X
surface	B-X
receptor	B-X
important	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
antigen-presenting	B-X
cells	B-X
during	B-X
immune	B-X
responses	B-X
.	B-X
In	B-X
macrophages	B-X
and	B-X
dendritic	B-X
cells	B-X
,	B-X
engagement	B-X
of	B-X
CD40	B-X
by	B-X
its	B-X
ligand	B-X
CD154	B-X
provides	B-X
signals	B-X
critical	B-X
for	B-X
anti-microbial	B-X
and	B-X
T	B-X
cell-mediated	B-X
immune	B-X
responses	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
B	B-X
cells	B-X
,	B-X
CD40	B-X
signaling	B-X
has	B-X
a	B-X
major	B-X
role	B-X
in	B-X
regulating	B-X
cell	B-X
proliferation	B-X
,	B-X
antibody	B-X
production	B-X
,	B-X
and	B-X
memory	B-X
B	B-X
cell	B-X
development	B-X
.	B-X
CD40	B-X
engagement	B-X
results	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
a	B-X
receptor-associated	B-X
complex	B-X
that	B-X
mediates	B-X
activation	B-X
of	B-X
NF-κB	B-X
,	B-X
stress-activated	B-X
protein	B-X
kinases	B-X
,	B-X
and	B-X
other	B-X
signaling	B-X
molecules	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanisms	B-X
that	B-X
link	B-X
CD40	B-X
to	B-X
these	B-X
signaling	B-X
events	B-X
have	B-X
been	B-X
only	B-X
partially	B-X
characterized	B-X
.	B-X
Known	B-X
components	B-X
of	B-X
the	B-X
CD40	B-X
signaling	B-X
complex	B-X
include	B-X
members	B-X
of	B-X
the	B-X
TNF	B-X
receptor-associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
family	B-X
of	B-X
proteins	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
the	B-X
TRAF	B-X
family	B-X
member	B-X
TRAF2	B-X
mediates	B-X
recruitment	B-X
of	B-X
HOIL-1L-interacting	B-X
protein	B-X
(	B-X
HOIP	B-X
)	B-X
to	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
CD40	B-X
,	B-X
suggesting	B-X
that	B-X
HOIP	B-X
has	B-X
a	B-X
role	B-X
in	B-X
the	B-X
CD40	B-X
signaling	B-X
pathway	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
role	B-X
of	B-X
HOIP	B-X
in	B-X
CD40	B-X
signaling	B-X
,	B-X
we	B-X
used	B-X
somatic	B-X
cell	B-X
gene	B-X
targeting	B-X
to	B-X
generate	B-X
mouse	B-X
B	B-X
cell	B-X
lines	B-X
deficient	B-X
in	B-X
HOIP	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
CD40-induced	B-X
upregulation	B-X
of	B-X
CD80	B-X
and	B-X
activation	B-X
of	B-X
germline	B-X
immunoglobulin	B-X
epsilon	B-X
transcription	B-X
were	B-X
defective	B-X
in	B-X
HOIP-deficient	B-X
cells	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
the	B-X
CD40-mediated	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
c-Jun	B-X
kinase	B-X
was	B-X
impaired	B-X
.	B-X
Recruitment	B-X
of	B-X
IκB	B-X
kinase	B-X
proteins	B-X
to	B-X
the	B-X
CD40	B-X
signaling	B-X
complex	B-X
was	B-X
undetectable	B-X
in	B-X
HOIP-deficient	B-X
cells	B-X
,	B-X
potentially	B-X
explaining	B-X
the	B-X
defect	B-X
in	B-X
NF-κB	B-X
activation	B-X
.	B-X
Restoration	B-X
of	B-X
HOIP	B-X
expression	B-X
reversed	B-X
the	B-X
defects	B-X
in	B-X
cellular	B-X
activation	B-X
and	B-X
signaling	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
HOIP	B-X
as	B-X
a	B-X
key	B-X
component	B-X
of	B-X
the	B-X
CD40	B-X
signaling	B-X
pathway	B-X
.	B-X

However	O
,	O
the	O
mechanisms	O
that	O
link	O
CD40	B-Protein
to	O
these	O
signaling	O
events	O
have	O
been	O
only	O
partially	O
characterized	O
.	O
<EOS>	B-X
CD40	B-X
is	B-X
a	B-X
cell	B-X
surface	B-X
receptor	B-X
important	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
antigen-presenting	B-X
cells	B-X
during	B-X
immune	B-X
responses	B-X
.	B-X
In	B-X
macrophages	B-X
and	B-X
dendritic	B-X
cells	B-X
,	B-X
engagement	B-X
of	B-X
CD40	B-X
by	B-X
its	B-X
ligand	B-X
CD154	B-X
provides	B-X
signals	B-X
critical	B-X
for	B-X
anti-microbial	B-X
and	B-X
T	B-X
cell-mediated	B-X
immune	B-X
responses	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
B	B-X
cells	B-X
,	B-X
CD40	B-X
signaling	B-X
has	B-X
a	B-X
major	B-X
role	B-X
in	B-X
regulating	B-X
cell	B-X
proliferation	B-X
,	B-X
antibody	B-X
production	B-X
,	B-X
and	B-X
memory	B-X
B	B-X
cell	B-X
development	B-X
.	B-X
CD40	B-X
engagement	B-X
results	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
a	B-X
receptor-associated	B-X
complex	B-X
that	B-X
mediates	B-X
activation	B-X
of	B-X
NF-κB	B-X
,	B-X
stress-activated	B-X
protein	B-X
kinases	B-X
,	B-X
and	B-X
other	B-X
signaling	B-X
molecules	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanisms	B-X
that	B-X
link	B-X
CD40	B-X
to	B-X
these	B-X
signaling	B-X
events	B-X
have	B-X
been	B-X
only	B-X
partially	B-X
characterized	B-X
.	B-X
Known	B-X
components	B-X
of	B-X
the	B-X
CD40	B-X
signaling	B-X
complex	B-X
include	B-X
members	B-X
of	B-X
the	B-X
TNF	B-X
receptor-associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
family	B-X
of	B-X
proteins	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
the	B-X
TRAF	B-X
family	B-X
member	B-X
TRAF2	B-X
mediates	B-X
recruitment	B-X
of	B-X
HOIL-1L-interacting	B-X
protein	B-X
(	B-X
HOIP	B-X
)	B-X
to	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
CD40	B-X
,	B-X
suggesting	B-X
that	B-X
HOIP	B-X
has	B-X
a	B-X
role	B-X
in	B-X
the	B-X
CD40	B-X
signaling	B-X
pathway	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
role	B-X
of	B-X
HOIP	B-X
in	B-X
CD40	B-X
signaling	B-X
,	B-X
we	B-X
used	B-X
somatic	B-X
cell	B-X
gene	B-X
targeting	B-X
to	B-X
generate	B-X
mouse	B-X
B	B-X
cell	B-X
lines	B-X
deficient	B-X
in	B-X
HOIP	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
CD40-induced	B-X
upregulation	B-X
of	B-X
CD80	B-X
and	B-X
activation	B-X
of	B-X
germline	B-X
immunoglobulin	B-X
epsilon	B-X
transcription	B-X
were	B-X
defective	B-X
in	B-X
HOIP-deficient	B-X
cells	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
the	B-X
CD40-mediated	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
c-Jun	B-X
kinase	B-X
was	B-X
impaired	B-X
.	B-X
Recruitment	B-X
of	B-X
IκB	B-X
kinase	B-X
proteins	B-X
to	B-X
the	B-X
CD40	B-X
signaling	B-X
complex	B-X
was	B-X
undetectable	B-X
in	B-X
HOIP-deficient	B-X
cells	B-X
,	B-X
potentially	B-X
explaining	B-X
the	B-X
defect	B-X
in	B-X
NF-κB	B-X
activation	B-X
.	B-X
Restoration	B-X
of	B-X
HOIP	B-X
expression	B-X
reversed	B-X
the	B-X
defects	B-X
in	B-X
cellular	B-X
activation	B-X
and	B-X
signaling	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
HOIP	B-X
as	B-X
a	B-X
key	B-X
component	B-X
of	B-X
the	B-X
CD40	B-X
signaling	B-X
pathway	B-X
.	B-X

Known	O
components	O
of	O
the	O
CD40	O
signaling	O
complex	O
include	O
members	O
of	O
the	O
TNF	O
receptor	O
-	O
associated	O
factor	O
(	O
TRAF	O
)	O
family	O
of	O
proteins	O
.	O
<EOS>	B-X
The	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
(	B-X
TNFR	B-X
)	B-X
superfamily	B-X
mediates	B-X
signals	B-X
critical	B-X
for	B-X
regulation	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
.	B-X
One	B-X
family	B-X
member	B-X
,	B-X
CD40	B-X
,	B-X
is	B-X
important	B-X
for	B-X
the	B-X
efficient	B-X
activation	B-X
of	B-X
antibody-producing	B-X
B	B-X
cells	B-X
and	B-X
other	B-X
antigen-presenting	B-X
cells	B-X
.	B-X
The	B-X
molecules	B-X
and	B-X
mechanisms	B-X
that	B-X
mediate	B-X
CD40	B-X
signaling	B-X
are	B-X
only	B-X
partially	B-X
characterized	B-X
.	B-X
Proteins	B-X
known	B-X
to	B-X
interact	B-X
with	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
CD40	B-X
include	B-X
members	B-X
of	B-X
the	B-X
TNF	B-X
receptor-associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
family	B-X
,	B-X
which	B-X
regulate	B-X
signaling	B-X
and	B-X
serve	B-X
as	B-X
links	B-X
to	B-X
other	B-X
signaling	B-X
molecules	B-X
.	B-X
To	B-X
identify	B-X
additional	B-X
proteins	B-X
important	B-X
for	B-X
CD40	B-X
signaling	B-X
,	B-X
we	B-X
used	B-X
a	B-X
combined	B-X
stimulation/immunoprecipitation	B-X
procedure	B-X
to	B-X
isolate	B-X
CD40	B-X
signaling	B-X
complexes	B-X
from	B-X
B	B-X
cells	B-X
and	B-X
characterized	B-X
the	B-X
associated	B-X
proteins	B-X
by	B-X
mass	B-X
spectrometry	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
known	B-X
CD40-interacting	B-X
proteins	B-X
,	B-X
we	B-X
detected	B-X
SMAC/DIABLO	B-X
,	B-X
HTRA2/Omi	B-X
,	B-X
and	B-X
HOIP/RNF31/PAUL/ZIBRA	B-X
.	B-X
We	B-X
found	B-X
that	B-X
these	B-X
previously	B-X
unknown	B-X
CD40-interacting	B-X
partners	B-X
were	B-X
recruited	B-X
in	B-X
a	B-X
TRAF2-dependent	B-X
manner	B-X
.	B-X
We	B-X
found	B-X
that	B-X
a	B-X
mutant	B-X
HOIP	B-X
molecule	B-X
engineered	B-X
to	B-X
lack	B-X
ubiquitin	B-X
ligase	B-X
activity	B-X
inhibited	B-X
the	B-X
CD40-mediated	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
results	B-X
demonstrate	B-X
a	B-X
powerful	B-X
approach	B-X
for	B-X
the	B-X
identification	B-X
of	B-X
signaling	B-X
molecules	B-X
associated	B-X
with	B-X
cell	B-X
surface	B-X
receptors	B-X
and	B-X
indicate	B-X
an	B-X
important	B-X
role	B-X
for	B-X
the	B-X
ubiquitin	B-X
ligase	B-X
activity	B-X
of	B-X
HOIP	B-X
in	B-X
proximal	B-X
CD40	B-X
signaling	B-X
.	B-X

We	O
previously	O
showed	O
that	O
the	O
TRAF	O
family	O
member	O
TRAF2	B-Protein
mediates	O
recruitment	O
of	O
HOIL	B-Protein
-	I-Protein
1L	I-Protein
-	I-Protein
interacting	I-Protein
protein	I-Protein
(	O
HOIP	B-Protein
)	O
to	O
the	O
cytoplasmic	O
domain	O
of	O
CD40	B-Protein
,	O
suggesting	O
that	O
HOIP	B-Protein
has	O
a	O
role	O
in	O
the	O
CD40	B-Protein
signaling	O
pathway	O
.	O

To	O
determine	O
the	O
role	O
of	O
HOIP	B-Protein
in	O
CD40	B-Protein
signaling	O
,	O
we	O
used	O
somatic	O
cell	O
gene	O
targeting	O
to	O
generate	O
mouse	O
B	O
cell	O
lines	O
deficient	O
in	O
HOIP	B-Protein
.	O
<EOS>	B-X
CD40	B-X
is	B-X
a	B-X
cell	B-X
surface	B-X
receptor	B-X
important	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
antigen-presenting	B-X
cells	B-X
during	B-X
immune	B-X
responses	B-X
.	B-X
In	B-X
macrophages	B-X
and	B-X
dendritic	B-X
cells	B-X
,	B-X
engagement	B-X
of	B-X
CD40	B-X
by	B-X
its	B-X
ligand	B-X
CD154	B-X
provides	B-X
signals	B-X
critical	B-X
for	B-X
anti-microbial	B-X
and	B-X
T	B-X
cell-mediated	B-X
immune	B-X
responses	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
B	B-X
cells	B-X
,	B-X
CD40	B-X
signaling	B-X
has	B-X
a	B-X
major	B-X
role	B-X
in	B-X
regulating	B-X
cell	B-X
proliferation	B-X
,	B-X
antibody	B-X
production	B-X
,	B-X
and	B-X
memory	B-X
B	B-X
cell	B-X
development	B-X
.	B-X
CD40	B-X
engagement	B-X
results	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
a	B-X
receptor-associated	B-X
complex	B-X
that	B-X
mediates	B-X
activation	B-X
of	B-X
NF-κB	B-X
,	B-X
stress-activated	B-X
protein	B-X
kinases	B-X
,	B-X
and	B-X
other	B-X
signaling	B-X
molecules	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanisms	B-X
that	B-X
link	B-X
CD40	B-X
to	B-X
these	B-X
signaling	B-X
events	B-X
have	B-X
been	B-X
only	B-X
partially	B-X
characterized	B-X
.	B-X
Known	B-X
components	B-X
of	B-X
the	B-X
CD40	B-X
signaling	B-X
complex	B-X
include	B-X
members	B-X
of	B-X
the	B-X
TNF	B-X
receptor-associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
family	B-X
of	B-X
proteins	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
the	B-X
TRAF	B-X
family	B-X
member	B-X
TRAF2	B-X
mediates	B-X
recruitment	B-X
of	B-X
HOIL-1L-interacting	B-X
protein	B-X
(	B-X
HOIP	B-X
)	B-X
to	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
CD40	B-X
,	B-X
suggesting	B-X
that	B-X
HOIP	B-X
has	B-X
a	B-X
role	B-X
in	B-X
the	B-X
CD40	B-X
signaling	B-X
pathway	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
role	B-X
of	B-X
HOIP	B-X
in	B-X
CD40	B-X
signaling	B-X
,	B-X
we	B-X
used	B-X
somatic	B-X
cell	B-X
gene	B-X
targeting	B-X
to	B-X
generate	B-X
mouse	B-X
B	B-X
cell	B-X
lines	B-X
deficient	B-X
in	B-X
HOIP	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
CD40-induced	B-X
upregulation	B-X
of	B-X
CD80	B-X
and	B-X
activation	B-X
of	B-X
germline	B-X
immunoglobulin	B-X
epsilon	B-X
transcription	B-X
were	B-X
defective	B-X
in	B-X
HOIP-deficient	B-X
cells	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
the	B-X
CD40-mediated	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
c-Jun	B-X
kinase	B-X
was	B-X
impaired	B-X
.	B-X
Recruitment	B-X
of	B-X
IκB	B-X
kinase	B-X
proteins	B-X
to	B-X
the	B-X
CD40	B-X
signaling	B-X
complex	B-X
was	B-X
undetectable	B-X
in	B-X
HOIP-deficient	B-X
cells	B-X
,	B-X
potentially	B-X
explaining	B-X
the	B-X
defect	B-X
in	B-X
NF-κB	B-X
activation	B-X
.	B-X
Restoration	B-X
of	B-X
HOIP	B-X
expression	B-X
reversed	B-X
the	B-X
defects	B-X
in	B-X
cellular	B-X
activation	B-X
and	B-X
signaling	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
HOIP	B-X
as	B-X
a	B-X
key	B-X
component	B-X
of	B-X
the	B-X
CD40	B-X
signaling	B-X
pathway	B-X
.	B-X

We	O
found	O
that	O
the	O
CD40	B-Protein
-	O
induced	O
upregulation	O
of	O
CD80	B-Protein
and	O
activation	O
of	O
germline	O
immunoglobulin	O
epsilon	O
transcription	O
were	O
defective	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
.	O
<EOS>	B-X
CD40	B-X
is	B-X
a	B-X
cell	B-X
surface	B-X
receptor	B-X
important	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
antigen-presenting	B-X
cells	B-X
during	B-X
immune	B-X
responses	B-X
.	B-X
In	B-X
macrophages	B-X
and	B-X
dendritic	B-X
cells	B-X
,	B-X
engagement	B-X
of	B-X
CD40	B-X
by	B-X
its	B-X
ligand	B-X
CD154	B-X
provides	B-X
signals	B-X
critical	B-X
for	B-X
anti-microbial	B-X
and	B-X
T	B-X
cell-mediated	B-X
immune	B-X
responses	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
B	B-X
cells	B-X
,	B-X
CD40	B-X
signaling	B-X
has	B-X
a	B-X
major	B-X
role	B-X
in	B-X
regulating	B-X
cell	B-X
proliferation	B-X
,	B-X
antibody	B-X
production	B-X
,	B-X
and	B-X
memory	B-X
B	B-X
cell	B-X
development	B-X
.	B-X
CD40	B-X
engagement	B-X
results	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
a	B-X
receptor-associated	B-X
complex	B-X
that	B-X
mediates	B-X
activation	B-X
of	B-X
NF-κB	B-X
,	B-X
stress-activated	B-X
protein	B-X
kinases	B-X
,	B-X
and	B-X
other	B-X
signaling	B-X
molecules	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanisms	B-X
that	B-X
link	B-X
CD40	B-X
to	B-X
these	B-X
signaling	B-X
events	B-X
have	B-X
been	B-X
only	B-X
partially	B-X
characterized	B-X
.	B-X
Known	B-X
components	B-X
of	B-X
the	B-X
CD40	B-X
signaling	B-X
complex	B-X
include	B-X
members	B-X
of	B-X
the	B-X
TNF	B-X
receptor-associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
family	B-X
of	B-X
proteins	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
the	B-X
TRAF	B-X
family	B-X
member	B-X
TRAF2	B-X
mediates	B-X
recruitment	B-X
of	B-X
HOIL-1L-interacting	B-X
protein	B-X
(	B-X
HOIP	B-X
)	B-X
to	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
CD40	B-X
,	B-X
suggesting	B-X
that	B-X
HOIP	B-X
has	B-X
a	B-X
role	B-X
in	B-X
the	B-X
CD40	B-X
signaling	B-X
pathway	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
role	B-X
of	B-X
HOIP	B-X
in	B-X
CD40	B-X
signaling	B-X
,	B-X
we	B-X
used	B-X
somatic	B-X
cell	B-X
gene	B-X
targeting	B-X
to	B-X
generate	B-X
mouse	B-X
B	B-X
cell	B-X
lines	B-X
deficient	B-X
in	B-X
HOIP	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
CD40-induced	B-X
upregulation	B-X
of	B-X
CD80	B-X
and	B-X
activation	B-X
of	B-X
germline	B-X
immunoglobulin	B-X
epsilon	B-X
transcription	B-X
were	B-X
defective	B-X
in	B-X
HOIP-deficient	B-X
cells	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
the	B-X
CD40-mediated	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
c-Jun	B-X
kinase	B-X
was	B-X
impaired	B-X
.	B-X
Recruitment	B-X
of	B-X
IκB	B-X
kinase	B-X
proteins	B-X
to	B-X
the	B-X
CD40	B-X
signaling	B-X
complex	B-X
was	B-X
undetectable	B-X
in	B-X
HOIP-deficient	B-X
cells	B-X
,	B-X
potentially	B-X
explaining	B-X
the	B-X
defect	B-X
in	B-X
NF-κB	B-X
activation	B-X
.	B-X
Restoration	B-X
of	B-X
HOIP	B-X
expression	B-X
reversed	B-X
the	B-X
defects	B-X
in	B-X
cellular	B-X
activation	B-X
and	B-X
signaling	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
HOIP	B-X
as	B-X
a	B-X
key	B-X
component	B-X
of	B-X
the	B-X
CD40	B-X
signaling	B-X
pathway	B-X
.	B-X

We	O
also	O
found	O
that	O
the	O
CD40	B-Protein
-	O
mediated	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
c	O
-	O
Jun	O
kinase	O
was	O
impaired	O
.	O

Recruitment	O
of	O
IkappaB	O
kinase	O
proteins	O
to	O
the	O
CD40	O
signaling	O
complex	O
was	O
undetectable	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
,	O
potentially	O
explaining	O
the	O
defect	O
in	O
NF	O
-	O
kappaB	O
activation	O
.	O

Restoration	O
of	O
HOIP	B-Protein
expression	O
reversed	O
the	O
defects	O
in	O
cellular	O
activation	O
and	O
signaling	O
.	O
<EOS>	B-X
CD40	B-X
is	B-X
a	B-X
cell	B-X
surface	B-X
receptor	B-X
important	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
antigen-presenting	B-X
cells	B-X
during	B-X
immune	B-X
responses	B-X
.	B-X
In	B-X
B	B-X
cells	B-X
,	B-X
CD40	B-X
signaling	B-X
has	B-X
a	B-X
major	B-X
role	B-X
in	B-X
regulating	B-X
cell	B-X
proliferation	B-X
,	B-X
antibody	B-X
production	B-X
,	B-X
and	B-X
memory	B-X
B	B-X
cell	B-X
development	B-X
.	B-X
CD40	B-X
engagement	B-X
results	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
a	B-X
receptor-associated	B-X
complex	B-X
that	B-X
mediates	B-X
activation	B-X
of	B-X
NF-κB	B-X
,	B-X
stress-activated	B-X
protein	B-X
kinases	B-X
,	B-X
and	B-X
other	B-X
signaling	B-X
molecules	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanisms	B-X
that	B-X
link	B-X
CD40	B-X
to	B-X
these	B-X
signaling	B-X
events	B-X
have	B-X
been	B-X
only	B-X
partially	B-X
characterized	B-X
.	B-X
Known	B-X
components	B-X
of	B-X
the	B-X
CD40	B-X
signaling	B-X
complex	B-X
include	B-X
members	B-X
of	B-X
the	B-X
TNF	B-X
receptor-associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
family	B-X
of	B-X
proteins	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
the	B-X
TRAF	B-X
family	B-X
member	B-X
TRAF2	B-X
mediates	B-X
recruitment	B-X
of	B-X
HOIL-1L-interacting	B-X
protein	B-X
(	B-X
HOIP	B-X
)	B-X
to	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
CD40	B-X
,	B-X
suggesting	B-X
that	B-X
HOIP	B-X
has	B-X
a	B-X
role	B-X
in	B-X
the	B-X
CD40	B-X
signaling	B-X
pathway	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
role	B-X
of	B-X
HOIP	B-X
in	B-X
CD40	B-X
signaling	B-X
,	B-X
we	B-X
used	B-X
somatic	B-X
cell	B-X
gene	B-X
targeting	B-X
to	B-X
generate	B-X
mouse	B-X
B	B-X
cell	B-X
lines	B-X
deficient	B-X
in	B-X
HOIP	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
CD40-induced	B-X
upregulation	B-X
of	B-X
CD80	B-X
and	B-X
activation	B-X
of	B-X
germline	B-X
immunoglobulin	B-X
epsilon	B-X
transcription	B-X
were	B-X
defective	B-X
in	B-X
HOIP-deficient	B-X
cells	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
the	B-X
CD40-mediated	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
c-Jun	B-X
kinase	B-X
was	B-X
impaired	B-X
.	B-X
Recruitment	B-X
of	B-X
IκB	B-X
kinase	B-X
proteins	B-X
to	B-X
the	B-X
CD40	B-X
signaling	B-X
complex	B-X
was	B-X
undetectable	B-X
in	B-X
HOIP-deficient	B-X
cells	B-X
,	B-X
potentially	B-X
explaining	B-X
the	B-X
defect	B-X
in	B-X
NF-κB	B-X
activation	B-X
.	B-X
Restoration	B-X
of	B-X
HOIP	B-X
expression	B-X
reversed	B-X
the	B-X
defects	B-X
in	B-X
cellular	B-X
activation	B-X
and	B-X
signaling	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
HOIP	B-X
as	B-X
a	B-X
key	B-X
component	B-X
of	B-X
the	B-X
CD40	B-X
signaling	B-X
pathway	B-X
.	B-X

These	O
results	O
reveal	O
HOIP	B-Protein
as	O
a	O
key	O
component	O
of	O
the	O
CD40	B-Protein
signaling	O
pathway	O
.	O
<EOS>	B-X
CD40	B-X
is	B-X
a	B-X
cell	B-X
surface	B-X
receptor	B-X
important	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
antigen-presenting	B-X
cells	B-X
during	B-X
immune	B-X
responses	B-X
.	B-X
In	B-X
macrophages	B-X
and	B-X
dendritic	B-X
cells	B-X
,	B-X
engagement	B-X
of	B-X
CD40	B-X
by	B-X
its	B-X
ligand	B-X
CD154	B-X
provides	B-X
signals	B-X
critical	B-X
for	B-X
anti-microbial	B-X
and	B-X
T	B-X
cell-mediated	B-X
immune	B-X
responses	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
B	B-X
cells	B-X
,	B-X
CD40	B-X
signaling	B-X
has	B-X
a	B-X
major	B-X
role	B-X
in	B-X
regulating	B-X
cell	B-X
proliferation	B-X
,	B-X
antibody	B-X
production	B-X
,	B-X
and	B-X
memory	B-X
B	B-X
cell	B-X
development	B-X
.	B-X
CD40	B-X
engagement	B-X
results	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
a	B-X
receptor-associated	B-X
complex	B-X
that	B-X
mediates	B-X
activation	B-X
of	B-X
NF-κB	B-X
,	B-X
stress-activated	B-X
protein	B-X
kinases	B-X
,	B-X
and	B-X
other	B-X
signaling	B-X
molecules	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanisms	B-X
that	B-X
link	B-X
CD40	B-X
to	B-X
these	B-X
signaling	B-X
events	B-X
have	B-X
been	B-X
only	B-X
partially	B-X
characterized	B-X
.	B-X
Known	B-X
components	B-X
of	B-X
the	B-X
CD40	B-X
signaling	B-X
complex	B-X
include	B-X
members	B-X
of	B-X
the	B-X
TNF	B-X
receptor-associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
family	B-X
of	B-X
proteins	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
the	B-X
TRAF	B-X
family	B-X
member	B-X
TRAF2	B-X
mediates	B-X
recruitment	B-X
of	B-X
HOIL-1L-interacting	B-X
protein	B-X
(	B-X
HOIP	B-X
)	B-X
to	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
CD40	B-X
,	B-X
suggesting	B-X
that	B-X
HOIP	B-X
has	B-X
a	B-X
role	B-X
in	B-X
the	B-X
CD40	B-X
signaling	B-X
pathway	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
role	B-X
of	B-X
HOIP	B-X
in	B-X
CD40	B-X
signaling	B-X
,	B-X
we	B-X
used	B-X
somatic	B-X
cell	B-X
gene	B-X
targeting	B-X
to	B-X
generate	B-X
mouse	B-X
B	B-X
cell	B-X
lines	B-X
deficient	B-X
in	B-X
HOIP	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
CD40-induced	B-X
upregulation	B-X
of	B-X
CD80	B-X
and	B-X
activation	B-X
of	B-X
germline	B-X
immunoglobulin	B-X
epsilon	B-X
transcription	B-X
were	B-X
defective	B-X
in	B-X
HOIP-deficient	B-X
cells	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
the	B-X
CD40-mediated	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
c-Jun	B-X
kinase	B-X
was	B-X
impaired	B-X
.	B-X
Recruitment	B-X
of	B-X
IκB	B-X
kinase	B-X
proteins	B-X
to	B-X
the	B-X
CD40	B-X
signaling	B-X
complex	B-X
was	B-X
undetectable	B-X
in	B-X
HOIP-deficient	B-X
cells	B-X
,	B-X
potentially	B-X
explaining	B-X
the	B-X
defect	B-X
in	B-X
NF-κB	B-X
activation	B-X
.	B-X
Restoration	B-X
of	B-X
HOIP	B-X
expression	B-X
reversed	B-X
the	B-X
defects	B-X
in	B-X
cellular	B-X
activation	B-X
and	B-X
signaling	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
HOIP	B-X
as	B-X
a	B-X
key	B-X
component	B-X
of	B-X
the	B-X
CD40	B-X
signaling	B-X
pathway	B-X
.	B-X

CD40	B-Protein
signaling	O
in	O
professional	O
antigen	O
-	O
presenting	O
cells	O
,	O
including	O
B	O
cells	O
,	O
macrophages	O
,	O
and	O
dendritic	O
cells	O
,	O
is	O
critical	O
for	O
the	O
efficient	O
activation	O
of	O
humoral	O
and	O
cell	O
-	O
mediated	O
immune	O
responses	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
,	O
[	O
3	O
]	O
.	O

CD40	B-Protein
signaling	O
is	O
activated	O
in	O
a	O
T	O
cell	O
-	O
dependent	O
manner	O
,	O
as	O
the	O
ligand	O
for	O
CD40	B-Protein
,	O
CD154	B-Protein
,	O
is	O
expressed	O
primarily	O
by	O
activated	O
T	O
cells	O
.	O

CD40	B-Protein
engagement	O
leads	O
to	O
the	O
activation	O
of	O
various	O
signaling	O
molecules	O
,	O
including	O
stress	O
-	O
activated	O
protein	O
kinases	O
and	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
which	O
upregulate	O
the	O
expression	O
of	O
cytokines	O
and	O
other	O
factors	O
that	O
promote	O
immune	O
responses	O
.	O

The	O
mechanism	O
by	O
which	O
CD40	B-Protein
induces	O
these	O
signaling	O
pathways	O
has	O
not	O
been	O
completely	O
defined	O
.	O
<EOS>	B-X
The	B-X
CD40	B-X
receptor	B-X
and	B-X
its	B-X
ligand	B-X
CD40L	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
critical	B-X
molecular	B-X
pairs	B-X
of	B-X
the	B-X
stimulatory	B-X
immune	B-X
checkpoints	B-X
.	B-X
Both	B-X
CD40	B-X
and	B-X
CD40L	B-X
have	B-X
a	B-X
membrane	B-X
form	B-X
and	B-X
a	B-X
soluble	B-X
form	B-X
generated	B-X
by	B-X
proteolytic	B-X
cleavage	B-X
or	B-X
alternative	B-X
splicing	B-X
.	B-X
CD40	B-X
and	B-X
CD40L	B-X
are	B-X
widely	B-X
expressed	B-X
in	B-X
various	B-X
types	B-X
of	B-X
cells	B-X
,	B-X
among	B-X
which	B-X
B	B-X
cells	B-X
and	B-X
myeloid	B-X
cells	B-X
constitutively	B-X
express	B-X
high	B-X
levels	B-X
of	B-X
CD40	B-X
,	B-X
and	B-X
T	B-X
cells	B-X
and	B-X
platelets	B-X
express	B-X
high	B-X
levels	B-X
of	B-X
CD40L	B-X
upon	B-X
activation	B-X
.	B-X
CD40L	B-X
self-assembles	B-X
into	B-X
functional	B-X
trimers	B-X
which	B-X
induce	B-X
CD40	B-X
trimerization	B-X
and	B-X
downstream	B-X
signaling	B-X
.	B-X
The	B-X
canonical	B-X
CD40/CD40L	B-X
signaling	B-X
is	B-X
mediated	B-X
by	B-X
recruitment	B-X
of	B-X
TRAFs	B-X
and	B-X
NF-κB	B-X
activation	B-X
,	B-X
which	B-X
is	B-X
supplemented	B-X
by	B-X
signal	B-X
pathways	B-X
such	B-X
as	B-X
PI3K/AKT	B-X
,	B-X
MAPKs	B-X
and	B-X
JAK3/STATs	B-X
.	B-X
CD40/CD40L	B-X
immune	B-X
checkpoint	B-X
leads	B-X
to	B-X
activation	B-X
of	B-X
both	B-X
innate	B-X
and	B-X
adaptive	B-X
immune	B-X
cells	B-X
via	B-X
two-way	B-X
signaling	B-X
.	B-X
CD40/CD40L	B-X
interaction	B-X
also	B-X
participates	B-X
in	B-X
regulating	B-X
thrombosis	B-X
,	B-X
tissue	B-X
inflammation	B-X
,	B-X
hematopoiesis	B-X
and	B-X
tumor	B-X
cell	B-X
fate	B-X
.	B-X
Because	B-X
of	B-X
its	B-X
essential	B-X
role	B-X
in	B-X
immune	B-X
activation	B-X
,	B-X
CD40/CD40L	B-X
interaction	B-X
has	B-X
been	B-X
regarded	B-X
as	B-X
an	B-X
attractive	B-X
immunotherapy	B-X
target	B-X
.	B-X
In	B-X
recent	B-X
years	B-X
,	B-X
significant	B-X
advance	B-X
has	B-X
been	B-X
made	B-X
in	B-X
CD40/CD40L-targeted	B-X
therapy	B-X
.	B-X
The	B-X
mechanisms	B-X
of	B-X
benefits	B-X
include	B-X
immune	B-X
cell	B-X
activation	B-X
and	B-X
tumor	B-X
cell	B-X
lysis/apoptosis	B-X
in	B-X
malignancies	B-X
,	B-X
or	B-X
immune	B-X
cell	B-X
inactivation	B-X
in	B-X
autoimmune	B-X
diseases	B-X
and	B-X
allograft	B-X
rejection	B-X
.	B-X
This	B-X
review	B-X
provides	B-X
a	B-X
comprehensive	B-X
overview	B-X
of	B-X
the	B-X
structure	B-X
,	B-X
processing	B-X
,	B-X
cellular	B-X
expression	B-X
pattern	B-X
,	B-X
signaling	B-X
and	B-X
effector	B-X
function	B-X
of	B-X
CD40/CD40L	B-X
checkpoint	B-X
molecules	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
summarize	B-X
the	B-X
progress	B-X
,	B-X
targeted	B-X
diseases	B-X
and	B-X
outcomes	B-X
of	B-X
current	B-X
ongoing	B-X
and	B-X
completed	B-X
clinical	B-X
trials	B-X
of	B-X
CD40/CD40L-targeted	B-X
therapy	B-X
.	B-X

The	O
cytoplasmic	O
domain	O
of	O
CD40	B-Protein
does	O
not	O
appear	O
to	O
have	O
intrinsic	O
enzymatic	O
activity	O
,	O
but	O
is	O
able	O
to	O
mediate	O
signaling	O
through	O
the	O
recruitment	O
of	O
several	O
intracellular	O
proteins	O
.	O
<EOS>	B-X
CD40	B-X
provides	B-X
signals	B-X
crucial	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
antigen-presenting	B-X
cells	B-X
during	B-X
humoral	B-X
and	B-X
cell-mediated	B-X
immune	B-X
responses	B-X
.	B-X
A	B-X
complex	B-X
cohort	B-X
of	B-X
proteins	B-X
interacts	B-X
with	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
CD40	B-X
and	B-X
mediates	B-X
signaling	B-X
.	B-X
TRAF6	B-X
contributes	B-X
to	B-X
the	B-X
CD40-mediated	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
,	B-X
stress-activated	B-X
protein	B-X
kinases	B-X
,	B-X
and	B-X
perhaps	B-X
other	B-X
signaling	B-X
molecules	B-X
.	B-X
TRAF6	B-X
may	B-X
have	B-X
roles	B-X
as	B-X
an	B-X
adapter	B-X
molecule	B-X
,	B-X
an	B-X
activator	B-X
of	B-X
mitogen-activated	B-X
protein	B-X
kinases	B-X
,	B-X
and	B-X
as	B-X
a	B-X
repressor	B-X
of	B-X
certain	B-X
signaling	B-X
circuits	B-X
.	B-X
Establishing	B-X
the	B-X
significance	B-X
and	B-X
interplay	B-X
of	B-X
these	B-X
roles	B-X
will	B-X
lead	B-X
to	B-X
a	B-X
more	B-X
complete	B-X
understanding	B-X
of	B-X
mechanisms	B-X
important	B-X
to	B-X
the	B-X
CD40-mediated	B-X
activation	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
and	B-X
will	B-X
reveal	B-X
novel	B-X
targets	B-X
for	B-X
the	B-X
development	B-X
of	B-X
therapeutic	B-X
agents	B-X
.	B-X

Members	O
of	O
the	O
TNF	O
receptor	O
-	O
associated	O
factor	O
(	O
TRAF	O
)	O
family	O
,	O
including	O
TRAF1	B-Protein
,	O
TRAF2	B-Protein
,	O
TRAF3	B-Protein
,	O
and	O
TRAF6	B-Protein
,	O
appear	O
to	O
be	O
particularly	O
important	O
for	O
the	O
initiation	O
and	O
regulation	O
of	O
CD40	B-Protein
signaling	O
[	O
4	O
]	O
.	O

These	O
proteins	O
function	O
in	O
part	O
as	O
adaptor	O
molecules	O
,	O
binding	O
to	O
the	O
cytoplasmic	O
tail	O
of	O
CD40	B-Protein
and	O
recruiting	O
other	O
proteins	O
to	O
the	O
receptor	O
-	O
associated	O
complex	O
.	O

Some	O
of	O
the	O
TRAFs	O
also	O
function	O
as	O
E3	O
ubiquitin	O
ligases	O
,	O
and	O
this	O
enzymatic	O
activity	O
may	O
contribute	O
to	O
signal	O
propagation	O
and	O
regulation	O
.	O

Among	O
the	O
multiple	O
TRAFs	O
that	O
associate	O
with	O
CD40	B-Protein
,	O
TRAF3	B-Protein
can	O
function	O
as	O
a	O
negative	O
regulator	O
of	O
signaling	O
,	O
while	O
TRAF2	B-Protein
and	O
TRAF6	B-Protein
promote	O
the	O
activation	O
of	O
downstream	O
signaling	O
pathways	O
[	O
4	O
]	O
.	O

We	O
recently	O
demonstrated	O
that	O
HOIL	B-Protein
-	I-Protein
1L	I-Protein
interacting	I-Protein
protein	I-Protein
(	O
HOIP	B-Protein
)	O
,	O
a	O
ubiquitin	O
ligase	O
that	O
can	O
catalyze	O
the	O
assembly	O
of	O
linear	O
polyubiquitin	O
chains	O
[	O
5	O
]	O
,	O
is	O
recruited	O
to	O
CD40	B-Protein
in	O
a	O
TRAF2	B-Protein
-	O
dependent	O
manner	O
following	O
engagement	O
of	O
CD40	B-Protein
by	O
agonistic	O
antibody	O
[	O
6	O
]	O
.	O

These	O
and	O
other	O
findings	O
led	O
us	O
to	O
hypothesize	O
that	O
HOIP	B-Protein
functions	O
downstream	O
of	O
TRAF2	B-Protein
in	O
the	O
CD40	B-Protein
signaling	O
pathway	O
and	O
that	O
HOIP	B-Protein
is	O
necessary	O
for	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
possibly	O
other	O
signaling	O
molecules	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
employed	O
somatic	O
cell	O
gene	O
targeting	O
to	O
ablate	O
expression	O
of	O
HOIP	B-Protein
in	O
a	O
mouse	O
B	O
cell	O
line	O
that	O
has	O
proven	O
to	O
be	O
a	O
useful	O
model	O
for	O
B	O
cell	O
CD40	B-Protein
signaling	O
[	O
7	O
]	O
,	O
[	O
8	O
]	O
,	O
[	O
9	O
]	O
.	O

We	O
found	O
that	O
the	O
CD40	B-Protein
-	O
induced	O
upregulation	O
of	O
CD80	B-Protein
(	O
a	O
costimulatory	O
molecule	O
for	O
T	O
cells	O
)	O
was	O
defective	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
.	O

Similarly	O
,	O
the	O
CD40	B-Protein
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
driven	O
production	O
of	O
germline	O
transcripts	O
from	O
the	O
immunoglobulin	O
epsilon	O
heavy	O
chain	O
locus	O
,	O
an	O
event	O
that	O
precedes	O
immunoglobulin	O
gene	O
rearrangement	O
and	O
isotype	O
switching	O
,	O
was	O
defective	O
in	O
the	O
absence	O
of	O
HOIP	B-Protein
.	O

We	O
also	O
found	O
that	O
the	O
CD40	B-Protein
-	O
mediated	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
the	O
stress	O
-	O
activated	O
protein	O
kinase	O
c	O
-	O
Jun	O
kinase	O
(	O
JNK	O
)	O
was	O
defective	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
.	O

Consistent	O
with	O
impaired	O
NF	O
-	O
kappaB	O
activation	O
,	O
association	O
of	O
the	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
complex	O
with	O
CD40	B-Protein
was	O
undetectable	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
.	O

Together	O
,	O
our	O
results	O
indicate	O
that	O
HOIP	B-Protein
plays	O
a	O
critical	O
role	O
in	O
the	O
activation	O
of	O
signaling	O
pathways	O
that	O
regulate	O
cellular	O
responses	O
to	O
CD40	B-Protein
engagement	O
.	O

Generation	O
of	O
HOIP	B-Protein
-	O
deficient	O
B	O
cells	O
via	O
targeted	O
disruption	O
of	O
Rnf31	B-Protein
,	O
the	O
gene	O
encoding	O
HOIP	B-Protein

In	O
our	O
previous	O
study	O
,	O
we	O
demonstrated	O
that	O
HOIP	B-Protein
is	O
recruited	O
to	O
the	O
CD40	O
signaling	O
complex	O
in	O
two	O
mouse	O
B	O
cell	O
lines	O
[	O
6	O
]	O
.	O

Similar	O
results	O
were	O
obtained	O
with	O
mouse	O
splenocytes	O
,	O
indicating	O
that	O
the	O
interaction	O
of	O
CD40	B-Protein
with	O
HOIP	B-Protein
is	O
not	O
limited	O
to	O
transformed	O
B	O
cell	O
lines	O
(	O
unpublished	O
observations	O
)	O
.	O

We	O
also	O
found	O
that	O
the	O
recruitment	O
of	O
HOIP	B-Protein
to	O
CD40	B-Protein
was	O
TRAF2	B-Protein
-	O
dependent	O
and	O
that	O
overexpression	O
of	O
a	O
truncated	O
HOIP	B-Protein
mutant	O
partially	O
inhibited	O
CD40	B-Protein
-	O
mediated	O
NF	O
-	O
kappaB	O
activation	O
.	O

These	O
results	O
support	O
the	O
hypothesis	O
that	O
HOIP	B-Protein
plays	O
a	O
role	O
in	O
CD40	B-Protein
signal	O
transduction	O
.	O

To	O
further	O
define	O
the	O
role	O
and	O
evaluate	O
the	O
importance	O
of	O
HOIP	B-Protein
in	O
CD40	B-Protein
signaling	O
,	O
we	O
used	O
somatic	O
cell	O
gene	O
targeting	O
to	O
disrupt	O
the	O
gene	O
encoding	O
HOIP	B-Protein
in	O
the	O
mouse	O
B	O
cell	O
line	O
A20	O
.	O
2J	O
.	O

This	O
cell	O
line	O
has	O
been	O
particularly	O
useful	O
in	O
the	O
characterization	O
of	O
CD40	B-Protein
signaling	O
mechanisms	O
due	O
to	O
the	O
relative	O
ease	O
with	O
which	O
its	O
genome	O
can	O
be	O
modified	O
by	O
homologous	O
recombination	O
[	O
7	O
]	O
,	O
[	O
8	O
]	O
,	O
[	O
9	O
]	O
.	O

We	O
used	O
a	O
targeting	O
vector	O
capable	O
of	O
undergoing	O
homologous	O
recombination	O
with	O
Rnf31	B-Protein
(	O
the	O
gene	O
encoding	O
HOIP	B-Protein
)	O
to	O
disrupt	O
the	O
coding	O
sequence	O
of	O
the	O
gene	O
in	O
exon	O
5	O
(	O
Fig	O
.	O
1A	O
)	O
.	O

Following	O
introduction	O
of	O
the	O
vector	O
,	O
the	O
neomycin	O
-	O
resistant	O
clones	O
that	O
arose	O
were	O
screened	O
by	O
PCR	O
amplification	O
of	O
genomic	O
DNA	O
to	O
identify	O
cells	O
containing	O
a	O
disrupted	O
Rnf31	B-Protein
allele	O
.	O

To	O
remove	O
the	O
selectable	O
marker	O
gene	O
cassette	O
from	O
the	O
disrupted	O
Rnf31	B-Protein
allele	O
,	O
recombinant	O
cell	O
lines	O
were	O
transiently	O
transfected	O
with	O
a	O
plasmid	O
that	O
encodes	O
Cre	B-Protein
recombinase	I-Protein
.	O

This	O
step	O
allowed	O
us	O
to	O
perform	O
a	O
second	O
round	O
of	O
targeting	O
and	O
drug	O
selection	O
,	O
generating	O
cells	O
in	O
which	O
both	O
copies	O
of	O
Rnf31	B-Protein
were	O
disrupted	O
.	O

Two	O
independent	O
clonal	O
cell	O
lines	O
were	O
chosen	O
for	O
further	O
analysis	O
.	O
<EOS>	B-X
Somatic	B-X
hybrids	B-X
between	B-X
two	B-X
glucocorticoid-resistant	B-X
clonal	B-X
cell	B-X
lines	B-X
,	B-X
CEM	B-X
C1	B-X
and	B-X
ICR-27	B-X
,	B-X
isolated	B-X
independently	B-X
from	B-X
the	B-X
CCRF-CEM	B-X
human	B-X
lymphoblastoid	B-X
cell	B-X
line	B-X
,	B-X
were	B-X
constructed	B-X
to	B-X
investigate	B-X
the	B-X
complementation	B-X
effect	B-X
between	B-X
the	B-X
glucocorticoid	B-X
receptor	B-X
and	B-X
the	B-X
gene	B-X
product	B-X
(	B-X
s	B-X
)	B-X
for	B-X
inducing	B-X
receptor-mediated	B-X
lymphocytolysis	B-X
.	B-X
CEM	B-X
C1	B-X
(	B-X
r+ly-	B-X
)	B-X
has	B-X
a	B-X
normal	B-X
amount	B-X
of	B-X
functional	B-X
glucocorticoid	B-X
receptor	B-X
as	B-X
compared	B-X
to	B-X
the	B-X
steroid-sensitive	B-X
clonal	B-X
line	B-X
CEM	B-X
C7	B-X
.	B-X
)	B-X
,	B-X
which	B-X
was	B-X
originally	B-X
isolated	B-X
following	B-X
mutagenesis	B-X
of	B-X
CEM	B-X
C7	B-X
with	B-X
the	B-X
mutagen	B-X
ICR	B-X
191	B-X
,	B-X
has	B-X
few	B-X
glucocorticoid	B-X
receptors	B-X
as	B-X
determined	B-X
by	B-X
whole-cell	B-X
receptor	B-X
assay	B-X
.	B-X
The	B-X
receptor	B-X
site	B-X
content	B-X
of	B-X
two	B-X
near-tetraploid	B-X
hybrids	B-X
chosen	B-X
for	B-X
analysis	B-X
was	B-X
close	B-X
to	B-X
that	B-X
of	B-X
CEM	B-X
C1	B-X
(	B-X
r+	B-X
)	B-X
.	B-X
Therefore	B-X
,	B-X
CEM	B-X
C1	B-X
cells	B-X
can	B-X
serve	B-X
as	B-X
a	B-X
donor	B-X
of	B-X
human	B-X
glucocorticoid	B-X
receptors	B-X
.	B-X

HOIP	B-Protein
protein	O
expression	O
was	O
undetectable	O
in	O
both	O
cell	O
lines	O
,	O
as	O
determined	O
by	O
Western	O
blot	O
analysis	O
of	O
cell	O
lysates	O
(	O
Fig	O
.	O
1B	O
)	O
,	O
demonstrating	O
that	O
the	O
targeting	O
process	O
was	O
successful	O
.	O

In	O
the	O
text	O
that	O
follows	O
,	O
the	O
two	O
gene	O
-	O
targeted	O
cell	O
lines	O
are	O
referred	O
to	O
as	O
HOIP	B-Protein
-	O
deficient	O
cells	O
.	O

To	O
enable	O
us	O
to	O
confirm	O
that	O
any	O
signaling	O
or	O
functional	O
defects	O
observed	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
were	O
due	O
to	O
disruption	O
of	O
the	O
Rnf31	B-Protein
gene	O
,	O
both	O
HOIP	B-Protein
-	O
deficient	O
cell	O
lines	O
were	O
transduced	O
with	O
a	O
retrovirus	O
encoding	O
FLAG	O
-	O
tagged	O
wild	O
-	O
type	O
HOIP	B-Protein
,	O
thus	O
restoring	O
HOIP	B-Protein
protein	O
expression	O
(	O
Fig	O
.	O
1B	O
)	O
.	O
<EOS>	B-X
Macroautophagy/autophagy	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
various	B-X
human	B-X
diseases	B-X
including	B-X
neurodegenerative	B-X
disorders	B-X
such	B-X
as	B-X
Parkinson	B-X
disease	B-X
(	B-X
PD	B-X
)	B-X
and	B-X
Huntington	B-X
disease	B-X
(	B-X
HD	B-X
)	B-X
.	B-X
Chemical	B-X
autophagy	B-X
inducers	B-X
are	B-X
expected	B-X
to	B-X
serve	B-X
as	B-X
disease-modifying	B-X
agents	B-X
by	B-X
eliminating	B-X
cytotoxic/damaged	B-X
proteins	B-X
.	B-X
Although	B-X
many	B-X
autophagy	B-X
inducers	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
their	B-X
precise	B-X
molecular	B-X
mechanisms	B-X
are	B-X
not	B-X
fully	B-X
understood	B-X
because	B-X
of	B-X
the	B-X
complicated	B-X
crosstalk	B-X
among	B-X
signaling	B-X
pathways	B-X
.	B-X
To	B-X
address	B-X
this	B-X
issue	B-X
,	B-X
we	B-X
performed	B-X
several	B-X
chemical	B-X
genomic	B-X
analyses	B-X
enabling	B-X
us	B-X
to	B-X
comprehend	B-X
the	B-X
dominancy	B-X
among	B-X
the	B-X
autophagy-associated	B-X
pathways	B-X
followed	B-X
by	B-X
an	B-X
aggresome-clearance	B-X
assay	B-X
.	B-X
In	B-X
a	B-X
first	B-X
step	B-X
,	B-X
more	B-X
than	B-X
400	B-X
target-established	B-X
small	B-X
molecules	B-X
were	B-X
assessed	B-X
for	B-X
their	B-X
ability	B-X
to	B-X
activate	B-X
autophagic	B-X
flux	B-X
in	B-X
neuronal	B-X
PC12D	B-X
cells	B-X
,	B-X
and	B-X
we	B-X
identified	B-X
39	B-X
compounds	B-X
as	B-X
autophagy	B-X
inducers	B-X
.	B-X
Our	B-X
principal	B-X
component	B-X
analysis	B-X
(	B-X
PCA	B-X
)	B-X
and	B-X
clustering	B-X
analysis	B-X
using	B-X
a	B-X
dataset	B-X
of	B-X
``	B-X
autophagy	B-X
profiles	B-X
''	B-X
revealed	B-X
that	B-X
two	B-X
Food	B-X
and	B-X
Drug	B-X
Administration	B-X
(	B-X
FDA	B-X
)	B-X
-approved	B-X
drugs	B-X
,	B-X
memantine	B-X
and	B-X
clemastine	B-X
,	B-X
activate	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
stress	B-X
responses	B-X
,	B-X
which	B-X
could	B-X
lead	B-X
to	B-X
autophagy	B-X
induction	B-X
.	B-X
We	B-X
also	B-X
confirmed	B-X
that	B-X
SMK-17	B-X
,	B-X
a	B-X
recently	B-X
identified	B-X
autophagy	B-X
inducer	B-X
,	B-X
induced	B-X
autophagy	B-X
via	B-X
the	B-X
PRKC/PKC-TFEB	B-X
pathway	B-X
,	B-X
as	B-X
had	B-X
been	B-X
predicted	B-X
from	B-X
PCA	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
almost	B-X
all	B-X
of	B-X
the	B-X
autophagy	B-X
inducers	B-X
tested	B-X
in	B-X
this	B-X
present	B-X
work	B-X
significantly	B-X
enhanced	B-X
the	B-X
clearance	B-X
of	B-X
the	B-X
protein	B-X
aggregates	B-X
observed	B-X
in	B-X
cellular	B-X
models	B-X
of	B-X
PD	B-X
and	B-X
HD	B-X
.	B-X
These	B-X
results	B-X
,	B-X
with	B-X
the	B-X
combined	B-X
approach	B-X
,	B-X
suggested	B-X
that	B-X
autophagy-activating	B-X
small	B-X
molecules	B-X
may	B-X
improve	B-X
proteinopathies	B-X
by	B-X
eliminating	B-X
nonfunctional	B-X
protein	B-X
aggregates	B-X
.	B-X

These	O
cells	O
are	O
referred	O
to	O
as	O
HOIP	B-Protein
-	O
reconstituted	O
cells	O
.	O

In	O
the	O
experiments	O
that	O
follow	O
,	O
responses	O
by	O
these	O
cells	O
were	O
compared	O
to	O
those	O
of	O
A20	O
.	O
2J	O
cells	O
and	O
HOIP	B-Protein
-	O
deficient	O
cells	O
transduced	O
with	O
a	O
retroviral	O
vector	O
(	O
pMIP	O
)	O
lacking	O
a	O
cDNA	O
insert	O
(	O
empty	O
vector	O
)	O
.	O

HOIP	B-Protein
is	O
required	O
for	O
CD40	B-Protein
-	O
mediated	O
CD80	B-Protein
upregulation	O
and	O
activation	O
of	O
germline	B-Protein
epsilon	I-Protein
transcription	O

Engagement	O
of	O
CD40	B-Protein
on	O
B	O
cells	O
upregulates	O
expression	O
of	O
CD80	B-Protein
[	O
10	O
]	O
,	O
a	O
cell	O
surface	O
protein	O
that	O
promotes	O
activation	O
of	O
T	O
cells	O
interacting	O
with	O
B	O
cells	O
and	O
other	O
APC	O
.	O

To	O
begin	O
evaluating	O
potential	O
contributions	O
of	O
HOIP	B-Protein
to	O
CD40	B-Protein
signaling	O
,	O
we	O
assayed	O
the	O
upregulation	O
of	O
CD80	B-Protein
induced	O
by	O
engagement	O
of	O
CD40	B-Protein
on	O
parental	O
A20	O
.	O
2J	O
,	O
HOIP	B-Protein
-	O
deficient	O
,	O
and	O
HOIP	B-Protein
-	O
reconstituted	O
cells	O
(	O
Fig	O
.	O
2	O
)	O
.	O

Compared	O
to	O
the	O
parental	O
cell	O
line	O
,	O
the	O
CD40	B-Protein
-	O
stimulated	O
upregulation	O
of	O
CD80	B-Protein
was	O
dramatically	O
reduced	O
in	O
all	O
HOIP	B-Protein
-	O
deficient	O
cells	O
tested	O
.	O

In	O
contrast	O
,	O
upregulation	O
of	O
CD80	B-Protein
was	O
restored	O
in	O
HOIP	B-Protein
-	O
reconstituted	O
cells	O
,	O
confirming	O
that	O
the	O
defect	O
in	O
CD80	B-Protein
upregulation	O
in	O
the	O
HOIP	B-Protein
-	O
deficient	O
cells	O
was	O
due	O
to	O
the	O
disruption	O
of	O
Rnf31	B-Protein
.	O

CD40	B-Protein
signals	O
in	O
B	O
cells	O
can	O
also	O
contribute	O
to	O
the	O
activation	O
of	O
DNA	O
recombination	O
in	O
the	O
immunoglobulin	O
heavy	O
chain	O
locus	O
[	O
11	O
]	O
,	O
[	O
12	O
]	O
.	O

This	O
process	O
,	O
known	O
as	O
immunoglobulin	O
class	O
switching	O
(	O
or	O
isotype	O
switching	O
)	O
,	O
allows	O
B	O
cells	O
,	O
initially	O
expressing	O
IgM	O
,	O
to	O
switch	O
to	O
IgA	O
,	O
IgG	O
,	O
or	O
IgE	O
depending	O
on	O
the	O
class	O
of	O
antibody	O
most	O
appropriate	O
for	O
a	O
particular	O
immune	O
response	O
.	O

Switching	O
to	O
IgE	O
can	O
be	O
induced	O
by	O
the	O
combination	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
CD40	B-Protein
signals	O
.	O
<EOS>	B-X
IL-4	B-X
and	B-X
IFN-gamma	B-X
each	B-X
have	B-X
potent	B-X
effects	B-X
on	B-X
B	B-X
cell	B-X
responses	B-X
as	B-X
well	B-X
as	B-X
strong	B-X
mutual	B-X
antagonism	B-X
.	B-X
Here	B-X
we	B-X
have	B-X
examined	B-X
the	B-X
quantitative	B-X
effects	B-X
of	B-X
these	B-X
cytokines	B-X
on	B-X
CD40	B-X
ligand-induced	B-X
B	B-X
cell	B-X
proliferation	B-X
,	B-X
cell	B-X
survival	B-X
,	B-X
and	B-X
division-linked	B-X
isotype	B-X
switching	B-X
.	B-X
Both	B-X
IL-4	B-X
(	B-X
strongly	B-X
)	B-X
and	B-X
IFN-gamma	B-X
(	B-X
weakly	B-X
)	B-X
enhanced	B-X
the	B-X
number	B-X
of	B-X
B	B-X
cells	B-X
found	B-X
in	B-X
culture	B-X
by	B-X
reducing	B-X
the	B-X
average	B-X
time	B-X
cells	B-X
take	B-X
to	B-X
enter	B-X
the	B-X
first	B-X
division	B-X
cycle	B-X
and	B-X
by	B-X
promoting	B-X
B	B-X
cell	B-X
survival	B-X
.	B-X
When	B-X
added	B-X
in	B-X
combination	B-X
,	B-X
the	B-X
net	B-X
effect	B-X
of	B-X
IL-4	B-X
and	B-X
IFN-gamma	B-X
on	B-X
time	B-X
to	B-X
division	B-X
and	B-X
survival	B-X
was	B-X
a	B-X
response	B-X
intermediate	B-X
between	B-X
that	B-X
of	B-X
the	B-X
two	B-X
cytokines	B-X
alone	B-X
,	B-X
indicating	B-X
a	B-X
partial	B-X
antagonism	B-X
of	B-X
IL-4	B-X
by	B-X
IFN-gamma	B-X
.	B-X
By	B-X
modulating	B-X
both	B-X
time	B-X
to	B-X
division	B-X
and	B-X
cell	B-X
survival	B-X
,	B-X
these	B-X
small	B-X
effects	B-X
of	B-X
IFN-gamma	B-X
are	B-X
amplified	B-X
and	B-X
give	B-X
rise	B-X
to	B-X
large	B-X
reductions	B-X
in	B-X
cell	B-X
number	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
IL-4	B-X
.	B-X
At	B-X
higher	B-X
concentrations	B-X
,	B-X
IFN-gamma	B-X
had	B-X
minor	B-X
inhibitory	B-X
effects	B-X
on	B-X
IL-4-induced	B-X
isotype	B-X
switching	B-X
to	B-X
IgG1	B-X
and	B-X
greater	B-X
effects	B-X
on	B-X
IgE	B-X
.	B-X
A	B-X
reciprocal	B-X
relation	B-X
was	B-X
observed	B-X
between	B-X
the	B-X
ability	B-X
to	B-X
inhibit	B-X
IgE	B-X
at	B-X
late	B-X
cell	B-X
divisions	B-X
vs	B-X
induction	B-X
of	B-X
IgG2a	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
IL-4	B-X
did	B-X
not	B-X
prevent	B-X
switching	B-X
to	B-X
IgG2a	B-X
induced	B-X
by	B-X
IFN-gamma	B-X
alone	B-X
.	B-X
Therefore	B-X
,	B-X
antagonism	B-X
between	B-X
IFN-gamma	B-X
and	B-X
IL-4	B-X
is	B-X
observed	B-X
at	B-X
multiple	B-X
levels	B-X
and	B-X
over	B-X
different	B-X
concentration	B-X
ranges	B-X
,	B-X
resulting	B-X
in	B-X
complex	B-X
net	B-X
outcomes	B-X
.	B-X

The	O
gene	O
rearrangement	O
necessary	O
for	O
IgE	O
production	O
is	O
preceded	O
by	O
the	O
production	O
of	O
non	O
-	O
coding	O
RNA	O
transcripts	O
from	O
germline	O
sequences	O
in	O
the	O
IgE	O
heavy	O
chain	O
locus	O
[	O
13	O
]	O
.	O

To	O
determine	O
whether	O
HOIP	B-Protein
is	O
required	O
in	O
the	O
initiation	O
of	O
the	O
class	O
switching	O
process	O
,	O
the	O
relevant	O
B	O
cell	O
lines	O
were	O
stimulated	O
through	O
CD40	B-Protein
in	O
the	O
presence	O
of	O
IL	B-Protein
-	I-Protein
4	I-Protein
and	O
tested	O
for	O
production	O
of	O
germline	B-Protein
epsilon	I-Protein
(	O
GLepsilon	B-Protein
)	O
transcripts	O
(	O
Fig	O
.	O
3	O
)	O
.	O

Anti	O
-	O
CD40	O
antibody	O
stimulation	O
alone	O
or	O
together	O
with	O
IL	B-Protein
-	I-Protein
4	I-Protein
induced	O
GLepsilon	B-Protein
transcription	O
in	O
parental	O
A20	O
.	O
2J	O
cells	O
as	O
expected	O
.	O
<EOS>	B-X
We	B-X
aimed	B-X
to	B-X
determine	B-X
whether	B-X
stimulating	B-X
antigen-presenting	B-X
cells	B-X
,	B-X
including	B-X
macrophages	B-X
and	B-X
dendritic	B-X
cells	B-X
,	B-X
using	B-X
a	B-X
CD40	B-X
agonist	B-X
could	B-X
improve	B-X
this	B-X
response	B-X
.	B-X
Recent	B-X
success	B-X
in	B-X
cancer	B-X
immunotherapy	B-X
(	B-X
anti-CTLA-4	B-X
,	B-X
anti-PD1/PD-L1	B-X
)	B-X
has	B-X
confirmed	B-X
the	B-X
hypothesis	B-X
that	B-X
the	B-X
immune	B-X
system	B-X
can	B-X
control	B-X
many	B-X
cancers	B-X
across	B-X
various	B-X
histologies	B-X
,	B-X
in	B-X
some	B-X
cases	B-X
producing	B-X
durable	B-X
responses	B-X
in	B-X
a	B-X
way	B-X
not	B-X
seen	B-X
with	B-X
many	B-X
small-molecule	B-X
drugs	B-X
.	B-X
To	B-X
improve	B-X
response	B-X
rates	B-X
and	B-X
to	B-X
overcome	B-X
resistance	B-X
,	B-X
novel	B-X
second-	B-X
and	B-X
third-generation	B-X
immuno-oncology	B-X
drugs	B-X
are	B-X
currently	B-X
evaluated	B-X
in	B-X
ongoing	B-X
phase	B-X
I/II	B-X
trials	B-X
(	B-X
either	B-X
alone	B-X
or	B-X
in	B-X
combination	B-X
)	B-X
including	B-X
novel	B-X
inhibitory	B-X
compounds	B-X
(	B-X
e.g	B-X
.	B-X
CD40	B-X
,	B-X
GITR	B-X
,	B-X
OX40	B-X
,	B-X
CD137	B-X
,	B-X
ICOS	B-X
)	B-X
.	B-X
It	B-X
is	B-X
important	B-X
to	B-X
note	B-X
that	B-X
co-stimulatory	B-X
agents	B-X
strikingly	B-X
differ	B-X
in	B-X
their	B-X
proposed	B-X
mechanism	B-X
of	B-X
action	B-X
compared	B-X
with	B-X
monoclonal	B-X
antibodies	B-X
that	B-X
accomplish	B-X
immune	B-X
activation	B-X
by	B-X
blocking	B-X
negative	B-X
checkpoint	B-X
molecules	B-X
such	B-X
as	B-X
CTLA-4	B-X
or	B-X
PD-1/PD-1	B-X
or	B-X
others	B-X
.	B-X
Concerns	B-X
include	B-X
the	B-X
prospect	B-X
of	B-X
triggering	B-X
cytokine-release	B-X
syndromes	B-X
,	B-X
autoimmune	B-X
reactions	B-X
and	B-X
hyper	B-X
immune	B-X
stimulation	B-X
leading	B-X
to	B-X
activation-induced	B-X
cell	B-X
death	B-X
or	B-X
tolerance	B-X
,	B-X
however	B-X
,	B-X
toxicity	B-X
has	B-X
not	B-X
been	B-X
a	B-X
major	B-X
issue	B-X
in	B-X
the	B-X
clinical	B-X
trials	B-X
reported	B-X
so	B-X
far	B-X
.	B-X
In	B-X
our	B-X
view	B-X
,	B-X
with	B-X
such	B-X
a	B-X
wealth	B-X
of	B-X
potential	B-X
mechanisms	B-X
of	B-X
action	B-X
and	B-X
with	B-X
the	B-X
ability	B-X
to	B-X
fine-tune	B-X
monoclonal	B-X
antibody	B-X
structure	B-X
and	B-X
function	B-X
to	B-X
suit	B-X
particular	B-X
requirements	B-X
,	B-X
the	B-X
second	B-X
and	B-X
third	B-X
wave	B-X
of	B-X
immuno-oncology	B-X
drugs	B-X
are	B-X
likely	B-X
to	B-X
provide	B-X
rapid	B-X
advances	B-X
with	B-X
new	B-X
combinations	B-X
of	B-X
novel	B-X
immunotherapy	B-X
(	B-X
especially	B-X
co-stimulatory	B-X
antibodies	B-X
)	B-X
.	B-X

In	O
contrast	O
,	O
only	O
low	O
levels	O
of	O
GLepsilon	B-Protein
expression	O
were	O
detected	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
stimulated	O
with	O
either	O
anti	O
-	O
CD40	O
antibody	O
alone	O
or	O
anti	O
-	O
CD40	O
and	O
IL	B-Protein
-	I-Protein
4	I-Protein
.	O
<EOS>	B-X
Immunologists	B-X
have	B-X
developed	B-X
a	B-X
range	B-X
of	B-X
in	B-X
vitro	B-X
techniques	B-X
for	B-X
probing	B-X
the	B-X
receptor	B-X
mediated	B-X
response	B-X
of	B-X
cells	B-X
comprising	B-X
the	B-X
immune	B-X
system	B-X
.	B-X
An	B-X
important	B-X
and	B-X
ubiquitous	B-X
method	B-X
is	B-X
the	B-X
use	B-X
of	B-X
antibodies	B-X
in	B-X
either	B-X
soluble	B-X
or	B-X
aggregated	B-X
form	B-X
to	B-X
engage	B-X
cell	B-X
surface	B-X
receptors	B-X
and	B-X
transmit	B-X
a	B-X
signal	B-X
.	B-X
Models	B-X
of	B-X
cell	B-X
and	B-X
molecular	B-X
interactions	B-X
,	B-X
derived	B-X
from	B-X
the	B-X
use	B-X
of	B-X
these	B-X
antibodies	B-X
,	B-X
form	B-X
the	B-X
basis	B-X
of	B-X
our	B-X
efforts	B-X
to	B-X
understand	B-X
and	B-X
explain	B-X
the	B-X
corresponding	B-X
in	B-X
vivo	B-X
systems	B-X
.	B-X
This	B-X
complexity	B-X
is	B-X
illustrated	B-X
here	B-X
using	B-X
B	B-X
cell	B-X
stimulation	B-X
by	B-X
surface	B-X
immunoglobulin	B-X
and	B-X
CD40	B-X
.	B-X
The	B-X
fluorescent	B-X
cell	B-X
labelling	B-X
dye	B-X
carboxyfluorescein	B-X
,	B-X
diacetate	B-X
,	B-X
succinimidyl	B-X
ester	B-X
(	B-X
CFSE	B-X
)	B-X
is	B-X
used	B-X
to	B-X
show	B-X
that	B-X
many	B-X
anti-Ig	B-X
and	B-X
CD40	B-X
stimulatory	B-X
agents	B-X
,	B-X
used	B-X
to	B-X
assess	B-X
the	B-X
role	B-X
of	B-X
B	B-X
cells	B-X
and	B-X
lymphokines	B-X
,	B-X
are	B-X
partial	B-X
agonists	B-X
.	B-X

Normal	O
levels	O
of	O
GLepsilon	B-Protein
expression	O
were	O
induced	O
in	O
HOIP	B-Protein
-	O
reconstituted	O
cells	O
stimulated	O
with	O
anti	O
-	O
CD40	O
antibody	O
alone	O
or	O
together	O
with	O
IL	B-Protein
-	I-Protein
4	I-Protein
.	O
<EOS>	B-X
Tissue	B-X
repair	B-X
is	B-X
a	B-X
subset	B-X
of	B-X
a	B-X
broad	B-X
repertoire	B-X
of	B-X
interleukin-4	B-X
(	B-X
IL-4	B-X
)	B-X
-	B-X
and	B-X
IL-13-dependent	B-X
host	B-X
responses	B-X
during	B-X
helminth	B-X
infection	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
IL-4	B-X
or	B-X
IL-13	B-X
alone	B-X
was	B-X
not	B-X
sufficient	B-X
,	B-X
but	B-X
IL-4	B-X
or	B-X
IL-13	B-X
together	B-X
with	B-X
apoptotic	B-X
cells	B-X
induced	B-X
the	B-X
tissue	B-X
repair	B-X
program	B-X
in	B-X
macrophages	B-X
.	B-X
Genetic	B-X
ablation	B-X
of	B-X
sensors	B-X
of	B-X
apoptotic	B-X
cells	B-X
impaired	B-X
the	B-X
proliferation	B-X
of	B-X
tissue-resident	B-X
macrophages	B-X
and	B-X
the	B-X
induction	B-X
of	B-X
anti-inflammatory	B-X
and	B-X
tissue	B-X
repair	B-X
genes	B-X
in	B-X
the	B-X
lungs	B-X
after	B-X
helminth	B-X
infection	B-X
or	B-X
in	B-X
the	B-X
gut	B-X
after	B-X
induction	B-X
of	B-X
colitis	B-X
.	B-X
By	B-X
contrast	B-X
,	B-X
the	B-X
recognition	B-X
of	B-X
apoptotic	B-X
cells	B-X
was	B-X
dispensable	B-X
for	B-X
cytokine-dependent	B-X
induction	B-X
of	B-X
pattern	B-X
recognition	B-X
receptor	B-X
,	B-X
cell	B-X
adhesion	B-X
,	B-X
or	B-X
chemotaxis	B-X
genes	B-X
in	B-X
macrophages	B-X
.	B-X
Detection	B-X
of	B-X
apoptotic	B-X
cells	B-X
can	B-X
therefore	B-X
spatially	B-X
compartmentalize	B-X
or	B-X
prevent	B-X
premature	B-X
or	B-X
ectopic	B-X
activity	B-X
of	B-X
pleiotropic	B-X
,	B-X
soluble	B-X
cytokines	B-X
such	B-X
as	B-X
IL-4	B-X
or	B-X
IL-13	B-X
.	B-X

Collectively	O
,	O
these	O
data	O
demonstrate	O
that	O
HOIP	B-Protein
has	O
a	O
critical	O
role	O
in	O
cellular	O
responses	O
to	O
CD40	B-Protein
signaling	O
.	O

HOIP	B-Protein
mediates	O
CD40	B-Protein
-	O
stimulated	O
NF	O
-	O
kappaB	O
and	O
JNK	O
activation	O

The	O
results	O
described	O
above	O
show	O
that	O
HOIP	B-Protein
plays	O
an	O
important	O
role	O
in	O
CD40	B-Protein
-	O
mediated	O
effector	O
functions	O
of	O
B	O
cells	O
.	O

It	O
follows	O
that	O
HOIP	B-Protein
is	O
likely	O
a	O
key	O
mediator	O
of	O
CD40	B-Protein
signaling	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
stimulated	O
A20	O
.	O
2J	O
and	O
HOIP	O
-	O
deficient	O
cells	O
with	O
CD154	B-Protein
(	O
CD40	B-Protein
ligand	I-Protein
)	O
expressed	O
by	O
HI5	O
insect	O
cells	O
[	O
7	O
]	O
,	O
[	O
8	O
]	O
and	O
measured	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
and	O
JNK	O
pathways	O
,	O
two	O
of	O
the	O
major	O
transcriptional	O
regulators	O
activated	O
by	O
CD40	B-Protein
[	O
4	O
]	O
.	O

Cell	O
-	O
associated	O
CD154	B-Protein
was	O
used	O
as	O
the	O
stimulus	O
in	O
these	O
experiments	O
as	O
it	O
typically	O
provides	O
more	O
robust	O
,	O
and	O
therefore	O
more	O
readily	O
detected	O
,	O
activation	O
signals	O
than	O
does	O
anti	O
-	O
CD40	O
antibody	O
.	O

Activation	O
of	O
the	O
canonical	O
NF	O
-	O
kappaB	O
pathway	O
is	O
initiated	O
with	O
the	O
phosphorylation	O
of	O
IkappaB	O
proteins	O
by	O
the	O
IkappaB	O
kinase	O
complex	O
(	O
IKK	O
)	O
.	O
<EOS>	B-X
The	B-X
K63-Ub	B-X
chains	B-X
,	B-X
which	B-X
are	B-X
formed	B-X
by	B-X
the	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
TRAF6	B-X
,	B-X
Pellino1	B-X
and	B-X
Pellino2	B-X
,	B-X
activate	B-X
TAK1	B-X
,	B-X
the	B-X
master	B-X
kinase	B-X
that	B-X
switches	B-X
on	B-X
mitogen-activated	B-X
protein	B-X
(	B-X
MAP	B-X
)	B-X
kinase	B-X
cascades	B-X
and	B-X
initiates	B-X
activation	B-X
of	B-X
the	B-X
canonical	B-X
IκB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
complex	B-X
.	B-X
The	B-X
M1-Ub	B-X
chains	B-X
,	B-X
which	B-X
are	B-X
formed	B-X
by	B-X
the	B-X
linear	B-X
ubiquitin	B-X
chain	B-X
assembly	B-X
complex	B-X
(	B-X
LUBAC	B-X
)	B-X
,	B-X
bind	B-X
to	B-X
the	B-X
NEMO	B-X
(	B-X
NF-κB	B-X
essential	B-X
modulator	B-X
)	B-X
component	B-X
of	B-X
the	B-X
IKK	B-X
complex	B-X
and	B-X
are	B-X
required	B-X
for	B-X
TAK1	B-X
to	B-X
activate	B-X
IKKs	B-X
,	B-X
but	B-X
not	B-X
MAP	B-X
kinases	B-X
.	B-X
An	B-X
essential	B-X
E3	B-X
ligase-independent	B-X
role	B-X
of	B-X
TRAF6	B-X
is	B-X
to	B-X
recruit	B-X
LUBAC	B-X
into	B-X
the	B-X
MyD88	B-X
signalling	B-X
complex	B-X
,	B-X
where	B-X
it	B-X
recognises	B-X
preformed	B-X
K63-Ub	B-X
chains	B-X
attached	B-X
to	B-X
protein	B-X
components	B-X
of	B-X
these	B-X
complexes	B-X
,	B-X
such	B-X
as	B-X
IRAK1	B-X
(	B-X
IL-1	B-X
receptor-associated	B-X
kinase	B-X
)	B-X
,	B-X
producing	B-X
ubiquitin	B-X
chains	B-X
containing	B-X
both	B-X
types	B-X
of	B-X
linkage	B-X
,	B-X
termed	B-X
K63/M1-Ub	B-X
hybrids	B-X
.	B-X
The	B-X
formation	B-X
of	B-X
K63/M1-Ub	B-X
hybrids	B-X
,	B-X
which	B-X
is	B-X
a	B-X
feature	B-X
of	B-X
several	B-X
innate	B-X
immune	B-X
signalling	B-X
pathways	B-X
,	B-X
permits	B-X
the	B-X
co-recruitment	B-X
of	B-X
proteins	B-X
that	B-X
interact	B-X
with	B-X
either	B-X
K63-Ub	B-X
or	B-X
M1-Ub	B-X
chains	B-X
.	B-X
Two	B-X
likely	B-X
roles	B-X
for	B-X
K63/M1-Ub	B-X
hybrids	B-X
are	B-X
to	B-X
facilitate	B-X
the	B-X
TAK1-dependent	B-X
activation	B-X
of	B-X
the	B-X
IKK	B-X
complex	B-X
and	B-X
to	B-X
prevent	B-X
the	B-X
hyperactivation	B-X
of	B-X
these	B-X
kinases	B-X
by	B-X
recruiting	B-X
A20	B-X
and	B-X
A20-binding	B-X
inhibitor	B-X
of	B-X
NF-κB1	B-X
(	B-X
ABIN1	B-X
)	B-X
.	B-X
These	B-X
proteins	B-X
restrict	B-X
activation	B-X
of	B-X
the	B-X
TAK1	B-X
and	B-X
IKK	B-X
complexes	B-X
,	B-X
probably	B-X
by	B-X
competing	B-X
with	B-X
them	B-X
for	B-X
binding	B-X
to	B-X
K63/M1-Ub	B-X
hybrids	B-X
.	B-X
The	B-X
IKK-catalysed	B-X
phosphorylation	B-X
of	B-X
some	B-X
of	B-X
its	B-X
substrates	B-X
permits	B-X
their	B-X
recognition	B-X
by	B-X
the	B-X
E3	B-X
ligase	B-X
SCF	B-X

In	O
resting	O
cells	O
,	O
IkappaB	O
proteins	O
are	O
responsible	O
for	O
sequestering	O
NF	B-Protein
-	I-Protein
kappaB	I-Protein
subunits	I-Protein
in	O
the	O
cytoplasm	O
.	O

Phosphorylation	O
by	O
the	O
IKK	O
complex	O
targets	O
IkappaB	O
proteins	O
for	O
ubiquitination	O
and	O
degradation	O
,	O
allowing	O
NF	O
-	O
kappaB	O
to	O
enter	O
the	O
nucleus	O
and	O
activate	O
gene	O
expression	O
.	O

CD40	B-Protein
-	O
mediated	O
phosphorylation	O
and	O
degradation	O
of	O
IkappaBalpha	B-Protein
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
was	O
dramatically	O
impaired	O
relative	O
to	O
that	O
observed	O
in	O
parental	O
A20	O
.	O
2J	O
cells	O
(	O
Fig	O
.	O
4	O
)	O
.	O

We	O
also	O
assayed	O
activation	O
of	O
the	O
stress	O
-	O
activated	O
protein	O
kinase	O
JNK	O
in	O
response	O
to	O
CD40	B-Protein
engagement	O
(	O
Fig	O
.	O
4	O
)	O
.	O

CD40	B-Protein
-	O
mediated	O
JNK	O
activation	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
was	O
impaired	O
as	O
measured	O
by	O
phosphorylation	O
of	O
Thr183	O
and	O
Tyr185	O
in	O
JNK	O
.	O

CD40	B-Protein
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
JNK	O
in	O
HOIP	B-Protein
-	O
reconstituted	O
cells	O
was	O
normal	O
,	O
demonstrating	O
that	O
the	O
defects	O
observed	O
in	O
gene	O
-	O
deficient	O
cells	O
were	O
due	O
to	O
the	O
absence	O
of	O
HOIP	B-Protein
expression	O
.	O

HOIP	B-Protein
is	O
necessary	O
for	O
association	O
of	O
the	O
IKK	O
complex	O
with	O
CD40	B-Protein

The	O
marked	O
defects	O
in	O
CD40	B-Protein
-	O
mediated	O
cell	O
activation	O
and	O
signaling	O
displayed	O
by	O
HOIP	B-Protein
-	O
deficient	O
cells	O
suggested	O
that	O
HOIP	B-Protein
mediates	O
recruitment	O
of	O
critical	O
components	O
of	O
the	O
CD40	O
signaling	O
apparatus	O
to	O
the	O
receptor	O
.	O

Previously	O
,	O
we	O
demonstrated	O
that	O
HOIP	B-Protein
is	O
recruited	O
to	O
the	O
CD40	O
signaling	O
complex	O
in	O
a	O
TRAF2	B-Protein
-	O
dependent	O
manner	O
,	O
suggesting	O
that	O
HOIP	B-Protein
functions	O
downstream	O
of	O
TRAF2	B-Protein
[	O
6	O
]	O
.	O

Studies	O
by	O
others	O
suggest	O
that	O
the	O
TRAF2	B-Protein
-	O
associated	O
proteins	O
cIAP1	B-Protein
and	O
cIAP2	B-Protein
play	O
a	O
role	O
in	O
the	O
recruitment	O
of	O
HOIP	B-Protein
to	O
TNFR1	B-Protein
and	O
CD40	B-Protein
[	O
14	O
]	O
.	O

Therefore	O
,	O
we	O
determined	O
whether	O
the	O
association	O
of	O
HOIP	B-Protein
with	O
CD40	B-Protein
in	O
A20	O
.	O
2J	O
cells	O
was	O
altered	O
by	O
treatment	O
of	O
cells	O
with	O
an	O
inhibitor	O
of	O
cIAP	O
activity	O
,	O
a	O
membrane	O
-	O
permeable	O
peptide	O
derived	O
from	O
the	O
apoptosis	O
regulator	O
SMAC	O
[	O
15	O
]	O
.	O

We	O
found	O
that	O
pretreatment	O
of	O
cells	O
with	O
the	O
SMAC	O
peptide	O
dramatically	O
reduced	O
the	O
amount	O
of	O
cIAP1	B-Protein
associated	O
with	O
the	O
CD40	O
signaling	O
complex	O
in	O
cells	O
stimulated	O
with	O
anti	O
-	O
CD40	O
antibody	O
-	O
coated	O
beads	O
(	O
Fig	O
.	O
5A	O
)	O
.	O

SMAC	O
peptide	O
treatment	O
also	O
resulted	O
in	O
a	O
slight	O
but	O
reproducible	O
decrease	O
in	O
the	O
amount	O
of	O
the	O
major	O
HOIP	B-Protein
form	O
recovered	O
by	O
CD40	B-Protein
immunoprecipitation	O
,	O
along	O
with	O
an	O
apparent	O
increase	O
in	O
higher	O
molecular	O
weight	O
species	O
recognized	O
by	O
anti	O
-	O
HOIP	O
antibody	O
.	O

In	O
contrast	O
,	O
treatment	O
with	O
the	O
SMAC	O
peptide	O
did	O
not	O
alter	O
the	O
amount	O
or	O
molecular	O
weight	O
of	O
HOIP	B-Protein
present	O
in	O
cell	O
lysates	O
.	O
<EOS>	B-X
In	B-X
contrast	B-X
to	B-X
CD4+	B-X
T	B-X
cells	B-X
,	B-X
HIV-Mφ	B-X
are	B-X
resistant	B-X
to	B-X
the	B-X
cytopathic	B-X
effects	B-X
of	B-X
acute	B-X
HIV	B-X
infection	B-X
and	B-X
have	B-X
increased	B-X
expression	B-X
of	B-X
cell	B-X
survival	B-X
factors	B-X
,	B-X
including	B-X
X-linked	B-X
inhibitor	B-X
of	B-X
apoptosis	B-X
(	B-X
XIAP	B-X
)	B-X
,	B-X
baculoviral	B-X
IAP	B-X
repeat	B-X
containing	B-X
(	B-X
BIRC	B-X
)	B-X
2/cIAP1	B-X
,	B-X
beclin-1	B-X
,	B-X
BCL2	B-X
,	B-X
BCL-xl	B-X
,	B-X
triggering	B-X
receptor	B-X
expressed	B-X
on	B-X
myeloid	B-X
cells	B-X
1	B-X
,	B-X
mitofusin	B-X
(	B-X
MFN	B-X
)	B-X
1	B-X
,	B-X
and	B-X
MFN2	B-X
.	B-X
DIABLO/SMAC	B-X
mimetics	B-X
are	B-X
therapeutic	B-X
agents	B-X
that	B-X
affect	B-X
cancer	B-X
cell	B-X
survival	B-X
and	B-X
induce	B-X
cell	B-X
death	B-X
.	B-X
We	B-X
found	B-X
that	B-X
DIABLO/SMAC	B-X
mimetics	B-X
(	B-X
LCL-161	B-X
,	B-X
AT-406	B-X
(	B-X
also	B-X
known	B-X
as	B-X
SM-406	B-X
or	B-X
Debio	B-X
1143	B-X
)	B-X
,	B-X
and	B-X
birinapant	B-X
)	B-X
selectively	B-X
kill	B-X
HIV-Mφ	B-X
without	B-X
increasing	B-X
bystander	B-X
cell	B-X
death	B-X
.	B-X
DIABLO/SMAC	B-X
mimetic	B-X
treatment	B-X
of	B-X
HIV-Mφ-induced	B-X
XIAP	B-X
and	B-X
BIRC2	B-X
degradation	B-X
,	B-X
leading	B-X
to	B-X
the	B-X
induction	B-X
of	B-X
autophagy	B-X
and	B-X
the	B-X
formation	B-X
of	B-X
a	B-X
death-inducing	B-X
signaling	B-X
complex	B-X
on	B-X
phagophore	B-X
membranes	B-X
that	B-X
includes	B-X
both	B-X
pro-apoptotic	B-X
or	B-X
necroptotic	B-X
(	B-X
FADD	B-X
,	B-X
receptor-interacting	B-X
protein	B-X
kinase	B-X
(	B-X
RIPK	B-X
)	B-X
1	B-X
,	B-X
RIPK3	B-X
,	B-X
caspase	B-X
8	B-X
,	B-X
and	B-X
MLKL	B-X
)	B-X
and	B-X
autophagy	B-X
(	B-X
ATG5	B-X
,	B-X
ATG7	B-X
,	B-X
and	B-X
SQSTM1	B-X
)	B-X
proteins	B-X
.	B-X
Furthermore	B-X
,	B-X
DIABLO/SMAC	B-X
mimetic-mediated	B-X
apoptosis	B-X
of	B-X
HIV-Mφ	B-X
is	B-X
dependent	B-X
upon	B-X
tumor	B-X
necrosis	B-X
factor	B-X
signaling	B-X
.	B-X
Our	B-X
findings	B-X
thus	B-X
demonstrate	B-X
that	B-X
DIABLO/SMAC	B-X
mimetics	B-X
selectively	B-X
induce	B-X
autophagy-dependent	B-X
apoptosis	B-X
in	B-X
HIV-Mφ	B-X
.	B-X

These	O
data	O
suggest	O
that	O
SMAC	O
peptide	O
treatment	O
specifically	O
alters	O
the	O
characteristics	O
of	O
CD40	B-Protein
-	O
associated	O
HOIP	B-Protein
rather	O
than	O
the	O
entire	O
cellular	O
pool	O
of	O
this	O
protein	O
.	O

Together	O
,	O
these	O
results	O
support	O
the	O
idea	O
that	O
the	O
cIAP	B-Protein
proteins	O
influence	O
the	O
recruitment	O
and	O
post	O
-	O
translational	O
modification	O
state	O
of	O
CD40	B-Protein
-	O
associated	O
HOIP	B-Protein
.	O

To	O
test	O
the	O
possibility	O
that	O
HOIP	B-Protein
is	O
responsible	O
for	O
the	O
recruitment	O
of	O
other	O
critical	O
signaling	O
proteins	O
to	O
CD40	B-Protein
,	O
we	O
immunoprecipitated	O
CD40	O
signaling	O
complexes	O
from	O
HOIP	B-Protein
-	O
deficient	O
and	O
HOIP	B-Protein
-	O
reconstituted	O
cells	O
(	O
Fig	O
.	O
5B	O
)	O
.	O

As	O
described	O
previously	O
,	O
CD40	O
signaling	O
complexes	O
immunoprecipitated	O
from	O
A20	O
.	O
2J	O
cells	O
contained	O
HOIP	B-Protein
as	O
well	O
as	O
TRAF2	B-Protein
,	O
TRAF3	B-Protein
,	O
IKKalpha	B-Protein
/	O
beta	B-Protein
,	O
and	O
IKKgamma	B-Protein
[	O
6	O
]	O
.	O

The	O
amounts	O
of	O
TRAF2	B-Protein
,	O
TRAF3	B-Protein
,	O
and	O
cIAP1	B-Protein
in	O
CD40	B-Protein
immunoprecipitates	O
from	O
HOIP	B-Protein
-	O
deficient	O
cells	O
were	O
similar	O
to	O
those	O
from	O
parental	O
A20	O
.	O
2J	O
cells	O
,	O
indicating	O
that	O
HOIP	B-Protein
is	O
not	O
required	O
for	O
the	O
association	O
of	O
these	O
proteins	O
with	O
CD40	B-Protein
.	O

In	O
contrast	O
,	O
IKKalpha	B-Protein
/	O
beta	B-Protein
and	O
IKKgamma	B-Protein
were	O
not	O
detectable	O
in	O
CD40	B-Protein
immunoprecipitates	O
recovered	O
from	O
HOIP	B-Protein
-	O
deficient	O
cells	O
(	O
Fig	O
.	O
5B	O
,	O
C	O
)	O
.	O
<EOS>	B-X
The	B-X
IKKbeta	B-X
and	B-X
NEMO/IKKgamma	B-X
subunits	B-X
of	B-X
the	B-X
NF-kappaB-activating	B-X
signalsome	B-X
complex	B-X
are	B-X
known	B-X
to	B-X
be	B-X
essential	B-X
for	B-X
activating	B-X
NF-kappaB	B-X
by	B-X
inflammatory	B-X
and	B-X
other	B-X
stress-like	B-X
stimuli	B-X
.	B-X
However	B-X
,	B-X
the	B-X
IKKalpha	B-X
subunit	B-X
is	B-X
believed	B-X
to	B-X
be	B-X
dispensable	B-X
for	B-X
the	B-X
latter	B-X
responses	B-X
and	B-X
instead	B-X
functions	B-X
as	B-X
an	B-X
in	B-X
vivo	B-X
mediator	B-X
of	B-X
other	B-X
novel	B-X
NF-kappaB-dependent	B-X
and	B-X
-independent	B-X
functions	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
this	B-X
generally	B-X
accepted	B-X
view	B-X
of	B-X
IKKalpha	B-X
's	B-X
physiological	B-X
functions	B-X
,	B-X
we	B-X
demonstrate	B-X
in	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
(	B-X
MEFs	B-X
)	B-X
that	B-X
,	B-X
akin	B-X
to	B-X
IKKbeta	B-X
and	B-X
NEMO/IKKgamma	B-X
,	B-X
IKKalpha	B-X
is	B-X
also	B-X
a	B-X
global	B-X
regulator	B-X
of	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha-	B-X
and	B-X
IL-1-responsive	B-X
IKK	B-X
signalsome-dependent	B-X
target	B-X
genes	B-X
including	B-X
many	B-X
known	B-X
NF-kappaB	B-X
targets	B-X
such	B-X
as	B-X
serum	B-X
amyloid	B-X
A3	B-X
,	B-X
C3	B-X
,	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-6	B-X
,	B-X
IL-11	B-X
,	B-X
IL-1	B-X
receptor	B-X
antagonist	B-X
,	B-X
vascular	B-X
endothelial	B-X
growth	B-X
factor	B-X
,	B-X
Ptx3	B-X
,	B-X
beta	B-X
(	B-X
2	B-X
)	B-X
-microglobulin	B-X
,	B-X
IL-1alpha	B-X
,	B-X
Mcp-1	B-X
and	B-X
-3	B-X
,	B-X
RANTES	B-X
(	B-X
regulated	B-X
on	B-X
activation	B-X
normal	B-X
T	B-X
cell	B-X
expressed	B-X
and	B-X
secreted	B-X
)	B-X
,	B-X
Fas	B-X
antigen	B-X
,	B-X
Jun-B	B-X
,	B-X
c-Fos	B-X
,	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
,	B-X
and	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
.	B-X
Only	B-X
a	B-X
small	B-X
number	B-X
of	B-X
NF-kappaB-dependent	B-X
target	B-X
genes	B-X
were	B-X
preferentially	B-X
dependent	B-X
on	B-X
IKKalpha	B-X
or	B-X
IKKbeta	B-X
.	B-X
Constitutive	B-X
expression	B-X
of	B-X
a	B-X
trans-dominant	B-X
IkappaBalpha	B-X
superrepressor	B-X
(	B-X
IkappaBalphaSR	B-X
)	B-X
in	B-X
wild	B-X
type	B-X
MEFs	B-X
confirmed	B-X
that	B-X
these	B-X
signalsome-dependent	B-X
target	B-X
genes	B-X
were	B-X
also	B-X
dependent	B-X
on	B-X
NF-kappaB	B-X
.	B-X
Overall	B-X
,	B-X
a	B-X
sizable	B-X
number	B-X
of	B-X
novel	B-X
NF-kappaB/IKK-dependent	B-X
genes	B-X
were	B-X
identified	B-X
including	B-X
Secreted	B-X
Frizzled	B-X
,	B-X
cadherin	B-X
13	B-X
,	B-X
protocadherin	B-X
7	B-X
,	B-X
CCAAT/enhancer-binding	B-X
protein-beta	B-X
and	B-X
-delta	B-X
,	B-X
osteoprotegerin	B-X
,	B-X
FOXC2	B-X
and	B-X
FOXF2	B-X
,	B-X
BMP-2	B-X
,	B-X
p75	B-X
neurotrophin	B-X
receptor	B-X
,	B-X
caspase-11	B-X
,	B-X
guanylate-binding	B-X
proteins	B-X
1	B-X
and	B-X
2	B-X
,	B-X
ApoJ/clusterin	B-X
,	B-X
interferon	B-X
(	B-X
alpha	B-X
and	B-X
beta	B-X
)	B-X
receptor	B-X
2	B-X
,	B-X
decorin	B-X
,	B-X
osteoglycin	B-X
,	B-X
epiregulin	B-X
,	B-X
proliferins	B-X
2	B-X
and	B-X
3	B-X
,	B-X
stromal	B-X
cell-derived	B-X
factor	B-X
,	B-X
and	B-X
cathepsins	B-X
B	B-X
,	B-X
F	B-X
,	B-X
and	B-X
Z.	B-X
SOCS-3	B-X
,	B-X
a	B-X
negative	B-X
effector	B-X
of	B-X
STAT3	B-X
signaling	B-X
,	B-X
was	B-X
found	B-X
to	B-X
be	B-X
an	B-X
NF-kappaB/IKK-induced	B-X
gene	B-X
,	B-X
suggesting	B-X
that	B-X
IKK-mediated	B-X
NF-kappaB	B-X
activation	B-X
can	B-X
coordinately	B-X
illicit	B-X
negative	B-X
effects	B-X
on	B-X
STAT	B-X
signaling	B-X
.	B-X

The	O
amounts	O
of	O
IKKalpha	B-Protein
/	O
beta	B-Protein
and	O
IKKgamma	B-Protein
in	O
CD40	B-Protein
immunoprecipitates	O
from	O
HOIP	B-Protein
-	O
reconstituted	O
cells	O
were	O
similar	O
to	O
those	O
detected	O
in	O
samples	O
prepared	O
from	O
parental	O
cells	O
,	O
demonstrating	O
that	O
the	O
defects	O
in	O
IKK	O
recruitment	O
we	O
observed	O
were	O
due	O
specifically	O
to	O
the	O
absence	O
of	O
HOIP	B-Protein
expression	O
.	O

These	O
data	O
indicate	O
that	O
HOIP	B-Protein
is	O
required	O
for	O
recruitment	O
of	O
the	O
NF	O
-	O
kappaB	O
-	O
activating	O
complex	O
to	O
the	O
CD40	O
signaling	O
complex	O
.	O

As	O
shown	O
here	O
and	O
in	O
our	O
previous	O
study	O
[	O
6	O
]	O
,	O
IKKgamma	B-Protein
present	O
in	O
CD40	B-Protein
immunoprecipitates	O
appears	O
to	O
have	O
a	O
higher	O
molecular	O
weight	O
than	O
that	O
found	O
in	O
cell	O
lysates	O
.	O

To	O
confirm	O
that	O
this	O
higher	O
molecular	O
weight	O
species	O
was	O
indeed	O
IKKgamma	B-Protein
,	O
we	O
generated	O
A20	O
.	O
2J	O
cell	O
lines	O
containing	O
a	O
stably	O
integrated	O
retroviral	O
vector	O
that	O
encoded	O
an	O
epitope	O
-	O
tagged	O
version	O
of	O
mouse	O
IKKgamma	B-Protein
.	O

Cell	O
lysates	O
and	O
CD40	B-Protein
immunoprecipitates	O
prepared	O
from	O
these	O
cells	O
were	O
analyzed	O
by	O
Western	O
blotting	O
for	O
the	O
epitope	O
tag	O
(	O
Fig	O
.	O
5C	O
)	O
.	O

This	O
analysis	O
produced	O
a	O
pattern	O
of	O
bands	O
that	O
was	O
essentially	O
the	O
same	O
as	O
that	O
obtained	O
using	O
an	O
antibody	O
specific	O
for	O
native	O
IKKgamma	B-Protein
(	O
compare	O
panels	O
B	O
and	O
C	O
in	O
Fig	O
.	O
5	O
)	O
.	O

Moreover	O
,	O
analysis	O
of	O
cells	O
expressing	O
epitope	O
tagged	O
-	O
IKKgamma	B-Protein
confirmed	O
that	O
recruitment	O
of	O
IKKgamma	B-Protein
to	O
CD40	B-Protein
requires	O
HOIP	B-Protein
.	O

To	O
determine	O
what	O
was	O
responsible	O
for	O
the	O
increased	O
molecular	O
weight	O
of	O
IKKgamma	B-Protein
in	O
CD40	B-Protein
immunoprecipitates	O
,	O
the	O
protein	O
samples	O
were	O
incubated	O
with	O
lambda	O
phosphatase	O
,	O
which	O
removes	O
phosphates	O
attached	O
to	O
tyrosine	O
,	O
threonine	O
,	O
or	O
serine	O
residues	O
in	O
proteins	O
.	O
<EOS>	B-X
Antibiotic	B-X
resistance	B-X
in	B-X
gram-negative	B-X
bacteria	B-X
has	B-X
emerged	B-X
as	B-X
a	B-X
major	B-X
health	B-X
threat	B-X
that	B-X
occurs	B-X
because	B-X
these	B-X
bacteria	B-X
actively	B-X
produce	B-X
β-lactamases	B-X
responsible	B-X
for	B-X
the	B-X
inactivation	B-X
of	B-X
β-lactam	B-X
antibiotics	B-X
.	B-X
Currently	B-X
,	B-X
numerous	B-X
three-dimensional	B-X
structures	B-X
of	B-X
serine	B-X
and	B-X
metallo-β-lactamases	B-X
have	B-X
been	B-X
solved	B-X
.	B-X
The	B-X
serine	B-X
β-lactamases	B-X
essentially	B-X
consist	B-X
of	B-X
two	B-X
structural	B-X
domains	B-X
(	B-X
an	B-X
all	B-X
α	B-X
and	B-X
an	B-X
α/β	B-X
domain	B-X
)	B-X
and	B-X
the	B-X
active	B-X
site	B-X
is	B-X
located	B-X
at	B-X
the	B-X
groove	B-X
between	B-X
the	B-X
two	B-X
domains	B-X
.	B-X
The	B-X
catalysis	B-X
of	B-X
serine	B-X
β-lactamase	B-X
proceeds	B-X
via	B-X
acylation	B-X
and	B-X
deacylation	B-X
reactions	B-X
.	B-X
Keeping	B-X
the	B-X
above	B-X
views	B-X
in	B-X
mind	B-X
,	B-X
in	B-X
this	B-X
review	B-X
we	B-X
have	B-X
shed	B-X
light	B-X
on	B-X
the	B-X
current	B-X
knowledge	B-X
of	B-X
the	B-X
structures	B-X
and	B-X
mechanisms	B-X
of	B-X
catalysis	B-X
of	B-X
serine	B-X
and	B-X
metallo-β-lactamases	B-X
.	B-X
Moreover	B-X
,	B-X
mutational	B-X
studies	B-X
on	B-X
β-lactamases	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
active	B-X
site	B-X
residues	B-X
and	B-X
residues	B-X
in	B-X
the	B-X
vicinity	B-X
to	B-X
the	B-X
active	B-X
site	B-X
pocket	B-X
in	B-X
the	B-X
catalysis	B-X
.	B-X

This	O
treatment	O
reduced	O
much	O
of	O
CD40	B-Protein
-	O
associated	O
IKKgamma	B-Protein
to	O
an	O
apparent	O
molecular	O
weight	O
similar	O
to	O
that	O
of	O
the	O
protein	O
in	O
cell	O
lysates	O
(	O
Fig	O
.	O
5C	O
)	O
.	O

However	O
,	O
at	O
least	O
one	O
band	O
of	O
significantly	O
higher	O
molecular	O
weight	O
remained	O
after	O
phosphatase	O
treatment	O
,	O
suggesting	O
that	O
CD40	B-Protein
-	O
associated	O
IKKgamma	B-Protein
is	O
subject	O
to	O
at	O
least	O
one	O
other	O
modification	O
in	O
addition	O
to	O
phosphorylation	O
.	O

Overall	O
,	O
these	O
data	O
demonstrate	O
that	O
HOIP	B-Protein
is	O
required	O
for	O
the	O
association	O
of	O
IKKgamma	B-Protein
with	O
CD40	B-Protein
,	O
and	O
suggest	O
that	O
this	O
event	O
is	O
coupled	O
to	O
post	O
-	O
translational	O
modifications	O
of	O
IKKgamma	B-Protein
.	O

Our	O
results	O
indicate	O
that	O
the	O
protein	O
HOIP	B-Protein
is	O
critical	O
for	O
CD40	B-Protein
-	O
induced	O
signals	O
that	O
regulate	O
B	O
cell	O
function	O
.	O

Our	O
data	O
show	O
that	O
HOIP	B-Protein
-	O
dependent	O
cellular	O
responses	O
include	O
CD40	B-Protein
-	O
mediated	O
upregulation	O
of	O
CD80	B-Protein
expression	O
and	O
synthesis	O
of	O
germline	O
RNA	O
transcripts	O
from	O
the	O
immunoglobulin	O
heavy	O
chain	O
locus	O
,	O
two	O
events	O
that	O
are	O
important	O
for	O
T	O
-	O
cell	O
-	O
dependent	O
antibody	O
-	O
mediated	O
immune	O
responses	O
.	O

At	O
the	O
molecular	O
level	O
,	O
our	O
data	O
indicate	O
that	O
HOIP	B-Protein
functions	O
downstream	O
of	O
TRAF2	B-Protein
in	O
the	O
CD40	B-Protein
signaling	O
pathway	O
and	O
that	O
HOIP	B-Protein
has	O
a	O
key	O
role	O
in	O
promoting	O
the	O
recruitment	O
of	O
the	O
IKK	O
complex	O
to	O
CD40	B-Protein
.	O

Consistent	O
with	O
this	O
,	O
CD40	B-Protein
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
is	O
dependent	O
on	O
the	O
presence	O
of	O
HOIP	O
.	O

In	O
addition	O
,	O
our	O
data	O
show	O
that	O
HOIP	B-Protein
facilitates	O
the	O
activation	O
of	O
JNK	O
in	O
response	O
to	O
CD40	B-Protein
engagement	O
.	O

Together	O
,	O
our	O
findings	O
provide	O
support	O
for	O
the	O
conclusion	O
that	O
HOIP	B-Protein
is	O
a	O
key	O
component	O
of	O
the	O
CD40	B-Protein
signaling	O
pathway	O
.	O

Given	O
the	O
importance	O
of	O
CD40	B-Protein
signaling	O
in	O
both	O
cellular	O
and	O
humoral	O
immune	O
responses	O
,	O
our	O
results	O
indicate	O
that	O
HOIP	B-Protein
has	O
a	O
critical	O
role	O
in	O
the	O
regulation	O
of	O
the	O
immune	O
system	O
.	O

The	O
functional	O
properties	O
of	O
HOIP	B-Protein
have	O
only	O
been	O
partially	O
characterized	O
.	O

Initial	O
studies	O
showed	O
that	O
HOIP	B-Protein
and	O
the	O
related	O
protein	O
HOIL	B-Protein
-	I-Protein
1	I-Protein
are	O
components	O
of	O
a	O
large	O
(	O
~	O
600	O
kDa	O
)	O
protein	O
complex	O
capable	O
of	O
synthesizing	O
linear	O
polyubiquitin	O
chains	O
[	O
5	O
]	O
.	O

Subsequent	O
studies	O
showed	O
that	O
a	O
HOIP	O
-	O
containing	O
complex	O
can	O
interact	O
with	O
IKKgamma	B-Protein
and	O
facilitate	O
activation	O
of	O
NF	O
-	O
kappaB	O
via	O
the	O
canonical	O
pathway	O
[	O
16	O
]	O
.	O

These	O
data	O
,	O
considered	O
together	O
with	O
ours	O
,	O
suggest	O
that	O
a	O
HOIP	O
-	O
containing	O
complex	O
mediates	O
recruitment	O
of	O
IKKgamma	B-Protein
to	O
the	O
CD40	O
signaling	O
complex	O
.	O

In	O
addition	O
,	O
CD40	B-Protein
-	O
associated	O
HOIP	B-Protein
could	O
play	O
a	O
role	O
in	O
activating	O
IKKgamma	B-Protein
after	O
its	O
recruitment	O
to	O
the	O
signaling	O
complex	O
[	O
16	O
]	O
.	O

The	O
higher	O
molecular	O
weight	O
forms	O
of	O
IKKgamma	B-Protein
we	O
observed	O
in	O
CD40	B-Protein
immunoprecipitates	O
would	O
be	O
consistent	O
with	O
the	O
presence	O
of	O
post	O
-	O
transcriptional	O
modifications	O
including	O
phosphorylation	O
and	O
ubiquitination	O
,	O
which	O
have	O
been	O
suggested	O
to	O
reduce	O
or	O
enhance	O
IKKgamma	B-Protein
activity	O
,	O
respectively	O
[	O
16	O
]	O
,	O
[	O
17	O
]	O
.	O

The	O
mechanisms	O
by	O
which	O
HOIP	B-Protein
mediates	O
recruitment	O
of	O
the	O
IKK	O
complex	O
to	O
CD40	B-Protein
and	O
by	O
which	O
HOIP	B-Protein
is	O
recruited	O
to	O
CD40	B-Protein
remain	O
unclear	O
.	O

A	O
previous	O
study	O
indicates	O
that	O
HOIP	B-Protein
may	O
mediate	O
direct	O
contacts	O
with	O
the	O
IKK	O
complex	O
[	O
16	O
]	O
,	O
suggesting	O
that	O
it	O
functions	O
as	O
an	O
adaptor	O
for	O
the	O
recruitment	O
of	O
the	O
IKK	O
complex	O
to	O
CD40	B-Protein
.	O

However	O
,	O
the	O
ubiquitin	O
ligase	O
activity	O
of	O
HOIP	B-Protein
suggests	O
that	O
it	O
is	O
more	O
than	O
a	O
simple	O
adapter	O
molecule	O
.	O

As	O
IKKgamma	B-Protein
appears	O
capable	O
of	O
binding	O
linear	O
polyubiquitin	O
[	O
18	O
]	O
,	O
[	O
19	O
]	O
,	O
it	O
is	O
possible	O
that	O
HOIP	B-Protein
directs	O
formation	O
of	O
linear	O
polyubiquitin	O
chains	O
on	O
a	O
CD40	O
-	O
associated	O
factor	O
,	O
and	O
it	O
is	O
these	O
chains	O
that	O
serve	O
to	O
recruit	O
IKKgamma	B-Protein
to	O
the	O
CD40	O
signaling	O
complex	O
.	O

The	O
molecular	O
interactions	O
necessary	O
for	O
recruitment	O
of	O
HOIP	B-Protein
itself	O
to	O
the	O
CD40	O
signaling	O
complex	O
also	O
remain	O
to	O
be	O
fully	O
characterized	O
.	O

We	O
previously	O
showed	O
that	O
the	O
recruitment	O
of	O
HOIP	B-Protein
to	O
the	O
signaling	O
complex	O
is	O
TRAF2	B-Protein
-	O
dependent	O
[	O
8	O
]	O
.	O

Potentially	O
,	O
TRAF2	B-Protein
and	O
HOIP	B-Protein
directly	O
interact	O
,	O
but	O
it	O
is	O
possible	O
that	O
the	O
ubiquitin	O
ligase	O
activity	O
of	O
TRAF2	B-Protein
[	O
20	O
]	O
(	O
or	O
TRAF2	O
-	O
associated	O
proteins	O
,	O
such	O
as	O
the	O
cIAPs	O
[	O
21	O
]	O
)	O
generates	O
K63	O
-	O
linked	O
polyubiquitin	O
chains	O
to	O
which	O
HOIP	B-Protein
can	O
bind	O
and	O
thus	O
associate	O
with	O
the	O
CD40	O
signaling	O
complex	O
[	O
22	O
]	O
.	O

While	O
our	O
previous	O
work	O
indicated	O
a	O
potentially	O
important	O
link	O
between	O
TRAF2	B-Protein
and	O
HOIP	B-Protein
in	O
CD40	B-Protein
signaling	O
,	O
the	O
signals	O
and	O
functions	O
tested	O
here	O
are	O
dependent	O
upon	O
TRAF6	B-Protein
as	O
well	O
as	O
TRAF2	B-Protein
.	O

In	O
previous	O
experiments	O
with	O
TRAF	O
-	O
deficient	O
A20	O
.	O
2J	O
cells	O
,	O
we	O
found	O
that	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
by	O
CD40	B-Protein
could	O
be	O
mediated	O
by	O
either	O
TRAF2	B-Protein
or	O
TRAF6	B-Protein
,	O
while	O
activation	O
of	O
JNK	O
by	O
CD40	B-Protein
was	O
largely	O
dependent	O
on	O
TRAF6	B-Protein
alone	O
[	O
8	O
]	O
.	O
<EOS>	B-X
Members	B-X
of	B-X
the	B-X
TNFR	B-X
family	B-X
play	B-X
critical	B-X
roles	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
.	B-X
One	B-X
member	B-X
of	B-X
the	B-X
family	B-X
critical	B-X
for	B-X
efficient	B-X
activation	B-X
of	B-X
T-dependent	B-X
humoral	B-X
immune	B-X
responses	B-X
is	B-X
CD40	B-X
,	B-X
a	B-X
cell	B-X
surface	B-X
protein	B-X
expressed	B-X
by	B-X
B	B-X
cells	B-X
and	B-X
other	B-X
APC	B-X
.	B-X
The	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
CD40	B-X
interacts	B-X
with	B-X
several	B-X
members	B-X
of	B-X
the	B-X
TNFR-associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
family	B-X
,	B-X
which	B-X
link	B-X
CD40	B-X
to	B-X
intracellular	B-X
signaling	B-X
pathways	B-X
.	B-X
TRAF2	B-X
and	B-X
6	B-X
appear	B-X
to	B-X
play	B-X
particularly	B-X
important	B-X
roles	B-X
in	B-X
CD40	B-X
signaling	B-X
.	B-X
To	B-X
better	B-X
define	B-X
the	B-X
roles	B-X
of	B-X
TRAF2	B-X
and	B-X
TRAF6	B-X
in	B-X
CD40	B-X
signaling	B-X
,	B-X
we	B-X
used	B-X
somatic	B-X
cell	B-X
gene	B-X
targeting	B-X
to	B-X
generate	B-X
TRAF-deficient	B-X
mouse	B-X
B	B-X
cell	B-X
lines	B-X
.	B-X
A20.2J	B-X
cells	B-X
deficient	B-X
in	B-X
TRAF6	B-X
exhibit	B-X
marked	B-X
defects	B-X
in	B-X
CD40-mediated	B-X
JNK	B-X
activation	B-X
and	B-X
the	B-X
up-regulation	B-X
of	B-X
CD80	B-X
.	B-X
Our	B-X
previous	B-X
experiments	B-X
with	B-X
TRAF2-deficient	B-X
B	B-X
cell	B-X
lines	B-X
suggest	B-X
that	B-X
TRAF6	B-X
and	B-X
TRAF2	B-X
may	B-X
have	B-X
redundant	B-X
roles	B-X
in	B-X
CD40-mediated	B-X
NF-kappaB	B-X
activation	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
found	B-X
CD40-mediated	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
intact	B-X
in	B-X
TRAF6-deficient	B-X
cells	B-X
and	B-X
defective	B-X
in	B-X
cells	B-X
lacking	B-X
both	B-X
TRAF2	B-X
and	B-X
TRAF6	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
that	B-X
TRAF6	B-X
mutants	B-X
defective	B-X
in	B-X
CD40	B-X
binding	B-X
were	B-X
able	B-X
to	B-X
restore	B-X
CD40-mediated	B-X
JNK	B-X
activation	B-X
and	B-X
CD80	B-X
up-regulation	B-X
in	B-X
TRAF6-deficient	B-X
cells	B-X
,	B-X
indicating	B-X
that	B-X
TRAF6	B-X
may	B-X
be	B-X
able	B-X
to	B-X
contribute	B-X
to	B-X
certain	B-X
CD40	B-X
signals	B-X
without	B-X
directly	B-X
binding	B-X
CD40	B-X
.	B-X

HOIP	B-Protein
deficiency	O
compromises	O
the	O
CD40	B-Protein
-	O
mediated	O
activation	O
of	O
both	O
NF	O
-	O
kappaB	O
and	O
JNK	O
,	O
indicating	O
that	O
signals	O
mediated	O
by	O
both	O
TRAF2	B-Protein
and	O
TRAF6	B-Protein
likely	O
pass	O
through	O
HOIP	B-Protein
.	O

Our	O
previous	O
work	O
also	O
demonstrated	O
that	O
the	O
CD40	B-Protein
-	O
mediated	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
JNK	O
,	O
while	O
TRAF6	B-Protein
-	O
dependent	O
,	O
was	O
not	O
compromised	O
by	O
the	O
disruption	O
of	O
the	O
binding	O
site	O
for	O
TRAF6	B-Protein
in	O
the	O
cytoplasmic	O
domain	O
of	O
CD40	B-Protein
or	O
deletion	O
of	O
the	O
receptor	O
binding	O
domain	O
(	O
the	O
TRAF	O
-	O
C	O
domain	O
)	O
in	O
TRAF6	B-Protein
[	O
8	O
]	O
.	O
<EOS>	B-X
Receptor	B-X
activator	B-X
of	B-X
NF-kappaB	B-X
(	B-X
RANK	B-X
)	B-X
is	B-X
a	B-X
recently	B-X
cloned	B-X
member	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
(	B-X
TNFR	B-X
)	B-X
superfamily	B-X
,	B-X
and	B-X
its	B-X
function	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
osteoclast	B-X
differentiation	B-X
and	B-X
dendritic	B-X
cell	B-X
survival	B-X
.	B-X
Many	B-X
of	B-X
the	B-X
TNFR	B-X
family	B-X
receptors	B-X
recruit	B-X
various	B-X
members	B-X
of	B-X
the	B-X
TNF	B-X
receptor-associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
family	B-X
for	B-X
transduction	B-X
of	B-X
their	B-X
signals	B-X
to	B-X
NF-kappaB	B-X
and	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
involvement	B-X
of	B-X
TRAF	B-X
family	B-X
members	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
JNK	B-X
pathway	B-X
in	B-X
signal	B-X
transduction	B-X
by	B-X
RANK	B-X
were	B-X
investigated	B-X
.	B-X
TRAF1	B-X
,	B-X
2	B-X
,	B-X
3	B-X
,	B-X
5	B-X
,	B-X
and	B-X
6	B-X
were	B-X
found	B-X
to	B-X
bind	B-X
RANK	B-X
in	B-X
vitro	B-X
.	B-X
Association	B-X
of	B-X
RANK	B-X
with	B-X
each	B-X
of	B-X
these	B-X
TRAF	B-X
proteins	B-X
was	B-X
also	B-X
detected	B-X
in	B-X
vivo	B-X
.	B-X
Expression	B-X
of	B-X
RANK	B-X
in	B-X
cultured	B-X
cells	B-X
also	B-X
induced	B-X
the	B-X
activation	B-X
of	B-X
JNK	B-X
,	B-X
which	B-X
was	B-X
blocked	B-X
by	B-X
a	B-X
dominant-negative	B-X
form	B-X
of	B-X
JNK	B-X
.	B-X
Furthermore	B-X
,	B-X
by	B-X
employing	B-X
various	B-X
C-terminal	B-X
deletion	B-X
mutants	B-X
of	B-X
RANK	B-X
,	B-X
the	B-X
regions	B-X
responsible	B-X
for	B-X
TRAF	B-X
interaction	B-X
and	B-X
JNK	B-X
activation	B-X
were	B-X
identified	B-X
.	B-X
TRAF5	B-X
was	B-X
determined	B-X
to	B-X
bind	B-X
to	B-X
the	B-X
C-terminal	B-X
11	B-X
amino	B-X
acids	B-X
and	B-X
the	B-X
other	B-X
TRAF	B-X
members	B-X
to	B-X
a	B-X
region	B-X
N-terminal	B-X
to	B-X
the	B-X
TRAF5	B-X
binding	B-X
site	B-X
.	B-X
The	B-X
domain	B-X
responsible	B-X
for	B-X
JNK	B-X
activation	B-X
was	B-X
localized	B-X
to	B-X
the	B-X
same	B-X
region	B-X
where	B-X
TRAF1	B-X
,	B-X
2	B-X
,	B-X
3	B-X
,	B-X
and	B-X
6	B-X
bound	B-X
,	B-X
which	B-X
suggests	B-X
that	B-X
these	B-X
TRAF	B-X
molecules	B-X
might	B-X
mediate	B-X
the	B-X
RANK-induced	B-X
JNK	B-X
activation	B-X
.	B-X

These	O
observations	O
indicate	O
that	O
TRAF6	B-Protein
need	O
not	O
directly	O
bind	O
CD40	B-Protein
in	O
order	O
to	O
mediate	O
certain	O
signals	O
,	O
suggesting	O
the	O
assembly	O
of	O
a	O
signaling	O
complex	O
not	O
directly	O
associated	O
with	O
the	O
receptor	O
.	O
<EOS>	B-X
Currently	B-X
,	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
beta	B-X
cell	B-X
death	B-X
are	B-X
partially	B-X
understood	B-X
,	B-X
and	B-X
there	B-X
is	B-X
a	B-X
need	B-X
to	B-X
identify	B-X
new	B-X
targets	B-X
for	B-X
developing	B-X
novel	B-X
therapeutics	B-X
to	B-X
treat	B-X
diabetes	B-X
.	B-X
Previously	B-X
,	B-X
our	B-X
group	B-X
established	B-X
that	B-X
Mig6	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
EGF	B-X
signaling	B-X
,	B-X
mediates	B-X
beta	B-X
cell	B-X
death	B-X
under	B-X
diabetogenic	B-X
conditions	B-X
.	B-X
Using	B-X
co-immunoprecipitation	B-X
and	B-X
mass	B-X
spectrometry	B-X
,	B-X
we	B-X
evaluated	B-X
the	B-X
binding	B-X
partners	B-X
of	B-X
Mig6	B-X
under	B-X
both	B-X
normal	B-X
glucose	B-X
(	B-X
NG	B-X
)	B-X
and	B-X
glucolipotoxic	B-X
(	B-X
GLT	B-X
)	B-X
conditions	B-X
in	B-X
beta	B-X
cells	B-X
.	B-X
We	B-X
identified	B-X
that	B-X
Mig6	B-X
interacted	B-X
dynamically	B-X
with	B-X
NumbL	B-X
,	B-X
whereas	B-X
Mig6	B-X
associated	B-X
with	B-X
NumbL	B-X
under	B-X
NG	B-X
,	B-X
and	B-X
this	B-X
interaction	B-X
was	B-X
disrupted	B-X
under	B-X
GLT	B-X
conditions	B-X
.	B-X
Further	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
the	B-X
siRNA-mediated	B-X
suppression	B-X
of	B-X
NumbL	B-X
expression	B-X
in	B-X
beta	B-X
cells	B-X
prevented	B-X
apoptosis	B-X
under	B-X
GLT	B-X
conditions	B-X
by	B-X
blocking	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
signaling	B-X
.	B-X
Using	B-X
co-immunoprecipitation	B-X
experiments	B-X
,	B-X
we	B-X
observed	B-X
that	B-X
NumbL	B-X
's	B-X
interactions	B-X
with	B-X
TRAF6	B-X
,	B-X
a	B-X
key	B-X
component	B-X
of	B-X
NFκB	B-X
signaling	B-X
,	B-X
were	B-X
increased	B-X
under	B-X
GLT	B-X
conditions	B-X
.	B-X
The	B-X
interactions	B-X
among	B-X
Mig6	B-X
,	B-X
NumbL	B-X
,	B-X
and	B-X
TRAF6	B-X
were	B-X
dynamic	B-X
and	B-X
context-dependent	B-X
.	B-X
We	B-X
proposed	B-X
a	B-X
model	B-X
wherein	B-X
these	B-X
interactions	B-X
activated	B-X
pro-apoptotic	B-X
NF-κB	B-X
signaling	B-X
while	B-X
blocking	B-X
pro-survival	B-X
EGF	B-X
signaling	B-X
under	B-X
diabetogenic	B-X
conditions	B-X
,	B-X
leading	B-X
to	B-X
beta	B-X
cell	B-X
apoptosis	B-X
.	B-X
These	B-X
findings	B-X
indicated	B-X
that	B-X
NumbL	B-X
should	B-X
be	B-X
further	B-X
investigated	B-X
as	B-X
a	B-X
candidate	B-X
anti-diabetic	B-X
therapeutic	B-X
target	B-X
.	B-X

If	O
such	O
a	O
complex	O
exists	O
,	O
our	O
results	O
indicate	O
that	O
the	O
absence	O
of	O
HOIP	B-Protein
compromises	O
its	O
function	O
as	O
well	O
.	O

Although	O
the	O
experiments	O
presented	O
here	O
focus	O
on	O
CD40	B-Protein
,	O
our	O
results	O
and	O
those	O
of	O
other	O
groups	O
[	O
16	O
]	O
,	O
[	O
22	O
]	O
support	O
the	O
possibility	O
that	O
HOIP	B-Protein
is	O
important	O
in	O
many	O
signaling	O
pathways	O
in	O
which	O
TRAF2	B-Protein
or	O
TRAF6	B-Protein
are	O
involved	O
,	O
including	O
those	O
associated	O
with	O
various	O
members	O
of	O
the	O
TNF	O
receptor	O
superfamily	O
and	O
the	O
Toll	O
-	O
like	O
receptors	O
.	O
<EOS>	B-X
Tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
(	B-X
TNFR	B-X
)	B-X
-associated	B-X
factor	B-X
6	B-X
(	B-X
TRAF6	B-X
)	B-X
is	B-X
an	B-X
adapter	B-X
protein	B-X
that	B-X
mediates	B-X
a	B-X
wide	B-X
array	B-X
of	B-X
protein-protein	B-X
interactions	B-X
via	B-X
its	B-X
TRAF	B-X
domain	B-X
and	B-X
a	B-X
RING	B-X
finger	B-X
domain	B-X
that	B-X
possesses	B-X
non-conventional	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
activity	B-X
.	B-X
First	B-X
identified	B-X
nearly	B-X
two	B-X
decades	B-X
ago	B-X
as	B-X
a	B-X
mediator	B-X
of	B-X
interleukin-1	B-X
receptor	B-X
(	B-X
IL-1R	B-X
)	B-X
-mediated	B-X
activation	B-X
of	B-X
NFκB	B-X
,	B-X
TRAF6	B-X
has	B-X
since	B-X
been	B-X
identified	B-X
as	B-X
an	B-X
actor	B-X
downstream	B-X
of	B-X
multiple	B-X
receptor	B-X
families	B-X
with	B-X
immunoregulatory	B-X
functions	B-X
,	B-X
including	B-X
members	B-X
of	B-X
the	B-X
TNFR	B-X
superfamily	B-X
,	B-X
the	B-X
Toll-like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
family	B-X
,	B-X
tumor	B-X
growth	B-X
factor-β	B-X
receptors	B-X
(	B-X
TGFβR	B-X
)	B-X
,	B-X
and	B-X
T-cell	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
NFκB	B-X
,	B-X
TRAF6	B-X
may	B-X
also	B-X
direct	B-X
activation	B-X
of	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
,	B-X
phosphoinositide	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
,	B-X
and	B-X
interferon	B-X
regulatory	B-X
factor	B-X
pathways	B-X
.	B-X
In	B-X
the	B-X
context	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
,	B-X
TRAF6-mediated	B-X
signals	B-X
have	B-X
proven	B-X
critical	B-X
for	B-X
the	B-X
development	B-X
,	B-X
homeostasis	B-X
,	B-X
and/or	B-X
activation	B-X
of	B-X
B	B-X
cells	B-X
,	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
myeloid	B-X
cells	B-X
,	B-X
including	B-X
macrophages	B-X
,	B-X
dendritic	B-X
cells	B-X
,	B-X
and	B-X
osteoclasts	B-X
,	B-X
as	B-X
well	B-X
as	B-X
for	B-X
organogenesis	B-X
of	B-X
thymic	B-X
and	B-X
secondary	B-X
lymphoid	B-X
tissues	B-X
.	B-X
In	B-X
multiple	B-X
cellular	B-X
contexts	B-X
,	B-X
TRAF6	B-X
function	B-X
is	B-X
essential	B-X
not	B-X
only	B-X
for	B-X
proper	B-X
activation	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
but	B-X
also	B-X
for	B-X
maintaining	B-X
immune	B-X
tolerance	B-X
,	B-X
and	B-X
more	B-X
recent	B-X
work	B-X
has	B-X
begun	B-X
to	B-X
identify	B-X
mechanisms	B-X
of	B-X
contextual	B-X
specificity	B-X
for	B-X
TRAF6	B-X
,	B-X
involving	B-X
both	B-X
regulatory	B-X
protein	B-X
interactions	B-X
,	B-X
and	B-X
messenger	B-X
RNA	B-X
regulation	B-X
by	B-X
microRNAs	B-X
.	B-X

The	O
potential	O
importance	O
of	O
HOIP	B-Protein
in	O
immune	O
function	O
and	O
TNFR	O
family	O
signaling	O
is	O
further	O
supported	O
by	O
the	O
recent	O
discovery	O
that	O
HOIP	B-Protein
interacts	O
with	O
a	O
protein	O
known	O
as	O
SHARPIN	B-Protein
(	O
SHANK	B-Protein
-	I-Protein
associated	I-Protein
RH	I-Protein
domain	I-Protein
interacting	I-Protein
protein	I-Protein
in	I-Protein
postsynaptic	I-Protein
density	I-Protein
)	O
,	O
which	O
appears	O
capable	O
of	O
working	O
together	O
with	O
HOIP	B-Protein
and	O
HOIL	B-Protein
to	O
mediate	O
the	O
assembly	O
of	O
linear	O
polyubiquitin	O
[	O
14	O
]	O
,	O
[	O
23	O
]	O
,	O
[	O
24	O
]	O
.	O

Interestingly	O
,	O
mice	O
with	O
a	O
spontaneous	O
mutation	O
in	O
the	O
gene	O
encoding	O
SHARPIN	B-Protein
(	O
chronic	O
proliferative	O
dermatitis	O
(	O
cpdm	O
)	O
mice	O
)	O
exhibit	O
chronic	O
inflammation	O
of	O
the	O
skin	O
and	O
internal	O
organs	O
,	O
defective	O
development	O
of	O
secondary	O
lymphoid	O
tissue	O
,	O
and	O
defects	O
in	O
the	O
production	O
of	O
switched	O
immunoglobulin	O
isotypes	O
[	O
17	O
]	O
,	O
[	O
25	O
]	O
.	O

The	O
apparently	O
intimate	O
functional	O
link	O
between	O
SHARPIN	B-Protein
and	O
HOIP	B-Protein
strongly	O
suggests	O
that	O
at	O
least	O
part	O
of	O
the	O
cpdm	O
phenotype	O
stems	O
from	O
defects	O
in	O
the	O
regulation	O
or	O
function	O
of	O
HOIP	B-Protein
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
viruses	B-X
induce	B-X
HOIP	B-X
expression	B-X
through	B-X
the	B-X
NF-κB	B-X
pathway	B-X
,	B-X
which	B-X
in	B-X
turn	B-X
increases	B-X
linear	B-X
ubiquitination	B-X
of	B-X
STAT1	B-X
and	B-X
thereby	B-X
inhibits	B-X
interferon	B-X
antiviral	B-X
response	B-X
.	B-X
LUBAC	B-X
key	B-X
component	B-X
RNF31/HOIP	B-X
translocates	B-X
to	B-X
the	B-X
LC3	B-X
puncta	B-X
area	B-X
when	B-X
autophagy	B-X
is	B-X
induced	B-X
.	B-X
SHARPIN	B-X
,	B-X
together	B-X
with	B-X
RNF31/HOIP	B-X
and	B-X
RBCK1/HOIL1	B-X
,	B-X
form	B-X
the	B-X
linear	B-X
ubiquitin	B-X
chain	B-X
assembly	B-X
complex	B-X
(	B-X
LUBAC	B-X
)	B-X
E3	B-X
ligase	B-X
that	B-X
catalyzes	B-X
M1-linked	B-X
polyubiquitination	B-X
.	B-X
LUBAC-mediated	B-X
linear	B-X
ubiquitination	B-X
plays	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
regulation	B-X
of	B-X
cell	B-X
death	B-X
and	B-X
inflammatory	B-X
pathways	B-X
.	B-X
Genetic	B-X
deficiency	B-X
in	B-X
LUBAC	B-X
components	B-X
leads	B-X
to	B-X
severe	B-X
immune	B-X
dysfunction	B-X
or	B-X
embryonic	B-X
lethality	B-X
.	B-X

Cell	O
lines	O
<EOS>	B-X
Although	B-X
most	B-X
biotherapeutic	B-X
proteins	B-X
developed	B-X
to	B-X
date	B-X
have	B-X
been	B-X
produced	B-X
using	B-X
the	B-X
mammalian	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
and	B-X
murine	B-X
myeloma	B-X
(	B-X
NS0	B-X
,	B-X
Sp2/0	B-X
)	B-X
cell	B-X
lines	B-X
,	B-X
there	B-X
has	B-X
been	B-X
a	B-X
recent	B-X
shift	B-X
toward	B-X
the	B-X
use	B-X
of	B-X
human	B-X
cell	B-X
lines	B-X
.	B-X
One	B-X
of	B-X
the	B-X
most	B-X
important	B-X
advantages	B-X
of	B-X
using	B-X
human	B-X
cell	B-X
lines	B-X
for	B-X
protein	B-X
production	B-X
is	B-X
the	B-X
greater	B-X
likelihood	B-X
that	B-X
the	B-X
resulting	B-X
recombinant	B-X
protein	B-X
will	B-X
bear	B-X
post-translational	B-X
modifications	B-X
(	B-X
PTMs	B-X
)	B-X
that	B-X
are	B-X
consistent	B-X
with	B-X
those	B-X
seen	B-X
on	B-X
endogenous	B-X
human	B-X
proteins	B-X
.	B-X
Although	B-X
other	B-X
mammalian	B-X
cell	B-X
lines	B-X
can	B-X
produce	B-X
PTMs	B-X
similar	B-X
to	B-X
human	B-X
cells	B-X
,	B-X
they	B-X
also	B-X
produce	B-X
non-human	B-X
PTMs	B-X
,	B-X
such	B-X
as	B-X
galactose-α1,3-galactose	B-X
and	B-X
N-glycolylneuraminic	B-X
acid	B-X
,	B-X
which	B-X
are	B-X
potentially	B-X
immunogenic	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
human	B-X
cell	B-X
lines	B-X
are	B-X
grown	B-X
easily	B-X
in	B-X
a	B-X
serum-free	B-X
suspension	B-X
culture	B-X
,	B-X
reproduce	B-X
rapidly	B-X
and	B-X
have	B-X
efficient	B-X
protein	B-X
production	B-X
.	B-X
A	B-X
possible	B-X
disadvantage	B-X
of	B-X
using	B-X
human	B-X
cell	B-X
lines	B-X
is	B-X
the	B-X
potential	B-X
for	B-X
human-specific	B-X
viral	B-X
contamination	B-X
,	B-X
although	B-X
this	B-X
risk	B-X
can	B-X
be	B-X
mitigated	B-X
with	B-X
multiple	B-X
viral	B-X
inactivation	B-X
or	B-X
clearance	B-X
steps	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
while	B-X
human	B-X
cell	B-X
lines	B-X
are	B-X
currently	B-X
widely	B-X
used	B-X
for	B-X
biopharmaceutical	B-X
research	B-X
,	B-X
vaccine	B-X
production	B-X
and	B-X
production	B-X
of	B-X
some	B-X
licensed	B-X
protein	B-X
therapeutics	B-X
,	B-X
there	B-X
is	B-X
a	B-X
relative	B-X
paucity	B-X
of	B-X
clinical	B-X
experience	B-X
with	B-X
human	B-X
cell	B-X
lines	B-X
because	B-X
they	B-X
have	B-X
only	B-X
recently	B-X
begun	B-X
to	B-X
be	B-X
used	B-X
for	B-X
the	B-X
manufacture	B-X
of	B-X
proteins	B-X
(	B-X
compared	B-X
with	B-X
other	B-X
types	B-X
of	B-X
cell	B-X
lines	B-X
)	B-X
.	B-X
With	B-X
additional	B-X
research	B-X
investment	B-X
,	B-X
human	B-X
cell	B-X
lines	B-X
may	B-X
be	B-X
further	B-X
optimized	B-X
for	B-X
routine	B-X
commercial	B-X
production	B-X
of	B-X
a	B-X
broader	B-X
range	B-X
of	B-X
biotherapeutic	B-X
proteins	B-X
.	B-X

The	O
mouse	O
B	O
cell	O
line	O
A20	O
.	O
2J	O
has	O
been	O
previously	O
described	O
[	O
26	O
]	O
,	O
[	O
27	O
]	O
.	O

Cells	O
were	O
grown	O
in	O
RPMI	O
1640	O
,	O
10	O
%	O
FCS	O
,	O
10	O
microM	O
2	O
-	O
ME	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
and	O
antibiotics	O
.	O

HI	O
-	O
5	O
insect	O
cells	O
(	O
Invitrogen	O
)	O
expressing	O
CD154	B-Protein
have	O
been	O
described	O
[	O
28	O
]	O
.	O

Antibodies	O
<EOS>	B-X
Antibodies	B-X
are	B-X
host	B-X
proteins	B-X
that	B-X
comprise	B-X
one	B-X
of	B-X
the	B-X
principal	B-X
effectors	B-X
of	B-X
the	B-X
adaptive	B-X
immune	B-X
system	B-X
.	B-X
Antibodies	B-X
are	B-X
utilized	B-X
for	B-X
analysis	B-X
,	B-X
purification	B-X
,	B-X
and	B-X
enrichment	B-X
,	B-X
and	B-X
to	B-X
mediate	B-X
or	B-X
modulate	B-X
physiological	B-X
responses	B-X
.	B-X
Structure	B-X
of	B-X
antibodies	B-X
.	B-X
Antibodies	B-X
can	B-X
also	B-X
be	B-X
modified	B-X
to	B-X
deliver	B-X
toxic	B-X
or	B-X
modulatory	B-X
payloads	B-X
(	B-X
small	B-X
molecules	B-X
,	B-X
radionuclides	B-X
and	B-X
enzymes	B-X
)	B-X
and	B-X
engineered	B-X
to	B-X
bind	B-X
multiple	B-X
epitopes	B-X
(	B-X
bispecifics	B-X
)	B-X
or	B-X
even	B-X
to	B-X
have	B-X
novel	B-X
catalytic	B-X
activity	B-X
(	B-X
abzymes	B-X
)	B-X
.	B-X

Mouse	O
anti	O
-	O
birch	O
profilin	O
antibody	O
(	O
4A6	O
[	O
29	O
]	O
)	O
,	O
rat	O
anti	O
-	O
mouse	O
CD40	O
(	O
1C10	O
[	O
30	O
]	O
)	O
and	O
a	O
rat	O
isotype	O
control	O
antibody	O
(	O
mAb72	O
,	O
Developmental	O
Studies	O
Hybridoma	O
Bank	O
,	O
University	O
of	O
Iowa	O
,	O
Iowa	O
City	O
,	O
IA	O
)	O
were	O
isolated	O
from	O
hybridoma	O
supernatants	O
.	O

FITC	O
-	O
labeled	O
anti	O
-	O
mouse	O
CD80	O
and	O
an	O
isotype	O
control	O
Ab	O
were	O
from	O
eBiosciences	O
.	O

Rabbit	O
anti	O
-	O
HOIP	O
Ab	O
[	O
6	O
]	O
was	O
the	O
kind	O
gift	O
of	O
Dr	O
.	O
Betty	O
Eipper	O
(	O
University	O
of	O
Connecticut	O
Health	O
Center	O
,	O
Farmington	O
,	O
Connecticut	O
)	O
.	O

Goat	O
anti	O
-	O
rat	O
IgG	O
,	O
and	O
HRP	O
-	O
labeled	O
secondary	O
Abs	O
were	O
from	O
Jackson	O
ImmunoResearch	O
Laboratories	O
,	O
Inc	O
.	O

All	O
other	O
antibodies	O
used	O
were	O
described	O
previously	O
[	O
6	O
]	O
.	O
<EOS>	B-X
Targeting	B-X
a	B-X
neoantigen	B-X
derived	B-X
from	B-X
a	B-X
common	B-X
Serology	B-X
tests	B-X
to	B-X
detect	B-X
the	B-X
presence	B-X
of	B-X
antibodies	B-X
to	B-X
SARS-CoV-2	B-X
enable	B-X
detection	B-X
of	B-X
past	B-X
infection	B-X
and	B-X
may	B-X
detect	B-X
cases	B-X
of	B-X
SARS-CoV-2	B-X
infection	B-X
that	B-X
were	B-X
missed	B-X
by	B-X
earlier	B-X
diagnostic	B-X
tests	B-X
.	B-X
Enfortumab	B-X
vedotin	B-X
is	B-X
a	B-X
first-in-class	B-X
Nectin-4-directed	B-X
antibody-drug	B-X
conjugate	B-X
approved	B-X
by	B-X
the	B-X
US	B-X
Food	B-X
and	B-X
Drug	B-X
Administration	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
patients	B-X
with	B-X
locally	B-X
advanced	B-X
or	B-X
metastatic	B-X
urothelial	B-X
cancer	B-X
(	B-X
la/mUC	B-X
)	B-X
previously	B-X
treated	B-X
with	B-X
a	B-X
platinum-based	B-X
chemotherapy	B-X
and	B-X
a	B-X
programmed	B-X
death	B-X
receptor-1/programmed	B-X
death-ligand	B-X
1	B-X
(	B-X
PD-1/L1	B-X
)	B-X
inhibitor	B-X
,	B-X
or	B-X
patients	B-X
with	B-X
la/mUC	B-X
who	B-X
are	B-X
ineligible	B-X
for	B-X
cisplatin-based	B-X
chemotherapy	B-X
and	B-X
have	B-X
previously	B-X
received	B-X
one	B-X
or	B-X
more	B-X
prior	B-X
lines	B-X
of	B-X
therapy	B-X
.	B-X
Enfortumab	B-X
vedotin	B-X
is	B-X
the	B-X
only	B-X
drug	B-X
to	B-X
have	B-X
demonstrated	B-X
survival	B-X
benefit	B-X
versus	B-X
chemotherapy	B-X
in	B-X
a	B-X
randomized	B-X
controlled	B-X
trial	B-X
in	B-X
patients	B-X
with	B-X
la/mUC	B-X
previously	B-X
treated	B-X
with	B-X
platinum-based	B-X
chemotherapy	B-X
and	B-X
a	B-X
PD-1/L1	B-X
inhibitor	B-X
.	B-X
There	B-X
is	B-X
the	B-X
potential	B-X
for	B-X
rare	B-X
but	B-X
severe	B-X
and	B-X
possibly	B-X
fatal	B-X
cutaneous	B-X
adverse	B-X
reactions	B-X
,	B-X
including	B-X
Stevens-Johnson	B-X
syndrome	B-X
and	B-X
toxic	B-X
epidermal	B-X
necrosis	B-X
,	B-X
as	B-X
described	B-X
in	B-X
the	B-X
boxed	B-X
warning	B-X
of	B-X
the	B-X
US	B-X
prescribing	B-X
information	B-X
for	B-X
enfortumab	B-X
vedotin	B-X
.	B-X

Somatic	O
cell	O
gene	O
targeting	O
<EOS>	B-X
A	B-X
number	B-X
of	B-X
recent	B-X
advances	B-X
have	B-X
significantly	B-X
facilitated	B-X
gene	B-X
targeting	B-X
in	B-X
somatic	B-X
cells	B-X
.	B-X
Gene	B-X
targeting	B-X
can	B-X
now	B-X
be	B-X
performed	B-X
with	B-X
the	B-X
same	B-X
ease	B-X
and	B-X
efficiency	B-X
in	B-X
somatic	B-X
cells	B-X
as	B-X
in	B-X
murine	B-X
embryonic	B-X
stem	B-X
cells	B-X
.	B-X
Rigorous	B-X
genetic	B-X
analyses	B-X
can	B-X
therefore	B-X
be	B-X
applied	B-X
for	B-X
the	B-X
first	B-X
time	B-X
to	B-X
the	B-X
large	B-X
number	B-X
of	B-X
excellent	B-X
human	B-X
cell	B-X
culture	B-X
systems	B-X
.	B-X
Although	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
(	B-X
CHO	B-X
)	B-X
cells	B-X
,	B-X
with	B-X
their	B-X
unique	B-X
characteristics	B-X
,	B-X
have	B-X
become	B-X
a	B-X
major	B-X
workhorse	B-X
for	B-X
the	B-X
manufacture	B-X
of	B-X
therapeutic	B-X
recombinant	B-X
proteins	B-X
,	B-X
one	B-X
of	B-X
the	B-X
major	B-X
challenges	B-X
in	B-X
CHO	B-X
cell	B-X
line	B-X
generation	B-X
(	B-X
CLG	B-X
)	B-X
is	B-X
how	B-X
to	B-X
efficiently	B-X
identify	B-X
those	B-X
rare	B-X
,	B-X
high-producing	B-X
clones	B-X
among	B-X
a	B-X
large	B-X
population	B-X
of	B-X
low-	B-X
and	B-X
non-productive	B-X
clones	B-X
.	B-X
It	B-X
is	B-X
not	B-X
unusual	B-X
that	B-X
several	B-X
hundred	B-X
individual	B-X
clones	B-X
need	B-X
to	B-X
be	B-X
screened	B-X
for	B-X
the	B-X
identification	B-X
of	B-X
a	B-X
commercial	B-X
clonal	B-X
cell	B-X
line	B-X
with	B-X
acceptable	B-X
productivity	B-X
and	B-X
growth	B-X
profile	B-X
making	B-X
the	B-X
cell	B-X
line	B-X
appropriate	B-X
for	B-X
commercial	B-X
application	B-X
.	B-X
Since	B-X
selection	B-X
of	B-X
recombinant	B-X
cell	B-X
lines	B-X
in	B-X
the	B-X
GS-CHO	B-X
system	B-X
is	B-X
based	B-X
on	B-X
the	B-X
balance	B-X
between	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
GS	B-X
gene	B-X
introduced	B-X
by	B-X
the	B-X
expression	B-X
plasmid	B-X
and	B-X
the	B-X
addition	B-X
of	B-X
the	B-X
GS	B-X
inhibitor	B-X
,	B-X
L-MSX	B-X
,	B-X
the	B-X
expression	B-X
of	B-X
GS	B-X
from	B-X
the	B-X
endogenous	B-X
GS	B-X
gene	B-X
in	B-X
parental	B-X
CHOK1SV	B-X
cells	B-X
will	B-X
likely	B-X
interfere	B-X
with	B-X
the	B-X
selection	B-X
process	B-X
.	B-X
To	B-X
study	B-X
endogenous	B-X
GS	B-X
expression	B-X
's	B-X
potential	B-X
impact	B-X
on	B-X
selection	B-X
efficiency	B-X
,	B-X
GS-knockout	B-X
CHOK1SV	B-X
cell	B-X
lines	B-X
were	B-X
generated	B-X
using	B-X
the	B-X
zinc	B-X
finger	B-X
nuclease	B-X
(	B-X
ZFN	B-X
)	B-X
technology	B-X
designed	B-X
to	B-X
specifically	B-X
target	B-X
the	B-X
endogenous	B-X
CHO	B-X
GS	B-X
gene	B-X
.	B-X
The	B-X
high	B-X
efficiency	B-X
(	B-X
∼2	B-X
%	B-X
)	B-X
of	B-X
bi-allelic	B-X
modification	B-X
on	B-X
the	B-X
CHO	B-X
GS	B-X
gene	B-X
supports	B-X
the	B-X
unique	B-X
advantages	B-X
of	B-X
the	B-X
ZFN	B-X
technology	B-X
,	B-X
especially	B-X
in	B-X
CHO	B-X
cells	B-X
.	B-X
GS	B-X
enzyme	B-X
function	B-X
disruption	B-X
was	B-X
confirmed	B-X
by	B-X
the	B-X
observation	B-X
of	B-X
glutamine-dependent	B-X
growth	B-X
of	B-X
all	B-X
GS-knockout	B-X
cell	B-X
lines	B-X
.	B-X
Full	B-X
evaluation	B-X
of	B-X
the	B-X
GS-knockout	B-X
cell	B-X
lines	B-X
in	B-X
a	B-X
standard	B-X
industrial	B-X
cell	B-X
culture	B-X
process	B-X
was	B-X
performed	B-X
.	B-X
Bulk	B-X
culture	B-X
productivity	B-X
improved	B-X
two-	B-X
to	B-X
three-fold	B-X
through	B-X
the	B-X
use	B-X
of	B-X
GS-knockout	B-X
cells	B-X
as	B-X
parent	B-X
cells	B-X
.	B-X
The	B-X
selection	B-X
stringency	B-X
was	B-X
significantly	B-X
increased	B-X
,	B-X
as	B-X
indicated	B-X
by	B-X
the	B-X
large	B-X
reduction	B-X
of	B-X
non-producing	B-X
and	B-X
low-producing	B-X
cells	B-X
after	B-X
25	B-X
µM	B-X
L-MSX	B-X
selection	B-X
,	B-X
and	B-X
resulted	B-X
in	B-X
a	B-X
six-fold	B-X
efficiency	B-X
improvement	B-X
in	B-X
identifying	B-X
similar	B-X
numbers	B-X
of	B-X
high-productive	B-X
cell	B-X
lines	B-X
for	B-X
a	B-X
given	B-X
recombinant	B-X
monoclonal	B-X
antibody	B-X
.	B-X
The	B-X
potential	B-X
impact	B-X
of	B-X
GS-knockout	B-X
cells	B-X
on	B-X
recombinant	B-X
protein	B-X
quality	B-X
is	B-X
also	B-X
discussed	B-X
.	B-X

The	O
generation	O
of	O
HOIP	B-Protein
-	O
deficient	O
cells	O
was	O
accomplished	O
using	O
a	O
homologous	O
recombination	O
approach	O
described	O
previously	O
[	O
7	O
]	O
,	O
[	O
8	O
]	O
.	O

Segments	O
of	O
Rnf31	B-Protein
gene	O
sequence	O
used	O
in	O
the	O
targeting	O
construct	O
(	O
Fig	O
.	O
1A	O
)	O
were	O
amplified	O
by	O
PCR	O
from	O
A20	O
.	O
2J	O
genomic	O
DNA	O
.	O

The	O
oligonucleotide	O
primers	O
used	O
to	O
generate	O
the	O
5	O
'	O
flank	O
(	O
1224	O
bp	O
)	O
were	O
5	O
'	O
-	O
ttttctagagcggtggcttaagtgaccc	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
tattctagatgcagcatctgagaaagcaagc	O
-	O
3	O
'	O
.	O

The	O
3	O
'	O
flank	O
(	O
6032	O
bp	O
)	O
primers	O
were	O
5	O
'	O
-	O
aaaaccggtgtatgcttctttacgggagaaaaatattag	O
-	O
3	O
'	O
and	O
5	O
'	O
-	O
tataccggtatgaagccaaaggaacactgagag	O
-	O
3	O
'	O
.	O

Restriction	O
endonuclease	O
sites	O
in	O
the	O
oligonucleotide	O
primers	O
allowed	O
insertion	O
of	O
the	O
PCR	O
products	O
into	O
the	O
targeting	O
vector	O
.	O
<EOS>	B-X
The	B-X
cloning	B-X
vector	B-X
encodes	B-X
a	B-X
C-terminally	B-X
truncated	B-X
CAT	B-X
protein	B-X
.	B-X
Restriction	B-X
sites	B-X
in	B-X
front	B-X
of	B-X
the	B-X
stop	B-X
codon	B-X
allow	B-X
the	B-X
insertion	B-X
of	B-X
target	B-X
DNA	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
production	B-X
of	B-X
properly	B-X
folded	B-X
CAT	B-X
fusion	B-X
proteins	B-X
and	B-X
regained	B-X
chloramphenicol	B-X
resistance	B-X
.	B-X
The	B-X
method	B-X
appears	B-X
particularly	B-X
convenient	B-X
for	B-X
the	B-X
cloning	B-X
of	B-X
DNA	B-X
fragments	B-X
amplified	B-X
by	B-X
the	B-X
PCR	B-X
because	B-X
minimal	B-X
information	B-X
to	B-X
restore	B-X
CAT	B-X
folding	B-X
can	B-X
be	B-X
included	B-X
in	B-X
the	B-X
primers	B-X
.	B-X
This	B-X
vector	B-X
may	B-X
also	B-X
contribute	B-X
to	B-X
the	B-X
determination	B-X
of	B-X
the	B-X
role	B-X
of	B-X
the	B-X
C-terminus	B-X
in	B-X
CAT	B-X
folding	B-X
.	B-X

A20	O
.	O
2J	O
cells	O
were	O
transfected	O
(	O
by	O
electroporation	O
[	O
7	O
]	O
)	O
with	O
the	O
targeting	O
construct	O
and	O
subcloned	O
in	O
medium	O
containing	O
600	O
microg	O
/	O
ml	O
G418	O
sulfate	O
.	O

Homologous	O
recombination	O
in	O
G418	O
-	O
resistant	O
clones	O
was	O
detected	O
by	O
PCR	O
of	O
genomic	O
DNA	O
,	O
as	O
described	O
[	O
7	O
]	O
.	O

Oligonucleotide	O
primers	O
used	O
for	O
screening	O
were	O
5	O
'	O
-	O
cttcctgatctcagctttaccgtcac	O
-	O
3	O
'	O
(	O
homologous	O
to	O
genomic	O
sequence	O
;	O
approximate	O
position	O
noted	O
in	O
Fig	O
.	O
1	O
)	O
and	O
5	O
'	O
-	O
caatccatcttgttcagccat	O
-	O
3	O
'	O
(	O
homologous	O
to	O
sequence	O
in	O
NeoR	O
)	O
.	O
<EOS>	B-X
In	B-X
this	B-X
report	B-X
,	B-X
amplified	B-X
fragment	B-X
length	B-X
polymorphism	B-X
(	B-X
AFLP	B-X
)	B-X
and	B-X
simple	B-X
sequence	B-X
repeat	B-X
(	B-X
SSR	B-X
)	B-X
techniques	B-X
were	B-X
used	B-X
to	B-X
identify	B-X
markers	B-X
linked	B-X
to	B-X
the	B-X
brown	B-X
seed	B-X
locus	B-X
in	B-X
an	B-X
F	B-X
(	B-X
2	B-X
)	B-X
population	B-X
consisting	B-X
of	B-X
1258	B-X
plants	B-X
.	B-X
After	B-X
screening	B-X
256	B-X
AFLP	B-X
primer	B-X
combinations	B-X
and	B-X
456	B-X
pairs	B-X
of	B-X
SSR	B-X
primers	B-X
,	B-X
we	B-X
found	B-X
14	B-X
AFLP	B-X
and	B-X
2	B-X
SSR	B-X
markers	B-X
that	B-X
were	B-X
closely	B-X
linked	B-X
to	B-X
the	B-X
brown	B-X
seed	B-X
locus	B-X
.	B-X
Among	B-X
these	B-X
markers	B-X
,	B-X
the	B-X
SSR	B-X
marker	B-X
CB1022	B-X
showed	B-X
codominant	B-X
inheritance	B-X
.	B-X
By	B-X
integrating	B-X
markers	B-X
previously	B-X
found	B-X
to	B-X
be	B-X
linked	B-X
to	B-X
the	B-X
brown	B-X
seed	B-X
locus	B-X
into	B-X
the	B-X
genetic	B-X
map	B-X
of	B-X
the	B-X
F	B-X
(	B-X
2	B-X
)	B-X
population	B-X
,	B-X
23	B-X
markers	B-X
were	B-X
linked	B-X
to	B-X
the	B-X
brown	B-X
seed	B-X
locus	B-X
.	B-X
The	B-X
two	B-X
closest	B-X
markers	B-X
,	B-X
EA02MC08	B-X
and	B-X
P03MC08	B-X
,	B-X
were	B-X
located	B-X
on	B-X
either	B-X
side	B-X
of	B-X
the	B-X
brown	B-X
seed	B-X
locus	B-X
at	B-X
a	B-X
distance	B-X
of	B-X
0.3	B-X
and	B-X
0.5	B-X
cM	B-X
,	B-X
respectively	B-X
.	B-X
To	B-X
use	B-X
the	B-X
markers	B-X
for	B-X
the	B-X
breeding	B-X
of	B-X
yellow-seeded	B-X
mustard	B-X
plants	B-X
,	B-X
two	B-X
AFLP	B-X
markers	B-X
(	B-X
EA06MC11	B-X
and	B-X
EA08MC13	B-X
)	B-X
were	B-X
converted	B-X
into	B-X
sequence-characterized	B-X
amplified	B-X
region	B-X
(	B-X
SCAR	B-X
)	B-X
markers	B-X
,	B-X
SC1	B-X
and	B-X
SC2	B-X
,	B-X
with	B-X
the	B-X
latter	B-X
as	B-X
the	B-X
codominant	B-X
marker	B-X
.	B-X
A	B-X
BLAST	B-X
analysis	B-X
indicated	B-X
that	B-X
the	B-X
sequences	B-X
of	B-X
seven	B-X
markers	B-X
showed	B-X
good	B-X
colinearity	B-X
with	B-X
those	B-X
of	B-X
Arabidopsis	B-X
chromosome	B-X
3	B-X
and	B-X
that	B-X
the	B-X
homolog	B-X
of	B-X
the	B-X
brown	B-X
seed	B-X
locus	B-X
might	B-X
exist	B-X
between	B-X
At3g14120	B-X
and	B-X
At3g29615	B-X
on	B-X
this	B-X
same	B-X
chromosome	B-X
.	B-X
To	B-X
develop	B-X
closer	B-X
markers	B-X
,	B-X
we	B-X
could	B-X
make	B-X
use	B-X
of	B-X
the	B-X
sequence	B-X
information	B-X
of	B-X
this	B-X
region	B-X
to	B-X
design	B-X
primers	B-X
for	B-X
future	B-X
studies	B-X
.	B-X

Clones	O
in	O
which	O
one	O
copy	O
of	O
Rnf31	B-Protein
had	O
been	O
disrupted	O
were	O
transiently	O
transfected	O
with	O
an	O
expression	O
plasmid	O
encoding	O
Cre	O
,	O
in	O
order	O
to	O
remove	O
NeoR	O
.	O

G418	O
-	O
sensitive	O
subclones	O
were	O
subjected	O
to	O
a	O
second	O
round	O
of	O
targeting	O
to	O
disrupt	O
the	O
remaining	O
copy	O
of	O
Rnf31	B-Protein
.	O

G418	O
-	O
resistant	O
clones	O
were	O
tested	O
for	O
homologous	O
recombination	O
by	O
PCR	O
and	O
HOIP	B-Protein
protein	O
expression	O
by	O
Western	O
blot	O
.	O

Retroviral	O
transduction	O
<EOS>	B-X
Retroviral-mediated	B-X
gene	B-X
transduction	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
method	B-X
in	B-X
the	B-X
genetic	B-X
manipulation	B-X
of	B-X
DN32.D3	B-X
cells	B-X
by	B-X
retrovirus	B-X
,	B-X
including	B-X
the	B-X
generation	B-X
and	B-X
concentration	B-X
of	B-X
retrovirus	B-X
,	B-X
retroviral	B-X
transduction	B-X
of	B-X
DN32.D3	B-X
cells	B-X
,	B-X
and	B-X
evaluation	B-X
of	B-X
transduction	B-X
efficiency	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
provide	B-X
procedures	B-X
for	B-X
the	B-X
insertion	B-X
of	B-X
the	B-X
RRM2-C2orf48	B-X
fusion	B-X
ORF	B-X
into	B-X
a	B-X
mammalian	B-X
expression	B-X
vector	B-X
,	B-X
achieving	B-X
the	B-X
overexpression	B-X
of	B-X
the	B-X
RRM2-C2orf48	B-X
fusion	B-X
protein	B-X
in	B-X
a	B-X
colon	B-X
cancer	B-X
cell	B-X
line	B-X
by	B-X
retroviral	B-X
transduction	B-X
.	B-X
Given	B-X
that	B-X
these	B-X
cells	B-X
are	B-X
ultimately	B-X
derived	B-X
from	B-X
bone	B-X
marrow	B-X
precursors	B-X
,	B-X
the	B-X
concept	B-X
of	B-X
performing	B-X
gene	B-X
therapy	B-X
for	B-X
atherosclerosis	B-X
through	B-X
the	B-X
retroviral	B-X
transduction	B-X
of	B-X
hematopoietic	B-X
stem	B-X
cells	B-X
has	B-X
received	B-X
much	B-X
attention	B-X
.	B-X

A	O
retroviral	O
vector	O
(	O
pMIP	O
)	O
was	O
used	O
for	O
the	O
stable	O
transduction	O
of	O
cells	O
with	O
HOIP	B-Protein
and	O
IKKgamma	B-Protein
cDNA	O
constructs	O
.	O

pMIP	O
was	O
constructed	O
by	O
replacing	O
the	O
IRES	O
and	O
GFP	O
encoding	O
sequences	O
in	O
pMIG	O
[	O
31	O
]	O
with	O
the	O
IRES	O
and	O
puromycin	O
resistance	O
gene	O
from	O
pIRESpuro2	O
(	O
Clontech	O
)	O
.	O

FLAG	O
-	O
tagged	O
mouse	O
HOIP	B-Protein
cDNA	O
was	O
inserted	O
into	O
the	O
multiple	O
cloning	O
site	O
of	O
pMIP	O
.	O

A	O
pMIP	O
construct	O
encoding	O
mouse	O
IKKgamma	B-Protein
with	O
an	O
amino	O
terminal	O
birch	O
profilin	O
peptide	O
(	O
BP	O
)	O
-	O
tag	O
was	O
also	O
prepared	O
.	O

Retroviral	O
particles	O
were	O
generated	O
by	O
transient	O
transfection	O
of	O
293T	O
cells	O
with	O
pMIP	O
,	O
pMIP	O
-	O
HOIP	B-Protein
,	O
or	O
pMIP	O
-	O
IKKgamma	B-Protein
and	O
the	O
packaging	O
vector	O
pCL	O
-	O
Eco	O
[	O
32	O
]	O
.	O

Two	O
days	O
after	O
transfection	O
,	O
culture	O
supernatants	O
were	O
harvested	O
and	O
filtered	O
.	O

A20	O
.	O
2J	O
or	O
HOIP	B-Protein
-	O
deficient	O
cells	O
were	O
added	O
to	O
24	O
-	O
well	O
plates	O
(	O
2	O
.	O
5x105	O
cells	O
/	O
well	O
)	O
with	O
1	O
ml	O
virus	O
-	O
containing	O
supernatant	O
and	O
8	O
microg	O
/	O
ml	O
polybrene	O
.	O
<EOS>	B-X
B-cell	B-X
receptor	B-X
(	B-X
BCR	B-X
)	B-X
cross-linking	B-X
with	B-X
antibodies	B-X
to	B-X
membrane	B-X
IgM	B-X
(	B-X
but	B-X
not	B-X
with	B-X
anti	B-X
IgD	B-X
)	B-X
induces	B-X
c-Myc	B-X
downregulation	B-X
via	B-X
nuclear	B-X
factor	B-X
kappaB	B-X
inactivation	B-X
and	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
accumulation	B-X
in	B-X
these	B-X
B	B-X
lymphomas	B-X
.	B-X
Anti-mu-treated	B-X
cells	B-X
then	B-X
undergo	B-X
G1	B-X
arrest	B-X
and	B-X
die	B-X
by	B-X
apoptosis	B-X
independent	B-X
of	B-X
Fas	B-X
.	B-X
Steroids	B-X
and	B-X
retinoids	B-X
similarly	B-X
downregulate	B-X
c-Myc	B-X
and	B-X
induce	B-X
apoptosis	B-X
in	B-X
these	B-X
B	B-X
cells	B-X
and	B-X
synergize	B-X
with	B-X
anti-mu	B-X
.	B-X
Rescue	B-X
from	B-X
apoptosis	B-X
induced	B-X
by	B-X
anti-mu	B-X
or	B-X
steroids	B-X
occurs	B-X
with	B-X
T-cell	B-X
signals	B-X
,	B-X
like	B-X
CD40L	B-X
,	B-X
or	B-X
a	B-X
broad-range	B-X
caspase	B-X
inhibitor	B-X
,	B-X
but	B-X
only	B-X
CD40L	B-X
prevents	B-X
the	B-X
loss	B-X
of	B-X
c-Myc	B-X
,	B-X
p27	B-X
accumulation	B-X
and	B-X
growth	B-X
arrest	B-X
.	B-X
Additional	B-X
studies	B-X
suggest	B-X
that	B-X
some	B-X
lymphomas	B-X
can	B-X
be	B-X
blocked	B-X
at	B-X
the	B-X
DISC	B-X
complex	B-X
by	B-X
anti-apoptotic	B-X
proteins	B-X
,	B-X
whereas	B-X
others	B-X
are	B-X
inhibited	B-X
downstream	B-X
of	B-X
caspase	B-X
8	B-X
activation	B-X
.	B-X
Anti-Ig	B-X
treatment	B-X
of	B-X
a	B-X
Fas-sensitive	B-X
line	B-X
,	B-X
A20.2J	B-X
,	B-X
activated	B-X
a	B-X
number	B-X
of	B-X
genes	B-X
whose	B-X
products	B-X
may	B-X
block	B-X
apoptosis	B-X
proximally	B-X
(	B-X
like	B-X
FLICE-inhibitory	B-X
protein	B-X
(	B-X
FLIP1	B-X
)	B-X
)	B-X
or	B-X
at	B-X
late	B-X
points	B-X
,	B-X
such	B-X
as	B-X
bcl-2-family	B-X
members	B-X
.	B-X

Plates	O
were	O
centrifuged	O
at	O
500	O
x	O
g	O
for	O
2	O
hrs	O
at	O
room	O
temperature	O
.	O

Cells	O
were	O
cultured	O
in	O
B	O
cell	O
culture	O
medium	O
for	O
48	O
hrs	O
,	O
after	O
which	O
the	O
transduced	O
cells	O
were	O
selected	O
in	O
3	O
microg	O
/	O
ml	O
puromycin	O
.	O

CD80	B-Protein
upregulation	O
and	O
flow	O
cytometry	O
<EOS>	B-X
We	B-X
have	B-X
established	B-X
an	B-X
experimental	B-X
protocol	B-X
to	B-X
follow	B-X
immune	B-X
polarization	B-X
of	B-X
myeloid-derived	B-X
cells	B-X
into	B-X
M1	B-X
(	B-X
classically	B-X
activated	B-X
)	B-X
or	B-X
M2	B-X
(	B-X
alternatively	B-X
activated	B-X
)	B-X
macrophage-like	B-X
cells	B-X
through	B-X
assessment	B-X
with	B-X
a	B-X
10-color	B-X
flow	B-X
cytometry	B-X
panel	B-X
that	B-X
allows	B-X
visualization	B-X
and	B-X
deep-characterization	B-X
of	B-X
green-fluorescent-protein	B-X
(	B-X
GFP	B-X
)	B-X
-labeled	B-X
Mtb	B-X
in	B-X
diverse	B-X
macrophages	B-X
subsets	B-X
.	B-X
Fully	B-X
polarized	B-X
M1	B-X
and	B-X
M2	B-X
cells	B-X
were	B-X
infected	B-X
with	B-X
Mtb-GFP	B-X
for	B-X
4	B-X
hours	B-X
before	B-X
detached	B-X
Mtb-infected	B-X
macrophages	B-X
were	B-X
stained	B-X
with	B-X
flow	B-X
cytometry	B-X
at	B-X
4-	B-X
or	B-X
24-hours	B-X
post-infection	B-X
.	B-X
Sample	B-X
acquisition	B-X
was	B-X
performed	B-X
with	B-X
flow	B-X
cytometry	B-X
and	B-X
the	B-X
data	B-X
was	B-X
analyzed	B-X
using	B-X
a	B-X
flow	B-X
cytometry	B-X
analysis	B-X
software	B-X
.	B-X
This	B-X
protocol	B-X
resulted	B-X
in	B-X
effective	B-X
M1/M2	B-X
polarization	B-X
characterized	B-X
by	B-X
elevated	B-X
levels	B-X
of	B-X
CD64	B-X
,	B-X
CD86	B-X
,	B-X
TLR2	B-X
,	B-X
HLA-DR	B-X
and	B-X
CCR7	B-X
on	B-X
uninfected	B-X
M1	B-X
cells	B-X
,	B-X
while	B-X
uninfected	B-X
M2	B-X
cells	B-X
exhibited	B-X
a	B-X
strong	B-X
up-regulation	B-X
of	B-X
the	B-X
M2	B-X
phenotype	B-X
markers	B-X
CD163	B-X
,	B-X
CD200R	B-X
,	B-X
CD206	B-X
and	B-X
CD80	B-X
.	B-X
This	B-X
M1/M2	B-X
flow	B-X
cytometry	B-X
protocol	B-X
could	B-X
be	B-X
used	B-X
as	B-X
a	B-X
backbone	B-X
in	B-X
Mtb-macrophage	B-X
research	B-X
and	B-X
be	B-X
adopted	B-X
for	B-X
special	B-X
needs	B-X
in	B-X
different	B-X
areas	B-X
of	B-X
research	B-X
.	B-X

Cells	O
(	O
5x104	O
in	O
2	O
ml	O
)	O
were	O
cultured	O
in	O
24	O
-	O
well	O
plates	O
for	O
3	O
days	O
with	O
5	O
microg	O
/	O
ml	O
anti	O
-	O
CD40	O
or	O
an	O
isotype	O
control	O
antibody	O
.	O
<EOS>	B-X
Immunoglobulins	B-X
(	B-X
Igs	B-X
)	B-X
,	B-X
as	B-X
one	B-X
of	B-X
the	B-X
hallmarks	B-X
of	B-X
adaptive	B-X
immunity	B-X
,	B-X
first	B-X
arose	B-X
approximately	B-X
500	B-X
million	B-X
years	B-X
ago	B-X
with	B-X
the	B-X
emergence	B-X
of	B-X
jawed	B-X
vertebrates	B-X
.	B-X
An	B-X
Inflammatory	B-X
Story	B-X
:	B-X
Antibodies	B-X
in	B-X
Tuberculosis	B-X
Comorbidities	B-X
.	B-X
To	B-X
assay	B-X
salivary	B-X
anti-nuclear	B-X
antibody	B-X
(	B-X
ANA	B-X
)	B-X
and	B-X
its	B-X
isotypes	B-X
in	B-X
patients	B-X
with	B-X
systemic	B-X
lupus	B-X
erythematosus	B-X
(	B-X
SLE	B-X
)	B-X
and	B-X
to	B-X
investigate	B-X
relevant	B-X
clinical	B-X
associations	B-X
.	B-X
IL-4	B-X
is	B-X
required	B-X
for	B-X
the	B-X
generation	B-X
of	B-X
both	B-X
primary	B-X
polyclonal	B-X
and	B-X
secondary	B-X
antigen-specific	B-X
IgE	B-X
responses	B-X
in	B-X
vivo	B-X
.	B-X
2	B-X
.	B-X
IL-4	B-X
is	B-X
required	B-X
to	B-X
maintain	B-X
established	B-X
,	B-X
ongoing	B-X
,	B-X
antigen-specific	B-X
and	B-X
polyclonal	B-X
IgE	B-X
responses	B-X
.	B-X
3	B-X
.	B-X
5	B-X
.	B-X
An	B-X
antibody	B-X
that	B-X
inhibits	B-X
IL-4	B-X
binding	B-X
to	B-X
IL-4	B-X
receptors	B-X
affects	B-X
Ig	B-X
isotype	B-X
selection	B-X
in	B-X
the	B-X
same	B-X
way	B-X
as	B-X
an	B-X
antibody	B-X
that	B-X
neutralizes	B-X
IL-4	B-X
.	B-X
IFN-gamma	B-X
can	B-X
also	B-X
suppress	B-X
IgG1	B-X
production	B-X
and	B-X
stimulate	B-X
IgG2a	B-X
production	B-X
.	B-X
However	B-X
,	B-X
IFN-gamma	B-X
appears	B-X
to	B-X
suppress	B-X
polyclonal	B-X
IgG1	B-X
responses	B-X
more	B-X
than	B-X
antigen-specific	B-X
IgG1	B-X
responses	B-X
,	B-X
and	B-X
it	B-X
enhances	B-X
,	B-X
but	B-X
is	B-X
not	B-X
required	B-X
for	B-X
,	B-X
the	B-X
generation	B-X
of	B-X
IgG2a	B-X
responses	B-X
.	B-X
IFN-alpha	B-X
appears	B-X
to	B-X
resemble	B-X
IFN-gamma	B-X
in	B-X
its	B-X
ability	B-X
to	B-X
inhibit	B-X
IgE	B-X
and	B-X
enhance	B-X
IgG2a	B-X
responses	B-X
in	B-X
GaM	B-X
delta-injected	B-X
mice	B-X
,	B-X
but	B-X
it	B-X
requires	B-X
the	B-X
presence	B-X
of	B-X
IFN-gamma	B-X
to	B-X
suppress	B-X
IgG1	B-X
production	B-X
in	B-X
these	B-X
mice	B-X
.	B-X
12	B-X
.	B-X
There	B-X
is	B-X
no	B-X
direct	B-X
evidence	B-X
that	B-X
IL-5	B-X
contributes	B-X
to	B-X
the	B-X
generation	B-X
of	B-X
in	B-X
vivo	B-X
antibody	B-X
responses	B-X
.	B-X

Cells	O
were	O
stained	O
for	O
flow	O
cytometry	O
with	O
FITC	O
-	O
anti	O
-	O
CD80	O
or	O
an	O
appropriate	O
control	O
antibody	O
as	O
described	O
[	O
28	O
]	O
.	O
<EOS>	B-X
The	B-X
assessment	B-X
of	B-X
dominant	B-X
genotype/lineage	B-X
and	B-X
prevalent	B-X
trends	B-X
and	B-X
confirmation	B-X
the	B-X
presence	B-X
of	B-X
infection	B-X
or	B-X
vaccination	B-X
not	B-X
only	B-X
provides	B-X
scientific	B-X
basis	B-X
and	B-X
first-hand	B-X
information	B-X
for	B-X
appropriate	B-X
control	B-X
measure	B-X
but	B-X
also	B-X
for	B-X
disease	B-X
eradication	B-X
and	B-X
regaining	B-X
FMD	B-X
free	B-X
status	B-X
following	B-X
an	B-X
outbreak	B-X
.	B-X
Although	B-X
different	B-X
biological	B-X
and	B-X
serological	B-X
approaches	B-X
are	B-X
still	B-X
applied	B-X
to	B-X
study	B-X
this	B-X
disease	B-X
,	B-X
ELISA	B-X
test	B-X
based	B-X
on	B-X
the	B-X
distinct	B-X
format	B-X
,	B-X
antigen	B-X
type	B-X
and	B-X
specific	B-X
antibody	B-X
reinforce	B-X
its	B-X
predominance	B-X
in	B-X
different	B-X
research	B-X
areas	B-X
of	B-X
FMD	B-X
,	B-X
and	B-X
this	B-X
may	B-X
replace	B-X
the	B-X
traditional	B-X
methods	B-X
in	B-X
the	B-X
near	B-X
future	B-X
.	B-X
This	B-X
review	B-X
gives	B-X
comprehensive	B-X
insight	B-X
on	B-X
ELISA	B-X
currently	B-X
available	B-X
for	B-X
typing	B-X
,	B-X
antigenic	B-X
analysis	B-X
,	B-X
vaccination	B-X
status	B-X
differentiation	B-X
and	B-X
surveillance	B-X
vaccine	B-X
purity	B-X
and	B-X
content	B-X
at	B-X
all	B-X
stages	B-X
of	B-X
manufacture	B-X
in	B-X
FMDV	B-X
.	B-X
Besides	B-X
,	B-X
some	B-X
viewpoint	B-X
about	B-X
the	B-X
recent	B-X
advances	B-X
and	B-X
trends	B-X
of	B-X
ELISA	B-X
reagent	B-X
for	B-X
FMD	B-X
are	B-X
described	B-X
here	B-X
.	B-X

Data	O
acquired	O
with	O
a	O
FACScan	O
flow	O
cytometer	O
(	O
BD	O
Biosciences	O
)	O
were	O
analyzed	O
with	O
WinMDI	O
2	O
.	O
8	O
(	O
Scripps	O
Research	O
Institute	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

GLepsilon	B-Protein
transcript	O
assay	O

The	O
CD40	B-Protein
-	O
simulated	O
activation	O
of	O
GLepsilon	B-Protein
transcription	O
was	O
evaluated	O
as	O
previously	O
reported	O
[	O
33	O
]	O
.	O

Briefly	O
,	O
1x106	O
cells	O
were	O
stimulated	O
overnight	O
with	O
anti	O
-	O
CD40	O
antibody	O
(	O
10	O
microg	O
/	O
ml	O
)	O
or	O
an	O
isotype	O
control	O
antibody	O
,	O
with	O
or	O
without	O
500	O
U	O
/	O
ml	O
mouse	O
IL	B-Protein
-	I-Protein
4	I-Protein
(	O
BD	O
Biosciences	O
)	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
characterize	B-X
the	B-X
human	B-X
immune	B-X
response	B-X
to	B-X
natural	B-X
CCHFV	B-X
infection	B-X
to	B-X
identify	B-X
potent	B-X
neutralizing	B-X
monoclonal	B-X
antibodies	B-X
(	B-X
nAbs	B-X
)	B-X
targeting	B-X
the	B-X
viral	B-X
glycoprotein	B-X
.	B-X
Competition	B-X
experiments	B-X
showed	B-X
that	B-X
these	B-X
nAbs	B-X
bind	B-X
six	B-X
distinct	B-X
antigenic	B-X
sites	B-X
in	B-X
the	B-X
Gc	B-X
subunit	B-X
.	B-X
Further	B-X
enhancements	B-X
in	B-X
neutralization	B-X
breadth	B-X
and	B-X
potency	B-X
were	B-X
attained	B-X
by	B-X
physically	B-X
linking	B-X
variable	B-X
domains	B-X
of	B-X
synergistic	B-X
nAb	B-X
pairs	B-X
through	B-X
bispecific	B-X
antibody	B-X
(	B-X
bsAb	B-X
)	B-X
engineering	B-X
.	B-X
Polysaccharide	B-X
and	B-X
conjugate	B-X
vaccines	B-X
to	B-X

RNA	O
was	O
isolated	O
using	O
Trizol	O
(	O
Invitrogen	O
)	O
,	O
and	O
reverse	O
-	O
transcribed	O
(	O
Superscript	O
III	O
kit	O
,	O
Invitrogen	O
)	O
.	O

Quantitative	O
PCR	O
for	O
GLepsilon	B-Protein
and	O
Hprt1	B-Protein
was	O
performed	O
using	O
SYBR	O
GREEN	O
master	O
mix	O
(	O
Applied	O
Biosystems	O
)	O
,	O
and	O
an	O
Applied	O
Biosystems	O
7900HT	O
Fast	O
Real	O
-	O
Time	O
PCR	O
instrument	O
.	O

Expression	O
of	O
GLepsilon	B-Protein
in	O
each	O
sample	O
was	O
normalized	O
to	O
the	O
expression	O
of	O
Hprt1	B-Protein
.	O

NF	O
-	O
kappaB	O
and	O
JNK	O
activation	O
assays	O
<EOS>	B-X
Moreover	B-X
,	B-X
administration	B-X
of	B-X
kaempferol	B-X
reduced	B-X
microglia	B-X
activation	B-X
and	B-X
oxidative	B-X
stress	B-X
level	B-X
in	B-X
the	B-X
spinal	B-X
cord	B-X
.	B-X
The	B-X
in	B-X
vitro	B-X
studies	B-X
showed	B-X
that	B-X
kaempferol	B-X
suppressed	B-X
the	B-X
microglia	B-X
activation	B-X
resulting	B-X
from	B-X
the	B-X
administration	B-X
of	B-X
LPS	B-X
with	B-X
ATP	B-X
to	B-X
BV-2	B-X
cells	B-X
.	B-X
Pretreated	B-X
BV2	B-X
cells	B-X
with	B-X
kaempferol	B-X
reduced	B-X
the	B-X
generation	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
by	B-X
inhibiting	B-X
NADPH	B-X
oxidase	B-X
4	B-X
,	B-X
and	B-X
then	B-X
,	B-X
suppressed	B-X
the	B-X
phosphorylation	B-X
of	B-X
p38	B-X
MAPK	B-X
and	B-X
JNK	B-X
,	B-X
which	B-X
subsequently	B-X
inhibited	B-X
nuclear	B-X
translocation	B-X
of	B-X
NF-κB	B-X
p65	B-X
to	B-X
express	B-X
pro-inflammatory	B-X
factors	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
kaempferol	B-X
was	B-X
able	B-X
to	B-X
reduce	B-X
oxidative	B-X
stress	B-X
and	B-X
inflammatory	B-X
response	B-X
through	B-X
down-regulation	B-X
of	B-X
ROS	B-X
dependent	B-X
MAPKs-	B-X
NF-κB	B-X
and	B-X
pyroptosis	B-X
signaling	B-X
pathway	B-X
,	B-X
which	B-X
suggested	B-X
that	B-X
kaempferol	B-X
might	B-X
be	B-X
a	B-X
novel	B-X
promising	B-X
therapeutic	B-X
agent	B-X
for	B-X
SCI	B-X
.	B-X

For	O
activation	O
of	O
CD40	B-Protein
signaling	O
,	O
5x104	O
HI5	O
insect	O
cells	O
or	O
HI5	O
insect	O
cells	O
expressing	O
mouse	O
CD154	B-Protein
(	O
CD40	B-Protein
ligand	I-Protein
)	O
were	O
added	O
to	O
1x106	O
B	O
cells	O
.	O

Cells	O
were	O
centrifuged	O
for	O
1	O
minute	O
at	O
400	O
x	O
g	O
(	O
to	O
promote	O
contact	O
between	O
ligand	O
cells	O
and	O
B	O
cells	O
)	O
then	O
incubated	O
at	O
37degreesC	O
for	O
times	O
indicated	O
in	O
Fig	O
.	O

4	O
.	O
<EOS>	B-X
Effect	B-X
of	B-X
chloroquine	B-X
on	B-X
cultured	B-X
fibroblasts	B-X
:	B-X
release	B-X
of	B-X
lysosomal	B-X
hydrolases	B-X
and	B-X
inhibition	B-X
of	B-X
their	B-X
uptake	B-X
.	B-X

Following	O
stimulation	O
,	O
cells	O
were	O
chilled	O
on	O
ice	O
for	O
2	O
minutes	O
.	O

Cell	O
pellets	O
were	O
dissolved	O
in	O
2X	O
SDS	O
-	O
PAGE	O
loading	O
buffer	O
,	O
sonicated	O
,	O
and	O
heated	O
for	O
5	O
minutes	O
at	O
95degreesC	O
.	O

Total	O
cell	O
lysates	O
(	O
1x105	O
cell	O
equivalents	O
per	O
lane	O
)	O
were	O
fractionated	O
by	O
SDS	O
-	O
PAGE	O
and	O
blotted	O
to	O
polyvinylidine	O
fluoride	O
(	O
PVDF	O
)	O
membranes	O
.	O

Membranes	O
were	O
probed	O
with	O
antibodies	O
as	O
indicated	O
in	O
Fig	O
.	O
<EOS>	B-X
Up	B-X
to	B-X
now	B-X
,	B-X
the	B-X
main	B-X
techniques	B-X
used	B-X
to	B-X
assess	B-X
the	B-X
partition	B-X
of	B-X
proteins	B-X
of	B-X
interest	B-X
inside	B-X
lipid	B-X
rafts	B-X
were	B-X
Detergent	B-X
Resistant	B-X
Membranes	B-X
(	B-X
DRMs	B-X
)	B-X
isolation	B-X
and	B-X
co-patching	B-X
with	B-X
antibodies	B-X
.	B-X
To	B-X
determine	B-X
diffusion	B-X
times	B-X
,	B-X
minute	B-X
fluorescence	B-X
fluctuations	B-X
are	B-X
measured	B-X
as	B-X
a	B-X
function	B-X
of	B-X
time	B-X
in	B-X
a	B-X
focal	B-X
volume	B-X
(	B-X
approximately	B-X
1	B-X
femtoliter	B-X
)	B-X
,	B-X
located	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
of	B-X
cells	B-X
with	B-X
a	B-X
confocal	B-X
microscope	B-X
(	B-X
Fig	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
obtained	B-X
4	B-X
clones	B-X
that	B-X
could	B-X
be	B-X
stably	B-X
grown	B-X
in	B-X
culture	B-X
medium	B-X
with	B-X
colchicine	B-X
at	B-X
200	B-X
ng/ml	B-X
and	B-X
designated	B-X
as	B-X
ES-mdr1	B-X
clones	B-X
A	B-X
,	B-X
B	B-X
,	B-X
C	B-X
,	B-X
and	B-X
D.	B-X
Southern	B-X
blot	B-X
analysis	B-X
of	B-X
DNA	B-X
from	B-X
ES-mdr1	B-X
A	B-X
and	B-X
D	B-X
cells	B-X
digested	B-X
by	B-X
Hind	B-X
III	B-X
and	B-X
hybridized	B-X
with	B-X
mdr1	B-X
cDNA	B-X
5	B-X
A	B-X
probe	B-X
was	B-X
shown	B-X
in	B-X
Fig	B-X
.	B-X
Slot	B-X
blot	B-X
and	B-X
Northern	B-X
analysis	B-X
of	B-X
total	B-X
RNA	B-X
and	B-X
poly	B-X
A+	B-X
RNA	B-X
extracted	B-X
from	B-X
ES-mdr1	B-X
cells	B-X
were	B-X
shown	B-X
in	B-X
Fig	B-X
.	B-X
Indirect	B-X
immunofluorescence	B-X
analysis	B-X
with	B-X
antibodies	B-X
against	B-X
p170	B-X
glycoprotein	B-X
indicated	B-X
that	B-X
p170	B-X
protein	B-X
translated	B-X
from	B-X
mdr1	B-X
mRNA	B-X
was	B-X
present	B-X
at	B-X
the	B-X
surface	B-X
of	B-X
ES-mdr1	B-X
cells	B-X
(	B-X
Plate	B-X
I	B-X
,	B-X
Fig	B-X
.	B-X
The	B-X
cells	B-X
maintained	B-X
their	B-X
undifferentiated	B-X
morphology	B-X
and	B-X
grew	B-X
in	B-X
nests	B-X
(	B-X
Plate	B-X
I	B-X
,	B-X
Fig	B-X
.	B-X
ES-mdr1	B-X
cells	B-X
injected	B-X
subcutaneously	B-X
into	B-X
129	B-X
mice	B-X
formed	B-X
tumor-like	B-X
outgrowths	B-X
giving	B-X
a	B-X
great	B-X
variety	B-X
of	B-X
cell	B-X
types	B-X
(	B-X
Plate	B-X
I	B-X
,	B-X
Fig	B-X
.	B-X
These	B-X
results	B-X
indicated	B-X
that	B-X
the	B-X
integration	B-X
and	B-X
expression	B-X
of	B-X
human	B-X
mdr1	B-X
gene	B-X
and	B-X
selection	B-X
against	B-X
colchicine	B-X
did	B-X
not	B-X
affect	B-X
the	B-X
pluripotency	B-X
of	B-X
ES-mdr1	B-X
cells	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
However	B-X
,	B-X
ES-mdr1	B-X
cells	B-X
,	B-X
unlike	B-X
their	B-X
parental	B-X
ES-5	B-X
cells	B-X
,	B-X
could	B-X
no	B-X
longer	B-X
be	B-X
induced	B-X
to	B-X
differentiate	B-X
by	B-X
either	B-X
RA	B-X
or	B-X
HMBA	B-X
(	B-X
Plate	B-X
I	B-X
,	B-X
Figs	B-X
.	B-X

4	O
.	O
<EOS>	B-X
Effect	B-X
of	B-X
chloroquine	B-X
on	B-X
cultured	B-X
fibroblasts	B-X
:	B-X
release	B-X
of	B-X
lysosomal	B-X
hydrolases	B-X
and	B-X
inhibition	B-X
of	B-X
their	B-X
uptake	B-X
.	B-X

Chemiluminescent	O
detection	O
(	O
Pierce	O
Biotechnology	O
)	O
was	O
used	O
for	O
the	O
visualization	O
of	O
bands	O
on	O
Western	O
blots	O
.	O
<EOS>	B-X
The	B-X
procedure	B-X
is	B-X
applicable	B-X
only	B-X
to	B-X
protein	B-X
blots	B-X
on	B-X
nitrocellulose	B-X
and	B-X
PVDF	B-X
membranes	B-X
.	B-X
The	B-X
turquoise-blue-stained	B-X
protein	B-X
bands	B-X
do	B-X
not	B-X
fade	B-X
with	B-X
time	B-X
and	B-X
are	B-X
easy	B-X
to	B-X
photograph	B-X
compared	B-X
to	B-X
those	B-X
stained	B-X
with	B-X
Ponceau	B-X
S.	B-X
Absorbance	B-X
in	B-X
the	B-X
blue	B-X
region	B-X
of	B-X
the	B-X
spectrum	B-X
offers	B-X
good	B-X
properties	B-X
for	B-X
photo	B-X
documentation	B-X
and	B-X
avoids	B-X
interference	B-X
from	B-X
common	B-X
biological	B-X
chromophores	B-X
.	B-X
The	B-X
stain	B-X
is	B-X
compatible	B-X
with	B-X
general	B-X
Western	B-X
blot	B-X
detection	B-X
systems	B-X
,	B-X
and	B-X
membrane	B-X
treatment	B-X
with	B-X
MemCode	B-X
stain	B-X
does	B-X
not	B-X
interfere	B-X
with	B-X
conventional	B-X
chemiluminescent	B-X
or	B-X
chromogenic	B-X
detection	B-X
using	B-X
horseradish	B-X
peroxide	B-X
and	B-X
alkaline	B-X
phosphatase	B-X
substrates	B-X
.	B-X

Images	O
of	O
blots	O
were	O
recorded	O
with	O
a	O
low	O
-	O
light	O
imaging	O
system	O
(	O
LAS4000	O
,	O
Fuji	O
Medical	O
Systems	O
)	O
and	O
on	O
X	O
-	O
ray	O
film	O
.	O

Immunoprecipitations	O
<EOS>	B-X
Cheap-seq	B-X
.	B-X
Enhanced	B-X
protein	B-X
recovery	B-X
and	B-X
reproducibility	B-X
from	B-X
pull-down	B-X
assays	B-X
and	B-X
immunoprecipitations	B-X
using	B-X
spin	B-X
columns	B-X
.	B-X

Immunoprecipitation	O
of	O
CD40	B-Protein
was	O
performed	O
by	O
activated	O
receptor	O
capture	O
,	O
as	O
previously	O
described	O
[	O
6	O
]	O
.	O

Briefly	O
,	O
3x107	O
cells	O
(	O
A20	O
.	O
2J	O
and	O
derivatives	O
)	O
were	O
incubated	O
for	O
60	O
minutes	O
at	O
room	O
temperature	O
with	O
10	O
microl	O
magnetic	O
protein	O
G	O
beads	O
(	O
Dynal	O
)	O
pre	O
-	O
coated	O
with	O
10	O
microg	O
goat	O
anti	O
-	O
rat	O
IgG	O
(	O
Jackson	O
)	O
,	O
and	O
10	O
microg	O
anti	O
-	O
CD40	O
(	O
1C10	O
)	O
or	O
an	O
isotype	O
control	O
antibody	O
(	O
mAb72	O
)	O
.	O

Cells	O
/	O
beads	O
were	O
then	O
pelleted	O
by	O
centrifugation	O
and	O
lysed	O
in	O
buffer	O
containing	O
1	O
%	O
Triton	O
X100	O
.	O

Beads	O
were	O
washed	O
with	O
lysis	O
buffer	O
to	O
remove	O
unbound	O
material	O
.	O

In	O
some	O
experiments	O
,	O
material	O
associated	O
with	O
the	O
beads	O
was	O
dephosphorylated	O
with	O
lambda	O
phosphatase	O
(	O
New	O
England	O
BioLabs	O
)	O
as	O
per	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Beads	O
were	O
resuspended	O
in	O
2X	O
SDS	O
-	O
PAGE	O
sample	O
buffer	O
and	O
heated	O
for	O
5	O
minutes	O
at	O
95degreesC	O
.	O

Material	O
eluted	O
from	O
the	O
beads	O
was	O
fractionated	O
by	O
SDS	O
-	O
PAGE	O
and	O
transferred	O
to	O
PVDF	O
membranes	O
for	O
Western	O
blotting	O
.	O

In	O
some	O
experiments	O
,	O
cells	O
were	O
cultured	O
for	O
6	O
hrs	O
with	O
25	O
microM	O
antennapedia	O
-	O
linked	O
SMAC	O
-	O
N7	O
peptide	O
(	O
Calbiochem	O
)	O
or	O
an	O
appropriate	O
volume	O
of	O
the	O
solvent	O
used	O
for	O
the	O
peptide	O
(	O
DMSO	O
)	O
.	O
<EOS>	B-X
Two	B-X
new	B-X
RCCS	B-X
sets	B-X
are	B-X
presented	B-X
here	B-X
,	B-X
determined	B-X
in	B-X
dimethyl	B-X
sulfoxide	B-X
(	B-X
DMSO	B-X
)	B-X
and	B-X
chloroform	B-X
:	B-X
methanol	B-X
:	B-X
water	B-X
(	B-X
4:4:1	B-X
by	B-X
volume	B-X
)	B-X
at	B-X
298	B-X
K.	B-X
A	B-X
web-based	B-X
program	B-X
,	B-X
CS-CHEMeleon	B-X
,	B-X
has	B-X
been	B-X
implemented	B-X
to	B-X
determine	B-X
the	B-X
accuracy	B-X
of	B-X
secondary	B-X
structure	B-X
assessment	B-X
by	B-X
calculating	B-X
and	B-X
comparing	B-X
Deltadelta	B-X
values	B-X
for	B-X
various	B-X
RCCS	B-X
datasets	B-X
.	B-X
Optimized	B-X
Deltadelta	B-X
thresholds	B-X
are	B-X
presented	B-X
both	B-X
for	B-X
published	B-X
and	B-X
for	B-X
the	B-X
DMSO	B-X
and	B-X
chloroform	B-X
:	B-X
methanol	B-X
:	B-X
water	B-X
derived	B-X
RCCS	B-X
tables	B-X
.	B-X
Comparative	B-X
assessment	B-X
of	B-X
multiple	B-X
RCCS	B-X
datasets	B-X
should	B-X
be	B-X
performed	B-X
,	B-X
and	B-X
resulting	B-X
Deltadelta-based	B-X
restraints	B-X
weighted	B-X
appropriately	B-X
relative	B-X
to	B-X
other	B-X
experimental	B-X
restraints	B-X
.	B-X

After	O
incubation	O
,	O
cells	O
(	O
in	O
peptide	O
-	O
or	O
DMSO	O
-	O
containing	O
medium	O
)	O
were	O
stimulated	O
with	O
antibody	O
-	O
coated	O
beads	O
as	O
outlined	O
above	O
.	O

HOIP	B-Protein
gene	O
targeting	O
.	O
<EOS>	B-X
LUBAC	B-X
key	B-X
component	B-X
RNF31/HOIP	B-X
translocates	B-X
to	B-X
the	B-X
LC3	B-X
puncta	B-X
area	B-X
when	B-X
autophagy	B-X
is	B-X
induced	B-X
.	B-X
HOIP	B-X
,	B-X
the	B-X
catalytic	B-X
component	B-X
of	B-X
the	B-X
linear	B-X
ubiquitin	B-X
chain	B-X
assembly	B-X
complex	B-X
(	B-X
LUBAC	B-X
)	B-X
,	B-X
is	B-X
a	B-X
critical	B-X
regulator	B-X
of	B-X
inflammation	B-X
.	B-X
However	B-X
,	B-X
how	B-X
HOIP	B-X
itself	B-X
is	B-X
regulated	B-X
to	B-X
control	B-X
inflammatory	B-X
responses	B-X
is	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
discover	B-X
that	B-X
site-specific	B-X
ubiquitination	B-X
of	B-X
K784	B-X
within	B-X
human	B-X
HOIP	B-X
promotes	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
-induced	B-X
inflammatory	B-X
signaling	B-X
.	B-X
A	B-X
HOIP	B-X
K784R	B-X
mutant	B-X
is	B-X
catalytically	B-X
active	B-X
but	B-X
shows	B-X
reduced	B-X
induction	B-X
of	B-X
an	B-X
NF-κB	B-X
reporter	B-X
relative	B-X
to	B-X
wild-type	B-X
HOIP	B-X
.	B-X
HOIP	B-X
K784	B-X
is	B-X
evolutionarily	B-X
conserved	B-X
,	B-X
equivalent	B-X
to	B-X
HOIP	B-X
K778	B-X
in	B-X
mice	B-X
.	B-X
We	B-X
generated	B-X
Hoip	B-X

(	O
A	O
)	O
Regions	O
of	O
Rnf31	B-Protein
gene	O
sequence	O
(	O
bottom	O
)	O
used	O
in	O
the	O
HOIP	B-Protein
gene	O
targeting	O
vector	O
(	O
top	O
)	O
are	O
shown	O
.	O

Arrows	O
(	O
F	O
and	O
R	O
)	O
indicate	O
approximate	O
positions	O
of	O
sequences	O
homologous	O
to	O
oligonucleotides	O
used	O
for	O
PCR	O
-	O
mediated	O
detection	O
of	O
homologous	O
recombination	O
.	O

Homologous	O
recombination	O
of	O
the	O
vector	O
with	O
Rnf31	B-Protein
resulted	O
in	O
a	O
small	O
chromosomal	O
deletion	O
and	O
the	O
in	O
-	O
frame	O
insertion	O
of	O
neomycin	O
phosphotransferase	O
(	O
NeoR	O
)	O
into	O
the	O
amino	O
-	O
terminal	O
HOIP	B-Protein
coding	O
sequence	O
.	O

A	O
diphtheria	O
toxin	O
(	O
DT	O
)	O
cassette	O
in	O
the	O
vector	O
facilitates	O
the	O
negative	O
selection	O
of	O
cells	O
in	O
which	O
random	O
chromosomal	O
insertion	O
of	O
the	O
vector	O
takes	O
place	O
.	O

LoxP	O
sequences	O
allow	O
the	O
Cre	O
-	O
mediated	O
deletion	O
of	O
the	O
NeoR	O
coding	O
sequence	O
.	O

The	O
SV40pA	O
sequence	O
helps	O
to	O
ensure	O
disruption	O
of	O
gene	O
expression	O
after	O
deletion	O
of	O
the	O
NeoR	O
sequence	O
.	O

(	O
B	O
)	O
Anti	O
-	O
HOIP	O
and	O
anti	O
-	O
FLAG	O
Western	O
blots	O
of	O
cell	O
lysates	O
from	O
A20	O
.	O
2J	O
cells	O
and	O
HOIP	B-Protein
-	O
deficient	O
(	O
HOIP	B-Protein
-	O
/	O
-	O
)	O
clones	O
.	O

A	O
partial	O
decrease	O
in	O
HOIP	B-Protein
protein	O
expression	O
is	O
evident	O
in	O
cells	O
following	O
disruption	O
of	O
one	O
copy	O
of	O
Rnf31	B-Protein
(	O
HOIP	B-Protein
-	O
/	O
+	O
)	O
.	O

HOIP	B-Protein
expression	O
in	O
clones	O
reconstituted	O
with	O
an	O
empty	O
retroviral	O
vector	O
(	O
pMIP	O
)	O
or	O
a	O
retroviral	O
vector	O
encoding	O
FLAG	O
-	O
tagged	O
HOIP	B-Protein
is	O
also	O
shown	O
.	O

Approximate	O
molecular	O
weight	O
of	O
HOIP	B-Protein
is	O
120	O
kD	O
.	O

CD40	B-Protein
-	O
mediated	O
CD80	B-Protein
upregulation	O
is	O
defective	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
.	O
<EOS>	B-X
CD40	B-X
is	B-X
a	B-X
cell	B-X
surface	B-X
receptor	B-X
important	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
antigen-presenting	B-X
cells	B-X
during	B-X
immune	B-X
responses	B-X
.	B-X
In	B-X
macrophages	B-X
and	B-X
dendritic	B-X
cells	B-X
,	B-X
engagement	B-X
of	B-X
CD40	B-X
by	B-X
its	B-X
ligand	B-X
CD154	B-X
provides	B-X
signals	B-X
critical	B-X
for	B-X
anti-microbial	B-X
and	B-X
T	B-X
cell-mediated	B-X
immune	B-X
responses	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
B	B-X
cells	B-X
,	B-X
CD40	B-X
signaling	B-X
has	B-X
a	B-X
major	B-X
role	B-X
in	B-X
regulating	B-X
cell	B-X
proliferation	B-X
,	B-X
antibody	B-X
production	B-X
,	B-X
and	B-X
memory	B-X
B	B-X
cell	B-X
development	B-X
.	B-X
CD40	B-X
engagement	B-X
results	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
a	B-X
receptor-associated	B-X
complex	B-X
that	B-X
mediates	B-X
activation	B-X
of	B-X
NF-κB	B-X
,	B-X
stress-activated	B-X
protein	B-X
kinases	B-X
,	B-X
and	B-X
other	B-X
signaling	B-X
molecules	B-X
.	B-X
However	B-X
,	B-X
the	B-X
mechanisms	B-X
that	B-X
link	B-X
CD40	B-X
to	B-X
these	B-X
signaling	B-X
events	B-X
have	B-X
been	B-X
only	B-X
partially	B-X
characterized	B-X
.	B-X
Known	B-X
components	B-X
of	B-X
the	B-X
CD40	B-X
signaling	B-X
complex	B-X
include	B-X
members	B-X
of	B-X
the	B-X
TNF	B-X
receptor-associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
family	B-X
of	B-X
proteins	B-X
.	B-X
We	B-X
previously	B-X
showed	B-X
that	B-X
the	B-X
TRAF	B-X
family	B-X
member	B-X
TRAF2	B-X
mediates	B-X
recruitment	B-X
of	B-X
HOIL-1L-interacting	B-X
protein	B-X
(	B-X
HOIP	B-X
)	B-X
to	B-X
the	B-X
cytoplasmic	B-X
domain	B-X
of	B-X
CD40	B-X
,	B-X
suggesting	B-X
that	B-X
HOIP	B-X
has	B-X
a	B-X
role	B-X
in	B-X
the	B-X
CD40	B-X
signaling	B-X
pathway	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
role	B-X
of	B-X
HOIP	B-X
in	B-X
CD40	B-X
signaling	B-X
,	B-X
we	B-X
used	B-X
somatic	B-X
cell	B-X
gene	B-X
targeting	B-X
to	B-X
generate	B-X
mouse	B-X
B	B-X
cell	B-X
lines	B-X
deficient	B-X
in	B-X
HOIP	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
CD40-induced	B-X
upregulation	B-X
of	B-X
CD80	B-X
and	B-X
activation	B-X
of	B-X
germline	B-X
immunoglobulin	B-X
epsilon	B-X
transcription	B-X
were	B-X
defective	B-X
in	B-X
HOIP-deficient	B-X
cells	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
the	B-X
CD40-mediated	B-X
activation	B-X
of	B-X
NF-κB	B-X
and	B-X
c-Jun	B-X
kinase	B-X
was	B-X
impaired	B-X
.	B-X
Recruitment	B-X
of	B-X
IκB	B-X
kinase	B-X
proteins	B-X
to	B-X
the	B-X
CD40	B-X
signaling	B-X
complex	B-X
was	B-X
undetectable	B-X
in	B-X
HOIP-deficient	B-X
cells	B-X
,	B-X
potentially	B-X
explaining	B-X
the	B-X
defect	B-X
in	B-X
NF-κB	B-X
activation	B-X
.	B-X
Restoration	B-X
of	B-X
HOIP	B-X
expression	B-X
reversed	B-X
the	B-X
defects	B-X
in	B-X
cellular	B-X
activation	B-X
and	B-X
signaling	B-X
.	B-X
These	B-X
results	B-X
reveal	B-X
HOIP	B-X
as	B-X
a	B-X
key	B-X
component	B-X
of	B-X
the	B-X
CD40	B-X
signaling	B-X
pathway	B-X
.	B-X

Cells	O
were	O
incubated	O
for	O
72	O
hrs	O
with	O
an	O
isotype	O
control	O
antibody	O
(	O
left	O
)	O
or	O
anti	O
-	O
CD40	O
antibody	O
(	O
right	O
)	O
and	O
then	O
stained	O
for	O
expression	O
of	O
CD80	B-Protein
(	O
filled	O
profiles	O
indicate	O
staining	O
with	O
anti	O
-	O
CD80	O
antibody	O
;	O
open	O
profiles	O
are	O
staining	O
with	O
an	O
isotype	O
control	O
antibody	O
)	O
.	O

Transduction	O
of	O
both	O
HOIP	B-Protein
-	O
deficient	O
(	O
HOIP	B-Protein
-	O
/	O
-	O
)	O
clones	O
with	O
a	O
retrovirus	O
encoding	O
FLAG	O
-	O
HOIP	B-Protein
reversed	O
defective	O
CD80	B-Protein
upregulation	O
,	O
while	O
transduction	O
with	O
an	O
empty	O
vector	O
(	O
pMIP	O
)	O
did	O
not	O
.	O

Similar	O
results	O
were	O
obtained	O
in	O
a	O
second	O
experiment	O
.	O

GLepsilon	B-Protein
transcription	O
is	O
defective	O
in	O
CD40	B-Protein
-	O
stimulated	O
HOIP	B-Protein
-	O
deficient	O
cells	O
.	O

A20	O
.	O
2J	O
and	O
HOIP	B-Protein
-	O
deficient	O
cells	O
transduced	O
with	O
an	O
empty	O
retroviral	O
vector	O
(	O
A20	O
.	O
2J	O
+	O
pMIP	O
and	O
HOIP	B-Protein
-	O
/	O
-	O
+	O
pMIP	O
,	O
respectively	O
)	O
,	O
or	O
HOIP	B-Protein
-	O
deficient	O
cells	O
transduced	O
with	O
a	O
HOIP	B-Protein
-	O
encoding	O
retrovirus	O
(	O
HOIP	B-Protein
-	O
/	O
-	O
+	O
HOIP	B-Protein
)	O
were	O
cultured	O
overnight	O
with	O
agonistic	O
anti	O
-	O
CD40	O
or	O
an	O
isotype	O
control	O
antibody	O
(	O
iso	O
)	O
,	O
with	O
or	O
without	O
IL	B-Protein
-	I-Protein
4	I-Protein
.	O
<EOS>	B-X
Interleukin	B-X
(	B-X
IL	B-X
)	B-X
-4	B-X
and	B-X
IL-13	B-X
belong	B-X
to	B-X
the	B-X
T	B-X
helper	B-X
2	B-X
(	B-X
Th2	B-X
)	B-X
cytokine	B-X
family	B-X
,	B-X
along	B-X
with	B-X
IL-3	B-X
,	B-X
IL-5	B-X
,	B-X
and	B-X
IL-9	B-X
.	B-X
They	B-X
have	B-X
important	B-X
immunomodulatory	B-X
activities	B-X
and	B-X
exert	B-X
influence	B-X
on	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
immune	B-X
cells	B-X
,	B-X
such	B-X
as	B-X
B	B-X
cells	B-X
,	B-X
eosinophils	B-X
,	B-X
basophils	B-X
,	B-X
monocytes	B-X
,	B-X
fibroblasts	B-X
,	B-X
endothelial	B-X
cells	B-X
,	B-X
airway	B-X
epithelial	B-X
cells	B-X
,	B-X
smooth	B-X
muscle	B-X
cells	B-X
,	B-X
and	B-X
keratinocytes	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
implicated	B-X
IL-4	B-X
and	B-X
IL-13	B-X
in	B-X
the	B-X
development	B-X
of	B-X
various	B-X
autoimmune	B-X
diseases	B-X
.	B-X
Recent	B-X
findings	B-X
suggest	B-X
that	B-X
the	B-X
IL-4	B-X
and	B-X
IL-13	B-X
might	B-X
play	B-X
a	B-X
significant	B-X
role	B-X
in	B-X
the	B-X
downregulation	B-X
of	B-X
inflammatory	B-X
processes	B-X
underlying	B-X
RA	B-X
pathology	B-X
,	B-X
and	B-X
beneficially	B-X
modulate	B-X
the	B-X
course	B-X
of	B-X
the	B-X
disease	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
biological	B-X
features	B-X
of	B-X
the	B-X
IL-4	B-X
and	B-X
IL-13	B-X
and	B-X
provides	B-X
current	B-X
knowledge	B-X
regarding	B-X
the	B-X
role	B-X
of	B-X
these	B-X
cytokines	B-X
in	B-X
inflammatory	B-X
arthritis	B-X
.	B-X

RNA	O
was	O
isolated	O
from	O
the	O
cells	O
,	O
reverse	O
-	O
transcribed	O
,	O
and	O
then	O
subjected	O
to	O
quantitative	O
PCR	O
to	O
determine	O
levels	O
of	O
GLepsilon	B-Protein
transcripts	O
.	O

Results	O
were	O
normalized	O
to	O
the	O
levels	O
of	O
Hprt1	B-Protein
transcripts	O
in	O
each	O
sample	O
.	O

Symbols	O
indicate	O
the	O
values	O
from	O
duplicate	O
cultures	O
(	O
a	O
line	O
indicates	O
the	O
mean	O
of	O
the	O
two	O
values	O
)	O
.	O

Similar	O
results	O
were	O
obtained	O
in	O
a	O
second	O
experiment	O
and	O
in	O
an	O
additional	O
experiment	O
with	O
a	O
second	O
HOIP	B-Protein
-	O
deficient	O
clone	O
.	O

CD40	B-Protein
-	O
induced	O
activation	O
of	O
NF	O
-	O
kappaB	O
and	O
JNK	O
is	O
defective	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
.	O

CD40	B-Protein
-	O
mediated	O
signaling	O
was	O
defective	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
(	O
HOIP	O
-	O
/	O
-	O
+	O
pMIP	O
)	O
,	O
but	O
intact	O
in	O
parental	O
cells	O
transduced	O
with	O
an	O
empty	O
retroviral	O
vector	O
(	O
A20	O
.	O
2J	O
+	O
pMIP	O
)	O
and	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
transduced	O
with	O
a	O
retroviral	O
vector	O
encoding	O
HOIP	B-Protein
(	O
HOIP	B-Protein
-	O
/	O
-	O
+	O
HOIP	B-Protein
)	O
.	O

Cells	O
were	O
activated	O
with	O
CD154	B-Protein
-	O
expressing	O
insect	O
cells	O
for	O
the	O
times	O
indicated	O
.	O

As	O
a	O
negative	O
control	O
,	O
cells	O
were	O
stimulated	O
with	O
insect	O
cells	O
lacking	O
CD154	B-Protein
(	O
5	O
minute	O
time	O
point	O
only	O
)	O
.	O

Western	O
blots	O
of	O
whole	O
-	O
cell	O
lysates	O
were	O
probed	O
with	O
the	O
indicated	O
antibodies	O
.	O
<EOS>	B-X
Specific	B-X
antibodies	B-X
were	B-X
raised	B-X
against	B-X
an	B-X
N-terminal	B-X
domain	B-X
(	B-X
residues	B-X
1-267	B-X
)	B-X
and	B-X
a	B-X
C-terminal	B-X
domain	B-X
(	B-X
residues	B-X
343-486	B-X
)	B-X
expressed	B-X
as	B-X
recombinant	B-X
proteins	B-X
in	B-X
Escherichia	B-X
coli	B-X
.	B-X
Western	B-X
blotting	B-X
of	B-X
lysates	B-X
of	B-X
wild-type	B-X
8325-4	B-X
and	B-X
Newman	B-X
and	B-X
the	B-X
corresponding	B-X
ebpS	B-X
mutants	B-X
showed	B-X
that	B-X
EbpS	B-X
migrated	B-X
with	B-X
an	B-X
apparent	B-X
molecular	B-X
mass	B-X
of	B-X
83	B-X
kDa	B-X
.	B-X
The	B-X
protein	B-X
was	B-X
found	B-X
exclusively	B-X
in	B-X
cytoplasmic	B-X
membrane	B-X
fractions	B-X
purified	B-X
from	B-X
protoplasts	B-X
or	B-X
lysed	B-X
cells	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
the	B-X
clumping	B-X
factor	B-X
ClfA	B-X
,	B-X
which	B-X
was	B-X
cell-wall-associated	B-X
.	B-X
The	B-X
ligand-binding	B-X
domain	B-X
of	B-X
EbpS	B-X
is	B-X
known	B-X
from	B-X
previous	B-X
studies	B-X
to	B-X
be	B-X
present	B-X
in	B-X
the	B-X
N	B-X
terminus	B-X
between	B-X
residues	B-X
14-34	B-X
and	B-X
probing	B-X
whole	B-X
cells	B-X
with	B-X
anti-EbpS1-267	B-X
antibodies	B-X
indicated	B-X
that	B-X
this	B-X
region	B-X
is	B-X
exposed	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
intact	B-X
cells	B-X
.	B-X
This	B-X
was	B-X
also	B-X
confirmed	B-X
by	B-X
the	B-X
observation	B-X
that	B-X
wild-type	B-X
S.	B-X
aureus	B-X
Newman	B-X
cells	B-X
bound	B-X
labeled	B-X
tropoelastin	B-X
whereas	B-X
the	B-X
ebpS	B-X
mutant	B-X
bound	B-X
72	B-X
%	B-X
less	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
C	B-X
terminus	B-X
,	B-X
which	B-X
carries	B-X
a	B-X
putative	B-X
LysM	B-X
peptidoglycan-binding	B-X
domain	B-X
,	B-X
is	B-X
not	B-X
exposed	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
intact	B-X
cells	B-X
and	B-X
presumably	B-X
remains	B-X
buried	B-X
within	B-X
the	B-X
peptidoglycan	B-X
.	B-X
Finally	B-X
,	B-X
expression	B-X
of	B-X
EbpS	B-X
was	B-X
correlated	B-X
with	B-X
the	B-X
ability	B-X
of	B-X
cells	B-X
to	B-X
grow	B-X
to	B-X
a	B-X
higher	B-X
density	B-X
in	B-X
liquid	B-X
culture	B-X
,	B-X
suggesting	B-X
that	B-X
EbpS	B-X
may	B-X
have	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
cell	B-X
growth	B-X
.	B-X

Phospho	B-Protein
-	I-Protein
IkappaBalpha	I-Protein
(	O
pIkappaBalpha	B-Protein
)	O
and	O
phospho	O
-	O
JNK	O
(	O
pJNK	O
)	O
blots	O
were	O
stripped	O
and	O
reprobed	O
for	O
total	O
IkappaBalpha	B-Protein
and	O
total	O
JNK	O
,	O
respectively	O
(	O
anti	O
-	O
JNK	O
antibodies	O
recognize	O
p46	O
and	O
p54	O
isoforms	O
)	O
.	O

IkappaBalpha	B-Protein
blots	O
were	O
also	O
reprobed	O
for	O
actin	O
to	O
demonstrate	O
equal	O
lane	O
loading	O
.	O

Molecular	O
weights	O
are	O
indicated	O
at	O
right	O
.	O
<EOS>	B-X
For	B-X
these	B-X
reasons	B-X
,	B-X
weight	B-X
stigma	B-X
damages	B-X
health	B-X
,	B-X
undermines	B-X
human	B-X
and	B-X
social	B-X
rights	B-X
,	B-X
and	B-X
is	B-X
unacceptable	B-X
in	B-X
modern	B-X
societies	B-X
.	B-X
The	B-X
individual	B-X
risk	B-X
for	B-X
PE-related	B-X
complications	B-X
and	B-X
death	B-X
increases	B-X
with	B-X
the	B-X
number	B-X
of	B-X
comorbidities	B-X
and	B-X
severity	B-X
of	B-X
right	B-X
ventricular	B-X
dysfunction	B-X
.	B-X
The	B-X
individual	B-X
risk	B-X
for	B-X
PE-related	B-X
complications	B-X
and	B-X
death	B-X
increases	B-X
with	B-X
the	B-X
number	B-X
of	B-X
comorbidities	B-X
and	B-X
severity	B-X
of	B-X
right	B-X
ventricular	B-X
dysfunction	B-X
.	B-X
In	B-X
massive	B-X
PE	B-X
,	B-X
the	B-X
use	B-X
of	B-X
thrombolytic	B-X
agents	B-X
is	B-X
suggested	B-X
to	B-X
reduce	B-X
systemic	B-X
hypotension	B-X
and	B-X
right	B-X
ventricular	B-X
failure	B-X
and	B-X
increase	B-X
cardiac	B-X
output	B-X
.	B-X
Recent	B-X
studies	B-X
suggest	B-X
the	B-X
use	B-X
of	B-X
thrombolytic	B-X
drugs	B-X
in	B-X
patients	B-X
with	B-X
normal	B-X
systemic	B-X
blood	B-X
pressure	B-X
who	B-X
show	B-X
right	B-X
ventricular	B-X
dysfunction	B-X
at	B-X
echocardiographic	B-X
examination	B-X
.	B-X
Anticoagulants	B-X
were	B-X
primarily	B-X
indicated	B-X
for	B-X
prevention	B-X
of	B-X
recurrences	B-X
.	B-X

Similar	O
results	O
were	O
obtained	O
in	O
a	O
second	O
experiment	O
and	O
in	O
two	O
additional	O
experiments	O
with	O
a	O
second	O
HOIP	B-Protein
-	O
deficient	O
clone	O
.	O

IKK	O
recruitment	O
to	O
the	O
CD40	O
signaling	O
complex	O
is	O
defective	O
in	O
HOIP	B-Protein
-	O
deficient	O
cells	O
.	O

(	O
A	O
)	O
SMAC	O
peptide	O
treatment	O
reduces	O
recruitment	O
of	O
cIAP1	B-Protein
to	O
CD40	B-Protein
and	O
may	O
modify	O
HOIP	B-Protein
recruitment	O
.	O

A20	O
.	O
2J	O
cells	O
were	O
incubated	O
for	O
six	O
hours	O
with	O
membrane	O
-	O
permeable	O
SMAC	O
-	O
N7	O
peptide	O
or	O
1	O
.	O
5	O
%	O
DMSO	O
(	O
solvent	O
used	O
for	O
the	O
peptide	O
)	O
.	O
<EOS>	B-X
In	B-X
an	B-X
experiment	B-X
designed	B-X
to	B-X
explore	B-X
the	B-X
mechanisms	B-X
of	B-X
fludrocortisone-induced	B-X
high	B-X
blood	B-X
pressure	B-X
,	B-X
we	B-X
serendipitously	B-X
observed	B-X
aortic	B-X
aneurysms	B-X
in	B-X
mice	B-X
infused	B-X
with	B-X
fludrocortisone	B-X
.	B-X
In	B-X
general	B-X
,	B-X
peptides	B-X
do	B-X
not	B-X
exhibit	B-X
a	B-X
well-defined	B-X
conformational	B-X
profile	B-X
in	B-X
solution	B-X
.	B-X
However	B-X
,	B-X
despite	B-X
the	B-X
experimental	B-X
blurred	B-X
picture	B-X
associated	B-X
with	B-X
their	B-X
structure	B-X
,	B-X
compelling	B-X
spectroscopic	B-X
evidence	B-X
shows	B-X
that	B-X
peptides	B-X
exhibit	B-X
local	B-X
order	B-X
.	B-X
The	B-X
conformational	B-X
profile	B-X
of	B-X
a	B-X
peptide	B-X
is	B-X
the	B-X
result	B-X
of	B-X
a	B-X
balance	B-X
between	B-X
intramolecular	B-X
interactions	B-X
between	B-X
different	B-X
atoms	B-X
of	B-X
the	B-X
molecule	B-X
and	B-X
intermolecular	B-X
interactions	B-X
between	B-X
atoms	B-X
of	B-X
the	B-X
molecule	B-X
and	B-X
the	B-X
solvent	B-X
.	B-X
Accordingly	B-X
,	B-X
the	B-X
conformational	B-X
profile	B-X
of	B-X
a	B-X
peptide	B-X
will	B-X
change	B-X
upon	B-X
the	B-X
properties	B-X
of	B-X
the	B-X
solvent	B-X
it	B-X
is	B-X
soaked	B-X
.	B-X
To	B-X
get	B-X
insight	B-X
into	B-X
the	B-X
balance	B-X
between	B-X
intra-	B-X
and	B-X
intermolecular	B-X
interactions	B-X
on	B-X
the	B-X
conformational	B-X
preferences	B-X
of	B-X
the	B-X
peptide	B-X
backbone	B-X
we	B-X
have	B-X
studied	B-X
the	B-X
conformational	B-X
profile	B-X
of	B-X
the	B-X
alanine	B-X
dipeptide	B-X
in	B-X
diverse	B-X
solvents	B-X
using	B-X
molecular	B-X
dynamics	B-X
as	B-X
sampling	B-X
technique	B-X
.	B-X
Different	B-X
treatments	B-X
of	B-X
the	B-X
solvent	B-X
have	B-X
been	B-X
studied	B-X
in	B-X
the	B-X
present	B-X
work	B-X
including	B-X
explicit	B-X
solvent	B-X
molecules	B-X
,	B-X
a	B-X
generalized	B-X
Born	B-X
model	B-X
and	B-X
using	B-X
the	B-X
bulk	B-X
dielectric	B-X
constant	B-X
of	B-X
the	B-X
solvent	B-X
.	B-X
The	B-X
diverse	B-X
calculations	B-X
identify	B-X
four	B-X
major	B-X
conformations	B-X
with	B-X
different	B-X
populations	B-X
in	B-X
the	B-X
diverse	B-X
solvents	B-X
:	B-X
the	B-X
C	B-X

Following	O
the	O
incubation	O
,	O
cell	O
lysates	O
were	O
prepared	O
,	O
fractionated	O
by	O
SDS	O
-	O
PAGE	O
,	O
and	O
evaluated	O
by	O
Western	O
blot	O
(	O
lanes	O
1	O
and	O
2	O
)	O
.	O

Cells	O
incubated	O
with	O
DMSO	O
or	O
SMAC	O
-	O
N7	O
were	O
also	O
stimulated	O
with	O
magnetic	O
beads	O
coated	O
with	O
anti	O
-	O
CD40	O
or	O
an	O
isotype	O
control	O
antibody	O
.	O
<EOS>	B-X
An	B-X
Inflammatory	B-X
Story	B-X
:	B-X
Antibodies	B-X
in	B-X
Tuberculosis	B-X
Comorbidities	B-X
.	B-X
To	B-X
assay	B-X
salivary	B-X
anti-nuclear	B-X
antibody	B-X
(	B-X
ANA	B-X
)	B-X
and	B-X
its	B-X
isotypes	B-X
in	B-X
patients	B-X
with	B-X
systemic	B-X
lupus	B-X
erythematosus	B-X
(	B-X
SLE	B-X
)	B-X
and	B-X
to	B-X
investigate	B-X
relevant	B-X
clinical	B-X
associations	B-X
.	B-X
IL-4	B-X
is	B-X
required	B-X
for	B-X
the	B-X
generation	B-X
of	B-X
both	B-X
primary	B-X
polyclonal	B-X
and	B-X
secondary	B-X
antigen-specific	B-X
IgE	B-X
responses	B-X
in	B-X
vivo	B-X
.	B-X
IL-4	B-X
is	B-X
required	B-X
to	B-X
maintain	B-X
established	B-X
,	B-X
ongoing	B-X
,	B-X
antigen-specific	B-X
and	B-X
polyclonal	B-X
IgE	B-X
responses	B-X
.	B-X
An	B-X
antibody	B-X
that	B-X
inhibits	B-X
IL-4	B-X
binding	B-X
to	B-X
IL-4	B-X
receptors	B-X
affects	B-X
Ig	B-X
isotype	B-X
selection	B-X
in	B-X
the	B-X
same	B-X
way	B-X
as	B-X
an	B-X
antibody	B-X
that	B-X
neutralizes	B-X
IL-4	B-X
.	B-X
IFN-gamma	B-X
can	B-X
also	B-X
suppress	B-X
IgG1	B-X
production	B-X
and	B-X
stimulate	B-X
IgG2a	B-X
production	B-X
.	B-X
However	B-X
,	B-X
IFN-gamma	B-X
appears	B-X
to	B-X
suppress	B-X
polyclonal	B-X
IgG1	B-X
responses	B-X
more	B-X
than	B-X
antigen-specific	B-X
IgG1	B-X
responses	B-X
,	B-X
and	B-X
it	B-X
enhances	B-X
,	B-X
but	B-X
is	B-X
not	B-X
required	B-X
for	B-X
,	B-X
the	B-X
generation	B-X
of	B-X
IgG2a	B-X
responses	B-X
.	B-X
There	B-X
is	B-X
no	B-X
direct	B-X
evidence	B-X
that	B-X
IL-5	B-X
contributes	B-X
to	B-X
the	B-X
generation	B-X
of	B-X
in	B-X
vivo	B-X
antibody	B-X
responses	B-X
.	B-X
Two	B-X
general	B-X
conclusions	B-X
may	B-X
also	B-X
be	B-X
drawn	B-X
.	B-X

Immunoprecipitated	O
(	O
IP	O
)	O
material	O
bound	O
to	O
the	O
beads	O
was	O
loaded	O
in	O
lanes	O
3	O
-	O
5	O
.	O

Samples	O
of	O
the	O
cell	O
lysates	O
after	O
immunoprecipitation	O
appear	O
in	O
lanes	O
6	O
-	O
8	O
.	O

Western	O
blots	O
were	O
probed	O
with	O
antibodies	O
specific	O
for	O
cIAP1	B-Protein
,	O
TRAF2	B-Protein
,	O
TRAF3	B-Protein
,	O
and	O
HOIP	B-Protein
(	O
approximate	O
molecular	O
weights	O
indicated	O
on	O
left	O
)	O
.	O

Similar	O
results	O
were	O
obtained	O
in	O
two	O
additional	O
experiments	O
.	O
<EOS>	B-X
Batch	B-X
experiments	B-X
confirmed	B-X
that	B-X
the	B-X
culture	B-X
medium	B-X
has	B-X
a	B-X
significant	B-X
impact	B-X
on	B-X
bioprocess	B-X
performance	B-X
,	B-X
but	B-X
high	B-X
amino	B-X
acid	B-X
concentrations	B-X
alone	B-X
were	B-X
not	B-X
sufficient	B-X
to	B-X
ensure	B-X
superior	B-X
cell	B-X
growth	B-X
and	B-X
high	B-X
antibody	B-X
production	B-X
.	B-X
In	B-X
additional	B-X
experiments	B-X
,	B-X
two	B-X
of	B-X
the	B-X
eight	B-X
basal	B-X
media	B-X
were	B-X
supplemented	B-X
with	B-X
feeds	B-X
from	B-X
two	B-X
different	B-X
manufacturers	B-X
in	B-X
six	B-X
combinations	B-X
,	B-X
in	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
combined	B-X
impact	B-X
of	B-X
media	B-X
and	B-X
feeds	B-X
on	B-X
cell	B-X
metabolism	B-X
in	B-X
a	B-X
CHO	B-X
fed-batch	B-X
process	B-X
.	B-X
The	B-X
domestic	B-X
pig	B-X
liver	B-X
is	B-X
suitable	B-X
for	B-X
preclinical	B-X
research	B-X
because	B-X
its	B-X
size	B-X
,	B-X
physiology	B-X
,	B-X
and	B-X
anatomy	B-X
are	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
the	B-X
human	B-X
liver	B-X
;	B-X
in	B-X
addition	B-X
,	B-X
there	B-X
is	B-X
a	B-X
high	B-X
degree	B-X
of	B-X
genetic	B-X
similarity	B-X
between	B-X
the	B-X
two	B-X
species	B-X
.	B-X
For	B-X
planning	B-X
experiments	B-X
and	B-X
identifying	B-X
improvements	B-X
in	B-X
both	B-X
invasive	B-X
and	B-X
noninvasive	B-X
methods	B-X
of	B-X
liver	B-X
disease	B-X
management	B-X
,	B-X
the	B-X
morphological	B-X
similarities	B-X
and	B-X
dissimilarities	B-X
of	B-X
the	B-X
pig	B-X
liver	B-X
to	B-X
its	B-X
human	B-X
counterpart	B-X
must	B-X
be	B-X
taken	B-X
into	B-X
consideration	B-X
along	B-X
with	B-X
sexual	B-X
dimorphism	B-X
and	B-X
interindividual	B-X
and	B-X
interspecific	B-X
variability	B-X
.	B-X
The	B-X
results	B-X
thereof	B-X
are	B-X
crucial	B-X
for	B-X
revealing	B-X
and	B-X
assessing	B-X
histological	B-X
changes	B-X
and	B-X
can	B-X
contribute	B-X
to	B-X
the	B-X
optimization	B-X
of	B-X
study	B-X
designs	B-X
.	B-X

(	O
B	O
)	O
CD40	B-Protein
was	O
isolated	O
by	O
immunoprecipitation	O
(	O
as	O
in	O
(	O
A	O
)	O
)	O
from	O
A20	O
.	O
2J	O
cells	O
and	O
HOIP	B-Protein
-	O
deficient	O
cells	O
transduced	O
with	O
an	O
empty	O
retroviral	O
vector	O
(	O
pMIP	O
)	O
or	O
a	O
retroviral	O
vector	O
encoding	O
HOIP	B-Protein
.	O

Material	O
immunoprecipitated	O
with	O
an	O
isotype	O
control	O
antibody	O
(	O
isotype	O
)	O
or	O
anti	O
-	O
CD40	O
antibody	O
was	O
examined	O
by	O
Western	O
blotting	O
for	O
CD40	B-Protein
,	O
TRAF2	B-Protein
,	O
TRAF3	B-Protein
,	O
cIAP1	B-Protein
,	O
HOIP	B-Protein
,	O
IKKalpha	B-Protein
/	O
beta	B-Protein
,	O
and	O
IKKgamma	B-Protein
(	O
right	O
panels	O
)	O
.	O

HOIP	B-Protein
expression	O
was	O
required	O
for	O
coprecipitation	O
of	O
IKK	O
proteins	O
with	O
CD40	B-Protein
.	O

Cell	O
lysates	O
from	O
unstimulated	O
cells	O
are	O
shown	O
in	O
the	O
left	O
panels	O
.	O

Similar	O
results	O
were	O
obtained	O
in	O
a	O
second	O
experiment	O
and	O
in	O
two	O
experiments	O
with	O
a	O
second	O
HOIP	B-Protein
-	O
deficient	O
clone	O
.	O

(	O
C	O
)	O
To	O
further	O
evaluate	O
HOIP	B-Protein
-	O
dependent	O
recruitment	O
of	O
IKKgamma	B-Protein
to	O
CD40	B-Protein
,	O
A20	O
.	O
2J	O
cells	O
or	O
HOIP	B-Protein
-	O
deficient	O
(	O
HOIP	B-Protein
-	O
/	O
-	O
)	O
A20	O
.	O
2J	O
cells	O
were	O
transduced	O
with	O
an	O
empty	O
retroviral	O
vector	O
or	O
a	O
retroviral	O
construct	O
encoding	O
BP	O
epitope	O
-	O
tagged	O
IKKgamma	B-Protein
(	O
noted	O
in	O
the	O
figure	O
as	O
pMIP	B-Protein
and	O
IKKgamma	B-Protein
,	O
respectively	O
)	O
.	O

Lysates	O
(	O
lanes	O
1	O
-	O
3	O
)	O
and	O
immunoprecipitation	O
(	O
IP	O
)	O
samples	O
(	O
lanes	O
4	O
-	O
11	O
)	O
from	O
the	O
cell	O
lines	O
were	O
fractionated	O
by	O
SDS	O
-	O
PAGE	O
and	O
evaluated	O
by	O
Western	O
blotting	O
with	O
antibodies	O
to	O
the	O
BP	O
tag	O
(	O
IKKgamma	B-Protein
,	O
upper	O
panel	O
)	O
and	O
TRAF2	B-Protein
.	O

The	O
anti	O
-	O
CD40	O
IP	O
sample	O
in	O
lane	O
11	O
was	O
treated	O
with	O
lambda	O
phosphatase	O
;	O
the	O
sample	O
in	O
lane	O
10	O
was	O
mock	O
-	O
treated	O
.	O

Protein	O
samples	O
(	O
minus	O
those	O
treated	O
with	O
phosphatase	O
)	O
were	O
also	O
fractionated	O
on	O
a	O
separate	O
gel	O
(	O
lower	O
acrylamide	O
concentration	O
)	O
for	O
the	O
evaluation	O
of	O
TRAF3	B-Protein
and	O
HOIP	B-Protein
(	O
bottom	O
two	O
panels	O
)	O
.	O

Similar	O
results	O
were	O
obtained	O
in	O
two	O
additional	O
experiments	O
.	O
<EOS>	B-X
Batch	B-X
experiments	B-X
confirmed	B-X
that	B-X
the	B-X
culture	B-X
medium	B-X
has	B-X
a	B-X
significant	B-X
impact	B-X
on	B-X
bioprocess	B-X
performance	B-X
,	B-X
but	B-X
high	B-X
amino	B-X
acid	B-X
concentrations	B-X
alone	B-X
were	B-X
not	B-X
sufficient	B-X
to	B-X
ensure	B-X
superior	B-X
cell	B-X
growth	B-X
and	B-X
high	B-X
antibody	B-X
production	B-X
.	B-X
In	B-X
additional	B-X
experiments	B-X
,	B-X
two	B-X
of	B-X
the	B-X
eight	B-X
basal	B-X
media	B-X
were	B-X
supplemented	B-X
with	B-X
feeds	B-X
from	B-X
two	B-X
different	B-X
manufacturers	B-X
in	B-X
six	B-X
combinations	B-X
,	B-X
in	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
combined	B-X
impact	B-X
of	B-X
media	B-X
and	B-X
feeds	B-X
on	B-X
cell	B-X
metabolism	B-X
in	B-X
a	B-X
CHO	B-X
fed-batch	B-X
process	B-X
.	B-X
The	B-X
domestic	B-X
pig	B-X
liver	B-X
is	B-X
suitable	B-X
for	B-X
preclinical	B-X
research	B-X
because	B-X
its	B-X
size	B-X
,	B-X
physiology	B-X
,	B-X
and	B-X
anatomy	B-X
are	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
the	B-X
human	B-X
liver	B-X
;	B-X
in	B-X
addition	B-X
,	B-X
there	B-X
is	B-X
a	B-X
high	B-X
degree	B-X
of	B-X
genetic	B-X
similarity	B-X
between	B-X
the	B-X
two	B-X
species	B-X
.	B-X
For	B-X
planning	B-X
experiments	B-X
and	B-X
identifying	B-X
improvements	B-X
in	B-X
both	B-X
invasive	B-X
and	B-X
noninvasive	B-X
methods	B-X
of	B-X
liver	B-X
disease	B-X
management	B-X
,	B-X
the	B-X
morphological	B-X
similarities	B-X
and	B-X
dissimilarities	B-X
of	B-X
the	B-X
pig	B-X
liver	B-X
to	B-X
its	B-X
human	B-X
counterpart	B-X
must	B-X
be	B-X
taken	B-X
into	B-X
consideration	B-X
along	B-X
with	B-X
sexual	B-X
dimorphism	B-X
and	B-X
interindividual	B-X
and	B-X
interspecific	B-X
variability	B-X
.	B-X
The	B-X
results	B-X
thereof	B-X
are	B-X
crucial	B-X
for	B-X
revealing	B-X
and	B-X
assessing	B-X
histological	B-X
changes	B-X
and	B-X
can	B-X
contribute	B-X
to	B-X
the	B-X
optimization	B-X
of	B-X
study	B-X
designs	B-X
.	B-X

M	O
-	O
CSF	O
Induces	O
Monocyte	O
Survival	O
by	O
Activating	O
NF	O
-	O
kappaB	O
p65	B-Protein
Phosphorylation	O
at	O
Ser276	O
via	O
Protein	O
Kinase	O
C	O
<EOS>	B-X
Macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
)	B-X
promotes	B-X
mononuclear	B-X
phagocyte	B-X
survival	B-X
and	B-X
proliferation	B-X
.	B-X
The	B-X
transcription	B-X
factor	B-X
Nuclear	B-X
Factor-kappaB	B-X
(	B-X
NF-κB	B-X
)	B-X
is	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
M-CSF-induced	B-X
mononuclear	B-X
phagocyte	B-X
survival	B-X
and	B-X
this	B-X
study	B-X
focused	B-X
at	B-X
identifying	B-X
the	B-X
mechanism	B-X
of	B-X
NF-κB	B-X
transcriptional	B-X
activation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
M-CSF	B-X
stimulated	B-X
NF-κB	B-X
transcriptional	B-X
activity	B-X
in	B-X
human	B-X
monocyte-derived	B-X
macrophages	B-X
(	B-X
MDMs	B-X
)	B-X
and	B-X
the	B-X
murine	B-X
macrophage	B-X
cell	B-X
line	B-X
RAW	B-X
264.7	B-X
.	B-X
The	B-X
general	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
inhibitor	B-X
Ro-31-8220	B-X
,	B-X
the	B-X
conventional	B-X
PKCα/β	B-X
inhibitor	B-X
Gö-6976	B-X
,	B-X
overexpression	B-X
of	B-X
dominant	B-X
negative	B-X
PKCα	B-X
constructs	B-X
and	B-X
PKCα	B-X
siRNA	B-X
reduced	B-X
NF-κB	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
M-CSF	B-X
.	B-X
Interestingly	B-X
,	B-X
Ro-31-8220	B-X
reduced	B-X
Ser276	B-X
phosphorylation	B-X
of	B-X
NF-κBp65	B-X
leading	B-X
to	B-X
decreased	B-X
M-CSF-induced	B-X
monocyte	B-X
survival	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
identify	B-X
conventional	B-X
PKCs	B-X
,	B-X
including	B-X
PKCα	B-X
as	B-X
important	B-X
upstream	B-X
kinases	B-X
for	B-X
M-CSF-induced	B-X
NF-κB	B-X
transcriptional	B-X
activation	B-X
,	B-X
NF-κB-regulated	B-X
gene	B-X
expression	B-X
,	B-X
NF-κB	B-X
p65	B-X
Ser276	B-X
phosphorylation	B-X
,	B-X
and	B-X
macrophage	B-X
survival	B-X
.	B-X
Lastly	B-X
,	B-X
we	B-X
find	B-X
that	B-X
NF-κB	B-X
p65	B-X
Ser276	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
basal	B-X
and	B-X
M-CSF-stimulated	B-X
NF-κB	B-X
activation	B-X
in	B-X
human	B-X
mononuclear	B-X
phagocytes	B-X
.	B-X

Macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
M	O
-	O
CSF	O
)	O
promotes	O
mononuclear	O
phagocyte	O
survival	O
and	O
proliferation	O
.	O
<EOS>	B-X
Colony-stimulating	B-X
factor	B-X
1	B-X
(	B-X
CSF-1	B-X
)	B-X
receptor	B-X
(	B-X
CSF-1R	B-X
,	B-X
or	B-X
macrophage	B-X
CSF	B-X
receptor	B-X
[	B-X
M-CSFR	B-X
]	B-X
)	B-X
is	B-X
the	B-X
primary	B-X
regulator	B-X
of	B-X
the	B-X
proliferation	B-X
,	B-X
survival	B-X
,	B-X
and	B-X
differentiation	B-X
of	B-X
mononuclear	B-X
phagocytes	B-X
(	B-X
MNPs	B-X
)	B-X
,	B-X
but	B-X
the	B-X
critical	B-X
CSF-1	B-X
signals	B-X
for	B-X
these	B-X
functions	B-X
are	B-X
unclear	B-X
.	B-X
The	B-X
scaffold	B-X
protein	B-X
Gab2	B-X
is	B-X
a	B-X
major	B-X
tyrosyl	B-X
phosphoprotein	B-X
in	B-X
the	B-X
CSF-1R	B-X
signaling	B-X
network	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
Gab2	B-X
deficiency	B-X
results	B-X
in	B-X
profoundly	B-X
defective	B-X
expansion	B-X
of	B-X
CSF-1R-dependent	B-X
MNP	B-X
progenitors	B-X
in	B-X
the	B-X
bone	B-X
marrow	B-X
,	B-X
through	B-X
decreased	B-X
proliferation	B-X
and	B-X
survival	B-X
.	B-X
Reconstitution	B-X
and	B-X
phospho-flow	B-X
studies	B-X
show	B-X
that	B-X
downstream	B-X
of	B-X
CSF-1R	B-X
,	B-X
Gab2	B-X
uses	B-X
phosphatidylinositol	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
-Akt	B-X
and	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
(	B-X
Erk	B-X
)	B-X
to	B-X
regulate	B-X
MNP	B-X
progenitor	B-X
expansion	B-X
.	B-X
Unexpectedly	B-X
,	B-X
Gab2	B-X
ablation	B-X
enhances	B-X
Jun	B-X
N-terminal	B-X
protein	B-X
kinase	B-X
1	B-X
(	B-X
JNK1	B-X
)	B-X
phosphorylation	B-X
in	B-X
differentiated	B-X
MNPs	B-X
but	B-X
reduces	B-X
their	B-X
proliferation	B-X
;	B-X
inhibition	B-X
of	B-X
JNK	B-X
signaling	B-X
or	B-X
reduction	B-X
of	B-X
JNK1	B-X
levels	B-X
restores	B-X
proliferation	B-X
.	B-X
Our	B-X
data	B-X
provide	B-X
genetic	B-X
and	B-X
biochemical	B-X
evidence	B-X
that	B-X
CSF-1R	B-X
,	B-X
through	B-X
Gab2	B-X
,	B-X
utilizes	B-X
different	B-X
effectors	B-X
at	B-X
different	B-X
stages	B-X
of	B-X
MNP	B-X
development	B-X
to	B-X
promote	B-X
their	B-X
expansion	B-X
.	B-X

The	O
transcription	O
factor	O
Nuclear	O
Factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
is	O
a	O
key	O
regulator	O
of	O
genes	O
involved	O
in	O
M	O
-	O
CSF	O
-	O
induced	O
mononuclear	O
phagocyte	O
survival	O
and	O
this	O
study	O
focused	O
at	O
identifying	O
the	O
mechanism	O
of	O
NF	O
-	O
kappaB	O
transcriptional	O
activation	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
M	O
-	O
CSF	O
stimulated	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
in	O
human	O
monocyte	O
-	O
derived	O
macrophages	O
(	O
MDMs	O
)	O
and	O
the	O
murine	O
macrophage	O
cell	O
line	O
RAW	O
264	O
.	O
7	O
.	O
<EOS>	B-X
Macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
)	B-X
promotes	B-X
mononuclear	B-X
phagocyte	B-X
survival	B-X
and	B-X
proliferation	B-X
.	B-X
The	B-X
transcription	B-X
factor	B-X
Nuclear	B-X
Factor-kappaB	B-X
(	B-X
NF-κB	B-X
)	B-X
is	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
M-CSF-induced	B-X
mononuclear	B-X
phagocyte	B-X
survival	B-X
and	B-X
this	B-X
study	B-X
focused	B-X
at	B-X
identifying	B-X
the	B-X
mechanism	B-X
of	B-X
NF-κB	B-X
transcriptional	B-X
activation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
M-CSF	B-X
stimulated	B-X
NF-κB	B-X
transcriptional	B-X
activity	B-X
in	B-X
human	B-X
monocyte-derived	B-X
macrophages	B-X
(	B-X
MDMs	B-X
)	B-X
and	B-X
the	B-X
murine	B-X
macrophage	B-X
cell	B-X
line	B-X
RAW	B-X
264.7	B-X
.	B-X
The	B-X
general	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
inhibitor	B-X
Ro-31-8220	B-X
,	B-X
the	B-X
conventional	B-X
PKCα/β	B-X
inhibitor	B-X
Gö-6976	B-X
,	B-X
overexpression	B-X
of	B-X
dominant	B-X
negative	B-X
PKCα	B-X
constructs	B-X
and	B-X
PKCα	B-X
siRNA	B-X
reduced	B-X
NF-κB	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
M-CSF	B-X
.	B-X
Interestingly	B-X
,	B-X
Ro-31-8220	B-X
reduced	B-X
Ser276	B-X
phosphorylation	B-X
of	B-X
NF-κBp65	B-X
leading	B-X
to	B-X
decreased	B-X
M-CSF-induced	B-X
monocyte	B-X
survival	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
identify	B-X
conventional	B-X
PKCs	B-X
,	B-X
including	B-X
PKCα	B-X
as	B-X
important	B-X
upstream	B-X
kinases	B-X
for	B-X
M-CSF-induced	B-X
NF-κB	B-X
transcriptional	B-X
activation	B-X
,	B-X
NF-κB-regulated	B-X
gene	B-X
expression	B-X
,	B-X
NF-κB	B-X
p65	B-X
Ser276	B-X
phosphorylation	B-X
,	B-X
and	B-X
macrophage	B-X
survival	B-X
.	B-X
Lastly	B-X
,	B-X
we	B-X
find	B-X
that	B-X
NF-κB	B-X
p65	B-X
Ser276	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
basal	B-X
and	B-X
M-CSF-stimulated	B-X
NF-κB	B-X
activation	B-X
in	B-X
human	B-X
mononuclear	B-X
phagocytes	B-X
.	B-X

The	O
general	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
inhibitor	O
Ro	O
-	O
31	O
-	O
8220	O
,	O
the	O
conventional	O
PKCalpha	B-Protein
/	O
beta	B-Protein
inhibitor	O
Go	O
-	O
6976	O
,	O
overexpression	O
of	O
dominant	B-Protein
negative	I-Protein
PKCalpha	I-Protein
constructs	O
and	O
PKCalpha	B-Protein
siRNA	I-Protein
reduced	O
NF	O
-	O
kappaB	O
activity	O
in	O
response	O
to	O
M	O
-	O
CSF	O
.	O

Interestingly	O
,	O
Ro	O
-	O
31	O
-	O
8220	O
reduced	O
Ser276	O
phosphorylation	O
of	O
NF	O
-	O
kappaBp65	B-Protein
leading	O
to	O
decreased	O
M	O
-	O
CSF	O
-	O
induced	O
monocyte	O
survival	O
.	O
<EOS>	B-X
Macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
)	B-X
promotes	B-X
mononuclear	B-X
phagocyte	B-X
survival	B-X
and	B-X
proliferation	B-X
.	B-X
The	B-X
transcription	B-X
factor	B-X
Nuclear	B-X
Factor-kappaB	B-X
(	B-X
NF-κB	B-X
)	B-X
is	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
M-CSF-induced	B-X
mononuclear	B-X
phagocyte	B-X
survival	B-X
and	B-X
this	B-X
study	B-X
focused	B-X
at	B-X
identifying	B-X
the	B-X
mechanism	B-X
of	B-X
NF-κB	B-X
transcriptional	B-X
activation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
M-CSF	B-X
stimulated	B-X
NF-κB	B-X
transcriptional	B-X
activity	B-X
in	B-X
human	B-X
monocyte-derived	B-X
macrophages	B-X
(	B-X
MDMs	B-X
)	B-X
and	B-X
the	B-X
murine	B-X
macrophage	B-X
cell	B-X
line	B-X
RAW	B-X
264.7	B-X
.	B-X
The	B-X
general	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
inhibitor	B-X
Ro-31-8220	B-X
,	B-X
the	B-X
conventional	B-X
PKCα/β	B-X
inhibitor	B-X
Gö-6976	B-X
,	B-X
overexpression	B-X
of	B-X
dominant	B-X
negative	B-X
PKCα	B-X
constructs	B-X
and	B-X
PKCα	B-X
siRNA	B-X
reduced	B-X
NF-κB	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
M-CSF	B-X
.	B-X
Interestingly	B-X
,	B-X
Ro-31-8220	B-X
reduced	B-X
Ser276	B-X
phosphorylation	B-X
of	B-X
NF-κBp65	B-X
leading	B-X
to	B-X
decreased	B-X
M-CSF-induced	B-X
monocyte	B-X
survival	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
identify	B-X
conventional	B-X
PKCs	B-X
,	B-X
including	B-X
PKCα	B-X
as	B-X
important	B-X
upstream	B-X
kinases	B-X
for	B-X
M-CSF-induced	B-X
NF-κB	B-X
transcriptional	B-X
activation	B-X
,	B-X
NF-κB-regulated	B-X
gene	B-X
expression	B-X
,	B-X
NF-κB	B-X
p65	B-X
Ser276	B-X
phosphorylation	B-X
,	B-X
and	B-X
macrophage	B-X
survival	B-X
.	B-X
Lastly	B-X
,	B-X
we	B-X
find	B-X
that	B-X
NF-κB	B-X
p65	B-X
Ser276	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
basal	B-X
and	B-X
M-CSF-stimulated	B-X
NF-κB	B-X
activation	B-X
in	B-X
human	B-X
mononuclear	B-X
phagocytes	B-X
.	B-X

In	O
this	O
report	O
,	O
we	O
identify	O
conventional	O
PKCs	O
,	O
including	O
PKCalpha	B-Protein
as	O
important	O
upstream	O
kinases	O
for	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
transcriptional	O
activation	O
,	O
NF	O
-	O
kappaB	O
-	O
regulated	O
gene	O
expression	O
,	O
NF	O
-	O
kappaB	O
p65	B-Protein
Ser276	O
phosphorylation	O
,	O
and	O
macrophage	O
survival	O
.	O
<EOS>	B-X
Macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
)	B-X
promotes	B-X
mononuclear	B-X
phagocyte	B-X
survival	B-X
and	B-X
proliferation	B-X
.	B-X
The	B-X
transcription	B-X
factor	B-X
Nuclear	B-X
Factor-kappaB	B-X
(	B-X
NF-κB	B-X
)	B-X
is	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
M-CSF-induced	B-X
mononuclear	B-X
phagocyte	B-X
survival	B-X
and	B-X
this	B-X
study	B-X
focused	B-X
at	B-X
identifying	B-X
the	B-X
mechanism	B-X
of	B-X
NF-κB	B-X
transcriptional	B-X
activation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
M-CSF	B-X
stimulated	B-X
NF-κB	B-X
transcriptional	B-X
activity	B-X
in	B-X
human	B-X
monocyte-derived	B-X
macrophages	B-X
(	B-X
MDMs	B-X
)	B-X
and	B-X
the	B-X
murine	B-X
macrophage	B-X
cell	B-X
line	B-X
RAW	B-X
264.7	B-X
.	B-X
The	B-X
general	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
inhibitor	B-X
Ro-31-8220	B-X
,	B-X
the	B-X
conventional	B-X
PKCα/β	B-X
inhibitor	B-X
Gö-6976	B-X
,	B-X
overexpression	B-X
of	B-X
dominant	B-X
negative	B-X
PKCα	B-X
constructs	B-X
and	B-X
PKCα	B-X
siRNA	B-X
reduced	B-X
NF-κB	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
M-CSF	B-X
.	B-X
Interestingly	B-X
,	B-X
Ro-31-8220	B-X
reduced	B-X
Ser276	B-X
phosphorylation	B-X
of	B-X
NF-κBp65	B-X
leading	B-X
to	B-X
decreased	B-X
M-CSF-induced	B-X
monocyte	B-X
survival	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
identify	B-X
conventional	B-X
PKCs	B-X
,	B-X
including	B-X
PKCα	B-X
as	B-X
important	B-X
upstream	B-X
kinases	B-X
for	B-X
M-CSF-induced	B-X
NF-κB	B-X
transcriptional	B-X
activation	B-X
,	B-X
NF-κB-regulated	B-X
gene	B-X
expression	B-X
,	B-X
NF-κB	B-X
p65	B-X
Ser276	B-X
phosphorylation	B-X
,	B-X
and	B-X
macrophage	B-X
survival	B-X
.	B-X
Lastly	B-X
,	B-X
we	B-X
find	B-X
that	B-X
NF-κB	B-X
p65	B-X
Ser276	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
basal	B-X
and	B-X
M-CSF-stimulated	B-X
NF-κB	B-X
activation	B-X
in	B-X
human	B-X
mononuclear	B-X
phagocytes	B-X
.	B-X

Lastly	O
,	O
we	O
find	O
that	O
NF	O
-	O
kappaB	O
p65	B-Protein
Ser276	O
plays	O
an	O
important	O
role	O
in	O
basal	O
and	O
M	O
-	O
CSF	O
-	O
stimulated	O
NF	O
-	O
kappaB	O
activation	O
in	O
human	O
mononuclear	O
phagocytes	O
.	O

Monocytes	O
are	O
produced	O
in	O
the	O
bone	O
marrow	O
and	O
circulate	O
in	O
blood	O
for	O
24	O
-	O
48	O
hours	O
[	O
1	O
]	O
.	O

In	O
the	O
absence	O
of	O
serum	O
,	O
monocytes	O
die	O
via	O
apoptosis	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
.	O

Macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
M	O
-	O
CSF	O
)	O
stimulates	O
mononuclear	O
phagocyte	O
survival	O
and	O
differentiation	O
[	O
3	O
]	O
.	O
<EOS>	B-X
The	B-X
proliferation	B-X
,	B-X
differentiation	B-X
and	B-X
survival	B-X
of	B-X
mononuclear	B-X
phagocytes	B-X
depend	B-X
on	B-X
signals	B-X
from	B-X
the	B-X
receptor	B-X
for	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
,	B-X
CSF1R	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
genomic	B-X
deletion	B-X
of	B-X
FIRE	B-X
in	B-X
mice	B-X
selectively	B-X
impacts	B-X
CSF1R	B-X
expression	B-X
and	B-X
tissue	B-X
macrophage	B-X
development	B-X
in	B-X
specific	B-X
tissues	B-X
.	B-X
The	B-X
macrophage	B-X
colony-stimulating	B-X
factor-1	B-X
(	B-X
CSF-1	B-X
,	B-X
M-CSF	B-X
)	B-X
induces	B-X
the	B-X
proliferation	B-X
and	B-X
supports	B-X
the	B-X
survival	B-X
of	B-X
mononuclear	B-X
phagocytes	B-X
and	B-X
mediates	B-X
its	B-X
pleiotropic	B-X
actions	B-X
by	B-X
binding	B-X
to	B-X
cell	B-X
surface	B-X
receptors	B-X
encoded	B-X
by	B-X
the	B-X
c-fms	B-X
proto-oncogene	B-X
.	B-X
The	B-X
structure	B-X
,	B-X
biologic	B-X
activities	B-X
,	B-X
and	B-X
therapeutic	B-X
potential	B-X
of	B-X
CSF-1	B-X
and	B-X
the	B-X
role	B-X
of	B-X
its	B-X
receptor	B-X
in	B-X
signal	B-X
transduction	B-X
in	B-X
normal	B-X
and	B-X
transformed	B-X
cells	B-X
are	B-X
discussed	B-X
.	B-X

Importantly	O
,	O
M	O
-	O
CSF	O
-	O
mediated	O
cell	O
survival	O
and	O
activation	O
is	O
associated	O
with	O
a	O
variety	O
of	O
human	O
diseases	O
,	O
including	O
atherosclerosis	O
,	O
transplant	O
vascular	O
sclerosis	O
and	O
breast	O
cancer	O
metastasis	O
[	O
4	O
]	O
,	O
[	O
5	O
]	O
,	O
[	O
6	O
]	O
.	O

We	O
previously	O
identified	O
that	O
NF	O
-	O
kappaB	O
activation	O
is	O
important	O
in	O
M	O
-	O
CSF	O
-	O
induced	O
monocyte	O
survival	O
[	O
7	O
]	O
.	O

In	O
addition	O
to	O
its	O
role	O
in	O
mononuclear	O
phagocyte	O
survival	O
,	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
regulates	O
numerous	O
genes	O
that	O
play	O
important	O
roles	O
in	O
cellular	O
signaling	O
,	O
stress	O
response	O
,	O
cell	O
growth	O
,	O
survival	O
,	O
differentiation	O
and	O
inflammation	O
[	O
8	O
]	O
.	O

There	O
are	O
five	O
members	O
in	O
the	O
NF	O
-	O
kappaB	O
family	O
:	O
RelA	B-Protein
/	O
p65	B-Protein
,	O
p50	B-Protein
,	O
p52	B-Protein
,	O
c	B-Protein
-	I-Protein
Rel	I-Protein
and	O
RelB	B-Protein
.	O
<EOS>	B-X
The	B-X
transcription	B-X
factor	B-X
NF-κB	B-X
is	B-X
a	B-X
critical	B-X
regulator	B-X
of	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
.	B-X
In	B-X
mammals	B-X
,	B-X
the	B-X
NF-κB/Rel	B-X
family	B-X
comprises	B-X
five	B-X
members	B-X
:	B-X
p50	B-X
,	B-X
p52	B-X
,	B-X
p65	B-X
(	B-X
Rel-A	B-X
)	B-X
,	B-X
c-Rel	B-X
,	B-X
and	B-X
Rel-B	B-X
proteins	B-X
,	B-X
which	B-X
form	B-X
homo-	B-X
or	B-X
heterodimers	B-X
and	B-X
remain	B-X
as	B-X
an	B-X
inactive	B-X
complex	B-X
with	B-X
the	B-X
inhibitory	B-X
molecules	B-X
called	B-X
IκB	B-X
proteins	B-X
in	B-X
resting	B-X
cells	B-X
.	B-X
Two	B-X
distinct	B-X
NF-κB	B-X
signaling	B-X
pathways	B-X
have	B-X
been	B-X
described	B-X
:	B-X
1	B-X
)	B-X
the	B-X
canonical	B-X
pathway	B-X
primarily	B-X
activated	B-X
by	B-X
pathogens	B-X
and	B-X
inflammatory	B-X
mediators	B-X
,	B-X
and	B-X
2	B-X
)	B-X
the	B-X
noncanonical	B-X
pathway	B-X
mostly	B-X
activated	B-X
by	B-X
developmental	B-X
cues	B-X
.	B-X
The	B-X
most	B-X
abundant	B-X
form	B-X
of	B-X
NF-κB	B-X
activated	B-X
by	B-X
pathologic	B-X
stimuli	B-X
via	B-X
the	B-X
canonical	B-X
pathway	B-X
is	B-X
the	B-X
p65	B-X
:	B-X
p50	B-X
heterodimer	B-X
.	B-X
Disproportionate	B-X
increase	B-X
in	B-X
activated	B-X
p65	B-X
and	B-X
subsequent	B-X
transactivation	B-X
of	B-X
effector	B-X
molecules	B-X
is	B-X
integral	B-X
to	B-X
the	B-X
pathogenesis	B-X
of	B-X
many	B-X
chronic	B-X
diseases	B-X
such	B-X
as	B-X
the	B-X
rheumatoid	B-X
arthritis	B-X
,	B-X
inflammatory	B-X
bowel	B-X
disease	B-X
,	B-X
multiple	B-X
sclerosis	B-X
,	B-X
and	B-X
even	B-X
neurodegenerative	B-X
pathologies	B-X
.	B-X
Hence	B-X
,	B-X
the	B-X
NF-κB	B-X
p65	B-X
signaling	B-X
pathway	B-X
has	B-X
been	B-X
a	B-X
pivotal	B-X
point	B-X
for	B-X
intense	B-X
drug	B-X
discovery	B-X
and	B-X
development	B-X
.	B-X
This	B-X
review	B-X
begins	B-X
with	B-X
an	B-X
overview	B-X
of	B-X
p65-mediated	B-X
signaling	B-X
followed	B-X
by	B-X
discussion	B-X
of	B-X
strategies	B-X
that	B-X
directly	B-X
target	B-X
NF-κB	B-X
p65	B-X
in	B-X
the	B-X
context	B-X
of	B-X
chronic	B-X
inflammation	B-X
.	B-X

The	O
most	O
common	O
activating	O
complex	O
is	O
the	O
p50	B-Protein
/	O
p65	B-Protein
heterodimer	O
,	O
driven	O
by	O
the	O
activation	O
domain	O
in	O
the	O
NF	O
-	O
kappaB	O
p65	B-Protein
subunit	O
.	O

NF	O
-	O
kappaB	O
p65	B-Protein
regulates	O
important	O
developmental	O
processes	O
[	O
9	O
]	O
,	O
[	O
10	O
]	O
.	O
<EOS>	B-X
Since	B-X
osteoporosis	B-X
critically	B-X
influences	B-X
the	B-X
lives	B-X
of	B-X
patients	B-X
with	B-X
a	B-X
high	B-X
incidence	B-X
,	B-X
effective	B-X
therapeutic	B-X
treatments	B-X
are	B-X
important	B-X
.	B-X
Consequently	B-X
,	B-X
55	B-X
targets	B-X
were	B-X
related	B-X
to	B-X
osteoporosis	B-X
disease	B-X
among	B-X
the	B-X
159	B-X
targets	B-X
of	B-X
quercetin	B-X
obtained	B-X
by	B-X
three	B-X
database	B-X
sources	B-X
.	B-X
Additionally	B-X
,	B-X
the	B-X
Gene	B-X
Ontology	B-X
functions	B-X
in	B-X
the	B-X
top	B-X
10	B-X
respective	B-X
biological	B-X
processes	B-X
,	B-X
molecular	B-X
functions	B-X
,	B-X
and	B-X
cell	B-X
components	B-X
as	B-X
well	B-X
as	B-X
the	B-X
top	B-X
20	B-X
Kyoto	B-X
Encyclopedia	B-X
of	B-X
Genes	B-X
and	B-X
Genomes	B-X
(	B-X
KEGG	B-X
)	B-X
pathways	B-X
were	B-X
depicted	B-X
.	B-X
The	B-X
most	B-X
significance	B-X
difference	B-X
in	B-X
the	B-X
KEGG	B-X
pathways	B-X
was	B-X
the	B-X
TNF	B-X
signaling	B-X
pathway	B-X
,	B-X
consisting	B-X
of	B-X
the	B-X
Nuclear	B-X
Factor	B-X
Kappa	B-X
B	B-X
Subunit	B-X
(	B-X
NF-κB	B-X
)	B-X
,	B-X
Extracellular	B-X
Regulated	B-X
Protein	B-X
Kinases	B-X
(	B-X
ERK	B-X
)	B-X
1/2	B-X
,	B-X
Activator	B-X
Protein	B-X
1	B-X
(	B-X
AP-1	B-X
)	B-X
,	B-X
Interleukin	B-X
6	B-X
(	B-X
IL6	B-X
)	B-X
,	B-X
Transcription	B-X
factor	B-X
AP-1	B-X
(	B-X
Jun	B-X
)	B-X
,	B-X
and	B-X
Phosphatidylinositol	B-X
3	B-X
Kinase	B-X
(	B-X
PI3K	B-X
)	B-X
,	B-X
which	B-X
were	B-X
probably	B-X
involved	B-X
in	B-X
the	B-X
pharmacological	B-X
effects	B-X
.	B-X
Moreover	B-X
,	B-X
molecular	B-X
docking	B-X
studies	B-X
revealed	B-X
that	B-X
the	B-X
top	B-X
three	B-X
entries	B-X
were	B-X
Interleukin	B-X
1	B-X
Beta	B-X
(	B-X
IL1B	B-X
)	B-X
,	B-X
the	B-X
Nuclear	B-X
Factor	B-X
NF-Kappa-B	B-X
p65	B-X
Subunit	B-X
(	B-X
RelA	B-X
)	B-X
,	B-X
and	B-X
the	B-X
Nuclear	B-X
Factor	B-X
Kappa	B-X
B	B-X
Subunit	B-X
1	B-X
(	B-X
NFKB1	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X

Mice	O
lacking	O
NF	O
-	O
kappaB	O
p65	B-Protein
die	O
in	O
utero	O
and	O
have	O
extensive	O
liver	O
damage	O
via	O
enhanced	O
apoptosis	O
[	O
9	O
]	O
.	O

Embryonic	O
macrophages	O
from	O
NF	O
-	O
kappaB	O
p65	B-Protein
null	O
mice	O
are	O
susceptible	O
to	O
TNFalpha	B-Protein
-	O
induced	O
apoptosis	O
which	O
is	O
rescued	O
by	O
overexpressing	O
the	O
NF	O
-	O
kappaB	O
p65	B-Protein
subunit	O
[	O
10	O
]	O
.	O

Moreover	O
,	O
inhibiting	O
NF	O
-	O
kappaB	O
induces	O
cell	O
death	O
in	O
many	O
cell	O
types	O
and	O
cytokine	O
-	O
independent	O
survival	O
is	O
mediated	O
by	O
constitutively	O
active	O
NF	O
-	O
kappaB	O
in	O
murine	O
macrophages	O
[	O
11	O
]	O
.	O

In	O
monocytes	O
and	O
macrophages	O
,	O
NF	O
-	O
kappaB	O
is	O
an	O
important	O
transcriptional	O
factor	O
for	O
expression	O
of	O
cytokines	O
and	O
cell	O
surface	O
receptors	O
[	O
12	O
]	O
.	O
<EOS>	B-X
Osteoclasts	B-X
develop	B-X
from	B-X
hematopoietic	B-X
cells	B-X
of	B-X
the	B-X
monocyte-macrophage	B-X
lineage	B-X
.	B-X
The	B-X
coculture	B-X
system	B-X
of	B-X
osteoblasts	B-X
and	B-X
hematopoietic	B-X
cells	B-X
was	B-X
devised	B-X
to	B-X
examine	B-X
osteoclastogenesis	B-X
in	B-X
vitro	B-X
.	B-X
Remarkable	B-X
progress	B-X
has	B-X
been	B-X
achieved	B-X
during	B-X
the	B-X
last	B-X
decade	B-X
in	B-X
our	B-X
understanding	B-X
the	B-X
molecular	B-X
mechanism	B-X
of	B-X
osteoclast	B-X
differentiation	B-X
,	B-X
largely	B-X
because	B-X
of	B-X
the	B-X
discovery	B-X
of	B-X
receptor	B-X
activator	B-X
of	B-X
NF-kappaB	B-X
ligand	B-X
(	B-X
RANKL	B-X
)	B-X
,	B-X
an	B-X
essential	B-X
cytokine	B-X
for	B-X
osteoclastogenesis	B-X
.	B-X
Osteoblasts	B-X
express	B-X
RANKL	B-X
in	B-X
response	B-X
to	B-X
bone-resorbing	B-X
factors	B-X
.	B-X
The	B-X
identification	B-X
of	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T-cells	B-X
cytoplasmic	B-X
1	B-X
(	B-X
NFATc1	B-X
)	B-X
as	B-X
a	B-X
master	B-X
transcription	B-X
!	B-X
factor	B-X
for	B-X
RANKL-induced	B-X
osteoclastogenesis	B-X
has	B-X
provided	B-X
major	B-X
insight	B-X
into	B-X
the	B-X
molecular	B-X
mechanism	B-X
of	B-X
osteoclast	B-X
differentiation	B-X
.	B-X
The	B-X
discovery	B-X
of	B-X
the	B-X
immunoreceptor	B-X
tyrosine-based	B-X
activation	B-X
motif	B-X
(	B-X
ITAM	B-X
)	B-X
-mediated	B-X
signals	B-X
as	B-X
a	B-X
costimulatory	B-X
signal	B-X
in	B-X
osteoclastogenesis	B-X
has	B-X
confirmed	B-X
that	B-X
osteoblasts	B-X
play	B-X
another	B-X
important	B-X
role	B-X
in	B-X
osteoclastogenesis	B-X
.	B-X

However	O
,	O
unlike	O
resting	O
T	O
-	O
cells	O
,	O
NF	O
-	O
kappaB	O
is	O
constitutively	O
present	O
in	O
the	O
nuclei	O
of	O
primary	O
monocytes	O
and	O
monocytic	O
cell	O
lines	O
in	O
the	O
absence	O
of	O
exogenous	O
stimuli	O
as	O
demonstrated	O
by	O
mobility	O
shift	O
analysis	O
[	O
13	O
]	O
.	O

Similarly	O
,	O
constitutively	O
active	O
NF	O
-	O
kappaB	O
was	O
observed	O
in	O
human	O
alveolar	O
macrophages	O
[	O
14	O
]	O
.	O

In	O
the	O
classic	O
/	O
canonical	O
pathway	O
,	O
the	O
NF	O
-	O
kappaB	O
p50	B-Protein
/	O
p65	B-Protein
complex	O
is	O
sequestered	O
in	O
the	O
cytosol	O
by	O
IkappaBalpha	B-Protein
[	O
15	O
]	O
.	O

Upon	O
stimulation	O
by	O
cytokines	O
or	O
UV	O
radiation	O
,	O
IkappaBalpha	B-Protein
is	O
phosphorylated	O
,	O
ubiquitinated	O
,	O
and	O
degraded	O
,	O
releasing	O
NF	O
-	O
kappaB	O
p50	B-Protein
/	O
p65	B-Protein
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
transactivate	O
target	O
genes	O
.	O
<EOS>	B-X
Upon	B-X
stimulation	B-X
with	B-X
Ag	B-X
plus	B-X
IL-12	B-X
,	B-X
naïve	B-X
T	B-X
cells	B-X
develop	B-X
into	B-X
IL-18	B-X
receptor	B-X
(	B-X
IL-18R	B-X
)	B-X
expressing	B-X
Th1	B-X
cells	B-X
,	B-X
which	B-X
increase	B-X
IFN-γ	B-X
production	B-X
in	B-X
response	B-X
to	B-X
IL-18	B-X
stimulation	B-X
.	B-X
IL-18	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
IL-1	B-X
family	B-X
of	B-X
cytokines	B-X
.	B-X
All	B-X
aspects	B-X
of	B-X
osteoclast	B-X
formation	B-X
and	B-X
functions	B-X
are	B-X
regulated	B-X
by	B-X
macrophage-colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
)	B-X
and	B-X
receptor	B-X
activator	B-X
of	B-X
NF-κB	B-X
ligand	B-X
(	B-X
RANKL	B-X
)	B-X
,	B-X
cytokines	B-X
essential	B-X
for	B-X
osteoclast	B-X
formation	B-X
and	B-X
expressed	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
cell	B-X
types	B-X
,	B-X
including	B-X
osteoblast	B-X
lineage	B-X
cells	B-X
.	B-X
mRNA	B-X
expression	B-X
studies	B-X
show	B-X
that	B-X
adipocytes	B-X
can	B-X
synthesise	B-X
both	B-X
tumour	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
and	B-X
several	B-X
interleukins	B-X
(	B-X
IL	B-X
)	B-X
,	B-X
notably	B-X
IL-1beta	B-X
and	B-X
IL-6	B-X
.	B-X
There	B-X
is	B-X
general	B-X
agreement	B-X
that	B-X
circulating	B-X
TNF-alpha	B-X
and	B-X
IL-6	B-X
concentrations	B-X
are	B-X
mildly	B-X
elevated	B-X
in	B-X
obesity	B-X
.	B-X
Most	B-X
studies	B-X
suggest	B-X
increased	B-X
TNF-alpha	B-X
mRNA	B-X
expression	B-X
or	B-X
secretion	B-X
in	B-X
vitro	B-X
in	B-X
adipose	B-X
tissue	B-X
from	B-X
obese	B-X
subjects	B-X
.	B-X
There	B-X
is	B-X
conflicting	B-X
data	B-X
about	B-X
whether	B-X
insulin	B-X
and	B-X
cortisol	B-X
regulate	B-X
TNF-alpha	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
cytokines	B-X
within	B-X
adipose	B-X
tissue	B-X
include	B-X
some	B-X
actions	B-X
that	B-X
might	B-X
be	B-X
characterised	B-X
as	B-X
metabolic	B-X
.	B-X
TNF-alpha	B-X
and	B-X
IL-6	B-X
inhibit	B-X
lipoprotein	B-X
lipase	B-X
,	B-X
and	B-X
TNF-alpha	B-X
additionally	B-X
stimulates	B-X
hormone-sensitive	B-X
lipase	B-X
and	B-X
induces	B-X
uncoupling	B-X
protein	B-X
expression	B-X
.	B-X
TNF-alpha	B-X
also	B-X
down	B-X
regulates	B-X
insulin-stimulated	B-X
glucose	B-X
uptake	B-X
via	B-X
effects	B-X
on	B-X
glucose	B-X
transporter	B-X
4	B-X
,	B-X
insulin	B-X
receptor	B-X
autophosphorylation	B-X
and	B-X
insulin	B-X
receptor	B-X
substrate-1	B-X
.	B-X
Cytokines	B-X
are	B-X
important	B-X
stimulators	B-X
and	B-X
repressors	B-X
of	B-X
other	B-X
cytokines	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
cytokines	B-X
appear	B-X
to	B-X
modulate	B-X
other	B-X
regulatory	B-X
systems	B-X
.	B-X
Examples	B-X
of	B-X
the	B-X
latter	B-X
include	B-X
effects	B-X
on	B-X
leptin	B-X
secretion	B-X
(	B-X
probably	B-X
stimulation	B-X
followed	B-X
by	B-X
inhibition	B-X
)	B-X
and	B-X
reduction	B-X
of	B-X
beta3-adrenoceptor	B-X
expression	B-X
.	B-X
There	B-X
seems	B-X
to	B-X
be	B-X
no	B-X
clear	B-X
agreement	B-X
as	B-X
to	B-X
which	B-X
cytokines	B-X
derived	B-X
from	B-X
adipose	B-X
tissue	B-X
act	B-X
as	B-X
remote	B-X
regulators	B-X
,	B-X
i.e	B-X
.	B-X
IL-6	B-X
appears	B-X
to	B-X
be	B-X
released	B-X
systemically	B-X
by	B-X
adipose	B-X
tissue	B-X
,	B-X
but	B-X
TNF-alpha	B-X
is	B-X
probably	B-X
not	B-X
.	B-X
The	B-X
importance	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
in	B-X
whole-body	B-X
energy	B-X
balance	B-X
provides	B-X
a	B-X
rationale	B-X
for	B-X
the	B-X
links	B-X
between	B-X
cytokines	B-X
and	B-X
adipose	B-X
tissue	B-X
.	B-X
It	B-X
seems	B-X
clear	B-X
that	B-X
TNF-alpha	B-X
is	B-X
a	B-X
powerful	B-X
autocrine	B-X
and	B-X
paracrine	B-X
regulator	B-X
of	B-X
adipose	B-X
tissue	B-X
.	B-X
Other	B-X
cytokines	B-X
,	B-X
notably	B-X
leptin	B-X
,	B-X
and	B-X
possibly	B-X
IL-6	B-X
,	B-X
have	B-X
lesser	B-X
actions	B-X
on	B-X
adipose	B-X
tissue	B-X
.	B-X
These	B-X
cytokines	B-X
act	B-X
as	B-X
hormones	B-X
,	B-X
reporting	B-X
the	B-X
state	B-X
of	B-X
adipose	B-X
tissue	B-X
stores	B-X
throughout	B-X
the	B-X
body	B-X
.	B-X

After	O
its	O
release	O
from	O
IkappaBalpha	B-Protein
,	O
NF	O
-	O
kappaB	O
p65	B-Protein
can	O
undergo	O
post	O
-	O
translational	O
modification	O
to	O
activate	O
gene	O
transcription	O
.	O

The	O
role	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
phosphorylation	O
on	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
varies	O
by	O
stimulus	O
,	O
time	O
of	O
stimulation	O
and	O
cell	O
type	O
[	O
16	O
]	O
.	O

Previous	O
research	O
shows	O
that	O
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
at	O
Ser276	O
,	O
Ser529	O
or	O
Ser536	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
transcriptional	O
activity	O
of	O
NF	O
-	O
kappaB	O
[	O
17	O
]	O
.	O
<EOS>	B-X
Nuclear	B-X
factor	B-X
kappaB	B-X
(	B-X
NF-κB	B-X
)	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
osteogenesis	B-X
.	B-X
This	B-X
study	B-X
was	B-X
performed	B-X
to	B-X
investigate	B-X
the	B-X
effects	B-X
of	B-X
mechanical	B-X
force	B-X
on	B-X
NF-κB	B-X
activity	B-X
in	B-X
osteoblast-like	B-X
cells	B-X
.	B-X
The	B-X
association	B-X
of	B-X
the	B-X
NF-kappaB	B-X
p65/p50	B-X
dimer	B-X
with	B-X
IkappaBalpha	B-X
plays	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
regulating	B-X
its	B-X
nuclear	B-X
translocation	B-X
and	B-X
gene	B-X
transcription	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
serine	B-X
phosphorylation	B-X
at	B-X
various	B-X
sites	B-X
of	B-X
the	B-X
p65	B-X
subunit	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
important	B-X
in	B-X
initiating	B-X
transcription	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
regulation	B-X
of	B-X
nuclear	B-X
translocation	B-X
of	B-X
p65	B-X
phosphorylated	B-X
at	B-X
serine	B-X
536	B-X
is	B-X
not	B-X
dependent	B-X
on	B-X
IkappaBalpha	B-X
.	B-X
Stimulation	B-X
of	B-X
either	B-X
Jurkat	B-X
or	B-X
normal	B-X
human	B-X
T	B-X
cells	B-X
resulted	B-X
in	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
phospho-p65	B-X
(	B-X
Ser	B-X
(	B-X
536	B-X
)	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
phospho-p65	B-X
(	B-X
Ser	B-X
(	B-X
536	B-X
)	B-X
)	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
either	B-X
IkappaBalpha	B-X
or	B-X
p50	B-X
,	B-X
and	B-X
the	B-X
nuclear	B-X
translocation	B-X
of	B-X
phospho-p65	B-X
(	B-X
Ser	B-X
(	B-X
536	B-X
)	B-X
)	B-X
,	B-X
but	B-X
not	B-X
total	B-X
p65	B-X
,	B-X
was	B-X
unaffected	B-X
by	B-X
the	B-X
proteosome	B-X
inhibitor	B-X
MG-132	B-X
,	B-X
which	B-X
blocks	B-X
IkappaB	B-X
protein	B-X
degradation	B-X
and	B-X
prevents	B-X
p65/p50	B-X
dimer	B-X
nuclear	B-X
translocation	B-X
.	B-X
Accordingly	B-X
,	B-X
the	B-X
co-expression	B-X
of	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
of	B-X
IkappaBalpha	B-X
blocked	B-X
the	B-X
transcriptional	B-X
activity	B-X
mediated	B-X
by	B-X
wild	B-X
type	B-X
but	B-X
not	B-X
the	B-X
dominant	B-X
positive	B-X
p65	B-X
mutant	B-X
(	B-X
S536D	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
transfection	B-X
of	B-X
the	B-X
S536D	B-X
form	B-X
of	B-X
p65	B-X
led	B-X
to	B-X
the	B-X
induction	B-X
of	B-X
interleukin-8	B-X
transcription	B-X
following	B-X
stimulation	B-X
,	B-X
whereas	B-X
the	B-X
S536A	B-X
form	B-X
,	B-X
which	B-X
can	B-X
not	B-X
be	B-X
phosphorylated	B-X
at	B-X
this	B-X
site	B-X
,	B-X
did	B-X
not	B-X
.	B-X
Together	B-X
,	B-X
the	B-X
findings	B-X
suggest	B-X
that	B-X
p65	B-X
phosphorylated	B-X
on	B-X
serine	B-X
536	B-X
is	B-X
not	B-X
associated	B-X
with	B-X
or	B-X
regulated	B-X
by	B-X
IkappaBalpha	B-X
,	B-X
that	B-X
it	B-X
has	B-X
a	B-X
distinct	B-X
set	B-X
of	B-X
target	B-X
genes	B-X
,	B-X
and	B-X
that	B-X
it	B-X
may	B-X
represent	B-X
a	B-X
noncanonical	B-X
NF-kappaB	B-X
pathway	B-X
that	B-X
is	B-X
independent	B-X
of	B-X
IkappaBalpha	B-X
regulation	B-X
.	B-X

In	O
TNFalpha	O
-	O
treated	O
murine	O
fibroblasts	O
,	O
Ser276	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
is	O
phosphorylated	O
by	O
MSK1	B-Protein
to	O
enhance	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
[	O
18	O
]	O
.	O

In	O
macrophages	O
treated	O
with	O
endotoxin	O
,	O
NF	O
-	O
kappaB	O
transcription	O
activity	O
is	O
associated	O
with	O
phosphorylation	O
on	O
Ser276	O
and	O
Ser536	O
that	O
is	O
regulated	O
through	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
and	O
IKKbeta	B-Protein
respectively	O
[	O
16	O
]	O
,	O
[	O
19	O
]	O
.	O

In	O
human	O
T	O
cells	O
,	O
NF	O
-	O
kappaB	O
p65	B-Protein
is	O
constitutively	O
phosphorylated	O
on	O
Ser536	O
to	O
facilitate	O
NF	O
-	O
kappaB	O
p65	B-Protein
nuclear	O
translocation	O
following	O
cellular	O
stimulation	O
[	O
20	O
]	O
.	O

Accumulating	O
evidence	O
reveals	O
that	O
NF	O
-	O
kappaB	O
p65	B-Protein
phosphorylation	O
at	O
Ser276	O
is	O
crucial	O
for	O
its	O
transcriptional	O
activity	O
.	O

Upon	O
nuclear	O
translocation	O
,	O
phosphorylation	O
of	O
Ser276	O
on	O
NF	O
-	O
kappaB	O
p65	B-Protein
by	O
PKA	O
recruits	O
the	O
transcription	O
co	O
-	O
activator	O
,	O
p300	B-Protein
to	O
potentiate	O
NF	O
-	O
kappaB	O
-	O
regulated	O
gene	O
transcription	O
[	O
21	O
]	O
.	O

However	O
,	O
other	O
studies	O
show	O
that	O
PKA	O
inhibits	O
NF	O
-	O
kappaB	O
-	O
regulated	O
gene	O
expression	O
by	O
stabilizing	O
IkappaBalpha	B-Protein
[	O
22	O
]	O
,	O
[	O
23	O
]	O
.	O

Interestingly	O
,	O
the	O
serine	O
/	O
threonine	O
kinase	O
Pim	B-Protein
-	I-Protein
1	I-Protein
directly	O
phosphorylates	O
NF	O
-	O
kappaB	O
p65	B-Protein
at	O
Ser276	O
by	O
stabilizing	O
to	O
prevent	O
ubiquitin	O
-	O
proteasome	O
degradation	O
[	O
24	O
]	O
.	O

Several	O
other	O
phosphorylation	O
sites	O
are	O
also	O
described	O
to	O
enhance	O
NF	O
-	O
kappaB	O
gene	O
transactivation	O
[	O
25	O
]	O
.	O

Here	O
,	O
we	O
investigate	O
the	O
role	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
in	O
M	O
-	O
CSF	O
-	O
stimulated	O
NF	O
-	O
kappaB	O
activation	O
.	O

PKC	O
proteins	O
are	O
multifunctional	O
kinases	O
that	O
differ	O
in	O
structure	O
,	O
function	O
and	O
co	O
-	O
factor	O
requirement	O
[	O
26	O
]	O
.	O

PKCs	O
are	O
involved	O
in	O
diverse	O
cell	O
responses	O
,	O
including	O
cell	O
growth	O
,	O
survival	O
,	O
differentiation	O
and	O
development	O
[	O
27	O
]	O
.	O

The	O
12	O
closely	O
related	O
enzymes	O
of	O
the	O
PKC	O
family	O
are	O
divided	O
into	O
three	O
classes	O
:	O
conventional	O
(	O
cPKCs	O
:	O
alpha	B-Protein
betaI	B-Protein
betaII	B-Protein
and	O
gamma	B-Protein
require	O
Ca2	O
+	O
and	O
diacylglycerol	O
(	O
DAG	O
)	O
;	O
novel	O
(	O
nPKCs	O
:	O
delta	B-Protein
,	O
epsilon	B-Protein
,	O
eta	B-Protein
,	O
theta	B-Protein
and	O
mu	B-Protein
)	O
require	O
DAG	O
;	O
and	O
atypical	O
(	O
aPKCs	O
:	O
xi	B-Protein
,	O
iota	B-Protein
and	O
lambda	B-Protein
)	O
require	O
neither	O
Ca2	O
+	O
nor	O
DAG	O
.	O

Monocytes	O
and	O
macrophages	O
predominantly	O
express	O
conventional	O
PKC	O
isoforms	O
(	O
PKCalpha	B-Protein
PKCbetaI	B-Protein
and	O
PKCbetaII	B-Protein
)	O
and	O
novel	O
PKCs	O
(	O
PKCdelta	B-Protein
and	O
PKCepsilon	B-Protein
)	O
.	O

Conventional	O
PKCs	O
regulate	O
differentiation	O
of	O
the	O
human	O
promyelocytic	O
leukemia	O
cell	O
line	O
HL60	O
to	O
macrophages	O
[	O
28	O
]	O
.	O

PKCalpha	B-Protein
induces	O
IL	B-Protein
-	I-Protein
1alpha	I-Protein
,	O
iNOS	B-Protein
and	O
TNFalpha	B-Protein
mRNA	O
production	O
after	O
lipopolysaccharide	O
(	O
LPS	O
)	O
exposure	O
[	O
29	O
]	O
.	O

In	O
addition	O
,	O
accumulating	O
evidence	O
suggests	O
that	O
conventional	O
PKCs	O
like	O
PKCalpha	B-Protein
have	O
anti	O
-	O
apoptotic	O
functions	O
.	O

For	O
example	O
,	O
PKCalpha	B-Protein
is	O
overexpressed	O
in	O
a	O
variety	O
of	O
tumor	O
cells	O
including	O
gliomas	O
,	O
liver	O
,	O
and	O
lung	O
[	O
30	O
]	O
,	O
[	O
31	O
]	O
.	O

In	O
epithelial	O
cells	O
,	O
inhibition	O
of	O
PKCalpha	B-Protein
induces	O
PKCdelta	B-Protein
-	O
dependent	O
apoptosis	O
[	O
31	O
]	O
.	O
<EOS>	B-X
We	B-X
have	B-X
used	B-X
expression	B-X
of	B-X
a	B-X
kinase	B-X
dead	B-X
mutant	B-X
of	B-X
PKCalpha	B-X
(	B-X
PKCalphaKD	B-X
)	B-X
to	B-X
explore	B-X
the	B-X
role	B-X
of	B-X
this	B-X
isoform	B-X
in	B-X
salivary	B-X
epithelial	B-X
cell	B-X
apoptosis	B-X
.	B-X
Expression	B-X
of	B-X
PKCalphaKD	B-X
by	B-X
adenovirus-mediated	B-X
transduction	B-X
results	B-X
in	B-X
a	B-X
dose-dependent	B-X
induction	B-X
of	B-X
apoptosis	B-X
in	B-X
salivary	B-X
epithelial	B-X
cells	B-X
as	B-X
measured	B-X
by	B-X
the	B-X
accumulation	B-X
of	B-X
sub-G1	B-X
DNA	B-X
,	B-X
activation	B-X
of	B-X
caspase-3	B-X
,	B-X
and	B-X
cleavage	B-X
of	B-X
PKCdelta	B-X
and	B-X
PKCzeta	B-X
,	B-X
known	B-X
caspase	B-X
substrates	B-X
.	B-X
Induction	B-X
of	B-X
apoptosis	B-X
is	B-X
accompanied	B-X
by	B-X
nine-fold	B-X
activation	B-X
of	B-X
c-Jun-N-terminal	B-X
kinase	B-X
,	B-X
and	B-X
an	B-X
approximately	B-X
two	B-X
to	B-X
three-fold	B-X
increase	B-X
in	B-X
activated	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
as	B-X
well	B-X
as	B-X
total	B-X
MAPK	B-X
protein	B-X
.	B-X
Previous	B-X
studies	B-X
from	B-X
our	B-X
laboratory	B-X
have	B-X
shown	B-X
that	B-X
PKCdelta	B-X
activity	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
apoptotic	B-X
response	B-X
of	B-X
salivary	B-X
epithelial	B-X
cells	B-X
to	B-X
a	B-X
variety	B-X
of	B-X
cell	B-X
toxins	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
contribution	B-X
of	B-X
PKCdelta	B-X
to	B-X
PKCalphaKD-induced	B-X
apoptosis	B-X
,	B-X
salivary	B-X
epithelial	B-X
cells	B-X
were	B-X
cotransduced	B-X
with	B-X
PKCalphaKD	B-X
and	B-X
PKCdeltaKD	B-X
expression	B-X
vectors	B-X
.	B-X
Inhibition	B-X
of	B-X
endogenous	B-X
PKCdelta	B-X
blocked	B-X
the	B-X
ability	B-X
of	B-X
PKCalphaKD	B-X
to	B-X
induce	B-X
apoptosis	B-X
as	B-X
indicated	B-X
by	B-X
cell	B-X
morphology	B-X
,	B-X
DNA	B-X
fragmentation	B-X
,	B-X
and	B-X
caspase-3	B-X
activation	B-X
,	B-X
indicating	B-X
that	B-X
PKCdelta	B-X
activity	B-X
is	B-X
required	B-X
for	B-X
the	B-X
apoptotic	B-X
program	B-X
induced	B-X
under	B-X
conditions	B-X
where	B-X
PKCalpha	B-X
is	B-X
inhibited	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
PKCalpha	B-X
functions	B-X
as	B-X
a	B-X
survival	B-X
factor	B-X
in	B-X
salivary	B-X
epithelial	B-X
cells	B-X
,	B-X
while	B-X
PKCdelta	B-X
functions	B-X
to	B-X
regulate	B-X
entry	B-X
into	B-X
the	B-X
apoptotic	B-X
pathway	B-X
.	B-X

Interestingly	O
,	O
in	O
human	O
monocytes	O
and	O
premonocytic	O
THP	O
-	O
1	O
leukemia	O
cells	O
,	O
novel	O
PKCs	O
like	O
PKCdelta	B-Protein
have	O
the	O
opposite	O
effect	O
on	O
cell	O
survival	O
,	O
Voss	O
et	O
al	O
showed	O
that	O
PKCdelta	B-Protein
directly	O
phosphorylates	O
caspase	B-Protein
-	I-Protein
3	I-Protein
and	O
promotes	O
etoposide	O
-	O
induced	O
apoptosis	O
[	O
32	O
]	O
.	O

Moreover	O
,	O
knockout	O
mouse	O
studies	O
suggest	O
that	O
another	O
novel	O
PKC	O
,	O
PKCepsilon	B-Protein
is	O
critically	O
involved	O
in	O
early	O
LPS	O
-	O
mediated	O
signaling	O
in	O
activated	O
macrophages	O
[	O
33	O
]	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
M	O
-	O
CSF	O
promotes	O
monocyte	O
survival	O
through	O
the	O
activation	O
of	O
the	O
PI3	O
-	O
K	O
/	O
AKT	O
pathway	O
[	O
3	O
]	O
.	O

In	O
addition	O
to	O
AKT	O
activation	O
,	O
M	O
-	O
CSF	O
stimulates	O
PKC	O
in	O
human	O
monocytes	O
and	O
increases	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
[	O
34	O
]	O
.	O

However	O
,	O
whether	O
PKC	O
and	O
/	O
or	O
NF	O
-	O
kappaB	O
activation	O
is	O
critical	O
in	O
M	O
-	O
CSF	O
-	O
stimulated	O
mononuclear	O
phagocyte	O
survival	O
and	O
/	O
or	O
differentiation	O
is	O
unclear	O
.	O
<EOS>	B-X
Given	B-X
the	B-X
durability	B-X
of	B-X
trained	B-X
immunity	B-X
,	B-X
it	B-X
is	B-X
unclear	B-X
which	B-X
leukocyte	B-X
populations	B-X
sustain	B-X
this	B-X
effect	B-X
.	B-X
Despite	B-X
intensive	B-X
investigations	B-X
,	B-X
numerous	B-X
mechanistic	B-X
aspects	B-X
of	B-X
adipogenesis	B-X
remain	B-X
unclear	B-X
,	B-X
and	B-X
many	B-X
potential	B-X
therapeutic	B-X
targets	B-X
have	B-X
yet	B-X
to	B-X
be	B-X
discovered	B-X
.	B-X
Transcriptomics	B-X
and	B-X
lipidomics	B-X
approaches	B-X
were	B-X
used	B-X
to	B-X
explore	B-X
the	B-X
functional	B-X
genes	B-X
regulating	B-X
adipogenic	B-X
differentiation	B-X
and	B-X
the	B-X
potential	B-X
mechanism	B-X
in	B-X
OP9	B-X
cells	B-X
and	B-X
adipose-derived	B-X
stem	B-X
cells	B-X
.	B-X
PI3K/AKT	B-X
is	B-X
one	B-X
of	B-X
the	B-X
key	B-X
pathways	B-X
that	B-X
regulate	B-X
cell	B-X
behaviors	B-X
including	B-X
apoptosis	B-X
,	B-X
proliferation	B-X
,	B-X
and	B-X
differentiation	B-X
.	B-X
Although	B-X
previous	B-X
studies	B-X
have	B-X
demonstrated	B-X
that	B-X
this	B-X
pathway	B-X
is	B-X
a	B-X
crucial	B-X
regulator	B-X
of	B-X
osteoblasts	B-X
,	B-X
the	B-X
role	B-X
of	B-X
PI3K/AKT	B-X
in	B-X
fracture	B-X
healing	B-X
remains	B-X
unclear	B-X
.	B-X
However	B-X
,	B-X
whether	B-X
there	B-X
exists	B-X
crosstalk	B-X
between	B-X
Wnt/β-catenin	B-X
and	B-X
PI3K/AKT	B-X
in	B-X
regulating	B-X
osteoblasts	B-X
and	B-X
bone	B-X
repair	B-X
has	B-X
not	B-X
been	B-X
reported	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
ICG001	B-X
,	B-X
the	B-X
inhibitor	B-X
of	B-X
β-catenin	B-X
transcriptional	B-X
activity	B-X
,	B-X
attenuates	B-X
PI3K/AKT-induced	B-X
osteoblast	B-X
proliferation	B-X
,	B-X
differentiation	B-X
,	B-X
and	B-X
mineralization	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
PI3K/AKT/β-catenin	B-X
axis	B-X
is	B-X
functional	B-X
in	B-X
regulating	B-X
osteoblasts	B-X
.	B-X
Notably	B-X
,	B-X
the	B-X
PI3K/AKT	B-X
pathway	B-X
is	B-X
also	B-X
activated	B-X
by	B-X
Wnt3a	B-X
and	B-X
is	B-X
involved	B-X
in	B-X
Wnt3a-induced	B-X
osteoblast	B-X
proliferation	B-X
and	B-X
differentiation	B-X
.	B-X
Hence	B-X
,	B-X
our	B-X
results	B-X
reveal	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
Wnt/PI3K/AKT/β-catenin	B-X
signaling	B-X
nexus	B-X
in	B-X
osteoblasts	B-X
,	B-X
highlighting	B-X
complex	B-X
crosstalk	B-X
between	B-X
PI3K/AKT	B-X
and	B-X
Wnt/β-catenin	B-X
pathways	B-X
that	B-X
are	B-X
critically	B-X
implicated	B-X
in	B-X
fracture	B-X
healing	B-X
.	B-X

In	O
other	O
cells	O
,	O
PKC	O
plays	O
an	O
important	O
role	O
in	O
NF	O
-	O
kappaB	O
activation	O
and	O
cell	O
survival	O
[	O
35	O
]	O
,	O
however	O
the	O
specific	O
mechanisms	O
of	O
this	O
activation	O
and	O
the	O
biological	O
effects	O
on	O
cellular	O
phenotype	O
are	O
not	O
known	O
.	O

Therefore	O
,	O
we	O
focused	O
at	O
understanding	O
the	O
role	O
of	O
PKC	O
in	O
the	O
regulation	O
of	O
NF	O
-	O
kappaB	O
activation	O
and	O
M	O
-	O
CSF	O
-	O
induced	O
monocyte	O
survival	O
.	O

Here	O
we	O
demonstrates	O
that	O
M	O
-	O
CSF	O
upregulated	O
the	O
NF	O
-	O
kappaB	O
transcription	O
and	O
cell	O
survival	O
in	O
human	O
and	O
mouse	O
macrophages	O
.	O
<EOS>	B-X
M-CSF	B-X
is	B-X
produced	B-X
by	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
cell	B-X
types	B-X
,	B-X
including	B-X
EC	B-X
,	B-X
fibroblasts	B-X
,	B-X
and	B-X
monocyte/macrophages	B-X
,	B-X
where	B-X
it	B-X
functions	B-X
as	B-X
a	B-X
survival	B-X
factor	B-X
and	B-X
a	B-X
chemotactic	B-X
agent	B-X
for	B-X
monocytes	B-X
.	B-X
Local	B-X
expression	B-X
of	B-X
M-CSF	B-X
by	B-X
EC	B-X
lining	B-X
the	B-X
blood	B-X
vessels	B-X
is	B-X
thought	B-X
to	B-X
promote	B-X
the	B-X
growth	B-X
and	B-X
survival	B-X
of	B-X
lesional	B-X
monocytes	B-X
and	B-X
macrophages	B-X
,	B-X
thus	B-X
enhancing	B-X
lesion	B-X
development	B-X
and	B-X
disease	B-X
progression	B-X
.	B-X
As	B-X
a	B-X
step	B-X
toward	B-X
identifying	B-X
a	B-X
representative	B-X
endothelial-like	B-X
cell	B-X
line	B-X
,	B-X
serum-dependent	B-X
and	B-X
IL-1-dependent	B-X
changes	B-X
in	B-X
M-CSF	B-X
gene	B-X
expression	B-X
in	B-X
two	B-X
endothelial-like	B-X
cell	B-X
lines	B-X
were	B-X
compared	B-X
to	B-X
that	B-X
detected	B-X
in	B-X
primary	B-X
EC	B-X
cultures	B-X
.	B-X
The	B-X
data	B-X
presented	B-X
here	B-X
demonstrate	B-X
that	B-X
the	B-X
two	B-X
endothelial-like	B-X
cell	B-X
lines	B-X
,	B-X
like	B-X
primary	B-X
cultures	B-X
of	B-X
EC	B-X
,	B-X
express	B-X
the	B-X
M-CSF	B-X
gene	B-X
under	B-X
basal	B-X
conditions	B-X
.	B-X
In	B-X
both	B-X
types	B-X
of	B-X
cell	B-X
cultures	B-X
,	B-X
IL-1alpha	B-X
stimulation	B-X
increased	B-X
M-CSF	B-X
mRNA	B-X
levels	B-X
2-7-fold	B-X
,	B-X
whereas	B-X
serum	B-X
stimulation	B-X
elicited	B-X
a	B-X
more	B-X
modest	B-X
effect	B-X
(	B-X
2-3-fold	B-X
increase	B-X
)	B-X
.	B-X
The	B-X
IL-1alpha-induced	B-X
change	B-X
in	B-X
M-CSF	B-X
gene	B-X
expression	B-X
is	B-X
mediated	B-X
at	B-X
the	B-X
transcriptional	B-X
level	B-X
,	B-X
and	B-X
M-CSF	B-X
promoter	B-X
activity	B-X
is	B-X
,	B-X
in	B-X
part	B-X
,	B-X
dependent	B-X
on	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
NF-kappaB-inducing	B-X
kinase	B-X
.	B-X
Collectively	B-X
,	B-X
our	B-X
results	B-X
demonstrate	B-X
that	B-X
either	B-X
endothelial-like	B-X
cell	B-X
line	B-X
would	B-X
be	B-X
a	B-X
representative	B-X
model	B-X
in	B-X
which	B-X
endothelial-specific	B-X
changes	B-X
in	B-X
M-CSF	B-X
gene	B-X
expression	B-X
could	B-X
be	B-X
identified	B-X
.	B-X

This	O
activity	O
was	O
reduced	O
by	O
the	O
conventional	O
,	O
but	O
not	O
novel	O
,	O
PKC	O
inhibitors	O
,	O
dominant	B-Protein
negative	I-Protein
PKCalpha	I-Protein
constructs	O
or	O
PKCalpha	B-Protein
siRNA	I-Protein
.	O
<EOS>	B-X
Some	B-X
running	B-X
shoe	B-X
constructions	B-X
positively	B-X
affect	B-X
athletic	B-X
performance-related	B-X
and	B-X
injury-related	B-X
variables	B-X
:	B-X
1	B-X
)	B-X
increasing	B-X
the	B-X
stiffness	B-X
of	B-X
running	B-X
shoes	B-X
at	B-X
the	B-X
optimal	B-X
range	B-X
can	B-X
benefit	B-X
performance-related	B-X
variables	B-X
;	B-X
2	B-X
)	B-X
softer	B-X
midsoles	B-X
can	B-X
reduce	B-X
impact	B-X
forces	B-X
and	B-X
loading	B-X
rates	B-X
;	B-X
3	B-X
)	B-X
thicker	B-X
midsoles	B-X
can	B-X
provide	B-X
better	B-X
cushioning	B-X
effects	B-X
and	B-X
attenuate	B-X
shock	B-X
during	B-X
impacts	B-X
but	B-X
may	B-X
also	B-X
decrease	B-X
plantar	B-X
sensations	B-X
of	B-X
a	B-X
foot	B-X
;	B-X
4	B-X
)	B-X
minimalist	B-X
shoes	B-X
can	B-X
improve	B-X
running	B-X
economy	B-X
and	B-X
increase	B-X
the	B-X
cross-sectional	B-X
area	B-X
and	B-X
stiffness	B-X
of	B-X
Achilles	B-X
tendon	B-X
but	B-X
it	B-X
would	B-X
increase	B-X
the	B-X
metatarsophalangeal	B-X
and	B-X
ankle	B-X
joint	B-X
loading	B-X
compared	B-X
to	B-X
the	B-X
conventional	B-X
shoes	B-X
.	B-X
Though	B-X
injury	B-X
prevention	B-X
programs	B-X
have	B-X
experienced	B-X
some	B-X
success	B-X
,	B-X
rates	B-X
of	B-X
injuries	B-X
have	B-X
not	B-X
declined	B-X
,	B-X
and	B-X
after	B-X
injury	B-X
,	B-X
individuals	B-X
often	B-X
return	B-X
to	B-X
activity	B-X
with	B-X
functionality	B-X
below	B-X
clinical	B-X
recommendations	B-X
.	B-X
Considering	B-X
alternative	B-X
therapies	B-X
to	B-X
the	B-X
conventional	B-X
concentric	B-X
exercise	B-X
approach	B-X
,	B-X
such	B-X
as	B-X
one	B-X
that	B-X
can	B-X
target	B-X
neuromuscular	B-X
injury	B-X
risk	B-X
and	B-X
postinjury	B-X
alterations	B-X
,	B-X
may	B-X
provide	B-X
for	B-X
more	B-X
effective	B-X
injury	B-X
prevention	B-X
and	B-X
rehabilitation	B-X
protocols	B-X
.	B-X
To	B-X
date	B-X
,	B-X
clinical	B-X
studies	B-X
have	B-X
considered	B-X
the	B-X
potential	B-X
role	B-X
of	B-X
curcumin	B-X
to	B-X
reduce	B-X
muscular	B-X
damage	B-X
following	B-X
treadmill	B-X
running	B-X
(	B-X
downhill	B-X
and	B-X
flat	B-X
)	B-X
,	B-X
conventional	B-X
walking/running	B-X
,	B-X
cycling	B-X
(	B-X
acute	B-X
and	B-X
chronic	B-X
)	B-X
,	B-X
single-leg	B-X
jumping	B-X
(	B-X
downhill	B-X
)	B-X
,	B-X
and	B-X
eccentric	B-X
muscular	B-X
fitness	B-X
exercises	B-X
of	B-X
the	B-X
upper	B-X
and	B-X
lower	B-X
body	B-X
(	B-X
single-	B-X
and	B-X
double-leg	B-X
)	B-X
.	B-X
Various	B-X
curcumin-based	B-X
interventions	B-X
have	B-X
improved	B-X
self-perceived	B-X
measures	B-X
of	B-X
pain	B-X
and	B-X
tenderness	B-X
,	B-X
reduced	B-X
evidence	B-X
of	B-X
muscle	B-X
damage	B-X
,	B-X
ameliorated	B-X
inflammatory	B-X
markers	B-X
,	B-X
increased	B-X
markers	B-X
of	B-X
antioxidant	B-X
capacity	B-X
,	B-X
diminished	B-X
markers	B-X
of	B-X
oxidative	B-X
stress	B-X
,	B-X
reduced	B-X
markers	B-X
of	B-X
AGEs	B-X
,	B-X
and	B-X
attenuated	B-X
loss	B-X
in	B-X
mean	B-X
power	B-X
of	B-X
single-leg	B-X
sprints	B-X
.	B-X

Conventional	O
PKC	O
regulated	O
NF	O
-	O
kappaB	O
-	O
regulated	O
gene	O
expression	O
and	O
phosphorylation	O
of	O
Ser276	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
occurred	O
in	O
an	O
M	O
-	O
CSF	O
-	O
dependent	O
fashion	O
correlating	O
with	O
its	O
maximal	O
transcriptional	O
activity	O
.	O

Furthermore	O
,	O
PKCalpha	O
-	O
regulated	O
phosphorylation	O
of	O
Ser276	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
plays	O
an	O
important	O
role	O
in	O
regulating	O
its	O
activity	O
in	O
mononuclear	O
phagocytes	O
and	O
murine	O
embryonic	O
fibroblasts	O
.	O

M	O
-	O
CSF	O
Induces	O
NF	O
-	O
kappaB	O
Transcriptional	O
Activity	O
in	O
Human	O
Monocyte	O
-	O
Derived	O
Macrophages	O
(	O
MDMs	O
)	O
and	O
Mouse	O
Macrophage	O
Cell	O
Line	O
,	O
RAW	O
264	O
.	O
7	O
<EOS>	B-X
Macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
)	B-X
promotes	B-X
mononuclear	B-X
phagocyte	B-X
survival	B-X
and	B-X
proliferation	B-X
.	B-X
The	B-X
transcription	B-X
factor	B-X
Nuclear	B-X
Factor-kappaB	B-X
(	B-X
NF-κB	B-X
)	B-X
is	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
M-CSF-induced	B-X
mononuclear	B-X
phagocyte	B-X
survival	B-X
and	B-X
this	B-X
study	B-X
focused	B-X
at	B-X
identifying	B-X
the	B-X
mechanism	B-X
of	B-X
NF-κB	B-X
transcriptional	B-X
activation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
M-CSF	B-X
stimulated	B-X
NF-κB	B-X
transcriptional	B-X
activity	B-X
in	B-X
human	B-X
monocyte-derived	B-X
macrophages	B-X
(	B-X
MDMs	B-X
)	B-X
and	B-X
the	B-X
murine	B-X
macrophage	B-X
cell	B-X
line	B-X
RAW	B-X
264.7	B-X
.	B-X
The	B-X
general	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
inhibitor	B-X
Ro-31-8220	B-X
,	B-X
the	B-X
conventional	B-X
PKCα/β	B-X
inhibitor	B-X
Gö-6976	B-X
,	B-X
overexpression	B-X
of	B-X
dominant	B-X
negative	B-X
PKCα	B-X
constructs	B-X
and	B-X
PKCα	B-X
siRNA	B-X
reduced	B-X
NF-κB	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
M-CSF	B-X
.	B-X
Interestingly	B-X
,	B-X
Ro-31-8220	B-X
reduced	B-X
Ser276	B-X
phosphorylation	B-X
of	B-X
NF-κBp65	B-X
leading	B-X
to	B-X
decreased	B-X
M-CSF-induced	B-X
monocyte	B-X
survival	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
identify	B-X
conventional	B-X
PKCs	B-X
,	B-X
including	B-X
PKCα	B-X
as	B-X
important	B-X
upstream	B-X
kinases	B-X
for	B-X
M-CSF-induced	B-X
NF-κB	B-X
transcriptional	B-X
activation	B-X
,	B-X
NF-κB-regulated	B-X
gene	B-X
expression	B-X
,	B-X
NF-κB	B-X
p65	B-X
Ser276	B-X
phosphorylation	B-X
,	B-X
and	B-X
macrophage	B-X
survival	B-X
.	B-X
Lastly	B-X
,	B-X
we	B-X
find	B-X
that	B-X
NF-κB	B-X
p65	B-X
Ser276	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
basal	B-X
and	B-X
M-CSF-stimulated	B-X
NF-κB	B-X
activation	B-X
in	B-X
human	B-X
mononuclear	B-X
phagocytes	B-X
.	B-X

To	O
determine	O
if	O
M	O
-	O
CSF	O
induced	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
in	O
human	O
macrophages	O
,	O
we	O
performed	O
EMSA	O
analysis	O
on	O
nuclear	O
lysates	O
from	O
M	O
-	O
CSF	O
-	O
treated	O
MDMs	O
.	O

Similar	O
to	O
previous	O
reports	O
[	O
11	O
]	O
,	O
nuclear	O
NF	O
-	O
kappaB	O
constitutively	O
bound	O
DNA	O
in	O
non	O
-	O
stimulated	O
monocytes	O
(	O
Figure	O
1A	O
)	O
.	O

Interestingly	O
,	O
adding	O
M	O
-	O
CSF	O
did	O
not	O
alter	O
NF	O
-	O
kappaB	O
DNA	O
binding	O
by	O
EMSA	O
.	O
<EOS>	B-X
Of	B-X
note	B-X
,	B-X
autophagy	B-X
and	B-X
ROS	B-X
,	B-X
although	B-X
strongly	B-X
interconnected	B-X
,	B-X
have	B-X
been	B-X
separately	B-X
reported	B-X
to	B-X
be	B-X
induced	B-X
by	B-X
CSF2/GM-CSF	B-X
(	B-X
colony	B-X
stimulating	B-X
factor	B-X
2	B-X
)	B-X
and	B-X
required	B-X
for	B-X
CSF2-IL4-driven	B-X
monocyte	B-X
in	B-X
vitro	B-X
differentiation	B-X
into	B-X
DCs	B-X
.	B-X
The	B-X
latter	B-X
activated	B-X
the	B-X
SQSTM1-KEAP1-	B-X
NFE2L2	B-X
axis	B-X
and	B-X
upregulated	B-X
the	B-X
anti-oxidant	B-X
response	B-X
,	B-X
reducing	B-X
ROS	B-X
and	B-X
further	B-X
inhibiting	B-X
autophagy	B-X
.	B-X
Interestingly	B-X
,	B-X
mitochondria	B-X
supply	B-X
membranes	B-X
and	B-X
ATP	B-X
required	B-X
for	B-X
autophagy	B-X
execution	B-X
,	B-X
thus	B-X
their	B-X
reduction	B-X
may	B-X
further	B-X
reduce	B-X
autophagy	B-X
in	B-X
EBV-infected	B-X
monocytes	B-X
.	B-X
M-CSF	B-X
promotes	B-X
the	B-X
differentiation	B-X
and	B-X
survival	B-X
of	B-X
macrophages	B-X
,	B-X
and	B-X
preferentially	B-X
induces	B-X
anti-inflammatory	B-X
M2	B-X
,	B-X
rather	B-X
than	B-X
proinflammatory	B-X
M1	B-X
macrophages	B-X
.	B-X
In	B-X
this	B-X
article	B-X
,	B-X
we	B-X
provide	B-X
the	B-X
first	B-X
evidence	B-X
,	B-X
to	B-X
our	B-X
knowledge	B-X
,	B-X
that	B-X
M-CSF	B-X
has	B-X
both	B-X
additive	B-X
and	B-X
inhibitory	B-X
effects	B-X
on	B-X
the	B-X
macrophage-related	B-X
activities	B-X
of	B-X
IL-32	B-X
.	B-X
When	B-X
added	B-X
to	B-X
M-CSF-derived	B-X
macrophages	B-X
,	B-X
M-CSF	B-X
and	B-X
IL-32	B-X
promoted	B-X
macrophage	B-X
survival	B-X
,	B-X
which	B-X
was	B-X
further	B-X
enhanced	B-X
by	B-X
their	B-X
combination	B-X
.	B-X
However	B-X
,	B-X
they	B-X
had	B-X
different	B-X
effects	B-X
on	B-X
HIV-1	B-X
replication	B-X
;	B-X
that	B-X
is	B-X
,	B-X
it	B-X
was	B-X
stimulated	B-X
by	B-X
M-CSF	B-X
and	B-X
inhibited	B-X
by	B-X
IL-32	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
anti-HIV-1	B-X
activity	B-X
of	B-X
IL-32	B-X
was	B-X
counteracted	B-X
by	B-X
M-CSF	B-X
.	B-X
Such	B-X
inhibitory	B-X
effect	B-X
of	B-X
M-CSF	B-X
was	B-X
not	B-X
observed	B-X
with	B-X
IL-32-induced	B-X
M1-like	B-X
features	B-X
including	B-X
high	B-X
cytokine/chemokine	B-X
production	B-X
and	B-X
strong	B-X
expression	B-X
of	B-X
the	B-X
costimulatory	B-X
molecule	B-X
CD80	B-X
.	B-X
However	B-X
,	B-X
IL-32-treated	B-X
macrophages	B-X
unexpectedly	B-X
showed	B-X
also	B-X
M2-like	B-X
features	B-X
including	B-X
increased	B-X
phagocytic	B-X
activity	B-X
,	B-X
and	B-X
high	B-X
expression	B-X
of	B-X
CD14	B-X
and	B-X
the	B-X
scavenger	B-X
receptor	B-X
CD163	B-X
,	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
CD14	B-X
and	B-X
CD163	B-X
was	B-X
further	B-X
upregulated	B-X
by	B-X
cotreatment	B-X
with	B-X
M-CSF	B-X
.	B-X
The	B-X
findings	B-X
of	B-X
this	B-X
study	B-X
regarding	B-X
the	B-X
unique	B-X
functional	B-X
interplay	B-X
between	B-X
M-CSF	B-X
and	B-X
IL-32	B-X
increase	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
that	B-X
regulate	B-X
the	B-X
survival	B-X
and	B-X
M1/M2	B-X
ratio	B-X
of	B-X
macrophages	B-X
,	B-X
as	B-X
well	B-X
as	B-X
HIV-1	B-X
replication	B-X
in	B-X
macrophages	B-X
.	B-X

In	O
contrast	O
,	O
after	O
transiently	O
transfecting	O
human	O
MDMs	O
with	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
constructs	O
containing	O
four	O
NF	O
-	O
kappaB	O
consensus	O
binding	O
sequences	O
,	O
M	O
-	O
CSF	O
treatment	O
of	O
the	O
transfected	O
cells	O
resulted	O
in	O
a	O
2	O
.	O
3	O
-	O
fold	O
increase	O
in	O
SEAP	O
release	O
in	O
the	O
culture	O
media	O
compared	O
to	O
PBS	O
(	O
vehicle	O
)	O
-	O
treated	O
transfected	O
MDMs	O
(	O
Figure	O
1B	O
)	O
.	O

As	O
a	O
control	O
,	O
the	O
pTAL	O
-	O
SEAP	O
construct	O
lacking	O
NF	O
-	O
kappaB	O
binding	O
sites	O
was	O
used	O
.	O

Cells	O
transfected	O
with	O
the	O
pTAL	O
-	O
SEAP	O
construct	O
did	O
not	O
produce	O
SEAP	O
in	O
the	O
absence	O
or	O
presence	O
of	O
M	O
-	O
CSF	O
(	O
Figure	O
1B	O
)	O
.	O

We	O
next	O
investigated	O
whether	O
M	O
-	O
CSF	O
induced	O
NF	O
-	O
kappaB	O
activity	O
in	O
the	O
mouse	O
macrophage	O
cell	O
line	O
,	O
RAW	O
264	O
.	O
7	O
.	O

RAW	O
264	O
.	O
7	O
cells	O
were	O
transfected	O
with	O
either	O
the	O
NF	O
-	O
kappaB	O
-	O
SEAP	O
reporter	O
or	O
control	O
pTAL	O
-	O
SEAP	O
construct	O
.	O
<EOS>	B-X
Necrotic	B-X
cells	B-X
passively	B-X
release	B-X
HMGB1	B-X
,	B-X
which	B-X
can	B-X
stimulate	B-X
TLR4	B-X
in	B-X
an	B-X
autocrine	B-X
fashion	B-X
to	B-X
potentially	B-X
initiate	B-X
``	B-X
sterile	B-X
''	B-X
inflammation	B-X
that	B-X
maintains	B-X
different	B-X
disease	B-X
states	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
prooxidants	B-X
can	B-X
induce	B-X
NF-κB	B-X
activation	B-X
through	B-X
TLR4	B-X
stimulation	B-X
.	B-X
We	B-X
examined	B-X
whether	B-X
prooxidants	B-X
enhance	B-X
HMGB1-induced	B-X
TLR4	B-X
signaling	B-X
through	B-X
NF-κB	B-X
activation	B-X
.	B-X
As	B-X
model	B-X
systems	B-X
,	B-X
we	B-X
used	B-X
HEK-Blue	B-X
cells	B-X
(	B-X
stably	B-X
transfected	B-X
with	B-X
mouse	B-X
TLR4	B-X
)	B-X
,	B-X
RAW-Blue™	B-X
cells	B-X
(	B-X
derived	B-X
from	B-X
murine	B-X
RAW	B-X
264.7	B-X
macrophages	B-X
)	B-X
and	B-X
primary	B-X
murine	B-X
macrophages	B-X
from	B-X
TLR4-KO	B-X
mice	B-X
.	B-X
Both	B-X
HEK-Blue	B-X
and	B-X
RAW-Blue	B-X
264.7	B-X
cells	B-X
express	B-X
optimized	B-X
secreted	B-X
embryonic	B-X
alkaline	B-X
phosphatase	B-X
(	B-X
SEAP	B-X
)	B-X
reporter	B-X
under	B-X
the	B-X
control	B-X
of	B-X
a	B-X
promoter	B-X
inducible	B-X
by	B-X
NF-κB	B-X
.	B-X
We	B-X
treated	B-X
cells	B-X
with	B-X
HMGB1	B-X
alone	B-X
and/or	B-X
in	B-X
conjunction	B-X
with	B-X
prooxidants	B-X
and/or	B-X
inhibitors	B-X
using	B-X
SEAP	B-X
release	B-X
as	B-X
a	B-X
measure	B-X
of	B-X
TLR4	B-X
stimulation	B-X
.	B-X
HMGB1	B-X
alone	B-X
and/or	B-X
in	B-X
conjunction	B-X
with	B-X
prooxidants	B-X
increased	B-X
TNFα	B-X
and	B-X
IL-6	B-X
released	B-X
from	B-X
TLR4-WT	B-X
,	B-X
but	B-X
not	B-X
from	B-X
TLR4-KO	B-X
macrophages	B-X
.	B-X
Prooxidants	B-X
promoted	B-X
HMGB1-induced	B-X
NF-κB	B-X
activation	B-X
as	B-X
determined	B-X
by	B-X
increased	B-X
release	B-X
of	B-X
SEAP	B-X
and	B-X
TNF-α	B-X
,	B-X
and	B-X
accumulation	B-X
of	B-X
iROS	B-X
.	B-X
HMGB1	B-X
(	B-X
Box	B-X
A	B-X
)	B-X
,	B-X
anti-HMGB1	B-X
and	B-X
anti-TLR4-neutralizing	B-X
pAbs	B-X
inhibited	B-X
HMGB1-induced	B-X
NF-κB	B-X
activation	B-X
,	B-X
but	B-X
HMGB1	B-X
(	B-X
Box	B-X
A	B-X
)	B-X
and	B-X
anti-HMGB1	B-X
pAb	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
prooxidant-induced	B-X
SEAP	B-X
release	B-X
.	B-X
The	B-X
present	B-X
results	B-X
confirm	B-X
that	B-X
prooxidants	B-X
enhance	B-X
proinflammatory	B-X
effects	B-X
of	B-X
HMGB1	B-X
by	B-X
activating	B-X
NF-κB	B-X
through	B-X
TLR4	B-X
signaling	B-X
.	B-X

As	O
shown	O
in	O
Figure	O
1C	O
,	O
M	O
-	O
CSF	O
treatment	O
of	O
RAW	O
264	O
.	O
7	O
cells	O
increased	O
NF	B-Protein
-	I-Protein
kappaB	I-Protein
reporter	O
activity	O
by	O
2	O
.	O
5	O
-	O
fold	O
over	O
that	O
of	O
non	O
-	O
treated	O
cells	O
.	O

Together	O
,	O
our	O
data	O
demonstrate	O
that	O
M	O
-	O
CSF	O
induced	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
in	O
macrophages	O
.	O
<EOS>	B-X
In	B-X
light	B-X
of	B-X
recent	B-X
efforts	B-X
in	B-X
the	B-X
mapping	B-X
of	B-X
transcription	B-X
start	B-X
site	B-X
landscape	B-X
using	B-X
high-throughput	B-X
sequencing	B-X
approaches	B-X
,	B-X
a	B-X
quantitative	B-X
and	B-X
automated	B-X
method	B-X
is	B-X
needed	B-X
to	B-X
process	B-X
all	B-X
the	B-X
data	B-X
that	B-X
are	B-X
being	B-X
produced	B-X
.	B-X
Genes	B-X
selected	B-X
by	B-X
the	B-X
classifiers	B-X
can	B-X
then	B-X
be	B-X
analyzed	B-X
together	B-X
with	B-X
additional	B-X
supporting	B-X
data	B-X
to	B-X
determine	B-X
their	B-X
biological	B-X
significance	B-X
.	B-X
We	B-X
use	B-X
a	B-X
set	B-X
of	B-X
time-course	B-X
TSS	B-X
data	B-X
from	B-X
mouse	B-X
dendritic	B-X
cells	B-X
stimulated	B-X
with	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
to	B-X
demonstrate	B-X
the	B-X
usefulness	B-X
of	B-X
our	B-X
method	B-X
.	B-X
It	B-X
is	B-X
characterized	B-X
by	B-X
the	B-X
formation	B-X
of	B-X
bone	B-X
by	B-X
osteoblasts	B-X
and	B-X
its	B-X
resorption	B-X
by	B-X
osteoclasts	B-X
,	B-X
and	B-X
the	B-X
bone	B-X
resorbed	B-X
by	B-X
osteoclasts	B-X
is	B-X
replaced	B-X
through	B-X
the	B-X
differentiation	B-X
and	B-X
activity	B-X
of	B-X
osteoblasts	B-X
.	B-X
Cell	B-X
proliferation	B-X
,	B-X
apoptosis	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
receptor	B-X
activator	B-X
of	B-X
NF‑κB	B-X
ligand	B-X
(	B-X
RANKL	B-X
)	B-X
,	B-X
osteoprotegerin	B-X
(	B-X
OPG	B-X
)	B-X
and	B-X
macrophage	B-X
colony‑stimulating	B-X
factor	B-X
(	B-X
M‑CSF	B-X
)	B-X
were	B-X
measured	B-X
following	B-X
treatment	B-X
using	B-X
multiple	B-X
detection	B-X
techniques	B-X
,	B-X
including	B-X
an	B-X
MTT	B-X
assay	B-X
,	B-X
flow	B-X
cytometry	B-X
,	B-X
reverse	B-X
transcription‑quantitative	B-X
polymerase	B-X
chain	B-X
reaction	B-X
and	B-X
western	B-X
blot	B-X
analysis	B-X
.	B-X
The	B-X
resulting	B-X
data	B-X
demonstrated	B-X
that	B-X
IMD	B-X
significantly	B-X
inhibited	B-X
the	B-X
apoptosis	B-X
of	B-X
MC3T3‑E1	B-X
cells	B-X
induced	B-X
by	B-X
serum‑free	B-X
culture	B-X
and	B-X
dexamethasone	B-X
,	B-X
however	B-X
,	B-X
no	B-X
significant	B-X
effects	B-X
on	B-X
MC3T3‑E1	B-X
cell	B-X
proliferation	B-X
were	B-X
observed	B-X
.	B-X
IMD	B-X
had	B-X
additional	B-X
functions	B-X
on	B-X
the	B-X
MC3T3‑E1	B-X
cells	B-X
,	B-X
including	B-X
inhibition	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
RANKL	B-X
and	B-X
M‑CSF	B-X
,	B-X
and	B-X
promotion	B-X
of	B-X
the	B-X
expression	B-X
of	B-X
OPG	B-X
.	B-X
Previous	B-X
studies	B-X
have	B-X
also	B-X
demonstrated	B-X
that	B-X
RANKL	B-X
and	B-X
M‑CSF	B-X
are	B-X
two	B-X
vital	B-X
factor	B-X
produced	B-X
by	B-X
osteoblasts	B-X
to	B-X
promote	B-X
the	B-X
maturation	B-X
and	B-X
differentiation	B-X
of	B-X
osteoclasts	B-X
,	B-X
and	B-X
it	B-X
has	B-X
been	B-X
reported	B-X
that	B-X
IMD	B-X
can	B-X
inhibit	B-X
the	B-X
osteoclast	B-X
formation	B-X
stimulated	B-X
by	B-X
RANKL	B-X
and	B-X
M‑CSF	B-X
.	B-X
Together	B-X
with	B-X
these	B-X
findings	B-X
,	B-X
the	B-X
present	B-X
study	B-X
concluded	B-X
that	B-X
IMD	B-X
reduces	B-X
bone	B-X
resorption	B-X
by	B-X
inhibiting	B-X
osteoblast	B-X
apoptosis	B-X
,	B-X
decreasing	B-X
the	B-X
RANKL/OPG	B-X
ratio	B-X
and	B-X
the	B-X
expression	B-X
of	B-X
M-CSF	B-X
,	B-X
and	B-X
inhibiting	B-X
osteoclast	B-X
maturation	B-X
and	B-X
differentiation	B-X
.	B-X

PKC	O
Inhibition	O
Reduces	O
NF	O
-	O
kappaB	O
Activity	O
in	O
Human	O
MDMs	O
and	O
RAW	O
264	O
.	O
7	O
Cells	O

Since	O
NF	O
-	O
kappaB	O
is	O
activated	O
by	O
PKC	O
in	O
several	O
cell	O
types	O
[	O
36	O
]	O
,	O
we	O
next	O
determined	O
if	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
was	O
dependent	O
on	O
PKC	O
activation	O
and	O
if	O
calcium	O
,	O
a	O
co	O
-	O
factor	O
for	O
conventional	O
PKC	O
isoform	O
activation	O
,	O
was	O
important	O
.	O

In	O
addition	O
,	O
because	O
of	O
the	O
number	O
of	O
conventional	O
PKCs	O
existing	O
within	O
mononuclear	O
cells	O
,	O
pharmacological	O
inhibitors	O
of	O
PKC	O
family	O
activation	O
was	O
used	O
to	O
determine	O
the	O
relationship	O
of	O
PKC	O
activation	O
to	O
M	O
-	O
CSF	O
-	O
induced	O
cellular	O
survival	O
.	O

MDMs	O
were	O
transfected	O
with	O
the	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
reporter	O
and	O
then	O
treated	O
with	O
the	O
general	O
PKC	O
inhibitor	O
,	O
Ro	O
-	O
31	O
-	O
8220	O
;	O
the	O
conventional	O
PKCalpha	B-Protein
/	O
beta	B-Protein
inhibitor	O
Go	O
-	O
6976	O
;	O
or	O
the	O
intracellular	O
calcium	O
blocker	O
BAPTA	O
/	O
AM	O
.	O

Ro	O
-	O
31	O
-	O
8220	O
significantly	O
suppressed	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
activity	O
compared	O
to	O
cells	O
treated	O
with	O
M	O
-	O
CSF	O
alone	O
(	O
Figure	O
2A	O
)	O
.	O

In	O
addition	O
,	O
Go	O
-	O
6976	O
and	O
BAPTA	O
/	O
AM	O
also	O
blocked	O
NF	O
-	O
kappaB	O
activity	O
in	O
M	O
-	O
CSF	O
-	O
treated	O
MDMs	O
.	O

Trypan	O
blue	O
exclusion	O
analysis	O
did	O
not	O
indicate	O
cell	O
death	O
suggesting	O
that	O
this	O
suppression	O
was	O
not	O
due	O
to	O
non	O
-	O
specific	O
toxicity	O
.	O
<EOS>	B-X
The	B-X
measurement	B-X
of	B-X
cell	B-X
viability	B-X
plays	B-X
a	B-X
fundamental	B-X
role	B-X
in	B-X
all	B-X
forms	B-X
of	B-X
cell	B-X
culture	B-X
.	B-X
Sometimes	B-X
it	B-X
is	B-X
the	B-X
main	B-X
purpose	B-X
of	B-X
the	B-X
experiment	B-X
,	B-X
such	B-X
as	B-X
in	B-X
toxicity	B-X
assays	B-X
.	B-X
Alternatively	B-X
,	B-X
cell	B-X
viability	B-X
can	B-X
be	B-X
used	B-X
to	B-X
-correlate	B-X
cell	B-X
behaviour	B-X
to	B-X
cell	B-X
number	B-X
,	B-X
providing	B-X
a	B-X
more	B-X
accurate	B-X
picture	B-X
of	B-X
,	B-X
for	B-X
example	B-X
,	B-X
anabolic	B-X
-activity	B-X
.	B-X
There	B-X
are	B-X
wide	B-X
arrays	B-X
of	B-X
cell	B-X
viability	B-X
methods	B-X
which	B-X
range	B-X
from	B-X
the	B-X
most	B-X
routine	B-X
trypan	B-X
blue	B-X
dye	B-X
exclusion	B-X
assay	B-X
to	B-X
highly	B-X
complex	B-X
analysis	B-X
of	B-X
individual	B-X
cells	B-X
,	B-X
such	B-X
as	B-X
using	B-X
RAMAN	B-X
microscopy	B-X
.	B-X

These	O
data	O
indicate	O
that	O
M	O
-	O
CSF	O
mediated	O
NF	O
-	O
kappaB	O
activation	O
through	O
calcium	O
-	O
dependent	O
conventional	O
PKC	O
activation	O
.	O

We	O
next	O
investigated	O
whether	O
PKC	O
inhibition	O
affected	O
NF	O
-	O
kappaB	O
activity	O
in	O
the	O
mouse	O
macrophage	O
cell	O
line	O
,	O
RAW	O
264	O
.	O
7	O
.	O

Similar	O
to	O
MDMs	O
,	O
PKC	O
inhibitors	O
Ro	O
-	O
31	O
-	O
8220	O
,	O
Go	O
-	O
6976	O
and	O
BAPTA	O
/	O
AM	O
reduced	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
in	O
RAW	O
264	O
.	O
7	O
macrophages	O
(	O
Figure	O
2B	O
)	O
.	O

To	O
ensure	O
that	O
PKC	O
specifically	O
regulated	O
NF	O
-	O
kappaB	O
p65	B-Protein
and	O
not	O
the	O
closely	O
related	O
family	O
member	O
,	O
c	B-Protein
-	I-Protein
Rel	I-Protein
,	O
we	O
co	O
-	O
transfected	O
c	O
-	O
Rel	O
and	O
NF	O
-	O
kappaB	O
-	O
SEAP	O
constructs	O
into	O
the	O
Raw	O
264	O
.	O
7	O
cell	O
line	O
and	O
measured	O
NF	O
-	O
kappaB	O
activity	O
in	O
response	O
to	O
M	O
-	O
CSF	O
.	O

There	O
was	O
no	O
increased	O
NF	O
-	O
kappaB	O
activity	O
in	O
cells	O
expressing	O
c	B-Protein
-	I-Protein
Rel	I-Protein
(	O
Figure	O
S1	O
)	O
.	O

These	O
observations	O
indicate	O
that	O
PKC	O
functioned	O
upstream	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
in	O
MDMs	O
and	O
RAW	O
264	O
.	O
7	O
cells	O
.	O

NF	O
-	O
kappaB	O
and	O
PKC	O
(	O
s	O
)	O
Mediate	O
Human	O
MDM	O
Survival	O
in	O
Response	O
to	O
M	O
-	O
CSF	O
Stimulation	O

Since	O
PKC	O
and	O
NF	O
-	O
kappaB	O
are	O
critical	O
in	O
cell	O
survival	O
[	O
37	O
]	O
,	O
[	O
38	O
]	O
,	O
we	O
hypothesized	O
that	O
M	O
-	O
CSF	O
promoted	O
cell	O
survival	O
through	O
PKC	O
in	O
human	O
MDMs	O
.	O

To	O
detect	O
apoptosis	O
,	O
the	O
expression	O
of	O
cleaved	O
caspase	B-Protein
-	I-Protein
3	I-Protein
,	O
a	O
marker	O
of	O
apoptosis	O
,	O
was	O
analyzed	O
in	O
the	O
presence	O
or	O
absence	O
of	O
M	O
-	O
CSF	O
and	O
PKC	O
inhibitors	O
.	O
<EOS>	B-X
Fibroblasts	B-X
respond	B-X
directly	B-X
to	B-X
titanium	B-X
particles	B-X
and	B-X
increase	B-X
RANKL	B-X
expression	B-X
through	B-X
a	B-X
COX-2/PGE2/EP4/PKA	B-X
signaling	B-X
pathway	B-X
.	B-X
Experimental	B-X
evidence	B-X
has	B-X
highlighted	B-X
the	B-X
role	B-X
of	B-X
light	B-X
effects	B-X
on	B-X
the	B-X
mechanisms	B-X
related	B-X
to	B-X
inflammation	B-X
,	B-X
apoptosis	B-X
and	B-X
autophagy	B-X
.	B-X
The	B-X
goal	B-X
of	B-X
this	B-X
project	B-X
was	B-X
the	B-X
evaluation	B-X
of	B-X
PBM	B-X
on	B-X
U937	B-X
,	B-X
an	B-X
established	B-X
cell	B-X
line	B-X
of	B-X
histiocytic	B-X
lymphoma	B-X
origin	B-X
.	B-X
Several	B-X
aspects	B-X
of	B-X
modulation	B-X
of	B-X
proinflammatory	B-X
pathways	B-X
were	B-X
analyzed	B-X
and	B-X
autophagic	B-X
and	B-X
proapoptotic	B-X
mechanisms	B-X
related	B-X
to	B-X
low	B-X
laser	B-X
light	B-X
exposure	B-X
of	B-X
cells	B-X
were	B-X
studied	B-X
.	B-X
Flow	B-X
cytometry	B-X
analysis	B-X
was	B-X
performed	B-X
on	B-X
supernatants	B-X
of	B-X
controls	B-X
and	B-X
treated	B-X
U937	B-X
cells	B-X
to	B-X
detect	B-X
inflammatory	B-X
cytokine	B-X
levels	B-X
.	B-X
In	B-X
order	B-X
to	B-X
evaluate	B-X
NF-kB	B-X
and	B-X
caspase3	B-X
expressions	B-X
,	B-X
Western	B-X
blot	B-X
analysis	B-X
was	B-X
performed	B-X
according	B-X
to	B-X
standard	B-X
procedures	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
show	B-X
the	B-X
effect	B-X
of	B-X
PBM	B-X
on	B-X
a	B-X
monocyte/macrophage	B-X
established	B-X
tumor	B-X
cell	B-X
line	B-X
(	B-X
U-937	B-X
)	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
LED	B-X
exposure	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
,	B-X
activates	B-X
cell	B-X
degranulation	B-X
,	B-X
increased	B-X
expression	B-X
of	B-X
Interleukin-8	B-X
(	B-X
IL-8	B-X
)	B-X
and	B-X
modulation	B-X
of	B-X
beta	B-X
galactosidase	B-X
activity	B-X
.	B-X
Evidence	B-X
shows	B-X
that	B-X
the	B-X
well-known	B-X
pro-inflammatory	B-X
nuclear	B-X
factor	B-X
kappa-light-chain-enhancer	B-X
of	B-X
activated	B-X
B	B-X
cells	B-X
(	B-X
NF-kB	B-X
)	B-X
and	B-X
the	B-X
apoptotic	B-X
marker	B-X
(	B-X
caspase3/cleaved-caspase3	B-X
ratio	B-X
)	B-X
are	B-X
up-regulated	B-X
in	B-X
response	B-X
to	B-X
a	B-X
proinflammatory	B-X
biochemical	B-X
pathway	B-X
.	B-X

In	O
MDMs	O
pretreated	O
with	O
PKC	O
inhibitors	O
(	O
Ro	O
-	O
31	O
-	O
8220	O
,	O
Go	O
-	O
6976	O
,	O
or	O
BAPTA	O
/	O
AM	O
)	O
and	O
stimulated	O
with	O
M	O
-	O
CSF	O
,	O
cleaved	O
caspase	B-Protein
-	I-Protein
3	I-Protein
was	O
elevated	O
to	O
levels	O
of	O
cells	O
treated	O
with	O
vehicle	O
alone	O
(	O
Figure	O
3A	O
)	O
.	O

In	O
contrast	O
,	O
cells	O
incubated	O
with	O
M	O
-	O
CSF	O
and	O
vehicle	O
had	O
less	O
cleaved	O
caspase	B-Protein
-	I-Protein
3	I-Protein
than	O
cells	O
incubated	O
with	O
vehicle	O
alone	O
or	O
M	O
-	O
CSF	O
with	O
PKC	O
inhibitors	O
.	O
<EOS>	B-X
The	B-X
current	B-X
therapeutic	B-X
focus	B-X
is	B-X
on	B-X
disrupting	B-X
the	B-X
interaction	B-X
of	B-X
MM	B-X
cells	B-X
with	B-X
its	B-X
protective	B-X
tumor	B-X
microenvironment	B-X
where	B-X
CXCR4	B-X
axis	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
relative	B-X
positions	B-X
of	B-X
type	B-X
I	B-X
phosphatidylinositol	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
and	B-X
phospholipase	B-X
C	B-X
(	B-X
PLC	B-X
)	B-X
in	B-X
this	B-X
pathway	B-X
,	B-X
we	B-X
analyzed	B-X
macropinocytosis	B-X
in	B-X
macrophages	B-X
stimulated	B-X
by	B-X
the	B-X
growth	B-X
factor	B-X
macrophage-colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
)	B-X
and	B-X
by	B-X
the	B-X
diacylglycerol	B-X
(	B-X
DAG	B-X
)	B-X
analog	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
PMA	B-X
)	B-X
.	B-X
In	B-X
cells	B-X
stimulated	B-X
with	B-X
M-CSF	B-X
,	B-X
microscopic	B-X
imaging	B-X
of	B-X
fluorescent	B-X
probes	B-X
for	B-X
intracellular	B-X
lipids	B-X
indicated	B-X
that	B-X
the	B-X
PI3K	B-X
product	B-X
phosphatidylinositol	B-X
(	B-X
3,4,5	B-X
)	B-X
-trisphosphate	B-X
(	B-X
PIP3	B-X
)	B-X
appeared	B-X
in	B-X
cups	B-X
just	B-X
prior	B-X
to	B-X
DAG	B-X
.	B-X
We	B-X
then	B-X
tested	B-X
the	B-X
hypothesis	B-X
that	B-X
PMA	B-X
and	B-X
DAG	B-X
function	B-X
after	B-X
PI3K	B-X
and	B-X
prior	B-X
to	B-X
Ras	B-X
and	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
during	B-X
macropinosome	B-X
formation	B-X
in	B-X
macrophages	B-X
.	B-X
Although	B-X
the	B-X
PI3K	B-X
target	B-X
Akt	B-X
was	B-X
activated	B-X
by	B-X
M-CSF	B-X
,	B-X
the	B-X
Akt	B-X
inhibitor	B-X
MK-2206	B-X
did	B-X
not	B-X
inhibit	B-X
macropinocytosis	B-X
.	B-X
The	B-X
phospholipase	B-X
C	B-X
(	B-X
PLC	B-X
)	B-X
inhibitor	B-X
U73122	B-X
blocked	B-X
macropinocytosis	B-X
by	B-X
M-CSF	B-X
but	B-X
not	B-X
PMA	B-X
.	B-X
Macropinocytosis	B-X
in	B-X
response	B-X
to	B-X
M-CSF	B-X
and	B-X
PMA	B-X
was	B-X
inhibited	B-X
by	B-X
the	B-X
Ras	B-X
inhibitor	B-X
farnesyl	B-X
thiosalicylate	B-X
(	B-X
FTS	B-X
)	B-X
,	B-X
by	B-X
the	B-X
PKC	B-X
inhibitor	B-X
Calphostin	B-X
C	B-X
and	B-X
by	B-X
the	B-X
broad	B-X
specificity	B-X
inhibitor	B-X
rottlerin	B-X
.	B-X
These	B-X
studies	B-X
support	B-X
a	B-X
model	B-X
in	B-X
which	B-X
M-CSF	B-X
stimulates	B-X
PI3K	B-X
in	B-X
macropinocytic	B-X
cups	B-X
,	B-X
and	B-X
the	B-X
resulting	B-X
increase	B-X
in	B-X
PIP3	B-X
activates	B-X
PLC	B-X
,	B-X
which	B-X
in	B-X
turn	B-X
generates	B-X
DAG	B-X
necessary	B-X
for	B-X
activation	B-X
of	B-X
PKC	B-X
,	B-X
Ras	B-X
and	B-X
the	B-X
late	B-X
stages	B-X
of	B-X
macropinosome	B-X
closure	B-X
.	B-X

These	O
data	O
supported	O
the	O
hypothesis	O
that	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
activity	O
was	O
regulated	O
by	O
conventional	O
PKCs	O
,	O
not	O
novel	O
PKCs	O
.	O

To	O
confirm	O
that	O
PKC	O
inhibition	O
decreased	O
cell	O
survival	O
,	O
cells	O
were	O
treated	O
with	O
M	O
-	O
CSF	O
in	O
the	O
absence	O
or	O
presence	O
of	O
PKC	O
inhibitors	O
and	O
then	O
also	O
examined	O
for	O
apoptosis	O
by	O
Annexin	B-Protein
V	I-Protein
/	O
PI	O
staining	O
.	O

PKC	O
inhibitors	O
in	O
the	O
presence	O
of	O
M	O
-	O
CSF	O
reduced	O
the	O
number	O
of	O
Annexin	B-Protein
V	I-Protein
/	O
PI	O
negative	O
MDMs	O
compared	O
to	O
cells	O
treated	O
with	O
M	O
-	O
CSF	O
alone	O
(	O
Figure	O
3B	O
)	O
.	O

These	O
observations	O
further	O
suggested	O
that	O
MDM	O
survival	O
is	O
promoted	O
by	O
M	O
-	O
CSF	O
and	O
critically	O
involves	O
conventional	O
PKCs	O
and	O
NF	O
-	O
kappaB	O
activity	O
.	O

M	O
-	O
CSF	O
-	O
Induces	O
PKCalpha	B-Protein
Kinase	O
Activity	O
<EOS>	B-X
Macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
)	B-X
promotes	B-X
mononuclear	B-X
phagocyte	B-X
survival	B-X
and	B-X
proliferation	B-X
.	B-X
The	B-X
transcription	B-X
factor	B-X
Nuclear	B-X
Factor-kappaB	B-X
(	B-X
NF-κB	B-X
)	B-X
is	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
M-CSF-induced	B-X
mononuclear	B-X
phagocyte	B-X
survival	B-X
and	B-X
this	B-X
study	B-X
focused	B-X
at	B-X
identifying	B-X
the	B-X
mechanism	B-X
of	B-X
NF-κB	B-X
transcriptional	B-X
activation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
M-CSF	B-X
stimulated	B-X
NF-κB	B-X
transcriptional	B-X
activity	B-X
in	B-X
human	B-X
monocyte-derived	B-X
macrophages	B-X
(	B-X
MDMs	B-X
)	B-X
and	B-X
the	B-X
murine	B-X
macrophage	B-X
cell	B-X
line	B-X
RAW	B-X
264.7	B-X
.	B-X
The	B-X
general	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
inhibitor	B-X
Ro-31-8220	B-X
,	B-X
the	B-X
conventional	B-X
PKCα/β	B-X
inhibitor	B-X
Gö-6976	B-X
,	B-X
overexpression	B-X
of	B-X
dominant	B-X
negative	B-X
PKCα	B-X
constructs	B-X
and	B-X
PKCα	B-X
siRNA	B-X
reduced	B-X
NF-κB	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
M-CSF	B-X
.	B-X
Interestingly	B-X
,	B-X
Ro-31-8220	B-X
reduced	B-X
Ser276	B-X
phosphorylation	B-X
of	B-X
NF-κBp65	B-X
leading	B-X
to	B-X
decreased	B-X
M-CSF-induced	B-X
monocyte	B-X
survival	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
identify	B-X
conventional	B-X
PKCs	B-X
,	B-X
including	B-X
PKCα	B-X
as	B-X
important	B-X
upstream	B-X
kinases	B-X
for	B-X
M-CSF-induced	B-X
NF-κB	B-X
transcriptional	B-X
activation	B-X
,	B-X
NF-κB-regulated	B-X
gene	B-X
expression	B-X
,	B-X
NF-κB	B-X
p65	B-X
Ser276	B-X
phosphorylation	B-X
,	B-X
and	B-X
macrophage	B-X
survival	B-X
.	B-X
Lastly	B-X
,	B-X
we	B-X
find	B-X
that	B-X
NF-κB	B-X
p65	B-X
Ser276	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
basal	B-X
and	B-X
M-CSF-stimulated	B-X
NF-κB	B-X
activation	B-X
in	B-X
human	B-X
mononuclear	B-X
phagocytes	B-X
.	B-X

Since	O
our	O
data	O
suggested	O
that	O
conventional	O
PKCs	O
were	O
involved	O
in	O
activating	O
NF	O
-	O
kappaB	O
in	O
response	O
to	O
M	O
-	O
CSF	O
in	O
primary	O
human	O
macrophages	O
,	O
we	O
next	O
investigated	O
whether	O
the	O
conventional	O
PKC	O
,	O
PKCalpha	B-Protein
was	O
a	O
downstream	O
target	O
of	O
M	O
-	O
CSF	O
in	O
human	O
MDMs	O
.	O

PKCalpha	O
was	O
immunoprecipitated	O
from	O
human	O
MDMs	O
at	O
the	O
indicated	O
time	O
points	O
(	O
Figure	O
4	O
)	O
,	O
and	O
then	O
a	O
PKC	O
kinase	O
assay	O
was	O
performed	O
using	O
a	O
fluorescein	O
-	O
tagged	O
peptide	O
as	O
a	O
substrate	O
.	O

As	O
shown	O
in	O
Figure	O
4	O
(	O
upper	O
panel	O
)	O
,	O
the	O
peptide	O
substrate	O
was	O
maximally	O
phosphorylated	O
within	O
10	O
minutes	O
of	O
stimulation	O
(	O
1	O
.	O
8	O
-	O
fold	O
over	O
resting	O
cells	O
,	O
lower	O
panel	O
)	O
,	O
and	O
then	O
returned	O
to	O
basal	O
levels	O
by	O
15	O
minutes	O
.	O

This	O
effect	O
was	O
not	O
seen	O
in	O
M	O
-	O
CSF	O
-	O
stimulated	O
monocytes	O
when	O
isogenic	O
antibodies	O
(	O
IgG	O
)	O
were	O
used	O
for	O
immunoprecipitation	O
.	O
<EOS>	B-X
Initial	B-X
research	B-X
suggests	B-X
that	B-X
mindfulness	B-X
meditation	B-X
may	B-X
be	B-X
an	B-X
effective	B-X
intervention	B-X
for	B-X
binge	B-X
eating	B-X
;	B-X
however	B-X
,	B-X
no	B-X
systematic	B-X
review	B-X
has	B-X
examined	B-X
interventions	B-X
where	B-X
mindfulness	B-X
meditation	B-X
was	B-X
the	B-X
primary	B-X
intervention	B-X
and	B-X
no	B-X
review	B-X
has	B-X
examined	B-X
its	B-X
effect	B-X
on	B-X
subclinical	B-X
disordered	B-X
eating	B-X
or	B-X
weight	B-X
.	B-X
Results	B-X
suggest	B-X
that	B-X
mindfulness	B-X
meditation	B-X
effectively	B-X
decreases	B-X
binge	B-X
eating	B-X
and	B-X
emotional	B-X
eating	B-X
in	B-X
populations	B-X
engaging	B-X
in	B-X
this	B-X
behavior	B-X
;	B-X
evidence	B-X
for	B-X
its	B-X
effect	B-X
on	B-X
weight	B-X
is	B-X
mixed	B-X
.	B-X
Additional	B-X
research	B-X
is	B-X
warranted	B-X
to	B-X
determine	B-X
comparative	B-X
effectiveness	B-X
and	B-X
long-term	B-X
effects	B-X
of	B-X
mindfulness	B-X
training	B-X
.	B-X
However	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
ACBT	B-X
on	B-X
COPD	B-X
patients	B-X
have	B-X
shown	B-X
mixed	B-X
results	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
effectiveness	B-X
of	B-X
ACBT	B-X
in	B-X
patients	B-X
with	B-X
COPD	B-X
by	B-X
conducting	B-X
a	B-X
systematic	B-X
review	B-X
of	B-X
the	B-X
literature	B-X
.	B-X

Western	O
blots	O
of	O
identical	O
samples	O
using	O
an	O
antibody	O
recognizing	O
PKCalpha	O
demonstrated	O
that	O
equal	O
amounts	O
of	O
PKCalpha	O
were	O
assayed	O
(	O
Figure	O
4	O
,	O
middle	O
panel	O
)	O
.	O

M	O
-	O
CSF	O
-	O
Dependent	O
Activation	O
of	O
PKC	O
Does	O
Not	O
Regulate	O
the	O
Classical	O
NF	O
-	O
kappaB	O
p65	B-Protein
Activation	O
Pathway	O

Canonical	O
activation	O
of	O
NF	O
-	O
kappaB	O
occurs	O
via	O
phosphorylation	O
and	O
degradation	O
of	O
IkappaBalpha	B-Protein
leading	O
to	O
the	O
release	O
and	O
nuclear	O
translocation	O
of	O
the	O
NF	O
-	O
kappaB	O
p50	B-Protein
/	O
p65	B-Protein
heterodimer	O
to	O
transactivate	O
target	O
genes	O
[	O
37	O
]	O
,	O
[	O
39	O
]	O
.	O

Since	O
conventional	O
PKC	O
activity	O
was	O
important	O
in	O
regulating	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
,	O
we	O
next	O
investigated	O
whether	O
IkappaBalpha	B-Protein
degradation	O
was	O
regulated	O
by	O
PKC	O
.	O

Cells	O
were	O
treated	O
with	O
cyclohexamide	O
(	O
CHX	O
)	O
to	O
inhibit	O
protein	O
synthesis	O
of	O
IkappaBalpha	B-Protein
,	O
and	O
its	O
degradation	O
was	O
followed	O
.	O

As	O
shown	O
in	O
Figure	O
5A	O
,	O
PKC	O
inhibition	O
with	O
Ro	O
-	O
31	O
-	O
8220	O
did	O
not	O
alter	O
M	O
-	O
CSF	O
-	O
induced	O
IkappaBalpha	B-Protein
degradation	O
,	O
suggesting	O
that	O
M	O
-	O
CSF	O
-	O
induced	O
PKC	O
activity	O
augmented	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
by	O
an	O
alternative	O
pathway	O
,	O
like	O
post	O
-	O
translational	O
modification	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
.	O

M	O
-	O
CSF	O
Induces	O
Phosphorylation	O
of	O
NF	O
-	O
kappaB	O
Ser276	O
in	O
a	O
PKC	O
-	O
dependent	O
Fashion	O

Since	O
M	O
-	O
CSF	O
did	O
not	O
regulate	O
NF	O
-	O
kappaB	O
activation	O
by	O
influencing	O
IkappaBalpha	B-Protein
,	O
we	O
next	O
sought	O
to	O
determine	O
if	O
M	O
-	O
CSF	O
affected	O
NF	O
-	O
kappaB	O
p65	B-Protein
by	O
post	O
-	O
translational	O
mechanisms	O
.	O

Thus	O
,	O
we	O
examined	O
the	O
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
with	O
specific	O
phospho	O
-	O
NFkappaB	O
p65	O
(	O
Ser276	O
and	O
Ser536	O
)	O
antibodies	O
.	O

M	O
-	O
CSF	O
induced	O
the	O
phosphorylation	O
of	O
Ser276	O
but	O
not	O
Ser536	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
in	O
MDMs	O
.	O
<EOS>	B-X
Macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
)	B-X
promotes	B-X
mononuclear	B-X
phagocyte	B-X
survival	B-X
and	B-X
proliferation	B-X
.	B-X
The	B-X
transcription	B-X
factor	B-X
Nuclear	B-X
Factor-kappaB	B-X
(	B-X
NF-κB	B-X
)	B-X
is	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
M-CSF-induced	B-X
mononuclear	B-X
phagocyte	B-X
survival	B-X
and	B-X
this	B-X
study	B-X
focused	B-X
at	B-X
identifying	B-X
the	B-X
mechanism	B-X
of	B-X
NF-κB	B-X
transcriptional	B-X
activation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
M-CSF	B-X
stimulated	B-X
NF-κB	B-X
transcriptional	B-X
activity	B-X
in	B-X
human	B-X
monocyte-derived	B-X
macrophages	B-X
(	B-X
MDMs	B-X
)	B-X
and	B-X
the	B-X
murine	B-X
macrophage	B-X
cell	B-X
line	B-X
RAW	B-X
264.7	B-X
.	B-X
The	B-X
general	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
inhibitor	B-X
Ro-31-8220	B-X
,	B-X
the	B-X
conventional	B-X
PKCα/β	B-X
inhibitor	B-X
Gö-6976	B-X
,	B-X
overexpression	B-X
of	B-X
dominant	B-X
negative	B-X
PKCα	B-X
constructs	B-X
and	B-X
PKCα	B-X
siRNA	B-X
reduced	B-X
NF-κB	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
M-CSF	B-X
.	B-X
Interestingly	B-X
,	B-X
Ro-31-8220	B-X
reduced	B-X
Ser276	B-X
phosphorylation	B-X
of	B-X
NF-κBp65	B-X
leading	B-X
to	B-X
decreased	B-X
M-CSF-induced	B-X
monocyte	B-X
survival	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
identify	B-X
conventional	B-X
PKCs	B-X
,	B-X
including	B-X
PKCα	B-X
as	B-X
important	B-X
upstream	B-X
kinases	B-X
for	B-X
M-CSF-induced	B-X
NF-κB	B-X
transcriptional	B-X
activation	B-X
,	B-X
NF-κB-regulated	B-X
gene	B-X
expression	B-X
,	B-X
NF-κB	B-X
p65	B-X
Ser276	B-X
phosphorylation	B-X
,	B-X
and	B-X
macrophage	B-X
survival	B-X
.	B-X
Lastly	B-X
,	B-X
we	B-X
find	B-X
that	B-X
NF-κB	B-X
p65	B-X
Ser276	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
basal	B-X
and	B-X
M-CSF-stimulated	B-X
NF-κB	B-X
activation	B-X
in	B-X
human	B-X
mononuclear	B-X
phagocytes	B-X
.	B-X

Compared	O
to	O
vehicle	O
,	O
the	O
general	O
PKC	O
inhibitor	O
Ro	O
-	O
31	O
-	O
8220	O
reduced	O
Ser276	O
phosphorylation	O
,	O
but	O
not	O
Ser536	O
,	O
phosphorylation	O
in	O
M	O
-	O
CSF	O
-	O
stimulated	O
cells	O
(	O
Figure	O
5B	O
)	O
.	O

Furthermore	O
,	O
M	O
-	O
CSF	O
-	O
stimulated	O
NF	O
-	O
kappaB	O
p65	B-Protein
phosphorylation	O
at	O
residue	O
Ser276	O
in	O
RAW	O
264	O
.	O
7	O
cells	O
was	O
also	O
PKC	O
dependent	O
(	O
Figure	O
5C	O
)	O
.	O

These	O
studies	O
suggested	O
that	O
PKC	O
(	O
s	O
)	O
regulated	O
Ser276	O
phosphorylation	O
but	O
not	O
Ser536	O
in	O
both	O
human	O
MDMs	O
and	O
mouse	O
macrophages	O
after	O
M	O
-	O
CSF	O
stimulation	O
.	O

We	O
next	O
performed	O
cellular	O
fractionation	O
to	O
identify	O
the	O
cellular	O
location	O
of	O
phosphorylated	O
NF	O
-	O
kappaB	O
p65	B-Protein
in	O
Raw	O
264	O
.	O
7	O
cells	O
.	O

Non	O
-	O
phosphorylated	O
NF	O
-	O
kappaB	O
p65	B-Protein
was	O
located	O
in	O
both	O
cytosolic	O
and	O
nuclear	O
fractions	O
,	O
but	O
phosphorylated	O
Ser276	O
and	O
Ser536	O
NF	O
-	O
kappaB	O
p65	B-Protein
was	O
primarily	O
located	O
in	O
nuclear	O
fraction	O
after	O
M	O
-	O
CSF	O
stimulation	O
(	O
Figure	O
5D	O
)	O
.	O

Notably	O
,	O
constitutive	O
phosphorylation	O
of	O
Ser536	O
NF	O
-	O
kappaB	O
p65	B-Protein
was	O
found	O
in	O
these	O
cells	O
.	O

Importantly	O
,	O
Ro	O
-	O
31	O
-	O
8220	O
reduced	O
M	O
-	O
CSF	O
-	O
induced	O
Ser276	O
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
in	O
both	O
the	O
cytosolic	O
and	O
nuclear	O
fractions	O
,	O
while	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
p65	B-Protein
Ser536	O
phosphorylation	O
was	O
present	O
in	O
the	O
nucleus	O
regardless	O
of	O
PKC	O
inhibition	O
.	O

These	O
observations	O
indicate	O
that	O
M	O
-	O
CSF	O
-	O
induced	O
Ser276	O
and	O
Ser536	O
are	O
regulated	O
differently	O
by	O
conventional	O
PKC	O
activation	O
in	O
mononuclear	O
phagocytes	O
.	O

The	O
purity	O
of	O
the	O
cytosol	O
and	O
nuclear	O
cell	O
fractions	O
was	O
confirmed	O
by	O
immunoblotting	O
with	O
GAPDH	O
and	O
Lamin	O
B	O
,	O
respectively	O
(	O
Figure	O
5D	O
)	O
.	O

M	O
-	O
CSF	O
-	O
dependent	O
PKC	O
Regulates	O
NF	O
-	O
kappaB	O
-	O
targeted	O
Genes	O

NF	O
-	O
kappaB	O
induces	O
a	O
number	O
of	O
downstream	O
genes	O
,	O
including	O
the	O
IkappaB	O
family	O
.	O

Among	O
the	O
IkappaB	O
molecules	O
,	O
IkappaBalpha	B-Protein
is	O
highly	O
induced	O
by	O
NF	O
-	O
kappaB	O
activation	O
[	O
40	O
]	O
.	O
<EOS>	B-X
The	B-X
well-known	B-X
Rel/NF-kappaB	B-X
family	B-X
of	B-X
vertebrate	B-X
transcription	B-X
factors	B-X
comprises	B-X
a	B-X
number	B-X
of	B-X
structurally	B-X
related	B-X
,	B-X
interacting	B-X
proteins	B-X
that	B-X
bind	B-X
DNA	B-X
as	B-X
dimers	B-X
and	B-X
whose	B-X
activity	B-X
is	B-X
regulated	B-X
by	B-X
subcellular	B-X
location	B-X
.	B-X
All	B-X
Rel	B-X
proteins	B-X
contain	B-X
a	B-X
highly	B-X
conserved	B-X
domain	B-X
of	B-X
approximately	B-X
300	B-X
amino-acids	B-X
,	B-X
called	B-X
the	B-X
Rel	B-X
homology	B-X
domain	B-X
(	B-X
RH	B-X
)	B-X
,	B-X
which	B-X
contains	B-X
sequences	B-X
necessary	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
dimers	B-X
,	B-X
nuclear	B-X
localization	B-X
,	B-X
DNA	B-X
binding	B-X
and	B-X
IkappaB	B-X
binding	B-X
.	B-X
Nuclear	B-X
expression	B-X
and	B-X
consequent	B-X
biological	B-X
action	B-X
of	B-X
the	B-X
eukaryotic	B-X
NF-kappaB	B-X
transcription	B-X
factor	B-X
complex	B-X
are	B-X
tightly	B-X
regulated	B-X
through	B-X
its	B-X
cytoplasmic	B-X
retention	B-X
by	B-X
ankyrin-rich	B-X
inhibitory	B-X
proteins	B-X
known	B-X
as	B-X
IkappaB	B-X
.	B-X
The	B-X
IkappaB	B-X
proteins	B-X
include	B-X
a	B-X
group	B-X
of	B-X
related	B-X
proteins	B-X
that	B-X
interact	B-X
with	B-X
Rel	B-X
dimers	B-X
and	B-X
regulate	B-X
their	B-X
activities	B-X
.	B-X
The	B-X
interaction	B-X
of	B-X
a	B-X
given	B-X
IkappaB	B-X
protein	B-X
with	B-X
a	B-X
Rel	B-X
complex	B-X
can	B-X
affect	B-X
the	B-X
Rel	B-X
complex	B-X
in	B-X
distinct	B-X
ways	B-X
.	B-X
In	B-X
the	B-X
best	B-X
characterized	B-X
example	B-X
,	B-X
IkappaB-alpha	B-X
interacts	B-X
with	B-X
a	B-X
p50/RelA	B-X
(	B-X
NF-kappaB	B-X
)	B-X
heterodimer	B-X
to	B-X
retain	B-X
the	B-X
complex	B-X
in	B-X
the	B-X
cytoplasm	B-X
and	B-X
inhibit	B-X
its	B-X
DNA-binding	B-X
activity	B-X
.	B-X
The	B-X
NF-kappaB/IkappaB-alpha	B-X
complex	B-X
is	B-X
located	B-X
in	B-X
the	B-X
cytoplasm	B-X
of	B-X
most	B-X
resting	B-X
cells	B-X
,	B-X
but	B-X
can	B-X
be	B-X
rapidly	B-X
induced	B-X
to	B-X
enter	B-X
the	B-X
cell	B-X
nucleus	B-X
.	B-X
Upon	B-X
receiving	B-X
a	B-X
variety	B-X
of	B-X
signals	B-X
,	B-X
many	B-X
of	B-X
which	B-X
are	B-X
probably	B-X
mediated	B-X
by	B-X
the	B-X
generation	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
,	B-X
IkappaB-alpha	B-X
undergoes	B-X
phosphorylation	B-X
at	B-X
serine	B-X
residues	B-X
by	B-X
a	B-X
ubiquitin-dependent	B-X
protein	B-X
kinase	B-X
,	B-X
is	B-X
then	B-X
ubiquitinated	B-X
at	B-X
nearby	B-X
lysine	B-X
residues	B-X
and	B-X
finally	B-X
degraded	B-X
by	B-X
the	B-X
proteasome	B-X
,	B-X
probably	B-X
while	B-X
still	B-X
complexed	B-X
with	B-X
NF-kappaB	B-X
.	B-X
Removal	B-X
of	B-X
IkappaB-alpha	B-X
uncovers	B-X
the	B-X
nuclear	B-X
localization	B-X
signals	B-X
on	B-X
subunits	B-X
of	B-X
NF-kappaB	B-X
,	B-X
allowing	B-X
the	B-X
complex	B-X
to	B-X
enter	B-X
the	B-X
nucleus	B-X
,	B-X
bind	B-X
to	B-X
DNA	B-X
and	B-X
affect	B-X
gene	B-X
expression	B-X
.	B-X
IL-1	B-X
,	B-X
TNF	B-X
)	B-X
,	B-X
various	B-X
ROS	B-X
(	B-X
peroxides	B-X
,	B-X
singlet	B-X
oxygen	B-X
,	B-X
...	B-X
)	B-X
as	B-X
well	B-X
as	B-X
UV	B-X
(	B-X
C	B-X
to	B-X
A	B-X
)	B-X
light	B-X
are	B-X
capable	B-X
of	B-X
mediating	B-X
NF-kappaB	B-X
nuclear	B-X
translocation	B-X
,	B-X
while	B-X
the	B-X
sensor	B-X
molecules	B-X
which	B-X
are	B-X
sensitive	B-X
to	B-X
these	B-X
agents	B-X
and	B-X
trigger	B-X
IkappaB-alpha	B-X
proteolysis	B-X
are	B-X
still	B-X
unidentified	B-X
.	B-X

Having	O
shown	O
that	O
PKC	O
regulated	O
NF	O
-	O
kappaB	O
activity	O
in	O
M	O
-	O
CSF	O
-	O
stimulated	O
MDMs	O
,	O
we	O
next	O
determined	O
whether	O
inhibition	O
of	O
PKC	O
activity	O
decreased	O
expression	O
of	O
NF	O
-	O
kappaB	O
-	O
regulated	O
genes	O
.	O

We	O
treated	O
both	O
MDMs	O
and	O
RAW	O
264	O
.	O
7	O
cells	O
with	O
the	O
PKC	O
inhibitor	O
Ro	O
-	O
31	O
-	O
8220	O
for	O
30	O
minutes	O
and	O
then	O
stimulated	O
with	O
M	O
-	O
CSF	O
.	O

IkappaBalpha	B-Protein
gene	O
was	O
measured	O
by	O
qRT	O
-	O
PCR	O
.	O
<EOS>	B-X
Osteoarthritis	B-X
(	B-X
OA	B-X
)	B-X
is	B-X
the	B-X
most	B-X
common	B-X
joint	B-X
disease	B-X
in	B-X
the	B-X
elderly	B-X
and	B-X
is	B-X
characterized	B-X
by	B-X
the	B-X
progressive	B-X
degeneration	B-X
of	B-X
articular	B-X
cartilage	B-X
.	B-X
The	B-X
differential	B-X
expression	B-X
genes	B-X
were	B-X
analyzed	B-X
based	B-X
on	B-X
the	B-X
GSE83500	B-X
and	B-X
GSE48060	B-X
datasets	B-X
from	B-X
the	B-X
Gene	B-X
Expression	B-X
Omnibus	B-X
(	B-X
GEO	B-X
)	B-X
database	B-X
.	B-X
The	B-X
upstream	B-X
regulatory	B-X
microRNAs	B-X
(	B-X
miRNAs	B-X
)	B-X
of	B-X
the	B-X
identified	B-X
genes	B-X
were	B-X
predicted	B-X
by	B-X
miRanda	B-X
,	B-X
miRWalk	B-X
,	B-X
and	B-X
TargetScan	B-X
websites	B-X
.	B-X
MiR-324	B-X
expression	B-X
was	B-X
measured	B-X
with	B-X
quantitative	B-X
real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
qRT-PCR	B-X
)	B-X
.	B-X

As	O
shown	O
in	O
Figures	O
6A	O
and	O
6B	O
,	O
M	O
-	O
CSF	O
enhanced	O
IkappaBalpha	B-Protein
gene	O
expression	O
and	O
PKC	O
inhibition	O
by	O
Ro	O
-	O
31	O
-	O
8220	O
decreased	O
IkappaBalpha	B-Protein
gene	O
expression	O
in	O
both	O
MDMs	O
and	O
RAW	O
264	O
.	O
7	O
cells	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
demonstrating	O
that	O
PKC	O
affected	O
NF	O
-	O
kappaB	O
-	O
regulated	O
gene	O
expression	O
in	O
macrophages	O
.	O

To	O
further	O
define	O
the	O
role	O
of	O
PKC	O
in	O
mediating	O
human	O
MDM	O
survival	O
in	O
response	O
to	O
M	O
-	O
CSF	O
,	O
we	O
examined	O
the	O
expression	O
of	O
the	O
anti	O
-	O
apoptotic	O
gene	O
BCL	B-Protein
-	I-Protein
xL	I-Protein
,	O
which	O
is	O
also	O
regulated	O
by	O
NF	O
-	O
kappaB	O
.	O

As	O
shown	O
in	O
Figure	O
6C	O
,	O
Ro	O
-	O
31	O
-	O
8220	O
reduced	O
M	O
-	O
CSF	O
-	O
stimulated	O
BCL	B-Protein
-	I-Protein
xL	I-Protein
expression	O
compared	O
to	O
cells	O
treated	O
with	O
M	O
-	O
CSF	O
and	O
the	O
vehicle	O
control	O
DMSO	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Identification	O
of	O
PKCalpha	O
as	O
the	O
Upstream	O
Activator	O
of	O
NF	O
-	O
kappaB	O
in	O
Myeloid	O
Cells	O

Even	O
though	O
the	O
PKC	O
family	O
consists	O
of	O
10	O
members	O
,	O
finding	O
that	O
PKCalpha	B-Protein
/	O
beta	B-Protein
inhibitors	O
and	O
intracellular	O
calcium	O
inhibitors	O
reduced	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
activity	O
,	O
suggested	O
PKCalpha	B-Protein
was	O
involved	O
in	O
NF	O
-	O
kappaB	O
activation	O
after	O
M	O
-	O
CSF	O
treatment	O
.	O

To	O
confirm	O
the	O
role	O
of	O
PKCalpha	B-Protein
in	O
NF	O
-	O
kappaB	O
activation	O
in	O
macrophages	O
,	O
constructs	O
for	O
either	O
wildtype	O
(	O
WT	O
)	O
-	O
PKCalpha	B-Protein
or	O
kinase	O
-	O
deficient	O
(	O
KD	O
)	O
-	O
PKCalpha	B-Protein
was	O
co	O
-	O
transfected	O
with	O
the	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
reporter	O
gene	O
and	O
SEAP	O
secretion	O
was	O
measured	O
.	O

As	O
shown	O
in	O
Figure	O
7A	O
,	O
MDMs	O
co	O
-	O
transfected	O
with	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
and	O
WT	O
-	O
PKCalpha	B-Protein
had	O
a	O
1	O
.	O
8	O
-	O
fold	O
increase	O
in	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
after	O
M	O
-	O
CSF	O
activation	O
compared	O
with	O
NS	O
cells	O
(	O
p	O
=	O
0	O
.	O
05	O
)	O
,	O
similar	O
to	O
M	O
-	O
CSF	O
-	O
treated	O
cells	O
expressing	O
only	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
.	O

Transfecting	O
human	O
macrophages	O
with	O
the	O
KD	O
-	O
PKCalpha	B-Protein
construct	O
significantly	O
reduced	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
activity	O
compared	O
to	O
WT	O
-	O
PKCalpha	B-Protein
transfected	O
cells	O
(	O
p	O
=	O
0	O
.	O
016	O
)	O
.	O

Similarly	O
,	O
RAW	O
264	O
.	O
7	O
cells	O
transfected	O
with	O
WT	O
-	O
PKCalpha	B-Protein
had	O
2	O
.	O
5	O
-	O
fold	O
more	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
after	O
M	O
-	O
CSF	O
activation	O
compared	O
to	O
unstimulated	O
RAW	O
264	O
.	O
7	O
cells	O
(	O
NS	O
)	O
transfected	O
with	O
WT	O
-	O
PKCalpha	B-Protein
(	O
Figure	O
7B	O
)	O
.	O

Expression	O
of	O
the	O
KD	O
-	O
PKCalpha	B-Protein
construct	O
into	O
RAW	O
264	O
.	O
7	O
cells	O
reduced	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
activity	O
to	O
1	O
.	O
5	O
-	O
fold	O
(	O
p	O
=	O
0	O
.	O
045	O
)	O
compared	O
to	O
cells	O
transfected	O
with	O
WT	O
PKCalpha	B-Protein
.	O

Cell	O
survival	O
was	O
also	O
examined	O
in	O
MDMs	O
expressing	O
either	O
WT	O
-	O
PKCalpha	B-Protein
or	O
KD	O
-	O
PKCalpha	B-Protein
constructs	O
by	O
Annexin	B-Protein
V	I-Protein
-	O
FITC	O
and	O
PI	O
staining	O
.	O

As	O
expected	O
,	O
M	O
-	O
CSF	O
increased	O
MDM	O
survival	O
as	O
measured	O
by	O
the	O
percent	O
of	O
Annexin	B-Protein
V	I-Protein
/	O
PI	O
negative	O
cells	O
.	O

Similarly	O
,	O
expression	O
of	O
WT	O
-	O
PKCalpha	B-Protein
protected	O
cells	O
from	O
apoptosis	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
KD	O
-	O
PKCalpha	B-Protein
decreased	O
M	O
-	O
CSF	O
-	O
induced	O
cell	O
survival	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
(	O
Figure	O
7C	O
)	O
.	O

Next	O
,	O
we	O
examined	O
the	O
effect	O
of	O
expressing	O
the	O
PKCalpha	B-Protein
constructs	O
on	O
NF	O
-	O
kappaB	O
phosphorylation	O
.	O

As	O
shown	O
in	O
Figure	O
7D	O
,	O
expression	O
of	O
KD	O
-	O
PKCalpha	B-Protein
in	O
RAW	O
264	O
.	O
7	O
cells	O
did	O
not	O
affect	O
the	O
constitutive	O
phosphorylation	O
at	O
Ser536	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
,	O
but	O
attenuated	O
the	O
phosphorylation	O
at	O
Ser276	O
.	O

Expression	O
of	O
WT	O
-	O
PKCalpha	B-Protein
did	O
not	O
effect	O
the	O
phosphorylation	O
of	O
either	O
residue	O
with	O
or	O
without	O
M	O
-	O
CSF	O
stimulation	O
.	O
<EOS>	B-X
Bone	B-X
marrow-derived	B-X
macrophages	B-X
(	B-X
BMDM	B-X
)	B-X
are	B-X
primary	B-X
macrophages	B-X
obtained	B-X
by	B-X
in	B-X
vitro	B-X
differentiation	B-X
of	B-X
bone	B-X
marrow	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
or	B-X
CSF1	B-X
)	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
we	B-X
describe	B-X
protocols	B-X
to	B-X
isolate	B-X
human	B-X
monocytes	B-X
from	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cell	B-X
and	B-X
how	B-X
to	B-X
differentiate	B-X
them	B-X
into	B-X
macrophages	B-X
by	B-X
using	B-X
growth	B-X
factors	B-X
(	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor-GM-CSF	B-X
or	B-X
colony-stimulating	B-X
factor-M-CSF	B-X
)	B-X
or	B-X
by	B-X
different	B-X
cell	B-X
culture	B-X
medium	B-X
concentration	B-X
.	B-X
M-CSF	B-X
and	B-X
GM-CSF	B-X
are	B-X
2	B-X
important	B-X
cytokines	B-X
that	B-X
regulate	B-X
macrophage	B-X
numbers	B-X
and	B-X
function	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
their	B-X
known	B-X
effects	B-X
on	B-X
cells	B-X
of	B-X
the	B-X
macrophage-monocyte	B-X
lineage	B-X
.	B-X
M-CSF	B-X
exhibits	B-X
a	B-X
mostly	B-X
homeostatic	B-X
expression	B-X
pattern	B-X
,	B-X
whereas	B-X
GM-CSF	B-X
is	B-X
a	B-X
product	B-X
of	B-X
cells	B-X
activated	B-X
during	B-X
inflammatory	B-X
or	B-X
pathologic	B-X
conditions	B-X
.	B-X
Accordingly	B-X
,	B-X
M-CSF	B-X
regulates	B-X
the	B-X
numbers	B-X
of	B-X
various	B-X
tissue	B-X
macrophage	B-X
and	B-X
monocyte	B-X
populations	B-X
without	B-X
altering	B-X
their	B-X
``	B-X
activation	B-X
''	B-X
status	B-X
.	B-X
Conversely	B-X
,	B-X
GM-CSF	B-X
induces	B-X
activation	B-X
of	B-X
monocytes/macrophages	B-X
and	B-X
also	B-X
mediates	B-X
differentiation	B-X
to	B-X
other	B-X
states	B-X
that	B-X
participate	B-X
in	B-X
immune	B-X
responses	B-X
[	B-X
i.e.	B-X
,	B-X
dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
]	B-X
.	B-X
Further	B-X
insights	B-X
into	B-X
their	B-X
function	B-X
have	B-X
come	B-X
from	B-X
analyses	B-X
of	B-X
mice	B-X
deficient	B-X
in	B-X
either	B-X
cytokine	B-X
.	B-X
M-CSF	B-X
signals	B-X
through	B-X
its	B-X
receptor	B-X
(	B-X
CSF-1R	B-X
)	B-X
.	B-X
Interestingly	B-X
,	B-X
mice	B-X
deficient	B-X
in	B-X
CSF-1R	B-X
expression	B-X
exhibit	B-X
a	B-X
more	B-X
significant	B-X
phenotype	B-X
than	B-X
mice	B-X
deficient	B-X
in	B-X
M-CSF	B-X
.	B-X
This	B-X
observation	B-X
was	B-X
explained	B-X
by	B-X
the	B-X
discovery	B-X
of	B-X
a	B-X
novel	B-X
cytokine	B-X
(	B-X
IL-34	B-X
)	B-X
that	B-X
represents	B-X
a	B-X
second	B-X
ligand	B-X
of	B-X
CSF-1R	B-X
.	B-X
Based	B-X
on	B-X
our	B-X
current	B-X
knowledge	B-X
,	B-X
several	B-X
therapeutic	B-X
molecules	B-X
targeting	B-X
either	B-X
the	B-X
M-CSF	B-X
or	B-X
the	B-X
GM-CSF	B-X
pathways	B-X
have	B-X
been	B-X
developed	B-X
and	B-X
are	B-X
currently	B-X
being	B-X
tested	B-X
in	B-X
clinical	B-X
trials	B-X
targeting	B-X
either	B-X
autoimmune	B-X
diseases	B-X
or	B-X
cancer	B-X
.	B-X

These	O
observations	O
demonstrate	O
that	O
PKCalpha	B-Protein
is	O
important	O
in	O
M	O
-	O
CSF	O
-	O
regulated	O
cell	O
survival	O
and	O
NF	O
-	O
kappaB	O
activation	O
and	O
likely	O
regulated	O
through	O
phosphorylation	O
of	O
Ser276	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
.	O

To	O
further	O
validate	O
the	O
impact	O
that	O
PKCalpha	B-Protein
played	O
in	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
,	O
we	O
next	O
employed	O
PKCalpha	B-Protein
siRNA	I-Protein
treatment	O
of	O
MDM	O
or	O
RAW	O
cells	O
.	O
<EOS>	B-X
Established	B-X
RAW264.7	B-X
cell	B-X
lines	B-X
for	B-X
osteoclastic	B-X
differentiation	B-X
has	B-X
been	B-X
widely	B-X
engaged	B-X
in	B-X
bone	B-X
homeostasis	B-X
research	B-X
,	B-X
however	B-X
,	B-X
the	B-X
efficacy	B-X
of	B-X
RANKL	B-X
independently	B-X
stimulating	B-X
has	B-X
rarely	B-X
been	B-X
defined	B-X
,	B-X
because	B-X
protocols	B-X
were	B-X
usually	B-X
developed	B-X
and	B-X
modified	B-X
by	B-X
various	B-X
laboratories	B-X
.	B-X
Otherwise	B-X
,	B-X
problematic	B-X
issues	B-X
are	B-X
also	B-X
lie	B-X
in	B-X
the	B-X
cell	B-X
's	B-X
seeding	B-X
density	B-X
,	B-X
RANKL	B-X
stimulating	B-X
time	B-X
point	B-X
,	B-X
and	B-X
distinguishing	B-X
osteoclastogenesis	B-X
ability	B-X
of	B-X
RANKL-treated	B-X
RAW264.7	B-X
cells	B-X
.	B-X
Therefore	B-X
,	B-X
in	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
efficacy	B-X
of	B-X
various	B-X
concentrations	B-X
of	B-X
RANKL-treated	B-X
RAW264.7	B-X
for	B-X
its	B-X
osteoclastic	B-X
differentiation	B-X
with	B-X
or	B-X
without	B-X
pretreated	B-X
other	B-X
costimulators	B-X
such	B-X
as	B-X
:	B-X
LPS	B-X
and/or	B-X
M-CSF	B-X
.	B-X
The	B-X
oteoclastogenesis	B-X
ability	B-X
of	B-X
RANKL-treated	B-X
RAW264.7	B-X
cells	B-X
was	B-X
demonstrated	B-X
by	B-X
bone	B-X
resorption	B-X
pit	B-X
,	B-X
F-actin	B-X
,	B-X
and	B-X
osteoclastogenesis	B-X
specific	B-X
marker	B-X
studies	B-X
.	B-X
Besides	B-X
that	B-X
,	B-X
through	B-X
tartrate-resistant	B-X
acid	B-X
phosphatase	B-X
(	B-X
TRAP	B-X
)	B-X
staining	B-X
,	B-X
we	B-X
clarified	B-X
to	B-X
start	B-X
the	B-X
treatment	B-X
with	B-X
30	B-X
ng/ml	B-X
RANKL	B-X
at	B-X
12	B-X
hr	B-X
after	B-X
seeded	B-X
RAW264.7	B-X
with	B-X
the	B-X
density	B-X
of	B-X
6.25	B-X
×	B-X
10	B-X

A	O
pool	O
of	O
specific	O
PKCalpha	B-Protein
siRNA	I-Protein
were	O
transfected	O
into	O
MDM	O
or	O
Raw	O
264	O
.	O
7	O
cells	O
in	O
the	O
presence	O
or	O
absence	O
or	O
M	O
-	O
CSF	O
.	O
<EOS>	B-X
Bone	B-X
marrow-derived	B-X
macrophages	B-X
(	B-X
BMDM	B-X
)	B-X
are	B-X
primary	B-X
macrophages	B-X
obtained	B-X
by	B-X
in	B-X
vitro	B-X
differentiation	B-X
of	B-X
bone	B-X
marrow	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
or	B-X
CSF1	B-X
)	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
,	B-X
we	B-X
present	B-X
the	B-X
method	B-X
for	B-X
obtaining	B-X
BMDMs	B-X
and	B-X
freezing	B-X
them	B-X
.	B-X
In	B-X
this	B-X
chapter	B-X
we	B-X
describe	B-X
protocols	B-X
to	B-X
isolate	B-X
human	B-X
monocytes	B-X
from	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cell	B-X
and	B-X
how	B-X
to	B-X
differentiate	B-X
them	B-X
into	B-X
macrophages	B-X
by	B-X
using	B-X
growth	B-X
factors	B-X
(	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor-GM-CSF	B-X
or	B-X
colony-stimulating	B-X
factor-M-CSF	B-X
)	B-X
or	B-X
by	B-X
different	B-X
cell	B-X
culture	B-X
medium	B-X
concentration	B-X
.	B-X
M-CSF	B-X
and	B-X
GM-CSF	B-X
are	B-X
2	B-X
important	B-X
cytokines	B-X
that	B-X
regulate	B-X
macrophage	B-X
numbers	B-X
and	B-X
function	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
their	B-X
known	B-X
effects	B-X
on	B-X
cells	B-X
of	B-X
the	B-X
macrophage-monocyte	B-X
lineage	B-X
.	B-X
M-CSF	B-X
exhibits	B-X
a	B-X
mostly	B-X
homeostatic	B-X
expression	B-X
pattern	B-X
,	B-X
whereas	B-X
GM-CSF	B-X
is	B-X
a	B-X
product	B-X
of	B-X
cells	B-X
activated	B-X
during	B-X
inflammatory	B-X
or	B-X
pathologic	B-X
conditions	B-X
.	B-X
Accordingly	B-X
,	B-X
M-CSF	B-X
regulates	B-X
the	B-X
numbers	B-X
of	B-X
various	B-X
tissue	B-X
macrophage	B-X
and	B-X
monocyte	B-X
populations	B-X
without	B-X
altering	B-X
their	B-X
``	B-X
activation	B-X
''	B-X
status	B-X
.	B-X
Conversely	B-X
,	B-X
GM-CSF	B-X
induces	B-X
activation	B-X
of	B-X
monocytes/macrophages	B-X
and	B-X
also	B-X
mediates	B-X
differentiation	B-X
to	B-X
other	B-X
states	B-X
that	B-X
participate	B-X
in	B-X
immune	B-X
responses	B-X
[	B-X
i.e.	B-X
,	B-X
dendritic	B-X
cells	B-X
(	B-X
DCs	B-X
)	B-X
]	B-X
.	B-X
M-CSF	B-X
signals	B-X
through	B-X
its	B-X
receptor	B-X
(	B-X
CSF-1R	B-X
)	B-X
.	B-X
Interestingly	B-X
,	B-X
mice	B-X
deficient	B-X
in	B-X
CSF-1R	B-X
expression	B-X
exhibit	B-X
a	B-X
more	B-X
significant	B-X
phenotype	B-X
than	B-X
mice	B-X
deficient	B-X
in	B-X
M-CSF	B-X
.	B-X
This	B-X
observation	B-X
was	B-X
explained	B-X
by	B-X
the	B-X
discovery	B-X
of	B-X
a	B-X
novel	B-X
cytokine	B-X
(	B-X
IL-34	B-X
)	B-X
that	B-X
represents	B-X
a	B-X
second	B-X
ligand	B-X
of	B-X
CSF-1R	B-X
.	B-X
Based	B-X
on	B-X
our	B-X
current	B-X
knowledge	B-X
,	B-X
several	B-X
therapeutic	B-X
molecules	B-X
targeting	B-X
either	B-X
the	B-X
M-CSF	B-X
or	B-X
the	B-X
GM-CSF	B-X
pathways	B-X
have	B-X
been	B-X
developed	B-X
and	B-X
are	B-X
currently	B-X
being	B-X
tested	B-X
in	B-X
clinical	B-X
trials	B-X
targeting	B-X
either	B-X
autoimmune	B-X
diseases	B-X
or	B-X
cancer	B-X
.	B-X
It	B-X
is	B-X
intriguing	B-X
to	B-X
consider	B-X
how	B-X
evolution	B-X
has	B-X
directed	B-X
these	B-X
pathways	B-X
to	B-X
develop	B-X
;	B-X
their	B-X
complexity	B-X
likely	B-X
mirrors	B-X
the	B-X
multiple	B-X
functions	B-X
in	B-X
which	B-X
cells	B-X
of	B-X
the	B-X
monocyte/macrophage	B-X
system	B-X
are	B-X
involved	B-X
.	B-X

Reducing	O
native	O
PKCalpha	B-Protein
expression	O
decreased	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
in	O
both	O
MDM	O
(	O
Figure	O
7E	O
)	O
(	O
p	O
=	O
0	O
.	O
012	O
)	O
and	O
Raw	O
264	O
.	O
7	O
cells	O
(	O
Figure	O
7F	O
)	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

We	O
also	O
examined	O
cell	O
survival	O
of	O
the	O
MDMs	O
by	O
Annexin	B-Protein
V	I-Protein
-	O
FITC	O
and	O
PI	O
staining	O
after	O
PKCalpha	B-Protein
siRNA	I-Protein
transfection	O
.	O

As	O
shown	O
in	O
Figure	O
7G	O
,	O
M	O
-	O
CSF	O
-	O
induced	O
MDM	O
survival	O
was	O
reduced	O
in	O
the	O
cells	O
transfected	O
with	O
PKCalpha	B-Protein
siRNA	I-Protein
compared	O
with	O
cells	O
transfected	O
with	O
control	O
siRNA	O
(	O
p	O
=	O
0	O
.	O
047	O
)	O
.	O

In	O
Figure	O
7H	O
,	O
we	O
confirmed	O
that	O
PKCalpha	B-Protein
siRNA	I-Protein
transfection	O
decreased	O
PKCalpha	B-Protein
protein	O
expression	O
in	O
both	O
MDM	O
and	O
Raw	O
264	O
.	O
7	O
cells	O
.	O

Our	O
results	O
indicated	O
that	O
PKCalpha	B-Protein
regulated	O
NF	O
-	O
kappaB	O
activation	O
and	O
M	O
-	O
CSF	O
-	O
regulated	O
cell	O
survival	O
.	O

PKC	O
is	O
Essential	O
in	O
Regulating	O
NF	O
-	O
kappaB	O
Activity	O
<EOS>	B-X
Subsequent	B-X
signal	B-X
transduction	B-X
resulting	B-X
in	B-X
cytokine	B-X
gene	B-X
expression	B-X
requires	B-X
the	B-X
activation	B-X
of	B-X
one	B-X
or	B-X
more	B-X
of	B-X
the	B-X
multiple	B-X
isoenzymes	B-X
of	B-X
serine/threonine-specific	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
.	B-X
Among	B-X
the	B-X
several	B-X
PKC	B-X
isoenzymes	B-X
expressed	B-X
in	B-X
T	B-X
cells	B-X
,	B-X
PKC-theta	B-X
is	B-X
unique	B-X
in	B-X
being	B-X
rapidly	B-X
recruited	B-X
to	B-X
the	B-X
site	B-X
of	B-X
TCR	B-X
clustering	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
PKC-theta	B-X
is	B-X
essential	B-X
for	B-X
TCR-mediated	B-X
T-cell	B-X
activation	B-X
,	B-X
but	B-X
is	B-X
dispensable	B-X
during	B-X
TCR-dependent	B-X
thymocyte	B-X
development	B-X
.	B-X
TCR-initiated	B-X
NF-kappaB	B-X
activation	B-X
was	B-X
absent	B-X
from	B-X
PKC-theta	B-X
(	B-X
-/-	B-X
)	B-X
mature	B-X
T	B-X
lymphocytes	B-X
,	B-X
but	B-X
was	B-X
intact	B-X
in	B-X
thymocytes	B-X
.	B-X
Activation	B-X
of	B-X
NF-kappaB	B-X
by	B-X
tumour-necrosis	B-X
factor	B-X
alpha	B-X
and	B-X
interleukin-1	B-X
was	B-X
unaffected	B-X
in	B-X
the	B-X
mutant	B-X
mice	B-X
.	B-X
Although	B-X
studies	B-X
in	B-X
T-cell	B-X
lines	B-X
had	B-X
suggested	B-X
that	B-X
PKC-theta	B-X
regulates	B-X
activation	B-X
of	B-X
the	B-X
JNK	B-X
signalling	B-X
pathway	B-X
,	B-X
induction	B-X
of	B-X
JNK	B-X
was	B-X
normal	B-X
in	B-X
T	B-X
cells	B-X
from	B-X
mutant	B-X
mice	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
PKC-theta	B-X
functions	B-X
in	B-X
a	B-X
unique	B-X
pathway	B-X
that	B-X
links	B-X
the	B-X
TCR	B-X
signalling	B-X
complex	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
in	B-X
mature	B-X
T	B-X
lymphocytes	B-X
.	B-X

M	O
-	O
CSF	O
-	O
dependent	O
PKC	O
activity	O
facilitated	O
NF	O
-	O
kappaB	O
p65	B-Protein
phosphorylation	O
at	O
Ser276	O
but	O
not	O
Ser536	O
.	O

To	O
confirm	O
the	O
role	O
of	O
PKC	O
and	O
p65	B-Protein
Ser276	O
phosphorylation	O
on	O
NF	O
-	O
kappaB	O
activity	O
,	O
we	O
co	O
-	O
transfected	O
the	O
NF	O
-	O
kappaB	O
-	O
SEAP	O
construct	O
with	O
either	O
WT	O
NF	O
-	O
kappaB	O
p65	B-Protein
or	O
NF	O
-	O
kappaB	O
p65	B-Protein
276S	O
/	O
A	O
constructs	O
in	O
Raw	O
264	O
.	O
7	O
cells	O
,	O
then	O
treated	O
cells	O
with	O
the	O
PKC	O
inhibitor	O
Ro	O
-	O
31	O
-	O
8220	O
in	O
the	O
absence	O
or	O
presences	O
of	O
M	O
-	O
CSF	O
.	O
<EOS>	B-X
Bone	B-X
marrow-derived	B-X
macrophages	B-X
(	B-X
BMDM	B-X
)	B-X
are	B-X
primary	B-X
macrophages	B-X
obtained	B-X
by	B-X
in	B-X
vitro	B-X
differentiation	B-X
of	B-X
bone	B-X
marrow	B-X
cells	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
or	B-X
CSF1	B-X
)	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
GM-CSF/M-CSF	B-X
,	B-X
hematopoietic	B-X
stem/progenitor	B-X
cells	B-X
from	B-X
the	B-X
bone	B-X
marrow	B-X
are	B-X
directed	B-X
into	B-X
monocytic	B-X
differentiation	B-X
,	B-X
followed	B-X
by	B-X
M1	B-X
or	B-X
M2	B-X
stimulation	B-X
.	B-X
In	B-X
rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
,	B-X
inflammatory	B-X
cytokines	B-X
play	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
triggering	B-X
abnormal	B-X
osteoclastogenesis	B-X
leading	B-X
to	B-X
articular	B-X
destruction	B-X
.	B-X
In	B-X
RA	B-X
,	B-X
strong	B-X
correlation	B-X
has	B-X
been	B-X
observed	B-X
between	B-X
tissue	B-X
inflammation	B-X
and	B-X
IL-9	B-X
expression	B-X
in	B-X
synovial	B-X
tissue	B-X
.	B-X
We	B-X
conducted	B-X
the	B-X
study	B-X
in	B-X
active	B-X
RA	B-X
patients	B-X
.	B-X
For	B-X
inducing	B-X
osteoclast	B-X
differentiation	B-X
,	B-X
mononuclear	B-X
cells	B-X
were	B-X
stimulated	B-X
with	B-X
soluble	B-X
receptor	B-X
activator	B-X
of	B-X
NF-kB	B-X
ligand	B-X
(	B-X
sRANKL	B-X
)	B-X
and	B-X
macrophage-colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
)	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
recombinant	B-X
(	B-X
r	B-X
)	B-X
IL-9	B-X
.	B-X
IL-9	B-X
stimulation	B-X
significantly	B-X
enhanced	B-X
M-CSF/sRANKL-mediated	B-X
osteoclast	B-X
formation	B-X
and	B-X
function	B-X
.	B-X

As	O
expected	O
in	O
cells	O
transfected	O
with	O
vector	O
control	O
,	O
inhibiting	O
PKC	O
reduced	O
M	O
-	O
CSF	O
-	O
stimulated	O
NF	O
-	O
kappaB	O
activity	O
compared	O
to	O
cells	O
treated	O
with	O
M	O
-	O
CSF	O
and	O
the	O
vehicle	O
DMSO	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
(	O
Figure	O
8A	O
)	O
.	O

In	O
contrast	O
,	O
expressing	O
WT	O
NF	O
-	O
kappaB	O
p65	B-Protein
(	O
p65	B-Protein
WT	O
)	O
increased	O
NF	O
-	O
kappaB	O
activity	O
,	O
while	O
the	O
general	O
PKC	O
inhibitor	O
Ro	O
-	O
31	O
-	O
8220	O
decreased	O
this	O
NF	O
-	O
kappaB	O
activity	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

Notably	O
,	O
the	O
introduction	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
276	O
S	O
/	O
A	O
construct	O
significantly	O
reduced	O
NF	O
-	O
kappaB	O
activity	O
compared	O
with	O
the	O
WT	O
NF	O
-	O
kappaB	O
p65	B-Protein
construct	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
and	O
M	O
-	O
CSF	O
treatment	O
was	O
unable	O
to	O
overcome	O
this	O
inhibition	O
.	O

Furthermore	O
,	O
we	O
co	O
-	O
transfected	O
the	O
NF	O
-	O
kappaB	O
-	O
SEAP	O
construct	O
along	O
with	O
either	O
the	O
WT	O
NF	O
-	O
kappaB	O
p65	B-Protein
,	O
NF	O
-	O
kappaB	O
p65	B-Protein
276S	O
/	O
A	O
or	O
NF	O
-	O
kappaB	O
p65	B-Protein
536S	O
/	O
A	O
constructs	O
into	O
a	O
NF	O
-	O
kappaB	O
p65	B-Protein
-	O
/	O
-	O
murine	O
fibroblast	O
cell	O
line	O
and	O
measured	O
NF	O
-	O
kappaB	O
activity	O
.	O

As	O
predicted	O
,	O
expression	O
of	O
WT	O
NF	O
-	O
kappaB	O
p65	B-Protein
(	O
p65	B-Protein
WT	O
)	O
in	O
NF	O
-	O
kappaB	O
p65	B-Protein
-	O
/	O
-	O
cell	O
line	O
constitutively	O
activated	O
NF	O
-	O
kappaB	O
compared	O
to	O
cells	O
transfected	O
with	O
vector	O
control	O
without	O
any	O
stimulation	O
(	O
Figure	O
8B	O
)	O
.	O

In	O
comparison	O
,	O
transfecting	O
the	O
NF	O
-	O
kappaB	O
p65	B-Protein
276S	O
/	O
A	O
construct	O
reduced	O
NF	O
-	O
kappaB	O
activity	O
by	O
5	O
-	O
fold	O
(	O
p	O
=	O
0	O
.	O
006	O
,	O
WT	O
NF	O
-	O
kappaB	O
p65	B-Protein
vs	O
.	O
NF	O
-	O
kappaB	O
p65	B-Protein
276S	O
/	O
A	O
)	O
,	O
while	O
expressing	O
the	O
NF	O
-	O
kappaB	O
p65	B-Protein
536S	O
/	O
A	O
construct	O
increased	O
NF	O
-	O
kappaB	O
activity	O
in	O
the	O
p65	B-Protein
-	O
/	O
-	O
cells	O
to	O
levels	O
similar	O
to	O
WT	O
NF	O
-	O
kappaB	O
p65	B-Protein
transfected	O
cells	O
.	O

Since	O
M	O
-	O
CSF	O
-	O
induced	O
PKC	O
activation	O
regulated	O
NF	O
-	O
kappaB	O
activity	O
via	O
Ser276	O
residue	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
in	O
primary	O
human	O
MDMs	O
and	O
RAW	O
264	O
.	O
7	O
cells	O
,	O
we	O
next	O
examined	O
if	O
this	O
occurred	O
in	O
NF	O
-	O
kappaB	O
p65	B-Protein
-	O
/	O
-	O
fibroblasts	O
in	O
response	O
to	O
a	O
native	O
stimulus	O
for	O
these	O
cells	O
,	O
TNFalpha	B-Protein
.	O

NF	O
-	O
kappaB	O
activity	O
was	O
measured	O
in	O
the	O
WT	O
NF	O
-	O
kappaB	O
p65	B-Protein
or	O
NF	O
-	O
kappaB	O
p65	B-Protein
276S	O
/	O
A	O
transfected	O
cells	O
treated	O
with	O
TNFalpha	B-Protein
in	O
the	O
absence	O
or	O
presence	O
of	O
Ro	O
-	O
31	O
-	O
8220	O
(	O
Figure	O
8C	O
)	O
.	O
<EOS>	B-X
SPTBN1	B-X
inhibits	B-X
inflammatory	B-X
responses	B-X
and	B-X
hepatocarcinogenesis	B-X
via	B-X
the	B-X
stabilization	B-X
of	B-X
SOCS1	B-X
and	B-X
downregulation	B-X
of	B-X
p65	B-X
in	B-X
hepatocellular	B-X
carcinoma	B-X
.	B-X
We	B-X
tested	B-X
the	B-X
hypothesis	B-X
that	B-X
ROS	B-X
activity	B-X
mediated	B-X
by	B-X
NADPH	B-X
oxidase	B-X
2	B-X
(	B-X
NOX2	B-X
)	B-X
contributes	B-X
to	B-X
acute	B-X
brain	B-X
injury	B-X
but	B-X
promotes	B-X
functional	B-X
recovery	B-X
during	B-X
the	B-X
delayed	B-X
phase	B-X
,	B-X
which	B-X
is	B-X
linked	B-X
with	B-X
neuroinflammation	B-X
,	B-X
autophagy	B-X
,	B-X
angiogenesis	B-X
,	B-X
and	B-X
the	B-X
PI3K/Akt	B-X
signaling	B-X
pathway	B-X
.	B-X
NF-κB	B-X
,	B-X
a	B-X
transcription	B-X
factor	B-X
activated	B-X
by	B-X
cellular	B-X
damage	B-X
and	B-X
stress	B-X
,	B-X
has	B-X
increased	B-X
activity	B-X
with	B-X
aging	B-X
and	B-X
aging-related	B-X
chronic	B-X
diseases	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
NF-κB	B-X
drives	B-X
aging	B-X
in	B-X
response	B-X
to	B-X
the	B-X
accumulation	B-X
of	B-X
spontaneous	B-X
,	B-X
endogenous	B-X
DNA	B-X
damage	B-X
,	B-X
we	B-X
measured	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
in	B-X
WT	B-X
and	B-X
progeroid	B-X
model	B-X
mice	B-X
.	B-X
As	B-X
both	B-X
WT	B-X
and	B-X
progeroid	B-X
mice	B-X
aged	B-X
,	B-X
NF-κB	B-X
was	B-X
activated	B-X
stochastically	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
cell	B-X
types	B-X
.	B-X
Genetic	B-X
depletion	B-X
of	B-X
one	B-X
allele	B-X
of	B-X
the	B-X
p65	B-X
subunit	B-X
of	B-X
NF-κB	B-X
or	B-X
treatment	B-X
with	B-X
a	B-X
pharmacological	B-X
inhibitor	B-X
of	B-X
the	B-X
NF-κB-activating	B-X
kinase	B-X
,	B-X
IKK	B-X
,	B-X
delayed	B-X
the	B-X
age-related	B-X
symptoms	B-X
and	B-X
pathologies	B-X
of	B-X
progeroid	B-X
mice	B-X
.	B-X
Additionally	B-X
,	B-X
inhibition	B-X
of	B-X
NF-κB	B-X
reduced	B-X
oxidative	B-X
DNA	B-X
damage	B-X
and	B-X
stress	B-X
and	B-X
delayed	B-X
cellular	B-X
senescence	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
DNA	B-X
damage	B-X
drives	B-X
aging	B-X
is	B-X
due	B-X
in	B-X
part	B-X
to	B-X
NF-κB	B-X
activation	B-X
.	B-X
IKK/NF-κB	B-X
inhibitors	B-X
are	B-X
sufficient	B-X
to	B-X
attenuate	B-X
this	B-X
damage	B-X
and	B-X
could	B-X
provide	B-X
clinical	B-X
benefit	B-X
for	B-X
degenerative	B-X
changes	B-X
associated	B-X
with	B-X
accelerated	B-X
aging	B-X
disorders	B-X
and	B-X
normal	B-X
aging	B-X
.	B-X

As	O
expected	O
,	O
TNFalpha	B-Protein
increased	O
NF	O
-	O
kappaB	O
activity	O
in	O
NF	O
-	O
kappaB	O
p65	B-Protein
-	O
/	O
-	O
cells	O
expressing	O
WT	O
p65	B-Protein
and	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
PKC	O
inhibitors	O
decreased	O
NF	O
-	O
kappaB	O
activity	O
to	O
the	O
non	O
-	O
stimulated	O
(	O
NS	O
)	O
level	O
(	O
p	O
=	O
0	O
.	O
007	O
)	O
.	O

Introducing	O
NF	O
-	O
kappaB	O
p65	B-Protein
276	O
S	O
/	O
A	O
constructs	O
significantly	O
reduced	O
NF	O
-	O
kappaB	O
activity	O
compared	O
with	O
the	O
WT	O
NF	O
-	O
kappaB	O
p65	B-Protein
construct	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

Notably	O
,	O
TNFalpha	B-Protein
failed	O
to	O
increase	O
NF	O
-	O
kappaB	O
activity	O
in	O
the	O
NF	O
-	O
kappaB	O
p65	B-Protein
-	O
/	O
-	O
cells	O
expressing	O
NF	O
-	O
kappaB	O
p65	B-Protein
276S	O
/	O
A	O
constructs	O
.	O

These	O
observations	O
are	O
similar	O
to	O
macrophages	O
overexpressing	O
the	O
NF	O
-	O
kappaB	O
p65	B-Protein
276S	O
/	O
A	O
(	O
Figure	O
8A	O
)	O
.	O

Our	O
data	O
demonstrate	O
that	O
Ser276	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
is	O
essential	O
in	O
regulating	O
NF	O
-	O
kappaB	O
activity	O
and	O
suggests	O
that	O
PKC	O
regulates	O
NF	O
-	O
kappaB	O
activity	O
by	O
modulating	O
the	O
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
at	O
Ser276	O
residue	O
.	O

NF	O
-	O
kappaB	O
transcriptional	O
activity	O
is	O
important	O
in	O
regulating	O
intracellular	O
signaling	O
,	O
stress	O
response	O
,	O
proliferation	O
,	O
survival	O
,	O
differentiation	O
and	O
inflammation	O
[	O
8	O
]	O
.	O

To	O
regulate	O
gene	O
transcription	O
,	O
NF	O
-	O
kappaB	O
p50	B-Protein
/	O
p65	B-Protein
heterodimers	O
translocate	O
to	O
the	O
nucleus	O
from	O
the	O
cytoplasm	O
,	O
however	O
,	O
their	B-Protein
translocation	O
is	O
not	O
sufficient	O
to	O
activate	O
gene	O
transcription	O
.	O

Post	O
-	O
translational	O
modification	O
of	O
NF	O
-	O
kappaB	O
heterodimers	O
such	O
as	O
phosphorylation	O
or	O
acetylation	O
also	O
contributes	O
to	O
its	O
transcriptional	O
activity	O
[	O
41	O
]	O
,	O
[	O
42	O
]	O
,	O
[	O
43	O
]	O
.	O
<EOS>	B-X
The	B-X
innate	B-X
immune	B-X
response	B-X
has	B-X
evolved	B-X
as	B-X
the	B-X
immediate	B-X
host	B-X
defence	B-X
system	B-X
in	B-X
response	B-X
to	B-X
foreign	B-X
structures	B-X
and	B-X
it	B-X
also	B-X
serves	B-X
to	B-X
prime	B-X
the	B-X
adaptive	B-X
immune	B-X
response	B-X
.	B-X
Following	B-X
engagement	B-X
of	B-X
the	B-X
cognate	B-X
ligand	B-X
to	B-X
the	B-X
ectodomain	B-X
of	B-X
each	B-X
TLR	B-X
,	B-X
the	B-X
assembly	B-X
of	B-X
intracellular	B-X
homo-	B-X
or	B-X
heterodimers	B-X
or	B-X
multimers	B-X
induces	B-X
cell	B-X
signalling	B-X
.	B-X
Activation	B-X
of	B-X
NF-kappa	B-X
B	B-X
by	B-X
various	B-X
cellular	B-X
stimuli	B-X
involves	B-X
the	B-X
phosphorylation	B-X
and	B-X
subsequent	B-X
degradation	B-X
of	B-X
its	B-X
inhibitor	B-X
,	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
although	B-X
the	B-X
underlying	B-X
mechanism	B-X
remains	B-X
unclear	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
the	B-X
role	B-X
of	B-X
serine/threonine	B-X
phosphatases	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
phosphorylation	B-X
was	B-X
investigated	B-X
.	B-X
Our	B-X
studies	B-X
demonstrate	B-X
that	B-X
incubation	B-X
of	B-X
human	B-X
T	B-X
cells	B-X
with	B-X
low	B-X
concentrations	B-X
(	B-X
approximately	B-X
1-5	B-X
nM	B-X
)	B-X
of	B-X
calyculin	B-X
A	B-X
or	B-X
okadaic	B-X
acid	B-X
,	B-X
potent	B-X
inhibitors	B-X
of	B-X
protein	B-X
phosphatase	B-X
type	B-X
1	B-X
(	B-X
PP-1	B-X
)	B-X
and	B-X
type	B-X
2A	B-X
(	B-X
PP-2A	B-X
)	B-X
,	B-X
induces	B-X
the	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
even	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
any	B-X
cellular	B-X
stimulus	B-X
.	B-X
This	B-X
action	B-X
of	B-X
the	B-X
phosphatase	B-X
inhibitors	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
RelA.p50	B-X
NF-kappa	B-X
B	B-X
heterodimer	B-X
,	B-X
is	B-X
not	B-X
affected	B-X
by	B-X
agents	B-X
that	B-X
block	B-X
the	B-X
induction	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
phosphorylation	B-X
by	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
phosphorylated	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
from	B-X
calyculin	B-X
A-treated	B-X
cells	B-X
,	B-X
but	B-X
not	B-X
that	B-X
from	B-X
TNF-alpha-stimulated	B-X
cells	B-X
,	B-X
is	B-X
sensitive	B-X
to	B-X
PP-2A	B-X
in	B-X
vitro	B-X
,	B-X
suggesting	B-X
the	B-X
existence	B-X
of	B-X
fundamental	B-X
differences	B-X
in	B-X
the	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
induced	B-X
by	B-X
the	B-X
two	B-X
different	B-X
NF-kappa	B-X
B	B-X
inducers	B-X
.	B-X
However	B-X
,	B-X
induction	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
phosphorylation	B-X
by	B-X
both	B-X
TNF-alpha	B-X
and	B-X
the	B-X
phosphatase	B-X
inhibitors	B-X
is	B-X
associated	B-X
with	B-X
the	B-X
subsequent	B-X
degradation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
TNF-alpha-	B-X
and	B-X
calyculin	B-X
A-induced	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
degradation	B-X
exhibits	B-X
similar	B-X
but	B-X
not	B-X
identical	B-X
sensitivities	B-X
to	B-X
a	B-X
proteasome	B-X
inhibitor	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
phosphorylation	B-X
of	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
,	B-X
mediated	B-X
through	B-X
both	B-X
the	B-X
TNF-alpha-inducible	B-X
and	B-X
the	B-X
PP-2A-opposing	B-X
kinases	B-X
,	B-X
may	B-X
serve	B-X
to	B-X
target	B-X
I	B-X
kappa	B-X
B	B-X
alpha	B-X
for	B-X
proteasome-mediated	B-X
degradation	B-X
.	B-X

Because	O
NF	O
-	O
kappaB	O
constitutively	O
translocates	O
to	O
the	O
nucleus	O
in	O
monocytic	O
lineage	O
[	O
13	O
]	O
and	O
activates	O
gene	O
transcription	O
and	O
survival	O
in	O
murine	O
macrophages	O
[	O
11	O
]	O
,	O
we	O
sought	O
to	O
determine	O
how	O
M	O
-	O
CSF	O
affected	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
in	O
human	O
MDMs	O
and	O
whether	O
this	O
activation	O
regulated	O
their	O
survival	O
.	O

The	O
present	O
study	O
demonstrated	O
that	O
M	O
-	O
CSF	O
stimulated	O
PKCalpha	B-Protein
kinase	O
upstream	O
of	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
in	O
primary	O
human	O
MDMs	O
and	O
RAW	O
264	O
.	O
7	O
cells	O
.	O

We	O
showed	O
inhibition	O
of	O
conventional	O
PKCs	O
by	O
PKC	O
inhibitors	O
,	O
kinase	O
deficient	O
PKCalpha	B-Protein
or	O
PKCalpha	B-Protein
siRNA	I-Protein
blocked	O
M	O
-	O
CSF	O
-	O
induced	O
cell	O
survival	O
and	O
NF	O
-	O
kappaB	O
-	O
regulated	O
gene	O
expression	O
.	O
<EOS>	B-X
The	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
family	B-X
centrally	B-X
regulates	B-X
platelet	B-X
activation	B-X
,	B-X
and	B-X
it	B-X
is	B-X
becoming	B-X
clear	B-X
that	B-X
the	B-X
individual	B-X
PKC	B-X
isoforms	B-X
play	B-X
distinct	B-X
roles	B-X
,	B-X
some	B-X
of	B-X
which	B-X
oppose	B-X
each	B-X
other	B-X
.	B-X
Here	B-X
,	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
we	B-X
address	B-X
all	B-X
four	B-X
of	B-X
the	B-X
major	B-X
platelet-expressed	B-X
PKC	B-X
isoforms	B-X
,	B-X
determining	B-X
their	B-X
comparative	B-X
roles	B-X
in	B-X
regulating	B-X
platelet	B-X
adhesion	B-X
to	B-X
collagen	B-X
and	B-X
their	B-X
subsequent	B-X
activation	B-X
under	B-X
physiological	B-X
flow	B-X
conditions	B-X
.	B-X
Using	B-X
mouse	B-X
gene	B-X
knock-out	B-X
and	B-X
pharmacological	B-X
approaches	B-X
in	B-X
human	B-X
platelets	B-X
,	B-X
we	B-X
show	B-X
that	B-X
collagen-dependent	B-X
alpha-granule	B-X
secretion	B-X
and	B-X
thrombus	B-X
formation	B-X
are	B-X
mediated	B-X
by	B-X
the	B-X
conventional	B-X
PKC	B-X
isoforms	B-X
,	B-X
PKCalpha	B-X
and	B-X
PKCbeta	B-X
,	B-X
whereas	B-X
the	B-X
novel	B-X
isoform	B-X
,	B-X
PKC	B-X
,	B-X
negatively	B-X
regulates	B-X
these	B-X
events	B-X
.	B-X
PKCdelta	B-X
also	B-X
negatively	B-X
regulates	B-X
thrombus	B-X
formation	B-X
but	B-X
not	B-X
alpha-granule	B-X
secretion	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
demonstrate	B-X
for	B-X
the	B-X
first	B-X
time	B-X
that	B-X
individual	B-X
PKC	B-X
isoforms	B-X
differentially	B-X
regulate	B-X
platelet	B-X
calcium	B-X
signaling	B-X
and	B-X
exposure	B-X
of	B-X
phosphatidylserine	B-X
under	B-X
flow	B-X
.	B-X
Although	B-X
platelet	B-X
deficient	B-X
in	B-X
PKCalpha	B-X
or	B-X
PKCbeta	B-X
showed	B-X
reduced	B-X
calcium	B-X
signaling	B-X
and	B-X
phosphatidylserine	B-X
exposure	B-X
,	B-X
these	B-X
responses	B-X
were	B-X
enhanced	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
PKC	B-X
.	B-X
In	B-X
summary	B-X
therefore	B-X
,	B-X
this	B-X
direct	B-X
comparison	B-X
between	B-X
individual	B-X
subtypes	B-X
of	B-X
PKC	B-X
,	B-X
by	B-X
standardized	B-X
methodology	B-X
under	B-X
flow	B-X
conditions	B-X
,	B-X
reveals	B-X
that	B-X
the	B-X
four	B-X
major	B-X
PKCs	B-X
expressed	B-X
in	B-X
platelets	B-X
play	B-X
distinct	B-X
non-redundant	B-X
roles	B-X
,	B-X
where	B-X
conventional	B-X
PKCs	B-X
promote	B-X
and	B-X
novel	B-X
PKCs	B-X
inhibit	B-X
thrombus	B-X
formation	B-X
on	B-X
collagen	B-X
.	B-X

This	O
block	O
correlated	O
with	O
a	O
reduction	O
in	O
M	O
-	O
CSF	O
-	O
induced	O
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
at	O
Ser276	O
.	O

Consistent	O
with	O
these	O
findings	O
the	O
dominant	B-Protein
negative	I-Protein
PKCalpha	I-Protein
constructs	O
also	O
inhibited	O
NF	O
-	O
kappaB	O
p65	B-Protein
phosphorylation	O
at	O
Ser276	O
but	O
not	O
at	O
Ser536	O
resulting	O
in	O
reduced	O
NF	O
-	O
kappaB	O
transcriptional	O
activation	O
and	O
M	O
-	O
CSF	O
-	O
induced	O
MDM	O
survival	O
.	O

A	O
simplified	O
proposed	O
cartoon	O
model	O
in	O
Figure	O
9	O
demonstrates	O
that	O
M	O
-	O
CSF	O
induced	O
monocytes	O
survival	O
is	O
regulated	O
by	O
activating	O
NF	O
-	O
kappaB	O
p65	B-Protein
phosphorylation	O
at	O
Ser276	O
via	O
PKC	O
.	O

Finally	O
,	O
in	O
a	O
NF	O
-	O
kappaB	O
p65	B-Protein
-	O
/	O
-	O
fibroblast	O
cell	O
line	O
,	O
we	O
confirmed	O
that	O
the	O
Ser276	O
residue	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
is	O
important	O
and	O
essential	O
for	O
PKC	O
modulation	O
of	O
NF	O
-	O
kappaB	O
activity	O
.	O

More	O
compelling	O
is	O
that	O
we	O
observed	O
a	O
similar	O
regulation	O
between	O
two	O
different	O
cell	O
lineages	O
in	O
our	O
study	O
.	O

Post	O
-	O
translational	O
modification	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
regulates	O
its	O
activating	O
or	O
repressing	O
effects	O
on	O
gene	O
expression	O
.	O
<EOS>	B-X
Targeted	B-X
gene	B-X
regulation	B-X
on	B-X
a	B-X
genome-wide	B-X
scale	B-X
is	B-X
a	B-X
powerful	B-X
strategy	B-X
for	B-X
interrogating	B-X
,	B-X
perturbing	B-X
,	B-X
and	B-X
engineering	B-X
cellular	B-X
systems	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
develop	B-X
a	B-X
method	B-X
for	B-X
controlling	B-X
gene	B-X
expression	B-X
based	B-X
on	B-X
Cas9	B-X
,	B-X
an	B-X
RNA-guided	B-X
DNA	B-X
endonuclease	B-X
from	B-X
a	B-X
type	B-X
II	B-X
CRISPR	B-X
system	B-X
.	B-X
We	B-X
show	B-X
that	B-X
a	B-X
catalytically	B-X
dead	B-X
Cas9	B-X
lacking	B-X
endonuclease	B-X
activity	B-X
,	B-X
when	B-X
coexpressed	B-X
with	B-X
a	B-X
guide	B-X
RNA	B-X
,	B-X
generates	B-X
a	B-X
DNA	B-X
recognition	B-X
complex	B-X
that	B-X
can	B-X
specifically	B-X
interfere	B-X
with	B-X
transcriptional	B-X
elongation	B-X
,	B-X
RNA	B-X
polymerase	B-X
binding	B-X
,	B-X
or	B-X
transcription	B-X
factor	B-X
binding	B-X
.	B-X
This	B-X
system	B-X
,	B-X
which	B-X
we	B-X
call	B-X
CRISPR	B-X
interference	B-X
(	B-X
CRISPRi	B-X
)	B-X
,	B-X
can	B-X
efficiently	B-X
repress	B-X
expression	B-X
of	B-X
targeted	B-X
genes	B-X
in	B-X
Escherichia	B-X
coli	B-X
,	B-X
with	B-X
no	B-X
detectable	B-X
off-target	B-X
effects	B-X
.	B-X
CRISPRi	B-X
can	B-X
be	B-X
used	B-X
to	B-X
repress	B-X
multiple	B-X
target	B-X
genes	B-X
simultaneously	B-X
,	B-X
and	B-X
its	B-X
effects	B-X
are	B-X
reversible	B-X
.	B-X
We	B-X
also	B-X
show	B-X
evidence	B-X
that	B-X
the	B-X
system	B-X
can	B-X
be	B-X
adapted	B-X
for	B-X
gene	B-X
repression	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
This	B-X
RNA-guided	B-X
DNA	B-X
recognition	B-X
platform	B-X
provides	B-X
a	B-X
simple	B-X
approach	B-X
for	B-X
selectively	B-X
perturbing	B-X
gene	B-X
expression	B-X
on	B-X
a	B-X
genome-wide	B-X
scale	B-X
.	B-X

Among	O
the	O
seven	O
reported	O
putative	O
NF	O
-	O
kappaB	O
p65	B-Protein
phosphorylation	O
sites	O
,	O
five	O
increase	O
nuclear	O
translocation	O
,	O
DNA	O
binding	O
and	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
[	O
17	O
]	O
.	O

Similar	O
to	O
our	O
finding	O
,	O
Zhong	O
et	O
al	O
.	O
found	O
that	O
in	O
response	O
to	O
LPS	O
,	O
NF	O
-	O
kappaB	O
p65	B-Protein
is	O
phosphorylated	O
at	O
the	O
highly	O
conserved	O
Ser276	O
residue	O
by	O
the	O
catalytic	O
subunit	O
of	O
PKA	O
[	O
16	O
]	O
.	O

In	O
addition	O
to	O
PKA	O
,	O
Ser276	O
can	O
be	O
phosphorylated	O
by	O
MSK1	B-Protein
in	O
the	O
nucleus	O
upon	O
TNFalpha	B-Protein
treatment	O
[	O
18	O
]	O
.	O

Phosphorylation	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
at	O
Ser536	O
occurs	O
in	O
response	O
to	O
many	O
inflammatory	O
stimuli	O
as	O
well	O
as	O
kinases	O
,	O
IKKalpha	B-Protein
,	O
IKKbeta	B-Protein
and	O
RSK1	B-Protein
[	O
17	O
]	O
,	O
[	O
18	O
]	O
,	O
[	O
19	O
]	O
,	O
[	O
20	O
]	O
,	O
[	O
21	O
]	O
.	O

Notably	O
,	O
in	O
addition	O
to	O
phosphorylating	O
Ser276	O
of	O
NF	O
-	O
kappaB	O
,	O
our	O
study	O
revealed	O
that	O
M	O
-	O
CSF	O
also	O
modulated	O
the	O
phosphorylation	O
of	O
the	O
NF	O
-	O
kappaB	O
p65	B-Protein
subunit	O
at	O
Ser536	O
,	O
however	O
,	O
PKC	O
inhibitors	O
or	O
kinase	O
deficient	O
PKCalpha	B-Protein
constructs	O
did	O
not	O
affect	O
this	O
phosphorylation	O
event	O
.	O
<EOS>	B-X
Stimulation	B-X
of	B-X
the	B-X
serotonin	B-X
1A	B-X
receptor	B-X
(	B-X
5-HT	B-X
(	B-X
1A	B-X
)	B-X
-R	B-X
)	B-X
causes	B-X
activation	B-X
of	B-X
extracellular	B-X
signal-regulated	B-X
protein	B-X
kinase	B-X
(	B-X
Erk	B-X
)	B-X
and	B-X
protein	B-X
kinase	B-X
C	B-X
alpha	B-X
(	B-X
PKCalpha	B-X
)	B-X
in	B-X
both	B-X
hippocampal	B-X
HN2-5	B-X
cells	B-X
and	B-X
cultured	B-X
hippocampal	B-X
slices	B-X
from	B-X
postnatal	B-X
day-15	B-X
(	B-X
P15	B-X
)	B-X
mice	B-X
.	B-X
Our	B-X
earlier	B-X
studies	B-X
demonstrated	B-X
that	B-X
PKCalpha	B-X
is	B-X
co-immunoprecipitated	B-X
with	B-X
Erk	B-X
and	B-X
the	B-X
phosphorylation	B-X
of	B-X
PKCalpha	B-X
in	B-X
this	B-X
Erk-PKCalpha	B-X
complex	B-X
is	B-X
dependent	B-X
on	B-X
the	B-X
Erk	B-X
pathway	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
T	B-X
(	B-X
638	B-X
)	B-X
residue	B-X
,	B-X
which	B-X
must	B-X
be	B-X
phosphorylated	B-X
for	B-X
the	B-X
complete	B-X
activation	B-X
of	B-X
PKCalpha	B-X
,	B-X
is	B-X
within	B-X
an	B-X
authentic	B-X
Erk	B-X
consensus	B-X
domain	B-X
(	B-X
S/TP	B-X
)	B-X
,	B-X
and	B-X
the	B-X
PKCalpha	B-X
protein	B-X
also	B-X
contains	B-X
two	B-X
docking	B-X
sites	B-X
for	B-X
Erk	B-X
such	B-X
as	B-X
KRGRIYL	B-X
and	B-X
KRGIIYRDLKL	B-X
.	B-X
Using	B-X
Föster	B-X
Resonance	B-X
Energy	B-X
Transfer	B-X
(	B-X
FRET	B-X
)	B-X
we	B-X
have	B-X
confirmed	B-X
an	B-X
association	B-X
between	B-X
Erk	B-X
and	B-X
PKCalpha	B-X
.	B-X
Employing	B-X
PKCalpha	B-X
and	B-X
Erk	B-X
mutants	B-X
we	B-X
next	B-X
demonstrated	B-X
that	B-X
Erk	B-X
causes	B-X
direct	B-X
phosphorylation	B-X
and	B-X
activation	B-X
of	B-X
PKCalpha	B-X
.	B-X
By	B-X
mutating	B-X
the	B-X
phosphoinositide-dependent	B-X
kinase-1	B-X
(	B-X
PDK-1	B-X
)	B-X
-promoted	B-X
phosphorylation	B-X
site	B-X
(	B-X
S	B-X
(	B-X
497	B-X
)	B-X
)	B-X
and	B-X
the	B-X
kinase	B-X
site	B-X
(	B-X
K	B-X
(	B-X
368	B-X
)	B-X
)	B-X
in	B-X
PKCalpha	B-X
,	B-X
we	B-X
observed	B-X
that	B-X
both	B-X
of	B-X
these	B-X
autophosphorylation-deficient	B-X
mutants	B-X
are	B-X
phosphorylated	B-X
at	B-X
T	B-X
(	B-X
638	B-X
)	B-X
in	B-X
an	B-X
Erk-dependent	B-X
manner	B-X
.	B-X
To	B-X
confirm	B-X
that	B-X
Erk	B-X
indeed	B-X
catalyzes	B-X
phosphorylation	B-X
of	B-X
PKCalpha	B-X
at	B-X
T	B-X
(	B-X
638	B-X
)	B-X
,	B-X
we	B-X
used	B-X
a	B-X
mutant	B-X
Erk	B-X
construct	B-X
in	B-X
which	B-X
a	B-X
relatively	B-X
large	B-X
amino	B-X
acid	B-X
residue	B-X
in	B-X
the	B-X
ATP	B-X
binding	B-X
site	B-X
(	B-X
Q	B-X
(	B-X
103	B-X
)	B-X
)	B-X
had	B-X
been	B-X
replaced	B-X
with	B-X
glycine	B-X
,	B-X
enabling	B-X
this	B-X
mutant	B-X
to	B-X
utilize	B-X
a	B-X
bulky	B-X
analog	B-X
of	B-X
ATP	B-X
,	B-X
cyclopentyl	B-X
ATP	B-X
.	B-X
An	B-X
in	B-X
vitro	B-X
kinase	B-X
assay	B-X
using	B-X
this	B-X
mutant	B-X
Erk	B-X
protein	B-X
,	B-X
radiolabeled	B-X
cyclopentyl	B-X
ATP	B-X
,	B-X
and	B-X
a	B-X
synthetic	B-X
oligopeptide	B-X
containing	B-X
the	B-X
S/TP	B-X
site	B-X
of	B-X
PKCalpha	B-X
demonstrated	B-X
phosphorylation	B-X
of	B-X
the	B-X
peptide	B-X
by	B-X
Erk1/2	B-X
.	B-X
These	B-X
results	B-X
confirm	B-X
the	B-X
novel	B-X
possibility	B-X
that	B-X
PKCalpha	B-X
is	B-X
a	B-X
direct	B-X
substrate	B-X
of	B-X
Erk1/2	B-X
in	B-X
neuronal	B-X
cells	B-X
and	B-X
help	B-X
link	B-X
two	B-X
important	B-X
signaling	B-X
molecules	B-X
that	B-X
regulate	B-X
maturation	B-X
and	B-X
protection	B-X
of	B-X
hippocampal	B-X
neurons	B-X
as	B-X
well	B-X
as	B-X
many	B-X
other	B-X
cell	B-X
types	B-X
.	B-X

Moreover	O
,	O
mutant	O
constructs	O
containing	O
a	O
point	O
mutation	O
at	O
Ser536	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
did	O
not	O
reduce	O
NF	O
-	O
kappaB	O
activity	O
in	O
cells	O
lacking	O
endogenous	O
NF	O
-	O
kappaB	O
p65	B-Protein
,	O
while	O
the	O
NF	O
-	O
kappaB	O
p65	B-Protein
276S	O
/	O
A	O
construct	O
did	O
reduce	O
NF	O
-	O
kappaB	O
activity	O
in	O
these	O
cells	O
.	O

Therefore	O
,	O
specific	O
post	O
-	O
translational	O
modification	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
is	O
likely	O
to	O
regulate	O
transcriptional	O
activation	O
in	O
response	O
to	O
specific	O
stimuli	O
[	O
15	O
]	O
,	O
[	O
43	O
]	O
.	O

It	O
is	O
notable	O
that	O
M	O
-	O
CSF	O
activated	O
NF	O
-	O
kappaB	O
p65	B-Protein
Ser276	O
phosphorylation	O
and	O
transcriptional	O
activation	O
in	O
a	O
PKCalpha	B-Protein
-	O
dependent	O
manner	O
.	O

PKCalpha	B-Protein
is	O
a	O
member	O
of	O
the	O
conventional	O
PKC	O
family	O
of	O
protein	O
kinases	O
that	O
are	O
critical	O
for	O
cell	O
growth	O
,	O
differentiation	O
and	O
cell	O
death	O
.	O

PKCalpha	B-Protein
primarily	O
modulates	O
anti	O
-	O
apoptotic	O
and	O
proliferation	O
signals	O
following	O
cytokine	O
treatment	O
in	O
various	O
cell	O
types	O
[	O
42	O
]	O
.	O

Expression	O
of	O
PKCalpha	B-Protein
attenuates	O
apoptosis	O
in	O
many	O
different	O
cell	O
types	O
,	O
while	O
PKCalpha	B-Protein
inhibition	O
generally	O
potentiates	O
apoptosis	O
[	O
42	O
]	O
.	O

In	O
our	O
studies	O
using	O
conventional	O
PKC	O
inhibitors	O
and	O
dominant	B-Protein
negative	I-Protein
PKCalpha	I-Protein
constructs	O
,	O
PKCalpha	B-Protein
was	O
critical	O
in	O
M	O
-	O
CSF	O
-	O
induced	O
macrophage	O
survival	O
by	O
inducing	O
Ser276	O
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
in	O
both	O
primary	O
human	O
MDMs	O
and	O
Raw	O
264	O
.	O
7	O
cells	O
.	O

We	O
also	O
demonstrated	O
PKC	O
inhibition	O
downregulated	O
NF	O
-	O
kappaB	O
-	O
induction	O
of	O
the	O
anti	O
-	O
apoptotic	O
gene	O
BCL	B-Protein
-	I-Protein
xL	I-Protein
.	O
<EOS>	B-X
Although	B-X
silymarin	B-X
's	B-X
role	B-X
as	B-X
an	B-X
antioxidant	B-X
and	B-X
hepatoprotective	B-X
agent	B-X
is	B-X
well	B-X
known	B-X
,	B-X
its	B-X
role	B-X
as	B-X
an	B-X
anticancer	B-X
agent	B-X
has	B-X
begun	B-X
to	B-X
emerge	B-X
.	B-X
Extensive	B-X
research	B-X
within	B-X
the	B-X
last	B-X
decade	B-X
has	B-X
shown	B-X
that	B-X
silymarin	B-X
can	B-X
suppress	B-X
the	B-X
proliferation	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
tumor	B-X
cells	B-X
(	B-X
e.g.	B-X
,	B-X
prostate	B-X
,	B-X
breast	B-X
,	B-X
ovary	B-X
,	B-X
colon	B-X
,	B-X
lung	B-X
,	B-X
bladder	B-X
)	B-X
;	B-X
this	B-X
is	B-X
accomplished	B-X
through	B-X
cell	B-X
cycle	B-X
arrest	B-X
at	B-X
the	B-X
G1/S-phase	B-X
,	B-X
induction	B-X
of	B-X
cyclin-dependent	B-X
kinase	B-X
inhibitors	B-X
(	B-X
such	B-X
as	B-X
p15	B-X
,	B-X
p21	B-X
and	B-X
p27	B-X
)	B-X
,	B-X
down-regulation	B-X
of	B-X
anti-apoptotic	B-X
gene	B-X
products	B-X
(	B-X
e.g.	B-X
,	B-X
Bcl-2	B-X
and	B-X
Bcl-xL	B-X
)	B-X
,	B-X
inhibition	B-X
of	B-X
cell-survival	B-X
kinases	B-X
(	B-X
AKT	B-X
,	B-X
PKC	B-X
and	B-X
MAPK	B-X
)	B-X
and	B-X
inhibition	B-X
of	B-X
inflammatory	B-X
transcription	B-X
factors	B-X
(	B-X
e.g.	B-X
,	B-X
NF-kappaB	B-X
)	B-X
.	B-X
Silymarin	B-X
can	B-X
also	B-X
down-regulate	B-X
gene	B-X
products	B-X
involved	B-X
in	B-X
the	B-X
proliferation	B-X
of	B-X
tumor	B-X
cells	B-X
(	B-X
cyclin	B-X
D1	B-X
,	B-X
EGFR	B-X
,	B-X
COX-2	B-X
,	B-X
TGF-beta	B-X
,	B-X
IGF-IR	B-X
)	B-X
,	B-X
invasion	B-X
(	B-X
MMP-9	B-X
)	B-X
,	B-X
angiogenesis	B-X
(	B-X
VEGF	B-X
)	B-X
and	B-X
metastasis	B-X
(	B-X
adhesion	B-X
molecules	B-X
)	B-X
.	B-X
The	B-X
antiinflammatory	B-X
effects	B-X
of	B-X
silymarin	B-X
are	B-X
mediated	B-X
through	B-X
suppression	B-X
of	B-X
NF-kappaB-regulated	B-X
gene	B-X
products	B-X
,	B-X
including	B-X
COX-2	B-X
,	B-X
LOX	B-X
,	B-X
inducible	B-X
iNOS	B-X
,	B-X
TNF	B-X
and	B-X
IL-1	B-X
.	B-X
Silymarin	B-X
has	B-X
also	B-X
been	B-X
shown	B-X
to	B-X
sensitize	B-X
tumors	B-X
to	B-X
chemotherapeutic	B-X
agents	B-X
through	B-X
down-regulation	B-X
of	B-X
the	B-X
MDR	B-X
protein	B-X
and	B-X
other	B-X
mechanisms	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
its	B-X
chemopreventive	B-X
effects	B-X
,	B-X
silymarin	B-X
exhibits	B-X
antitumor	B-X
activity	B-X
against	B-X
human	B-X
tumors	B-X
(	B-X
e.g.	B-X
,	B-X
prostate	B-X
and	B-X
ovary	B-X
)	B-X
in	B-X
rodents	B-X
.	B-X

Consistent	O
with	O
our	O
finding	O
,	O
others	O
reported	O
NF	O
-	O
kappaB	O
regulated	O
the	O
gene	O
expression	O
of	O
many	O
anti	O
-	O
apoptotic	O
proteins	O
including	O
other	O
BCL	O
-	O
2	O
family	O
members	O
and	O
inhibitor	O
of	O
apoptosis	O
(	O
IAP	O
)	O
proteins	O
which	O
are	O
regulators	O
of	O
apoptosis	O
and	O
function	O
upstream	O
of	O
caspases	O
[	O
44	O
]	O
.	O

It	O
has	O
been	O
shown	O
that	O
phosphorylation	O
of	O
p65	B-Protein
at	O
Ser276	O
prevents	O
its	O
degradation	O
by	O
ubiquitin	B-Protein
-	O
mediated	O
proteolysis	O
and	O
promotes	O
cell	O
survival	O
in	O
HeLa	O
cells	O
[	O
24	O
]	O
.	O

In	O
addition	O
to	O
BCL	B-Protein
-	I-Protein
xL	I-Protein
expression	O
as	O
examined	O
in	O
this	O
study	O
,	O
we	O
are	O
evaluating	O
the	O
possibility	O
that	O
PKCalpha	B-Protein
-	O
regulated	O
NF	O
-	O
kappaB	O
activity	O
upregulates	O
additional	O
anti	O
-	O
apoptotic	O
genes	O
in	O
an	O
M	O
-	O
CSF	O
-	O
dependent	O
fashion	O
to	O
modulate	O
cell	O
survival	O
.	O

The	O
use	O
of	O
inhibitors	O
and	O
siRNA	O
in	O
our	O
study	O
has	O
not	O
ruled	O
out	O
that	O
other	O
conventional	O
PKCs	O
might	O
also	O
be	O
important	O
in	O
M	O
-	O
CSF	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
and	O
macrophage	O
survival	O
.	O
<EOS>	B-X
Efficient	B-X
and	B-X
safe	B-X
delivery	B-X
of	B-X
siRNA	B-X
in	B-X
vivo	B-X
is	B-X
the	B-X
biggest	B-X
roadblock	B-X
to	B-X
clinical	B-X
translation	B-X
of	B-X
RNA	B-X
interference	B-X
(	B-X
RNAi	B-X
)	B-X
-based	B-X
therapeutics	B-X
.	B-X
To	B-X
date	B-X
,	B-X
lipid	B-X
nanoparticles	B-X
(	B-X
LNPs	B-X
)	B-X
have	B-X
shown	B-X
efficient	B-X
delivery	B-X
of	B-X
siRNA	B-X
to	B-X
the	B-X
liver	B-X
;	B-X
however	B-X
,	B-X
delivery	B-X
to	B-X
other	B-X
organs	B-X
,	B-X
especially	B-X
hematopoietic	B-X
tissues	B-X
still	B-X
remains	B-X
a	B-X
challenge	B-X
.	B-X
We	B-X
developed	B-X
DLin-MC3-DMA	B-X
lipid-based	B-X
LNP-siRNA	B-X
formulations	B-X
for	B-X
systemic	B-X
delivery	B-X
against	B-X
a	B-X
driver	B-X
oncogene	B-X
to	B-X
target	B-X
human	B-X
chronic	B-X
myeloid	B-X
leukemia	B-X
(	B-X
CML	B-X
)	B-X
cells	B-X
in	B-X
vivo	B-X
.	B-X
A	B-X
microfluidic	B-X
mixing	B-X
technology	B-X
was	B-X
used	B-X
to	B-X
obtain	B-X
reproducible	B-X
ionizable	B-X
cationic	B-X
LNPs	B-X
loaded	B-X
with	B-X
siRNA	B-X
molecules	B-X
targeting	B-X
the	B-X
BCR-ABL	B-X
fusion	B-X
oncogene	B-X
found	B-X
in	B-X
CML	B-X
.	B-X
We	B-X
show	B-X
a	B-X
highly	B-X
efficient	B-X
and	B-X
non-toxic	B-X
delivery	B-X
of	B-X
siRNA	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
with	B-X
nearly	B-X
100	B-X
%	B-X
uptake	B-X
of	B-X
LNP-siRNA	B-X
formulations	B-X
in	B-X
bone	B-X
marrow	B-X
of	B-X
a	B-X
leukemic	B-X
model	B-X
.	B-X
By	B-X
targeting	B-X
the	B-X
BCR-ABL	B-X
fusion	B-X
oncogene	B-X
,	B-X
we	B-X
show	B-X
a	B-X
reduction	B-X
of	B-X
leukemic	B-X
burden	B-X
in	B-X
our	B-X
myeloid	B-X
leukemia	B-X
mouse	B-X
model	B-X
and	B-X
demonstrate	B-X
reduced	B-X
disease	B-X
burden	B-X
in	B-X
mice	B-X
treated	B-X
with	B-X
LNP-BCR-ABL	B-X
siRNA	B-X
as	B-X
compared	B-X
with	B-X
LNP-CTRL	B-X
siRNA	B-X
.	B-X
Our	B-X
study	B-X
provides	B-X
proof-of-principle	B-X
that	B-X
fusion	B-X
oncogene	B-X
specific	B-X
RNAi	B-X
therapeutics	B-X
can	B-X
be	B-X
exploited	B-X
against	B-X
leukemic	B-X
cells	B-X
and	B-X
promise	B-X
novel	B-X
treatment	B-X
options	B-X
for	B-X
leukemia	B-X
patients	B-X
.	B-X

In	O
contrast	O
to	O
the	O
actions	O
of	O
PKCalpha	B-Protein
activation	O
of	O
other	O
conventional	O
PKC	O
isoforms	O
,	O
like	O
PKCbetaI	B-Protein
/	O
betaII	B-Protein
,	O
appear	O
necessary	O
for	O
macrophage	O
apoptosis	O
.	O

The	O
PKCbetaI	B-Protein
/	O
betaII	B-Protein
isoforms	O
are	O
expressed	O
in	O
apoptotic	O
U937	O
myelomonocytic	O
cells	O
[	O
45	O
]	O
.	O

The	O
human	O
myeloid	O
cell	O
line	O
HL	O
-	O
525	O
which	O
is	O
devoid	O
of	O
endogenous	O
PKCbetaII	B-Protein
is	O
resistant	O
to	O
TNFalpha	B-Protein
-	O
induced	O
apoptosis	O
[	O
46	O
]	O
.	O

Re	O
-	O
expression	O
of	O
PKCbetaII	B-Protein
in	O
HL	O
-	O
525	O
cells	O
restores	O
their	O
susceptibility	O
to	O
TNFalpha	B-Protein
-	O
induced	O
apoptosis	O
implying	O
that	O
PKCbetaII	B-Protein
is	O
pro	O
-	O
apoptotic	O
and	O
may	O
be	O
required	O
to	O
induce	O
macrophage	O
apoptosis	O
.	O

Recent	O
studies	O
demonstrated	O
that	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
can	O
be	O
regulated	O
by	O
phosphorylation	O
of	O
the	O
NF	O
-	O
kappaB	O
p65	B-Protein
subunit	O
in	O
the	O
absence	O
of	O
IkappaBalpha	B-Protein
degradation	O
[	O
47	O
]	O
.	O
<EOS>	B-X
We	B-X
recently	B-X
reported	B-X
that	B-X
NF-κB-mediated	B-X
inflammation	B-X
caused	B-X
by	B-X
breakpoint	B-X
cluster	B-X
region	B-X
(	B-X
BCR	B-X
)	B-X
is	B-X
dependent	B-X
on	B-X
the	B-X
α	B-X
subunit	B-X
of	B-X
casein	B-X
kinase	B-X
II	B-X
(	B-X
CK2α	B-X
)	B-X
complex	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
presenilin	B-X
1	B-X
(	B-X
Psen1	B-X
)	B-X
,	B-X
which	B-X
is	B-X
a	B-X
catalytic	B-X
component	B-X
of	B-X
the	B-X
γ-secretase	B-X
complex	B-X
and	B-X
the	B-X
mutations	B-X
of	B-X
which	B-X
are	B-X
known	B-X
to	B-X
cause	B-X
familial	B-X
Alzheimer	B-X
disease	B-X
,	B-X
acts	B-X
as	B-X
a	B-X
scaffold	B-X
of	B-X
the	B-X
BCR-CK2α-p65	B-X
complex	B-X
to	B-X
induce	B-X
NF-κB	B-X
activation	B-X
.	B-X
Indeed	B-X
,	B-X
Psen1	B-X
deficiency	B-X
in	B-X
mouse	B-X
endothelial	B-X
cells	B-X
showed	B-X
a	B-X
significant	B-X
reduction	B-X
of	B-X
NF-κB	B-X
p65	B-X
recruitment	B-X
to	B-X
target	B-X
gene	B-X
promoters	B-X
.	B-X
Conversely	B-X
,	B-X
Psen1	B-X
overexpression	B-X
enhanced	B-X
reporter	B-X
activation	B-X
under	B-X
NF-κB	B-X
responsive	B-X
elements	B-X
and	B-X
IL-6	B-X
promoter	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
transcription	B-X
of	B-X
NF-κB	B-X
target	B-X
genes	B-X
was	B-X
not	B-X
inhibited	B-X
by	B-X
a	B-X
γ-secretase	B-X
inhibitor	B-X
,	B-X
suggesting	B-X
that	B-X
Psen1	B-X
regulates	B-X
NF-κB	B-X
activation	B-X
in	B-X
a	B-X
manner	B-X
independent	B-X
of	B-X
γ-secretase	B-X
activity	B-X
.	B-X
Mechanistically	B-X
,	B-X
Psen1	B-X
associated	B-X
with	B-X
the	B-X
BCR-CK2α	B-X
complex	B-X
,	B-X
which	B-X
is	B-X
required	B-X
for	B-X
phosphorylation	B-X
of	B-X
p65	B-X
at	B-X
serine	B-X
529	B-X
.	B-X
Consistently	B-X
,	B-X
TNF-α-induced	B-X
phosphorylation	B-X
of	B-X
p65	B-X
at	B-X
serine	B-X
529	B-X
was	B-X
significantly	B-X
decreased	B-X
in	B-X
Psen1-deficient	B-X
cells	B-X
.	B-X
The	B-X
association	B-X
of	B-X
the	B-X
BCR-CK2α-p65	B-X
complex	B-X
was	B-X
perturbed	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
Psen1	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Psen1	B-X
functions	B-X
as	B-X
a	B-X
scaffold	B-X
of	B-X
the	B-X
BCR-CK2α-p65	B-X
complex	B-X
and	B-X
that	B-X
this	B-X
signaling	B-X
cascade	B-X
could	B-X
be	B-X
a	B-X
novel	B-X
therapeutic	B-X
target	B-X
for	B-X
various	B-X
chronic	B-X
inflammation	B-X
conditions	B-X
,	B-X
including	B-X
those	B-X
in	B-X
Alzheimer	B-X
disease	B-X
.	B-X

By	O
this	O
pathway	O
,	O
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
regulates	O
its	O
interaction	O
with	O
other	O
components	O
of	O
the	O
basal	O
transcriptional	O
machinery	O
without	O
affecting	O
its	O
capability	O
to	O
bind	O
DNA	O
[	O
21	O
]	O
.	O

Since	O
NF	O
-	O
kappaB	O
can	O
bind	O
the	O
promoters	O
of	O
numerous	O
gene	O
targets	O
,	O
post	O
-	O
translational	O
modification	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
may	O
affect	O
its	O
interaction	O
with	O
other	O
proteins	O
,	O
refining	O
the	O
expression	O
of	O
gene	O
targets	O
.	O

We	O
did	O
not	O
find	O
that	O
PKC	O
was	O
involved	O
in	O
IkappaBalpha	B-Protein
degradation	O
or	O
NF	O
-	O
kappaB	O
p65	B-Protein
nuclear	O
translocation	O
induced	O
by	O
M	O
-	O
CSF	O
,	O
but	O
that	O
M	O
-	O
CSF	O
-	O
induced	O
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
at	O
Ser276	O
was	O
dramatically	O
reduced	O
by	O
the	O
conventional	O
PKC	O
inhibitor	O
and	O
kinase	O
deficient	O
PKCalpha	B-Protein
and	O
by	O
siRNA	B-Protein
towards	O
PKCalpha	B-Protein
.	O

Current	O
studies	O
are	O
underway	O
to	O
delineate	O
the	O
protein	O
complexes	O
formed	O
by	O
activated	O
NF	O
-	O
kappaB	O
and	O
other	O
transcriptional	O
co	O
-	O
activators	O
in	O
response	O
to	O
M	O
-	O
CSF	O
and	O
PKC	O
activation	O
.	O

Recently	O
studies	O
indicated	O
that	O
the	O
non	O
-	O
canonical	O
pathway	O
was	O
activated	O
during	O
human	O
monocyte	O
-	O
macrophage	O
differentiation	O
[	O
48	O
]	O
.	O

During	O
this	O
process	O
,	O
expression	O
of	O
IKKalpha	B-Protein
among	O
other	O
proteins	O
,	O
is	O
elevated	O
leading	O
to	O
increased	O
p52	B-Protein
NF	O
-	O
kappaB	O
(	O
relB	B-Protein
)	O
expression	O
through	O
partial	O
proteolytic	O
degradation	O
of	O
the	O
p100	B-Protein
NF	O
-	O
kappaB	O
protein	O
.	O

Thus	O
,	O
it	O
is	O
possible	O
that	O
M	O
-	O
CSF	O
regulates	O
monocyte	O
survival	O
through	O
both	O
the	O
canonical	O
and	O
non	O
-	O
canonical	O
NF	O
-	O
kappaB	O
pathways	O
,	O
which	O
will	O
be	O
a	O
focus	O
in	O
future	O
research	O
.	O

We	O
previously	O
showed	O
that	O
M	O
-	O
CSF	O
reduced	O
caspase	B-Protein
-	I-Protein
3	I-Protein
and	O
-	B-Protein
9	I-Protein
activity	O
and	O
prevented	O
monocyte	O
apoptosis	O
[	O
3	O
]	O
.	O

This	O
study	O
reveals	O
that	O
treatment	O
of	O
monocytes	O
with	O
conventional	O
PKC	O
inhibitors	O
,	O
or	O
overexpression	O
of	O
kinase	O
-	O
deficient	O
PKCalpha	B-Protein
blocked	O
M	O
-	O
CSF	O
-	O
induced	O
cell	O
survival	O
.	O
<EOS>	B-X
We	B-X
reported	B-X
previously	B-X
that	B-X
interleukin-13	B-X
(	B-X
IL-13	B-X
)	B-X
induces	B-X
tyrosine	B-X
phosphorylation/activation	B-X
of	B-X
Jak2	B-X
and	B-X
Tyk2	B-X
kinases	B-X
and	B-X
Stats	B-X
1	B-X
,	B-X
3	B-X
,	B-X
5	B-X
,	B-X
and	B-X
6	B-X
in	B-X
primary	B-X
human	B-X
monocytes	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
present	B-X
data	B-X
indicating	B-X
that	B-X
another	B-X
serine/threonine	B-X
kinase	B-X
,	B-X
PKCdelta	B-X
,	B-X
is	B-X
also	B-X
required	B-X
for	B-X
IL-13-induced	B-X
15-LO	B-X
expression	B-X
.	B-X
PKCdelta	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
novel	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
subclass	B-X
,	B-X
was	B-X
rapidly	B-X
phosphorylated	B-X
and	B-X
activated	B-X
upon	B-X
exposure	B-X
to	B-X
IL-13	B-X
.	B-X
Treatment	B-X
of	B-X
cells	B-X
with	B-X
rottlerin	B-X
,	B-X
a	B-X
PKCdelta	B-X
inhibitor	B-X
,	B-X
blocked	B-X
IL-13-induced	B-X
15-LO	B-X
mRNA	B-X
and	B-X
protein	B-X
expression	B-X
,	B-X
whereas	B-X
Go6976	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
the	B-X
conventional	B-X
PKC	B-X
subclass	B-X
,	B-X
had	B-X
no	B-X
inhibitory	B-X
effects	B-X
.	B-X
Down-regulation	B-X
of	B-X
cellular	B-X
PKCdelta	B-X
protein	B-X
levels	B-X
by	B-X
PKCdelta-specific	B-X
antisense	B-X
oligodeoxyribonucleotides	B-X
also	B-X
inhibited	B-X
15-LO	B-X
expression	B-X
markedly	B-X
.	B-X
IL-13-induced	B-X
15-LO	B-X
expression	B-X
resulted	B-X
in	B-X
significant	B-X
inhibition	B-X
of	B-X
synthesis	B-X
of	B-X
the	B-X
potent	B-X
chemotactic	B-X
factor	B-X
leukotriene	B-X
B4	B-X
,	B-X
and	B-X
that	B-X
process	B-X
was	B-X
reversed	B-X
by	B-X
rottlerin	B-X
,	B-X
presumably	B-X
through	B-X
the	B-X
blockage	B-X
of	B-X
PKCdelta-dependent	B-X
15-LO	B-X
expression	B-X
.	B-X
Furthermore	B-X
,	B-X
our	B-X
data	B-X
demonstrate	B-X
that	B-X
IL-13-mediated	B-X
activation	B-X
of	B-X
PKCdelta	B-X
and	B-X
p38	B-X
MAPK	B-X
are	B-X
independent	B-X
pathways	B-X
,	B-X
because	B-X
inhibition	B-X
of	B-X
one	B-X
kinase	B-X
activity	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
the	B-X
other	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
two	B-X
pathways	B-X
act	B-X
in	B-X
parallel	B-X
to	B-X
regulate	B-X
the	B-X
downstream	B-X
targets	B-X
necessary	B-X
for	B-X
15-LO	B-X
expression	B-X
.	B-X
Inhibition	B-X
of	B-X
PKCdelta	B-X
activation	B-X
by	B-X
rottlerin	B-X
also	B-X
markedly	B-X
attenuated	B-X
IL-13-induced	B-X
Stat3	B-X
DNA	B-X
binding	B-X
activity	B-X
.	B-X
Our	B-X
findings	B-X
indicate	B-X
that	B-X
PKCdelta	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
regulating	B-X
IL-13-induced	B-X
15-LO	B-X
expression	B-X
in	B-X
human	B-X
monocytes	B-X
and	B-X
subsequently	B-X
modulates	B-X
the	B-X
inflammatory	B-X
responses	B-X
mediated	B-X
by	B-X
15-LO	B-X
products	B-X
.	B-X

Our	O
data	O
revealed	O
that	O
conventional	O
PKCs	O
are	O
upstream	O
of	O
NF	O
-	O
kappaB	O
activation	O
in	O
response	O
to	O
M	O
-	O
CSF	O
and	O
mediate	O
post	O
-	O
translational	O
activation	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
by	O
phosphorylating	O
Ser276	O
to	O
regulate	O
gene	O
transcription	O
and	O
cell	O
survival	O
.	O

Thus	O
,	O
our	O
observation	O
may	O
provide	O
insight	O
in	O
potential	O
therapeutic	O
targets	O
for	O
inflammatory	O
diseases	O
.	O
<EOS>	B-X
The	B-X
histological	B-X
changes	B-X
observed	B-X
in	B-X
the	B-X
SM	B-X
in	B-X
OA	B-X
generally	B-X
include	B-X
features	B-X
indicative	B-X
of	B-X
an	B-X
inflammatory	B-X
``	B-X
synovitis	B-X
''	B-X
;	B-X
specifically	B-X
they	B-X
encompass	B-X
a	B-X
range	B-X
of	B-X
abnormalities	B-X
,	B-X
such	B-X
as	B-X
synovial	B-X
lining	B-X
hyperplasia	B-X
,	B-X
infiltration	B-X
of	B-X
macrophages	B-X
and	B-X
lymphocytes	B-X
,	B-X
neoangiogenesis	B-X
and	B-X
fibrosis	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
synovitis	B-X
may	B-X
be	B-X
predictive	B-X
of	B-X
faster	B-X
rates	B-X
of	B-X
cartilage	B-X
loss	B-X
in	B-X
certain	B-X
patient	B-X
populations	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
provided	B-X
insights	B-X
into	B-X
the	B-X
pathogenic	B-X
mechanisms	B-X
underlying	B-X
the	B-X
development	B-X
of	B-X
synovitis	B-X
in	B-X
OA	B-X
.	B-X
Available	B-X
evidence	B-X
suggests	B-X
that	B-X
the	B-X
inflammatory	B-X
process	B-X
involves	B-X
engagement	B-X
of	B-X
Toll-like	B-X
receptors	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
complement	B-X
cascade	B-X
by	B-X
degradation	B-X
products	B-X
of	B-X
extracellular	B-X
matrices	B-X
of	B-X
cartilage	B-X
and	B-X
other	B-X
joint	B-X
tissues	B-X
.	B-X
Some	B-X
of	B-X
these	B-X
inflammatory	B-X
mediators	B-X
are	B-X
detected	B-X
in	B-X
joint	B-X
tissues	B-X
and	B-X
SF	B-X
in	B-X
OA	B-X
and	B-X
have	B-X
catabolic	B-X
effects	B-X
on	B-X
chondrocytes	B-X
.	B-X
These	B-X
inflammatory	B-X
mediators	B-X
represent	B-X
potential	B-X
targets	B-X
for	B-X
therapeutic	B-X
interventions	B-X
designed	B-X
to	B-X
reduce	B-X
both	B-X
symptoms	B-X
and	B-X
structural	B-X
joint	B-X
damage	B-X
in	B-X
OA	B-X
.	B-X

Materials	O
<EOS>	B-X
Materials	B-X
used	B-X
without	B-X
adequate	B-X
knowledge	B-X
of	B-X
their	B-X
characteristics	B-X
can	B-X
impair	B-X
a	B-X
successful	B-X
outcome	B-X
.	B-X

Recombinant	O
human	O
M	O
-	O
CSF	O
was	O
purchased	O
from	O
R	O
&	O
D	O
Systems	O
(	O
Minneapolis	O
,	O
MN	O
)	O
.	O

Ro	O
-	O
31	O
-	O
8220	O
,	O
Go	O
-	O
6976	O
,	O
Rotterin	O
,	O
and	O
BAPTA	O
/	O
AM	O
were	O
obtained	O
from	O
Calbiochem	O
(	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

Low	O
endotoxin	O
RPMI	O
and	O
X	O
-	O
vivo	O
serum	O
free	O
medium	O
were	O
obtained	O
from	O
Lonza	O
Walkersville	O
Inc	O
(	O
Walkersville	O
,	O
MD	O
)	O
.	O

Fetal	O
bovine	O
serum	O
(	O
FBS	O
,	O
certified	O
<	O
0	O
.	O
06	O
endotoxin	O
units	O
/	O
ml	O
endotoxin	O
levels	O
)	O
was	O
purchased	O
from	O
Atlanta	O
Biological	O
(	O
Lawrenceville	O
,	O
GA	O
)	O
.	O

All	O
other	O
cell	O
culture	O
reagents	O
were	O
obtained	O
through	O
Invitrogen	O
(	O
Carlsbad	O
,	O
CA	O
)	O
.	O
<EOS>	B-X
Retinal	B-X
ganglion	B-X
cells	B-X
(	B-X
RGCs	B-X
)	B-X
die	B-X
as	B-X
a	B-X
result	B-X
of	B-X
axonal	B-X
injury	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
optic	B-X
neuropathies	B-X
,	B-X
including	B-X
glaucoma	B-X
.	B-X
Reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
act	B-X
as	B-X
intracellular	B-X
signaling	B-X
molecules	B-X
and	B-X
initiate	B-X
apoptosis	B-X
in	B-X
nerve	B-X
growth	B-X
factor-deprived	B-X
sympathetic	B-X
neurons	B-X
and	B-X
axotomized	B-X
RGCs	B-X
.	B-X
The	B-X
pro-	B-X
or	B-X
anti-cell-death	B-X
effect	B-X
of	B-X
several	B-X
ROS	B-X
generating	B-X
and	B-X
scavenging	B-X
systems	B-X
in	B-X
cultured	B-X
RGCs	B-X
was	B-X
correlated	B-X
with	B-X
their	B-X
activity	B-X
in	B-X
cell-free	B-X
assays	B-X
.	B-X

PKCalpha	O
NF	O
-	O
kappaB	O
p65	O
,	O
Lamin	O
B	O
,	O
beta	O
-	O
actin	O
,	O
and	O
GAPDH	O
antibodies	O
,	O
anti	O
-	O
mouse	O
and	O
rabbit	O
IgG	O
-	O
HRP	O
conjugated	O
antibodies	O
,	O
and	O
PKCalpha	B-Protein
siRNA	I-Protein
were	O
obtained	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
,	O
CA	O
)	O
.	O

Phospho	O
-	O
NFkappaB	O
p65	O
(	O
Ser276	O
or	O
Ser536	O
)	O
antibodies	O
were	O
purchased	O
from	O
Cell	O
Signaling	O
Technology	O
(	O
Danvers	O
,	O
MA	O
)	O
.	O

DNA	O
constructs	O
pTAL	O
-	O
SEAP	O
and	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
were	O
obtained	O
from	O
Clontech	O
(	O
Mountian	O
View	O
,	O
CA	O
)	O
.	O

Expression	O
vectors	O
containing	O
CMV	O
-	O
p65	B-Protein
WT	O
,	O
CMV	O
-	O
p65	B-Protein
276S	O
/	O
A	O
and	O
CMV	O
-	O
p65	B-Protein
536S	O
/	O
A	O
were	O
cloned	O
in	O
pBa5e	O
Puro	O
vector	O
or	O
pFLAG	O
-	O
CMV	O
-	O
2	O
vector	O
as	O
described	O
previously	O
[	O
49	O
]	O
.	O

Kinase	O
deficient	O
CMV	O
-	O
PKCalpha	B-Protein
(	O
KD	O
-	O
PKCalpha	B-Protein
)	O
or	O
wild	O
type	O
pCMV	O
-	O
PKCalpha	B-Protein
(	O
WT	O
-	O
PKCalpha	B-Protein
)	O
were	O
generous	O
gifts	O
from	O
Alexandra	O
C	O
.	O
Newton	O
(	O
University	O
of	O
California	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

IkappaBalpha	B-Protein
(	O
NFKBIA	O
)	O
and	O
GAPDH	O
primers	O
for	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
were	O
obtained	O
from	O
SABiosciences	O
(	O
Frederick	O
,	O
MD	O
)	O
.	O

A	O
pool	O
of	O
mouse	O
or	O
human	O
PKCalpha	B-Protein
specific	I-Protein
siRNA	I-Protein
were	O
purchased	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
cruz	O
,	O
CA	O
)	O
.	O
<EOS>	B-X
We	B-X
found	B-X
here	B-X
that	B-X
light-zone	B-X
(	B-X
LZ	B-X
)	B-X
GC	B-X
B	B-X
cells	B-X
with	B-X
B	B-X
cell	B-X
antigen	B-X
receptors	B-X
(	B-X
BCRs	B-X
)	B-X
of	B-X
lower	B-X
affinity	B-X
were	B-X
prone	B-X
to	B-X
enter	B-X
the	B-X
memory	B-X
B	B-X
cell	B-X
pool	B-X
.	B-X
Thus	B-X
,	B-X
we	B-X
propose	B-X
an	B-X
instructive	B-X
model	B-X
in	B-X
which	B-X
weak	B-X
help	B-X
from	B-X
T	B-X
cells	B-X
maintains	B-X
relatively	B-X
high	B-X
expression	B-X
of	B-X
Bach2	B-X
,	B-X
which	B-X
predisposes	B-X
GC	B-X
cells	B-X
to	B-X
enter	B-X
the	B-X
memory	B-X
pool	B-X
.	B-X
Periostin-deficient	B-X
periosteum	B-X
can	B-X
not	B-X
reconstitute	B-X
a	B-X
pool	B-X
of	B-X
PCs	B-X
after	B-X
injury	B-X
demonstrating	B-X
the	B-X
presence	B-X
of	B-X
SSCs	B-X
within	B-X
periosteum	B-X
and	B-X
the	B-X
requirement	B-X
of	B-X
Periostin	B-X
in	B-X
maintaining	B-X
this	B-X
pool	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
graft	B-X
a	B-X
molecular	B-X
framework	B-X
onto	B-X
the	B-X
known	B-X
neuroanatomic	B-X
developmental	B-X
plan	B-X
by	B-X
considering	B-X
the	B-X
phenotypes	B-X
of	B-X
several	B-X
mouse	B-X
mutants	B-X
that	B-X
have	B-X
well	B-X
characterized	B-X
dentate	B-X
gyrus	B-X
developmental	B-X
abnormalities	B-X
.	B-X
This	B-X
effort	B-X
reveals	B-X
that	B-X
there	B-X
are	B-X
at	B-X
least	B-X
six	B-X
distinct	B-X
developmental	B-X
steps	B-X
that	B-X
need	B-X
to	B-X
occur	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
dentate	B-X
gyrus	B-X
,	B-X
which	B-X
can	B-X
be	B-X
associated	B-X
with	B-X
specific	B-X
gene	B-X
defects	B-X
:	B-X
(	B-X
1	B-X
)	B-X
defining	B-X
the	B-X
dentate	B-X
neuroepithelium	B-X
;	B-X
(	B-X
2	B-X
)	B-X
forming	B-X
the	B-X
primary	B-X
radial	B-X
glial	B-X
scaffolding	B-X
;	B-X
(	B-X
3	B-X
)	B-X
radial	B-X
migration	B-X
of	B-X
granule	B-X
neurons	B-X
to	B-X
form	B-X
the	B-X
primordial	B-X
granule	B-X
cell	B-X
layer	B-X
;	B-X
(	B-X
4	B-X
)	B-X
establishing	B-X
the	B-X
precursor	B-X
pool	B-X
in	B-X
the	B-X
hilus	B-X
;	B-X
(	B-X
5	B-X
)	B-X
radial	B-X
transformation	B-X
of	B-X
the	B-X
tertiary	B-X
matrix	B-X
,	B-X
and	B-X
(	B-X
6	B-X
)	B-X
differentiation	B-X
of	B-X
dentate	B-X
granule	B-X
cells	B-X
.	B-X

Cell	O
Culture	O
<EOS>	B-X
Cultures	B-X
,	B-X
supposedly	B-X
of	B-X
tissues	B-X
such	B-X
as	B-X
breast	B-X
cancer	B-X
or	B-X
mouse	B-X
,	B-X
proved	B-X
to	B-X
be	B-X
HeLa	B-X
cells	B-X
.	B-X
Cell	B-X
culture	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
valuable	B-X
tools	B-X
which	B-X
is	B-X
being	B-X
applied	B-X
in	B-X
both	B-X
fundamental	B-X
and	B-X
applied	B-X
gastrointestinal	B-X
research	B-X
.	B-X
Cell	B-X
culture	B-X
-	B-X
Fact	B-X
and	B-X
fiction	B-X
.	B-X
Cell	B-X
culture	B-X
is	B-X
a	B-X
well-established	B-X
standard	B-X
technique	B-X
and	B-X
a	B-X
fundamental	B-X
tool	B-X
in	B-X
biology	B-X
and	B-X
medicine	B-X
.	B-X

The	O
murine	O
macrophage	O
cell	O
line	O
RAW	O
264	O
.	O
7	O
was	O
purchased	O
from	O
ATCC	O
(	O
Manassas	O
,	O
VA	O
)	O
.	O

RAW	O
264	O
.	O
7	O
cells	O
were	O
maintained	O
in	O
RPMI	O
supplemented	O
with	O
5	O
%	O
FBS	O
and	O
antibiotic	O
-	O
antimycotic	O
(	O
1000	O
U	O
/	O
ml	O
penicillin	O
,	O
1000	O
microg	O
/	O
ml	O
streptomycin	O
sulfate	O
,	O
and	O
250	O
ng	O
/	O
ml	O
amphotericin	O
B	O
)	O
at	O
37degreesC	O
.	O

Mouse	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
cell	O
line	O
lacking	O
specific	O
NFkappaB	O
signaling	O
subunits	O
NF	O
-	O
kappaB	O
p65	B-Protein
(	O
p65	B-Protein
-	O
/	O
-	O
cell	O
line	O
)	O
[	O
50	O
]	O
were	O
cultured	O
in	O
DMEM	O
medium	O
supplemented	O
with	O
10	O
%	O
FBS	O
and	O
antibiotic	O
-	O
antimycotic	O
solution	O
.	O

Purification	O
of	O
Peripheral	O
Blood	O
Monocytes	O
and	O
Monocyte	O
-	O
Derived	O
Macrophages	O
(	O
MDMs	O
)	O
<EOS>	B-X
Peripheral	B-X
blood	B-X
from	B-X
healthy	B-X
sheep	B-X
(	B-X
n	B-X
=	B-X
3	B-X
)	B-X
and	B-X
goats	B-X
(	B-X
n	B-X
=	B-X
3	B-X
)	B-X
were	B-X
employed	B-X
to	B-X
establish	B-X
an	B-X
efficient	B-X
method	B-X
for	B-X
simultaneous	B-X
isolation	B-X
of	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cells	B-X
(	B-X
PBMCs	B-X
)	B-X
and	B-X
neutrophils	B-X
and	B-X
to	B-X
standardize	B-X
protocols	B-X
for	B-X
monocyte	B-X
purification	B-X
and	B-X
generation	B-X
of	B-X
monocyte-derived	B-X
macrophages	B-X
(	B-X
MDMs	B-X
)	B-X
.	B-X
HIV-1	B-X
infection	B-X
of	B-X
peripheral	B-X
blood	B-X
monocyte-derived	B-X
macrophages	B-X
(	B-X
MDMs	B-X
)	B-X
is	B-X
unrelated	B-X
to	B-X
the	B-X
level	B-X
of	B-X
CD4	B-X
expression	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
the	B-X
cell	B-X
,	B-X
is	B-X
associated	B-X
with	B-X
considerable	B-X
donor	B-X
variability	B-X
,	B-X
causes	B-X
minimal	B-X
cytopathology	B-X
,	B-X
and	B-X
results	B-X
in	B-X
peak	B-X
viral	B-X
antigen	B-X
production	B-X
after	B-X
2	B-X
weeks	B-X
of	B-X
infection	B-X
.	B-X
Phagocytosis	B-X
of	B-X
opsonized	B-X
Candida	B-X
albicans	B-X
by	B-X
MDMs	B-X
infected	B-X
in	B-X
vitro	B-X
with	B-X
several	B-X
strains	B-X
of	B-X
HIV	B-X
was	B-X
compared	B-X
with	B-X
that	B-X
of	B-X
uninfected	B-X
cells	B-X
from	B-X
the	B-X
same	B-X
donors	B-X
;	B-X
the	B-X
proportion	B-X
of	B-X
MDMs	B-X
containing	B-X
the	B-X
fluorescein	B-X
isothiocyanate-labeled	B-X
yeast	B-X
was	B-X
determined	B-X
by	B-X
flow	B-X
cytometry	B-X
and	B-X
phase	B-X
contrast	B-X
microscopy	B-X
.	B-X
Using	B-X
paired	B-X
MDMs	B-X
from	B-X
nine	B-X
donors	B-X
,	B-X
81	B-X
%	B-X
of	B-X
uninfected	B-X
and	B-X
53	B-X
%	B-X
of	B-X
HIV-infected	B-X
MDMs	B-X
phagocytosed	B-X
C.	B-X
albicans	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
number	B-X
of	B-X
yeast	B-X
per	B-X
cell	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
uninfected	B-X
MDMs	B-X
than	B-X
in	B-X
HIV-infected	B-X
cells	B-X
(	B-X
mean	B-X
6.1	B-X
versus	B-X
2.5	B-X
)	B-X
.	B-X

Monocytes	O
were	O
isolated	O
from	O
source	O
leukocyte	O
packs	O
obtained	O
from	O
the	O
American	O
Red	O
Cross	O
as	O
described	O
previously	O
[	O
51	O
]	O
.	O

Monocytes	O
used	O
in	O
real	O
time	O
PCR	O
experiments	O
and	O
transfection	O
experiments	O
were	O
purified	O
by	O
positive	O
selection	O
using	O
CD14	B-Protein
Monocyte	O
Isolation	O
Kit	O
from	O
Miltenyi	O
Biotech	O
(	O
Auburn	O
,	O
CA	O
)	O
(	O
>	O
90	O
%	O
pure	O
)	O
.	O

In	O
some	O
experiments	O
,	O
monocytes	O
were	O
isolated	O
by	O
clumping	O
method	O
(	O
70	O
%	O
pure	O
)	O
.	O

To	O
obtain	O
monocyte	O
-	O
derived	O
macrophages	O
(	O
MDMs	O
)	O
,	O
monocytes	O
were	O
cultured	O
in	O
RPMI	O
-	O
1640	O
medium	O
containing	O
10	O
%	O
FBS	O
,	O
and	O
10	O
microg	O
/	O
ml	O
polymyxin	O
B	O
and	O
20	O
ng	O
/	O
ml	O
M	O
-	O
CSF	O
.	O

Electrophoresis	O
of	O
the	O
Mobility	O
Shift	O
Analysis	O
(	O
EMSA	O
)	O
<EOS>	B-X
The	B-X
gel	B-X
electrophoresis	B-X
mobility	B-X
shift	B-X
assay	B-X
(	B-X
EMSA	B-X
)	B-X
is	B-X
used	B-X
to	B-X
detect	B-X
protein	B-X
complexes	B-X
with	B-X
nucleic	B-X
acids	B-X
.	B-X
IRE/IRP	B-X
interactions	B-X
have	B-X
been	B-X
widely	B-X
studied	B-X
by	B-X
EMSA	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
EMSA	B-X
protocol	B-X
for	B-X
analyzing	B-X
the	B-X
IRE-binding	B-X
activity	B-X
of	B-X
IRP1	B-X
and	B-X
IRP2	B-X
,	B-X
which	B-X
can	B-X
be	B-X
generalized	B-X
to	B-X
assess	B-X
the	B-X
activity	B-X
of	B-X
other	B-X
RNA-binding	B-X
proteins	B-X
as	B-X
well	B-X
.	B-X
Moreover	B-X
,	B-X
EMSA	B-X
can	B-X
also	B-X
be	B-X
used	B-X
to	B-X
determine	B-X
specificity	B-X
,	B-X
binding	B-X
affinity	B-X
,	B-X
and	B-X
stoichiometry	B-X
of	B-X
the	B-X
RNA/protein	B-X
interaction	B-X
under	B-X
investigation	B-X
.	B-X

Nuclear	O
extracts	O
were	O
isolated	O
from	O
MDMs	O
by	O
using	O
a	O
nuclear	O
extraction	O
kit	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
from	O
Active	O
Motif	O
(	O
Carlsbad	O
,	O
CA	O
)	O
.	O

Briefly	O
,	O
MDMs	O
were	O
lysed	O
in	O
hypotonic	O
lysis	O
buffer	O
(	O
20	O
mM	O
Hepes	O
,	O
pH	O
7	O
.	O
5	O
;	O
5	O
mM	O
NaF	O
,	O
10	O
microM	O
Na2MoO4	O
0	O
.	O
5	O
%	O
NP	O
-	O
40	O
and	O
0	O
.	O
1	O
mM	O
EDTA	O
)	O
,	O
and	O
then	O
nuclei	O
were	O
resuspended	O
in	O
lysis	O
buffer	O
supplemented	O
with	O
0	O
.	O
5	O
mM	O
DTT	O
and	O
0	O
.	O
2	O
mM	O
PMSF	O
.	O

The	O
NF	O
-	O
kappaB	O
consensus	O
oligonucleotides	O
(	O
sense	O
:	O
AGTTGAGGGGACTTTCCCAGGC	O
;	O
antisense	O
:	O
GCCTGGGAAAGTCCCCTCAACT	O
)	O
labeled	O
with	O
32P	O
by	O
T4	O
polynucleokinase	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
)	O
were	O
incubated	O
with	O
nuclear	O
extracts	O
in	O
binding	O
buffer	O
(	O
10	O
mM	O
Tris	O
pH	O
7	O
.	O
6	O
,	O
1	O
mM	O
DTT	O
,	O
0	O
.	O
5	O
mM	O
EDTA	O
,	O
2	O
microg	O
polydI	O
-	O
dC	O
and	O
10	O
%	O
Glycerol	O
)	O
at	O
30degreesC	O
for	O
30	O
minutes	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
nuclear	B-X
factor-kappa	B-X
B	B-X
(	B-X
NF-κB	B-X
)	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
important	B-X
pro-inflammatory	B-X
mechanisms	B-X
in	B-X
disease	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
5-aminoimidazole-4-carboxamide	B-X
ribonucleoside	B-X
(	B-X
AICAR	B-X
)	B-X
,	B-X
an	B-X
intermediate	B-X
in	B-X
nucleoside	B-X
metabolism	B-X
,	B-X
inhibits	B-X
signalling	B-X
by	B-X
NF-κB	B-X
in	B-X
three	B-X
cell	B-X
types	B-X
,	B-X
including	B-X
bovine	B-X
aortic	B-X
endothelial	B-X
cells	B-X
(	B-X
BAEC	B-X
)	B-X
.	B-X
The	B-X
block	B-X
in	B-X
the	B-X
NF-κB	B-X
signalling	B-X
pathway	B-X
occurred	B-X
beyond	B-X
degradation	B-X
of	B-X
IκB-α	B-X
and	B-X
movement	B-X
of	B-X
p65	B-X
into	B-X
the	B-X
nucleus	B-X
of	B-X
BAEC	B-X
.	B-X
There	B-X
was	B-X
,	B-X
however	B-X
,	B-X
reduced	B-X
binding	B-X
of	B-X
NF-κB	B-X
from	B-X
AICAR-treated	B-X
cells	B-X
to	B-X
a	B-X
κB-consensus	B-X
oligonucleotide	B-X
,	B-X
suggesting	B-X
that	B-X
part	B-X
of	B-X
the	B-X
mechanism	B-X
was	B-X
a	B-X
reduction	B-X
in	B-X
NF-κB	B-X
DNA-binding	B-X
activity	B-X
.	B-X
Although	B-X
AICAR	B-X
is	B-X
metabolized	B-X
to	B-X
ZMP	B-X
and	B-X
then	B-X
adenosine	B-X
,	B-X
adenosine	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
activation	B-X
of	B-X
an	B-X
NF-κB	B-X
reporter	B-X
.	B-X
Transfection	B-X
of	B-X
active	B-X
AMPK	B-X
into	B-X
BAEC	B-X
reduced	B-X
NF-κB	B-X
reporter	B-X
activity	B-X
compared	B-X
with	B-X
a	B-X
kinase-dead	B-X
mutant	B-X
,	B-X
suggesting	B-X
that	B-X
part	B-X
of	B-X
the	B-X
ability	B-X
of	B-X
AICAR	B-X
to	B-X
inhibit	B-X
NF-κB	B-X
signalling	B-X
is	B-X
due	B-X
to	B-X
activation	B-X
of	B-X
AMPK	B-X
.	B-X
Inhibition	B-X
of	B-X
NF-κB	B-X
signalling	B-X
may	B-X
be	B-X
important	B-X
in	B-X
the	B-X
anti-inflammatory	B-X
action	B-X
of	B-X
drugs	B-X
such	B-X
as	B-X
sulfasalazine	B-X
and	B-X
methotrexate	B-X
,	B-X
which	B-X
led	B-X
to	B-X
the	B-X
accumulation	B-X
of	B-X
AICAR	B-X
within	B-X
target	B-X
cells	B-X
.	B-X

The	O
free	O
DNA	O
and	O
DNA	O
-	O
protein	O
mixtures	O
were	O
resolved	O
in	O
5	O
%	O
native	O
polyacrylamide	O
gels	O
in	O
0	O
.	O
5x	O
TBE	O
buffer	O
(	O
45	O
mM	O
Tris	O
,	O
45	O
mM	O
boric	O
acid	O
and	O
1	O
mM	O
EDTA	O
,	O
pH	O
8	O
.	O
3	O
)	O
by	O
electrophoresis	O
.	O

The	O
gel	O
was	O
dried	O
and	O
subjected	O
to	O
autoradiography	O
analysis	O
.	O
<EOS>	B-X
Various	B-X
glycosphingolipids	B-X
were	B-X
chromatographed	B-X
on	B-X
high-performance	B-X
silica	B-X
gel	B-X
thin-layer	B-X
chromatography	B-X
plates	B-X
,	B-X
and	B-X
the	B-X
plates	B-X
were	B-X
coated	B-X
with	B-X
a	B-X
thin	B-X
film	B-X
of	B-X
poly	B-X
(	B-X
isobutyl	B-X
methacrylate	B-X
)	B-X
and	B-X
mounted	B-X
in	B-X
a	B-X
specially	B-X
designed	B-X
plexiglass	B-X
chamber	B-X
.	B-X
The	B-X
plate	B-X
was	B-X
removed	B-X
from	B-X
the	B-X
chamber	B-X
,	B-X
the	B-X
adherent	B-X
cells	B-X
were	B-X
fixed	B-X
in	B-X
place	B-X
with	B-X
glutaraldehyde	B-X
,	B-X
and	B-X
the	B-X
plate	B-X
was	B-X
dried	B-X
and	B-X
subjected	B-X
to	B-X
autoradiography	B-X
.	B-X
Of	B-X
15	B-X
proteins	B-X
tested	B-X
,	B-X
7	B-X
were	B-X
found	B-X
to	B-X
be	B-X
sulfated	B-X
as	B-X
indicated	B-X
by	B-X
[	B-X
35S	B-X
]	B-X
sulfate	B-X
incorporation	B-X
into	B-X
proteins	B-X
separated	B-X
by	B-X
NaDodSO4/PAGE	B-X
and	B-X
detected	B-X
by	B-X
autoradiography	B-X
.	B-X
The	B-X
35S-labeled	B-X
bands	B-X
were	B-X
excised	B-X
from	B-X
the	B-X
dried	B-X
gel	B-X
and	B-X
subjected	B-X
to	B-X
extensive	B-X
Pronase	B-X
hydrolysis	B-X
and	B-X
the	B-X
hydrolysates	B-X
were	B-X
analyzed	B-X
for	B-X
tyrosine	B-X
[	B-X
35S	B-X
]	B-X
sulfate	B-X
by	B-X
a	B-X
two-dimensional	B-X
procedure	B-X
combining	B-X
high-voltage	B-X
electrophoresis	B-X
and	B-X
thin-layer	B-X
chromatography	B-X
[	B-X
Liu	B-X
,	B-X
M.	B-X
C.	B-X
&	B-X
Lipmann	B-X
,	B-X
F.	B-X
(	B-X
1984	B-X
)	B-X
Proc	B-X
.	B-X

Transient	O
Transfection	O
of	O
RAW	O
264	O
.	O
7	O
Cells	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
LPS	B-X
stimulation	B-X
of	B-X
Raw	B-X
264.7	B-X
mouse	B-X
macrophage	B-X
cells	B-X
induces	B-X
the	B-X
association	B-X
of	B-X
SHIP	B-X
with	B-X
lipid	B-X
rafts	B-X
,	B-X
along	B-X
with	B-X
IL-1R-associated	B-X
kinase	B-X
.	B-X
Transient	B-X
transfection	B-X
experiments	B-X
analyzing	B-X
the	B-X
function	B-X
of	B-X
SHIP	B-X
indicated	B-X
that	B-X
overexpression	B-X
of	B-X
a	B-X
wild-type	B-X
SHIP	B-X
,	B-X
but	B-X
not	B-X
the	B-X
SHIP	B-X
Src	B-X
homology	B-X
2	B-X
domain-lacking	B-X
catalytic	B-X
activity	B-X
,	B-X
up-regulates	B-X
NF-kappaB-dependent	B-X
gene	B-X
transcription	B-X
in	B-X
response	B-X
to	B-X
LPS	B-X
stimulation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
SHIP	B-X
positively	B-X
regulates	B-X
LPS-induced	B-X
activation	B-X
of	B-X
Raw	B-X
264.7	B-X
cells	B-X
.	B-X
MyD88	B-X
is	B-X
a	B-X
major	B-X
regulator	B-X
of	B-X
nuclear	B-X
factor	B-X
kappa	B-X
light	B-X
chain	B-X
enhancer	B-X
of	B-X
activated	B-X
B	B-X
cells	B-X
(	B-X
NFκB	B-X
)	B-X
pathway	B-X
in	B-X
Raw	B-X
264.7	B-X
macrophages	B-X
.	B-X
CRISPR/Cas9-mediated	B-X
MyD88	B-X
knockdown	B-X
macrophages	B-X
treated	B-X
with	B-X
LPS	B-X
for	B-X
24	B-X
h	B-X
showed	B-X
a	B-X
65	B-X
%	B-X
reduction	B-X
in	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNFα	B-X
)	B-X
secretion	B-X
,	B-X
and	B-X
a	B-X
67	B-X
%	B-X
reduction	B-X
in	B-X
interleukin-10	B-X
(	B-X
IL-10	B-X
)	B-X
secretion	B-X
when	B-X
compared	B-X
to	B-X
LPS-stimulated	B-X
control	B-X
cells	B-X
(	B-X

RAW	O
264	O
.	O
7	O
cells	O
were	O
seeded	O
in	O
12	O
-	O
well	O
plates	O
in	O
RPMI	O
medium	O
containing	O
5	O
%	O
FBS	O
one	O
day	O
prior	O
to	O
transfection	O
,	O
Secreted	O
alkaline	O
phosphatase	O
(	O
SEAP	O
)	O
reporter	O
plasmids	O
pTAL	O
-	O
SEAP	O
or	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
were	O
transfected	O
into	O
cells	O
using	O
Qiagene	O
Effectene	O
or	O
Attractene	O
transfection	O
kit	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

For	O
co	O
-	O
transfection	O
studies	O
,	O
PKCalpha	B-Protein
or	O
NF	O
-	O
kappaB	O
p65	B-Protein
constructs	O
were	O
mixed	O
at	O
a	O
ratio	O
of	O
5	O
:	O
1	O
with	O
the	O
reporter	O
plasmid	O
.	O
<EOS>	B-X
Two-photon-excitation	B-X
fluorescence	B-X
lifetime	B-X
imaging	B-X
(	B-X
2P-FLIM	B-X
)	B-X
was	B-X
used	B-X
to	B-X
investigate	B-X
the	B-X
association	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
alpha	B-X
(	B-X
PKCalpha	B-X
)	B-X
with	B-X
caveolin	B-X
in	B-X
CHO	B-X
cells	B-X
.	B-X
PKCalpha	B-X
is	B-X
found	B-X
widely	B-X
in	B-X
the	B-X
cytoplasm	B-X
and	B-X
nucleus	B-X
in	B-X
most	B-X
cells	B-X
.	B-X
Upon	B-X
activation	B-X
,	B-X
as	B-X
a	B-X
result	B-X
of	B-X
increased	B-X
intracellular	B-X
Ca2+	B-X
and	B-X
production	B-X
of	B-X
DAG	B-X
,	B-X
through	B-X
G-protein	B-X
coupled-phospholipase	B-X
C	B-X
signalling	B-X
,	B-X
PKC	B-X
translocates	B-X
to	B-X
a	B-X
variety	B-X
of	B-X
regions	B-X
in	B-X
the	B-X
cell	B-X
where	B-X
it	B-X
phosphorylates	B-X
and	B-X
interacts	B-X
with	B-X
many	B-X
signalling	B-X
pathways	B-X
.	B-X
Activation	B-X
of	B-X
conventional	B-X
PKCs	B-X
(	B-X
cPKC	B-X
)	B-X
is	B-X
a	B-X
key	B-X
signaling	B-X
that	B-X
directs	B-X
the	B-X
cardiac	B-X
toxicity	B-X
of	B-X
hyperglycemia	B-X
.	B-X
AKAP150	B-X
,	B-X
a	B-X
scaffold	B-X
protein	B-X
of	B-X
the	B-X
A-kinase	B-X
anchoring	B-X
proteins	B-X
(	B-X
AKAPs	B-X
)	B-X
family	B-X
,	B-X
is	B-X
less	B-X
defined	B-X
regarding	B-X
its	B-X
capability	B-X
to	B-X
anchor	B-X
and	B-X
regulate	B-X
cardiac	B-X
cPKC	B-X
signaling	B-X
.	B-X
This	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
AKAP150	B-X
in	B-X
cPKC-mediated	B-X
cardiac	B-X
glucotoxicity	B-X
.	B-X
In	B-X
cardiac	B-X
tissues	B-X
from	B-X
streptozotocin-induced	B-X
diabetic	B-X
rats	B-X
and	B-X
high-glucose-treated	B-X
neonatal	B-X
rat	B-X
cardiomyocytes	B-X
,	B-X
both	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
of	B-X
AKAP150	B-X
increased	B-X
significantly	B-X
,	B-X
and	B-X
marked	B-X
elevations	B-X
were	B-X
observed	B-X
in	B-X
cPKC	B-X
activity	B-X
and	B-X
both	B-X
expression	B-X
and	B-X
phosphorylation	B-X
levels	B-X
of	B-X
p65	B-X
NF-κB	B-X
and	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
.	B-X
AKAP150	B-X
knockdown	B-X
was	B-X
established	B-X
via	B-X
intramyocardial	B-X
injection	B-X
in	B-X
vivo	B-X
and	B-X
transfection	B-X
in	B-X
vitro	B-X
of	B-X
adenovirus	B-X
carrying	B-X
AKAP150-targeted	B-X
shRNA	B-X
.	B-X
Downregulation	B-X
of	B-X
AKAP150	B-X
reversed	B-X
diabetes-induced	B-X
diastolic	B-X
dysfunction	B-X
as	B-X
manifested	B-X
by	B-X
decreased	B-X
left	B-X
ventricular	B-X
end-diastolic	B-X
diameter	B-X
and	B-X
early/late	B-X
mitral	B-X
diastolic	B-X
wave	B-X
ratio	B-X
.	B-X
AKAP150	B-X
inhibition	B-X
also	B-X
abrogated	B-X
high-glucose-induced	B-X
cardiomyocyte	B-X
apoptosis	B-X
(	B-X
TUNEL	B-X
staining	B-X
and	B-X
annexin	B-X
V/propidium	B-X
iodide	B-X
flow	B-X
cytometry	B-X
)	B-X
and	B-X
oxidative	B-X
stress	B-X
(	B-X
ROS	B-X
production	B-X
,	B-X
NADPH	B-X
oxidase	B-X
activity	B-X
,	B-X
and	B-X
lipid	B-X
peroxidation	B-X
)	B-X
.	B-X
More	B-X
importantly	B-X
,	B-X
reduced	B-X
AKAP150	B-X
expression	B-X
significantly	B-X
inhibited	B-X
high-glucose-induced	B-X
membrane	B-X
translocation	B-X
and	B-X
activation	B-X
of	B-X
cPKC	B-X
and	B-X
suppressed	B-X
the	B-X
increases	B-X
in	B-X
the	B-X
phosphorylation	B-X
of	B-X
p65	B-X
NF-κB	B-X
and	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
.	B-X
Immunofluorescent	B-X
coexpression	B-X
and	B-X
immunoprecipitation	B-X
indicated	B-X
enhanced	B-X
anchoring	B-X
of	B-X
AKAP150	B-X
with	B-X
cPKC	B-X
within	B-X
the	B-X
plasma	B-X
membrane	B-X
under	B-X
hyperglycemia	B-X
,	B-X
and	B-X
AKAP150	B-X
preferentially	B-X
colocalized	B-X
and	B-X
functionally	B-X
bound	B-X
with	B-X
PKCα	B-X
and	B-X
-β	B-X
isoforms	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
cardiac	B-X
AKAP150	B-X
positively	B-X
responds	B-X
to	B-X
hyperglycemia	B-X
and	B-X
enhances	B-X
the	B-X
efficiency	B-X
of	B-X
glucotoxicity	B-X
signaling	B-X
through	B-X
a	B-X
cPKC/p47	B-X
(	B-X
phox	B-X
)	B-X
/ROS	B-X
pathway	B-X
that	B-X
induces	B-X
myocardial	B-X
dysfunction	B-X
,	B-X
cardiomyocyte	B-X
apoptosis	B-X
,	B-X
and	B-X
oxidative	B-X
stress	B-X
.	B-X

For	O
siRNA	O
transfection	O
,	O
100	O
nM	O
of	O
PKCalpha	B-Protein
siRNA	I-Protein
or	O
control	O
siRNA	O
were	O
used	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
many	B-X
preclinical	B-X
and	B-X
clinical	B-X
studies	B-X
,	B-X
including	B-X
the	B-X
siRNA-LNP	B-X
product	B-X
,	B-X
Onpattro®	B-X
,	B-X
highlight	B-X
that	B-X
LNPs	B-X
unlock	B-X
the	B-X
potential	B-X
of	B-X
nucleic	B-X
acid-based	B-X
therapies	B-X
and	B-X
vaccines	B-X
.	B-X
This	B-X
included	B-X
designing	B-X
better	B-X
methods	B-X
for	B-X
the	B-X
successful	B-X
delivery	B-X
of	B-X
small	B-X
interfering	B-X
RNAs	B-X
(	B-X
siRNAs	B-X
)	B-X
and	B-X
short	B-X
hairpin	B-X
RNAs	B-X
(	B-X
shRNAs	B-X
)	B-X
into	B-X
mammalian	B-X
cells	B-X
.	B-X
While	B-X
the	B-X
simplest	B-X
method	B-X
for	B-X
RNAi	B-X
is	B-X
the	B-X
cytosolic	B-X
delivery	B-X
of	B-X
siRNA	B-X
oligonucleotides	B-X
,	B-X
this	B-X
technique	B-X
is	B-X
limited	B-X
to	B-X
cells	B-X
capable	B-X
of	B-X
transfection	B-X
and	B-X
is	B-X
primarily	B-X
utilized	B-X
during	B-X
transient	B-X
in	B-X
vitro	B-X
studies	B-X
.	B-X
We	B-X
provide	B-X
suggestions	B-X
for	B-X
designing	B-X
shRNA	B-X
targets	B-X
and	B-X
controls	B-X
,	B-X
a	B-X
protocol	B-X
for	B-X
sequencing	B-X
through	B-X
the	B-X
secondary	B-X
structure	B-X
of	B-X
the	B-X
shRNA	B-X
hairpin	B-X
structure	B-X
,	B-X
and	B-X
protocols	B-X
for	B-X
packaging	B-X
and	B-X
delivery	B-X
of	B-X
shRNA	B-X
lentiviral	B-X
particles	B-X
.	B-X
These	B-X
studies	B-X
demonstrate	B-X
the	B-X
practicality	B-X
of	B-X
including	B-X
two	B-X
shRNAs	B-X
with	B-X
different	B-X
efficacies	B-X
of	B-X
knockdown	B-X
to	B-X
provide	B-X
an	B-X
additional	B-X
level	B-X
of	B-X
control	B-X
and	B-X
to	B-X
verify	B-X
dose	B-X
dependency	B-X
of	B-X
functional	B-X
effects	B-X
.	B-X

Cells	O
were	O
incubated	O
with	O
the	O
transfection	O
reagents	O
for	O
16	O
-	O
24	O
hours	O
,	O
washed	O
and	O
starved	O
in	O
RPMI	O
without	O
FBS	O
for	O
4	O
hours	O
.	O

Samples	O
were	O
then	O
stimulated	O
with	O
100	O
ng	O
/	O
ml	O
M	O
-	O
CSF	O
for	O
4	O
hours	O
at	O
which	O
point	O
the	O
medium	O
was	O
collected	O
for	O
the	O
SEAP	O
analysis	O
.	O

For	O
inhibition	O
studies	O
,	O
cells	O
were	O
pre	O
-	O
incubated	O
with	O
inhibitors	O
for	O
30	O
minutes	O
before	O
M	O
-	O
CSF	O
treatment	O
.	O

On	O
average	O
,	O
we	O
realized	O
30	O
-	O
40	O
%	O
transfection	O
efficiency	O
as	O
confirmed	O
by	O
GFP	B-Protein
expression	O
in	O
Raw	O
264	O
.	O
7	O
cells	O
.	O

Transient	O
Transfection	O
of	O
Primary	O
Human	O
Monocytes	O
<EOS>	B-X
Transient	B-X
transfection	B-X
experiments	B-X
analyzing	B-X
the	B-X
function	B-X
of	B-X
SHIP	B-X
indicated	B-X
that	B-X
overexpression	B-X
of	B-X
a	B-X
wild-type	B-X
SHIP	B-X
,	B-X
but	B-X
not	B-X
the	B-X
SHIP	B-X
Src	B-X
homology	B-X
2	B-X
domain-lacking	B-X
catalytic	B-X
activity	B-X
,	B-X
up-regulates	B-X
NF-kappaB-dependent	B-X
gene	B-X
transcription	B-X
in	B-X
response	B-X
to	B-X
LPS	B-X
stimulation	B-X
.	B-X
Monocytes	B-X
are	B-X
critical	B-X
precursors	B-X
of	B-X
dendritic	B-X
cells	B-X
and	B-X
macrophages	B-X
,	B-X
which	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
.	B-X
Transfection	B-X
of	B-X
monocytes	B-X
by	B-X
nucleofection	B-X
with	B-X
HIV-1	B-X
proviral	B-X
DNA	B-X
could	B-X
not	B-X
produce	B-X
infectious	B-X
HIV-1	B-X
.	B-X
Transient	B-X
expression	B-X
of	B-X
CycT1	B-X
in	B-X
undifferentiated	B-X
monocytes	B-X
could	B-X
not	B-X
rescue	B-X
Tat	B-X
transactivation	B-X
,	B-X
suggesting	B-X
that	B-X
CycT1	B-X
is	B-X
not	B-X
the	B-X
only	B-X
limiting	B-X
factor	B-X
of	B-X
HIV-1	B-X
infection	B-X
in	B-X
monocytes	B-X
.	B-X

Monocytes	O
were	O
transfected	O
using	O
the	O
human	O
monocyte	O
Amaxa	O
nucleofector	O
kit	O
(	O
Lonza	O
Walkersville	O
Inc	O
,	O
Walkersville	O
,	O
MD	O
)	O
as	O
previously	O
described	O
[	O
51	O
]	O
.	O

Briefly	O
,	O
monocytes	O
were	O
resuspended	O
in	O
Amaxa	O
Nucleofactor	O
solution	O
at	O
a	O
density	O
of	O
20x106	O
cells	O
/	O
ml	O
,	O
and	O
2	O
microg	O
of	O
total	O
plasmid	O
DNA	O
100	O
nM	O
of	O
PKCalpha	B-Protein
siRNA	I-Protein
or	O
control	O
siRNA	O
was	O
added	O
and	O
transfected	O
using	O
program	O
Amaxa	O
Y	O
-	O
01	O
.	O

For	O
co	O
-	O
transfection	O
studies	O
,	O
PKCalpha	B-Protein
or	O
NF	O
-	O
kappaB	O
p65	B-Protein
constructs	O
were	O
mixed	O
at	O
a	O
ratio	O
of	O
5	O
:	O
1	O
with	O
the	O
reporter	O
plasmid	O
.	O
<EOS>	B-X
Two-photon-excitation	B-X
fluorescence	B-X
lifetime	B-X
imaging	B-X
(	B-X
2P-FLIM	B-X
)	B-X
was	B-X
used	B-X
to	B-X
investigate	B-X
the	B-X
association	B-X
of	B-X
protein	B-X
kinase	B-X
C	B-X
alpha	B-X
(	B-X
PKCalpha	B-X
)	B-X
with	B-X
caveolin	B-X
in	B-X
CHO	B-X
cells	B-X
.	B-X
PKCalpha	B-X
is	B-X
found	B-X
widely	B-X
in	B-X
the	B-X
cytoplasm	B-X
and	B-X
nucleus	B-X
in	B-X
most	B-X
cells	B-X
.	B-X
Upon	B-X
activation	B-X
,	B-X
as	B-X
a	B-X
result	B-X
of	B-X
increased	B-X
intracellular	B-X
Ca2+	B-X
and	B-X
production	B-X
of	B-X
DAG	B-X
,	B-X
through	B-X
G-protein	B-X
coupled-phospholipase	B-X
C	B-X
signalling	B-X
,	B-X
PKC	B-X
translocates	B-X
to	B-X
a	B-X
variety	B-X
of	B-X
regions	B-X
in	B-X
the	B-X
cell	B-X
where	B-X
it	B-X
phosphorylates	B-X
and	B-X
interacts	B-X
with	B-X
many	B-X
signalling	B-X
pathways	B-X
.	B-X
Activation	B-X
of	B-X
conventional	B-X
PKCs	B-X
(	B-X
cPKC	B-X
)	B-X
is	B-X
a	B-X
key	B-X
signaling	B-X
that	B-X
directs	B-X
the	B-X
cardiac	B-X
toxicity	B-X
of	B-X
hyperglycemia	B-X
.	B-X
AKAP150	B-X
,	B-X
a	B-X
scaffold	B-X
protein	B-X
of	B-X
the	B-X
A-kinase	B-X
anchoring	B-X
proteins	B-X
(	B-X
AKAPs	B-X
)	B-X
family	B-X
,	B-X
is	B-X
less	B-X
defined	B-X
regarding	B-X
its	B-X
capability	B-X
to	B-X
anchor	B-X
and	B-X
regulate	B-X
cardiac	B-X
cPKC	B-X
signaling	B-X
.	B-X
This	B-X
study	B-X
was	B-X
designed	B-X
to	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
AKAP150	B-X
in	B-X
cPKC-mediated	B-X
cardiac	B-X
glucotoxicity	B-X
.	B-X
In	B-X
cardiac	B-X
tissues	B-X
from	B-X
streptozotocin-induced	B-X
diabetic	B-X
rats	B-X
and	B-X
high-glucose-treated	B-X
neonatal	B-X
rat	B-X
cardiomyocytes	B-X
,	B-X
both	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
of	B-X
AKAP150	B-X
increased	B-X
significantly	B-X
,	B-X
and	B-X
marked	B-X
elevations	B-X
were	B-X
observed	B-X
in	B-X
cPKC	B-X
activity	B-X
and	B-X
both	B-X
expression	B-X
and	B-X
phosphorylation	B-X
levels	B-X
of	B-X
p65	B-X
NF-κB	B-X
and	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
.	B-X
AKAP150	B-X
knockdown	B-X
was	B-X
established	B-X
via	B-X
intramyocardial	B-X
injection	B-X
in	B-X
vivo	B-X
and	B-X
transfection	B-X
in	B-X
vitro	B-X
of	B-X
adenovirus	B-X
carrying	B-X
AKAP150-targeted	B-X
shRNA	B-X
.	B-X
Downregulation	B-X
of	B-X
AKAP150	B-X
reversed	B-X
diabetes-induced	B-X
diastolic	B-X
dysfunction	B-X
as	B-X
manifested	B-X
by	B-X
decreased	B-X
left	B-X
ventricular	B-X
end-diastolic	B-X
diameter	B-X
and	B-X
early/late	B-X
mitral	B-X
diastolic	B-X
wave	B-X
ratio	B-X
.	B-X
AKAP150	B-X
inhibition	B-X
also	B-X
abrogated	B-X
high-glucose-induced	B-X
cardiomyocyte	B-X
apoptosis	B-X
(	B-X
TUNEL	B-X
staining	B-X
and	B-X
annexin	B-X
V/propidium	B-X
iodide	B-X
flow	B-X
cytometry	B-X
)	B-X
and	B-X
oxidative	B-X
stress	B-X
(	B-X
ROS	B-X
production	B-X
,	B-X
NADPH	B-X
oxidase	B-X
activity	B-X
,	B-X
and	B-X
lipid	B-X
peroxidation	B-X
)	B-X
.	B-X
More	B-X
importantly	B-X
,	B-X
reduced	B-X
AKAP150	B-X
expression	B-X
significantly	B-X
inhibited	B-X
high-glucose-induced	B-X
membrane	B-X
translocation	B-X
and	B-X
activation	B-X
of	B-X
cPKC	B-X
and	B-X
suppressed	B-X
the	B-X
increases	B-X
in	B-X
the	B-X
phosphorylation	B-X
of	B-X
p65	B-X
NF-κB	B-X
and	B-X
p47	B-X
(	B-X
phox	B-X
)	B-X
.	B-X
Immunofluorescent	B-X
coexpression	B-X
and	B-X
immunoprecipitation	B-X
indicated	B-X
enhanced	B-X
anchoring	B-X
of	B-X
AKAP150	B-X
with	B-X
cPKC	B-X
within	B-X
the	B-X
plasma	B-X
membrane	B-X
under	B-X
hyperglycemia	B-X
,	B-X
and	B-X
AKAP150	B-X
preferentially	B-X
colocalized	B-X
and	B-X
functionally	B-X
bound	B-X
with	B-X
PKCα	B-X
and	B-X
-β	B-X
isoforms	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
cardiac	B-X
AKAP150	B-X
positively	B-X
responds	B-X
to	B-X
hyperglycemia	B-X
and	B-X
enhances	B-X
the	B-X
efficiency	B-X
of	B-X
glucotoxicity	B-X
signaling	B-X
through	B-X
a	B-X
cPKC/p47	B-X
(	B-X
phox	B-X
)	B-X
/ROS	B-X
pathway	B-X
that	B-X
induces	B-X
myocardial	B-X
dysfunction	B-X
,	B-X
cardiomyocyte	B-X
apoptosis	B-X
,	B-X
and	B-X
oxidative	B-X
stress	B-X
.	B-X

Immediately	O
after	O
transfection	O
,	O
cells	O
were	O
washed	O
with	O
1	O
ml	O
of	O
RPMI	O
medium	O
containing	O
2	O
mM	O
glutamine	O
and	O
10	O
%	O
FBS	O
or	O
serum	O
free	O
LGM	O
medium	O
(	O
Lonza	O
Walkersville	O
Inc	O
.	O
)	O
then	O
plated	O
at	O
4x105	O
cells	O
/	O
well	O
in	O
24	O
-	O
well	O
plates	O
.	O

The	O
original	O
medium	O
was	O
replaced	O
by	O
serum	O
free	O
LGM	O
medium	O
without	O
or	O
with	O
M	O
-	O
CSF	O
(	O
100	O
ng	O
/	O
ml	O
)	O
one	O
hour	O
later	O
.	O

The	O
next	O
day	O
,	O
cell	O
-	O
free	O
supernatants	O
were	O
collected	O
for	O
the	O
SEAP	O
analysis	O
.	O

Cells	O
were	O
stained	O
with	O
Annexin	B-Protein
V	I-Protein
/	O
propidium	O
iodide	O
(	O
PI	O
)	O
.	O
<EOS>	B-X
Annexin	B-X
V	B-X
,	B-X
a	B-X
36-kDa	B-X
calcium-binding	B-X
protein	B-X
,	B-X
binds	B-X
to	B-X
PS	B-X
;	B-X
therefore	B-X
,	B-X
fluorescently	B-X
labeled	B-X
Annexin	B-X
V	B-X
can	B-X
be	B-X
used	B-X
to	B-X
detect	B-X
PS	B-X
that	B-X
is	B-X
exposed	B-X
on	B-X
the	B-X
outside	B-X
of	B-X
apoptotic	B-X
cells	B-X
.	B-X
Annexin	B-X
V	B-X
can	B-X
also	B-X
stain	B-X
necrotic	B-X
cells	B-X
because	B-X
these	B-X
cells	B-X
have	B-X
ruptured	B-X
membranes	B-X
that	B-X
permit	B-X
Annexin	B-X
V	B-X
to	B-X
access	B-X
the	B-X
entire	B-X
plasma	B-X
membrane	B-X
.	B-X
However	B-X
,	B-X
apoptotic	B-X
cells	B-X
can	B-X
be	B-X
distinguished	B-X
from	B-X
necrotic	B-X
cells	B-X
by	B-X
co-staining	B-X
with	B-X
propidium	B-X
iodide	B-X
(	B-X
PI	B-X
)	B-X
because	B-X
PI	B-X
enters	B-X
necrotic	B-X
cells	B-X
but	B-X
is	B-X
excluded	B-X
from	B-X
apoptotic	B-X
cells	B-X
.	B-X
This	B-X
protocol	B-X
describes	B-X
Annexin	B-X
V	B-X
binding	B-X
and	B-X
PI	B-X
uptake	B-X
followed	B-X
by	B-X
flow	B-X
cytometry	B-X
to	B-X
detect	B-X
and	B-X
quantify	B-X
apoptotic	B-X
and	B-X
necrotic	B-X
cells	B-X
.	B-X

For	O
the	O
inhibition	O
studies	O
,	O
cells	O
were	O
pre	O
-	O
incubated	O
with	O
inhibitor	O
for	O
30	O
minutes	O
in	O
X	O
-	O
vivo	O
medium	O
prior	O
to	O
the	O
addition	O
of	O
M	O
-	O
CSF	O
.	O

Secreted	O
Alkaline	O
Phosphatase	O
(	O
SEAP	O
)	O
Analysis	O
<EOS>	B-X
Here	B-X
we	B-X
report	B-X
an	B-X
improved	B-X
method	B-X
of	B-X
the	B-X
use	B-X
of	B-X
genetically	B-X
modified	B-X
,	B-X
secreted	B-X
alkaline	B-X
phosphatase	B-X
(	B-X
SEAP	B-X
)	B-X
as	B-X
a	B-X
reporter	B-X
glycoprotein	B-X
which	B-X
may	B-X
be	B-X
used	B-X
for	B-X
glycoanalysis	B-X
.	B-X
An	B-X
improved	B-X
purification	B-X
protocol	B-X
of	B-X
recombinant	B-X
SEAP	B-X
from	B-X
serum	B-X
or	B-X
serum-free	B-X
media	B-X
is	B-X
also	B-X
proposed	B-X
.	B-X
As	B-X
a	B-X
result	B-X
,	B-X
purified	B-X
SEAP	B-X
was	B-X
ready	B-X
for	B-X
enzymatic	B-X
de-glycosylation	B-X
without	B-X
buffer	B-X
exchange	B-X
,	B-X
sample	B-X
volume	B-X
reductions	B-X
or	B-X
other	B-X
procedures	B-X
,	B-X
which	B-X
are	B-X
usually	B-X
time-consuming	B-X
and	B-X
may	B-X
cause	B-X
partial	B-X
loss	B-X
of	B-X
the	B-X
reporter	B-X
glycoprotein	B-X
.	B-X
A	B-X
BacMam	B-X
baculovirus	B-X
was	B-X
designed	B-X
in	B-X
our	B-X
laboratory	B-X
to	B-X
express	B-X
the	B-X
reporter	B-X
protein	B-X
secreted	B-X
alkaline	B-X
phosphatase	B-X
(	B-X
SEAP	B-X
)	B-X
driven	B-X
by	B-X
the	B-X
immediate	B-X
early	B-X
promoter	B-X
of	B-X
human	B-X
cytomegalovirus	B-X
promoter	B-X
(	B-X
CMV	B-X
)	B-X
.	B-X
Initial	B-X
studies	B-X
clearly	B-X
demonstrated	B-X
that	B-X
the	B-X
transient	B-X
expression	B-X
of	B-X
SEAP	B-X
was	B-X
at	B-X
least	B-X
10-fold	B-X
higher	B-X
in	B-X
the	B-X
HEK	B-X
293	B-X
cells	B-X
than	B-X
the	B-X
CHO	B-X
cells	B-X
under	B-X
equivalent	B-X
experimental	B-X
conditions	B-X
.	B-X

Secreted	O
alkaline	O
phosphatase	O
activity	O
was	O
analyzed	O
by	O
GreatEscape	O
SEAP	O
kit	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
.	O

Briefly	O
,	O
medium	O
was	O
diluted	O
in	O
the	O
dilution	O
buffer	O
and	O
heated	O
to	O
65degreesC	O
to	O
inactivate	O
endogenous	O
phosphatases	O
then	O
incubated	O
with	O
the	O
substrate	O
for	O
30	O
minutes	O
.	O

The	O
chemiluminence	O
signal	O
was	O
recorded	O
using	O
a	O
luminometer	O
.	O

Annexin	B-Protein
V	I-Protein
/	O
PI	O
Apoptosis	O
Assay	O
<EOS>	B-X
Propidium	B-X
iodide	B-X
(	B-X
PI	B-X
)	B-X
is	B-X
widely	B-X
used	B-X
in	B-X
conjunction	B-X
with	B-X
Annexin	B-X
V	B-X
to	B-X
determine	B-X
if	B-X
cells	B-X
are	B-X
viable	B-X
,	B-X
apoptotic	B-X
,	B-X
or	B-X
necrotic	B-X
through	B-X
differences	B-X
in	B-X
plasma	B-X
membrane	B-X
integrity	B-X
and	B-X
permeability	B-X
.	B-X
The	B-X
Annexin	B-X
V/PI	B-X
protocol	B-X
is	B-X
a	B-X
commonly	B-X
used	B-X
approach	B-X
for	B-X
studying	B-X
apoptotic	B-X
cells	B-X
.	B-X
PI	B-X
is	B-X
used	B-X
more	B-X
often	B-X
than	B-X
other	B-X
nuclear	B-X
stains	B-X
because	B-X
it	B-X
is	B-X
economical	B-X
,	B-X
stable	B-X
and	B-X
a	B-X
good	B-X
indicator	B-X
of	B-X
cell	B-X
viability	B-X
,	B-X
based	B-X
on	B-X
its	B-X
capacity	B-X
to	B-X
exclude	B-X
dye	B-X
in	B-X
living	B-X
cells	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
PI	B-X
to	B-X
enter	B-X
a	B-X
cell	B-X
is	B-X
dependent	B-X
upon	B-X
the	B-X
permeability	B-X
of	B-X
the	B-X
membrane	B-X
;	B-X
PI	B-X
does	B-X
not	B-X
stain	B-X
live	B-X
or	B-X
early	B-X
apoptotic	B-X
cells	B-X
due	B-X
to	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
intact	B-X
plasma	B-X
membrane	B-X
.	B-X
In	B-X
late	B-X
apoptotic	B-X
and	B-X
necrotic	B-X
cells	B-X
,	B-X
the	B-X
integrity	B-X
of	B-X
the	B-X
plasma	B-X
and	B-X
nuclear	B-X
membranes	B-X
decreases	B-X
,	B-X
allowing	B-X
PI	B-X
to	B-X
pass	B-X
through	B-X
the	B-X
membranes	B-X
,	B-X
intercalate	B-X
into	B-X
nucleic	B-X
acids	B-X
,	B-X
and	B-X
display	B-X
red	B-X
fluorescence	B-X
.	B-X
Unfortunately	B-X
,	B-X
we	B-X
find	B-X
that	B-X
conventional	B-X
Annexin	B-X
V/	B-X
PI	B-X
protocols	B-X
lead	B-X
to	B-X
a	B-X
significant	B-X
number	B-X
of	B-X
false	B-X
positive	B-X
events	B-X
(	B-X
up	B-X
to	B-X
40	B-X
%	B-X
)	B-X
,	B-X
which	B-X
are	B-X
associated	B-X
with	B-X
PI	B-X
staining	B-X
of	B-X
RNA	B-X
within	B-X
the	B-X
cytoplasmic	B-X
compartment	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
demonstrate	B-X
a	B-X
modified	B-X
Annexin	B-X
V/	B-X
PI	B-X
method	B-X
that	B-X
provides	B-X
a	B-X
significant	B-X
improvement	B-X
for	B-X
assessment	B-X
of	B-X
cell	B-X
death	B-X
compared	B-X
to	B-X
conventional	B-X
methods	B-X
.	B-X
The	B-X
result	B-X
is	B-X
a	B-X
significant	B-X
improvement	B-X
over	B-X
conventional	B-X
Annexin	B-X
V/	B-X
PI	B-X
protocols	B-X
(	B-X
<	B-X
5	B-X
%	B-X
events	B-X
with	B-X
cytoplasmic	B-X
PI	B-X
staining	B-X
)	B-X
.	B-X

Cell	O
apoptosis	O
assay	O
was	O
performed	O
as	O
described	O
previously	O
[	O
51	O
]	O
using	O
the	O
Annexin	B-Protein
V	I-Protein
-	O
FITC	O
apoptosis	O
detection	O
kit	O
(	O
BD	O
PharMingen	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

Briefly	O
,	O
human	O
monocytes	O
(	O
5x106	O
)	O
were	O
incubated	O
with	O
inhibitors	O
for	O
30	O
minutes	O
in	O
X	O
-	O
vivo	O
medium	O
and	O
restimulated	O
with	O
100	O
ng	O
/	O
ml	O
M	O
-	O
CSF	O
overnight	O
.	O

The	O
cells	O
were	O
removed	O
from	O
the	O
culture	O
dish	O
using	O
Accutase	O
(	O
eBioscience	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
and	O
stained	O
with	O
Annexin	B-Protein
V	I-Protein
-	O
FITC	O
and	O
PI	O
and	O
analyzed	O
by	O
flow	O
cytometry	O
(	O
FACSCalibur	O
;	O
BD	O
PharMingen	O
)	O
.	O

Annexin	B-Protein
V	I-Protein
-	O
FITC	O
and	O
PI	O
double	O
negative	O
cells	O
were	O
considered	O
non	O
-	O
apoptotic	O
cells	O
for	O
statistical	O
analysis	O
.	O

Western	O
Blot	O
Analysis	O
<EOS>	B-X
Like	B-X
with	B-X
any	B-X
other	B-X
technology	B-X
in	B-X
life-sciences	B-X
research	B-X
,	B-X
Western	B-X
blotting	B-X
can	B-X
produce	B-X
erroneous	B-X
and	B-X
irreproducible	B-X
data	B-X
.	B-X
We	B-X
provide	B-X
a	B-X
systematic	B-X
approach	B-X
to	B-X
generate	B-X
quantitative	B-X
data	B-X
from	B-X
Western	B-X
blot	B-X
experiments	B-X
that	B-X
incorporates	B-X
critical	B-X
validation	B-X
steps	B-X
to	B-X
identify	B-X
and	B-X
minimize	B-X
sources	B-X
of	B-X
error	B-X
and	B-X
variability	B-X
throughout	B-X
the	B-X
Western	B-X
blot	B-X
process	B-X
.	B-X
Biochemical	B-X
approaches	B-X
,	B-X
including	B-X
Western	B-X
blot	B-X
analysis	B-X
,	B-X
have	B-X
emerged	B-X
as	B-X
a	B-X
powerful	B-X
tool	B-X
in	B-X
C.	B-X
elegans	B-X
biology	B-X
for	B-X
understanding	B-X
molecular	B-X
mechanisms	B-X
that	B-X
link	B-X
genotypes	B-X
to	B-X
phenotypes	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
provide	B-X
a	B-X
protocol	B-X
for	B-X
Western	B-X
blot	B-X
analysis	B-X
using	B-X
protein	B-X
extracts	B-X
obtained	B-X
from	B-X
C.	B-X
elegans	B-X
samples	B-X
.	B-X

Cells	O
were	O
washed	O
with	O
PBS	O
and	O
resuspended	O
in	O
cell	O
lysis	O
buffer	O
.	O

(	O
Cell	O
Signaling	O
Technology	O
)	O
and	O
incubated	O
for	O
10	O
minutes	O
on	O
ice	O
then	O
centrifuged	O
to	O
remove	O
the	O
insoluble	O
fraction	O
.	O

The	O
protein	O
concentration	O
was	O
determined	O
by	O
the	O
BCA	O
protein	O
assay	O
(	O
Bio	O
-	O
Rad	O
,	O
Hercules	O
,	O
CA	O
)	O
.	O

Cell	O
lysates	O
were	O
separated	O
by	O
SDS	O
-	O
PAGE	O
on	O
10	O
%	O
polyacrylamide	O
gels	O
and	O
then	O
transferred	O
onto	O
nitrocellulose	O
membranes	O
and	O
subjected	O
to	O
Western	O
blotting	O
.	O

The	O
immunoblotted	O
proteins	O
were	O
detected	O
by	O
ECL	O
reagent	O
(	O
GE	O
Healthcare	O
Bio	O
-	O
Sciences	O
Corp	O
.	O
,	O
Piscataway	O
,	O
NJ	O
)	O
.	O

Analysis	O
of	O
PKCalpha	B-Protein
Kinase	O
Activity	O
<EOS>	B-X
Analysis	B-X
of	B-X
hippocampal	B-X
neurons	B-X
from	B-X
PKCα	B-X
M489V	B-X
mice	B-X
reveals	B-X
enhanced	B-X
amyloid-β-induced	B-X
synaptic	B-X
depression	B-X
and	B-X
reduced	B-X
spine	B-X
density	B-X
compared	B-X
to	B-X
wild-type	B-X
mice	B-X
.	B-X
In	B-X
this	B-X
article	B-X
we	B-X
show	B-X
that	B-X
PKCzeta	B-X
but	B-X
not	B-X
PKCalpha	B-X
and	B-X
PKCdelta	B-X
can	B-X
co-immunoprecipitate	B-X
PKB	B-X
from	B-X
CHO	B-X
cell	B-X
lysates	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
activities	B-X
of	B-X
the	B-X
interacting	B-X
kinases	B-X
showed	B-X
that	B-X
PDGF-induced	B-X
activation	B-X
of	B-X
PKCzeta	B-X
was	B-X
not	B-X
affected	B-X
by	B-X
co-expression	B-X
of	B-X
PKB	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
demonstrate	B-X
using	B-X
genetic	B-X
analysis	B-X
,	B-X
pharmacological	B-X
inhibition	B-X
,	B-X
and	B-X
RNA	B-X
interference	B-X
(	B-X
RNAi	B-X
)	B-X
that	B-X
the	B-X
conventional	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
isoform	B-X
PKCalpha	B-X
,	B-X
but	B-X
not	B-X
PKCbeta1	B-X
,	B-X
is	B-X
required	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
IKK	B-X
complex	B-X
following	B-X
T-cell	B-X
activation	B-X
triggered	B-X
by	B-X
CD3/CD28	B-X
cross-linking	B-X
.	B-X
We	B-X
find	B-X
that	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
influx	B-X
,	B-X
the	B-X
catalytically	B-X
active	B-X
PKCalphaA25E	B-X
induces	B-X
IKK	B-X
activity	B-X
and	B-X
NF-kappaB-dependent	B-X
transcription	B-X
;	B-X
which	B-X
is	B-X
abrogated	B-X
following	B-X
the	B-X
mutations	B-X
of	B-X
two	B-X
aspartates	B-X
at	B-X
positions	B-X
246	B-X
and	B-X
248	B-X
,	B-X
which	B-X
are	B-X
required	B-X
for	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
binding	B-X
to	B-X
PKCalpha	B-X
and	B-X
cell	B-X
membrane	B-X
recruitment	B-X
.	B-X
Kinetic	B-X
studies	B-X
reveal	B-X
that	B-X
an	B-X
early	B-X
phase	B-X
(	B-X
1	B-X
to	B-X
5	B-X
min	B-X
)	B-X
of	B-X
IKK	B-X
activation	B-X
following	B-X
TCR/CD28	B-X
cross-linking	B-X
is	B-X
PKCalpha	B-X
dependent	B-X
and	B-X
that	B-X
a	B-X
later	B-X
phase	B-X
(	B-X
5	B-X
to	B-X
25	B-X
min	B-X
)	B-X
of	B-X
IKK	B-X
activation	B-X
is	B-X
PKCtheta	B-X
dependent	B-X
.	B-X
Activation	B-X
of	B-X
IKK-	B-X
and	B-X
NF-kappaB-dependent	B-X
transcription	B-X
by	B-X
PKCalphaA25E	B-X
is	B-X
abrogated	B-X
by	B-X
the	B-X
PKCtheta	B-X
inhibitor	B-X
rottlerin	B-X
or	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
kinase-inactive	B-X
form	B-X
of	B-X
PKCtheta	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
PKCalpha	B-X
acts	B-X
upstream	B-X
of	B-X
PKCtheta	B-X
to	B-X
activate	B-X
the	B-X
IKK	B-X
complex	B-X
and	B-X
NF-kappaB	B-X
in	B-X
T	B-X
lymphocytes	B-X
following	B-X
TCR	B-X
activation	B-X
.	B-X

Human	O
MDMs	O
were	O
starved	O
for	O
2	O
hours	O
before	O
stimulation	O
with	O
M	O
-	O
CSF	O
(	O
0	O
-	O
60	O
minutes	O
)	O
,	O
then	O
washed	O
with	O
cold	O
PBS	O
and	O
removed	O
from	O
the	O
plates	O
.	O

The	O
cells	O
were	O
resuspended	O
in	O
lysis	O
buffer	O
(	O
20	O
mM	O
Tris	O
,	O
5	O
mM	O
MgCl2	O
,	O
1	O
mM	O
EGTA	O
,	O
20	O
mM	O
beta	O
-	O
glycerol	O
phosphate	O
,	O
1	O
mM	O
PMSF	O
2	O
microg	O
/	O
ml	O
aprotinin	O
and	O
2	O
microg	O
/	O
ml	O
leupeptin	O
,	O
pH	O
7	O
.	O
5	O
)	O
,	O
sonicated	O
and	O
centrifuged	O
to	O
obtain	O
whole	O
cell	O
lysates	O
,	O
which	O
were	O
then	O
immunoprecipitated	O
with	O
anti	O
-	O
PKCalpha	O
antibody	O
and	O
protein	O
G	O
-	O
agarose	O
(	O
Invitrogen	O
)	O
.	O

Immune	O
complexes	O
were	O
washed	O
twice	O
,	O
and	O
PKCalpha	B-Protein
activity	O
was	O
analyzed	O
by	O
non	O
-	O
radioactive	O
Peptag	O
assay	O
kit	O
(	O
Promega	O
)	O
.	O

Briefly	O
,	O
kinase	O
buffer	O
,	O
activator	O
,	O
peptide	O
protection	O
solution	O
and	O
Peptag	O
peptide	O
were	O
incubated	O
with	O
the	O
immune	O
complexes	O
at	O
30degreesC	O
for	O
30	O
minutes	O
.	O

Reactions	O
were	O
stopped	O
by	O
boiling	O
for	O
10	O
minutes	O
and	O
samples	O
were	O
separated	O
on	O
0	O
.	O
8	O
%	O
agarose	O
gel	O
.	O

Phosphorylated	O
peptide	O
migrated	O
toward	O
the	O
anode	O
(	O
+	O
)	O
,	O
while	O
non	O
-	O
phosphorylated	O
peptide	O
migrated	O
toward	O
the	O
cathode	O
(	O
-	O
)	O
.	O
<EOS>	B-X
The	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
is	B-X
to	B-X
report	B-X
the	B-X
development	B-X
of	B-X
a	B-X
non-radioactive	B-X
fluorescent	B-X
peptide	B-X
assay	B-X
for	B-X
measuring	B-X
protein	B-X
kinase	B-X
C	B-X
activity	B-X
(	B-X
PKC	B-X
)	B-X
.	B-X
The	B-X
assay	B-X
is	B-X
based	B-X
on	B-X
a	B-X
glycogen	B-X
synthase	B-X
derived	B-X
fluorescent	B-X
peptide	B-X
that	B-X
is	B-X
phosphorylated	B-X
by	B-X
PKC	B-X
.	B-X
Phosphorylation	B-X
causes	B-X
the	B-X
peptide	B-X
to	B-X
migrate	B-X
toward	B-X
the	B-X
anode	B-X
while	B-X
the	B-X
non-phosphorylated	B-X
peptide	B-X
migrates	B-X
toward	B-X
the	B-X
cathode	B-X
during	B-X
agarose	B-X
gel	B-X
electrophoresis	B-X
.	B-X
An	B-X
apparent	B-X
KM	B-X
value	B-X
of	B-X
40	B-X
microM	B-X
was	B-X
obtained	B-X
for	B-X
the	B-X
fluorescent	B-X
peptide	B-X
substrate	B-X
with	B-X
a	B-X
control	B-X
Vmax	B-X
value	B-X
of	B-X
300	B-X
pmol/min	B-X
.	B-X

Fluorescein	O
-	O
tagged	O
peptides	O
were	O
visualized	O
by	O
UV	O
light	O
.	O

RNA	O
Isolation	O
and	O
Quantitative	O
Real	O
-	O
time	O
PCR	O
<EOS>	B-X
Quantitative	B-X
real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
QRT-PCR	B-X
)	B-X
has	B-X
become	B-X
an	B-X
extensively	B-X
applied	B-X
technique	B-X
.	B-X
Nowadays	B-X
,	B-X
it	B-X
is	B-X
broadly	B-X
used	B-X
to	B-X
describe	B-X
messenger	B-X
RNA	B-X
(	B-X
mRNA	B-X
)	B-X
expression	B-X
patterns	B-X
and	B-X
to	B-X
compare	B-X
the	B-X
relative	B-X
levels	B-X
of	B-X
mRNA	B-X
within	B-X
distinct	B-X
biological	B-X
samples	B-X
.	B-X
The	B-X
scope	B-X
of	B-X
the	B-X
QRT-PCR	B-X
technique	B-X
makes	B-X
it	B-X
applicable	B-X
across	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
experimental	B-X
conditions	B-X
and	B-X
allows	B-X
experimental	B-X
comparison	B-X
between	B-X
normal	B-X
and	B-X
abnormal	B-X
tissue	B-X
.	B-X
An	B-X
inherent	B-X
advantage	B-X
of	B-X
QRT-PCR	B-X
is	B-X
the	B-X
large	B-X
dynamic	B-X
range	B-X
,	B-X
remarkable	B-X
sensitivity	B-X
,	B-X
and	B-X
sequence-specificity	B-X
.	B-X
We	B-X
provide	B-X
a	B-X
detailed	B-X
step	B-X
by	B-X
step	B-X
guide	B-X
to	B-X
the	B-X
principles	B-X
underlying	B-X
a	B-X
successful	B-X
QRT-PCR	B-X
experiment	B-X
.	B-X

MDMs	O
or	O
RAW	O
264	O
.	O
7	O
cells	O
were	O
serum	O
-	O
starved	O
overnight	O
or	O
for	O
2	O
hours	O
,	O
respectively	O
,	O
prior	O
to	O
incubating	O
with	O
inhibitors	O
for	O
30	O
minutes	O
.	O
<EOS>	B-X
To	B-X
get	B-X
further	B-X
insight	B-X
on	B-X
their	B-X
role	B-X
during	B-X
chronic	B-X
hepatitis	B-X
B	B-X
virus	B-X
(	B-X
HBV	B-X
)	B-X
infections	B-X
,	B-X
our	B-X
aim	B-X
was	B-X
to	B-X
phenotypically	B-X
and	B-X
functionally	B-X
characterize	B-X
in	B-X
vivo	B-X
and	B-X
ex	B-X
vivo	B-X
the	B-X
interplay	B-X
between	B-X
HBV	B-X
,	B-X
primary	B-X
human	B-X
liver	B-X
macrophages	B-X
(	B-X
PLMs	B-X
)	B-X
and	B-X
primary	B-X
blood	B-X
monocytes	B-X
differentiated	B-X
into	B-X
pro-inflammatory	B-X
or	B-X
anti-inflammatory	B-X
macrophages	B-X
(	B-X
M1-MDMs	B-X
or	B-X
M2-MDMs	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
Mesenchymal	B-X
stromal	B-X
cells	B-X
(	B-X
MSCs	B-X
)	B-X
are	B-X
a	B-X
promising	B-X
candidate	B-X
for	B-X
a	B-X
cell-based	B-X
therapy	B-X
.	B-X
Monocyte-derived	B-X
macrophages	B-X
(	B-X
MDMs	B-X
)	B-X
generated	B-X
from	B-X
peripheral	B-X
blood	B-X
monocytes	B-X
are	B-X
widely	B-X
used	B-X
to	B-X
model	B-X
human	B-X
macrophages	B-X
for	B-X
in	B-X
vitro	B-X
studies	B-X
.	B-X
Prominent	B-X
desmoplastic	B-X
reaction	B-X
involving	B-X
cancer-associated	B-X
fibroblasts	B-X
(	B-X
CAFs	B-X
)	B-X
and	B-X
the	B-X
immune	B-X
cells	B-X
in	B-X
the	B-X
tumor	B-X
microenvironment	B-X
(	B-X
TME	B-X
)	B-X
and	B-X
their	B-X
cross-talk	B-X
play	B-X
a	B-X
significant	B-X
role	B-X
in	B-X
tumor	B-X
immune	B-X
escape	B-X
and	B-X
progression	B-X
.	B-X
To	B-X
identify	B-X
the	B-X
key	B-X
cellular	B-X
mechanisms	B-X
induce	B-X
an	B-X
immunosuppressive	B-X
tumor	B-X
microenvironment	B-X
,	B-X
we	B-X
established	B-X
3D	B-X
co-culture	B-X
model	B-X
with	B-X
pancreatic	B-X
cancer	B-X
cells	B-X
,	B-X
CAFs	B-X
and	B-X
monocytes	B-X
.	B-X
Using	B-X
this	B-X
model	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
influence	B-X
of	B-X
tumor	B-X
cells	B-X
and	B-X
fibroblasts	B-X
on	B-X
monocytes	B-X
and	B-X
their	B-X
immune	B-X
suppressive	B-X
phenotype	B-X
.	B-X
3D	B-X
co-culture	B-X
of	B-X
monocytes	B-X
with	B-X
pancreatic	B-X
cancer	B-X
cells	B-X
and	B-X
fibroblasts	B-X
induced	B-X
the	B-X
production	B-X
of	B-X
immunosuppressive	B-X
cytokines	B-X
which	B-X
are	B-X
known	B-X
to	B-X
promote	B-X
polarization	B-X
of	B-X
M2	B-X
like	B-X
macrophages	B-X
and	B-X
myeloid	B-X
derived	B-X
suppressive	B-X
cells	B-X
(	B-X
MDSCs	B-X
)	B-X
.	B-X
These	B-X
co-culture	B-X
spheroid	B-X
polarized	B-X
monocyte	B-X
derived	B-X
macrophages	B-X
(	B-X
MDMs	B-X
)	B-X
were	B-X
poorly	B-X
differentiated	B-X
and	B-X
had	B-X
an	B-X
M2	B-X
phenotype	B-X
.	B-X
The	B-X
immunosuppressive	B-X
function	B-X
of	B-X
these	B-X
co-culture	B-X
spheroids	B-X
polarized	B-X
MDMs	B-X
was	B-X
demonstrated	B-X
by	B-X
their	B-X
ability	B-X
to	B-X
inhibit	B-X
CD4+	B-X
and	B-X
CD8+	B-X
T	B-X
cell	B-X
activation	B-X
and	B-X
proliferation	B-X
in	B-X
vitro	B-X
,	B-X
which	B-X
we	B-X
could	B-X
partially	B-X
reverse	B-X
by	B-X
3D	B-X
co-culture	B-X
spheroid	B-X
treatment	B-X
with	B-X
therapeutic	B-X
molecules	B-X
that	B-X
are	B-X
able	B-X
to	B-X
re-activated	B-X
spheroid	B-X
polarized	B-X
MDMs	B-X
or	B-X
block	B-X
immune	B-X
suppressive	B-X
factors	B-X
such	B-X
as	B-X
Arginase-I	B-X
.	B-X

The	O
cells	O
were	O
restimulated	O
with	O
100	O
ng	O
/	O
ml	O
M	O
-	O
CSF	O
and	O
total	O
mRNA	O
was	O
extracted	O
from	O
cells	O
with	O
Trizol	O
(	O
Invitrogen	O
)	O
and	O
1	O
-	O
2	O
microg	O
of	O
total	O
RNA	O
was	O
used	O
to	O
synthesized	O
cDNA	O
using	O
SuperScript	O
III	O
(	O
Invitrogen	O
)	O
.	O

Quantitative	O
real	O
-	O
time	O
(	O
qRT	O
)	O
-	O
PCR	O
was	O
performed	O
using	O
SYBR	O
Green	O
Master	O
Mix	O
(	O
Applied	O
BioSystems	O
,	O
Carlsbad	O
,	O
CA	O
)	O
.	O

The	O
reactions	O
were	O
performed	O
using	O
an	O
ABI	O
PRIZM	O
7700	O
machine	O
with	O
software	O
Sequence	O
Detector	O
version	O
1	O
.	O
7	O
(	O
Applied	O
Biosystems	O
)	O
.	O

The	O
target	O
gene	O
values	O
were	O
normalized	O
to	O
the	O
values	O
of	O
GAPDH	O
as	O
a	O
housekeeping	O
gene	O
and	O
expressed	O
as	O
relative	O
fold	O
increase	O
2	O
(	O
-	O
deltadeltaCt	O
)	O
over	O
the	O
non	O
-	O
stimulated	O
samples	O
(	O
NS	O
)	O
.	O

Statistical	O
Analysis	O

Statistical	O
comparisons	O
were	O
performed	O
using	O
analysis	O
of	O
variance	O
testing	O
(	O
Minitab	O
software	O
,	O
State	O
Park	O
,	O
PA	O
or	O
SPSS16	O
software	O
,	O
SPSS	O
Inc	O
.	O
Chicago	O
,	O
IL	O
)	O
.	O

Statistical	O
significance	O
was	O
defined	O
as	O
p	O
<	O
=	O
0	O
.	O
05	O
.	O

Ethics	O
Statement	O
<EOS>	B-X
The	B-X
American	B-X
Nurses	B-X
Association	B-X
has	B-X
guided	B-X
and	B-X
supported	B-X
nursing	B-X
practice	B-X
through	B-X
creation	B-X
and	B-X
implementation	B-X
of	B-X
a	B-X
nationally	B-X
accepted	B-X
Code	B-X
of	B-X
Ethics	B-X
for	B-X
Nurses	B-X
with	B-X
Interpretive	B-X
Statements	B-X
.	B-X
We	B-X
also	B-X
offer	B-X
a	B-X
brief	B-X
history	B-X
of	B-X
the	B-X
Code	B-X
of	B-X
Ethics	B-X
,	B-X
discuss	B-X
the	B-X
modern	B-X
Code	B-X
of	B-X
Ethics	B-X
,	B-X
and	B-X
describe	B-X
the	B-X
importance	B-X
of	B-X
periodic	B-X
revision	B-X
,	B-X
including	B-X
the	B-X
inclusive	B-X
and	B-X
thorough	B-X
process	B-X
used	B-X
to	B-X
develop	B-X
the	B-X
2015	B-X
Code	B-X
and	B-X
a	B-X
summary	B-X
of	B-X
recent	B-X
changes	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
Statement	B-X
is	B-X
to	B-X
increase	B-X
awareness	B-X
of	B-X
all	B-X
stakeholders	B-X
of	B-X
science	B-X
communication	B-X
of	B-X
the	B-X
emerging	B-X
ethical	B-X
issues	B-X
in	B-X
journal	B-X
editing	B-X
and	B-X
publishing	B-X
and	B-X
initiate	B-X
a	B-X
campaign	B-X
of	B-X
upgrading	B-X
and	B-X
enforcing	B-X
related	B-X
journal	B-X
instructions	B-X
.	B-X
A	B-X
review	B-X
of	B-X
the	B-X
literature	B-X
related	B-X
to	B-X
caring	B-X
theory	B-X
,	B-X
the	B-X
concepts	B-X
of	B-X
moral	B-X
accountability	B-X
and	B-X
integrity	B-X
,	B-X
and	B-X
the	B-X
documents	B-X
that	B-X
speak	B-X
of	B-X
these	B-X
values	B-X
and	B-X
concepts	B-X
in	B-X
professional	B-X
practice	B-X
(	B-X
eg	B-X
,	B-X
Code	B-X
of	B-X
Ethics	B-X
for	B-X
Nurses	B-X
with	B-X
Interpretive	B-X
Statements	B-X
,	B-X
Nursing	B-X
's	B-X
Social	B-X
Policy	B-X
Statement	B-X
)	B-X
are	B-X
presented	B-X
in	B-X
this	B-X
article	B-X
.	B-X

All	O
research	O
involving	O
human	O
blood	O
(	O
Buffy	O
coat	O
)	O
were	O
ordered	O
from	O
American	O
Red	O
cross	O
and	O
have	O
been	O
approved	O
by	O
the	O
Ohio	O
State	O
University	O
review	O
board	O
(	O
ARC	O
IRB	O
Protocol	O
#	O
2001	O
-	O
26	O
)	O
.	O

M	O
-	O
CSF	O
induces	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
in	O
macrophages	O
.	O
<EOS>	B-X
The	B-X
differentiation	B-X
of	B-X
osteoclasts	B-X
is	B-X
dependent	B-X
on	B-X
a	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
family	B-X
cytokine	B-X
,	B-X
receptor	B-X
activator	B-X
of	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
ligand	B-X
(	B-X
RANKL	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
)	B-X
.	B-X
Congenital	B-X
lack	B-X
of	B-X
osteoclasts	B-X
causes	B-X
osteopetrosis	B-X
,	B-X
investigation	B-X
of	B-X
which	B-X
has	B-X
provided	B-X
insights	B-X
into	B-X
the	B-X
essential	B-X
molecules	B-X
for	B-X
osteoclastogenesis	B-X
,	B-X
including	B-X
TNF	B-X
receptor-associated	B-X
factor	B-X
(	B-X
TRAF	B-X
)	B-X
6	B-X
,	B-X
NF-kappaB	B-X
and	B-X
c-Fos	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
genome-wide	B-X
screening	B-X
techniques	B-X
have	B-X
shed	B-X
light	B-X
on	B-X
an	B-X
additional	B-X
set	B-X
of	B-X
gene	B-X
products	B-X
such	B-X
as	B-X
nuclear	B-X
factor	B-X
of	B-X
activated	B-X
T	B-X
cells	B-X
(	B-X
NFAT	B-X
)	B-X
c1	B-X
.	B-X
TRAF6	B-X
activates	B-X
NF-kappaB	B-X
,	B-X
which	B-X
is	B-X
important	B-X
for	B-X
the	B-X
initial	B-X
induction	B-X
of	B-X
NFATc1	B-X
.	B-X
NFATc1	B-X
is	B-X
activated	B-X
by	B-X
calcium	B-X
signaling	B-X
and	B-X
binds	B-X
to	B-X
its	B-X
own	B-X
promoter	B-X
,	B-X
thus	B-X
switching	B-X
on	B-X
an	B-X
autoregulatory	B-X
loop	B-X
.	B-X
An	B-X
activator	B-X
protein	B-X
(	B-X
AP	B-X
)	B-X
-1	B-X
complex	B-X
containing	B-X
c-Fos	B-X
is	B-X
required	B-X
for	B-X
the	B-X
autoamplification	B-X
of	B-X
NFATc1	B-X
,	B-X
enabling	B-X
the	B-X
robust	B-X
induction	B-X
of	B-X
NFATc1	B-X
.	B-X
Finally	B-X
,	B-X
NFATc1	B-X
cooperates	B-X
with	B-X
other	B-X
transcriptional	B-X
partners	B-X
to	B-X
activate	B-X
osteoclast-specific	B-X
genes	B-X
.	B-X
NFATc1	B-X
autoregulation	B-X
is	B-X
controlled	B-X
by	B-X
an	B-X
epigenetic	B-X
mechanism	B-X
,	B-X
which	B-X
has	B-X
profound	B-X
implications	B-X
for	B-X
an	B-X
understanding	B-X
of	B-X
the	B-X
general	B-X
mechanism	B-X
of	B-X
irreversible	B-X
cell	B-X
fate	B-X
determination	B-X
.	B-X

(	O
A	O
)	O
Nuclei	O
were	O
extracted	O
from	O
human	O
MDMs	O
treated	O
without	O
or	O
with	O
M	O
-	O
CSF	O
for	O
15	O
or	O
30	O
minutes	O
.	O
<EOS>	B-X
Nine	B-X
healthy	B-X
male	B-X
subjects	B-X
(	B-X
age	B-X
,	B-X
21	B-X
±	B-X
1	B-X
year	B-X
)	B-X
performed	B-X
45	B-X
minutes	B-X
of	B-X
cycling	B-X
in	B-X
a	B-X
hot	B-X
environment	B-X
(	B-X
35°	B-X
C	B-X
,	B-X
40-60	B-X
%	B-X
relative	B-X
humidity	B-X
)	B-X
at	B-X
65	B-X
%	B-X
of	B-X
peak	B-X
oxygen	B-X
uptake	B-X
.	B-X
Thereafter	B-X
,	B-X
subjects	B-X
underwent	B-X
the	B-X
CWS	B-X
condition	B-X
(	B-X
15	B-X
minutes	B-X
,	B-X
15°	B-X
C	B-X
water	B-X
shower	B-X
)	B-X
or	B-X
control	B-X
(	B-X
SIT25	B-X
;	B-X
15	B-X
minutes	B-X
passive	B-X
recovery	B-X
in	B-X
25°	B-X
C	B-X
room	B-X
)	B-X
in	B-X
a	B-X
randomized	B-X
crossover	B-X
design	B-X
.	B-X
After	B-X
each	B-X
15	B-X
minutes	B-X
,	B-X
subjects	B-X
sat	B-X
in	B-X
a	B-X
25°	B-X
C	B-X
room	B-X
for	B-X
another	B-X
2-hour	B-X
recovery	B-X
.	B-X
Heart	B-X
rate	B-X
,	B-X
Tc	B-X
,	B-X
and	B-X
TCS	B-X
were	B-X
recorded	B-X
before	B-X
and	B-X
immediately	B-X
after	B-X
exercise	B-X
,	B-X
immediately	B-X
after	B-X
CWS	B-X
or	B-X
SIT25	B-X
,	B-X
and	B-X
at	B-X
30	B-X
minutes	B-X
,	B-X
1	B-X
,	B-X
and	B-X
2	B-X
hours	B-X
during	B-X
additional	B-X
recovery	B-X
.	B-X
Salivary	B-X
cortisol	B-X
was	B-X
collected	B-X
at	B-X
the	B-X
same	B-X
time	B-X
points	B-X
except	B-X
at	B-X
30	B-X
minutes	B-X
of	B-X
the	B-X
additional	B-X
recovery	B-X
period	B-X
.	B-X
The	B-X
change	B-X
of	B-X
HR	B-X
decreased	B-X
faster	B-X
with	B-X
CWS	B-X
(	B-X
-18.3	B-X
±	B-X
2.3	B-X
%	B-X
)	B-X
than	B-X
with	B-X
SIT25	B-X
(	B-X
-7.0	B-X
±	B-X
4.6	B-X
%	B-X
)	B-X
at	B-X
the	B-X
first	B-X
30-minute	B-X
recovery	B-X
time	B-X
point	B-X
(	B-X
p	B-X
<	B-X
0.01	B-X
)	B-X
.	B-X
The	B-X
findings	B-X
demonstrate	B-X
that	B-X
a	B-X
15-minute	B-X
,	B-X
15°	B-X
C	B-X
CWS	B-X
was	B-X
not	B-X
effective	B-X
in	B-X
reducing	B-X
Tc	B-X
or	B-X
salivary	B-X
cortisol	B-X
during	B-X
recovery	B-X
from	B-X
exercise	B-X
in	B-X
a	B-X
hot	B-X
environment	B-X
.	B-X
However	B-X
,	B-X
CWS	B-X
can	B-X
promote	B-X
TCS	B-X
by	B-X
facilitating	B-X
a	B-X
faster	B-X
HR	B-X
recovery	B-X
after	B-X
30-minute	B-X
postintervention	B-X
compared	B-X
with	B-X
passive	B-X
recovery	B-X
.	B-X

NF	O
-	O
kappaB	O
DNA	O
binding	O
activity	O
was	O
analyzed	O
by	O
EMSA	O
Shown	O
is	O
a	O
representative	O
blot	O
from	O
three	O
independent	O
experiments	O
.	O

NS	O
:	O
non	O
-	O
stimulated	O
.	O
<EOS>	B-X
A	B-X
significant	B-X
portion	B-X
of	B-X
the	B-X
total	B-X
daily	B-X
growth	B-X
hormone	B-X
(	B-X
GH	B-X
)	B-X
secretion	B-X
is	B-X
associated	B-X
with	B-X
deep	B-X
non-REM	B-X
sleep	B-X
(	B-X
NREMS	B-X
)	B-X
.	B-X
GH	B-X
secretion	B-X
is	B-X
stimulated	B-X
by	B-X
the	B-X
hypothalamic	B-X
neurohormone	B-X
,	B-X
GH-releasing	B-X
hormone	B-X
(	B-X
GHRH	B-X
)	B-X
.	B-X
Magnetic	B-X
materials	B-X
have	B-X
shown	B-X
promise	B-X
in	B-X
this	B-X
field	B-X
,	B-X
as	B-X
they	B-X
can	B-X
be	B-X
manipulated	B-X
non-invasively	B-X
,	B-X
are	B-X
easily	B-X
functionalized	B-X
,	B-X
and	B-X
can	B-X
be	B-X
used	B-X
to	B-X
mechanically	B-X
stimulate	B-X
cells	B-X
.	B-X
The	B-X
high	B-X
energy	B-X
consumption	B-X
of	B-X
the	B-X
brain	B-X
at	B-X
rest	B-X
and	B-X
its	B-X
quantitative	B-X
usage	B-X
for	B-X
neurotransmission	B-X
reflect	B-X
a	B-X
high	B-X
level	B-X
of	B-X
neuronal	B-X
activity	B-X
for	B-X
the	B-X
non-stimulated	B-X
brain	B-X
.	B-X

(	O
B	O
)	O
Human	O
MDMs	O
transiently	O
transfected	O
with	O
pTAL	O
-	O
SEAP	O
or	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
constructs	O
were	O
treated	O
with	O
M	O
-	O
CSF	O
in	O
X	O
-	O
vivo	O
medium	O
and	O
incubated	O
for	O
6	O
hours	O
before	O
the	O
collection	O
of	O
medium	O
.	O

NF	O
-	O
kappaB	O
activity	O
was	O
analyzed	O
by	O
measuring	O
the	O
amount	O
of	O
SEAP	O
secreted	O
into	O
the	O
medium	O
and	O
data	O
are	O
expressed	O
as	O
fold	O
increase	O
of	O
SEAP	O
activity	O
over	O
that	O
in	O
pTAL	O
-	O
SEAP	O
transfected	O
resting	O
cells	O
.	O

(	O
C	O
)	O
RAW	O
264	O
.	O
7	O
cells	O
were	O
transiently	O
transfected	O
with	O
pTAL	O
-	O
SEAP	O
or	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
construct	O
.	O
<EOS>	B-X
A	B-X
cell-based	B-X
assay	B-X
system	B-X
for	B-X
monitoring	B-X
NF-kappaB	B-X
activity	B-X
was	B-X
developed	B-X
to	B-X
determine	B-X
the	B-X
influence	B-X
of	B-X
activated	B-X
NF-kappaB	B-X
in	B-X
human	B-X
HaCaT	B-X
cells	B-X
.	B-X
The	B-X
pNF-kappaB-SEAP-NPT	B-X
plasmid	B-X
that	B-X
permits	B-X
expression	B-X
of	B-X
the	B-X
secretory	B-X
alkaline	B-X
phosphatase	B-X
(	B-X
SEAP	B-X
)	B-X
reporter	B-X
gene	B-X
in	B-X
response	B-X
to	B-X
the	B-X
NF-kappaB	B-X
activity	B-X
and	B-X
contains	B-X
the	B-X
neomycin	B-X
phosphotransferase	B-X
(	B-X
NPT	B-X
)	B-X
gene	B-X
for	B-X
geneticin	B-X
resistance	B-X
in	B-X
host	B-X
cells	B-X
was	B-X
constructed	B-X
and	B-X
transfected	B-X
into	B-X
the	B-X
human	B-X
keratinocyte	B-X
cell	B-X
line	B-X
HaCaT	B-X
.	B-X
Human	B-X
HaCaT	B-X
transfectant	B-X
cells	B-X
were	B-X
demonstrated	B-X
to	B-X
secrete	B-X
the	B-X
SEAP	B-X
enzyme	B-X
into	B-X
the	B-X
culture	B-X
medium	B-X
in	B-X
a	B-X
time-dependent	B-X
manner	B-X
until	B-X
72	B-X
h.	B-X
NF-kappaB	B-X
activities	B-X
were	B-X
measured	B-X
by	B-X
the	B-X
SEAP	B-X
reporter	B-X
gene	B-X
assay	B-X
using	B-X
a	B-X
fluorescence	B-X
detection	B-X
method	B-X
.	B-X
HaCaT	B-X
cell	B-X
transfectants	B-X
treated	B-X
with	B-X
antioxidants	B-X
[	B-X
e.g.	B-X
,	B-X
N-acetyl-l-cysteine	B-X
and	B-X
vitamin	B-X
C	B-X
]	B-X
showed	B-X
reduction	B-X
of	B-X
NF-kappaB	B-X
activity	B-X
in	B-X
a	B-X
time-	B-X
and	B-X
concentration-dependent	B-X
manner	B-X
,	B-X
whereas	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
known	B-X
as	B-X
a	B-X
stimulator	B-X
of	B-X
NF-kappaB	B-X
expression	B-X
increased	B-X
NF-kappaB	B-X
activity	B-X
in	B-X
a	B-X
time-	B-X
and	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
This	B-X
assay	B-X
system	B-X
could	B-X
be	B-X
used	B-X
to	B-X
determine	B-X
the	B-X
quantitative	B-X
measurement	B-X
of	B-X
NF-kappaB	B-X
activity	B-X
in	B-X
the	B-X
human	B-X
skin	B-X
and	B-X
allow	B-X
the	B-X
screening	B-X
of	B-X
anti-inflammatory	B-X
agents	B-X
for	B-X
dermatological	B-X
purpose	B-X
from	B-X
various	B-X
synthetic	B-X
chemicals	B-X
and	B-X
natural	B-X
products	B-X
.	B-X

Cells	O
were	O
serum	O
starved	O
for	O
4	O
hours	O
prior	O
to	O
2	O
hours	O
stimulation	O
with	O
mouse	O
recombinant	O
M	O
-	O
CSF	O
(	O
100	O
ng	O
/	O
ml	O
)	O
.	O

Culture	O
media	O
was	O
collected	O
to	O
measure	O
SEAP	O
production	O
.	O

Data	O
are	O
expressed	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
,	O
for	O
three	O
independent	O
experiments	O
.	O

Inhibition	O
of	O
PKC	O
reduces	O
NF	O
-	O
kappaB	O
activity	O
in	O
M	O
-	O
CSF	O
stimulated	O
macrophages	O
.	O

(	O
A	O
)	O
Human	O
MDMs	O
transfected	O
with	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
were	O
pre	O
-	O
incubated	O
with	O
inhibitors	O
;	O
Ro	O
-	O
31	O
-	O
8220	O
,	O
Go	O
-	O
6976	O
,	O
or	O
BAPTA	O
/	O
AM	O
for	O
30	O
minutes	O
prior	O
to	O
6	O
hours	O
M	O
-	O
CSF	O
stimulation	O
.	O

(	O
B	O
)	O
RAW	O
264	O
.	O
7	O
cells	O
transfected	O
with	O
the	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
construct	O
were	O
pre	O
-	O
incubated	O
with	O
inhibitors	O
for	O
30	O
minutes	O
prior	O
to	O
2	O
hours	O
of	O
stimulation	O
with	O
mouse	O
recombinant	O
M	O
-	O
CSF	O
.	O

The	O
NF	O
-	O
kappaB	O
activity	O
was	O
analyzed	O
by	O
measuring	O
SEAP	O
production	O
in	O
the	O
medium	O
and	O
data	O
are	O
expressed	O
as	O
fold	O
increase	O
of	O
SEAP	O
activity	O
over	O
that	O
in	O
pTAL	O
-	O
SEAP	O
transfected	O
resting	O
cells	O
.	O

The	O
graph	O
represents	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
for	O
three	O
independent	O
experiments	O
.	O

*	O
The	O
p	O
-	O
values	O
of	O
cells	O
treated	O
with	O
inhibitors	O
/	O
M	O
-	O
CSF	O
compared	O
to	O
vehicle	O
/	O
M	O
-	O
CSF	O
were	O
<	O
=	O
0	O
.	O
05	O
.	O

Inhibition	O
of	O
PKC	O
or	O
NF	O
-	O
kappaB	O
induces	O
apoptosis	O
in	O
MDMs	O
.	O
<EOS>	B-X
LPS	B-X
and	B-X
cytokine-induced	B-X
NOS	B-X
mRNA	B-X
are	B-X
dependent	B-X
on	B-X
NF-kappaB/Rel	B-X
(	B-X
NFkappaB	B-X
)	B-X
and	B-X
Activator	B-X
Protein-1	B-X
(	B-X
AP-1	B-X
)	B-X
,	B-X
which	B-X
are	B-X
regulated	B-X
in	B-X
turn	B-X
by	B-X
protein	B-X
kinase	B-X
C	B-X
and	B-X
tyrosine	B-X
kinase-dependent	B-X
phosphorylation	B-X
.	B-X
ETOH	B-X
does	B-X
not	B-X
directly	B-X
inhibit	B-X
NFkappaB	B-X
or	B-X
AP-1	B-X
,	B-X
in	B-X
vivo	B-X
,	B-X
but	B-X
rather	B-X
inhibits	B-X
LPS-induced	B-X
activation	B-X
of	B-X
the	B-X
MEKK/MAP	B-X
kinase	B-X
system	B-X
and	B-X
inhibition	B-X
of	B-X
inhibitory	B-X
protein	B-X
IkappaBalpha	B-X
required	B-X
for	B-X
formation	B-X
of	B-X
AP-1	B-X
and	B-X
NFkappaB	B-X
,	B-X
respectively	B-X
.	B-X
LPS-induced	B-X
upregulation	B-X
of	B-X
MEKK/MAP	B-X
tyrosine	B-X
kinase	B-X
upregulates	B-X
NADPH	B-X
oxidase	B-X
activity	B-X
and	B-X
oxygen	B-X
free	B-X
radical	B-X
formation	B-X
required	B-X
for	B-X
activation	B-X
of	B-X
NFkappaB	B-X
and	B-X
AP-1	B-X
and	B-X
phosphorylation	B-X
of	B-X
IkappaBalpha	B-X
.	B-X
LPS	B-X
downregulates	B-X
endogenous	B-X
calcium-sensitive	B-X
PKC	B-X
isozymes	B-X
(	B-X
PKCdelta	B-X
)	B-X
,	B-X
which	B-X
repress	B-X
iNOS	B-X
mRNA	B-X
expression	B-X
.	B-X
ETOH	B-X
inhibits	B-X
LPS-induced	B-X
upregulation	B-X
of	B-X
iNOS	B-X
mRNA	B-X
by	B-X
preventing	B-X
its	B-X
ability	B-X
to	B-X
decrease	B-X
PKCdelta	B-X
and	B-X
upregulate	B-X
tyrosine	B-X
kinase-mediated	B-X
phosphorylation	B-X
.	B-X
This	B-X
effect	B-X
of	B-X
ETOH	B-X
is	B-X
prevented	B-X
by	B-X
inhibitors	B-X
of	B-X
PKC	B-X
and	B-X
tyrosine	B-X
kinase	B-X
.	B-X
The	B-X
data	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
ETOH	B-X
inhibits	B-X
LPS-induced	B-X
upregulation	B-X
of	B-X
iNOS	B-X
mRNA	B-X
by	B-X
interfering	B-X
with	B-X
the	B-X
phosphorylation	B-X
processes	B-X
involved	B-X
in	B-X
activation	B-X
of	B-X
the	B-X
nuclear	B-X
transcription	B-X
factors	B-X
NFkappaB	B-X
and	B-X
AP-1	B-X
.	B-X

(	O
A	O
)	O
MDMs	O
were	O
pre	O
-	O
incubated	O
in	O
RPMI	O
medium	O
containing	O
inhibitors	O
(	O
Ro	O
-	O
31	O
-	O
8220	O
:	O
5	O
microM	O
,	O
Go	O
-	O
6976	O
:	O
5	O
microM	O
,	O
BAPTA	O
/	O
AM	O
:	O
2	O
.	O
5	O
microM	O
)	O
for	O
30	O
minutes	O
prior	O
to	O
the	O
addition	O
of	O
M	O
-	O
CSF	O
.	O

As	O
a	O
control	O
,	O
untreated	O
cells	O
were	O
incubated	O
with	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
)	O
.	O
<EOS>	B-X
Mouse	B-X
breast	B-X
cancer	B-X
cells	B-X
(	B-X
4T1	B-X
)	B-X
and	B-X
cells	B-X
derived	B-X
from	B-X
metastatic	B-X
lesions	B-X
(	B-X
4THMpc	B-X
)	B-X
were	B-X
treated	B-X
with	B-X
various	B-X
doses	B-X
of	B-X
thalidomide	B-X
[	B-X
10	B-X
(	B-X
-2	B-X
)	B-X
-100	B-X
µM	B-X
dissolved	B-X
in	B-X
dimethyl	B-X
sulfoxide	B-X
(	B-X
DMSO	B-X
)	B-X
as	B-X
recommended	B-X
]	B-X
and	B-X
1.4	B-X
µM	B-X
DMSO	B-X
(	B-X
maximum	B-X
DMSO	B-X
concentration	B-X
in	B-X
the	B-X
highest	B-X
thalidomide	B-X
dose	B-X
)	B-X
as	B-X
a	B-X
DMSO	B-X
control	B-X
against	B-X
the	B-X
untreated	B-X
control	B-X
groups	B-X
.	B-X
Thalidomide	B-X
dissolved	B-X
in	B-X
DMSO	B-X
exhibited	B-X
cytotoxic	B-X
effects	B-X
on	B-X
4T1	B-X
and	B-X
4THMpc	B-X
cells	B-X
compared	B-X
to	B-X
the	B-X
control	B-X
groups	B-X
incubated	B-X
without	B-X
any	B-X
supplement	B-X
.	B-X
Treatment	B-X
with	B-X
thalidomide	B-X
resulted	B-X
in	B-X
apoptosis	B-X
of	B-X
mouse	B-X
breast	B-X
cancer	B-X
cells	B-X
in	B-X
a	B-X
time-	B-X
and	B-X
dose-dependent	B-X
manner	B-X
as	B-X
demonstrated	B-X
by	B-X
caspase-3	B-X
enzyme	B-X
activity	B-X
.	B-X
However	B-X
,	B-X
DMSO	B-X
alone	B-X
suppressed	B-X
cell	B-X
proliferation	B-X
more	B-X
effectively	B-X
than	B-X
thalidomide	B-X
.	B-X
In	B-X
cultured	B-X
mouse	B-X
breast	B-X
cancer	B-X
cells	B-X
the	B-X
inhibitory	B-X
effect	B-X
of	B-X
thalidomide	B-X
may	B-X
be	B-X
partially	B-X
attributed	B-X
to	B-X
the	B-X
solvent	B-X
DMSO	B-X
alone	B-X
.	B-X

Cell	O
lysates	O
were	O
resolved	O
by	O
SDS	O
-	O
PAGE	O
and	O
immunoblotted	O
with	O
antibody	O
recognizing	O
the	O
active	O
cleaved	O
form	O
of	O
caspase	O
-	O
3	O
.	O

The	O
blots	O
were	O
reblotted	O
with	O
beta	B-Protein
-	I-Protein
actin	I-Protein
that	O
served	O
as	O
a	O
loading	O
control	O
.	O

The	O
ratio	O
of	O
active	O
caspase	B-Protein
-	I-Protein
3	I-Protein
bands	O
(	O
17	O
kD	O
and	O
19	O
kD	O
)	O
to	O
beta	B-Protein
-	I-Protein
actin	I-Protein
control	O
was	O
determined	O
by	O
densitometry	O
analysis	O
(	O
bottom	O
panel	O
)	O
.	O

Data	O
represents	O
the	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
from	O
two	O
independent	O
donors	O
.	O

(	O
B	O
)	O
Apoptosis	O
of	O
the	O
treated	O
MDMs	O
was	O
also	O
measured	O
by	O
Annexin	B-Protein
V	I-Protein
-	O
FITC	O
and	O
propidium	O
iodine	O
(	O
PI	O
)	O
staining	O
and	O
analyzed	O
by	O
flow	O
cytometry	O
.	O

The	O
percentage	O
of	O
surviving	O
cells	O
(	O
Annexin	B-Protein
V	I-Protein
/	O
PI	O
negative	O
)	O
for	O
the	O
cells	O
treated	O
with	O
vehicle	O
/	O
M	O
-	O
CSF	O
was	O
arbitrarily	O
set	O
as	O
100	O
.	O

Data	O
shown	O
represent	O
the	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
from	O
three	O
independent	O
experiments	O
.	O

*	O
The	O
p	O
-	O
values	O
of	O
inhibitors	O
/	O
M	O
-	O
CSF	O
compared	O
to	O
vehicle	O
/	O
M	O
-	O
CSF	O
were	O
<	O
=	O
0	O
.	O
05	O
.	O

M	O
-	O
CSF	O
activates	O
PKCalpha	B-Protein
in	O
human	O
MDMs	O
.	O
<EOS>	B-X
Macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
)	B-X
promotes	B-X
mononuclear	B-X
phagocyte	B-X
survival	B-X
and	B-X
proliferation	B-X
.	B-X
The	B-X
transcription	B-X
factor	B-X
Nuclear	B-X
Factor-kappaB	B-X
(	B-X
NF-κB	B-X
)	B-X
is	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
M-CSF-induced	B-X
mononuclear	B-X
phagocyte	B-X
survival	B-X
and	B-X
this	B-X
study	B-X
focused	B-X
at	B-X
identifying	B-X
the	B-X
mechanism	B-X
of	B-X
NF-κB	B-X
transcriptional	B-X
activation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
M-CSF	B-X
stimulated	B-X
NF-κB	B-X
transcriptional	B-X
activity	B-X
in	B-X
human	B-X
monocyte-derived	B-X
macrophages	B-X
(	B-X
MDMs	B-X
)	B-X
and	B-X
the	B-X
murine	B-X
macrophage	B-X
cell	B-X
line	B-X
RAW	B-X
264.7	B-X
.	B-X
The	B-X
general	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
inhibitor	B-X
Ro-31-8220	B-X
,	B-X
the	B-X
conventional	B-X
PKCα/β	B-X
inhibitor	B-X
Gö-6976	B-X
,	B-X
overexpression	B-X
of	B-X
dominant	B-X
negative	B-X
PKCα	B-X
constructs	B-X
and	B-X
PKCα	B-X
siRNA	B-X
reduced	B-X
NF-κB	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
M-CSF	B-X
.	B-X
Interestingly	B-X
,	B-X
Ro-31-8220	B-X
reduced	B-X
Ser276	B-X
phosphorylation	B-X
of	B-X
NF-κBp65	B-X
leading	B-X
to	B-X
decreased	B-X
M-CSF-induced	B-X
monocyte	B-X
survival	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
identify	B-X
conventional	B-X
PKCs	B-X
,	B-X
including	B-X
PKCα	B-X
as	B-X
important	B-X
upstream	B-X
kinases	B-X
for	B-X
M-CSF-induced	B-X
NF-κB	B-X
transcriptional	B-X
activation	B-X
,	B-X
NF-κB-regulated	B-X
gene	B-X
expression	B-X
,	B-X
NF-κB	B-X
p65	B-X
Ser276	B-X
phosphorylation	B-X
,	B-X
and	B-X
macrophage	B-X
survival	B-X
.	B-X
Lastly	B-X
,	B-X
we	B-X
find	B-X
that	B-X
NF-κB	B-X
p65	B-X
Ser276	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
basal	B-X
and	B-X
M-CSF-stimulated	B-X
NF-κB	B-X
activation	B-X
in	B-X
human	B-X
mononuclear	B-X
phagocytes	B-X
.	B-X

MDMs	O
treated	O
with	O
M	O
-	O
CSF	O
(	O
100	O
ng	O
/	O
ml	O
)	O
for	O
varying	O
amounts	O
of	O
time	O
were	O
lysed	O
and	O
immunoprecipitated	O
using	O
anti	O
-	O
PKC	O
antibody	O
or	O
control	O
IgG	O
antibody	O
.	O
<EOS>	B-X
Vaccination	B-X
represents	B-X
a	B-X
cornerstone	B-X
in	B-X
mastering	B-X
the	B-X
COVID-19	B-X
pandemic	B-X
.	B-X
Data	B-X
on	B-X
immunogenicity	B-X
and	B-X
safety	B-X
of	B-X
messenger	B-X
RNA	B-X
(	B-X
mRNA	B-X
)	B-X
vaccines	B-X
in	B-X
patients	B-X
with	B-X
autoimmune	B-X
inflammatory	B-X
rheumatic	B-X
diseases	B-X
(	B-X
AIIRD	B-X
)	B-X
are	B-X
limited	B-X
.	B-X
Placental	B-X
transfer	B-X
of	B-X
maternal	B-X
IgG	B-X
antibodies	B-X
to	B-X
the	B-X
fetus	B-X
is	B-X
an	B-X
important	B-X
mechanism	B-X
that	B-X
provides	B-X
protection	B-X
to	B-X
the	B-X
infant	B-X
while	B-X
his/her	B-X
humoral	B-X
response	B-X
is	B-X
inefficient	B-X
.	B-X
IgG	B-X
is	B-X
the	B-X
only	B-X
antibody	B-X
class	B-X
that	B-X
significantly	B-X
crosses	B-X
the	B-X
human	B-X
placenta	B-X
.	B-X
This	B-X
crossing	B-X
is	B-X
mediated	B-X
by	B-X
FcRn	B-X
expressed	B-X
on	B-X
syncytiotrophoblast	B-X
cells	B-X
.	B-X
There	B-X
is	B-X
evidence	B-X
that	B-X
IgG	B-X
transfer	B-X
depends	B-X
on	B-X
the	B-X
following	B-X
:	B-X
(	B-X
i	B-X
)	B-X
maternal	B-X
levels	B-X
of	B-X
total	B-X
IgG	B-X
and	B-X
specific	B-X
antibodies	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
gestational	B-X
age	B-X
,	B-X
(	B-X
iii	B-X
)	B-X
placental	B-X
integrity	B-X
,	B-X
(	B-X
iv	B-X
)	B-X
IgG	B-X
subclass	B-X
,	B-X
and	B-X
(	B-X
v	B-X
)	B-X
nature	B-X
of	B-X
antigen	B-X
,	B-X
being	B-X
more	B-X
intense	B-X
for	B-X
thymus-dependent	B-X
ones	B-X
.	B-X
These	B-X
features	B-X
represent	B-X
the	B-X
basis	B-X
for	B-X
maternal	B-X
immunization	B-X
strategies	B-X
aimed	B-X
at	B-X
protecting	B-X
newborns	B-X
against	B-X
neonatal	B-X
and	B-X
infantile	B-X
infectious	B-X
diseases	B-X
.	B-X
In	B-X
some	B-X
situations	B-X
,	B-X
such	B-X
as	B-X
mothers	B-X
with	B-X
primary	B-X
immunodeficiencies	B-X
,	B-X
exogenous	B-X
IgG	B-X
acquired	B-X
by	B-X
intravenous	B-X
immunoglobulin	B-X
therapy	B-X
crosses	B-X
the	B-X
placenta	B-X
in	B-X
similar	B-X
patterns	B-X
to	B-X
endogenous	B-X
immunoglobulins	B-X
and	B-X
may	B-X
also	B-X
protect	B-X
the	B-X
offspring	B-X
from	B-X
infections	B-X
in	B-X
early	B-X
life	B-X
.	B-X
Inversely	B-X
,	B-X
harmful	B-X
autoantibodies	B-X
may	B-X
cross	B-X
the	B-X
placenta	B-X
and	B-X
cause	B-X
transitory	B-X
autoimmune	B-X
disease	B-X
in	B-X
the	B-X
neonate	B-X
.	B-X

One	O
half	O
of	O
the	O
samples	O
was	O
used	O
to	O
analyze	O
PKC	O
kinase	O
activity	O
using	O
a	O
fluorescein	O
tagged	O
peptide	O
and	O
visualized	O
by	O
agarose	O
gel	O
electrophoresis	O
(	O
top	O
panel	O
)	O
,	O
while	O
the	O
other	O
half	O
was	O
subjected	O
to	O
Western	O
blot	O
analysis	O
to	O
confirm	O
equal	O
amounts	O
of	O
PKCalpha	B-Protein
were	O
immunoprecipitated	O
from	O
each	O
sample	O
(	O
middle	O
panel	O
)	O
.	O

The	O
kinase	O
assay	O
was	O
quantitated	O
using	O
Quantity	O
One	O
software	O
(	O
Bio	O
-	O
Rad	O
)	O
(	O
bottom	O
panel	O
)	O
.	O

Data	O
represents	O
the	O
average	O
fold	O
increase	O
of	O
PKCalpha	B-Protein
activity	O
in	O
non	O
-	O
stimulated	O
samples	O
compared	O
to	O
M	O
-	O
CSF	O
-	O
treated	O
MDM	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
for	O
three	O
independent	O
experiments	O
.	O

NS	O
:	O
non	O
-	O
stimulated	O
.	O
<EOS>	B-X
A	B-X
significant	B-X
portion	B-X
of	B-X
the	B-X
total	B-X
daily	B-X
growth	B-X
hormone	B-X
(	B-X
GH	B-X
)	B-X
secretion	B-X
is	B-X
associated	B-X
with	B-X
deep	B-X
non-REM	B-X
sleep	B-X
(	B-X
NREMS	B-X
)	B-X
.	B-X
GH	B-X
secretion	B-X
is	B-X
stimulated	B-X
by	B-X
the	B-X
hypothalamic	B-X
neurohormone	B-X
,	B-X
GH-releasing	B-X
hormone	B-X
(	B-X
GHRH	B-X
)	B-X
.	B-X
Magnetic	B-X
materials	B-X
have	B-X
shown	B-X
promise	B-X
in	B-X
this	B-X
field	B-X
,	B-X
as	B-X
they	B-X
can	B-X
be	B-X
manipulated	B-X
non-invasively	B-X
,	B-X
are	B-X
easily	B-X
functionalized	B-X
,	B-X
and	B-X
can	B-X
be	B-X
used	B-X
to	B-X
mechanically	B-X
stimulate	B-X
cells	B-X
.	B-X
The	B-X
high	B-X
energy	B-X
consumption	B-X
of	B-X
the	B-X
brain	B-X
at	B-X
rest	B-X
and	B-X
its	B-X
quantitative	B-X
usage	B-X
for	B-X
neurotransmission	B-X
reflect	B-X
a	B-X
high	B-X
level	B-X
of	B-X
neuronal	B-X
activity	B-X
for	B-X
the	B-X
non-stimulated	B-X
brain	B-X
.	B-X

*	O
The	O
p	O
-	O
values	O
of	O
M	O
-	O
CSF	O
stimulated	O
compared	O
to	O
non	O
-	O
stimulated	O
were	O
<	O
=	O
0	O
.	O
05	O
.	O

M	O
-	O
CSF	O
-	O
induced	O
PKC	O
activity	O
does	O
not	O
regulate	O
IkappaBalpha	B-Protein
degradation	O
but	O
regulates	O
the	O
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
at	O
Ser276	O
.	O
<EOS>	B-X
The	B-X
various	B-X
cell	B-X
surface	B-X
receptors	B-X
trigger	B-X
very	B-X
diverse	B-X
signal	B-X
transduction	B-X
pathways	B-X
including	B-X
activation	B-X
of	B-X
heterotrimeric	B-X
and	B-X
monomeric	B-X
G-proteins	B-X
,	B-X
receptor-induced	B-X
and	B-X
store-operated	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
signals	B-X
,	B-X
protein	B-X
and	B-X
lipid	B-X
kinases	B-X
,	B-X
adapter	B-X
proteins	B-X
and	B-X
cytoskeletal	B-X
rearrangement	B-X
.	B-X
The	B-X
various	B-X
cell	B-X
surface	B-X
receptors	B-X
trigger	B-X
very	B-X
diverse	B-X
signal	B-X
transduction	B-X
pathways	B-X
including	B-X
activation	B-X
of	B-X
heterotrimeric	B-X
and	B-X
monomeric	B-X
G-proteins	B-X
,	B-X
receptor-induced	B-X
and	B-X
store-operated	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
signals	B-X
,	B-X
protein	B-X
and	B-X
lipid	B-X
kinases	B-X
,	B-X
adapter	B-X
proteins	B-X
and	B-X
cytoskeletal	B-X
rearrangement	B-X
.	B-X
CXCR4	B-X
is	B-X
a	B-X
pleiotropic	B-X
chemokine	B-X
receptor	B-X
which	B-X
acts	B-X
through	B-X
its	B-X
ligand	B-X
CXCL12	B-X
to	B-X
regulate	B-X
diverse	B-X
physiological	B-X
processes	B-X
.	B-X
Macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
M-CSF	B-X
)	B-X
promotes	B-X
mononuclear	B-X
phagocyte	B-X
survival	B-X
and	B-X
proliferation	B-X
.	B-X
The	B-X
transcription	B-X
factor	B-X
Nuclear	B-X
Factor-kappaB	B-X
(	B-X
NF-κB	B-X
)	B-X
is	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
M-CSF-induced	B-X
mononuclear	B-X
phagocyte	B-X
survival	B-X
and	B-X
this	B-X
study	B-X
focused	B-X
at	B-X
identifying	B-X
the	B-X
mechanism	B-X
of	B-X
NF-κB	B-X
transcriptional	B-X
activation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
M-CSF	B-X
stimulated	B-X
NF-κB	B-X
transcriptional	B-X
activity	B-X
in	B-X
human	B-X
monocyte-derived	B-X
macrophages	B-X
(	B-X
MDMs	B-X
)	B-X
and	B-X
the	B-X
murine	B-X
macrophage	B-X
cell	B-X
line	B-X
RAW	B-X
264.7	B-X
.	B-X
The	B-X
general	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
inhibitor	B-X
Ro-31-8220	B-X
,	B-X
the	B-X
conventional	B-X
PKCα/β	B-X
inhibitor	B-X
Gö-6976	B-X
,	B-X
overexpression	B-X
of	B-X
dominant	B-X
negative	B-X
PKCα	B-X
constructs	B-X
and	B-X
PKCα	B-X
siRNA	B-X
reduced	B-X
NF-κB	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
M-CSF	B-X
.	B-X
Interestingly	B-X
,	B-X
Ro-31-8220	B-X
reduced	B-X
Ser276	B-X
phosphorylation	B-X
of	B-X
NF-κBp65	B-X
leading	B-X
to	B-X
decreased	B-X
M-CSF-induced	B-X
monocyte	B-X
survival	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
identify	B-X
conventional	B-X
PKCs	B-X
,	B-X
including	B-X
PKCα	B-X
as	B-X
important	B-X
upstream	B-X
kinases	B-X
for	B-X
M-CSF-induced	B-X
NF-κB	B-X
transcriptional	B-X
activation	B-X
,	B-X
NF-κB-regulated	B-X
gene	B-X
expression	B-X
,	B-X
NF-κB	B-X
p65	B-X
Ser276	B-X
phosphorylation	B-X
,	B-X
and	B-X
macrophage	B-X
survival	B-X
.	B-X
Lastly	B-X
,	B-X
we	B-X
find	B-X
that	B-X
NF-κB	B-X
p65	B-X
Ser276	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
basal	B-X
and	B-X
M-CSF-stimulated	B-X
NF-κB	B-X
activation	B-X
in	B-X
human	B-X
mononuclear	B-X
phagocytes	B-X
.	B-X

(	O
A	O
)	O
MDMs	O
were	O
pretreated	O
with	O
cycloheximide	O
(	O
CHX	O
)	O
in	O
the	O
absence	O
or	O
presence	O
of	O
Ro	O
-	O
31	O
-	O
8220	O
for	O
30	O
minutes	O
prior	O
to	O
M	O
-	O
CSF	O
stimulation	O
for	O
the	O
indicated	O
times	O
.	O

Whole	O
cell	O
lysates	O
were	O
subjected	O
to	O
Western	O
blotting	O
with	O
anti	O
-	O
IkappaBalpha	O
antibody	O
.	O

Data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O
<EOS>	B-X
We	B-X
performed	B-X
a	B-X
meta-analysis	B-X
of	B-X
gene	B-X
expression	B-X
profiles	B-X
in	B-X
data	B-X
sets	B-X
from	B-X
eight	B-X
independent	B-X
patient	B-X
cohorts	B-X
across	B-X
the	B-X
world	B-X
.	B-X
We	B-X
observed	B-X
three	B-X
robust	B-X
HCC	B-X
subclasses	B-X
(	B-X
termed	B-X
S1	B-X
,	B-X
S2	B-X
,	B-X
and	B-X
S3	B-X
)	B-X
,	B-X
each	B-X
correlated	B-X
with	B-X
clinical	B-X
parameters	B-X
such	B-X
as	B-X
tumor	B-X
size	B-X
,	B-X
extent	B-X
of	B-X
cellular	B-X
differentiation	B-X
,	B-X
and	B-X
serum	B-X
alpha-fetoprotein	B-X
levels	B-X
.	B-X
These	B-X
experiments	B-X
establish	B-X
the	B-X
first	B-X
consensus	B-X
classification	B-X
framework	B-X
for	B-X
HCC	B-X
based	B-X
on	B-X
gene	B-X
expression	B-X
profiles	B-X
and	B-X
highlight	B-X
the	B-X
power	B-X
of	B-X
integrating	B-X
multiple	B-X
data	B-X
sets	B-X
to	B-X
define	B-X
a	B-X
robust	B-X
molecular	B-X
taxonomy	B-X
of	B-X
the	B-X
disease	B-X
.	B-X
In	B-X
model-based	B-X
medical	B-X
image	B-X
analysis	B-X
,	B-X
three	B-X
relevant	B-X
features	B-X
are	B-X
the	B-X
shape	B-X
of	B-X
structures	B-X
of	B-X
interest	B-X
,	B-X
their	B-X
relative	B-X
pose	B-X
,	B-X
and	B-X
image	B-X
intensity	B-X
profiles	B-X
representative	B-X
of	B-X
some	B-X
physical	B-X
properties	B-X
.	B-X
However	B-X
,	B-X
analysing	B-X
articulated	B-X
objects	B-X
in	B-X
an	B-X
image	B-X
using	B-X
independent	B-X
single	B-X
object	B-X
models	B-X
may	B-X
lead	B-X
to	B-X
large	B-X
uncertainties	B-X
and	B-X
impingement	B-X
,	B-X
especially	B-X
around	B-X
organ	B-X
boundaries	B-X
.	B-X
Questions	B-X
that	B-X
come	B-X
to	B-X
mind	B-X
are	B-X
the	B-X
feasibility	B-X
of	B-X
building	B-X
a	B-X
unique	B-X
model	B-X
that	B-X
combines	B-X
all	B-X
three	B-X
features	B-X
of	B-X
interest	B-X
in	B-X
the	B-X
same	B-X
statistical	B-X
space	B-X
,	B-X
and	B-X
what	B-X
advantages	B-X
can	B-X
be	B-X
gained	B-X
for	B-X
image	B-X
analysis	B-X
.	B-X
We	B-X
validate	B-X
the	B-X
method	B-X
using	B-X
controlled	B-X
synthetic	B-X
data	B-X
and	B-X
we	B-X
perform	B-X
experiments	B-X
on	B-X
bone	B-X
structures	B-X
from	B-X
CT	B-X
images	B-X
of	B-X
the	B-X
shoulder	B-X
to	B-X
illustrate	B-X
the	B-X
efficacy	B-X
of	B-X
the	B-X
model	B-X
for	B-X
pose	B-X
and	B-X
shape	B-X
prediction	B-X
.	B-X

(	O
B	O
)	O
MDMs	O
were	O
pretreated	O
with	O
either	O
vehicle	O
or	O
Ro	O
-	O
31	O
-	O
8220	O
for	O
30	O
minutes	O
before	O
the	O
addition	O
of	O
M	O
-	O
CSF	O
for	O
10	O
minutes	O
.	O

Whole	O
cell	O
lysates	O
were	O
resolved	O
by	O
SDS	O
-	O
PAGE	O
and	O
phospho	O
-	O
Ser276	O
or	O
phospho	O
-	O
Ser536	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
was	O
detected	O
using	O
phospho	O
-	O
specific	O
antibodies	O
to	O
either	O
residue	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
.	O

(	O
C	O
)	O
Whole	O
cell	O
lysates	O
of	O
RAW	O
264	O
.	O
7	O
cells	O
treated	O
with	O
vehicle	O
control	O
or	O
Ro	O
-	O
31	O
-	O
8220	O
in	O
the	O
absence	O
or	O
presence	O
of	O
M	O
-	O
CSF	O
were	O
subjected	O
to	O
Western	O
blot	O
analysis	O
with	O
phospho	O
-	O
Ser276	O
or	O
phospho	O
-	O
Ser536	O
NF	O
-	O
kappaB	O
p65	O
antibodies	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
PTH	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
in	B-X
human	B-X
colon	B-X
adenocarcinoma	B-X
Caco-2	B-X
cells	B-X
.	B-X
Flow	B-X
cytometry	B-X
analysis	B-X
revealed	B-X
that	B-X
PTH	B-X
(	B-X
10	B-X
(	B-X
-8	B-X
)	B-X
M	B-X
,	B-X
12-24h	B-X
)	B-X
treatment	B-X
increases	B-X
the	B-X
number	B-X
of	B-X
cells	B-X
in	B-X
the	B-X
G0/G1	B-X
phase	B-X
and	B-X
diminishes	B-X
the	B-X
number	B-X
in	B-X
both	B-X
phases	B-X
S	B-X
and	B-X
G2/M	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
analysis	B-X
by	B-X
Western	B-X
blot	B-X
showed	B-X
that	B-X
the	B-X
hormone	B-X
increases	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
inhibitory	B-X
protein	B-X
p27Kip1	B-X
and	B-X
diminishes	B-X
the	B-X
expression	B-X
of	B-X
cyclin	B-X
D1	B-X
,	B-X
cyclin	B-X
D3	B-X
and	B-X
CDK6	B-X
.	B-X
However	B-X
,	B-X
the	B-X
amounts	B-X
of	B-X
CDK4	B-X
,	B-X
p21Cip1	B-X
,	B-X
p15INK4B	B-X
and	B-X
p16INK4A	B-X
were	B-X
not	B-X
different	B-X
in	B-X
the	B-X
absence	B-X
or	B-X
presence	B-X
of	B-X
PTH	B-X
.	B-X
Inhibitors	B-X
of	B-X
PKC	B-X
(	B-X
Ro-318220	B-X
,	B-X
bisindolylmaleimide	B-X
and	B-X
chelerythine	B-X
)	B-X
,	B-X
but	B-X
not	B-X
JNK	B-X
(	B-X
SP600125	B-X
)	B-X
and	B-X
PP2A	B-X
(	B-X
okadaic	B-X
acid	B-X
and	B-X
calyculin	B-X
A	B-X
)	B-X
,	B-X
reversed	B-X
PTH	B-X
response	B-X
in	B-X
Caco-2	B-X
cells	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
PTH	B-X
induces	B-X
G0/G1	B-X
phase	B-X
arrest	B-X
of	B-X
Caco-2	B-X
intestinal	B-X
cells	B-X
and	B-X
changes	B-X
the	B-X
expression	B-X
of	B-X
proteins	B-X
involved	B-X
in	B-X
cell	B-X
cycle	B-X
regulation	B-X
via	B-X
the	B-X
PKC	B-X
signaling	B-X
pathway	B-X
.	B-X

(	O
D	O
)	O
Cytosolic	O
and	O
nuclear	O
fractions	O
of	O
RAW	O
264	O
.	O
7	O
were	O
obtained	O
from	O
the	O
treated	O
cells	O
and	O
immunoblotted	O
for	O
phospho	O
-	O
NF	O
-	O
kappaB	O
.	O

The	O
purity	O
of	O
the	O
cytosolic	O
and	O
nuclear	O
fractions	O
was	O
confirmed	O
by	O
immunoblotting	O
with	O
GAPDH	O
and	O
Lamin	O
B	O
,	O
respectively	O
.	O

Shown	O
are	O
representative	O
blots	O
from	O
three	O
independent	O
experiments	O
.	O
<EOS>	B-X
The	B-X
gene	B-X
is	B-X
structurally	B-X
complex	B-X
,	B-X
demonstrated	B-X
in	B-X
part	B-X
by	B-X
Northern	B-X
blotting	B-X
experiments	B-X
which	B-X
detected	B-X
multiple	B-X
RNAs	B-X
ranging	B-X
in	B-X
size	B-X
from	B-X
4.2	B-X
to	B-X
9.6	B-X
kb	B-X
(	B-X
1	B-X
kb	B-X
=	B-X
10	B-X
(	B-X
3	B-X
)	B-X
bases	B-X
or	B-X
base-pairs	B-X
)	B-X
.	B-X
To	B-X
characterize	B-X
these	B-X
RNAs	B-X
and	B-X
to	B-X
understand	B-X
their	B-X
sequence	B-X
heterogeneity	B-X
,	B-X
we	B-X
isolated	B-X
and	B-X
analyzed	B-X
29	B-X
new	B-X
and	B-X
independent	B-X
cDNA	B-X
clones	B-X
representing	B-X
the	B-X
dnc	B-X
RNAs	B-X
.	B-X
The	B-X
RNAs	B-X
are	B-X
transcribed	B-X
from	B-X
at	B-X
least	B-X
three	B-X
initiation	B-X
sites	B-X
:	B-X
two	B-X
of	B-X
these	B-X
were	B-X
mapped	B-X
by	B-X
parallel	B-X
S1-nuclease	B-X
and	B-X
primer	B-X
extension	B-X
experiments	B-X
.	B-X
However	B-X
,	B-X
the	B-X
specific	B-X
effect	B-X
of	B-X
HDAC	B-X
inhibitors	B-X
on	B-X
androgen-sensitive	B-X
and	B-X
androgen-independent	B-X
cell	B-X
lines	B-X
have	B-X
not	B-X
been	B-X
thoroughly	B-X
studied	B-X
which	B-X
we	B-X
hypothesized	B-X
could	B-X
be	B-X
different	B-X
.	B-X
We	B-X
therefore	B-X
assessed	B-X
whether	B-X
three	B-X
structurally	B-X
unrelated	B-X
HDAC	B-X
inhibitors	B-X
,	B-X
trichostatin	B-X
A	B-X
(	B-X
TSA	B-X
)	B-X
,	B-X
depsipeptide	B-X
(	B-X
FR901228	B-X
)	B-X
,	B-X
and	B-X
sodium	B-X
butyrate	B-X
,	B-X
affect	B-X
cell	B-X
death	B-X
in	B-X
the	B-X
prostate	B-X
cancer	B-X
cell	B-X
lines	B-X
LNCaP	B-X
,	B-X
DU-145	B-X
,	B-X
and	B-X
PC-3	B-X
.	B-X

Inhibition	O
of	O
M	O
-	O
CSF	O
-	O
induced	O
PKC	O
reduces	O
NF	O
-	O
kappaB	O
-	O
regulated	O
genes	O
in	O
both	O
MDMs	O
and	O
RAW	O
264	O
.	O
7	O
cells	O
.	O

MDMs	O
(	O
A	O
and	O
C	O
)	O
and	O
RAW	O
264	O
.	O
7	O
(	O
B	O
)	O
cells	O
were	O
pretreated	O
with	O
Ro	O
-	O
31	O
-	O
8220	O
or	O
solvent	O
control	O
DMSO	O
for	O
30	O
minutes	O
prior	O
to	O
M	O
-	O
CSF	O
stimulation	O
for	O
the	O
indicated	O
times	O
.	O

Total	O
RNA	O
was	O
isolated	O
and	O
converted	O
to	O
cDNA	O
.	O
<EOS>	B-X
Reverse	B-X
transcription	B-X
PCR	B-X
(	B-X
RT-PCR	B-X
)	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
important	B-X
techniques	B-X
for	B-X
analyzing	B-X
RNA	B-X
abundance	B-X
.	B-X
MicroRNAs	B-X
(	B-X
miRNAs	B-X
)	B-X
are	B-X
a	B-X
group	B-X
of	B-X
20-	B-X
to	B-X
24-nucleotide	B-X
regulatory	B-X
small	B-X
RNAs	B-X
which	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
plants	B-X
and	B-X
animals	B-X
.	B-X
However	B-X
,	B-X
the	B-X
small	B-X
size	B-X
of	B-X
miRNAs	B-X
makes	B-X
them	B-X
difficult	B-X
to	B-X
be	B-X
detected	B-X
and	B-X
quantified	B-X
by	B-X
conventional	B-X
RT-PCR	B-X
techniques	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
a	B-X
poly	B-X
(	B-X
T	B-X
)	B-X
adaptor	B-X
RT-PCR	B-X
method	B-X
specifically	B-X
designed	B-X
for	B-X
quantifying	B-X
miRNAs	B-X
.	B-X
In	B-X
this	B-X
method	B-X
,	B-X
total	B-X
RNAs	B-X
,	B-X
including	B-X
miRNAs	B-X
,	B-X
are	B-X
extended	B-X
by	B-X
a	B-X
poly	B-X
(	B-X
A	B-X
)	B-X
tailing	B-X
reaction	B-X
using	B-X
poly	B-X
(	B-X
A	B-X
)	B-X
polymerase	B-X
and	B-X
ATP	B-X
.	B-X
The	B-X
miRNA	B-X
with	B-X
a	B-X
poly	B-X
(	B-X
A	B-X
)	B-X
tail	B-X
is	B-X
converted	B-X
into	B-X
cDNA	B-X
through	B-X
reverse	B-X
transcription	B-X
primed	B-X
by	B-X
a	B-X
poly	B-X
(	B-X
T	B-X
)	B-X
adaptor	B-X
,	B-X
and	B-X
then	B-X
PCR-amplified	B-X
using	B-X
a	B-X
miRNA-specific	B-X
forward	B-X
primer	B-X
and	B-X
a	B-X
universal	B-X
poly	B-X
(	B-X
T	B-X
)	B-X
adaptor	B-X
reverse	B-X
primer	B-X
.	B-X
The	B-X
RT-PCR	B-X
amplification	B-X
can	B-X
be	B-X
monitored	B-X
by	B-X
real-time	B-X
detection	B-X
or	B-X
by	B-X
end-point	B-X
detection	B-X
for	B-X
quantifying	B-X
the	B-X
miRNA	B-X
transcript	B-X
level	B-X
.	B-X
The	B-X
PCR	B-X
amplicons	B-X
can	B-X
be	B-X
sequenced	B-X
for	B-X
validating	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
specific	B-X
miRNA	B-X
gene	B-X
.	B-X

Real	O
-	O
time	O
RT	O
PCR	O
was	O
performed	O
using	O
primers	O
for	O
IkappaBalpha	B-Protein
,	O
BCL	B-Protein
-	I-Protein
xl	I-Protein
or	O
GAPDH	O
.	O
<EOS>	B-X
Glyceraldehyde-3-phosphate	B-X
dehydrogenase	B-X
(	B-X
GAPDH	B-X
)	B-X
has	B-X
long	B-X
been	B-X
recognized	B-X
as	B-X
an	B-X
important	B-X
enzyme	B-X
for	B-X
energy	B-X
metabolism	B-X
and	B-X
the	B-X
production	B-X
of	B-X
ATP	B-X
and	B-X
pyruvate	B-X
through	B-X
anaerobic	B-X
glycolysis	B-X
in	B-X
the	B-X
cytoplasm	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
GAPDH	B-X
has	B-X
multiple	B-X
functions	B-X
independent	B-X
of	B-X
its	B-X
role	B-X
in	B-X
energy	B-X
metabolism	B-X
.	B-X
Although	B-X
increased	B-X
GAPDH	B-X
gene	B-X
expression	B-X
and	B-X
enzymatic	B-X
function	B-X
is	B-X
associated	B-X
with	B-X
cell	B-X
proliferation	B-X
and	B-X
tumourigenesis	B-X
,	B-X
conditions	B-X
such	B-X
as	B-X
oxidative	B-X
stress	B-X
impair	B-X
GAPDH	B-X
catalytic	B-X
activity	B-X
and	B-X
lead	B-X
to	B-X
cellular	B-X
aging	B-X
and	B-X
apoptosis	B-X
.	B-X
The	B-X
mechanism	B-X
(	B-X
s	B-X
)	B-X
underlying	B-X
the	B-X
effects	B-X
of	B-X
GAPDH	B-X
on	B-X
cellular	B-X
proliferation	B-X
remains	B-X
unclear	B-X
,	B-X
yet	B-X
much	B-X
evidence	B-X
has	B-X
been	B-X
accrued	B-X
that	B-X
demonstrates	B-X
a	B-X
variety	B-X
of	B-X
interacting	B-X
partners	B-X
for	B-X
GAPDH	B-X
,	B-X
including	B-X
proteins	B-X
,	B-X
various	B-X
RNA	B-X
species	B-X
and	B-X
telomeric	B-X
DNA	B-X
.	B-X
The	B-X
present	B-X
mini	B-X
review	B-X
summarizes	B-X
recent	B-X
findings	B-X
relating	B-X
to	B-X
the	B-X
extraglycolytic	B-X
functions	B-X
of	B-X
GAPDH	B-X
and	B-X
highlights	B-X
the	B-X
significant	B-X
role	B-X
this	B-X
enzyme	B-X
plays	B-X
in	B-X
regulating	B-X
both	B-X
cell	B-X
survival	B-X
and	B-X
apoptotic	B-X
death	B-X
.	B-X

Data	O
are	O
expressed	O
as	O
relative	O
fold	O
increase	O
of	O
IkappaBalpha	B-Protein
or	O
BCL	B-Protein
-	I-Protein
xl	I-Protein
gene	O
expression	O
upon	O
treatment	O
over	O
non	O
-	O
stimulated	O
cells	O
.	O
<EOS>	B-X
Previously	B-X
,	B-X
we	B-X
observed	B-X
differential	B-X
gene	B-X
expression	B-X
between	B-X
the	B-X
two	B-X
populations	B-X
,	B-X
suggesting	B-X
that	B-X
colon	B-X
tumors	B-X
from	B-X
AA	B-X
patients	B-X
display	B-X
a	B-X
decreased	B-X
antitumor	B-X
immune	B-X
response	B-X
and	B-X
an	B-X
increased	B-X
expression	B-X
of	B-X
genes	B-X
encoding	B-X
proteins	B-X
involved	B-X
in	B-X
inflammatory	B-X
processes	B-X
,	B-X
such	B-X
as	B-X
Interleukin-1β	B-X
(	B-X
IL-1β	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
IL-1β	B-X
in	B-X
modifying	B-X
chemotherapeutic	B-X
response	B-X
and	B-X
altering	B-X
expression	B-X
of	B-X
proteins	B-X
in	B-X
novel	B-X
AA	B-X
and	B-X
well-established	B-X
CA	B-X
colon	B-X
cancer	B-X
cell	B-X
lines	B-X
.	B-X
NF-kappaB/Rel	B-X
is	B-X
a	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
which	B-X
are	B-X
expressed	B-X
in	B-X
all	B-X
cells	B-X
;	B-X
however	B-X
,	B-X
in	B-X
most	B-X
non-B	B-X
cells	B-X
,	B-X
they	B-X
are	B-X
sequestered	B-X
in	B-X
the	B-X
cytoplasm	B-X
in	B-X
inactive	B-X
complexes	B-X
with	B-X
specific	B-X
inhibitory	B-X
proteins	B-X
,	B-X
termed	B-X
IkappaBs	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
have	B-X
examined	B-X
the	B-X
time-course	B-X
of	B-X
induction	B-X
of	B-X
NF-kappaB/Rel	B-X
factors	B-X
upon	B-X
carcinogen	B-X
treatment	B-X
of	B-X
female	B-X
Sprague-Dawley	B-X
(	B-X
S-D	B-X
)	B-X
rats	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
human	B-X
mammary	B-X
epithelial	B-X
cells	B-X
(	B-X
HMECs	B-X
)	B-X
in	B-X
culture	B-X
.	B-X
In	B-X
S-D	B-X
rats	B-X
,	B-X
increased	B-X
NF-kappaB/Rel	B-X
binding	B-X
was	B-X
detected	B-X
in	B-X
nuclear	B-X
extracts	B-X
of	B-X
mammary	B-X
glands	B-X
from	B-X
40	B-X
%	B-X
of	B-X
animals	B-X
3	B-X
weeks	B-X
post-treatment	B-X
with	B-X
15	B-X
mg/kg	B-X
7,12-dimethylbenz	B-X
[	B-X
a	B-X
]	B-X
anthracene	B-X
(	B-X
DMBA	B-X
)	B-X
;	B-X
this	B-X
is	B-X
prior	B-X
to	B-X
formation	B-X
of	B-X
tumors	B-X
which	B-X
normally	B-X
begin	B-X
to	B-X
be	B-X
detected	B-X
after	B-X
7-9	B-X
weeks	B-X
.	B-X
In	B-X
non-tumorigenic	B-X
MCF-10F	B-X
cells	B-X
,	B-X
in	B-X
vitro	B-X
malignant	B-X
transformation	B-X
upon	B-X
treatment	B-X
with	B-X
either	B-X
DMBA	B-X
or	B-X
benzo	B-X
[	B-X
a	B-X
]	B-X
pyrene	B-X
(	B-X
B	B-X
[	B-X
a	B-X
]	B-X
P	B-X
)	B-X
resulted	B-X
in	B-X
a	B-X
4-	B-X
to	B-X
12-fold	B-X
increase	B-X
in	B-X
activity	B-X
of	B-X
classical	B-X
NF-kappaB	B-X
(	B-X
p65/p50	B-X
)	B-X
.	B-X
Ectopic	B-X
expression	B-X
of	B-X
the	B-X
transactivating	B-X
p65	B-X
subunit	B-X
of	B-X
NF-kappaB	B-X
in	B-X
MCF-10F	B-X
cells	B-X
induced	B-X
the	B-X
c-myc	B-X
oncogene	B-X
promoter	B-X
,	B-X
which	B-X
is	B-X
driven	B-X
by	B-X
two	B-X
NF-kappaB	B-X
elements	B-X
,	B-X
and	B-X
endogenous	B-X
c-Myc	B-X
levels	B-X
.	B-X

Data	O
represent	O
the	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
for	O
three	O
independent	O
experiments	O
.	O

PKCalpha	B-Protein
regulates	O
phosphorylation	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
at	O
Ser276	O
.	O
<EOS>	B-X
The	B-X
transcription	B-X
factor	B-X
Nuclear	B-X
Factor-kappaB	B-X
(	B-X
NF-κB	B-X
)	B-X
is	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
genes	B-X
involved	B-X
in	B-X
M-CSF-induced	B-X
mononuclear	B-X
phagocyte	B-X
survival	B-X
and	B-X
this	B-X
study	B-X
focused	B-X
at	B-X
identifying	B-X
the	B-X
mechanism	B-X
of	B-X
NF-κB	B-X
transcriptional	B-X
activation	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
M-CSF	B-X
stimulated	B-X
NF-κB	B-X
transcriptional	B-X
activity	B-X
in	B-X
human	B-X
monocyte-derived	B-X
macrophages	B-X
(	B-X
MDMs	B-X
)	B-X
and	B-X
the	B-X
murine	B-X
macrophage	B-X
cell	B-X
line	B-X
RAW	B-X
264.7	B-X
.	B-X
The	B-X
general	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
inhibitor	B-X
Ro-31-8220	B-X
,	B-X
the	B-X
conventional	B-X
PKCα/β	B-X
inhibitor	B-X
Gö-6976	B-X
,	B-X
overexpression	B-X
of	B-X
dominant	B-X
negative	B-X
PKCα	B-X
constructs	B-X
and	B-X
PKCα	B-X
siRNA	B-X
reduced	B-X
NF-κB	B-X
activity	B-X
in	B-X
response	B-X
to	B-X
M-CSF	B-X
.	B-X
Interestingly	B-X
,	B-X
Ro-31-8220	B-X
reduced	B-X
Ser276	B-X
phosphorylation	B-X
of	B-X
NF-κBp65	B-X
leading	B-X
to	B-X
decreased	B-X
M-CSF-induced	B-X
monocyte	B-X
survival	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
we	B-X
identify	B-X
conventional	B-X
PKCs	B-X
,	B-X
including	B-X
PKCα	B-X
as	B-X
important	B-X
upstream	B-X
kinases	B-X
for	B-X
M-CSF-induced	B-X
NF-κB	B-X
transcriptional	B-X
activation	B-X
,	B-X
NF-κB-regulated	B-X
gene	B-X
expression	B-X
,	B-X
NF-κB	B-X
p65	B-X
Ser276	B-X
phosphorylation	B-X
,	B-X
and	B-X
macrophage	B-X
survival	B-X
.	B-X
Lastly	B-X
,	B-X
we	B-X
find	B-X
that	B-X
NF-κB	B-X
p65	B-X
Ser276	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
basal	B-X
and	B-X
M-CSF-stimulated	B-X
NF-κB	B-X
activation	B-X
in	B-X
human	B-X
mononuclear	B-X
phagocytes	B-X
.	B-X

(	O
A	O
)	O
MDM	O
or	O
(	O
B	O
)	O
RAW	O
264	O
.	O
7	O
cells	O
were	O
transiently	O
transfected	O
with	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
along	O
with	O
either	O
WT	O
-	O
PKCalpha	B-Protein
or	O
the	O
kinase	O
-	O
deficient	O
(	O
KD	O
)	O
-	O
PKCalpha	B-Protein
construct	O
at	O
a	O
1	O
:	O
5	O
ratio	O
.	O

Cells	O
were	O
serum	O
starved	O
and	O
stimulated	O
with	O
M	O
-	O
CSF	O
and	O
then	O
SEAP	O
secretion	O
in	O
the	O
medium	O
was	O
measured	O
.	O

Data	O
is	O
from	O
of	O
three	O
independent	O
experiments	O
.	O
<EOS>	B-X
Gene	B-X
knockout	B-X
experiments	B-X
for	B-X
the	B-X
Mur	B-X
(	B-X
ein	B-X
)	B-X
genes	B-X
,	B-X
including	B-X
MurE	B-X
in	B-X
P.	B-X
patens	B-X
,	B-X
showed	B-X
that	B-X
the	B-X
peptidoglycan	B-X
synthesis	B-X
pathway	B-X
is	B-X
related	B-X
to	B-X
plastid	B-X
division	B-X
,	B-X
although	B-X
no	B-X
structure	B-X
can	B-X
be	B-X
detected	B-X
between	B-X
the	B-X
inner	B-X
and	B-X
outer	B-X
envelopes	B-X
of	B-X
the	B-X
chloroplasts	B-X
by	B-X
electron	B-X
microscopy	B-X
.	B-X
Based	B-X
on	B-X
data	B-X
regarding	B-X
plant	B-X
genomes	B-X
and	B-X
antibiotic	B-X
treatment	B-X
experiments	B-X
of	B-X
plastid	B-X
division	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
the	B-X
loss	B-X
of	B-X
peptidoglycan	B-X
occurred	B-X
independently	B-X
at	B-X
least	B-X
three	B-X
times	B-X
during	B-X
plant	B-X
evolution	B-X
:	B-X
from	B-X
the	B-X
lineage	B-X
of	B-X
red	B-X
algae	B-X
,	B-X
from	B-X
the	B-X
chlorophytes	B-X
,	B-X
and	B-X
during	B-X
land	B-X
plant	B-X
evolution	B-X
.	B-X
Data	B-X
independent	B-X
acquisition	B-X
(	B-X
DIA	B-X
)	B-X
has	B-X
emerged	B-X
as	B-X
a	B-X
powerful	B-X
proteomic	B-X
technique	B-X
with	B-X
exceptional	B-X
reproducibility	B-X
and	B-X
throughput	B-X
,	B-X
and	B-X
has	B-X
been	B-X
widely	B-X
applied	B-X
to	B-X
clinical	B-X
sample	B-X
analysis	B-X
.	B-X
We	B-X
employed	B-X
three	B-X
software	B-X
tools	B-X
(	B-X
DIA-NN	B-X
,	B-X
Spectronaut	B-X
,	B-X
and	B-X
EncyclopeDIA	B-X
)	B-X
for	B-X
data	B-X
analysis	B-X
and	B-X
generated	B-X
three	B-X
types	B-X
of	B-X
libraries	B-X
,	B-X
including	B-X
an	B-X
experiment-specific	B-X
library	B-X
built	B-X
by	B-X
DDA	B-X
analysis	B-X
of	B-X
off-line	B-X
fractions	B-X
,	B-X
a	B-X
FASTA	B-X
sequence	B-X
database	B-X
,	B-X
and	B-X
a	B-X
library	B-X
generated	B-X
by	B-X
gas-phase	B-X
fractionation	B-X
(	B-X
GPF	B-X
)	B-X
,	B-X
resulting	B-X
in	B-X
eight	B-X
analysis	B-X
pipelines	B-X
.	B-X

The	O
p	O
-	O
value	O
of	O
cells	O
transfected	O
with	O
KD	O
compared	O
to	O
those	O
transfected	O
with	O
WT	O
was	O
0	O
.	O
05	O
.	O

(	O
C	O
)	O
MDMs	O
were	O
removed	O
from	O
the	O
plate	O
using	O
accutase	O
and	O
apoptosis	O
of	O
MDMs	O
was	O
measured	O
by	O
flow	O
cytometry	O
using	O
Annexin	B-Protein
V	I-Protein
-	O
FITC	O
and	O
propidium	O
iodine	O
(	O
PI	O
)	O
.	O

(	O
D	O
)	O
Whole	O
cell	O
lysates	O
from	O
the	O
transfected	O
RAW	O
264	O
.	O
7	O
cells	O
were	O
subjected	O
to	O
Western	O
blot	O
analysis	O
with	O
phospho	O
-	O
Ser276	O
or	O
phospho	O
-	O
Ser536	O
NF	O
-	O
kappaB	O
p65	O
antibodies	O
.	O
<EOS>	B-X
The	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
regulated	B-X
by	B-X
multiple	B-X
phosphorylations	B-X
of	B-X
IkappaBs	B-X
and	B-X
the	B-X
NF-kappaB	B-X
p65	B-X
subunit	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
characterized	B-X
the	B-X
intracellular	B-X
signaling	B-X
pathway	B-X
leading	B-X
to	B-X
phosphorylation	B-X
of	B-X
p65	B-X
on	B-X
Ser-536	B-X
using	B-X
a	B-X
novel	B-X
anti-phospho-p65	B-X
(	B-X
Ser-536	B-X
)	B-X
antibody	B-X
.	B-X
The	B-X
Ser-536	B-X
of	B-X
endogenous	B-X
p65	B-X
was	B-X
rapidly	B-X
phosphorylated	B-X
in	B-X
response	B-X
to	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
NF-kappaB	B-X
stimulants	B-X
including	B-X
TNF-alpha	B-X
in	B-X
the	B-X
cytoplasm	B-X
and	B-X
rapidly	B-X
dephosphorylated	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
The	B-X
TNF-alpha-but	B-X
not	B-X
IL-1beta-induced	B-X
Ser-536	B-X
phosphorylation	B-X
was	B-X
severely	B-X
impaired	B-X
in	B-X
murine	B-X
embryonic	B-X
fibroblasts	B-X
derived	B-X
from	B-X
traf2-/-traf5-/-	B-X
mice	B-X
.	B-X
Bay	B-X
11-7082	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
IkappaB	B-X
phosphorylation	B-X
,	B-X
inhibited	B-X
the	B-X
TNF-alpha-induced	B-X
phosphorylation	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
overexpression	B-X
of	B-X
TGF-beta-activated	B-X
kinase	B-X
1	B-X
(	B-X
TAK1	B-X
)	B-X
,	B-X
IKKalpha	B-X
and	B-X
IKKbeta	B-X
stimulated	B-X
the	B-X
phosphorylation	B-X
,	B-X
and	B-X
their	B-X
dominant	B-X
negative	B-X
mutants	B-X
blocked	B-X
the	B-X
TNF-alpha-induced	B-X
phosphorylation	B-X
.	B-X
Moreover	B-X
,	B-X
small	B-X
interfering	B-X
RNAs	B-X
(	B-X
siRNAs	B-X
)	B-X
against	B-X
TAK1	B-X
,	B-X
IKKalpha	B-X
and	B-X
IKKbeta	B-X
blocked	B-X
the	B-X
phosphorylation	B-X
of	B-X
endogenous	B-X
p65	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
calyculin-A	B-X
,	B-X
a	B-X
protein	B-X
phosphatase	B-X
inhibitor	B-X
,	B-X
blocked	B-X
the	B-X
dephosphorylation	B-X
in	B-X
the	B-X
nucleus	B-X
in	B-X
vivo	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
similar	B-X
signaling	B-X
pathways	B-X
were	B-X
utilized	B-X
for	B-X
the	B-X
phosphorylations	B-X
of	B-X
IkappaBalpha	B-X
and	B-X
p65	B-X
,	B-X
which	B-X
further	B-X
support	B-X
the	B-X
idea	B-X
that	B-X
both	B-X
IkappaB	B-X
and	B-X
NF-kappaB	B-X
are	B-X
substrates	B-X
for	B-X
the	B-X
IKK	B-X
complex	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
.	B-X

Blots	O
were	O
immunoblotted	O
with	O
PKCalpha	B-Protein
to	O
determine	O
equal	O
protein	O
expression	O
for	O
the	O
PKCalpha	B-Protein
constructs	O
.	O
beta	B-Protein
-	I-Protein
actin	I-Protein
served	O
as	O
a	O
loading	O
control	O
.	O

Shown	O
is	O
a	O
representative	O
blot	O
from	O
three	O
independent	O
experiments	O
.	O
<EOS>	B-X
Could	B-X
the	B-X
follicle	B-X
proteome	B-X
be	B-X
mapped	B-X
by	B-X
identifying	B-X
specific	B-X
proteins	B-X
that	B-X
are	B-X
common	B-X
or	B-X
differ	B-X
between	B-X
three	B-X
developmental	B-X
stages	B-X
from	B-X
the	B-X
secondary	B-X
follicle	B-X
(	B-X
SF	B-X
)	B-X
to	B-X
the	B-X
antrum-like	B-X
stage	B-X
?	B-X
Results	B-X
from	B-X
three	B-X
independent	B-X
microarray	B-X
experiments	B-X
revealed	B-X
that	B-X
the	B-X
expression	B-X
of	B-X
many	B-X
transcripts	B-X
was	B-X
affected	B-X
by	B-X
aldosterone	B-X
treatment	B-X
.	B-X
Northern	B-X
blot	B-X
analysis	B-X
confirmed	B-X
the	B-X
upregulation	B-X
of	B-X
four	B-X
distinct	B-X
transcripts	B-X
identified	B-X
by	B-X
the	B-X
microarray	B-X
analysis	B-X
,	B-X
namely	B-X
,	B-X
the	B-X
serum	B-X
and	B-X
glucose-regulated	B-X
kinase	B-X
sgk	B-X
,	B-X
connective	B-X
tissue	B-X
growth	B-X
factor	B-X
,	B-X
period	B-X
homolog	B-X
,	B-X
and	B-X
preproendothelin	B-X
.	B-X
Immunoblot	B-X
analysis	B-X
for	B-X
preproendothelin	B-X
demonstrated	B-X
increased	B-X
protein	B-X
expression	B-X
.	B-X

(	O
E	O
)	O
MDM	O
or	O
(	O
F	O
)	O
RAW	O
264	O
.	O
7	O
cells	O
were	O
transiently	O
transfected	O
with	O
a	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
along	O
with	O
either	O
100	O
nM	O
PKCalpha	B-Protein
siRNA	I-Protein
or	O
control	O
siRNA	O
for	O
20	O
-	O
24	O
hours	O
.	O
<EOS>	B-X
Although	B-X
transcriptional	B-X
changes	B-X
in	B-X
hypoxic	B-X
cardiomyocytes	B-X
are	B-X
well	B-X
studied	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
proteins	B-X
that	B-X
are	B-X
actively	B-X
secreted	B-X
from	B-X
these	B-X
cells	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
metformin	B-X
in	B-X
endothelial	B-X
cell	B-X
injury	B-X
and	B-X
endothelial-mesenchymal	B-X
transition	B-X
(	B-X
EndMT	B-X
)	B-X
induced	B-X
by	B-X
hypoxia	B-X
.	B-X
All	B-X
experiments	B-X
were	B-X
performed	B-X
in	B-X
human	B-X
cardiac	B-X
microvascular	B-X
endothelial	B-X
cells	B-X
(	B-X
HCMECs	B-X
)	B-X
.	B-X
HCMECs	B-X
were	B-X
exposed	B-X
to	B-X
hypoxic	B-X
conditions	B-X
for	B-X
24	B-X
,	B-X
48	B-X
,	B-X
72	B-X
,	B-X
and	B-X
96	B-X
hours	B-X
,	B-X
and	B-X
we	B-X
assessed	B-X
the	B-X
cell	B-X
viability	B-X
by	B-X
cell	B-X
counting	B-X
kit	B-X
8	B-X
;	B-X
metformin	B-X
(	B-X
2	B-X
,	B-X
5	B-X
,	B-X
10	B-X
,	B-X
and	B-X
20	B-X
mmol/L	B-X
)	B-X
was	B-X
added	B-X
to	B-X
the	B-X
cells	B-X
after	B-X
exposure	B-X
to	B-X
the	B-X
hypoxic	B-X
conditions	B-X
for	B-X
48	B-X
hours	B-X
.	B-X
The	B-X
cells	B-X
were	B-X
randomly	B-X
divided	B-X
into	B-X
the	B-X
control	B-X
group	B-X
,	B-X
hypoxia	B-X
group	B-X
,	B-X
hypoxia	B-X
+	B-X
metformin	B-X
group	B-X
,	B-X
hypoxia	B-X
+	B-X
control	B-X
small	B-X
interfering	B-X
RNA	B-X
group	B-X
,	B-X
hypoxia	B-X
+	B-X
small	B-X
interfering	B-X
Prkaa1	B-X
(	B-X
siPrkaa1	B-X
)	B-X
group	B-X
,	B-X
and	B-X
hypoxia	B-X
+	B-X
siPrkaa1	B-X
+	B-X
metformin	B-X
group	B-X
.	B-X
Flow	B-X
cytometry	B-X
and	B-X
cell	B-X
counting	B-X
kit	B-X
8	B-X
were	B-X
used	B-X
to	B-X
monitor	B-X
apoptosis	B-X
and	B-X
assess	B-X
cell	B-X
viability	B-X
.	B-X
Immunofluorescence	B-X
staining	B-X
was	B-X
used	B-X
to	B-X
identify	B-X
the	B-X
CD31+/alpha	B-X
smooth	B-X
muscle	B-X
actin+	B-X
double-positive	B-X
cells	B-X
.	B-X
Hypoxia	B-X
contributed	B-X
to	B-X
endothelial	B-X
injuries	B-X
and	B-X
EndMT	B-X
of	B-X
HCMECs	B-X
in	B-X
a	B-X
time-dependent	B-X
manner	B-X
,	B-X
which	B-X
was	B-X
mainly	B-X
manifested	B-X
as	B-X
decreases	B-X
in	B-X
cell	B-X
viability	B-X
,	B-X
increases	B-X
in	B-X
apoptotic	B-X
rate	B-X
,	B-X
and	B-X
changes	B-X
in	B-X
expression	B-X
of	B-X
apoptosis-related	B-X
and	B-X
EndMT-related	B-X
mRNAs	B-X
and	B-X
proteins	B-X
.	B-X
Furthermore	B-X
,	B-X
metformin	B-X
could	B-X
attenuate	B-X
the	B-X
injuries	B-X
and	B-X
EndMT	B-X
caused	B-X
by	B-X
hypoxia	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
metformin	B-X
can	B-X
attenuate	B-X
endothelial	B-X
injuries	B-X
and	B-X
suppress	B-X
EndMT	B-X
of	B-X
HCMECs	B-X
under	B-X
hypoxic	B-X
conditions	B-X
because	B-X
of	B-X
its	B-X
ability	B-X
to	B-X
activate	B-X
the	B-X
AMPK	B-X
pathway	B-X
,	B-X
increase	B-X
p-AMPK/AMP-activated	B-X
protein	B-X
kinase	B-X
,	B-X
and	B-X
inhibit	B-X
mammalian	B-X
target	B-X
of	B-X
rapamycin	B-X
.	B-X

Cells	O
were	O
serum	O
starved	O
for	O
2	O
-	O
4	O
hours	O
and	O
stimulated	O
with	O
100	O
ng	O
/	O
ml	O
M	O
-	O
CSF	O
for	O
6	O
hours	O
for	O
MDM	O
or	O
RAW	O
264	O
.	O
7	O
for	O
2	O
hours	O
and	O
then	O
SEAP	O
secretion	O
in	O
the	O
medium	O
was	O
measured	O
.	O

Shown	O
is	O
data	O
of	O
three	O
independent	O
experiments	O
.	O
<EOS>	B-X
Gene	B-X
knockout	B-X
experiments	B-X
for	B-X
the	B-X
Mur	B-X
(	B-X
ein	B-X
)	B-X
genes	B-X
,	B-X
including	B-X
MurE	B-X
in	B-X
P.	B-X
patens	B-X
,	B-X
showed	B-X
that	B-X
the	B-X
peptidoglycan	B-X
synthesis	B-X
pathway	B-X
is	B-X
related	B-X
to	B-X
plastid	B-X
division	B-X
,	B-X
although	B-X
no	B-X
structure	B-X
can	B-X
be	B-X
detected	B-X
between	B-X
the	B-X
inner	B-X
and	B-X
outer	B-X
envelopes	B-X
of	B-X
the	B-X
chloroplasts	B-X
by	B-X
electron	B-X
microscopy	B-X
.	B-X
Based	B-X
on	B-X
data	B-X
regarding	B-X
plant	B-X
genomes	B-X
and	B-X
antibiotic	B-X
treatment	B-X
experiments	B-X
of	B-X
plastid	B-X
division	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
the	B-X
loss	B-X
of	B-X
peptidoglycan	B-X
occurred	B-X
independently	B-X
at	B-X
least	B-X
three	B-X
times	B-X
during	B-X
plant	B-X
evolution	B-X
:	B-X
from	B-X
the	B-X
lineage	B-X
of	B-X
red	B-X
algae	B-X
,	B-X
from	B-X
the	B-X
chlorophytes	B-X
,	B-X
and	B-X
during	B-X
land	B-X
plant	B-X
evolution	B-X
.	B-X
Data	B-X
independent	B-X
acquisition	B-X
(	B-X
DIA	B-X
)	B-X
has	B-X
emerged	B-X
as	B-X
a	B-X
powerful	B-X
proteomic	B-X
technique	B-X
with	B-X
exceptional	B-X
reproducibility	B-X
and	B-X
throughput	B-X
,	B-X
and	B-X
has	B-X
been	B-X
widely	B-X
applied	B-X
to	B-X
clinical	B-X
sample	B-X
analysis	B-X
.	B-X
DIA	B-X
approaches	B-X
normally	B-X
rely	B-X
on	B-X
project-specific	B-X
spectral	B-X
libraries	B-X
generated	B-X
by	B-X
data	B-X
dependent	B-X
acquisition	B-X
(	B-X
DDA	B-X
)	B-X
,	B-X
requiring	B-X
extensive	B-X
off-line	B-X
fractionation	B-X
and	B-X
large	B-X
amounts	B-X
of	B-X
input	B-X
material	B-X
.	B-X
We	B-X
employed	B-X
three	B-X
software	B-X
tools	B-X
(	B-X
DIA-NN	B-X
,	B-X
Spectronaut	B-X
,	B-X
and	B-X
EncyclopeDIA	B-X
)	B-X
for	B-X
data	B-X
analysis	B-X
and	B-X
generated	B-X
three	B-X
types	B-X
of	B-X
libraries	B-X
,	B-X
including	B-X
an	B-X
experiment-specific	B-X
library	B-X
built	B-X
by	B-X
DDA	B-X
analysis	B-X
of	B-X
off-line	B-X
fractions	B-X
,	B-X
a	B-X
FASTA	B-X
sequence	B-X
database	B-X
,	B-X
and	B-X
a	B-X
library	B-X
generated	B-X
by	B-X
gas-phase	B-X
fractionation	B-X
(	B-X
GPF	B-X
)	B-X
,	B-X
resulting	B-X
in	B-X
eight	B-X
analysis	B-X
pipelines	B-X
.	B-X
Then	B-X
we	B-X
systematically	B-X
compared	B-X
the	B-X
performance	B-X
of	B-X
the	B-X
eight	B-X
strategies	B-X
by	B-X
analyzing	B-X
the	B-X
DIA	B-X
data	B-X
from	B-X
HEK293T	B-X
cell	B-X
tryptic	B-X
peptides	B-X
with	B-X
sample	B-X
loads	B-X
of	B-X
500	B-X
ng	B-X
,	B-X
100	B-X
ng	B-X
,	B-X
20	B-X
ng	B-X
,	B-X
and	B-X
4	B-X
ng	B-X
.	B-X

(	O
G	O
)	O
MDMs	O
were	O
removed	O
from	O
the	O
plate	O
using	O
accutase	O
and	O
apoptosis	O
of	O
MDMs	O
was	O
measured	O
by	O
Annexin	B-Protein
V	I-Protein
-	O
FITC	O
and	O
propidium	O
iodine	O
(	O
PI	O
)	O
staining	O
and	O
analyzed	O
by	O
flow	O
cytometry	O
.	O

(	O
H	O
)	O
Whole	O
cell	O
lysates	O
from	O
the	O
transfected	O
MDM	O
and	O
RAW	O
264	O
.	O
7	O
cells	O
were	O
subjected	O
to	O
Western	O
blot	O
analysis	O
with	O
PKCalpha	O
antibody	O
.	O
beta	B-Protein
-	I-Protein
actin	I-Protein
served	O
as	O
a	O
loading	O
control	O
.	O

Shown	O
is	O
a	O
representative	O
blot	O
from	O
at	O
least	O
three	O
independent	O
experiments	O
.	O

NF	O
-	O
kappaB	O
p65	B-Protein
Ser276	O
is	O
essential	O
in	O
regulating	O
NF	O
-	O
kappaB	O
activity	O
.	O
<EOS>	B-X
Epithelial-mesenchymal	B-X
transition	B-X
(	B-X
EMT	B-X
)	B-X
is	B-X
an	B-X
essential	B-X
process	B-X
in	B-X
breast	B-X
cancer	B-X
metastasis	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
determine	B-X
the	B-X
role	B-X
of	B-X
secretions	B-X
of	B-X
tumor-associated	B-X
leukocytes	B-X
(	B-X
TALs	B-X
)	B-X
isolated	B-X
from	B-X
negative	B-X
and	B-X
positive	B-X
lymph	B-X
nodes	B-X
(	B-X
nLNs	B-X
and	B-X
pLNs	B-X
,	B-X
respectively	B-X
)	B-X
breast	B-X
cancer	B-X
patients	B-X
in	B-X
regulating	B-X
EMT	B-X
mechanism	B-X
and	B-X
the	B-X
associated	B-X
signaling	B-X
pathways	B-X
.	B-X
Secretome	B-X
of	B-X
TALs	B-X
of	B-X
pLNs	B-X
possessed	B-X
higher	B-X
TARC	B-X
,	B-X
IGF-1	B-X
,	B-X
IL-3	B-X
,	B-X
TNF-β	B-X
,	B-X
IL-5	B-X
,	B-X
G-CSF	B-X
,	B-X
IL-4	B-X
,	B-X
and	B-X
IL-1α	B-X
with	B-X
more	B-X
than	B-X
a	B-X
fivefold	B-X
compared	B-X
to	B-X
those	B-X
of	B-X
nLNs	B-X
.	B-X
The	B-X
Transcription	B-X
Factor	B-X
NF-κB	B-X
Mediates	B-X
Thyrotropin-Stimulated	B-X
Expression	B-X
of	B-X
Thyroid	B-X
Differentiation	B-X
Markers	B-X
.	B-X

(	O
A	O
)	O
Raw	O
264	O
.	O
7	O
cell	O
line	O
was	O
transiently	O
transfected	O
with	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
along	O
with	O
empty	O
vector	O
or	O
plasmid	O
encoding	O
either	O
NF	O
-	O
kappaB	O
p65	B-Protein
WT	O
or	O
NF	O
-	O
kappaB	O
p65	B-Protein
276S	O
/	O
A	O
.	O
<EOS>	B-X
The	B-X
NF-κB	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
and	B-X
associated	B-X
signalling	B-X
pathways	B-X
are	B-X
abundant	B-X
and	B-X
ubiquitous	B-X
in	B-X
human	B-X
immune	B-X
responses	B-X
.	B-X
Activation	B-X
of	B-X
NF-κB	B-X
transcription	B-X
factors	B-X
by	B-X
viral	B-X
pathogen-associated	B-X
molecular	B-X
patterns	B-X
,	B-X
such	B-X
as	B-X
viral	B-X
RNA	B-X
and	B-X
DNA	B-X
,	B-X
is	B-X
fundamental	B-X
to	B-X
anti-viral	B-X
innate	B-X
immune	B-X
defences	B-X
and	B-X
pro-inflammatory	B-X
cytokine	B-X
production	B-X
that	B-X
steers	B-X
adaptive	B-X
immune	B-X
responses	B-X
.	B-X
Diverse	B-X
non-viral	B-X
stimuli	B-X
,	B-X
such	B-X
as	B-X
lipopolysaccharide	B-X
and	B-X
cytokines	B-X
,	B-X
also	B-X
activate	B-X
NF-κB	B-X
and	B-X
the	B-X
same	B-X
anti-pathogen	B-X
gene	B-X
networks	B-X
.	B-X
Viruses	B-X
adapted	B-X
to	B-X
human	B-X
cells	B-X
often	B-X
encode	B-X
multiple	B-X
proteins	B-X
targeting	B-X
the	B-X
NF-κB	B-X
pathway	B-X
to	B-X
mitigate	B-X
the	B-X
anti-viral	B-X
effects	B-X
of	B-X
NF-κB-dependent	B-X
host	B-X
immunity	B-X
.	B-X

The	O
cells	O
were	O
transfected	O
for	O
18	O
-	O
24	O
hours	O
,	O
serum	O
starved	O
for	O
4	O
hours	O
,	O
and	O
then	O
incubated	O
with	O
10	O
microM	O
of	O
Ro	O
-	O
31	O
-	O
8220	O
for	O
30	O
minutes	O
prior	O
to	O
treatment	O
with	O
100	O
ng	O
/	O
ml	O
of	O
M	O
-	O
CSF	O
for	O
2	O
hours	O
and	O
SEAP	O
secretion	O
in	O
the	O
medium	O
was	O
measured	O
.	O

(	O
B	O
)	O
NF	O
-	O
kappaB	O
p65	B-Protein
-	O
/	O
-	O
cell	O
line	O
was	O
transiently	O
transfected	O
with	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
along	O
with	O
empty	O
vector	O
or	O
plasmid	O
encoding	O
either	O
NF	O
-	O
kappaB	O
p65	B-Protein
WT	O
,	O
NF	O
-	O
kappaB	O
p65	B-Protein
276S	O
/	O
A	O
,	O
or	O
NF	O
-	O
kappaB	O
p65	B-Protein
536S	O
/	O
A	O
.	O

The	O
cells	O
were	O
cultured	O
for	O
24	O
hours	O
and	O
then	O
serum	O
starved	O
for	O
4	O
hours	O
.	O
<EOS>	B-X
The	B-X
cells	B-X
were	B-X
then	B-X
simultaneously	B-X
stained	B-X
for	B-X
DNA	B-X
content	B-X
and	B-X
protein	B-X
content	B-X
and	B-X
the	B-X
percentages	B-X
of	B-X
cells	B-X
in	B-X
G1	B-X
,	B-X
G0	B-X
,	B-X
S	B-X
,	B-X
and	B-X
G2	B-X
+	B-X
M	B-X
were	B-X
estimated	B-X
.	B-X
In	B-X
the	B-X
first	B-X
experiment	B-X
,	B-X
cells	B-X
were	B-X
either	B-X
cycling	B-X
,	B-X
grown	B-X
to	B-X
confluence	B-X
,	B-X
or	B-X
serum-starved	B-X
for	B-X
5	B-X
days	B-X
.	B-X
Serum	B-X
starvation	B-X
increased	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
the	B-X
percentage	B-X
of	B-X
cells	B-X
in	B-X
G0	B-X
compared	B-X
to	B-X
confluent	B-X
or	B-X
cycling	B-X
cells	B-X
from	B-X
3	B-X
%	B-X
to	B-X
8	B-X
%	B-X
to	B-X
22	B-X
%	B-X
.	B-X
By	B-X
using	B-X
forward	B-X
scatter	B-X
to	B-X
determine	B-X
the	B-X
size	B-X
of	B-X
the	B-X
cells	B-X
it	B-X
was	B-X
determined	B-X
that	B-X
if	B-X
small	B-X
cells	B-X
(	B-X
7-15	B-X
microm	B-X
)	B-X
were	B-X
selected	B-X
from	B-X
the	B-X
serum-starved	B-X
group	B-X
43.9	B-X
%	B-X
will	B-X
be	B-X
in	B-X
G	B-X
(	B-X
0	B-X
)	B-X
as	B-X
compared	B-X
to	B-X
4.5	B-X
%	B-X
of	B-X
cycling	B-X
cells	B-X
and	B-X
9.9	B-X
%	B-X
of	B-X
confluent	B-X
cells	B-X
.	B-X
Dimethyl	B-X
sulfoxide	B-X
(	B-X
DMSO	B-X
)	B-X
treatment	B-X
(	B-X
0	B-X
%	B-X
,	B-X
0.5	B-X
%	B-X
,	B-X
or	B-X
1.0	B-X
%	B-X
)	B-X
for	B-X
72	B-X
hours	B-X
(	B-X
shown	B-X
to	B-X
synchronize	B-X
some	B-X
cell	B-X
types	B-X
in	B-X
G0	B-X
)	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
the	B-X
percentage	B-X
of	B-X
cells	B-X
in	B-X
G0	B-X
,	B-X
G1	B-X
,	B-X
S	B-X
,	B-X
or	B-X
G2	B-X
+	B-X
M.	B-X
Treatment	B-X
with	B-X
mimosine	B-X
(	B-X
0	B-X
microM	B-X
,	B-X
0.4	B-X
microM	B-X
,	B-X
0.8	B-X
microM	B-X
or	B-X
1.2	B-X
microM	B-X
)	B-X
,	B-X
a	B-X
compound	B-X
that	B-X
should	B-X
synchronize	B-X
the	B-X
cells	B-X
in	B-X
G1	B-X
,	B-X
increased	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
the	B-X
percentage	B-X
of	B-X
cells	B-X
in	B-X
G1	B-X
from	B-X
66.7	B-X
%	B-X
(	B-X
0	B-X
microM	B-X
mimosine	B-X
)	B-X
to	B-X
79.0	B-X
%	B-X
to	B-X
82.0	B-X
%	B-X
.	B-X
Finally	B-X
,	B-X
treatment	B-X
with	B-X
colchicine	B-X
for	B-X
24	B-X
hours	B-X
(	B-X
shown	B-X
to	B-X
synchronize	B-X
some	B-X
cell	B-X
types	B-X
in	B-X
G2	B-X
+	B-X
M	B-X
)	B-X
increased	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
the	B-X
percentage	B-X
of	B-X
cells	B-X
in	B-X
G2	B-X
+	B-X
M	B-X
(	B-X
0	B-X
microM	B-X
colchicine	B-X
)	B-X
from	B-X
13.3	B-X
%	B-X
to	B-X
27.2	B-X
%	B-X
to	B-X
31.6	B-X
%	B-X
.	B-X

Cells	O
were	O
then	O
incubated	O
in	O
fresh	O
DMEM	O
medium	O
for	O
2	O
hours	O
and	O
SEAP	O
secretion	O
in	O
the	O
medium	O
was	O
measured	O
.	O

The	O
results	O
shown	O
are	O
fold	O
change	O
over	O
empty	O
vector	O
+	O
pTAL	O
-	O
SEAP	O
.	O

(	O
C	O
)	O
NF	O
-	O
kappaB	O
p65	B-Protein
-	O
/	O
-	O
cell	O
line	O
was	O
transiently	O
transfected	O
with	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
with	O
either	O
empty	O
vector	O
or	O
plasmid	O
encoding	O
either	O
NF	O
-	O
kappaB	O
p65	B-Protein
WT	O
or	O
NF	O
-	O
kappaB	O
p65	B-Protein
276S	O
/	O
A	O
.	O
<EOS>	B-X
DDR1	B-X
is	B-X
expressed	B-X
in	B-X
the	B-X
intestinal	B-X
epithelium	B-X
,	B-X
but	B-X
its	B-X
role	B-X
in	B-X
Ulcerative	B-X
Colitis	B-X
(	B-X
UC	B-X
)	B-X
is	B-X
poorly	B-X
understand	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
identify	B-X
the	B-X
function	B-X
of	B-X
DDR1	B-X
in	B-X
maintaining	B-X
the	B-X
homeostasis	B-X
of	B-X
UC	B-X
.	B-X
The	B-X
NF-κB	B-X
family	B-X
of	B-X
transcription	B-X
factors	B-X
and	B-X
associated	B-X
signalling	B-X
pathways	B-X
are	B-X
abundant	B-X
and	B-X
ubiquitous	B-X
in	B-X
human	B-X
immune	B-X
responses	B-X
.	B-X
Activation	B-X
of	B-X
NF-κB	B-X
transcription	B-X
factors	B-X
by	B-X
viral	B-X
pathogen-associated	B-X
molecular	B-X
patterns	B-X
,	B-X
such	B-X
as	B-X
viral	B-X
RNA	B-X
and	B-X
DNA	B-X
,	B-X
is	B-X
fundamental	B-X
to	B-X
anti-viral	B-X
innate	B-X
immune	B-X
defences	B-X
and	B-X
pro-inflammatory	B-X
cytokine	B-X
production	B-X
that	B-X
steers	B-X
adaptive	B-X
immune	B-X
responses	B-X
.	B-X
Diverse	B-X
non-viral	B-X
stimuli	B-X
,	B-X
such	B-X
as	B-X
lipopolysaccharide	B-X
and	B-X
cytokines	B-X
,	B-X
also	B-X
activate	B-X
NF-κB	B-X
and	B-X
the	B-X
same	B-X
anti-pathogen	B-X
gene	B-X
networks	B-X
.	B-X
Viruses	B-X
adapted	B-X
to	B-X
human	B-X
cells	B-X
often	B-X
encode	B-X
multiple	B-X
proteins	B-X
targeting	B-X
the	B-X
NF-κB	B-X
pathway	B-X
to	B-X
mitigate	B-X
the	B-X
anti-viral	B-X
effects	B-X
of	B-X
NF-κB-dependent	B-X
host	B-X
immunity	B-X
.	B-X

The	O
cells	O
were	O
transfected	O
for	O
24	O
hours	O
and	O
serum	O
starved	O
for	O
4	O
hours	O
,	O
and	O
then	O
incubated	O
with	O
10	O
microM	O
of	O
Ro	O
-	O
31	O
-	O
8220	O
for	O
30	O
minutes	O
prior	O
to	O
treatment	O
with	O
10	O
ng	O
/	O
ml	O
of	O
TNFalpha	B-Protein
.	O

The	O
supernatant	O
were	O
collected	O
after	O
2	O
hours	O
of	O
treatment	O
and	O
SEAP	O
secretion	O
in	O
the	O
medium	O
was	O
measured	O
.	O

The	O
results	O
shown	O
are	O
the	O
fold	O
change	O
over	O
empty	O
vector	O
+	O
pNF	O
-	O
kappaB	O
-	O
SEAP	O
.	O

Data	O
shown	O
are	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
for	O
at	O
least	O
three	O
independent	O
experiments	O
performed	O
in	O
duplicate	O
.	O

Proposed	O
model	O
for	O
M	O
-	O
CSF	O
-	O
induced	O
monocyte	O
survival	O
via	O
PKC	O
regulation	O
by	O
activating	O
NF	O
-	O
kappaB	O
p65	B-Protein
phosphorylation	O
at	O
Ser276	O
.	O

SHARPIN	B-Protein
Is	O
Essential	O
for	O
Cytokine	O
Production	O
,	O
NF	O
-	O
kappaB	O
Signaling	O
,	O
and	O
Induction	O
of	O
Th1	O
Differentiation	O
by	O
Dendritic	O
Cells	O
<EOS>	B-X
Spontaneous	B-X
mutations	B-X
of	B-X
the	B-X
Sharpin	B-X
(	B-X
SHANK-associated	B-X
RH	B-X
domain-interacting	B-X
protein	B-X
,	B-X
other	B-X
aliases	B-X
:	B-X
Rbckl1	B-X
,	B-X
Sipl1	B-X
)	B-X
gene	B-X
in	B-X
mice	B-X
result	B-X
in	B-X
systemic	B-X
inflammation	B-X
that	B-X
is	B-X
characterized	B-X
by	B-X
chronic	B-X
proliferative	B-X
dermatitis	B-X
and	B-X
dysregulated	B-X
secretion	B-X
of	B-X
T	B-X
helper1	B-X
(	B-X
Th1	B-X
)	B-X
and	B-X
Th2	B-X
cytokines	B-X
.	B-X
Dendritic	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
initiation	B-X
and	B-X
progression	B-X
of	B-X
the	B-X
phenotype	B-X
of	B-X
SHARPIN-deficient	B-X
mice	B-X
because	B-X
of	B-X
their	B-X
pivotal	B-X
role	B-X
in	B-X
innate	B-X
and	B-X
adaptive	B-X
immunity	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
by	B-X
flow	B-X
cytometry	B-X
that	B-X
SHARPIN-	B-X
deficiency	B-X
did	B-X
not	B-X
alter	B-X
the	B-X
distribution	B-X
of	B-X
different	B-X
DC	B-X
subtypes	B-X
in	B-X
the	B-X
spleen	B-X
.	B-X
However	B-X
,	B-X
stimulated	B-X
SHARPIN-deficient	B-X
BMDC	B-X
had	B-X
reduced	B-X
transcription	B-X
and	B-X
secretion	B-X
of	B-X
pro-inflammatory	B-X
mediators	B-X
IL6	B-X
,	B-X
IL12P70	B-X
,	B-X
GMCSF	B-X
,	B-X
and	B-X
nitric	B-X
oxide	B-X
.	B-X
Mutant	B-X
BMDC	B-X
had	B-X
defective	B-X
activation	B-X
of	B-X
NF-κB	B-X
signaling	B-X
,	B-X
whereas	B-X
the	B-X
MAPK1/3	B-X
(	B-X
ERK1/2	B-X
)	B-X
and	B-X
MAPK11/12/13/14	B-X
(	B-X
p38	B-X
MAP	B-X
kinase	B-X
isoforms	B-X
)	B-X
and	B-X
TBK1	B-X
signaling	B-X
pathways	B-X
were	B-X
intact	B-X
.	B-X
A	B-X
mixed	B-X
lymphocyte	B-X
reaction	B-X
showed	B-X
that	B-X
mutant	B-X
BMDC	B-X
only	B-X
induced	B-X
a	B-X
weak	B-X
Th1	B-X
immune	B-X
response	B-X
but	B-X
stimulated	B-X
increased	B-X
Th2	B-X
cytokine	B-X
production	B-X
from	B-X
allogeneic	B-X
naïve	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X

Spontaneous	O
mutations	O
of	O
the	O
Sharpin	B-Protein
(	O
SHANK	B-Protein
-	I-Protein
associated	I-Protein
RH	I-Protein
domain	I-Protein
-	I-Protein
interacting	I-Protein
protein	I-Protein
,	O
other	O
aliases	O
:	O
Rbckl1	B-Protein
,	O
Sipl1	B-Protein
)	O
gene	O
in	O
mice	O
result	O
in	O
systemic	O
inflammation	O
that	O
is	O
characterized	O
by	O
chronic	O
proliferative	O
dermatitis	O
and	O
dysregulated	O
secretion	O
of	O
T	O
helper1	O
(	O
Th1	O
)	O
and	O
Th2	O
cytokines	O
.	O
<EOS>	B-X
Spontaneous	B-X
mutations	B-X
of	B-X
the	B-X
Sharpin	B-X
(	B-X
SHANK-associated	B-X
RH	B-X
domain-interacting	B-X
protein	B-X
,	B-X
other	B-X
aliases	B-X
:	B-X
Rbckl1	B-X
,	B-X
Sipl1	B-X
)	B-X
gene	B-X
in	B-X
mice	B-X
result	B-X
in	B-X
systemic	B-X
inflammation	B-X
that	B-X
is	B-X
characterized	B-X
by	B-X
chronic	B-X
proliferative	B-X
dermatitis	B-X
and	B-X
dysregulated	B-X
secretion	B-X
of	B-X
T	B-X
helper1	B-X
(	B-X
Th1	B-X
)	B-X
and	B-X
Th2	B-X
cytokines	B-X
.	B-X
Dendritic	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
initiation	B-X
and	B-X
progression	B-X
of	B-X
the	B-X
phenotype	B-X
of	B-X
SHARPIN-deficient	B-X
mice	B-X
because	B-X
of	B-X
their	B-X
pivotal	B-X
role	B-X
in	B-X
innate	B-X
and	B-X
adaptive	B-X
immunity	B-X
.	B-X
In	B-X
response	B-X
to	B-X
TOLL-like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
agonists	B-X
LPS	B-X
and	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
,	B-X
cultured	B-X
bone	B-X
marrow-derived	B-X
dendritic	B-X
cells	B-X
(	B-X
BMDC	B-X
)	B-X
from	B-X
WT	B-X
and	B-X
mutant	B-X
mice	B-X
exhibited	B-X
similar	B-X
increases	B-X
in	B-X
expression	B-X
of	B-X
co-stimulatory	B-X
molecules	B-X
CD40	B-X
,	B-X
CD80	B-X
,	B-X
and	B-X
CD86	B-X
.	B-X
However	B-X
,	B-X
stimulated	B-X
SHARPIN-deficient	B-X
BMDC	B-X
had	B-X
reduced	B-X
transcription	B-X
and	B-X
secretion	B-X
of	B-X
pro-inflammatory	B-X
mediators	B-X
IL6	B-X
,	B-X
IL12P70	B-X
,	B-X
GMCSF	B-X
,	B-X
and	B-X
nitric	B-X
oxide	B-X
.	B-X
A	B-X
mixed	B-X
lymphocyte	B-X
reaction	B-X
showed	B-X
that	B-X
mutant	B-X
BMDC	B-X
only	B-X
induced	B-X
a	B-X
weak	B-X
Th1	B-X
immune	B-X
response	B-X
but	B-X
stimulated	B-X
increased	B-X
Th2	B-X
cytokine	B-X
production	B-X
from	B-X
allogeneic	B-X
naïve	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
loss	B-X
of	B-X
Sharpin	B-X
in	B-X
mice	B-X
significantly	B-X
affects	B-X
the	B-X
immune	B-X
function	B-X
of	B-X
DC	B-X
and	B-X
this	B-X
may	B-X
partially	B-X
account	B-X
for	B-X
the	B-X
systemic	B-X
inflammation	B-X
and	B-X
Th2-biased	B-X
immune	B-X
response	B-X
.	B-X

The	O
cellular	O
and	O
molecular	O
mechanisms	O
underlying	O
this	O
inflammatory	O
phenotype	O
remain	O
elusive	O
.	O
<EOS>	B-X
Microglial	B-X
TLR4-dependent	B-X
autophagy	B-X
induces	B-X
ischemic	B-X
white	B-X
matter	B-X
damage	B-X
Amino	B-X
acid	B-X
metabolism	B-X
is	B-X
crucial	B-X
for	B-X
inflammatory	B-X
processes	B-X
during	B-X
atherogenesis	B-X
.	B-X
However	B-X
,	B-X
the	B-X
underlying	B-X
mechanisms	B-X
remain	B-X
elusive	B-X
.	B-X
Rosacea	B-X
is	B-X
a	B-X
chronic	B-X
inflammatory	B-X
skin	B-X
disease	B-X
characterized	B-X
by	B-X
immune	B-X
response-dependent	B-X
erythema	B-X
and	B-X
pustules	B-X
.	B-X
Although	B-X
the	B-X
precise	B-X
etiology	B-X
of	B-X
rosacea	B-X
remains	B-X
elusive	B-X
,	B-X
its	B-X
pathogenesis	B-X
is	B-X
reportedly	B-X
associated	B-X
with	B-X
an	B-X
increased	B-X
level	B-X
of	B-X
antimicrobial	B-X
peptide	B-X
LL-37	B-X
.	B-X
However	B-X
,	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
the	B-X
progression	B-X
of	B-X
rosacea	B-X
via	B-X
LL-37	B-X
remain	B-X
poorly	B-X
understood	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
examined	B-X
the	B-X
potential	B-X
role	B-X
of	B-X
LL-37	B-X
in	B-X
rosacea-like	B-X
skin	B-X
inflammatory	B-X
phenotypes	B-X
at	B-X
a	B-X
molecular	B-X
level	B-X
.	B-X
Intracellular	B-X
LL-37	B-X
triggered	B-X
the	B-X
assembly	B-X
and	B-X
activation	B-X
of	B-X
NLRP3-ASC	B-X
inflammasome	B-X
complex	B-X
by	B-X
facilitating	B-X
lysosomal	B-X
destabilization	B-X
.	B-X
Intradermal	B-X
injection	B-X
of	B-X
LL-37	B-X
elicited	B-X
profound	B-X
recruitment	B-X
of	B-X
inflammatory	B-X
Gr1	B-X

Dendritic	O
cells	O
may	O
contribute	O
to	O
the	O
initiation	O
and	O
progression	O
of	O
the	O
phenotype	O
of	O
SHARPIN	B-Protein
-	O
deficient	O
mice	O
because	O
of	O
their	O
pivotal	O
role	O
in	O
innate	O
and	O
adaptive	O
immunity	O
.	O

Here	O
we	O
show	O
by	O
flow	O
cytometry	O
that	O
SHARPIN	B-Protein
-	O
deficiency	O
did	O
not	O
alter	O
the	O
distribution	O
of	O
different	O
DC	O
subtypes	O
in	O
the	O
spleen	O
.	O
<EOS>	B-X
SHARPIN	B-X
forms	B-X
a	B-X
linear-ubiquitin-chain-assembly	B-X
complex	B-X
that	B-X
promotes	B-X
signaling	B-X
via	B-X
the	B-X
transcription	B-X
factor	B-X
NF-κB	B-X
.	B-X
SHARPIN	B-X
deficiency	B-X
leads	B-X
to	B-X
progressive	B-X
multi-organ	B-X
inflammation	B-X
and	B-X
immune	B-X
system	B-X
malfunction	B-X
,	B-X
but	B-X
how	B-X
SHARPIN	B-X
regulates	B-X
T	B-X
cell	B-X
responses	B-X
is	B-X
unclear	B-X
.	B-X
Here	B-X
we	B-X
found	B-X
that	B-X
SHARPIN	B-X
deficiency	B-X
resulted	B-X
in	B-X
a	B-X
substantial	B-X
reduction	B-X
in	B-X
the	B-X
number	B-X
of	B-X
and	B-X
defective	B-X
function	B-X
of	B-X
regulatory	B-X
T	B-X
cells	B-X
(	B-X
Treg	B-X
cells	B-X
)	B-X
.	B-X
Transfer	B-X
of	B-X
SHARPIN-sufficient	B-X
Treg	B-X
cells	B-X
into	B-X
SHARPIN-deficient	B-X
mice	B-X
considerably	B-X
alleviated	B-X
their	B-X
systemic	B-X
inflammation	B-X
.	B-X
SHARPIN-deficient	B-X
T	B-X
cells	B-X
displayed	B-X
enhanced	B-X
proximal	B-X
signaling	B-X
via	B-X
the	B-X
T	B-X
cell	B-X
antigen	B-X
receptor	B-X
(	B-X
TCR	B-X
)	B-X
without	B-X
an	B-X
effect	B-X
on	B-X
the	B-X
activation	B-X
of	B-X
NF-κB	B-X
.	B-X
SHARPIN	B-X
conjugated	B-X
with	B-X
Lys63	B-X
(	B-X
K63	B-X
)	B-X
-linked	B-X
ubiquitin	B-X
chains	B-X
,	B-X
which	B-X
led	B-X
to	B-X
inhibition	B-X
of	B-X
the	B-X
association	B-X
of	B-X
TCRζ	B-X
with	B-X
the	B-X
signaling	B-X
kinase	B-X
Zap70	B-X
;	B-X
this	B-X
affected	B-X
the	B-X
generation	B-X
of	B-X
Treg	B-X
cells	B-X
.	B-X
Our	B-X
study	B-X
therefore	B-X
identifies	B-X
a	B-X
role	B-X
for	B-X
SHARPIN	B-X
in	B-X
TCR	B-X
signaling	B-X
whereby	B-X
it	B-X
maintains	B-X
immunological	B-X
homeostasis	B-X
and	B-X
tolerance	B-X
by	B-X
regulating	B-X
Treg	B-X
cells	B-X
.	B-X

In	O
response	O
to	O
TOLL	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
agonists	O
LPS	O
and	O
poly	O
I	O
:	O
C	O
,	O
cultured	O
bone	O
marrow	O
-	O
derived	O
dendritic	O
cells	O
(	O
BMDC	O
)	O
from	O
WT	O
and	O
mutant	O
mice	O
exhibited	O
similar	O
increases	O
in	O
expression	O
of	O
co	O
-	O
stimulatory	O
molecules	O
CD40	B-Protein
,	O
CD80	B-Protein
,	O
and	O
CD86	B-Protein
.	O
<EOS>	B-X
Spontaneous	B-X
mutations	B-X
of	B-X
the	B-X
Sharpin	B-X
(	B-X
SHANK-associated	B-X
RH	B-X
domain-interacting	B-X
protein	B-X
,	B-X
other	B-X
aliases	B-X
:	B-X
Rbckl1	B-X
,	B-X
Sipl1	B-X
)	B-X
gene	B-X
in	B-X
mice	B-X
result	B-X
in	B-X
systemic	B-X
inflammation	B-X
that	B-X
is	B-X
characterized	B-X
by	B-X
chronic	B-X
proliferative	B-X
dermatitis	B-X
and	B-X
dysregulated	B-X
secretion	B-X
of	B-X
T	B-X
helper1	B-X
(	B-X
Th1	B-X
)	B-X
and	B-X
Th2	B-X
cytokines	B-X
.	B-X
Dendritic	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
initiation	B-X
and	B-X
progression	B-X
of	B-X
the	B-X
phenotype	B-X
of	B-X
SHARPIN-deficient	B-X
mice	B-X
because	B-X
of	B-X
their	B-X
pivotal	B-X
role	B-X
in	B-X
innate	B-X
and	B-X
adaptive	B-X
immunity	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
by	B-X
flow	B-X
cytometry	B-X
that	B-X
SHARPIN-	B-X
deficiency	B-X
did	B-X
not	B-X
alter	B-X
the	B-X
distribution	B-X
of	B-X
different	B-X
DC	B-X
subtypes	B-X
in	B-X
the	B-X
spleen	B-X
.	B-X
In	B-X
response	B-X
to	B-X
TOLL-like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
agonists	B-X
LPS	B-X
and	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
,	B-X
cultured	B-X
bone	B-X
marrow-derived	B-X
dendritic	B-X
cells	B-X
(	B-X
BMDC	B-X
)	B-X
from	B-X
WT	B-X
and	B-X
mutant	B-X
mice	B-X
exhibited	B-X
similar	B-X
increases	B-X
in	B-X
expression	B-X
of	B-X
co-stimulatory	B-X
molecules	B-X
CD40	B-X
,	B-X
CD80	B-X
,	B-X
and	B-X
CD86	B-X
.	B-X
However	B-X
,	B-X
stimulated	B-X
SHARPIN-deficient	B-X
BMDC	B-X
had	B-X
reduced	B-X
transcription	B-X
and	B-X
secretion	B-X
of	B-X
pro-inflammatory	B-X
mediators	B-X
IL6	B-X
,	B-X
IL12P70	B-X
,	B-X
GMCSF	B-X
,	B-X
and	B-X
nitric	B-X
oxide	B-X
.	B-X
Mutant	B-X
BMDC	B-X
had	B-X
defective	B-X
activation	B-X
of	B-X
NF-κB	B-X
signaling	B-X
,	B-X
whereas	B-X
the	B-X
MAPK1/3	B-X
(	B-X
ERK1/2	B-X
)	B-X
and	B-X
MAPK11/12/13/14	B-X
(	B-X
p38	B-X
MAP	B-X
kinase	B-X
isoforms	B-X
)	B-X
and	B-X
TBK1	B-X
signaling	B-X
pathways	B-X
were	B-X
intact	B-X
.	B-X
A	B-X
mixed	B-X
lymphocyte	B-X
reaction	B-X
showed	B-X
that	B-X
mutant	B-X
BMDC	B-X
only	B-X
induced	B-X
a	B-X
weak	B-X
Th1	B-X
immune	B-X
response	B-X
but	B-X
stimulated	B-X
increased	B-X
Th2	B-X
cytokine	B-X
production	B-X
from	B-X
allogeneic	B-X
naïve	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
loss	B-X
of	B-X
Sharpin	B-X
in	B-X
mice	B-X
significantly	B-X
affects	B-X
the	B-X
immune	B-X
function	B-X
of	B-X
DC	B-X
and	B-X
this	B-X
may	B-X
partially	B-X
account	B-X
for	B-X
the	B-X
systemic	B-X
inflammation	B-X
and	B-X
Th2-biased	B-X
immune	B-X
response	B-X
.	B-X

However	O
,	O
stimulated	O
SHARPIN	B-Protein
-	O
deficient	O
BMDC	O
had	O
reduced	O
transcription	O
and	O
secretion	O
of	O
pro	O
-	O
inflammatory	O
mediators	O
IL6	B-Protein
,	O
IL12P70	O
,	O
GMCSF	B-Protein
,	O
and	O
nitric	O
oxide	O
.	O
<EOS>	B-X
Spontaneous	B-X
mutations	B-X
of	B-X
the	B-X
Sharpin	B-X
(	B-X
SHANK-associated	B-X
RH	B-X
domain-interacting	B-X
protein	B-X
,	B-X
other	B-X
aliases	B-X
:	B-X
Rbckl1	B-X
,	B-X
Sipl1	B-X
)	B-X
gene	B-X
in	B-X
mice	B-X
result	B-X
in	B-X
systemic	B-X
inflammation	B-X
that	B-X
is	B-X
characterized	B-X
by	B-X
chronic	B-X
proliferative	B-X
dermatitis	B-X
and	B-X
dysregulated	B-X
secretion	B-X
of	B-X
T	B-X
helper1	B-X
(	B-X
Th1	B-X
)	B-X
and	B-X
Th2	B-X
cytokines	B-X
.	B-X
The	B-X
cellular	B-X
and	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
this	B-X
inflammatory	B-X
phenotype	B-X
remain	B-X
elusive	B-X
.	B-X
Dendritic	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
initiation	B-X
and	B-X
progression	B-X
of	B-X
the	B-X
phenotype	B-X
of	B-X
SHARPIN-deficient	B-X
mice	B-X
because	B-X
of	B-X
their	B-X
pivotal	B-X
role	B-X
in	B-X
innate	B-X
and	B-X
adaptive	B-X
immunity	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
by	B-X
flow	B-X
cytometry	B-X
that	B-X
SHARPIN-	B-X
deficiency	B-X
did	B-X
not	B-X
alter	B-X
the	B-X
distribution	B-X
of	B-X
different	B-X
DC	B-X
subtypes	B-X
in	B-X
the	B-X
spleen	B-X
.	B-X
In	B-X
response	B-X
to	B-X
TOLL-like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
agonists	B-X
LPS	B-X
and	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
,	B-X
cultured	B-X
bone	B-X
marrow-derived	B-X
dendritic	B-X
cells	B-X
(	B-X
BMDC	B-X
)	B-X
from	B-X
WT	B-X
and	B-X
mutant	B-X
mice	B-X
exhibited	B-X
similar	B-X
increases	B-X
in	B-X
expression	B-X
of	B-X
co-stimulatory	B-X
molecules	B-X
CD40	B-X
,	B-X
CD80	B-X
,	B-X
and	B-X
CD86	B-X
.	B-X
However	B-X
,	B-X
stimulated	B-X
SHARPIN-deficient	B-X
BMDC	B-X
had	B-X
reduced	B-X
transcription	B-X
and	B-X
secretion	B-X
of	B-X
pro-inflammatory	B-X
mediators	B-X
IL6	B-X
,	B-X
IL12P70	B-X
,	B-X
GMCSF	B-X
,	B-X
and	B-X
nitric	B-X
oxide	B-X
.	B-X
Mutant	B-X
BMDC	B-X
had	B-X
defective	B-X
activation	B-X
of	B-X
NF-κB	B-X
signaling	B-X
,	B-X
whereas	B-X
the	B-X
MAPK1/3	B-X
(	B-X
ERK1/2	B-X
)	B-X
and	B-X
MAPK11/12/13/14	B-X
(	B-X
p38	B-X
MAP	B-X
kinase	B-X
isoforms	B-X
)	B-X
and	B-X
TBK1	B-X
signaling	B-X
pathways	B-X
were	B-X
intact	B-X
.	B-X
A	B-X
mixed	B-X
lymphocyte	B-X
reaction	B-X
showed	B-X
that	B-X
mutant	B-X
BMDC	B-X
only	B-X
induced	B-X
a	B-X
weak	B-X
Th1	B-X
immune	B-X
response	B-X
but	B-X
stimulated	B-X
increased	B-X
Th2	B-X
cytokine	B-X
production	B-X
from	B-X
allogeneic	B-X
naïve	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X

Mutant	O
BMDC	O
had	O
defective	O
activation	O
of	O
NF	O
-	O
kappaB	O
signaling	O
,	O
whereas	O
the	O
MAPK1	B-Protein
/	O
3	B-Protein
(	O
ERK1	B-Protein
/	O
2	B-Protein
)	O
and	O
MAPK11	B-Protein
/	O
12	B-Protein
/	O
13	B-Protein
/	O
14	B-Protein
(	O
p38	O
MAP	O
kinase	O
isoforms	O
)	O
and	O
TBK1	B-Protein
signaling	O
pathways	O
were	O
intact	O
.	O
<EOS>	B-X
Spontaneous	B-X
mutations	B-X
of	B-X
the	B-X
Sharpin	B-X
(	B-X
SHANK-associated	B-X
RH	B-X
domain-interacting	B-X
protein	B-X
,	B-X
other	B-X
aliases	B-X
:	B-X
Rbckl1	B-X
,	B-X
Sipl1	B-X
)	B-X
gene	B-X
in	B-X
mice	B-X
result	B-X
in	B-X
systemic	B-X
inflammation	B-X
that	B-X
is	B-X
characterized	B-X
by	B-X
chronic	B-X
proliferative	B-X
dermatitis	B-X
and	B-X
dysregulated	B-X
secretion	B-X
of	B-X
T	B-X
helper1	B-X
(	B-X
Th1	B-X
)	B-X
and	B-X
Th2	B-X
cytokines	B-X
.	B-X
In	B-X
response	B-X
to	B-X
TOLL-like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
agonists	B-X
LPS	B-X
and	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
,	B-X
cultured	B-X
bone	B-X
marrow-derived	B-X
dendritic	B-X
cells	B-X
(	B-X
BMDC	B-X
)	B-X
from	B-X
WT	B-X
and	B-X
mutant	B-X
mice	B-X
exhibited	B-X
similar	B-X
increases	B-X
in	B-X
expression	B-X
of	B-X
co-stimulatory	B-X
molecules	B-X
CD40	B-X
,	B-X
CD80	B-X
,	B-X
and	B-X
CD86	B-X
.	B-X
However	B-X
,	B-X
stimulated	B-X
SHARPIN-deficient	B-X
BMDC	B-X
had	B-X
reduced	B-X
transcription	B-X
and	B-X
secretion	B-X
of	B-X
pro-inflammatory	B-X
mediators	B-X
IL6	B-X
,	B-X
IL12P70	B-X
,	B-X
GMCSF	B-X
,	B-X
and	B-X
nitric	B-X
oxide	B-X
.	B-X
Mutant	B-X
BMDC	B-X
had	B-X
defective	B-X
activation	B-X
of	B-X
NF-κB	B-X
signaling	B-X
,	B-X
whereas	B-X
the	B-X
MAPK1/3	B-X
(	B-X
ERK1/2	B-X
)	B-X
and	B-X
MAPK11/12/13/14	B-X
(	B-X
p38	B-X
MAP	B-X
kinase	B-X
isoforms	B-X
)	B-X
and	B-X
TBK1	B-X
signaling	B-X
pathways	B-X
were	B-X
intact	B-X
.	B-X
A	B-X
mixed	B-X
lymphocyte	B-X
reaction	B-X
showed	B-X
that	B-X
mutant	B-X
BMDC	B-X
only	B-X
induced	B-X
a	B-X
weak	B-X
Th1	B-X
immune	B-X
response	B-X
but	B-X
stimulated	B-X
increased	B-X
Th2	B-X
cytokine	B-X
production	B-X
from	B-X
allogeneic	B-X
naïve	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
loss	B-X
of	B-X
Sharpin	B-X
in	B-X
mice	B-X
significantly	B-X
affects	B-X
the	B-X
immune	B-X
function	B-X
of	B-X
DC	B-X
and	B-X
this	B-X
may	B-X
partially	B-X
account	B-X
for	B-X
the	B-X
systemic	B-X
inflammation	B-X
and	B-X
Th2-biased	B-X
immune	B-X
response	B-X
.	B-X

A	O
mixed	O
lymphocyte	O
reaction	O
showed	O
that	O
mutant	O
BMDC	O
only	O
induced	O
a	O
weak	O
Th1	O
immune	O
response	O
but	O
stimulated	O
increased	O
Th2	O
cytokine	O
production	O
from	O
allogeneic	O
naive	O
CD4	O
+	O
T	O
cells	O
.	O
<EOS>	B-X
Spontaneous	B-X
mutations	B-X
of	B-X
the	B-X
Sharpin	B-X
(	B-X
SHANK-associated	B-X
RH	B-X
domain-interacting	B-X
protein	B-X
,	B-X
other	B-X
aliases	B-X
:	B-X
Rbckl1	B-X
,	B-X
Sipl1	B-X
)	B-X
gene	B-X
in	B-X
mice	B-X
result	B-X
in	B-X
systemic	B-X
inflammation	B-X
that	B-X
is	B-X
characterized	B-X
by	B-X
chronic	B-X
proliferative	B-X
dermatitis	B-X
and	B-X
dysregulated	B-X
secretion	B-X
of	B-X
T	B-X
helper1	B-X
(	B-X
Th1	B-X
)	B-X
and	B-X
Th2	B-X
cytokines	B-X
.	B-X
Dendritic	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
initiation	B-X
and	B-X
progression	B-X
of	B-X
the	B-X
phenotype	B-X
of	B-X
SHARPIN-deficient	B-X
mice	B-X
because	B-X
of	B-X
their	B-X
pivotal	B-X
role	B-X
in	B-X
innate	B-X
and	B-X
adaptive	B-X
immunity	B-X
.	B-X
In	B-X
response	B-X
to	B-X
TOLL-like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
agonists	B-X
LPS	B-X
and	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
,	B-X
cultured	B-X
bone	B-X
marrow-derived	B-X
dendritic	B-X
cells	B-X
(	B-X
BMDC	B-X
)	B-X
from	B-X
WT	B-X
and	B-X
mutant	B-X
mice	B-X
exhibited	B-X
similar	B-X
increases	B-X
in	B-X
expression	B-X
of	B-X
co-stimulatory	B-X
molecules	B-X
CD40	B-X
,	B-X
CD80	B-X
,	B-X
and	B-X
CD86	B-X
.	B-X
However	B-X
,	B-X
stimulated	B-X
SHARPIN-deficient	B-X
BMDC	B-X
had	B-X
reduced	B-X
transcription	B-X
and	B-X
secretion	B-X
of	B-X
pro-inflammatory	B-X
mediators	B-X
IL6	B-X
,	B-X
IL12P70	B-X
,	B-X
GMCSF	B-X
,	B-X
and	B-X
nitric	B-X
oxide	B-X
.	B-X
Mutant	B-X
BMDC	B-X
had	B-X
defective	B-X
activation	B-X
of	B-X
NF-κB	B-X
signaling	B-X
,	B-X
whereas	B-X
the	B-X
MAPK1/3	B-X
(	B-X
ERK1/2	B-X
)	B-X
and	B-X
MAPK11/12/13/14	B-X
(	B-X
p38	B-X
MAP	B-X
kinase	B-X
isoforms	B-X
)	B-X
and	B-X
TBK1	B-X
signaling	B-X
pathways	B-X
were	B-X
intact	B-X
.	B-X
A	B-X
mixed	B-X
lymphocyte	B-X
reaction	B-X
showed	B-X
that	B-X
mutant	B-X
BMDC	B-X
only	B-X
induced	B-X
a	B-X
weak	B-X
Th1	B-X
immune	B-X
response	B-X
but	B-X
stimulated	B-X
increased	B-X
Th2	B-X
cytokine	B-X
production	B-X
from	B-X
allogeneic	B-X
naïve	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
loss	B-X
of	B-X
Sharpin	B-X
in	B-X
mice	B-X
significantly	B-X
affects	B-X
the	B-X
immune	B-X
function	B-X
of	B-X
DC	B-X
and	B-X
this	B-X
may	B-X
partially	B-X
account	B-X
for	B-X
the	B-X
systemic	B-X
inflammation	B-X
and	B-X
Th2-biased	B-X
immune	B-X
response	B-X
.	B-X

In	O
conclusion	O
,	O
loss	O
of	O
Sharpin	B-Protein
in	O
mice	O
significantly	O
affects	O
the	O
immune	O
function	O
of	O
DC	O
and	O
this	O
may	O
partially	O
account	O
for	O
the	O
systemic	O
inflammation	O
and	O
Th2	O
-	O
biased	O
immune	O
response	O
.	O
<EOS>	B-X
Spontaneous	B-X
mutations	B-X
of	B-X
the	B-X
Sharpin	B-X
(	B-X
SHANK-associated	B-X
RH	B-X
domain-interacting	B-X
protein	B-X
,	B-X
other	B-X
aliases	B-X
:	B-X
Rbckl1	B-X
,	B-X
Sipl1	B-X
)	B-X
gene	B-X
in	B-X
mice	B-X
result	B-X
in	B-X
systemic	B-X
inflammation	B-X
that	B-X
is	B-X
characterized	B-X
by	B-X
chronic	B-X
proliferative	B-X
dermatitis	B-X
and	B-X
dysregulated	B-X
secretion	B-X
of	B-X
T	B-X
helper1	B-X
(	B-X
Th1	B-X
)	B-X
and	B-X
Th2	B-X
cytokines	B-X
.	B-X
Dendritic	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
initiation	B-X
and	B-X
progression	B-X
of	B-X
the	B-X
phenotype	B-X
of	B-X
SHARPIN-deficient	B-X
mice	B-X
because	B-X
of	B-X
their	B-X
pivotal	B-X
role	B-X
in	B-X
innate	B-X
and	B-X
adaptive	B-X
immunity	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
by	B-X
flow	B-X
cytometry	B-X
that	B-X
SHARPIN-	B-X
deficiency	B-X
did	B-X
not	B-X
alter	B-X
the	B-X
distribution	B-X
of	B-X
different	B-X
DC	B-X
subtypes	B-X
in	B-X
the	B-X
spleen	B-X
.	B-X
In	B-X
response	B-X
to	B-X
TOLL-like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
agonists	B-X
LPS	B-X
and	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
,	B-X
cultured	B-X
bone	B-X
marrow-derived	B-X
dendritic	B-X
cells	B-X
(	B-X
BMDC	B-X
)	B-X
from	B-X
WT	B-X
and	B-X
mutant	B-X
mice	B-X
exhibited	B-X
similar	B-X
increases	B-X
in	B-X
expression	B-X
of	B-X
co-stimulatory	B-X
molecules	B-X
CD40	B-X
,	B-X
CD80	B-X
,	B-X
and	B-X
CD86	B-X
.	B-X
However	B-X
,	B-X
stimulated	B-X
SHARPIN-deficient	B-X
BMDC	B-X
had	B-X
reduced	B-X
transcription	B-X
and	B-X
secretion	B-X
of	B-X
pro-inflammatory	B-X
mediators	B-X
IL6	B-X
,	B-X
IL12P70	B-X
,	B-X
GMCSF	B-X
,	B-X
and	B-X
nitric	B-X
oxide	B-X
.	B-X
Mutant	B-X
BMDC	B-X
had	B-X
defective	B-X
activation	B-X
of	B-X
NF-κB	B-X
signaling	B-X
,	B-X
whereas	B-X
the	B-X
MAPK1/3	B-X
(	B-X
ERK1/2	B-X
)	B-X
and	B-X
MAPK11/12/13/14	B-X
(	B-X
p38	B-X
MAP	B-X
kinase	B-X
isoforms	B-X
)	B-X
and	B-X
TBK1	B-X
signaling	B-X
pathways	B-X
were	B-X
intact	B-X
.	B-X
A	B-X
mixed	B-X
lymphocyte	B-X
reaction	B-X
showed	B-X
that	B-X
mutant	B-X
BMDC	B-X
only	B-X
induced	B-X
a	B-X
weak	B-X
Th1	B-X
immune	B-X
response	B-X
but	B-X
stimulated	B-X
increased	B-X
Th2	B-X
cytokine	B-X
production	B-X
from	B-X
allogeneic	B-X
naïve	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
loss	B-X
of	B-X
Sharpin	B-X
in	B-X
mice	B-X
significantly	B-X
affects	B-X
the	B-X
immune	B-X
function	B-X
of	B-X
DC	B-X
and	B-X
this	B-X
may	B-X
partially	B-X
account	B-X
for	B-X
the	B-X
systemic	B-X
inflammation	B-X
and	B-X
Th2-biased	B-X
immune	B-X
response	B-X
.	B-X

SHARPIN	B-Protein
was	O
originally	O
identified	O
in	O
post	O
-	O
synaptic	O
densities	O
of	O
excitatory	O
synapses	O
in	O
the	O
brain	O
of	O
rats	O
[	O
1	O
]	O
,	O
but	O
this	O
protein	O
is	O
widely	O
expressed	O
in	O
a	O
variety	O
of	O
tissues	O
[	O
2	O
]	O
.	O

Two	O
allelic	O
,	O
autosomal	O
recessive	O
mutations	O
in	O
the	O
Sharpin	B-Protein
gene	O
occurred	O
spontaneously	O
in	O
two	O
inbred	O
strains	O
of	O
mice	O
,	O
C57B	O
/	O
KaLawRij	O
-	O
Sharpincpdm	O
/	O
Sharpincpdm	O
and	O
CBy	O
.	O
Ocb3	O
/	O
Dem	O
-	O
Sharpincpdm	O
-	O
Dem	O
/	O
Sharpincpdm	O
-	O
Dem	O
,	O
resulting	O
in	O
premature	O
termination	O
of	O
mRNA	O
synthesis	O
and	O
absence	O
of	O
a	O
functional	O
protein	O
product	O
[	O
2	O
]	O
.	O

Despite	O
different	O
genetic	O
backgrounds	O
,	O
both	O
mutations	O
cause	O
similar	O
inflammatory	O
disease	O
with	O
severe	O
chronic	O
progressive	O
dermatitis	O
and	O
defective	O
development	O
of	O
secondary	O
lymphoid	O
organs	O
[	O
2	O
]	O
-	O
[	O
4	O
]	O
.	O

The	O
dermatitis	O
becomes	O
clinically	O
apparent	O
at	O
about	O
four	O
weeks	O
of	O
age	O
.	O

There	O
are	O
accumulations	O
of	O
eosinophils	O
,	O
neutrophils	O
and	O
macrophages	O
in	O
the	O
skin	O
of	O
Sharpincpdm	O
/	O
Sharpincpdm	O
mutant	O
mice	O
(	O
hereafter	O
referred	O
to	O
as	O
cpdm	O
mice	O
)	O
associated	O
with	O
increased	O
expression	O
of	O
Th2	O
cytokines	O
in	O
the	O
skin	O
and	O
in	O
the	O
supernatants	O
of	O
activated	O
splenocytes	O
[	O
5	O
]	O
.	O

The	O
mice	O
have	O
an	O
impaired	O
delayed	O
type	O
hypersensitivity	O
response	O
and	O
decreased	O
secretion	O
of	O
IFNgamma	B-Protein
[	O
5	O
]	O
,	O
indicating	O
a	O
defect	O
in	O
Th1	O
immune	O
responses	O
and	O
a	O
bias	O
towards	O
a	O
Th2	O
immune	O
response	O
.	O

Systemic	O
treatment	O
of	O
cpdm	O
mice	O
with	O
recombinant	O
IL12	O
caused	O
complete	O
remission	O
of	O
the	O
dermatitis	O
[	O
5	O
]	O
.	O

Neutralization	O
of	O
IL5	B-Protein
by	O
antibody	O
treatment	O
or	O
crosses	O
with	O
IL5	B-Protein
-	O
deficient	O
mice	O
reduced	O
the	O
number	O
of	O
circulating	O
and	O
cutaneous	O
eosinophils	O
,	O
but	O
failed	O
to	O
reduce	O
the	O
onset	O
and	O
severity	O
of	O
the	O
dermatitis	O
[	O
6	O
]	O
.	O
<EOS>	B-X
Interleukin	B-X
(	B-X
IL	B-X
)	B-X
-5	B-X
mediates	B-X
the	B-X
development	B-X
of	B-X
eosinophils	B-X
(	B-X
EOS	B-X
)	B-X
that	B-X
are	B-X
essential	B-X
for	B-X
tissue	B-X
post-injury	B-X
repair	B-X
.	B-X
We	B-X
hypothesize	B-X
that	B-X
glucagon-like	B-X
peptide-1	B-X
receptor	B-X
agonist	B-X
(	B-X
GLP-1RA	B-X
)	B-X
treatment	B-X
inhibits	B-X
aeroallergen-induced	B-X
early	B-X
innate	B-X
airway	B-X
inflammation	B-X
in	B-X
a	B-X
mouse	B-X
model	B-X
of	B-X
asthma	B-X
in	B-X
the	B-X
setting	B-X
of	B-X
obesity	B-X
.	B-X
Passive	B-X
Prophylactic	B-X
Administration	B-X
with	B-X
a	B-X
Single	B-X
Dose	B-X
of	B-X
Anti-Fel	B-X
d	B-X
1	B-X
Monoclonal	B-X
Antibodies	B-X
REGN1908-1909	B-X
in	B-X
Cat	B-X
Allergen-induced	B-X
Allergic	B-X
Rhinitis	B-X
:	B-X
A	B-X
Randomized	B-X
,	B-X
Double-Blind	B-X
,	B-X
Placebo-controlled	B-X
Clinical	B-X
Trial	B-X
.	B-X
Reslizumab	B-X
,	B-X
a	B-X
neutralizing	B-X
anti-IL-5	B-X
monoclonal	B-X
antibody	B-X
,	B-X
is	B-X
a	B-X
promising	B-X
adjunctive	B-X
treatment	B-X
for	B-X
severe	B-X
eosinophilic	B-X
asthma	B-X
.	B-X
Rebound	B-X
eosinophilia	B-X
after	B-X
cessation	B-X
of	B-X
reslizumab	B-X
and	B-X
attenuation	B-X
of	B-X
the	B-X
treatment	B-X
response	B-X
with	B-X
repeated	B-X
dosing	B-X
had	B-X
been	B-X
reported	B-X
.	B-X
Stringent	B-X
selection	B-X
of	B-X
patients	B-X
with	B-X
a	B-X
high	B-X
eosinophil	B-X
burden	B-X
,	B-X
who	B-X
are	B-X
poorly	B-X
controlled	B-X
despite	B-X
moderate	B-X
to	B-X
high	B-X
doses	B-X
of	B-X
inhaled	B-X
corticosteroid	B-X
,	B-X
confers	B-X
the	B-X
most	B-X
significant	B-X
treatment	B-X
response	B-X
.	B-X

Recently	O
,	O
three	O
independent	O
groups	O
identified	O
SHARPIN	B-Protein
as	O
an	O
essential	O
component	O
of	O
the	O
linear	O
ubiquitin	O
chain	O
assembly	O
complex	O
(	O
LUBAC	O
)	O
that	O
regulates	O
TNFalpha	B-Protein
-	O
induced	O
canonical	O
NF	O
-	O
kappaB	O
signaling	O
[	O
7	O
]	O
-	O
[	O
9	O
]	O
.	O

SHARPIN	B-Protein
-	O
deficient	O
mouse	O
embryonic	O
fibroblast	O
(	O
MEF	O
)	O
were	O
sensitized	O
to	O
TNFalpha	B-Protein
-	O
induced	O
apoptosis	O
and	O
cell	O
death	O
was	O
implicated	O
as	O
a	O
factor	O
in	O
the	O
dermatitis	O
of	O
cpdm	O
mice	O
[	O
7	O
]	O
-	O
[	O
9	O
]	O
.	O

Dendritic	O
cells	O
(	O
DC	O
)	O
have	O
a	O
sentinel	O
role	O
in	O
sensing	O
pathogen	O
or	O
danger	O
signals	O
and	O
initiate	O
and	O
direct	O
activation	O
of	O
the	O
adaptive	O
immune	O
response	O
[	O
10	O
]	O
.	O
<EOS>	B-X
Many	B-X
solid	B-X
cancers	B-X
contain	B-X
dysfunctional	B-X
immune	B-X
microenvironments	B-X
.	B-X
Immune	B-X
system	B-X
modulators	B-X
that	B-X
initiate	B-X
responses	B-X
to	B-X
foreign	B-X
pathogens	B-X
could	B-X
be	B-X
promising	B-X
candidates	B-X
for	B-X
reigniting	B-X
productive	B-X
responses	B-X
toward	B-X
tumors	B-X
.	B-X
IL-36γ	B-X
,	B-X
in	B-X
classic	B-X
alarmin	B-X
fashion	B-X
,	B-X
acts	B-X
in	B-X
damaged	B-X
tissues	B-X
,	B-X
whereas	B-X
IL-23	B-X
centrally	B-X
coordinates	B-X
immune	B-X
responses	B-X
to	B-X
danger	B-X
signals	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
direct	B-X
intratumoral	B-X
delivery	B-X
of	B-X
messenger	B-X
RNAs	B-X
(	B-X
mRNAs	B-X
)	B-X
encoding	B-X
these	B-X
cytokines	B-X
produced	B-X
robust	B-X
anticancer	B-X
responses	B-X
in	B-X
a	B-X
broad	B-X
range	B-X
of	B-X
tumor	B-X
microenvironments	B-X
.	B-X
The	B-X
addition	B-X
of	B-X
mRNA	B-X
encoding	B-X
the	B-X
T	B-X
cell	B-X
costimulator	B-X
OX40L	B-X
increased	B-X
complete	B-X
response	B-X
rates	B-X
in	B-X
treated	B-X
and	B-X
untreated	B-X
distal	B-X
tumors	B-X
compared	B-X
to	B-X
the	B-X
cytokine	B-X
mRNAs	B-X
alone	B-X
.	B-X
Mice	B-X
exhibiting	B-X
complete	B-X
responses	B-X
were	B-X
subsequently	B-X
protected	B-X
from	B-X
tumor	B-X
rechallenge	B-X
.	B-X
Treatments	B-X
with	B-X
these	B-X
mRNA	B-X
mixtures	B-X
induced	B-X
downstream	B-X
cytokine	B-X
and	B-X
chemokine	B-X
expression	B-X
,	B-X
and	B-X
also	B-X
activated	B-X
multiple	B-X
dendritic	B-X
cell	B-X
(	B-X
DC	B-X
)	B-X
and	B-X
T	B-X
cell	B-X
types	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
,	B-X
efficacy	B-X
was	B-X
dependent	B-X
on	B-X
Batf3-dependent	B-X
cross-presenting	B-X
DCs	B-X
and	B-X
cytotoxic	B-X
CD8	B-X

Activated	O
and	O
mature	O
DC	O
can	O
carry	O
processed	O
antigenic	O
peptides	O
,	O
migrate	O
to	O
lymphoid	O
organs	O
,	O
and	O
induce	O
T	O
-	O
cell	O
-	O
mediated	O
immune	O
responses	O
or	O
tolerance	O
.	O
<EOS>	B-X
However	B-X
,	B-X
by	B-X
comparing	B-X
tolerance	B-X
and	B-X
persistence	B-X
during	B-X
Salmonella	B-X
Typhimurium	B-X
infection	B-X
,	B-X
we	B-X
reveal	B-X
that	B-X
these	B-X
two	B-X
phenomena	B-X
are	B-X
underpinned	B-X
by	B-X
different	B-X
bacterial	B-X
physiologies	B-X
.	B-X
Multidrug-tolerant	B-X
mutant	B-X
Salmonella	B-X
enter	B-X
a	B-X
near-dormant	B-X
state	B-X
protected	B-X
from	B-X
immune-mediated	B-X
genotoxic	B-X
damages	B-X
.	B-X
However	B-X
,	B-X
the	B-X
numerous	B-X
tolerant	B-X
cells	B-X
,	B-X
optimized	B-X
for	B-X
survival	B-X
,	B-X
lack	B-X
the	B-X
capabilities	B-X
necessary	B-X
to	B-X
initiate	B-X
infection	B-X
relapse	B-X
following	B-X
antibiotic	B-X
withdrawal	B-X
.	B-X
This	B-X
leaves	B-X
them	B-X
vulnerable	B-X
to	B-X
accumulation	B-X
of	B-X
macrophage-induced	B-X
dsDNA	B-X
breaks	B-X
but	B-X
concurrently	B-X
confers	B-X
the	B-X
versatility	B-X
to	B-X
initiate	B-X
infection	B-X
relapse	B-X
if	B-X
protected	B-X
by	B-X
RecA-mediated	B-X
DNA	B-X
repair	B-X
.	B-X
Accordingly	B-X
,	B-X
recurrent	B-X
,	B-X
invasive	B-X
,	B-X
non-typhoidal	B-X
Salmonella	B-X
clinical	B-X
isolates	B-X
display	B-X
hallmarks	B-X
of	B-X
persistence	B-X
rather	B-X
than	B-X
tolerance	B-X
during	B-X
antibiotic	B-X
treatment	B-X
.	B-X

DC	O
direct	O
the	O
differentiation	O
of	O
CD4	O
+	O
T	O
cells	O
,	O
and	O
hence	O
the	O
type	O
of	O
immune	O
response	O
,	O
through	O
the	O
selective	O
secretion	O
of	O
cytokines	O
.	O

We	O
hypothesized	O
that	O
defective	O
cytokine	O
secretion	O
by	O
DC	O
contributed	O
to	O
the	O
Th2	O
-	O
biased	O
inflammatory	O
phenotype	O
in	O
SHARPIN	B-Protein
-	O
deficient	O
mice	O
.	O

The	O
studies	O
reported	O
here	O
found	O
that	O
lack	O
of	O
SHARPIN	B-Protein
protein	O
in	O
BMDC	O
caused	O
defective	O
expression	O
of	O
pro	O
-	O
inflammatory	O
mediators	O
and	O
impaired	O
NF	O
-	O
kappaB	O
activation	O
upon	O
ligand	O
stimulation	O
.	O

The	O
ability	O
of	O
cpdm	O
BMDC	O
to	O
stimulate	O
Th1	O
cytokine	O
production	O
in	O
allogeneic	O
CD4	O
+	O
T	O
cells	O
was	O
compromised	O
.	O

Taken	O
together	O
,	O
these	O
results	O
reveal	O
that	O
SHARPIN	B-Protein
is	O
a	O
novel	O
regulatory	O
molecule	O
in	O
DC	O
biology	O
and	O
suggest	O
that	O
the	O
dysregulated	O
function	O
of	O
SHARPIN	B-Protein
-	O
deficient	O
DC	O
plays	O
a	O
role	O
in	O
the	O
cpdm	O
phenotype	O
.	O

Characterization	O
of	O
Sharpin	B-Protein
<EOS>	B-X
Mice	B-X
with	B-X
spontaneous	B-X
mutations	B-X
in	B-X
the	B-X
Sharpin	B-X
gene	B-X
develop	B-X
chronic	B-X
proliferative	B-X
dermatitis	B-X
that	B-X
is	B-X
characterized	B-X
by	B-X
eosinophilic	B-X
inflammation	B-X
of	B-X
the	B-X
skin	B-X
and	B-X
other	B-X
organs	B-X
with	B-X
increased	B-X
expression	B-X
of	B-X
type	B-X
2	B-X
cytokines	B-X
and	B-X
dysregulated	B-X
development	B-X
of	B-X
lymphoid	B-X
tissues	B-X
.	B-X
Spontaneous	B-X
mutations	B-X
of	B-X
the	B-X
Sharpin	B-X
(	B-X
SHANK-associated	B-X
RH	B-X
domain-interacting	B-X
protein	B-X
,	B-X
other	B-X
aliases	B-X
:	B-X
Rbckl1	B-X
,	B-X
Sipl1	B-X
)	B-X
gene	B-X
in	B-X
mice	B-X
result	B-X
in	B-X
systemic	B-X
inflammation	B-X
that	B-X
is	B-X
characterized	B-X
by	B-X
chronic	B-X
proliferative	B-X
dermatitis	B-X
and	B-X
dysregulated	B-X
secretion	B-X
of	B-X
T	B-X
helper1	B-X
(	B-X
Th1	B-X
)	B-X
and	B-X
Th2	B-X
cytokines	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
loss	B-X
of	B-X
Sharpin	B-X
in	B-X
mice	B-X
significantly	B-X
affects	B-X
the	B-X
immune	B-X
function	B-X
of	B-X
DC	B-X
and	B-X
this	B-X
may	B-X
partially	B-X
account	B-X
for	B-X
the	B-X
systemic	B-X
inflammation	B-X
and	B-X
Th2-biased	B-X
immune	B-X
response	B-X
.	B-X
The	B-X
chronic	B-X
proliferative	B-X
dermatitis	B-X
mutation	B-X
(	B-X
CPDM	B-X
)	B-X
in	B-X
mice	B-X
,	B-X
due	B-X
to	B-X
Sharpin	B-X
deficiency	B-X
(	B-X
Sharpin	B-X
(	B-X
cpdm	B-X
)	B-X
)	B-X
,	B-X
is	B-X
a	B-X
multisystem	B-X
disorder	B-X
characterized	B-X
by	B-X
peripheral	B-X
blood	B-X
eosinophilia	B-X
and	B-X
eosinophil	B-X
infiltration	B-X
of	B-X
affected	B-X
tissues	B-X
including	B-X
the	B-X
skin	B-X
,	B-X
bone	B-X
marrow	B-X
,	B-X
spleen	B-X
,	B-X
lung	B-X
,	B-X
heart	B-X
,	B-X
and	B-X
other	B-X
organs	B-X
.	B-X

Orthologs	O
of	O
SHARPIN	B-Protein
protein	O
are	O
found	O
in	O
various	O
species	O
,	O
including	O
human	O
,	O
mouse	O
and	O
rat	O
.	O

Motif	O
prediction	O
programming	O
,	O
using	O
COILS	O
[	O
11	O
]	O
and	O
MotifScan	O
[	O
12	O
]	O
,	O
suggests	O
that	O
SHARPIN	B-Protein
contains	O
a	O
coiled	O
-	O
coil	O
(	O
CC	O
)	O
domain	O
,	O
a	O
ubiquitin	O
-	O
like	O
(	O
UBL	O
)	O
domain	O
,	O
and	O
a	O
zinc	O
-	O
finger	O
Ran	O
-	O
binding	O
protein	O
2	O
(	O
ZFRBP	O
)	O
domain	O
.	O

These	O
functional	O
motifs	O
constitute	O
similar	O
domain	O
profiles	O
that	O
are	O
present	O
in	O
the	O
SHARPIN	B-Protein
protein	O
of	O
all	O
three	O
origins	O
(	O
Fig	O
.	O
1A	O
)	O
,	O
suggesting	O
that	O
SHARPIN	B-Protein
exerts	O
highly	O
conserved	O
functions	O
across	O
species	O
.	O

Spontaneous	O
mutations	O
in	O
the	O
mouse	O
Sharpin	B-Protein
gene	O
results	O
in	O
a	O
complex	O
inflammatory	O
phenotype	O
characterized	O
by	O
severe	O
dermatitis	O
(	O
Fig	O
.	O
1B	O
)	O
,	O
systemic	O
inflammation	O
and	O
an	O
enlarged	O
spleen	O
(	O
Fig	O
.	O
1C	O
)	O
caused	O
by	O
extramedullary	O
hematopoiesis	O
[	O
3	O
]	O
.	O

The	O
endogenous	O
expression	O
of	O
Sharpin	B-Protein
mRNA	O
in	O
BMDC	O
was	O
determined	O
by	O
quantitative	O
real	O
time	O
-	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
following	O
culture	O
in	O
medium	O
only	O
or	O
after	O
stimulation	O
with	O
LPS	O
.	O
<EOS>	B-X
Production	B-X
of	B-X
interleukin	B-X
1	B-X
beta	B-X
(	B-X
IL-1	B-X
beta	B-X
)	B-X
,	B-X
interleukin	B-X
6	B-X
(	B-X
IL-6	B-X
)	B-X
,	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha	B-X
(	B-X
TNF-alpha	B-X
)	B-X
,	B-X
interleukin	B-X
2	B-X
(	B-X
IL-2	B-X
)	B-X
,	B-X
interferon	B-X
gamma	B-X
(	B-X
IFN-gamma	B-X
)	B-X
and	B-X
granulocyte-macrophage	B-X
colony-stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
after	B-X
stimulation	B-X
by	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
and	B-X
phytohemagglutinin	B-X
(	B-X
PHA	B-X
)	B-X
was	B-X
studied	B-X
in	B-X
1/10	B-X
diluted	B-X
whole	B-X
blood	B-X
(	B-X
WB	B-X
)	B-X
culture	B-X
and	B-X
in	B-X
peripheral	B-X
blood	B-X
mononuclear	B-X
cell	B-X
(	B-X
PBMC	B-X
)	B-X
culture	B-X
.	B-X
Cytokines	B-X
IL-1	B-X
beta	B-X
,	B-X
TNF-alpha	B-X
and	B-X
IL-6	B-X
are	B-X
preferentially	B-X
stimulated	B-X
by	B-X
LPS	B-X
whereas	B-X
IL-2	B-X
,	B-X
IFN-gamma	B-X
and	B-X
GM-CSF	B-X
are	B-X
stimulated	B-X
by	B-X
PHA	B-X
.	B-X
Combination	B-X
of	B-X
5	B-X
micrograms/ml	B-X
PHA	B-X
and	B-X
25	B-X
micrograms/ml	B-X
LPS	B-X
gave	B-X
the	B-X
most	B-X
reliable	B-X
production	B-X
of	B-X
the	B-X
six	B-X
cytokines	B-X
studied	B-X
.	B-X
IL-1	B-X
beta	B-X
,	B-X
TNF-alpha	B-X
and	B-X
IL-6	B-X
represent	B-X
a	B-X
homogeneous	B-X
group	B-X
of	B-X
early-produced	B-X
cytokines	B-X
positively	B-X
correlated	B-X
among	B-X
themselves	B-X
and	B-X
with	B-X
the	B-X
number	B-X
of	B-X
monocytes	B-X
in	B-X
the	B-X
culture	B-X
(	B-X
LeuM3	B-X
)	B-X
.	B-X
Kinetics	B-X
and	B-X
production	B-X
levels	B-X
of	B-X
IL-6	B-X
and	B-X
GM-CSF	B-X
are	B-X
similar	B-X
in	B-X
WB	B-X
and	B-X
PBMC	B-X
cultures	B-X
.	B-X
Individual	B-X
variation	B-X
in	B-X
responses	B-X
to	B-X
PHA	B-X
+	B-X
LPS	B-X
was	B-X
always	B-X
higher	B-X
in	B-X
PBMC	B-X
cultures	B-X
than	B-X
in	B-X
WB	B-X
cultures	B-X
.	B-X
The	B-X
capacity	B-X
of	B-X
cytokine	B-X
production	B-X
in	B-X
relation	B-X
to	B-X
the	B-X
number	B-X
of	B-X
mononuclear	B-X
cells	B-X
is	B-X
higher	B-X
in	B-X
WB	B-X
,	B-X
or	B-X
in	B-X
PBMC	B-X
having	B-X
the	B-X
same	B-X
mononuclear	B-X
cell	B-X
concentration	B-X
as	B-X
WB	B-X
,	B-X
than	B-X
in	B-X
conventional	B-X
cultures	B-X
of	B-X
concentrated	B-X
PBMC	B-X
(	B-X
10	B-X
(	B-X
6	B-X
)	B-X
/ml	B-X
)	B-X
.	B-X
Because	B-X
it	B-X
mimics	B-X
the	B-X
natural	B-X
environment	B-X
,	B-X
diluted	B-X
WB	B-X
culture	B-X
may	B-X
be	B-X
the	B-X
most	B-X
appropriate	B-X
milieu	B-X
in	B-X
which	B-X
to	B-X
study	B-X
cytokine	B-X
production	B-X
in	B-X
vitro	B-X
.	B-X

Sharpin	B-Protein
mRNA	O
was	O
present	O
in	O
BMDC	O
generated	O
from	O
WT	O
mice	O
(	O
Fig	O
.	O
1D	O
)	O
and	O
its	O
level	O
was	O
modestly	O
decreased	O
by	O
LPS	O
stimulation	O
.	O

There	O
was	O
a	O
significant	O
reduction	O
of	O
Sharpin	B-Protein
mRNA	O
(	O
6	O
-	O
7	O
-	O
fold	O
)	O
in	O
BMDC	O
generated	O
from	O
cpdm	O
mice	O
.	O

Transfection	O
of	O
Flag	O
-	O
tagged	O
Sharpin	B-Protein
in	O
fibroblasts	O
(	O
NIH3T3	O
)	O
and	O
macrophages	O
(	O
RAW264	O
.	O
7	O
)	O
indicated	O
cytoplasmic	O
localization	O
of	O
the	O
SHARPIN	B-Protein
protein	O
(	O
Fig	O
.	O
1E	O
)	O
.	O

Phenotyping	O
splenic	O
DC	O
and	O
BMDC	O
from	O
WT	O
and	O
cpdm	O
mice	O

DC	O
are	O
heterogeneous	O
and	O
can	O
be	O
categorized	O
into	O
multiple	O
subtypes	O
based	O
on	O
surface	O
markers	O
[	O
13	O
]	O
.	O

To	O
determine	O
if	O
the	O
Sharpin	B-Protein
mutation	O
affects	O
DC	O
development	O
in	O
lymphoid	O
tissues	O
,	O
mouse	O
spleens	O
were	O
examined	O
for	O
the	O
distribution	O
of	O
conventional	O
DC	O
(	O
cDC	O
;	O
CD11c	B-Protein
+	O
CD8alpha	B-Protein
+	O
and	O
CD11c	B-Protein
+	O
CD8alpha	B-Protein
-	O
)	O
[	O
13	O
]	O
and	O
plasmacytoid	O
DC	O
(	O
pDC	O
;	O
CD11c	B-Protein
-	O
PDCA	B-Protein
-	I-Protein
1	I-Protein
+	O
)	O
[	O
14	O
]	O
.	O

The	O
percentages	O
for	O
splenic	O
cDC	O
and	O
pDC	O
were	O
both	O
reduced	O
in	O
cpdm	O
mice	O
when	O
compared	O
with	O
WT	O
controls	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

However	O
,	O
when	O
gated	O
on	O
CD11c	O
+	O
cDC	O
,	O
the	O
percentages	O
of	O
CD8alpha	O
+	O
and	O
CD8alpha	O
-	O
cells	O
were	O
not	O
affected	O
by	O
SHARPIN	B-Protein
deficiency	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

Since	O
the	O
spleen	O
of	O
cpdm	O
mice	O
is	O
markedly	O
enlarged	O
and	O
contains	O
three	O
times	O
as	O
many	O
cells	O
(	O
Fig	O
.	O
1C	O
)	O
,	O
the	O
different	O
percentages	O
of	O
splenic	O
cDC	O
and	O
pDC	O
between	O
WT	O
and	O
mutant	O
mice	O
reflect	O
the	O
increased	O
number	O
of	O
total	O
spleen	O
cells	O
rather	O
than	O
a	O
reduction	O
in	O
cDC	O
and	O
pDC	O
numbers	O
.	O

These	O
data	O
indicate	O
that	O
the	O
Sharpin	B-Protein
mutation	O
does	O
not	O
affect	O
the	O
distribution	O
of	O
the	O
examined	O
DC	O
subsets	O
in	O
the	O
spleen	O
.	O
<EOS>	B-X
We	B-X
hypothesized	B-X
that	B-X
increased	B-X
integrin	B-X
activity	B-X
due	B-X
to	B-X
loss	B-X
of	B-X
SHARPIN	B-X
protein	B-X
would	B-X
affect	B-X
the	B-X
uptake	B-X
of	B-X
α	B-X
SHARPIN-deficient	B-X
(	B-X
Sharpincpdm/cpdm	B-X
)	B-X
mice	B-X
display	B-X
multi-organ	B-X
inflammation	B-X
and	B-X
chronic	B-X
proliferative	B-X
dermatitis	B-X
(	B-X
cpdm	B-X
)	B-X
due	B-X
to	B-X
TNF-induced	B-X
keratinocyte	B-X
apoptosis	B-X
.	B-X
In	B-X
cells	B-X
,	B-X
SHARPIN	B-X
also	B-X
inhibits	B-X
integrins	B-X
independently	B-X
of	B-X
LUBAC	B-X
,	B-X
but	B-X
it	B-X
has	B-X
remained	B-X
enigmatic	B-X
whether	B-X
elevated	B-X
integrin	B-X
activity	B-X
levels	B-X
in	B-X
the	B-X
dermis	B-X
of	B-X
Sharpincpdm/cpdm	B-X
mice	B-X
is	B-X
due	B-X
to	B-X
increased	B-X
integrin	B-X
activity	B-X
or	B-X
is	B-X
secondary	B-X
to	B-X
inflammation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
functional	B-X
contribution	B-X
of	B-X
increased	B-X
integrin	B-X
activation	B-X
to	B-X
the	B-X
Sharpincpdm/cpdm	B-X
phenotype	B-X
has	B-X
not	B-X
been	B-X
investigated	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
find	B-X
increased	B-X
integrin	B-X
activity	B-X
in	B-X
keratinocytes	B-X
from	B-X
Tnfr1-/-	B-X
Sharpincpdm/cpdm	B-X
double	B-X
knockout	B-X
mice	B-X
,	B-X
which	B-X
do	B-X
not	B-X
display	B-X
chronic	B-X
inflammation	B-X
or	B-X
proliferative	B-X
dermatitis	B-X
,	B-X
thus	B-X
suggesting	B-X
that	B-X
SHARPIN	B-X
indeed	B-X
acts	B-X
as	B-X
an	B-X
integrin	B-X
inhibitor	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
present	B-X
evidence	B-X
for	B-X
a	B-X
functional	B-X
contribution	B-X
of	B-X
integrin	B-X
activity	B-X
to	B-X
the	B-X
Sharpincpdm/cpdm	B-X
skin	B-X
phenotype	B-X
.	B-X
Treatment	B-X
with	B-X
an	B-X
integrin	B-X
beta	B-X
1	B-X
function	B-X
blocking	B-X
antibody	B-X
reduced	B-X
epidermal	B-X
hyperproliferation	B-X
and	B-X
epidermal	B-X
thickness	B-X
in	B-X
Sharpincpdm/cpdm	B-X
mice	B-X
.	B-X
Our	B-X
data	B-X
indicate	B-X
that	B-X
,	B-X
while	B-X
TNF-induced	B-X
cell	B-X
death	B-X
triggers	B-X
the	B-X
chronic	B-X
inflammation	B-X
and	B-X
proliferative	B-X
dermatitis	B-X
,	B-X
absence	B-X
of	B-X
SHARPIN-dependent	B-X
integrin	B-X
inhibition	B-X
exacerbates	B-X
the	B-X
epidermal	B-X
hyperproliferation	B-X
in	B-X
Sharpincpdm/cpdm	B-X
mice	B-X
.	B-X

BMDC	O
from	O
in	O
vitro	O
cultures	O
functionally	O
resemble	O
non	O
-	O
lymphoid	O
tissue	O
DC	O
and	O
monocyte	O
-	O
derived	O
inflammatory	O
DC	O
[	O
15	O
]	O
,	O
[	O
16	O
]	O
.	O

The	O
yields	O
of	O
BMDC	O
from	O
WT	O
and	O
cpdm	O
mice	O
were	O
similar	O
.	O

BMDC	O
were	O
CD11c	B-Protein
+	O
and	O
MHC	O
II	O
+	O
with	O
low	O
expression	O
of	O
co	O
-	O
stimulatory	O
molecules	O
CD40	B-Protein
,	O
CD80	B-Protein
,	O
and	O
CD86	B-Protein
.	O
<EOS>	B-X
Nattectin	B-X
induced	B-X
a	B-X
significant	B-X
neutrophilic	B-X
recruitment	B-X
into	B-X
peritoneal	B-X
cavity	B-X
of	B-X
mice	B-X
,	B-X
followed	B-X
by	B-X
macrophages	B-X
,	B-X
with	B-X
lipidic	B-X
mediators	B-X
and	B-X
IL-12	B-X
p70	B-X
synthesis	B-X
.	B-X
Macrophages	B-X
derived	B-X
from	B-X
7day-Nattectin	B-X
mice	B-X
were	B-X
CD11c+CD11b	B-X
(	B-X
low	B-X
)	B-X
Ly6	B-X
(	B-X
high	B-X
)	B-X
F4/80R	B-X
(	B-X
high	B-X
)	B-X
and	B-X
express	B-X
high	B-X
levels	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
and	B-X
CD80	B-X
molecules	B-X
.	B-X
Culture	B-X
of	B-X
peritoneal	B-X
exudates	B-X
derived	B-X
macrophages	B-X
from	B-X
7day	B-X
Nattectin-mice	B-X
and	B-X
immature	B-X
BMDCs	B-X
with	B-X
Nattectin	B-X
markedly	B-X
increased	B-X
the	B-X
surface	B-X
expression	B-X
of	B-X
CD40	B-X
,	B-X
CD80	B-X
,	B-X
CD86	B-X
,	B-X
and	B-X
MHC	B-X
class	B-X
II	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
,	B-X
and	B-X
the	B-X
production	B-X
of	B-X
MMP-2	B-X
and	B-X
MMP-9	B-X
distributed	B-X
in	B-X
nucleus	B-X
and	B-X
cytoplasm	B-X
of	B-X
cells	B-X
,	B-X
that	B-X
was	B-X
associated	B-X
with	B-X
strong	B-X
activity	B-X
in	B-X
the	B-X
culture	B-X
supernatant	B-X
.	B-X
The	B-X
Nattectin-treated	B-X
BMDC	B-X
or	B-X
macrophage-derived	B-X
DCs	B-X
were	B-X
highly	B-X
efficient	B-X
at	B-X
Ag	B-X
capture	B-X
.	B-X
Macrophage-derived	B-X
DCs	B-X
mature	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
cytokine	B-X
milieu	B-X
generated	B-X
against	B-X
Nattectin	B-X
,	B-X
exhibiting	B-X
T	B-X
cell	B-X
co-stimulatory	B-X
molecule	B-X
expression	B-X
and	B-X
induced	B-X
a	B-X
Th1	B-X
polarized	B-X
response	B-X
.	B-X

The	O
TLR3	B-Protein
ligand	O
poly	O
I	O
:	O
C	O
and	O
the	O
TLR4	B-Protein
ligand	O
LPS	O
each	O
activate	O
overlapping	O
but	O
different	O
signaling	O
pathways	O
and	O
were	O
used	O
to	O
induce	O
DC	O
maturation	O
[	O
17	O
]	O
,	O
[	O
18	O
]	O
.	O

Incubation	O
with	O
the	O
TLR	O
agonists	O
for	O
24	O
hours	O
resulted	O
in	O
increased	O
expression	O
of	O
CD40	B-Protein
,	O
CD80	B-Protein
,	O
and	O
CD86	B-Protein
on	O
BMDC	O
;	O
however	O
,	O
there	O
was	O
no	O
difference	O
in	O
the	O
expression	O
levels	O
of	O
these	O
markers	O
between	O
WT	O
and	O
cpdm	O
BMDC	O
(	O
Fig	O
.	O
2B	O
)	O
.	O

Thus	O
,	O
SHARPIN	B-Protein
deficiency	O
did	O
not	O
influence	O
the	O
expression	O
of	O
co	O
-	O
stimulatory	O
molecules	O
by	O
BMDC	O
.	O
<EOS>	B-X
SHARPIN	B-X
,	B-X
together	B-X
with	B-X
RNF31/HOIP	B-X
and	B-X
RBCK1/HOIL1	B-X
,	B-X
form	B-X
the	B-X
linear	B-X
ubiquitin	B-X
chain	B-X
assembly	B-X
complex	B-X
(	B-X
LUBAC	B-X
)	B-X
E3	B-X
ligase	B-X
that	B-X
catalyzes	B-X
M1-linked	B-X
polyubiquitination	B-X
.	B-X
Mice	B-X
with	B-X
spontaneous	B-X
mutations	B-X
in	B-X
the	B-X
Sharpin	B-X
gene	B-X
develop	B-X
chronic	B-X
proliferative	B-X
dermatitis	B-X
that	B-X
is	B-X
characterized	B-X
by	B-X
eosinophilic	B-X
inflammation	B-X
of	B-X
the	B-X
skin	B-X
and	B-X
other	B-X
organs	B-X
with	B-X
increased	B-X
expression	B-X
of	B-X
type	B-X
2	B-X
cytokines	B-X
and	B-X
dysregulated	B-X
development	B-X
of	B-X
lymphoid	B-X
tissues	B-X
.	B-X
The	B-X
biological	B-X
function	B-X
of	B-X
SHARPIN	B-X
and	B-X
how	B-X
its	B-X
absence	B-X
leads	B-X
to	B-X
such	B-X
a	B-X
complex	B-X
inflammatory	B-X
phenotype	B-X
in	B-X
mice	B-X
are	B-X
poorly	B-X
understood	B-X
.	B-X
However	B-X
,	B-X
recent	B-X
studies	B-X
identified	B-X
SHARPIN	B-X
as	B-X
a	B-X
novel	B-X
modulator	B-X
of	B-X
immune	B-X
and	B-X
inflammatory	B-X
responses	B-X
.	B-X
The	B-X
emerging	B-X
mechanistic	B-X
model	B-X
suggests	B-X
that	B-X
SHARPIN	B-X
functions	B-X
as	B-X
an	B-X
important	B-X
adaptor	B-X
component	B-X
of	B-X
the	B-X
linear	B-X
ubiquitin	B-X
chain	B-X
assembly	B-X
complex	B-X
that	B-X
modulates	B-X
activation	B-X
of	B-X
NF-κB	B-X
signalling	B-X
pathway	B-X
,	B-X
thereby	B-X
regulating	B-X
cell	B-X
survival	B-X
and	B-X
apoptosis	B-X
,	B-X
cytokine	B-X
production	B-X
and	B-X
development	B-X
of	B-X
lymphoid	B-X
tissues	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
summarize	B-X
the	B-X
current	B-X
understanding	B-X
of	B-X
the	B-X
ubiquitin-dependent	B-X
regulatory	B-X
mechanisms	B-X
involved	B-X
in	B-X
NF-κB	B-X
signalling	B-X
,	B-X
and	B-X
incorporate	B-X
the	B-X
recently	B-X
obtained	B-X
molecular	B-X
insights	B-X
of	B-X
SHARPIN	B-X
into	B-X
this	B-X
pathway	B-X
.	B-X
Recent	B-X
studies	B-X
identified	B-X
SHARPIN	B-X
as	B-X
an	B-X
inhibitor	B-X
of	B-X
β1-integrin	B-X
activation	B-X
and	B-X
signalling	B-X
,	B-X
and	B-X
this	B-X
may	B-X
be	B-X
another	B-X
mechanism	B-X
by	B-X
which	B-X
SHARPIN	B-X
regulates	B-X
inflammation	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
disrupted	B-X
lymphoid	B-X
organogenesis	B-X
in	B-X
SHARPIN-deficient	B-X
mice	B-X
suggests	B-X
that	B-X
SHARPIN-mediated	B-X
NF-κB	B-X
regulation	B-X
is	B-X
important	B-X
for	B-X
de	B-X
novo	B-X
development	B-X
of	B-X
lymphoid	B-X
tissues	B-X
.	B-X

Production	O
of	O
proinflammatory	O
mediators	O
by	O
cpdm	O
BMDC	O
is	O
impaired	O

Incubation	O
with	O
LPS	O
or	O
poly	O
I	O
:	O
C	O
resulted	O
in	O
secretion	O
of	O
IL6	B-Protein
,	O
IL12P70	O
,	O
and	O
GMCSF	B-Protein
from	O
both	O
WT	O
and	O
cpdm	O
BMDC	O
;	O
however	O
,	O
BMDC	O
from	O
cpdm	O
mice	O
produced	O
significantly	O
less	O
of	O
all	O
three	O
cytokines	O
compared	O
with	O
WT	O
BMDC	O
(	O
Fig	O
.	O
3A	O
-	O
C	O
,	O
E	O
-	O
F	O
)	O
.	O
<EOS>	B-X
CD45	B-X
is	B-X
a	B-X
transmembrane	B-X
glycoprotein	B-X
and	B-X
protein	B-X
tyrosine	B-X
phosphatase	B-X
expressed	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
all	B-X
nucleated	B-X
hematopoietic	B-X
cells	B-X
.	B-X
While	B-X
there	B-X
is	B-X
increasing	B-X
evidence	B-X
demonstrating	B-X
the	B-X
involvement	B-X
of	B-X
CD45	B-X
in	B-X
immune	B-X
system	B-X
regulation	B-X
,	B-X
no	B-X
information	B-X
on	B-X
CD45	B-X
expression	B-X
in	B-X
inflammation	B-X
and	B-X
sepsis	B-X
is	B-X
currently	B-X
available	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
determined	B-X
the	B-X
CD45	B-X
surface	B-X
expression	B-X
on	B-X
granulocytes	B-X
,	B-X
lymphocytes	B-X
,	B-X
and	B-X
monocytes	B-X
in	B-X
patients	B-X
with	B-X
COVID-19	B-X
and	B-X
healthy	B-X
volunteers	B-X
in	B-X
both	B-X
absence	B-X
and	B-X
presence	B-X
of	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
.	B-X
Following	B-X
approval	B-X
by	B-X
the	B-X
local	B-X
ethics	B-X
committee	B-X
,	B-X
whole	B-X
blood	B-X
samples	B-X
were	B-X
obtained	B-X
from	B-X
patients	B-X
with	B-X
COVID-19	B-X
infection	B-X
on	B-X
day	B-X
1	B-X
of	B-X
hospital	B-X
admission	B-X
and	B-X
healthy	B-X
volunteers	B-X
.	B-X
Samples	B-X
were	B-X
incubated	B-X
in	B-X
absence	B-X
and	B-X
presence	B-X
of	B-X
LPS	B-X
and	B-X
CD45	B-X
was	B-X
measured	B-X
in	B-X
granulocytes	B-X
,	B-X
lymphocytes	B-X
,	B-X
and	B-X
monocytes	B-X
using	B-X
flow	B-X
cytometry	B-X
.	B-X
In	B-X
comparison	B-X
with	B-X
healthy	B-X
individuals	B-X
,	B-X
COVID-19	B-X
patients	B-X
showed	B-X
an	B-X
increased	B-X
CD45	B-X
expression	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
granulocytes	B-X
(	B-X
+35	B-X
%	B-X
,	B-X
p	B-X
<	B-X
0.02	B-X
)	B-X
and	B-X
lymphocytes	B-X
(	B-X
+39	B-X
%	B-X
,	B-X
p	B-X
<	B-X
0.0001	B-X
)	B-X
,	B-X
but	B-X
a	B-X
reduced	B-X
CD45	B-X
expression	B-X
on	B-X
monocytes	B-X
(	B-X
−35	B-X
%	B-X
,	B-X
p	B-X
<	B-X
0.0001	B-X
)	B-X
.	B-X
LPS	B-X
incubation	B-X
of	B-X
whole	B-X
blood	B-X
from	B-X
healthy	B-X
individuals	B-X
increased	B-X
the	B-X
CD45	B-X
expression	B-X
on	B-X
granulocytes	B-X
(	B-X
+430	B-X
%	B-X
,	B-X
p	B-X
<	B-X
0.0001	B-X
)	B-X
,	B-X
lymphocytes	B-X
(	B-X
+32	B-X
%	B-X
,	B-X
p	B-X
=	B-X
0.0012	B-X
)	B-X
,	B-X
and	B-X
monocytes	B-X
(	B-X
+36	B-X
%	B-X
,	B-X
p	B-X
=	B-X
0.0005	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
LPS	B-X
incubation	B-X
of	B-X
whole	B-X
blood	B-X
samples	B-X
from	B-X
COVID-19	B-X
patients	B-X
increased	B-X
the	B-X
CD45	B-X
expression	B-X
on	B-X
granulocytes	B-X
and	B-X
monocytes	B-X
,	B-X
and	B-X
decreased	B-X
the	B-X
CD45	B-X
expression	B-X
on	B-X
lymphocytes	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
CD45	B-X
expression	B-X
on	B-X
leucocytes	B-X
is	B-X
altered	B-X
:	B-X
(	B-X
1	B-X
)	B-X
in	B-X
COVID-19	B-X
patients	B-X
,	B-X
and	B-X
(	B-X
2	B-X
)	B-X
in	B-X
in	B-X
vitro	B-X
endotoxemia	B-X
in	B-X
a	B-X
complex	B-X
cell-specific	B-X
way	B-X
,	B-X
thus	B-X
representing	B-X
a	B-X
new	B-X
immunoregulatory	B-X
mechanism	B-X
.	B-X

The	O
amount	O
of	O
nitric	O
oxide	O
generated	O
by	O
mutant	O
BMDC	O
was	O
also	O
significantly	O
reduced	O
compared	O
with	O
WT	O
cells	O
(	O
Fig	O
.	O
3D	O
)	O
,	O
indicating	O
severely	O
disrupted	O
production	O
of	O
proinflammatory	O
mediators	O
from	O
Sharpin	B-Protein
-	O
deficient	O
BMDC	O
.	O

In	O
vivo	O
complementation	O
with	O
a	O
Sharpin	B-Protein
gene	O
-	O
containing	O
BAC	O
reversed	O
the	O
phenotype	O
of	O
the	O
mutant	O
mice	O
[	O
2	O
]	O
,	O
and	O
BMDC	O
generated	O
from	O
these	O
rescued	O
mice	O
secreted	O
significantly	O
more	O
IL12P70	O
than	O
BMDC	O
from	O
cpdm	O
mice	O
(	O
Fig	O
.	O
3G	O
)	O
,	O
supporting	O
a	O
necessary	O
role	O
of	O
SHARPIN	B-Protein
for	O
the	O
production	O
of	O
IL12P70	O
.	O

In	O
addition	O
,	O
the	O
transcript	O
levels	O
of	O
the	O
inflammatory	O
cytokines	O
Il6	B-Protein
,	O
Il12p40	B-Protein
,	O
Gmcsf	B-Protein
,	O
and	O
Ifnb	B-Protein
were	O
examined	O
,	O
and	O
these	O
were	O
all	O
significantly	O
reduced	O
in	O
stimulated	O
cpdm	O
BMDC	O
when	O
compared	O
with	O
WT	O
controls	O
(	O
Fig	O
.	O
4	O
)	O
.	O

Impaired	O
cytokine	O
production	O
by	O
cpdm	O
BMDC	O
is	O
correlated	O
with	O
selective	O
defects	O
in	O
NF	O
-	O
kappaB	O
signaling	O

There	O
are	O
a	O
number	O
of	O
possible	O
explanations	O
for	O
the	O
defective	O
cytokine	O
secretion	O
in	O
stimulated	O
cpdm	O
BMDC	O
,	O
including	O
1	O
)	O
reduced	O
surface	O
expression	O
of	O
the	O
LPS	O
receptor	O
complex	O
,	O
2	O
)	O
increased	O
production	O
of	O
anti	O
-	O
inflammatory	O
mediators	O
,	O
3	O
)	O
increased	O
expression	O
of	O
negative	O
regulators	O
of	O
TLR	O
pathways	O
,	O
and	O
4	O
)	O
impaired	O
TLR	O
-	O
induced	O
signaling	O
activation	O
.	O

We	O
determined	O
the	O
surface	O
expression	O
of	O
the	O
LPS	O
receptor	O
complex	O
that	O
comprises	O
TLR4	B-Protein
,	O
the	O
accessory	O
proteins	O
CD14	B-Protein
and	O
myeloid	B-Protein
differentiation	I-Protein
factor	I-Protein
2	I-Protein
(	O
MD2	B-Protein
/	O
LY96	B-Protein
)	O
[	O
19	O
]	O
.	O

Flow	O
cytometric	O
analysis	O
shows	O
that	O
the	O
expression	O
levels	O
of	O
CD14	B-Protein
and	O
TLR4	B-Protein
/	O
MD2	B-Protein
between	O
WT	O
and	O
cpdm	O
BMDC	O
were	O
similar	O
(	O
Fig	O
.	O
5A	O
)	O
.	O

We	O
then	O
quantified	O
the	O
secretion	O
of	O
the	O
suppressive	O
cytokines	O
IL10	B-Protein
that	O
can	O
inhibit	O
IL12	O
secretion	O
in	O
an	O
autocrine	O
manner	O
[	O
20	O
]	O
,	O
[	O
21	O
]	O
.	O

The	O
supernatants	O
from	O
LPS	O
-	O
stimulated	O
cpdm	O
BMDC	O
contained	O
significantly	O
lower	O
levels	O
of	O
IL10	B-Protein
than	O
stimulated	O
WT	O
BMDC	O
(	O
Fig	O
.	O
5B	O
)	O
,	O
suggesting	O
that	O
IL10	B-Protein
was	O
not	O
responsible	O
for	O
decreased	O
secretion	O
of	O
IL12P70	O
by	O
cpdm	O
BMDC	O
.	O

Increased	O
expression	O
of	O
a	O
negative	O
regulator	O
of	O
TLR	O
signaling	O
such	O
as	O
A20	B-Protein
[	O
22	O
]	O
may	O
also	O
suppress	O
cytokine	O
secretion	O
.	O
<EOS>	B-X
Hypomorphic	B-X
NEMO	B-X
mutations	B-X
result	B-X
in	B-X
X-linked	B-X
ectodermal	B-X
dysplasia	B-X
with	B-X
anhidrosis	B-X
and	B-X
immunodeficiency	B-X
,	B-X
also	B-X
referred	B-X
to	B-X
as	B-X
NEMO	B-X
syndrome	B-X
.	B-X
Both	B-X
primary	B-X
cells	B-X
from	B-X
these	B-X
patients	B-X
,	B-X
as	B-X
well	B-X
as	B-X
reconstituted	B-X
cell	B-X
lines	B-X
with	B-X
this	B-X
deletion	B-X
,	B-X
exhibited	B-X
increased	B-X
IκB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
activity	B-X
and	B-X
production	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
.	B-X
Investigation	B-X
of	B-X
the	B-X
underlying	B-X
mechanisms	B-X
revealed	B-X
impaired	B-X
interactions	B-X
with	B-X
A20	B-X
,	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
NF-κB	B-X
activation	B-X
,	B-X
leading	B-X
to	B-X
prolonged	B-X
accumulation	B-X
of	B-X
K63-ubiquitinated	B-X
RIP	B-X
within	B-X
the	B-X
TNFR1	B-X
signaling	B-X
complex	B-X
.	B-X
Recruitment	B-X
of	B-X
A20	B-X
to	B-X
the	B-X
C-terminal	B-X
domain	B-X
of	B-X
NEMO	B-X
represents	B-X
a	B-X
novel	B-X
mechanism	B-X
limiting	B-X
NF-κB	B-X
activation	B-X
by	B-X
NEMO	B-X
,	B-X
and	B-X
its	B-X
absence	B-X
results	B-X
in	B-X
autoinflammatory	B-X
disease	B-X
.	B-X

However	O
,	O
the	O
transcript	O
level	O
of	O
A20	B-Protein
was	O
lower	O
in	O
LPS	O
-	O
activated	O
cpdm	O
BMDC	O
than	O
WT	O
controls	O
(	O
Fig	O
.	O
5C	O
)	O
,	O
thereby	O
ruling	O
out	O
overexpression	O
of	O
A20	B-Protein
as	O
a	O
factor	O
in	O
the	O
reduced	O
cytokine	O
production	O
.	O

The	O
transcription	O
of	O
TLR3	B-Protein
/	O
4	B-Protein
-	O
induced	O
proinflammatory	O
intermediates	O
is	O
tightly	O
regulated	O
by	O
cellular	O
signaling	O
pathways	O
,	O
in	O
particular	O
NF	O
-	O
kappaB	O
,	O
TBK1	B-Protein
/	O
IRF3	B-Protein
,	O
and	O
MAPK	O
[	O
23	O
]	O
-	O
[	O
27	O
]	O
.	O

We	O
next	O
determined	O
if	O
disrupted	O
NF	O
-	O
kappaB	O
,	O
TBK1	B-Protein
/	O
IRF3	B-Protein
,	O
and	O
/	O
or	O
MAPK	O
signaling	O
may	O
underlie	O
the	O
impaired	O
cytokine	O
production	O
from	O
stimulated	O
Sharpin	B-Protein
-	O
deficient	O
BMDC	O
.	O

Stimulus	O
-	O
induced	O
phosphorylation	O
of	O
the	O
IkappaB	O
kinase	O
(	O
IKK1	B-Protein
/	O
2	B-Protein
)	O
is	O
an	O
essential	O
step	O
in	O
NF	O
-	O
kappaB	O
signaling	O
,	O
allowing	O
phosphorylation	O
and	O
proteasome	O
-	O
mediated	O
degradation	O
of	O
the	O
NF	O
-	O
kappaB	O
inhibitor	O
IkappaBalpha	B-Protein
to	O
release	O
the	O
NF	O
-	O
kappaB	O
transcription	O
factors	O
into	O
the	O
nucleus	O
.	O

The	O
amount	O
of	O
phosphorylated	O
IKK1	B-Protein
/	O
2	B-Protein
(	O
p	O
-	O
IKK1	B-Protein
/	O
2	B-Protein
)	O
and	O
IkappaBalpha	B-Protein
(	O
p	O
-	O
IkappaBalpha	B-Protein
)	O
following	O
incubation	O
with	O
LPS	O
or	O
poly	O
I	O
:	O
C	O
was	O
severely	O
decreased	O
in	O
cpdm	O
BMDC	O
as	O
compared	O
with	O
WT	O
controls	O
(	O
Fig	O
.	O
6	O
)	O
.	O

The	O
cpdm	O
BMDC	O
exhibited	O
similar	O
levels	O
of	O
TBK1	B-Protein
,	O
ERK1	B-Protein
/	O
2	B-Protein
,	O
and	O
p38	O
phosphorylation	O
to	O
those	O
of	O
WT	O
cells	O
(	O
Fig	O
.	O
6	O
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
absence	O
of	O
functional	O
SHARPIN	B-Protein
decreased	O
NF	O
-	O
kappaB	O
activation	O
but	O
did	O
not	O
affect	O
TBK1	B-Protein
/	O
IRF3	B-Protein
,	O
ERK1	B-Protein
/	O
2	B-Protein
,	O
and	O
p38	O
signaling	O
in	O
BMDC	O
.	O
<EOS>	B-X
The	B-X
NF-κB	B-X
pathway	B-X
performs	B-X
pivotal	B-X
roles	B-X
in	B-X
diverse	B-X
physiological	B-X
processes	B-X
such	B-X
as	B-X
immunity	B-X
,	B-X
inflammation	B-X
,	B-X
proliferation	B-X
,	B-X
and	B-X
apoptosis	B-X
.	B-X
NF-κB	B-X
is	B-X
kept	B-X
inactive	B-X
in	B-X
the	B-X
cytoplasm	B-X
through	B-X
association	B-X
with	B-X
inhibitors	B-X
(	B-X
IκB	B-X
)	B-X
,	B-X
and	B-X
translocates	B-X
to	B-X
the	B-X
nucleus	B-X
to	B-X
activate	B-X
its	B-X
target	B-X
genes	B-X
after	B-X
the	B-X
IκBs	B-X
are	B-X
phosphorylated	B-X
and	B-X
degraded	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
loss	B-X
of	B-X
function	B-X
of	B-X
SHANK-associated	B-X
RH	B-X
domain	B-X
interacting	B-X
protein	B-X
(	B-X
SHARPIN	B-X
)	B-X
leads	B-X
to	B-X
activation	B-X
of	B-X
NF-κB	B-X
signaling	B-X
in	B-X
skin	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
development	B-X
of	B-X
an	B-X
idiopathic	B-X
hypereosinophilic	B-X
syndrome	B-X
(	B-X
IHES	B-X
)	B-X
with	B-X
eosinophilic	B-X
dermatitis	B-X
in	B-X
C57BL/KaLawRij-Sharpin	B-X
(	B-X
cpdm	B-X
)	B-X
/RijSunJ	B-X
mice	B-X
,	B-X
and	B-X
clonal	B-X
expansion	B-X
of	B-X
B-1	B-X
B	B-X
cells	B-X
and	B-X
CD3	B-X
(	B-X
+	B-X
)	B-X
CD4	B-X
(	B-X
-	B-X
)	B-X
CD8	B-X
(	B-X
-	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
Transcription	B-X
profiling	B-X
in	B-X
skin	B-X
revealed	B-X
constitutive	B-X
activation	B-X
of	B-X
classical	B-X
NF-κB	B-X
pathways	B-X
,	B-X
predominantly	B-X
by	B-X
overexpressed	B-X
members	B-X
of	B-X
IL1	B-X
family	B-X
.	B-X
Compound-null	B-X
mutants	B-X
for	B-X
both	B-X
the	B-X
IL1	B-X
receptor	B-X
accessory	B-X
protein	B-X
(	B-X
Il1rap	B-X
(	B-X
tm1Roml	B-X
)	B-X
)	B-X
and	B-X
SHARPIN	B-X
(	B-X
Sharpin	B-X
(	B-X
cpdm	B-X
)	B-X
)	B-X
resulted	B-X
in	B-X
mice	B-X
having	B-X
decreased	B-X
skin	B-X
disease	B-X
severity	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
absence	B-X
of	B-X
SHARPIN	B-X
causes	B-X
IHES	B-X
with	B-X
eosinophilic	B-X
dermatitis	B-X
by	B-X
NF-κB	B-X
activation	B-X
,	B-X
and	B-X
bortezomib	B-X
may	B-X
be	B-X
an	B-X
effective	B-X
treatment	B-X
for	B-X
skin	B-X
problems	B-X
of	B-X
IHES	B-X
.	B-X

Th2	O
-	O
biased	O
immunogenicity	O
of	O
stimulated	O
cpdm	O
BMDC	O

The	O
defective	O
IL12	O
production	O
(	O
Fig	O
.	O
3A	O
)	O
and	O
Th2	O
-	O
dominant	O
cytokine	O
profile	O
in	O
cpdm	O
mice	O
[	O
5	O
]	O
suggest	O
that	O
the	O
absence	O
of	O
SHARPIN	B-Protein
affects	O
the	O
ability	O
of	O
cpdm	O
BMDC	O
to	O
induce	O
T	O
cell	O
differentiation	O
into	O
effector	O
cells	O
.	O

Co	O
-	O
culture	O
of	O
allogeneic	O
naive	O
CD4	O
+	O
T	O
cells	O
with	O
WT	O
BMDC	O
stimulated	O
with	O
LPS	O
or	O
poly	O
I	O
:	O
C	O
elicited	O
robust	O
IFNgamma	B-Protein
production	O
,	O
whereas	O
the	O
concentration	O
of	O
IFNgamma	B-Protein
in	O
cpdm	O
BMDC	O
-	O
T	O
cell	O
cultures	O
was	O
significantly	O
lower	O
after	O
LPS	O
stimulation	O
(	O
Fig	O
.	O
7A	O
)	O
,	O
indicating	O
impaired	O
Th1	O
-	O
polarizing	O
abilities	O
of	O
cpdm	O
BMDC	O
.	O

In	O
addition	O
to	O
TLR3	B-Protein
/	O
4	B-Protein
agonists	O
,	O
the	O
TLR2	B-Protein
ligand	O
Pam3CYS	B-Protein
was	O
used	O
since	O
it	O
has	O
been	O
shown	O
to	O
induce	O
both	O
Th1	O
and	O
Th2	O
responses	O
[	O
28	O
]	O
-	O
[	O
30	O
]	O
.	O

Pam3CYS	B-Protein
-	O
matured	O
WT	O
BMDC	O
induced	O
robust	O
IFNgamma	B-Protein
production	O
at	O
a	O
significantly	O
higher	O
level	O
than	O
cpdm	O
BMDC	O
(	O
Fig	O
.	O
7A	O
)	O
.	O

The	O
reduced	O
Th1	O
differentiation	O
following	O
Pam3CYS	B-Protein
stimulation	O
is	O
consistent	O
with	O
the	O
recent	O
report	O
of	O
decreased	O
IL12	O
production	O
in	O
cpdm	O
macrophages	O
following	O
TLR2	B-Protein
stimulation	O
[	O
31	O
]	O
.	O

In	O
contrast	O
,	O
more	O
Th2	O
-	O
specific	O
IL4	B-Protein
cytokine	O
was	O
produced	O
in	O
the	O
cpdm	O
BMDC	O
co	O
-	O
cultures	O
than	O
the	O
WT	O
control	O
(	O
Fig	O
.	O
7B	O
)	O
,	O
suggesting	O
Th2	O
-	O
skewed	O
immunogenicity	O
of	O
cpdm	O
BMDC	O
.	O

The	O
production	O
of	O
Th17	O
-	O
specific	O
cytokine	O
IL17A	B-Protein
following	O
LPS	O
stimulation	O
of	O
dendritic	O
cells	O
was	O
similar	O
between	O
stimulated	O
WT	O
and	O
cpdm	O
BMDC	O
cocultures	O
(	O
data	O
not	O
shown	O
)	O
.	O

Despite	O
the	O
distinct	O
Th1	O
-	O
and	O
Th2	O
-	O
stimulating	O
abilities	O
of	O
WT	O
and	O
cpdm	O
BMDC	O
,	O
they	O
were	O
equally	O
effective	O
in	O
IL2	B-Protein
production	O
from	O
BMDC	O
-	O
T	O
cell	O
co	O
-	O
cultures	O
except	O
for	O
poly	O
I	O
:	O
C	O
stimulation	O
where	O
WT	O
BMDC	O
induced	O
more	O
IL2	B-Protein
than	O
cpdm	O
BMDC	O
(	O
Fig	O
.	O
7C	O
)	O
.	O

The	O
Th2	O
-	O
biased	O
stimulating	O
capability	O
of	O
cpdm	O
BMDC	O
when	O
co	O
-	O
cultured	O
with	O
allogeneic	O
naive	O
CD4	O
+	O
T	O
cells	O
is	O
consistent	O
with	O
the	O
Th2	O
-	O
dominant	O
cytokine	O
phenotype	O
observed	O
in	O
cpdm	O
mice	O
.	O

The	O
present	O
report	O
showed	O
that	O
null	O
mutations	O
of	O
the	O
mouse	O
Sharpin	B-Protein
gene	O
did	O
not	O
affect	O
the	O
steady	O
-	O
state	O
distribution	O
of	O
splenic	O
DC	O
subsets	O
nor	O
the	O
development	O
and	O
phenotype	O
of	O
BMDC	O
.	O
<EOS>	B-X
Two	B-X
independent	B-X
,	B-X
spontaneous	B-X
mutations	B-X
in	B-X
the	B-X
mouse	B-X
Sharpin	B-X
gene	B-X
(	B-X
Sharpin	B-X
(	B-X
cpdm	B-X
)	B-X
and	B-X
Sharpin	B-X
(	B-X
cpdm-Dem	B-X
)	B-X
)	B-X
result	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
PP	B-X
and	B-X
disrupted	B-X
splenic	B-X
white	B-X
pulp	B-X
in	B-X
adult	B-X
mice	B-X
,	B-X
although	B-X
a	B-X
full	B-X
complement	B-X
of	B-X
lymph	B-X
nodes	B-X
is	B-X
present	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
rudimentary	B-X
PP	B-X
begin	B-X
to	B-X
develop	B-X
in	B-X
Sharpin	B-X
(	B-X
cpdm	B-X
)	B-X
mice	B-X
during	B-X
embryogenesis	B-X
,	B-X
but	B-X
lack	B-X
the	B-X
organizational	B-X
patterns	B-X
that	B-X
are	B-X
typical	B-X
of	B-X
this	B-X
tissue	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
small	B-X
intestines	B-X
examined	B-X
at	B-X
weekly	B-X
intervals	B-X
from	B-X
birth	B-X
to	B-X
maturity	B-X
showed	B-X
spontaneous	B-X
regression	B-X
of	B-X
PP	B-X
in	B-X
mutant	B-X
mice	B-X
with	B-X
concurrent	B-X
infiltration	B-X
of	B-X
granulocytes	B-X
.	B-X
Transplantation	B-X
of	B-X
normal	B-X
bone	B-X
marrow	B-X
into	B-X
Sharpin	B-X
(	B-X
cpdm	B-X
)	B-X
mice	B-X
at	B-X
7	B-X
days	B-X
of	B-X
age	B-X
did	B-X
not	B-X
prevent	B-X
regression	B-X
of	B-X
PP	B-X
in	B-X
bone	B-X
marrow	B-X
chimeras	B-X
examined	B-X
at	B-X
7	B-X
to	B-X
8	B-X
weeks	B-X
of	B-X
age	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
SHARPIN	B-X
expression	B-X
is	B-X
required	B-X
for	B-X
the	B-X
normal	B-X
development	B-X
and	B-X
maintenance	B-X
,	B-X
but	B-X
not	B-X
initiation	B-X
,	B-X
of	B-X
PP	B-X
.	B-X

However	O
,	O
loss	O
of	O
SHARPIN	B-Protein
significantly	O
diminished	O
the	O
capacity	O
of	O
BMDC	O
to	O
secrete	O
inflammatory	O
cytokines	O
and	O
nitric	O
oxide	O
.	O

The	O
attenuated	O
cytokine	O
production	O
was	O
not	O
due	O
to	O
the	O
presence	O
of	O
anti	O
-	O
inflammatory	O
inhibitors	O
,	O
and	O
can	O
be	O
largely	O
explained	O
by	O
selective	O
inactivation	O
of	O
NF	O
-	O
kappaB	O
signaling	O
.	O
<EOS>	B-X
Symptomatic	B-X
relief	B-X
can	B-X
be	B-X
achieved	B-X
in	B-X
up	B-X
to	B-X
50	B-X
%	B-X
of	B-X
patients	B-X
using	B-X
biological	B-X
agents	B-X
that	B-X
inhibit	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
or	B-X
other	B-X
mechanisms	B-X
of	B-X
action	B-X
,	B-X
but	B-X
there	B-X
are	B-X
no	B-X
universally	B-X
effective	B-X
therapies	B-X
.	B-X
Recent	B-X
advances	B-X
in	B-X
basic	B-X
and	B-X
preclinical	B-X
science	B-X
reveal	B-X
that	B-X
reflex	B-X
neural	B-X
circuits	B-X
inhibit	B-X
the	B-X
production	B-X
of	B-X
cytokines	B-X
and	B-X
inflammation	B-X
in	B-X
animal	B-X
models	B-X
.	B-X
One	B-X
well-characterized	B-X
cytokine-inhibiting	B-X
mechanism	B-X
,	B-X
termed	B-X
the	B-X
``	B-X
inflammatory	B-X
reflex	B-X
,	B-X
''	B-X
is	B-X
dependent	B-X
upon	B-X
vagus	B-X
nerve	B-X
signals	B-X
that	B-X
inhibit	B-X
cytokine	B-X
production	B-X
and	B-X
attenuate	B-X
experimental	B-X
arthritis	B-X
severity	B-X
in	B-X
mice	B-X
and	B-X
rats	B-X
.	B-X
It	B-X
previously	B-X
was	B-X
unknown	B-X
whether	B-X
directly	B-X
stimulating	B-X
the	B-X
inflammatory	B-X
reflex	B-X
in	B-X
humans	B-X
inhibits	B-X
TNF	B-X
production	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
an	B-X
implantable	B-X
vagus	B-X
nerve-stimulating	B-X
device	B-X
in	B-X
epilepsy	B-X
patients	B-X
inhibits	B-X
peripheral	B-X
blood	B-X
production	B-X
of	B-X
TNF	B-X
,	B-X
IL-1β	B-X
,	B-X
and	B-X
IL-6	B-X
.	B-X
Vagus	B-X
nerve	B-X
stimulation	B-X
(	B-X
up	B-X
to	B-X
four	B-X
times	B-X
daily	B-X
)	B-X
in	B-X
RA	B-X
patients	B-X
significantly	B-X
inhibited	B-X
TNF	B-X
production	B-X
for	B-X
up	B-X
to	B-X
84	B-X
d.	B-X
Moreover	B-X
,	B-X
RA	B-X
disease	B-X
severity	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
standardized	B-X
clinical	B-X
composite	B-X
scores	B-X
,	B-X
improved	B-X
significantly	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
results	B-X
establish	B-X
that	B-X
vagus	B-X
nerve	B-X
stimulation	B-X
targeting	B-X
the	B-X
inflammatory	B-X
reflex	B-X
modulates	B-X
TNF	B-X
production	B-X
and	B-X
reduces	B-X
inflammation	B-X
in	B-X
humans	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
it	B-X
is	B-X
possible	B-X
to	B-X
use	B-X
mechanism-based	B-X
neuromodulating	B-X
devices	B-X
in	B-X
the	B-X
experimental	B-X
therapy	B-X
of	B-X
RA	B-X
and	B-X
possibly	B-X
other	B-X
autoimmune	B-X
and	B-X
autoinflammatory	B-X
diseases	B-X
.	B-X

Stimulated	O
cpdm	O
BMDC	O
exhibited	O
Th2	O
-	O
biased	O
T	O
cell	O
-	O
polarizing	O
capabilities	O
,	O
consistent	O
with	O
the	O
Th2	O
cytokine	O
-	O
dominant	O
phenotype	O
in	O
cpdm	O
mice	O
.	O

Together	O
,	O
these	O
results	O
indicate	O
an	O
indispensible	O
role	O
of	O
SHARPIN	B-Protein
in	O
regulating	O
DC	O
immunological	O
functions	O
,	O
disruption	O
of	O
which	O
may	O
contribute	O
to	O
the	O
development	O
of	O
immune	O
diseases	O
.	O

Since	O
WT	O
and	O
cpdm	O
mice	O
are	O
both	O
specific	O
pathogen	O
-	O
free	O
,	O
the	O
nature	O
of	O
the	O
trigger	O
of	O
the	O
severe	O
inflammation	O
in	O
cpdm	O
mice	O
is	O
not	O
obvious	O
.	O

One	O
such	O
initiating	O
factor	O
could	O
be	O
endogenous	O
apoptotic	O
and	O
/	O
or	O
necrotic	O
cells	O
that	O
can	O
release	O
danger	O
-	O
associated	O
molecular	O
patterns	O
(	O
DAMPs	O
)	O
to	O
launch	O
and	O
amplify	O
an	O
inflammatory	O
response	O
[	O
32	O
]	O
.	O
<EOS>	B-X
Tumor	B-X
necrosis	B-X
factor-related	B-X
apoptosis	B-X
inducing	B-X
ligand	B-X
(	B-X
TRAIL	B-X
)	B-X
is	B-X
a	B-X
promising	B-X
death	B-X
ligand	B-X
who	B-X
has	B-X
received	B-X
significant	B-X
attention	B-X
due	B-X
to	B-X
its	B-X
specific	B-X
anti-cancer	B-X
activity	B-X
.	B-X
One	B-X
major	B-X
caveat	B-X
in	B-X
TRAIL-based	B-X
anti-cancer	B-X
therapies	B-X
is	B-X
that	B-X
a	B-X
considerable	B-X
number	B-X
of	B-X
cancer	B-X
cells	B-X
are	B-X
notorious	B-X
resistant	B-X
to	B-X
apoptosis	B-X
induction	B-X
by	B-X
TRAIL	B-X
.	B-X
The	B-X
current	B-X
literature	B-X
suggests	B-X
that	B-X
TRAIL	B-X
resistance	B-X
is	B-X
mediated	B-X
by	B-X
a	B-X
number	B-X
of	B-X
endogenous	B-X
factors	B-X
.	B-X
15-deoxy-Δ	B-X
(	B-X
12,14	B-X
)	B-X
-prostagandin	B-X
J	B-X
(	B-X
2	B-X
)	B-X
(	B-X
15d-PGJ2	B-X
)	B-X
is	B-X
produced	B-X
in	B-X
the	B-X
inflamed	B-X
cells	B-X
and	B-X
tissues	B-X
as	B-X
a	B-X
consequence	B-X
of	B-X
upregulation	B-X
of	B-X
cyclooxygenase-2	B-X
(	B-X
COX-2	B-X
)	B-X
.	B-X
15d-PGJ2	B-X
is	B-X
known	B-X
to	B-X
be	B-X
the	B-X
endogenous	B-X
ligand	B-X
of	B-X
peroxisome	B-X
proliferator-activated	B-X
receptor	B-X
gamma	B-X
(	B-X
PPARγ	B-X
)	B-X
with	B-X
multiple	B-X
physiological	B-X
properties	B-X
.	B-X
Though	B-X
one	B-X
of	B-X
the	B-X
terminal	B-X
products	B-X
of	B-X
the	B-X
COX-2-catalyzed	B-X
reactions	B-X
,	B-X
this	B-X
cyclopentenone	B-X
prostaglandin	B-X
exerts	B-X
potent	B-X
anti-inflammatory	B-X
actions	B-X
,	B-X
in	B-X
part	B-X
,	B-X
by	B-X
antagonizing	B-X
the	B-X
activities	B-X
of	B-X
pro-inflammatory	B-X
transcription	B-X
factors	B-X
,	B-X
such	B-X
as	B-X
NF-κB	B-X
,	B-X
STAT3	B-X
,	B-X
and	B-X
AP-1	B-X
,	B-X
while	B-X
stimulating	B-X
the	B-X
anti-inflammatory	B-X
transcription	B-X
factor	B-X
Nrf2	B-X
.	B-X
The	B-X
locally	B-X
produced	B-X
15d-PGJ2	B-X
is	B-X
also	B-X
involved	B-X
in	B-X
the	B-X
resolution	B-X
of	B-X
inflammatory	B-X
responses	B-X
.	B-X
Thus	B-X
,	B-X
15d-PGJ2	B-X
,	B-X
especially	B-X
formed	B-X
during	B-X
the	B-X
late	B-X
phase	B-X
of	B-X
inflammation	B-X
,	B-X
might	B-X
inhibit	B-X
cytokine	B-X
secretion	B-X
and	B-X
other	B-X
events	B-X
by	B-X
antigen-presenting	B-X
cells	B-X
like	B-X
dendritic	B-X
cells	B-X
or	B-X
macrophages	B-X
.	B-X
15d-PGJ2	B-X
can	B-X
also	B-X
affect	B-X
the	B-X
priming	B-X
and	B-X
effector	B-X
functions	B-X
of	B-X
T	B-X
lymphocytes	B-X
and	B-X
induce	B-X
their	B-X
apoptotic	B-X
cell	B-X
death	B-X
.	B-X
These	B-X
represent	B-X
a	B-X
negative	B-X
feedback	B-X
explaining	B-X
how	B-X
once-initiated	B-X
immunologic	B-X
and	B-X
inflammatory	B-X
responses	B-X
are	B-X
switched	B-X
off	B-X
and	B-X
terminated	B-X
.	B-X
In	B-X
this	B-X
context	B-X
,	B-X
15d-PGJ2	B-X
and	B-X
its	B-X
synthetic	B-X
derivatives	B-X
have	B-X
therapeutic	B-X
potential	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
inflammatory	B-X
disorders	B-X
.	B-X

Such	O
'	O
sterile	O
'	O
inflammation	O
could	O
be	O
initiated	O
and	O
take	O
place	O
in	O
all	O
organs	O
and	O
tissues	O
affected	O
in	O
cpdm	O
mice	O
,	O
thus	O
causing	O
multi	O
-	O
organ	O
inflammatory	O
disorders	O
.	O

This	O
hypothesis	O
is	O
supported	O
by	O
several	O
recent	O
studies	O
.	O
<EOS>	B-X
A	B-X
variety	B-X
of	B-X
preclinical	B-X
and	B-X
clinical	B-X
studies	B-X
have	B-X
implicated	B-X
impaired	B-X
BDNF	B-X
signaling	B-X
through	B-X
its	B-X
receptor	B-X
TrkB	B-X
(	B-X
neurotrophic	B-X
receptor	B-X
tyrosine	B-X
kinase	B-X
2	B-X
)	B-X
in	B-X
the	B-X
pathophysiology	B-X
of	B-X
mood	B-X
disorders	B-X
,	B-X
but	B-X
many	B-X
of	B-X
the	B-X
initial	B-X
findings	B-X
have	B-X
not	B-X
been	B-X
fully	B-X
supported	B-X
by	B-X
more	B-X
recent	B-X
meta-analyses	B-X
,	B-X
and	B-X
more	B-X
both	B-X
basic	B-X
and	B-X
clinical	B-X
research	B-X
is	B-X
needed	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
increased	B-X
expression	B-X
and	B-X
signaling	B-X
of	B-X
BDNF	B-X
has	B-X
been	B-X
repeatedly	B-X
implicated	B-X
in	B-X
the	B-X
mechanisms	B-X
of	B-X
both	B-X
typical	B-X
and	B-X
rapid-acting	B-X
antidepressant	B-X
drugs	B-X
,	B-X
and	B-X
recent	B-X
findings	B-X
have	B-X
started	B-X
to	B-X
elucidate	B-X
the	B-X
mechanisms	B-X
through	B-X
which	B-X
antidepressants	B-X
regulate	B-X
BDNF	B-X
signaling	B-X
.	B-X
Although	B-X
some	B-X
equivocal	B-X
data	B-X
exist	B-X
,	B-X
the	B-X
hypothesis	B-X
of	B-X
a	B-X
connection	B-X
between	B-X
neurotrophic	B-X
factors	B-X
and	B-X
neuronal	B-X
plasticity	B-X
with	B-X
mood	B-X
disorders	B-X
and	B-X
antidepressant	B-X
action	B-X
has	B-X
recently	B-X
been	B-X
further	B-X
strengthened	B-X
by	B-X
converging	B-X
evidence	B-X
from	B-X
a	B-X
variety	B-X
of	B-X
more	B-X
recent	B-X
data	B-X
reviewed	B-X
here	B-X
.	B-X
To	B-X
review	B-X
advances	B-X
in	B-X
structural	B-X
and	B-X
functional	B-X
MRI	B-X
studies	B-X
regarding	B-X
the	B-X
neural	B-X
underpinnings	B-X
of	B-X
social	B-X
atypicalities	B-X
in	B-X
autism	B-X
spectrum	B-X
disorder	B-X
(	B-X
ASD	B-X
)	B-X
.	B-X

Fibroblasts	O
of	O
cpdm	O
mice	O
are	O
highly	O
sensitive	O
to	O
TNFalpha	B-Protein
-	O
induced	O
cell	O
death	O
and	O
the	O
cpdm	O
phenotype	O
can	O
be	O
partially	O
rescued	O
by	O
deletion	O
of	O
TNF	B-Protein
[	O
7	O
]	O
,	O
[	O
8	O
]	O
,	O
suggesting	O
that	O
deficiency	O
of	O
SHARPIN	B-Protein
compromises	O
the	O
anti	O
-	O
apoptotic	O
mechanisms	O
in	O
cpdm	O
mice	O
resulting	O
in	O
cell	O
death	O
-	O
induced	O
inflammatory	O
disease	O
.	O

Apoptosis	O
of	O
keratinocytes	O
is	O
a	O
prominent	O
feature	O
of	O
the	O
skin	O
lesions	O
in	O
cpdm	O
mice	O
[	O
33	O
]	O
and	O
this	O
is	O
mediated	O
by	O
caspase	O
-	O
dependent	O
mitochondrial	O
pathways	O
[	O
34	O
]	O
.	O

These	O
induced	O
and	O
/	O
or	O
intrinsic	O
apoptotic	O
cells	O
can	O
release	O
various	O
types	O
of	O
DAMPs	O
that	O
exert	O
their	O
pro	O
-	O
inflammatory	O
properties	O
by	O
activating	O
DC	O
through	O
pattern	O
recognition	O
receptors	O
[	O
32	O
]	O
,	O
[	O
35	O
]	O
,	O
such	O
as	O
HMGB1	B-Protein
recognized	O
by	O
TLR2	B-Protein
/	O
4	B-Protein
[	O
36	O
]	O
,	O
[	O
37	O
]	O
.	O
<EOS>	B-X
In	B-X
response	B-X
to	B-X
pathogen	B-X
attacks	B-X
,	B-X
plants	B-X
activate	B-X
defense	B-X
systems	B-X
that	B-X
are	B-X
mediated	B-X
through	B-X
various	B-X
signaling	B-X
pathways	B-X
.	B-X
Chemical	B-X
defense	B-X
inducers	B-X
,	B-X
such	B-X
as	B-X
benzothiadiazole	B-X
and	B-X
probenazole	B-X
,	B-X
act	B-X
on	B-X
the	B-X
SA	B-X
pathway	B-X
and	B-X
induce	B-X
strong	B-X
resistance	B-X
to	B-X
various	B-X
pathogens	B-X
without	B-X
major	B-X
fitness	B-X
costs	B-X
,	B-X
owing	B-X
to	B-X
their	B-X
'priming	B-X
effect	B-X
.	B-X
'	B-X
Studies	B-X
on	B-X
how	B-X
benzothiadiazole	B-X
induces	B-X
disease	B-X
resistance	B-X
in	B-X
rice	B-X
have	B-X
identified	B-X
WRKY45	B-X
,	B-X
a	B-X
key	B-X
transcription	B-X
factor	B-X
in	B-X
the	B-X
branched	B-X
SA	B-X
pathway	B-X
,	B-X
and	B-X
OsNPR1/NH1	B-X
.	B-X
Rice	B-X
plants	B-X
overexpressing	B-X
WRKY45	B-X
were	B-X
extremely	B-X
resistant	B-X
to	B-X
rice	B-X
blast	B-X
disease	B-X
caused	B-X
by	B-X
the	B-X
fungus	B-X
Magnaporthe	B-X
oryzae	B-X
and	B-X
bacterial	B-X
leaf	B-X
blight	B-X
disease	B-X
caused	B-X
by	B-X
Xanthomonas	B-X
oryzae	B-X
pv	B-X
.	B-X
Disease	B-X
resistance	B-X
is	B-X
often	B-X
accompanied	B-X
by	B-X
fitness	B-X
costs	B-X
;	B-X
however	B-X
,	B-X
WRKY45	B-X
overexpression	B-X
imposed	B-X
relatively	B-X
small	B-X
fitness	B-X
costs	B-X
on	B-X
rice	B-X
because	B-X
of	B-X
its	B-X
priming	B-X
effect	B-X
.	B-X
WRKY45	B-X
is	B-X
degraded	B-X
by	B-X
the	B-X
ubiquitin-proteasome	B-X
system	B-X
,	B-X
and	B-X
the	B-X
dual	B-X
role	B-X
of	B-X
this	B-X
degradation	B-X
partly	B-X
explains	B-X
the	B-X
priming	B-X
effect	B-X
.	B-X
The	B-X
synergistic	B-X
interaction	B-X
between	B-X
SA	B-X
and	B-X
cytokinin	B-X
signaling	B-X
that	B-X
activates	B-X
WRKY45	B-X
also	B-X
likely	B-X
contributes	B-X
to	B-X
the	B-X
priming	B-X
effect	B-X
.	B-X

Consistent	O
with	O
the	O
impaired	O
Th1	O
immune	O
response	O
in	O
cpdm	O
mice	O
[	O
5	O
]	O
,	O
stimulated	O
BMDC	O
weakly	O
polarized	O
Th1	O
differentiation	O
,	O
but	O
strongly	O
supported	O
the	O
development	O
of	O
Th2	O
effector	O
cells	O
.	O

Combined	O
with	O
the	O
dramatic	O
effect	O
of	O
IL12	O
treatment	O
on	O
the	O
phenotype	O
of	O
these	O
mice	O
[	O
5	O
]	O
,	O
this	O
suggests	O
that	O
the	O
Th2	O
-	O
biased	O
systemic	O
inflammation	O
in	O
cpdm	O
mice	O
is	O
caused	O
by	O
reduced	O
IL12P70	O
production	O
from	O
DC	O
.	O

The	O
importance	O
of	O
IL12P70	O
in	O
regulating	O
Th1	O
and	O
Th2	O
immune	O
responses	O
in	O
mice	O
was	O
clearly	O
demonstrated	O
in	O
IL12P35	B-Protein
-	O
and	O
IL12P40	B-Protein
-	O
deficient	O
mice	O
[	O
38	O
]	O
,	O
[	O
39	O
]	O
and	O
through	O
clinical	O
studies	O
in	O
human	O
patients	O
[	O
40	O
]	O
-	O
[	O
42	O
]	O
.	O

NF	O
-	O
kappaB	O
,	O
TBK	O
/	O
IRF3	B-Protein
,	O
and	O
MAPK	O
signaling	O
are	O
important	O
pathways	O
activated	O
by	O
LPS	O
or	O
poly	O
I	O
:	O
C	O
and	O
disruption	O
of	O
either	O
pathway	O
may	O
lead	O
to	O
decreased	O
cytokine	O
expression	O
.	O

NF	O
-	O
kappaB	O
activation	O
was	O
selectively	O
inhibited	O
in	O
LPS	O
and	O
poly	O
I	O
:	O
C	O
stimulated	O
cpdm	O
BMDC	O
compared	O
to	O
wild	O
type	O
,	O
while	O
activation	O
of	O
TBK1	B-Protein
/	O
IRF3	B-Protein
,	O
ERK1	B-Protein
/	O
2	B-Protein
,	O
or	O
p38	O
was	O
not	O
,	O
indicating	O
that	O
disrupted	O
NF	O
-	O
kappaB	O
signaling	O
in	O
cpdm	O
DC	O
is	O
responsible	O
for	O
the	O
defective	O
cytokine	O
expression	O
.	O
<EOS>	B-X
The	B-X
p38	B-X
MAPK	B-X
(	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
)	B-X
signalling	B-X
pathway	B-X
allows	B-X
cells	B-X
to	B-X
interpret	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
external	B-X
signals	B-X
and	B-X
respond	B-X
appropriately	B-X
by	B-X
generating	B-X
a	B-X
plethora	B-X
of	B-X
different	B-X
biological	B-X
effects	B-X
.	B-X
In	B-X
the	B-X
present	B-X
review	B-X
,	B-X
we	B-X
dissect	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
p38	B-X
MAPK	B-X
functions	B-X
,	B-X
with	B-X
special	B-X
emphasis	B-X
on	B-X
the	B-X
activation	B-X
and	B-X
regulation	B-X
of	B-X
the	B-X
core	B-X
kinases	B-X
,	B-X
the	B-X
interplay	B-X
with	B-X
other	B-X
signalling	B-X
pathways	B-X
and	B-X
the	B-X
nature	B-X
of	B-X
p38	B-X
MAPK	B-X
substrates	B-X
as	B-X
a	B-X
source	B-X
of	B-X
functional	B-X
diversity	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
discuss	B-X
how	B-X
genetic	B-X
mouse	B-X
models	B-X
are	B-X
facilitating	B-X
the	B-X
identification	B-X
of	B-X
physiological	B-X
functions	B-X
for	B-X
p38	B-X
MAPKs	B-X
,	B-X
which	B-X
may	B-X
impinge	B-X
on	B-X
their	B-X
eventual	B-X
use	B-X
as	B-X
therapeutic	B-X
targets	B-X
.	B-X
Many	B-X
studies	B-X
have	B-X
revealed	B-X
a	B-X
central	B-X
role	B-X
of	B-X
p38	B-X
MAPK	B-X
in	B-X
neuronal	B-X
plasticity	B-X
and	B-X
the	B-X
regulation	B-X
of	B-X
long-term	B-X
changes	B-X
in	B-X
synaptic	B-X
efficacy	B-X
,	B-X
such	B-X
as	B-X
long-term	B-X
potentiation	B-X
(	B-X
LTP	B-X
)	B-X
and	B-X
long-term	B-X
depression	B-X
(	B-X
LTD	B-X
)	B-X
.	B-X
However	B-X
,	B-X
p38	B-X
MAPK	B-X
is	B-X
classically	B-X
known	B-X
as	B-X
a	B-X
responsive	B-X
element	B-X
to	B-X
stress	B-X
stimuli	B-X
,	B-X
including	B-X
neuroinflammation	B-X
.	B-X
Specific	B-X
to	B-X
the	B-X
pathophysiology	B-X
of	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
,	B-X
several	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
the	B-X
p38	B-X
MAPK	B-X
cascade	B-X
is	B-X
activated	B-X
either	B-X
in	B-X
response	B-X
to	B-X
the	B-X
Aβ	B-X
peptide	B-X
or	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
tauopathies	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
role	B-X
of	B-X
p38	B-X
MAPK	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
synaptic	B-X
plasticity	B-X
and	B-X
its	B-X
implication	B-X
in	B-X
an	B-X
animal	B-X
model	B-X
of	B-X
neurodegeneration	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
recent	B-X
evidence	B-X
suggests	B-X
the	B-X
p38	B-X
MAPK	B-X
α	B-X
isoform	B-X
as	B-X
a	B-X
potential	B-X
neurotherapeutic	B-X
target	B-X
,	B-X
and	B-X
specific	B-X
inhibitors	B-X
have	B-X
been	B-X
developed	B-X
and	B-X
have	B-X
proven	B-X
to	B-X
be	B-X
effective	B-X
in	B-X
ameliorating	B-X
synaptic	B-X
and	B-X
memory	B-X
deficits	B-X
in	B-X
AD	B-X
mouse	B-X
models	B-X
.	B-X

These	O
results	O
seem	O
to	O
contradict	O
a	O
recent	O
study	O
that	O
found	O
increased	O
levels	O
of	O
NF	O
-	O
kappaB	O
activation	O
and	O
IL1	O
transcription	O
in	O
cpdm	O
mice	O
[	O
43	O
]	O
.	O

This	O
difference	O
can	O
probably	O
be	O
attributed	O
to	O
the	O
different	O
cells	O
and	O
tissues	O
used	O
in	O
these	O
studies	O
,	O
and	O
may	O
point	O
to	O
cell	O
-	O
and	O
tissue	O
-	O
type	O
specific	O
functions	O
of	O
SHARPIN	B-Protein
.	O

This	O
is	O
consistent	O
with	O
recent	O
reports	O
of	O
tissue	O
-	O
specific	O
effects	O
of	O
NF	O
-	O
kappaB	O
signaling	O
[	O
44	O
]	O
.	O

Ubiquitous	O
activation	O
of	O
NF	O
-	O
kappaB	O
by	O
removing	O
inhibitors	O
such	O
as	O
A20	B-Protein
and	O
ITCH	B-Protein
through	O
genetic	O
manipulation	O
results	O
in	O
widespread	O
inflammation	O
,	O
consistent	O
with	O
the	O
role	O
of	O
NF	O
-	O
kappaB	O
in	O
the	O
production	O
of	O
pro	O
-	O
inflammatory	O
mediators	O
[	O
45	O
]	O
,	O
[	O
46	O
]	O
.	O

However	O
,	O
selective	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
activation	O
in	O
parenchymal	O
cells	O
of	O
the	O
skin	O
,	O
liver	O
,	O
and	O
intestine	O
results	O
in	O
chronic	O
inflammation	O
driven	O
by	O
NF	O
-	O
kappaB	O
competent	O
leukocytes	O
[	O
47	O
]	O
-	O
[	O
50	O
]	O
.	O

This	O
indicates	O
that	O
a	O
balance	O
between	O
the	O
pro	O
-	O
inflammatory	O
role	O
of	O
NF	O
-	O
kappaB	O
in	O
leukocytes	O
and	O
the	O
anti	O
-	O
inflammatory	O
role	O
in	O
parenchymal	O
cells	O
is	O
critical	O
in	O
the	O
maintenance	O
of	O
tissue	O
homeostasis	O
.	O

Experiments	O
with	O
mice	O
with	O
cell	O
-	O
and	O
tissue	O
-	O
specific	O
deletion	O
of	O
Sharpin	B-Protein
,	O
currently	O
under	O
way	O
,	O
will	O
help	O
to	O
elucidate	O
the	O
role	O
of	O
SHARPIN	B-Protein
in	O
inflammation	O
.	O

Despite	O
defective	O
NF	O
-	O
kappaB	O
activation	O
in	O
the	O
absence	O
of	O
Sharpin	B-Protein
expression	O
,	O
there	O
was	O
no	O
significant	O
change	O
in	O
splenic	O
DC	O
populations	O
or	O
expression	O
of	O
co	O
-	O
stimulatory	O
molecules	O
on	O
BMDC	O
.	O
<EOS>	B-X
Spontaneous	B-X
mutations	B-X
of	B-X
the	B-X
Sharpin	B-X
(	B-X
SHANK-associated	B-X
RH	B-X
domain-interacting	B-X
protein	B-X
,	B-X
other	B-X
aliases	B-X
:	B-X
Rbckl1	B-X
,	B-X
Sipl1	B-X
)	B-X
gene	B-X
in	B-X
mice	B-X
result	B-X
in	B-X
systemic	B-X
inflammation	B-X
that	B-X
is	B-X
characterized	B-X
by	B-X
chronic	B-X
proliferative	B-X
dermatitis	B-X
and	B-X
dysregulated	B-X
secretion	B-X
of	B-X
T	B-X
helper1	B-X
(	B-X
Th1	B-X
)	B-X
and	B-X
Th2	B-X
cytokines	B-X
.	B-X
Dendritic	B-X
cells	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
initiation	B-X
and	B-X
progression	B-X
of	B-X
the	B-X
phenotype	B-X
of	B-X
SHARPIN-deficient	B-X
mice	B-X
because	B-X
of	B-X
their	B-X
pivotal	B-X
role	B-X
in	B-X
innate	B-X
and	B-X
adaptive	B-X
immunity	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
by	B-X
flow	B-X
cytometry	B-X
that	B-X
SHARPIN-	B-X
deficiency	B-X
did	B-X
not	B-X
alter	B-X
the	B-X
distribution	B-X
of	B-X
different	B-X
DC	B-X
subtypes	B-X
in	B-X
the	B-X
spleen	B-X
.	B-X
In	B-X
response	B-X
to	B-X
TOLL-like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
agonists	B-X
LPS	B-X
and	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
,	B-X
cultured	B-X
bone	B-X
marrow-derived	B-X
dendritic	B-X
cells	B-X
(	B-X
BMDC	B-X
)	B-X
from	B-X
WT	B-X
and	B-X
mutant	B-X
mice	B-X
exhibited	B-X
similar	B-X
increases	B-X
in	B-X
expression	B-X
of	B-X
co-stimulatory	B-X
molecules	B-X
CD40	B-X
,	B-X
CD80	B-X
,	B-X
and	B-X
CD86	B-X
.	B-X
However	B-X
,	B-X
stimulated	B-X
SHARPIN-deficient	B-X
BMDC	B-X
had	B-X
reduced	B-X
transcription	B-X
and	B-X
secretion	B-X
of	B-X
pro-inflammatory	B-X
mediators	B-X
IL6	B-X
,	B-X
IL12P70	B-X
,	B-X
GMCSF	B-X
,	B-X
and	B-X
nitric	B-X
oxide	B-X
.	B-X
Mutant	B-X
BMDC	B-X
had	B-X
defective	B-X
activation	B-X
of	B-X
NF-κB	B-X
signaling	B-X
,	B-X
whereas	B-X
the	B-X
MAPK1/3	B-X
(	B-X
ERK1/2	B-X
)	B-X
and	B-X
MAPK11/12/13/14	B-X
(	B-X
p38	B-X
MAP	B-X
kinase	B-X
isoforms	B-X
)	B-X
and	B-X
TBK1	B-X
signaling	B-X
pathways	B-X
were	B-X
intact	B-X
.	B-X
A	B-X
mixed	B-X
lymphocyte	B-X
reaction	B-X
showed	B-X
that	B-X
mutant	B-X
BMDC	B-X
only	B-X
induced	B-X
a	B-X
weak	B-X
Th1	B-X
immune	B-X
response	B-X
but	B-X
stimulated	B-X
increased	B-X
Th2	B-X
cytokine	B-X
production	B-X
from	B-X
allogeneic	B-X
naïve	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
loss	B-X
of	B-X
Sharpin	B-X
in	B-X
mice	B-X
significantly	B-X
affects	B-X
the	B-X
immune	B-X
function	B-X
of	B-X
DC	B-X
and	B-X
this	B-X
may	B-X
partially	B-X
account	B-X
for	B-X
the	B-X
systemic	B-X
inflammation	B-X
and	B-X
Th2-biased	B-X
immune	B-X
response	B-X
.	B-X

Different	O
NF	O
-	O
kappaB	O
subunits	O
involved	O
in	O
the	O
canonical	O
and	O
non	O
-	O
canonical	O
branches	O
of	O
the	O
NF	O
-	O
kappaB	O
signaling	O
pathway	O
have	O
distinct	O
functions	O
to	O
control	O
specific	O
aspects	O
of	O
DC	O
development	O
and	O
function	O
[	O
51	O
]	O
,	O
[	O
52	O
]	O
.	O

The	O
non	O
-	O
canonical	O
pathway	O
(	O
p100	B-Protein
processing	O
to	O
produce	O
p52	B-Protein
)	O
appears	O
to	O
be	O
intact	O
in	O
SHARPIN	B-Protein
-	O
deficient	O
cells	O
[	O
7	O
]	O
,	O
[	O
9	O
]	O
suggesting	O
that	O
the	O
NF	O
-	O
kappaB	O
heterodimer	O
p52	B-Protein
/	O
RELB	B-Protein
is	O
sufficient	O
to	O
maintain	O
the	O
normal	O
regulation	O
of	O
DC	O
homeostasis	O
and	O
maturation	O
.	O

The	O
molecular	O
basis	O
by	O
which	O
the	O
Sharpin	B-Protein
mutation	O
causes	O
reduced	O
NF	O
-	O
kappaB	O
activation	O
in	O
BMDC	O
remains	O
to	O
be	O
determined	O
.	O

LPS	O
and	O
poly	O
I	O
:	O
C	O
used	O
here	O
are	O
well	O
-	O
defined	O
ligands	O
that	O
specifically	O
engage	O
TLR4	B-Protein
and	O
TLR3	B-Protein
,	O
respectively	O
.	O

The	O
expression	O
profile	O
of	O
surface	O
TLR4	O
complexes	O
is	O
similar	O
between	O
WT	O
and	O
cpdm	O
BMDC	O
suggesting	O
that	O
defective	O
NF	O
-	O
kappaB	O
activation	O
is	O
not	O
a	O
result	O
of	O
differential	O
TLR	O
expression	O
on	O
target	O
cells	O
.	O

LPS	O
engages	O
TLR4	B-Protein
to	O
activate	O
MYD88	B-Protein
-	O
dependent	O
and	O
TRIF	B-Protein
-	O
dependent	O
pathways	O
,	O
whereas	O
TLR3	B-Protein
stimulated	O
by	O
poly	O
I	O
:	O
C	O
only	O
triggers	O
TRIF	B-Protein
-	O
dependent	O
signaling	O
[	O
53	O
]	O
.	O

The	O
defective	O
NF	O
-	O
kappaB	O
activation	O
by	O
both	O
stimuli	O
suggests	O
that	O
the	O
Sharpin	B-Protein
mutation	O
interferes	O
with	O
the	O
protein	O
adaptors	O
or	O
kinases	O
shared	O
by	O
both	O
signaling	O
pathways	O
,	O
such	O
as	O
RIP1	B-Protein
and	O
TRAF6	B-Protein
[	O
18	O
]	O
.	O
<EOS>	B-X
The	B-X
CATERPILLER	B-X
(	B-X
CLR	B-X
,	B-X
also	B-X
NOD	B-X
and	B-X
NLR	B-X
)	B-X
proteins	B-X
share	B-X
structural	B-X
similarities	B-X
with	B-X
the	B-X
nucleotide	B-X
binding	B-X
domain	B-X
(	B-X
NBD	B-X
)	B-X
-leucine-rich	B-X
repeat	B-X
(	B-X
LRR	B-X
)	B-X
superfamily	B-X
of	B-X
plant	B-X
disease-resistance	B-X
(	B-X
R	B-X
)	B-X
proteins	B-X
and	B-X
are	B-X
emerging	B-X
as	B-X
important	B-X
immune	B-X
regulators	B-X
in	B-X
animals	B-X
.	B-X
CLR	B-X
proteins	B-X
contain	B-X
NBD-LRR	B-X
motifs	B-X
and	B-X
are	B-X
linked	B-X
to	B-X
a	B-X
limited	B-X
number	B-X
of	B-X
distinct	B-X
N-terminal	B-X
domains	B-X
including	B-X
transactivation	B-X
,	B-X
CARD	B-X
(	B-X
caspase	B-X
activation	B-X
and	B-X
recruitment	B-X
)	B-X
,	B-X
and	B-X
pyrin	B-X
domains	B-X
(	B-X
PyD	B-X
)	B-X
.	B-X
The	B-X
CLR	B-X
gene	B-X
,	B-X
Monarch-1/Pypaf7	B-X
,	B-X
is	B-X
expressed	B-X
by	B-X
resting	B-X
primary	B-X
myeloid/monocytic	B-X
cells	B-X
,	B-X
and	B-X
its	B-X
expression	B-X
in	B-X
these	B-X
cells	B-X
is	B-X
reduced	B-X
by	B-X
Toll-like	B-X
receptor	B-X
(	B-X
TLR	B-X
)	B-X
agonists	B-X
tumor	B-X
necrosis	B-X
factor	B-X
(	B-X
TNF	B-X
)	B-X
alpha	B-X
and	B-X
Mycobacterium	B-X
tuberculosis	B-X
.	B-X
Monarch-1	B-X
reduces	B-X
NFkappaB	B-X
activation	B-X
by	B-X
TLR-signaling	B-X
molecules	B-X
MyD88	B-X
,	B-X
IRAK-1	B-X
(	B-X
type	B-X
I	B-X
interleukin-1	B-X
receptor-associated	B-X
protein	B-X
kinase	B-X
)	B-X
,	B-X
and	B-X
TRAF6	B-X
(	B-X
TNF	B-X
receptor	B-X
(	B-X
TNFR	B-X
)	B-X
-associated	B-X
factor	B-X
)	B-X
as	B-X
well	B-X
as	B-X
TNFR	B-X
signaling	B-X
molecules	B-X
TRAF2	B-X
and	B-X
RIP1	B-X
but	B-X
not	B-X
the	B-X
downstream	B-X
NFkappaB	B-X
subunit	B-X
p65	B-X
.	B-X
This	B-X
indicates	B-X
that	B-X
Monarch-1	B-X
is	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
both	B-X
TLR	B-X
and	B-X
TNFR	B-X
pathways	B-X
.	B-X
Reducing	B-X
Monarch-1	B-X
expression	B-X
with	B-X
small	B-X
interference	B-X
RNA	B-X
in	B-X
myeloid/monocytic	B-X
cells	B-X
caused	B-X
a	B-X
dramatic	B-X
increase	B-X
in	B-X
NFkappaB	B-X
activation	B-X
and	B-X
cytokine	B-X
expression	B-X
in	B-X
response	B-X
to	B-X
TLR2/TLR4	B-X
agonists	B-X
,	B-X
TNFalpha	B-X
,	B-X
or	B-X
M.	B-X
tuberculosis	B-X
infection	B-X
,	B-X
suggesting	B-X
that	B-X
Monarch-1	B-X
is	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
inflammation	B-X
.	B-X
Because	B-X
Monarch-1	B-X
is	B-X
the	B-X
first	B-X
CLR	B-X
protein	B-X
that	B-X
interferes	B-X
with	B-X
both	B-X
TLR2	B-X
and	B-X
TLR4	B-X
activation	B-X
,	B-X
the	B-X
mechanism	B-X
of	B-X
this	B-X
interference	B-X
is	B-X
significant	B-X
.	B-X
Mutants	B-X
containing	B-X
the	B-X
NBD-LRR	B-X
or	B-X
PyD-NBD	B-X
also	B-X
blocked	B-X
IRAK-1	B-X
activation	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
example	B-X
of	B-X
a	B-X
CLR	B-X
protein	B-X
that	B-X
antagonizes	B-X
inflammatory	B-X
responses	B-X
initiated	B-X
by	B-X
TLR	B-X
agonists	B-X
via	B-X
interference	B-X
with	B-X
IRAK-1	B-X
activation	B-X
.	B-X

Recent	O
studies	O
demonstrated	O
that	O
SHARPIN	B-Protein
interacts	O
with	O
HOIP	B-Protein
to	O
form	O
LUBAC	O
that	O
exerts	O
its	O
linear	O
-	O
ubiquitin	O
-	O
chain	O
-	O
ligase	O
activity	O
on	O
NF	O
-	O
kappaB	O
signaling	O
players	O
RIP1	B-Protein
and	O
NEMO	B-Protein
[	O
7	O
]	O
,	O
an	O
essential	O
step	O
for	O
intact	O
TNFalpha	B-Protein
-	O
stimulated	O
NF	O
-	O
kappaB	O
activation	O
.	O

The	O
Sharpin	B-Protein
null	O
mutation	O
disrupts	O
the	O
ubiquitylation	O
process	O
and	O
abrogates	O
the	O
TNFalpha	B-Protein
-	O
induced	O
NF	O
-	O
kappaB	O
signaling	O
pathway	O
.	O

Since	O
TNFR	O
and	O
TLR	O
partially	O
share	O
their	O
downstream	O
signaling	O
cascades	O
,	O
a	O
similar	O
ubiquitin	O
-	O
mediated	O
regulation	O
may	O
hold	O
true	O
for	O
SHARPIN	B-Protein
in	O
LPS	O
-	O
and	O
poly	O
I	O
:	O
C	O
-	O
induced	O
NF	O
-	O
kappaB	O
activation	O
.	O

In	O
summary	O
,	O
the	O
present	O
study	O
identified	O
an	O
indispensible	O
role	O
of	O
SHARPIN	B-Protein
in	O
the	O
production	O
of	O
pro	O
-	O
inflammatory	O
mediators	O
and	O
TLR	O
-	O
induced	O
NF	O
-	O
kappaB	O
signaling	O
.	O

The	O
impaired	O
Th1	O
-	O
stimulating	O
ability	O
of	O
Sharpin	B-Protein
-	O
deficient	O
DC	O
may	O
account	O
for	O
the	O
Th2	O
-	O
dominant	O
inflammatory	O
phenotype	O
of	O
cpdm	O
mice	O
.	O

The	O
balance	O
between	O
Th1	O
and	O
Th2	O
differentiation	O
is	O
critical	O
for	O
immune	O
homeostasis	O
.	O
<EOS>	B-X
In	B-X
this	B-X
way	B-X
,	B-X
Bach2	B-X
serves	B-X
as	B-X
a	B-X
highly	B-X
conserved	B-X
repressor	B-X
which	B-X
controls	B-X
the	B-X
terminal	B-X
differentiation	B-X
and	B-X
maturation	B-X
of	B-X
both	B-X
B	B-X
and	B-X
T	B-X
lymphocytes	B-X
.	B-X
It	B-X
is	B-X
required	B-X
for	B-X
class	B-X
switch	B-X
recombination	B-X
(	B-X
CSR	B-X
)	B-X
and	B-X
somatic	B-X
hypermutation	B-X
(	B-X
SHM	B-X
)	B-X
of	B-X
immunoglobulin	B-X
genes	B-X
in	B-X
activated	B-X
B	B-X
cells	B-X
,	B-X
and	B-X
its	B-X
function	B-X
in	B-X
B	B-X
cell	B-X
differentiation	B-X
has	B-X
been	B-X
well-described	B-X
.	B-X
Furthermore	B-X
,	B-X
emerging	B-X
data	B-X
show	B-X
that	B-X
Bach2	B-X
regulates	B-X
transcriptional	B-X
activity	B-X
in	B-X
T	B-X
cells	B-X
at	B-X
super	B-X
enhancers	B-X
or	B-X
regions	B-X
of	B-X
high	B-X
transcriptional	B-X
activity	B-X
,	B-X
thus	B-X
stabilizing	B-X
immunoregulatory	B-X
capacity	B-X
and	B-X
maintaining	B-X
T	B-X
cell	B-X
homeostasis	B-X
.	B-X
Bach2	B-X
is	B-X
also	B-X
critical	B-X
for	B-X
the	B-X
formation	B-X
and	B-X
function	B-X
of	B-X
CD4	B-X

A	O
better	O
understanding	O
of	O
how	O
such	O
balance	O
is	O
maintained	O
will	O
help	O
design	O
cytokine	O
treatment	O
for	O
human	O
diseases	O
with	O
Th2	O
-	O
biased	O
cytokine	O
secretion	O
similar	O
to	O
the	O
mouse	O
cpdm	O
,	O
such	O
as	O
allergies	O
and	O
hypereosinophilic	O
syndromes	O
.	O

Ethics	O
Statement	O
<EOS>	B-X
The	B-X
American	B-X
Nurses	B-X
Association	B-X
has	B-X
guided	B-X
and	B-X
supported	B-X
nursing	B-X
practice	B-X
through	B-X
creation	B-X
and	B-X
implementation	B-X
of	B-X
a	B-X
nationally	B-X
accepted	B-X
Code	B-X
of	B-X
Ethics	B-X
for	B-X
Nurses	B-X
with	B-X
Interpretive	B-X
Statements	B-X
.	B-X
We	B-X
also	B-X
offer	B-X
a	B-X
brief	B-X
history	B-X
of	B-X
the	B-X
Code	B-X
of	B-X
Ethics	B-X
,	B-X
discuss	B-X
the	B-X
modern	B-X
Code	B-X
of	B-X
Ethics	B-X
,	B-X
and	B-X
describe	B-X
the	B-X
importance	B-X
of	B-X
periodic	B-X
revision	B-X
,	B-X
including	B-X
the	B-X
inclusive	B-X
and	B-X
thorough	B-X
process	B-X
used	B-X
to	B-X
develop	B-X
the	B-X
2015	B-X
Code	B-X
and	B-X
a	B-X
summary	B-X
of	B-X
recent	B-X
changes	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
Statement	B-X
is	B-X
to	B-X
increase	B-X
awareness	B-X
of	B-X
all	B-X
stakeholders	B-X
of	B-X
science	B-X
communication	B-X
of	B-X
the	B-X
emerging	B-X
ethical	B-X
issues	B-X
in	B-X
journal	B-X
editing	B-X
and	B-X
publishing	B-X
and	B-X
initiate	B-X
a	B-X
campaign	B-X
of	B-X
upgrading	B-X
and	B-X
enforcing	B-X
related	B-X
journal	B-X
instructions	B-X
.	B-X
A	B-X
review	B-X
of	B-X
the	B-X
literature	B-X
related	B-X
to	B-X
caring	B-X
theory	B-X
,	B-X
the	B-X
concepts	B-X
of	B-X
moral	B-X
accountability	B-X
and	B-X
integrity	B-X
,	B-X
and	B-X
the	B-X
documents	B-X
that	B-X
speak	B-X
of	B-X
these	B-X
values	B-X
and	B-X
concepts	B-X
in	B-X
professional	B-X
practice	B-X
(	B-X
eg	B-X
,	B-X
Code	B-X
of	B-X
Ethics	B-X
for	B-X
Nurses	B-X
with	B-X
Interpretive	B-X
Statements	B-X
,	B-X
Nursing	B-X
's	B-X
Social	B-X
Policy	B-X
Statement	B-X
)	B-X
are	B-X
presented	B-X
in	B-X
this	B-X
article	B-X
.	B-X

All	O
mouse	O
work	O
was	O
carried	O
out	O
in	O
strict	O
accordance	O
with	O
protocols	O
approved	O
by	O
the	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committees	O
.	O

Mice	O
<EOS>	B-X
The	B-X
problem	B-X
of	B-X
passenger	B-X
genes	B-X
in	B-X
transgenic	B-X
mice	B-X
.	B-X
Studies	B-X
on	B-X
cryopreservation	B-X
of	B-X
embryos	B-X
and	B-X
gametes	B-X
in	B-X
mice	B-X
.	B-X
Mice	B-X
may	B-X
become	B-X
caught	B-X
in	B-X
nesting	B-X
material	B-X
.	B-X
Mice	B-X
cloned	B-X
from	B-X
cultured	B-X
stem	B-X
cells	B-X
.	B-X

Specific	O
-	O
pathogen	O
free	O
colonies	O
of	O
C57BL	O
/	O
KaLawRij	O
-	O
Sharpincpdm	O
/	O
RijSunJ	O
(	O
JR	O
#	O
7599	O
)	O
and	O
WT	O
mice	O
were	O
obtained	O
from	O
The	O
Jackson	O
Laboratory	O
(	O
Bar	O
Harbor	O
,	O
ME	O
)	O
and	O
were	O
maintained	O
in	O
a	O
barrier	O
facility	O
.	O

Normal	O
littermate	O
controls	O
were	O
either	O
+	O
/	O
+	O
or	O
+	O
/	O
Sharpincpdm	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
mechanisms	B-X
by	B-X
which	B-X
SIRT1	B-X
controls	B-X
hepatic	B-X
steatosis	B-X
in	B-X
mice	B-X
.	B-X
Although	B-X
GF	B-X
Fiaf-/-	B-X
animals	B-X
exhibit	B-X
similar	B-X
levels	B-X
of	B-X
phosphorylated	B-X
AMPK	B-X
as	B-X
their	B-X
wild-type	B-X
littermates	B-X
in	B-X
liver	B-X
and	B-X
gastrocnemius	B-X
muscle	B-X
,	B-X
they	B-X
have	B-X
reduced	B-X
expression	B-X
of	B-X
genes	B-X
encoding	B-X
the	B-X
peroxisomal	B-X
proliferator-activated	B-X
receptor	B-X
coactivator	B-X
(	B-X
Pgc-1alpha	B-X
)	B-X
and	B-X
enzymes	B-X
involved	B-X
in	B-X
fatty	B-X
acid	B-X
oxidation	B-X
.	B-X
SHARPIN-deficient	B-X
(	B-X
Sharpincpdm/cpdm	B-X
)	B-X
mice	B-X
display	B-X
multi-organ	B-X
inflammation	B-X
and	B-X
chronic	B-X
proliferative	B-X
dermatitis	B-X
(	B-X
cpdm	B-X
)	B-X
due	B-X
to	B-X
TNF-induced	B-X
keratinocyte	B-X
apoptosis	B-X
.	B-X
In	B-X
cells	B-X
,	B-X
SHARPIN	B-X
also	B-X
inhibits	B-X
integrins	B-X
independently	B-X
of	B-X
LUBAC	B-X
,	B-X
but	B-X
it	B-X
has	B-X
remained	B-X
enigmatic	B-X
whether	B-X
elevated	B-X
integrin	B-X
activity	B-X
levels	B-X
in	B-X
the	B-X
dermis	B-X
of	B-X
Sharpincpdm/cpdm	B-X
mice	B-X
is	B-X
due	B-X
to	B-X
increased	B-X
integrin	B-X
activity	B-X
or	B-X
is	B-X
secondary	B-X
to	B-X
inflammation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
functional	B-X
contribution	B-X
of	B-X
increased	B-X
integrin	B-X
activation	B-X
to	B-X
the	B-X
Sharpincpdm/cpdm	B-X
phenotype	B-X
has	B-X
not	B-X
been	B-X
investigated	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
find	B-X
increased	B-X
integrin	B-X
activity	B-X
in	B-X
keratinocytes	B-X
from	B-X
Tnfr1-/-	B-X
Sharpincpdm/cpdm	B-X
double	B-X
knockout	B-X
mice	B-X
,	B-X
which	B-X
do	B-X
not	B-X
display	B-X
chronic	B-X
inflammation	B-X
or	B-X
proliferative	B-X
dermatitis	B-X
,	B-X
thus	B-X
suggesting	B-X
that	B-X
SHARPIN	B-X
indeed	B-X
acts	B-X
as	B-X
an	B-X
integrin	B-X
inhibitor	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
present	B-X
evidence	B-X
for	B-X
a	B-X
functional	B-X
contribution	B-X
of	B-X
integrin	B-X
activity	B-X
to	B-X
the	B-X
Sharpincpdm/cpdm	B-X
skin	B-X
phenotype	B-X
.	B-X
Treatment	B-X
with	B-X
an	B-X
integrin	B-X
beta	B-X
1	B-X
function	B-X
blocking	B-X
antibody	B-X
reduced	B-X
epidermal	B-X
hyperproliferation	B-X
and	B-X
epidermal	B-X
thickness	B-X
in	B-X
Sharpincpdm/cpdm	B-X
mice	B-X
.	B-X
Our	B-X
data	B-X
indicate	B-X
that	B-X
,	B-X
while	B-X
TNF-induced	B-X
cell	B-X
death	B-X
triggers	B-X
the	B-X
chronic	B-X
inflammation	B-X
and	B-X
proliferative	B-X
dermatitis	B-X
,	B-X
absence	B-X
of	B-X
SHARPIN-dependent	B-X
integrin	B-X
inhibition	B-X
exacerbates	B-X
the	B-X
epidermal	B-X
hyperproliferation	B-X
in	B-X
Sharpincpdm/cpdm	B-X
mice	B-X
.	B-X

These	O
control	O
animals	O
were	O
phenotypically	O
indistinguishable	O
and	O
are	O
referred	O
to	O
as	O
WT	O
.	O

Sex	O
-	O
matched	O
WT	O
and	O
mutant	O
mice	O
were	O
used	O
at	O
6	O
-	O
10	O
weeks	O
of	O
age	O
.	O

For	O
some	O
experiments	O
,	O
cpdm	O
mice	O
were	O
crossed	O
with	O
transgenic	O
mice	O
with	O
a	O
bacterial	O
artificial	O
chromosome	O
(	O
BAC	O
)	O
containing	O
the	O
Sharpin	B-Protein
gene	O
(	O
FVB	O
/	O
NJ	O
-	O
Tg	O
(	O
RP24	O
-	O
173I23	O
)	O
1Sun	O
/	O
Sun	O
,	O
JR	O
#	O
8279	O
)	O
.	O

These	O
mice	O
were	O
backcrossed	O
onto	O
the	O
C57BL	O
/	O
KaLawRij	O
-	O
Sharpincpdm	O
/	O
RijSunJ	O
background	O
and	O
N4	O
mice	O
were	O
used	O
in	O
the	O
experiments	O
reported	O
here	O
.	O

All	O
mouse	O
work	O
was	O
carried	O
out	O
in	O
strict	O
accordance	O
with	O
the	O
approved	O
protocols	O
by	O
the	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
.	O
<EOS>	B-X
Previous	B-X
work	B-X
from	B-X
our	B-X
laboratory	B-X
has	B-X
demonstrated	B-X
that	B-X
glial	B-X
cells	B-X
modulate	B-X
antiviral	B-X
T-cell	B-X
effector	B-X
responses	B-X
through	B-X
the	B-X
programmed	B-X
death	B-X
(	B-X
PD	B-X
)	B-X
-1	B-X
:	B-X
PD-L1	B-X
pathway	B-X
,	B-X
thereby	B-X
limiting	B-X
the	B-X
deleterious	B-X
consequences	B-X
of	B-X
unrestrained	B-X
neuroinflammation	B-X
.	B-X
Herein	B-X
,	B-X
we	B-X
tested	B-X
a	B-X
subunit	B-X
vaccine	B-X
containing	B-X
the	B-X
450	B-X
amino	B-X
acids	B-X
at	B-X
the	B-X
N-terminus	B-X
of	B-X
the	B-X
ZIKV	B-X
envelope	B-X
protein	B-X
(	B-X
E90	B-X
)	B-X
in	B-X
mouse	B-X
models	B-X
for	B-X
either	B-X
in	B-X
utero	B-X
or	B-X
neonatal	B-X
ZIKV	B-X
infection	B-X
.	B-X
This	B-X
work	B-X
directly	B-X
demonstrates	B-X
that	B-X
immunization	B-X
of	B-X
pregnant	B-X
mice	B-X
protects	B-X
the	B-X
developing	B-X
brains	B-X
of	B-X
offspring	B-X
both	B-X
in	B-X
utero	B-X
and	B-X
in	B-X
the	B-X
neonatal	B-X
period	B-X
from	B-X
subsequent	B-X
ZIKV	B-X
infection	B-X
and	B-X
microcephaly	B-X
.	B-X

Constructs	O
and	O
transfection	O
<EOS>	B-X
We	B-X
describe	B-X
here	B-X
a	B-X
number	B-X
of	B-X
techniques	B-X
to	B-X
introduce	B-X
nucleic	B-X
acids	B-X
into	B-X
eukaryotic	B-X
cells	B-X
,	B-X
ranging	B-X
from	B-X
conventional	B-X
plasmid	B-X
transfection	B-X
to	B-X
lentiviral	B-X
-transduction	B-X
and	B-X
adeno-associated	B-X
viral	B-X
(	B-X
AAV	B-X
)	B-X
-mediated	B-X
DNA	B-X
transfer	B-X
.	B-X
Vector	B-X
supernatants	B-X
are	B-X
free	B-X
of	B-X
helper	B-X
virus	B-X
and	B-X
are	B-X
of	B-X
sufficiently	B-X
high	B-X
titer	B-X
within	B-X
2	B-X
days	B-X
of	B-X
transient	B-X
transfection	B-X
in	B-X
293	B-X
cells	B-X
to	B-X
permit	B-X
infection	B-X
of	B-X
more	B-X
than	B-X
50	B-X
%	B-X
of	B-X
randomly	B-X
cycling	B-X
target	B-X
cells	B-X
in	B-X
culture	B-X
.	B-X
The	B-X
practical	B-X
details	B-X
cover	B-X
:	B-X
transfection	B-X
of	B-X
insect	B-X
cells	B-X
with	B-X
either	B-X
virus	B-X
DNA	B-X
or	B-X
virus	B-X
DNA	B-X
and	B-X
plasmid	B-X
transfer	B-X
vector	B-X
;	B-X
a	B-X
reliable	B-X
plaque-assay	B-X
method	B-X
that	B-X
can	B-X
be	B-X
used	B-X
to	B-X
separate	B-X
recombinant	B-X
virus	B-X
from	B-X
parental	B-X
(	B-X
nonrecombinant	B-X
)	B-X
virus	B-X
where	B-X
this	B-X
is	B-X
necessary	B-X
;	B-X
methods	B-X
for	B-X
the	B-X
small-scale	B-X
amplification	B-X
of	B-X
recombinant	B-X
virus	B-X
;	B-X
and	B-X
subsequent	B-X
titration	B-X
by	B-X
plaque-assay	B-X
or	B-X
real-time	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
.	B-X
Methods	B-X
unique	B-X
to	B-X
the	B-X
Bac-to-Bac	B-X
(	B-X
®	B-X
)	B-X
system	B-X
are	B-X
also	B-X
covered	B-X
and	B-X
include	B-X
the	B-X
transformation	B-X
of	B-X
bacterial	B-X
cells	B-X
and	B-X
isolation	B-X
of	B-X
bacmid	B-X
DNA	B-X
ready	B-X
for	B-X
transfection	B-X
of	B-X
insect	B-X
cells	B-X
.	B-X

The	O
complementary	O
DNA	O
(	O
cDNA	O
)	O
of	O
the	O
mouse	O
Sharpin	B-Protein
gene	O
was	O
cloned	O
and	O
amplified	O
from	O
RAW264	O
.	O
7	O
RNA	O
extracts	O
.	O

The	O
primer	O
sequences	O
were	O
forward	O
,	O
5	O
'	O
-	O
CC	O
ATG	O
GCG	O
ATG	O
TCG	O
CCG	O
CCC	O
GCC	O
GGC	O
GGT	O
;	O
reverse	O
,	O
5	O
'	O
-	O
AAG	O
CTT	O
CTA	O
GGT	O
GGA	O
AGC	O
TGC	O
AGC	O
AAG	O
A	O
.	O

The	O
Sharpin	B-Protein
cDNA	O
was	O
cloned	O
into	O
expression	O
vector	O
pFLAG	O
-	O
CMV	O
-	O
2	O
.	O

Murine	O
fibroblasts	O
and	O
macrophages	O
were	O
were	O
used	O
to	O
express	O
recombinant	O
SHARPIN	B-Protein
protein	O
.	O

Cells	O
(	O
2x104	O
)	O
were	O
seeded	O
in	O
96	O
-	O
well	O
treated	O
plates	O
the	O
day	O
before	O
transfection	O
.	O

After	O
overnight	O
incubation	O
,	O
200	O
ng	O
pFLAG	O
-	O
SHARPIN	B-Protein
plasmids	O
were	O
transfected	O
with	O
0	O
.	O
5	O
ul	O
Lipofectamine	O
2000	O
.	O

24	O
hours	O
later	O
,	O
cells	O
were	O
incubated	O
with	O
fresh	O
culture	O
medium	O
.	O
<EOS>	B-X
Mesenchymal	B-X
cells	B-X
are	B-X
pluripotent	B-X
cells	B-X
,	B-X
which	B-X
have	B-X
the	B-X
potential	B-X
to	B-X
differentiate	B-X
to	B-X
specialized	B-X
tissues	B-X
under	B-X
appropriate	B-X
stimuli	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
direct	B-X
differentiation	B-X
of	B-X
the	B-X
adult	B-X
mesenchymal	B-X
stem	B-X
cells	B-X
isolated	B-X
from	B-X
fatty	B-X
tissue	B-X
into	B-X
cardiomyocytes	B-X
using	B-X
5-azacytidine	B-X
.	B-X
A	B-X
bioassay	B-X
for	B-X
thyroid	B-X
stimulating	B-X
immunoglobulins	B-X
(	B-X
TSI	B-X
)	B-X
of	B-X
patients	B-X
with	B-X
Graves	B-X
'	B-X
disease	B-X
was	B-X
developed	B-X
by	B-X
porcine	B-X
thyroid	B-X
monolayer	B-X
cells	B-X
.	B-X
Thyroid	B-X
cells	B-X
were	B-X
prepared	B-X
by	B-X
dispersion	B-X
using	B-X
collagenase	B-X
and	B-X
trypsin	B-X
.	B-X
Aliquots	B-X
of	B-X
the	B-X
cell	B-X
suspension	B-X
(	B-X
2	B-X
X	B-X
10	B-X
(	B-X
6	B-X
)	B-X
cells/1.5	B-X
ml/dish	B-X
)	B-X
in	B-X
Ham	B-X
's	B-X
F-12	B-X
medium	B-X
(	B-X
pH	B-X
7.2	B-X
)	B-X
containing	B-X
10	B-X
%	B-X
calf	B-X
serum	B-X
and	B-X
1.5	B-X
mM	B-X
Hepes	B-X
were	B-X
seeded	B-X
and	B-X
cultured	B-X
in	B-X
air	B-X
at	B-X
36	B-X
C.	B-X
On	B-X
day	B-X
6	B-X
of	B-X
culture	B-X
,	B-X
cells	B-X
were	B-X
incubated	B-X
with	B-X
test	B-X
samples	B-X
(	B-X
IgG	B-X
or	B-X
bTSH	B-X
)	B-X
in	B-X
1	B-X
ml	B-X
of	B-X
serum-free	B-X
,	B-X
0.5	B-X
mM	B-X
IMX-included	B-X
fresh	B-X
medium	B-X
for	B-X
an	B-X
additional	B-X
time	B-X
,	B-X
and	B-X
cAMP	B-X
in	B-X
the	B-X
cells	B-X
was	B-X
measured	B-X
by	B-X
radioimmunoassay	B-X
.	B-X
With	B-X
the	B-X
addition	B-X
of	B-X
IgG	B-X
from	B-X
untreated	B-X
Graves	B-X
'	B-X
patients	B-X
,	B-X
dose-related	B-X
increases	B-X
in	B-X
cAMP	B-X
were	B-X
also	B-X
observed	B-X
up	B-X
to	B-X
10	B-X
mg/ml	B-X
IgG	B-X
and	B-X
the	B-X
maximal	B-X
response	B-X
was	B-X
seen	B-X
at	B-X
2	B-X
hours	B-X
incubation	B-X
.	B-X
Thyroid	B-X
stimulating	B-X
activity	B-X
in	B-X
IgG	B-X
's	B-X
from	B-X
normal	B-X
subjects	B-X
and	B-X
patients	B-X
with	B-X
Graves	B-X
'	B-X
disease	B-X
was	B-X
tested	B-X
with	B-X
a	B-X
dose	B-X
of	B-X
10	B-X
mg/ml	B-X
and	B-X
2	B-X
hours	B-X
incubation	B-X
and	B-X
the	B-X
activity	B-X
was	B-X
expressed	B-X
as	B-X
a	B-X
percent	B-X
of	B-X
the	B-X
control	B-X
(	B-X
incubated	B-X
in	B-X
the	B-X
same	B-X
experiment	B-X
without	B-X
IgG	B-X
)	B-X
.	B-X
One	B-X
hundred	B-X
forty	B-X
one	B-X
of	B-X
145	B-X
untreated	B-X
patients	B-X
showed	B-X
higher	B-X
activity	B-X
(	B-X
228	B-X
+/-	B-X
51.8	B-X
%	B-X
,	B-X
mean	B-X
+/-	B-X
SD	B-X
;	B-X
127-393	B-X
%	B-X
,	B-X
range	B-X
)	B-X
than	B-X
normal	B-X
subjects	B-X
(	B-X
103	B-X
+/-	B-X
13.3	B-X
%	B-X
,	B-X
mean	B-X
+/-	B-X
SD	B-X
,	B-X
n	B-X
=	B-X
24	B-X
;	B-X
80-129	B-X
%	B-X
,	B-X
range	B-X
)	B-X
.	B-X
Sequential	B-X
changes	B-X
in	B-X
TSI	B-X
activity	B-X
in	B-X
27	B-X
patients	B-X
after	B-X
initiating	B-X
thionamide	B-X
drugs	B-X
were	B-X
studied	B-X
for	B-X
24	B-X
months	B-X
.	B-X
Initially	B-X
all	B-X
27	B-X
patients	B-X
showed	B-X
positive	B-X
TSI	B-X
and	B-X
6	B-X
months	B-X
later	B-X
15	B-X
remained	B-X
positive	B-X
.	B-X

After	O
another	O
24	O
hours	O
,	O
cells	O
were	O
lysed	O
to	O
confirm	O
the	O
FLAG	O
-	O
SHARPIN	B-Protein
expression	O
by	O
immunoblots	O
with	O
anti	O
-	O
FLAG	O
.	O

Cells	O
with	O
no	O
transfection	O
and	O
transfected	O
with	O
empty	O
vector	O
pFLAG	O
-	O
CMV	O
-	O
2	O
were	O
used	O
as	O
negative	O
control	O
in	O
all	O
transfection	O
experiments	O
.	O

Generation	O
of	O
BMDC	O
<EOS>	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
investigation	B-X
was	B-X
to	B-X
verify	B-X
if	B-X
temporary	B-X
elimination	B-X
of	B-X
IL-10	B-X
just	B-X
before	B-X
injection	B-X
of	B-X
bone	B-X
marrow-derived	B-X
DCs	B-X
(	B-X
BMDCs	B-X
)	B-X
enhance	B-X
the	B-X
antitumour	B-X
activity	B-X
of	B-X
applied	B-X
vaccines	B-X
and	B-X
help	B-X
to	B-X
overcome	B-X
the	B-X
immunosuppressive	B-X
tumour	B-X
barrier	B-X
.	B-X
Mice	B-X
bearing	B-X
colon	B-X
carcinoma	B-X
MC38	B-X
were	B-X
given	B-X
single	B-X
dose	B-X
of	B-X
cyclophosphamide	B-X
(	B-X
CY	B-X
)	B-X
followed	B-X
by	B-X
alternate	B-X
injections	B-X
of	B-X
anti-IL-10	B-X
antibodies	B-X
and	B-X
BMDC-based	B-X
vaccines	B-X
consisted	B-X
of	B-X
BMDCs	B-X
stimulated	B-X
with	B-X
MC38	B-X
tumour	B-X
antigen	B-X
(	B-X
BMDC/TAg	B-X
)	B-X
or	B-X
the	B-X
combination	B-X
of	B-X
BMDC/TAg	B-X
with	B-X
BMDCs	B-X
transduced	B-X
with	B-X
IL-12	B-X
genes	B-X
(	B-X
BMDC/IL-12	B-X
)	B-X
.	B-X
The	B-X
high	B-X
tumour	B-X
growth	B-X
inhibition	B-X
was	B-X
observed	B-X
in	B-X
mice	B-X
treated	B-X
with	B-X
CY+anti-IL-10+BMDC/TAg	B-X
as	B-X
well	B-X
as	B-X
CY±anti-IL-10+BMDC/TAg+BMDC/IL-12	B-X
.	B-X
However	B-X
,	B-X
anti-IL-10	B-X
Abs	B-X
in	B-X
combination	B-X
with	B-X
diversely	B-X
composed	B-X
BMDC-based	B-X
vaccines	B-X
induced	B-X
different	B-X
components	B-X
of	B-X
an	B-X
antitumour	B-X
response	B-X
.	B-X
The	B-X
high	B-X
cytotoxic	B-X
activity	B-X
of	B-X
spleen-derived	B-X
NK	B-X
cells	B-X
and	B-X
increased	B-X
influx	B-X
of	B-X
these	B-X
cells	B-X
into	B-X
tumours	B-X
of	B-X
mice	B-X
treated	B-X
with	B-X
CY+anti-IL-10+BMDC/TAg	B-X
indicate	B-X
that	B-X
mice	B-X
from	B-X
the	B-X
group	B-X
developed	B-X
strong	B-X
NK-dependent	B-X
response	B-X
.	B-X
Whereas	B-X
,	B-X
application	B-X
of	B-X
anti-IL-10	B-X
Abs	B-X
just	B-X
before	B-X
injection	B-X
of	B-X
BMDC/TAg+BMDC/IL-12	B-X
did	B-X
not	B-X
enhanced	B-X
NK	B-X
cell	B-X
activity	B-X
.	B-X
Furthermore	B-X
,	B-X
it	B-X
significantly	B-X
impaired	B-X
effectiveness	B-X
of	B-X
therapy	B-X
composed	B-X
of	B-X
CY+BMDC/TAg+BMDC/IL-12	B-X
vaccine	B-X
in	B-X
induction	B-X
of	B-X
Th1	B-X
type	B-X
immune	B-X
response	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
indicate	B-X
that	B-X
temporary	B-X
elimination	B-X
of	B-X
IL-10	B-X
is	B-X
an	B-X
important	B-X
and	B-X
effective	B-X
way	B-X
to	B-X
decrease	B-X
the	B-X
immune	B-X
suppression	B-X
associated	B-X
with	B-X
MDSCs	B-X
activity	B-X
and	B-X
represents	B-X
a	B-X
useful	B-X
strategy	B-X
for	B-X
successful	B-X
enhancement	B-X
of	B-X
the	B-X
antitumour	B-X
activity	B-X
of	B-X
BMDC/TAg-based	B-X
vaccines	B-X
.	B-X

BMDC	O
were	O
developed	O
as	O
previously	O
reported	O
[	O
54	O
]	O
,	O
[	O
55	O
]	O
.	O

Cells	O
were	O
collected	O
after	O
10	O
-	O
12	O
days	O
of	O
culture	O
.	O
<EOS>	B-X
Therefore	B-X
,	B-X
previous	B-X
expansion	B-X
protocols	B-X
for	B-X
those	B-X
effector	B-X
cells	B-X
were	B-X
improved	B-X
and	B-X
optimized	B-X
by	B-X
using	B-X
newly	B-X
developed	B-X
culture	B-X
medium	B-X
,	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-21	B-X
,	B-X
and	B-X
autologous	B-X
feeder	B-X
cells	B-X
(	B-X
FCs	B-X
)	B-X
.	B-X
In	B-X
the	B-X
first	B-X
part	B-X
,	B-X
four	B-X
different	B-X
commercially	B-X
available	B-X
centrifuges	B-X
were	B-X
used	B-X
to	B-X
produce	B-X
L-PRF	B-X
,	B-X
following	B-X
the	B-X
original	B-X
L-PRF	B-X
production	B-X
method	B-X
(	B-X
glass-coated	B-X
plastic	B-X
tubes	B-X
,	B-X
400	B-X
g	B-X
force	B-X
,	B-X
12	B-X
minutes	B-X
)	B-X
.	B-X
The	B-X
tested	B-X
systems	B-X
were	B-X
the	B-X
original	B-X
L-PRF	B-X
centrifuge	B-X
(	B-X
Intra-Spin	B-X
,	B-X
Intra-Lock	B-X
,	B-X
the	B-X
only	B-X
CE	B-X
and	B-X
FDA	B-X
cleared	B-X
system	B-X
for	B-X
the	B-X
preparation	B-X
of	B-X
L-PRF	B-X
)	B-X
and	B-X
three	B-X
other	B-X
laboratory	B-X
centrifuges	B-X
(	B-X
not	B-X
CE/FDA	B-X
cleared	B-X
for	B-X
L-PRF	B-X
)	B-X
:	B-X
A-PRF	B-X
12	B-X
(	B-X
Advanced	B-X
PRF	B-X
,	B-X
Process	B-X
)	B-X
,	B-X
LW-UPD8	B-X
(	B-X
LW	B-X
Scientific	B-X
)	B-X
and	B-X
Salvin	B-X
1310	B-X
(	B-X
Salvin	B-X
Dental	B-X
)	B-X
.	B-X
Each	B-X
centrifuge	B-X
was	B-X
opened	B-X
for	B-X
inspection	B-X
,	B-X
two	B-X
accelerometers	B-X
were	B-X
installed	B-X
(	B-X
one	B-X
radial	B-X
,	B-X
one	B-X
vertical	B-X
)	B-X
,	B-X
and	B-X
data	B-X
were	B-X
collected	B-X
with	B-X
a	B-X
spectrum	B-X
analyzer	B-X
in	B-X
two	B-X
configurations	B-X
(	B-X
full-load	B-X
or	B-X
half	B-X
load	B-X
)	B-X
.	B-X
All	B-X
clots	B-X
and	B-X
membranes	B-X
were	B-X
collected	B-X
into	B-X
a	B-X
sterile	B-X
surgical	B-X
box	B-X
(	B-X
Xpression	B-X
kit	B-X
,	B-X
Intra-Lock	B-X
)	B-X
.	B-X
In	B-X
the	B-X
second	B-X
part	B-X
,	B-X
venous	B-X
blood	B-X
was	B-X
taken	B-X
in	B-X
two	B-X
groups	B-X
,	B-X
respectively	B-X
,	B-X
Intra-Spin	B-X
9	B-X
ml	B-X
glass-coated	B-X
plastic	B-X
tubes	B-X
(	B-X
Intra-Lock	B-X
)	B-X
and	B-X
A-PRF	B-X
10	B-X
ml	B-X
glass	B-X
tubes	B-X
(	B-X
Process	B-X
)	B-X
.	B-X
Tubes	B-X
were	B-X
immediately	B-X
centrifuged	B-X
at	B-X
2700	B-X
rpm	B-X
(	B-X
around	B-X
400	B-X
g	B-X
)	B-X
during	B-X
12	B-X
minutes	B-X
to	B-X
produce	B-X
L-PRF	B-X
or	B-X
at	B-X
1500	B-X
rpm	B-X
during	B-X
14	B-X
minutes	B-X
to	B-X
produce	B-X
A-PRF	B-X
.	B-X
Half	B-X
of	B-X
the	B-X
membranes	B-X
were	B-X
placed	B-X
individually	B-X
in	B-X
culture	B-X
media	B-X
and	B-X
transferred	B-X
in	B-X
a	B-X
new	B-X
tube	B-X
at	B-X
seven	B-X
experimental	B-X
times	B-X
(	B-X
up	B-X
to	B-X
7	B-X
days	B-X
)	B-X
.	B-X
A	B-X
slow	B-X
release	B-X
of	B-X
BMP2	B-X
was	B-X
detected	B-X
during	B-X
at	B-X
least	B-X
7	B-X
days	B-X
in	B-X
the	B-X
original	B-X
L-PRF	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
original	B-X
L-PRF	B-X
clots	B-X
and	B-X
membranes	B-X
(	B-X
produced	B-X
with	B-X
9	B-X
mL	B-X
blood	B-X
)	B-X
were	B-X
always	B-X
significantly	B-X
larger	B-X
than	B-X
the	B-X
A-PRF	B-X
(	B-X
produced	B-X
with	B-X
10	B-X
mL	B-X
blood	B-X
)	B-X
.	B-X
The	B-X
A-PRF	B-X
membranes	B-X
dissolved	B-X
in	B-X
vitro	B-X
after	B-X
less	B-X
than	B-X
3	B-X
days	B-X
,	B-X
while	B-X
the	B-X
L-PRF	B-X
membrane	B-X
remained	B-X
in	B-X
good	B-X
shape	B-X
during	B-X
at	B-X
least	B-X
7	B-X
days	B-X
.	B-X

The	O
cell	O
yield	O
was	O
2	O
-	O
3x107	O
cells	O
/	O
mouse	O
with	O
80	O
-	O
95	O
%	O
BMDC	O
.	O

Phenotype	O
of	O
BMDC	O
and	O
splenic	O
DC	O
subsets	O
<EOS>	B-X
CD11c+/CD11b+dendritic	B-X
cells	B-X
(	B-X
DC	B-X
)	B-X
with	B-X
high	B-X
levels	B-X
of	B-X
major	B-X
histocompatibility	B-X
complex	B-X
(	B-X
MHC	B-X
)	B-X
class	B-X
II	B-X
and	B-X
co-stimulatory	B-X
molecules	B-X
have	B-X
been	B-X
derived	B-X
from	B-X
spleen	B-X
cells	B-X
cultured	B-X
with	B-X
granulocyte-macrophage	B-X
colony	B-X
stimulating	B-X
factor	B-X
(	B-X
GM-CSF	B-X
)	B-X
+	B-X
flt-3L	B-X
+	B-X
interleukin	B-X
(	B-X
IL	B-X
)	B-X
-6	B-X
(	B-X
flt-3L-DC	B-X
)	B-X
.	B-X
Investigating	B-X
in	B-X
vivo	B-X
the	B-X
function	B-X
of	B-X
DC	B-X
in	B-X
non-obese	B-X
diabetic	B-X
mice	B-X
(	B-X
NOD	B-X
)	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
a	B-X
single	B-X
injection	B-X
of	B-X
this	B-X
in	B-X
vitro-derived	B-X
subset	B-X
of	B-X
DC	B-X
prevents	B-X
the	B-X
development	B-X
of	B-X
diabetes	B-X
into	B-X
prediabetic	B-X
female	B-X
mice	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
DC	B-X
derived	B-X
from	B-X
bone	B-X
marrow	B-X
cells	B-X
cultured	B-X
with	B-X
GM-CSF	B-X
+	B-X
IL-4	B-X
[	B-X
bone	B-X
marrow	B-X
(	B-X
BM	B-X
)	B-X
-DC	B-X
]	B-X
induced	B-X
no	B-X
protection	B-X
.	B-X
Moreover	B-X
,	B-X
protection	B-X
against	B-X
diabetes	B-X
following	B-X
injection	B-X
of	B-X
flt-3L-DC	B-X
was	B-X
associated	B-X
with	B-X
IL-4	B-X
and	B-X
IL-10	B-X
production	B-X
in	B-X
the	B-X
spleen	B-X
and	B-X
the	B-X
pancreatic	B-X
lymph	B-X
nodes	B-X
of	B-X
recipient	B-X
mice	B-X
,	B-X
indicating	B-X
that	B-X
this	B-X
DC	B-X
population	B-X
is	B-X
able	B-X
to	B-X
polarize	B-X
the	B-X
immune	B-X
response	B-X
towards	B-X
a	B-X
Th2	B-X
pathway	B-X
.	B-X
As	B-X
we	B-X
shown	B-X
previously	B-X
,	B-X
NOD	B-X
BM-DC	B-X
exhibit	B-X
an	B-X
enhanced	B-X
capacity	B-X
to	B-X
produce	B-X
IL-12p70	B-X
in	B-X
response	B-X
to	B-X
lipopolysaccharide	B-X
(	B-X
LPS	B-X
)	B-X
and	B-X
anti-CD40	B-X
stimulation	B-X
compared	B-X
to	B-X
BM-DC	B-X
from	B-X
control	B-X
mice	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
NOD	B-X
flt-3L-DC	B-X
,	B-X
as	B-X
their	B-X
control	B-X
mouse	B-X
counterpart	B-X
,	B-X
produced	B-X
no	B-X
IL-12p70	B-X
to	B-X
these	B-X
stimuli	B-X
.	B-X
Our	B-X
findings	B-X
show	B-X
that	B-X
a	B-X
subset	B-X
of	B-X
DC	B-X
,	B-X
characterized	B-X
by	B-X
a	B-X
mature	B-X
phenotype	B-X
and	B-X
the	B-X
absence	B-X
of	B-X
IL-12p70	B-X
production	B-X
can	B-X
be	B-X
derived	B-X
from	B-X
NOD	B-X
mouse	B-X
spleen	B-X
favouring	B-X
IL-4	B-X
and	B-X
IL-10	B-X
regulatory	B-X
responses	B-X
and	B-X
protection	B-X
from	B-X
diabetes	B-X
development	B-X
.	B-X

The	O
phenotype	O
of	O
BMDC	O
was	O
determined	O
before	O
and	O
after	O
24	O
hour	O
culture	O
in	O
the	O
presence	O
of	O
100	O
ng	O
/	O
mL	O
LPS	O
.	O

The	O
cells	O
were	O
incubated	O
in	O
PBS	O
with	O
0	O
.	O
1	O
%	O
NaN3	O
,	O
1	O
%	O
BSA	O
and	O
10	O
%	O
normal	O
rabbit	O
serum	O
for	O
20	O
minutes	O
on	O
ice	O
,	O
washed	O
and	O
incubated	O
for	O
30	O
minutes	O
on	O
ice	O
with	O
Alex	O
Fluor	O
-	O
labeled	O
anti	O
-	O
CD11c	O
(	O
MCD11C20	O
,	O
CALTAG	O
)	O
in	O
combination	O
with	O
PE	O
-	O
anti	O
-	O
CD40	O
(	O
3	O
/	O
23	O
,	O
BD	O
Biosciences	O
)	O
,	O
PE	O
-	O
anti	O
-	O
CD80	O
(	O
16	O
-	O
10A1	O
,	O
eBioscience	O
)	O
,	O
PE	O
-	O
anti	O
-	O
CD86	O
(	O
P03	O
.	O
1	O
,	O
eBioscience	O
)	O
,	O
PE	O
-	O
anti	O
-	O
CD14	O
(	O
Sa2	O
.	O
8	O
,	O
eBioscience	O
)	O
and	O
biotinylated	O
anti	O
-	O
TLR4	O
(	O
BioLegend	O
)	O
.	O

The	O
cells	O
incubated	O
with	O
biotinylated	O
anti	O
-	O
TLR4	O
/	O
MD	O
-	O
2	O
were	O
washed	O
twice	O
and	O
incubated	O
for	O
30	O
minutes	O
on	O
ice	O
with	O
avidin	O
-	O
PE	O
.	O

To	O
isolate	O
splenic	O
DC	O
,	O
spleens	O
were	O
collagenase	O
digested	O
and	O
subject	O
to	O
Percoll	O
gradient	O
centrifugation	O
.	O

The	O
bands	O
at	O
the	O
35	O
-	O
55	O
%	O
interface	O
were	O
collected	O
to	O
stain	O
with	O
PE	O
-	O
anti	O
-	O
CD11c	O
(	O
HL3	O
,	O
BioLegend	O
)	O
,	O
APC	O
-	O
anti	O
-	O
PDCA	O
-	O
1	O
(	O
927	O
,	O
BioLegend	O
)	O
and	O
FITC	O
-	O
anti	O
-	O
CD8alpha	O
(	O
53	O
-	O
6	O
.	O
7	O
,	O
BD	O
BioScience	O
)	O
.	O

The	O
cells	O
were	O
washed	O
twice	O
,	O
fixed	O
in	O
2	O
%	O
paraformaldehyde	O
,	O
and	O
stored	O
at	O
4degreesC	O
until	O
analysis	O
.	O

Flow	O
cytometry	O
was	O
performed	O
in	O
an	O
Excel	O
(	O
Coulter	O
)	O
instrument	O
.	O

Dead	O
cells	O
were	O
omitted	O
from	O
the	O
analysis	O
by	O
gating	O
on	O
forward	O
and	O
90degrees	O
light	O
scatter	O
,	O
and	O
10	O
,	O
000	O
cells	O
were	O
analyzed	O
by	O
FlowJo	O
software	O
.	O

BMDC	O
-	O
T	O
cell	O
in	O
vitro	O
interaction	O
<EOS>	B-X
There	B-X
is	B-X
considerable	B-X
interest	B-X
to	B-X
develop	B-X
antigen-carriers	B-X
for	B-X
immune-modulatory	B-X
clinical	B-X
applications	B-X
,	B-X
but	B-X
insufficient	B-X
information	B-X
is	B-X
available	B-X
on	B-X
their	B-X
effects	B-X
on	B-X
antigen-presenting	B-X
cells	B-X
.	B-X
We	B-X
employed	B-X
virosomes	B-X
coupled	B-X
to	B-X
ovalbumin	B-X
(	B-X
OVA	B-X
)	B-X
to	B-X
study	B-X
their	B-X
interaction	B-X
with	B-X
murine	B-X
bone	B-X
marrow-derived	B-X
dendritic	B-X
cells	B-X
(	B-X
BMDCs	B-X
)	B-X
and	B-X
modulation	B-X
of	B-X
downstream	B-X
T	B-X
cell	B-X
responses	B-X
.	B-X
BMDCs	B-X
were	B-X
treated	B-X
in	B-X
vitro	B-X
with	B-X
virosomes	B-X
or	B-X
liposomes	B-X
prior	B-X
to	B-X
determining	B-X
BMDC	B-X
phenotype	B-X
,	B-X
viability	B-X
,	B-X
and	B-X
intracellular	B-X
trafficking	B-X
.	B-X
To	B-X
further	B-X
study	B-X
antigen	B-X
presentation	B-X
by	B-X
MG	B-X
:	B-X
vaccine	B-X
conjugates	B-X
,	B-X
bone	B-X
marrow-derived	B-X
dendritic	B-X
cells	B-X
(	B-X
BMDC	B-X
)	B-X
were	B-X
treated	B-X
with	B-X
MG	B-X
conjugated	B-X
to	B-X
ovalbumin	B-X
(	B-X
OVA	B-X
)	B-X
,	B-X
then	B-X
interacted	B-X
with	B-X
splenocytes	B-X
from	B-X
DO11.10	B-X
transgenic	B-X
mice	B-X
expressing	B-X
an	B-X
OVA	B-X
peptide-specific	B-X
T	B-X
cell	B-X
receptor	B-X
.	B-X
BMDC	B-X
treated	B-X
with	B-X
MG	B-X
:	B-X
OVA	B-X
induced	B-X
significantly	B-X
higher	B-X
numbers	B-X
of	B-X
activated	B-X
(	B-X
CD25+CD69+	B-X
)	B-X
OVA-specific	B-X
CD4+	B-X
T	B-X
cells	B-X
than	B-X
BMDC	B-X
treated	B-X
with	B-X
OVA	B-X
alone	B-X
.	B-X
BMDC	B-X
treated	B-X
with	B-X
MG	B-X
:	B-X
OVA	B-X
upregulated	B-X
CD86	B-X
and	B-X
CD40	B-X
expression	B-X
as	B-X
well	B-X
as	B-X
MG	B-X
alone	B-X
,	B-X
indicating	B-X
that	B-X
conjugation	B-X
of	B-X
OVA	B-X
does	B-X
not	B-X
alter	B-X
the	B-X
immunostimulatory	B-X
capacity	B-X
of	B-X
MG.	B-X
Activation	B-X
of	B-X
CD8+	B-X
OVA-specific	B-X
OT-1	B-X
cells	B-X
showed	B-X
that	B-X
MG	B-X
:	B-X
OVA	B-X
is	B-X
also	B-X
capable	B-X
of	B-X
enhancing	B-X
cross-presentation	B-X
by	B-X
BMDC	B-X
to	B-X
CD8+	B-X
cytotoxic	B-X
T	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
show	B-X
that	B-X
MG	B-X
acts	B-X
as	B-X
an	B-X
adjuvant	B-X
to	B-X
enhance	B-X
antigen	B-X
presentation	B-X
by	B-X
dendritic	B-X
cells	B-X
to	B-X
naïve	B-X
,	B-X
antigen-specific	B-X
CD4	B-X
and	B-X
CD8	B-X
T	B-X
cells	B-X
.	B-X

WT	O
and	O
cpdm	O
BMDC	O
(	O
5x104	O
)	O
were	O
stimulated	O
with	O
medium	O
,	O
1	O
microg	O
/	O
mL	O
LPS	O
,	O
25	O
microg	O
/	O
mL	O
and	O
5	O
microg	O
/	O
mL	O
Pam3CYS	O
.	O

24	O
hours	O
later	O
,	O
cells	O
were	O
collected	O
and	O
washed	O
with	O
PBS	O
.	O

Allogeneic	O
naive	O
CD4	O
+	O
T	O
cells	O
were	O
isolated	O
from	O
spleens	O
of	O
BALB	O
/	O
c	O
mice	O
by	O
negative	O
selection	O
kit	O
(	O
Invitrogen	O
)	O
and	O
were	O
then	O
added	O
at	O
2	O
.	O
5x105	O
and	O
co	O
-	O
cultured	O
with	O
activated	O
BMDC	O
.	O

After	O
5	O
days	O
,	O
supernatant	O
was	O
collected	O
and	O
the	O
secretion	O
of	O
IFNgamma	B-Protein
,	O
IL4	B-Protein
,	O
IL2	B-Protein
,	O
and	O
IL17A	B-Protein
measured	O
by	O
ELISA	O
.	O

Negative	O
controls	O
are	O
1	O
)	O
stimulated	O
BMDC	O
without	O
co	O
-	O
culture	O
with	O
allogeneic	O
CD4	O
+	O
T	O
cells	O
;	O
2	O
)	O
allogeneic	O
CD4	O
+	O
T	O
cells	O
without	O
co	O
-	O
culture	O
with	O
stimulated	O
BMDC	O
.	O

Both	O
negative	O
controls	O
show	O
no	O
production	O
of	O
aforementioned	O
cytokines	O
.	O
<EOS>	B-X
However	B-X
,	B-X
its	B-X
role	B-X
in	B-X
the	B-X
production	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
,	B-X
particularly	B-X
mitochondrial	B-X
ROS	B-X
(	B-X
mtROS	B-X
)	B-X
and	B-X
the	B-X
subsequent	B-X
decrease	B-X
in	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
in	B-X
endothelial	B-X
cells	B-X
remains	B-X
unclear	B-X
.	B-X
Human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cells	B-X
(	B-X
HUVECs	B-X
)	B-X
were	B-X
treated	B-X
with	B-X
TWEAK	B-X
with	B-X
Fn14	B-X
small	B-X
interfering	B-X
(	B-X
si	B-X
)	B-X
RNA	B-X
or	B-X
negative	B-X
control	B-X
RNA	B-X
.	B-X
It	B-X
was	B-X
demonstrated	B-X
that	B-X
TWEAK	B-X
induced	B-X
the	B-X
production	B-X
of	B-X
ROS	B-X
and	B-X
mtROS	B-X
in	B-X
HUVECs	B-X
,	B-X
which	B-X
were	B-X
detected	B-X
by	B-X
fluorescent	B-X
microscope	B-X
,	B-X
and	B-X
flow	B-X
cytometry	B-X
.	B-X
Inhibition	B-X
of	B-X
Fn14	B-X
by	B-X
Fn14	B-X
siRNA	B-X
decreased	B-X
TWEAK‑induced	B-X
ROS	B-X
and	B-X
mtROS	B-X
production	B-X
,	B-X
as	B-X
well	B-X
as	B-X
mtDNA	B-X
damage	B-X
,	B-X
while	B-X
it	B-X
increased	B-X
the	B-X
production	B-X
of	B-X
NO	B-X
in	B-X
endothelial	B-X
cells	B-X
.	B-X
Notably	B-X
,	B-X
Fn14	B-X
siRNA	B-X
enhanced	B-X
the	B-X
expression	B-X
of	B-X
the	B-X
aforementioned	B-X
proteins	B-X
.	B-X

RNA	O
expression	O
by	O
BMDC	O
<EOS>	B-X
Much	B-X
work	B-X
has	B-X
been	B-X
dedicated	B-X
to	B-X
the	B-X
elucidation	B-X
of	B-X
the	B-X
signalling	B-X
cascades	B-X
that	B-X
activate	B-X
this	B-X
DNA-induced	B-X
gene	B-X
expression	B-X
programme	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
lentivirus-mediated	B-X
silencing	B-X
of	B-X
RelA	B-X
expression	B-X
in	B-X
a	B-X
bone	B-X
marrow-derived	B-X
dendritic	B-X
cell	B-X
(	B-X
BMDC	B-X
)	B-X
model	B-X
was	B-X
tested	B-X
.	B-X
The	B-X
BMDCs	B-X
were	B-X
transfected	B-X
with	B-X
RelA-shRNA	B-X
to	B-X
induce	B-X
an	B-X
immature	B-X
,	B-X
maturation-resistant	B-X
and	B-X
tolerogenic	B-X
phenotype	B-X
,	B-X
while	B-X
not	B-X
significantly	B-X
changing	B-X
IFN-γ	B-X
,	B-X
IL-10	B-X
and	B-X
IL-17	B-X
expression	B-X
.	B-X
The	B-X
allograft	B-X
mean	B-X
survival	B-X
time	B-X
(	B-X
MST	B-X
)	B-X
of	B-X
lv-shRelA-DC	B-X
injection	B-X
groups	B-X
were	B-X
significantly	B-X
longer	B-X
than	B-X
the	B-X
untreated	B-X
BMDC	B-X
group	B-X
and	B-X
control	B-X
group	B-X
.	B-X
ELISA	B-X
and	B-X
qRT-PCR	B-X
analyses	B-X
of	B-X
serum	B-X
showed	B-X
that	B-X
IFN-γ	B-X
and	B-X
IL-17	B-X
expression	B-X
were	B-X
suppressed	B-X
by	B-X
lv-shRelA-DC	B-X
treatement	B-X
.	B-X
Luciferase	B-X
and	B-X
Chromatin	B-X
IP	B-X
evaluation	B-X
showed	B-X
that	B-X
RelA	B-X
knockdown	B-X
in	B-X
BMDCs	B-X
significantly	B-X
reduces	B-X
DNA	B-X
binding	B-X
to	B-X
IFN-γ	B-X
,	B-X
IL-10	B-X
and	B-X
the	B-X
IL-17	B-X
promoter	B-X
and	B-X
inhibited	B-X
of	B-X
transcriptional	B-X
activity	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
this	B-X
study	B-X
illustrates	B-X
a	B-X
significant	B-X
role	B-X
of	B-X
RelA	B-X
in	B-X
mediating	B-X
the	B-X
corneal	B-X
neovascularization	B-X
by	B-X
affecting	B-X
IL-17	B-X
expression	B-X
.	B-X

BMDC	O
were	O
cultured	O
at	O
106	O
cells	O
/	O
mL	O
in	O
10	O
mL	O
of	O
RPMI	O
-	O
1640	O
complete	O
medium	O
in	O
the	O
presence	O
or	O
absence	O
of	O
100	O
ng	O
/	O
mL	O
LPS	O
or	O
25	O
microg	O
/	O
mL	O
poly	O
I	O
:	O
C	O
.	O
<EOS>	B-X
RT-PCR	B-X
analyses	B-X
showed	B-X
that	B-X
both	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
and	B-X
interferon	B-X
containing	B-X
supernatants	B-X
induced	B-X
expression	B-X
of	B-X
Mx1	B-X
in	B-X
RTG	B-X
cells	B-X
.	B-X
Kinetic	B-X
analyses	B-X
suggest	B-X
that	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
acts	B-X
indirectly	B-X
through	B-X
the	B-X
production	B-X
of	B-X
interferons	B-X
(	B-X
IFN	B-X
)	B-X
,	B-X
as	B-X
shown	B-X
in	B-X
other	B-X
studies	B-X
.	B-X
By	B-X
gene	B-X
walking	B-X
with	B-X
trout	B-X
genomic	B-X
DNA	B-X
the	B-X
regulatory	B-X
sequence	B-X
of	B-X
the	B-X
Mx1	B-X
gene	B-X
was	B-X
cloned	B-X
and	B-X
sequenced	B-X
.	B-X
Sequence	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
5	B-X
'	B-X
flanking	B-X
region	B-X
has	B-X
a	B-X
structure	B-X
,	B-X
which	B-X
is	B-X
typical	B-X
for	B-X
an	B-X
interferon-induced	B-X
gene	B-X
promoter	B-X
.	B-X
Relative	B-X
to	B-X
the	B-X
transcription	B-X
start	B-X
,	B-X
it	B-X
has	B-X
a	B-X
TATA	B-X
box	B-X
at	B-X
-29	B-X
to	B-X
-25	B-X
,	B-X
a	B-X
13	B-X
nucleotide	B-X
interferon	B-X
response	B-X
element	B-X
(	B-X
ISRE	B-X
)	B-X
between	B-X
-101	B-X
to	B-X
-89	B-X
,	B-X
and	B-X
a	B-X
Sp1	B-X
binding	B-X
site	B-X
at	B-X
-382	B-X
to	B-X
-374	B-X
.	B-X
This	B-X
region	B-X
,	B-X
with	B-X
a	B-X
single	B-X
ISRE	B-X
,	B-X
is	B-X
enough	B-X
to	B-X
induce	B-X
strong	B-X
expression	B-X
of	B-X
a	B-X
luciferase	B-X
reporter	B-X
gene	B-X
after	B-X
stimulation	B-X
of	B-X
RTG	B-X
cells	B-X
with	B-X
poly	B-X
I	B-X
:	B-X
C.	B-X
A	B-X
time-course	B-X
of	B-X
induction	B-X
of	B-X
this	B-X
reporter	B-X
construct	B-X
showed	B-X
maximal	B-X
expression	B-X
(	B-X
22-fold	B-X
increase	B-X
)	B-X
after	B-X
incubation	B-X
with	B-X
100	B-X
microg	B-X
mL	B-X
(	B-X
-1	B-X
)	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
for	B-X
48	B-X
h.	B-X
An	B-X
optimized	B-X
method	B-X
of	B-X
transient	B-X
transfection	B-X
of	B-X
RTG	B-X
cells	B-X
is	B-X
also	B-X
described	B-X
.	B-X

After	O
1	O
and	O
2	O
hours	O
,	O
RNA	O
was	O
isolated	O
with	O
TRI	O
-	O
reagent	O
(	O
Sigma	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

The	O
expression	O
of	O
Il6	B-Protein
,	O
Il12p40	B-Protein
,	O
Gmcsf	B-Protein
,	O
and	O
Sharpin	B-Protein
mRNA	O
was	O
determined	O
by	O
qRT	O
-	O
PCR	O
.	O

Primers	O
and	O
probes	O
were	O
purchased	O
from	O
Applied	O
Biosystems	O
.	O
<EOS>	B-X
SNP	B-X
genotyping	B-X
was	B-X
performed	B-X
using	B-X
primer/probe	B-X
sets	B-X
purchased	B-X
from	B-X
Applied	B-X
Biosystems	B-X
.	B-X
These	B-X
were	B-X
evaluated	B-X
for	B-X
performance	B-X
and	B-X
assay	B-X
conditions	B-X
on	B-X
the	B-X
Applied	B-X
Biosystems	B-X
7500	B-X
FAST	B-X
System	B-X
.	B-X

Reverse	O
transcription	O
was	O
performed	O
at	O
42degreesC	O
for	O
60	O
minutes	O
with	O
the	O
final	O
denaturation	O
step	O
at	O
90degreesC	O
for	O
5	O
minutes	O
in	O
30	O
microl	O
containing	O
0	O
.	O
5	O
microg	O
of	O
total	O
RNA	O
.	O

dNTPs	O
,	O
oligo	O
(	O
dT	O
)	O
15	O
primer	O
,	O
recombinant	O
RNasin	O
Ribonuclease	O
Inhibitor	O
,	O
and	O
M	B-Protein
-	I-Protein
MLV	I-Protein
Reverse	I-Protein
Transcriptase	I-Protein
(	O
all	O
from	O
Promega	O
,	O
Madison	O
,	O
WI	O
)	O
were	O
used	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instruction	O
.	O

Reverse	O
transcription	O
was	O
done	O
in	O
a	O
PTC	O
-	O
200	O
Peltier	O
Thermal	O
Cycler	O
(	O
MJ	O
Research	O
,	O
Watertown	O
,	O
MA	O
)	O
.	O

qRT	O
-	O
PCR	O
was	O
performed	O
in	O
ABI	O
Prism	O
7700	O
Sequence	O
Detection	O
System	O
with	O
TaqMan	O
(	O
R	O
)	O
Gene	O
Expression	O
Assays	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
for	O
mouse	O
Actb	B-Protein
,	O
IL6	B-Protein
,	O
IL12p40	B-Protein
,	O
Ifnbeta	B-Protein
,	O
Gmcsf	B-Protein
,	O
and	O
Sharpin	B-Protein
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

The	O
endogenous	O
standard	O
for	O
normalization	O
of	O
the	O
target	O
gene	O
was	O
beta	B-Protein
-	I-Protein
actin	I-Protein
.	O
<EOS>	B-X
With	B-X
the	B-X
current	B-X
rise	B-X
in	B-X
obesity-related	B-X
morbidities	B-X
,	B-X
real-time	B-X
quantitative	B-X
reverse	B-X
transcription	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
qRT-PCR	B-X
)	B-X
has	B-X
become	B-X
a	B-X
widely	B-X
used	B-X
method	B-X
for	B-X
assessment	B-X
of	B-X
genes	B-X
expressed	B-X
and	B-X
regulated	B-X
by	B-X
adipocytes	B-X
.	B-X
In	B-X
order	B-X
to	B-X
measure	B-X
accurate	B-X
changes	B-X
in	B-X
relative	B-X
gene	B-X
expression	B-X
and	B-X
monitor	B-X
intersample	B-X
variability	B-X
,	B-X
normalization	B-X
to	B-X
endogenous	B-X
control	B-X
genes	B-X
that	B-X
do	B-X
not	B-X
change	B-X
in	B-X
relative	B-X
expression	B-X
is	B-X
commonly	B-X
used	B-X
with	B-X
qRT-PCR	B-X
determinations	B-X
.	B-X
However	B-X
,	B-X
historical	B-X
evidence	B-X
has	B-X
clearly	B-X
demonstrated	B-X
that	B-X
the	B-X
expression	B-X
profiles	B-X
of	B-X
traditional	B-X
control	B-X
genes	B-X
(	B-X
e.g.	B-X
,	B-X
β-actin	B-X
,	B-X
GAPDH	B-X
,	B-X
α-tubulin	B-X
)	B-X
are	B-X
differentially	B-X
regulated	B-X
across	B-X
multiple	B-X
tissue	B-X
types	B-X
and	B-X
experimental	B-X
conditions	B-X
.	B-X
Real-time	B-X
quantitative	B-X
PCR	B-X
(	B-X
qPCR	B-X
)	B-X
is	B-X
the	B-X
most	B-X
reliable	B-X
and	B-X
accurate	B-X
technique	B-X
for	B-X
analyses	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
Endogenous	B-X
reference	B-X
genes	B-X
are	B-X
being	B-X
used	B-X
to	B-X
normalize	B-X
qPCR	B-X
data	B-X
even	B-X
though	B-X
their	B-X
expression	B-X
may	B-X
vary	B-X
under	B-X
different	B-X
conditions	B-X
and	B-X
in	B-X
different	B-X
tissues	B-X
.	B-X
Nonetheless	B-X
,	B-X
verification	B-X
of	B-X
expression	B-X
of	B-X
reference	B-X
genes	B-X
in	B-X
selected	B-X
studied	B-X
tissue	B-X
is	B-X
essential	B-X
in	B-X
order	B-X
to	B-X
accurately	B-X
assess	B-X
the	B-X
level	B-X
of	B-X
expression	B-X
of	B-X
target	B-X
genes	B-X
of	B-X
interest	B-X
.	B-X
Therefore	B-X
,	B-X
in	B-X
this	B-X
study	B-X
,	B-X
we	B-X
attempted	B-X
to	B-X
examine	B-X
six	B-X
commonly	B-X
used	B-X
reference	B-X
genes	B-X
in	B-X
order	B-X
to	B-X
identify	B-X
the	B-X
gene	B-X
being	B-X
expressed	B-X
most	B-X
constantly	B-X
under	B-X
the	B-X
influence	B-X
of	B-X
testosterone	B-X
in	B-X
the	B-X
kidneys	B-X
and	B-X
hypothalamus	B-X
.	B-X
The	B-X
reference	B-X
genes	B-X
include	B-X
glyceraldehyde-3-phosphate	B-X
dehydrogenase	B-X
(	B-X
GAPDH	B-X
)	B-X
,	B-X
actin	B-X
beta	B-X
(	B-X
ACTB	B-X
)	B-X
,	B-X
beta-2	B-X
microglobulin	B-X
(	B-X
B2m	B-X
)	B-X
,	B-X
hypoxanthine	B-X
phosphoribosyltransferase	B-X
1	B-X
(	B-X
HPRT	B-X
)	B-X
,	B-X
peptidylprolylisomerase	B-X
A	B-X
(	B-X
Ppia	B-X
)	B-X
and	B-X
hydroxymethylbilane	B-X
synthase	B-X
(	B-X
Hmbs	B-X
)	B-X
.	B-X
The	B-X
cycle	B-X
threshold	B-X
(	B-X
Ct	B-X
)	B-X
value	B-X
for	B-X
each	B-X
gene	B-X
was	B-X
determined	B-X
and	B-X
data	B-X
obtained	B-X
were	B-X
analyzed	B-X
using	B-X
the	B-X
software	B-X
programs	B-X
NormFinder	B-X
,	B-X
geNorm	B-X
,	B-X
BestKeeper	B-X
,	B-X
and	B-X
rank	B-X
aggregation	B-X
.	B-X
Results	B-X
showed	B-X
that	B-X
Hmbs	B-X
and	B-X
Ppia	B-X
genes	B-X
were	B-X
the	B-X
most	B-X
stably	B-X
expressed	B-X
in	B-X
the	B-X
hypothalamus	B-X
.	B-X
Meanwhile	B-X
,	B-X
in	B-X
kidneys	B-X
,	B-X
Hmbs	B-X
and	B-X
GAPDH	B-X
appeared	B-X
to	B-X
be	B-X
the	B-X
most	B-X
constant	B-X
genes	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
variations	B-X
in	B-X
expression	B-X
levels	B-X
of	B-X
reference	B-X
genes	B-X
occur	B-X
in	B-X
kidneys	B-X
and	B-X
hypothalamus	B-X
under	B-X
similar	B-X
conditions	B-X
;	B-X
thus	B-X
,	B-X
it	B-X
is	B-X
important	B-X
to	B-X
verify	B-X
reference	B-X
gene	B-X
levels	B-X
in	B-X
these	B-X
tissues	B-X
prior	B-X
to	B-X
commencing	B-X
any	B-X
studies	B-X
.	B-X

Relative	O
gene	O
expression	O
was	O
calculated	O
using	O
the	O
2	O
-	O
deltadeltaCt	O
method	O
[	O
56	O
]	O
.	O
<EOS>	B-X
Two	B-X
different	B-X
methods	B-X
of	B-X
presenting	B-X
quantitative	B-X
gene	B-X
expression	B-X
exist	B-X
:	B-X
absolute	B-X
and	B-X
relative	B-X
quantification	B-X
.	B-X
Absolute	B-X
quantification	B-X
calculates	B-X
the	B-X
copy	B-X
number	B-X
of	B-X
the	B-X
gene	B-X
usually	B-X
by	B-X
relating	B-X
the	B-X
PCR	B-X
signal	B-X
to	B-X
a	B-X
standard	B-X
curve	B-X
.	B-X
Relative	B-X
gene	B-X
expression	B-X
presents	B-X
the	B-X
data	B-X
of	B-X
the	B-X
gene	B-X
of	B-X
interest	B-X
relative	B-X
to	B-X
some	B-X
calibrator	B-X
or	B-X
internal	B-X
control	B-X
gene	B-X
.	B-X
A	B-X
widely	B-X
used	B-X
method	B-X
to	B-X
present	B-X
relative	B-X
gene	B-X
expression	B-X
is	B-X
the	B-X
comparative	B-X
C	B-X
(	B-X
T	B-X
)	B-X
method	B-X
also	B-X
referred	B-X
to	B-X
as	B-X
the	B-X
2	B-X
(	B-X
-DeltaDeltaC	B-X
(	B-X
T	B-X
)	B-X
)	B-X
method	B-X
.	B-X
This	B-X
protocol	B-X
provides	B-X
an	B-X
overview	B-X
of	B-X
the	B-X
comparative	B-X
C	B-X
(	B-X
T	B-X
)	B-X
method	B-X
for	B-X
quantitative	B-X
gene	B-X
expression	B-X
studies	B-X
.	B-X
Also	B-X
presented	B-X
here	B-X
are	B-X
various	B-X
examples	B-X
to	B-X
present	B-X
quantitative	B-X
gene	B-X
expression	B-X
data	B-X
using	B-X
this	B-X
method	B-X
.	B-X

In	O
vitro	O
cytokine	O
secretion	O
by	O
BMDC	O
<EOS>	B-X
We	B-X
propose	B-X
that	B-X
beyond	B-X
its	B-X
role	B-X
in	B-X
WNT	B-X
secretion	B-X
,	B-X
WLS/GPR177	B-X
(	B-X
wntless	B-X
,	B-X
WNT	B-X
ligand	B-X
secretion	B-X
mediator	B-X
)	B-X
acts	B-X
as	B-X
an	B-X
essential	B-X
regulator	B-X
controlling	B-X
protein	B-X
glycosylation	B-X
,	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
homeostasis	B-X
,	B-X
and	B-X
dendritic	B-X
cell	B-X
(	B-X
DC	B-X
)	B-X
-mediated	B-X
immunity	B-X
.	B-X
WLS	B-X
deficiency	B-X
in	B-X
bone	B-X
marrow-derived	B-X
DCs	B-X
(	B-X
BMDCs	B-X
)	B-X
resulted	B-X
in	B-X
poor	B-X
growth	B-X
and	B-X
an	B-X
inability	B-X
to	B-X
mount	B-X
cytokine	B-X
and	B-X
T-cell	B-X
responses	B-X
To	B-X
further	B-X
confirm	B-X
this	B-X
finding	B-X
,	B-X
we	B-X
isolated	B-X
exosomes	B-X
from	B-X
bone	B-X
marrow	B-X
dendritic	B-X
cell	B-X
(	B-X
BMDC	B-X
)	B-X
culture	B-X
medium	B-X
(	B-X
named	B-X
DC-exos	B-X
)	B-X
and	B-X
stimulated	B-X
human	B-X
umbilical	B-X
vein	B-X
endothelial	B-X
cell	B-X
(	B-X
HUVEC	B-X
)	B-X
with	B-X
these	B-X
DC-exos	B-X
.	B-X
The	B-X
objective	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
characterize	B-X
the	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
response	B-X
of	B-X
two	B-X
European	B-X
subtype	B-X
1	B-X
strains	B-X
,	B-X
Belgium	B-X
A	B-X
and	B-X
Lelystad-Ter	B-X
Huurne	B-X
(	B-X
LV	B-X
)	B-X
,	B-X
and	B-X
a	B-X
virulent	B-X
subtype	B-X
3	B-X
strain	B-X
,	B-X
Lena	B-X
,	B-X
in	B-X
bone	B-X
marrow-derived	B-X
dendritic	B-X
cells	B-X
(	B-X
BM-DC	B-X
)	B-X
(	B-X
in	B-X
vitro	B-X
)	B-X
and	B-X
alveolar	B-X
macrophages	B-X
(	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
)	B-X
.	B-X
It	B-X
was	B-X
shown	B-X
that	B-X
infection	B-X
with	B-X
the	B-X
Lena	B-X
strain	B-X
resulted	B-X
in	B-X
a	B-X
higher	B-X
apoptosis	B-X
of	B-X
cells	B-X
in	B-X
vitro	B-X
and	B-X
a	B-X
higher	B-X
level	B-X
of	B-X
infectivity	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
than	B-X
the	B-X
other	B-X
virus	B-X
strains	B-X
.	B-X
Furthermore	B-X
,	B-X
infection	B-X
with	B-X
Lena	B-X
resulted	B-X
in	B-X
a	B-X
small	B-X
downregulation	B-X
of	B-X
the	B-X
immunologically	B-X
relevant	B-X
cell	B-X
surface	B-X
molecules	B-X
SLA-I	B-X
,	B-X
SLA-II	B-X
and	B-X
CD80/86	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
SLA-II	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
spite	B-X
of	B-X
these	B-X
differences	B-X
,	B-X
in	B-X
vitro	B-X
cytokine	B-X
responses	B-X
did	B-X
not	B-X
differ	B-X
significantly	B-X
between	B-X
strains	B-X
,	B-X
except	B-X
for	B-X
the	B-X
absence	B-X
of	B-X
IL-10	B-X
production	B-X
by	B-X
Lena	B-X
in	B-X
BM-DC	B-X
.	B-X

The	O
BMDC	O
were	O
cultured	O
in	O
triplicate	O
wells	O
of	O
24	O
-	O
well	O
or	O
96	O
-	O
well	O
plates	O
at	O
106	O
or	O
105	O
cells	O
/	O
mL	O
,	O
respectively	O
,	O
in	O
RPMI	O
-	O
1640	O
complete	O
medium	O
.	O
<EOS>	B-X
Among	B-X
viability	B-X
assays	B-X
that	B-X
depend	B-X
on	B-X
the	B-X
conversion	B-X
of	B-X
substrate	B-X
to	B-X
chromogenic	B-X
product	B-X
by	B-X
live	B-X
cells	B-X
,	B-X
the	B-X
MTT	B-X
assay	B-X
is	B-X
still	B-X
among	B-X
one	B-X
of	B-X
the	B-X
most	B-X
versatile	B-X
and	B-X
popular	B-X
assays	B-X
.	B-X
Anti-CPV-2	B-X
antibodies	B-X
were	B-X
immobilized	B-X
on	B-X
96-well	B-X
plates	B-X
to	B-X
capture	B-X
CPV-2-Ag	B-X
,	B-X
and	B-X
then	B-X
bound	B-X
together	B-X
with	B-X
the	B-X
detection	B-X
antibodies	B-X
labeled	B-X
with	B-X
Europium	B-X
(	B-X
III	B-X
)	B-X
(	B-X
Eu	B-X
The	B-X
screening	B-X
method	B-X
was	B-X
based	B-X
on	B-X
the	B-X
measurement	B-X
of	B-X
growth	B-X
in	B-X
acrolein-supplemented	B-X
medium	B-X
,	B-X
in	B-X
96-well	B-X
microtiter	B-X
plate	B-X
cultures	B-X
.	B-X
Skin	B-X
specimens	B-X
were	B-X
obtained	B-X
following	B-X
blepharoplasty	B-X
,	B-X
and	B-X
the	B-X
melanocytes	B-X
were	B-X
primary	B-X
cultured	B-X
and	B-X
passaged	B-X
to	B-X
the	B-X
third	B-X
generation	B-X
.	B-X
The	B-X
melanocytes	B-X
were	B-X
seeded	B-X
in	B-X
96-well	B-X
plates	B-X
,	B-X
each	B-X
well	B-X
had	B-X
5×10	B-X

The	O
cells	O
were	O
washed	O
and	O
stimulated	O
with	O
100	O
ng	O
/	O
mL	O
LPS	O
or	O
25	O
microg	O
/	O
mL	O
poly	O
I	O
:	O
C	O
.	O
<EOS>	B-X
RT-PCR	B-X
analyses	B-X
showed	B-X
that	B-X
both	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
and	B-X
interferon	B-X
containing	B-X
supernatants	B-X
induced	B-X
expression	B-X
of	B-X
Mx1	B-X
in	B-X
RTG	B-X
cells	B-X
.	B-X
Kinetic	B-X
analyses	B-X
suggest	B-X
that	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
acts	B-X
indirectly	B-X
through	B-X
the	B-X
production	B-X
of	B-X
interferons	B-X
(	B-X
IFN	B-X
)	B-X
,	B-X
as	B-X
shown	B-X
in	B-X
other	B-X
studies	B-X
.	B-X
By	B-X
gene	B-X
walking	B-X
with	B-X
trout	B-X
genomic	B-X
DNA	B-X
the	B-X
regulatory	B-X
sequence	B-X
of	B-X
the	B-X
Mx1	B-X
gene	B-X
was	B-X
cloned	B-X
and	B-X
sequenced	B-X
.	B-X
Sequence	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
5	B-X
'	B-X
flanking	B-X
region	B-X
has	B-X
a	B-X
structure	B-X
,	B-X
which	B-X
is	B-X
typical	B-X
for	B-X
an	B-X
interferon-induced	B-X
gene	B-X
promoter	B-X
.	B-X
Relative	B-X
to	B-X
the	B-X
transcription	B-X
start	B-X
,	B-X
it	B-X
has	B-X
a	B-X
TATA	B-X
box	B-X
at	B-X
-29	B-X
to	B-X
-25	B-X
,	B-X
a	B-X
13	B-X
nucleotide	B-X
interferon	B-X
response	B-X
element	B-X
(	B-X
ISRE	B-X
)	B-X
between	B-X
-101	B-X
to	B-X
-89	B-X
,	B-X
and	B-X
a	B-X
Sp1	B-X
binding	B-X
site	B-X
at	B-X
-382	B-X
to	B-X
-374	B-X
.	B-X
This	B-X
region	B-X
,	B-X
with	B-X
a	B-X
single	B-X
ISRE	B-X
,	B-X
is	B-X
enough	B-X
to	B-X
induce	B-X
strong	B-X
expression	B-X
of	B-X
a	B-X
luciferase	B-X
reporter	B-X
gene	B-X
after	B-X
stimulation	B-X
of	B-X
RTG	B-X
cells	B-X
with	B-X
poly	B-X
I	B-X
:	B-X
C.	B-X
A	B-X
time-course	B-X
of	B-X
induction	B-X
of	B-X
this	B-X
reporter	B-X
construct	B-X
showed	B-X
maximal	B-X
expression	B-X
(	B-X
22-fold	B-X
increase	B-X
)	B-X
after	B-X
incubation	B-X
with	B-X
100	B-X
microg	B-X
mL	B-X
(	B-X
-1	B-X
)	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
for	B-X
48	B-X
h.	B-X
An	B-X
optimized	B-X
method	B-X
of	B-X
transient	B-X
transfection	B-X
of	B-X
RTG	B-X
cells	B-X
is	B-X
also	B-X
described	B-X
.	B-X

After	O
24	O
hours	O
,	O
supernatants	O
were	O
harvested	O
for	O
ELISA	O
analysis	O
.	O
<EOS>	B-X
To	B-X
assess	B-X
the	B-X
cytokines	B-X
,	B-X
supernatants	B-X
of	B-X
cell	B-X
cultures	B-X
were	B-X
harvested	B-X
after	B-X
12	B-X
,	B-X
24	B-X
and	B-X
48	B-X
hours	B-X
.	B-X
Cytokine	B-X
production	B-X
was	B-X
evaluated	B-X
by	B-X
ELISA	B-X
.	B-X

The	O
presence	O
of	O
nitrite	O
in	O
the	O
supernatants	O
was	O
determined	O
using	O
the	O
Griess	O
reagent	O
.	O
<EOS>	B-X
Cell	B-X
supernatants	B-X
were	B-X
tested	B-X
for	B-X
nitric	B-X
oxide	B-X
using	B-X
the	B-X
Griess	B-X
reagent	B-X
system	B-X
.	B-X
Nitric	B-X
oxide	B-X
was	B-X
detected	B-X
in	B-X
extract-treated	B-X
cell	B-X
supernatants	B-X
and	B-X
also	B-X
in	B-X
the	B-X
extracts	B-X
only	B-X
,	B-X
suggesting	B-X
presence	B-X
of	B-X
nitrite	B-X
in	B-X
the	B-X
soluble	B-X
content	B-X
of	B-X
the	B-X
tested	B-X
materials	B-X
.	B-X
Leprosy	B-X
is	B-X
characterized	B-X
by	B-X
a	B-X
disease	B-X
spectrum	B-X
having	B-X
two	B-X
polar	B-X
clinical	B-X
forms	B-X
dependent	B-X
on	B-X
the	B-X
presence	B-X
or	B-X
not	B-X
of	B-X
cell-mediated	B-X
immunity	B-X
.	B-X

Immunofluorescence	O
<EOS>	B-X
Immunofluorescence	B-X
(	B-X
IF	B-X
)	B-X
is	B-X
an	B-X
important	B-X
immunochemical	B-X
technique	B-X
that	B-X
allows	B-X
for	B-X
detection	B-X
and	B-X
localization	B-X
of	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
antigens	B-X
in	B-X
different	B-X
types	B-X
of	B-X
tissues	B-X
of	B-X
various	B-X
cell	B-X
preparations	B-X
.	B-X
Immunofluorescence	B-X
techniques	B-X
.	B-X
Immunofluorescence	B-X
(	B-X
IF	B-X
)	B-X
studies	B-X
have	B-X
now	B-X
become	B-X
an	B-X
invaluable	B-X
supplement	B-X
to	B-X
clinical	B-X
and	B-X
histological	B-X
examination	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
dermatological	B-X
diseases	B-X
.	B-X
Immunofluorescence	B-X
(	B-X
IF	B-X
)	B-X
on	B-X
tissue	B-X
sections	B-X
allows	B-X
for	B-X
the	B-X
detection	B-X
of	B-X
protein	B-X
species	B-X
subcellular	B-X
localization	B-X
.	B-X

Fibroblast	O
and	O
macrophage	O
cells	O
were	O
transfected	O
with	O
pFLAG	O
-	O
SHARPIN	B-Protein
.	O

48	O
hours	O
later	O
,	O
cells	O
were	O
washed	O
briefly	O
with	O
PBS	O
,	O
then	O
fixed	O
in	O
cold	O
methanol	O
at	O
-	O
20degreesC	O
for	O
10	O
minutes	O
and	O
cold	O
acetone	O
at	O
-	O
20degreesC	O
for	O
1	O
minute	O
.	O

Incubate	O
cells	O
with	O
PBS	O
+	O
1	O
%	O
BSA	O
for	O
15	O
minutes	O
to	O
block	O
non	O
-	O
specific	O
binding	O
.	O

Fixed	O
cells	O
were	O
then	O
incubated	O
with	O
anti	O
-	O
FLAG	O
(	O
1	O
:	O
100	O
)	O
as	O
the	O
primary	O
antibody	O
at	O
room	O
temperature	O
for	O
1	O
hour	O
,	O
followed	O
by	O
three	O
5	O
-	O
minute	O
washes	O
.	O

Cells	O
were	O
further	O
incubated	O
with	O
goat	O
anti	O
-	O
rabbit	O
IgG	O
-	O
FITC	O
(	O
1	O
:	O
100	O
)	O
as	O
the	O
secondary	O
antibody	O
at	O
room	O
temperature	O
for	O
30	O
minutes	O
,	O
followed	O
by	O
three	O
5	O
-	O
minute	O
washes	O
.	O

Cells	O
were	O
then	O
examined	O
using	O
inverse	O
fluorescence	O
microscope	O
.	O
<EOS>	B-X
We	B-X
combine	B-X
QLIPP	B-X
with	B-X
deep	B-X
neural	B-X
networks	B-X
to	B-X
predict	B-X
fluorescence	B-X
images	B-X
of	B-X
diverse	B-X
cell	B-X
and	B-X
tissue	B-X
structures	B-X
.	B-X
QLIPP	B-X
images	B-X
reveal	B-X
anatomical	B-X
regions	B-X
and	B-X
axon	B-X
tract	B-X
orientation	B-X
in	B-X
prenatal	B-X
human	B-X
brain	B-X
tissue	B-X
sections	B-X
that	B-X
are	B-X
not	B-X
visible	B-X
using	B-X
brightfield	B-X
imaging	B-X
.	B-X
We	B-X
report	B-X
a	B-X
variant	B-X
of	B-X
U-Net	B-X
architecture	B-X
,	B-X
multi-channel	B-X
2.5D	B-X
U-Net	B-X
,	B-X
for	B-X
computationally	B-X
efficient	B-X
prediction	B-X
of	B-X
fluorescence	B-X
images	B-X
in	B-X
three	B-X
dimensions	B-X
and	B-X
over	B-X
large	B-X
fields	B-X
of	B-X
view	B-X
.	B-X
The	B-X
KYSE-30	B-X
ESCC	B-X
cells	B-X
were	B-X
transduced	B-X
with	B-X
produced	B-X
viral	B-X
particles	B-X
and	B-X
examined	B-X
with	B-X
inverted	B-X
fluorescence	B-X
microscope	B-X
.	B-X

Immunoblots	O
<EOS>	B-X
Instantaneous	B-X
blocking	B-X
for	B-X
immunoblots	B-X
.	B-X

After	O
adding	O
stimulating	O
ligands	O
,	O
100	O
ng	O
/	O
mL	O
LPS	O
or	O
25	O
microg	O
/	O
mL	O
poly	O
I	O
:	O
C	O
,	O
BMDC	O
were	O
collected	O
and	O
lysed	O
at	O
0	O
-	O
,	O
15	O
-	O
,	O
30	O
-	O
,	O
and	O
60	O
-	O
minute	O
time	O
points	O
.	O

Immunoblots	O
were	O
performed	O
with	O
antibodies	O
(	O
Cell	O
Signaling	O
Technology	O
)	O
against	O
p	O
-	O
IKK1	B-Protein
/	O
2	B-Protein
(	O
#	O
2697	O
)	O
,	O
p	O
-	O
IkappaBalpha	B-Protein
(	O
#	O
9246	O
)	O
,	O
IkappaBalpha	B-Protein
(	O
#	O
4814	O
)	O
,	O
p	O
-	O
TBK1	B-Protein
(	O
#	O
5483	O
)	O
,	O
p	O
-	O
p38	O
(	O
#	O
9216	O
)	O
,	O
p38	O
(	O
#	O
9212	O
)	O
,	O
p	O
-	O
ERK1	B-Protein
/	O
2	B-Protein
(	O
#	O
4376	O
)	O
,	O
and	O
ERK1	B-Protein
/	O
2	B-Protein
(	O
#	O
4695	O
)	O
.	O

Beta	B-Protein
-	I-Protein
actin	I-Protein
(	O
sc	O
-	O
47778	O
,	O
Santa	O
Cruz	O
Biotechnology	O
)	O
was	O
used	O
as	O
loading	O
control	O
.	O

Statistical	O
analysis	O

Data	O
are	O
expressed	O
as	O
mean	O
+	O
/	O
-	O
SD	O
.	O
<EOS>	B-X
The	B-X
ΔΔct	B-X
estimate	B-X
aggregates	B-X
replicates	B-X
using	B-X
mean	B-X
and	B-X
standard	B-X
deviation	B-X
(	B-X
sd	B-X
)	B-X
and	B-X
is	B-X
not	B-X
robust	B-X
to	B-X
outliers	B-X
which	B-X
are	B-X
in	B-X
practice	B-X
often	B-X
removed	B-X
before	B-X
the	B-X
non-outlying	B-X
replicates	B-X
are	B-X
aggregated	B-X
.	B-X
we	B-X
extracted	B-X
mean	B-X
±	B-X
SD	B-X
or	B-X
fold	B-X
change	B-X
of	B-X
miRNAs	B-X
expression	B-X
levels	B-X
in	B-X
PC	B-X
versus	B-X
BPH	B-X
or	B-X
normal	B-X
controls	B-X
.	B-X
There	B-X
are	B-X
no	B-X
general	B-X
recommendations	B-X
on	B-X
how	B-X
changes	B-X
in	B-X
outcome	B-X
measure	B-X
(	B-X
effect	B-X
size	B-X
)	B-X
should	B-X
be	B-X
expressed	B-X
.	B-X
We	B-X
therefore	B-X
used	B-X
data	B-X
from	B-X
a	B-X
recently	B-X
published	B-X
study	B-X
to	B-X
express	B-X
change	B-X
as	B-X
:	B-X
a	B-X
)	B-X
the	B-X
mean	B-X
of	B-X
the	B-X
change	B-X
from	B-X
baseline	B-X
divided	B-X
by	B-X
the	B-X
individual	B-X
baseline	B-X
,	B-X
b	B-X
)	B-X
the	B-X
median	B-X
of	B-X
the	B-X
change	B-X
from	B-X
baseline	B-X
divided	B-X
by	B-X
the	B-X
individual	B-X
baseline	B-X
,	B-X
c	B-X
)	B-X
the	B-X
mean	B-X
of	B-X
the	B-X
change	B-X
from	B-X
baseline	B-X
divided	B-X
by	B-X
the	B-X
SD	B-X
of	B-X
baseline	B-X
and	B-X
d	B-X
)	B-X
the	B-X
median	B-X
of	B-X
change	B-X
from	B-X
baseline	B-X
divided	B-X
by	B-X
the	B-X
SD	B-X
of	B-X
baseline	B-X
.	B-X
The	B-X
results	B-X
show	B-X
that	B-X
the	B-X
correlations	B-X
between	B-X
different	B-X
ways	B-X
of	B-X
expressing	B-X
effect	B-X
sizes	B-X
were	B-X
poor	B-X
and	B-X
the	B-X
perceived	B-X
relative	B-X
magnitudes	B-X
of	B-X
various	B-X
effects	B-X
depended	B-X
on	B-X
how	B-X
they	B-X
were	B-X
expressed	B-X
.	B-X
Organisations	B-X
aiming	B-X
at	B-X
consensus	B-X
ought	B-X
to	B-X
recommend	B-X
the	B-X
way	B-X
in	B-X
which	B-X
change	B-X
ought	B-X
to	B-X
be	B-X
expressed	B-X
.	B-X

The	O
statistical	O
significance	O
of	O
differences	O
of	O
means	O
between	O
experimental	O
groups	O
was	O
determined	O
by	O
Students	O
'	O
t	O
-	O
test	O
.	O
<EOS>	B-X
Subjects	B-X
were	B-X
divided	B-X
into	B-X
five	B-X
groups	B-X
:	B-X
group	B-X
1	B-X
,	B-X
aphakic	B-X
without	B-X
contact	B-X
lens	B-X
;	B-X
group	B-X
2	B-X
,	B-X
phakic	B-X
with	B-X
daily-wear	B-X
hard	B-X
contact	B-X
lens	B-X
;	B-X
group	B-X
3	B-X
,	B-X
phakic	B-X
with	B-X
daily-wear	B-X
soft	B-X
contact	B-X
lens	B-X
;	B-X
group	B-X
4	B-X
,	B-X
phakic	B-X
with	B-X
extended-wear	B-X
soft	B-X
contact	B-X
lens	B-X
;	B-X
and	B-X
group	B-X
5	B-X
,	B-X
aphakic	B-X
with	B-X
extended-wear	B-X
soft	B-X
contact	B-X
lens	B-X
.	B-X
The	B-X
experimental	B-X
groups	B-X
were	B-X
compared	B-X
with	B-X
age-	B-X
and	B-X
sex-matched	B-X
control	B-X
groups	B-X
for	B-X
statistical	B-X
analysis	B-X
of	B-X
tear	B-X
variables	B-X
by	B-X
means	B-X
of	B-X
the	B-X
Student	B-X
's	B-X
t-test	B-X
.	B-X
Less	B-X
significant	B-X
differences	B-X
in	B-X
tear	B-X
osmolarity	B-X
were	B-X
found	B-X
in	B-X
phakic	B-X
subjects	B-X
with	B-X
hard	B-X
daily-wear	B-X
lenses	B-X
or	B-X
with	B-X
extended-wear	B-X
soft	B-X
lenses	B-X
.	B-X
Tear	B-X
albumin	B-X
,	B-X
lysozyme	B-X
,	B-X
and	B-X
lactoferrin	B-X
in	B-X
basal	B-X
and	B-X
reflex	B-X
tears	B-X
were	B-X
not	B-X
significantly	B-X
different	B-X
in	B-X
the	B-X
different	B-X
groups	B-X
of	B-X
contact	B-X
lens	B-X
wearers	B-X
or	B-X
in	B-X
the	B-X
group	B-X
of	B-X
aphakic	B-X
subjects	B-X
without	B-X
contact	B-X
lenses	B-X
compared	B-X
with	B-X
their	B-X
control	B-X
groups	B-X
.	B-X
Individual	B-X
variations	B-X
in	B-X
tear	B-X
albumin	B-X
,	B-X
lysozyme	B-X
,	B-X
and	B-X
lactoferrin	B-X
appeared	B-X
to	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
inability	B-X
to	B-X
demonstrate	B-X
significant	B-X
differences	B-X
in	B-X
tear	B-X
composition	B-X
in	B-X
association	B-X
with	B-X
the	B-X
wearing	B-X
of	B-X
different	B-X
types	B-X
of	B-X
contact	B-X
lenses	B-X
.	B-X

In	O
vivo	O
and	O
in	O
vitro	O
features	O
of	O
SHARPIN	B-Protein
.	O
<EOS>	B-X
SHARPIN	B-X
is	B-X
an	B-X
important	B-X
component	B-X
of	B-X
the	B-X
linear	B-X
ubiquitin	B-X
chain	B-X
assembly	B-X
complex	B-X
(	B-X
LUBAC	B-X
)	B-X
.	B-X
Loss	B-X
of	B-X
function	B-X
of	B-X
SHARPIN	B-X
results	B-X
in	B-X
eosinophilic	B-X
inflammation	B-X
in	B-X
multiple	B-X
organs	B-X
including	B-X
skin	B-X
with	B-X
Th	B-X

(	O
A	O
)	O
COILS	O
and	O
MotifScan	O
programs	O
were	O
used	O
to	O
predict	O
the	O
presence	O
of	O
CC	O
(	O
coiled	O
-	O
coil	O
)	O
domain	O
,	O
UBL	O
(	O
ubiquitin	O
-	O
like	O
)	O
domain	O
and	O
ZFRBP	O
(	O
zinc	O
-	O
finger	O
Ran	O
-	O
Binding	O
protein	O
2	O
)	O
domain	O
which	O
form	O
similar	O
motif	O
patterns	O
in	O
the	O
SHARPIN	B-Protein
protein	O
of	O
human	O
,	O
mouse	O
and	O
rat	O
origins	O
.	O

(	O
B	O
)	O
Eight	O
week	O
-	O
old	O
females	O
of	O
WT	O
and	O
cpdm	O
mice	O
.	O

The	O
mutant	O
mice	O
(	O
above	O
)	O
develop	O
progressive	O
skin	O
inflammation	O
starting	O
at	O
about	O
four	O
weeks	O
.	O

(	O
C	O
)	O
Extramedullary	O
hematopoiesis	O
causes	O
marked	O
enlargement	O
of	O
the	O
spleen	O
of	O
cpdm	O
mice	O
.	O

(	O
D	O
)	O
BMDC	O
were	O
incubated	O
in	O
the	O
absence	O
or	O
presence	O
of	O
100	O
ng	O
/	O
ml	O
LPS	O
for	O
4	O
hours	O
.	O

The	O
mRNA	O
level	O
of	O
Sharpin	B-Protein
was	O
measured	O
by	O
qRT	O
-	O
PCR	O
and	O
presented	O
relative	O
to	O
the	O
mRNA	O
expression	O
in	O
non	O
-	O
stimulated	O
WT	O
BMDC	O
.	O

Bars	O
represent	O
the	O
mean	O
+	O
/	O
-	O
s	O
.	O
d	O
.	O
of	O
3	O
mice	O
.	O

*	O
P	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
P	O
<	O
0	O
.	O
001	O
.	O
<EOS>	B-X
The	B-X
NAb	B-X
response	B-X
was	B-X
also	B-X
assessed	B-X
in	B-X
90	B-X
individuals	B-X
who	B-X
had	B-X
received	B-X
the	B-X
complete	B-X
dose	B-X
regimen	B-X
of	B-X
BNT162b2	B-X
.	B-X
The	B-X
effectiveness	B-X
of	B-X
messenger	B-X
RNA	B-X
coronavirus	B-X
disease	B-X
2019	B-X
(	B-X
COVID-19	B-X
)	B-X
vaccines	B-X
in	B-X
patients	B-X
with	B-X
atopic	B-X
dermatitis	B-X
(	B-X
AD	B-X
)	B-X
is	B-X
yet	B-X
to	B-X
be	B-X
delineated	B-X
.	B-X
Estimated	B-X
background	B-X
rate	B-X
of	B-X
CVST	B-X
with	B-X
thrombocytopenia	B-X
is	B-X
0.1	B-X
per	B-X
million	B-X
per	B-X
month	B-X
.	B-X
However	B-X
,	B-X
there	B-X
are	B-X
concerns	B-X
about	B-X
dampened	B-X
immune	B-X
responses	B-X
to	B-X
COVID-19	B-X
vaccination	B-X
among	B-X
immunocompromised	B-X
patients	B-X
,	B-X
including	B-X
people	B-X
living	B-X
with	B-X
HIV	B-X
(	B-X
PLWH	B-X
)	B-X
,	B-X
which	B-X
may	B-X
blunt	B-X
the	B-X
vaccine	B-X
's	B-X
efficacy	B-X
and	B-X
durability	B-X
of	B-X
protection	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
assess	B-X
the	B-X
qualitative	B-X
SARS-CoV-2	B-X
vaccine	B-X
immunogenicity	B-X
among	B-X
PLWH	B-X
after	B-X
vaccination	B-X
.	B-X

(	O
E	O
)	O
Fibroblast	O
(	O
NIH3T3	O
)	O
and	O
macrophages	O
(	O
RAW264	O
.	O
7	O
)	O
cells	O
were	O
transfected	O
with	O
the	O
expression	O
plasmid	O
pFLAG	O
-	O
SHARPIN	B-Protein
.	O

After	O
48	O
hours	O
,	O
cells	O
were	O
fixed	O
and	O
probed	O
with	O
anti	O
-	O
FLAG	O
and	O
FITC	O
-	O
conjugated	O
secondary	O
antibody	O
.	O

Nuclei	O
were	O
stained	O
with	O
DAPI	O
.	O
<EOS>	B-X
Dyes	B-X
that	B-X
bind	B-X
to	B-X
DNA	B-X
,	B-X
such	B-X
as	B-X
Hoechst	B-X
33342	B-X
or	B-X
4',6-diamidino-2-phenylindole	B-X
(	B-X
DAPI	B-X
)	B-X
,	B-X
can	B-X
be	B-X
used	B-X
to	B-X
observe	B-X
nuclear	B-X
condensation	B-X
.	B-X
This	B-X
protocol	B-X
describes	B-X
staining	B-X
and	B-X
visualization	B-X
of	B-X
cells	B-X
stained	B-X
with	B-X
Hoechst	B-X
33342	B-X
,	B-X
but	B-X
it	B-X
can	B-X
be	B-X
adapted	B-X
for	B-X
staining	B-X
with	B-X
DAPI	B-X
or	B-X
other	B-X
dyes	B-X
.	B-X
Then	B-X
,	B-X
the	B-X
slides	B-X
were	B-X
sequentially	B-X
stained	B-X
with	B-X
DAPI	B-X
(	B-X
4',6-diamidino-2-phenylindole	B-X
)	B-X
and/or	B-X
the	B-X
Diff-Quik	B-X
reagent	B-X
,	B-X
and	B-X
the	B-X
percentages	B-X
of	B-X
sperm	B-X
with	B-X
nondispersed	B-X
and	B-X
dispersed	B-X
chromatin	B-X
loops	B-X
were	B-X
monitored	B-X
by	B-X
fluorescence	B-X
and	B-X
brightfield	B-X
microscopy	B-X
,	B-X
respectively	B-X
.	B-X
This	B-X
study	B-X
revealed	B-X
a	B-X
new	B-X
,	B-X
simple	B-X
,	B-X
and	B-X
fast	B-X
diagnostic	B-X
tool	B-X
to	B-X
detect	B-X
pathological	B-X
cells	B-X
by	B-X
measuring	B-X
and	B-X
imaging	B-X
the	B-X
fluorescence	B-X
lifetime	B-X
(	B-X
FLT	B-X
)	B-X
using	B-X
FLT	B-X
imaging	B-X
microscopy	B-X
(	B-X
FLIM	B-X
)	B-X
of	B-X
the	B-X
peripheral	B-X
blood	B-X
(	B-X
PB	B-X
)	B-X
cells	B-X
of	B-X
B-CLL	B-X
samples	B-X
that	B-X
were	B-X
labeled	B-X
with	B-X
the	B-X
DNA	B-X
binder	B-X
,	B-X
DAPI	B-X
.	B-X
The	B-X
FLT	B-X
of	B-X
DAPI	B-X
in	B-X
healthy	B-X
individuals	B-X
was	B-X
found	B-X
to	B-X
be	B-X
2.66	B-X
±	B-X
0.12	B-X
ns	B-X
.	B-X
The	B-X
FLT	B-X
of	B-X
DAPI	B-X
was	B-X
divided	B-X
into	B-X
four	B-X
subgroups	B-X
,	B-X
relative	B-X
to	B-X
2.66	B-X
ns	B-X
:	B-X
short+	B-X
,	B-X
normal	B-X
,	B-X
prolonged	B-X
,	B-X
and	B-X
prolonged+	B-X
.	B-X
Notably	B-X
,	B-X
extremely	B-X
long	B-X
FLT	B-X
of	B-X
nuclear	B-X
DAPI	B-X
correlate	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
extra	B-X
chromosome	B-X
12	B-X
,	B-X
while	B-X
moderate	B-X
increases	B-X
compared	B-X
to	B-X
normal	B-X
characterize	B-X
the	B-X
deletion	B-X
of	B-X
p53	B-X
.	B-X

In	O
both	O
transfected	O
cell	O
lines	O
,	O
FLAG	O
-	O
SHARPIN	B-Protein
was	O
found	O
to	O
be	O
cytoplasm	O
-	O
localized	O
.	O

Effect	O
of	O
Sharpin	B-Protein
mutation	O
on	O
DC	O
subpopulations	O
and	O
maturation	O
.	O

(	O
A	O
)	O
Spleens	O
from	O
WT	O
and	O
cpdm	O
mice	O
were	O
isolated	O
and	O
subject	O
to	O
collagenase	O
and	O
DNase	O
digestion	O
.	O

The	O
obtained	O
splenic	O
homogenates	O
were	O
centrifuged	O
over	O
a	O
Percoll	O
gradient	O
(	O
35	O
%	O
and	O
55	O
%	O
density	O
)	O
for	O
15	O
minutes	O
.	O

The	O
bands	O
at	O
the	O
35	O
%	O
-	O
medium	O
and	O
the	O
35	O
-	O
55	O
%	O
interface	O
were	O
pooled	O
,	O
washed	O
and	O
stained	O
with	O
a	O
combination	O
of	O
various	O
antibodies	O
to	O
stain	O
different	O
DC	O
subsets	O
,	O
conventional	O
CD11c	O
+	O
CD8alpha	O
+	O
,	O
CD11c	O
+	O
CD8alpha	O
-	O
and	O
plasmacytoid	O
DC	O
(	O
CD11c	O
-	O
PDCA	O
-	O
1	O
+	O
)	O
.	O
The	O
top	O
panels	O
were	O
gated	O
on	O
FSChiSSClo	O
cells	O
to	O
show	O
separate	O
populations	O
of	O
CD11c	O
+	O
PDCA	O
-	O
1	O
-	O
and	O
CD11c	O
-	O
PDCA	O
-	O
1	O
+	O
cells	O
.	O

Further	O
gating	O
on	O
the	O
CD11c	O
+	O
PDCA	O
-	O
1	O
-	O
subpopulation	O
gave	O
the	O
bottom	O
panel	O
that	O
showed	O
two	O
distinct	O
pools	O
of	O
CD11c	O
+	O
CD8alpha	O
+	O
and	O
CD11c	O
+	O
CD8alpha	O
-	O
cells	O
.	O

Percentages	O
were	O
calculated	O
based	O
on	O
the	O
parental	O
population	O
and	O
were	O
additionally	O
shown	O
as	O
bar	O
graphs	O
(	O
n	O
=	O
2	O
)	O
(	O
B	O
)	O
.	O

(	O
C	O
)	O
WT	O
and	O
cpdm	O
BMDC	O
(	O
5x105	O
)	O
cells	O
were	O
stimulated	O
with	O
medium	O
,	O
100	O
ng	O
/	O
ml	O
LPS	O
or	O
25	O
microg	O
/	O
ml	O
poly	O
I	O
:	O
C	O
for	O
24	O
hours	O
.	O

The	O
cells	O
were	O
labeled	O
with	O
PE	O
-	O
labeled	O
anti	O
-	O
CD40	O
,	O
anti	O
-	O
CD80	O
,	O
and	O
anti	O
-	O
CD86	O
,	O
and	O
subjected	O
to	O
flow	O
cytometry	O
analysis	O
.	O

The	O
populations	O
shown	O
in	O
histograms	O
were	O
gated	O
on	O
CD11c	O
+	O
cells	O
.	O

Unstained	O
cells	O
served	O
as	O
negative	O
controls	O
.	O

Results	O
are	O
representative	O
of	O
two	O
independent	O
experiments	O
.	O
<EOS>	B-X
It	B-X
turns	B-X
out	B-X
that	B-X
this	B-X
approach	B-X
can	B-X
unmix	B-X
an	B-X
unknown	B-X
number	B-X
of	B-X
independent	B-X
data	B-X
sources	B-X
by	B-X
extracting	B-X
a	B-X
minimal	B-X
number	B-X
of	B-X
low-complexity	B-X
features	B-X
necessary	B-X
for	B-X
representing	B-X
the	B-X
data	B-X
.	B-X
Although	B-X
LOCOCODE	B-X
is	B-X
not	B-X
explicitly	B-X
designed	B-X
to	B-X
enforce	B-X
sparse	B-X
or	B-X
factorial	B-X
codes	B-X
,	B-X
it	B-X
extracts	B-X
optimal	B-X
codes	B-X
for	B-X
difficult	B-X
versions	B-X
of	B-X
the	B-X
``	B-X
bars	B-X
''	B-X
benchmark	B-X
problem	B-X
,	B-X
whereas	B-X
independent	B-X
component	B-X
analysis	B-X
(	B-X
ICA	B-X
)	B-X
and	B-X
principal	B-X
component	B-X
analysis	B-X
(	B-X
PCA	B-X
)	B-X
do	B-X
not	B-X
.	B-X
Unlike	B-X
ICA	B-X
,	B-X
it	B-X
does	B-X
not	B-X
need	B-X
to	B-X
know	B-X
the	B-X
number	B-X
of	B-X
independent	B-X
sources	B-X
.	B-X
Our	B-X
results	B-X
reveal	B-X
an	B-X
interesting	B-X
,	B-X
previously	B-X
ignored	B-X
connection	B-X
between	B-X
two	B-X
important	B-X
fields	B-X
:	B-X
regularizer	B-X
research	B-X
and	B-X
ICA-related	B-X
research	B-X
.	B-X

Defective	O
production	O
of	O
pro	O
-	O
inflammatory	O
mediators	O
from	O
stimulated	O
cpdm	O
BMDC	O
.	O

(	O
A	O
-	O
D	O
)	O
Cultured	O
WT	O
and	O
cpdm	O
BMDC	O
(	O
1x105	O
cells	O
in	O
0	O
.	O
1	O
ml	O
complete	O
medium	O
)	O
were	O
washed	O
and	O
stimulated	O
with	O
medium	O
,	O
100	O
ng	O
/	O
ml	O
LPS	O
or	O
25	O
microg	O
/	O
ml	O
poly	O
I	O
:	O
C	O
for	O
24	O
hours	O
.	O

Supernatants	O
were	O
collected	O
for	O
ELISA	O
of	O
IL12P70	O
,	O
IL6	B-Protein
,	O
and	O
GMCSF	B-Protein
,	O
and	O
for	O
quantification	O
of	O
nitric	O
oxide	O
(	O
NO	O
)	O
.	O

(	O
E	O
-	O
F	O
)	O
Gradient	O
numbers	O
(	O
1x104	O
,	O
2x104	O
,	O
and	O
4x104	O
cells	O
in	O
0	O
.	O
1	O
mL	O
complete	O
medium	O
)	O
of	O
BMDC	O
were	O
used	O
for100	O
ng	O
/	O
mL	O
LPS	O
stimulation	O
.	O

After	O
24	O
hours	O
,	O
the	O
amounts	O
of	O
IL12P70	O
and	O
IL6	B-Protein
from	O
the	O
supernatant	O
were	O
measured	O
.	O

(	O
G	O
)	O
The	O
cpdm	O
mice	O
rescued	O
by	O
Sharpin	B-Protein
-	O
containing	O
BAC	O
had	O
complete	O
remission	O
of	O
the	O
inflammatory	O
phenotype	O
[	O
2	O
]	O
.	O

BMDC	O
developed	O
from	O
cpdm	O
and	O
rescued	O
cpdm	O
mice	O
were	O
plated	O
(	O
1x106	O
cells	O
in	O
0	O
.	O
3	O
mL	O
)	O
and	O
stimulated	O
with	O
100	O
ng	O
/	O
mL	O
LPS	O
.	O

After	O
24	O
hours	O
,	O
supernatants	O
were	O
collected	O
for	O
analysis	O
of	O
IL12P70	O
production	O
.	O

Data	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O
<EOS>	B-X
We	B-X
performed	B-X
a	B-X
meta-analysis	B-X
of	B-X
gene	B-X
expression	B-X
profiles	B-X
in	B-X
data	B-X
sets	B-X
from	B-X
eight	B-X
independent	B-X
patient	B-X
cohorts	B-X
across	B-X
the	B-X
world	B-X
.	B-X
We	B-X
observed	B-X
three	B-X
robust	B-X
HCC	B-X
subclasses	B-X
(	B-X
termed	B-X
S1	B-X
,	B-X
S2	B-X
,	B-X
and	B-X
S3	B-X
)	B-X
,	B-X
each	B-X
correlated	B-X
with	B-X
clinical	B-X
parameters	B-X
such	B-X
as	B-X
tumor	B-X
size	B-X
,	B-X
extent	B-X
of	B-X
cellular	B-X
differentiation	B-X
,	B-X
and	B-X
serum	B-X
alpha-fetoprotein	B-X
levels	B-X
.	B-X
These	B-X
experiments	B-X
establish	B-X
the	B-X
first	B-X
consensus	B-X
classification	B-X
framework	B-X
for	B-X
HCC	B-X
based	B-X
on	B-X
gene	B-X
expression	B-X
profiles	B-X
and	B-X
highlight	B-X
the	B-X
power	B-X
of	B-X
integrating	B-X
multiple	B-X
data	B-X
sets	B-X
to	B-X
define	B-X
a	B-X
robust	B-X
molecular	B-X
taxonomy	B-X
of	B-X
the	B-X
disease	B-X
.	B-X
In	B-X
model-based	B-X
medical	B-X
image	B-X
analysis	B-X
,	B-X
three	B-X
relevant	B-X
features	B-X
are	B-X
the	B-X
shape	B-X
of	B-X
structures	B-X
of	B-X
interest	B-X
,	B-X
their	B-X
relative	B-X
pose	B-X
,	B-X
and	B-X
image	B-X
intensity	B-X
profiles	B-X
representative	B-X
of	B-X
some	B-X
physical	B-X
properties	B-X
.	B-X
However	B-X
,	B-X
analysing	B-X
articulated	B-X
objects	B-X
in	B-X
an	B-X
image	B-X
using	B-X
independent	B-X
single	B-X
object	B-X
models	B-X
may	B-X
lead	B-X
to	B-X
large	B-X
uncertainties	B-X
and	B-X
impingement	B-X
,	B-X
especially	B-X
around	B-X
organ	B-X
boundaries	B-X
.	B-X
Questions	B-X
that	B-X
come	B-X
to	B-X
mind	B-X
are	B-X
the	B-X
feasibility	B-X
of	B-X
building	B-X
a	B-X
unique	B-X
model	B-X
that	B-X
combines	B-X
all	B-X
three	B-X
features	B-X
of	B-X
interest	B-X
in	B-X
the	B-X
same	B-X
statistical	B-X
space	B-X
,	B-X
and	B-X
what	B-X
advantages	B-X
can	B-X
be	B-X
gained	B-X
for	B-X
image	B-X
analysis	B-X
.	B-X
We	B-X
validate	B-X
the	B-X
method	B-X
using	B-X
controlled	B-X
synthetic	B-X
data	B-X
and	B-X
we	B-X
perform	B-X
experiments	B-X
on	B-X
bone	B-X
structures	B-X
from	B-X
CT	B-X
images	B-X
of	B-X
the	B-X
shoulder	B-X
to	B-X
illustrate	B-X
the	B-X
efficacy	B-X
of	B-X
the	B-X
model	B-X
for	B-X
pose	B-X
and	B-X
shape	B-X
prediction	B-X
.	B-X

*	O
P	O
<	O
0	O
.	O
01	O
;	O
*	O
*	O
P	O
<	O
0	O
.	O
005	O
.	O
<EOS>	B-X
Nevertheless	B-X
,	B-X
concerns	B-X
have	B-X
been	B-X
raised	B-X
regarding	B-X
their	B-X
possible	B-X
detrimental	B-X
impact	B-X
on	B-X
male	B-X
fertility	B-X
OBJECTIVE	B-X
:	B-X
To	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
covid-19	B-X
BNT162b2	B-X
(	B-X
Pfizer	B-X
)	B-X
vaccine	B-X
on	B-X
semen	B-X
parameters	B-X
among	B-X
semen	B-X
donors	B-X
(	B-X
SD	B-X
)	B-X
.	B-X
Data	B-X
on	B-X
BNT162b2	B-X
messenger	B-X
RNA	B-X
(	B-X
mRNA	B-X
)	B-X
vaccine	B-X
(	B-X
Pfizer-BioNTech	B-X
)	B-X
effectiveness	B-X
and	B-X
safety	B-X
in	B-X
pregnancy	B-X
are	B-X
currently	B-X
lacking	B-X
because	B-X
pregnant	B-X
women	B-X
were	B-X
excluded	B-X
from	B-X
the	B-X
phase	B-X
3	B-X
trial	B-X
.	B-X
We	B-X
studied	B-X
humoral	B-X
responses	B-X
after	B-X
coronavirus	B-X
disease	B-X
2019	B-X
(	B-X
COVID-19	B-X
)	B-X
vaccination	B-X
across	B-X
varying	B-X
causes	B-X
of	B-X
immunodeficiency	B-X
.	B-X
Thirty-two	B-X
participants	B-X
(	B-X
mean	B-X
age	B-X
37	B-X
±	B-X
8	B-X
years	B-X
,	B-X
20	B-X
men	B-X
)	B-X
who	B-X
received	B-X
the	B-X
BNT162b2	B-X
mRNA	B-X
COVID-19	B-X
vaccine	B-X
were	B-X
studied	B-X
in	B-X
three	B-X
sessions	B-X
in	B-X
a	B-X
sequence-randomized	B-X
,	B-X
sham-controlled	B-X
,	B-X
assessor-blinded	B-X
,	B-X
crossover	B-X
design	B-X
.	B-X
The	B-X
primary	B-X
outcome	B-X
was	B-X
endothelial	B-X
function	B-X
(	B-X
assessed	B-X
by	B-X
brachial	B-X
artery	B-X
flow-mediated	B-X
dilatation	B-X
(	B-X
FMD	B-X
)	B-X
)	B-X
,	B-X
and	B-X
the	B-X
secondary	B-X
outcomes	B-X
were	B-X
aortic	B-X
stiffness	B-X
(	B-X
evaluated	B-X
with	B-X
carotid-femoral	B-X
pulse	B-X
wave	B-X
velocity	B-X
(	B-X
PWV	B-X
)	B-X
)	B-X
and	B-X
inflammation	B-X
(	B-X
measured	B-X
by	B-X
high-sensitivity	B-X
C-reactive	B-X
protein	B-X
(	B-X
hsCRP	B-X
)	B-X
in	B-X
blood	B-X
samples	B-X
)	B-X
.	B-X
There	B-X
was	B-X
an	B-X
increase	B-X
in	B-X
hsCRP	B-X
that	B-X
was	B-X
apparent	B-X
at	B-X
24	B-X
h	B-X
after	B-X
both	B-X
the	B-X
1st	B-X
dose	B-X
(	B-X
-0.60	B-X
[	B-X
95	B-X
%	B-X
confidence	B-X
intervals	B-X
[	B-X
CI	B-X
]	B-X
:	B-X
-1.60	B-X
to	B-X
-0.20	B-X
]	B-X
,	B-X
p	B-X
=	B-X
0.013	B-X
)	B-X
and	B-X
the	B-X
2nd	B-X
dose	B-X
(	B-X
maximum	B-X
median	B-X
difference	B-X
at	B-X
48	B-X
h	B-X
-6.60	B-X
[	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
-9.80	B-X
to	B-X
-3.40	B-X
]	B-X
,	B-X
p	B-X
<	B-X
0.001	B-X
)	B-X
compared	B-X
to	B-X
placebo	B-X
.	B-X
The	B-X
vaccine	B-X
did	B-X
not	B-X
change	B-X
PWV	B-X
.	B-X
FMD	B-X
remained	B-X
unchanged	B-X
during	B-X
the	B-X
1st	B-X
dose	B-X
but	B-X
decreased	B-X
significantly	B-X
by	B-X
1.5	B-X
%	B-X
(	B-X
95	B-X
%	B-X
CI	B-X
:	B-X
0.1	B-X
%	B-X
to	B-X
2.9	B-X
%	B-X
,	B-X
p	B-X
=	B-X
0.037	B-X
)	B-X
at	B-X
24	B-X
h	B-X
after	B-X
the	B-X
2nd	B-X
dose	B-X
.	B-X

Decreased	O
mRNA	O
levels	O
of	O
inflammatory	O
cytokines	O
from	O
cpdm	O
BMDC	O
.	O

Cultured	O
WT	O
and	O
cpdm	O
BMDC	O
(	O
5x105	O
cells	O
in	O
0	O
.	O
2	O
ml	O
complete	O
medium	O
)	O
were	O
washed	O
and	O
stimulated	O
with	O
100	O
ng	O
/	O
ml	O
LPS	O
(	O
A	O
,	O
C	O
,	O
E	O
,	O
G	O
)	O
or	O
25	O
microg	O
/	O
ml	O
poly	O
I	O
:	O
C	O
(	O
B	O
,	O
D	O
,	O
F	O
,	O
H	O
)	O
.	O

At	O
0	O
,	O
1	O
and	O
2	O
hours	O
,	O
total	O
RNA	O
was	O
extracted	O
and	O
subject	O
to	O
qRT	O
-	O
PCR	O
to	O
measure	O
the	O
expression	O
of	O
Il12p40	B-Protein
(	O
A	O
,	O
B	O
)	O
,	O
Il6	B-Protein
(	O
C	O
,	O
D	O
)	O
,	O
Gmcsf	B-Protein
(	O
E	O
,	O
F	O
)	O
,	O
and	O
Ifnb	B-Protein
(	O
G	O
,	O
H	O
)	O
mRNA	O
.	O

Bars	O
represent	O
mean	O
+	O
/	O
-	O
SD	O
.	O
<EOS>	B-X
In	B-X
extinct	B-X
organisms	B-X
,	B-X
tooth	B-X
formation	B-X
times	B-X
and	B-X
tooth	B-X
replacement	B-X
rate	B-X
are	B-X
calculated	B-X
,	B-X
in	B-X
part	B-X
via	B-X
extrapolation	B-X
of	B-X
the	B-X
space	B-X
between	B-X
incremental	B-X
lines	B-X
in	B-X
dental	B-X
tissues	B-X
representing	B-X
daily	B-X
growth	B-X
(	B-X
von	B-X
Ebner	B-X
Line	B-X
Increment	B-X
Width	B-X
;	B-X
VEIW	B-X
)	B-X
.	B-X
To	B-X
address	B-X
this	B-X
,	B-X
we	B-X
tested	B-X
a	B-X
variety	B-X
of	B-X
intradental	B-X
,	B-X
intramandibular	B-X
,	B-X
and	B-X
ontogentic	B-X
sampling	B-X
effects	B-X
on	B-X
calculations	B-X
of	B-X
mean	B-X
VEIW	B-X
,	B-X
tooth	B-X
formation	B-X
times	B-X
,	B-X
and	B-X
replacement	B-X
rates	B-X
using	B-X
histological	B-X
sections	B-X
and	B-X
CT	B-X
reconstructions	B-X
of	B-X
a	B-X
growth	B-X
series	B-X
of	B-X
three	B-X
specimens	B-X
of	B-X
the	B-X
extant	B-X
archosaurian	B-X
To	B-X
date	B-X
,	B-X
however	B-X
,	B-X
policy	B-X
interventions	B-X
intended	B-X
to	B-X
achieve	B-X
epidemic	B-X
mitigation	B-X
in	B-X
US	B-X
communities	B-X
have	B-X
neglected	B-X
to	B-X
account	B-X
for	B-X
decarceration	B-X
as	B-X
a	B-X
possible	B-X
means	B-X
of	B-X
protecting	B-X
public	B-X
health	B-X
and	B-X
safety	B-X
.	B-X

Data	O
are	O
representative	O
of	O
two	O
independent	O
experiments	O
.	O
<EOS>	B-X
As	B-X
an	B-X
alternative	B-X
approach	B-X
,	B-X
regenerative	B-X
endodontics	B-X
aims	B-X
to	B-X
regenerate	B-X
dental	B-X
pulp-like	B-X
tissues	B-X
using	B-X
two	B-X
possible	B-X
strategies	B-X
:	B-X
cell	B-X
transplantation	B-X
and	B-X
cell	B-X
homing	B-X
.	B-X
This	B-X
systematic	B-X
review	B-X
examines	B-X
cell	B-X
homing	B-X
for	B-X
dental	B-X
pulp	B-X
regeneration	B-X
,	B-X
selecting	B-X
articles	B-X
on	B-X
in	B-X
vitro	B-X
experiments	B-X
,	B-X
in	B-X
vivo	B-X
ectopic	B-X
transplantation	B-X
models	B-X
and	B-X
in	B-X
situ	B-X
pulp	B-X
revascularization	B-X
.	B-X
Two	B-X
reviewers	B-X
independently	B-X
screened	B-X
and	B-X
included	B-X
papers	B-X
according	B-X
to	B-X
the	B-X
predefined	B-X
selection	B-X
criteria	B-X
.	B-X
To	B-X
increase	B-X
the	B-X
identification	B-X
rate	B-X
of	B-X
label	B-X
free	B-X
DIA	B-X
experiments	B-X
of	B-X
Braeburn	B-X
apple	B-X
a	B-X
new	B-X
workflow	B-X
was	B-X
developed	B-X
where	B-X
a	B-X
DDA	B-X
database	B-X
was	B-X
constructed	B-X
and	B-X
linked	B-X
to	B-X
the	B-X
DIA	B-X
data	B-X
.	B-X
As	B-X
proof	B-X
of	B-X
principle	B-X
,	B-X
the	B-X
designed	B-X
workflow	B-X
was	B-X
applied	B-X
to	B-X
determine	B-X
the	B-X
changes	B-X
during	B-X
a	B-X
storage	B-X
experiment	B-X
,	B-X
achieving	B-X
a	B-X
two-fold	B-X
identification	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
significant	B-X
peptides	B-X
.	B-X

Normal	O
TLR4	B-Protein
and	O
MD2	B-Protein
expression	O
and	O
decreased	O
IL10	B-Protein
secretion	O
and	O
A20	B-Protein
expression	O
by	O
cpdm	O
BMDC	O
.	O

(	O
A	O
)	O
Unstimulated	O
WT	O
and	O
cpdm	O
BMDC	O
(	O
5x105	O
)	O
were	O
labeled	O
with	O
PE	O
-	O
labeled	O
anti	O
-	O
TLR4	O
/	O
MD2	O
or	O
anti	O
-	O
CD14	O
and	O
then	O
subject	O
to	O
flow	O
cytometry	O
analysis	O
.	O
<EOS>	B-X
Innate	B-X
immunity	B-X
,	B-X
armed	B-X
with	B-X
pattern	B-X
recognition	B-X
receptors	B-X
including	B-X
Toll-like	B-X
receptors	B-X
(	B-X
TLR	B-X
)	B-X
,	B-X
is	B-X
critical	B-X
for	B-X
immune	B-X
cell	B-X
activation	B-X
and	B-X
the	B-X
connection	B-X
to	B-X
anti-microbial	B-X
adaptive	B-X
immunity	B-X
.	B-X
The	B-X
links	B-X
between	B-X
cardiovascular	B-X
risk	B-X
predictors	B-X
and	B-X
pro	B-X
and	B-X
anti-inflammatory	B-X
macrophages	B-X
in	B-X
human	B-X
adipose	B-X
tissue	B-X
were	B-X
analysed	B-X
to	B-X
gain	B-X
an	B-X
insight	B-X
into	B-X
the	B-X
pathophysiology	B-X
of	B-X
cardiovascular	B-X
disease	B-X
.	B-X
Design	B-X
Subcutaneous	B-X
and	B-X
visceral	B-X
adipose	B-X
tissues	B-X
were	B-X
obtained	B-X
from	B-X
79	B-X
subjects	B-X
,	B-X
52	B-X
living	B-X
kidney	B-X
donors	B-X
(	B-X
during	B-X
nephrectomy	B-X
)	B-X
and	B-X
27	B-X
patients	B-X
with	B-X
peripheral	B-X
artery	B-X
disease	B-X
(	B-X
during	B-X
arterial	B-X
tree	B-X
reconstruction	B-X
)	B-X
.	B-X
Methods	B-X
Macrophage	B-X
subsets	B-X
were	B-X
isolated	B-X
from	B-X
adipose	B-X
tissues	B-X
and	B-X
analysed	B-X
by	B-X
flow	B-X
cytometry	B-X
using	B-X
CD14	B-X
,	B-X
CD16	B-X
,	B-X
CD36	B-X
and	B-X
CD163	B-X
monoclonal	B-X
antibodies	B-X
.	B-X
The	B-X
mutually	B-X
adjusted	B-X
differences	B-X
of	B-X
phagocytic	B-X
pro-inflammatory	B-X
(	B-X
CD14	B-X
+	B-X
CD16	B-X
+	B-X
CD36	B-X

Unstained	O
cells	O
serve	O
as	O
negative	O
controls	O
.	O

(	O
B	O
)	O
Cultured	O
WT	O
and	O
cpdm	O
BMDC	O
(	O
1x105	O
cells	O
in	O
0	O
.	O
1	O
ml	O
complete	O
medium	O
)	O
were	O
washed	O
and	O
stimulated	O
with	O
medium	O
,	O
100	O
ng	O
/	O
ml	O
LPS	O
or	O
25	O
microg	O
/	O
ml	O
poly	O
I	O
:	O
C	O
for	O
24	O
hours	O
.	O

Supernatants	O
were	O
collected	O
for	O
ELISA	O
of	O
IL10	B-Protein
.	O
<EOS>	B-X
The	B-X
supernatant	B-X
of	B-X
PDLSCs	B-X
was	B-X
collected	B-X
,	B-X
centrifuged	B-X
,	B-X
filtered	B-X
,	B-X
and	B-X
used	B-X
as	B-X
PDLSCs-CM	B-X
.	B-X
Midkine	B-X
,	B-X
TNF-α	B-X
,	B-X
IL-10	B-X
and	B-X
IFN-γ	B-X
cytokine	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
ELISA	B-X
in	B-X
the	B-X
supernatants	B-X
of	B-X
the	B-X
cells	B-X
collected	B-X
at	B-X
the	B-X
end	B-X
of	B-X
incubation	B-X
times	B-X
.	B-X
Vaginal	B-X
mucus	B-X
samples	B-X
were	B-X
collected	B-X
for	B-X
diagnosis	B-X
of	B-X
the	B-X
severity	B-X
degree	B-X
of	B-X
endometritis	B-X
and	B-X
the	B-X
detection	B-X
of	B-X
S100A4	B-X
protein	B-X
content	B-X
.	B-X
Blood	B-X
samples	B-X
and	B-X
endometrial	B-X
biopsies	B-X
were	B-X
collected	B-X
and	B-X
divided	B-X
into	B-X
the	B-X
control	B-X
(	B-X
CN	B-X
)	B-X
,	B-X
mild	B-X
endometrtis	B-X
(	B-X
M	B-X
)	B-X
,	B-X
and	B-X
severe	B-X
endometritis	B-X
(	B-X
S	B-X
)	B-X
groups	B-X
according	B-X
to	B-X
the	B-X
characteristics	B-X
of	B-X
the	B-X
vaginal	B-X
mucus	B-X
type	B-X
.	B-X

(	O
C	O
)	O
Cultured	O
WT	O
and	O
cpdm	O
BMDC	O
(	O
5x105	O
cells	O
in	O
0	O
.	O
2	O
ml	O
complete	O
medium	O
)	O
were	O
washed	O
and	O
stimulated	O
with	O
100	O
ng	O
/	O
ml	O
LPS	O
or	O
25	O
microg	O
/	O
ml	O
poly	O
I	O
:	O
C	O
.	O
<EOS>	B-X
RT-PCR	B-X
analyses	B-X
showed	B-X
that	B-X
both	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
and	B-X
interferon	B-X
containing	B-X
supernatants	B-X
induced	B-X
expression	B-X
of	B-X
Mx1	B-X
in	B-X
RTG	B-X
cells	B-X
.	B-X
Kinetic	B-X
analyses	B-X
suggest	B-X
that	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
acts	B-X
indirectly	B-X
through	B-X
the	B-X
production	B-X
of	B-X
interferons	B-X
(	B-X
IFN	B-X
)	B-X
,	B-X
as	B-X
shown	B-X
in	B-X
other	B-X
studies	B-X
.	B-X
By	B-X
gene	B-X
walking	B-X
with	B-X
trout	B-X
genomic	B-X
DNA	B-X
the	B-X
regulatory	B-X
sequence	B-X
of	B-X
the	B-X
Mx1	B-X
gene	B-X
was	B-X
cloned	B-X
and	B-X
sequenced	B-X
.	B-X
Sequence	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
5	B-X
'	B-X
flanking	B-X
region	B-X
has	B-X
a	B-X
structure	B-X
,	B-X
which	B-X
is	B-X
typical	B-X
for	B-X
an	B-X
interferon-induced	B-X
gene	B-X
promoter	B-X
.	B-X
Relative	B-X
to	B-X
the	B-X
transcription	B-X
start	B-X
,	B-X
it	B-X
has	B-X
a	B-X
TATA	B-X
box	B-X
at	B-X
-29	B-X
to	B-X
-25	B-X
,	B-X
a	B-X
13	B-X
nucleotide	B-X
interferon	B-X
response	B-X
element	B-X
(	B-X
ISRE	B-X
)	B-X
between	B-X
-101	B-X
to	B-X
-89	B-X
,	B-X
and	B-X
a	B-X
Sp1	B-X
binding	B-X
site	B-X
at	B-X
-382	B-X
to	B-X
-374	B-X
.	B-X
This	B-X
region	B-X
,	B-X
with	B-X
a	B-X
single	B-X
ISRE	B-X
,	B-X
is	B-X
enough	B-X
to	B-X
induce	B-X
strong	B-X
expression	B-X
of	B-X
a	B-X
luciferase	B-X
reporter	B-X
gene	B-X
after	B-X
stimulation	B-X
of	B-X
RTG	B-X
cells	B-X
with	B-X
poly	B-X
I	B-X
:	B-X
C.	B-X
A	B-X
time-course	B-X
of	B-X
induction	B-X
of	B-X
this	B-X
reporter	B-X
construct	B-X
showed	B-X
maximal	B-X
expression	B-X
(	B-X
22-fold	B-X
increase	B-X
)	B-X
after	B-X
incubation	B-X
with	B-X
100	B-X
microg	B-X
mL	B-X
(	B-X
-1	B-X
)	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
for	B-X
48	B-X
h.	B-X
An	B-X
optimized	B-X
method	B-X
of	B-X
transient	B-X
transfection	B-X
of	B-X
RTG	B-X
cells	B-X
is	B-X
also	B-X
described	B-X
.	B-X

At	O
0	O
,	O
1	O
,	O
and	O
2	O
hours	O
,	O
total	O
RNA	O
was	O
extracted	O
and	O
subject	O
to	O
qRT	O
-	O
PCR	O
to	O
measure	O
the	O
production	O
of	O
A20	B-Protein
.	O

Inhibition	O
of	O
NF	O
-	O
kappaB	O
signaling	O
in	O
cpdm	O
BMDC	O
.	O

Supernatants	O
were	O
collected	O
for	O
ELISA	O
of	O
IL10	B-Protein
.	O
<EOS>	B-X
The	B-X
supernatant	B-X
of	B-X
PDLSCs	B-X
was	B-X
collected	B-X
,	B-X
centrifuged	B-X
,	B-X
filtered	B-X
,	B-X
and	B-X
used	B-X
as	B-X
PDLSCs-CM	B-X
.	B-X
Midkine	B-X
,	B-X
TNF-α	B-X
,	B-X
IL-10	B-X
and	B-X
IFN-γ	B-X
cytokine	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
ELISA	B-X
in	B-X
the	B-X
supernatants	B-X
of	B-X
the	B-X
cells	B-X
collected	B-X
at	B-X
the	B-X
end	B-X
of	B-X
incubation	B-X
times	B-X
.	B-X
Vaginal	B-X
mucus	B-X
samples	B-X
were	B-X
collected	B-X
for	B-X
diagnosis	B-X
of	B-X
the	B-X
severity	B-X
degree	B-X
of	B-X
endometritis	B-X
and	B-X
the	B-X
detection	B-X
of	B-X
S100A4	B-X
protein	B-X
content	B-X
.	B-X
Blood	B-X
samples	B-X
and	B-X
endometrial	B-X
biopsies	B-X
were	B-X
collected	B-X
and	B-X
divided	B-X
into	B-X
the	B-X
control	B-X
(	B-X
CN	B-X
)	B-X
,	B-X
mild	B-X
endometrtis	B-X
(	B-X
M	B-X
)	B-X
,	B-X
and	B-X
severe	B-X
endometritis	B-X
(	B-X
S	B-X
)	B-X
groups	B-X
according	B-X
to	B-X
the	B-X
characteristics	B-X
of	B-X
the	B-X
vaginal	B-X
mucus	B-X
type	B-X
.	B-X

(	O
C	O
)	O
Cultured	O
WT	O
and	O
cpdm	O
BMDC	O
(	O
5x105	O
cells	O
in	O
0	O
.	O
2	O
ml	O
complete	O
medium	O
)	O
were	O
washed	O
and	O
stimulated	O
with	O
100	O
ng	O
/	O
ml	O
LPS	O
or	O
25	O
microg	O
/	O
ml	O
poly	O
I	O
:	O
C	O
.	O
<EOS>	B-X
RT-PCR	B-X
analyses	B-X
showed	B-X
that	B-X
both	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
and	B-X
interferon	B-X
containing	B-X
supernatants	B-X
induced	B-X
expression	B-X
of	B-X
Mx1	B-X
in	B-X
RTG	B-X
cells	B-X
.	B-X
Kinetic	B-X
analyses	B-X
suggest	B-X
that	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
acts	B-X
indirectly	B-X
through	B-X
the	B-X
production	B-X
of	B-X
interferons	B-X
(	B-X
IFN	B-X
)	B-X
,	B-X
as	B-X
shown	B-X
in	B-X
other	B-X
studies	B-X
.	B-X
By	B-X
gene	B-X
walking	B-X
with	B-X
trout	B-X
genomic	B-X
DNA	B-X
the	B-X
regulatory	B-X
sequence	B-X
of	B-X
the	B-X
Mx1	B-X
gene	B-X
was	B-X
cloned	B-X
and	B-X
sequenced	B-X
.	B-X
Sequence	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
5	B-X
'	B-X
flanking	B-X
region	B-X
has	B-X
a	B-X
structure	B-X
,	B-X
which	B-X
is	B-X
typical	B-X
for	B-X
an	B-X
interferon-induced	B-X
gene	B-X
promoter	B-X
.	B-X
Relative	B-X
to	B-X
the	B-X
transcription	B-X
start	B-X
,	B-X
it	B-X
has	B-X
a	B-X
TATA	B-X
box	B-X
at	B-X
-29	B-X
to	B-X
-25	B-X
,	B-X
a	B-X
13	B-X
nucleotide	B-X
interferon	B-X
response	B-X
element	B-X
(	B-X
ISRE	B-X
)	B-X
between	B-X
-101	B-X
to	B-X
-89	B-X
,	B-X
and	B-X
a	B-X
Sp1	B-X
binding	B-X
site	B-X
at	B-X
-382	B-X
to	B-X
-374	B-X
.	B-X
This	B-X
region	B-X
,	B-X
with	B-X
a	B-X
single	B-X
ISRE	B-X
,	B-X
is	B-X
enough	B-X
to	B-X
induce	B-X
strong	B-X
expression	B-X
of	B-X
a	B-X
luciferase	B-X
reporter	B-X
gene	B-X
after	B-X
stimulation	B-X
of	B-X
RTG	B-X
cells	B-X
with	B-X
poly	B-X
I	B-X
:	B-X
C.	B-X
A	B-X
time-course	B-X
of	B-X
induction	B-X
of	B-X
this	B-X
reporter	B-X
construct	B-X
showed	B-X
maximal	B-X
expression	B-X
(	B-X
22-fold	B-X
increase	B-X
)	B-X
after	B-X
incubation	B-X
with	B-X
100	B-X
microg	B-X
mL	B-X
(	B-X
-1	B-X
)	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
for	B-X
48	B-X
h.	B-X
An	B-X
optimized	B-X
method	B-X
of	B-X
transient	B-X
transfection	B-X
of	B-X
RTG	B-X
cells	B-X
is	B-X
also	B-X
described	B-X
.	B-X

At	O
0	O
,	O
1	O
,	O
and	O
2	O
hours	O
,	O
total	O
RNA	O
was	O
extracted	O
and	O
subject	O
to	O
qRT	O
-	O
PCR	O
to	O
measure	O
the	O
production	O
of	O
A20	B-Protein
.	O

Inhibition	O
of	O
NF	O
-	O
kappaB	O
signaling	O
in	O
cpdm	O
BMDC	O
.	O

WT	O
and	O
cpdm	O
BMDC	O
(	O
2x106	O
cells	O
in	O
0	O
.	O
5	O
mL	O
complete	O
medium	O
)	O
were	O
stimulated	O
with	O
100	O
ng	O
/	O
mL	O
LPS	O
(	O
A	O
)	O
or	O
25	O
microg	O
/	O
mL	O
poly	O
I	O
:	O
C	O
(	O
B	O
)	O
.	O
<EOS>	B-X
RT-PCR	B-X
analyses	B-X
showed	B-X
that	B-X
both	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
and	B-X
interferon	B-X
containing	B-X
supernatants	B-X
induced	B-X
expression	B-X
of	B-X
Mx1	B-X
in	B-X
RTG	B-X
cells	B-X
.	B-X
Kinetic	B-X
analyses	B-X
suggest	B-X
that	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
acts	B-X
indirectly	B-X
through	B-X
the	B-X
production	B-X
of	B-X
interferons	B-X
(	B-X
IFN	B-X
)	B-X
,	B-X
as	B-X
shown	B-X
in	B-X
other	B-X
studies	B-X
.	B-X
By	B-X
gene	B-X
walking	B-X
with	B-X
trout	B-X
genomic	B-X
DNA	B-X
the	B-X
regulatory	B-X
sequence	B-X
of	B-X
the	B-X
Mx1	B-X
gene	B-X
was	B-X
cloned	B-X
and	B-X
sequenced	B-X
.	B-X
Sequence	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
5	B-X
'	B-X
flanking	B-X
region	B-X
has	B-X
a	B-X
structure	B-X
,	B-X
which	B-X
is	B-X
typical	B-X
for	B-X
an	B-X
interferon-induced	B-X
gene	B-X
promoter	B-X
.	B-X
Relative	B-X
to	B-X
the	B-X
transcription	B-X
start	B-X
,	B-X
it	B-X
has	B-X
a	B-X
TATA	B-X
box	B-X
at	B-X
-29	B-X
to	B-X
-25	B-X
,	B-X
a	B-X
13	B-X
nucleotide	B-X
interferon	B-X
response	B-X
element	B-X
(	B-X
ISRE	B-X
)	B-X
between	B-X
-101	B-X
to	B-X
-89	B-X
,	B-X
and	B-X
a	B-X
Sp1	B-X
binding	B-X
site	B-X
at	B-X
-382	B-X
to	B-X
-374	B-X
.	B-X
This	B-X
region	B-X
,	B-X
with	B-X
a	B-X
single	B-X
ISRE	B-X
,	B-X
is	B-X
enough	B-X
to	B-X
induce	B-X
strong	B-X
expression	B-X
of	B-X
a	B-X
luciferase	B-X
reporter	B-X
gene	B-X
after	B-X
stimulation	B-X
of	B-X
RTG	B-X
cells	B-X
with	B-X
poly	B-X
I	B-X
:	B-X
C.	B-X
A	B-X
time-course	B-X
of	B-X
induction	B-X
of	B-X
this	B-X
reporter	B-X
construct	B-X
showed	B-X
maximal	B-X
expression	B-X
(	B-X
22-fold	B-X
increase	B-X
)	B-X
after	B-X
incubation	B-X
with	B-X
100	B-X
microg	B-X
mL	B-X
(	B-X
-1	B-X
)	B-X
poly	B-X
I	B-X
:	B-X
C	B-X
for	B-X
48	B-X
h.	B-X
An	B-X
optimized	B-X
method	B-X
of	B-X
transient	B-X
transfection	B-X
of	B-X
RTG	B-X
cells	B-X
is	B-X
also	B-X
described	B-X
.	B-X

At	O
0	O
,	O
15	O
,	O
30	O
,	O
and	O
60	O
minutes	O
,	O
whole	O
-	O
cell	O
lysates	O
were	O
obtained	O
and	O
subject	O
to	O
immunoblots	O
with	O
antibodies	O
against	O
proteins	O
involved	O
in	O
NF	O
-	O
kappaB	O
,	O
TBK1	B-Protein
/	O
IRF3	B-Protein
,	O
ERK1	B-Protein
/	O
2	B-Protein
,	O
and	O
p38	O
signaling	O
pathways	O
.	O

Beta	B-Protein
-	I-Protein
actin	I-Protein
was	O
used	O
as	O
loading	O
control	O
.	O
<EOS>	B-X
Western	B-X
blotting	B-X
is	B-X
an	B-X
analytical	B-X
method	B-X
widely	B-X
used	B-X
for	B-X
detecting	B-X
and	B-X
(	B-X
semi-	B-X
)	B-X
quantifying	B-X
specific	B-X
proteins	B-X
in	B-X
given	B-X
samples	B-X
.	B-X
This	B-X
review	B-X
article	B-X
focuses	B-X
on	B-X
a	B-X
significant	B-X
,	B-X
but	B-X
not	B-X
yet	B-X
well-established	B-X
,	B-X
improvement	B-X
concerning	B-X
the	B-X
internal	B-X
loading	B-X
control	B-X
as	B-X
a	B-X
prerequisite	B-X
to	B-X
accurately	B-X
quantifying	B-X
Western	B-X
blots	B-X
.	B-X
Currently	B-X
,	B-X
housekeeping	B-X
proteins	B-X
(	B-X
HKPs	B-X
)	B-X
like	B-X
actin	B-X
,	B-X
tubulin	B-X
,	B-X
or	B-X
GAPDH	B-X
are	B-X
often	B-X
used	B-X
to	B-X
check	B-X
for	B-X
equal	B-X
loading	B-X
or	B-X
to	B-X
compensate	B-X
potential	B-X
loading	B-X
differences	B-X
.	B-X
However	B-X
,	B-X
this	B-X
loading	B-X
control	B-X
has	B-X
multiple	B-X
drawbacks	B-X
.	B-X
Staining	B-X
of	B-X
the	B-X
total	B-X
protein	B-X
on	B-X
the	B-X
blotting	B-X
membrane	B-X
has	B-X
emerged	B-X
as	B-X
a	B-X
better	B-X
loading	B-X
control	B-X
.	B-X
Total	B-X
protein	B-X
staining	B-X
(	B-X
TPS	B-X
)	B-X
represents	B-X
the	B-X
actual	B-X
loading	B-X
amount	B-X
more	B-X
accurately	B-X
than	B-X
HKPs	B-X
due	B-X
to	B-X
minor	B-X
technical	B-X
and	B-X
biological	B-X
variation	B-X
.	B-X
Further	B-X
,	B-X
the	B-X
broad	B-X
dynamic	B-X
range	B-X
of	B-X
TPS	B-X
solves	B-X
the	B-X
issue	B-X
of	B-X
HKPs	B-X
that	B-X
commonly	B-X
fail	B-X
to	B-X
show	B-X
loading	B-X
differences	B-X
above	B-X
small	B-X
loading	B-X
amounts	B-X
of	B-X
0.5-10	B-X
μg	B-X
.	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
review	B-X
article	B-X
is	B-X
to	B-X
collect	B-X
and	B-X
compare	B-X
information	B-X
about	B-X
TPS	B-X
options	B-X
and	B-X
to	B-X
invite	B-X
users	B-X
to	B-X
reconsider	B-X
their	B-X
applied	B-X
loading	B-X
control	B-X
.	B-X
I	B-X
conclude	B-X
that	B-X
TPS	B-X
should	B-X
be	B-X
the	B-X
preferred	B-X
loading	B-X
control	B-X
in	B-X
future	B-X
Western	B-X
blot	B-X
approaches	B-X
.	B-X

(	O
C	O
)	O
Cellular	O
levels	O
of	O
p	O
-	O
IKK1	B-Protein
/	O
2	B-Protein
and	O
p	O
-	O
IkappaBalpha	B-Protein
in	O
LPS	O
-	O
or	O
poly	O
I	O
:	O
C	O
-	O
stimulated	O
BMDC	O
were	O
quantitated	O
with	O
ImageJ	O
(	O
NIH	O
)	O
and	O
presented	O
as	O
trend	O
lines	O
.	O

Results	O
are	O
representative	O
of	O
at	O
least	O
two	O
independent	O
experiments	O
.	O
<EOS>	B-X
Across	B-X
two	B-X
studies	B-X
(	B-X
The	B-X
presence	B-X
of	B-X
hybrid	B-X
genotypes	B-X
has	B-X
been	B-X
widely	B-X
reported	B-X
in	B-X
surveys	B-X
of	B-X
natural	B-X
populations	B-X
,	B-X
genetic	B-X
variation	B-X
reported	B-X
in	B-X
a	B-X
number	B-X
of	B-X
Leishmania	B-X
species	B-X
,	B-X
and	B-X
the	B-X
extant	B-X
capacity	B-X
for	B-X
genetic	B-X
exchange	B-X
demonstrated	B-X
in	B-X
laboratory	B-X
experiments	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
these	B-X
hybrids	B-X
originate	B-X
from	B-X
recombination	B-X
between	B-X
two	B-X
different	B-X
lineages	B-X
of	B-X
Ethiopian	B-X
L.	B-X
donovani	B-X
occurring	B-X
in	B-X
the	B-X
same	B-X
region	B-X
.	B-X
Patterns	B-X
of	B-X
inheritance	B-X
are	B-X
more	B-X
complex	B-X
than	B-X
previously	B-X
reported	B-X
with	B-X
multiple	B-X
,	B-X
apparently	B-X
independent	B-X
,	B-X
origins	B-X
from	B-X
similar	B-X
parents	B-X
that	B-X
include	B-X
backcrossing	B-X
with	B-X
parental	B-X
types	B-X
.	B-X
Analysis	B-X
indicates	B-X
that	B-X
hybrids	B-X
are	B-X
representative	B-X
of	B-X
at	B-X
least	B-X
three	B-X
different	B-X
histories	B-X
.	B-X

Stimulated	O
cpdm	O
BMDC	O
induced	O
Th2	O
-	O
biased	O
cytokine	O
production	O
from	O
naive	O
CD4	O
+	O
T	O
cells	O
.	O

WT	O
and	O
cpdm	O
BMDC	O
(	O
5x104	O
cells	O
in	O
0	O
.	O
1	O
mL	O
complete	O
medium	O
;	O
MHC	O
haplotype	O
:	O
H	O
-	O
2b	O
)	O
were	O
incubated	O
with	O
medium	O
,	O
100	O
ng	O
/	O
mL	O
LPS	O
,	O
25	O
microg	O
/	O
mL	O
poly	O
I	O
:	O
C	O
or	O
5	O
microg	O
/	O
mL	O
Pam3CYS	O
.	O

After	O
24	O
hours	O
,	O
cells	O
were	O
washed	O
with	O
PBS	O
and	O
incubated	O
with	O
freshly	O
isolated	O
allogeneic	O
naive	O
CD4	O
+	O
T	O
cells	O
(	O
2	O
.	O
5x105	O
cells	O
in	O
0	O
.	O
1	O
mL	O
complete	O
medium	O
;	O
MHC	O
haplotype	O
:	O
H	O
-	O
2d	O
)	O
.	O

After	O
5	O
days	O
,	O
supernatants	O
were	O
collected	O
and	O
the	O
secretion	O
of	O
IFNgamma	B-Protein
,	O
IL4	B-Protein
,	O
and	O
IL2	B-Protein
were	O
measured	O
by	O
ELISA	O
.	O

Negative	O
controls	O
are	O
1	O
)	O
stimulated	O
BMDC	O
without	O
co	O
-	O
culture	O
with	O
allogeneic	O
CD4	O
+	O
T	O
cells	O
;	O
2	O
)	O
allogeneic	O
CD4	O
+	O
T	O
cells	O
without	O
co	O
-	O
culture	O
with	O
stimulated	O
BMDC	O
.	O

Samples	O
from	O
both	O
negative	O
controls	O
had	O
no	O
detectable	O
production	O
of	O
the	O
aforementioned	O
cytokines	O
(	O
not	O
shown	O
)	O
.	O

Results	O
are	O
analyzed	O
based	O
on	O
2	O
-	O
4	O
mice	O
per	O
group	O
.	O
<EOS>	B-X
Mebendazole	B-X
(	B-X
MBZ	B-X
)	B-X
is	B-X
a	B-X
well-known	B-X
anti-parasite	B-X
drug	B-X
with	B-X
significant	B-X
anti-cancer	B-X
properties	B-X
.	B-X
The	B-X
major	B-X
routes	B-X
of	B-X
metabolic	B-X
activation	B-X
of	B-X
dibenz	B-X
[	B-X
a	B-X
,	B-X
h	B-X
]	B-X
-anthracene	B-X
(	B-X
DBA	B-X
)	B-X
have	B-X
been	B-X
studied	B-X
in	B-X
transformable	B-X
C3H10T1/2CL8	B-X
(	B-X
C3H10T1/2	B-X
)	B-X
mouse	B-X
embryo	B-X
fibroblasts	B-X
in	B-X
culture	B-X
.	B-X
The	B-X
morphological	B-X
transforming	B-X
activities	B-X
of	B-X
three	B-X
potential	B-X
intermediates	B-X
formed	B-X
by	B-X
metabolism	B-X
of	B-X
DBA	B-X
by	B-X
C3H10T1/2	B-X
cells	B-X
,	B-X
trans-3,4-dihydroxy-3,4-dihydro-DBA-	B-X
(	B-X
DBA-3,4-diol	B-X
)	B-X
,	B-X
trans-dihydroxy-3,4-dihydro-DBA-anti-1,2-oxide	B-X
(	B-X
DBA-3,4-diol-1,2-oxide	B-X
)	B-X
and	B-X
DBA-5,6-oxide	B-X
were	B-X
determined	B-X
.	B-X
DBA-3,4-diol-1,2-oxide	B-X
was	B-X
a	B-X
strong	B-X
morphological	B-X
transforming	B-X
agent	B-X
giving	B-X
a	B-X
mean	B-X
of	B-X
73	B-X
%	B-X
dishes	B-X
with	B-X
Type	B-X
II	B-X
or	B-X
III	B-X
foci	B-X
and	B-X
1.63	B-X
Type	B-X
II	B-X
and	B-X
III	B-X
foci	B-X
per	B-X
dish	B-X
at	B-X
0.5	B-X
microgram/ml	B-X
.	B-X
DBA-3,4-diol	B-X
produced	B-X
a	B-X
mean	B-X
of	B-X
42	B-X
%	B-X
dishes	B-X
with	B-X
Type	B-X
II	B-X
or	B-X
III	B-X
foci	B-X
and	B-X
0.81	B-X
Type	B-X
II	B-X
and	B-X
III	B-X
foci	B-X
per	B-X
dish	B-X
at	B-X
2.5	B-X
micrograms/ml	B-X
.	B-X
DBA	B-X
gave	B-X
a	B-X
mean	B-X
of	B-X
24	B-X
%	B-X
dishes	B-X
with	B-X
Type	B-X
II	B-X
or	B-X
III	B-X
foci	B-X
and	B-X
0.29	B-X
Type	B-X
II	B-X
and	B-X
III	B-X
foci	B-X
per	B-X
dish	B-X
at	B-X
2.5	B-X
micrograms/ml	B-X
.	B-X
DNA	B-X
adducts	B-X
of	B-X
DBA	B-X
,	B-X
DBA-3,4-diol	B-X
,	B-X
DBA-3,4-diol-1,2-oxide	B-X
,	B-X
DBA-1,4/2,3-tetrol	B-X
and	B-X
DBA-5,6-oxide	B-X
in	B-X
C3H10T1/2	B-X
cells	B-X
were	B-X
analyzed	B-X
by	B-X
32P-postlabeling	B-X
method	B-X
.	B-X
DBA	B-X
gave	B-X
11	B-X
adducts	B-X
,	B-X
nine	B-X
of	B-X
which	B-X
were	B-X
observed	B-X
in	B-X
the	B-X
DNA	B-X
of	B-X
cells	B-X
treated	B-X
with	B-X
DBA-3,4-diol	B-X
and	B-X
seven	B-X
from	B-X
cells	B-X
treated	B-X
with	B-X
DBA-3,4-diol-1,2-oxide	B-X
.	B-X
Two	B-X
of	B-X
these	B-X
adducts	B-X
that	B-X
appear	B-X
in	B-X
each	B-X
of	B-X
the	B-X
treatment	B-X
groups	B-X
have	B-X
been	B-X
identified	B-X
as	B-X
the	B-X
product	B-X
of	B-X
the	B-X
interaction	B-X
of	B-X
DBA-3,4-diol-1,2-oxide	B-X
with	B-X
2'-deoxyguanosine	B-X
.	B-X
Furthermore	B-X
,	B-X
there	B-X
is	B-X
evidence	B-X
for	B-X
DBA-DNA	B-X
adducts	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
DBA	B-X
,	B-X
DBA-3,4-diol	B-X
and	B-X
DBA-3,4-diol-1,2-oxide	B-X
arising	B-X
from	B-X
metabolism	B-X
to	B-X
(	B-X
+	B-X
,	B-X
-	B-X
)	B-X
-trans	B-X
,	B-X
trans-3,4,10,11-tetrahydroxy-3,4,10,11-tetrahydro-DBA	B-X
(	B-X
DBA-3,4,10,11-bis-diol	B-X
)	B-X
.	B-X
These	B-X
results	B-X
are	B-X
based	B-X
on	B-X
co-migration	B-X
of	B-X
C3H10T1/2	B-X
DNA	B-X
adducts	B-X
with	B-X
skin	B-X
DNA	B-X
adducts	B-X
formed	B-X
after	B-X
topical	B-X
treatment	B-X
of	B-X
mice	B-X
with	B-X
DBA-3,4,10,11-bis-diol	B-X
.	B-X
In	B-X
C3H10T1/2	B-X
cells	B-X
,	B-X
DBA	B-X
is	B-X
metabolically	B-X
activated	B-X
through	B-X
DBA-3,4-diol	B-X
,	B-X
which	B-X
is	B-X
further	B-X
activated	B-X
via	B-X
the	B-X
DBA-3,4-diol-1,2-oxide	B-X
and	B-X
DBA-3,4,10,11-bis-diol	B-X
pathways	B-X
.	B-X

*	O
P	O
<	O
0	O
.	O
05	O
.	O
<EOS>	B-X
The	B-X
NAb	B-X
response	B-X
was	B-X
also	B-X
assessed	B-X
in	B-X
90	B-X
individuals	B-X
who	B-X
had	B-X
received	B-X
the	B-X
complete	B-X
dose	B-X
regimen	B-X
of	B-X
BNT162b2	B-X
.	B-X
The	B-X
effectiveness	B-X
of	B-X
messenger	B-X
RNA	B-X
coronavirus	B-X
disease	B-X
2019	B-X
(	B-X
COVID-19	B-X
)	B-X
vaccines	B-X
in	B-X
patients	B-X
with	B-X
atopic	B-X
dermatitis	B-X
(	B-X
AD	B-X
)	B-X
is	B-X
yet	B-X
to	B-X
be	B-X
delineated	B-X
.	B-X
Estimated	B-X
background	B-X
rate	B-X
of	B-X
CVST	B-X
with	B-X
thrombocytopenia	B-X
is	B-X
0.1	B-X
per	B-X
million	B-X
per	B-X
month	B-X
.	B-X
However	B-X
,	B-X
there	B-X
are	B-X
concerns	B-X
about	B-X
dampened	B-X
immune	B-X
responses	B-X
to	B-X
COVID-19	B-X
vaccination	B-X
among	B-X
immunocompromised	B-X
patients	B-X
,	B-X
including	B-X
people	B-X
living	B-X
with	B-X
HIV	B-X
(	B-X
PLWH	B-X
)	B-X
,	B-X
which	B-X
may	B-X
blunt	B-X
the	B-X
vaccine	B-X
's	B-X
efficacy	B-X
and	B-X
durability	B-X
of	B-X
protection	B-X
.	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
assess	B-X
the	B-X
qualitative	B-X
SARS-CoV-2	B-X
vaccine	B-X
immunogenicity	B-X
among	B-X
PLWH	B-X
after	B-X
vaccination	B-X
.	B-X